<SEC-DOCUMENT>0001104659-26-076958.txt : 20260624
<SEC-HEADER>0001104659-26-076958.hdr.sgml : 20260624
<ACCEPTANCE-DATETIME>20260623212829
ACCESSION NUMBER:		0001104659-26-076958
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		109
FILED AS OF DATE:		20260624
DATE AS OF CHANGE:		20260623

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Liminatus Pharma, Inc.
		CENTRAL INDEX KEY:			0001971387
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-296986
		FILM NUMBER:		261112839

	BUSINESS ADDRESS:	
		STREET 1:		12611 HIDDENCREEK WAY
		STREET 2:		UNIT C
		CITY:			CERRITOS
		STATE:			CA
		ZIP:			90703
		BUSINESS PHONE:		213-273-5453

	MAIL ADDRESS:	
		STREET 1:		12611 HIDDENCREEK WAY
		STREET 2:		UNIT C
		CITY:			CERRITOS
		STATE:			CA
		ZIP:			90703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Iris Parent Holding Corp.
		DATE OF NAME CHANGE:	20230328
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>limn-20260331xs1.htm
<DESCRIPTION>S-1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.3.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 6/24/2026 1:16:38 AM -->
<!-- iXBRL Library version: 1.0.9561.79 -->
<!-- iXBRL Service Job ID: 00000000-0000-0000-0000-000000000000 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:limn="http://www.liminatuspharma.com/20260331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>LIMINATUS PHARMA, INC.</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="dei:EntityCentralIndexKey" id="Tc_U__4sQzrbke-hSym0dDFMQ_1_1">0001971387</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="dei:AmendmentFlag" id="Tc_w9GC9n3kNUWYJzh4ZKfZvQ_2_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" xs:nil="true" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" name="us-gaap:CommitmentsAndContingencies" id="Hidden_8HWQfwbA_ECbVlKERimhRA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" xs:nil="true" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_Vh0f4VxQ7U6dzZ4_M6Iklg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" xs:nil="true" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" name="us-gaap:PreferredStockValue" id="Hidden_Ksx2stOFWk6AY84IddPepw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" xs:nil="true" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" name="us-gaap:PreferredStockValue" id="Hidden_ZOiuN5kpm0G41AqH6e2UJw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_limn_RedeemableWarrantMember_viAcaQl82UKtOAfy6rdZ4Q" decimals="2" name="limn:NumberOfWarrantsHeldInEachUnit" id="Hidden_V3HXcsnI6E-gQG2CW85ZjA">0.25</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_ZDd5yizsikO5sTlcUH09FA" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Hidden_nl21qyvNY06G3jQDgQwLzg">1.5</ix:nonFraction><ix:nonNumeric contextRef="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_Ky__aiunWkee6a2CP8ZTOQ" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_y0XoPBMFT0K_m6ZKSdgGew">P5Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_segment_pfATFfq5ukiWsqLhRIg_Iw" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="INF" name="us-gaap:NumberOfReportableSegments" id="Hidden_oRglHBbi5kiQPSddjK0rrg">1</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_segment_pfATFfq5ukiWsqLhRIg_Iw" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="INF" name="us-gaap:NumberOfOperatingSegments" id="Hidden_skpW_fMTs0qgK5TqjOzinQ">1</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" xs:nil="true" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_j5iZXpaqRUepqSK5i47XiA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" xs:nil="true" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_sQpi6bpFc0qQ5LX21s7swA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" xs:nil="true" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" name="us-gaap:PreferredStockValue" id="Hidden_rF9jsGd2PEyzELvf4YbZ2g"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" xs:nil="true" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" name="us-gaap:PreferredStockValue" id="Hidden_W9yMXh1gvU6pZJS4SioUZg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_VnuFzE-7Pk6xiqbZGsYVKw">23753561</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_QfG0tNXDh0OFhH449Pr4Mg">17500000</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" sign="-" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_F4R9DCODRUSd1g3LlIjEqw">0.43</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" sign="-" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_cM-Z0zzNDUaiQqfL9Zw3UA">0.20</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_limn_RedeemableWarrantMember_viAcaQl82UKtOAfy6rdZ4Q" decimals="2" name="limn:NumberOfWarrantsHeldInEachUnit" id="Hidden_ZxKK64VsEUG8mm4V7fNrqQ">0.25</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_qUlxIbYw4Uyvh13v3JGs3g" decimals="0" name="limn:PrincipalAndAccruedInterestOnPrivatePlacement" id="Hidden_5_bKoANxokGAW-xbn0qRBA">3316756</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration" id="Hidden_gt31aPXKykC4c-4bEt6laQ">http://xbrl.sec.gov/country/2025#CA</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration" id="Hidden_sNEuRXTazkSm5Xw7h_81ew">http://xbrl.sec.gov/country/2025#CA</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_01Es_yiBG0a6u9R-nLydbg" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_rGRJ0qc7tEGPO6XNQVjRbw">P5Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kX_yWG231E-RYOerQjujQA" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" id="Hidden_pRGIcWXwZE-WeEaxj87wJg">1</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wuQDuaMWckW-5cDSn3bI2w" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" id="Hidden_kq3mrqvJyU-ExJ_p7HGPjQ">1.5</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PrivatePlacementWarrantsMember_ioEniwa8PEunNaQ7J6fSnA" decimals="0" name="us-gaap:WarrantsAndRightsOutstanding" id="Hidden_wUaYXsrirkKbOmu3ilr3Zg">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="limn-20260331.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Fj9tEUl42E6MBhnKApp0zA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_KxviRH7DfUuHBTu5r6l8NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_6blY871CSEOApTf8LuQfmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GUMRHws20E-hQftGj0JvTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NcxMLUOjV0-W98TcYBomsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gZkGDq_I9UKTee9n9IgYZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5kfGOGRcqUu2Y62sJIl6Iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Y5cch1GNXkWKRHTF2v1JhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4f2Cj2MzIUuqkE9ozbbB6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_It0aMMr5RUGH0v6aV7qdrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lO_UINB71EmnK4inw1sNDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9gmJIjAObE6K8dYKyoRMyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MuLWEtlz5E2UN4YJiAi4YQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9uu8nJPlZE2Ewx4WJxhvoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mdCeT08ds0iD_QBBfMY-1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_RvqHKU6YWkmEJhD9fotvqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-SnrU4W24kCYErwDqqD2uA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8haIXs4y3EGbc6exykltFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJune2023LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YX6lsxQHS0-d9Bt2ThMAkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJuly2023LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EBIJxgFtuUu-6zOIAkmcqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMay2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_89RhalbceUGFHBdneVrdYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMarch2025LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_A1W50Uj-NUO6hThaQ_OHyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMarch2024LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NWZ-m0WBA0qJ23vP65-HJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseJuly2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_vHGFMJf22kGulBghrO3_RQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseFebruary2025LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DpWp6FQcKk2ToUxk9I8I-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseFebruary2024LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3iko9KeMAkGp5regWs_4Nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseAugust2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Up5NOzVX402q1o88UijPvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_bIvWOEL1hEqZwZYGgrwYpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaAugust2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__TXA9F6q8kWE6TNY3k0qkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_dKxFvloVNESsveu8CClPfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:CarTcellkorLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8q0dzuwVGEShgTwjOwX7bQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesNovember2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_embE8oVddUqzPD1utl4Z7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_HiTcUoWDTEqyHvNgB9TCRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesJanuary2025LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_r25euOvngkmrw8iQThV-hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_148jP040dUadKsjmVdStxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VlA87RaJeEq06zmKK_H7kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJune2023LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_eAOXFYGTJk-hpkYZ9yVryA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJuly2023LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ay2QMWFbV0SdpGM1KxxUJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMay2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tu28ZL0W00ydtm8NRLecmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMarch2025LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tPoEXxTBuEas6Sj74xYwPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMarch2024LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Wgs8NC0FrEu0hK8Qjljnog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseJuly2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YhVm-9q0AUSPz-vllz68rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseFebruary2025LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_9WDN8eHoHUWQK3nMpHkYtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseFebruary2024LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__dCVK3BY3EeDKZi28xUkew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseAugust2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0PybUMyl7UupuiSkslBW7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NQoRaZtKZUCGus-3AHoDuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaAugust2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EnLDESj0oUmykTsMHpBM4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wmmbaObSukiDB_4zDCmrgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:CarTcellkorLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_j5CQtBVz5UqKzenH5qp4Pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesNovember2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_s7XNeN2VrkyoKgFvQn08HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_vlYz7WYM0065Rv0yQrEanA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesJanuary2025LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_14_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_176IvMRvuUeNEtEQXDudUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseApril2025LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_99oewdhpVEC5wJhe7rhkyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseApril2025LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_2_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GRnA5Kx7-kGf8N58SRLWrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseApril2025LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_7OFPS-3HHUK9zZcMTjtGcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KnFjty5H1UqDezjsL8ecyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_sFe_sIQl8kC62ZR9mOyaiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoNovember2023LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EegrTR0jGkqYkwr1xCASoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_x5Od1Z7sZ0CQp8ZF554jRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJune2023LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ASPx2q5_QU-KM6mmU-4OjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJuly2023LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gfQEfMTEl0ObGw-d3_mziQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJanuary2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_lrwGKHLBAESOZpAyQq956w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoDecember2022LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_CQA91rS8pUClgpt3N0razg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoAugust2023LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_QRBk_Nfwt0WDpSDktLsbZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMay2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Jq1v2ZuaPEej3PGvRk2DSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMarch2024LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_HDV6ibzOjEy9uUy1EA4FRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseJuly2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_rkyvImjcI02ndBME1T3Fyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseFebruary2024LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ANKNxWmzXk2q4khG39LhMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseAugust2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_obg_hYZhh0yPZ2jeTy8gQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseApril2024LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GP3ES2qH4USRDiPV41OBjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wQjd250e8E-nWSdS93gx4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaAugust2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8mMfG6ZJX0COX4Qohfx8lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonSeptember2023LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3egjKmWE3UiVynBt7G9rJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_EwonDecember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_7O7aQgSHYU6aHfIWbXQSzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonDecember2023LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_TpCVK5HsVEK8Wyv55C0lig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:CarTcellkorLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_JMZfrNFf_E-RRAz3gORKJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesNovember2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VyY5JFYy4EKLtKt2cqj8Iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_skGpvhLamkmTX8ZC32NJjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesNovember2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_13_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DqH0O8M-DkKolyZ-CdcShA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseAugust2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_12_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NGQDh1rA3UGEJwXQpQqNWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseAugust2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_29_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_hOP6gIf6X0uZ7Ge6Uhb8yA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseJuly2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_24_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_4Vld9uwuRkuuQHHIzYvKZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseJuly2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_14_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-IXbBujRXkiVzw9mXk784w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseJuly2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_mxhubmgnJ06DzAurKf0Uug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMay2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VxMZqFXR_UaO5azmVes0dA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMay2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoanTwoMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_roRuh60jM0eb54g1Pq5hLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJanuary2024LoanTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6andgdbpxkqRlyLXl4XDHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJanuary2024LoanOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_19_2023_us-gaap_DebtInstrumentAxis_limn_EwonDecember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_PobELNhVp0CNZjEIGlpjlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonDecember2023LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoanTwoMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_jZaCTxa_V0CXdNygheYPjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoAugust2023LoanTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KWt-xK4eN0-5OFBxkx3LGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoAugust2023LoanOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoanTwoMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_uvAg88eC10OdVCXZ0b8E3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJune2023LoanTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_u39Cd4S7GEqUxTPP5qv_Qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJune2023LoanOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_18_2019_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_zVHTzo-UxEy__UArL1VThQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:CarTcellkorLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_18_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_1t1X0h92206D-tAJKXlt8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_AjxQK7FsCE6Ub2hVGkXXEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockAndPreFundedWarrantsMember_eVpfLX3CYEK8jnIUcxuvGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockAndPreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_JSVgKnyZI0uvIBPJsCar7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-18</xbrli:startDate><xbrli:endDate>2026-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_8Eb_-va_j0mdcFrq6b8KwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-18</xbrli:startDate><xbrli:endDate>2026-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_XYwkzRP4y0ClnxSz9bnyLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:Cd47LicenseAndDevelopmentAgreementWithInnobationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_lUoEyYWXh0OCUietIBRj9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:Cd47LicenseAndDevelopmentAgreementWithInnobationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2025_To_5_1_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Tvb57Yoz8kWjg8oYPKuxig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJune2023LoanOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-01</xbrli:startDate><xbrli:endDate>2025-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2025_To_5_1_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_qNI4ieKD3kSp3GUUyiiVsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoDecember2022LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-01</xbrli:startDate><xbrli:endDate>2025-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2023_To_3_31_2023_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1IIHRUTkZkq60Pm0ATLdfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonDecember2022LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2023_To_2_28_2023_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_fyxYB55LcESYXg1VrFa0SQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonDecember2022LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_PowKVbIlSEav6_it2o0cuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_5jXRkTedV06dtacIjxLWQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_15_2018_To_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Ue0f9e9AF0CCuPCxkaHeGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-15</xbrli:startDate><xbrli:endDate>2018-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ViralGeneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_7wxNNnmVW0OOyrl6dcdkLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ViralGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_ViralGeneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FJJZ1ZZ6TEyxVYe-BaGI8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ViralGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_limn_EmploymentAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_AwztCb84TEyTOzqvwRwIZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">limn:EmploymentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y6Lx3mXqwk-nBkJ5KlLBYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_limn_EmploymentAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_bhT6iPgTMUSC0cikBkivgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">limn:EmploymentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FbpcEF3_bUqHFwpcC9Wy4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_limn_EmploymentAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8W6kVGwgx0651YJT0suHMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">limn:EmploymentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_eXLYHI_roUaYmfoOmSYVxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_s19qgo8JfkOPRkLjJuXHug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vn8s2LBdIUK1HIqRW6N8fQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XRD_hVv4DkGY6KlSlQA6NA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__4kj97EHqEunWT3sM4bCbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AfWb2cWlZEaFlDlquz3ozQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_6H9UrA2MZUWmfOm8ySparQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ClearStreetLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tviGQUjEIkuzwoMOZhqbEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6WgYpfkMwE2wXyUE6YqM6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_r1BpvCN0KEySovh0Qns8yA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EuwARZ5Gg0yVzO8ExZuY7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_JON9ufuZd0Kog8xAC5tcKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_MXaZ3yp_lE6x5RxdHImRoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_m79xoi74tEWD31ya03Rcmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:FeeluxCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_aIiVDq13L0qm8FpFM6Fe7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GRgwbB0go06YmvYSCv-xlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y7jrRcuOPU6wYyUiEQtHhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_meaC4-NT6kOsHGvZt--vtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gXDAk9MAnEC31blcdud-TQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Ol_1m0h-L0KQZ73KaVpZtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__wyANh8s8EOfWyC9HSPygQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NUKGQueFCUK3NV6S4f6neA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_vmR4xWUUp0CvtoWAqoOIRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_uwAdfAZSGEaAVubIisn7qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KyurFw6NFU6DbWNR_JVlJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_uBbaU3A6rUOpfYYDB4euDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:FeeluxCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_BrctH0R4SUmey2o6z162mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_2rdRQZDLhkWmVg-aznAVoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_PKtruhg-mke1cWwu6HOpJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ykDgVNc-WUGp-HHNFZJzIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Vyrd4E71aEKV2JlX3zDSMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_JogJT3JKnkStw7CCF--1Dw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_doQ-5t8E_kahW9UFnsMLNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_3B7id13HUEKPGohf_GYnnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_pY-u8pAzO0OcP5FC3J0aNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_NOD7vwuXLUmAhk-2mkyvLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_yYxsL6Igmk6L3jX5IPvofQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_yZvCrOb-Wk-Oqgi1kTrEqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xvNc1S3hqkGpqvsF2_IC5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseApril2025LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xe3qXzjS0EC39aN_LENA8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMarch2025LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Rs3R6YntuECvjfLJCKGrWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseFebruary2025LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_23_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPR03tDKjUmpyRyQld8qmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesJanuary2025LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_2_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UoLTcnkgY0ia4LxmBqWZzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesJanuary2025LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_27_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xZbOD6QvXU2eioglXc3B9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesNovember2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wdQAw9pClkqJCJydARCG4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseAugust2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_1_2024_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_lO3aHrFMUE2_9b_GTJGSBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaAugust2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0HW6FGsO8Ei7AXcLtjboyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseJuly2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPL1Zq0iyE2-9FTal0qJ5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMay2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KWzMWCDwzEShWHgZreE_vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseApril2024LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_6_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_U0Xo3fqs00OpXo_SeuDtWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMarch2024LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_26_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_dMLi4mVbI0mnfUUmfRTl1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseFebruary2024LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1AItK1QO2kitXmKJcOl1Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJanuary2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1Od3S-eoaUCXHX3nnz2htg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoNovember2023LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_10_2023_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DWdmZjGmCEiRashhGcBpXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonSeptember2023LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_K45l7DmgQE-CQ-xyraew7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoAugust2023LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RoR1eW_fpUmHYmBoFmDg1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJuly2023LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_12_2022_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RpHDxwA5eU6MNdXkdEU0lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonDecember2022LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_v60EouUdLUqn8toxvOltkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:CarTcellkorLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_hxqxTUYPkUOVXBEWPh59bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMay2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_XNzgVBB9EUSW9XJBeTQYXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMarch2025LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gHk208o8a02buGlMK7GoGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseFebruary2025LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VgfZxKguUE6IvyhFTK0bgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseFebruary2024LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_MxNDVYopJUCTnAtVRr2BCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseApril2025LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_WqQ7kEZqMUGKJ2Civ5wmHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseApril2024LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VtKf0F4u50yYAUlGncV4kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaAugust2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_AHn-E6mSh0WMg57djpR6sA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-A5AQrt620qPuuH6l9tvXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonSeptember2023LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_EwonDecember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FAzAi_otIkiuLKLUZIGGZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonDecember2023LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YHOGjDLmVUK3iyhkoffTvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonDecember2022LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ConsortiumLoanOfRelatedPartiesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4nTHRjjm9E64EIS8-8O57A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ConsortiumLoanOfRelatedPartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y5QPj6cnBkqxLO8bzZMweA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesNovember2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_mmocMhxQQE-9TDe7UCuBDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesJanuary2025LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6Oq29UcKvkeSSN5rpNIW6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoNovember2023LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ZaQ3e71ewUK0aSmJ56rcsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJanuary2024LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_rDx80SlYbU-El3v0ZF9uAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoAugust2023LoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionHoldingsLlcMember_HNZDVq5GE0GEgfHcGTUA1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionHoldingsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_gsYeVbSjA0ijBUxcCNZtvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:FeeluxCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Gi0t5_gUYU-FQON95jjxrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__vfMa6eSe02_iSgKMlEjFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LJS_bgYOWkOcBywnif6GLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p3dvj_Io2E-N-bZQMUAM-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHu7s1FxgEmdi0qyZEPN4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HFF_MgUngEePnxJ9ysVB6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PrivatePlacementWarrantsMember_GmwTGx3Js0KBpkdQA1hx1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PrivatePlacementWarrantsMember_ioEniwa8PEunNaQ7J6fSnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_Y7EtLUI_pk6RZ-oTbRPBxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_Gx1dPATNHkOGW-Snv4cHLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_go0DO65rkkqPaWM8iCPEeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_BhVP8T9QzU6thchw3BBoLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_us-gaap_ClassOfWarrantOrRightAxis_limn_NonRedeemableWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_ZG-LffBZq0OabS0uAuJI-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">limn:LiminatusAndIrisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:NonRedeemableWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_slm9IzocEkSBb1GZOKqnZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_j2wjtBDr30CGi5w2RrtSMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kX_yWG231E-RYOerQjujQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wuQDuaMWckW-5cDSn3bI2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_1ZmaX6FlIkeWdeKISX-IUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_ZDd5yizsikO5sTlcUH09FA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_01Es_yiBG0a6u9R-nLydbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_Ky__aiunWkee6a2CP8ZTOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_us-gaap_ClassOfWarrantOrRightAxis_limn_NonRedeemableWarrantMember_xHQZeSCsiEGkdYLlyBZaXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">limn:LiminatusAndIrisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:NonRedeemableWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_VCFxQaKNIEuk0z9tPKoniw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_hJv_UjccpUSIXy-caXvHdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2024_0fsIJRo8qkmwqwDgqs1FdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_PCxMs4QP-k2uBuXoZKiE1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:LicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_9PPk1IhN6EmJm5MGsGwEDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZSeIP3LMQEiCyd2vZgeG5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_nnP7Qz9VeUGy0wjX4yxcQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:FeeluxCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_BXcmOS2BJEKYVp-Znixfsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:VaccineProductsAndVaccineDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:TenYearsPeriodFromFirstCommercialSaleOfProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:VaccineLicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-10</xbrli:startDate><xbrli:endDate>2020-04-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_AysCyyacDk6EgeXu96kqgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:VaccineProductsAndVaccineDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:VaccineLicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-10</xbrli:startDate><xbrli:endDate>2020-04-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_kzj2YTUmsUqdNgLEb6ecrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:VaccineProductsAndVaccineDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:TenYearsPeriodFromFirstCommercialSaleOfProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:VaccineLicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-10</xbrli:startDate><xbrli:endDate>2020-04-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_xdnRdKDui0uO30li7vEb9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:VaccineProductsAndVaccineDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:VaccineLicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-10</xbrli:startDate><xbrli:endDate>2020-04-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_F5M5DAEMCUGaVGfvYeyHNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:TenYearsPeriodFromFirstCommercialSaleOfProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:LicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_tvMLwMEPF0OgoT8qvqNtOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:LicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_Ze3T2NMaj0Ge4Cdvcxk6nQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:TenYearsPeriodFromFirstCommercialSaleOfProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:LicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_e8pHl9vKL0iD2UdUCsGsVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:LicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_9RVHQy9tTkeZj8t4JvLMeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:VaccineProductsAndVaccineDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:TenYearsPeriodFromFirstCommercialSaleOfProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:VaccineLicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-10</xbrli:startDate><xbrli:endDate>2020-04-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_8RdOebh7f0C05gFluwIFFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:TenYearsPeriodFromFirstCommercialSaleOfProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:LicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_1_2022_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_35Sjj6Gfl0yNGiX5Qt5Qmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoDecember2022LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VYxJe3-ZlEKGtf77rNoRJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_tErYwLwjB0maTrnKFX-S_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:Cd47LicenseAndDevelopmentAgreementWithInnobationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_17_2026_To_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_0DwlS1YhD0uVubSzwvOJJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-17</xbrli:startDate><xbrli:endDate>2026-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_17_2026_To_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_xU41UBVWPEGgrfXyxay-nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-17</xbrli:startDate><xbrli:endDate>2026-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_20_2026_To_2_20_2026_srt_CounterpartyNameAxis_limn_InnobationBioCoLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_3V203J1Zg0mfoaBaDb3DcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:InnobationBioCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:Cd47LicenseAndDevelopmentAgreementWithInnobationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-20</xbrli:startDate><xbrli:endDate>2026-02-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_20_2026_To_2_20_2026_srt_CounterpartyNameAxis_limn_InnobationBioCoLtdMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_uS2EVzFvKkO1OaU1FG7Fdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:InnobationBioCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:Cd47LicenseAndDevelopmentAgreementWithInnobationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-20</xbrli:startDate><xbrli:endDate>2026-02-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_ViralGeneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_a0Rd98uIckinvKo03Da_gQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ViralGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_limn_RedeemableWarrantMember_viAcaQl82UKtOAfy6rdZ4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:RedeemableWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_o6DHM9UbBkSNjCOhIS_9VA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:VaccineProductsAndVaccineDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:VaccineLicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-10</xbrli:startDate><xbrli:endDate>2020-04-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_0lDWBPW2vkuWvH-HiGeZyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:LicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_809IbYMTbUCQEIVjWuaGsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-17</xbrli:startDate><xbrli:endDate>2026-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_yl8JpI15U0KUQtNmfOFI3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-17</xbrli:startDate><xbrli:endDate>2026-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2025_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_Lbu1miIqSkupTrmz199Hbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">limn:FeeReductionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_srt_CounterpartyNameAxis_limn_CurisBiotechHoldingsLlcMember_us-gaap_CapitalUnitsByClassAxis_us-gaap_CapitalUnitClassAMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_MfcULb3sYEWNTNOdJMM4Mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:CurisBiotechHoldingsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:Cd47LicenseAndDevelopmentAgreementWithInnobationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2018_srt_ProductOrServiceAxis_limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember_srt_StatementScenarioAxis_limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_5kAI3vX6BkKP69_x9ufqDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:LicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_h1stl_iThEi0wHNuwBrmew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:VaccineProductsAndVaccineDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:VaccineLicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_c5l6cvRI4EqXlctlS8Hl9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:LicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_limn_CarTLicenseAndVaccineLicenseWithTdtMember_mWk8tah9gUuCRPqsFLhQWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:CarTLicenseAndVaccineLicenseWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_limn_CarTLicenseAndVaccineLicenseWithTdtMember_aVFA-tb0MUC-EmBUAPe-xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:CarTLicenseAndVaccineLicenseWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_jBCIg7TF3U2nA2e4ZL4LPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:VaccineProductsAndVaccineDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:VaccineLicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0P2Hk6Fm0UCfvB5hIDbvbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_XvqOOBEml06fz43DO14A7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_hUVQhIvVLUiqyQjkyt2gOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsMember_kZc3BMaUdUGTUqWXCxwF2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_N4PkFcbsfkOoWh1rhs7g7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_ILl90TwynkGTc6BgSwur3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_eIyVw3ZwBkWNjXiNqU4kaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_hXB18br9yUGm2G-QE5h2uQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_TypeOfArrangementAxis_limn_CarTLicenseAndVaccineLicenseWithTdtMember_cvbZ4e18Jk2WLlTRj8K7eQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:CarTLicenseAndVaccineLicenseWithTdtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_3KBXe2AusUautripdVqXLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:AltaPartnersLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_1_2025_CZJvPOCOcUySCDRAwOkqBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_tzr9osJ2S0C-6yY56Bt5Ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:Cd47LicenseAndDevelopmentAgreementWithInnobationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_27_2025_WHc2wpxA30auOyOjgUueLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_brJVgPrmTkGylFftjvNsDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_rriXg5_Dp0mBV3id5bODsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_13QwrEzmwEyKOTC43D2VFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_TzHnTBOE4E6UpnLXPy51MA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_11_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_3xBPTdDIoEKDwiqXuL9Qyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">limn:FeeReductionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_10_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_8jW8A96_rUGTBNiKY7EncA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">limn:FeeReductionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_zu3KxzCVkkuK5CuyZXWLYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxAndCarTcellkorMember_zWurOUpaU0i-IKmnDLLc4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:FeeluxAndCarTcellkorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_qUlxIbYw4Uyvh13v3JGs3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxAndCarTcellkorMember_IRaHwKWzMU-DElAHyQN8Tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:FeeluxAndCarTcellkorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_aADDeFhV70K5BS2735863Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_YSNqwrY3BEKU8q1HG1qjeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ClearStreetLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qRAwhaLP1EWqdsQcq1AtbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ClearStreetLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_c18r92u3KkG5BLQb4LzJlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ClearStreetLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_thV_eeooNEe0x29eHltR5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ClearStreetLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_cgSRAUkHA0i2y04jy71KAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">limn:LiminatusAndIrisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_W2lQ6Gn-NEep1cZ7YVoF1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z416a0UcpESjBa-8wQ9m5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z2RJFeIu4keoqDO4x5BOag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_jjYhKZRSskurVxz2qWHRfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_19_2026_To_2_19_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_SLmuQgYcLUyKdGqqpYwayw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-19</xbrli:startDate><xbrli:endDate>2026-02-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_BC5_6M-QyUmQOf1sjtWaMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-18</xbrli:startDate><xbrli:endDate>2026-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_YV5sLiK4506wsErDca1zNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-18</xbrli:startDate><xbrli:endDate>2026-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_ggP8Qf9lAEK8UwvoEQkLpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-18</xbrli:startDate><xbrli:endDate>2026-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_rUeXM1hqFEmNCkHtxT9MOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-18</xbrli:startDate><xbrli:endDate>2026-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_19_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_nVZL2iH4ikeTyIHCOmUqAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_IbplB2gb40qdMMz9BIq6qA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ClearStreetLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-06</xbrli:startDate><xbrli:endDate>2026-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_c_d3VxIAXUGyxXVEc8AngQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ClearStreetLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-06</xbrli:startDate><xbrli:endDate>2026-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_16_2025_To_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_bvbBg5HF0E2idzp2cAdrIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:AltaPartnersLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-16</xbrli:startDate><xbrli:endDate>2025-07-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_eTUFwzCAf0WPdoyAqoxppg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_U70qipalZUSb0nCwfCrzfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uTi3iJsKTUG1RhrJIbdN7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_HanaImmunotherapeuticsLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_k9NmbfrirkmFjETfcoPvjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:HanaImmunotherapeuticsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_AmantesLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YmK0PQG_Ck6qgjUgdZnidg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:AmantesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_ValetudoTherapeuticsLlcMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_zN6GYwa30EiLaz5lZyZFBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ValetudoTherapeuticsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_E0TXzEQ0YEKb3rQzLXh72w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ProphaseSciencesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_EwonComfortechCoLtdMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_SJg_pgNr3UGbcKPDWHQG5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:EwonComfortechCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tBg1QKOCjkulRGKkllXaGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_HanaImmunotherapeuticsLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_M0xZpqNfSUiePS0rqmBJQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:HanaImmunotherapeuticsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_AmantesLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_HgSigzsdAE2ZWAOutjYfWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:AmantesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ValetudoTherapeuticsLlcMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_u2V6Q8F86kqWl2rCR_ZLxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ValetudoTherapeuticsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Hjob6bfNJ0yH9IccwyqnFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ProphaseSciencesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_EwonComfortechCoLtdMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0bsPPj_X9U-t6aFyc57i1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:EwonComfortechCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UCZY1ZeR3UG6JVOXPTBI8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_HanaImmunotherapeuticsLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NKk10HcAC0izvcIcwzePTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:HanaImmunotherapeuticsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_AmantesLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_uroe3WmRfk2-MXkmturUGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:AmantesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_ValetudoTherapeuticsLlcMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_4VRhmQHacUKineZTnXswaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ValetudoTherapeuticsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Rea6tsWHW0yjkY8Ibu9urQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ProphaseSciencesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_EwonComfortechCoLtdMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_LGib2VMD3kWL01MA1301Pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:EwonComfortechCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6wD9AAP08UeDG0Qs6p5Q2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_D_P_lZhqU5gEiyf8nABG1U1w"><xbrli:measure>limn:D</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_pVdT3YsDMEiv7zpsvfY2UA"><xbrli:measure>limn:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Milestone_17WZ1k4BqkSsiQd-8K0NPw"><xbrli:measure>limn:Milestone</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_pfATFfq5ukiWsqLhRIg_Iw"><xbrli:measure>limn:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Y_OxQzCXHfk02aUB5FPKeCrg"><xbrli:measure>limn:Y</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_sZwEW9zD10aVsHVqFTELDQ_4_2" toRefs="_0a013712_0ec7_4e02_8987_4de262708134" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_uHx5DuLpAEO1yylp-kybYA_6_2" toRefs="_0a013712_0ec7_4e02_8987_4de262708134" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_7ROUESS25EOckwg8ALPOvA_4_2" toRefs="_0a013712_0ec7_4e02_8987_4de262708134" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_2WISg8IU-0WKtEuff6lBmQ_34_6" toRefs="_0a013712_0ec7_4e02_8987_4de262708134" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_gkMv0vRfWUeB1iRn8oy9SQ_34_3" toRefs="_0a013712_0ec7_4e02_8987_4de262708134" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Hidden_W9yMXh1gvU6pZJS4SioUZg" toRefs="_0a013712_0ec7_4e02_8987_4de262708134" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Hidden_rF9jsGd2PEyzELvf4YbZ2g" toRefs="_0a013712_0ec7_4e02_8987_4de262708134" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_x56Y14AyeUu4PVvsK2xtfA_4_14" toRefs="_0a013712_0ec7_4e02_8987_4de262708134" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_PREj0jMsnE6uUWTGBUiLpQ_4_8" toRefs="_0a013712_0ec7_4e02_8987_4de262708134" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_GrnXgKUNgkmBMdi-ZoZ_3w_4_5" toRefs="_0a013712_0ec7_4e02_8987_4de262708134" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_lrp0UnlvWUWv5MwTXJ74KA_4_11" toRefs="_0a013712_0ec7_4e02_8987_4de262708134" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Mlc4m5k8Fkedtj1BUQ0ZWQ_6_14" toRefs="_0a013712_0ec7_4e02_8987_4de262708134" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_rhAk77c-QUCmJHUppKQptQ_4_14" toRefs="_0a013712_0ec7_4e02_8987_4de262708134" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_rbq935VjbUKRIodNkWRssw_4_8" toRefs="_0a013712_0ec7_4e02_8987_4de262708134" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_WSiTCK1d7kWwjU75pUtOxg_6_8" toRefs="_0a013712_0ec7_4e02_8987_4de262708134" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_CVIGz5hPNUqu-ltzIf7NHA_4_5" toRefs="_0a013712_0ec7_4e02_8987_4de262708134" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_2j-StSoYh0i221VVtJbN8A_6_5" toRefs="_0a013712_0ec7_4e02_8987_4de262708134" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_xBiVk0vTUUuW4SRVVn7nLw_6_11" toRefs="_0a013712_0ec7_4e02_8987_4de262708134" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_YP-t6420zUuJGiagviX8Sg_4_11" toRefs="_0a013712_0ec7_4e02_8987_4de262708134" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_zsPKN6SEekWY3d2I44dmXw_4_2" toRefs="_3ff2511c_245c_4e73_aadd_3aa97d52401a" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_--g1J3AQv0qKyyz8xQSB9w_4_2" toRefs="_3ff2511c_245c_4e73_aadd_3aa97d52401a" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_9g7XhG98L0-hjr-ibTvlWw_4_14" toRefs="_3ff2511c_245c_4e73_aadd_3aa97d52401a" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_sOXwOs1NWUqL90HO1pSPsQ_4_8" toRefs="_3ff2511c_245c_4e73_aadd_3aa97d52401a" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_eKNO23yJNUWFC8dvbXuTTQ_4_5" toRefs="_3ff2511c_245c_4e73_aadd_3aa97d52401a" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_gVrV0xOrV0K_rG-K207NgQ_4_11" toRefs="_3ff2511c_245c_4e73_aadd_3aa97d52401a" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc__nGSvNLeEUuD2q3Pv8TGvg_4_14" toRefs="_3ff2511c_245c_4e73_aadd_3aa97d52401a" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Pek-NRLViUyVyREk8mXLgQ_4_8" toRefs="_3ff2511c_245c_4e73_aadd_3aa97d52401a" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_XR-sd7H54kGW0PiFR5oIoA_4_5" toRefs="_3ff2511c_245c_4e73_aadd_3aa97d52401a" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_HA7POEqghEqEeslKVHNRfg_4_11" toRefs="_3ff2511c_245c_4e73_aadd_3aa97d52401a" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_z_syvq_f3Ee2TH7BNETQUA_21_6" toRefs="_458cdbcf_7aee_4fc0_9cbc_944ad97ef513" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc__FiEmY5-uEmnJvHY1psPwA_21_3" toRefs="_458cdbcf_7aee_4fc0_9cbc_944ad97ef513" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Hidden_cM-Z0zzNDUaiQqfL9Zw3UA" toRefs="_458cdbcf_7aee_4fc0_9cbc_944ad97ef513" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Hidden_F4R9DCODRUSd1g3LlIjEqw" toRefs="_458cdbcf_7aee_4fc0_9cbc_944ad97ef513" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Hidden_QfG0tNXDh0OFhH449Pr4Mg" toRefs="_458cdbcf_7aee_4fc0_9cbc_944ad97ef513" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Hidden_VnuFzE-7Pk6xiqbZGsYVKw" toRefs="_458cdbcf_7aee_4fc0_9cbc_944ad97ef513" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_9RX2rQ0RCU6Dk_ZL1Iek7w_19_6" toRefs="_458cdbcf_7aee_4fc0_9cbc_944ad97ef513" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_aHtfXI09SECe6XdEMLiOBQ_19_3" toRefs="_458cdbcf_7aee_4fc0_9cbc_944ad97ef513" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_VCWz9vVrB0qIHg1ZysCVAw_17_6" toRefs="_ad033d65_277e_4e5e_9e19_7b37ba4f3ada" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_-OJZcUa8QEilwlvS02CGdw_17_3" toRefs="_ad033d65_277e_4e5e_9e19_7b37ba4f3ada" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_VCWz9vVrB0qIHg1ZysCVAw_17_6_2" toRefs="_ad033d65_277e_4e5e_9e19_7b37ba4f3ada" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_-OJZcUa8QEilwlvS02CGdw_17_3_2" toRefs="_ad033d65_277e_4e5e_9e19_7b37ba4f3ada" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_6zPXfbljDUO3vovR4VpTpA_15_6" toRefs="_ad033d65_277e_4e5e_9e19_7b37ba4f3ada" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_IIJrVh996USagDgLCTa8-A_15_3" toRefs="_ad033d65_277e_4e5e_9e19_7b37ba4f3ada" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_6zPXfbljDUO3vovR4VpTpA_15_6_2" toRefs="_ad033d65_277e_4e5e_9e19_7b37ba4f3ada" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_IIJrVh996USagDgLCTa8-A_15_3_2" toRefs="_ad033d65_277e_4e5e_9e19_7b37ba4f3ada" order="1"/></ix:resources></ix:header></div><div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;margin-bottom:36pt;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;display:flex;flex-direction:column;flex-grow:1;justify-content:center;max-width:100%;position:relative;z-index:1;"><a id="_8020b3ac_0c9f_410a_a8ee_4e468c0312f8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">As filed with the U.S. Securities and Exchange Commission on June 23, 2026.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Registration No. 333-</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="dei:DocumentType" id="Narr_jutq0ggcwkuJbCEn8-5eJA"><b style="font-weight:bold;">S-1</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REGISTRATION STATEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNDER THE SECURITIES ACT OF 1933</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><a id="_4fb0ead6_83df_4e82_8f19_786a066b95b2"></a><a id="Tc_EFiX3fBJVE-i6548V7Yxsw_2_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:540pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:540pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:14.94pt;"><td style="vertical-align:bottom;width:540pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="dei:EntityRegistrantName" id="Tc_ZF733adW5US7UWwt-FOrzA_1_0"><b style="font-weight:bold;">LIMINATUS PHARMA, INC.</b></ix:nonNumeric></p></td></tr><tr style="height:10.34pt;"><td style="vertical-align:bottom;width:540pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:180.25pt;padding:0pt;"/><td style="width:15pt;padding:0pt;"/><td style="width:160.25pt;padding:0pt;"/><td style="width:13.6pt;padding:0pt;"/><td style="width:170.9pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:180.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:15pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:160.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:13.6pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:170.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:10.59pt;"><td style="vertical-align:bottom;width:180.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Delaware</b></p></td><td style="vertical-align:top;width:15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:160.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">6770</b></p></td><td style="vertical-align:top;width:13.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:170.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">93-2710748</b></p></td></tr><tr style="height:20.94pt;"><td style="vertical-align:top;width:180.25pt;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or other jurisdiction of<br/>incorporation)</p></td><td style="vertical-align:top;width:15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:160.25pt;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Primary Standard Industrial<br/>Classification Code Number)</p></td><td style="vertical-align:top;width:13.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:170.9pt;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(IRS Employer<br/>Identification Number)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2251 Stern Goodman Street, Suite E</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fullerton, California 92833</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(213) 273-5453</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chris Kim</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chief Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2251 Stern Goodman Street, Suite E</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fullerton, California 92833</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(213) 273-5453</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Name, address including zip code, and telephone number, including area code, of agent for service)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 2pt 0pt;"><span style="font-style:italic;font-weight:bold;">With copies to:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:539.5pt;"><tr><td style="width:269.75pt;padding:0pt;"/><td style="width:269.75pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:top;width:269.75pt;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:269.75pt;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:62.09pt;"><td colspan="2" style="vertical-align:top;width:539.5pt;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Mitchell S. Nussbaum</b><br/><b style="font-weight:bold;">Giovanni Caruso</b><br/><b style="font-weight:bold;">Loeb &amp; Loeb LLP</b><br/><b style="font-weight:bold;">345 Park Avenue</b><br/><b style="font-weight:bold;">New York, NY 10154</b><br/><b style="font-weight:bold;">Telephone: (212) 407-4000</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Approximate date of commencement of proposed sale to the public:</b> From time to time after the effective date of this registration statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box: <span style="font-family:'Segoe UI Symbol';">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><a id="_8aa6e4c9_916e_408a_a1c4_48a059f6df81"></a><a id="Tc_irFzLidNv0KXC7OCIU9Wbg_1_0"></a><a id="Tc_5n5DXI0_ZEWAWI249frlcQ_1_1"></a><a id="Tc_7bLKRfSX40edu2gkaAzRvQ_1_3"></a><a id="Tc_M9KgYUqye0G1xmfWvN32Rg_1_4"></a><a id="Tc_hGfkcMhVwUOHB6Pwas7j3A_2_1"></a><a id="Tc_NpAPplhHD0yzSRCTf4TqAA_2_3"></a><a id="Tc_Cgk1poQhwE2Yw0k2qhI6gg_3_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:96.15pt;padding:0pt;"/><td style="width:11.85pt;padding:0pt;"/><td style="width:189pt;padding:0pt;"/><td style="width:122.9pt;padding:0pt;"/><td style="width:12.1pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:96.15pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:189pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:122.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:11.97pt;"><td style="vertical-align:bottom;width:96.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:bottom;width:11.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:189pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:122.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:bottom;width:12.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr style="height:11.97pt;"><td style="vertical-align:bottom;width:96.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="dei:EntityFilerCategory" id="Tc_MYqs_8un60GOr97htdxxkQ_2_0"><span style="font-size:9pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:11.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:189pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:122.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:bottom;width:12.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="dei:EntitySmallBusiness" id="Tc_DDgcQpNrXU6BXv5oXtVH4Q_2_4"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr style="height:11.97pt;"><td style="vertical-align:bottom;width:96.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:189pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:122.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Emerging Growth Company</p></td><td style="vertical-align:bottom;width:12.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="dei:EntityEmergingGrowthCompany" id="Tc_-Z88PoXu10eke6hnuByTwg_3_4"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="dei:EntityExTransitionPeriod" id="Narr_ulCNkQSJtUmuNS-FT74qAg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until this Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 0pt 1.5pt;"><span style="font-size:0pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><div style="height:0pt;position:relative;width:100%;"><div style="height:606pt;left:-0.95pt;position:absolute;top:27.8pt;width:49.5pt;z-index:251658240;"><div style="height:606pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:48.9pt;"><div style="align-items:center;display:flex;left:0pt;max-height:100%;position:relative;text-indent:0pt;top:0pt;transform:rotate(180.1deg);width:48.9pt;writing-mode:vertical-rl;-ms-writing-mode:tb-rl;"><div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="color:#ff0000;font-weight:bold;">The information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offeror sale is not permitted.</b></p></div></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_0b550a0f_8701_4919_a929_4c805a4e8cc0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:157.5pt;padding:0pt;"/><td style="width:149.05pt;padding:0pt;"/><td style="width:125.45pt;padding:0pt;"/></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:157.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#ff0000;font-weight:bold;">PRELIMINARY PROSPECTS</b></p></td><td style="vertical-align:bottom;width:149.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#ff0000;font-weight:bold;">SUBJECT TO COMPLETION</b></p></td><td style="vertical-align:bottom;width:125.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="color:#ff0000;font-weight:bold;">DATED JUNE 23, 2026</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 54pt;"><b style="font-weight:bold;">LIMINATUS PHARMA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 54pt;"><b style="font-weight:bold;">Up to 20,688,000 Shares of Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">This prospectus relates to the offer and sale by Armistice Capital Master Fund Ltd. (&#8220;Armistice&#8221; or the &#8220;Selling Stockholder&#8221;) of up to an aggregate of 20,688,000 shares (the &#8220;Shares&#8221;) of common stock of Liminatus Pharma, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or the &#8220;Company&#8221;), par value $0.0001 per share (the &#8220;Common Stock&#8221;), issuable upon exercise of warrants to purchase up to 10,344,000 Shares at an exercise price per share of $0.18 (the &#8220;Black-Scholes Warrants&#8221;) and warrants to purchase up to 10,344,000 Shares at an exercise price per share of $0.18 (the &#8220;Change of Control Warrants,&#8221; and, together with the Black-Scholes Warrants, the &#8220;Inducement Warrants&#8221;) issued by us to the Selling Stockholder pursuant to an inducement letter agreement, dated June 3, 2026, between us and the Selling Stockholder (the &#8220;Inducement Letter Agreement&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">The Selling Stockholder may sell or otherwise dispose of the Shares described in this prospectus in a number of different ways and at varying prices, which may be determined by the prevailing market price for the Common Stock or in negotiated transactions. We are not selling any shares of Common Stock under this prospectus and will not receive any of the proceeds from the sale or other disposition of the Shares by the Selling Stockholder. However, we may receive up to $3,723,840 upon the Selling Stockholder&#8217;s exercise of the Inducement Warrants, if such Inducement Warrants are exercised for cash. All expenses of registration incurred in connection with this offering are being borne by us. All selling and other expenses incurred by the Selling Stockholder will be borne by the Selling Stockholder. The Inducement Warrants were issued to the Selling Stockholder in connection with private placement offerings pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and/or Regulation D promulgated thereunder, and the Shares are issuable upon exercise of the Inducement Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">This prospectus describes the manner in which the Shares may be sold or otherwise disposed of by the Selling Stockholder. You should carefully read this prospectus, as well as the documents incorporated by reference or deemed to be incorporated by reference into this prospectus, carefully before you invest. See &#8220;Plan of Distribution&#8221; for additional information regarding the sale or other disposition by the Selling Stockholder of the Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">Our Common Stock is listed on The Nasdaq Global Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;LIMN&#8221;. The last reported sale price for our Common Stock as reported on Nasdaq on June 22, 2026 was $0.11 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"><b style="font-weight:bold;">Investing in our securities is highly speculative and involves a high degree of risk. You should carefully consider the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; beginning on page </b><span style="font-weight:bold;">8</span><b style="font-weight:bold;"> of this prospectus before making a decision to purchase our securities.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"><b style="font-weight:bold;">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">The date of this prospectus is &#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 18pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_10553e59_7c30_4dbc_abf8_d09c869bc0c1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ABOUT THIS PROSPECTUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In this prospectus, unless the context suggests otherwise, references to &#8220;the Company,&#8221; &#8220;Liminatus,&#8221; &#160;&#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Liminatus Pharma,&#160;Inc. and its consolidated subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This prospectus is part of a registration statement on Form&#160;S-1 that we filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). The Selling Stockholder may, from time to time, sell or otherwise dispose of the Shares as described in this prospectus. We will not receive any proceeds from the sale or other disposition of the Shares by Selling Stockholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Neither the Company, nor any of its officers, directors, agents, representatives, or the Selling Stockholder make any representation to you about the legality of an investment in the Company&#8217;s Common Stock. You should not interpret the contents of this prospectus to be legal, business, investment, or tax advice. You should consult with your own advisors for that type of advice and consult with them about the legal, tax, business, financial, and other issues that you should consider before investing in the Company&#8217;s securities.</p><a id="_9b18a31f_58a3_4700_b6ec_8e6cc85cca7a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ADDITIONAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">You should rely only on the information contained in this prospectus and in any accompanying prospectus supplement. No one has been authorized to provide you with different or additional information. The shares of Common Stock and warrants are not being offered in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus or any prospectus supplement is accurate as of any date other than the date on the front of such documents.</p><a id="_f4818d6c_028e_430b_9b57_49390a2e9a85"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TRADEMARKS AND TRADE NAMES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This prospectus contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the &#174; or &#8482; symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</p><a id="_5f4a5bc8_3274_432d_99ea_cba58b95d4a3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INDUSTRY AND MARKET DATA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unless otherwise indicated, information contained in this prospectus concerning the Company&#8217;s industry and the markets in which it operates, including market position and market opportunity, is based on information from management&#8217;s estimates, as well as from industry publications and research, surveys and studies conducted by third parties. The third-party sources from which the Company has obtained information generally state that the information contained therein has been obtained from sources believed to be reliable, but the Company cannot assure you that this information is accurate or complete. The Company has not independently verified any of the data from third-party sources nor has it verified the underlying economic assumptions relied upon by those third parties. Similarly, internal company surveys, industry forecasts, and market research, which the Company believes to be reliable, based upon management&#8217;s knowledge of the industry, have not been verified by any independent sources. The Company&#8217;s internal surveys are based on data it has collected over the past several&#160;years, which it believes to be reliable. Management estimates are derived from publicly available information, its knowledge of the industry, and assumptions based on such information and knowledge, which management believes to be reasonable and appropriate. However, assumptions and estimates of the Company&#8217;s future performance, and the future performance of its industry, are subject to numerous known and unknown risks and uncertainties, including those described under the heading &#8220;Risk Factors&#8221; in this prospectus and those described elsewhere in this prospectus, and the other documents the Company files with the Securities and Exchange Commission, or SEC, from time to time. These and other important factors could result in its estimates and assumptions being materially different from future results. You should read the information contained in this prospectus completely and with the understanding that future results may be materially different and worse from what the Company expects. See the information included under the heading &#8220;Cautionary Note&#160;Regarding Forward-Looking Statements.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Implications of Being a Smaller Reporting Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are a &#8220;smaller reporting company&#8221; as defined in Item&#160;10(f)(1)&#160;of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two&#160;years of audited financial statements. We will remain a smaller reporting company until the last day of any fiscal&#160;year for so long as either (1)&#160;the market value of our shares of Common Stock held by non-affiliates does not equal or exceed $250.0 million as of the prior June&#160;30th, or (2)&#160;our annual revenues did not equal or exceed $100.0 million during such completed fiscal&#160;year and the market value of our shares of Common Stock held by non-</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">i</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">affiliates did not equal or exceed $700.0 million as of the prior June&#160;30th. To the extent we take advantage of any reduced disclosure obligations, it may make comparison of our financial statements with other public companies difficult or impossible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Implications of Being an Emerging Growth Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In April&#160;2012, the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an &#8220;emerging growth company.&#8221; We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our audited financial statements might not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have chosen to rely on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an &#8220;emerging growth company&#8221; we are not required to, among other things, (i)&#160;provide an auditor&#8217;s attestation report on our system of internal control over financial reporting pursuant to Section&#160;404 of SOX, (ii)&#160;provide all of the compensation disclosure that may be required of non-emerging growth public companies, (iii)&#160;comply with any requirement that may be adopted by the Public Company Accounting Oversight Board (United States) regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the consolidated financial statements (auditor discussion and analysis) and (iv)&#160;disclose certain executive compensation-related items, such as the correlation between executive compensation and performance and comparisons of the chief executive officer&#8217;s compensation to median employee compensation. We may remain an &#8220;emerging growth company&#8221; until the last day of the fiscal&#160;year following the fifth anniversary of the completion of the IPO. However, if certain events occur prior to the end of such five-year period, including if we become a &#8220;large accelerated filer,&#8221; our annual gross revenue equals or exceeds $1.235 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an &#8220;emerging growth company&#8221; prior to the end of such five-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">ii</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_04075ce0_8e89_4a23_a63a_5c22bd58c38b"></a><a id="CAUTIONARYNOTEREGARDINGFORWARDLOOKINGSTA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CAUTIONARY NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This prospectus, any amendment, and the information incorporated by reference into this prospectus contain various forward-looking statements within the meaning of Section&#160;27A of the Securities Act and Section&#160;21E of the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), which represent our expectations or beliefs concerning future events. Forward-looking statements include, but are not limited to, statements regarding the Company or its management team&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;appear,&#8221; &#8220;approximate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;foresee,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;would&#8221; and similar expressions (or the negative version of such words or expressions) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The forward-looking statements are based on the current expectations of the management of the Company, as applicable, and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These risks and uncertainties include, but are not limited to, those factors described in &#8220;<i style="font-style:italic;">Risk Factors</i>,&#8221; those discussed and identified in public filings made with the SEC by the Company and the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the competitive industries and markets in which the Company operates or plans to operate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in applicable laws or regulations affecting the Company&#8217;s business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company&#8217;s ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to the Company&#8217;s potential inability to achieve or maintain profitability and generate significant revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">current and future conditions in the global economy, including as a result of economic uncertainty, and its impact on the Company, its business and the markets in which it operates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company&#8217;s potential inability to manage growth effectively;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company&#8217;s ability to recruit, train and retain qualified personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">estimates for the prospects and financial performance of the Company&#8217;s business may prove to be incorrect or materially different from actual results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to the Company&#8217;s marketing and growth strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of competition on the Company&#8217;s business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectations with respect to future operating and financial performance and growth, including when the Company will generate positive cash flow from operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company&#8217;s ability to raise funding on reasonable terms as necessary to develop its products in the timeframe contemplated by its business plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to maintain the listing of the Company&#8217;s common stock and warrants on Nasdaq;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">iii</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other risks and uncertainties indicated in this prospectus, including those under &#8220;Risk Factors&#8221; beginning on page&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of this prospectus and other filings that have been made or will be made with the SEC by the Company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, there may be events that the Company&#8217;s management is not able to predict accurately or over which the Company has no control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Should one or more of these risks or uncertainties materialize or should any of the assumptions made by the management of the Company proves incorrect, actual results may vary in material respects from those projected in these forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All subsequent written and oral forward-looking statements concerning the Company or other matters addressed in this prospectus and attributable to the Company or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this prospectus. Except to the extent required by applicable law or regulation, the Company undertakes no obligation to update these forward-looking statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">iv</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_e93c5f6d_6495_467c_8757_281d331f6dd7"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:504.05pt;padding:0pt;"/><td style="width:35.95pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page No.</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CAUTIONARYNOTEREGARDINGFORWARDLOOKINGSTA"><span style="font-style:normal;font-weight:normal;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">iii</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PROSPECTUSSUMMARY_225150"><span style="font-style:normal;font-weight:normal;">PROSPECTUS SUMMARY</span></a></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#THEOFFERING_997853"><span style="font-style:normal;font-weight:normal;">THE OFFERING</span></a></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#RISKFACTORS_921215"><span style="font-style:normal;font-weight:normal;">RISK FACTORS</span></a></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#USEOFPROCEEDS_918479"><span style="font-style:normal;font-weight:normal;">USE OF PROCEEDS</span></a></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">59</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#DIVIDENDPOLICY_971761"><span style="font-style:normal;font-weight:normal;">DIVIDEND POLICY</span></a></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">59</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#MANAGEMENTSDISCUSSIONANDANALYSISO_373850"><span style="font-style:normal;font-weight:normal;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">60</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BUSINESS_673000"><span style="font-style:normal;font-weight:normal;">BUSINESS</span></a></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#MANAGEMENT_945379"><span style="font-style:normal;font-weight:normal;">MANAGEMENT</span></a></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">85</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#EXECUTIVECOMPENSATION_552177"><span style="font-style:normal;font-weight:normal;">EXECUTIVE COMPENSATION</span></a></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#DESCRIPTIONOFSECURITIESTHATTHESELLINGSTO"><span style="font-style:normal;font-weight:normal;">DESCRIPTION OF SECURITIES THAT THE SELLING STOCKHOLDER IS OFFERING</span></a></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">97</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SELLINGSTOCKHOLDER_298737"><span style="font-style:normal;font-weight:normal;">SELLING STOCKHOLDER</span></a></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">99</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BENEFICIALOWNERSHIPOFSECURITIES_795007"><span style="font-style:normal;font-weight:normal;">BENEFICIAL OWNERSHIP OF SECURITIES</span></a></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">101</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CERTAINRELATIONSHIPSANDRELATEDPERSONTRAN"><span style="font-style:normal;font-weight:normal;">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</span></a></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">103</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PLANOFDISTRIBUTION_869767"><span style="font-style:normal;font-weight:normal;">PLAN OF DISTRIBUTION</span></a></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">105</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#LEGALMATTERS_497536"><span style="font-style:normal;font-weight:normal;">LEGAL MATTERS</span></a></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">107</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#EXPERTS_755234"><span style="font-style:normal;font-weight:normal;">EXPERTS</span></a></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">107</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#WHEREYOUCANFINDADDITIONALINFORMATION_541"><span style="font-style:normal;font-weight:normal;">WHERE YOU CAN FIND ADDITIONAL INFORMATION</span></a></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">107</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:504.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#INDEXTOFINANCIALSTATEMENTS_944665"><span style="font-style:normal;font-weight:normal;">INDEX TO FINANCIAL STATEMENTS</span></a></p></td><td style="vertical-align:bottom;width:35.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-1</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">v</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_f9bf7fd7_5349_4436_beef_b45f4a8b18e1"></a><a id="PROSPECTUSSUMMARY_225150"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">PROSPECTUS SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This summary highlights selected information from this prospectus and might not contain all of the information that is important to you in making an investment decision. Before investing in our securities, you should carefully read this entire prospectus, including our financial statements and the related notes included in this prospectus and the information set forth under the headings &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; See also the section entitled &#8220;Where You Can Find Additional Information.&#8221; Unless the context otherwise requires, all references in this prospectus to the &#8220;Company,&#8221; the &#8220;Registrant,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Liminatus Pharma,&#160;Inc., a Delaware corporation, and its consolidated subsidiaries. All references herein to the &#8220;Board&#8221; refer to the board of directors of the Company.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus Pharma,&#160;Inc. is a pre-clinical stage life sciences and pre-revenue company developing a next generation CD47 checkpoint inhibitor under a license agreement. In October&#160;2022, the Company was assigned a license and development agreement, as amended, with InnoBation Bio Co. Ltd (the &#8220;CD47 License&#8221;), whereby, effective March&#160;31, 2023, the Company received an exclusive license to develop and commercialize products for the CD47 immune checkpoint inhibitor to treat solid cancers, and companion diagnostics used to monitor treatment with CD47 products (collectively, &#8220;CD47 Products&#8221;), from Curis Biotech Holdings LLC, the parent company of Valetudo Therapeutics LLC (&#8220;Valetudo&#8221;), a related party of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Business Combination</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April&#160;30, 2025, the Company acquired Liminatus Pharma, LLC, a Delaware limited liability company (&#8220;Liminatus&#8221;). In connection with the closing of the Business Combination, pursuant to the Business Combination Agreement, dated as of November&#160;30, 2022 (as amended, the &#8220;Business Combination Agreement&#8221;), by and among the Company, Liminatus, Iris Acquisition Corp, a Delaware corporation (&#8220;Iris&#8221;), Liminatus Pharma Merger Sub,&#160;Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#8220;Liminatus Merger Sub&#8221;), and SPAC Merger Sub,&#160;Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#8220;SPAC Merger Sub&#8221;), (a)&#160;Liminatus Merger Sub merged with and into Liminatus, with Liminatus surviving as a direct wholly-owned subsidiary of the Company and (b)&#160;simultaneously, SPAC Merger Sub merged with and into Iris, with Iris surviving as a direct wholly-owned subsidiary of the Company (the transactions contemplated by the foregoing clauses (a)&#160;and (b), the &#8220;Business Combination&#8221;), and in connection therewith the Company changed its name from &#8220;Iris Parent Holding Corp.&#8221; to &#8220;Liminatus Pharma,&#160;Inc.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Business Combination Agreement, among other matters, at the effective time of the Business Combination (the &#8220;Effective Time&#8221;), (i)&#160;every issued and outstanding unit issued by Iris during its initial public offering (each, an &#8220;Iris Unit&#8221;) was automatically separated and broken out into its constituent parts and the holder thereof was deemed to hold one share of Iris Class&#160;A common stock, par value $0.0001 per share (the &#8220;Iris Class&#160;A Shares&#8221;) and one-fourth of one public warrant (the &#8220;Public Warrants&#8221;), and such underlying constituent securities of Iris were converted in accordance with the applicable terms of the Business Combination Agreement, (ii)&#160;at the Effective Time, each issued and outstanding Iris Class&#160;A Share was converted automatically into and thereafter represent the right to receive one share of Common Stock of the Company, following which all Iris Class&#160;A Shares ceased to be outstanding and were automatically canceled and ceased to exist, (iii)&#160;at the Effective Time, each issued and outstanding Public Warrant immediately and automatically represented the right to purchase shares of Common Stock on the same terms and conditions as are set forth in the applicable warrant agreement, (iv)&#160;at the Effective Time, each issued and outstanding non-redeemable warrant of Iris that was issued by Iris in a private placement at the time of the consummation of its initial public offering, entitling the holder thereof to purchase one Iris Class&#160;A Share at $11.50 per share, except those issued to Cantor Fitzgerald&#160;&amp; Co. (&#8220;Cantor&#8221;), were forfeited, and (v)&#160;the private placement warrants issued to Cantor (the &#8220;Private Warrants&#8221;) immediately and automatically represented the right to purchase shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At the closing of the Business Combination, pursuant to the terms of the Business Combination Agreement, the aggregate consideration paid in the transactions contemplated by the Business Combination Agreement to the direct or indirect owners of Liminatus consisted of 17.5 million shares of Common Stock (based on a deemed price of $10.00 per share of Common Stock).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Business Combination, pursuant to the terms of a subscription agreement with an accredited investor (the &#8220;PIPE Investor&#8221;), the Company issued and sold to the PIPE Investor, in a private placement closed concurrently with the closing of the Business Combination, 1,500,000 shares of Common Stock at $10.00 per share, for an aggregate purchase price of $15,000,000.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">1</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon the consummation of the Business Combination, the Iris Class&#160;A Shares, Iris Units and Public Warrants ceased trading on the OTC Pink Marketplace, and the Common Stock and Public Warrants began trading on Nasdaq under the trading symbols &#8220;LIMN&#8221; and &#8220;LIMNW,&#8221; respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain Recent Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">InnocsAI Merger Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May&#160;17, 2026, the Company entered into a Merger Agreement (as it may be amended, supplemented or otherwise modified from time to time, the &#8220;Merger Agreement&#8221;) with InnocsAI LLC, Delaware limited liability company (&#8220;InnocsAI&#8221;), and NamChul Jung, an individual, as the representative of the members of InnocsAI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Acquisition and Merger Consideration</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon the closing of the transactions contemplated in the Merger Agreement, and subject to the terms and conditions set forth therein, and in accordance with the applicable provisions of the Delaware General Corporation Law and the Delaware Limited Liability Company Act, InnocsAI will merge with an into a new wholly-owned Delaware subsidiary of the Company (&#8220;Merger Sub&#8221;), the separate corporate existence of InnocsAI will cease and Merger Sub will continue as the surviving corporation (the &#8220;Merger&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Merger Agreement, the aggregate consideration to be paid to existing members of InnocsAI is 1,600,000,000 shares of the Company&#8217;s common stock, at an issue price of $0.20 per share (the &#8220;Closing Payment Shares&#8221;), and contingent value rights to be agreed upon by the parties representing in the aggregate the right to receive 20% of net proceeds from any future strategic sale, out-license, transfer, or exit of the assets acquired from InnocsAI. Upon the effectiveness of the Merger, all issued and outstanding membership interests of InnocsAI will be canceled and automatically converted into the Closing Payment Shares. Valetudo Therapeutics LLC is a member of InnocsAI, and Chris Kim, the CEO and a director of the Company, is the CEO and controlling member of Valetudo Therapeutics&#160;LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Overview of Acquired Pipeline Assets</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The assets to be acquired in the Merger include a portfolio of oncology-focused biologic and cellular therapy programs. The portfolio is centered on CAR-T and antibody-related technologies designed to address certain limitations observed in current approaches to hematologic malignancies and solid tumors, including antigen escape, tumor heterogeneity, limited T-cell persistence, tumor microenvironment-mediated suppression, and lineage-restricted target coverage. The Company believes that these assets may provide development opportunities across hematologic oncology, solid tumor indications, and future multi-target platform applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">IBC101</b>. IBC101 is an autologous CD19xCD22 bivalent CAR-T cell therapy candidate designed for relapsed or refractory B-cell malignancies. The product is intended to function as an OR-gate CAR-T therapy, enabling recognition of malignant B cells expressing either CD19 or CD22. According to InnocsAI materials, IBC101 has received authorization from the Ministry of Food and Drug Safety of the Republic of Korea for a Phase 1/2a clinical study in relapsed or refractory diffuse large B-cell lymphoma, with Seoul St. Mary&#8217;s Hospital identified as the lead clinical site.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">IBC101 is designed to address antigen escape and tumor heterogeneity, which are recognized mechanisms of relapse following single-antigen CD19-directed CAR-T therapy. By combining CD19 and CD22 targeting, IBC101 is intended to broaden antigen coverage in B-cell malignancies. InnocsAI materials also describe an ex vivo expansion process using IL-7 and IL-15, with the goal of supporting T-cell fitness and persistence. If successfully developed, IBC101 could represent a next-generation hematologic CAR-T candidate with potential applicability in relapsed or refractory DLBCL and other B-cell malignancies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">INC101</b>. INC101 is a preclinical autologous bicistronic CAR-T cell therapy candidate for solid tumors based on a dual-antigen MSLNxCD276 design. The construct is designed as an AND-gate system in which mesothelin provides the primary tumor-associated activation signal and CD276, also known as B7-H3, provides a secondary costimulatory signal. This design is intended to improve tumor selectivity by requiring convergence of two tumor-associated signals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">The INC101 program is designed to address challenges that have limited CAR-T development in solid tumors, including on-target/off-tumor risk, antigen heterogeneity, tonic signaling, T-cell exhaustion, and tumor microenvironment-mediated suppression. InnocsAI materials describe a bicistronic architecture that separates activation and costimulation into two modules and incorporates engineering features intended to reduce signal leakage. A related follow-on construct, INC102, incorporates </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">2</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">a dominant-negative TGF-&#946; receptor armoring strategy intended to support T-cell function in TGF-&#946;-rich tumor microenvironments. The proposed development focus includes biomarker-selected solid tumors with mesothelin and CD276 expression, including malignant pleural mesothelioma, ovarian cancer, pancreatic cancer, and other selected solid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">CS1 Antibody Platform</b>. The CS1 antibody platform consists of proprietary anti-CS1 monoclonal antibodies intended to serve as an enabling module for InnocsAI&#8217;s hematologic CAR-T platform. Rather than being positioned primarily as a standalone CS1-directed CAR-T program, the CS1 binders are intended to be combined with the CD19xCD22 bivalent CAR-T backbone to support development of a potential CD19xCD22xCS1 trivalent CAR-T candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">This strategy is intended to extend the platform from B-cell malignancies into plasma-cell malignancies, including multiple myeloma. CD19 and CD22 are intended to provide coverage of B-cell leukemias and lymphomas, while CS1 is intended to add plasma-cell targeting capability. By integrating these targets into one trivalent CAR-T framework, InnocsAI may be able to bridge B-cell malignancy and plasma-cell malignancy targeting strategies and support broader hematologic oncology platform-development opportunities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Representations and Warranties</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Merger Agreement contains customary representations and warranties of the parties, except as provided in the Merger Agreement. Certain representations and warranties are qualified by materiality or Material Adverse Effect. &#8220;Material Adverse Effect&#8221; as used in the Merger Agreement means a material adverse change or a material adverse effect upon on the assets, liabilities, condition (financial or otherwise), prospects, net worth, management, earnings, cash flows, business, operations or properties of InnocsAI and its subsidiary (the &#8220;InnocsAI Group&#8221;) and the business of the InnocsAI Group, taken as a whole, whether or not arising from transactions in the ordinary course of business, subject to certain customary exceptions. Certain representations are subject to specified exceptions and qualifications contained in the Merger Agreement or in information provided pursuant to certain disclosure schedules to the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Conduct Prior to Closing; Covenants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each of InnocsAI and the Company has agreed to, and cause its subsidiaries to, operate its respective business in the ordinary course, consistent with past practices, and to refrain from taking certain specified actions without the prior written consent of certain other parties, in each case, subject to certain exceptions and qualifications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Merger Agreement also contains, among other things, covenants providing for:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each party not soliciting, initiating, encouraging or continuing discussions with any third party with respect to any merger, consolidation, business combination, or similar transaction, or any sale or transfer of a substantial portion of assets or equity interests, other than the transactions contemplated or permitted by the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each party not amending, modifying or supplementing its certificate of incorporation and bylaws or other organizational or governing documents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each party not paying, declaring or promising to pay any dividends or other distributions with respect to its capital stock or other equity securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each party not obtaining or incurring any loan or other indebtedness;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each party not merging or consolidating with or acquiring any other person or be acquired by any other person;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each party not issuing, redeeming or repurchasing any capital stock, membership interests or other securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each party providing access to their books and records and providing information relating to their respective businesses to the other party, its legal counsel and representatives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">InnocsAI delivering annual and interim financial statements; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">3</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">key personnel of InnocsAI entering into non-competition, non-solicitation and confidentiality agreements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company will prepare and file with the SEC a registration statement relating to the transactions contemplated by the Merger Agreement, registering the Closing Payment Shares to be issued under the Merger Agreement, which will also contain a proxy statement of the Company for the purpose of soliciting proxies from the Company&#8217;s stockholders for approval of certain matters related to the transactions contemplated by the Merger Agreement. InnocsAI will provide the Company with all reasonable information concerning the business of the InnocsAI Group and the management, operations and financial condition of the InnocsAI Group as is required by the SEC for inclusion in the registration statement, including, all financial statements required by relevant securities laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General Conditions to Closing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Consummation of the Merger is subject to customary closing conditions for similar transactions, including, among other things, (i)&#160;the Company and InnocsAI receiving approval from their respective stockholders and members to the transactions and (ii)&#160;the absence of injunctions or other legal restraints preventing or prohibiting the consummation of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The Company&#8217;s Conditions to Closing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The obligations of the Company to consummate the transactions contemplated by the Merger Agreement, in addition to the conditions described above, will be conditioned upon each of the following, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">InnocsAI complying with all of its obligations under the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the representations and warranties of InnocsAI being true on and as of the closing date of the transactions, other than as would not in the aggregate reasonably be expected to have a Material Adverse Effect;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there having been no occurrence of a Material Adverse Effect with respect to InnocsAI;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the key personnel of InnocsAI having entered into the non-compete agreements, and the Company having entered into labor agreements with its employees to the extent required by law; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company&#8217;s stockholders having approved the transactions contemplated by the Merger Agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">InnocsAI&#8217;s Conditions to Closing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The obligations of InnocsAI to consummate the transactions contemplated by the Merger Agreement, in addition to the conditions described above, will be conditioned upon each of the following, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company complying with all of their obligations under the Merger Agreement in all material respects; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the representations and warranties of the Company being true on and as of the closing date of the transactions, other than as would not in the aggregate reasonably be expected to have a material adverse effect with respect to the Company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Termination</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Merger Agreement may be terminated and/or abandoned at any time prior to the closing as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by mutual written consent of the Company and InnocsAI;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by either InnocsAI or the Company, in the event the Closing has not occurred by December&#160;31, 2026, provided the party seeking to terminate the agreement is not in material breach of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by either InnocsAI or the Company, in the event that any applicable authority has issued a final and non-appealable injunction or order making the Merger illegal or prohibiting their consummation;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">4</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by the Company, if InnocsAI has materially breached any representation, warranty, covenant or agreement set forth in the Merger Agreement and such breach has not been cured within 30&#160;days following the date that InnocsAI is notified in writing of such breach; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by InnocsAI, if the Company has materially breached any representation, warranty, covenant or agreement set forth in the Merger Agreement and such breach has not been cured within 30&#160;days following the date that the Company is notified in writing of such breach.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrant Inducement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Inducement Letter Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June&#160;3, 2026, we entered into the Inducement Letter Agreement with Armistice, which was a holder of certain warrants (the &#8220;Existing Warrants&#8221;) to purchase up to 10,344,000 shares of the Common Stock. The Existing Warrants were originally issued on February&#160;18, 2026, with an exercise price of $0.29 per share. Pursuant to the Inducement Letter Agreement, Armistice agreed to exercise the Existing Warrants for cash at a reduced exercise price of $0.18 per share in consideration for the Company&#8217;s agreement to issue the Inducement Warrants to purchase up to an aggregate of 20,688,000 shares of Common Stock at an exercise price per share of $0.18.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The issuance of the shares of Common Stock upon exercise of the Existing Warrants is registered pursuant to a registration statement on Form&#160;S-1 (File No.&#160;333-293364), which was declared effective by the Securities and Exchange Commission on February&#160;13, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We agreed to file a registration statement on Form&#160;S-3 (or other appropriate form if the Company is not then S-3 eligible) providing for the resale of the shares (the &#8220;Inducement Warrant Shares&#8221;) of Common Stock issuable upon the exercise of the Inducement Warrants (the &#8220;Resale Registration Statement&#8221;) on or before the 20th calendar day following the date of the closing of the exercise of the Existing Warrants (the &#8220;Closing Date&#8221;), and to use commercially reasonable efforts to cause the Resale Registration Statement to become effective within 50 calendar&#160;days following the Closing Date (or within 90 calendar&#160;days following the Closing Date in case of &#8220;full review&#8221; of such registration statement by the Commission).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Inducement Letter Agreement, except for certain exempt issuances set forth in the Inducement Letter Agreement, we agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any Common Stock or Common Stock equivalents or file any registration statement or any amendment or supplement to any existing registration statement, subject to certain exceptions (including in connection with the InnocsAI acquisition), until the earlier of 90&#160;days after the Closing Date and the date the Resale Registration Statement is declared effective by the SEC. In addition, from the date of the Inducement Letter Agreement until six (6)&#160;months following the Closing Date, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. &#8220;Variable Rate Transaction&#8221; means a transaction in which the Company (i)&#160;issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive, additional shares of Common Stock either (A)&#160;at a conversion price, exercise price or exchange rate or other price that is based upon, and/or varies with, the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities or (B)&#160;with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii)&#160;enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line of credit, whereby the Company may issue securities at a future determined price; provided, however, that after 45&#160;days following the Closing Date, the issuance of shares of Common Stock in an &#8220;at-the-market offering&#8221; shall not be deemed a Variable Rate Transaction.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">5</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We agreed to hold an annual or special meeting of stockholders on or prior to the date that is 90 days following the Closing Date for the purpose of obtaining stockholder approval of the exercise of the Inducement Warrants in accordance with the rules&#160;of The Nasdaq Stock Market LLC, and if necessary, the approval of the authorization for sufficient additional shares of Common Stock to allow for the exercise of the Inducement Warrants (&#8220;Stockholder Approval&#8221;), with the recommendation of our Board that such proposals be approved, and we shall solicit proxies from its stockholders in connection therewith in the same manner as all other management proposals in such proxy statement and all management-appointed proxyholders shall vote their proxies in favor of such proposals. If we do not obtain Stockholder Approval at the first meeting, we shall call a meeting every 90&#160;days thereafter to seek Stockholder Approval until the earlier of the date on which Stockholder Approval is obtained or the Inducement Warrants are no longer outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The aggregate gross proceeds to the Company from the exercise of the Existing Warrants was approximately $1,861,920, before deducting offering expenses payable by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financial Advisor Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Inducement Letter Agreement, on June&#160;3, 2026, we entered into a letter agreement (the &#8220;Financial Advisor Agreement&#8221;) with Maxim Group LLC (the &#8220;Financial Advisor&#8221;), pursuant to which (i)&#160;the Financial Advisor agreed to act as exclusive lead warrant solicitation agent on a &#8220;reasonable best efforts&#8221; basis in connection with the transactions contemplated by the Inducement Letter Agreement, and (ii)&#160;we agreed to pay the Financial Advisor an aggregate fee equal to 8.0% of the gross proceeds received by the Company from the exercise of the Existing Warrants. Additionally, we reimbursed the Financial Advisor for certain expenses and legal fees up to $15,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">6</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_ce713d5b_9036_41d9_ab6a_6175d978fb55"></a><a id="THEOFFERING_997853"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">THE OFFERING</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;table-layout:fixed;width:100%;"><tr><td style="width:134.9pt;padding:0pt;"/><td style="width:11pt;padding:0pt;"/><td style="width:394.1pt;padding:0pt;"/></tr><tr style="height:22.99pt;"><td style="vertical-align:top;width:134.9pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Stock Offered by the <br/>Selling Stockholder</p></td><td style="vertical-align:top;width:11pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:top;width:394.1pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Up to a maximum of 20,688,000 shares of Common Stock</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:134.9pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:394.1pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:34.49pt;"><td style="vertical-align:top;width:134.9pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Stock to be Outstanding <br/>after this Offering</p></td><td style="vertical-align:top;width:11pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:394.1pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">71,295,633 shares of Common Stock</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:134.9pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:394.1pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:34.49pt;"><td style="vertical-align:top;width:134.9pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Use of Proceeds</p></td><td style="vertical-align:top;width:11pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:394.1pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We will not receive any proceeds from the sale or other disposition of the Shares by the Selling Stockholder. However, we may receive aggregate gross proceeds of up to $3,723,840 only to the extent the Inducement Warrants are exercised for cash.</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:134.9pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:394.1pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:134.9pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trading Symbol</p></td><td style="vertical-align:top;width:11pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:394.1pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our common stock is currently trading on The Nasdaq Global Market under the symbol of &#8220;LIMN.&#8221;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:134.9pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:394.1pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:34.49pt;"><td style="vertical-align:top;width:134.9pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk Factors</p></td><td style="vertical-align:top;width:11pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:394.1pt;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">You should carefully consider the information set forth in this prospectus and, in particular, the specific factors set forth in the &#8220;Risk Factors&#8221; section beginning on page&#160;8 of this prospectus before deciding whether or not to invest in the Company&#8217;s common stock.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The number of shares of Common Stock to be outstanding immediately after this offering is based on 50,607,633 shares of Common Stock outstanding as of June&#160;23, 2026 and excludes as of that date:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7,915,500 shares of Common Stock issuable upon the exercise of common stock warrants at an exercise price of $0.29 per share; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5,094,598 shares of Common Stock issuable upon the exercise of public warrants at an exercise price of $11.50 per share;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">835,555 shares of Common Stock issuable upon the exercise of private placement warrants at an exercise price of $11.50 per share;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">690,650 shares of Common Stock issuable upon the exercise of placement agent warrants at an exercise price of $0.319 per share;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2,000,000 shares of Common Stock reserved for future issuance under the 2025 Omnibus Equity Incentive Plan.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Except as otherwise indicated herein, all information in this prospectus reflects or assumes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no exercise of the outstanding options and/or warrants described above.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">7</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_526a4545_4d34_458f_b3bd_8c64b0d21cc5"></a><a id="RISKFACTORS_921215"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">RISK FACTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">An investment in our securities involves a high degree of risk. You should carefully consider the risks described below before making an investment decision. In the course of conducting our business operations, we are exposed to a variety of risks. Any of the risk factors we describe below have affected or could materially adversely affect our business, prospects, financial condition and results of operations as could other risks not currently known to us or that we currently consider immaterial. The market price of shares of our Common Stock and the value of your Warrants could decline, possibly significantly or permanently, if one or more of these risks and uncertainties occurs, and, as a result, you may lose all or part of your investment.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Unless the context otherwise requires, all references in this subsection to &#8220;Liminatus,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to Liminatus Pharma, LLC prior to the consummation of the Business Combination and to Liminatus Pharma,&#160;Inc. and its consolidated subsidiaries following the Business Combination.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Liminatus&#8217;s Limited Operating History, Financial Condition and Capital Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus is in the early stages of pre-clinical drug development and has a limited operating history and no products approved for commercial sale, which may make it difficult for investors to evaluate its current business and predict its future success and viability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus is an early pre-clinical stage biopharmaceutical company with a limited operating history. Liminatus was formed in Delaware and commenced operations on April&#160;12, 2018. Therapeutic drug development is a highly speculative undertaking and involves a substantial degree of risk. To become and remain profitable, Liminatus must develop and eventually commercialize a product or products with significant market potential. This will require Liminatus to be successful in a range of challenging activities, including establishing its business model and key third-party relationships with payers, completing preclinical studies and clinical trials of its product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing, selling those products for which Liminatus may obtain marketing approval and satisfying any post-marketing requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus has no products approved for commercial sale and has not generated any revenue from commercial product sales. Its operations to date have been limited to performing research and development activities in support of its product development and licensing efforts, hiring personnel, raising capital to support and expand such activities, providing general and administrative support for these operations, developing potential product candidates, conducting preclinical studies and clinical trials, and entering into, and performing its obligations under, licensing arrangements that have resulted in additional product candidates in clinical development or commercialization by its licensees. All of its wholly owned programs are in preclinical or research development. Liminatus has not yet demonstrated its ability to successfully complete any large-scale pivotal clinical trials, obtain marketing approvals, manufacture a drug on a commercial scale or arrange for a third party to do so on its behalf, or conduct sales and marketing activities. In addition, none of Liminatus&#8217;s licensees has obtained marketing approvals for product candidates it has out-licensed. As a result, it may be more difficult for investors to accurately predict Liminatus&#8217;s future success or viability than it would be if Liminatus had a longer operating history.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, as a business with a limited operating history, Liminatus may encounter unforeseen expenses, difficulties, complications, delays, and other known and unknown factors and risks frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields. Liminatus also would need to transition from a company with a research and development focus to a company capable of supporting commercial activities after approval of any of its product candidates. Liminatus has not yet demonstrated an ability to successfully overcome such risks and difficulties, or to make such a transition. If it does not adequately address these risks and difficulties or successfully make such a transition, Liminatus&#8217;s business will suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus has incurred net losses since inception and expects to continue to incur significant net losses for the foreseeable future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus has incurred net losses since inception, has not generated any significant revenue to date, and has financed its operations prior to this business combination primarily through the issuance of bonds, warrants, common stock, proceeds from collaborative research and development and out-license agreements, certain non-dilutive funding sources, and borrowings under debt arrangements. Liminatus&#8217;s net loss was approximately $1.1 million for the three&#160;months ended March&#160;31, 2026, approximately $10.2 million for the&#160;year ended December&#160;31, 2025, and approximately $3.5 million for the&#160;year ended December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of March&#160;31, 2026, we had an accumulated deficit of $40.0 million. Liminatus&#8217;s internal programs are in preclinical or research development. As a result, Liminatus expects that it will be several&#160;years, if ever, before Liminatus generates revenue from product sales. Even if Liminatus succeeds in receiving marketing approval for and commercializing one or more of its product candidates, it expects </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">8</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">that it will continue to incur substantial research and development and other expenses in order to develop and market additional potential products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus&#8217;s financial statements for the three&#160;months ended March&#160;31, 2026 and audited financial statements for the&#160;year ended December&#160;31, 2025, included herein, have been prepared assuming it will continue as a going concern. As a development stage company, Liminatus expects to incur significant and increasing losses until regulatory approval is granted for a product candidate. Regulatory approval is not guaranteed and may never be obtained. As a result, these conditions raise substantial doubt about Liminatus&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus expects to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses Liminatus incurs may fluctuate significantly from quarter-to-quarter such that a period-to-period comparison of its results of operations may not be a good indication of its future performance. The size of Liminatus&#8217;s future net losses will depend, in part, on the rate of future growth of its expenses and its ability to generate revenue. Liminatus&#8217;s expected future losses will continue to have an adverse effect on its working capital and its ability to achieve and maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus has identified a material weakness in its internal control over financial reporting as of December&#160;31, 2025, which remains unremediated as of March&#160;31, 2026. If Liminatus is unable to develop and maintain an effective system of internal control over financial reporting, it may not be able to accurately report its financial results in a timely manner, which may adversely affect investor confidence in Liminatus and materially and adversely affect its business and operating results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus identified a material weakness in its internal control over financial reporting as of December&#160;31, 2025 related to its lack of: (i)&#160;a formalized control environment, (ii)&#160;oversite of controls over financial reporting, and (iii)&#160;segregation of duties. This material weakness remains unremediated at March&#160;31, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented, or detected and corrected on a timely basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective internal controls are necessary for us to provide reliable financial reports and prevent fraud. We continue to evaluate steps to remediate the identified material weaknesses. These remediation measures may be time consuming and costly and there is no assurance that these initiatives will ultimately have the intended effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we identify any new material weaknesses in the future, any such newly identified material weakness could limit our ability to prevent or detect a misstatement of our accounts or disclosures that could result in a material misstatement of our annual or interim financial statements. In such case, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting and our stock price may decline as a result. We cannot assure you that the measures we have taken to date, or any measures we may take in the future, will be sufficient to avoid potential future material weaknesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus has no products approved for commercial sale and have not generated any revenue from product sales.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus&#8217;s ability to become profitable depends upon our ability to generate revenue. To date, it has not generated any revenue from product sales, and it does not expect to generate any revenue from the sale of products in the near future. Liminatus&#8217;s business depends entirely on the successful development and commercialization of its product candidates. Liminatus currently generates no revenue from commercial sales of any products. Liminatus has no products approved for commercial sale and it does not anticipate generating any revenue from product sales unless and until sometime after it has successfully completed clinical development and received marketing approval for the commercial sale of a product candidate, if ever. Liminatus&#8217;s ability to generate revenue and achieve profitability depends significantly on its ability to achieve a number of objectives, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful and timely completion of preclinical and clinical development of current and any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely receipt of marketing approvals from applicable regulatory authorities for current and any future product candidates for which it successfully completes clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent of any required post-marketing approval commitments to applicable regulatory authorities;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">9</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing an efficient and scalable manufacturing process for current and any future product candidates, including establishing and maintaining commercially viable supply and manufacturing relationships with third parties to obtain finished products that are appropriately packaged for sale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful launch of commercial sales following any marketing approval, including the development of a commercial infrastructure, whether in-house or with one or more partners or collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a continued acceptable safety profile following any marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercial acceptance of current and any future product candidates as viable treatment options by patients, the medical community, and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing any competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying, assessing, acquiring, and developing new product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent protection, regulatory exclusivity, and other intellectual property-related protection, both in the United States and internationally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enforcing and defending Liminatus&#8217;s rights in its intellectual property portfolio, including its licensed intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negotiating favorable terms in any partnership, collaboration, licensing, or other arrangements that may be necessary to develop, manufacture, or commercialize its product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attracting, hiring, and retaining qualified personnel.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus may never be successful in achieving its objectives and, even if it does, may never generate revenue that is significant or large enough to achieve profitability. If it does achieve profitability, it may not sustain or increase profitability on a quarterly or annual basis. Liminatus&#8217;s failure to become and remain profitable would decrease the value of the company and could impair its ability to maintain or further its research and development efforts, raise additional necessary capital, grow its business, and/or continue its operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus will require substantial additional capital to finance its operations. If Liminatus is unable to raise such capital when needed, or on acceptable terms, it may be forced to delay, reduce, and/or eliminate one or more of its research and drug development programs or future commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive, and uncertain process that takes&#160;years to complete. Liminatus expects its expenses to increase in connection with its ongoing activities, particularly as it conducts clinical trials of, and seeks marketing approval for its product candidates. In addition, if it obtains marketing approval for any of its product candidates, Liminatus expects to incur significant commercialization expenses related to drug sales, marketing, manufacturing, and distribution. Liminatus also incurs additional costs associated with operating as a public company. Accordingly, Liminatus will need to obtain substantial additional funding in order to maintain its continuing operations. If Liminatus is unable to raise capital when needed or on acceptable terms, it may be forced to delay, reduce, and/or eliminate one or more of its research and drug development programs or future commercialization efforts. Changing circumstances, some of which may be beyond its control, could cause it to consume capital significantly faster than it currently anticipates, and Liminatus may need to seek additional funds sooner than planned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus plans to continue to use its cash on hand to fund the development of its CD47 immune checkpoint inhibitor and for other research and development activities, working capital, and other general corporate purposes. This may include additional research, hiring additional personnel, capital expenditures, and the costs of operating as a public company. Advancing the development of its current and any future product candidates will require a significant amount of capital. The cash and cash equivalents available to Liminatus are not sufficient to fund all of the actions that are necessary to complete the development of its product candidate. Liminatus will be required to obtain further funding through public or private equity offerings, debt financings, partnerships, collaborations, and licensing arrangements or other sources, which may dilute the Company&#8217;s stockholders or restrict its operating activities. Adequate additional financing may not be available on acceptable terms, or at all. Liminatus&#8217;s failure to raise capital as and when needed would have a negative impact on its financial condition and ability to pursue its business strategy.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">10</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">In order to successfully implement Liminatus&#8217;s plans and strategies, it will need to grow the size of its organization, and it may experience difficulties in managing this growth.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March&#160;31, 2026, Liminatus had one full-time employee, its CEO, Chris Kim. Liminatus also engaged advisors and several third-party contractors, including its CFO, Scott Dam, who were engaged in research and development activities. In order to successfully implement its development and commercialization plans and strategies, and as the Company continues operating as a public company, the Company expects to need additional managerial, operational, sales, marketing, financial, and other personnel. Future growth would impose significant added responsibilities on members of management, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying, recruiting, integrating, maintaining, and motivating additional employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">managing internal development efforts effectively, including the clinical and FDA and EMA review process for current and any future product candidates, while complying with any contractual obligations to contractors and other third parties Liminatus may have; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">improving operational, financial and management controls, reporting systems and procedures.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus&#8217;s future financial performance and its ability to successfully develop and, if approved, commercialize its current and any future product candidates will depend, in part, on its ability to effectively manage any future growth, and its management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus currently relies, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including substantially all aspects of clinical management and manufacturing. Liminatus cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to it on a timely basis when needed, or that it can find qualified replacements. In addition, if Liminatus is unable to effectively manage its outsourced activities or if the quality or accuracy of the services provided by third party service providers is compromised for any reason, Liminatus&#8217;s clinical trials may be extended, delayed or terminated, and it may not obtain marketing approval of its current and any future product candidates or otherwise advance its business. Liminatus cannot assure you that it will manage its existing third-party service providers or find other competent outside contractors and consultants on economically reasonable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If Liminatus is not able to effectively expand its organization by hiring new employees and/or engaging additional third-party service providers, it may not successfully implement the tasks necessary to further develop and commercialize its current and any future product candidates and, accordingly, may not achieve its research, development, and commercialization goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Discovery, Development, and Commercialization of Liminatus&#8217;s Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus is dependent on the success of its product candidates. If Liminatus is unable to obtain approval for and commercialize its product candidates for one or more indications in a timely manner, its business will be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus&#8217;s success is dependent on its ability to timely complete clinical trials and obtain marketing approval for, and then successfully commercialize, its product candidates for one or more indications. Liminatus&#8217;s product candidate is in the early stages of development and Liminatus is investing the majority of its efforts and financial resources in the research and development of its CD47 immune checkpoint inhibitor, both directly through its own efforts and indirectly through clinical collaboration arrangements, including investigator- and cooperative group-sponsored trials (&#8220;ISTs&#8221;). Liminatus&#8217;s product candidate will require additional clinical development, preclinical and manufacturing activities, marketing approval from government regulators, substantial investment, and significant marketing efforts before it generates any revenue from licensing arrangements. Liminatus is not permitted to market or promote any product candidates, in a jurisdiction before receiving marketing approval from the relevant regulatory authority, including, for example, the FDA for marketing in the United States and the European Medicines Agency (&#8220;EMA&#8221;) for marketing in the European Union, and it may never receive such marketing approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The success of Liminatus&#8217;s product candidate will depend on numerous factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful and timely completion of its ongoing preclinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation and successful patient enrollment and completion of clinical trials on a timely basis;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">11</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efficacy, safety and tolerability profiles that are satisfactory to the FDA, EMA or any comparable foreign regulatory authority for marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">raising additional funds necessary to complete the clinical development of and to commercialize product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely receipt of marketing approvals for product candidates from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent of any required post-marketing approval commitments to applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the maintenance of existing or the establishment of new supply arrangements with third-party drug product suppliers and manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the maintenance of existing or the establishment of new scaled production arrangements with third-party manufacturers to obtain finished products that are appropriately packaged for sale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">protection of Liminatus&#8217;s rights in its intellectual property portfolio, including its licensed intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful launch of commercial sales following any marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a continued acceptable safety profile following any marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercial acceptance by patients, the medical community, and third-party payors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liminatus&#8217;s ability to compete with other therapies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus does not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, including trial design, implementation, and timely provision of data in its collaboration based clinical trials and ISTs; potential threats to its intellectual property rights; and the manufacturing, marketing, distribution, and sales efforts of any future collaborator. If Liminatus is unable to achieve one or more of the objectives set forth above, its business will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of Liminatus&#8217;s clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus will be required to demonstrate with substantial evidence through well-controlled clinical trials that its product candidates are safe and effective for use in a diverse population before it can seek marketing approvals for their commercial sale. Preclinical and clinical testing is expensive and can take many&#160;years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the preclinical study and clinical trial processes, and, because Liminatus&#8217;s product candidates are in early stages of developments, there is a high risk of failure and Liminatus may never succeed in developing marketable products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The results of preclinical studies may not be predictive of the results of clinical trials of Liminatus&#8217;s product candidates. Moreover, the results of early clinical trials may not be predictive of the results of later-stage clinical trials. Although product candidates may demonstrate promising results in preclinical studies and early clinical trials, they may not prove to be safe or effective in subsequent clinical trials. Favorable results from certain animal studies may not accurately predict the results of other animal studies or of human trials, due to the inherent biologic differences in species, the differences between testing conditions in animal studies and human trials, and the particular goals, purposes, and designs of the relevant studies and trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There is typically an extremely high rate of attrition from the failure of product candidates proceeding through preclinical studies and clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. Likewise, early, smaller-scale clinical trials may not be predictive of eventual safety or effectiveness in large-scale pivotal clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">12</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy, insufficient durability of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence preclinical studies and clinical trials are never approved as products. The development of Liminatus&#8217;s product candidates and Liminatus&#8217;s stock price may also be impacted by inferences, whether correct or not, that are drawn between the success or failure of preclinical studies or clinical trials of Liminatus&#8217;s competitors or other companies in the biopharmaceutical industry, in addition to Liminatus&#8217;s own preclinical studies and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dose and dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. Patients treated with Liminatus&#8217;s product candidates may also be undergoing surgical, radiation and chemotherapy treatments and may be using other approved products or investigational new drugs, which can cause side effects or adverse events that are unrelated to Liminatus&#8217;s product candidates. As a result, assessments of efficacy can vary widely for a particular patient, and from patient to patient and site to site within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, Liminatus&#8217;s clinical trial outcomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any preclinical studies or clinical trials that Liminatus conducts may not demonstrate the safety and efficacy necessary to obtain regulatory approval to market its product candidates. If the results of Liminatus&#8217;s ongoing or future preclinical studies and clinical trials are inconclusive with respect to the safety and efficacy of its product candidates, if it does not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with its product candidates, Liminatus may be prevented or delayed in obtaining marketing approval for such product candidates. In some instances, there can be significant variability in safety or efficacy results between different preclinical studies and clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus does not know whether any preclinical studies or clinical trials it may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain approval to market any of its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus&#8217;s clinical trials may reveal serious adverse events, toxicities, or other side effects of its current and any future product candidates that result in a safety profile that could inhibit regulatory approval or market acceptance of its product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In order to obtain marketing approval for its current or any future product candidates, Liminatus must demonstrate the safety and efficacy of the product candidate for the relevant clinical indication or indications through preclinical studies and clinical trials as well as additional supporting data. If Liminatus&#8217;s product candidates are associated with undesirable side effects in preclinical studies or clinical trials, or have unexpected characteristics, it may need to interrupt, delay, or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe, or more acceptable from a risk-benefit perspective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although Liminatus has conducted various preclinical studies and has data from various early-stage clinical trials, it does not know the predictive value of these studies and trials for future clinical trials, and it cannot guarantee that any positive results in preclinical studies or previous clinical trials will successfully translate to patients in its future clinical trials. It is not uncommon to observe results in clinical trials that are unexpected based on preclinical testing or previous clinical trials, and many product candidates fail in clinical trials despite promising preclinical or early-stage clinical results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Liminatus expects that subjects in its future clinical trials for its product candidates may suffer adverse events (&#8220;AEs&#8221;), series adverse events (&#8220;SAEs&#8221;) or other side effects, including those not observed in its preclinical studies or previous clinical trials. Results of these trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by Liminatus&#8217;s product candidates could result in the delay, suspension, or termination of clinical trials by Liminatus or the FDA, EMA or comparable foreign regulatory authority for a number of reasons. Additionally, a number of the subjects in these clinical trials are expected to die during a trial due to the cancers they suffer and any of the treatment regimens they may have previously experienced, which could impact the development of Liminatus&#8217;s product candidates. If Liminatus elects or is required to delay, suspend, or terminate any clinical trial, the commercial prospects of its product candidates will be harmed and its ability to generate product revenue from this product candidate will be delayed or eliminated. SAEs observed in clinical trials could hinder or prevent market acceptance of its drug </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">13</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">candidates. Any of these occurrences may harm Liminatus&#8217;s business, prospects, financial condition, and results of operations significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even in circumstances in which Liminatus does not believe that an AE is related to its product candidates, the investigation into the circumstances of such AE may be time-consuming or inconclusive. In particular, patients may face serious medical issues associated with the underlying cancer indications that Liminatus&#8217;s product candidates target, as well as AEs from toxicities and other complications related to other study drugs administered alongside or in combination with its product candidates in clinical trials. As a result, while not directly associated with its product candidates, there are attendant risks with the space in which its product candidates operate, and any related investigations may interrupt its development and commercialization efforts, delay its regulatory approval process or impact and limit the type of regulatory approvals its product candidates receive or maintain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If SAEs or other side effects are observed in any of Liminatus&#8217;s clinical trials, it may have difficulty recruiting patients to future clinical trials, patients may discontinue treatment or withdraw from its trials or it may be required to abandon the trials or its development efforts of that product candidate altogether. Liminatus, the FDA, the EMA, other applicable regulatory authorities or an Institutional Review Board (&#8220;IRB&#8221;)/Ethics Committee may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage studies have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude a drug from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm Liminatus&#8217;s business, financial condition, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, if any of Liminatus&#8217;s product candidates obtain marketing approval, toxicities associated with its product candidates may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional warnings being added to the labeling, significant restrictions on the use of the product, or the withdrawal of the product from the market. Liminatus cannot predict whether its product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on preclinical studies or early-stage clinical testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Liminatus experiences delays or difficulties in the enrollment of patients in clinical trials, its receipt of necessary marketing approvals could be delayed or prevented.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus may not initiate, continue or complete clinical trials for its product candidates if it is unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA, EMA, or comparable foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patient enrollment is a significant factor in the timing of clinical trials, and Liminatus&#8217;s ability to enroll eligible patients may be limited or may result in slower enrollment than it anticipates. Patient enrollment may also be affected by other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">size and nature of the patient population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability and efficacy of approved drugs for the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient eligibility criteria for the trial in question;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efforts to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient referral practices of physicians;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and patients&#8217; awareness of, and perceptions as to the potential advantages and risks of, Liminatus&#8217;s product candidates in relation to other available therapies, including any new drugs that may be approved for the indications it is investigating;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to monitor patients adequately during and after treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing ongoing clinical trials for the same indications as Liminatus&#8217;s product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">14</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proximity and availability of clinical trial sites for prospective patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether Liminatus becomes subject to a partial or full clinical hold on any of its clinical trials; and continued enrollment of prospective patients by clinical trial sites, including delays due to pandemics, wars etc. that can impact patient willingness to participate and travel for investigative therapy and reductions in clinical trial site staff and services.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus&#8217;s inability to enroll a sufficient number of patients for its clinical trials would result in significant delays or may require it to abandon one or more of its clinical trials altogether. Enrollment delays in Liminatus&#8217;s clinical trials may result in increased development costs for its product candidates and jeopardize its ability to obtain marketing approval for the sale of its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus&#8217;s clinical trials may reveal serious adverse events, toxicities, or other side effects of its current and any future product candidates that result in a safety profile that could inhibit regulatory approval or market acceptance of its product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In order to obtain marketing approval for its current or any future product candidates, Liminatus must demonstrate the safety and efficacy of the product candidate for the relevant clinical indication or indications through preclinical studies and clinical trials as well as additional supporting data. If Liminatus&#8217;s product candidates are associated with undesirable side effects in preclinical studies or clinical trials, or have unexpected characteristics, it may need to interrupt, delay, or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe, or more acceptable from a risk-benefit perspective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although Liminatus has conducted various preclinical studies and has data from various early-stage clinical trials, it does not know the predictive value of these studies and trials for future clinical trials, and it cannot guarantee that any positive results in preclinical studies or previous clinical trials will successfully translate to patients in its future clinical trials. It is not uncommon to observe results in clinical trials that are unexpected based on preclinical testing or previous clinical trials, and many product candidates fail in clinical trials despite promising preclinical or early-stage clinical results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus expects that subjects in its future clinical trials for its product candidates may suffer adverse events (&#8220;AEs&#8221;), series adverse events (&#8220;SAEs&#8221;) or other side effects, including those not observed in its preclinical studies or previous clinical trials. Results of these trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by Liminatus&#8217;s product candidates could result in the delay, suspension, or termination of clinical trials by Liminatus or the FDA, EMA or comparable foreign regulatory authority for a number of reasons. Additionally, a number of the subjects in these clinical trials are expected to die during a trial due to the cancers they suffer and any of the treatment regimens they may have previously experienced, which could impact the development of Liminatus&#8217;s product candidates. If Liminatus elects or is required to delay, suspend, or terminate any clinical trial, the commercial prospects of its product candidates will be harmed and its ability to generate product revenue from this product candidate will be delayed or eliminated. SAEs observed in clinical trials could hinder or prevent market acceptance of its drug candidates. Any of these occurrences may harm Liminatus&#8217;s business, prospects, financial condition, and results of operations significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even in circumstances in which Liminatus does not believe that an AE is related to its product candidates, the investigation into the circumstances of such AE may be time-consuming or inconclusive. In particular, patients may face serious medical issues associated with the underlying cancer indications that Liminatus&#8217;s product candidates target, as well as AEs from toxicities and other complications related to other study drugs administered alongside or in combination with its product candidates in clinical trials. As a result, while not directly associated with its product candidates, there are attendant risks with the space in which its product candidates operate, and any related investigations may interrupt its development and commercialization efforts, delay its regulatory approval process or impact and limit the type of regulatory approvals its product candidates receive or maintain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If SAEs or other side effects are observed in any of Liminatus&#8217;s clinical trials, it may have difficulty recruiting patients to future clinical trials, patients may discontinue treatment or withdraw from its trials or it may be required to abandon the trials or its development efforts of that product candidate altogether. Liminatus, the FDA, the EMA, other applicable regulatory authorities or an Institutional Review Board (&#8220;IRB&#8221;)/Ethics Committee may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage studies have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude a drug from obtaining or maintaining marketing </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">15</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm Liminatus&#8217;s business, financial condition, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, if any of Liminatus&#8217;s product candidates obtain marketing approval, toxicities associated with its product candidates may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional warnings being added to the labeling, significant restrictions on the use of the product, or the withdrawal of the product from the market. Liminatus cannot predict whether its product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on preclinical studies or early-stage clinical testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Liminatus experiences delays or difficulties in the enrollment of patients in clinical trials, its receipt of necessary marketing approvals could be delayed or prevented.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus may not initiate, continue or complete clinical trials for its product candidates if it is unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA, EMA, or comparable foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patient enrollment is a significant factor in the timing of clinical trials, and Liminatus&#8217;s ability to enroll eligible patients may be limited or may result in slower enrollment than it anticipates. Patient enrollment may also be affected by other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">size and nature of the patient population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability and efficacy of approved drugs for the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient eligibility criteria for the trial in question;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efforts to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient referral practices of physicians;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and patients&#8217; awareness of, and perceptions as to the potential advantages and risks of, Liminatus&#8217;s product candidates in relation to other available therapies, including any new drugs that may be approved for the indications it is investigating;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to monitor patients adequately during and after treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing ongoing clinical trials for the same indications as Liminatus&#8217;s product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proximity and availability of clinical trial sites for prospective patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether Liminatus becomes subject to a partial or full clinical hold on any of its clinical trials; and continued enrollment of prospective patients by clinical trial sites, including delays due to pandemics, wars etc. that can impact patient willingness to participate and travel for investigative therapy and reductions in clinical trial site staff and services.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus&#8217;s inability to enroll a sufficient number of patients for its clinical trials would result in significant delays or may require it to abandon one or more of its clinical trials altogether. Enrollment delays in Liminatus&#8217;s clinical trials may result in increased development costs for its product candidates and jeopardize its ability to obtain marketing approval for the sale of its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The clinical trials of Liminatus&#8217;s current and any future product candidates may not demonstrate safety and efficacy to the satisfaction of regulatory authorities or otherwise be timely conducted or produce positive results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Before obtaining marketing approval from regulatory authorities for the sale of its product candidates, Liminatus must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of its product candidates. Clinical testing is expensive, difficult to design and implement, can take many&#160;years to complete, and its ultimate outcome is uncertain. A failure of one or more clinical trials can occur at any stage of the process. The outcome of preclinical studies and early-stage clinical </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">16</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus does not know whether its future clinical trials will begin on time or enroll patients on time, or whether its ongoing and/or future clinical trials will be completed on schedule or at all. Clinical trials can be delayed for a variety of reasons, including delays related to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining regulatory approval to commence a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching, or the inability to reach, agreement on acceptable terms with prospective CROs, clinical trial sites, laboratory service providers, companion diagnostic development partners, contract manufacturing organizations (CMOs), and other service providers Liminatus may engage to support the conduct of its clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining IRB approval at each clinical trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recruiting a sufficient number of suitable patients to participate in a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients failing to comply with trial protocol or dropping out of a trial, rendering them not evaluable for study endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trial sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of any applicable combination therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments in the safety and efficacy of any applicable combination therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the need to add new clinical trial sites; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in the testing, validation and manufacturing of product candidates and the delivery of these product candidates to clinical trial sites.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent receipt of marketing approval or its ability to commercialize its product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of feedback from regulatory authorities that requires Liminatus to modify the design of its clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negative or inconclusive clinical trial results that may require Liminatus to conduct additional clinical trials or abandon certain drug development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators or IRBs may not authorize Liminatus, its collaborators, or its investigators to commence a clinical trial or to conduct a clinical trial at a prospective site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients required for clinical trials being larger than anticipated, enrollment in these clinical trials being slower than anticipated, or participants dropping out of these clinical trials at a higher rate than anticipated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party contractors failing to comply with regulatory requirements or meet their contractual obligations to Liminatus in a timely manner, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the suspension or termination of Liminatus&#8217; clinical trials for various reasons, including non-compliance with regulatory requirements, a finding that Liminatus&#8217;s product candidates have undesirable side effects, safety or efficacy concerns, or any particular combination therapy or other unexpected characteristics or risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical trials of Liminatus&#8217;s product candidates being greater than anticipated;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">17</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for clinical trials testing combination treatment of Liminatus&#8217;s product candidates with third-party drug products, delays in procuring such third-party drug products and the delivery of such third-party drug products to clinical trial sites, or the inability to procure such third-party drug products at all; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators revising the requirements for approving Liminatus&#8217;s product candidates, including as a result of newly approved agents changing the standard of care of an indication.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any unforeseen events may cause Liminatus to be required to conduct additional clinical trials or other testing of Liminatus&#8217;s product candidates beyond those that it currently contemplates, or to be unable to successfully complete clinical trials of Liminatus&#8217;s product candidates or other testing. Clinical trial or test results may also not be positive or may be only modestly positive or may have safety concerns. Any of the foregoing events may cause us to incur unplanned costs, be delayed in obtaining marketing approval, if ever, receive more limited or restrictive marketing approval, be subject to additional post-marketing testing requirements, or have the drug removed from the market after obtaining marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The outcome of preclinical testing and early clinical trials that Liminatus obtains and that it publishes may not be predictive of the success of later clinical trials, and the results of its clinical trials may not satisfy the requirements of the FDA, EMA, or comparable foreign regulatory authorities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus currently has no products approved for sale and it cannot guarantee that it will ever have marketable drugs. Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and Liminatus or any future collaborators may decide, or regulators may require it, to conduct additional clinical trials or preclinical studies. Liminatus will be required to demonstrate with substantial evidence through well-controlled clinical trials that its product candidates are safe and effective for use in a diverse population before it can seek marketing approvals for their commercial sale. Success in preclinical studies and early-stage clinical trials does not mean that future larger registration clinical trials will be successful. This is because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA, EMA, and other regulatory authorities despite having progressed through preclinical studies and early-stage clinical trials. In addition, the outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later-stage clinical trials. Liminatus does not know whether any clinical trials it may conduct will demonstrate consistent or adequate efficacy and safety results sufficient to obtain marketing approval to market its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Summary or preliminary data from Liminatus&#8217;s clinical trials that it announces or publishes may change as new or revised patient data becomes available, and is subject to source verification procedures that could result in material changes in the final data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As more patient data becomes available, Liminatus may publicly disclose new or revised preliminary data from its clinical trials. These preliminary updates are based on analyses of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. Liminatus also makes assumptions, estimations, calculations and conclusions as part of its analyses of data, and it may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the summary or preliminary results that Liminatus reports may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data has been received and fully evaluated. Summary or preliminary data also remains subject to source verification procedures that may result in the final data being materially different from the summary or preliminary data previously published. As a result, summary or preliminary data should be viewed with caution until the final data are available. In addition, Liminatus may report interim analyses of only certain endpoints rather than all endpoints. Preliminary data from clinical trials that Liminatus conducts may not be indicative of the final results of the trials and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse changes between preliminary data and final data could significantly harm Liminatus&#8217;s business and prospects. Further, additional disclosure of preliminary data by Liminatus or by its competitors in the future could result in volatility in the price of Liminatus&#8217;s Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Further, others, including regulatory agencies, may not accept or agree with Liminatus&#8217;s assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate, and Liminatus&#8217;s in general. In addition, the information Liminatus chooses to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. Interested parties may not agree with what Liminatus determines is the material or otherwise appropriate information to include in its disclosure, and any information Liminatus determines not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities, or otherwise regarding a particular product candidate or its business. If the preliminary or topline data that Liminatus reports differs from late, final or actual results, or if others, including regulatory </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">18</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">authorities, disagree with the conclusions reached, Liminatus&#8217;s ability to obtain approval for, and commercialize, its product candidates may be harmed, which could harm its business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dosing regimen and other trial protocols, use in combination with other therapies, and the rate of discontinuations by clinical trial participants. In addition, Liminatus may use patient-reported outcome assessments in some of its clinical trials, which involve patients&#8217; subjective assessments of efficacy of the treatments they receive in the trial. Such assessments can vary widely from day to day for a particular patient, and from patient to patient and site to site within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, Liminatus&#8217;s clinical trial outcomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA, EMA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If Liminatus is ultimately unable to obtain regulatory approval of its product candidates, Liminatus will be unable to generate product revenue and its business will be substantially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus&#8217;s product candidates are and will continue to be subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process must be successfully completed in the United States and in many foreign jurisdictions before a new drug can be approved for marketing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Obtaining approval by the FDA, EMA and other comparable foreign regulatory authorities is unpredictable, typically takes many&#160;years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. For example, FDA&#8217;s Oncology Center of Excellence initiated Project Optimus to reform the dose optimization and dose selection paradigm in oncology drug development and Project FrontRunner to help develop and implement strategies to support approvals in early clinical setting, among other goals. How the FDA plans to implement these goals and their impact on specific clinical programs and the industry are unclear. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that Liminatus&#8217;s data are insufficient for approval and require additional preclinical, clinical or other data. Even if Liminatus eventually completes clinical testing and receives approval for Liminatus&#8217;s product candidates, the FDA, EMA and other comparable foreign regulatory authorities may approve its product candidates for a more limited indication or a narrower patient population than it originally requested or may impose other prescribing limitations or warnings that limit the product candidate&#8217;s commercial potential. Liminatus has not submitted for, or obtained, regulatory approval for any product candidate, and it is possible that none of its product candidates will ever obtain regulatory approval. Further, development of Liminatus&#8217;s product candidates and/or regulatory approval may be delayed for reasons beyond its control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Applications for Liminatus&#8217;s product candidates could fail to receive regulatory approval for many reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, EMA or other comparable foreign regulatory authorities may disagree with the design, implementation or results of Liminatus&#8217;s clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, EMA or other comparable foreign regulatory authorities may determine that Liminatus&#8217;s product candidates are not safe and effective, are only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude its obtaining marketing approval or prevent or limit commercial use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which Liminatus seeks approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, EMA or other comparable foreign regulatory authorities may disagree with Liminatus&#8217;s interpretation of data from preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liminatus may be unable to demonstrate to the FDA, EMA or other comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">19</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, EMA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which Liminatus contracts for clinical and commercial supplies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, EMA or other comparable regulatory authorities may fail to approve companion diagnostic tests required for Liminatus&#8217;s product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA, EMA or other comparable foreign regulatory authorities may significantly change in a manner rendering Liminatus&#8217;s clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in Liminatus failing to obtain regulatory approval to market any of its product candidates, which would significantly harm its business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus is also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries, and generally includes all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus&#8217;s product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors, and others in the medical community necessary for commercial success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if Liminatus&#8217;s product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, healthcare payors, and others in the medical community. For example, current standard-of-care cancer treatments, such as existing chemotherapy and radiation therapy, are well established in the medical community, and doctors may continue to rely on these treatments. The degree of market acceptance of any of Liminatus&#8217;s approved product candidates, if approved for commercial sale, will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and safety profile as demonstrated in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of market introduction of the product candidate as well as competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval of other new therapies for the same indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which the product candidate is approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the use of Liminatus&#8217;s products, if approved, such as boxed warnings, contraindications in labeling, or restrictions on use of Liminatus&#8217;s products together with other medications, or a risk evaluation and mitigation strategy (REMS), if any, which may not be required of alternative treatments and competitor products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential and perceived advantages of product candidates over alternative treatments or in combination therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of treatment in relation to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of coverage and adequate reimbursement and pricing by third parties and government authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relative convenience and ease of administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of sales and marketing efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target population to try new therapies and of physicians to prescribe these therapies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unfavorable publicity relating to the product candidate.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">20</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors, and patients, Liminatus may generate less revenue from that product candidate than anticipated, which could harm its financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The sizes of the patient populations suffering from some of the diseases Liminatus is targeting may be based on estimates that are inaccurate, may be small, or may be smaller than estimated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus relies on estimates to project the incidence and prevalence of diseases it is targeting and the subset of patients with these diseases who have the potential to benefit from treatment with its product candidates. Liminatus derives these estimates from a variety of sources, including United States and global cancer databases, scientific literature, surveys of clinics, physician interviews, patient foundations, and market research, and they may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for its product candidates may be more limited than Liminatus originally estimated or may not be amenable to treatment with its product candidates, if and when approved. Even if Liminatus obtains significant market share for its product candidates, small potential target populations for certain indications means it may never achieve profitability without obtaining market approval for additional indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Many of Liminatus&#8217;s additional internal programs and our CD&#160;47 immune checkpoint inhibitor are at early stages of development and may fail in development or suffer delays that adversely affect their commercial viability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All of Liminatus&#8217;s internal programs are in preclinical development or at the research stage and may fail in development or suffer delays that adversely affect their commercial viability. These programs may fail to yield product candidates. A product candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for product candidates is high due to risks relating to safety, efficacy, clinical execution, changing standards of medical care, and other unpredictable variables. The results from preclinical testing or early clinical trials of a product candidate may not be predictive of the results that will be obtained in later-stage clinical trials of the product candidate. The success of any product candidates Liminatus may develop will depend on many factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">generating sufficient data to support the initiation or continuation of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining regulatory permission to initiate clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">contracting with the necessary parties to conduct clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the successful enrollment of patients in, and the completion of, clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timely manufacture of sufficient quantities of the product candidate, and any combination therapy, for use in clinical trials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptable adverse profile in the clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if Liminatus successfully advances any other product candidates into clinical development, their success will be subject to all of the clinical, regulatory and commercial risks described elsewhere in this &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; section. Accordingly, Liminatus cannot assure you that it will ever develop, obtain regulatory approval of, commercialize, or generate significant revenue from any product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any product candidates Liminatus develops may become subject to unfavorable third-party reimbursement practices and pricing regulations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The availability and extent of coverage and adequate reimbursement by governmental and private payors is essential for most patients to afford the expense of therapeutics like our CD47 immune checkpoint inhibitor. Sales of any of Liminatus&#8217;s product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of its product candidates will be paid by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations or reimbursed by government health administration authorities, private health coverage insurers, and other third-party payors. If reimbursement is not available, or is available only to limited levels, Liminatus may not successfully commercialize its product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which Liminatus obtains marketing approval. If coverage and reimbursement are not available or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">21</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">reimbursement is available only to limited levels, Liminatus may not successfully commercialize any product candidate for which it obtains marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There is significant uncertainty related to insurance coverage and reimbursement of newly approved products. In the United States, principal decisions about reimbursement for new products are typically made by Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;), an agency within the U.S. Department of Health and Human Services (&#8220;HHS&#8221;). CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. As a result, the coverage determination process is often time-consuming and costly. This process will require Liminatus to provide scientific and clinical support for the use of its products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Increasingly, third-party payors require that drug companies provide them with predetermined discounts from list prices and challenge the prices charged for medical products. Further, such payors increasingly challenge the price, examine the medical necessity and review the cost effectiveness of medical drug products. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific drug products on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. Liminatus may need to conduct expensive studies to demonstrate the medical necessity and cost-effectiveness of its products. Nonetheless, Liminatus&#8217;s product candidates may not be considered medically necessary or cost effective. Liminatus cannot be sure that coverage and reimbursement will be available for any product that it commercialize and, if reimbursement is available, what the level of reimbursement will be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and Liminatus believes the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as its product candidates. In many countries, particularly the countries of the European Union, medical product prices are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing approval. To obtain reimbursement or pricing approval in some countries, Liminatus may be required to conduct a clinical trial that compares the cost-effectiveness of its product candidate to other available therapies. In general, product prices under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products, but monitor and control company profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additional foreign price controls or other changes in pricing regulation could restrict the amount that Liminatus is able to charge for its product candidates. Accordingly, in markets outside the United States, the reimbursement for its products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If Liminatus is unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates. Coverage policies and third-party reimbursement rates may change at any time. Even if Liminatus attains favorable coverage and reimbursement status for one or more products for which it receives regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Liminatus&#8217;s competitors develop and market products that are more effective, safer, or less expensive than Liminatus&#8217;s product candidates, its commercial opportunities will be negatively impacted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The biotechnology industry is highly competitive and subject to rapid and significant technological change. Moreover, the oncology field is characterized by strong and increasing competition, with a strong emphasis on intellectual property. Products Liminatus may develop in the future for the treatment of cancer and any other diseases are likely to face competition from other drugs and therapies, including those of which Liminatus may not currently be aware. In addition, Liminatus&#8217;s products may need to compete with off-label drugs used by physicians to treat the indications for which Liminatus seeks approval. This may make it difficult for Liminatus to replace existing therapies with its products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Major multinational pharmaceutical and biotechnology companies, emerging and start-up companies, universities, and other research institutions, could focus their future efforts on developing competing therapies and treatments for any of the indications Liminatus is currently targeting or may target in the future. Many of these current and potential competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources, and commercial expertise than Liminatus does. Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">22</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">recruiting patients, and manufacturing biotechnology products. These companies also have significantly greater research, development, and marketing capabilities than Liminatus does and may also have products that have been approved or are in late stages of development, and collaborative arrangements in Liminatus&#8217;s target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that Liminatus develops obsolete. As a result of any of these factors, Liminatus&#8217;s competitors may succeed in obtaining approval from the FDA, EMA, or foreign regulatory authorities or discovering, developing, and commercializing products in Liminatus&#8217;s field before or more successfully than it does.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These companies compete with Liminatus in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for planned clinical trials, as well as in acquiring technologies complementary to, or necessary for, its programs. In addition, the biotechnology industry is characterized by rapid technological change. If Liminatus fails to stay at the forefront of technological change, it may be unable to compete effectively. Technological advances or products developed by Liminatus&#8217;s competitors may render its technologies or product candidates obsolete, less competitive or not economical.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus has limited resources and is currently focusing its efforts on developing the CD47 immune checkpoint inhibitor. As a result, Liminatus may fail to capitalize on other product candidates or indications that may ultimately have proven to be more profitable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus is currently focusing its efforts on developing the CD47 immune checkpoint inhibitor. As a result, Liminatus may forego or delay pursuit of opportunities for other indications or with other product candidates that may have greater commercial potential. Liminatus&#8217;s resource allocation decisions may cause it to fail to capitalize on viable product candidates or profitable market opportunities. Liminatus&#8217;s spending on current and future research and development activities for specific indications may not yield any commercially viable drugs. If Liminatus does not accurately evaluate the commercial potential or target markets for a particular product candidate, it may relinquish valuable rights to that product candidate through collaboration, licensing, or other strategic arrangements in cases in which it would have been more advantageous for Liminatus to retain sole development and commercialization rights to such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus may not succeed in its efforts to expand its pipeline of product candidates and develop marketable products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because Liminatus has limited financial and managerial resources, it focuses its pipeline research and development efforts to develop its product candidates. Liminatus&#8217;s business depends on its successful development and commercialization of the CD47 immune checkpoint inhibitor, and internal product candidates that may emerge from its preclinical research and development activities. Even if it continues to successfully expand its pipeline, development of the potential product candidates that Liminatus identifies will require substantial investment in clinical development, management of preclinical, clinical, and manufacturing activities, regulatory approval in multiple jurisdictions, obtaining manufacturing supply capability, building a commercial organization, and significant marketing efforts before Liminatus generates any revenue from product sales. Furthermore, such product candidates may not be suitable for clinical development, including as a result of their harmful side effects, limited efficacy, or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If Liminatus cannot successfully develop and commercialize its product candidates based upon its approach, it may not obtain product or partnership revenue in future periods, which would adversely affect its business, prospects, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus is developing some of its product candidates for use in combination with standard-of-care as well as emerging or experimental cancer therapies, which exposes it to several risks beyond its control.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus is developing some of its product candidates, including the CD47 immune checkpoint inhibitor, for use in combination with current standard of care or other emerging or experimental cancer therapies. This exposes Liminatus to supply risk to the extent there is not an adequate supply of these therapies for use in combination with its product candidates, either in clinical trials or after any approval, as well as pricing risk if these combination therapies are expensive and the addition of its product candidates would be too costly to support reimbursement or payor coverage. In particular, providers of some of these emerging or experimental therapies have been contributing their therapies to use in combination trials at generally no or limited cost to Liminatus. If this were to change, Liminatus&#8217;s trial costs could increase substantially. Also, although combinations with an experimental agent that has not been approved may prove to be clinically beneficial, the experimental agent will still need to meet regulatory approval requirements for the combined therapy to become commercially available. In addition, if the standard of care were to evolve or change, the clinical utility of Liminatus&#8217;s product candidates could be diminished or eliminated. If any of these were to occur, Liminatus&#8217;s business could be materially harmed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">23</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus may use companion diagnostics in the future in its development programs, and if such companion diagnostics for its product candidates are not successfully, and in a timely manner, validated, developed, or approved, Liminatus may not achieve marketing approval or realize the full commercial potential of its product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus may use companion diagnostics in its future product candidate development programs. If such companion diagnostics are developed in conjunction with clinical programs, the FDA, EMA, or comparable regulatory authority may require regulatory approval of a companion diagnostic as a condition to approval of the product candidate. For example, if Liminatus uses a diagnostic to test which patients are most likely to benefit from its product candidate for the treatment of a particular indication as a criterion for enrollment, then it will likely be required to obtain FDA approval or clearance of the companion diagnostic, concurrent with approval of its product candidate. Liminatus may also be required to demonstrate to the FDA the predictive utility of a companion diagnostic,&#160;<i style="font-style:italic;">i.e.</i>, that the diagnostic selects for patients in whom the therapy will be effective or more effective compared to patients not selected for by the diagnostic. Liminatus does not have experience or capabilities in developing or commercializing diagnostics and plan to rely in large part on third parties to perform these functions. Liminatus does not currently have any agreement in place with any third party to develop or commercialize companion diagnostics for any of its product candidates. Companion diagnostics are subject to regulation by the FDA, the EMA, and other foreign regulatory authorities as medical devices and require separate regulatory approval or clearance prior to commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If Liminatus or its partners, or any third party, are unable to successfully develop companion diagnostics in the future in its product candidates, or experience delays in doing so:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the development of Liminatus&#8217;s product candidates may be adversely affected if it is unable to appropriately select patients for enrollment in its planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liminatus&#8217;s product candidates may not receive marketing approval if their safe and effective use depends on a companion diagnostic; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liminatus may not realize the full commercial potential of any product candidates that receive marketing approval if, among other reasons, it is unable to appropriately identify patients targeted by its product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, any future product candidates developed in conjunction with companion diagnostics may be perceived negatively compared to alternative treatments that do not require the use of companion diagnostics, either due to the additional cost of the companion diagnostic, the requirement of samples for testing, or the need to complete additional procedures to identify genetic markers prior to administering Liminatus&#8217;s product candidates. If any of these events were to occur, it would significantly harm Liminatus&#8217;s business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus&#8217;s business entails a significant risk of product liability, and if Liminatus is unable to obtain sufficient insurance coverage, the costs of product liability could have an adverse effect on its business and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus&#8217;s business exposes it to significant product liability risks inherent in the development, testing, manufacturing, and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of Liminatus&#8217;s development programs. If Liminatus succeeds in marketing products, such claims could result in an FDA, EMA, or other regulatory investigation of the safety and effectiveness of its products, its manufacturing processes and facilities, or its marketing programs. Such regulatory investigation could potentially lead to a recall of Liminatus&#8217;s products or more serious enforcement action, limitations on the approved indications for which they may be used, or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for Liminatus&#8217;s products, injury to its reputation, costs to defend the related litigation, a diversion of management&#8217;s time and resources, and substantial monetary awards to trial participants or patients. Liminatus would expect to obtain product liability insurance prior to marketing any of its product candidates. Any insurance Liminatus has now or that it may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, Liminatus may be unable to obtain sufficient insurance at a reasonable cost to protect it against losses caused by product liability claims that could have an adverse effect on its business and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">24</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Regulatory Approval and Other Legal Compliance Matters for Liminatus&#8217;s Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA, EMA, and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If Liminatus is ultimately unable to obtain regulatory approval for its product candidates, Liminatus will be unable to generate product revenue and its business will be substantially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The time required to obtain approval by the FDA, EMA, and comparable foreign regulatory authorities is unpredictable, typically takes many&#160;years following the commencement of clinical trials, and depends upon numerous factors, including the type, complexity, and novelty of the product candidates involved. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that Liminatus&#8217;s data is insufficient for approval and require additional preclinical, clinical, or other studies. Liminatus has not submitted for, or obtained regulatory approval for, any product candidate, and it is possible that none of its existing product candidates or any product candidates it may seek to develop in the future will ever obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Applications for Liminatus&#8217;s product candidates could fail to receive regulatory approval in an initial or subsequent indication for many reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, EMA, or comparable foreign regulatory authorities may disagree with the design, implementation, or results of Liminatus&#8217;s clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, EMA, or comparable foreign regulatory authorities may determine that Liminatus&#8217;s product candidates are not safe and effective, only moderately effective, or have undesirable or unintended side effects, toxicities, or other characteristics that preclude it obtaining marketing approval or prevent or limit commercial use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the population studied in the clinical program may not be sufficiently broad or representative to assure safety and efficacy in the full population for which Liminatus seeks approval, including, for example, due to biologic and genetic differences that might occur in subjects in certain populations such as defined by race or other factors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liminatus may be unable to demonstrate to the FDA, EMA, or comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio when compared to the standard of care is acceptable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, EMA, or comparable foreign regulatory authorities may disagree with Liminatus&#8217;s interpretation of data from preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from clinical trials of Liminatus&#8217;s product candidates may not be sufficient to support the submission of a Biologics License Application (&#8220;BLA&#8221;), New Drug Application (&#8220;NDA&#8221;), or other submission or to obtain regulatory approval in the United States or elsewhere;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liminatus may be unable to demonstrate to the FDA, EMA, or comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio for a proposed indication is acceptable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, EMA, or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with which Liminatus contracts for clinical and commercial supplies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA, EMA, or comparable foreign regulatory authorities may significantly change in a manner rendering Liminatus&#8217;s clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, development of Liminatus&#8217;s product candidates and/or regulatory approval may be delayed for reasons beyond its control. For example, a U.S. federal government shutdown, such as one that occurred during from December&#160;2018 to January&#160;2019, or other FDA priorities, such as responding to a pandemic, may result in significant reductions to, or demands on, the FDA&#8217;s budget, employees, and operations, which may lead to slower response times and longer review periods, potentially affecting Liminatus&#8217;s ability to progress development of its product candidates or obtain regulatory approval for its product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">25</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in Liminatus failing to obtain regulatory approval to market any of its product candidates, which would significantly harm its business, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus&#8217;s product candidates may cause undesirable side effects or have other properties that could prevent their regulatory approval or result in significant negative consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Adverse events or other undesirable side effects caused by Liminatus&#8217;s product candidates could cause it or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA, or other comparable foreign regulatory authorities. Drug-related side effects could affect patient recruitment, the ability of enrolled patients to complete the trial, and/or result in potential product liability claims. Regardless of merit or eventual outcome, product liability claims may result in impairment of Liminatus&#8217;s business reputation, withdrawal of clinical trial participants, costs due to related litigation, distraction of management&#8217;s attention from Liminatus&#8217;s primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize its product candidates, and decreased demand for Liminatus&#8217;s product candidates, if approved for commercial sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, if one or more of Liminatus&#8217;s product candidates receives marketing approval, and Liminatus or others later identify undesirable side effects or adverse events caused by such products, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw approvals of such product and cause Liminatus to recall its products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings on the label or impose a more restrictive, narrower indication for use of the agent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liminatus may be required to change the way the product is administered or conduct additional clinical trials or post-approval studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liminatus may be required to create a REMS plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements, such as boxed warning on the packaging, to assure safe use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liminatus could be sued and held liable for harm caused to patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liminatus&#8217;s reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent Liminatus from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm Liminatus&#8217;s business, financial condition, results of operations, and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">For any current and future clinical trials for Liminatus&#8217;s product candidates outside the United States, the FDA, EMA, and applicable foreign regulatory authorities may not accept data from such trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus conducts clinical trials outside the United States, and may choose to conduct future clinical trials outside the United States. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA, EMA, or applicable foreign regulatory authority may be subject to certain conditions. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless the data are applicable to the United States population and United States medical practice, and the trials were performed by clinical investigators of recognized competence and pursuant to Good Clinical Practice (&#8220;GCP&#8221;) regulations. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have comparable approval requirements, including appropriate examination of the product in the country-specific population. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA, or any applicable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA, EMA, or any applicable foreign regulatory authority does not accept such data, it may result in the need for additional trials, which would be costly and time-consuming and delay aspects of Liminatus&#8217;s business plan, and may result in its product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">26</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining regulatory approval of Liminatus&#8217;s product candidates in one jurisdiction does not mean that it will succeed in obtaining regulatory approval of its product candidates in other jurisdictions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining regulatory approval of Liminatus&#8217;s product candidates in one jurisdiction does not guarantee that it will obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA, EMA, or comparable foreign regulatory authority grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing, and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that Liminatus intends to charge for its products is also subject to approval. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties, and costs for Liminatus and could delay or prevent the introduction of its products in certain countries. If Liminatus or any partner it works with fails to comply with the regulatory requirements in international markets or fails to receive applicable marketing approvals, its target market will be reduced, and its ability to realize the full market potential of its product candidates will be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if Liminatus applies for and obtains accelerated approval or Breakthrough Therapy, Fast Track or other designation intended to expedite, facilitate or reduce the cost pursuing development or regulatory review or approval with the FDA or other regulatory authorities for any of Liminatus&#8217;s product candidates, there is no guarantee that such designation would lead to faster development, regulatory review, or approval, nor would it increase the likelihood that any such product candidate will receive marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If a product candidate is intended for the treatment of a serious condition and nonclinical or clinical data demonstrates the potential to address unmet medical need for such condition or a substantial improvement over available therapy for such condition, a product candidate sponsor may apply for FDA Fast Track or Breakthrough Therapy designation, and there may be other priority designations available under various regulatory bodies. In the future, Liminatus may apply for such priority designation depending on the results of its clinical trials. Even though Liminatus may apply for and receive a Fast Track, Breakthrough Therapy or other priority designations, such priority designation does not ensure that it will receive marketing approval or that approval will be granted within any particular timeframe. Liminatus may not experience a faster development or regulatory review or approval process with the priority designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track or Breakthrough Therapy designation if it believes that the designation is no longer supported by data from Liminatus&#8217;s clinical development program. Fast Track or Breakthrough Therapy designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures. Further, even if any of Liminatus&#8217;s products obtain Fast Track or Breakthrough Therapy designation, this may not lead to earlier regulatory approval or commercialization of its products due to the extensive and time-consuming steps necessary to obtain FDA approval and commercialize a product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if Liminatus obtains regulatory approval for a product candidate, its products will remain subject to extensive regulatory scrutiny.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If any of Liminatus&#8217;s product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive requirements imposed by the FDA, EMA, and comparable foreign regulatory authorities, including ensuring that quality control and manufacturing procedures conform to Good Manufacturing Practice (&#8220;GMP&#8221;) regulations. As such, Liminatus and its contract manufacturers will be subject to continual review and inspections to assess compliance with GMP and adherence to commitments made in any BLA, NDA, or Marketing Authorization Application (&#8220;MAA&#8221;). Accordingly, Liminatus and others with whom it works must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Any regulatory approvals that Liminatus receives for its product candidates will be subject to limitations on the approved indicated uses for which the product may be marketed and promoted or to the conditions of approval (including potentially the requirement to implement a Risk Evaluation and Mitigation Strategy), or contain requirements for potentially costly post-marketing testing. Liminatus will be required to report certain adverse reactions and production problems, if any, to the FDA, EMA, and comparable foreign regulatory authorities. Any new legislation addressing drug safety issues could result in delays in product development or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">27</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">commercialization, or increased costs to assure compliance. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed, and distributed only for the approved indications and in accordance with the provisions of the approved labeling. Liminatus will have to comply with requirements concerning advertising and promotion for its products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, Liminatus may not promote its products for indications or uses for which it does not have approval. The holder of an approved BLA, NDA, or MAA must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling, or manufacturing process. Liminatus could also be asked to conduct post-marketing clinical trials to verify the safety and efficacy of its products in general or in specific patient subsets. If original marketing approval was obtained via the accelerated approval pathway, Liminatus could be required to conduct a successful post-marketing clinical trial to confirm clinical benefit for its products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing, or labeling of a product, such regulatory agency may impose restrictions on that product or Liminatus, including requiring withdrawal of the product from the market. If Liminatus fails to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue warning letters that would result in adverse publicity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impose civil or criminal penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend or withdraw regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend any of its ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refuse to approve pending applications or supplements to approved applications submitted by Liminatus;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impose restrictions on Liminatus&#8217;s operations, including closing its contract manufacturers&#8217; facilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seize or detain products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require a product recall.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any government investigation of alleged violations of law could require Liminatus to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect Liminatus&#8217;s ability to commercialize and generate revenue from its products. If regulatory sanctions are applied or if regulatory approval is withdrawn, this would significantly harm Liminatus&#8217;s business, financial condition, results of operations, and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on Liminatus&#8217;s business and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell our products profitably. In particular, in 2010, the Patient Protection and Affordable Care Act (&#8220;ACA&#8221;) was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research. Changes in the U.S. presidential administration could lead to repeal of or changes in some or all of the ACA and complying with any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business. Moreover, litigation over the ACA is likely to continue, with unpredictable and uncertain </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">28</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">results. Until there is more certainty concerning the future of the ACA, it will be difficult to predict its full impact and influence on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at containing or lowering the cost of healthcare. Liminatus cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the demand for our products after obtaining any regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liminatus&#8217;s ability to receive or set a price that it believes is fair for its products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liminatus&#8217;s ability to generate revenue and achieve or maintain profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of taxes that Liminatus is required to pay; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of capital.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus expects that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement and new payment methodologies. This could lower the price that Liminatus receives for any approved product. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent Liminatus from being able to generate sufficient revenue, attain profitability or commercialize its product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus&#8217;s employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus is exposed to the risk of fraud, misconduct or other illegal activity by its employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">comply with the laws of the FDA, EMA and other comparable foreign regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide true, complete and accurate information to the FDA, EMA and other comparable foreign regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">comply with manufacturing standards Liminatus has established;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">report financial information or data accurately or to disclose unauthorized activities to Liminatus.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If Liminatus obtains FDA approval of any of its product candidates and begins commercializing those products in the United States, its potential exposure under such laws will increase significantly, and its costs associated with compliance with such laws are also likely to increase. In particular, research, sales, marketing, education and other business arrangements in the healthcare industry are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials, which could result in regulatory sanctions and cause serious harm to Liminatus&#8217;s reputation. Liminatus plans to adopt a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by employees and third parties, and the precautions it takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting it from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against Liminatus, and it is not successful in defending itself or asserting its rights, those actions could have a significant impact on its business, including the imposition of significant fines or other sanctions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">29</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Liminatus fails to comply with healthcare laws, it could face substantial penalties and its business, operations, and financial conditions could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If Liminatus obtains FDA approval for any of its product candidates and begin commercializing those products in the United States, its operations will be subject to various federal and state fraud and abuse laws. The laws that may impact its operations include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The federal healthcare program anti-kickback statute (the &#8220;Anti-Kickback Statute&#8221;) prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering, or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order, or recommendation of any good, facility, item, or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, impose criminal and civil penalties, including through civil actions, against individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other third-party payors that are false or fraudulent, or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;) and their respective implementing regulations, impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security, and transmission of individually identifiable health information without appropriate authorization.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The federal Physician Payment Sunshine Act, created under the ACA, and its implementing regulations, require manufacturers of drugs, devices, biologicals, and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the HHS under the Open Payments Program, information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities that potentially harm consumers.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection, and unfair competition laws may apply to pharmaceutical business practices, including research, distribution, sales, and marketing arrangements, as well as submitting claims involving healthcare items or services reimbursed by any third-party payor, including commercial insurers.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">State laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">30</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">State laws also require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations, and other remuneration, and items of value provided to healthcare professionals and entities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">State and foreign laws also govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of Liminatus&#8217;s business activities could, despite its efforts to comply, be subject to challenge under one or more of such laws. Efforts to ensure that Liminatus&#8217;s business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that Liminatus business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against Liminatus, and it is not successful in defending itself or asserting its rights, those actions could have a significant impact on its business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of its operations, any of which could adversely affect its ability to operate its business and its results of operations. In addition, the approval and commercialization of any of Liminatus&#8217;s product candidates outside the United States will also likely subject it to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. Further, achieving and sustaining compliance with applicable federal and state privacy, security, and fraud laws may prove costly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we or any clinical collaborators, CROs, contract manufacturers, or other contractors and suppliers that we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We and any clinical collaborators, CROs, contract manufacturers, or other contractors and suppliers that we engage are subject to numerous federal, state, and local environmental, health and safety laws, regulations, and permitting requirements, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">those governing laboratory procedures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the generation, handling, use, storage, treatment and disposal of hazardous and regulated materials and wastes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the emission and discharge of hazardous materials into the ground, air and water; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee health and safety.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research, product development, and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business activities may be subject to the FCPA and similar anti-bribery and anti-corruption laws.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our business activities may be subject to the Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) and similar anti-bribery or anti-corruption laws, regulations, or rules&#160;of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">31</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the researchers with whom we conduct clinical trials, and the healthcare providers who prescribe pharmaceuticals, are employed by their government, and the purchasers of pharmaceuticals are government entities. As a result, our dealings with these researchers, prescribers, and purchasers are subject to regulation under the FCPA. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents, contractors or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure to comply with privacy and data protection laws, regulations, or contractual obligations could lead to government enforcement actions (which could include civil or criminal penalties), private disputes and litigation, and/or adverse publicity and could negatively affect our operating results and business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We receive, generate, and store significant and increasing volumes of sensitive information, such as employee, personal, patient and collaborator data. In addition, we actively seek access to medical information, including patient data, through research and development partnerships and collaborations or otherwise. We have legal and contractual obligations regarding the protection of confidentiality and appropriate use of personal data. We and our partners may be subject to federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security). These data protection laws and regulations continue to evolve and may result in ever-increasing public scrutiny and escalating levels of enforcement and sanctions and increased costs of compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section&#160;5 of the FTC Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our partners, including during our clinical trials. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA, as amended by HITECH, which establish privacy and security standards that limit the use and disclosure of individually identifiable health information and require the implementation of administrative, physical, and technological safeguards to protect the privacy of individually identifiable health information and ensure the confidentiality, integrity, and availability of electronic protected health information. Determining whether individually identifiable health information has been handled in compliance with applicable privacy standards and our contractual obligations can require complex factual and statistical analyses and may be subject to changing interpretation. Depending on the facts and circumstances, we could be subject to civil and criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. Enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. We cannot be sure how these regulations will be interpreted, enforced, or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems. Failure to comply with any of these laws could result in enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by customers and other affected individuals, damage to our reputation, and loss of goodwill (both in relation to existing and prospective customers), any of which could have a material adverse effect on our business, financial condition, results of operations, or prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Although we take measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance, or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, manipulated, publicly disclosed, lost or stolen. Any such access, breach or other loss of information could result in legal claims or proceedings, and liability under federal or state laws that protect the privacy of personal information, such as HIPAA and HITECH, and regulatory penalties. Notice of breaches must be made to affected individuals, the Secretary of the HHS, and for extensive breaches, notice may need to be made to the media or State Attorneys General. Such a notice could harm our reputation and our ability to compete. The HHS has the discretion to impose penalties without attempting to resolve violations through informal </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">32</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">means. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. Although we have implemented security measures to prevent unauthorized access to patient data, such data is currently accessible through multiple channels, and there is no guarantee we can protect our data from breach. Unauthorized access, loss, or dissemination could also damage our reputation or disrupt our operations, including our ability to conduct our analyses, deliver test results, process claims and appeals, provide customer assistance, conduct research and development activities, collect, process and prepare company financial information, provide information about our tests and other patient and physician education and outreach efforts through our website, and manage the administrative aspects of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may collect, process, use or transfer personal information from individuals located in the European Union in connection with our business, including in connection with conducting clinical trials in the European Union. Additionally, if any of our product candidates are approved, we may seek to commercialize those products in the European Union. The collection and use of personal health data in the European Union are governed by laws, regulations, and directives, including the General Data Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;). This legislation imposes requirements relating to having legal bases for processing personal information relating to identifiable individuals and transferring such information outside of the European Economic Area, including to the United States, providing details to those individuals regarding the processing of their personal information, keeping personal information secure, having data processing agreements with third parties who process personal information, responding to individuals&#8217; requests to exercise their rights in respect of their personal information, reporting security breaches involving personal data to the competent national data protection authority and affected individuals, appointing data protection officers, conducting data protection impact assessments and record-keeping. This legislation imposes significant responsibilities and liabilities in relation to personal data that we process, and we may be required to put in place additional mechanisms ensuring compliance. In particular, with respect to cross-border transfers of personal data, judicial and regulatory developments in the European Union have created uncertainty. In a decision issued by the Court of Justice of the European Union (&#8220;CJEU&#8221;) on July&#160;16, 2020, the CJEU invalidated one mechanism for cross-border personal data transfer, the EU-U.S. Privacy Shield, and imposed additional obligations on companies, including us, relying on standard contractual clauses (&#8220;SCCs&#8221;) issued by the European Commission for cross-border personal data transfers. The European Commission released new SCCs designed to address the CJEU concerns on June&#160;4, 2021. We have undertaken certain efforts to conform transfers of personal data from the European Economic Area (&#8220;EEA&#8221;) to the United States to our understanding of current regulatory obligations and guidance of data protection authorities, but the CJEU&#8217;s decision, the revised SCCs, regulatory guidance and opinions, and other developments relating to cross-border data transfer may require us to implement additional contractual and technical safeguards for any personal data transferred out of the EEA, which may increase compliance costs, lead to increased regulatory scrutiny or liability, may require additional contractual negotiations, and may adversely impact our business, financial condition and operating results. Any actual or alleged failure to comply with the requirements of the GDPR or other laws, regulations, and directives of the member states of the European Union may result in substantial fines, other administrative penalties and civil claims being brought against us, which could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, U.S. states are adopting new laws or amending existing laws and regulations, requiring attention to frequently changing regulatory requirements applicable to data related to individuals. For example, California has enacted the California Consumer Privacy Act (&#8220;CCPA&#8221;). The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined and which can include any of our current or future employees who may be California residents or any other California residents whose data we collect or process) and provide such residents new ways to opt out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. As we expand our operations and trials (both preclinical or clinical), the CCPA may increase our compliance costs and potential liability. Additionally, a new privacy law, the California Privacy Rights Act (CPRA), was approved by California voters in the election on November&#160;3, 2020. The CPRA creates obligations relating to consumer data beginning on January&#160;1, 2022, and comes fully into force on January&#160;1, 2023, with enforcement beginning July&#160;1, 2023. The CPRA modifies the CCPA significantly, potentially resulting in further uncertainty and requiring us to incur additional costs and expenses in an effort to comply. Additionally, other U.S. states continue to propose, and in certain cases adopt, privacy-focused legislation such as Colorado, Virginia, and Utah. Aspects of these state laws remain unclear, resulting in further uncertainty and potentially requiring us to modify our data practices and policies and to incur substantial additional costs and expenses in an effort to comply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, patients about whom we or our partners obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">33</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we or third parties fail to adequately safeguard confidential personal, employee, or patient data, or if such information or data are wrongfully used by us or third parties or disclosed to unauthorized persons or entities, our reputation could suffer and we could be subject to claims for damages or other liabilities, regulatory investigations and enforcement action, litigation, the imposition of fines or other penalties, and significant costs for remediation. Any of these risks could have a material adverse effect on our business, financial condition, results of operations, or prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Liminatus&#8217;s Employee Matters, Managing Growth and Other Risks Related to Liminatus&#8217;s Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our success is highly dependent on our ability to attract, hire and retain highly skilled executive officers and employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus currently has a small team focused on research and development. Our ability to discover and develop any product candidates is dependent on our chemists. To succeed, we must recruit, hire, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face significant competition for experienced personnel. Following the closing of the Business Combination, Liminatus will be highly dependent on the principal members of its management and scientific and medical staff, particularly Mr.&#160;Chris Kim, our President and Chief Executive Officer, Mr.&#160;Scott Dam, our Chief Financial Officer, Mr.&#160;Byong C Yoo, our Chief Science Officer, Mr.&#160;Sang-jin Daniel Lee, our Head of Research and Development, and Mr.&#160;Beom K. Choi, our Chief Technology Officer. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more of Liminatus&#8217;s executive officers could be detrimental to Liminatus if it cannot recruit suitable replacements in a timely manner. We do not maintain &#8220;Key Person&#8221; insurance for any of our executives or other employees. Liminatus could in the future have difficulty attracting and retaining experienced personnel and may be required to expend significant financial resources in its employee recruitment and retention efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many of the other biotechnology companies that Liminatus competes against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than Liminatus does. They also may provide higher compensation, more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what Liminatus has to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize our product candidates will be limited and the potential for successfully growing our business will be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus&#8217;s scientific and clinical advisors and consultants typically will not enter into non-compete agreements with it. If a conflict of interest arises between their work for Liminatus and their work for another entity, Liminatus may lose their services. Furthermore, Liminatus&#8217;s advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with Liminatus&#8217;s. In particular, if Liminatus is unable to maintain consulting or employment relationships with its scientific founders and other scientific and clinical advisors and consultants, or if they provide services to Liminatus&#8217;s competitors, Liminatus&#8217;s development and commercialization efforts will be impaired and its business will be significantly harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Many members of Liminatus&#8217;s management team joined our company following the closing of the Business Combination and will need to be successfully integrated in order to effectively execute our business plan.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain members of Liminatus&#8217;s management team joined our company full time following the closing of the Business Combination. Such executive officers will need to be successfully integrated in order to effectively execute our business plan and developmental strategies. Our management team has limited historical experience with our clients, our business and our industry and the process of transitioning our new members into our business is complex and time consuming. This may impact our ability to collectively respond to issues in a quick and efficient manner. If our management team is unable to develop a business strategy that can be executed in a successful manner, it could materially adversely impact our business and our revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates after any approvals, we may not successfully sell or market our product candidates that obtain regulatory approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently do not have and have never had a marketing or sales team for the marketing, sales and distribution of any of our product candidates that may obtain regulatory approval in the future. In order to commercialize any product candidates, we must build marketing, sales, distribution, managerial, and other non-technical capabilities or make arrangements with third parties to perform these services for each of the territories in which we may have approval to sell or market our product candidates. We may not be successful in accomplishing these required tasks.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">34</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Establishing an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates will be expensive and time-consuming, and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing, and distribution capabilities could adversely impact the commercialization of any of our product candidates that we obtain approval to market, if we do not have arrangements in place with third parties to provide such services on our behalf. Alternatively, if we choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration. If we are unable to enter into such arrangements when needed on acceptable terms, or at all, we may not successfully commercialize any of our product candidates that receive regulatory approval or any such commercialization may experience delays or limitations. If we are unable to successfully commercialize our approved product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our international operations may expose us to business, regulatory, political, operational, financial, pricing, and reimbursement risks associated with doing business outside of the United States.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business strategy incorporates potential international expansion as we seek to obtain regulatory approval for, and commercialize, our current and any future product candidates in patient populations outside the United States. If our product candidates are approved, we may hire sales representatives and conduct physician and patient association outreach activities outside of the United States. Doing business internationally involves a number of risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">multiple, conflicting, and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements, and other governmental approvals, permits and licenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rejection or qualification of foreign clinical trial data by the competent authorities of other countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional potentially relevant third-party patent rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">complexities and difficulties in obtaining protection and enforcing our intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in staffing and managing foreign operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limits in our ability to penetrate international markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products, and exposure to foreign currency exchange rate fluctuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">natural disasters, political and economic instability, including wars, terrorism, and political unrest, outbreak of disease, boycotts, curtailment of trade, and other business restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">certain expenses including, among others, expenses for travel, translation, and insurance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory and compliance risks that relate to anti-corruption compliance and record-keeping that may fall within the purview of the FCPA, its accounting provisions or its anti-bribery provisions, or provisions of anti-corruption or anti-bribery laws in other countries.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">35</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Liminatus&#8217;s Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus&#8217;s proprietary rights may not adequately protect our intellectual property and potential products, and if Liminatus cannot obtain adequate protection of its intellectual property and potential products, it may not be able to successfully market its potential products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus&#8217;s commercial success will depend in part on obtaining and maintaining intellectual property protection for our products, formulations, processes, methods and other technologies. Liminatus will only be able to protect these technologies and products from unauthorized use by third parties to the extent that valid and enforceable intellectual property rights, including patents, cover them, or other market exclusionary rights apply. The patent positions of pharmaceutical companies, like Liminatus, can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in such companies&#8217; patents has emerged to date in the United States. The general environment for pharmaceutical patents outside the United States also involves significant uncertainty. Accordingly, we cannot predict the breadth of claims that may be allowed (if any are allowed at all) or enforced, or that the scope of these patent rights could provide a sufficient degree of future protection that could permit us to gain or keep our competitive advantage with respect to these products and technology. For example, we cannot predict:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the degree and range of protection any patents will afford us against competitors, including whether third parties will find ways to make, use, sell, offer to sell or import competitive products without infringing our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if and when patents will issue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether or not others will obtain patents claiming inventions similar to those covered by our patents and patent applications; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether we will need to initiate or defend litigation or administrative proceedings in connection with patent rights, which may be costly whether we win or lose, and the outcome of which is unpredictable.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in either the patent laws or in the interpretations of patent laws in the United States or other countries may diminish the value of our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, others may independently develop similar or alternative products and technologies that may be outside the scope of our intellectual property. Furthermore, others may have invented technology claimed by our patents before we or our licensors did so, and they may have filed patents claiming such technology before we did so, weakening our ability to obtain and maintain patent protection for such technology. Should third parties obtain patent rights to similar products or technology, this may have an adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may also rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. Trade secrets, however, are difficult to protect. While we believe that we will use reasonable efforts to protect our trade secrets, our own or our strategic partners&#8217; employees, consultants, contractors or advisors may unintentionally or willfully disclose our information to competitors. Such disclosure could adversely affect our ability to prevent further disclosures of our trade secrets. We seek to protect this information, in part, through the use of non-disclosure and confidentiality agreements with employees, consultants, advisors and others. These agreements may be breached, and we may not have adequate remedies for a breach. In addition, we cannot ensure that those agreements will be enforceable, provide adequate protection for our trade secrets, know-how or other proprietary information, or prevent their unauthorized use or disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">To the extent that consultants or key employees apply technological information independently developed by them or by others to our potential products, disputes may arise as to the proprietary rights in such information, which may not be resolved in our favor. Consultants and key employees who work with our confidential and proprietary technologies are required to assign all intellectual property rights in their discoveries to us. However, these consultants or key employees may terminate their relationship with us, and we cannot preclude them indefinitely from dealing with our competitors. If our trade secrets become known to competitors with greater experience and financial resources, the competitors may copy or use our trade secrets and other proprietary information in the advancement of their products, methods or technologies. If we were to prosecute a claim that a third party had illegally obtained and was using our trade secrets, it could be expensive and time consuming and the outcome could be unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets than courts in the United States. Moreover, if our competitors </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">36</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">independently develop equivalent knowledge, we would lack any legal or contractual claim to prevent them from using such information, and our business could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain, maintain or protect intellectual property rights in any products that we develop or if the scope of the intellectual property protection obtained is not sufficiently broad, third parties could develop and commercialize products and technology similar or identical to ours, and we may not compete effectively in our market.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our success depends in significant part on our and our licensors&#8217; ability to obtain, maintain and protect patents and other intellectual property rights and operate without infringing, misappropriating, or otherwise violating the intellectual property rights of others. If we or our licensors are unable to obtain or maintain patent protection with respect to such inventions and technology, our business, financial condition, results of operations, and prospects could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patent prosecution process is expensive, time-consuming, and complex, and we and our current or future licensors may not prepare, file, prosecute, maintain, and enforce all necessary or desirable patent applications at a reasonable cost or in a timely manner. Patents may be invalidated and patent applications may not be granted for a number of reasons, including known and unknown prior art, deficiencies in the patent applications or the lack of novelty of the underlying inventions or technology. It is also possible that we or our current and future licensors will fail to identify patentable aspects of inventions made in the course of research, development and commercialization activities in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research, development, and commercialization activities, such as our employees, collaborators, CROs, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such activities before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, publications of discoveries in the scientific literature often lag behind actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our current or future licensors were the first to make the inventions claimed in our owned or any licensed patents or patent applications, or that we or our current or future licensors were the first to file for patent protection of such inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patent position of biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has in recent&#160;years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#8217; patent rights are highly uncertain. Our and our current or future licensors&#8217; pending and future patent applications may not result in patents being issued which protect the technology or products we use, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Moreover, the patent examination process may require us or our current and future licensors to narrow the scope of the claims of our or our current and future licensors&#8217; pending and future patent applications, which may limit the scope of patent protection that may be obtained. Additionally, the scope of patent protection can be reinterpreted after issuance. Even if our or our current or future licensors&#8217; pending and future patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we apply for any products that we may develop may be challenged, narrowed, circumvented, or invalidated by third parties in court or in patent offices in the United States and abroad. Our licensors&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology. Our competitors or other third parties may also circumvent our licensor&#8217;s patents by developing similar or alternative technologies or products in a non-infringing manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We cannot assure you that we have found all of the potentially relevant prior art relating to our patents and patent applications. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if our patents do issue and even if such patents cover our product candidates, third parties may initiate oppositions, interferences, re-examinations, post-grant reviews,&#160;<i style="font-style:italic;">inter partes</i>&#160;reviews, nullification or derivation actions in court or before patent offices, or similar proceedings challenging the inventorship, validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated. An adverse determination in any such proceeding or litigation could reduce the scope of, or invalidate, the patent rights we own or license, allow third parties to commercialize the technology or products we use and compete directly with us, without payment to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Moreover, we, or our current or future licensors, may have to participate in interference or derivation proceedings declared by the United States Patent and Trademark Office (USPTO) to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge priority of invention or other features of patentability. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of the technology and product candidates we use. Such proceedings also may result in substantial cost and require significant </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">37</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">time from our scientists and management, even if the eventual outcome is favorable to us. Consequently, we do not know whether any of the technology or product candidates we use will be protectable or remain protected by valid and enforceable patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our current and future licensors were the first to file any patent application related to a product candidate. Furthermore, if third parties have filed such patent applications on or before March&#160;15, 2013, an interference proceeding in the United States can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If third parties have filed such applications after March&#160;15, 2013, a derivation proceeding in the United States can be initiated by such third parties to determine whether our invention was derived from theirs. Even where we have a valid and enforceable patent, we may not exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not protect our intellectual property rights throughout the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting, enforcing, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our or our current and future licensors&#8217; intellectual property rights may not exist in some countries outside the United States or may be less extensive in some countries than in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we and our current and future licensors may not prevent third parties from practicing our and our current or future licensors&#8217; inventions in all countries, or from selling or importing products made using our and our current or future licensors&#8217; inventions in and into all jurisdictions. Competitors may use our and our current or future licensors&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our current and future licensors have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our and our current or future licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us and our current and future licensors to stop the infringement of our and our current or future licensors&#8217; patents or marketing of competing products in violation of our and our current or future licensors&#8217; intellectual property and proprietary rights generally. Proceedings to enforce our and our current or future licensors&#8217; intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our and our current or future licensors&#8217; efforts and attention from other aspects of our business, could put our and our current or future licensors&#8217; patents at risk of being invalidated or interpreted narrowly, could put our and our current or future licensors&#8217; patent applications at risk of not issuing, and could provoke third parties to assert claims against us or our current and future licensors. We or our current and future licensors may not prevail in any lawsuits that we or our current and future licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Some jurisdictions may refuse to honor intellectual property rights due to legislation or geopolitical reasons, such as Russia recently stating that it will not honor patent rights of companies from countries that have imposed sanctions on Russia in response to the war in Ukraine. Accordingly, our and our current and future licensors&#8217; efforts to enforce intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or our current and future licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time-consuming, and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (Leahy-Smith Act), could increase those uncertainties and costs. The Leahy-Smith Act includes provisions that affect the way patent applications are prosecuted, redefine prior art, and provide more efficient and cost-effective avenues for competitors to challenge the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">38</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">validity of patents, and may also affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review,&#160;<i style="font-style:italic;">inter partes</i>&#160;review, and derivation proceedings. In addition, assuming that other requirements for patentability are met, prior to March&#160;15, 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March&#160;15, 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the U.S. Supreme Court has ruled on several patent cases in recent&#160;years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on any issued patent or patent application are due to be paid to the USPTO and various government patent agencies outside of the United States in several stages over the lifetime of our owned or licensed patents and applications. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent lapse can, in some cases, be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to properly legalize and submit formal documents. If we or our current and future licensors fail to maintain the patents and patent applications covering our product candidates, our patent protection could be reduced or eliminated and our competitors might be better able to enter the market with competing products or technology, which could have a material adverse effect on our business, financial condition, results of operation, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose the ability to continue the development and commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a party to a number of intellectual property and technology licenses that are important to our business. All assets are in-licensed. The CD&#160;47 License originates with a Korean company InnoBation Bio Co.&#160;Ltd. If we, or our licensors, fail to comply with our, or their, obligations under these license agreements, including payment and diligence terms, or other specified events occur such as our insolvency or change of control, the licensors may have the right to terminate these agreements or may reduce or eliminate our rights under these agreements, in which event we may not develop, manufacture, market or sell any product that is covered by these agreements or may face other penalties under the agreements. Such an occurrence could adversely affect the value of the technology or product candidate being developed or licensed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements, which may not be available to us on equally favorable terms, or at all, or cause us to lose our rights under these agreements, including our rights to intellectual property or technology important to our development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Disputes may arise regarding intellectual property subject to a licensing agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which the technology and processes we use infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">39</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sublicensing of patent and other rights under our existing collaborative development relationships and any collaboration relationships we might enter into in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our current and future licensors and us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the priority of invention of patented technology.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the agreements under which Liminatus licenses intellectual property or technology from third parties are generally complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, result of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not succeed in obtaining necessary rights to any product candidates we may develop through acquisitions and in-licenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our current or future product candidates. In order to avoid infringing these third-party patents, we may find it necessary or prudent to obtain licenses from such third-party intellectual property holders. Moreover, we may need to obtain additional licenses from our existing licensors and others to advance our research or allow commercialization of product candidates we may develop. In addition, with respect to any patents we may co-own with third parties, we may require licenses to such co-owners&#8217; interest to such patents. However, we may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for product candidates we develop. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development or commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. As a result, we may be unable to obtain any such licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign the technology we use, product candidates, or the methods for manufacturing them, or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. In addition, even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Moreover, some of our owned and in-licensed patents and patent applications are, and may in the future be, co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may license their rights to other third parties, including our competitors, and such third parties could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third parties may initiate legal proceedings against us alleging that we infringe, misappropriate, or otherwise violate their intellectual property rights, or we may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, the outcome of which would be uncertain and could have an adverse effect on the success of our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our commercial success depends upon our ability to develop, manufacture, market and sell our product candidates and use our and our current or future licensors&#8217; proprietary technologies without infringing, misappropriating, or otherwise violating the intellectual property rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. Third parties may initiate legal proceedings against us or our current and future licensors alleging that </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">40</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">we or our current and future licensors infringe, misappropriate, or otherwise violate their intellectual property rights. In addition, we or our current and future licensors may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, including in oppositions, interferences, reexaminations,&#160;<i style="font-style:italic;">inter partes</i>&#160;reviews, or derivation proceedings in the United States or other jurisdictions. These proceedings can be expensive and time-consuming, and many of our or our current and future licensors&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our current and future licensors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Third parties that currently hold patents, have patent applications pending or may submit patent applications in the future may allege that our product candidates, including our CD47 immune checkpoint inhibitor, infringe these patents. Parties making infringement, misappropriation, or other intellectual property claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. In addition, even if we believe any third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of validity, enforceability, priority, or non-infringement. A court of competent jurisdiction could hold that such third-party patents are valid, enforceable, and infringed, which could materially and adversely affect our ability to commercialize any of our products or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such third-party U.S. patents in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. An unfavorable outcome could require us or our current and future licensors to cease using the related technology or developing or commercializing our product candidates, or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our current and future licensors a license on commercially reasonable terms or at all. Even if we or our current and future licensors obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our current and future licensors, and it could require us to make substantial licensing and royalty payments. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent. A finding of infringement, misappropriation, or other violation of third-party intellectual property could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims by third parties asserting that we or our employees, consultants, or advisors have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many of our employees, consultants, and advisors, including our senior management, were previously employed at other biopharmaceutical companies, including our competitors or potential competitors. Some of these employees executed proprietary rights, non-disclosure, and/or non-competition agreements in connection with such previous employment. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize the technology or products we use. Such a license may not be available on commercially reasonable terms, or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">41</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our inability to protect our confidential information and trade secrets would harm our business and competitive position.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to seeking patents for some of the technology and products we use, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position. Trade secrets can be difficult to protect. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties. We also enter into confidentiality agreements with our employees and consultants. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not obtain adequate remedies for such breaches. Misappropriation or unauthorized disclosure of our trade secrets could significantly affect our competitive position and may have a material adverse effect on our business. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. Some courts both within and outside the United States may be less willing or unwilling to protect trade secrets. Furthermore, trade secret protection does not prevent competitors from independently developing substantially equivalent information and techniques and we cannot guarantee that our competitors will not independently develop substantially equivalent information and techniques. If a competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to compete with us. Failure on our part to adequately protect our trade secrets and our confidential information would harm our business and our competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Issued patents covering one or more of our product candidates or technologies could be found invalid or unenforceable if challenged in court.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To protect our competitive position, we may from time to time need to resort to litigation in order to enforce or defend any patents or other intellectual property rights owned by or licensed to us, or to determine or challenge the scope or validity of patents or other intellectual property rights of third parties. Enforcement of intellectual property rights is difficult, unpredictable, and expensive, and many of our or our licensors&#8217; or collaboration partners&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors or collaboration partners can. Accordingly, despite our or our licensors&#8217; or collaboration partners&#8217; efforts, we or our licensors or collaboration partners may not prevent third parties from infringing upon or misappropriating intellectual property rights we own or control, particularly in countries where the laws may not protect those rights as fully as in the European Union and the United States. We may fail in enforcing our rights&#8201;&#8212;&#8201;in which case our competitors may be permitted to use the technology we use without being required to pay us any license fees. In addition, however, litigation involving our patents carries the risk that one or more of our patents will be held invalid (in whole or in part, on a claim-by-claim basis) or held unenforceable. Such an adverse court ruling could allow third parties to commercialize our products, including our CD47 immune checkpoint inhibitor, and then compete directly with us, without payment to&#160;us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we or one of our licensors were to initiate legal proceedings against a third party to enforce a patent covering one of our products, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States or in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. A claim for a validity challenge may be based on failure to meet any of several statutory requirements, for example, lack of novelty, obviousness, or non-enablement. A claim for unenforceability could involve an allegation that someone connected with prosecution of the patent withheld relevant information from the European Patent Office or the USPTO or made a misleading statement, during prosecution. Third parties may also raise similar claims before the USPTO or an equivalent foreign body, even outside the context of litigation. Potential proceedings include re-examination, post-grant review,&#160;<i style="font-style:italic;">inter partes</i>&#160;review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover the technology we use or any product candidates that we may develop. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our licensing partners and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our product candidates. Such a loss of patent protection could have a material adverse impact on our business, financial condition, results of operations, and prospects. Further, litigation could result in substantial costs and diversion of management resources, regardless of the outcome, and this could harm our business and financial results. Patents and other intellectual property rights also will not protect the technology we use if competitors design around the protected technology we use without infringing our patents or other intellectual property rights.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">42</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may become involved in disputes or lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming, unsuccessful, and lead to challenges to our intellectual property ownership.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Competitors and other third parties may infringe, misappropriate, or otherwise violate our issued patents or other intellectual property or the patents or other intellectual property of our licensors, or we or our licensors may be required to defend against claims of infringement, misappropriation, or other violation. In addition, our patents or the patents of our licensors may become involved in inventorship or priority disputes. Other disputes may arise related to intellectual property rights that we believe are derived from, or related to, our patents or technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To counter infringement, misappropriation, or other unauthorized use, we or our licensors may be required to negotiate a solution to such dispute or file infringement claims, either of which can be expensive and time-consuming. Any claims we or our licensors assert against perceived infringers could provoke these parties to assert counterclaims against us or our licensors alleging that we or our licensors infringe their patents or that our or our licensors&#8217; patents are invalid or unenforceable. In a patent infringement proceeding, a court may decide that a patent of ours or one of our licensors&#8217; is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our or our licensors&#8217; patents do not cover the technology. An adverse result in any litigation proceeding could put one or more of our owned or licensed patents at risk of being invalidated, held unenforceable, or interpreted narrowly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may find it impractical or undesirable to enforce our intellectual property against some third parties. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interference proceedings provoked by third parties or brought by us or declared by the USPTO or by an equivalent foreign body may be necessary to determine the priority of inventions with respect to our or our licensors&#8217; patents or patent applications. If we or our licensors are unsuccessful in any interference proceedings to which we or they are subject, we may lose valuable intellectual property rights through the loss of one or more patents owned or licensed or our owned or licensed patent claims may be narrowed, invalidated, or held unenforceable. If we or our licensors are unsuccessful in any interference proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority of inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or narrowing of our owned or licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any of the foregoing intellectual property disputes or litigation could result in a material adverse effect on our business, financial condition, results of operations, or prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property litigation or proceedings could cause us to spend substantial resources and distract our personnel.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims could result in substantial costs and diversion of management resources, which could harm our business. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs or in-license needed technology or other product candidates. There could also be public announcements of the results of the hearing, motions or other interim proceedings or developments. If securities analysts or investors perceive those results to be negative, it could cause the price of shares of our common stock to decline. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not prevent third parties from infringing upon, misappropriating, or otherwise violating our intellectual property. Any of the foregoing events could harm our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we do not obtain patent term extension or data exclusivity for any product candidates we may develop, our business may be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Patents have a limited lifespan. Due to the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">43</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. filing date of a non-provisional patent application. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including biosimilar or generic medications. At the time of the expiration of the relevant patents, the underlying technology covered by such patents can be used by any third party, including competitors. Although the patent term extensions under the Drug Price Competition and Patent Term Restoration Action of 1984 (Hatch-Waxman Act) in the United States may be available to extend the patent term, we cannot provide any assurances that any such patent term extension will be obtained and, if so, for how long.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term extension of up to five&#160;years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent may be extended, and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and prospects could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our trademark and tradenames are not adequately protected, then we may not build name recognition in our markets and our business may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We cannot assure you that competitors will not infringe our future trademarks or that we will have adequate resources to enforce such trademarks. We cannot assure you that any future trademark applications that we will file will be approved. During trademark registration proceedings, we may receive rejections and although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in proceedings before the USPTO and in proceedings before comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. An opposition or cancellation proceeding may be filed against our trademarks and our trademarks may not survive such proceedings, which may force us to rebrand our name.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property rights do not necessarily address all potential threats.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may make products that are similar to any product candidates we may develop or utilize similar technology but that are not covered by the claims of the patents that we license or may own in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of the technologies we use without infringing our owned or licensed intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies that are patentable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">44</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Liminatus&#8217;s Dependence on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus relies on third parties to conduct its clinical trials and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research and studies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus does not have the ability to independently conduct its clinical trials. Liminatus currently relies on third parties to conduct clinical trials of its product candidates, including ISTs sponsored by third parties; these third parties also include CROs, clinical data management organizations, medical institutions and clinical investigators. Liminatus expects to continue to rely upon third parties to conduct additional clinical trials of Liminatus&#8217;s product candidates. Third parties have a significant role in the conduct of Liminatus&#8217;s clinical trials and the subsequent collection and analysis of data. These third parties are not Liminatus&#8217;s employees, and except for remedies available to Liminatus under Liminatus&#8217;s agreements, Liminatus has limited ability to control the amount or timing of resources that any such third party will devote to Liminatus&#8217;s clinical trials. In some cases, these third parties may not provide Liminatus with information about the ongoing clinical trials on a timely basis. The third parties may also violate the terms of the agreements governing such clinical trials in various ways, including asserting intellectual property rights that contractually belong to Liminatus. Some of these third parties may terminate their engagements with Liminatus at any time. If Liminatus needs to enter into alternative arrangements, it would delay Liminatus&#8217;s drug development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus&#8217;s reliance on these third parties for research and development activities will reduce Liminatus&#8217;s control over these activities but will not relieve Liminatus of its regulatory responsibilities. For example, Liminatus will remain responsible for ensuring that each of its clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires Liminatus to comply with GCP standards, regulations for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. The EMA also requires Liminatus to comply with similar standards. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators, and trial sites. If Liminatus or any of its CROs fail to comply with applicable GCP requirements, the clinical data generated in Liminatus&#8217;s clinical trials may be deemed unreliable and the FDA, EMA, or comparable foreign regulatory authorities may require Liminatus to perform additional clinical trials before approving its marketing applications. Liminatus cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of Liminatus&#8217;s clinical trials comply with GCP regulations. In addition, Liminatus&#8217;s clinical trials must be conducted with product produced under current GMP regulations. Liminatus&#8217;s failure or the failure of the third parties Liminatus engages to comply with these regulations may require Liminatus to repeat clinical trials, which would delay the marketing approval process. Liminatus also is required to register certain ongoing clinical trials and post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in delays in being permitted to initiate patient recruitment at some trial sites, slowing the delivery of clinical trial data, which can lead to sanctions from scientific journals in which Liminatus would seek to publish its study results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The third parties Liminatus relies on for these services may also have relationships with other entities, some of which may be Liminatus&#8217;s competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or conduct Liminatus&#8217;s clinical trials in accordance with regulatory requirements or Liminatus&#8217;s stated protocols, Liminatus will not obtain, or may be delayed in obtaining, marketing approvals for its product candidates and will not be able to, or may be delayed in its efforts to, successfully commercialize its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus contracts with third parties for the production of Liminatus&#8217;s product candidates for preclinical studies, and expects to continue to do so for clinical trials and ultimately for commercialization and for additional product candidates. This reliance on third parties increases the risk that Liminatus will not have sufficient quantities of its product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent, or impair Liminatus&#8217;s development or commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus does not currently have the infrastructure or internal capability to manufacture its product candidates for use in clinical development and commercialization. Liminatus relies, and expects to continue to rely, on third-party manufacturers for the production of Liminatus&#8217;s product candidates in compliance with GMP requirements for clinical trials under the guidance of members of Liminatus&#8217;s organization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The manufacture of small molecule therapeutics is complex. It is anticipated that during development from early clinical trials to commercialization that changes to the manufacturing process or analytical methods will occur. These changes carry the risk that the intended goals of such changes are not achievable and that further development work may be needed to reach these goals, which may delay Liminatus&#8217;s ability to meet clinical or commercial supply needs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">45</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If Liminatus were to experience an unexpected loss of supply of its product candidates for any reason, whether as a result of manufacturing, supply, or storage issues or otherwise, Liminatus could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. Replacement of Liminatus&#8217;s current manufacturers for each product would likely result in substantial delay and could interrupt Liminatus&#8217;s clinical trials if Liminatus had not previously obtained enough supply of its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus expects to continue to rely on third-party manufacturers for the commercial supply of any of its product candidates for which Liminatus obtains marketing approval. Liminatus may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if Liminatus is able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible failure of the third party to manufacture Liminatus&#8217;s product candidates according to its specifications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible failure of the third party to manufacture Liminatus&#8217;s product candidates according to Liminatus&#8217;s schedule, or at all, including if Liminatus&#8217;s third-party contractors give greater priority to the supply of other products over Liminatus&#8217;s product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between Liminatus and them;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible failure of Liminatus&#8217;s third-party manufacturer to procure raw materials from third-party suppliers and potential exposure to supply chain issues impacting delivery dates, quality, quantity and pricing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">raw materials, which may result in additional costs and delays in production of clinical trial materials, commercial product and regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible termination or nonrenewal of agreements by Liminatus&#8217;s third-party contractors at a time that is costly or inconvenient for Liminatus;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible breach by the third-party contractors of Liminatus&#8217;s agreements with them;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the failure of third-party contractors to comply with applicable regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility of clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or, following approval by regulatory authorities, of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible misappropriation of Liminatus&#8217;s proprietary information, including Liminatus&#8217;s trade secrets and know-how.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus does not have control over many aspects of the manufacturing process of and is dependent on its contract manufacturing partners for compliance with GMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not comply with GMP regulations or similar regulatory requirements outside of the United States. If Liminatus&#8217;s contract manufacturers cannot successfully manufacture material that conforms to Liminatus&#8217;s specifications and the strict regulatory requirements of the FDA, EMA, or others, they will not secure and/or maintain marketing approval for their manufacturing facilities. In addition, Liminatus does not have control over the ability of its contract manufacturers to maintain adequate quality control, quality assurance, and qualified personnel. If the FDA, EMA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of Liminatus&#8217;s product candidates or if it withdraws any such approval in the future, Liminatus may need to find alternative manufacturing facilities, which would significantly impact Liminatus&#8217;s ability to develop, obtain marketing approval for, or market Liminatus&#8217;s product candidates, if approved. Liminatus&#8217;s failure, or the failure of its third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on Liminatus, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of Liminatus&#8217;s drugs and harm its business and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">46</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus&#8217;s current and anticipated future dependence upon others for the manufacture of its product candidates or drugs may adversely affect its future profit margins and its ability to commercialize any drugs that receive marketing approval on a timely and competitive basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus may not gain the efficiencies it expects from further scale-up of manufacturing of its product candidates, and Liminatus&#8217;s third-party manufacturers may be unable to successfully scale up manufacturing in sufficient quality and quantity for Liminatus&#8217;s product candidates, which could delay or prevent the conducting of Liminatus&#8217;s clinical trials or the development or commercialization of Liminatus&#8217;s other product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus expects that third-party manufacturers will manufacture Liminatus&#8217;s product candidates at a scale and on a timeline that is sufficient for Liminatus to conduct its future clinical trials and, if Liminatus receives marketing approval, to commercialize Liminatus&#8217;s product candidates for the indications Liminatus is currently targeting. However, Liminatus may consider increasing the batch scale to gain cost efficiencies. If Liminatus&#8217;s current manufacturer or any other manufacturer Liminatus uses is unable to scale-up the manufacture of Liminatus&#8217;s product candidates at such time, Liminatus may not gain such cost efficiencies and may not realize the benefits that would typically be expected from further scale-up of manufacturing. In addition, quality or other technical issues may arise during scale-up activities. If Liminatus&#8217;s third-party manufacturers are unable to successfully scale up the manufacture of Liminatus&#8217;s product candidates in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed or become infeasible, and marketing approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm Liminatus&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As product candidates progress through preclinical and late-stage clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield, manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause Liminatus&#8217;s product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. The FDA may not approve Liminatus&#8217;s third-party manufacturers&#8217; processes or facilities. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of Liminatus&#8217;s product candidates, and jeopardize its ability to commercialize its product candidates and generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus has and may in the future enter into additional agreements with third parties under which those parties have or will be granted a license to develop product candidates. If any such programs are not successful or if disputes arise related to such programs, Liminatus may not realize the full commercial benefits from such programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A pipeline of several product candidates may be licensed to third parties, including larger global biopharmaceutical companies and mid-sized regional or China-focused companies. Liminatus&#8217;s likely counterparties for future licensing and collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies, and biotechnology companies. Such arrangements generally allow the licensing parties to control the amount and timing of resources that they dedicate to the development or potential commercialization of any product candidates they develop from the technology Liminatus has licensed to them, subject to any territorial or field of use restrictions in the license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus typically negotiates milestone payments and royalty fees from its licensees that will require various levels of success with their product candidate development program in order for Liminatus to generate revenue from them. Liminatus&#8217;s ability to generate revenue from these licensing arrangements will depend on Liminatus&#8217;s counterparties&#8217; abilities to successfully develop and commercialize the product candidates they are developing. Liminatus cannot predict the success of any licensing program that Liminatus enters into or whether such program will lead to any meaningful milestone or royalty revenue to Liminatus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Licensing programs involving third-party development of product candidates derived from Liminatus&#8217;s licensed technology pose the following risks to Liminatus:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">counterparties generally have significant discretion, if not total control, in determining the efforts and resources that they will apply to these development efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">counterparties may not properly or adequately obtain, maintain, enforce, or defend intellectual property or proprietary rights relating to Liminatus&#8217;s intellectual property or may use Liminatus&#8217;s proprietary information in such a way as to expose </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">47</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liminatus to potential litigation or other intellectual property-related proceedings, including proceedings challenging the scope, ownership, validity, and enforceability of Liminatus&#8217;s intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">counterparties may own or co-own with Liminatus intellectual property covering their product candidates, and, in such cases, Liminatus typically will not have the exclusive right to commercialize such intellectual property or their product candidates based on the terms of the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liminatus may need the cooperation of these counterparties to enforce or defend any intellectual property Liminatus contributes to the program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">counterparties typically will control the interactions with regulatory authorities related to their product candidates, which may impact Liminatus&#8217;s ability to obtain and maintain regulatory approval of its own product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between the counterparties and Liminatus that result in the delay or termination of the research, development, or commercialization of Liminatus&#8217;s product candidates or research programs or that result in costly litigation or arbitration that diverts management attention and resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">counterparties may decide to not pursue development and commercialization of any product candidates that are derived from Liminatus&#8217;s licensed technology, or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the counterparties&#8217; strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities, or counterparties may elect to fund or commercialize a competing product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">counterparties could independently develop, or develop with third parties, products that compete directly or indirectly with Liminatus&#8217;s product candidates or research programs if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than Liminatus&#8217;s;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">counterparties may not commit sufficient resources to the marketing and distribution of their product candidates, resulting in lower royalties to Liminatus;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">counterparties may grant sublicenses to Liminatus&#8217;s technology or undergo a change of control, and the sublicensees or new owners may decide to pursue a strategy with respect to the program which is not in Liminatus&#8217;s best interest;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">counterparties may become bankrupt, which may significantly delay Liminatus&#8217;s research or development programs, or may cause Liminatus to lose access to valuable technology, know-how, or intellectual property of the counterparty relating to Liminatus&#8217;s technology in relation to the terms of the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if these counterparties do not satisfy their obligations under Liminatus&#8217;s agreements with them, or if they terminate Liminatus&#8217;s licensing agreements with them, Liminatus may be adversely impacted; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">licensing agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There can be no assurance that any of Liminatus&#8217;s pending in-licensed patent applications will be approved and patents issue. Furthermore, there can be no assurance that Liminatus will benefit from any patent term extension or favorable adjustments to the term of any of Liminatus&#8217;s in-licensed issued patents or patents that are issued in the future. The applicable authorities, including the FDA, may not agree with Liminatus&#8217;s assessment of whether such patent term extensions should be granted, and, if granted, they may grant more limited extensions than Liminatus requests. Liminatus also relies upon know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain Liminatus&#8217;s competitive position. Liminatus seeks to protect Liminatus&#8217;s proprietary information, in part, using confidentiality and invention assignment agreements with Liminatus&#8217;s commercial partners, collaborators, employees, and consultants. These agreements are designed to protect Liminatus&#8217;s proprietary information and, in the case of invention assignment agreements, to grant Liminatus ownership of technologies that are developed through a relationship with an employee or a third party. These agreements may be breached, and Liminatus may not have adequate remedies for any such breach. To the extent that Liminatus&#8217;s commercial partners, collaborators, employees and consultants use intellectual property owned by others in their work for Liminatus, disputes may arise as to the rights in related or resulting know-how and inventions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">48</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many of the risks relating to product development, intellectual property, regulatory approval, and commercialization described in this &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; section also apply to the activities of Liminatus&#8217;s licensees and any negative impact on these counterparties and their product development programs may adversely affect Liminatus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Liminatus seeks to establish additional collaborations, but are unable to do so, Liminatus may have to alter its development and commercialization plans.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus&#8217;s drug development programs and the potential commercialization of Liminatus&#8217;s product candidates will require substantial additional cash to fund expenses. Liminatus may seek to selectively form collaborations to expand its capabilities, potentially accelerate research and development activities, and provide for commercialization activities by third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus faces significant competition in seeking appropriate collaborators. Whether Liminatus reaches a definitive agreement for a collaboration will depend, among other things, upon Liminatus&#8217;s assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, EMA, or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to Liminatus&#8217;s ownership of intellectual property and industry and market conditions generally. The potential collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with Liminatus for Liminatus&#8217;s product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Even if Liminatus successfully enters into a collaboration, the terms and conditions of that collaboration may restrict Liminatus from entering into future agreements on certain terms with potential collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If and when Liminatus seeks to enter into collaborations, Liminatus may not negotiate collaborations on a timely basis, on acceptable terms, or at all. If Liminatus is unable to do so, Liminatus may have to curtail the development of a product candidate, reduce or delay its development program or one or more of Liminatus&#8217;s other development programs, delay its potential commercialization, or reduce the scope of any sales or marketing activities, or increase Liminatus&#8217;s expenditures and undertake development or commercialization activities at Liminatus&#8217;s own expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Liminatus engages in acquisitions or strategic partnerships or collaborations, this may increase Liminatus&#8217;s capital requirements, dilute Liminatus&#8217;s stockholders, cause Liminatus to incur debt or assume contingent liabilities, and subject Liminatus to other risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus may evaluate various acquisition opportunities and strategic partnerships or collaborations, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exposure to unknown liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased operating expenses and cash requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the assumption of additional indebtedness or contingent liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of Liminatus&#8217;s equity securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assimilation of operations, intellectual property, and products of an acquired company, including costs and difficulties associated with integrating new personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the diversion of Liminatus&#8217;s management&#8217;s attention from Liminatus&#8217;s existing product programs and initiatives in pursuing such a strategic merger or acquisition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">retention of key employees, the loss of key personnel, and uncertainties in Liminatus&#8217;s ability to maintain key business relationships;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">49</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment of relationships with key collaborators and other counterparties of any acquired businesses due to changes in management and ownership;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and marketing approvals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liminatus&#8217;s inability to generate revenue from acquired technology and/or products sufficient to meet Liminatus&#8217;s objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, if Liminatus undertakes acquisitions, Liminatus may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses, and acquire intangible assets that could result in significant future amortization expense. Moreover, Liminatus may not locate suitable acquisition opportunities, and this inability could impair Liminatus&#8217;s ability to grow or obtain access to technology or products that may be important to the development of Liminatus&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other General Risks Applicable to Liminatus</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Health epidemics and other outbreaks could adversely impact Liminatus&#8217;s business including Liminatus&#8217;s ongoing and planned preclinical research and clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus could experience disruptions that could severely impact its business, current and planned preclinical research and clinical trials due to health epidemics or other outbreaks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in enrolling and retaining subjects in Liminatus&#8217;s ongoing preclinical research and Liminatus&#8217;s future clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in clinical site initiation, including due to difficulties in staffing and recruiting at clinical sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties interpreting data from Liminatus&#8217;s clinical trials due to the possible effects of health epidemics, on subjects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as Liminatus&#8217;s clinical trial sites and hospital staff supporting the conduct of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations in resources, including Liminatus&#8217;s employees, that would otherwise be focused on the conduct of Liminatus&#8217;s business or its current or planned clinical trials or preclinical research, including because of sickness, the desire to avoid contact with large groups of people, or restrictions on movement or access to Liminatus&#8217;s facility as a result of government-imposed &#8220;shelter in place&#8221; or similar working restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in receiving approval from regulatory authorities to initiate Liminatus&#8217;s clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruptions in preclinical studies due to restricted or limited operations at the CROs conducting such studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruptions or delays in the operations of the FDA or other domestic or foreign regulatory authorities, which may impact review and approval timelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in receiving the supplies, materials and services needed to conduct clinical trials and preclinical research;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in regulations as part of a response to a health epidemic or outbreak which may require Liminatus to change the ways in which Liminatus&#8217;s clinical trials are conducted, which may result in unexpected costs or require Liminatus to discontinue the clinical trial altogether;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruptions or delays to Liminatus&#8217;s development pipeline;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">50</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to accept data from clinical trials in affected geographies outside of the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liminatus&#8217;s internal computer systems, or those used by Liminatus&#8217;s third-party research institution collaborators, other contractors, or consultants, may fail or suffer other breakdowns, cyberattacks or information security breaches that could compromise the confidentiality, integrity and availability of such systems and data, result in material disruptions of Liminatus&#8217;s development programs and business operations, risk disclosure of confidential, financial or proprietary information, and affect Liminatus&#8217;s reputation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Despite the implementation of security measures, Liminatus&#8217;s internal computer systems or those used by Liminatus&#8217;s third-party research institution collaborators, other contractors, or consultants, may be vulnerable to damage from computer viruses and unauthorized access. As the cyber-threat landscape evolves, attacks are growing in frequency, sophistication, and intensity, and are becoming increasingly difficult to detect. Such attacks could include the use of key loggers or other harmful and virulent malware, including ransomware or other denials of service, and can be deployed through malicious websites, the use of social engineering, and/or other means. If a breakdown, cyberattack, or other information security breach were to occur and cause interruptions in Liminatus&#8217;s operations, it could result in a misappropriation of confidential information, including Liminatus&#8217;s intellectual property or financial information, and a material disruption of Liminatus&#8217;s development programs and Liminatus&#8217;s business operations. For example, the loss of clinical trial data from completed, ongoing, or future clinical trials could result in delays in Liminatus&#8217;s regulatory approval efforts and significantly increase Liminatus&#8217;s costs to recover or reproduce the data. Likewise, Liminatus relies on Liminatus&#8217;s third-party research institution collaborators for research and development of Liminatus&#8217;s product candidates and other third parties for the manufacture of Liminatus&#8217;s product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on Liminatus&#8217;s business. To the extent that any disruption or security breach were to result in a loss of, or damage to, Liminatus&#8217;s data or systems, or inappropriate disclosure of confidential, financial, or proprietary information, including data related to Liminatus&#8217;s personnel, Liminatus could incur liability or risk disclosure of confidential, financial, or proprietary information, and the further development and commercialization of Liminatus&#8217;s product candidates could be delayed. There can be no assurance that Liminatus and Liminatus&#8217;s business counterparties will be successful in efforts to detect, prevent, or fully recover systems or data from all breakdowns, service interruptions, attacks, or breaches of systems that could adversely affect Liminatus&#8217;s business and operations and/or result in the loss of critical or sensitive data, which could result in financial, legal, business, or reputational harm to Liminatus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business disruptions could seriously harm Liminatus&#8217;s future revenue and financial condition and increase Liminatus&#8217;s costs and expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus&#8217;s operations, and those of Liminatus&#8217;s third-party research institution and pharmaceutical company collaborators, manufacturers, and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical or public health crises, and other natural or man-made disasters or business interruptions, including terrorism and war. In addition, for some of Liminatus&#8217;s clinical trials, Liminatus relies on third-party research institution collaborators for conducting research and development of Liminatus&#8217;s product candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions could seriously harm Liminatus&#8217;s operations and financial condition and increase Liminatus&#8217;s costs and expenses. Liminatus relies on third-party manufacturers to produce and process its product candidates. Liminatus&#8217;s ability to obtain clinical supplies of Liminatus&#8217;s product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Damage or extended periods of interruption to Liminatus&#8217;s office, development or research facilities due to fire, natural disaster, power loss, communications failure, unauthorized entry or other events could cause Liminatus to cease or delay development of some or all of Liminatus&#8217;s product candidates. Although Liminatus maintains customary insurance coverage, Liminatus&#8217;s insurance might not cover all losses under such circumstances and Liminatus&#8217;s business may be seriously harmed by such delays and interruption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any legal proceedings or claims against Liminatus could be costly and time-consuming to defend and could harm Liminatus&#8217;s reputation regardless of the outcome.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Liminatus may become subject to legal proceedings and claims that arise in the ordinary course of business, including intellectual property, collaboration, licensing agreement, product liability, employment, class action, whistleblower and other litigation claims, and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">51</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">governmental and other regulatory investigations and proceedings, such as the Sidhu Matter (as defined below). Such matters can be time-consuming, divert management&#8217;s attention and resources, cause Liminatus to incur significant expenses or liability, or require Liminatus to change its business practices. In addition, the expense of litigation and the timing of this expense from period to period are difficult to estimate, subject to change, and could adversely affect Liminatus&#8217;s financial condition and results of operations. Because of the potential risks, expenses, and uncertainties of litigation, Liminatus may, from time to time, settle disputes, even where Liminatus has meritorious claims or defenses, by agreeing to settlement agreements. In addition, if Liminatus is found liable for damages in such a proceeding the amount of such damages may be material and have a significant impact on the Company&#8217;s cash flows and cash reserves. Any of the foregoing could adversely affect Liminatus&#8217;s business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Currently, our Common Stock and Public Warrants are listed on Nasdaq. However, there may not be enough liquidity in such market to enable stockholders to sell their securities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Currently, our Common Stock and Public Warrants are listed on the Global Market tier of Nasdaq and the Capital Market tier of Nasdaq, respectively. If a public market for our securities does not develop, investors may not be able to re-sell their Common Stock or Warrants, rendering their securities illiquid and possibly resulting in a complete loss of their investment. We cannot predict the extent to which investor interest in us will lead to the development of an active, liquid trading market. The trading price of and demand for the Common Stock and the development and continued existence of a market and favorable price for the Common Stock will depend on a number of conditions, including the development of a market following, including by analysts and other investment professionals, the businesses, operations, results, and prospects of the Company, general market and economic conditions, governmental actions, regulatory considerations, legal proceedings, and developments or other factors. These and other factors may impair the development of a liquid market and the ability of investors to sell shares at an attractive price. These factors also could cause the market price and demand for the Common Stock to fluctuate substantially, which may limit or prevent investors from readily selling their shares and may otherwise negatively affect the price and liquidity of the Common Stock. Many of these factors and conditions are beyond the control of the Company or the stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We incur substantial costs as a result of being a public company and the requirements of being a public company may strain the Company&#8217;s resources and distract management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, and the Securities Act. These rules, regulations and requirements are extensive. We incur significant costs associated with our public company corporate governance and reporting requirements. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management&#8217;s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may need to hire more corporate employees to comply with these requirements or engage outside consultants, which would increase our costs and expenses. This may divert management&#8217;s attention from other business concerns, which could have a material adverse effect on our business, financial condition and results of operations. These applicable rules&#160;and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance and it may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on the Board or as executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">52</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a result of disclosure of information in this prospectus and in the filings that we are required to make as a public company, our business, operating results and financial condition have become more visible, which may result in threatened or actual litigation, including by competitors and other third parties. If any such claims are successful, our business, operating results and financial condition could be adversely affected, and even if the claims do not result in litigation or are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management and adversely affect our business, operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sales of a substantial amount of Common Stock in the public market, particularly sales by our executive officers, directors and significant stockholders, or the perception that these sales could occur, could cause the market price of Common Stock to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Sales of a substantial number of shares of Common Stock in the public market, particularly sales by our executive officers, directors and principal stockholders, or the perception that these sales might occur, could cause the market price of Common Stock to decline. Some of our executive officers, directors and the holders of a substantial number of shares of Common Stock are subject to lock-up provisions that prohibit them from offering for sale, selling, contracting to sell, granting any option for the sale of, transferring or otherwise disposing of any shares of Common Stock and of any securities convertible into or exercisable for Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">When the applicable lock-up periods expire, our security holders subject to lock-up provisions will be able to sell shares of Common Stock in the public market. Sales of a substantial number of such shares upon expiration of the lock-up provisions, the perception that such sales may occur or early release of these provisions could cause our market price to fall or make it more difficult for you to sell your shares of Common Stock at a time and price that you deem appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, we may file a registration statement to register shares reserved for future issuance under our equity compensation plans. Subject to the satisfaction of applicable vesting requirements and expiration of the lock-up provisions referred to above, the shares issued upon exercise of outstanding stock options would be available for immediate resale in the open market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A decline in the price of Common Stock could affect our ability to raise working capital and adversely impact our ability to continue operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A prolonged decline in the price of Common Stock could result in a reduction in the liquidity of the Common Stock and a reduction in our ability to raise capital. A decline in the price of Common Stock could be especially detrimental to our liquidity, operations and strategic plans. Such reductions may force us to reallocate funds from other planned uses and may have a significant negative effect on our business plan and operations, including our ability to develop new products and services and continue current operations. If our Common Stock&#8217;s price declines, we can offer no assurance that we will be able to raise additional capital or generate funds from operations sufficient to meet our obligations. If we are unable to raise sufficient capital in the future, we may not be able to have the resources to continue our normal operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about us or our business, our Common Stock price and trading volume could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The trading market for our Common Stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on us. If no securities or industry analysts commence coverage of us, the trading price for our Common Stock would likely be negatively affected. In the event securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrade our securities or publish inaccurate or unfavorable research about our business, our share price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us, demand for our Common Stock could decrease, which might cause the share price and trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We do not intend to pay any cash dividends in the foreseeable future and, therefore, any return on your investment in our capital stock must come from increases in the fair market value and trading price of the capital stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not paid any cash dividends on Common Stock and do not intend to pay cash dividends on Common Stock in the foreseeable future. We intend to retain future earnings, if any, for reinvestment in the development and expansion of our business. Any credit agreements which we may enter into with institutional lenders may restrict our ability to pay dividends. Whether we pay cash dividends in the future will be at the discretion of the Board and will be dependent upon our financial condition, results of operations, capital requirements and any other factors that the Board decides is relevant. Therefore, any return on your investment in our capital stock must come from increases in the fair market value and trading price of the capital stock.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">53</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market price of our equity securities may be volatile, and you could lose a significant part of your investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The stock markets, including Nasdaq, on which certain of our securities are listed, have from time to time experienced significant price and volume fluctuations. Even if an active, liquid and orderly trading market develops and is sustained for the Common Stock and our Public Warrants, the market price of the Common Stock and our Public Warrants may be volatile and could decline significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June&#160;22, 2026, the last reported sales price of our Common Stock was $0.11. The exercise price of the Public Warrants is $11.50, which is higher than the current market price of our Common Stock and accordingly, Warrant holders may not be able to exercise their warrants at this time. Cash proceeds associated with the exercises of our outstanding warrants are dependent on our stock price and given the recent price volatility of our Common Stock and relative lack of liquidity in our stock, we may not receive any cash proceeds in relation to our outstanding warrants. In addition, the trading volume in our Common Stock and our Public Warrants may fluctuate and cause significant price variations to occur. We cannot assure you that the market price of the Common Stock and our Public Warrants will not fluctuate widely or decline significantly in the future in response to a number of factors, including, among others, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the realization of any of the risk factors presented in this prospectus;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the concentration of the ownership of our shares by a limited number of affiliated stockholders may limit interest in our securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limited &#8220;public float&#8221; with a small number of persons whose sales or lack of sales could result in positive or negative pricing pressure on the market price for the Common Stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of a strategic relationship;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in operating results from the expectations of securities analysts or investors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of new products or services by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">investor perception of our industry or prospects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">insider selling or buying;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">investors entering into short sale contracts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments affecting our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitive pricing pressures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain working capital financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to execute our business plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operating results that fall below expectations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">revisions in securities analysts&#8217; estimates or reductions in security analysts&#8217; coverage; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">economic and other external factors.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">54</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many of these factors are beyond our control and may decrease the market price of the Common Stock, regardless of our operating performance. We cannot make any predictions or projections as to what the prevailing market price for the Common Stock will be at any time, including as to whether the Common Stock will sustain current market prices, or as to what effect that the sale of shares or the availability of the Common Stock for sale at any time will have on the prevailing market price. In addition, the securities markets have from time-to-time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of the Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the past, many companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we do not maintain compliance with the Nasdaq continued listing requirements, it could result in a suspension or delisting of the Common Stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Common Stock is listed for trading on The Nasdaq Global Market, and the continued listing of the Common Stock on The Nasdaq Global Market is subject to compliance with a number of listing standards. These listing standards include the requirement of maintaining a minimum Market Value of Listed Securities and maintaining a minimum Market Value of Publicly Held Shares. The failure to meet any listing standard would subject Company to potential loss of listing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November&#160;19, 2025, we received notices from Nasdaq indicating that we were no longer in compliance with (i)&#160;Nasdaq Listing Rule&#160;5450(b)(2)(A)&#160;due to our failure to maintain a minimum Market Value of Listed Securities (MVLS) of $50,000,000 (the &#8220;MVLS Rule&#8221;), based upon a review of our MVLS for the last 30 consecutive business&#160;days and (ii)&#160;Nasdaq Listing Rule&#160;5450(b)(2)(C)&#160;due to our failure to maintain a minimum Market Value of Publicly Held Shares (MVPHS) of $15,000,000 (the &#8220;MVPHS Rule&#8221;), based upon a review of our MVPHS for the last 30 consecutive business&#160;days. The Nasdaq staff noted that we also do not meet the requirements under Listing Rule&#160;5450(b)(3)(A), which requires us to have total assets and total revenue of at least $50 million each for the most recently completed fiscal&#160;year or two of the three most recently completed fiscal&#160;years. Under the Nasdaq rules, we were provided a compliance period of 180 calendar&#160;days, or until May&#160;18, 2026, in which to regain compliance with the MVLS Rule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May&#160;20, 2026, the Company received a notice from Nasdaq stating that the Company had not regained compliance with the MVLS Rule&#160;and the MVPHS Rule. Accordingly, its securities were to be delisted from The Nasdaq Global Market. Unless the Company requested an appeal of the determination before the Nasdaq Hearings Panel (the &#8220;Panel&#8221;) by May&#160;27, 2026, trading of the Company&#8217;s Common Stock and Warrants would have been suspended at the opening of business on May&#160;29, 2026, and a Form&#160;25-NSE would have been filed with the SEC, which would have removed the Company&#8217;s securities from listing and registration on Nasdaq. On May&#160;26, 2026, the Company requested an appeal before the Panel. The hearing request will result in a stay of any suspension or delisting action pending the hearing. We are working diligently to regain compliance with Nasdaq&#8217;s listing rules. However, there can be no assurance that we will be able to regain compliance within the prescribed time period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the Common Stock were no longer listed on The Nasdaq Global Market or any other Nasdaq market, investors might only be able to trade on one of the over-the-counter markets, including the OTC Pink Market (a quotation medium operated by the OTC Markets Group). This would impair the liquidity of the Common Stock, not only in the number of shares that could be bought and sold at a given price, which might be depressed by the relative illiquidity, but also through delays in the timing of transactions and reduction in media coverage. In addition, we could face significant material adverse consequences, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a limited availability of market quotations for our securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a limited amount of news and analyst coverage for us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decreased ability to issue additional securities or obtain additional financing in the future.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event of a future delisting, we intend to take actions to restore our compliance with Nasdaq&#8217;s continued listing requirements, but we can provide no assurance that any such action taken by us would allow our Common Stock to become listed again, stabilize the market price or improve the liquidity of our Common Stock or prevent future non-compliance with Nasdaq&#8217;s continued listing requirements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">55</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our shares become subject to the penny stock rules, it would become more difficult to trade our shares.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The SEC has adopted rules&#160;that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. If our common stock is no longer listed on a national securities exchange such as Nasdaq and if the price of our common stock is less than $5.00, our common stock may be deemed a penny stock. The penny stock rules&#160;require a broker-dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing specified information. In addition, the penny stock rules&#160;require that before effecting any transaction in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive: (i)&#160;the purchaser&#8217;s written acknowledgment of the receipt of a risk disclosure statement; (ii)&#160;a written agreement to transactions involving penny stocks; and (iii)&#160;a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common stock, and therefore stockholders may have difficulty selling their shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are a &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; under the U.S. federal securities laws, and the reduced reporting requirements applicable to smaller reporting companies and emerging growth companies could make our common stock less attractive to investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a &#8220;smaller reporting company&#8221; and an &#8220;emerging growth company&#8221; under U.S. federal securities laws. For as long as we continue to be a smaller reporting company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not smaller reporting companies, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. Furthermore, as an emerging growth company, we may take advantage of exemptions from certain reporting requirements including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and exemptions from the requirements of holding a non-binding advisory vote on executive compensation. Investors may not find our common stock attractive because we may rely on these exemptions and reduced disclosures. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will remain a smaller reporting company until the last day of the fiscal&#160;year in which (1)&#160;the market value of our common stock held by non-affiliates exceeds $250 million as of the prior June&#160;30, or (2)&#160;our annual revenues exceeded $100 million during such completed fiscal&#160;year and the market value of our common stock held by non-affiliates exceeds $700 million as of the prior June&#160;30.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will remain an emerging growth company until the earlier of: (1)&#160;the last day of the fiscal&#160;year (a)&#160;following the fifth anniversary of the closing of the IPO, (b)&#160;in which we have total annual gross revenue of at least $1.235 billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common equity that is held by non-affiliates exceeds $700 million as of the end of the prior fiscal&#160;year&#8217;s second fiscal quarter; and (2)&#160;the date on which we have issued more than $1.00 billion in non-convertible debt securities during the prior three-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Anti-takeover provisions contained in our certificate of incorporation and bylaws could impair a takeover attempt.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our charter and bylaws afford certain rights and powers to our board of directors that could contribute to the delay or prevention of an acquisition that it deems undesirable, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of our board of directors to issue shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the right of our board of directors to elect a director to fill a vacancy created by the expansion of our board of directors or the resignation, death or removal of a director, which may prevent stockholders from being able to fill vacancies on our board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the requirement that a special meeting of stockholders may be called only by our board of directors, the chairman of the board of directors, the chief executive officer or the president, which could delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">56</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are also subject to other provisions of Delaware law that limit the ability of stockholders in certain situations to effect certain mergers. Any of the foregoing provisions and terms that has the effect of delaying or deterring a change in control could limit the opportunity for stockholders to receive a premium for their shares of Common Stock, and could also affect the price that some investors are willing to pay for the Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our certificate of incorporation provides, subject to limited exceptions, that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for certain stockholder litigation matters, which could limit stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our charter requires, to the fullest extent permitted by law, that derivative actions brought in our name, actions against directors, officers and employees for breach of fiduciary duty and other similar actions may be brought in the Court of Chancery in the State of Delaware or, if that court lacks subject matter jurisdiction, another federal or state court situated in the State of Delaware. These provisions will not apply to suits brought to enforce any liability or duty created by the Securities Act, the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provisions in our charter. In addition, our charter and bylaws provide that, to the fullest extent permitted by law, claims made under the Securities Act must be brought in federal district court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims and result in increased costs for investors to bring a claim. Alternatively, if a court were to find the choice of forum provision contained in our charter to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to this Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Selling Stockholder may choose to sell the shares at prices below the current market price.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Selling Stockholder is not restricted as to the prices at which it may sell or otherwise dispose of the Shares covered by this prospectus. Sales or other dispositions of the Shares below the then-current market prices could adversely affect the market price of our Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Neither we nor the Selling Stockholder has authorized any other party to provide you with information concerning us or this offering.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">You should carefully evaluate all of the information in this prospectus, including the documents incorporated by reference herein. We may receive media coverage regarding our Company, including coverage that is not directly attributable to statements made by our officers, that incorrectly reports on statements made by our officers or employees, or that is misleading as a result of omitting information provided by us, our officers or employees. Neither we nor the Selling Stockholder has authorized any other party to provide you with information concerning us or this offering, and recipients should not rely on this information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Investors who buy shares at different times will likely pay different prices.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Investors who purchase Shares in this offering at different times will likely pay different prices and so may experience different levels of dilution and different outcomes in their investment results. The Selling Stockholder may sell shares of Common Stock underlying the Inducement Warrants at different times and at different prices.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">57</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The issuance of Common Stock to the Selling Stockholder upon exercise of the Inducement Warrants may cause substantial dilution to our existing stockholders, and the sale of such shares acquired by the Selling Stockholder could cause the price of our Common Stock to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are registering for resale by the Selling Stockholder of up to 20,688,000 shares of Common Stock that we may issue to the Selling Stockholder upon exercise of the Inducement Warrants. The number of shares of our Common Stock ultimately offered for resale by the Selling Stockholder under this prospectus is dependent upon the number of shares of Common Stock issued to the Selling Stockholder upon exercise of the Inducement Warrants. Depending on a variety of factors, including market liquidity of our Common Stock, the issuance of Shares to the Selling Stockholder may cause the trading price of our Common Stock to decline. Following receipt by the Selling Stockholder of Shares issued to the Selling Stockholder upon exercise of the Inducement Warrants, the Selling Stockholder may sell all, some or none of such Shares. The sale of a substantial number of shares of our Common Stock by the Selling Stockholder in this offering, or anticipation of such sales, could cause the trading price of our Common Stock to decline or make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise desire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our management will have broad discretion over the use of the net proceeds received upon any cash exercise of the Inducement Warrants, you may not agree with how we use the proceeds, and the proceeds may not be invested successfully.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our management will have broad discretion over the use of proceeds, if any, received upon any cash exercise of the Inducement Warrants. We intend to use the net proceeds primarily for working capital and general corporate purposes. The net proceeds, if any, may be used for corporate purposes that do not improve our operating results or enhance the value of our Common Stock. The failure of our management to use these funds effectively could have a material adverse effect on our business or cause the market price of our Common Stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">58</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_ea7fac06_b929_4817_8231_3b6052e7b193"></a><a id="USEOFPROCEEDS_918479"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">USE OF PROCEEDS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will not receive any proceeds from the sale of Shares by the Selling Stockholder pursuant to this prospectus. However, we may receive aggregate gross proceeds of up to $3,723,840 only to the extent the Inducement Warrants are exercised for cash. We intend to use the net proceeds primarily for working capital and general corporate purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will pay all expenses associated with effecting the registration of the Shares, including filing and printing fees, the Company&#8217;s counsel and accounting fees and expenses, costs associated with clearing the shares for sale under applicable state securities laws, and listing fees, but excluding discounts, commissions, fees of underwriters, selling brokers, dealer managers or similar securities industry professionals with respect to the sale or other disposition of the Shares.</p><a id="_0e207998_ae4a_42e8_a446_9aab5c19bf30"></a><a id="DIVIDENDPOLICY_971761"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">DIVIDEND POLICY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have not paid any cash dividends on our Common Stock to date. The payment of cash dividends by us in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition. The payment of any dividends will be within the discretion of our Board. The Board currently anticipates that we will retain all or our earnings, if any, for use in our business and operations and, accordingly, the Board does not anticipate declaring any dividends in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">59</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_03500408_3bd4_46c4_899f_ccd21785b34f"></a><a id="MANAGEMENTSDISCUSSIONANDANALYSISO_373850"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF LIMINATUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Unless the context otherwise requires, for purposes of this section, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221; or &#8220;Liminatus&#8221; refer to Liminatus Pharma, LLC prior to the consummation of the Business Combination and to Liminatus Pharma,&#160;Inc. and its consolidated subsidiaries following the Business Combination. You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere herein, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks, uncertainties, and assumptions. As a result of many factors, including those set forth in the &#8220;Risk Factors&#8221; section of this prospectus, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The discussion contains forward-looking statements that are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. Actual results could differ materially from those discussed in or implied by forward-looking statements as a result of various factors, including those discussed below and elsewhere in this prospectus, particularly in the sections titled &#8220;Risk Factors&#8221; and &#8220;Cautionary Note&#160;Regarding Forward-Looking Statements.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is a pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company&#8217;s candidate IBA101, is a humanized anti CD47 monoclonal antibody. The next generation CD47 checkpoint inhibitor&#8217;s initial indication is expected to be patients with advanced solid cancers including non-small cell lung cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is subject to the uncertainty of whether the Company&#8217;s intellectual property will develop into successful commercial products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November&#160;30, 2022, Iris Acquisition Corp, a Delaware corporation (&#8220;Iris&#8221;), the Company, Liminatus Pharma, LLC, a Delaware limited liability company (&#8220;Liminatus&#8221;), Liminatus Merger Sub and SPAC Merger Sub entered into a business combination agreement (as it may be amended, supplemented or otherwise modified from time to time, the &#8220;Business Combination Agreement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March&#160;4, 2025, Iris held a special meeting of stockholders. At the special meeting, Iris&#8217;s stockholders voted to approve the Business Combination and adopt the Business Combination Agreement, among other items. In connection with the special meeting, stockholders holding 59,844 Iris Class&#160;A Shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $11.74 per share, subject to adjustment for taxes payable from the trust account, for an aggregate redemption amount of $702,359. The redemptions were settled on April&#160;30, 2025 upon the consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On April&#160;30, 2025 (the &#8220;Closing Date&#8221;), the Company consummated the business combination contemplated by the Business Combination Agreement, pursuant to which (a)&#160;Liminatus Merger Sub merged with and into Liminatus (the &#8220;Liminatus Merger&#8221;), with Liminatus surviving the Liminatus Merger as a direct wholly-owned subsidiary of the Company, and (b)&#160;simultaneously with the Liminatus Merger, SPAC Merger Sub merged with and into Iris (the &#8220;SPAC Merger&#8221; and, together with the Liminatus Merger, the &#8220;Mergers&#8221;), with Iris surviving the SPAC Merger as a direct wholly-owned subsidiary of the Company (the transactions contemplated by the foregoing clauses (a)&#160;and (b), the &#8220;Business Combination&#8221;), and in connection therewith the Company changed its name from &#8220;Iris Parent Holding Corp.&#8221; to &#8220;Liminatus Pharma,&#160;Inc.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">60</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Business Combination Agreement, among other matters, at the effective time of the Business Combination (the &#8220;Effective Time&#8221;), (i)&#160;every issued and outstanding unit issued by Iris during its initial public offering (each, an &#8220;Iris Unit&#8221;) was automatically separated and broken out into its constituent parts and the holder thereof was deemed to hold one share of Iris Class&#160;A common stock, par value $0.0001 per share (the &#8220;Iris Class&#160;A Shares&#8221;) and one-fourth of one redeemable warrant that was included as part of each Iris Unit (the &#8220;Public Warrants&#8221;), and such underlying constituent securities of Iris were converted in accordance with the applicable terms of the Business Combination Agreement, (ii)&#160;at the Effective Time, each issued and outstanding Iris Class&#160;A Share was converted automatically into and thereafter represent the right to receive one share of common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;), of the Company, following which all Iris Class&#160;A Shares ceased to be outstanding and were automatically canceled and ceased to exist, (iii)&#160;at the Effective Time, each issued and outstanding Public Warrant immediately and automatically represented the right to purchase shares of Common Stock on the same terms and conditions as are set forth in the applicable warrant agreement, (iv)&#160;at the Effective Time, each issued and outstanding non-redeemable warrant of Iris that was issued by Iris in a private placement at the time of the consummation of its initial public offering, entitling the holder thereof to purchase one Iris Class&#160;A Share at $11.50 per share, except those issued to Cantor Fitzgerald&#160;&amp; Co. (&#8220;Cantor&#8221;), were forfeited, and (v)&#160;the private placement warrants issued to Cantor immediately and automatically represented the right to purchase shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon the consummation of the Business Combination, the Company&#8217;s certificate of incorporation was amended and restated to, among other things, set the total number of authorized shares of capital to 501,000,000 shares, of which 500,000,000 were designated as common stock, $0.0001 par value per share, and 1,000,000 shares were designated as preferred stock, $0.0001 par value per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At the Closing Date, 7,014,633 shares of Iris Class&#160;A Shares automatically converted into shares of the Company&#8217;s common stock, on a one-for-one basis. Of the total 7,014,633 newly converted shares, 6,900,000 were issued to Iris Acquisition Holdings, LLC, the sponsor of Iris and 114,633 were issued to Iris&#8217; public stockholders in a noncash transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At the Closing Date, the Company issued an aggregate of 1,500,000 shares of the Company&#8217;s common stock in a private placement (the &#8220;PIPE Shares&#8221;) for the total consideration of $15,000,000 (the &#8220;PIPE Financing&#8221;). The PIPE Financing consisted of a cash and non&#160;- cash component. Under the cash component, the Company received gross proceeds of $10,556,500, of which $7,129,500 came directly from the PIPE investor and $3,427,000 were funded indirectly by the PIPE investor, through promissory notes between Prophase Sciences, LLC, a related party of the Company, and Liminatus. At the Closing Date, the $3,427,000 in related party debts between Prophase Sciences, LLC and Liminatus was ultimately converted into shares as part of the PIPE Financing. As part of the PIPE Financing, the gross proceeds satisfied principal and accrued interest totaling $3,316,756, which was ultimately converted into shares as part of the PIPE Financing. The non&#160;- cash component of the PIPE Financing included the conversion of $4,443,500 in amounts borrowed from a consortium of related parties. The $4,443,500 borrowed from the related parties were used to fund an unsecured promissory note between Liminatus and Iris. At the Closing Date, the unsecured promissory note was settled and the $4,443,500 in related party debts were ultimately converted into shares of the Company in a noncash transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At the Closing Date, 112,222,220 Liminatus&#8217; member units converted into 17,500,000 shares of the Company&#8217;s common stock. Of the 17,500,000 shares of common stock, 4,000,000 were issued to Feelux Co,&#160;Ltd. as part of an agreement between the Company, Feelux Co,&#160;Ltd. and Car-Tcellkor,&#160;Inc. As part of the agreement, the outstanding principal and accrued interest on the Feelux and Car-Tcellkor bonds, totaling $11,481,146, and 9,999,999 member units of Liminatus were converted into 4,000,000 shares of the Company&#8217;s common stock. The remaining Liminatus member units were converted based on a conversion ratio of 0.1559 shares per member unit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon consummation of the Business Combination, the Company assumed a total of $10,694,604 in liabilities from Iris. The Company incurred $1,518,381 in transaction costs associated with the closing of the Business Combination. The Company converted a total of $14,797,901 of related party debt and accrued interest, $3,316,756 from the PIPE investor and $11,481,146 from Feelux and Car-Tcellkor (as described above) into common stock. Additionally, a total of $169,201 in accrued interest on related party debts that were converted, as discussed above, was eliminated upon consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, at the Closing Date, the Company settled Iris&#8217; liabilities for $7,000,000 of the deferred underwriting fees incurred prior to the Closing Date for 700,000 shares of common stock to the underwriters in Iris&#8217;s initial public offering. At the Closing Date, the shares were not issued to the underwriter and the Company recorded as a liability with a fair value of $7,049,000. On July&#160;1, 2025, the Company issued the shares to the underwriters, which on July&#160;1, 2025 had a fair value of $7,245,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Liminatus was deemed the accounting acquirer in the Business Combination based on an analysis of the criteria outlined in Accounting Standards Codification (&#8220;ASC&#8221;) 805, <i style="font-style:italic;">Business Combinations</i> (&#8220;ASC 805&#8221;). The determination was primarily based on Liminatus&#8217; members prior to the Business Combination having a majority of the voting interests in the combined company, Liminatus&#8217; ability to exert control over the majority of the board of directors of the combined company, Liminatus&#8217; ability to maintain control of the board </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">61</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of directors on a go-forward basis, Liminatus&#8217; senior management comprising the senior management of the combined company, and Liminatus&#8217; operations prior to the Business Combination comprise the ongoing operations of the combined company. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Liminatus&#8217; issuing stock for the net assets of Iris, accompanied by a recapitalization. The net assets of Iris were stated at fair value, with no goodwill or other intangible assets recorded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon the consummation of the Business Combination, the Iris Class&#160;A Shares, Iris Units and Public Warrants ceased trading on the OTC Pink Marketplace, and the Common Stock and Public Warrants began trading on Nasdaq under the trading symbols &#8220;LIMN&#8221; and &#8220;LIMNW,&#8221; respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">February 2026 Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 18, 2026, we closed a best efforts public offering for the sale of (i) 8,270,000 shares of our common stock, (ii) 5,543,000 pre-funded warrants to purchase up to 5,543,000 shares of our common stock and (iii) 13,813,000 common stock purchase warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per pre-funded warrant) and accompanying warrant (the &#8220;Offering&#8221;), for aggregate net proceeds of approximately $3.44 million after deducting the estimated offering expenses, including the placement agent fees. Each pre-funded warrant has an exercise price of $0.0001 per share upon issuance for one share of common stock and will not expire prior to exercise. Each warrant has an exercise price of $0.29 per share, is exercisable upon issuance for one and a half shares of common stock, and will expire five years following the date of issuance. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the common stock and the exercise price. Maxim Group LLC acted as the placement agent in connection with the Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Offering, on February 17, 2026, we entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers party thereto. Pursuant to the Purchase Agreement, we agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock or file any registration statement or prospectus, or any amendment or supplement thereto for 180 days after the closing date of the Offering, subject to certain exceptions. We also agreed not to effect or enter into an agreement to effect any issuance of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock involving a Variable Rate Transaction (as defined in the Purchase Agreement) until 180 days after the closing date of the Offering, subject to certain exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Offering, on February 17, 2026, we entered into a placement agency agreement with Maxim Group LLC, as placement agent in connection with the Offering (the &#8220;Placement Agent&#8221;). We paid the Placement Agent a cash fee of 8.0% of the aggregate gross proceeds raised in the Offering. We also agreed to reimburse the Placement Agent for all reasonable out-of-pocket costs and expenses incurred in connection with the Offering in an aggregate amount up to $100,000. In addition, we issued to the Placement Agent warrants (the &#8220;Placement Agent Warrants&#8221;) to purchase 690,650 shares of common stock (representing 5.0% of the number of shares of common stock sold in the Offering). The Placement Agent Warrants are immediately exercisable at an exercise price of $0.319 (or 110% of the public offering price for the shares of common stock and common warrants offered in the Offering) and will expire on the fifth anniversary of the commencement of sales of the Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain Recent Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">InnocsAI Merger Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 17, 2026, the Company entered into a Merger Agreement (as it may be amended, supplemented or otherwise modified from time to time, the &#8220;Merger Agreement&#8221;) with InnocsAI LLC, Delaware limited liability company (&#8220;InnocsAI&#8221;), and NamChul Jung, an individual, as the representative of the members of InnocsAI. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Acquisition and Merger Consideration</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon the closing of the transactions contemplated in the Merger Agreement, and subject to the terms and conditions set forth therein, and in accordance with the applicable provisions of the Delaware General Corporation Law and the Delaware Limited Liability Company Act, InnocsAI will merge with an into a new wholly-owned Delaware subsidiary of the Company (&#8220;Merger Sub&#8221;), the separate corporate existence of InnocsAI will cease and Merger Sub will continue as the surviving corporation (the &#8220;Merger&#8221;).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">62</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Merger Agreement, the aggregate consideration to be paid to existing members of InnocsAI is 1,600,000,000 shares of Common Stock, at an issue price of $0.20 per share (the &#8220;Closing Payment Shares&#8221;), and contingent value rights to be agreed upon by the parties representing in the aggregate the right to receive 20% of net proceeds from any future strategic sale, out-license, transfer, or exit of the assets acquired from InnocsAI. Upon the effectiveness of the Merger, all issued and outstanding membership interests of InnocsAI will be canceled and automatically converted into the Closing Payment Shares. Valetudo Therapeutics LLC is a member of InnocsAI, and Chris Kim, the CEO and a director of the Company, is the CEO and controlling member of Valetudo Therapeutics LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Overview of Acquired Pipeline Assets</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The assets to be acquired in the Merger include a portfolio of oncology-focused biologic and cellular therapy programs. The portfolio is centered on CAR-T and antibody-related technologies designed to address certain limitations observed in current approaches to hematologic malignancies and solid tumors, including antigen escape, tumor heterogeneity, limited T-cell persistence, tumor microenvironment-mediated suppression, and lineage-restricted target coverage. The Company believes that these assets may provide development opportunities across hematologic oncology, solid tumor indications, and future multi-target platform applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">IBC101</b>. IBC101 is an autologous CD19xCD22 bivalent CAR-T cell therapy candidate designed for relapsed or refractory B-cell malignancies. The product is intended to function as an OR-gate CAR-T therapy, enabling recognition of malignant B cells expressing either CD19 or CD22. According to InnocsAI materials, IBC101 has received authorization from the Ministry of Food and Drug Safety of the Republic of Korea for a Phase 1/2a clinical study in relapsed or refractory diffuse large B-cell lymphoma, with Seoul St. Mary&#8217;s Hospital identified as the lead clinical site.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">IBC101 is designed to address antigen escape and tumor heterogeneity, which are recognized mechanisms of relapse following single-antigen CD19-directed CAR-T therapy. By combining CD19 and CD22 targeting, IBC101 is intended to broaden antigen coverage in B-cell malignancies. InnocsAI materials also describe an ex vivo expansion process using IL-7 and IL-15, with the goal of supporting T-cell fitness and persistence. If successfully developed, IBC101 could represent a next-generation hematologic CAR-T candidate with potential applicability in relapsed or refractory DLBCL and other B-cell malignancies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">INC101</b>. INC101 is a preclinical autologous bicistronic CAR-T cell therapy candidate for solid tumors based on a dual-antigen MSLNxCD276 design. The construct is designed as an AND-gate system in which mesothelin provides the primary tumor-associated activation signal and CD276, also known as B7-H3, provides a secondary costimulatory signal. This design is intended to improve tumor selectivity by requiring convergence of two tumor-associated signals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The INC101 program is designed to address challenges that have limited CAR-T development in solid tumors, including on-target/off-tumor risk, antigen heterogeneity, tonic signaling, T-cell exhaustion, and tumor microenvironment-mediated suppression. InnocsAI materials describe a bicistronic architecture that separates activation and costimulation into two modules and incorporates engineering features intended to reduce signal leakage. A related follow-on construct, INC102, incorporates a dominant-negative TGF-&#946; receptor armoring strategy intended to support T-cell function in TGF-&#946;-rich tumor microenvironments. The proposed development focus includes biomarker-selected solid tumors with mesothelin and CD276 expression, including malignant pleural mesothelioma, ovarian cancer, pancreatic cancer, and other selected solid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">CS1 Antibody Platform</b>. The CS1 antibody platform consists of proprietary anti-CS1 monoclonal antibodies intended to serve as an enabling module for InnocsAI&#8217;s hematologic CAR-T platform. Rather than being positioned primarily as a standalone CS1-directed CAR-T program, the CS1 binders are intended to be combined with the CD19xCD22 bivalent CAR-T backbone to support development of a potential CD19xCD22xCS1 trivalent CAR-T candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">This strategy is intended to extend the platform from B-cell malignancies into plasma-cell malignancies, including multiple myeloma. CD19 and CD22 are intended to provide coverage of B-cell leukemias and lymphomas, while CS1 is intended to add plasma-cell targeting capability. By integrating these targets into one trivalent CAR-T framework, InnocsAI may be able to bridge B-cell malignancy and plasma-cell malignancy targeting strategies and support broader hematologic oncology platform-development opportunities.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">63</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrant Inducement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Inducement Letter Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 3, 2026, the Company entered into the Inducement Letter Agreement with Armistice, which was a holder of certain warrants (the &#8220;Existing Warrants&#8221;) to purchase up to 10,344,000 shares of the Common Stock. The Existing Warrants were originally issued on February 18, 2026, with an exercise price of $0.29 per share. Pursuant to the Inducement Letter Agreement, Armistice agreed to exercise the Existing Warrants for cash at a reduced exercise price of $0.18 per share in consideration for the Company&#8217;s agreement to issue the Inducement Warrants to purchase up to an aggregate of 20,688,000 shares of Common Stock at an exercise price per share of $0.18.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The issuance of the shares of Common Stock upon exercise of the Existing Warrants is registered pursuant to a registration statement on Form S-1 (File No. 333-293364), which was declared effective by the Securities and Exchange Commission on February 13, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The aggregate gross proceeds to the Company from the exercise of the Existing Warrants was approximately $1,861,920, before deducting offering expenses payable by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financial Advisor Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the Inducement Letter Agreement, on June 3, 2026, we entered into a letter agreement (the &#8220;Financial Advisor Agreement&#8221;) with Maxim Group LLC (the &#8220;Financial Advisor&#8221;), pursuant to which (i) the Financial Advisor agreed to act as exclusive lead warrant solicitation agent on a &#8220;reasonable best efforts&#8221; basis in connection with the transactions contemplated by the Inducement Letter Agreement, and (ii) we agreed to pay the Financial Advisor an aggregate fee equal to 8.0% of the gross proceeds received by the Company from the exercise of the Existing Warrants. Additionally, we reimbursed the Financial Advisor for certain expenses and legal fees up to $15,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations for the Three&#160;Months Ended March&#160;31, 2026 and 2025</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following is a comparative of our results of operations for the three&#160;months ended March&#160;31, 2026 and 2025:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:227.05pt;padding:0pt;"/><td style="width:10.5pt;padding:0pt;"/><td style="width:5.1pt;padding:0pt;"/><td style="width:64.5pt;padding:0pt;"/><td style="width:10.5pt;padding:0pt;"/><td style="width:5.1pt;padding:0pt;"/><td style="width:64.5pt;padding:0pt;"/><td style="width:10.5pt;padding:0pt;"/><td style="width:5.1pt;padding:0pt;"/><td style="width:64.5pt;padding:0pt;"/><td style="width:10.55pt;padding:0pt;"/><td style="width:53.75pt;padding:0pt;"/><td style="width:8.35pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:227.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:53.75pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:227.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;width:149.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the three&#160;months ended March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="border-bottom-color:transparent;border-bottom-style:solid;border-bottom-width:1px;color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:bottom;width:5.1pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="border-bottom-color:transparent;border-bottom-style:solid;border-bottom-width:1px;color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:bottom;white-space:nowrap;width:53.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr style="height:9.69pt;"><td style="vertical-align:bottom;width:227.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:69.6pt;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;width:69.6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:69.6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.75pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:227.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">700,898</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">264,220</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">436,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.75pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:227.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">400,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">400,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.75pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:227.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,100,898</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">264,220</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">836,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55pt;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.75pt;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">317</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:227.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,100,898)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(264,220)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(836,678)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.75pt;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">317</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:227.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(22,816)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(63,306)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">40,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55pt;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.75pt;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(64)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:227.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,123,714)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(327,526)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(796,188)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55pt;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.75pt;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of professional service fees, including accounting and legal services and other general operating expenses. General and administrative expenses increased by $436,678 during the three&#160;months ended March&#160;31, 2026 as compared to the three&#160;months ended March&#160;31, 2025 primarily due to increases in accounting and legal expenses incurred in connection with the Company now operating as a publicly traded company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of costs incurred by InnoBation Bio Co,&#160;Ltd. (&#8220;Innobation&#8221;) who was performing the research and development activities for the Company in accordance with the license agreements with Innobation. Research and development expenses increased by $400,000 as a result of costs incurred under the CD47 license agreement during the three&#160;months ended March&#160;31, 2026 as compared no such costs incurring during the three&#160;months ended March&#160;31, 2025.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">64</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Expenses, net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The other expense, net decreased by $40,490 from $63,306 of other expense for the three&#160;months ended March&#160;31, 2025 to $22,816 of other expense for the three&#160;months ended March&#160;31, 2026. The Company recognized interest expense of $18,638 on related party promissory notes during the three&#160;months ended March&#160;31, 2026 as compared to interest expense of $115,512 during the three&#160;months ended March&#160;31, 2025 due to a decrease in the related party promissory notes principal balance following the closing of the Business Combination. Further, the Company recognized no interest income on loans receivable with Iris during the three&#160;months ended March&#160;31, 2026 as compared to interest income of $52,206 during the three&#160;months ended March&#160;31, 2025. In connection with the closing of the Business Combination on April&#160;30, 2025, the loans receivable with Iris were terminated, thus no interest income is expected in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations for the&#160;Years Ended December&#160;31, 2025 and 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were $3.0 million for the&#160;year ended December&#160;31, 2025 as compared to $0.6 million for the&#160;year ended December&#160;31, 2024. The increase by approximately $2.3 million was primarily related to increases in accounting and legal costs related to the Business Combination and general corporate matters during the&#160;year ended December&#160;31, 2025 as compared to the&#160;year ended December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses were $0 for the&#160;year ended December&#160;31, 2025 as compared to $2.7 million for the&#160;year ended December&#160;31, 2024. Research and development expenses decreased by approximately $2.7 million during the&#160;year ended December&#160;31, 2025 as compared to the&#160;year ended December&#160;31, 2024 as a result of the termination of TDT&#8217;s license agreements on August&#160;11, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Expense, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other expense, net increased by approximately $7.0 million from $0.2 million of other expense for the&#160;year ended December&#160;31, 2024 to $7.2 million of other expense for the&#160;year ended December&#160;31, 2025. The increase is primarily due the Company recognizing other income of $2.1 million related to the settlement of TDT&#8217;s payables and an unrealized gain on the change in fair value of the warrant liabilities of $54,312, offset by an unrealized loss on the change in the fair value of deferred underwriting fee paid in common stock of $196,000, a loss on the issuance of common stock of approximately $1.7 million related to the issuance of common stock in exchange for the cancellation of warrants and approximately $7.4 million of expenses related to the fair value of common stock to be issued in February&#160;of 2026 due to settlement of the Clear Street litigation, discussed elsewhere in this filing, for a contingent liability that became reasonably estimable prior to the issuance of these consolidated financial statements. No such transactions occurred during the&#160;year ended December&#160;31, 2024. The Company recognized interest expense of $215,903 on related party promissory notes during the&#160;year ended December&#160;31, 2025 as compared to interest expense of $338,882 during the&#160;year ended December&#160;31, 2024 due to a decrease in the related party promissory notes principal balance following the closing of the Business Combination. Further, the Company recognized interest income of $76,589 on loans receivable with Iris during the&#160;year ended December&#160;31, 2025 as compared to interest income of $122,526 during the&#160;year ended December&#160;31, 2024. In connection with the closing of the Business Combination on April&#160;30, 2025, the loans receivable with Iris were terminated, thus no interest income is expected in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Going Concern, Liquidity and Capital Resources as of March&#160;31, 2026 and 2025</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for one&#160;year after the date that the condensed consolidated financial statements are issued. Through March&#160;31, 2026, the Company has funded its operations mainly through equity and debt financings, including the proceeds from the Mergers and the PIPE Financing, and the Offering (as described below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March&#160;31, 2026, the Company had $1,907,674 of cash in its bank accounts. As of March&#160;31, 2026 and December&#160;31, 2025, there was $1,442,500 of related party debts, which are included in Short-term debt, related parties in the accompanying unaudited condensed consolidated balance sheets.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">65</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has an accumulated deficit of $39,995,447 as of March&#160;31, 2026. The Company had a loss from operations and net loss of $1,100,898 and $1,123,714, respectively, for the three&#160;months ended March&#160;31, 2026. The Company had a loss from operations and net loss of $264,220 and $327,526, respectively, for the three&#160;months ended March&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February&#160;18, 2026, the Company completed a &#8220;best efforts&#8221; public offering of (i)&#160;8,270,000 shares of its common stock, (ii)&#160;5,543,000 pre-funded warrants to purchase up to 5,543,000 shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) and (ii)&#160;13,813,000 common stock purchase warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per Pre-Funded Warrant) and accompanying warrant (the &#8220;Offering&#8221;). In connection with the Offering, the Company received net proceeds of approximately $3.44 million, after deducting the estimated offering expenses payable by the Company, including the placement agent fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 205-40, <i style="font-style:italic;">Presentation of Financial Statements&#8212;Going Concern</i>, management has concluded that there is substantial doubt about its ability to continue as a going concern for one&#160;year after the date that the accompanying unaudited condensed consolidated financial statements are issued. The Company&#8217;s unaudited condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management&#8217;s plans relating to the above include raising additional cash through equity and debt financings or other arrangements to fund operations. There can be no assurance that the Company will be able to raise adequate capital under acceptable terms, if at all. The sale of additional equity may dilute existing members and newly issued equity securities may contain senior rights and preferences compared to currently outstanding common stock. Issued debt securities may contain covenants and limit the Company&#8217;s ability to pay dividends or make other distributions to stockholders. If the Company is unable to obtain such additional financing, future operations would need to be reevaluated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes our cash flows for the three&#160;months ended March&#160;31, 2026 and 2025:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:227.05pt;padding:0pt;"/><td style="width:10.5pt;padding:0pt;"/><td style="width:5.1pt;padding:0pt;"/><td style="width:64.5pt;padding:0pt;"/><td style="width:10.5pt;padding:0pt;"/><td style="width:5.1pt;padding:0pt;"/><td style="width:64.5pt;padding:0pt;"/><td style="width:10.5pt;padding:0pt;"/><td style="width:5.1pt;padding:0pt;"/><td style="width:64.5pt;padding:0pt;"/><td style="width:10.55pt;padding:0pt;"/><td style="width:53.75pt;padding:0pt;"/><td style="width:8.35pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:227.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:53.75pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:227.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;width:149.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the three&#160;months ended March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="border-bottom-color:transparent;border-bottom-style:solid;border-bottom-width:1px;color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:bottom;width:5.1pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="border-bottom-color:transparent;border-bottom-style:solid;border-bottom-width:1px;color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:bottom;white-space:nowrap;width:53.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr style="height:9.69pt;"><td style="vertical-align:bottom;width:227.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:69.6pt;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;width:69.6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:69.6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.75pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:227.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,015,289)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(159,393)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,855,896)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.75pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:227.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net cash used in investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(575,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">575,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:227.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net cash provided by financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">3,585,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">713,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2,872,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55pt;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.75pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:227.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net change in cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,570,019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(21,393)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5pt;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.1pt;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.5pt;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,591,412</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55pt;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.75pt;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(7,439)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the three&#160;months ended March&#160;31, 2026 increased by $1,855,896 as compared to the three&#160;months ended March&#160;31, 2025. The increase in cash used in operating activities is primarily due to an increase in net loss during the three&#160;months ended March&#160;31, 2026 of $935,688, when compared to the net loss for the three&#160;months ended March&#160;31, 2025, an increase in prepaid expenses of $657,107 and an increase in payment of accounts payable and accrued expenses of $173,923 for the three&#160;months ended March&#160;31, 2026 as compared to the same period in the prior&#160;year. The increase is further a result of operating activities, adjusted for non-cash transactions including depreciation expense of $518 and a change in fair value of warrant liabilities of $4,178 for the three&#160;months ended March&#160;31, 2026 as compared to no such activity during the three&#160;months ended March&#160;31, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities for the three&#160;months ended March&#160;31, 2026 decreased by $575,000 as compared to the three&#160;months ended March&#160;31, 2025. The decrease in cash used in investing activities is primarily to less issuances of loans to Iris prior to the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities for the three&#160;months ended March&#160;31, 2026 increased by $2,872,308 as compared to the three&#160;months ended March&#160;31, 2025. The increase in cash provided by financing activities is primarily due to proceeds received of $3,585,308 from the Offering, net of offering costs. Further, the Company received no proceeds from related party debt during the three&#160;months ended March&#160;31, 2026 as compared to proceeds of $713,000 during the three&#160;months ended March&#160;31, 2025.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">66</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of unaudited condensed consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Making estimates requires management to exercise significant judgement. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. The actual results could materially differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC 480, Distinguishing liabilities from equity (&#8220;ASC 480&#8221;), and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance, modification, and as of each subsequent quarterly period end date while the warrants are outstanding. As of March&#160;31, 2026, 13,813,000 of the Company&#8217;s Common Stock Warrants, 690,650 Placement Agent Warrants and 5,094,623 of the Company&#8217;s Public Warrants were accounted for as equity-classified instruments and 835,555 private placement warrants were accounted for as liability-classified instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the liability-classified warrants are recognized as a non-cash gain or loss on the accompanying consolidated statements of operations and comprehensive loss. The Company assesses the classification of its warrants at each reporting date to determine whether a change in classification between equity and liability is required. During the three&#160;months ended March&#160;31, 2026, the Company had an unrealized gain on the change in fair value of the warrant liabilities of $4,178. During the three&#160;months ended March&#160;31, 2025, the Company had no unrealized gain or loss on the change in fair value of the warrant liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently Adopted Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation decisions. Public entities must adopt the new guidance for fiscal&#160;years beginning after December&#160;15, 2024. The amendments in this ASU must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The Company adopted this standard on January&#160;1, 2025 and determined that the adoption does not have a material impact on these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently Issued Accounting Pronouncements&#160;&#8211; Not Yet Adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November&#160;4, 2024, the FASB issued ASU 2024-03, Accounting Standards Update 2024-03, <i style="font-style:italic;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i> to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods beginning after December&#160;15, 2026, and interim reporting periods beginning after December&#160;15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">67</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Going Concern, Liquidity and Capital Resources as of December&#160;31, 2025 and 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for one&#160;year after the date that the consolidated financial statements are issued. Through December&#160;31, 2025, the Company has funded its operations mainly through equity and debt financings, including the proceeds from the Mergers and the PIPE Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2025, the Company had $337,655 of cash in its bank accounts. As of December&#160;31, 2025 and 2024, there was approximately $1.4 million and $20.0 million, respectively, of related party debts, which are included in Short-term debt, related parties in the accompanying consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has incurred operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The Company has an accumulated deficit of $38,871,733 as of December&#160;31, 2025. The Company had a (loss) from operations and net (loss) of $(2,967,812) and $(10,206,517), respectively, for the&#160;year ended December&#160;31, 2025. The Company had a (loss) from operations and net (loss) of $(3,329,953) and $(3,546,309), respectively, for the&#160;year ended December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern over the next twelve&#160;months after the financial statements are issued. The Company&#8217;s cash requirements include, but are not limited to, research and development costs, license fees and working capital requirements. Due to these cash requirements, the Company does not believe that it will have sufficient cash to fund operations for one&#160;year after the date that the accompanying financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one&#160;year after the date that the accompanying financial statements are issued. The Company&#8217;s financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company intends to raise additional cash through equity financings, debt financings or other arrangements to fund operations; however, there can be no assurance that the Company will be able to raise adequate capital under acceptable terms, if at all. The sale of additional equity may dilute existing members and newly issued member units may contain senior rights and preferences compared to currently outstanding ordinary shares. Issued debt securities may contain covenants and limit the Company&#8217;s ability to pay dividends or make other distributions to members. If the Company is unable to obtain such additional financing, future operations would need to be reevaluated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Capital Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, we have not generated any revenues from any source, including the commercial sale of approved drug products, and we do not expect to generate revenue for at least the next few&#160;years. If we fail to complete the development of our product candidate in a timely manner or fail to obtain their regulatory approval, our ability to generate future revenue will be adversely affected. We do not know when, or if, we will generate any revenue from our product candidate, and we do not expect to generate revenue unless and until we obtain regulatory approval of, and commercialize, our product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect our expenses to increase significantly in connection with our ongoing activities, particularly as we continue the research and development of, and seek marketing approval for, our product candidate. In addition, if we obtain approval for our product candidate, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing, and distribution. Furthermore, following the completion of the Business Combination, we expect to incur additional costs associated with operating as a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will also be required to pay all clinical trial costs and expenses in connection with the development of the CD47 Products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">68</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are also required to repay our loans with Valetudo of $0.5 million issued in June 2023 and due in December 2023 that does not bear interest (the &#8220;Valetudo June 2023 Loans&#8221;) with an outstanding balance of $0.2 million, our additional loan with Valetudo of $0.3 million issued in July 2023 and due in January 2024, and related interest of 6% per annum (the &#8220;Valetudo July 2023 Loan&#8221;), our loan with Prophase Sciences LLC (&#8220;Prophase&#8221;) of $0.2 million issued February 2024 that bears 6% interest per annum and due June 1, 2024 (the &#8220;Prophase February 2024 Loan&#8221;) with an outstanding balance of less than $0.1 million, our loan with Prophase issued in March 2024 of $0.3 million that bears interest of 6% per annum and due June 1, 2024 (the &#8220;Prophase March 2024 Loan&#8221;), our loans with Prophase issued in May 2024 totaling $0.8 million that bears interest of 6% per annum and due June 1, 2024 and July 1, 2024 (the &#8220;Prophase May 2024 Loans&#8221;) with an outstanding balance of $0.2 million, our loans with Prophase issued in July 2024 of $0.1 million that bears interest of 6% per annum and due September 14, 2024, September 24, 2024 and September 29, 2024 (the &#8220;Prophase July 2024 Loans&#8221;), our loans with Prophase issued in August 2024 of $0.1 million that bears interest of 6% per annum and due October 12, 2024 and October 13, 2024 (the &#8220;Prophase August 2024 Loans&#8221;), our loan with Hana Immunotherapeutics, LLC (&#8220;Hana&#8221;) issued in August 2024 of $0.6 million that bears interest of 6% per annum and due October 26, 2024 (the &#8220;Hana August 2024 Loan&#8221;) with an outstanding balance of less than $0.1 million, our loans with Amantes LLC (&#8220;Amantes&#8221;) issued November 2024 totaling $0.7 million that bear interest of 6% per annum and due January 1, 2025 (the &#8220;Amantes November 2024 Loans&#8221;) with an outstanding balance of $0.2 million, our loans with Amantes issued in January 2025 totaling $0.3 million that bear interest of 6% per annum and due March 1, 2025 and March 22, 2025 (the &#8220;Amantes January 2025 Loans&#8221;) with an outstanding balance of less than $0.1 million, our loan with Prophase issued in February 2025 of $0.2 million that bears interest of 6% per annum and due April 11, 2025 (the &#8220;Prophase February 2025 Loan&#8221;) with an outstanding balance of $0.1 million, and our loan with Prophase issued in March 2025 of $0.2 million that bears interest of 6% per annum and due June 6, 2025 (the &#8220;Prophase March 2025 Loan&#8221;) with an outstanding balance of less than $0.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As the Company&#8217;s loans are with related parties, the Company and its related parties have mutually agreed to defer repayment of the past due loans until a time that is mutually agreed upon between the Company and its related parties. As such, the Company deems that it is not in default of its loan agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We therefore anticipate that we will need substantial additional funding in connection with our continuing operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with research, development, and commercialization of pharmaceutical drug products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we develop, in-license or acquire other product candidates and technologies in our product candidate pipeline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs as we advance them through clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and development requirements of product candidates that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing, and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and amount of our milestone and royalty payments to InnoBation under the CD47 License;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales, and distributions, for any of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue, if any, received from sales of our product candidates for which we receive marketing approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive, and uncertain process that takes many&#160;years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidate, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of our product candidates that we do not expect to be commercially available </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">69</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">in the near term, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the terms of these equity securities or this debt may restrict our ability to operate. Any future debt financing and equity financing, if available, may involve covenants limiting and restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, entering into profit-sharing or other arrangements or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise capital when needed or on acceptable terms, we could be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the&#160;years ended December&#160;31, 2025 increased by $8,512,252 as compared to the&#160;year ended December&#160;31, 2024. The increase in cash used in operating activities is primarily due to an increase in net loss during the&#160;year ended December&#160;31, 2025 of $6,660,208 when compared to the net loss for the&#160;year ended December&#160;31, 2024, an increase in payments of accounts payable and accrued expenses of $4,035,340 as a result of increased compliance and legal fees as a public entity, settlement of amounts due to related parties of $3,427,000, and amounts due to research and development partner of $1,540,359 for the&#160;year ended December&#160;31, 2025 as compared to the same period in the prior&#160;year. The increase is further a result of the operating activities, adjusted for non-cash transactions including a contingent liability for common stock to be issued of $7,360,000, issuance of common stock in connection with surrender of warrants of $1,740,000, change in fair value of deferred underwriting fee payable of $196,000 and forgiveness of related party receivables of $126,275, offset by the non-cash settlement of the TDT payables of $2,142,297 for the&#160;year ended December&#160;31, 2025 as compared to no such activity during the same period in the prior&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities for the&#160;year ended December&#160;31, 2025 decreased by $2,061,892 as compared to the&#160;year ended December&#160;31, 2024. The decrease in cash used in investing activities is primarily due to less issuances of loans to Iris prior to the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities for the&#160;year ended December&#160;31, 2025 increased by $7,109,762 as compared to the&#160;year ended December&#160;31, 2024. The increase in cash provided by financing activities is primarily due to proceeds received of $10,556,500 from the PIPE Financing, offset by $2,563,738 in payments for the transaction costs in connection with the Business Combination. Further, the Company had proceeds from related party debt of $4,340,000, which is offset by payments of related party debt of $1,300,000 during the&#160;year ended December&#160;31, 2025 as compared to proceeds of $3,923,000 during the&#160;year ended December&#160;31, 2024. No such payments occurred during the&#160;year ended December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contractual Obligations and Other Commitments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See <i style="font-style:italic;">Capital Requirements</i>, above for discussion of our commitments and contractual obligations. Additionally, in the future we may enter into agreements in the normal course of business with contract research organizations, contract manufacturing organizations and other vendors for research and development services for operating purposes, which are generally cancelable upon written notice. In addition, some third party CMOs have intellectual property, such as patents and/or know-how with an annual fee and royalty bearing license to their customers that forms part of the manufacturing agreement. These payments are therefore not included in our contractual obligations herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note&#160;8 to our audited financial statements included elsewhere in this prospectus.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">70</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses, and the disclosure of contingent assets and liabilities, in our financial statements. In accordance with U.S. GAAP, we evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We define our critical accounting policies as those accounting principles that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. While our significant accounting policies are more fully described in Note&#160;2 to our audited financial statements appearing elsewhere in this report, we believe the following are the critical accounting policies used in the preparation of our financial statements that require significant estimates and judgments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development costs primarily consist of costs incurred for preclinical and clinical trials for our products. Research and development expenses are recognized as incurred and payments made prior to costs being incurred are capitalized until the costs are incurred. Costs incurred in obtaining technology licenses through asset acquisitions are charged to research and development expense if the licensed technology has not reached technological feasibility and has no alternative future use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note&#160;2 to our audited financial statements included elsewhere in this prospectus for information about recent accounting pronouncements, the timing of their adoption, and our assessment, if any, of their potential impact on our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Emerging Growth Company and Smaller Reporting Company Status</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In April&#160;2012, the JOBS Act was enacted. Section&#160;107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B)&#160;of the Securities Act for complying with new or revised accounting standards. Upon the closing of the Business Combination, we became an emerging growth company and delayed the adoption of certain accounting standards until those standards would otherwise apply to private companies. We elected the extended transition period for complying with new or revised accounting standards, which delays the adoption of these accounting standards until they would apply to private companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, as an emerging growth company, we have taken advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">being permitted to present only two&#160;years of audited financial statements in addition to any required financial statements, with correspondingly reduced disclosure in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an exception from compliance with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and registration statements;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">71</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exemptions from the requirements of holding non-binding advisory votes on executive compensation or golden parachute arrangements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the communication of critical audit matters in the auditor&#8217;s report on financial statements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We would cease to qualify as an emerging growth company on the date that is the earliest of: (i)&#160;December&#160;31, 2026, (ii)&#160;the last day of the fiscal&#160;year in which we have more than $1.235 billion in total annual gross revenues, (iii)&#160;the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules&#160;of the SEC, which means the market value of our common shares that is held by non-affiliates exceeds $700.0 million as of the prior June&#160;30th, or (iv)&#160;the date on which we have issued more than $1.0 billion of non-convertible debt over the prior three-year period. We may choose to take advantage of some but not all of these reduced reporting burdens. We have taken advantage of certain reduced reporting requirements in this filing. Accordingly, the information contained herein may be different than you might obtain from other public companies in which you hold equity interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">72</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_cd4cadcb_dfba_46a3_887c_3fe50e1afbc2"></a><a id="BUSINESS_673000"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Unless the context otherwise requires, all references in this section to the &#8220;Company,&#8221; &#8220;Liminatus,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to the business and operations of Liminatus Pharma, LLC prior to the consummation of the Business Combination and to Liminatus Pharma,&#160;Inc. and its consolidated subsidiaries following the consummation of the Business Combination.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Executive Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus is a pre-clinical stage, single-asset biopharmaceutical company. Liminatus is developing novel cancer therapies that exploit the body&#8217;s immune system. The Company&#8217;s clinical candidate is a humanized anti CD47 monoclonal antibody. The next generation CD47 checkpoint inhibitor&#8217;s (code name: IBA101) initial indication is expected to be patients with advanced solid cancers including non-small cell lung cancer (&#8220;NSCLC&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">CD47 is a potent &#8216;do not eat me&#8217; signal that enables cancer cells to evade detection by the immune system. CD47 blockade promotes uptake of tumor antigens and tumor cells by macrophages. The first generation of CD47 agents generally induced anemia and thrombocytopenia (deficiency of platelets in the blood) due to their binding to red blood cells (&#8220;RBCs&#8221;) and platelets. The Liminatus CD47 next generation antibody has shown to preferentially bind to immune cells, but not to red blood cells and platelets without inducing destruction of red blood cells which is a key differentiating feature. The next generation of anti CD47 monoclonal antibodies have catalysed a resurgence of interest in the field. Key preclinical studies, including CMC development and monkey toxicity studies, have already been completed, allowing for a swift preparation of the IND application and enabling a timely transition into the clinical trial phase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">CD47 immune checkpoint inhibitors are expected to penetrate the market primarily through combination therapy with already established PD-1/PD-L1 blockades rather than as standalone treatments. The global market for PD-1/PD-L1 blockades was estimated at $49.5&#160;billion in 2023 and is projected to reach $123.3&#160;billion by 2033. If CD47 immune checkpoint inhibitors are successfully brought to market, they are expected to grow alongside the PD-1/PD-L1 blockade market, potentially starting at 10-20% of the PD-1/PD-L1 market size by 2030 and rapidly expanding to reach the same market scale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="limn-20260331xs1002.jpg" alt="Graphic" style="display:inline-block;height:125.4pt;left:0pt;padding-bottom:0.6pt;position:relative;top:0pt;width:384pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Global Market Size Projections for PD-1/PD-L1 Blockades (adapted from Future Market Insights)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our asset targets patients with significant unmet need. Our vision is to develop a broad array of transformative therapies for cancer patients as a leading global biopharmaceutical company. We intend to do this through establishing a leadership position in immune-oncology and by strengthening the differentiation of the next generation anti-CD47 monoclonal antibody from IND enabling studies through to clinical development and broadening the portfolio through in-licensing highly promising and differentiated therapeutic assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus is a pre-clinical stage biopharmaceutical company developing novel cancer therapies. Our product candidate is exploiting CD47 antibodies to target cancer cells. Our product candidate has the potential to become cornerstones of treatment for solid cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are developing a next generation CD47 immune checkpoint inhibitor. CD47 is a potent &#8216;do not eat me&#8217; signal that enables cancer cells to evade detection by the immune system. CD47 blockade promotes uptake of tumor antigens and tumor cells by macrophages. Anti-CD47 monoclonal antibodies (mAb) generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">73</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">not induce hemolysis. Our clinical candidate is currently in the late preclinical stage, with most of the necessary research completed. The next steps in the clinical process will include preparing the IND package required for the submission of a Phase&#160;1 clinical trial approval application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">InnoBation (licensor to Liminatus) has actively invested in the CD47 asset following its licensing to Liminatus. Funds were allocated towards critical preclinical work, including CMC development and the monkey toxicity study, which were essential steps in advancing the CD47 asset. These studies were completed in collaboration with GenScript ProBio and Charles River Laboratories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to these developments, InnoBation conducted its own independent animal studies to explore the effects of long-term administration of the CD47 asset. During these studies, we discovered that the CD47 asset, in addition to its potential as an anti-cancer therapeutic, also shows promise in reducing chronic inflammation and inducing weight loss. This is likely due to the asset&#8217;s ability to enhance macrophage proliferation and differentiation, which improves the scavenging of apoptotic cells. This effect not only aids in cancer treatment by enhancing the immune response but also suggests potential applications in preventing or mitigating age-related diseases such as cardiovascular disease and obesity, which are often driven by chronic low-grade inflammation due to accumulated senescent cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">InnoBation&#8217;s ongoing research into the CD47 asset has uncovered these potential new therapeutic applications, expanding the scope of its utility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following overview shows our clinical plan after closing the business combination:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:107.35pt;padding:0pt;"/><td style="width:10.05pt;padding:0pt;"/><td style="width:103.15pt;padding:0pt;"/><td style="width:10.5pt;padding:0pt;"/><td style="width:70.3pt;padding:0pt;"/><td style="width:11.75pt;padding:0pt;"/><td style="width:226.9pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:107.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:103.15pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:70.3pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.75pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:226.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:107.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Candidate</b></p></td><td style="vertical-align:bottom;width:10.05pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:103.15pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Indication</b></p></td><td style="vertical-align:bottom;width:10.5pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:70.3pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Clinical&#160;trial</b></p></td><td style="vertical-align:bottom;width:11.75pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:226.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes</b></p></td></tr><tr style="height:34.74pt;"><td style="vertical-align:top;width:107.35pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">IBA101 Mono</p></td><td style="vertical-align:top;width:10.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:103.15pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Advanced solid cancers</p></td><td style="vertical-align:top;width:10.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:70.3pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:top;width:11.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:226.9pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Phase 1 clinical trial is scheduled solely for safety confirmation. A global Phase 1 clinical trial in South Korea will focus on lung cancer patients.</p></td></tr><tr style="height:34.49pt;"><td style="vertical-align:top;width:107.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">IBA101 + Durvalumab or pembrolizumab</p></td><td style="vertical-align:top;width:10.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:103.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8805; stage III NSCLC</p></td><td style="vertical-align:top;width:10.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:70.3pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2027</p></td><td style="vertical-align:top;width:11.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:226.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Both PD-L1High and PD-L1Low patients. A global Phase 1 clinical trial in South Korea will focus on lung cancer patients.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Corporate History and Our Team</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus was founded in 2018, having obtained an exclusive license for GCC CAR-T-related patents and know-how from Targeted Diagnostics&#160;&amp; Therapeutics,&#160;Inc. (TDT), which licensed the GCC CAR-T intellectual property from Thomas Jefferson University, and assignment of a sub-license from Viral Gene for the GCC vaccine diagnostics. Subsequently, the Company was assigned the license to the CD47 immune checkpoint inhibitor from InnoBation Bio Co.&#160;Ltd. and Valetudo Therapeutics&#160;LLC. The TDT licenses have been terminated as of August&#160;2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that our leadership team&#8217;s extensive global experience within the biopharma industry, which spans all stages of development, commercialization and financing of pharmaceutical products, is a key competitive advantage for Liminatus in maximizing the full potential value of its pipeline. Members of our team have also been heavily involved in business development, capital formation and investor engagement across a range of industries. For further information and biographies of our management team, see &#8220;<i style="font-style:italic;">Management.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Vision and Our Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our vision is to develop transformative therapies for cancer patients as a global biopharmaceutical company offering advanced, differentiated, best-in-class therapies that induce powerful and durable responses in patients resulting in quality survival and a chance for cure. To accomplish this goal, we plan to execute on the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Strengthen the differentiation of our anti-CD47 monoclonal antibody from IND enabling studies through to clinical development.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Maximize the value of our product candidate by selectively entering into strategic collaborations with world leading academic and industrial partners.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Build a leading immuno-oncology company while maintaining a strong culture of innovation, valuing diversity, and putting patients at the center of everything we do.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">74</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Maintain, deepen, and protect our intellectual property portfolio. We intend to continue extending our global intellectual property portfolio to protect our assets.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursue business development and strategic partnerships. We may seek to form strategic alliances, enter into licensing agreements, or collaborate with third parties with the aim of strengthening and aiding our research, development, and commercialization of our assets more broadly.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Broaden our portfolio. We are actively engaged in evaluating additional assets for in-licensing or partnership and may execute additional transactions to add to our pipeline. We believe that our leadership team has a proven track record for identifying and transacting upon de-risked clinical stage assets.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Approach to Cancer Immunotherapy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our product candidate exploits the body&#8217;s immune system to recognize and attack cancer cells. Our product candidate has the potential to become a significant treatment option for cancer patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Checkpoint Inhibitor CD47</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A critical feature of the immune system is its ability to distinguish between normal cells in the body and those deemed as &#8220;foreign&#8221; (such as germs and cancer cells). This allows the immune system to attack the foreign cells while leaving normal cells unharmed. The immune system does this, in part, by using &#8220;checkpoint&#8221; proteins on immune cells. The checkpoints act like switches that need to be turned on or off to start an immune response. But tumors can find ways to manipulate these on/off immune checkpoints to avoid being attacked by the immune system. Monoclonal antibodies targeting immune checkpoints are designed as therapies to forcefully activate the &#8220;on&#8221; switch of the immune response, allowing the immune system to mount an effective anti-tumor attack. These medicines, known as immune checkpoint inhibitors, work by targeting checkpoint proteins to block the tumor&#8217;s ability to shut down the immune response and thereby induce a potent anti-cancer effect. Rather than killing cancer cells directly, they aid the immune system to detect and mount an attack on cancer cells. Several therapeutics that target different checkpoint proteins have been approved to treat some types of cancer including PD-1 (Pembrolizumab, Merck&#160;&amp; Co; Novolumab, BMS; Cemiplimab, Regeneron), PD-L1(Atezolizumab, Genentech; Avelumab EMD Serono&#160;&amp; Pfizer; Durvalumab, AstraZeneca), CTLA-4 (Ipilumab, BMS; tremelimumab, AstraZeneca), and LAG-3 (Opdulag, BMS) inhibitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although such therapies have revolutionized cancer treatment showing to be remarkably effective in certain subsets of patients with specific types of tumors, there are a significant number of cancer patients for whom these therapies are not effective. Another novel, yet well-established immune checkpoint is CD47 which plays a broad role in cancer immune evasion across multiple cancers. CD47 is a transmembrane protein, an integral membrane protein that spans the entirety of the cell membrane, and upon its interaction with SIRP&#945;, which is expressed on macrophages, a &#8220;don&#8217;t eat me&#8221; signal is sent to the macrophages. This helps tumors achieve immune escape by stopping macrophages from acting on these tumor cells to undergo phagocytosis. Blockade of the interaction between CD47 and SIRP&#945; could restore phagocytic activity and eliminate tumor cells. However, the first generation of anti-CD47 monoclonal antibodies have induced anemia and thrombocytopenia due to their binding to red blood cells and platelets. Our CD47 therapeutic candidate is a next generation anti-CD47 monoclonal antibody and has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis (destruction of red blood cells). Furthermore, the CD47 mAb has been shown to synergistically enhance anti-tumor responses in combination with other immune-oncology therapies. The CD47 mAb has completed key preclinical studies and is now preparing for the IND application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CD47 Immune Checkpoint Inhibitor Program</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The CD47 therapeutic candidate is a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRP&#945; blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Benefits</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">K D (equilibrium dissociation constant) value of 0.48 nM for human CD47 protein and effectively blocked the interaction of CD47 on cancer cells and soluble SIRP&#945; protein, in vitro.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">75</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Did not bind to red blood cells and platelets and did not cause hemolysis.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In an animal tumor model, where MC38 murine colon adenocarcinoma cells expressing human CD47 were implanted in immune competent mice, the CD47 mAb (Hu3A5) completely suppressed the tumor in combination with an anti PD1 antibody.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CD47 mAb (Hu3A5) showed the expected moderate tumor suppression in the hCD47/hSIRP&#945; knock-in mice model expressing human CD47 and human SIRPalpha, using MC38 cells expressing hCD47.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pre-Clinical Development to Date</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The anti-CD47 monoclonal antibody has been generated by immunizing mice with the extracellular domain of human CD47 protein. This antibody has been further humanized by CDR grafting and selecting the clone 3A5-V10 (Hu3A5) for further screening. Hu3A5 has a KD (equilibrium dissociation constant) value of 0.48 nM for human CD47 protein and has shown to effectively block the interaction of CD47 on cancer cells and soluble SIRP&#945; protein, in vitro.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In vitro assay, Hu3A5 did not bind to red blood cells and platelets and did not cause hemolysis (destruction of red blood cells) in vitro.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In an animal tumor model, where MC38 murine colon adenocarcinoma cells expressing human CD47&#160;&#8212; the only commercially available cancer cell line used in immune-competent animal models for human CD47 research&#160;&#8212; were implanted in immune-competent mice, the CD47 mAb (Hu3A5) completely suppressed the tumor in combination with an anti-PD1 antibody. Additionally, the Hu3A5 antibody demonstrated moderate tumor suppression in a mouse model that was engineered to express human CD47 and SIRP&#945;, after being implanted with MC38 tumor cells. However, when combined with other treatments like anti-PD-1, anti-TIGIT blocking antibodies, or an agonistic anti-4-1BB antibody, the Hu3A5 antibody completely suppressed tumor growth. This result shows that Hu3A5 can work synergistically with various immune checkpoint inhibitors, highlighting its versatility as a potential cancer therapy. In addition, DSC analysis has shown good thermostability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Further IND-enabling studies are underway in preparation for early-stage clinical testing. Based on the prepared data, a pre-IND meeting will be prioritized with the FDA. Since the primary indication for CD47 mAb (Hu3A5) is lung cancer, additional preclinical animal studies utilizing mouse lung cancer cell lines, such as LL/2, will be conducted if requested to evaluate efficacy in lung cancer models by the FDA. For this purpose, LL/2 expressing human CD47 has been prepared.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Toxicity-related experiments</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CD47 mAb preferentially binds to CD47 on tumor and immune cells, but not to RBCs and platelets.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Murine 3A5, humanized 3A5 with human IgG1 Fc (Hu3A5-V10), and humanized 3A5 with human IgG4 (Hu3A5-G4) strongly bind to CD47-positive MCF-7 human cancer cells and most of immune cells including T/B lymphocytes and phagocytic cells, but not to human RBCs and platelets.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CD47 mAb does not induce hemolysis of RBCs in vitro.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Anti-CD47 blocking mAb (Hu3A5) typically induce hemolysis of RBCs and thus developing anemia.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">However, Hu3A5 does not induce hemolysis of RBCs (perhaps due to the inability of binding to CD47 on RBCs).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CD47 mAb does not induce severe hematologic disorder.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Animal in vivo experiments using C57BL/6-hCD47/hSIRP&#945; mice showed that although Hu3A5-G4 was binding to human CD47 over-expressed on mouse RBCs of C57BL/6-hCD47/hSIRP&#945; mice, it did not induce hemolysis of mouse RBCs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">C57BL/6-hCD47/hSIRP&#945; mice were repeatedly injected with Hu3A5-G4 mAb even in combination with anti-mPD-1 mAb, but they survived over the experimental period and their body weight barely changed compared with that of rat IgG-treated mice.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">76</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Anti-human CD47 mAb induces no/minimal inflammation in organs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">C57BL/6-hCD47/hSIRP&#945; mice were subcutaneously engrafted with MC38-hCD47 tumor cells and were repeatedly injected with Hu3A5-G4 mAb and/or anti-mPD-1 mAb.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lung, liver and kidney from each group of mice were collected 4th injection of Abs. H&amp;E staining of organs showed that there was minimal or no inflammation in those organs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">A 4-week Toxicity Study in Cynomolgus Monkeys Followed by a 4-Week Recovery Period</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Objective of monkey toxicity study</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The objective of this study was to determine the potential toxicity of IBA101(Anti-CD47 mAb), a monoclonal antibody conjugated with IgG4 Fc, when administered as an intravenous bolus injection once weekly (Days 1, 8, 15, 22, and 29) to non-human primates and to evaluate the potential reversibility of any findings following a 4-Week recovery period. In addition, the toxicokinetic characteristics of IBA101(Anti-CD47 mAb) were determined. The study design was as follows:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:98.65pt;padding:0pt;"/><td style="width:8.9pt;padding:0pt;"/><td style="width:71.55pt;padding:0pt;"/><td style="width:8.9pt;padding:0pt;"/><td style="width:48.95pt;padding:0pt;"/><td style="width:8.85pt;padding:0pt;"/><td style="width:60.6pt;padding:0pt;"/><td style="width:8.85pt;padding:0pt;"/><td style="width:54.85pt;padding:0pt;"/><td style="width:8.85pt;padding:0pt;"/><td style="width:29.6pt;padding:0pt;"/><td style="width:8.85pt;padding:0pt;"/><td style="width:35.1pt;padding:0pt;"/><td style="width:8.85pt;padding:0pt;"/><td style="width:35pt;padding:0pt;"/><td style="width:8.85pt;padding:0pt;"/><td style="width:34.8pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:98.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:71.55pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:48.95pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:60.6pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:29.6pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:35.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:34.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1.14pt;"><td style="vertical-align:bottom;width:98.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:71.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:98.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:71.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:73.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Main&#160;Study</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:78.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Recovery&#160;Study</b></p></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:98.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:71.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dose</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:9.19pt;"><td style="vertical-align:bottom;width:98.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:71.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dose&#160;Level</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dose&#160;Volume(a)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Concentration</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">No.&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">No.&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">No.&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">No.&#160;of</b></p></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:98.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Group No.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:71.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Test&#160;Article</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(mg/kg/dose)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(mL/kg)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(mg/mL)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Males</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Females</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Males</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Females</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:98.65pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:71.55pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Vehicle Control</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.95pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.6pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.6pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.1pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:35pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.8pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:98.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:71.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;&#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:98.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:71.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">IBA101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;&#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:98.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:71.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 50</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Study design and standards</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The 4-week toxicity study of IBA101 in Cynomolgus monkeys, conducted by Charles River Laboratories, was designed and analyzed according to GLP (Good Laboratory Practice) standards. This ensured the reliability and reproducibility of the data, adhering to rigorous quality standards throughout the study.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Parameters and endpoints of evaluation</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on the most recent body weight measurement, the following parameters and endpoints were evaluated:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mortality, clinical signs, body weight, ophthalmology, electrocardiographic examinations</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical pathology parameters (hematology, coagulation, clinical chemistry, and urinalysis)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Anti-drug antibody analysis, toxicokinetic parameters, organ weights, and macroscopic and microscopic examinations.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Conclusion:&#160;&#160;&#160;Toxicokinetic Analysis</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Following once-weekly (Days 1, 8, 15, 22, and 29) intravenous dosing of IBA101 to Cynomolgus monkeys at 0, 10, 30, or 100 mg/kg/dose:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No significant IBA101-related effects were noted at any dose level, indicating that 100 mg/kg/dose was well-tolerated.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All study parameters, including body weight, clinical pathology results, and toxicokinetic measurements, were analyzed for statistical significance using standard statistical methods. At the highest dose tested (100 mg/kg), no statistically significant differences were observed in any parameter compared to the vehicle control group, supporting the determination of the No Observed Adverse Effect Level (NOAEL) at 100 mg/kg/ dose. Anti-drug antibody analysis, toxicokinetic parameters, organ weights, and macroscopic and microscopic examinations.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">77</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On Day 22, the combined sex mean C0, Cmax, and AUC0-168hr values of IBA101 at the NOAEL were:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No C0 (Initial Plasma Concentration): 4,310,000 ng/mL</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cmax (Maximum Plasma Concentration): 4,080,000 ng/mL</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AUC0-168hr (Area Under the Concentration-Time Curve): 359,000,000 hr*ng/mL.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These toxicokinetic results suggest a good safety profile of IBA101 under the tested conditions and provide statistical evidence for its tolerability.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Efficacy-related studies</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CD47 antibody blocks interaction of CD47 and SIRP&#945;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A competitive ELISA assay demonstrated that the interaction between recombinant CD47 and recombinant SIRP&#945; proteins was blocked by Hu3A5 in vitro.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CD47 antibody promotes phagocytosis of live tumor cells by human macrophages.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In vitro phagocytosis assay demonstrated that human macrophages promoted the uptake of live tumor cells in the presence of as low as &gt; 0.1 micro grams/ml of CD47 mAb.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Exclusive blockade of human CD47 on tumor cells with Hu3A5 in combination with check-point inhibitors induces a limited synergistic suppression of tumor growth.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To assess how effectively CD47 blockade enhances anti-tumor responses, hCD47-expressing MC38 tumor cells were subcutaneously engrafted into normal C57BL/6 mice, and anti-human CD47 monoclonal antibodies were injected to specifically block the function of the hCD47 protein on tumor cells, allowing evaluation of the resulting increase in anti-tumor effects.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This induced moderate delayed tumor growth.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">However, in combination with anti-PD-L1 and anti-TIGIT check-point inhibitors significant synergistic activity was observed where tumor growth was regressed and most of the mice became tumor-free.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Global blockade of human CD47 on tumor and immune cells induces significant reduction of tumor growth.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Investigated whether global effects of CD47 blockade would be beneficial if all cells including immune cells were expressing human CD47.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Instillation of Hu3A5 alone to C57BL/6-hCD47/hSIRP&#945; knock-in mice engrafted with MC38- </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hCD47 tumor cells suppressed tumor growth.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">When Hu3A5 treatment was combined with anti-mPD-1 mAb, tumor-free mice were generated.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">New Aspects of the CD47 Asset and Expanded Indications</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Chronic Inflammation</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">:&#160;&#160;&#160;Hu3A5, an anti-CD47 antibody, plays a unique role in helping immune cells called macrophages develop and survive in the body. These cells are critical in fighting disease. IBA101 not only promotes the formation of these macrophages but also increases the number of a special type, called M1 macrophages, that actively destroy harmful cells.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Reducing Chronic Inflammation</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">:&#160;&#160;&#160;As we age, our body becomes less effective at clearing out dead cells, leading to a buildup that contributes to chronic inflammation and diseases such as atherosclerosis (narrowing of arteries), obesity, and dementia. By </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">78</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enhancing the activity of macrophages, Hu3A5 could help reduce this buildup and, in turn, lower the risk of these inflammation-related diseases.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Animal Study</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">:&#160;&#160;&#160;To explore this possibility, we conducted an experiment on mice fed a high-fat diet. These mice were given Hu3A5&#8201;&#8212;&#8201;CD47 blockade to see if it could help reduce obesity and improve overall health. The early results were promising: mice treated with Hu3A5 showed significant reductions in obesity, along with improvements in fat tissue health.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Industry Context</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">:&#160;&#160;&#160;Dr.&#160;Irving Weissman, a pioneer in CD47 research, founded a company called Forty Seven&#160;Inc. to develop CD47-targeted therapies for cancer. Though Gilead Sciences acquired the company for $4.9&#160;billion in 2020, some of the clinical trials were stopped due to serious side effects. However, Dr.&#160;Weissman didn&#8217;t give up on CD47 research. He later founded Bitterroot in 2023, aiming to use CD47 blockers for cardiovascular diseases. This shift aligns with our own findings, suggesting that Hu3A5 could have broader applications, not only in cancer but also in reducing chronic inflammation and potentially treating diseases like obesity, heart disease, and dementia.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will rely upon established, large scale, GMP compliant, third-party manufacturers for our current and future manufacturing needs for both bulk drug substance and finished drug product. There are no current plans to build our own manufacturing capabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our commercial success depends in large part on our ability to obtain and maintain patent protection for our assets, their uses, components, formulations, methods of manufacturing and methods of treatment in the U.S. and other countries; to operate without infringing valid and enforceable patents and proprietary rights of others; and to prevent others from infringing on our proprietary or intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our intellectual property strategy is, where appropriate, to file new patent applications in the U.S. and certain other regions/countries (including the EU) on inventions, including improvements to existing products/ candidate(s)&#160;and formulations, methods of treatment and processes to improve our competitive edge or to improve business opportunities. We continually assess and refine our intellectual property strategy to ensure appropriate protection and rights are obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely on trade secrets and know-how to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection, and which are difficult to reverse engineer. We intend to take advantage of regulatory protection afforded through data exclusivity, market exclusivity and patent term extensions, where available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our asset is in-licensed. CD47 originates with a Korean company, InnoBation Bio Co.&#160;Ltd. The Anti-CD47 antibody is covered by three early-stage applications. Additional work is being done to characterize the mechanisms and properties that differentiate the antibody. One is a published application directed to CDRs, which essentially define the target and specificity of the antibody. There is also an unpublished application to the humanized antibody, i.e., the therapeutic entity Hu3A5. There is also a separate application covering back-ups. If granted, the cases have a long duration with a normal expiry of 2040 and 2041.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus will, where appropriate, seek to file on future IP opportunities that may arise, such as commercial formulations, dosing regimens, combination therapies, manufacturing methods, biomarkers, and new patient populations. The strategy going forward will be to file an International PCT application claiming priority from the U.S. or other provisional applications, with a view to ultimately entering the national/ regional phase in core pharmaceutical markets (such as US, Europe, Japan, China, etc.).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The life of a patent and the protection it affords is limited. For example, in the United States, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. In Europe the expiration of an invention patent is 20&#160;years from its filing date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to patent protection there is regulatory protection for licensed products. Biologicals currently receive 12&#160;years regulatory protection in the U.S. In Europe there is 8&#160;years data exclusivity followed by 2&#160;years market exclusivity, plus 1&#160;year for further significant indications. This means that during the first 8&#160;years from the grant of the first marketing authorization in the E.U., data exclusivity applies. After the initial 8&#160;year period has expired, a generic company can make use of the pre-clinical and clinical trial data of the originator in their regulatory application in an application for regulatory approval, but they still cannot market their drug during the two&#160;year period of market exclusivity. This therefore provides a total 10-year period of exclusivity.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">79</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liminatus is not currently aware of any third-party patent property that presents a barrier to the proposed commercialization of our therapeutic asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">License Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The InnoBation License</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December&#160;2022, the Company entered into a Subscription Agreement In Kind (the &#8220;Metavagen License&#8221;) with Metavagen LLC, owned by Chris Kim (&#8220;Metavagen&#8221;), whereby the Company received the license rights initially granted from InnoBation Bio Co.,&#160;Ltd., a Korean company (&#8220;InnoBation&#8221;) to Metavagen to develop, market and sell YN1203, InnoBation Bio CAR NK biomarkers, including devices, compounds and products used to detect analyte in body or tissue, in exchange for 40,000,000 shares of Class&#160;A membership interest in the Company. The Metavagen License transaction was consummated as the Company had the right to use the license, but the license was not transferred. In March&#160;2023, the Metavagen License was cancelled, and the Company membership interest was returned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 1, 2022, Metavagen was assigned the License and Development Agreement dated as of March 30, 2022, by and between InnoBation Bio Co. Ltd. and Valetudo Therapeutics LLC, as may have been amended (the &#8220;InnoBation License&#8221;), granting exclusive worldwide rights to Develop and Commercialize the CD47 Product in the Field and exclusive worldwide rights to Develop and Commercialize the Companion Diagnostics to the CD47 Products in the Field (such italicized items bearing the meanings ascribed to them in the InnoBation License). Under the InnoBation License, the licensee is responsible for all of the developmental costs for the CD47 Products after the upfront payment of $8.2 million, which was paid by Viral Gene to InnoBation. The Company will also pay license fees and management fees to be mutually agreed with InnoBation from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The term of the InnoBation License expires on a licensed product-by-licensed product and country-by- country basis until the expiration of all royalty terms. &#8220;Royalty Term&#8221; means, on a royalty bearing CD47 product-by-royalty bearing CD47 Product and country-by-country basis, the period beginning upon commencement of the Patent Royalty Term in the applicable country and ending upon the expiration of Know-How Royalty Term in the applicable country. The License Agreement can be terminated (i)&#160;by either party if the other party remains in material breach of the license agreement following a cure period to remedy the breach, (ii)&#160;by us at will, or (iii)&#160;by either party, in its entirety, upon the other party&#8217;s bankruptcy or insolvency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S. patent term restoration and marketing exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration and specifics of the FDA approval of a biological product, some of a sponsor&#8217;s U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five&#160;years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent for more than five&#160;years, or beyond a total of 14&#160;years from the product&#8217;s approval date. The patent term restoration period is composed of a &#8220;testing phase&#8221; and a &#8220;review phase&#8221; (also referred to as an &#8220;approval phase&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The testing phase begins on the effective date of an IND and ends on the date a BLA or a New Drug Application (&#8220;NDA&#8221;) is initially submitted to FDA. The review phase is the period between the initial submission of the BLA or NDA and approval. The term of a patent may be extended for a period that is the sum of one-half of the time in the testing phase, plus all the time in the review phase, and minus any of the regulatory review period that occurs prior to the patent grant or where the sponsor did not act with due diligence. Only one patent applicable to an approved biological product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. In addition, a patent can only be extended once and only for a single product. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Similar provisions for supplementary protection to compensate applicants for regulatory delays also exist in a number of territories, including Europe and Japan. Where possible we intend to apply for supplementary protection for our therapeutic assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Data and market exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">80</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This amendment to the PHS Act attempts to minimize duplicative testing. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or trials. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the large, and often complex, structure of biological products, as well as the process by which such products are manufactured, may pose significant hurdles to implementation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At the present time, the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four&#160;years after the date of first licensure of the reference product, and FDA will not approve an application for a biosimilar or interchangeable product based on the reference biological product until 12&#160;years after the date of first licensure of the reference product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the U.S. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity, or potency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate implementation and impact of the BPCIA is subject to significant uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In Europe (EEA), upon receiving marketing authorization, innovative medicinal products generally receive eight&#160;years of data exclusivity and an additional two&#160;years of market exclusivity. If granted, data exclusivity prevents generic or biosimilar applicants from referencing the innovator&#8217;s pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EEA, during a period of eight&#160;years from the date on which the reference product was first authorized in the EEA. During the additional two-year period of market exclusivity, a generic or biosimilar marketing authorization application can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of eleven&#160;years if, during the first eight&#160;years of those ten&#160;years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing therapies. There is no guarantee that a product will be considered by the EMA to be an innovative medicinal product, and products may not qualify for data exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Another company may market another version of the product if such company obtained a marketing authorization based on a completely independent data package of pharmaceutical tests, preclinical tests and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pediatric Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A biological product can obtain pediatric market exclusivity in the U.S. Pediatric exclusivity, if granted, adds six&#160;months to existing exclusivity periods, including some regulatory exclusivity periods. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study. Similar provisions are also available in other territories, such as Europe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the EEA, companies developing a new medicinal product must agree upon a Pediatric Investigation Plan, or PIP, with the EMA&#8217;s pediatric committee, or PDCO. Products that are granted a marketing authorization with the results of the pediatric clinical trials conducted in accordance with the PIP are eligible for a six&#160;month extension of exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We face competition with respect to our current product candidate and will face competition with respect to future product candidates from segments of the pharmaceutical, biotechnology and other related markets that pursue immune-oncology treatments. Specifically, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">81</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">there are many companies that commercialize or are developing immuno-oncology treatments for cancer including large pharmaceutical and biotechnology companies such as Amgen, AstraZeneca, BMS, Merck, Novartis, Pfizer, Roche, and its subsidiary Genentech. Some of these competitors and competitor assets could also be opportunities for combination opportunities which is an established method that all these pharma companies have employed and are constantly searching for highly promising Liminatus type assets for such opportunities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">CD47</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There are currently several CD47-targeting drug candidates in development for various cancer treatments. Magrolimab, developed by Forty Seven (acquired by Gilead Sciences), has been one of the most advanced CD47/ SIRP&#945; axis-targeting drug candidates in development for cancer treatment. Initially seen as a frontrunner, it was under investigation in Phase&#160;3 clinical trials for indications such as acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), often in combination with Azacitidine. However, the program has faced substantial setbacks due to efficacy concerns and safety risks. Below is an update on Magrolimab&#8217;s current status:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Investigated ENHANCE-3 (AML):&#160;&#160;&#160;This trial evaluated a combination therapy of Magrolimab, Azacitidine, and Venetoclax. A futility analysis revealed a lack of therapeutic benefit and an increased risk of mortality, leading to the trial&#8217;s termination.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ENHANCE (High-Risk MDS):&#160;&#160;&#160;The Phase 3 ENHANCE trial compared Magrolimab plus Azacitidine versus placebo plus Azacitidine. On July&#160;25, 2023, the trial was discontinued due to insufficient efficacy.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ENHANCE-2 (TP53-Mutated AML):&#160;&#160;&#160;This trial tested Magrolimab and Azacitidine against Venetoclax plus Azacitidine and other standard-of-care regimens in patients with TP53-mutated AML. It was terminated on September&#160;26, 2023, again due to futility concerns.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Solid Tumor Studies (ELEVATE Program):&#160;&#160;&#160;Gilead placed a partial clinical hold on Magrolimab&#8217;s solid tumor studies, including Phase 2 trials for head and neck squamous cell carcinoma (NCT04854499), solid tumors (NCT04827576), triple-negative breast cancer (NCT04958785), and colorectal cancer (NCT05330429). Although enrollment is paused, patients already enrolled and deriving clinical benefit may continue treatment after re-consenting.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">82</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Despite its potential, Magrolimab&#8217;s clinical development has been significantly hampered by challenges such as anemia caused by red blood cell binding, which remains a major safety concern. These setbacks highlight the need for improved CD47-targeting strategies, emphasizing the importance of addressing both efficacy and safety issues to realize the therapeutic promise of this target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In contrast, our CD47 program has been designed specifically to avoid RBC binding and prevent anemia, a common side effect seen with first-generation CD47 inhibitors. This key advantage has been initially demonstrated through in vitro experiments using human blood and in vivo toxicity studies in monkeys, further supporting its safety profile. In addition, the strong results from our preclinical in vivo studies show that when our CD47 antibody is combined not only with already marketed PD-1/PD-L1 blockades but also with T cell boosters like LAG-3, TIGIT, TIM-3, and ICOS blockades, which are currently in active clinical development, it demonstrates a powerful synergistic effect. This versatility suggests significant market expansion potential as it could enhance the efficacy of various immune checkpoint inhibitors across multiple indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Figure 4: Second generation anti-CD47 monoclonal antibodies leading immuno-oncology drug development targeting innate immunity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="limn-20260331xs1003.jpg" alt="Graphic" style="display:inline-block;height:254.4pt;left:0pt;padding-bottom:0.6pt;position:relative;top:0pt;width:417pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Properties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On April 1, 2026, the Company entered into a lease in Fullerton, CA for office space of approximately 1,057 sq. ft. commencing April&#160;1, 2026 and ending July 1, 2027. The&#160;monthly rent is $3,485.05.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We believe the property has been adequately maintained, is generally in good condition, and is suitable and adequate for our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Employees</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, Liminatus had one full-time employee, its Chief Executive Officer, Chris Kim. Liminatus also engaged advisors, including its Chief Financial Officer, Scott Dam, and several third-party contractors, who were engaged in research and development activities. In order to successfully implement its development and commercialization plans and strategies, and as the Company continues operating as a public company, the Company expects to need additional managerial, operational, sales, marketing, financial, and other personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Insurance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our insurance policies currently include policies that cover product liability and property, casualty and general liability risks, protecting us against certain risks of loss consistent with the exposures associated with the nature and scope of our operations. Our policies are generally subject to certain deductibles, limits and policy terms and conditions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">83</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">From time to time, we may become involved in actions, claims, litigation, and other legal proceedings occurring in the ordinary course of its business from time to time, including assertions by third parties relating to intellectual property infringement, contract breaches, or employment-related matters. Except as described below, we are not currently a party to any actions, claims, suits, or other legal procedures whose conclusion, if not determined in our favor, would have a major adverse effect on our business, financial condition, or results of operations, either individually or in the aggregate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On August&#160;4, 2025, Dr.&#160;Someit Sidhu (&#8220;Dr.&#160;Sidhu&#8221;) filed a complaint against the Company (collectively, the &#8220;Sidhu Matter&#8221;) for breach of contract in the New York State Supreme Court, County of New York. Dr.&#160;Sidhu alleges the Company breached a certain Letter Agreement for Consulting Services, dated December&#160;8, 2022 (the &#8220;Consulting Agreement&#8221;) entered into by Dr.&#160;Sidhu and Iris prior to the Business Combination by failing to pay Dr.&#160;Sidhu an advisory fee of $25,000 (&#8220;Advisory Fee&#8221;) upon the execution of the Business Combination Agreement, and a $1,400,000 despac success fee (&#8220;Despac Fee&#8221; together with the Advisory Fee, the &#8220;Fees&#8221;) upon consummation of the Business Combination. Dr.&#160;Sidhu also alleges claims of unjust enrichment and quantum meruit, which likewise arise out of the Company&#8217;s alleged failure to pay Dr.&#160;Sidhu the Fees. On December&#160;10, 2025, the Company filed a motion to dismiss Dr.&#160;Sidhu&#8217;s complaint with prejudice (the &#8220;Motion&#8221;). Dr.&#160;Sidhu had a deadline of January&#160;15, 2026 to oppose the Motion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February&#160;6, 2026, the Company entered into a settlement and release agreement (the &#8220;Settlement Agreement&#8221;) with Clear Street LLC ( &#8220;Clear Street&#8221;), pursuant to which the Company agreed to issue 4,000,000 shares of its Common Stock, to the Holder in exchange for the surrender and cancellation of 805,377 warrants to purchase shares of Common Stock held by Clear Street. No commission or other remuneration was paid or given, directly or indirectly, in connection with the exchange of the warrants for the shares. Pursuant to the Settlement Agreement, the Company and Clear Street agreed to dismiss (a)&#160;an action pending in the United States District Court for the Central District of California and (b)&#160;an action pending in the United States District Court for the Southern District of New York, in which, on September&#160;11, 2025, the Court entered a default judgment against the Company in the amount of $7,500,000 plus approximately $515,000 in interest, which judgment was registered in the Central District of California on October&#160;22, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">84</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_e8a40f63_bb45_4ac1_baf5_3055f7714681"></a><a id="MANAGEMENT_945379"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MANAGEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Executive Officers and Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth information as of the date of this prospectus, with respect to the individuals who serve as the executive officers and directors of Company, including their positions, and is followed by a biography of each such individual.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:193.45pt;padding:0pt;"/><td style="width:13.8pt;padding:0pt;"/><td style="width:31.55pt;padding:0pt;"/><td style="width:13.8pt;padding:0pt;"/><td style="width:287.4pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:top;width:193.45pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:31.55pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:287.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:top;width:193.45pt;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Name</b></p></td><td style="vertical-align:top;width:13.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:top;width:31.55pt;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Age</b></p></td><td style="vertical-align:top;width:13.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:top;width:287.4pt;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Position</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:top;width:193.45pt;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Chris Kim</span></p></td><td style="vertical-align:top;width:13.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.55pt;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;">67</span></p></td><td style="vertical-align:top;width:13.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:287.4pt;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Chief Executive Officer and Director</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:193.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Scott Dam</span></p></td><td style="vertical-align:top;width:13.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;">47</span></p></td><td style="vertical-align:top;width:13.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:287.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Chief Financial Officer</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:193.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Byong C. Yoo,&#160;PhD</span></p></td><td style="vertical-align:top;width:13.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;">54</span></p></td><td style="vertical-align:top;width:13.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:287.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Chief Science Officer</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:193.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Sang-jin Daniel Lee,&#160;PhD</span></p></td><td style="vertical-align:top;width:13.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;">58</span></p></td><td style="vertical-align:top;width:13.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:287.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Head of Research&#160;&amp; Development</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:193.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Beom K. Choi</span></p></td><td style="vertical-align:top;width:13.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;">54</span></p></td><td style="vertical-align:top;width:13.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:287.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Chief Technology Officer</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:193.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Eun Sook Lee, MD,&#160;PhD</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)(2)(3)</sup></p></td><td style="vertical-align:top;width:13.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;">64</span></p></td><td style="vertical-align:top;width:13.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:287.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Independent Director</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:193.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Nicholas Fernandez</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)(2)(3)</sup></p></td><td style="vertical-align:top;width:13.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;">42</span></p></td><td style="vertical-align:top;width:13.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:287.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Independent Director</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:193.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Ji Yeon Baek</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)(2)(3)</sup></p></td><td style="vertical-align:top;width:13.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;">55</span></p></td><td style="vertical-align:top;width:13.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:287.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Independent Director</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:193.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Philip Lemons</p></td><td style="vertical-align:top;width:13.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">55</p></td><td style="vertical-align:top;width:13.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:287.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Independent Director</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:193.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Richard Baek</p></td><td style="vertical-align:top;width:13.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></td><td style="vertical-align:top;width:13.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:287.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Independent Director</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Member of the Audit Committee.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Member of the Nominating and Corporate Governance Committee.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Member of the Compensation Committee.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Executive Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mr.&#160;Chris Kim, JD, LLM&#160;&#8212;Chief Executive Officer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mr.&#160;Chris Kim has been Liminatus Pharma, LLC&#8217;s Chief Executive Officer and Managing Member since its founding in May&#160;2018 and has been the Chief Executive Officer and Director of Liminatus Pharma,&#160;Inc. since November&#160;23, 2022. From December&#160;2016 to the present, he has also served as Chief Executive Officer of Viral Gene,&#160;Inc., Philadelphia, PA. From January&#160;2007 to October&#160;2017, he was Counsel for DeHeng Law Office NY, the largest law firm in China. Mr.&#160;Kim has over 30&#160;years of experience in intellectual property law including patent, trademark, copyright, trade secret, unfair competition, and other related areas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mr.&#160;Kim is a graduate of University of Pennsylvania Law School, LLM, SJD (C), M&amp;A, Corporate Financing, Investment. He completed Sa&#239;d Business School, University of Oxford, Oxford Entrepreneurship: Venture Finance Programme, Certificate, 2019&#160;&#8211; 2020, and the Harvard University Business School, Entrepreneurs Essentials, Certificate, 2018&#160;&#8211; 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mr.&#160;Scott Dam&#160;&#8212; Chief Financial Officer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mr.&#160;Dam has been the Chief Financial Officer of Liminatus Pharma,&#160;Inc. since April&#160;30, 2025. Since July&#160;2020, Mr.&#160;Dam has been Head of Credit&#160;&amp; Market Risk for NTT Data, a global innovator of IT and business services. From January&#160;2018 to June&#160;2020, Mr.&#160;Dam was a Business Partner of Thynk Digital. Mr.&#160;Dam&#8217;s prior professional experience includes working as an executive at Bank of America, Merrill Lynch and Wells Fargo and advisory to C-Level clients at Global Significant Investment Banks and Private Equity Firms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mr.&#160;Dam received a MBA from Queens University, McColl School of Business, and a Bachelor of Science in Business Administration from the University of North Carolina at Charlotte. He serves on the Board of Cleveland Diabetes Care and as Treasurer and on the Board of Directors for Hope Haven, a 501(c)3 Non&#160;- Profit in Charlotte, North Carolina.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">85</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mr.&#160;Byong Chul Yoo,&#160;PhD&#160;&#8212; Chief Science Officer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dr.&#160;Yoo has been the Chief Science Officer of Liminatus Pharma,&#160;Inc. since April&#160;30, 2025. Since March&#160;2023, Dr.&#160;Yoo has been the Chief Executive Officer of InnoBation Bio&#160;Inc. From 2019 to 2023, Dr.&#160;Yoo was the Principal Scientist at the Division of Translational Science, National Cancer Center, Republic of Korea. From 2018 to 2023, he has also been an Adjunct Professor at Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Republic of Korea. From 2013 to 2019, Dr.&#160;Yoo was a Senior Scientist at Colorectal Cancer Branch and the Biomarker Branch, Research Institute, National Cancer Center, Republic of Korea. From 2006 to 2013, he was an Associate Scientist in the Colorectal Cancer Branch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dr.&#160;Yoo received a PhD from the University of Vienna, Vienna, Austria. He did a one&#160;year post-doctorate program at Yale University. He received his Master of Science and Bachelor of Science degrees from Sung Kyun Kwan University, Graduate School, Republic of Korea.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dr.&#160;Sang-jin Daniel Lee,&#160;PhD&#160;&#8212; Head of Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dr.&#160;Lee has been the Head of Research and Development of Liminatus Pharma,&#160;Inc. since April&#160;30, 2025. Dr.&#160;Lee has been Principal Scientist, National Cancer Center of Korea, Immunology Division, since 2017. From 2019 to 2021, Dr.&#160;Lee was the Head, Cancer Immunology Division, National Cancer Center. From 2014 to the present, he has been a Professor, Graduate School of Cancer Science and Policy. From 2010 to 2016, Dr.&#160;Lee was the Chief, Genitourinary Cancer Branch, National Cancer Center.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">He received a Doctorate of Philosophy from the University of Virginia, Charlottesville, Virginia, a Master of Science from the University of Wisconsin, Madison, and a Bachelor of Science from Seoul National University, Seoul, Korea.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dr.&#160;Beom K. Choi&#160;&#8212; Chief Technology Officer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dr.&#160;Yoo has been the Chief Technology Officer of Liminatus Pharma,&#160;Inc. since April&#160;30, 2025. Since 2022, Dr.&#160;Choi has been Chief Technology Officer for InnoBation Bio,&#160;Inc., based in Seoul, Republic of Korea. Since 2022, he has also been the Chief Executive Officer of Samda BioLab, which focuses on the efficacy of biopharmaceuticals. From 2018 to 2022, Dr.&#160;Choi was the QA manager, Biomedicine Production Branch, National Cancer Center. From 2012 to 2017, he was the Chief, Biomedicine Production Branch (cGMP facility for T cell therapeutics), National Cancer Center. From 2011 to 2019, Dr.&#160;Choi held the position of Senior Scientist, Cancer Immunology Branch, National Cancer Center.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dr.&#160;Choi received his PhD in 2005 from Department of Immunology and Biomedicine, University of Ulsan, Ulsan, Korea. He received his Master of Science and Bachelor of Science degrees from the Department of Microbiology, College of Life Science, Hannam University, Daejeon, Korea. Dr.&#160;Choi is the author of numerous research papers and articles about cellular immunology and various treatments for cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Independent Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Eun Sook Lee, MD,&#160;PhD</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dr.&#160;Lee has been a director of Liminatus Pharma,&#160;Inc. since April&#160;30, 2025. Since 2020, Dr.&#160;Lee has been a surgeon at the Center for Breast Cancer, National Cancer Center, Korea. She is also currently Honorary Professor, Graduate School of Cancer Science and Policy National Cancer Center, Korea. From 2017 to 2020, she was the President of the National Cancer Center, Korea. From 2017 to 2020, Dr.&#160;Lee was also President of the National Cancer Center Graduate School of Cancer Science and Policy. From 2016 to 2017, she was the Head of the Program for Immunotherapy Research, National Cancer Center.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dr.&#160;Lee received her MD and PhD from Korea University Graduate School, Seoul, Korea. She also received a Master&#8217;s degree in Medicine from Medicine Korea University Graduate School. Dr.&#160;Lee received a Bachelor&#8217;s Degree from Korea University College of Medicine. She is a board member of numerous medical societies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nicholas Fernandez</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Mr.&#160;Fernandez has been a director of Liminatus Pharma,&#160;Inc. since April&#160;30, 2025. Mr.&#160;Fernandez has almost 20&#160;years of experience across operations, accounting and finance. Mr.&#160;Fernandez has been with Athanor Capital, a hedge fund, since December&#160;2019, most recently serving as Chief Operating Officer and Chief Financial Officer. Mr.&#160;Fernandez has chaired the Valuation Committee in addition </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">86</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to sitting on the Management Committee. Previously, he was the Chief Financial Officer of the Asset Management and Alternative Investments Divisions of Jeffries LLC, a global bulge bracket investment bank, from February&#160;2017 to April&#160;2019. Prior to that, Mr.&#160;Fernandez worked at a variety of alternative investment managers in several capacities, progressing from a Fund Accountant to a Controller/Director of Operations. He started his career in public accounting with Ernst&#160;&amp; Young in their Financial Services Office in New York, in their asset management practice with a concentration/serving Hedge, Private Equity and Venture Funds, as well as consulting. Mr.&#160;Fernandez earned a BS in Accounting and Finance with a minor in Business Administration from the University at Albany, SUNY. Mr.&#160;Fernandez holds an active Certified Public Accountant License in the state of New York.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ji Yeon Baek, MD,&#160;PhD</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dr.&#160;Baek has been a director of Liminatus Pharma,&#160;Inc. since April&#160;30, 2025. Dr.&#160;Baek has extensive clinical experience, combined with a track record of successfully leading impactful studies in colorectal and rectal cancer. Since March&#160;2024, Dr.&#160;Baek has been a clinical professor at Korea University Guro Hospital. From 2009 to 2024, Dr.&#160;Baek was a research medical oncologist at National Cancer Center, Republic of Korea. From 2018 to 2019, she was a visiting investigator at Dana- Farber Cancer Center. Dr.&#160;Baek received her MD, MS and PhD at The Catholic University of Korea.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Philip Lemons</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mr.&#160;Lemons has been a director of Liminatus Pharma,&#160;Inc. since July&#160;10, 2025. Mr.&#160;Lemons brings extensive expertise in clinical research and development, with over two decades of leadership roles across global research institutions and consulting firms. Mr.&#160;Lemons has served as Chief Business Officer and a board member of ICE Global Consulting,&#160;Inc., a clinical research consulting company, since October&#160;2020 and as consultant and owner of Nine18 Consulting, LLC since July&#160;2013. Mr.&#160;Lemons has also held senior executive positions at Duke Clinical Research Institute, Clintrax Global, and Momentum Research, where he led clinical trial strategy, business development, and international collaborations. Mr.&#160;Lemons holds a Bachelor of Science degree in business management from Guilford College.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Richard Baek</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Richard Baek has been a director of Liminatus Pharma,&#160;Inc. since July&#160;10, 2025. Mr.&#160;Baek brings extensive expertise across multiple sectors in financial oversight, internal controls and regulatory compliance. He has demonstrated the ability to ensure adherence to accounting standards and financial regulations. Since December&#160;2022, Mr.&#160;Baek has served as Vice President, Head of Finance&#160;&amp; Business at Studio City PXL, a marketing and advertising agency. From November&#160;2021 to June&#160;2022, Mr.&#160;Baek was Finance Director at Hawke Media. From April&#160;2021 to November&#160;2021, Mr.&#160;Baek was Associate Finance Director at RAPP (an Omnicom company). Mr.&#160;Baek holds a Bachelor of Science degree in business management from the University of San Francisco.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Family Relationships</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There are no family relationships among any of the Company&#8217;s directors or executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Corporate Governance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Composition of the Board</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s business and affairs are organized under the direction of its board of directors. Chris Kim serves as Chair of the Board. The primary responsibilities of the Board are to provide oversight, strategic guidance, counseling and direction to the Company&#8217;s management. The Board meets on a regular basis and additionally as required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with the terms of the Company&#8217;s Bylaws, the Board may establish the authorized number of directors from time to time by resolution. The Board consists of six (6)&#160;members. In accordance with the Company&#8217;s Certificate of Incorporation, the Board is divided into three classes with staggered three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. The Company&#8217;s directors are divided among the three classes as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Class&#160;I directors are Nicholas Fernandez and Dr.&#160;Ji Yeon Baek, with terms that will expire at the annual meeting of stockholders to be held in 2026;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">87</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Class&#160;II directors are Dr.&#160;Eun Sook Lee and Richard Baek, with terms that will expire at the annual meeting of stockholders to be held in 2027; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Class&#160;III directors are Chris Kim and Philip Lemons, with terms that will expire at the annual meeting of stockholders to be held in 2028.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The division of the Board into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Director Independence</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is required to comply with the applicable rules&#160;of Nasdaq in determining whether a director is independent. The Company undertook a review of the independence of the individuals named above and has determined that each of Dr.&#160;Eun Sook Lee, Dr.&#160;Ji Yeon Baek, Nicholas Fernandez, Philip Lemons and Richard Baek qualifies as &#8220;independent&#8221; as defined under the applicable Nasdaq rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Board Leadership Structure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Board has not adopted a formal policy regarding the separation of the offices of Chief Executive Officer and Chairman of the Board. However, our Bylaws provide that an executive officer may also hold the position of Chairman of the Board. The Board has determined that combining the roles of Chief Executive Officer and Chairman of the Board is appropriate for the Company at this time. This leadership structure provides unified direction and facilitates efficient and timely decision-making. The Chief Executive Officer&#8217;s extensive experience, institutional knowledge, and deep understanding of the Company&#8217;s business, technology, and strategic objectives enable effective leadership of both management and the Board. The Board believes this structure promotes clear accountability and enhances the Company&#8217;s ability to execute its strategic initiatives. The Board retains responsibility for independent oversight of management and corporate governance matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Role of the Board in Risk Oversight</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">One of the key functions of the Board is informed oversight of the Company&#8217;s risk management process. The Board does not anticipate having a standing risk management committee, but rather anticipates administering this oversight function directly through the Board as a whole, as well as through various standing committees of the Board that address risks inherent in their respective areas of oversight. In particular, the Board is responsible for monitoring and assessing strategic risk exposure and the Company&#8217;s audit committee will have the responsibility to consider and discuss the Company&#8217;s major financial risk exposures and the steps its management will take to monitor and control such exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The audit committee also monitors compliance with legal and regulatory requirements. The Company&#8217;s compensation committee also assesses and monitors whether the Company&#8217;s compensation plans, policies and programs comply with applicable legal and regulatory requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Committees of the Board</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Board has established an audit committee, a compensation committee and a nominating and corporate governance committee. The composition and responsibilities of each of the committees of the Board are described below. Members serve on these committees until their resignation or until otherwise determined by the Board. The Board may establish other committees as it deems necessary or appropriate from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Audit Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s audit committee consists of Dr.&#160;Eun Sook Lee, Dr.&#160;Ji Yeon Baek and Nicholas Fernandez.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Board has determined that each member of the audit committee satisfies the independence requirements under Nasdaq listing standards and Rule&#160;10A-3(b)(1)&#160;of the Exchange Act. The chairperson of the audit committee is Nicholas Fernandez. The Board has determined that Nicholas Fernandez is qualified as an &#8220;audit committee financial expert&#8221; within the meaning of SEC regulations to serve on the Board and the audit committee. Each member of our audit committee can read and understand fundamental financial statements </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">88</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">in accordance with applicable requirements. In arriving at these determinations, the Board has examined each audit committee member&#8217;s scope of experience and the nature of their employment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The primary purpose of the audit committee is to discharge the responsibilities of the Board with respect to our corporate accounting and financial reporting processes, systems of internal control and financial statement audits, and to oversee the Company&#8217;s independent registered public accounting firm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Specific responsibilities of our audit committee include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">helping the Board oversee corporate accounting and financial reporting processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">managing the selection, engagement, qualifications, independence and performance of a qualified firm to serve as the independent registered public accounting firm to audit the Company&#8217;s consolidated financial statements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, the Company&#8217;s interim and&#160;year-end operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing related person transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and reviewing a report by the independent registered public accounting firm at least annually that describes the Company&#8217;s internal quality control procedures, any material issues with such procedures, and any steps taken to deal with such issues when required by applicable law; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approving or, as permitted, pre-approving, audit and permissible non-audit services to be performed by the independent registered public accounting firm.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Compensation Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The compensation committee consists of Dr.&#160;Eun Sook Lee. Dr.&#160;Ji Yeon Baek and Nicholas Fernandez. The chair of the compensation committee is Dr.&#160;Eun Sook Lee. The Board has determined that each member of the compensation committee is independent under the Nasdaq listing standards and a &#8220;non-employee director&#8221; as defined in Rule&#160;16b-3 promulgated under the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The primary purpose of the compensation committee is to discharge the responsibilities of the Board in overseeing the compensation policies, plans and programs and to review and determine the compensation to be paid to executive officers, directors and other senior management, as appropriate. Specific responsibilities of the compensation committee include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving the compensation of the chief executive officer, other executive officers and senior management;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and recommending to the Board the compensation of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">administering the equity incentive plans and other benefit programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing, adopting, amending and terminating incentive compensation and equity plans, severance agreements, profit sharing plans, bonus plans, change-of-control protections and any other compensatory arrangements for the executive officers and other senior management; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and establishing general policies relating to compensation and benefits of the employees, including the overall compensation philosophy.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">89</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nominating and Corporate Governance Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The nominating and corporate governance committee consists of Dr.&#160;Eun Sook Lee, Dr.&#160;Ji Yeon Baek and Nicholas Fernandez. The chair of the nominating and corporate governance committee is Nicholas Fernandez. The Board has determined that each member of the nominating and corporate governance committee is independent under the Nasdaq listing standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Specific responsibilities of the nominating and corporate governance committee include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying and evaluating candidates, including the nomination of incumbent directors for re-election and nominees recommended by stockholders, to serve on the Board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">considering and making recommendations to the Board regarding the composition and chairmanship of the committees of the Board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing and making recommendations to the Board regarding corporate governance guidelines and matters, including in relation to corporate social responsibility; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overseeing periodic evaluations of the performance of the Board, including its individual directors and committees.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Code of Ethics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has adopted a code of ethics that applies to all of its executive officers, directors and employees, including its principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions. The code of ethics is available on the Company&#8217;s website. In addition, the Company has posted on its website all disclosures that are required by law or the listing standards of Nasdaq concerning any amendments to, or waivers from, any provision of the Code of Ethics. The reference to the Company&#8217;s website address does not constitute incorporation by reference of the information contained at or available through the Company&#8217;s website, and you should not consider it to be a part of this registration statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Compensation Committee Interlocks and Insider Participation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None of the intended members of the Company&#8217;s compensation committee has ever been an executive officer or employee of the Company. None of the Company&#8217;s executive officers currently serve, or has served during the last completed fiscal&#160;year, on the compensation committee or board of directors of any other entity that has one or more executive officers that will serve as a member of the Board or compensation committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Limitation on Liability and Indemnification of Directors and Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Certificate of Incorporation limits a directors&#8217; liability to the fullest extent permitted under the DGCL. The DGCL provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except for liability:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for any transaction from which the director derives an improper personal benefit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for any unlawful payment of dividends or redemption of shares; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for any breach of a director&#8217;s duty of loyalty to the corporation or its stockholders.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of the directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Delaware law and the amended and restated bylaws provide that the Company will, in certain situations, indemnify its directors and officers and may indemnify other employees and other agents, to the fullest extent permitted by law. Any indemnified person is also </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">90</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">entitled, subject to certain limitations, to advancement, direct payment, or reimbursement of reasonable expenses (including attorneys&#8217; fees and disbursements) in advance of the final disposition of the proceeding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the Company has entered into separate indemnification agreements with its directors and officers. These agreements, among other things, require the Company to indemnify its directors and officers for certain expenses, including attorneys&#8217; fees, judgments, fines, and settlement amounts incurred by a director or officer in any action or proceeding arising out of their services as one of its directors or officers or any other company or enterprise to which the person provides services at the Company&#8217;s request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company maintains a directors&#8217; and officers&#8217; insurance policy pursuant to which its directors and officers are insured against liability for actions taken in their capacities as directors and officers. We believe these provisions in the Company&#8217;s Certificate of Incorporation and amended and restated bylaws and these indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, or control persons, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">91</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_923fa837_763c_4375_97a6_6fa3f8645afc"></a><a id="EXECUTIVECOMPENSATION_552177"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXECUTIVE COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Unless the context requires otherwise, references to &#8220;Liminatus,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Company&#8221; in this section are to the business and operations of Liminatus Pharma, LLC prior to the consummation of the Business Combination and of Liminatus Pharma,&#160;Inc. and its consolidated subsidiaries following the consummation of the Business Combination.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This section discusses the material components of the executive compensation program for (i)&#160;the individual who served as our principal executive officer during fiscal&#160;years 2025 and 2024; and (ii)&#160;our next two most highly compensated executive officers who earned more than $100,000 during fiscal&#160;years 2025 and 2024 and were serving as executive officers as of December&#160;31, 2025 or 2024. We refer to these individuals as our &#8220;named executive officers.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This discussion may contain&#160;forward-looking&#160;statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. As an &#8220;emerging growth company&#8221; as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure requirements applicable to emerging growth companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary Compensation Table&#160;&#8211;&#160;Years Ended December&#160;31, 2025 and 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth information concerning the compensation of our named executive officers for the&#160;years ended December&#160;31, 2025 and 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:152.55pt;padding:0pt;"/><td style="width:8.9pt;padding:0pt;"/><td style="width:50.8pt;padding:0pt;"/><td style="width:8.9pt;padding:0pt;"/><td style="width:0.35pt;padding:0pt;"/><td style="width:36.25pt;padding:0pt;"/><td style="width:8.9pt;padding:0pt;"/><td style="width:23.79pt;padding:0pt;"/><td style="width:8.86pt;padding:0pt;"/><td style="width:29.7pt;padding:0pt;"/><td style="width:8.85pt;padding:0pt;"/><td style="width:54.85pt;padding:0pt;"/><td style="width:8.85pt;padding:0pt;"/><td style="width:29.7pt;padding:0pt;"/><td style="width:8.85pt;padding:0pt;"/><td style="width:54.85pt;padding:0pt;"/><td style="width:8.85pt;padding:0pt;"/><td style="width:36.2pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:152.55pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:36.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:29.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:29.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:36.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1.14pt;"><td style="vertical-align:bottom;width:152.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:9.19pt;"><td style="vertical-align:bottom;width:152.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Non-Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style="height:9.19pt;"><td style="vertical-align:bottom;width:152.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incentive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:9.19pt;"><td style="vertical-align:bottom;width:152.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Plan</b></p></td><td style="vertical-align:bottom;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:9.19pt;"><td style="vertical-align:bottom;width:152.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:36.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Salary</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Bonus</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Compensation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Compensation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:152.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name and Principal Position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:36.6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.2pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:152.55pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chris Kim, Chief Executive Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.8pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/31/2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">183,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.8pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.7pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.7pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.2pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">183,333</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:152.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/31/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">144,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">144,000</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These amounts reflect the grant date market value as required by Regulation S-K Item&#160;402(n)(2), computed in accordance with FASB ASC Topic 718.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Executive Compensation Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April&#160;15, 2018, we entered into an employment agreement with Chris Kim, to serve as our Chief Executive Officer. Pursuant to the employment agreement, Mr.&#160;Kim is entitled to receive a base annual salary of at least $120,000, which is subject to review and potential increase by the Board at least once per fiscal&#160;year. Unless the Board decides otherwise, the base salary will be increased by predetermined&#160;percentages on specified dates: 15% in 2020, 20% in 2022, 25% in 2024, and 30% in 2026. These increases (the &#8220;Increased Margin&#8221;) are to be paid in cash as additional salary. However, any personal expenses charged to the Company credit card will be counted together with the increased salary and may not exceed the applicable Increased Margin. Under the terms of the employment agreement, Mr.&#160;Kim&#8217;s base salary will be set at $200,000 per&#160;year if the Company is listed on Nasdaq or the New York Stock Exchange, regardless of the foregoing provisions. Notwithstanding the foregoing, Mr.&#160;Kim received $12,000 per&#160;month through April&#160;2025, and has been receiving $16,667 per&#160;month beginning May&#160;2025 as compensation. Mr.&#160;Kim is entitled to participate in the Company&#8217;s employee benefit plans and the Board has the discretion to award Mr.&#160;Kim a bonus in an amount up to 100% of Mr.&#160;Kim&#8217;s salary at the end of each&#160;year. If the Company terminates Mr.&#160;Kim&#8217;s employment without cause, the Company will be obligated to pay Mr.&#160;Kim&#8217;s then salary for two&#160;years following termination in accordance with the Company&#8217;s regular payroll practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2025 and 2024, the Company has $0.21 million and $0.19 million, respectively, in deferred compensation due to Chris Kim, our Chief Executive Officer, under his employment agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other than the compensation agreement described above, the Company has no other executive compensation, change in control or similar agreements or arrangements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">92</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2025 Omnibus Equity Incentive Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has adopted the 2025 Omnibus Equity Incentive Plan, which plan was approved by stockholders at the extraordinary general meeting. The purpose of the Incentive Plan is to help us attract, motivate and retain such persons with awards designed for the U.S. market and thereby enhance stockholder value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Administration</i>. The Incentive Plan is administered by the compensation committee of the Board (the &#8220;Plan Committee&#8221;). The Plan Committee will have the power to determine, among other items, the terms of the awards granted under the Incentive Plan, including the exercise price, the number of shares subject to each award (and the class of shares), and the exercisability and vesting terms of the awards. The Plan Committee also will have the power to determine the persons to whom and the time or times at which awards will be made and to make all other determinations and take all other actions advisable for the administration of the Incentive Plan. All decisions made by the Plan Committee pursuant to the provisions of the Incentive Plan will be final, conclusive and binding. To the extent desirable to qualify transactions under the Incentive Plan as exempt under Rule&#160;16b-3 of the Exchange Act, the transactions contemplated under the Incentive Plan will be structured to satisfy the requirements for exemption under Rule&#160;16b-3. Awards granted to participants who are insiders subject to Section&#160;16 of the Exchange Act must be approved by two or more &#8220;non-employee directors&#8221; of the Company Board (as defined in the regulations promulgated under Section&#160;16 of the Exchange Act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Grant of Awards; Shares Available for Awards.</i> The Incentive Plan provides for the grant of awards which are distribution equivalent rights, incentive share options, non-qualified share options, performance stock, performance&#160;units, restricted common stock, restricted stock&#160;units, share appreciation rights (&#8220;SARs&#8221;), tandem share appreciation rights, unrestricted common stock or any combination of the foregoing, to key management employees and non-employee directors of, and non-employee consultants of, Company or any of its subsidiaries (each a &#8220;Participant&#8221;) (however, solely Company employees or employees of Company subsidiaries are eligible for awards which are incentive share options). We have reserved a total of 2,000,000 shares of common stock for issuance as or under awards to be made under the Incentive Plan. To the extent that an award lapses, expires, is canceled, is terminated unexercised or ceases to be exercisable for any reason, or the rights of its holder terminate, any common stock subject to such award shall again be available for the grant of a new award. The Incentive Plan shall continue in effect, unless sooner terminated, until the tenth (10th) anniversary of the date on which it is adopted by the Company Board (except as to awards outstanding on that date). The Company Board in its discretion may terminate the Incentive Plan at any time with respect to any shares for which awards have not theretofore been granted; provided, however, that the Incentive Plan&#8217;s termination shall not materially and adversely impair the rights of a holder, without the consent of the holder, with respect to any award previously granted. The number of shares of common stock for which awards which are options or SARs may be granted to a Participant under the Incentive Plan during any calendar&#160;year is limited to a number of shares equal to ten&#160;percent (10%) of the total number of shares of common stock of the Company outstanding on the last day of the prior calendar&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Future new hires, non-employee directors and additional non-employee consultants are eligible to participate in the Incentive Plan as well. The number of awards to be granted to officers, non-employee directors, employees and non-employee consultants cannot be determined at this time as the grant of awards is dependent upon various factors such as hiring requirements and job performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Options</i>. The term of each share option shall be as specified in the option agreement; provided, however, that except for share options which are incentive share options (&#8220;ISOs&#8221;), granted to an employee who owns or is deemed to own (by reason of the attribution rules&#160;applicable under Code Section&#160;424(d)) more than 10% of the combined voting power of all classes of our common stock or the capital stock of our subsidiaries (a &#8220;ten&#160;percent stockholder&#8221;), no option shall be exercisable after the expiration of ten (10)&#160;years from the date of its grant (five (5)&#160;years for an employee who is a ten&#160;percent stockholder).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The price at which a share may be purchased upon exercise of a share option shall be determined by the Plan&#160;Committee; provided, however, that such option price: (i)&#160;shall not be less than the fair market value of a share on the date such share option is granted, and (ii)&#160;shall be subject to adjustment as provided in the Incentive Plan. The Plan&#160;Committee or the Company Board shall determine the time or times at which or the circumstances under which a share option may be exercised in whole or in part, the time or times at which options shall cease to be or become exercisable following termination of the share option holder&#8217;s employment or upon other conditions, the methods by which such exercise price may be paid or deemed to be paid, the form of such payment, and the methods by or forms in which common stock will be delivered or deemed to be delivered to Participants who exercise share options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Options which are ISOs shall comply in all respects with Section&#160;422 of the Code. In the case of ISOs granted to a ten&#160;percent stockholder, the per share exercise price under such ISO (to the extent required by the Code at the time of grant) shall be no less than 110% of the fair market value of a share on the date such ISO is granted. ISOs may only be granted to employees of Company or one of its subsidiaries. In addition, the aggregate fair market value of the shares subject to an ISO (determined at the time of grant) which are exercisable for the first time by an employee during any calendar&#160;year may not exceed $100,000. And Option which specifies that it is not intended to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">93</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">qualify as ISOs or any Option that fails to meet the requirement of an ISO at any point in time will automatically be treated as a nonqualified option (&#8220;NQSO&#8221;) under the terms of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Restricted Stock Awards. </i>A restricted stock award is a grant or sale of common stock to the Participant, subject to such restrictions on transferability, risk of forfeiture and other restrictions, if any, as the Plan&#160;Committee or the Company Board may impose, which restrictions may lapse separately or in combination at such times, under such circumstances (including based on achievement of performance goals and/or future service requirements), in such installments or otherwise, as the Plan&#160;Committee or the Company Board may determine at the date of grant or purchase or thereafter. Except to the extent restricted under the terms of the Incentive Plan and any agreement relating to the restricted stock award, a Participant who is granted or has purchased restricted stock shall have all of the rights of a stockholder, including the right to vote the restricted stock and the right to receive dividends thereon (subject to any mandatory reinvestment or other requirement imposed by the Plan&#160;Committee or the Company Board or in the award agreement). During the restricted period applicable to the restricted stock, subject to certain exceptions, the restricted stock may not be sold, transferred, pledged, hypothecated, or otherwise disposed of by the Participant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Unrestricted Stock Awards. </i>An unrestricted stock award is the award of common stock which are not subject to transfer restrictions. Pursuant to the terms of the applicable unrestricted stock award agreement, a holder may be awarded (or sold) common stock which are not subject to transfer restrictions, in consideration for past services rendered thereby to us or an affiliate or for other valid consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Restricted Stock Unit Awards. </i>A restricted stock unit award provides for a cash payment to be made to the holder upon the satisfaction of predetermined individual service-related vesting requirements, based on the number of&#160;units awarded to the holder. The Plan&#160;Committee shall set forth in the applicable restricted stock unit award agreement the individual service-based or performance-based vesting requirement which the holder would be required to satisfy before the holder would become entitled to payment and the number of&#160;units awarded to the holder. The vesting restrictions under any restricted stock unit award shall constitute a &#8220;substantial risk of forfeiture&#8221; under Section&#160;409A of the Code. At the time of such award, the Plan&#160;Committee may, in its sole discretion, prescribe additional terms and conditions or restrictions. The holder of a restricted stock unit shall be entitled to receive a cash payment equal to the fair market value of a stock, or one (1)&#160;share, as determined in the sole discretion of the Plan&#160;Committee and as set forth in the restricted stock unit award agreement, for each restricted stock unit subject to such restricted stock unit award, if and to the extent the applicable vesting requirement is satisfied. Such payment shall be made no later than by the fifteenth (15th) day of the third (3rd) calendar&#160;month next following the end of the calendar&#160;year in which the restricted stock unit first becomes vested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Performance Unit Awards. </i>A performance unit award provides for a cash payment to be made to the holder upon the satisfaction of predetermined individual and/or Company performance goals or objectives, based on the number of&#160;units awarded to the holder. The Plan&#160;Committee shall set forth in the applicable performance unit award agreement the performance goals and objectives (and the period of time to which such goals and objectives shall apply) which the holder and/or Company would be required to satisfy before the holder would become entitled to payment, the number of&#160;units awarded to the holder and the dollar value assigned to each such unit. The vesting restrictions under any performance under award shall constitute a &#8220;substantial risk of forfeiture&#8221; under Section&#160;409A of the Code. At the time of such award, the Plan&#160;Committee may, in its sole discretion, prescribe additional terms and conditions or restrictions. The holder of a performance unit shall be entitled to receive a cash payment equal to the dollar value assigned to such unit under the applicable performance unit award agreement if the holder and/or Company satisfy (or partially satisfy, if applicable under the applicable performance unit award agreement) the performance goals and objectives set forth in such performance unit award agreement. If achieved, such payment shall be made no later than by the fifteenth (15th) day of the third (3rd) calendar&#160;month next following the end of Company&#8217;s fiscal&#160;year to which such performance goals and objectives relate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Performance Stock Awards. </i>A performance stock award provides for distribution of common stock (or cash equal to the fair market value of shares) to the holder upon the satisfaction of predetermined individual and/or Company goals or objectives. The Plan&#160;Committee shall set forth in the applicable performance stock award agreement the performance goals and objectives (and the period of time to which such goals and objectives shall apply) which the holder and/or Company would be required to satisfy before the holder would become entitled to the receipt of common stock pursuant to such holder&#8217;s performance stock award and the number of shares of common stock subject to such performance stock award. The vesting restrictions under any performance under award shall constitute a &#8220;substantial risk of forfeiture&#8221; under Section&#160;409A of the Code and, if such goals and objectives are achieved, the distribution of such common stock shall be made no later than by the fifteenth (15th) day of the third (3rd) calendar&#160;month next following the end of our fiscal&#160;year to which such goals and objectives relate. At the time of such award, the Plan&#160;Committee may, in its sole discretion, prescribe additional terms and conditions or restrictions. The holder of a performance stock award shall have no rights as a Company stockholder until such time, if any, as the holder actually receives common stock pursuant to the performance stock award.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">94</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Distribution Equivalent Rights. </i>A distribution equivalent right entitles the holder to receive bookkeeping credits, cash payment and/or share distributions equal in amount to the distributions that would be made to the holder had the holder held a specified number of common stock during the period the holder held the distribution equivalent rights. The Plan&#160;Committee shall set forth in the applicable distribution equivalent rights award agreement the terms and conditions, if any, including whether the holder is to receive credits currently in cash, is to have such credits reinvested (at fair market value determined as of the date of reinvestment) in additional common stock or is to be entitled to choose among such alternatives. Such receipt shall be subject to a &#8220;substantial risk of forfeiture&#8221; under Section&#160;409A of the Code and, if such award becomes vested, the distribution of such cash or common stock shall be made no later than by the fifteenth (15th) day of the third (3rd) calendar&#160;month next following the end of Iris&#8217;s fiscal&#160;year in which the holder&#8217;s interest in the award vests. Distribution equivalent rights awards may be settled in cash or in common stock, as set forth in the applicable distribution equivalent rights award agreement. A distribution equivalent rights award may, but need not be, awarded in tandem with another award other than an Option or SAR award, whereby, if so awarded, such distribution equivalent rights award shall terminate or be forfeited by the holder, as applicable, under the same conditions as under such other award. The distribution equivalent rights award agreement for a distribution equivalent rights award may provide for the crediting of interest on a distribution rights award to be settled in cash at a future date (but in no event later than by the fifteenth (15th) day of the third (3rd) calendar&#160;month next following the end of Iris&#8217;s fiscal&#160;year in which such interest was credited), at a rate set forth in the applicable distribution equivalent rights award agreement, on the amount of cash payable thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Share Appreciation Rights. </i>A SAR provides the Participant to whom it is granted the right to receive, upon its exercise, the excess of (A)&#160;the fair market value of the number of shares of common stock subject to the SAR on the date of exercise, over (B)&#160;the product of the number of shares of common stock subject to the SAR multiplied by the base value under the SAR, as determined by the Plan&#160;Committee or the Company Board. The base value of a SAR shall not be less than the fair market value of a share on the date of grant. If the Plan&#160;Committee grants a share appreciation right which is intended to be a tandem SAR, additional restrictions apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Recapitalization or Reorganization. </i>Subject to certain restrictions, the Incentive Plan provides for the adjustment of common stock underlying awards previously granted if, and whenever, prior to the expiration or distribution to the holder of common stock underlying an award theretofore granted, we shall effect a subdivision or consolidation of our common stock or the payment of a share dividend on common stock without receipt of consideration by us. If we recapitalize or otherwise change our capital structure, thereafter upon any exercise or satisfaction, as applicable, of a previously granted award, the holder shall be entitled to receive (or entitled to purchase, if applicable) under such award, in lieu of the number of shares of common stock then covered by such award, the number and class of shares and securities to which the holder would have been entitled pursuant to the terms of the recapitalization if, immediately prior to such recapitalization, the holder had been the holder of record of the number of shares of common stock then covered by such award. The Incentive Plan also provides for the adjustment of shares underlying awards previously granted by the Company Board in the event of changes to the outstanding common stock by reason of extraordinary cash dividend, reorganization, mergers, consolidations, combinations, split ups, spin offs, exchanges or other relevant changes in capitalization occurring after the date of the grant of any award, subject to certain restrictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Amendment and Termination</i>. The Incentive Plan shall continue in effect, unless sooner terminated pursuant to its terms, until the tenth (10th) anniversary of the date on which it is adopted by the Company Board (except as to awards outstanding on that date). The Company Board may terminate the Incentive Plan at any time with respect to any shares for which awards have not theretofore been granted; provided, however, that the Incentive Plan&#8217;s termination shall not materially and adversely impair the rights of a holder with respect to any award theretofore granted without the consent of the holder. The Company Board shall have the right to alter or amend the Incentive Plan or any part hereof from time to time; provided, however, that without the approval by a majority of the votes cast at a meeting of our stockholders at which a quorum representing a majority of our common stock entitled to vote generally in the election of directors is present in person or by proxy, no amendment or modification of the Incentive Plan may: (i)&#160;materially increase the benefits accruing to holders, (ii)&#160;except as otherwise expressly provided in the Incentive Plan, materially increase the number of shares of common stock subject to the Incentive Plan or the individual award agreements, (iii)&#160;materially modify the requirements for participation, or (iv)&#160;amend, modify or suspend certain repricing prohibitions or amendment and termination provisions as specified therein. In addition, no change in any award theretofore granted may be made which would materially and adversely impair the rights of a holder with respect to such award without the consent of the holder (unless such change is required in order to exempt the Incentive Plan or any Award from Section&#160;409A of the Code).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">95</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of the date of this prospectus, no awards have been granted under the Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Outstanding Equity Awards at Fiscal&#160;Year-End Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None of the named executive officers held any unexercised options and unvested stock awards previously awarded as of December&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Director Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not currently intend to compensate our non-employee directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Policies and Procedures Related to the Grant of Certain Equity Awards</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not purposefully time our grants to coincide or be near in time to the release of material non-public information (&#8220;MNPI&#8221;). However, from time to time, we may grant options close in time to the release of MNPI to the extent those options are being granted upon the hiring of new executive officers and in connection with annual grants being made as part of our director compensation policy, upon appointment of a new director and on an annual basis at each annual meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">96</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_c6507a8c_2e84_486d_adb6_d6d12fe6531b"></a><a id="DESCRIPTIONOFSECURITIESTHATTHESELLINGSTO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">DESCRIPTION OF SECURITIES THAT THE SELLING STOCKHOLDER IS OFFERING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following summary of certain provisions of the Company&#8217;s common stock does not purport to be complete and is subject to the Company&#8217;s Certificate of Incorporation, Bylaws and the provisions of applicable law. Copies of our Certificate of Incorporation and Bylaws are attached to this registration statement as Exhibits 3.1 and 3.2, respectively.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are authorized to issue 500,000,000 shares of Common Stock, $0.0001 par value. All of the outstanding shares of our Common Stock are fully paid and non-assessable. The holders of a majority of the shares entitled to vote, present in person or represented by proxy shall constitute a quorum at all meetings of our stockholders. Our Common Stock does not provide preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions or rights. The holders of our Common Stock are not entitled to cumulative voting for election of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Holders of Common Stock are entitled to receive ratably such dividends as may be declared by the Board out of funds legally available therefor, as well as any distributions to the security holders, subject to the rights of the Preferred Stock holders or any class or series of stock having a preference senior to or the right to participate with the Company&#8217;s Common Stock with respect to the payment of dividends. We have never paid cash dividends on our Common Stock, and do not expect to pay such dividends in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event of a liquidation, dissolution or winding up of our Company, holders of Common Stock are entitled to share ratably in all of our assets remaining after payment or provision for payment of the debts and other liabilities of the Company and of the preferential and other amounts, if any, to which the holders of preferred stock are entitled, if any, the holders of all outstanding shares of the Company&#8217;s Common Stock will be entitled to receive all the remaining assets of the Company available for distribution ratably in proportion to the number of shares of the Company&#8217;s Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The rights, preferences and privileges of the holders of Common Stock are subject to, and might be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future. We are authorized to issue 1,000,000 shares of preferred stock, $0.0001 par value. Our Board is authorized to cause us to issue, from our authorized but unissued shares of preferred stock, one or more series of preferred stock, to establish from time to time the number of shares to be included in each such series, as well as to fix the designation and any preferences, conversion and other rights and limitations of such series. These rights and limitations may include voting powers, limitations as to dividends, and qualifications and terms and conditions of redemption of the shares of each such series.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Inducement Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following description of the Inducement Warrants is a summary and is qualified by reference to the Inducement Warrants and Inducement Letter Agreement.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercisability</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Inducement Warrants will (i)&#160;not be exercisable until the date upon which stockholder approval of the exercise of the Inducement Warrants in accordance with the rules&#160;of The Nasdaq Stock Market LLC, and if necessary, the approval of the authorization for sufficient additional shares of Common Stock to allow for the exercise of the Inducement Warrants (the &#8220;Nasdaq Stockholder Approval&#8221;) have been obtained at a meeting of Company stockholders and such approvals become effective (collectively, the &#8220;Exercise Date&#8221;) and (ii)&#160;have a term of five (5)&#160;years from the Exercise Date. If a registration statement registering the issuance of the Inducement Warrant Shares under the Securities Act is not effective or available, the holder may, in its sole discretion, elect to exercise the Inducement Warrants through a cashless exercise, in which case the holder would receive upon such exercise the net number of Inducement Warrant Shares determined according to the formula set forth in the Inducement Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise Limitation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A holder of the Inducement Warrants will not have the right to exercise any portion of the Inducement Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% or 9.99% (as selected by the Holder, the &#8220;Beneficial Ownership Limitation&#8221;) of the number of shares of the Common Stock outstanding immediately after giving effect to the exercise, as such&#160;percentage ownership is determined in accordance with the terms of the Inducement Warrants; provided, however, such holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions, provided that the Beneficial </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">97</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of the Inducement Warrants held by such holder. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise Price Adjustment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Subject to the aforementioned limitations, the exercise price of the Inducement Warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications, or similar events affecting the Common Stock, and upon any distributions of assets, including cash, stock, or other property to our stockholders. In addition, subject to the rules&#160;and regulations of Nasdaq (or any successor entity), the Company may, at any time during the term of the Inducement Warrants, reduce the then current exercise price to any amount and for any period of time deemed appropriate by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsequent Rights Offerings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Inducement Warrants provide that, if the Company conducts a pro rata distribution of rights, warrants or other securities to holders of its Common Stock, the holder of the Inducement Warrants will be entitled to participate in such offering as if it held the shares of Common Stock issuable upon full exercise of the Inducement Warrants immediately prior to the applicable record date. Participation is subject to the Beneficial Ownership Limitation, and any portion of such rights that would cause the holder of the Inducement Warrants to exceed those limitations will be deferred until such limitations no longer apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pro Rata Distributions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While the Inducement Warrants are outstanding, the holder of the Inducement Warrants is entitled to participate in any dividend or other pro rata distribution of cash, securities, or other property to holders of Common Stock as if it held the shares of Common Stock issuable upon full exercise of the Inducement Warrants immediately prior to the applicable record date. Participation is subject to the Beneficial Ownership Limitations, with any portion of a distribution that would cause such holder to exceed such limitations deferred until the limitation no longer applies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fundamental or Change of Control Transactions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon the occurrence of certain fundamental or change of control transactions, including mergers, consolidations, asset sales, tender or exchange offers, recapitalizations or changes of control, the holder of the Inducement Warrants will be entitled, upon exercise of the Inducement Warrants, to receive the same form and amount of consideration that would have been received had the Inducement Warrants been exercised immediately prior to such transaction, with the exercise price appropriately adjusted as set forth in the Inducement Warrants. In certain fundamental transactions, the holder of the Black-Scholes Warrants may instead elect to require the Company or a successor entity to repurchase the unexercised portion of the warrant for its Black-Scholes Value (as defined in the Black-Scholes Warrants). The Inducement Warrants further provide for assumption by any successor entity and continuation of the Inducement Warrant holder&#8217;s rights following a fundamental or change of control transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">98</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_f92aef5e_0440_4dd7_a72d_9b8dd89fbe49"></a><a id="SELLINGSTOCKHOLDER_298737"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">SELLING STOCKHOLDER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This prospectus relates to the resale by the Selling Stockholder from time to time of the Shares, consisting of up to 20,688,000 shares of Common Stock issuable upon exercise of the Inducement Warrants. We are registering the shares of Common Stock to permit the Selling Stockholder to offer the Shares for resale from time to time. The Stockholder has not had any material relationship with us within the past three&#160;years, except as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</span>the Inducement Letter Agreement and the transactions contemplated thereby; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</span>the participation of Armistice in our public offering (the &#8220;February&#160;2026 Offering&#8221;) in which we issued 8,270,000 shares of our Common Stock, 5,543,000 pre-funded warrants to purchase up to 5,543,000 shares of our Common Stock and 13,813,000 Common Stock purchase warrants to purchase up to 20,719,500 shares of Common Stock, which consummated on February&#160;18, 2026.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The table below lists the Selling Stockholder and other information regarding the beneficial ownership (as determined under Section&#160;13(d)&#160;of the Exchange Act, and the rules&#160;and regulations thereunder) of the shares of Common Stock held by the Selling Stockholder. The second column lists the number of shares of Common Stock beneficially owned by the Selling Stockholder, based on its ownership of shares of Common Stock, the Inducement Warrants, and any other warrants, as of June&#160;23, 2026, assuming the exercise of the Inducement Warrants and any other warrants held by the Selling Stockholder on that date, taking into account any limitations on exercise set forth therein. The third column lists the shares of Common Stock being offered by this prospectus by the Selling Stockholder and does not take into account any limitations on (i)&#160;exercise of the Inducement Warrants set forth therein, or (ii)&#160;exercise of any other warrants set forth therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with the terms of the Inducement Letter Agreement, this prospectus generally covers the resale of the sum of 100% of the shares of Common Stock issuable upon exercise of the Inducement Warrants. Because the exercise price of the Inducement Warrants may be adjusted in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications, or similar events affecting the Common Stock, and upon any distributions of assets, including cash, stock, or other property to our stockholders, the number of shares that will actually be issued may be more or less than the number of shares being offered by this prospectus. The fourth column assumes the sale of all of the shares offered by the Selling Stockholder pursuant to this prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the terms of the Inducement Warrants, the Selling Stockholder may not exercise the Inducement Warrants to the extent (but only to the extent) the Selling Stockholder or any of its affiliates would beneficially own a number of shares of Common Stock which would exceed 4.99% of the outstanding shares of the Company. The number of shares in the second column reflects these limitations. The number of shares in the second column reflects these limitations, whereas the fourth column do not reflect this limitation The Selling Stockholder may sell all, some, or none of their shares in this offering. See &#8220;Plan of Distribution.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">99</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Beneficial ownership is determined in accordance with Rule&#160;13d-3(d)&#160;promulgated by the SEC under the Exchange Act and includes shares of Common Stock with respect to which the Selling Stockholder has voting and investment power. The&#160;percentage of shares of Common Stock beneficially owned by the Selling Stockholder prior to the offering shown in the table below is based on an aggregate of 50,607,633 shares of Common Stock outstanding as of June&#160;23, 2026. The number of Shares that may actually be sold by the Selling Stockholder may be fewer than those being offered by this prospectus.</p><a id="RANGEA3L7"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:223.55pt;padding:0pt;"/><td style="width:9.5pt;padding:0pt;"/><td style="width:59.75pt;padding:0pt;"/><td style="width:12.39pt;padding:0pt;"/><td style="width:46.05pt;padding:0pt;"/><td style="width:14.85pt;padding:0pt;"/><td style="width:55.25pt;padding:0pt;"/><td style="width:9.5pt;padding:0pt;"/><td style="width:46.1pt;padding:0pt;"/><td style="width:9.55pt;padding:0pt;"/><td style="width:43.65pt;padding:0pt;"/><td style="width:9.85pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:223.55pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:59.75pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:46.05pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:55.25pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:46.1pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:43.65pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:9.94pt;"><td style="vertical-align:bottom;width:223.55pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:118.2pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficial&#160;Ownership&#160;Prior&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:55.25pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:99.3pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficial&#160;Ownership&#160;After</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style="height:10.19pt;"><td style="vertical-align:bottom;width:223.55pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"/><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:118.2pt;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:55.25pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"/><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:99.3pt;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style="height:9.94pt;"><td style="vertical-align:bottom;width:223.55pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name of Selling</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:59.75pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:12.4pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:46.05pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:14.85pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:55.25pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:46.1pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:43.65pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style="height:10.19pt;"><td style="vertical-align:bottom;width:223.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Stockholder</b></p></td><td style="border-bottom-color:transparent;border-bottom-style:solid;border-bottom-width:1px;color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0.75pt;padding-right:0.75pt;padding-top:0.75pt;text-align:left;vertical-align:bottom;white-space:nowrap;width:9.5pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:59.75pt;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="border-bottom-color:transparent;border-bottom-style:solid;border-bottom-width:1px;color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0.75pt;padding-right:0.75pt;padding-top:0.75pt;text-align:left;vertical-align:bottom;white-space:nowrap;width:12.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="border-bottom-color:transparent;border-bottom-style:solid;border-bottom-width:1px;color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0.75pt;padding-right:0.75pt;padding-top:0.75pt;text-align:left;vertical-align:bottom;white-space:nowrap;width:14.85pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:55.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">to&#160;be&#160;Offered</b></p></td><td style="border-bottom-color:transparent;border-bottom-style:solid;border-bottom-width:1px;color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0.75pt;padding-right:0.75pt;padding-top:0.75pt;text-align:left;vertical-align:bottom;white-space:nowrap;width:9.5pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:46.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="border-bottom-color:transparent;border-bottom-style:solid;border-bottom-width:1px;color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0.75pt;padding-right:0.75pt;padding-top:0.75pt;text-align:left;vertical-align:bottom;white-space:nowrap;width:9.55pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="border-bottom-color:transparent;border-bottom-style:solid;border-bottom-width:1px;color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0.75pt;padding-right:0.75pt;padding-top:0.75pt;text-align:left;vertical-align:bottom;white-space:nowrap;width:9.85pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:top;width:223.55pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Armistice Capital, LLC<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.75pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> 5,588,410 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4pt;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)&#160;&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.05pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">9.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85pt;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:55.25pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,688,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.1pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.65pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The securities are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the &#8220;Master Fund&#8221;), and may be deemed to be beneficially owned by: (i) Armistice Capital, LLC (&#8220;Armistice Capital&#8221;), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. The Inducement Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the Selling Stockholder from exercising that portion of the Inducement Warrants that would result in the Selling Stockholder and its affiliates owning, after exercise, a number of shares of Common Stock in excess of the beneficial ownership limitation. The address of Armistice Capital Master Fund Ltd. is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, NY 10022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The aggregate number of shares set forth above represents shares that the Master Fund may obtain under a 9.99% beneficial ownership restriction set forth in the terms of the Pre-Funded Warrants. The full conversion and/or exercise of the securities of the Master Fund would exceed this restriction.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">100</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_8d61f4c5_9645_4d2c_a1bb_c00ae7bd1f2f"></a><a id="BENEFICIALOWNERSHIPOFSECURITIES_795007"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BENEFICIAL OWNERSHIP OF SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table shows the amount of our Common Stock beneficially owned as of June&#160;23, 2026 by:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person or group (as those terms are used in Section&#160;13(d)(3)&#160;of the Exchange Act) believed by us to beneficially own more than 5% of our Common Stock,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of our current directors,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of our Named Executive Officers, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all of our directors and executive officers as a group.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have determined beneficial ownership in accordance with the rules&#160;and regulations of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under those rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power, and includes securities that the individual or entity has the right to acquire, such as through the exercise of stock options, within 60&#160;days of June&#160;23, 2026. Except as noted by footnote, and subject to community property laws where applicable, we believe, based on the information provided to us, that the persons and entities named in the table below have sole voting and investment power with respect to all common stock shown as beneficially owned by them. Except as otherwise noted, each person named in the table has sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The&#160;percentage of beneficial ownership in the table below is based on 50,607,633 shares of Common Stock deemed to be outstanding as of June&#160;23, 2026.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:351.4pt;padding:0pt;"/><td style="width:9.2pt;padding:0pt;"/><td style="width:99.8pt;padding:0pt;"/><td style="width:9.2pt;padding:0pt;"/><td style="width:60.8pt;padding:0pt;"/><td style="width:9.6pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:351.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:99.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:60.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.19pt;"><td style="vertical-align:bottom;width:351.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:99.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style="height:9.19pt;"><td style="vertical-align:bottom;width:351.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:99.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;of&#160;Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:351.4pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Name and Address of Beneficial Owner</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:99.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially&#160;Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:351.4pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Directors and Executive Officers</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:99.8pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.8pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:351.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chris Kim<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:99.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,169,406</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">12.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:351.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Scott Dam</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:99.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:351.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Byong C Yoo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:99.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:351.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Sang-jin Daniel Lee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:99.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:351.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Beom K. Choi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:99.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:351.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Eun Sook Lee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:99.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:351.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Nicholas Fernandez</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:99.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">16,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:351.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Ji Yeon Baek</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:99.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:351.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All executive officers and directors as a group (8 individuals)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:99.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,169,406</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">12.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:351.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:99.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:351.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">5% or More Stockholders:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:99.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:351.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Iris Acquisition Holdings LLC<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:99.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,530,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:351.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Valetudo Therapeutics LLC<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:99.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,169,406</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">12.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:351.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">KH Feelux Co., Ltd <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:99.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,666,667</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Less than 1%</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unless otherwise noted, the business address of each of the directors and executive officers is c/o Liminatus Pharma,&#160;Inc., 2251 Stern Goodman Street, Suite&#160;E, Fullerton, CA 92833.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of shares of Common Stock held of record by Valetudo Therapeutics&#160;LLC. Mr.&#160;Chris Kim is the CEO and controlling member of Valetudo and has voting and dispositive power over, and may be deemed to be the beneficial owner of, the shares held by Valetudo. The business address of Valetudo is 2251 Stern Goodman Street, Suite&#160;E, Fullerton, CA 92833. Mr.&#160;Kim disclaims any beneficial ownership of any shares held by Valetudo except to the extent of his ultimate pecuniary interest therein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of shares of Common Stock held of record by Iris Equity Holdings LLC. The natural person who has voting and/or investment power over the shares held by Iris Equity Holdings LLC is Joon Seok Yoo.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">101</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of shares of Common Stock held by KH Feelux Co., Ltd, a company formed in the Republic of Korea. The business address of Feelux is 624-8, Sukwoo-Ri, Gwangjuk-Myeon, Yangju-Gun, Yangju, Gyeonggi, South Korea. Feelux is a publicly traded company in Korea.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Securities Authorized for Issuance under Equity Compensation Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth information as of December&#160;31, 2025, with respect to our compensation plans under which equity securities may be issued.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:294.15pt;padding:0pt;"/><td style="width:9.95pt;padding:0pt;"/><td style="width:70.2pt;padding:0pt;"/><td style="width:10.79pt;padding:0pt;"/><td style="width:70.75pt;padding:0pt;"/><td style="width:10.8pt;padding:0pt;"/><td style="width:73.35pt;padding:0pt;"/></tr><tr style="height:2.75pt;"><td style="vertical-align:bottom;width:294.15pt;margin:0pt;padding:0pt 0pt 1.75pt 0pt;"><div style="height:2.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95pt;margin:0pt;padding:0pt 0pt 1.75pt 0pt;"><div style="height:2.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:70.2pt;margin:0pt;padding:0pt 0pt 1.75pt 0pt;"><div style="height:2.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt 0pt 1.75pt 0pt;"><div style="height:2.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:70.75pt;margin:0pt;padding:0pt 0pt 1.75pt 0pt;"><div style="height:2.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt 0pt 1.75pt 0pt;"><div style="height:2.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:73.35pt;margin:0pt;padding:0pt 0pt 1.75pt 0pt;"><div style="height:2.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:103.19pt;"><td style="vertical-align:bottom;width:294.15pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 1.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Plan Category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0pt 1.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:70.2pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 1.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b><br/><b style="font-weight:bold;">Securities&#160;to&#160;be</b><br/><b style="font-weight:bold;">Issued&#160;upon</b><br/><b style="font-weight:bold;">Exercise&#160;of</b><br/><b style="font-weight:bold;">Outstanding</b><br/><b style="font-weight:bold;">Options,&#160;Warrants</b><br/><b style="font-weight:bold;">and&#160;Rights</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0pt 1.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:70.75pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 1.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b><br/><b style="font-weight:bold;">Exercise&#160;Price&#160;of</b><br/><b style="font-weight:bold;">Outstanding</b><br/><b style="font-weight:bold;">Options,&#160;Warrants</b><br/><b style="font-weight:bold;">and&#160;Rights</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0pt 1.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:73.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 1.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b><br/><b style="font-weight:bold;">Securities</b><br/><b style="font-weight:bold;">Remaining</b><br/><b style="font-weight:bold;">Available&#160;for</b><br/><b style="font-weight:bold;">Future&#160;Issuance</b><br/><b style="font-weight:bold;">under&#160;Equity</b><br/><b style="font-weight:bold;">Compensation</b><br/><b style="font-weight:bold;">Plans&#160;(Excluding</b><br/><b style="font-weight:bold;">Securities</b><br/><b style="font-weight:bold;">Reflected&#160;in</b><br/><b style="font-weight:bold;">Column&#160;(a))</b></p></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;white-space:nowrap;width:294.15pt;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:9.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:70.2pt;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(a)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:70.75pt;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(b)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:73.35pt;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(c)</b></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:294.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Equity compensation plans approved by security holders:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:73.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:294.15pt;margin:0pt;padding:0pt 0pt 0pt 10.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 2.9pt;">2025 Omnibus Equity Incentive Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:70.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:70.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:73.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2,000,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:294.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Equity compensation plans not approved by security holders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:73.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:294.15pt;margin:0pt;padding:0pt 0pt 0pt 10.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 2.9pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:70.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:70.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:73.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2,000,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">102</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_84083cc8_8f29_4c89_b233_3bc670fa1838"></a><a id="CERTAINRELATIONSHIPSANDRELATEDPERSONTRAN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Iris&#8217;s Related Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Administrative Support Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March&#160;11, 2024, Iris entered into an administrative support agreement with Arrow Capital Management LLC (&#8220;Arrow&#8221;). Pursuant to the agreement, Arrow will provide certain office space, utilities and secretarial and administrative support (the &#8220;Services&#8221;) to Iris. In exchange for the Services, Iris will pay to Arrow $10,000 per&#160;month, beginning January&#160;1, 2024, and continuing until the earlier of the consummation by Iris of an initial business combination or Iris&#8217; liquidation. On August&#160;30, 2024, Iris amended the agreement with Arrow. In exchange for the Services mentioned above, Iris will pay to Arrow $30,000 per&#160;month, beginning September&#160;1, 2024, and continuing until the earlier of the consummation by Iris of an initial business combination or Iris&#8217; liquidation. Upon completion of the initial business combination or Iris&#8217; liquidation, Iris will cease paying these&#160;monthly fees. For the&#160;year ended December&#160;31, 2024, Iris incurred $200,000 for the administrative support agreement, which is included in formation and operating costs on the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Loan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July&#160;24, 2024, Hana Immunotherapeutics, LLC, an affiliate of Chris Kim, the Chief Executive Officer of Liminatus, agreed to loan Gaius Investment Partners (&#8220;Gaius&#8221;), the buyer of the managing member of Iris&#8217;s Sponsor, Columbass Limited (&#8220;Columbass&#8221;), approximately $1.216 million to facilitate Gaius&#8217; acquisition of Columbass. As a result of the acquisition, the former managing member, Columbass Limited, resigned as managing member of the Sponsor on October&#160;30, 2024, and Iris Equity Holdings LLC was appointed as managing member of the Sponsor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Advances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October&#160;4, 2023, Iris issued an unsecured promissory note in the aggregate principal amount up to $1,500,000 to Liminatus. Pursuant to the note, Liminatus agreed to loan to Iris an aggregate amount up to $1,500,000 payable following the earlier of (i)&#160;closing of the Business Combination, or (ii)&#160;thirty (30)&#160;days following the termination of the Business Combination Agreement; provided, however, in the event Iris commences liquidation proceedings, this note shall be cancelled and all amounts due, including all principal and accrued interest, shall be forgiven.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interest on the note compounds annually and accrues on each unpaid advance made under this note at the rate of 5% per annum. On February&#160;28, 2024, the Liminatus unsecured promissory note was amended and restated to increase the aggregate principal amount to up to $2,500,000, and add advances that occurred under the note. On August&#160;2, 2024, the Liminatus unsecured promissory note was amended and restated to increase the aggregate principal amount to up to $3,500,000, and add advances that occurred under the note. On November&#160;27, 2024, the Liminatus unsecured promissory note was amended and restated to increase the aggregate principal amount to up to $5,000,000, and add advances that occurred under the note. As of December 31, 2025 and December 31, 2024, Iris&#8217; outstanding balance was $0 and $3,668,500, respectively. For the years ended December 31, 2025 and December 31, 2024, Iris recorded interest expense of $0 and $119,843, respectively, which is included within interest expense on the statements of operations and accounts payable and accrued expenses on the balance sheets. For the year ended December 31, 2025, there was no outstanding accrued interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Underwriting Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October&#160;11, 2023, Iris executed a fee reduction agreement with the underwriters to reduce the deferred underwriting discount of $9,660,000 to $8,000,000, of which $7,000,000 were payable in shares of Common Stock. The share price was subject to adjustment based on the five-day volume-weighted average price prior to the filing of a resale registration statement covering such shares. As of April&#160;30, 2025, Iris and the Company amended the fee reduction agreement with the underwriters to limit the total number of shares of Common Stock issuable to the underwriters to 1,750,000. On July 1, 2025, the Company issued 700,000 shares of Common Stock to Cantor pursuant to the fee reduction agreement, as amended, based on a deemed price of $10.00 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liminatus Pharma,&#160;Inc. (formerly known as Iris Parent Holding Corp.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In November&#160;2022, the Company issued 100 shares of the Company&#8217;s common stock for an aggregate purchase price of $10 to Chris Kim, the Company&#8217;s Chief Executive Officer. Such shares on the date of issuance were duly and validly authorized and issued. Each outstanding share of stock has voting power equal to one vote on each matter submitted at any stockholder&#8217;s meeting. As of March 31, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">103</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">2026 no consideration has been received from Mr.&#160;Kim for the issuance of these shares. Accordingly, the Company has recorded a &#8220;Stock subscription receivable&#8221; within the stockholder&#8217;s deficit section on its unaudited condensed consolidated balance sheet as of March&#160;31, 2025 and December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Indemnification</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s charter and bylaws provide that the Company will indemnify its directors and officers to the fullest extent permitted by Delaware law. In addition, the Company has entered into indemnification agreements with its directors and executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Policies and Procedures for Related Persons Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to its Audit Committee charter, the Audit Committee will have the responsibility to review related party transactions. A &#8220;related person transaction&#8221; is a transaction, arrangement or relationship in which the post-combination&#160;company or any of its subsidiaries was, is or will be a participant, the amount of which involved exceeds $120,000 (or, for so long as we remain a &#8220;smaller reporting company&#8221; the lesser of (i)&#160;$120,000 and (ii)&#160;1% of our average total assets of the two completed fiscal&#160;years), and in which any related person had, has or will have a direct or indirect material interest. A &#8220;related person&#8221; means:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any person who is, or at any time during the applicable period was, one of the Company&#8217;s executive officers or directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any person who is known by the post-combination company to be the beneficial owner of more than 5% of the Company voting stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any immediate family member of any of the foregoing persons, which means any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law of a director, executive officer or a beneficial owner of more than 5% of the Company&#8217;s voting stock, and any person (other than a tenant or employee) sharing the household of such director, executive officer or beneficial owner of more than 5% of the Company&#8217;s voting stock; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any firm, corporation or other entity in which any of the foregoing persons is a partner or principal, or in a similar position, or in which such person has a 10% or greater beneficial ownership interest.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Director Independence</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Nasdaq listing standards require that a majority of the Company&#8217;s board of directors be independent. For a description of the director independence, see &#8220;<i style="font-style:italic;">Management</i>&#8221; for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">104</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_5a64bf5c_c378_476c_bfde_75a226960715"></a><a id="PLANOFDISTRIBUTION_869767"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">PLAN OF DISTRIBUTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Selling Stockholder of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the principal trading market or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. the Selling Stockholder may use any one or more of the following methods when selling securities:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ordinary brokerage transactions and transactions in which the broker dealer solicits purchasers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">block trades in which the broker dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">purchases by a broker dealer as principal and resale by the broker dealer for its account;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an exchange distribution in accordance with the rules&#160;of the applicable exchange;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">privately negotiated transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">settlement of short sales;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in transactions through broker dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a combination of any such methods of sale; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any other method permitted pursuant to applicable law.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Selling Stockholders may also sell securities under Rule&#160;144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Broker dealers engaged by the Selling Stockholder may arrange for other broker dealers to participate in sales. Broker dealers may receive commissions or discounts from the Selling Stockholder (or, if any broker dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule&#160;2121, and, in the case of a principal transaction, a markup or markdown in compliance with FINRA Rule&#160;2121.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the sale of the securities or interests therein, the Selling Stockholder may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholder may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholder may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Selling Stockholder and any broker-dealers or agents that are involved in selling the securities may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. The Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify the Selling Stockholder against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">105</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We agreed to keep this prospectus effective until the earlier of (i)&#160;the date on which the securities may be resold by the Selling Stockholder without registration and without regard to any volume or manner-of-sale limitations by reason of Rule&#160;144, without the requirement for the Company to be in compliance with the current public information under Rule&#160;144 under the Securities Act or any other rule&#160;of similar effect or (ii)&#160;all of the securities have been sold pursuant to this prospectus or Rule&#160;144 under the Securities Act or any other rule&#160;of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under applicable rules&#160;and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholder will be subject to applicable provisions of the Exchange Act and the rules&#160;and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the Selling Stockholder or any other person. We will make copies of this prospectus available to the Selling Stockholder and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule&#160;172 under the Securities Act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">106</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_08d9859c_a3a5_41ee_95c0_7fab5535ca25"></a><a id="LEGALMATTERS_497536"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">LEGAL MATTERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The validity of the securities offered hereby will be passed upon for us by Loeb&#160;&amp; Loeb&#160;LLP.</p><a id="_74ecb2cd_b9be_4599_8b82_785cf368f2dd"></a><a id="EXPERTS_755234"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">EXPERTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements of Liminatus Pharma,&#160;Inc. as of December&#160;31, 2025 and 2024, and for each of the two&#160;years in the period ended December&#160;31, 2025, included in this prospectus, have been included in reliance on the report of WithumSmith+Brown PC, an independent registered public accounting firm, given on the authority of said firm, which report includes an explanatory paragraph about the existence of substantial doubt concerning the Company&#8217;s ability to continue as a going concern, as experts in auditing and accounting.</p><a id="_65133c4b_c8fb_4c22_b002_f2f51d018a47"></a><a id="WHEREYOUCANFINDADDITIONALINFORMATION_541"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">WHERE YOU CAN FIND ADDITIONAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have filed a registration statement on Form&#160;S-1, including exhibits, under the Securities Act, with respect to the shares of Common Stock offered by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information pertaining to us and our securities, you should refer to the registration statement and its exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, we file annual and current reports, and other information with the SEC. Our SEC filings are available to the public on a website maintained by the SEC located at www.sec.gov. The information contained on, or that may be accessed through, our website is not part of, and is not incorporated into, this prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;"><span style="text-transform:uppercase;">107</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_82e7ed38_8e54_45ea_a4d8_d48e31cfdc70"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LIMINATUS PHARMA,&#160;INC.</b></p><a id="INDEXTOFINANCIALSTATEMENTS_944665"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INDEX TO FINANCIAL STATEMENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:494.95pt;padding:0pt;"/><td style="width:45.05pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:494.95pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:45.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:494.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:494.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:5.75pt;text-align:justify;text-indent:-5.75pt;margin:0pt;"><b style="font-weight:bold;">Unaudited Financial Statements of Liminatus Pharma,&#160;Inc.</b></p></td><td style="vertical-align:bottom;width:45.05pt;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:494.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:5.75pt;text-align:justify;text-indent:-5.75pt;margin:0pt;"><a href="#CondensedConsolidatedBalanceSheets_15953"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets as of March&#160;31, 2026 (unaudited) and December&#160;31, 2025</span></a></p></td><td style="vertical-align:bottom;width:45.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-2</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:494.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:5.75pt;text-align:justify;text-indent:-5.75pt;margin:0pt;"><a href="#CondensedConsolidatedStatementsofOperati"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations for the three&#160;months ended March&#160;31, 2026 and 2025 (Unaudited)</span></a></p></td><td style="vertical-align:bottom;width:45.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-3</p></td></tr><tr style="height:22.99pt;"><td style="vertical-align:bottom;width:494.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:5.75pt;text-align:justify;text-indent:-5.75pt;margin:0pt;"><a href="#CondensedConsolidatedStatementsofChanges"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Changes in Stockholder&#8217;s Deficit for the three&#160;months ended March&#160;31, 2026 and 2025 (Unaudited)</span></a></p></td><td style="vertical-align:bottom;width:45.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-4</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:494.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:5.75pt;text-align:justify;text-indent:-5.75pt;margin:0pt;"><a href="#CondensedConsolidatedStatementsofCashFlo"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows for the three&#160;months ended March&#160;31, 2026 and 2025 (Unaudited)</span></a></p></td><td style="vertical-align:bottom;width:45.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-5</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:494.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:5.75pt;text-align:justify;text-indent:-5.75pt;margin:0pt;"><a href="#NOTESTOUNAUDITEDCONDENSEDCONSOLIDATEDFIN"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Condensed Financial Statements (Unaudited)</span></a></p></td><td style="vertical-align:bottom;width:45.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-6</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:495.2pt;padding:0pt;"/><td style="width:44.8pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:495.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:44.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:495.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Audited Financial Statements of Liminatus Pharma,&#160;Inc.</b></p></td><td style="vertical-align:bottom;width:44.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:495.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:bottom;width:44.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-21</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:495.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ConsolidatedBalanceSheets_734776"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December&#160;31, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;width:44.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-22</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:495.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ConsolidatedStatementsofOperations_26549"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations for the&#160;years ended December&#160;31, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;width:44.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-23</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:495.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ConsolidatedStatementsofChan_705196"><span style="font-style:normal;font-weight:normal;">Consolidated Statements </span><span style="font-style:normal;font-weight:normal;">of Changes in Stockholders&#8217; Deficit for the&#160;years ended December&#160;31, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;width:44.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-24</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:495.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ConsolidatedStatementsofCashFlows_703268"><span style="font-style:normal;font-weight:normal;">Consolidated Statements </span><span style="font-style:normal;font-weight:normal;">of Cash Flows for the&#160;years ended December&#160;31, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;width:44.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-25</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:495.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_7"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:44.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-26</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-1</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_f24f7f05_7729_43a9_b3fd_3f38fd8c7312"></a><a id="PARTIFINANCIALINFORMATION_875393"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;I&#160;&#8211; FINANCIAL INFORMATION</b></p><a id="Item1FinancialStatements_733344"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;1. Financial Statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liminatus Pharma, Inc.</b></p><a id="CondensedConsolidatedBalanceSheets_15953"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_42571cce_f4bb_44dd_8d90_dc6c9179cca6"></a><a id="Tc_rGb4gGqAFk6equ4xj4-AMQ_1_2"></a><a id="Tc_X4qAkHvEvUWn5V3_ltqtpw_1_5"></a><a id="Tc_dmYbP_avaEKMB8LYJjLcNA_2_2"></a><a id="Tc_IRXuJkQ3M06Qrc7p0E8pIw_2_5"></a><a id="Tc_D5zr-69upEOP4k3Liywfvg_3_0"></a><a id="Tc_yKA4pzJ3UkCu4EXP24U3gA_3_2"></a><a id="Tc_lgl_d1QK5kuMJ_bBSA4QXA_4_0"></a><a id="Tc_tTKp1BdZP0SRZSBhiOTo5g_5_0"></a><a id="Tc_znUkecq8ZUqvb3NCr0hmSw_5_2"></a><a id="Tc_sio1fUzQtkeAzbOOiXHggQ_5_5"></a><a id="Tc_TN5aE4g7ukCAsr5kyjwnNA_6_0"></a><a id="Tc_3cVzHJiJkEeXcODmTEeSMw_7_0"></a><a id="Tc_sVZUUbNGNEeskJP-GCn6Qg_8_0"></a><a id="Tc_5g9swPqKxE6qcfnZOxY-kw_9_0"></a><a id="Tc_Ul-Gz0czy0WxcmjgTxX9JQ_10_0"></a><a id="Tc_-Xt9p1_jm0avLPeMTYX3rA_11_0"></a><a id="Tc_XspMg_0L6UeJfTQiMEgJWA_11_2"></a><a id="Tc_Dxoc0EYjpkSkuls7NfkyiA_11_5"></a><a id="Tc_oFnecmgvb0eY45Xrc1Ey_w_13_0"></a><a id="Tc_RsollI1K1EKqe6XhNle5-A_14_0"></a><a id="Tc_0wxZ2WG7kkSXwJSH7aOFxQ_15_0"></a><a id="Tc_9Q961SJVWECfK6VrNh-yNw_15_2"></a><a id="Tc_elP8S-ObAUSZVRlAp14y-Q_15_5"></a><a id="Tc_HYWAG6pxQ0O8ZArQdHnqKw_16_0"></a><a id="Tc_EoPxKLrNVU-EwonTLoLplw_17_0"></a><a id="Tc_6exztWdfg0m3CBcr3EdOdQ_18_0"></a><a id="Tc_DBTMln39mkGO0U9Zab0JqQ_19_0"></a><a id="Tc_RCpFhZmpbEKtJg3D_L5GIQ_20_0"></a><a id="Tc_XUX2Z4i5K0yOJTHmyC1zRg_20_3"></a><a id="Tc_uE5h_dBdX0uh9wVzOpwuAQ_21_0"></a><a id="Tc_DoPZZ-En-E6UkttTK0gscQ_22_0"></a><a id="Tc_zoY1hFxqdUezLdorpy0Htw_23_0"></a><a id="Tc_VdgcdtBaxkm70EXExtBLaQ_25_0"></a><a id="Tc_GEcjeOrolEGzEThX9bGjhA_27_0"></a><a id="Tc_00fuASarA0Gw14mZTDMC9A_28_0"></a><a id="Tc_W4yTsHKEfEO_H4WSj3RqVQ_29_0"></a><a id="Tc_1Wt-8Nw7q0Sx6DFpSVpKtw_30_0"></a><a id="Tc_G6sitdYkdUq4iFZ-9pYlNg_31_0"></a><a id="Tc_mrbvy-Tqc0uNDGBpq0Oe4Q_32_0"></a><a id="Tc_YnlLFXe1OE2EiBS7pE9paQ_33_0"></a><a id="Tc_MiE40jtt6UeCtWhJ_iAE_Q_33_2"></a><a id="Tc_J7xoPwyUyUGoKOoNt4QsWA_33_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:385.8pt;padding:0pt;"/><td style="width:12.2pt;padding:0pt;"/><td style="width:7.65pt;padding:0pt;"/><td style="width:57.25pt;padding:0pt;"/><td style="width:12.2pt;padding:0pt;"/><td style="width:7.65pt;padding:0pt;"/><td style="width:57.25pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.19pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;</b></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" id="Tc_CwYJHoNvf02oxkG8MDd5Dw_5_3">1,907,674</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" id="Tc_tRVA2e3PTUyFGOYedst8hA_5_6">337,655</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Prepaid and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_Bi9L9aoh5E-4VpgmTt8-Ig_6_3">870,872</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_5P3cGKX4uUGQsmoqNnPnLA_6_6">162,919</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_WfADcdHuoEC9estvmKxICw_7_3">2,778,546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_YrvnpxKNrEm5sJaKYUXwBg_7_6">500,574</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_ghQzZLNJqEOs22TlafA5zw_9_3">11,703</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_7kHbdOO320a8XLsq0o_IJQ_9_6">12,221</ix:nonFraction></p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" id="Tc_t1ehY9y1PEqwCykwYrNq9Q_10_3">11,703</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" id="Tc_xwYKuQSfW0eUy80T4Be5XA_10_6">12,221</ix:nonFraction></p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="Tc_IQ0uzaqOM0qvBrFJ8M6pVQ_11_3">2,790,249</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="Tc_X6z_T0vVYUWkoMFH39uJTw_11_6">512,795</ix:nonFraction></p></td></tr><tr style="height:12.24pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_eYnq5j9330iI9Vg95QitMw_15_3">529,778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc__Tqq4KCmjUSNyDwPheNaKw_15_6">582,234</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accrued interest, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Tc_NKkRNQixTEir-0TM7sIYfA_16_3">222,558</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Tc_J3jqYUIR2kCzIjt8gSwmTg_16_6">203,921</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Due to related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y6Lx3mXqwk-nBkJ5KlLBYg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_cOyBa6vBD0yAw-djFPL9Nw_17_3">194,587</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FbpcEF3_bUqHFwpcC9Wy4w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_AK5aZiXmMUGIGyLeyIk8Eg_17_6">209,586</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Short-term debt, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_sfbF_kOJqk2aXF9HUaGXeA_18_3">1,442,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_MrJ_suHLzkOh8Sm2ECxkdg_18_6">1,442,500</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Deferred underwriting fee payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeesPayableInCashCurrent" scale="0" id="Tc_tSxPr0Yu8U6ArTfBq324hw_19_3">500,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeesPayableInCashCurrent" scale="0" id="Tc_EoEDqshKQ0ChlVYMtvVtAw_19_6">500,000</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Settlement payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="limn:CommonStockPayable" scale="0" id="Tc_4x-S_nsYkkOBx-WgfA449A_20_6">7,360,000</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_bGWRUksf-UK98soYTdJLow_21_3">2,889,423</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_ViaevaCnzE2v8oqapzIVUQ_21_6">10,298,241</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" id="Tc_xvf4qMHYWk-RXDAa2il5Og_22_3">33,422</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" id="Tc_bnUjugDb7kycVwavIHt8ZA_22_6">29,244</ix:nonFraction></p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" id="Tc_2oAgteJDcU6K8tnFtUzKRw_23_3">2,922,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" id="Tc_e472Jwjdj0iZRXCg54YS0w_23_6">10,327,485</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Commitments and Contingencies (Note 7)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_geYQ8-Q9fEy3NBXGbpIELA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_PSSfWujE0U-gQ6Gkb9AU_Q">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_VIyeJvL9xUOwCP2VXQ1UzQ"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_hJ-J4zjI6UWDZpNjdjSREQ">1,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_2dXQh-v9OEyBuFOQlMaTBg"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_doLH6Hjytk2du9T5ppzdKw"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_ZxihCV3JMUO92DKpK5Y2Xw"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_uewSIKB7b0SGA28vfT-SXQ">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ksx2stOFWk6AY84IddPepw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_ZOiuN5kpm0G41AqH6e2UJw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr style="height:22.99pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_jH-xER_trkeVroskVOVzdQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_aj3q42IJv0izPod5Ji2v_w">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_FrL-qxj-50mg2U4xGL9fMw"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_qO_86bWt30iYhFa47U6KiA">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_u88Be5NwAEaF28jVo9Q8IQ"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_bY2UQ6SaoEuQcEwM4BLzhw">44,877,633</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_sJhOVCpW4keCBVsc_xYBzw"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_koV2dT1AwkWSYJJonY9cGA">27,064,633</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively</p></td><td style="vertical-align:bottom;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_LXB9F7ZWJECMi_fRzPpfvQ_29_3">4,823</ix:nonFraction></p></td><td style="vertical-align:bottom;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_c6zlSbUgxkibHA7vLbSYuw_29_6">2,706</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Additional paid-in capital </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_GwVi0LBfl0O10wcxNJhxQQ_30_3">39,858,028</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_kT_inCXdo0OBeleTSPw3vQ_30_6">29,054,337</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_OVuTo7V-KECI7CkjjNMc_Q_31_3">39,995,447</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_iwiQU5qMzEKQpltrfSYIjA_31_6">38,871,733</ix:nonFraction>)</p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total stockholders&#8217; deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_FDa2Nd4NVU6OHV85YDq6qA_32_3">132,596</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_fGKzZQ-NlUSXI4HhNb2bRA_32_6">9,814,690</ix:nonFraction>)</p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities and stockholders&#8217; deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_vYEqQxKLkEChZcGbze6IeQ_33_3">2,790,249</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_HwERpipsZ0uAUNYVr3itGw_33_6">512,795</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-2</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_ba195f13_14b9_4cc3_b4dc_8185da20c779"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liminatus Pharma, Inc.</b></p><a id="CondensedConsolidatedStatementsofOperati"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><a id="_2323c082_7988_4fc0_b48f_1814c25c465b"></a><a id="_45888054_e462_44df_ad3f_7e54e4f92996"></a><a id="Tc_pbyJI8LUo0u7w_Ntrue3xA_1_2"></a><a id="Tc_jUmzwZCVvUKHR3rmiiAKqw_2_2"></a><a id="Tc_ontz5NRpDEaLFj5lVm_W1g_2_5"></a><a id="Tc_AGCYDocq7ECiAd8RJTZbwA_4_0"></a><a id="Tc_pBxOPQrWkEecaoZHG6Ulug_4_2"></a><a id="Tc_5iAKYwTVnEiaXnrjwWwAdg_4_5"></a><a id="Tc_MUMpGVbL60uqdAiQOIAHVg_5_0"></a><a id="Tc_5q9-Aa8w8UimVss_16lwVQ_5_6"></a><a id="Tc_aH5dOIYUyUqGgmxDt-eoJQ_6_0"></a><a id="Tc_-OhnOi-aOEe3PAWA0dnngQ_7_0"></a><a id="Tc_Cz1mX6DwHE-6O-dvlINgSw_8_0"></a><a id="Tc_gqqUyoKPekW0KySoAslTow_9_0"></a><a id="Tc_fOZZGybrOkO6XsOD2w6t0g_10_0"></a><a id="Tc_R2gZ4VqLmEyxI-CmDyM7ZQ_10_3"></a><a id="Tc_LPVvcf4F90iR_s9RUo5Iww_11_0"></a><a id="Tc_WZL-_FNjtUyLBphuNc56HA_11_6"></a><a id="Tc_BS7k6o5uN0i0qPtyfSaiMw_12_0"></a><a id="Tc__0iFuGZkn0GAXn3hDk4t3w_13_0"></a><a id="Tc_29nMpPUszUOU5OErc88ZDQ_13_2"></a><a id="Tc_PiEFpaPtfE-sGG04IhLl3A_13_5"></a><a id="Tc_N8N7yW6kwUeG66On3ZY-aA_15_0"></a><a id="Tc_5RRnpk9sQ0a8bnzIKm3c_w_17_0"></a><a id="Tc_xR9AVZPym0-k52Xz7swu5A_17_2"></a><a id="Tc_cvrDOQf0wEuih6_O7UH7bg_17_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:385.8pt;padding:0pt;"/><td style="width:12.2pt;padding:0pt;"/><td style="width:7.65pt;padding:0pt;"/><td style="width:57.25pt;padding:0pt;"/><td style="width:12.2pt;padding:0pt;"/><td style="width:7.65pt;padding:0pt;"/><td style="width:57.25pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:142pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the three months ended March&#160;31,&#160;</b></p></td></tr><tr style="height:9.69pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_bYd6vtHub0iJBciFP2xhSA_4_3">700,898</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_XihrR83u5ES44Bh7BTNZUg_4_6">264,220</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_orU4IDl97UKPbAOuHOWFfQ_5_3">400,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_e3MRMSMBQUqnKNSytpVOCw_6_3">1,100,898</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_F9hkhmJVwUqrzweWQJFgUA_6_6">264,220</ix:nonFraction></p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_IE_EN_FUkkmlBqq2ifx0aw_7_3">1,100,898</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_8BY4U6V8nEWgkzEh98xKBA_7_6">264,220</ix:nonFraction>)</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" id="Tc_IVjUYWcx1k2loLWd_iEGrQ_9_3">18,638</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" id="Tc_t3GnswwkjEiJwREptF-vmQ_9_6">115,512</ix:nonFraction>)</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_yrs7V6sYzkKAsd_a0kbxrA_10_6">52,206</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in the fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="Tc_yqYvqERnWUav_Gt4Ea5QPQ_11_3">4,178</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total other expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="0" id="Tc_SoL_m1lsGESnvMuN1VSmFg_12_3">22,816</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="0" id="Tc_8Oh6OnVNH0KbQvF0snYCog_12_6">63,306</ix:nonFraction>)</p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_uIMgiVBNYEyJ8nK1nq72fg_13_3">1,123,714</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_G_JafU7-rE2B_vKKKhAGDg_13_6">327,526</ix:nonFraction>)</p></td></tr><tr style="height:12.24pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares outstanding, basic and diluted*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_IIJrVh996USagDgLCTa8-A_15_3"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_IIJrVh996USagDgLCTa8-A_15_3_2">35,999,589</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_6zPXfbljDUO3vovR4VpTpA_15_6"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_6zPXfbljDUO3vovR4VpTpA_15_6_2">17,500,000</ix:nonFraction></ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basic and diluted net loss per share*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_-OJZcUa8QEilwlvS02CGdw_17_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_-OJZcUa8QEilwlvS02CGdw_17_3_2">0.03</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_VCWz9vVrB0qIHg1ZysCVAw_17_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_VCWz9vVrB0qIHg1ZysCVAw_17_6_2">0.02</ix:nonFraction></ix:nonFraction>)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">* <ix:footnote xml:lang="en-US" id="_ad033d65_277e_4e5e_9e19_7b37ba4f3ada">Shares and per share data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-3</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_6dbbb967_6585_43ff_9e9f_911604f3bd6e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liminatus Pharma, Inc.</b></p><a id="CondensedConsolidatedStatementsofChanges"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Changes in Stockholders&#8217; Deficit</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the three months ended March 31, 2026 and 2025</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9f5fbfd7_e8da_4ede_8f3c_d3529928ec42"></a><a id="Tc_ZdyiraTXg0q3oXB8UJmu8A_1_13"></a><a id="Tc_hAOW39p820a3nXGh7KWiBA_2_2"></a><a id="Tc_Omb9Xmkx-U2Aw0YzWl8pAQ_2_7"></a><a id="Tc_RZu06Na_2EiAOWlzHjZHFA_2_10"></a><a id="Tc_4L8RECQwrEOQe6O6iMsjPg_2_13"></a><a id="Tc_t1TuDOyWOk2fF-CivaDwsQ_3_2"></a><a id="Tc_Yo_AGnkSMEe430rJ2T-hRw_3_4"></a><a id="Tc_YNMjUbEqnEGF_DyG4O9F3w_3_7"></a><a id="Tc_jp-DuMMl4kSeRmbUJWlIiQ_3_10"></a><a id="Tc_uSsr_RUh50-p8HfDOkg9Ew_3_13"></a><a id="Tc_4wMVJxeQS0GUktjirksWKg_4_0"></a><a id="Tc_SjlUc2ybgUeMRoo5fHuN3Q_4_4"></a><a id="Tc_DTCqa4b5cEe_S41mM7e6VA_4_7"></a><a id="Tc__7tggKnqh0iUOYrEEZRvqw_4_10"></a><a id="Tc_qnJAlahNkUuhdFLHTQlrWg_4_13"></a><a id="Tc_LDkq7FDPJkm1Gf255--sxA_5_0"></a><a id="Tc_F6edd11s6E2Jiy56bRThCw_5_11"></a><a id="Tc_SYm8K03quEChL1EgnpkZeQ_6_0"></a><a id="Tc_HwbrpXMQ8Ua11507Uf-eDQ_6_11"></a><a id="Tc_-Yvxs5zGqkCJ-N6kf1Z8vA_7_0"></a><a id="Tc_p4z-yzHMc0KZQfJEV_4wYw_7_2"></a><a id="Tc_KPmb7tJhQkqX23cyavfd1Q_7_5"></a><a id="Tc_MUtIzYQwO0eaa8Yl2I0wSA_7_8"></a><a id="Tc_jRAKjhiSyECrjzIlA9oHdA_8_0"></a><a id="Tc_MD4jKEF__0e39wYkVKsSiQ_8_4"></a><a id="Tc_mDIiIKvKiEqHDwmtfxS3HA_8_7"></a><a id="Tc_r64IZuxeA0eczxf1tQGRqw_8_10"></a><a id="Tc_fjIxmyMyxECagPDovH2uuQ_8_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:207.25pt;padding:0pt;"/><td style="width:9.5pt;padding:0pt;"/><td style="width:50.55pt;padding:0pt;"/><td style="width:9.5pt;padding:0pt;"/><td style="width:5.7pt;padding:0pt;"/><td style="width:50.65pt;padding:0pt;"/><td style="width:9.5pt;padding:0pt;"/><td style="width:7.04pt;padding:0pt;"/><td style="width:56.4pt;padding:0pt;"/><td style="width:9.5pt;padding:0pt;"/><td style="width:8pt;padding:0pt;"/><td style="width:50.65pt;padding:0pt;"/><td style="width:9.5pt;padding:0pt;"/><td style="width:5.7pt;padding:0pt;"/><td style="width:50.56pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:207.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.55pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:56.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.55pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.19pt;"><td style="vertical-align:bottom;width:207.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:56.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:207.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:116.4pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:63.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional&#160;Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:58.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:56.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr style="height:9.69pt;"><td style="vertical-align:bottom;width:207.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:56.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:63.45pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:58.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:56.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;Deficit</b></p></td></tr><tr style="height:10.59pt;"><td style="vertical-align:bottom;width:207.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Balance - December&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LJS_bgYOWkOcBywnif6GLQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_--g1J3AQv0qKyyz8xQSB9w_4_2">27,064,633</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LJS_bgYOWkOcBywnif6GLQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_XR-sd7H54kGW0PiFR5oIoA_4_5">2,706</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_It0aMMr5RUGH0v6aV7qdrw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Pek-NRLViUyVyREk8mXLgQ_4_8">29,054,337</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4f2Cj2MzIUuqkE9ozbbB6w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_HA7POEqghEqEeslKVHNRfg_4_11">38,871,733</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc__nGSvNLeEUuD2q3Pv8TGvg_4_14">9,814,690</ix:nonFraction>)</b></p></td></tr><tr style="height:20.69pt;"><td style="vertical-align:bottom;width:207.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issuance of common stock in connection with the Clear Street settlement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0P2Hk6Fm0UCfvB5hIDbvbw" decimals="INF" format="ixt:num-dot-decimal" name="limn:StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants" scale="0" id="Tc_wX0DPmPzbEusasO14M7ESA_5_2">4,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0P2Hk6Fm0UCfvB5hIDbvbw" decimals="0" format="ixt:num-dot-decimal" name="limn:StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants" scale="0" id="Tc_FwsvgI3B7ESYmbJ0Kkhd1Q_5_5">736</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZSeIP3LMQEiCyd2vZgeG5w" decimals="0" format="ixt:num-dot-decimal" name="limn:StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants" scale="0" id="Tc_jdV_9c-n8EepKADKoAM-2A_5_8">7,359,264</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="limn:StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants" scale="0" id="Tc_8kOTnPtNdkyDIB501mlsSw_5_14">7,360,000</ix:nonFraction></p></td></tr><tr style="height:20.69pt;"><td style="vertical-align:bottom;width:207.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issuance of common stock in connection with the Offering, net of offering costs of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="limn:OfferingCosts" scale="0" id="Narr_BhKdmCitIEucEaPs9VvfEA">559,962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0P2Hk6Fm0UCfvB5hIDbvbw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_L-Q_D0Sgi0aCiryfXneXNA_6_2">13,813,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0P2Hk6Fm0UCfvB5hIDbvbw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_--C5WNj7oEe5ksxJBWwCKQ_6_5">1,381</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZSeIP3LMQEiCyd2vZgeG5w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_TuY6uTFFmkqZcrvhLY_VEw_6_8">3,444,427</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_xVdD5e0r-ECV1qrCYwiATQ_6_14">3,445,808</ix:nonFraction></p></td></tr><tr style="height:10.59pt;"><td style="vertical-align:bottom;width:207.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.4pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vn8s2LBdIUK1HIqRW6N8fQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_SoamhPlcokGoAoME_X6cEw_7_11">1,123,714</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_570XF3kHfEG6RLc26fDSnQ_7_14">1,123,714</ix:nonFraction>)</p></td></tr><tr style="height:11.34pt;"><td style="vertical-align:bottom;width:207.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Balance - March&#160;31,&#160;2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.55pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__vfMa6eSe02_iSgKMlEjFQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_3fCgSJX0YEKMyJcSCkKgEg_8_2">44,877,633</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__vfMa6eSe02_iSgKMlEjFQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_qL6VS_XYykqgvA-0MpNMnw_8_5">4,823</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.4pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Y5cch1GNXkWKRHTF2v1JhQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_3KRaC5FzFUeFEzyb1RLwOw_8_8">39,858,028</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5kfGOGRcqUu2Y62sJIl6Iw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_9bhZgn_BDEeK5oj3_iOYYA_8_11">39,995,447</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.55pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Qq0wURWxhkSyavWEohmX7g_8_14">132,596</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e514e929_778d_4d28_8bbe_3309d40035e2"></a><a id="Tc_f6L3cSMhgUOInFtT8k3S8A_1_13"></a><a id="Tc_yPiaVAZFskGTZqkNga3gaA_2_2"></a><a id="Tc_f5pynNA1lEqairJvhVpGIg_2_7"></a><a id="Tc_pSTKkuikjE6FOjVQPEFc9w_2_10"></a><a id="Tc_qTp60xFJ6U-GGf67zQT0mQ_2_13"></a><a id="Tc_QXsrkUHT0E-gFn7BejfKww_3_2"></a><a id="Tc_RTq5V_RDMEGRJgjunUMlsQ_3_4"></a><a id="Tc_y7XsvdpSok28aJ5dpuf5aA_3_7"></a><a id="Tc_SkHtyqySqEmqfluhch-8ug_3_10"></a><a id="Tc_KhMJHEhCFUmyU-_qxBC1Hw_3_13"></a><a id="Tc_6eq-xVIzskCExY3JiqygMg_4_0"></a><a id="Tc_pAvFDqqeM02DhrNCgj_T6w_4_4"></a><a id="Tc_T-ZQDWrdjkCeMdhQZWpXWQ_4_7"></a><a id="Tc_6uSPCU4GEEq-4o-kCfA0sw_4_10"></a><a id="Tc_UOoSe5pktES1qeJ0K2lL5A_4_13"></a><a id="Tc_ohU-JCH0P0CA7Fn-2PIbiA_5_0"></a><a id="Tc_tscEbJ6ClkmNmPfeADOaVw_5_2"></a><a id="Tc_TY9YZY2ZfESvysEE7puDXA_5_5"></a><a id="Tc_DCCHgHs0xU-fq1Fxy897Gg_5_8"></a><a id="Tc_mx8CCgBJ1k2pcaHHKJ8SBg_6_0"></a><a id="Tc_OeFyHYeTwUus80vKzxK1hg_6_4"></a><a id="Tc_8-weUeN0B0u8fUtem8R01g_6_7"></a><a id="Tc_AiVhI0_zJEWTYsT8RJOUoA_6_10"></a><a id="Tc_TMMt50ftS0ewkauXqcSeyw_6_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:207.1pt;padding:0pt;"/><td style="width:9.4pt;padding:0pt;"/><td style="width:50.45pt;padding:0pt;"/><td style="width:9.4pt;padding:0pt;"/><td style="width:5.5pt;padding:0pt;"/><td style="width:50.45pt;padding:0pt;"/><td style="width:9.4pt;padding:0pt;"/><td style="width:7.25pt;padding:0pt;"/><td style="width:58.2pt;padding:0pt;"/><td style="width:9.4pt;padding:0pt;"/><td style="width:8pt;padding:0pt;"/><td style="width:50.45pt;padding:0pt;"/><td style="width:9.4pt;padding:0pt;"/><td style="width:5.6pt;padding:0pt;"/><td style="width:50pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:207.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.45pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.45pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:58.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.45pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.19pt;"><td style="vertical-align:bottom;width:207.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:58.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:55.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:207.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:115.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:65.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional&#160;Paid-in&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:58.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:55.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr style="height:9.69pt;"><td style="vertical-align:bottom;width:207.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.45pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:55.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:65.45pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:58.45pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:55.6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td></tr><tr style="height:10.59pt;"><td style="vertical-align:bottom;width:207.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Balance - December&#160;31,&#160;2024*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHu7s1FxgEmdi0qyZEPN4g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_zsPKN6SEekWY3d2I44dmXw_4_2">17,500,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHu7s1FxgEmdi0qyZEPN4g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_eKNO23yJNUWFC8dvbXuTTQ_4_5">1,750</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:58.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9uu8nJPlZE2Ewx4WJxhvoQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_sOXwOs1NWUqL90HO1pSPsQ_4_8">9,323,403</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MuLWEtlz5E2UN4YJiAi4YQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_gVrV0xOrV0K_rG-K207NgQ_4_11">28,665,216</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_9g7XhG98L0-hjr-ibTvlWw_4_14">19,340,063</ix:nonFraction>)</b></p></td></tr><tr style="height:10.59pt;"><td style="vertical-align:bottom;width:207.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.45pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.45pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:58.2pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.45pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__4kj97EHqEunWT3sM4bCbw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_Gr4OUhbLSkqiGjMVkLJykA_5_11">327,526</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_JXltSoX9e0uRgUMkiRMojQ_5_14">327,526</ix:nonFraction>)</p></td></tr><tr style="height:11.34pt;"><td style="vertical-align:bottom;width:207.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Balance - March&#160;31,&#160;2025*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.45pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p3dvj_Io2E-N-bZQMUAM-w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_50Q7YqE7lUKdd0j_-dl0DQ_6_2">17,500,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.45pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p3dvj_Io2E-N-bZQMUAM-w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Xt_wJP7dJkKhrFhNXTtlGw_6_5">1,750</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:58.2pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9gmJIjAObE6K8dYKyoRMyw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_El4IjDSW3UCH26c1m9yFpQ_6_8">9,323,403</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.45pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lO_UINB71EmnK4inw1sNDQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_FTVM3DYkxEiJuMIrO1_aYA_6_11">28,992,742</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2025_VCFxQaKNIEuk0z9tPKoniw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_I5daGb_3i0GiMQydwwoksA_6_14">19,667,589</ix:nonFraction>)</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">* <ix:footnote xml:lang="en-US" id="_3ff2511c_245c_4e73_aadd_3aa97d52401a">Shares, preferred stock amount, common stock amount and additional paid - in capital data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-4</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_fb04468c_036f_4cbe_af90_1f17f670edf6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liminatus Pharma, Inc.</b></p><a id="CondensedConsolidatedStatementsofCashFlo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c0c672a8_d4f8_43cc_9763_4027fb73d6f2"></a><a id="Tc_QBNFemGnekuK8Heq7PGDaw_1_2"></a><a id="Tc_cHrYAPsvQEuQmi6TVAFHSw_2_2"></a><a id="Tc_lmy42WJD5Uebycg0nQuW6A_2_5"></a><a id="Tc_CQ5UG50GBEqnUIRqU343nQ_3_0"></a><a id="Tc_xwpnQney_E6zumrB20sAUQ_4_0"></a><a id="Tc_Y8cibQqlwkm-60KwJUAXGA_5_0"></a><a id="Tc_FyvMHVGQJEmgvjhSLXG7qQ_5_2"></a><a id="Tc_phPIN5ASMEKRUU0-Y35Y_A_5_5"></a><a id="Tc_3V06vx16T0uFUT6zjpCDFA_6_0"></a><a id="Tc_-Oz6LnhubU2Q9va_rFkEDw_6_6"></a><a id="Tc_MuSPzfhjKEaiZYFxHDOCjw_7_0"></a><a id="Tc_z-BiJmaac06HNqB_4Yb6tQ_7_6"></a><a id="Tc_9p44lVGLxUaMFLi9CwH9pw_8_0"></a><a id="Tc_TN1kgjNV30iYScH2QQNZvg_9_0"></a><a id="Tc_cXJ0RuJjFUCD8Ue76dPxOQ_10_0"></a><a id="Tc_OY8iR-nSYkOAr4q8mVbH3w_11_0"></a><a id="Tc_vcwLUYBSIE2pdMsl0vwarQ_12_0"></a><a id="Tc_hbkLTcRV9ku0g1T2zYLM5A_13_0"></a><a id="Tc_2HRO1TbCDEuVngfVH9WgRg_15_0"></a><a id="Tc_eZjbdcw2ukGie6-5SVrgrQ_16_0"></a><a id="Tc_pWr6xWtVLECt2Qgg3jIhkA_16_3"></a><a id="Tc_KWf50QzWjU2PyRHpeI6GXQ_17_0"></a><a id="Tc_pg4DQ2QkBUeuiOzxomc3xA_17_3"></a><a id="Tc_LekMHzzjkku6o_cqbD1UIw_19_0"></a><a id="Tc_as2TT3anJkaBHxTuXG0hrg_20_0"></a><a id="Tc_1zjaCZGLR0yNzGvg2hrWvg_20_6"></a><a id="Tc_lNehVHzhiUO0Br1VSZtSKg_21_0"></a><a id="Tc_avpMqUv7WUODMD9ubVVTcA_21_3"></a><a id="Tc_IjXz2SWjCUOfScsCaJrLCg_22_0"></a><a id="Tc_RZn1Uj4Vk0qny1GRC5q5tg_24_0"></a><a id="Tc_Me4HSIEn4ESXCvMl0gWAug_26_0"></a><a id="Tc_EtA72d6pckez3cHmrPQStQ_27_0"></a><a id="Tc_9vWJaVkgOkm6iShtIozIvA_27_2"></a><a id="Tc_d7H2RE1vpE-RCPPOYyEwtg_27_5"></a><a id="Tc_dTmWcLngd0SbDp4wAMQUtg_29_0"></a><a id="Tc_MD35G027aU6o_wEdwHtENA_30_0"></a><a id="Tc_Vvi23w0jd0O6VxQZBGkNxQ_30_2"></a><a id="Tc_XLbK5fsN_EOOPYo6oPCxAg_30_5"></a><a id="Tc_d1cucz3H10KAZ02HHJCjJA_30_6"></a><a id="Tc_Rbe4DP4pJU2cndk9SK1utw_31_0"></a><a id="Tc_vJ46rm3fF0ajspyo_m0zlg_31_2"></a><a id="Tc_aratKOZXSEW_YBsKOHs5Ng_31_5"></a><a id="Tc_Hi1nP3q9SE-WF4iCSsXj0Q_31_6"></a><a id="Tc_gjgTrP0pQ0efsmgVYa6FaA_32_0"></a><a id="Tc_dmr5eYqON0Cq0AfPwJ-Y0Q_32_2"></a><a id="Tc_hy00zWB4Xkq2-7XZr7mBJA_32_3"></a><a id="Tc_9OIP8eF5mkCNhbFiii6Agg_32_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:385.8pt;padding:0pt;"/><td style="width:12.2pt;padding:0pt;"/><td style="width:7.65pt;padding:0pt;"/><td style="width:57.25pt;padding:0pt;"/><td style="width:12.2pt;padding:0pt;"/><td style="width:7.65pt;padding:0pt;"/><td style="width:57.25pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:142pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the three months ended March&#160;31,&#160;</b></p></td></tr><tr style="height:9.69pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Operating Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_YRPAb4AG6EaVuSM7ZuZ92w_5_3">1,123,714</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_bgSqVndl6E6Q0wqxmT07PQ_5_6">327,526</ix:nonFraction>)</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" id="Tc_sBBHIZLQyEuHRyQFySWjsg_6_3">518</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in the fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="Tc_b_qrb51JZ0OtlNr1XkHCOA_7_3">4,178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes in operating assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_y7FqVbahxU-bYSNVoeDk7g_9_3">707,953</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_8oLT30H5jU2kFObJMfE4Sw_9_6">50,846</ix:nonFraction>)</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="0" id="Tc_065YO5IHoUSgkKTP6BipSQ_10_3">191,956</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_ir74VIkMHEiRHFkEWO0vlQ_10_6">121,467</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued interest, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="limn:IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent" sign="-" scale="0" id="Tc_vOxfVneRiUONx4rgB_XB2Q_11_3">18,637</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="limn:IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent" sign="-" scale="0" id="Tc_FNAPfCMOeEStzzKJ7BRNQQ_11_6">115,512</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Due to related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" sign="-" scale="0" id="Tc_h5QUQVxsR0WH-TFGpLsZCg_12_3">14,999</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" sign="-" scale="0" id="Tc_JFBRz33GHUS4HJfI7n2ynw_12_6">18,000</ix:nonFraction>)</p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Net cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_s0x2UkSpx0u0UVZiiE39IA_13_3">2,015,289</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_3V1TrCra0EGcvMbzcTCmPQ_13_6">159,393</ix:nonFraction>)</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Investing Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loans to Iris Acquisition Corp</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireLoansReceivable" scale="0" id="Tc_Aj8ogMJKd0uJZ8D74OP49g_16_6">575,000</ix:nonFraction>)</p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Net cash used in investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_h5r8TIpFVEu2F-nyICcn7g_17_6">575,000</ix:nonFraction>)</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Financing Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of common stock, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" id="Tc_O5k2NjoTp0q6TSWdFEGHqg_20_3">3,585,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of short-term debt, related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="0" id="Tc_e2w_WmWQeUW2OqYww12apQ_21_6">713,000</ix:nonFraction></p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Net cash provided by financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_ywp-Df-MmkKLWSoCqXiNTg_22_3">3,585,308</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_T1hb7kpdX0-HjWwBvbdltg_22_6">713,000</ix:nonFraction></b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net change in cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_XEpsqJ93Zk664Ia_RD129Q_24_3">1,570,019</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_GG1hWAru6UKhVeYhLEXUFQ_24_6">21,393</ix:nonFraction>)</b></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" id="Tc_wwX-WcpXqkWHZdA2xOMxgg_26_3">337,655</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" id="Tc_7YcPjznCQUuhZpAametJEw_26_6">56,319</ix:nonFraction></p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" id="Tc_w0q58oToFkeWx2fHNCBGPQ_27_3">1,907,674</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2025_VCFxQaKNIEuk0z9tPKoniw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" id="Tc_Pj5Vhn0akU-rS1RlpH7X6g_27_6">34,926</ix:nonFraction></b></p></td></tr><tr style="height:12.24pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-cash investing and financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock in connection with the Clear Street settlement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="limn:CommonStockIssuedInConnectionWithSettlement" scale="0" id="Tc_mP1Wa9V3Q0C7mGmQ57mTEA_30_3">7,360,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Costs incurred in connection with the issuance of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="limn:CostsIncurredInConnectionWithIssuanceOfCommonStock" scale="0" id="Tc_qzgzsFaMxkSj-FLwAgX99A_31_3">139,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred transaction costs in accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredTransactionCostsInAccountsPayable" scale="0" id="Tc_z0USZRivn0KZx4iPQJiu3A_32_6">112,112</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-5</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_238d5e79_2e75_4e65_868f_7da279d2e277"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LIMINATUS PHARMA,&#160;INC.</b></p><a id="NOTESTOUNAUDITEDCONDENSEDCONSOLIDATEDFIN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES&#160;TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_w2s6fS2YuUeqMk0u_cTBGA" continuedAt="Tb_w2s6fS2YuUeqMk0u_cTBGA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;1. Description of Organization and Business Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Liminatus Pharma, Inc. (the &#8220;Company&#8221;), a Delaware corporation, is a pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company&#8217;s candidate, IBA101, is a humanized anti CD47 monoclonal antibody. The next generation CD47 checkpoint inhibitor&#8217;s initial indication is expected to be patients with advanced solid cancers including non-small cell lung cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the uncertainty of whether the Company&#8217;s intellectual property will develop into successful commercial products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 30, 2022, Iris Acquisition Corp, a Delaware corporation (&#8220;Iris&#8221;), the Company, Liminatus Pharma, LLC, a Delaware limited liability company (&#8220;Liminatus&#8221;), Liminatus Pharma Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#8220;Liminatus Merger Sub&#8221;), and SPAC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#8220;SPAC Merger Sub&#8221;), entered into a business combination agreement (as amended, the &#8220;Business Combination Agreement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;4, 2025, Iris held a special meeting of stockholders. At the special meeting, Iris&#8217;s stockholders voted to approve the Business Combination and adopt the Business Combination Agreement, among other items. In connection with the special meeting, stockholders holding <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw" decimals="INF" format="ixt:num-dot-decimal" name="limn:CommonStockCashRedemptionShares" scale="0" id="Narr_7OyXlMGcZE-K-Z51rvAqlw">59,844</ix:nonFraction> Iris Class&#160;A Shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw" decimals="2" format="ixt:num-dot-decimal" name="limn:CommonStockCashRedemptionPricePerShare" scale="0" id="Narr_5-Uon_wsEk66GyUkLpP6vw">11.74</ix:nonFraction> per share, subject to adjustment for taxes payable from the trust account, for an aggregate redemption amount of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw" decimals="0" format="ixt:num-dot-decimal" name="limn:CommonStockCashRedemptionAmount" scale="0" id="Narr_hTpnYxuqpUykNDLZzxjT9Q">702,359</ix:nonFraction>. The redemptions were settled on April 30, 2025 upon the consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April&#160;30, 2025 (the &#8220;Closing Date&#8221;), the Company consummated the business combination contemplated by the Business Combination Agreement, pursuant to which <span style="color:#231f20;">(a)&#160;Liminatus Merger Sub merged with and into Liminatus (the &#8220;Liminatus Merger&#8221;), with Liminatus surviving the Liminatus Merger as a direct wholly-owned subsidiary of the Company, and (b)&#160;simultaneously with the Liminatus Merger, SPAC Merger Sub merged with and into Iris (the &#8220;SPAC Merger&#8221; and, together with the Liminatus Merger, the &#8220;Mergers&#8221;), with Iris surviving the SPAC Merger as a direct wholly-owned subsidiary of the Company (the transactions contemplated by the foregoing clauses (a)&#160;and (b)&#160;the &#8220;Business Combination&#8221;)</span>, and in connection therewith the Company changed its name from &#8220;Iris Parent Holding Corp.&#8221; to &#8220;Liminatus Pharma,&#160;Inc.<span style="color:#231f20;">&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Business Combination Agreement, among other matters, at the effective time of the Business Combination (the &#8220;Effective Time&#8221;), (i)&#160;every issued and outstanding security issued by Iris during its initial public offering (each, an &#8220;Iris Unit&#8221;) was automatically separated and broken out into its constituent parts and the holder thereof was deemed to hold <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw" decimals="INF" format="ixt-sec:numwordsen" name="limn:NumberOfSharesHeldInEachUnit" scale="0" id="Narr_ltcsZJimy0KNy9JbjkhLlw">one</ix:nonFraction> share of Iris Class&#160;A common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_9pZCqRynuEm4Rh-oH6kQ2Q">0.0001</ix:nonFraction> per share (the &#8220;Iris Class&#160;A Shares&#8221;) and <span style="-sec-ix-hidden:Hidden_V3HXcsnI6E-gQG2CW85ZjA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-fourth</span></span> of one redeemable warrant that was included as part of each Iris Unit (the &#8220;Public Warrants&#8221;), and such underlying constituent securities of Iris were converted in accordance with the applicable terms of the Business Combination Agreement, (ii)&#160;at the Effective Time, each issued and outstanding Iris Class&#160;A Share was converted automatically into and thereafter represent the right to receive <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_cgSRAUkHA0i2y04jy71KAw" decimals="0" format="ixt-sec:numwordsen" name="limn:CommonStockConversionRatioBusinessCombination" scale="0" id="Narr_9CGn_H913kia9PtzsuLKmw">one</ix:nonFraction> share of common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_cgSRAUkHA0i2y04jy71KAw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_6uwY1daGmkWggXZs5z3cLg">0.0001</ix:nonFraction> per share (&#8220;Common Stock&#8221;), of the Company, following which all Iris Class&#160;A Shares ceased to be outstanding and were automatically canceled and ceased to exist, (iii)&#160;at the Effective Time, each issued and outstanding Public Warrant immediately and automatically represented the right to purchase shares of Common Stock on the same terms and conditions as are set forth in the applicable warrant agreement, (iv)&#160;at the Effective Time, each issued and outstanding non-redeemable warrant of Iris that was issued by Iris in a private placement at the time of the consummation of its initial public offering, entitling the holder thereof to purchase <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_us-gaap_ClassOfWarrantOrRightAxis_limn_NonRedeemableWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_ZG-LffBZq0OabS0uAuJI-Q" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr__p9SgWwt_UOx10zee2Dtag">one</ix:nonFraction> Iris Class&#160;A Share at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_us-gaap_ClassOfWarrantOrRightAxis_limn_NonRedeemableWarrantMember_xHQZeSCsiEGkdYLlyBZaXA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_slmlpEdzIkqeRtd9Tfb_JQ">11.50</ix:nonFraction> per share, except those issued to Cantor Fitzgerald&#160;&amp; Co. (&#8220;Cantor&#8221;), were forfeited, and (v)&#160;the private placement warrants issued to Cantor immediately and automatically represented the right to purchase shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the consummation of the Business Combination, the Company&#8217;s certificate of incorporation was amended and restated to, among other things, set the total number of authorized shares of capital to <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="INF" format="ixt:num-dot-decimal" name="limn:SharesAuthorized" scale="0" id="Narr_Aka-xSt4YkCBNGWBJs9Nkg">501,000,000</ix:nonFraction> shares, of which <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_SfciC4M0CkGD2BIPnvMY3Q">500,000,000</ix:nonFraction> were designated as common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr__d3U-bg9UUG8umMw1aYKOg">0.0001</ix:nonFraction> par value per share, and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_BpGciHFGZEeO0WSvgcOQLg">1,000,000</ix:nonFraction> shares were designated as preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_G2AEfyqCnkGE-kOo7kiZXQ">0.0001</ix:nonFraction> par value per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing Date, <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Gi0t5_gUYU-FQON95jjxrA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_W9l0HTbo4kyrcV2JHgjCeA">7,014,633</ix:nonFraction> shares of Iris Class A Shares automatically converted into shares of the Company&#8217;s common stock, on a <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_zu3KxzCVkkuK5CuyZXWLYA" decimals="0" format="ixt-sec:numwordsen" name="limn:ConversionOfStockOrUnitConversionRatio" scale="0" id="Narr_ZKdhJzl-oEmfVpVRQrAV-w">one</ix:nonFraction>-for-one basis. Of the total <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Gi0t5_gUYU-FQON95jjxrA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_arTZ7IdWOEi1aSX9nrEnrQ">7,014,633</ix:nonFraction> newly converted shares, <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionHoldingsLlcMember_HNZDVq5GE0GEgfHcGTUA1A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_6egYqLsV_UGlBZjthm8vRw">6,900,000</ix:nonFraction> were issued to Iris Acquisition Holdings, LLC, the sponsor of Iris, and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_aADDeFhV70K5BS2735863Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_Nm_MhVTdn06SJUIjoE518g">114,633</ix:nonFraction> were issued to Iris&#8217; public stockholders in a noncash transaction.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-6</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_w2s6fS2YuUeqMk0u_cTBGA_cont1" continuedAt="Tb_w2s6fS2YuUeqMk0u_cTBGA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing Date, the Company issued an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_z8b5svoZ20G3nsK282YqMg">1,500,000</ix:nonFraction> shares of the Company&#8217;s common stock in a private placement (the &#8220;PIPE Shares&#8221;) for the total consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_y9iG2hn23U6a7BefO3WrVA">15,000,000</ix:nonFraction> (the &#8220;PIPE Financing&#8221;). The PIPE Financing consisted of a cash and non-cash component. Under the cash component, the Company received gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" id="Narr_la7dQlbNSUKR_GfFtkg4Cg">10,556,500</ix:nonFraction>, of which $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ" decimals="0" format="ixt:num-dot-decimal" name="limn:ProceedsFromIssuanceOfPrivatePlacementInvestor" scale="0" id="Narr_uZ-aBlxQfEuiBsvLHCYwEA">7,129,500</ix:nonFraction> came directly from the PIPE investor and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ" decimals="0" format="ixt:num-dot-decimal" name="limn:ProceedsFromIssuanceOfPrivatePlacementInvestorFunded" scale="0" id="Narr_krTV0uUk802xisscLiRwiA">3,427,000</ix:nonFraction> were funded indirectly by the PIPE investor, through promissory notes between Prophase Sciences, LLC, a related party of the Company, and Liminatus. At the Closing Date, the $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_Mrfb0VhrMkud7Exjn01dhg">3,427,000</ix:nonFraction> in related party debts between Prophase Sciences, LLC and Liminatus was ultimately converted into shares as part of the PIPE Financing. As part of the PIPE Financing, the gross proceeds satisfied principal and accrued interest totaling $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VYxJe3-ZlEKGtf77rNoRJQ" decimals="0" format="ixt:num-dot-decimal" name="limn:PrincipalAndAccruedInterestOnPrivatePlacement" scale="0" id="Narr_DjblYAK4vkm6EmecRKMrrw">3,316,756</ix:nonFraction>, which was ultimately converted into shares as part of the PIPE Financing. The non-cash component of the PIPE Financing included the conversion of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ConsortiumLoanOfRelatedPartiesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4nTHRjjm9E64EIS8-8O57A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_uYxfg7kKtUSQMWw3nKWo8Q">4,443,500</ix:nonFraction> in amounts borrowed from a consortium of related parties. The $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VYxJe3-ZlEKGtf77rNoRJQ" decimals="0" format="ixt:num-dot-decimal" name="limn:RelatedPartiesDebtToUnsecuredPromissoryNote" scale="0" id="Narr_Fkv_pNPmykiY-6H1gd6q1Q">4,443,500</ix:nonFraction> borrowed from the related parties was used to fund an unsecured promissory note between Liminatus and Iris. At the Closing Date, the unsecured promissory note was settled and the $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VYxJe3-ZlEKGtf77rNoRJQ" decimals="0" format="ixt:num-dot-decimal" name="limn:UnsecuredPromissoryNoteSettledAndConverted" scale="0" id="Narr_XPaRX8Wu8kOKyHNCsf39Eg">4,443,500</ix:nonFraction> in related party debts were ultimately converted into shares of the Company in a noncash transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing Date, <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_9PPk1IhN6EmJm5MGsGwEDA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_4JXWb_1aDEGIqYuj6lNMmQ">112,222,220</ix:nonFraction> of Liminatus&#8217; member units converted into <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_9PPk1IhN6EmJm5MGsGwEDA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_KsFIyEetNEG52ZL3ljjB2Q">17,500,000</ix:nonFraction> shares of the Company&#8217;s common stock. Of the <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_9PPk1IhN6EmJm5MGsGwEDA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_tmNHc-YBf026JGYIFXlzBA">17,500,000</ix:nonFraction> shares of common stock, <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_gsYeVbSjA0ijBUxcCNZtvA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_qQgqIdXqkky5UnzuI4JECQ">4,000,000</ix:nonFraction> were issued to Feelux Co, Ltd. as part of an agreement between the Company, Feelux Co, Ltd. and Car-Tcellkor, Inc. As part of the agreement, the outstanding principal and accrued interest on the Feelux and Car-Tcellkor bonds, totaling $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxAndCarTcellkorMember_IRaHwKWzMU-DElAHyQN8Tg" decimals="0" format="ixt:num-dot-decimal" name="limn:ConversionOfPrincipalAndAccruedInterestAmount" scale="0" id="Narr_uifkfOU9M0ScK3jnaGhR3g">11,481,146</ix:nonFraction>, and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxAndCarTcellkorMember_zWurOUpaU0i-IKmnDLLc4w" decimals="INF" format="ixt:num-dot-decimal" name="limn:ConversionOfPrincipalAndAccruedInterestShares" scale="0" id="Narr_vcKS9zx7aUm8K-YWtD7tNg">9,999,999</ix:nonFraction> member units of Liminatus were converted into <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_gsYeVbSjA0ijBUxcCNZtvA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_GP5l7pbcpk6BXbWxlblhiw">4,000,000</ix:nonFraction> shares of the Company&#8217;s common stock. The remaining Liminatus member units were converted based on a conversion ratio of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="4" format="ixt:num-dot-decimal" name="limn:ConversionOfStockOrUnitConversionRatio" scale="0" id="Narr_nM8qkd6JGU2E2jCjjkKSsQ">0.1559</ix:nonFraction> shares per member unit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon consummation of the Business Combination, the Company assumed a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_qUlxIbYw4Uyvh13v3JGs3g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="0" id="Narr_vtk8fyDYr0aASz3lTZb5WQ">10,694,604</ix:nonFraction> in liabilities from Iris. The Company incurred $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_aADDeFhV70K5BS2735863Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="Narr_nJGv7dEai0OhnAerXM1h9Q">1,518,381</ix:nonFraction> in transaction costs associated with the closing of the Business Combination. The Company converted a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_aADDeFhV70K5BS2735863Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_E1unWltgs0OQGB4reQabGw">14,797,901</ix:nonFraction> of related party debt and accrued interest, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_qUlxIbYw4Uyvh13v3JGs3g" decimals="0" format="ixt:num-dot-decimal" name="limn:PrincipalAndAccruedInterestOnPrivatePlacement" scale="0" id="Narr_jlBhur8tEE23DGiJp_iUpw">3,316,756</ix:nonFraction> from the PIPE investor and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_qUlxIbYw4Uyvh13v3JGs3g" decimals="0" format="ixt:num-dot-decimal" name="limn:ConversionOfPrincipalAndAccruedInterestAmount" scale="0" id="Narr_rGSKKKSHB0C4NRZsZOnU6Q">11,481,146</ix:nonFraction> from Feelux and Car-Tcellkor (as described above) into common stock. Additionally, a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_aADDeFhV70K5BS2735863Q" decimals="0" format="ixt:num-dot-decimal" name="limn:ConversionOfAccruedInterestOnRelatedPartyDebts" scale="0" id="Narr_qAfjG3CqMEi3NNn33M2MIg">169,201</ix:nonFraction> in accrued interest on related party debts that were converted, as discussed above, was eliminated upon consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, at the Closing Date, the Company settled Iris&#8217; liabilities for $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" scale="0" id="Narr_oM5qLvua-E6lUSUrAXzTPw">7,000,000</ix:nonFraction> of the deferred underwriting fees incurred prior to the Closing Date for <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="INF" format="ixt:num-dot-decimal" name="limn:StockIssuableForSettlementOfDeferredUnderwritingFees" scale="0" id="Narr_91Y1GF8Um06UT2IKLaMu1g">700,000</ix:nonFraction> shares of common stock to the underwriters in Iris&#8217;s initial public offering. At the Closing Date, the shares were not issued to the underwriter and the Company recorded as a liability with a fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="0" format="ixt:num-dot-decimal" name="limn:LiabilityOfUnderwritingFeesFairValue" scale="0" id="Narr_hl50AZVXu0-WTNVzIaoLGQ">7,049,000</ix:nonFraction>. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_7_1_2025_CZJvPOCOcUySCDRAwOkqBA" decimals="0" format="ixt:num-dot-decimal" name="limn:FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" scale="0" id="Narr_SCV6cLfAPkmMrF8BC1XSyA">7,245,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Liminatus was deemed the accounting acquirer in the Business Combination based on an analysis of the criteria outlined in Accounting Standards Codification (&#8220;ASC&#8221;) 805, <i style="font-style:italic;">Business Combinations</i> (&#8220;ASC 805&#8221;). The determination was primarily based on Liminatus&#8217; members prior to the Business Combination having a majority of the voting interests in the combined company, Liminatus&#8217; ability to exert control over the majority of the board of directors of the combined company, Liminatus&#8217; ability to maintain control of the board of directors on a go-forward basis, Liminatus&#8217; senior management comprising the senior management of the combined company, and Liminatus&#8217; operations prior to the Business Combination comprise the ongoing operations of the combined company. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Liminatus&#8217; issuing stock for the net assets of Iris, accompanied by a recapitalization. The net assets of Iris were stated at fair value, with no goodwill or other intangible assets recorded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the consummation of the Business Combination, the Iris Class&#160;A Shares, Iris Units and Public Warrants ceased trading on the OTC Pink Marketplace, and the Common Stock and Public Warrants began trading on The Nasdaq Stock Market (&#8220;Nasdaq&#8221;) under the trading symbols &#8220;LIMN&#8221; and &#8220;LIMNW,&#8221; respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Notices from Nasdaq</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 22, 2025, the Company received a notice from the Nasdaq Listing Qualifications Department indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025. The deficiency letter had no immediate effect on the listing of the Company&#8217;s common stock, and its common stock continued to trade on Nasdaq under the symbol &#8220;LIMN&#8221;. Under the Nasdaq rules, the Company had 60 calendar days, or until October 21, 2025, to submit a plan to regain compliance and if the plan was accepted, Nasdaq can grant an exception of up to 180 calendar days from the filing&#8217;s due date, or until February 16, 2026, to regain compliance. If the compliance plan was not accepted, the Company had the opportunity to appeal that decision to a Nasdaq Hearings Panel. On October 6, 2025, the Company filed its Form 10-Q for the period ended June 30, 2025 and the matter was closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On November 19, 2025, the Company received notices from the Nasdaq indicating that the Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value of Listed Securities (&#8220;MVLS&#8221;) of </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-7</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_w2s6fS2YuUeqMk0u_cTBGA_cont2" continuedAt="Tb_w2s6fS2YuUeqMk0u_cTBGA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$50,000,000 (the &#8220;MVLS Rule&#8221;), based upon a review of the Company&#8217;s MVLS for the last 30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly Held Shares (&#8220;MVPHS&#8221;) of $15,000,000 (the &#8220;MVPHS Rule&#8221;), based upon a review of the Company&#8217;s MVPHS for the last 30 consecutive business days. The Nasdaq staff noted that the Company also does not meet the requirements under Listing Rule 5450(b)(3)(A), which requires the Company to have total assets and total revenue of at least $50 million each for the most recently completed fiscal year or two of the three most recently completed fiscal years. Under the Nasdaq rules, the Company has 180 calendar days, or until May 18, 2026, to regain compliance with the MVLS Rule and MVPHS Rule. In the event the Company does not regain compliance with the MVLS Rule and MVPHS Rule prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Hearings Panel. Alternatively, the Company may consider applying to transfer the Company&#8217;s securities to the Capital Market, provided it meets the Capital Market&#8217;s continued listing requirements. The Company is working diligently to regain compliance with Nasdaq&#8217;s listing rules. However, there can be no assurance that the Company will be able to regain compliance within the prescribed time period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 15, 2026, the Company received a notice from Nasdaq indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rule 5450(a)(1) (the &#8220;Bid Price Rule&#8221;) which requires listed securities to maintain a minimum bid price of $1 per share. Under the Nasdaq rules, the Company has 180 calendar days, or until July 14, 2026, to regain compliance with the Bid Price Rule. In the event the Company does not regain compliance during the initial compliance period, the Company may be eligible for additional time to regain compliance with the Bid Price Rule. The Company is working diligently to regain compliance with Nasdaq&#8217;s listing rules. However, there can be no assurance that the Company will be able to regain compliance within the prescribed time period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">February 2026 Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 18, 2026, the Company closed a best efforts public offering for the sale of (i) <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_8Eb_-va_j0mdcFrq6b8KwQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_SVJt5tV4D0i6H5Lz23wmXQ">8,270,000</ix:nonFraction> shares of common stock, (ii) <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_ggP8Qf9lAEK8UwvoEQkLpw" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="0" id="Narr_XQWkQKqkPUGIHTYmgfmcTA">5,543,000</ix:nonFraction> pre-funded warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_U70qipalZUSb0nCwfCrzfg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_28d98P08kUavW1riZr0SIw">5,543,000</ix:nonFraction> shares of common stock and (iii) <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_rUeXM1hqFEmNCkHtxT9MOQ" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="0" id="Narr_WrjkfeJc0UeAM7VFEYDv4w">13,813,000</ix:nonFraction> common stock purchase warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_Gx1dPATNHkOGW-Snv4cHLg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_1T2B1mY_GkurvcSEFQebtA">20,719,500</ix:nonFraction> shares of common stock, at a combined public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_AjxQK7FsCE6Ub2hVGkXXEA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_OjOJ2tTM5ES-CPDBr5_HLA">0.29</ix:nonFraction> per share (or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_U70qipalZUSb0nCwfCrzfg" decimals="4" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightIssuePricePerWarrant" scale="0" id="Narr_uWsWGi9O5U6CPsFzaDh4QA">0.2899</ix:nonFraction> per pre-funded warrant) and accompanying warrant (the &#8220;Offering&#8221;), for aggregate net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_8Eb_-va_j0mdcFrq6b8KwQ" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_kAwQ-ZPswU-2ZjRQBFpJrw">3.44</ix:nonFraction> million after deducting the estimated offering expenses, including the placement agent fees. Each pre-funded warrant has an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_1ZmaX6FlIkeWdeKISX-IUw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_XlG8ks_a0EGn_QepYgM4NA">0.0001</ix:nonFraction> per share upon issuance for <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_1ZmaX6FlIkeWdeKISX-IUw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_jLOg6Xv88EqnuWFVdbjJlg">one</ix:nonFraction> share of common stock and will not expire prior to exercise. Each warrant has an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_ZDd5yizsikO5sTlcUH09FA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_zBaRb9gUB0C3pLIvWwBCAg">0.29</ix:nonFraction> per share, is exercisable upon issuance for <span style="-sec-ix-hidden:Hidden_nl21qyvNY06G3jQDgQwLzg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one and a half</span></span> shares of common stock, and will expire <ix:nonNumeric contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_ZDd5yizsikO5sTlcUH09FA" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_9DYNbAySaEaPZMpiAOjV3A">five years</ix:nonNumeric> following the date of issuance. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the common stock and the exercise price. Maxim Group LLC acted as the placement agent in connection with the Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Offering, on February 17, 2026, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers party thereto. Pursuant to the Purchase Agreement, the Company agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock or file any registration statement or prospectus, or any amendment or supplement thereto for <ix:nonNumeric contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_yl8JpI15U0KUQtNmfOFI3w" format="ixt-sec:durwordsen" name="limn:PeriodOfNonIssuanceOfCommonStockFollowingClosingDate" id="Narr_CECoCqo81kWQ_AGC4SHavA">180 days</ix:nonNumeric> after the closing date of the Offering, subject to certain exceptions. The Company also agreed not to effect or enter into an agreement to effect any issuance of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock involving a Variable Rate Transaction (as defined in the Purchase Agreement) until <ix:nonNumeric contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_yl8JpI15U0KUQtNmfOFI3w" format="ixt-sec:durwordsen" name="limn:PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate" id="Narr_LAm01GWQO0Wouq4uLbc87w">180 days</ix:nonNumeric> after the closing date of the Offering, subject to certain exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Offering, on February 17, 2026, the Company entered into a placement agency agreement with Maxim Group LLC, as placement agent in connection with the Offering (the &#8220;Placement Agent&#8221;). The Company paid the Placement Agent a cash fee of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_yl8JpI15U0KUQtNmfOFI3w" decimals="3" format="ixt:num-dot-decimal" name="limn:PlacementAgentCashFeePercentage" scale="-2" id="Narr_1jswrHC95kS67yldPcRp4w">8.0</ix:nonFraction>% of the aggregate gross proceeds raised in the Offering. The Company also agreed to reimburse the Placement Agent for all reasonable out-of-pocket costs and expenses incurred in connection with the Offering in an aggregate amount up to $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_yl8JpI15U0KUQtNmfOFI3w" decimals="0" format="ixt:num-dot-decimal" name="limn:MaximumReimbursementForPlacementAgentExpenses" scale="0" id="Narr_WuAF68UOr0mvr_k4W75b8Q">100,000</ix:nonFraction>. In addition, the Company issued to the Placement Agent warrants (the &#8220;Placement Agent Warrants&#8221;) to purchase <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_BhVP8T9QzU6thchw3BBoLA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_PdgPJZRfH0GrJOLldi6fyQ">690,650</ix:nonFraction> shares of common stock (representing <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_xU41UBVWPEGgrfXyxay-nw" decimals="3" format="ixt:num-dot-decimal" name="limn:PercentOfSharesIssuedInOffering" scale="-2" id="Narr_M40AF1qRK0-Y_XlkcpARqQ">5.0</ix:nonFraction>% of the number of shares of common stock sold in the Offering). The Placement Agent Warrants are immediately exercisable at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_Ky__aiunWkee6a2CP8ZTOQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_OVcI5K4LWU2Lfe-ONMR04g">0.319</ix:nonFraction> (or <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_xU41UBVWPEGgrfXyxay-nw" decimals="2" format="ixt:num-dot-decimal" name="limn:PercentOfOfferingPriceRepresentingExercisePrice" scale="-2" id="Narr_sYfTTjYC80uofC_G1UUwqQ">110</ix:nonFraction>% of the public offering price for the shares of common stock and common warrants offered in the Offering) and will expire on the <span style="-sec-ix-hidden:Hidden_y0XoPBMFT0K_m6ZKSdgGew;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fifth anniversary</span></span> of the commencement of sales of the Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity and Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for one year after the date that the condensed consolidated financial statements are issued. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-8</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_w2s6fS2YuUeqMk0u_cTBGA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Through March 31, 2026, the Company has funded its operations mainly through equity and debt financings, including the proceeds from the Mergers and the PIPE Financing and the Offering (as described below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" id="Narr_Wxt0bdt1yU2kaWPRyZR4Bg">1,907,674</ix:nonFraction> of cash in its bank accounts. As of March 31, 2026 and December 31, 2025, there was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_z5PT4xUZ6ESn_2xJ7hOBpQ"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_RhAKI5FVZUGND4zGEIg-5A">1,442,500</ix:nonFraction></ix:nonFraction> of related party debts, which are included in short-term debt, related parties in the accompanying unaudited condensed consolidated balance sheets (see Note 4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Narr_CMf8HilIF0KGWCJv0zAToA">39,995,447</ix:nonFraction> as of March 31, 2026. The Company had a loss from operations and net loss of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Narr_iGHIPWyijkGpZgigmmvbZg">1,100,898</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Narr_9Zof4swf4UK0icW7PxTPCw">1,123,714</ix:nonFraction>, respectively, for the three months ended March 31, 2026. The Company had a loss from operations and net loss of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Narr_IdxI2EgaDEK0txsximDrgw">264,220</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Narr_nHT3oy1Fo0qCL-P3ZgH8vw">327,526</ix:nonFraction>, respectively, for the three months ended March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 18, 2026, the Company completed a &#8220;best efforts&#8221; public offering of (i) <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_8Eb_-va_j0mdcFrq6b8KwQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_tSayoiZ6j0Wed_1XAUizDQ">8,270,000</ix:nonFraction> shares of its common stock, (ii) <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_ggP8Qf9lAEK8UwvoEQkLpw" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="0" id="Narr_lHT2tCFwrU2tEc1bjoTwbQ">5,543,000</ix:nonFraction> Pre-Funded Warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_U70qipalZUSb0nCwfCrzfg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_XpkjdR8f7Um1hpe50xjh9g">5,543,000</ix:nonFraction> shares of common stock and (ii) <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_rUeXM1hqFEmNCkHtxT9MOQ" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="0" id="Narr_1PFzZPQ14E-hcxSUy0EutQ">13,813,000</ix:nonFraction> Common Stock Warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_Gx1dPATNHkOGW-Snv4cHLg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_betm5r3PwkSCM_gR5Lw3_g">20,719,500</ix:nonFraction> shares of common stock, at a combined public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_AjxQK7FsCE6Ub2hVGkXXEA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_ckYtZYDrTU2M1aeHT-dV4g">0.29</ix:nonFraction> per share (or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_U70qipalZUSb0nCwfCrzfg" decimals="4" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightIssuePricePerWarrant" scale="0" id="Narr_rWi9HvhjEk-NBMXb_VPyhg">0.2899</ix:nonFraction> per Pre-Funded Warrant) and accompanying warrant. In connection with the Offering, the Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_8Eb_-va_j0mdcFrq6b8KwQ" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_xi_k3vcORUKXgkDsflzlWg">3.44</ix:nonFraction> million, after deducting the estimated offering expenses payable by the Company, including the placement agent fees. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 205-40, <i style="font-style:italic;">Presentation of Financial Statements&#8212;Going Concern</i>, management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying unaudited condensed consolidated financial statements are issued. The Company&#8217;s unaudited condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management&#8217;s plans relating to the above include raising additional cash through further equity and debt financings or other arrangements to fund operations. There can be no assurance that the Company will be able to raise adequate capital under acceptable terms, if at all. The sale of additional equity may dilute existing members and newly issued equity securities may contain senior rights and preferences compared to currently outstanding common stock. Issued debt securities may contain covenants and limit the Company&#8217;s ability to pay dividends or make other distributions to stockholders. If the Company is unable to obtain such additional financing, future operations would need to be reevaluated.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_Cv21vD6sjEGGxaQI2ZNJEw" continuedAt="Tb_Cv21vD6sjEGGxaQI2ZNJEw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;2. Significant Accounting Policies</b></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_jpjbHkXYUkWkk0BmTdKCxQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) as determined by the FASB ASC and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The unaudited condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements do not include all of the disclosures required by U.S. GAAP for annual consolidated financial statements and should be read in conjunction with the audited consolidated financial statements of the Company as of and for the year ended December 31, 2025 (the &#8220;Annual Financial Statements&#8221;). In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary to fairly present its financial position as of March 31, 2026, its results of operations for the three months ended March 31, 2026 and 2025, its cash flows for the three months ended March 31, 2026 and 2025, and its changes in stockholders&#8217; deficit for the three months ended March 31, 2026 and 2025. Results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year ending December 31, 2026 or any future period. The condensed consolidated balance sheet as of December 31, 2025 was derived from the Annual Financial Statements but does not contain all of the footnote disclosures from the Annual Financial Statements.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="limn:EmergingGrowthCompanyPolicyPolicyTextBlock" id="Tb_K8kC8d-WekiLU51HvmkBDA" continuedAt="Tb_K8kC8d-WekiLU51HvmkBDA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company Status</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">After the closing of the Business Combination, the Company has elected to be an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-9</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_Cv21vD6sjEGGxaQI2ZNJEw_cont1" continuedAt="Tb_Cv21vD6sjEGGxaQI2ZNJEw_cont2"><ix:continuation id="Tb_K8kC8d-WekiLU51HvmkBDA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s unaudited condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:UseOfEstimates" id="Tb_3gs5v6L6FE2ITDfzHoz8bw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results may differ materially and adversely from these estimates. The Company is not aware of any significant estimates that required management to exercise significant judgment with the exception of the Company&#8217;s warrant liability and research and development costs. If the underlying estimates and assumptions upon which the estimates are based change in the future, actual amounts may differ from those included in the Company&#8217;s unaudited condensed consolidated financial statements.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_VcxpF4YxWkiBDxmM1eaEtg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), the Chief Executive Officer, manages the Company&#8217;s business activities as a <span style="-sec-ix-hidden:Hidden_skpW_fMTs0qgK5TqjOzinQ;"><span style="-sec-ix-hidden:Hidden_oRglHBbi5kiQPSddjK0rrg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">single</span></span></span> operating and reportable segment. Accordingly, the Company&#8217;s CODM uses net income/loss to measure the Company&#8217;s single segment&#8217;s performance and allocate resources. Further, the CODM reviews and utilizes functional expenses (general and administrative and research and development) to manage the Company&#8217;s operations. The Company&#8217;s general and administrative expenses for the three months ended March 31, 2026 and 2025 included $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_N4PkFcbsfkOoWh1rhs7g7w" decimals="0" format="ixt:num-dot-decimal" name="limn:FranchiseTaxExpenseIncludingInterestAndPenalty" scale="0" id="Narr_1e1HtHCaA0G4w3VABocj0w">60,500</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_eIyVw3ZwBkWNjXiNqU4kaQ" decimals="0" format="ixt:num-dot-decimal" name="limn:FranchiseTaxExpenseIncludingInterestAndPenalty" scale="0" id="Narr_pEqgzB6UKU2A6NAMHh1IWg">37,500</ix:nonFraction>, respectively, of compensation expenses related to the compensation agreement the Company has executed with its Chief Executive Officer. The remaining general and administrative expenses are related to legal and accounting-related expenses for contractors. The Company&#8217;s research and development expenses did not include any compensation-related expenses. Other segment items included in net loss are interest expense, related parties and interest income which are reflected in the Company&#8217;s unaudited condensed consolidated statements of operations.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_CJsW-Q3MhUCDV8Aw7W3Eng" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which can exceed government insured limits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company did <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" id="Narr_XNHtnk2l406fvsxXiwD-dg"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" id="Narr_4N_LqjKH7EafX2IaDpT7WQ">no</ix:nonFraction></ix:nonFraction>t have any cash equivalents as of March 31, 2026 and December 31, 2025.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_HYsQlLfI8UStfuvudKe8yg" continuedAt="Tb_HYsQlLfI8UStfuvudKe8yg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial assets and liabilities are accounted for in accordance with FASB ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures,</i> which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-10</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_Cv21vD6sjEGGxaQI2ZNJEw_cont2" continuedAt="Tb_Cv21vD6sjEGGxaQI2ZNJEw_cont3"><ix:continuation id="Tb_HYsQlLfI8UStfuvudKe8yg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value hierarchy requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 1 &#8212; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 2 &#8212; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the instrument&#8217;s anticipated life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 3 &#8212; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgement. Accordingly, the degree of judgement exercised by management in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the warrant liability reported in the Company&#8217;s unaudited condensed consolidated balance sheets represent a Level 3 instrument (see Note 8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying values reported in the Company&#8217;s unaudited condensed consolidated balance sheets for prepaid expenses and other current assets, due from related party, accounts payable and accrued expenses, accrued interest, short-term debt with related parties, due to related parties and its deferred underwriting fee payable are reasonable estimates of their fair values due to the short-term nature of these items.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="limn:WarrantsPolicyPolicyTextBlock" id="Tb_Vuy0XL-ohUKj2GUfM8jE2g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC 480, <i style="font-style:italic;">Distinguishing liabilities from equity</i> (&#8220;ASC 480&#8221;), and ASC 815, <i style="font-style:italic;">Derivatives and Hedging</i> (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance, modification, and as of each subsequent quarterly period end date while the warrants are outstanding. As of March 31, 2026, <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_j2wjtBDr30CGi5w2RrtSMw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_zkoACqTV6ke1qnd0ik8SZA">13,813,000</ix:nonFraction> of the Company&#8217;s Common Stock Warrants, <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_slm9IzocEkSBb1GZOKqnZA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_kTBubWANMEidd14CuL-gyg">690,650</ix:nonFraction> Placement Agent Warrants and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_W2lQ6Gn-NEep1cZ7YVoF1w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_ysY4nzGAb0-CArS8PiKEfA">5,094,623</ix:nonFraction> Public Warrants were accounted for as equity-classified instruments and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PrivatePlacementWarrantsMember_GmwTGx3Js0KBpkdQA1hx1g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_HvATPzIav0WZOPx9dRh8SQ">835,555</ix:nonFraction> private placement warrants were accounted for as liability-classified instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the liability-classified warrants are recognized as a non-cash gain or loss on the accompanying condensed consolidated statements of operations. The Company assesses the classification of its warrants at each reporting date to determine whether a change in classification between equity and liability is required. During the three months ended March 31, 2026, the Company had an unrealized gain on the change in fair value of the warrant liabilities of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="Narr_O9dgxU8-RkSDRiocZLZAog">4,178</ix:nonFraction>. During the three months ended March 31, 2025, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="Narr_5uUf_c5hk02q4Y2lEkA4dw">no</ix:nonFraction> unrealized gain or loss on the change in fair value of the warrant liabilities.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="limn:NetIncomeLossPerCommonStockPolicyPolicyTextBlock" id="Tb_GQ8jemrJQ0K0PJPLK8LhcQ" continuedAt="Tb_GQ8jemrJQ0K0PJPLK8LhcQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss per Share of Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company complies with accounting and disclosure requirements of ASC Topic 260, <i style="font-style:italic;">Earnings Per Share</i>. The Company has one class of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities if their effect is antidilutive. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined by using the treasury stock method. Dilutive common stock equivalents are comprised of <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="0" id="Narr_3KQQQIowrU2SEdh_P7Nj6A">19,598,273</ix:nonFraction> warrants, comprised of <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_JogJT3JKnkStw7CCF--1Dw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="0" id="Narr_Vmok-B0ci0aY08LTQtIwag">13,813,000</ix:nonFraction> Common Stock Warrants, <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_hUVQhIvVLUiqyQjkyt2gOg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="0" id="Narr_dBj08pzWV0ufPIxU_HXUJA">690,650</ix:nonFraction> Placement Agent Warrants and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z2RJFeIu4keoqDO4x5BOag" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="0" id="Narr_K0TycdmbXEWKuGslAAFdlg">5,094,623</ix:nonFraction> Public Warrants. For all periods </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-11</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_Cv21vD6sjEGGxaQI2ZNJEw_cont3" continuedAt="Tb_Cv21vD6sjEGGxaQI2ZNJEw_cont4"><ix:continuation id="Tb_GQ8jemrJQ0K0PJPLK8LhcQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">presented, there is no difference in the number of shares used to calculated basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive given that their inclusion would reduce the net loss per share during the three months ended March 31, 2026 and 2025.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_Bxib2T68g0-dvUMzXnC9vQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of costs incurred by InnoBation Bio Co, Ltd. (&#8220;Innobation&#8221;) in accordance with the license agreement with Innobation and are recorded as research and development expenses as incurred (see Note 3).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_Ji2xKl1OHU6Og-Vdau9lbw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes its leases in accordance with ASC Topic 842, <i style="font-style:italic;">Leases</i> (&#8220;ASC 842&#8221;). Under ASC 842, lessees are required to recognize all qualified operating leases at the commencement date including a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use (&#8220;ROU&#8221;) asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. The initial lease liability is equal to the future fixed minimum lease payments discounted using the Company&#8217;s incremental borrowing rate, on a secured basis. The lease term includes option renewal periods and early termination payments when it is reasonably certain that the Company will exercise those rights. The initial measurement of the ROU asset is equal to the initial lease liability plus any initial direct costs and prepayments, less any lease incentives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has leased office space for a fixed period of <ix:nonNumeric contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_-ERi2eSH8k6nwQ15pvx_Hw">10</ix:nonNumeric> months. In accordance with ASC 842, a short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The short-term lease election can only be made at the commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A lessee that makes this accounting policy election does not recognize a lease liability or right-of-use asset on its balance sheets. Instead, the lessee recognizes lease payments on a straight-line basis over the lease term.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_udhKWqxKKEyEq21JFF0nTA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes in accordance with ASC Topic 740,&#160;<i style="font-style:italic;">Income Taxes</i>&#160;(&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. There were <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_dpAivU4s60OelsKXfTrH-w">no</ix:nonFraction> tax accruals relating to uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax positions as income tax expense. There were <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_5se4biOpIkCf1trzMvP4FA"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_Pt859vU9RUi6rULCZMeM0g">no</ix:nonFraction></ix:nonFraction> unrecognized tax positions, and <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" id="Narr_tC714IOGuEGIam_KeTaA7A"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" id="Narr_YUKrZt01BE2pyRWebZArAg">no</ix:nonFraction></ix:nonFraction> amounts accrued for interest and penalties as of March 31, 2026 and December 31, 2025. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only &#8220;major&#8221; tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_Owb5T8k4FEKJs9h19NEh9A"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_cJ_ZldvURkysrIiPlh_Tng">No</ix:nonFraction></ix:nonFraction> unrecognized tax benefits were identified as of March 31, 2026 or December 31, 2025.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_MRkPKkuMUU2oSotPGBShxA" continuedAt="Tb_MRkPKkuMUU2oSotPGBShxA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements&#160;&#8211; Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On November 4, 2024, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2024-03, <i style="font-style:italic;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i> (&#8220;ASU 2024-03&#8221;), to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-12</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_Cv21vD6sjEGGxaQI2ZNJEw_cont4"><ix:continuation id="Tb_MRkPKkuMUU2oSotPGBShxA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this standard will have on its unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#8217;s unaudited condensed consolidated financial statements.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="limn:LicenseAgreementsTextBlock" id="Tb_5A9SSSpMQ0K855oln0rGdg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 3. License Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CD47 License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October 2022, the Company was assigned a license and development agreement, as amended, with InnoBation Bio Co., Ltd. (the &#8220;CD47 License&#8221;), whereby, effective March 31, 2023, the Company received an exclusive license to develop and commercialize products for the CD47 immune checkpoint inhibitor to treat solid cancers, and companion diagnostics used to monitor treatment with CD47 products (collectively, &#8220;CD47 Products&#8221;), from Curis Biotech Holdings LLC, the parent company of Valetudo, a related party of the Company, in exchange for <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_10_31_2022_srt_CounterpartyNameAxis_limn_CurisBiotechHoldingsLlcMember_us-gaap_CapitalUnitsByClassAxis_us-gaap_CapitalUnitClassAMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_MfcULb3sYEWNTNOdJMM4Mg" decimals="INF" format="ixt:num-dot-decimal" name="limn:NumberOfUnitsExchangeForLicenseRights" scale="0" id="Narr_DcQrvfjSFES2QFcJauKHIg">78,555,554</ix:nonFraction> of Liminatus&#8217; Class A member units. The license was recorded at Valetudo&#8217;s cost basis of zero, and the Company recorded an approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_10_31_2022_srt_CounterpartyNameAxis_limn_CurisBiotechHoldingsLlcMember_us-gaap_CapitalUnitsByClassAxis_us-gaap_CapitalUnitClassAMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_MfcULb3sYEWNTNOdJMM4Mg" decimals="0" format="ixt:num-dot-decimal" name="limn:LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital" scale="0" id="Narr_WNr92xUnz0yxmHE3wZZDFA">800,000</ix:nonFraction> Class A membership interest with an offset to additional paid-in capital on the balance sheets. The Company is obligated to pay all development costs for CD47 Products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 20, 2026, the Company issued a payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_2_20_2026_To_2_20_2026_srt_CounterpartyNameAxis_limn_InnobationBioCoLtdMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_uS2EVzFvKkO1OaU1FG7Fdw" decimals="0" format="ixt:num-dot-decimal" name="limn:PaymentForCostsAssociatedWithClinicalTrials" scale="0" id="Narr_ICRYwWBDrkGIc-3DC98F0Q">1,000,000</ix:nonFraction> to Innobation for the total estimated costs associated with the preparation activities for Phase 1 clinical trials of IBA101, the Company&#8217;s product candidate. As of March 31, 2026, the Company estimated approximately <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_3_31_2026_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_tzr9osJ2S0C-6yY56Bt5Ug" decimals="2" format="ixt:num-dot-decimal" name="limn:EstimatedPercentageOfActivitiesCompleted" scale="-2" id="Narr_jWAX3_EDLUq9Bb80IKgQ2A">40</ix:nonFraction>% of the activities were completed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of March 31, 2026 and December 31, 2025, prepaid research and development costs of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_tzr9osJ2S0C-6yY56Bt5Ug" decimals="0" format="ixt:num-dot-decimal" name="limn:PrepaidResearchAndDevelopmentExpenseCurrent" scale="0" id="Narr_Bs1FYerfqUediwemUEfctA">600,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_tErYwLwjB0maTrnKFX-S_w" decimals="0" format="ixt:num-dot-decimal" name="limn:PrepaidResearchAndDevelopmentExpenseCurrent" scale="0" id="Narr_QXsdDNLWhE-WcNwz69yS5A">0</ix:nonFraction>, respectively, are recorded in prepaid and other current assets in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, research and development expense related to the CD47 License was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_XYwkzRP4y0ClnxSz9bnyLw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_-gk1xBWOZ0KDWRNiicYZ-Q">400,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_lUoEyYWXh0OCUietIBRj9g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_oV8J7-TkZkqFKeUDWbpVDw">0</ix:nonFraction>, respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_TPrsIgV8jkiOw9Igf4qC4Q" continuedAt="Tb_TPrsIgV8jkiOw9Igf4qC4Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;4. Related Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Related Party Debt</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Feelux Bonds</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 15, 2018, the Company issued $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_XYdF0lVEFESS_UvcwZiLjA">10,000,000</ix:nonFraction> of bonds to Feelux Co., Ltd., the parent company of Car-Tcellkor, Inc. (&#8220;Car-Tcellkor&#8221;) (see below), the only holder of Liminatus&#8217; Class A member units (the &#8220;Feelux Bonds&#8221;). The bonds bear interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_Kva8nxlRY0aokyNftL7hzw">1</ix:nonFraction>% per annum, compounded annually, and were due on October 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the issuance of the Feelux Bonds, Liminatus issued <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_gTUs_al0JkWAK9z3Rsbeaw">6,666,666</ix:nonFraction> equity-classified warrants to purchase member units at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_2Mp-jh0w00iKDFgBkZtZnA">1.50</ix:nonFraction> per unit, which expired on June 30, 2023. The fair value of the warrants to purchase member units of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" id="Narr_DWf8xdNq8U-dWCfCXd5l9g">6,400,000</ix:nonFraction> was estimated using the option pricing framework on the issuance date. The Company&#8217;s assumptions included (a) its expected stock volatility of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NcxMLUOjV0-W98TcYBomsA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Narr_r2W6uh4PhUaxG7nE6HL0Lw">82.0</ix:nonFraction>% based on the historical volatility of a publicly traded set of peer companies, (b) the contractual term of <ix:nonNumeric contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_21BjYfzV9U22bKJDD4GooA">five years</ix:nonNumeric>, (c) the risk-free interest rate of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GUMRHws20E-hQftGj0JvTA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Narr_4Hkdfe51-E22wEA-tlhmJw">2.9</ix:nonFraction>% based on the U.S. Treasury yield curve in effect at the time of grant of the award for a <ix:nonNumeric contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_DPXQtLR5zk2mYtTgXei1Yw">five-year</ix:nonNumeric> contractual term and (d) <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gZkGDq_I9UKTee9n9IgYZw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_aq0hr6Egp0Sy5zwNZChEJQ">no</ix:nonFraction> expected dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_9_15_2018_To_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Ue0f9e9AF0CCuPCxkaHeGw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="0" id="Narr_DB5KX_JXE0GeXqRWgPbjUA">10,000,000</ix:nonFraction> of proceeds from the Feelux Bonds were allocated to the bonds and warrants using the relative fair value method resulting in a debt discount for the relative fair value of the warrants of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" id="Narr_NqaHX5pH_ECLjKkEsEOHFw">4,499,142</ix:nonFraction> that was amortized to interest expense over the term of the Feelux Bonds using the effective interest method using an effective interest rate of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="Narr_pl5_iam_oUOp7GF9NNsOIw">21.0</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, upon consummation of the Business Combination, the outstanding principal and accrued interest on the Feelux Bonds, totaling $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_AHn-E6mSh0WMg57djpR6sA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_Pg50N8rWuU6PrOOxJCJXzA">10,681,146</ix:nonFraction>, and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_nnP7Qz9VeUGy0wjX4yxcQA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_yHkWLX067UKYB9nBzN_LXw">9,999,999</ix:nonFraction> member units of Liminatus were converted into <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_nnP7Qz9VeUGy0wjX4yxcQA" decimals="INF" format="ixt:num-dot-decimal" name="limn:StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits" scale="0" id="Narr_FDWNKR7aBUS0-NhjiepL7Q">4,000,000</ix:nonFraction> shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, there was <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tBg1QKOCjkulRGKkllXaGg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_cNmA1YAJvEiSxt-TiBEs5w"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UCZY1ZeR3UG6JVOXPTBI8g" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_Nv2TlbcGuE2ngBxGyNC0_g">no</ix:nonFraction></ix:nonFraction> outstanding balance on the Feelux Bonds. As of March 31, 2026 and December 31, 2025, there was <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tBg1QKOCjkulRGKkllXaGg" decimals="0" format="ixt-sec:numwordsen" name="limn:AccruedInterestCurrent" scale="0" id="Narr_R6AGOgjwr0ynA5rwg7F32Q"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UCZY1ZeR3UG6JVOXPTBI8g" decimals="0" format="ixt-sec:numwordsen" name="limn:AccruedInterestCurrent" scale="0" id="Narr_XlzxOkg8nk65BW-x-iaQHg">no</ix:nonFraction></ix:nonFraction> accrued interest on the Feelux Bonds. For the three months ended March 31, 2026 and 2025, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6WgYpfkMwE2wXyUE6YqM6w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_ebTj4gfyTUiChBtyFmHUnQ">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GRgwbB0go06YmvYSCv-xlQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_hF7L6WBSuUyuE-XhYHtx3g">26,251</ix:nonFraction>, respectively, of interest expense in the unaudited condensed consolidated statements of operations for the Feelux Bonds.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-13</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_TPrsIgV8jkiOw9Igf4qC4Q_cont1" continuedAt="Tb_TPrsIgV8jkiOw9Igf4qC4Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Car-Tcellkor Loan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 18, 2019, the Company borrowed $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_5_18_2019_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_zVHTzo-UxEy__UArL1VThQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_3xmnmYpCJEu75pDy91t-QQ">800,000</ix:nonFraction> from its parent at the time of the loan, Car- Tcellkor (the &#8220;Car-Tcellkor Loan&#8221;). The Car-Tcellkor Loan does not bear interest and was due on March 18, 2020. In November 2022, the maturity date was extended to May 18, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_v60EouUdLUqn8toxvOltkQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentDecreaseForgiveness" scale="0" id="Narr_aU6vCmgSxki6NQJFIRV9ng">800,000</ix:nonFraction> was forgiven.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, there was <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_dKxFvloVNESsveu8CClPfw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_IWFURH2ai0uifKqHhDmpow"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wmmbaObSukiDB_4zDCmrgA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_n53EzuMcI0CnUzZVSt1Xeg">no</ix:nonFraction></ix:nonFraction> outstanding balance on the Car-Tcellkor Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Valetudo Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 1, 2022, the Company borrowed $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_1_2022_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_35Sjj6Gfl0yNGiX5Qt5Qmw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_e1KBb8ppj06NeZcokGOIXg">700,000</ix:nonFraction> from Valetudo Therapeutics LLC (&#8220;Valetudo&#8221;), a related party of the Company due to having common executives, in conjunction with the repayment of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_1_2022_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_35Sjj6Gfl0yNGiX5Qt5Qmw" decimals="0" format="ixt:num-dot-decimal" name="limn:RepaymentOfMembershipInterest" scale="0" id="Narr_CYpZMpPiskWMcJQdyQlinQ">700,000</ix:nonFraction> of membership interest from a member (the &#8220;Valetudo Loan&#8221;). The Valetudo Loan bears no interest and was due on June 1, 2023. On May 1, 2025, the Company paid the outstanding principal balance of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_5_1_2025_To_5_1_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_qNI4ieKD3kSp3GUUyiiVsA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="0" id="Narr_vTWpxCsWUkuth4-1kKHXyw">700,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June 2023, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_u39Cd4S7GEqUxTPP5qv_Qg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_wOGCBD3bTEq57IREB4qS_w">300,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoanTwoMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_uvAg88eC10OdVCXZ0b8E3A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_M3M9MU2kukegaaU9TH_20g">200,000</ix:nonFraction> (the &#8220;Valetudo June 2023 Loans&#8221;). The Valetudo June 2023 Loans bear no interest and were due in December 2023. On May 1, 2025, the Company paid $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_5_1_2025_To_5_1_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Tvb57Yoz8kWjg8oYPKuxig" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="0" id="Narr_MWcm0ixLR0ScC44frg4k-Q">300,000</ix:nonFraction> of the outstanding principal balance on the Valetudo June 2023 Loans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July 2023, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_7_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RoR1eW_fpUmHYmBoFmDg1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_2sS7p1aOwkmD5x9XS0J4qQ">250,000</ix:nonFraction> (the &#8220;Valetudo July 2023 Loan&#8221;). The Valetudo July 2023 Loan bears interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_7_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RoR1eW_fpUmHYmBoFmDg1w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_HFC4z79KtUaYkqSW01Qp-A">6</ix:nonFraction>% per annum and was due on January 9, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2023, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KWt-xK4eN0-5OFBxkx3LGw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_bvvXmgXzG0qnT_rVWDYENA">250,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoanTwoMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_jZaCTxa_V0CXdNygheYPjA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_RE98dmsTYUKPXN6J4S_bMA">150,000</ix:nonFraction> (the &#8220;Valetudo August 2023 Loans&#8221;). The Valetudo August 2023 Loans each bear interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_K45l7DmgQE-CQ-xyraew7w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_UnDgpSlygEufE3KaJLEq-A">6</ix:nonFraction>% interest per annum and were due on January 31, 2024 and February 2, 2024, respectively. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_rDx80SlYbU-El3v0ZF9uAw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" id="Narr_bZCsjEWxOE-nhSB8XXGM1Q">400,000</ix:nonFraction>, along with accrued interest, of the Valetudo August 2023 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2023, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_11_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1Od3S-eoaUCXHX3nnz2htg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_ak_xQeAsK02xiqnwOFk8UA">200,000</ix:nonFraction> (the &#8220;Valetudo November 2023 Loan&#8221;). The Valetudo November 2023 Loan bears interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_11_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1Od3S-eoaUCXHX3nnz2htg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_EQedI-bR0Eqy9Mu0ay5uQA">6</ix:nonFraction>% per annum and was due on January 26, 2024. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6Oq29UcKvkeSSN5rpNIW6w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" id="Narr_e9anC9bbr0CF9YDSNiM6vg">200,000</ix:nonFraction>, along with accrued interest, on the Valetudo November 2023 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2024, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_1_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6andgdbpxkqRlyLXl4XDHg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_sOAOA8KoYEm94_3WvSZaDQ">600,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_1_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoanTwoMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_roRuh60jM0eb54g1Pq5hLQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_lfqp13hlH0m9dHykpCvNCA">150,000</ix:nonFraction> (the &#8220;Valetudo January 2024 Loans&#8221;). The Valetudo January 2024 Loans each bear interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_1_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1AItK1QO2kitXmKJcOl1Fg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_N8-33mQVE0am4JdFRZBEHA">6</ix:nonFraction>% per annum and were due on February 28, 2024. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ZaQ3e71ewUK0aSmJ56rcsw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" id="Narr_DkN0GpGadUq-SLkuibHzhw">750,000</ix:nonFraction>, along with accrued interest, of the Valetudo August 2023 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, the loans from Valetudo of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_7OFPS-3HHUK9zZcMTjtGcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_TGUx8NswwUe9DKr0c-JVDg"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-SnrU4W24kCYErwDqqD2uA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_ClEZkWEaHka-AGTTVtFN_w">450,000</ix:nonFraction></ix:nonFraction> are recorded in short-term debt, related parties in the unaudited condensed consolidated balance sheets (see Note 5). As of March 31, 2026 and December 31, 2025, the related accrued interest of the loans from Valetudo was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_ValetudoTherapeuticsLlcMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_zN6GYwa30EiLaz5lZyZFBg" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr_ex6j-4FQiEqFOPgKm2KRXg">117,058</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ValetudoTherapeuticsLlcMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_u2V6Q8F86kqWl2rCR_ZLxg" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr_t284qDK2f0mSO_f6HfamgA">113,308</ix:nonFraction>, respectively, and is included in accrued interest, related parties in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, interest expense related to the Valetudo loans was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tviGQUjEIkuzwoMOZhqbEQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_8vsolhTiaU6rhwsqC5zHpA">3,750</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__wyANh8s8EOfWyC9HSPygQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr__zePHhYie0-L63XGM_vWBQ">24,000</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Ewon Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 12, 2022, the Company borrowed $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_12_2022_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RpHDxwA5eU6MNdXkdEU0lg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_s2kYL-NAuki78R7VSU8eIw">5,000,000</ix:nonFraction> from Ewon Comfortech Co., Ltd. (&#8220;Ewon&#8221;), a member and related party of the Company (the &#8220;Ewon Loan&#8221;). The Ewon Loan bears interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_12_12_2022_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RpHDxwA5eU6MNdXkdEU0lg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_7d43xHC5R0CNoGkl76pLrg">2</ix:nonFraction>% per annum and was due on December 12, 2023, which may be extended one year upon mutual agreement of the parties, or upon failure to close the Business Combination. In February 2023, the Company repaid $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_2_1_2023_To_2_28_2023_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_fyxYB55LcESYXg1VrFa0SQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="0" id="Narr_wwGI9-o2BkWMeVz119WzzQ">1,000,000</ix:nonFraction> of the short-term loan. In March 2023, the Company repaid an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1IIHRUTkZkq60Pm0ATLdfg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="0" id="Narr_0_Sj2tFu1UC5MGrav1EqOA">2,000,000</ix:nonFraction> of the loan. On April 30, 2025, upon consummation of the Business Combination, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YHOGjDLmVUK3iyhkoffTvQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_DPyhA6b2306CnW005MQtvg">2,000,000</ix:nonFraction>, along with accrued interest, of the Ewon Loan was converted into common stock of the Company. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-14</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_TPrsIgV8jkiOw9Igf4qC4Q_cont2" continuedAt="Tb_TPrsIgV8jkiOw9Igf4qC4Q_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 10, 2023, the Company entered into a loan agreement to borrow $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_9_10_2023_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DWdmZjGmCEiRashhGcBpXQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_4P-pymdYu0Gc4PFB7Iqtdg">200,000</ix:nonFraction> from Ewon (&#8220;Ewon September 2023 Loan&#8221;). The Ewon September 2023 Loan bears interest of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_9_10_2023_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DWdmZjGmCEiRashhGcBpXQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_j29j2-eL4ECRxL0arbJnaQ">2</ix:nonFraction>% per annum and was due on September 9, 2024, which may be extended one year upon mutual agreement of the parties, or upon failure to close the Business Combination. On April 30, 2025, upon consummation of the Business Combination, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-A5AQrt620qPuuH6l9tvXw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr__w4u0iWPmUqwiaaVxxifwQ">200,000</ix:nonFraction>, along with accrued interest, of the Ewon September 2023 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 19, 2023, the Company and Ewon entered into an additional loan agreement and the Company borrowed $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_19_2023_us-gaap_DebtInstrumentAxis_limn_EwonDecember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_PobELNhVp0CNZjEIGlpjlg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_Q9sQ4PpRpken9U1Lg-K9CQ">1,000,000</ix:nonFraction> (the &#8220;Ewon December 2023 Loan&#8221;). The Ewon December 2023 Loan bears no interest. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_EwonDecember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FAzAi_otIkiuLKLUZIGGZQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_QTN8F8AoU0iuOICMDbbAQg">1,000,000</ix:nonFraction>, along with accrued interest, of the Ewon December 2023 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, there was <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__TXA9F6q8kWE6TNY3k0qkg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_VdBQiika40m499PGZbqvsw"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EnLDESj0oUmykTsMHpBM4w" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr__X1STutWjU-Bl9kYs8TQAQ">no</ix:nonFraction></ix:nonFraction> outstanding balance on the Ewon. As of March 31, 2026 and December 31, 2025, there was <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_EwonComfortechCoLtdMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_SJg_pgNr3UGbcKPDWHQG5A" decimals="0" format="ixt-sec:numwordsen" name="limn:AccruedInterestCurrent" scale="0" id="Narr_XpAk9ZjROUKfDNrkR7TO1w"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_EwonComfortechCoLtdMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0bsPPj_X9U-t6aFyc57i1w" decimals="0" format="ixt-sec:numwordsen" name="limn:AccruedInterestCurrent" scale="0" id="Narr_7CRET57AfUCWUea5HBaS6w">no</ix:nonFraction></ix:nonFraction> accrued interest on the loans from Ewon. For the three months ended March 31, 2026 and 2025, interest expense related to the Ewon loans was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_JON9ufuZd0Kog8xAC5tcKw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_zwChm1u0oUG6OWJLtl3exA">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_uwAdfAZSGEaAVubIisn7qg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_93Y9uxI990awzRvYqWmvTA">11,000</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Prophase Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 26, 2024, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_2_26_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_dMLi4mVbI0mnfUUmfRTl1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_8S0xJ4KA80-I3L3XN2qDRQ">200,000</ix:nonFraction> from Prophase Sciences LLC (&#8220;Prophase&#8221;) (the &#8220;Prophase February 2024 Loan&#8221;). The loan bears <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_2_26_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_dMLi4mVbI0mnfUUmfRTl1w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_pxQjg9QKlky2sUsBt6NKGQ">6</ix:nonFraction>% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VgfZxKguUE6IvyhFTK0bgw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_4LWB-R4H8UKcG2KJKksR2Q">168,500</ix:nonFraction>, along with accrued interest, of the Prophase February 2024 Loan was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 6, 2024, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_6_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_U0Xo3fqs00OpXo_SeuDtWg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_22Lc1PEVk0yiv1ESuVf8qw">250,000</ix:nonFraction> from Prophase (the &#8220;Prophase March 2024 Loan&#8221;). The loan bears <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_3_6_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_U0Xo3fqs00OpXo_SeuDtWg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr__GJ6Jx6UFUOvO5w99SgVnQ">6</ix:nonFraction>% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 1, 2024, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KWzMWCDwzEShWHgZreE_vw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_vT2UU33_jEe0x0ydsAaMtQ">250,000</ix:nonFraction> from Prophase (the &#8220;Prophase April 2024 Loan&#8221;). The loan bears <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_4_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KWzMWCDwzEShWHgZreE_vw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_0pb-HwKB_kKIK4JaeXNpPQ">6</ix:nonFraction>% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_WqQ7kEZqMUGKJ2Civ5wmHQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_abK4PH2raUObwthWJipf7g">250,000</ix:nonFraction>, along with accrued interest, on the Prophase April 2024 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May 2024, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_5_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPL1Zq0iyE2-9FTal0qJ5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_Zr5upumiaE2l9UnhAikhRA">790,000</ix:nonFraction> from Prophase (the &#8220;Prophase May 2024 Loans&#8221;). The loans bear <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_5_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPL1Zq0iyE2-9FTal0qJ5A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_KkTsWAMt8UyV7Wlrazbl8Q">6</ix:nonFraction>% interest per annum. Of the aggregate $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_5_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPL1Zq0iyE2-9FTal0qJ5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_5C0MoIxGjkSmJ0yPwrcohg">790,000</ix:nonFraction> Prophase May 2024 Loans, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_6_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VxMZqFXR_UaO5azmVes0dA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_nWQLt2mv9E2ArMbGKe3nRQ">270,000</ix:nonFraction> was due on June 1, 2024 and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_7_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_mxhubmgnJ06DzAurKf0Uug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_YHNQBhUqH06kO_iAD7yKkA">520,000</ix:nonFraction> was due on July 1, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_hxqxTUYPkUOVXBEWPh59bw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_8XSTSSjjCUCZG3uG8eeFKA">550,000</ix:nonFraction>, along with accrued interest of the Prophase May 2024 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July 2024, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_7_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0HW6FGsO8Ei7AXcLtjboyA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_SuYhId-o20OEdVdnLUXM-Q">83,000</ix:nonFraction> from Prophase (the &#8220;Prophase July 2024 Loans&#8221;). The loans bear <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_7_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0HW6FGsO8Ei7AXcLtjboyA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_wsMIZJKGyUiRkiyc8021PA">6</ix:nonFraction>% interest per annum. Of the aggregate $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_7_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0HW6FGsO8Ei7AXcLtjboyA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_SKveGhKBZUmNNE6n-yFi3A">83,000</ix:nonFraction> Prophase July 2024 Loans, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_9_14_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-IXbBujRXkiVzw9mXk784w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_h30pwD3y_ki6DecA1l60vQ">30,000</ix:nonFraction> was due on September 14, 2024, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_9_24_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_4Vld9uwuRkuuQHHIzYvKZg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_v2CFLRehQkuuBSz9PkIyjw">3,000</ix:nonFraction> was due on September 24, 2024 and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_9_29_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_hOP6gIf6X0uZ7Ge6Uhb8yA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_hQAs52Tw70yOp9GdRIiKUA">50,000</ix:nonFraction> was due on September 29, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2024, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_8_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wdQAw9pClkqJCJydARCG4g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_D7mkEID0pEqaAeibqEOo3w">50,000</ix:nonFraction> from Prophase (the &#8220;Prophase August 2024 Loans&#8221;). The loans bear <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_8_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wdQAw9pClkqJCJydARCG4g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_ZljR98jFXk-Hhp9ydgpTDQ">6</ix:nonFraction>% interest per annum. Of the aggregate $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_8_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wdQAw9pClkqJCJydARCG4g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_K7dEax5tOkOGn1iMkSnWXw">50,000</ix:nonFraction> Prophase August 2024 Loans, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_10_12_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NGQDh1rA3UGEJwXQpQqNWA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_uKburhh0G0mJZn9smaJNqg">30,000</ix:nonFraction> was due on October 12, 2024 and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_10_13_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DqH0O8M-DkKolyZ-CdcShA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_VdbyY81UfEuEZUsOnnhacA">20,000</ix:nonFraction> was due on October 13, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February of 2025, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_2_28_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Rs3R6YntuECvjfLJCKGrWA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_WNcBEFp_VUWRiNvsjCxniA">206,000</ix:nonFraction> from Prophase (the &#8220;Prophase February 2025 Loan&#8221;). The Prophase February 2025 Loan bears interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_2_28_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Rs3R6YntuECvjfLJCKGrWA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_xAfpPIySxEO070W5RhQq2Q">6</ix:nonFraction>% per annum and was due on April 11, 2025, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gHk208o8a02buGlMK7GoGA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_SbUkcHpLXk6p_Fin5SKumg">125,000</ix:nonFraction>, along with accrued interest, on the Prophase February 2025 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March of 2025, the Company borrowed $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xe3qXzjS0EC39aN_LENA8g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_aqDAaXunIUmGrt8Znb8LAA">207,000</ix:nonFraction> from Prophase (the &#8220;Prophase March 2025 Loan&#8221;). The Prophase March 2025 Loan bears interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xe3qXzjS0EC39aN_LENA8g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_IWEfgmS8OkG7rkXbhVhgaQ">6</ix:nonFraction>% per annum and was due on June 6, 2025, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_XNzgVBB9EUSW9XJBeTQYXg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_Cdeg1lc6u0-tooXpOuRsCw">200,000</ix:nonFraction>, along with accrued interest, on the Prophase March 2025 Loan was converted into common stock of the Company.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-15</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_TPrsIgV8jkiOw9Igf4qC4Q_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April of 2025, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xvNc1S3hqkGpqvsF2_IC5g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_RrtmaP-S80ehoJvOBgLReA">3,627,000</ix:nonFraction> from Prophase (the &#8220;Prophase April 2025 Loans&#8221;). The loans bear <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xvNc1S3hqkGpqvsF2_IC5g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_LSTOo1YUT0K8Ga3wVA7QzA">6</ix:nonFraction>% interest per annum. Of the aggregate $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xvNc1S3hqkGpqvsF2_IC5g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_G4NtsH3kNEqcVivrKZp1ow">3,627,000</ix:nonFraction> Prophase April 2025 Loans, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_5_2_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GRnA5Kx7-kGf8N58SRLWrw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_va3n2SyN4ke6PlzYF-fDSg">200,000</ix:nonFraction> was due on May 2, 2025, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_5_13_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_99oewdhpVEC5wJhe7rhkyQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_6qJwSZNWb0yi43St3nneWw">1,920,120</ix:nonFraction> was due on May 13, 2025 and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_5_14_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_176IvMRvuUeNEtEQXDudUQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_xg9TQ_rqWUWtYeQshv6SJA">1,506,880</ix:nonFraction> was due on May 14, 2025. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_MxNDVYopJUCTnAtVRr2BCQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_6ezx4ggjMkSESv2S70aCew">3,627,000</ix:nonFraction>, along with accrued interest, on the Prophase April 2025 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, the balance of the Prophase loans is $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_E0TXzEQ0YEKb3rQzLXh72w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_ktBfCDMTGE2mGk_Exx4EXQ"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Hjob6bfNJ0yH9IccwyqnFw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_-8EVpxZIKkucrSsUAMFpaQ">742,500</ix:nonFraction></ix:nonFraction>. As of March 31, 2026 and December 31, 2025, the related accrued interest of the loans from Prophase was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_E0TXzEQ0YEKb3rQzLXh72w" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr__fvHL1kqp0e7esLxcdxVow">90,421</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Hjob6bfNJ0yH9IccwyqnFw" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr_50mRDJCKbUybPt0IaPjU0w">79,283</ix:nonFraction>, respectively, and is included in accrued interest, related parties in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, interest expense related to the Prophase Loans was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_r1BpvCN0KEySovh0Qns8yA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_nTO_7zWA10q-DvaUfuN4tw">11,138</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NUKGQueFCUK3NV6S4f6neA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_nrhot3ip8EidW3z3O0iedA">26,787</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Hana Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 1, 2024, the Company borrowed $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_8_1_2024_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_lO3aHrFMUE2_9b_GTJGSBw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_Qbb6UQI4lUWdSW4lBwANmA">850,000</ix:nonFraction> from Hana Immunotherapeutics, LLC (&#8220;Hana&#8221;), a related party of the Company due to having common executives (the &#8220;Hana Loans&#8221;). The Hana Loans bear interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_8_1_2024_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_lO3aHrFMUE2_9b_GTJGSBw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_XWGYO0L2u0uXPu_DL3U2qA">6</ix:nonFraction>% per annum and were due on September 30, 2024 and October 26, 2024, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VtKf0F4u50yYAUlGncV4kA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_CEYFydEI3U2xFKLCyah6nw">800,000</ix:nonFraction>, along with accrued interest, of the Hana Loans was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, the balance of the Hana Loans is $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Up5NOzVX402q1o88UijPvg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_7sAwDkBuX0elxmmu5bs5vg"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0PybUMyl7UupuiSkslBW7Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_hBOCzzqkiE-A5THp_kEjvQ">50,000</ix:nonFraction></ix:nonFraction>. As of March 31, 2026 and December 31, 2025, the related accrued interest of the loans from Hana was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_HanaImmunotherapeuticsLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_k9NmbfrirkmFjETfcoPvjQ" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr_xepMDl6K9EOQ26sP1DCBXg">2,792</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_HanaImmunotherapeuticsLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_M0xZpqNfSUiePS0rqmBJQQ" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr_FNqdC5ggV0SCKPGZGhhu8A">2,042</ix:nonFraction>, respectively, and is included in accrued interest, related parties in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, interest expense related to the Hana Loans was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EuwARZ5Gg0yVzO8ExZuY7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_W-lSIXcitkikRrOFEmz_sA">750</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_vmR4xWUUp0CvtoWAqoOIRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_PIohZCPMjESVxd9UKYccMw">12,750</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Amantes Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 1, 2024, the Company borrowed $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_11_1_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_skGpvhLamkmTX8ZC32NJjg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_vEVTqxNr4EOCEewAyzb43g">400,000</ix:nonFraction> from Amantes LLC (&#8220;Amantes&#8221;), a related party of the Company due to having common executives, pursuant to a loan agreement between the Company and Amantes (the &#8220;Amantes Loan&#8221;). On November 27, 2024, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_11_27_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xZbOD6QvXU2eioglXc3B9Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_9h56o0pl9UeyzdJCuOvzJQ">300,000</ix:nonFraction> from Amantes (the &#8220;Additional Amantes Loan&#8221;) (together with the Amantes Loan, the &#8220;Amantes November 2024 Loans&#8221;). The Amantes November 2024 Loans bear interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_11_27_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xZbOD6QvXU2eioglXc3B9Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_EYsAQeSX2U2lDFNU38LoBg">6</ix:nonFraction>% per annum and are due on January 1, 2025. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y5QPj6cnBkqxLO8bzZMweA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_ic1k_JJxVEGhjtADKU1Cvg">550,000</ix:nonFraction>, along with accrued interest, on the Amantes November 2024 Loans was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 2, 2025 and January 23, 2025, the Company borrowed a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_1_2_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UoLTcnkgY0ia4LxmBqWZzA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_8361cvSPKEWoa92hbX8c-Q"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_1_23_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPR03tDKjUmpyRyQld8qmA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_MXSD25irSUu45SwtS4iWxg">300,000</ix:nonFraction></ix:nonFraction> from Amantes, pursuant to loan agreements between the Company and Amantes (the &#8220;Amantes January 2025 Loans&#8221;). The Amantes January 2025 Loans bear interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_1_2_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UoLTcnkgY0ia4LxmBqWZzA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_XsZypUmbikGl_wfnUaiKQw"><ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_1_23_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPR03tDKjUmpyRyQld8qmA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_uLpsZ0nTX0SKGVuZqvvU6Q">6</ix:nonFraction></ix:nonFraction>% per annum and are due on March 1, 2025 and March 22, 2025, respectively, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_mmocMhxQQE-9TDe7UCuBDQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_rvUc_vcezkOPt1angijghA">250,000</ix:nonFraction>, along with accrued interest, on the Amantes January 2025 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, the balance of the Amantes Loans is $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_embE8oVddUqzPD1utl4Z7Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_XcijagMu2kyMSJ5Y0f6vLQ"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_s7XNeN2VrkyoKgFvQn08HQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_bdnWcOrkbkCRSB7Fm6Tr_A">200,000</ix:nonFraction></ix:nonFraction>. As of March 31, 2026 and December 31, 2025, the related accrued interest of the loans from Amantes was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_AmantesLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YmK0PQG_Ck6qgjUgdZnidg" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr_wa1adTagIk6vZ2wsHmfK-w">12,287</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_AmantesLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_HgSigzsdAE2ZWAOutjYfWA" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr_qWl4A-7wzEKH5AyhNsSJ8A">9,288</ix:nonFraction>, respectively, and is included in accrued interest, related parties in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, interest expense related to the Amantes Loans was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_MXaZ3yp_lE6x5RxdHImRoQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_utj_Ue0T102tPEV3tUCCMg">3,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KyurFw6NFU6DbWNR_JVlJA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_A6P5QdE9AkmWBuOLF59hoQ">14,724</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Due to Related Party</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of March 31, 2026 and December 31, 2025, the Company has $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_limn_EmploymentAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_AwztCb84TEyTOzqvwRwIZw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Narr_uLQ984m7aU6czZuV0Go13w">194,587</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_limn_EmploymentAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_bhT6iPgTMUSC0cikBkivgg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Narr_od5joPx1ZUmrtNhHCn1fJw">209,586</ix:nonFraction>, respectively, due to the Company&#8217;s executive team for compensation under their employment agreements. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-16</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="Tc_gxXrHWEmrU2ALoy_u34auQ_1_4"></a><a id="Tc_HW1XPFAuskuSHn6q7OzxyQ_1_7"></a><a id="Tc_418gKezYCEeWmK4r1dDFEQ_2_0"></a><a id="Tc_C7fEYGboNkmXCLN60sUnzw_2_2"></a><a id="Tc_pJOA1-ze8Uepz0LDyI3z0g_2_4"></a><a id="Tc_wTn8Yt1PYkqoc98EztF4Ng_2_7"></a><a id="Tc_VqRo9QTHnU-nUpt-WgQBAA_3_0"></a><a id="Tc_TNrkPPizE0mcs_hnyOXmPQ_3_2"></a><a id="Tc_pwzGWAm88UugGvBp9ytRkA_4_0"></a><a id="Tc_pMN4s9fEf0KYa9-esxwSRg_4_2"></a><a id="Tc_dKQhLp2iC0uce2GbR6XlQQ_5_0"></a><a id="Tc_xBh6TQvcoEq8ZKTKahTsuQ_5_2"></a><a id="Tc_gETgEUCnQkKblSJkPo_wLQ_6_0"></a><a id="Tc_l5sCpSjuK0GqKB_QlBmswQ_6_2"></a><a id="Tc_OhcRptIoSEeQraK8r5dfLQ_7_0"></a><a id="Tc_JX33Rw9xzkugG-VsRU3EFA_7_2"></a><a id="Tc_mLi6n-wzE0GjKC5IENYJNg_8_0"></a><a id="Tc_H2UnWrWdJUmlEQY7IOouPQ_8_2"></a><a id="Tc_xH7ETeRNJUSycbd6hD-RpA_9_0"></a><a id="Tc_yG1QT7lZOUufsgn6kWGYVw_9_2"></a><a id="Tc_IHyYv8lso0qB90wlFO8-Sw_10_0"></a><a id="Tc_jKPdIIVQ10ySggX8CrW2Xw_10_2"></a><a id="Tc_OJadpL80ZEGAJZAzMlErVA_11_0"></a><a id="Tc_L_D7ZFPwZkORbaXohsy-mg_11_2"></a><a id="Tc_uW67Hu-SFU-EOSbChBmVMQ_12_0"></a><a id="Tc_zY4oFAukjU6h0UAWSGGhUw_12_2"></a><a id="Tc_NYLKc30xCUmKLejVxYI_DA_13_0"></a><a id="Tc_dwu0ySzO40SklSFfMSjnwA_13_2"></a><a id="Tc_w0kVPLUHd0ajU45t_1Ku9A_15_0"></a><a id="Tc_IAuqzFuOFE-rePFRZdcG4Q_15_4"></a><a id="Tc_tHN-L7K4G0C1TI84RkiS3Q_15_7"></a><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:DebtDisclosureTextBlock" id="Tb_SCcLhxOX_U6ycrLesZCmqg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 5. Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Outstanding debt classified as short-term debt as of March 31, 2026 and December 31, 2025 consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:ScheduleOfShortTermDebtTextBlock" id="Tb_yT-BzAAT6U2vG99-IAIQdQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:225.1pt;padding:0pt;"/><td style="width:8.9pt;padding:0pt;"/><td style="width:157.4pt;padding:0pt;"/><td style="width:8.85pt;padding:0pt;"/><td style="width:5.85pt;padding:0pt;"/><td style="width:53.25pt;padding:0pt;"/><td style="width:8.85pt;padding:0pt;"/><td style="width:7pt;padding:0pt;"/><td style="width:64.8pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:59.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:71.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2025</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo June 2023 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8haIXs4y3EGbc6exykltFw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_sLtNpo0nOkyYKYknVSC9Ww_2_5">200,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VlA87RaJeEq06zmKK_H7kg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_Et05T5aI-EmPbM5ZRjw0EQ_2_8">200,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo July 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YX6lsxQHS0-d9Bt2ThMAkQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_F1wY3mkaO0m0xGaqf-sY2Q_3_5">250,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_eAOXFYGTJk-hpkYZ9yVryA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_zcxa0l2h_0mSm5M1Dat2dQ_3_8">250,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DpWp6FQcKk2ToUxk9I8I-w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_32h618HS2kyfmMxjrb2iTQ_4_5">31,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_9WDN8eHoHUWQK3nMpHkYtQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_Im9tbBXEbUuwcJp4jkNhNg_4_8">31,500</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_A1W50Uj-NUO6hThaQ_OHyw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_Vp2LBPc12UW8cXtpSELGog_5_5">250,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tPoEXxTBuEas6Sj74xYwPA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_n8Z6EuJKRUKHYj6gxWlt2w_5_8">250,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase May 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EBIJxgFtuUu-6zOIAkmcqw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_n9rT4iqYXEeHG3j6sz86nQ_6_5">240,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ay2QMWFbV0SdpGM1KxxUJw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_Ebpa1ikHPkqeiDclGs8JoA_6_8">240,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase July 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NWZ-m0WBA0qJ23vP65-HJw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_JyRIJXh1E0K8AIQrdB7-jA_7_5">83,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Wgs8NC0FrEu0hK8Qjljnog" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_HGMeP-g-pEC39zVvHHbruw_7_8">83,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3iko9KeMAkGp5regWs_4Nw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_DcX8YRL-DESCtdaYdJYbFg_8_5">50,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__dCVK3BY3EeDKZi28xUkew" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_pgs346P8e0q7Kb6FBOTLNw_8_8">50,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hana August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_bIvWOEL1hEqZwZYGgrwYpQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_pLNXol3CqUKUCBogLvKnxg_9_5">50,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NQoRaZtKZUCGus-3AHoDuQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_2_yZ4wapEEGDQLgtasD_9A_9_8">50,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes November 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8q0dzuwVGEShgTwjOwX7bQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_TaI4HVWTp0-msS-j_Vq9HA_10_5">150,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_j5CQtBVz5UqKzenH5qp4Pg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_E5kDailJXkiSspPZp7Lrzg_10_8">150,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes January 2025 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_HiTcUoWDTEqyHvNgB9TCRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_XyjRf9kwgEmfEc6T1BOT9g_11_5">50,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_vlYz7WYM0065Rv0yQrEanA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_lpXb5xU8v0SMQe_sfE7Utw_11_8">50,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_vHGFMJf22kGulBghrO3_RQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_ttnkvxr3xkCQoSd4cU8Nng_12_5">81,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YhVm-9q0AUSPz-vllz68rg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_q6gP_Dl13EKXhU9FpQLcwQ_12_8">81,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_89RhalbceUGFHBdneVrdYg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_eQvmd8N0S0qvF3HnnmkV0w_13_5">7,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tu28ZL0W00ydtm8NRLecmQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_qqaV4sP7hkGzHVOlOxZrqA_13_8">7,000</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short-term debt, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y6Lx3mXqwk-nBkJ5KlLBYg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_yxlJpXE940WlFUGnglx8EA_15_5">1,442,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FbpcEF3_bUqHFwpcC9Wy4w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_XYqETaY88EWZ89vLwkyRcg_15_8">1,442,500</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, the Company&#8217;s outstanding debt agreements are all past due and are classified as current in the accompanying unaudited condensed consolidated balance sheets. All of the loans are with related parties (see Note 4). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As the Company&#8217;s loans are with related parties, the Company and its related parties have agreed to defer repayment until a time that is mutually agreed upon between the Company and its related parties. Accordingly, none of these notes are considered to be in default.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_3-kGuOJTVkuLxAMIgd-S7A" continuedAt="Tb_3-kGuOJTVkuLxAMIgd-S7A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 6. Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Business Company, the Company&#8217;s certificate of incorporation was amended and restated to designate two classes of stock; preferred and common stock. The certificate of incorporation authorized <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_ALz-FckufkKRCKPrbHnexg">1,000,000</ix:nonFraction> shares of preferred stock and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_g66_j-Bfp0GvLDoUcgL6EQ">500,000,000</ix:nonFraction> shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preferred Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Amended and Restated Certificate of Incorporation provides the Company&#8217;s board of directors with the authority to issue up to <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_1LPFHz6gFUCGFfe6Y83L8Q">1,000,000</ix:nonFraction> shares of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_HwERAKHXJEi1i2lyY3NKnQ">0.0001</ix:nonFraction> par value preferred stock in one or more series and to establish from time to time the number of shares to be included in each such series, by adopting a resolution and filing a certification of designations. Voting powers, designations, powers, preferences and relative, participating, optional, special and other rights will be stated and expressed in such resolutions. There were <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_puSPePEIE0qAz42NnPHxjQ"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_EqXPCxGs2UWqwL-WvMbnKQ">zero</ix:nonFraction></ix:nonFraction> preferred shares outstanding as of March 31, 2026 and December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Common Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is authorized to issue <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_DKJ-y9BaGECJlXyXNmpong">500,000,000</ix:nonFraction> shares of common stock, with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_EPA3TRjrxUGkBXLEtd-XDA">0.0001</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 16, 2025, the Company entered into a settlement and release agreement with Alta Partners, LLC (&#8220;Alta&#8221;), pursuant to which the Company agreed to issue <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_7_16_2025_To_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_bvbBg5HF0E2idzp2cAdrIg" decimals="INF" format="ixt:num-dot-decimal" name="limn:SharesIssuedForSurrenderAndCancellationOfWarrants" scale="0" id="Narr_zJYro2VM0kmSFas-FzcRAA">350,000</ix:nonFraction> shares of its common stock to Alta in exchange for the surrender and cancellation of <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_7_16_2025_To_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_bvbBg5HF0E2idzp2cAdrIg" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" scale="0" id="Narr_FSivPHoLNEqtwLV5KrRVYA">1,000,000</ix:nonFraction> Public Warrants held by Alta. On July 16, 2025, the common stock issued to Alta and Public Warrants surrendered by Alta had a fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_3KBXe2AusUautripdVqXLA" decimals="0" format="ixt:num-dot-decimal" name="limn:FairValueOfCommonStockIssued" scale="0" id="Narr_U0c0b2ts6ku9gE2Dn97XOQ">1,890,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_3KBXe2AusUautripdVqXLA" decimals="0" format="ixt:num-dot-decimal" name="limn:FairValueOfWarrantsSurrendered" scale="0" id="Narr_3I5bRCWogUqaFghkpUhxhw">150,000</ix:nonFraction>, respectively. As a result of the exchange, the Company recognized a loss of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_7_16_2025_To_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_bvbBg5HF0E2idzp2cAdrIg" decimals="0" format="ixt:num-dot-decimal" name="limn:GainLossOnIssuanceOfCommonStockForWarrants" sign="-" scale="0" id="Narr_WpfC79WME0iXnEJvaHEUNw">1,740,000</ix:nonFraction> on the difference in fair value between the common stock and Public Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, the Company settled Iris&#8217; liabilities for $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" scale="0" id="Narr_vW1mvBLE4Eq5PXuLwvm0KQ">7,000,000</ix:nonFraction> of the deferred underwriting fees incurred prior to the Closing Date for <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="INF" format="ixt:num-dot-decimal" name="limn:StockIssuableForSettlementOfDeferredUnderwritingFees" scale="0" id="Narr_mW_0d45eAUWjrqJCujcCZw">700,000</ix:nonFraction> shares of common stock to the underwriters in Iris&#8217;s initial public offering. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_7_1_2025_CZJvPOCOcUySCDRAwOkqBA" decimals="0" format="ixt:num-dot-decimal" name="limn:FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" scale="0" id="Narr_haB2uTixm0qIPFz8nTAUtw">7,245,000</ix:nonFraction>.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-17</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="Tc_yiy8Kc5k20CO4xIh4JAdhw_1_0"></a><a id="Tc_zjPCtJhPBkaODagyNH321w_1_3"></a><a id="Tc_p9k5jV4ljEeGzinAPcb7Ow_2_0"></a><a id="Tc_l2ybfDS1QE-TUaANM_6SrA_2_3"></a><a id="Tc_jRPMEAkUC0eYHP6A18-ZVw_3_0"></a><a id="Tc_Qq1bnTWo30a0coqkT7jEOQ_3_2"></a><a id="Tc_FrBcEdMUM06XONWSyHMBuQ_3_3"></a><a id="Tc_4EITpN0oo0yRvqTA9v7f6g_4_0"></a><a id="Tc_F1jYwDsArUmQg4-oXvCvIg_1_2"></a><a id="Tc_8e4JfUXWsEqgJM3YJCTNmA_1_4"></a><a id="Tc_VONmGg_fSkSrRNFTkJ7ypA_1_6"></a><a id="Tc_bN25wJ3jn0achfsulym7DA_2_2"></a><a id="Tc_HyanjAL8mkOGMCtzfD7x1g_2_4"></a><a id="Tc_PPkwjVIaHUWHGTpxDofrIQ_2_6"></a><a id="Tc_lrxBNBchIkex2kWcChv2bw_3_0"></a><a id="Tc_omF8I_0VNESMtLIDSDjZnQ_4_0"></a><a id="Tc_qiknUoBAnUeETZeRNlg1fA_5_0"></a><a id="Tc_4Dj9YWPGWkSWxDVOiPWiAg_6_0"></a><a id="Tc_7pHkaWF_VEC0Y5TUBcjO_A_7_0"></a><ix:continuation id="Tb_3-kGuOJTVkuLxAMIgd-S7A_cont1" continuedAt="Tb_3-kGuOJTVkuLxAMIgd-S7A_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 6, 2026, the Company entered into a settlement and release agreement with the Holder (as defined in Note 7), pursuant to which the Company agreed to issue <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_c_d3VxIAXUGyxXVEc8AngQ" decimals="INF" format="ixt:num-dot-decimal" name="limn:SharesIssuedForSurrenderAndCancellationOfWarrants" scale="0" id="Narr_ZcbuhDzrFUaCnWTmcZ2_Rw">4,000,000</ix:nonFraction> shares of its common stock to the Holder in exchange for the surrender and cancellation of <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_c_d3VxIAXUGyxXVEc8AngQ" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" scale="0" id="Narr_RPgMF71BAUqDtUGIsHQYYQ">805,377</ix:nonFraction> warrants to purchase shares of common stock held by the Holder. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 18, 2026, the Company completed a &#8220;best efforts&#8221; public offering of (i) <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_8Eb_-va_j0mdcFrq6b8KwQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_pBRDvSeUw0ikVc6Iw0G3nw">8,270,000</ix:nonFraction> shares of its common stock, (ii) <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_ggP8Qf9lAEK8UwvoEQkLpw" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="0" id="Narr_g4RmbKPfxEiUKYoLjTE7VQ">5,543,000</ix:nonFraction> Pre-Funded Warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_U70qipalZUSb0nCwfCrzfg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_4YKuY6F35EKFacAn9wyRUw">5,543,000</ix:nonFraction> shares of common stock and (ii) <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_rUeXM1hqFEmNCkHtxT9MOQ" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="0" id="Narr_HzGerzfqaUiQ1vBme5SjVA">13,813,000</ix:nonFraction> Common Stock Warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_Gx1dPATNHkOGW-Snv4cHLg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_mUpwjgE7606yDPQDinF82g">20,719,500</ix:nonFraction> shares of common stock, at a combined public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_AjxQK7FsCE6Ub2hVGkXXEA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_3uUrZMENxEmJtC_JIIPyPQ">0.29</ix:nonFraction> per share (or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_U70qipalZUSb0nCwfCrzfg" decimals="4" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightIssuePricePerWarrant" scale="0" id="Narr_D77PreeMkE2We0CIRl_Row">0.2899</ix:nonFraction> per Pre-Funded Warrant) and accompanying warrant. Immediately upon closing of the Offering, <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_U70qipalZUSb0nCwfCrzfg" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="0" id="Narr_bN5gtaP6WkenfKtUGjN0Sw">4,281,000</ix:nonFraction> Pre-Funded Warrants were exercised and converted into <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_ggP8Qf9lAEK8UwvoEQkLpw" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions" scale="0" id="Narr_TxEWHv33wkWmPZCotvaBJA">4,281,000</ix:nonFraction> shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company allocated the Offering proceeds between the common stock, Pre-Funded Warrants, Common Stock Warrants and Placement Agent Warrants based on their relative fair values in accordance with ASC 505, <i style="font-style:italic;">Equity</i>. The fair value of the common stock and Pre-Funded Warrants was based on the Company&#8217;s closing stock price on the closing date of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockAndPreFundedWarrantsMember_eVpfLX3CYEK8jnIUcxuvGA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" id="Narr_pAxa2ix8T0CcGhxk95Z6ZA">0.2449</ix:nonFraction> per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of the Common Stock Warrants and Placement Agent Warrants was estimated using a Black-Scholes option pricing model with the following assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_UoX6-i4y3kKZXGQbZL5t6w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:369.05pt;padding:0pt;"/><td style="width:10pt;padding:0pt;"/><td style="width:44.6pt;padding:0pt;"/><td style="width:8.35pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:369.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:369.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_KxviRH7DfUuHBTu5r6l8NQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_hQ-zde_sjUWjT7-QE3iIHg_1_2">92.51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:369.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Fj9tEUl42E6MBhnKApp0zA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_tCmGPFNWDUCxAsKLZyF3tQ_2_2">3.66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:369.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:369.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected life of warrants (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_OxQzCXHfk02aUB5FPKeCrg" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_6blY871CSEOApTf8LuQfmA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_3fd1eqWfokGgirzxXLCB_Q_4_2">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Offering proceeds and related issuance costs were allocated to the common stock, Pre-Funded Warrants, Common Stock Warrants and Placement Agent Warrants as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="limn:ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock" id="Tb_rICnJ36bF0O6-xJMSNFg9A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:259.65pt;padding:0pt;"/><td style="width:8pt;padding:0pt;"/><td style="width:52.7pt;padding:0pt;"/><td style="width:8.05pt;padding:0pt;"/><td style="width:50.04pt;padding:0pt;"/><td style="width:8.05pt;padding:0pt;"/><td style="width:45.5pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.24pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Allocated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Allocated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Allocated</b></p></td></tr><tr style="height:9.49pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross&#160;Proceeds</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuance&#160;Costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net&#160;Proceeds</b></p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:259.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0P2Hk6Fm0UCfvB5hIDbvbw" decimals="0" format="ixt:num-dot-decimal" name="limn:GrossProceedsFromIssuanceOfWarrants" scale="0" id="Tc_fti0K2Bcw0Ws4g31Oc6a0w_3_2">1,208,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0P2Hk6Fm0UCfvB5hIDbvbw" decimals="0" format="ixt:num-dot-decimal" name="limn:OfferingCosts" scale="0" id="Tc_1IzjYS0BekSGtGzOQcmJ_g_3_4">168,891</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0P2Hk6Fm0UCfvB5hIDbvbw" decimals="0" format="ixt:num-dot-decimal" name="limn:NetProceedsFromIssuanceOfWarrants" scale="0" id="Tc_5VpWN7pOokm8BA3RlNjN6Q_3_6">1,039,295</ix:nonFraction></p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Common Stock Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsMember_kZc3BMaUdUGTUqWXCxwF2Q" decimals="0" format="ixt:num-dot-decimal" name="limn:GrossProceedsFromIssuanceOfWarrants" scale="0" id="Tc_XrzQkQ_KbkuNARQEJoXF7A_4_2">1,977,998</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsMember_kZc3BMaUdUGTUqWXCxwF2Q" decimals="0" format="ixt:num-dot-decimal" name="limn:OfferingCosts" scale="0" id="Tc_FAaxvV10ZEynBIcz5GMP3w_4_4">276,502</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsMember_kZc3BMaUdUGTUqWXCxwF2Q" decimals="0" format="ixt:num-dot-decimal" name="limn:NetProceedsFromIssuanceOfWarrants" scale="0" id="Tc_213z9ll9C0WcN6q0fA6T7A_4_6">1,701,497</ix:nonFraction></p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:259.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Pre-Funded Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_XvqOOBEml06fz43DO14A7w" decimals="0" format="ixt:num-dot-decimal" name="limn:GrossProceedsFromIssuanceOfWarrants" scale="0" id="Tc_fQwLDPxxWUOGY2XRD6gEUg_5_2">755,014</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_XvqOOBEml06fz43DO14A7w" decimals="0" format="ixt:num-dot-decimal" name="limn:OfferingCosts" scale="0" id="Tc_rouQeWak10ijqs-O3Se1lA_5_4">105,542</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_XvqOOBEml06fz43DO14A7w" decimals="0" format="ixt:num-dot-decimal" name="limn:NetProceedsFromIssuanceOfWarrants" scale="0" id="Tc__I-wBUR9O0CtdiFppIvmjA_5_6">649,471</ix:nonFraction></p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Placement Agent Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_hUVQhIvVLUiqyQjkyt2gOg" decimals="0" format="ixt:num-dot-decimal" name="limn:GrossProceedsFromIssuanceOfWarrants" scale="0" id="Tc__VuoIhOqJkSVVGCit_4g3Q_6_2">64,572</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_hUVQhIvVLUiqyQjkyt2gOg" decimals="0" format="ixt:num-dot-decimal" name="limn:OfferingCosts" scale="0" id="Tc_DorAdBXBd06TWVnT4eIweg_6_4">9,026</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_hUVQhIvVLUiqyQjkyt2gOg" decimals="0" format="ixt:num-dot-decimal" name="limn:NetProceedsFromIssuanceOfWarrants" scale="0" id="Tc_Rd7H9_BCp0C2w8XaY7J0wA_6_6">55,546</ix:nonFraction></p></td></tr><tr style="height:12.54pt;"><td style="vertical-align:bottom;width:259.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="limn:GrossProceedsFromIssuanceOfWarrants" scale="0" id="Tc_m6Dtc3umsUqxqLsmvyTqow_7_2">4,005,770</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="limn:OfferingCosts" scale="0" id="Tc_f8YYn-4OxEKfGTyOTvO5Zw_7_4">559,962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="limn:NetProceedsFromIssuanceOfWarrants" scale="0" id="Tc_aakGSslxLE2ZG-N0egdDlg_7_6">3,445,808</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The amount allocated to the common stock and Pre-Funded Warrants was recorded in common stock at par value and the excess over par value in additional paid-in capital in the accompanying unaudited condensed consolidated balance sheet as of March 31, 2026. The amounts allocated to the Common Stock Warrants and Placement Agent Warrants were recorded in additional paid-in capital as the Common Stock Warrants and Placement Agent Warrants are equity-classified instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Issuance costs, including placement agent fees, legal fees and accountant related expenses were recorded as reduction to additional paid-in capital in proportion to the allocation of proceeds between the equity instruments issued, as summarized above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 19, 2026, the remaining <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_2_19_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_nVZL2iH4ikeTyIHCOmUqAA" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="0" id="Narr_dHuwNtvTKE-OJw7cy3k6Mg">1,262,000</ix:nonFraction> Pre-Funded Warrants were exercised and converted into <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_19_2026_To_2_19_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_SLmuQgYcLUyKdGqqpYwayw" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="0" id="Narr_T0jC-hFVEUyTPq71BEXfdg">1,262,000</ix:nonFraction> shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, there were <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_PLZCnY0t-U2TUNEYxhKZlQ"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_siN4o9jjlkiVS46xrH91tA">44,877,633</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_MJkunHVC9UmbD0gt9lI9mA"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_sBab865rdU64v9D4k2mb3Q">27,064,633</ix:nonFraction></ix:nonFraction> shares of common stock issued and outstanding, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of the Company&#8217;s common stock are entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_pVdT3YsDMEiv7zpsvfY2UA" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="INF" format="ixt-sec:numwordsen" name="limn:CommonStockNumberOfVotesPerShare" scale="0" id="Narr_USd1VT7Vu0SfL9UjQt7gfQ">one</ix:nonFraction> vote for each share held of record, on all matters submitted to a vote of stockholders. Additionally, holders of common stock have dividend rights, in the event of a declared dividend declared by the Company&#8217;s Board of Directors, and liquidation rights, in the event of an involuntary or voluntary event of liquidation that allow for the Company&#8217;s common stockholders to receive all remaining assets of the Company, after payments of debts and other liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of March 31, 2026, <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_W2lQ6Gn-NEep1cZ7YVoF1w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_9-CqJsdix0W3J2MidQK20A">5,094,623</ix:nonFraction> Public Warrants and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PrivatePlacementWarrantsMember_GmwTGx3Js0KBpkdQA1hx1g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_9uQamXG5oUqx__aKqvegUA">835,555</ix:nonFraction> private placement warrants (together, the &#8220;Warrants&#8221;) were outstanding. Each Warrant entitles the holder to purchase <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_48WNPwfF30KmnGhwzUXXGQ">one</ix:nonFraction> share of the Company&#8217;s common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_unGDqsB0YUSEdqaySDaslw">11.50</ix:nonFraction> per share. No </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-18</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_3-kGuOJTVkuLxAMIgd-S7A_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">fractional shares will be issued upon exercise of the Warrants. The Company may elect to redeem the Public Warrants, in whole and not in part at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_W2lQ6Gn-NEep1cZ7YVoF1w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_6evkJt6QJEOjAbN8Kcjfiw">0.01</ix:nonFraction> per Warrant if (i) <ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z2RJFeIu4keoqDO4x5BOag" format="ixt-sec:durwordsen" name="limn:ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants" id="Narr_5V1XD4Vpf02hvCGZOIG5sw">30 days</ix:nonNumeric>&#8217; prior written notice of redemption is provided to the holders, and (ii) the last reported sale price of the Company&#8217;s common stock equals or exceeds $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_W2lQ6Gn-NEep1cZ7YVoF1w" decimals="2" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption" scale="0" id="Narr_kofeWY8Myka1UbAYmKGKZA">18.00</ix:nonFraction> per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any <ix:nonFraction unitRef="Unit_Standard_D_P_lZhqU5gEiyf8nABG1U1w" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z2RJFeIu4keoqDO4x5BOag" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" scale="0" id="Narr_yGEPh4ZOuEG8DXa8uvYaDg">20</ix:nonFraction> trading days within a <ix:nonFraction unitRef="Unit_Standard_D_P_lZhqU5gEiyf8nABG1U1w" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z2RJFeIu4keoqDO4x5BOag" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" scale="0" id="Narr_rXyN6LvV90OxcwHCeWy47Q">30</ix:nonFraction>-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders. Upon issuance of a redemption notice by the Company, the warrant holders have a period of <ix:nonNumeric contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_W2lQ6Gn-NEep1cZ7YVoF1w" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_BjsZ5ZD6F0W8MWxtublPMg">30 days</ix:nonNumeric> to exercise for cash, or on a cashless basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of March 31, 2026, <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_j2wjtBDr30CGi5w2RrtSMw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_T8S6b9sv7kGhIaxqKCKK-w">13,813,000</ix:nonFraction> Common Stock Warrants were outstanding. Each Common Stock Warrant entitles the holder to purchase one and a half shares of the Company&#8217;s common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_j2wjtBDr30CGi5w2RrtSMw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_lLNONhpI5ESxMHTPuDEAlw">0.29</ix:nonFraction> per share and will expire five years following the date of issuance. No fractional shares will be issued upon exercise of the Common Stock Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of March 31, 2026, <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_slm9IzocEkSBb1GZOKqnZA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_6NEbqMTqQEGQCkvz8m-3jg">690,650</ix:nonFraction> Placement Agent Warrants were outstanding. Each Placement Agent Warrant entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_slm9IzocEkSBb1GZOKqnZA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_uh_7zHB_BEKyI88htRQhqQ">0.319</ix:nonFraction> per share and will expire five years following the date of issuance. No fractional shares will be issued upon exercise of the Placement Agent Warrants.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_OikZgxD8AkWRcgwWpi_6lA" continuedAt="Tb_OikZgxD8AkWRcgwWpi_6lA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;7. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 17, 2025, the Company entered into a short-term lease for an office space in Cerritos, California (the &#8220;Lease&#8221;). The Lease commenced on September 1, 2025 and expires on June 30, 2026 and does not have any renewal option. The Company has made the short-term lease election and recognizes lease payments for its short-term lease on a straight line basis over the lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2026, lease expense related to the short-term lease was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="0" id="Narr_QjUoLS6mB0m8CMejM6W7RQ">22,272</ix:nonFraction>. <span style="background:#ffffff;">For the three months ended March 31, 2025,</span> there was <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShortTermLeaseCost" scale="0" id="Narr_1TCSpeCUsEOF02NEmdz9BQ">no</ix:nonFraction> lease expense related to the short-term lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Legal Proceedings</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 6, 2026, the Company entered into a settlement and release agreement with Clear Street LLC (the &#8220;Holder&#8221;), pursuant to which the Company agreed to issue <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_c_d3VxIAXUGyxXVEc8AngQ" decimals="INF" format="ixt:num-dot-decimal" name="limn:SharesIssuedForSurrenderAndCancellationOfWarrants" scale="0" id="Narr_tWcsEMhxXUqrIWixrpcN3Q">4,000,000</ix:nonFraction> shares of its common stock to the Holder in exchange for the surrender and cancellation of <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_c_d3VxIAXUGyxXVEc8AngQ" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" scale="0" id="Narr_Y_HV_pDnKk2tjNNNs6dxSg">805,377</ix:nonFraction> warrants to purchase shares of common stock held by the Holder. As of December 31, 2025, the Company determined this represented a Type I subsequent event in accordance with the guidance of ASC 855, <i style="font-style:italic;">Subsequent Events</i> (&#8220;ASC 855&#8221;), in which the Company obtained additional evidence about conditions that existed at the date of the consolidated balance sheets. The Company estimated a settlement of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_c18r92u3KkG5BLQb4LzJlg" decimals="0" format="ixt:num-dot-decimal" name="limn:CommonStockPayable" scale="0" id="Narr_ULnaHCJeIUqQX832JNWchg">7,360,000</ix:nonFraction>, which was calculated using the fair value of the Company&#8217;s common stock on February 6, 2026, which was the day that stock was issued to the Holder. As of March 31, 2026 and December 31, 2025, the Company&#8217;s settlement payable was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_YSNqwrY3BEKU8q1HG1qjeg" decimals="0" format="ixt:num-dot-decimal" name="limn:CommonStockPayable" scale="0" id="Narr_9s6EJM_bw0CS_8c3RTa4NA">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_thV_eeooNEe0x29eHltR5Q" decimals="0" format="ixt:num-dot-decimal" name="limn:CommonStockPayable" scale="0" id="Narr_ya0xLbXDNEm9ZyJOkJRRjw">7,360,000</ix:nonFraction>, respectively, which is included in settlement payable in the Company&#8217;s unaudited condensed consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Settlement Agreement, the Company and the Holder agreed to dismiss (a) an action pending in the United States District Court for the Central District of California and (b) an action pending in the United States District Court for the Southern District of New York, in which previously the Court entered a default judgment against the Company in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_10_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_6H9UrA2MZUWmfOm8ySparQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="0" id="Narr_seBa7OEtD0K5_0kCJsSAXw">7,500,000</ix:nonFraction> plus approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_10_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_6H9UrA2MZUWmfOm8ySparQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementInterest" scale="0" id="Narr_c0_h0_LAK06s11PV6rDPmg">515,000</ix:nonFraction> in interest, which judgment was registered in the Central District of California in the fourth quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims other than those already disclosed. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Underwriting Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Business Combination in connection with its initial public offering, Iris entered into an underwriting agreement with Cantor was engaged as the underwriters to Iris&#8217; IPO. Cantor was entitled to an underwriting discount of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2026_To_3_31_2026_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_brJVgPrmTkGylFftjvNsDw" decimals="2" format="ixt:num-dot-decimal" name="limn:UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" scale="-2" id="Narr_WonNnTKzk0ixO4iIT1bbQg">2</ix:nonFraction>% (or $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_13QwrEzmwEyKOTC43D2VFg" decimals="0" format="ixt:num-dot-decimal" name="limn:UnderwritingCostsNoncurrent" scale="0" id="Narr_La3NwImEbE-NiV2G-vZp2A">5,520,000</ix:nonFraction>) of the gross proceeds of the IPO and deferred underwriting discount of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2026_To_3_31_2026_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_brJVgPrmTkGylFftjvNsDw" decimals="3" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" scale="-2" id="Narr_Gpm-YrSaPk6K6wLp4BbfZQ">3.5</ix:nonFraction>% (or $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_13QwrEzmwEyKOTC43D2VFg" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredOfferingCostsNoncurrent" scale="0" id="Narr_XDyiMCgUlU-2zgX1FPvRSw">9,660,000</ix:nonFraction>) of the gross proceeds of the IPO upon the completion of an initial business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On October 11, 2023, Iris executed a fee reduction agreement with the underwriters to reduce the deferred underwriting discount of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_10_10_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_8jW8A96_rUGTBNiKY7EncA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredOfferingCostsNoncurrent" scale="0" id="Narr_4YufxaxXA0WazvXYuzhy1A">9,660,000</ix:nonFraction> to $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_10_11_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_3xBPTdDIoEKDwiqXuL9Qyg" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredOfferingCostsNoncurrent" scale="0" id="Narr_ogGA_AYTb0iOEs7zw98BZg">8,000,000</ix:nonFraction> in the event the Business Combination was consummated. Pursuant to the terms of the agreement, the </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-19</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_OikZgxD8AkWRcgwWpi_6lA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">reduced deferred underwriting discount was payable by the Iris to the underwriters in $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_10_11_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_3xBPTdDIoEKDwiqXuL9Qyg" decimals="0" format="ixt:num-dot-decimal" name="limn:PaymentOfOfferingCostsInCash" scale="0" id="Narr_h0hEZKdzxE-a2E-s3A6E1g">1,000,000</ix:nonFraction> cash and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_10_11_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_3xBPTdDIoEKDwiqXuL9Qyg" decimals="0" format="ixt:num-dot-decimal" name="limn:UnderwritingDiscountPaidInSecurities" scale="0" id="Narr_Y6_k9RhTMEeSNJVv2rXZXg">7,000,000</ix:nonFraction> of the common equity securities of the public entity that survives the transaction. The share price is subject to adjustment based on the five day volume-weighted average price prior to the filing of a resale registration statement covering such shares. As of April 30, 2025, Iris and the Company amended the fee reduction agreement with the underwriters to limit the total number of shares of common stock issuable to the underwriters to <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_4_30_2025_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_Lbu1miIqSkupTrmz199Hbw" decimals="INF" format="ixt:num-dot-decimal" name="limn:MaximumNumbersOfSharesIssuable" scale="0" id="Narr_b8AlLk5V40eVVETlnjnPGw">1,750,000</ix:nonFraction>. Upon the consummation of the Business Combination, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination" scale="0" id="Narr_mmBLUcdHFkmgy9jMj0qtPw">9,160,000</ix:nonFraction> in deferred underwriting fees were settled, of which $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination" scale="0" id="Narr_SMKqYIcL9E2NuDaUs-3yZw">7,000,000</ix:nonFraction> will be settled in common shares of the combined company, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination" scale="0" id="Narr_0U01ny_Jb0qiFkq66cdQDw">500,000</ix:nonFraction> was settled in cash and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination" scale="0" id="Narr_eTAxsPhyIUmFn0h5zy8piA">1,660,000</ix:nonFraction> was waived and no longer payable. The remaining $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering" scale="0" id="Narr_25NKnVvv-0-iVfQPVVY9fA">500,000</ix:nonFraction> was to be settled upon the earlier of the consummation of the combined company&#8217;s next share offering, or in <ix:nonNumeric contextRef="Duration_4_30_2025_To_4_30_2025_9PPk1IhN6EmJm5MGsGwEDA" format="ixt-sec:durwordsen" name="limn:ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination" id="Narr_j5GbKI0CqEGT3FRCpQmRqg">six months</ix:nonNumeric> from the closing date of the Business Combination. As of March 31, 2026, the deferred underwriting fee payable was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeesPayableInCashCurrent" scale="0" id="Narr_wQKk5cUax02Vb0HP9sx-Ug">500,000</ix:nonFraction>, which is included in deferred underwriting fee payable in the Company&#8217;s unaudited condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, the Company settled Iris&#8217; liabilities for $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" scale="0" id="Narr_g0Mc9P__oUOOQEoxHpGYtg">7,000,000</ix:nonFraction> of the deferred underwriting fees incurred prior to the Closing Date for <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="INF" format="ixt:num-dot-decimal" name="limn:StockIssuableForSettlementOfDeferredUnderwritingFees" scale="0" id="Narr_J2KLIRhecEC2PQD1Hoi1sw">700,000</ix:nonFraction> shares of common stock to the underwriters in Iris&#8217;s initial public offering. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_7_1_2025_CZJvPOCOcUySCDRAwOkqBA" decimals="0" format="ixt:num-dot-decimal" name="limn:FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" scale="0" id="Narr_DBuUnpU65UONoyEVnnb-Lg">7,245,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On October 27, 2025, six months from the closing date of the Business Combination, the remaining $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_10_27_2025_WHc2wpxA30auOyOjgUueLA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeesPayableInCashCurrent" scale="0" id="Narr_zYX4ElEq_0GUPakNdOr7jA">500,000</ix:nonFraction> underwriting fee became due. As of the date of this Form 10-Q, the $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeesPayableInCashCurrent" scale="0" id="Narr_ymJfESJc4kKxcvNa2Yf2kg">500,000</ix:nonFraction> underwriting fees remains unpaid.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc__IkZHojnnEmVZYT8-PHxsA_1_0"></a><a id="Tc_7go1yApFaU-9tQtE-iblOg_1_2"></a><a id="Tc_dCk307jNZUKY-DgKQd7naw_1_4"></a><a id="Tc_RHG-YGRzUEGTf8zePpDrvA_1_7"></a><a id="Tc_JZp9ttU2ukq_hKrpM2guRQ_2_0"></a><a id="Tc_It010qDBX0qMNuo1S1Dsiw_2_4"></a><a id="Tc_gbVrcY91MEO_-nr7eBe5mA_2_5"></a><a id="Tc_gS6_unAb4UmrVciT0xY6JA_2_7"></a><a id="Tc_EtD2xEoDeUWyrjbu0xGlbg_2_8"></a><a id="Tc_QaGBJ5Q6Ok2rat-t8rsnUw_3_0"></a><a id="Tc_KIsu2eQJUUmR_2Rqa64yFw_4_0"></a><a id="Tc_u82XMOjGHU-0hQ3XIlgPIQ_4_2"></a><a id="Tc_sAEN_ekoMUaUrAswrEEFCQ_4_4"></a><a id="Tc__kX_5_ts7E-9a34Bahbd2g_4_7"></a><a id="Tc_YUJIj7ZOwECEixKj1sy6XA_1_2"></a><a id="Tc_XDhffo6QVk-AoNpohrHsFA_2_0"></a><a id="Tc_Nsd9BLKUPkeaeUQizFkyUA_2_2"></a><a id="Tc_pVqUwd7_yUyx6RWHLojhBw_3_0"></a><a id="Tc_a4J3R65ogEWkosBtr2WIKA_4_0"></a><a id="Tc_8o4t4R5lZEGWW0X-VlfADw_4_2"></a><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_vCYX-EZGOkaGqMdqxWux4w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 8. Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2026 and December 31, 2025 and indicates the fair value hierarchy of the valuation inputs the Company&#8217;s utilized to determine such fair value:</p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_te4Pbm204k65Wyg_QKqLDQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:340.7pt;padding:0pt;"/><td style="width:9.8pt;padding:0pt;"/><td style="width:49.65pt;padding:0pt;"/><td style="width:9.85pt;padding:0pt;"/><td style="width:6.25pt;padding:0pt;"/><td style="width:49.25pt;padding:0pt;"/><td style="width:9.85pt;padding:0pt;"/><td style="width:7.7pt;padding:0pt;"/><td style="width:56.95pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:340.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:340.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:55.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2025</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:340.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:340.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:340.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_doQ-5t8E_kahW9UFnsMLNA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="0" id="Tc_2avY8QyPs0eeDkSKLna6AQ_4_5">33,422</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_3B7id13HUEKPGohf_GYnnw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="0" id="Tc_P5jC7P4-vUWEeJdc0qs_yA_4_8">29,244</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrant Liability</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon closing of the Mergers, Iris&#8217; public and private placement warrants were converted into warrants of the Company, which entitle the holders to purchase shares of the Company&#8217;s common stock. The Company&#8217;s private placement warrants meet the requirements for liability classification. The fair value of the warrant liabilities were determined using observable data points, such as the fair value of the public warrants as of March 31, 2026 and December 31, 2025. The Company further considered specific unobservable inputs, such as the probability and timing of events and the expected equity value of the underlying shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The changes in fair value of Level 3 financial assets and liabilities for the three months ended March 31, 2026 are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="limn:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="Tb_OXDv5hLNm0KsAwpBjXGwKQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:360.05pt;padding:0pt;"/><td style="width:11.39pt;padding:0pt;"/><td style="width:7.15pt;padding:0pt;"/><td style="width:53.4pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:60.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant&#160;liability</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of January 1, 2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_NOD7vwuXLUmAhk-2mkyvLQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_Gin7nsCoLUOXwLpdrAy96w_2_3">29,244</ix:nonFraction></b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_yYxsL6Igmk6L3jX5IPvofQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="0" id="Tc_CcDxxkcipES9B8ZtNqwu9Q_3_3">4,178</ix:nonFraction></p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of March&#160;31,&#160;2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_pY-u8pAzO0OcP5FC3J0aNA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_pwsui4Nr5UGuiuWTCpHhYQ_4_3">33,422</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw" name="us-gaap:SubsequentEventsTextBlock" id="Tb_wDENZsvoTkKJxVXgr799yQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;9. Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has completed an evaluation of all subsequent events through the date of this filing to ensure that these unaudited condensed consolidated financial statements include appropriate disclosure of events both recognized in the unaudited condensed consolidated financial statements and events which occurred but were not recognized in the unaudited condensed consolidated financial statements. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-20</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_a2c7ffd7_5801_46f9_ae64_2615babbcc22"></a><a id="REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Report of Independent Registered Public Accounting Firm</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">To the Board of Directors and Stockholders of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Liminatus Pharma, Inc.:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Opinion on the Consolidated Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have audited the accompanying consolidated balance sheets of Liminatus Pharma, Inc. (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, and the related consolidated statements of operations, changes in stockholders&#8217; deficit, and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1, the Company has had recurring losses and negative operating cash flows since inception, an accumulated deficit as of December 31, 2025, and insufficient cash and cash equivalents as of December 31, 2025, to fund operations for twelve months from the date of this report. All of these matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Basis for Opinion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ WithumSmith+Brown, PC </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have served as Company&#8217;s auditor since 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Whippany, New Jersey </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">March 31, 2026</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PCAOB ID Number 100</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-21</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="Item1FinancialStatements_733344_0"></a><a id="_8564b9c9_e168_4f5a_a6de_18b2faa870de"></a><a id="Balancesheet2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liminatus Pharma, Inc.</b></p><a id="ConsolidatedBalanceSheets_734776"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_4dac9a2d_8548_4248_bc04_e1debe94af1f"></a><a id="Tc_oUP64oQU8EKrsUN64FPYTA_1_2"></a><a id="Tc_aCN3dZo-6EWHZ_HcM_XZtw_2_2"></a><a id="Tc_E9wOc_xQ3UWkeYNNPZcY-Q_2_5"></a><a id="Tc_jmfF-WG6Zk-P7bsTatjy1g_3_0"></a><a id="Tc_gpcLpqippUKsl-xZH1zN3Q_4_0"></a><a id="Tc_DMJxoFJI80GG6Nr6CIO7Sw_5_0"></a><a id="Tc_dLgkrMA24kSDeTrEXpyu5A_5_2"></a><a id="Tc_GhNUC7cnH0qXIKYK78s9yA_5_5"></a><a id="Tc_2HD5tNvgn0GkC1ii_gXsMQ_6_0"></a><a id="Tc_TH_20Hu6WU-A1HyX2ItAbg_6_3"></a><a id="Tc_ZEC_zyd6Vk6E1mtdRHqPJg_7_0"></a><a id="Tc_2Vdh3nCI6EmWrXRsxQBtLQ_7_3"></a><a id="Tc_Wa7rppgZtESV0CyceM2FQA_8_0"></a><a id="Tc_au6AAf6b20ekdlF2GMNMDg_9_0"></a><a id="Tc_hUHVgpX2IEixK4fFkUJBdQ_10_0"></a><a id="Tc_lgJ21Pi4mEuhEiIBVaKDsQ_11_0"></a><a id="Tc_4mNAAa56TE2aaulpxKjw_Q_11_3"></a><a id="Tc_mB0D2j_5pUOCp8jlIfqh2Q_12_0"></a><a id="Tc_gvmeTcNUaESg0qXxczcMLQ_13_0"></a><a id="Tc_Q825T8TPBk27w85sXqj3hw_14_0"></a><a id="Tc_uhicjIMmR02_3Cu5FibrYQ_14_2"></a><a id="Tc_vyprK9K-5EWs1sQkk7-7vw_14_5"></a><a id="Tc_j_lAabeIP0Kg78kEQHMWnA_16_0"></a><a id="Tc_tH9W2lUlPkiEYsS_nAgC3A_17_0"></a><a id="Tc_4YhCTwEluUud0AaLpY17xg_18_0"></a><a id="Tc_c-NmcH5RD02L3wns70rIyg_18_2"></a><a id="Tc_INiTvQyJzUuqfgOArgPI2g_18_5"></a><a id="Tc_OCReZwtpfUKE01VDQRObRg_19_0"></a><a id="Tc_dXK7PAk3uEO5agRAv4aebw_20_0"></a><a id="Tc_Dr_SeFHHsEmRHBZ79c511Q_20_3"></a><a id="Tc_XNymGBconU6ZOx6L4SrZXA_21_0"></a><a id="Tc_H-dEjdzn-0qOKNtpHc9fLA_21_3"></a><a id="Tc_4XLL_CkIMECNoY815H5plw_22_0"></a><a id="Tc_7gfhtAsofEin-omQHWwTJQ_23_0"></a><a id="Tc_qN-afDbOR0yNPim7Z8kjQg_24_0"></a><a id="Tc_ypVKPVApcECrizTA4L6Mcw_24_6"></a><a id="Tc_o1-AhBSLrUqf7ftmCl5eUw_25_0"></a><a id="Tc_YYP_sp4czU26eq-WyZRYog_25_6"></a><a id="Tc_S-0Vrhd7Q0uQS4zrQi7OTQ_26_0"></a><a id="Tc_U4aiy6w-D0i3tCdH-VKDRA_27_0"></a><a id="Tc_0MyBPIKfAUyEAt0behdPOQ_27_6"></a><a id="Tc_q0exvcCC2UyknLMEasMh_g_28_0"></a><a id="Tc_hJSWceY6vkKmDQ_kcOlrXQ_30_0"></a><a id="Tc_P5uCJZwZ90mKZTucH9mwqQ_32_0"></a><a id="Tc_vPU92-m4rUmzsfYQK7x9-A_33_0"></a><a id="Tc_9TWSEXrgnk-q0fXuGbpo-w_34_0"></a><a id="Tc_SkIxLNY3t0eJnPfLG9WQ3w_35_0"></a><a id="Tc_B1DJgWNmP0-JsEpxkcgu3w_36_0"></a><a id="Tc_YyORB-XeTUePBaXxo-9EXg_37_0"></a><a id="Tc_U7vtjnh76Ei9MZupzDlQNQ_38_0"></a><a id="Tc_vP6l2DhwQkGbZGyLWhXvww_38_2"></a><a id="Tc_rOSaRVek-Ea4r_SdEF_YaA_38_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:385.8pt;padding:0pt;"/><td style="width:12.2pt;padding:0pt;"/><td style="width:7.65pt;padding:0pt;"/><td style="width:57.25pt;padding:0pt;"/><td style="width:12.2pt;padding:0pt;"/><td style="width:7.65pt;padding:0pt;"/><td style="width:57.25pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:142pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style="height:9.69pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;</b></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" id="Tc_m9pK8RJrnkOWbo_RzwagZg_5_3">337,655</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" id="Tc_BXj9gwnH3kim12nZx5SmOw_5_6">56,319</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Loan receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="0" id="Tc_20KMK-NnBk6X4WkY5QS7gQ_6_6">3,668,500</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Deferred transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCostsCurrent" scale="0" id="Tc_kewJwBDsEEWUW1BQ-UhMJw_7_6">1,401,323</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Prepaid and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_Ynz4YsD7sEO35qKZq05ItA_8_3">162,919</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_3NXZoRaxEUCHMiqLAbIC6g_8_6">155,501</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_JEwAEaIaNEea73FM7mxXfQ_9_3">500,574</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_Wm_rQsltk0eqaIrzY56LcQ_9_6">5,281,643</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Due from related party, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent" scale="0" id="Tc_5yPKn4eX4UOAJZy7mqjBWw_11_6">126,275</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_CfIe31XL7U-sVR0myqF3UQ_12_3">12,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_-9Viz0XY0UmflDqSLOJ7pA_12_6">941</ix:nonFraction></p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" id="Tc_I8QZG1Nqkk-0TZMs7FoYvg_13_3">12,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" id="Tc_TYypc-An8EmhwZ6QWeddOg_13_6">127,216</ix:nonFraction></p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="Tc_oU5oiEGiZkaFle4hXYJkOQ_14_3">512,795</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="Tc_cUJTjw8OWEO2IB7J2ueuTA_14_6">5,408,859</ix:nonFraction></p></td></tr><tr style="height:12.24pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_2z8DK-88AEyTQZn_0tlakA_18_3">582,234</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_BwWF9Ab2EEaClUP4q89JMQ_18_6">1,483,253</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accrued interest, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Tc_bkS8WTKVfk-pkoeuwjyG6g_19_3">203,921</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Tc_jRI4aRdREUC_arf02mXE7g_19_6">955,119</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accrued maintenance fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedMaintenanceFeeCurrent" scale="0" id="Tc_8Ftavxh6hUKlbm44Vtcpew_20_6">360,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Due to research and development partner</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_s19qgo8JfkOPRkLjJuXHug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_GubzrkTHV0Oy-xA-ZwVC2w_21_6">1,782,297</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Due to related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FbpcEF3_bUqHFwpcC9Wy4w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_20VnN7DJBUmEgnoJTuYNHw_22_3">209,586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_eXLYHI_roUaYmfoOmSYVxA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_A99pkPZEe0yZ5K4dZwVItA_22_6">195,253</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Short-term debt, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_HGZM0WDCWEOsGYvYxTrP-Q_23_3">1,442,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_v3NJhimAs0Ca6JSsa9XswQ_23_6">19,973,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Deferred underwriting fee payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeesPayableInCashCurrent" scale="0" id="Tc_rhlMBADpGk6Vh3Gv0FNO_Q_24_3">500,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Settlement payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="limn:CommonStockPayable" scale="0" id="Tc_rRX0ZbNvLk2lr_l7AwPOYA_25_3">7,360,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_qYd6gRtKF06YsmjtgM2jzA_26_3">10,298,241</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_7ghxd1iQ-0GaDI5mi8-j-g_26_6">24,748,922</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" id="Tc_xdKLe8ZHzUC_W6ykAFmlkw_27_3">29,244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" id="Tc_oYFpbpE1Gk-WrQYO_B8IjQ_28_3">10,327,485</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" id="Tc_XAMgndUoykadaqD7D5vhOg_28_6">24,748,922</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Commitments and Contingencies (Note 7)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_nd9EC6llVEuXahbG6bAoAA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_t1Xr-jSZS0Wg9UjCMoPpFA">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_BCQVMkDnCkuguyRHGU6V1A"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_YTeUEJ8YQkyihUWdXyoCQQ">1,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_e5Ri4fQb1EqFCSiuM6hRPg"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_xuCy8DB9vUW7GbP7_j3qGA"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_Pf7Aa4mMIkGFeqev-122Aw"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_7GIpPa2rqUiZgTwaMcJNfA">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_rF9jsGd2PEyzELvf4YbZ2g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_W9yMXh1gvU6pZJS4SioUZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr style="height:22.99pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_Nj2RZ0fIeUyIoMBcaFgK8A"><ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_TZc1NjJRfk6VMizFdbA-ew">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_R1WBxvs1bkWPrjcJvtk7JA"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_34e-bd4iQE6KXG-zkQ9KDw">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="limn:CommonStockShareOutstanding" scale="0" id="Narr_lgOWyV9AN0u49Ut0nlUYZQ"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_Ju7E-MDODUWRNGd6qTiBgQ">27,064,633</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_o8EjiU18O0CCH8GbZ5P73Q"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="INF" format="ixt:num-dot-decimal" name="limn:CommonStockShareOutstanding" scale="0" id="Narr_LtlUDHzZ4k-Jdx668lLcPA">17,500,000</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31,&#160;2025 and 2024, respectively*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_gkMv0vRfWUeB1iRn8oy9SQ_34_3">2,706</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_2WISg8IU-0WKtEuff6lBmQ_34_6">1,750</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Additional paid-in capital </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_M3R1-vp2IEeRr1cyHYL5yA_35_3">29,054,337</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_RG68EkzRNkq_yZwX8Jo2wQ_35_6">9,323,403</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_MFOkL_t2Gk6HBlT4WsM1XA_36_3">38,871,733</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_VdtTSX3QqEeRWz_NEz1MgA_36_6">28,665,216</ix:nonFraction>)</p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total stockholders&#8217; deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_cek9YvuhrUO0Q5Kv4zJ31g_37_3">9,814,690</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_uvnp0XV5vUePo2lHVK1Nlg_37_6">19,340,063</ix:nonFraction>)</p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities and stockholders&#8217; deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_KDkdAs9BL0G13rEmDUuqrA_38_3">512,795</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_b7TFyuZv3UW67dj0BcEHTQ_38_6">5,408,859</ix:nonFraction></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">* Shares, preferred stock amount, common stock amount and additional paid-in capital data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.<br/><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-22</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_082dea29_8b75_4091_87ef_beb07aa6a39c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liminatus Pharma, Inc.</b></p><a id="ConsolidatedStatementsofOperations_26549"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_83cb59e7_8ca0_47e7_a5a4_f2bcbcb23d7d"></a><a id="Tc_SSeCaRfVhkGf9XkBBapCKg_1_2"></a><a id="Tc_4rivfohxskKf1XbSdFNjjQ_2_2"></a><a id="Tc_6CBIDJQcTUWpETGfJXDxhQ_2_5"></a><a id="Tc_4GUGsW24F0-zAkXKh2SQ8g_4_0"></a><a id="Tc_I5q_21a9L02h2nIgnKuuEA_4_2"></a><a id="Tc_IaAxHaomEUiQ5fSS4lr6mw_4_5"></a><a id="Tc_faxrkWtEqECfoeBTUPPnBg_5_0"></a><a id="Tc_wG3kmCjVhEa1SAcGpG3iKw_5_3"></a><a id="Tc_-S5AKax7JUG1mardK3y9vQ_6_0"></a><a id="Tc_WB7I4NHKbkKyw4yUfudu5w_7_0"></a><a id="Tc_daYA28P7FEaeLVilReAaQA_8_0"></a><a id="Tc_jCYSFwh_D0Gvsxv4ZICUWg_9_0"></a><a id="Tc_oGOo9MEePkCzVC6Go1gbKQ_10_0"></a><a id="Tc_VFxDpMw7M0ycB-e1tzo0HA_11_0"></a><a id="Tc_qle-jHoUSES3oXq9dv3gGA_11_6"></a><a id="Tc_kMqywWiExEiRhOPnkvMG1g_12_0"></a><a id="Tc_4JHktaheEUy8xaHQ529wiQ_12_6"></a><a id="Tc_e06eSE5mOke1c7cc3xy2Bg_13_0"></a><a id="Tc_Bg3sS8qGdEGeD3WYHfmFBQ_13_6"></a><a id="Tc_Mg7089MbvkGYnHCvP4yBgw_14_0"></a><a id="Tc_sPRsB4BvWEe1kLWUy8XeBQ_14_6"></a><a id="Tc_pzWa0UbSLkatF1jAFTTiaA_15_0"></a><a id="Tc_DaYaMZ9V1UmWqjz4_A_NCw_15_6"></a><a id="Tc__OCPpUL9dUOi9AJlREV8cA_16_0"></a><a id="Tc_eu_VNxSQwE-kJQxkwyCx-g_17_0"></a><a id="Tc_aX-Cy5kg7UiO4vKJfIdUEg_17_2"></a><a id="Tc_58Ev8E-PfUyE6-Cl6jOmzQ_17_5"></a><a id="Tc_Njx6vKzXe0uV_m2kK_42lQ_19_0"></a><a id="Tc_b9HvC6HhK0O0qMvXMS8Ajg_21_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:386.15pt;padding:0pt;"/><td style="width:12.2pt;padding:0pt;"/><td style="width:7.8pt;padding:0pt;"/><td style="width:57.25pt;padding:0pt;"/><td style="width:12.2pt;padding:0pt;"/><td style="width:7.8pt;padding:0pt;"/><td style="width:56.6pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:386.15pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:386.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:141.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended December&#160;31,&#160;</b></p></td></tr><tr style="height:9.69pt;"><td style="vertical-align:bottom;width:386.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:65.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.4pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:386.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:386.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_yuGMN5Ck20KqVMN_nTaTng_4_3">2,967,812</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_ofZky8kU60WvZ7NYBb6i6w_4_6">644,619</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:386.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc__fGPpeRoF0KRV4LaUEoKVg_5_6">2,685,334</ix:nonFraction></p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:386.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_CWEE234ak06xa69kGIv3Gg_6_3">2,967,812</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_zR7OspLiI0-pkBbZd-oRSA_6_6">3,329,953</ix:nonFraction></p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:386.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_3P1HfU2B7UmVM6Odc5e58g_7_3">2,967,812</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_PtsKTTwBEE-souLNJ_Zu7w_7_6">3,329,953</ix:nonFraction>)</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:386.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:386.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" id="Tc_ZQ2tT_maCE24DQUpR0FuMA_9_3">215,903</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" id="Tc_pZ01VL-yMUy3MdJ7h0Novw_9_6">338,882</ix:nonFraction>)</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:386.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_bC74PHp4xkuLck9pXr-xQw_10_3">76,589</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_A486Vek3lkWSDGnR_FyQlg_10_6">122,526</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:386.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forgiveness of unrelated vendor payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:ForgivenessOfUnrelatedVendorPayable" scale="0" id="Tc_6yDmWTsHa0OZ1ghq5KfWBA_11_3">2,142,297</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:12.2pt;"><td style="vertical-align:bottom;width:386.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of deferred underwriting fee <span style="font-family:'Aptos Narrow';">&#8211;</span> paid in common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue" sign="-" scale="0" id="Tc_wX1xfjUUtk-3TLBX_3iHdw_12_3">196,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:386.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in the fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="0" id="Tc_ifL0J6OO0k6m6_LUc8drQQ_13_3">54,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:386.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss on exchange of common stock for warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:GainLossOnIssuanceOfCommonStockForWarrants" sign="-" scale="0" id="Tc_OCKwIFkVNkig6n0hZf69Yw_14_3">1,740,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:386.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value of common stock to be issued for contingent liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:FairValueOfCommonStockIssuanceForContingentLiability" scale="0" id="Tc_93v1B_awfEuoOGGo5Wejmg_15_3">7,360,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:386.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total other expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="0" id="Tc_0LxkHCo1v0-NxvQVRY_R3w_16_3">7,238,705</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="0" id="Tc_XKWkOvJFQ06iSSvBC7rjBw_16_6">216,356</ix:nonFraction>)</p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:386.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_b_hnnHxZ5EC6M_f30f1MeA_17_3">10,206,517</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_3IFcNIRi3kShU4k2-7_Fqg_17_6">3,546,309</ix:nonFraction>)</p></td></tr><tr style="height:12.24pt;"><td style="vertical-align:bottom;width:386.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:386.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares outstanding, basic and diluted*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_aHtfXI09SECe6XdEMLiOBQ_19_3">23,753,561</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_9RX2rQ0RCU6Dk_ZL1Iek7w_19_6">17,500,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:386.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:386.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basic and diluted net loss per share*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_F4R9DCODRUSd1g3LlIjEqw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc__FiEmY5-uEmnJvHY1psPwA_21_3">0.43</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_cM-Z0zzNDUaiQqfL9Zw3UA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_z_syvq_f3Ee2TH7BNETQUA_21_6">0.20</ix:nonFraction>)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">* <ix:footnote xml:lang="en-US" id="_458cdbcf_7aee_4fc0_9cbc_944ad97ef513">Shares and per share data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-23</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_cac5194b_78ab_4fca_8725_61379b3a994a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liminatus Pharma, Inc.</b></p><a id="ConsolidatedStatementsofChan_705196"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Changes in Stockholders&#8217; Deficit</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the years ended December 31, 2025 and 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_24156e38_740a_4180_9446_bff05b8aac1f"></a><a id="Tc_-y6TDEteK0eDfL4hIMhSCw_1_13"></a><a id="Tc_xnhEgTv_d0SsnJWD7uGeiA_2_2"></a><a id="Tc_Pghc20YzsE6MwQgV8sRUkg_2_7"></a><a id="Tc_PRbMhBsUUEujnM7gkhWFDw_2_10"></a><a id="Tc_vPQKKys6PUaMCNQzc0nYLA_2_13"></a><a id="Tc_bllbKG9HJ0mXn0hhvLUx0A_3_2"></a><a id="Tc_kHn_mwE3QUOMyad08NgFew_3_4"></a><a id="Tc_LZwFzUiXI0Wkh4QRUJwsZQ_3_7"></a><a id="Tc_9qu7wctqlka0pbmihs9jqA_3_10"></a><a id="Tc_smT2a9gMEkqmTDqtL1ei_g_3_13"></a><a id="Tc_yhRb79g0TEC3wFkREwQ-7A_4_0"></a><a id="Tc_BansowQeokaxwnDu4kPoIg_4_4"></a><a id="Tc_I3aJn440NkWo2K8jEf_Dvg_4_7"></a><a id="Tc_j3wqnz2sk0iPQE93jlxTTw_4_10"></a><a id="Tc_0apNhJ6GGU--zQVDEaso8Q_4_13"></a><a id="Tc_U0II7HGRD06770MVGWOvog_5_0"></a><a id="Tc_KiNBa3EebkOYGVbDtE0zqQ_5_11"></a><a id="Tc_olQgB_3_TEaNVGXx4ontSw_6_0"></a><a id="Tc_iMVrAHJ1ykmz9wTvVQ7HCw_6_2"></a><a id="Tc_b1vNzEGHdkOo5pY4ohlorw_6_5"></a><a id="Tc_fB-GZsWC2UiKWDXLF5toLA_6_11"></a><a id="Tc_o8iThy3Se0CDop5RLAEjaA_7_0"></a><a id="Tc_LQNu2893J0W8_SYhZPa2gg_7_11"></a><a id="Tc_Ys4jviAXQk2XZ3y82QfTnw_7_14"></a><a id="Tc_CtDUQHDH-0yxN0FjxD-qOQ_8_0"></a><a id="Tc_v26GGTAs1UyuREdnjYNYmA_8_11"></a><a id="Tc_Ak2CdfGSlE-dub2ARSD8rg_9_0"></a><a id="Tc_h8SlCZzvH0mcGk3UMg81IA_9_11"></a><a id="Tc_MZdcl7ZXEUSRqA1mz5OYSw_10_0"></a><a id="Tc_9MdDui5NrEGyNTeDezNksg_10_11"></a><a id="Tc_4hp3rMT7wkKE8JnXgWtE1w_11_0"></a><a id="Tc_GecvvPO8FE68GKhQlr54Yw_11_2"></a><a id="Tc_vKyNaPWR90aB02Z21oy5Hw_11_5"></a><a id="Tc_BXIqj6BApUGj8JvN6KHmFQ_11_8"></a><a id="Tc_JdEs_ApcYUqtnit7ClXP4A_12_0"></a><a id="Tc_jNYRd9VGtUu-eKG6XOrhnA_12_4"></a><a id="Tc_c_hPwEapZUmtIzFDqwYxnQ_12_7"></a><a id="Tc_8oK2uwoWdEK867OZX4-PKA_12_10"></a><a id="Tc_zaHps3JKq0CnXC7_ECsFAw_12_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:207.3pt;padding:0pt;"/><td style="width:9.55pt;padding:0pt;"/><td style="width:50.6pt;padding:0pt;"/><td style="width:9.55pt;padding:0pt;"/><td style="width:5.75pt;padding:0pt;"/><td style="width:50.6pt;padding:0pt;"/><td style="width:9.55pt;padding:0pt;"/><td style="width:7.25pt;padding:0pt;"/><td style="width:58.15pt;padding:0pt;"/><td style="width:9.54pt;padding:0pt;"/><td style="width:5.75pt;padding:0pt;"/><td style="width:50.6pt;padding:0pt;"/><td style="width:9.55pt;padding:0pt;"/><td style="width:5.75pt;padding:0pt;"/><td style="width:50.51pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:207.3pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:58.15pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.19pt;"><td style="vertical-align:bottom;width:207.3pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:58.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:56.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:207.3pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:116.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:65.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional&#160;Paid-in&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:56.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:56.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr style="height:9.69pt;"><td style="vertical-align:bottom;width:207.3pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:56.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:65.4pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:56.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:56.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:207.3pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Balance - December&#160;31,&#160;2024*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHu7s1FxgEmdi0qyZEPN4g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_7ROUESS25EOckwg8ALPOvA_4_2">17,500,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHu7s1FxgEmdi0qyZEPN4g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_CVIGz5hPNUqu-ltzIf7NHA_4_5">1,750</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:58.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9uu8nJPlZE2Ewx4WJxhvoQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_rbq935VjbUKRIodNkWRssw_4_8">9,323,403</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MuLWEtlz5E2UN4YJiAi4YQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_YP-t6420zUuJGiagviX8Sg_4_11">28,665,216</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_rhAk77c-QUCmJHUppKQptQ_4_14">19,340,063</ix:nonFraction>)</b></p></td></tr><tr style="height:9.19pt;"><td style="vertical-align:bottom;width:207.3pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Business combination with IRIS, net of transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg" decimals="INF" format="ixt:num-dot-decimal" name="limn:StockIssuedDuringPeriodSharesBusinessCombination" scale="0" id="Tc_xBWjbP5i2E2yAjFrTsBCyw_5_2">114,633</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg" decimals="0" format="ixt:num-dot-decimal" name="limn:StockIssuedDuringPeriodValueBusinessCombination" scale="0" id="Tc_2-0Y_lUDcUu-0i1LclfYyw_5_5">11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:58.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uTi3iJsKTUG1RhrJIbdN7Q" decimals="0" format="ixt:num-dot-decimal" name="limn:StockIssuedDuringPeriodValueBusinessCombination" scale="0" id="Tc_OPyQAqjN6Uyi4zDFesSqrg_5_8">190,379</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:StockIssuedDuringPeriodValueBusinessCombination" scale="0" id="Tc_uiGTHhKjUkayvdbg73rIgg_5_14">190,390</ix:nonFraction></p></td></tr><tr style="height:18.39pt;"><td style="vertical-align:bottom;width:207.3pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Settlement of loans to Iris Acquisition Corp upon closing of the business combination</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:58.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uTi3iJsKTUG1RhrJIbdN7Q" decimals="0" format="ixt:num-dot-decimal" name="limn:AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans" scale="0" id="Tc_2nZuor5kLUSUC1XPOWfmzg_6_8">4,443,500</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans" scale="0" id="Tc_XppqtBOgnEyMoh-4wmu4zQ_6_14">4,443,500</ix:nonFraction>)</p></td></tr><tr style="height:9.19pt;"><td style="vertical-align:bottom;width:207.3pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issuance of common stock to Iris Acquisition Holdings, LLC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="Tc_sKWZR52_0UWojuY1l6bnKg_7_2">6,900,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" id="Tc_aKCjlA8pQEW5BV2PNSGMSg_7_5">690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:58.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uTi3iJsKTUG1RhrJIbdN7Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" sign="-" scale="0" id="Tc_gtV1Utk0kkirvoEfQcjoqg_7_8">690</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:9.19pt;"><td style="vertical-align:bottom;width:207.3pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issuance of common stock for the PIPE investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_T-oGFYqr30GqDxzrkYF0aQ_8_2">1,500,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_auPDbpFnREq36Ut1uflIqQ_8_5">150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:58.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uTi3iJsKTUG1RhrJIbdN7Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_TmqX78czmEqqq2i1zcHddA_8_8">14,999,850</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_q3Kls_IdD0OeI0Ew54P9TQ_8_14">15,000,000</ix:nonFraction></p></td></tr><tr style="height:9.19pt;"><td style="vertical-align:bottom;width:207.3pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issuance of common stock to underwriter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg" decimals="INF" format="ixt:num-dot-decimal" name="limn:StockIssuedPeriodOfCommonStockToUnderwriter" scale="0" id="Tc_yHZaikCaCUO4Q8ii5-EdPQ_9_2">700,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg" decimals="0" format="ixt:num-dot-decimal" name="limn:StockIssuedPeriodValueOfCommonStockToUnderwriter" scale="0" id="Tc_EMF2NnM_X0mpmqIt8rZ2hw_9_5">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:58.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uTi3iJsKTUG1RhrJIbdN7Q" decimals="0" format="ixt:num-dot-decimal" name="limn:StockIssuedPeriodValueOfCommonStockToUnderwriter" scale="0" id="Tc_QkhK9BLQ2UeuMRoTJdI8_g_9_8">7,244,930</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:StockIssuedPeriodValueOfCommonStockToUnderwriter" scale="0" id="Tc_pW8_H7Q8EU6N3QpVf7Px2Q_9_14">7,245,000</ix:nonFraction></p></td></tr><tr style="height:18.39pt;"><td style="vertical-align:bottom;width:207.3pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issuance of common stock in connection with the surrender of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg" decimals="INF" format="ixt:num-dot-decimal" name="limn:SharesIssuedForSurrenderAndCancellationOfWarrants" scale="0" id="Tc_rpyNlS5PpUKANgBnP0GcJg_10_2">350,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg" decimals="0" format="ixt:num-dot-decimal" name="limn:StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants" scale="0" id="Tc_MK6mQYgiVkGBKNGckVp17g_10_5">35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:58.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uTi3iJsKTUG1RhrJIbdN7Q" decimals="0" format="ixt:num-dot-decimal" name="limn:StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants" scale="0" id="Tc_pg-72xRs4EKW6MYASps_Tw_10_8">1,739,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants" scale="0" id="Tc_kSmE-oB2U0aQD6DvkGFQIA_10_14">1,740,000</ix:nonFraction></p></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:207.3pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:58.15pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XRD_hVv4DkGY6KlSlQA6NA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_HVbYM1q97kCHHIkMz3n87A_11_11">10,206,517</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_1R2QtY-HtUiElq4wob8jpw_11_14">10,206,517</ix:nonFraction>)</p></td></tr><tr style="height:10.19pt;"><td style="vertical-align:bottom;width:207.3pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Balance - December&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LJS_bgYOWkOcBywnif6GLQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_NAkeP72VvE6R7dQBaDED3Q_12_2">27,064,633</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LJS_bgYOWkOcBywnif6GLQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_6NAdKmQhdE2x6w3YoPSpOQ_12_5">2,706</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:58.15pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_It0aMMr5RUGH0v6aV7qdrw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_wqqRgGWmu0SzNJ8uGZVTOA_12_8">29,054,337</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.6pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4f2Cj2MzIUuqkE9ozbbB6w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_ULYhgN8fxkiLCtypOocB9Q_12_11">38,871,733</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.5pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_LCsiQAF9rUO1YrrSZKCExQ_12_14">9,814,690</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7782eab8_f19f_40c2_be59_3850c70fc4f1"></a><a id="Tc__2hJuu2qA0iGguUXRAKPZA_1_13"></a><a id="Tc_nxECwxc6zEOvXixZ0EjNoA_2_2"></a><a id="Tc_bMtwK3onc0OKcOdUg0RGlw_2_7"></a><a id="Tc_rUDpRP16yEW8dzV-qyQtXQ_2_10"></a><a id="Tc_rs4zgcjyxUSw-99baYIWHA_2_13"></a><a id="Tc_P8_rm2cQzk6aiZ_Xr77g2w_3_2"></a><a id="Tc_S3HQ_m3zBkiqSoQ-xLl3KQ_3_4"></a><a id="Tc_Mj0LPowchUGs3dyQQZL7Hw_3_7"></a><a id="Tc_xF46oejMF06RGq2pLTxuoQ_3_10"></a><a id="Tc_CNBsNWz-Zk6QNRBVMtH_qw_3_13"></a><a id="Tc_LaXKctP2MUW7lGBMFE73kA_4_0"></a><a id="Tc_puLmA9kF7kifDLD7YY39Wg_4_4"></a><a id="Tc_Frg_i8sgIEGtZB75fuVhfw_4_7"></a><a id="Tc_3m6n1jAD0kKoXBYFUMfc0w_4_10"></a><a id="Tc_ho3SNHGbKkK0xk9ZWTDg9w_4_13"></a><a id="Tc_5BxiGk3NG0u3dcMaNsvQxg_5_0"></a><a id="Tc_AjLzHDM4BUSL9_SP1C1vjA_5_2"></a><a id="Tc_6x5JYNHAukeJwD2K_c6w_w_5_5"></a><a id="Tc_W0e1fdNZE0e29UlwkoKQvA_5_8"></a><a id="Tc_IM2O893kIke4ruhLeN66fA_6_0"></a><a id="Tc_EbbL1IP71EK3RUiqgE9UZA_6_4"></a><a id="Tc_7qtdIdLi_EmUdepJirztcg_6_7"></a><a id="Tc_9RgrMKqTN0K9ypE0TLfw0g_6_10"></a><a id="Tc_jB6zFKs5rEmw0KAYHFKHZA_6_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:207.45pt;padding:0pt;"/><td style="width:9.7pt;padding:0pt;"/><td style="width:50.75pt;padding:0pt;"/><td style="width:9.7pt;padding:0pt;"/><td style="width:5.9pt;padding:0pt;"/><td style="width:50.75pt;padding:0pt;"/><td style="width:9.7pt;padding:0pt;"/><td style="width:7.05pt;padding:0pt;"/><td style="width:56.35pt;padding:0pt;"/><td style="width:9.7pt;padding:0pt;"/><td style="width:5.9pt;padding:0pt;"/><td style="width:50.75pt;padding:0pt;"/><td style="width:9.7pt;padding:0pt;"/><td style="width:5.9pt;padding:0pt;"/><td style="width:50.7pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:207.45pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:56.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.19pt;"><td style="vertical-align:bottom;width:207.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:56.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:207.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:117.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:63.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional&#160;Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:56.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:56.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr style="height:9.69pt;"><td style="vertical-align:bottom;width:207.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:56.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:63.4pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:56.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:56.6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:207.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance - December&#160;31,&#160;2023*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HFF_MgUngEePnxJ9ysVB6Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_sZwEW9zD10aVsHVqFTELDQ_4_2">17,500,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HFF_MgUngEePnxJ9ysVB6Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_GrnXgKUNgkmBMdi-ZoZ_3w_4_5">1,750</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_RvqHKU6YWkmEJhD9fotvqw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_PREj0jMsnE6uUWTGBUiLpQ_4_8">9,323,403</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mdCeT08ds0iD_QBBfMY-1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_lrp0UnlvWUWv5MwTXJ74KA_4_11">25,118,907</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2023_hJv_UjccpUSIXy-caXvHdA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_x56Y14AyeUu4PVvsK2xtfA_4_14">15,793,754</ix:nonFraction>)</b></p></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:207.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AfWb2cWlZEaFlDlquz3ozQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_FEgNwtOAJU20z4LR0OUlLQ_5_11">3,546,309</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_k7opdg1mbEuDoDMkurwPQg_5_14">3,546,309</ix:nonFraction>)</p></td></tr><tr style="height:10.19pt;"><td style="vertical-align:bottom;width:207.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance - December&#160;31,&#160;2024*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHu7s1FxgEmdi0qyZEPN4g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_uHx5DuLpAEO1yylp-kybYA_6_2">17,500,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHu7s1FxgEmdi0qyZEPN4g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_2j-StSoYh0i221VVtJbN8A_6_5">1,750</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.35pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9uu8nJPlZE2Ewx4WJxhvoQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_WSiTCK1d7kWwjU75pUtOxg_6_8">9,323,403</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MuLWEtlz5E2UN4YJiAi4YQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_xBiVk0vTUUuW4SRVVn7nLw_6_11">28,665,216</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.7pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Mlc4m5k8Fkedtj1BUQ0ZWQ_6_14">19,340,063</ix:nonFraction>)</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">* <ix:footnote xml:lang="en-US" id="_0a013712_0ec7_4e02_8987_4de262708134">Shares, preferred stock amount, common stock amount and additional paid-in capital data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-24</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_ebf5fd50_cd10_4f53_bbff_c3e134d2fb5d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liminatus Pharma, Inc.</b></p><a id="ConsolidatedStatementsofCashFlows_703268"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_79cf7d8b_ffb8_4be0_b6b8_4eeb7ca68585"></a><a id="Tc_UJXo_JKzGUGm2HsjXpVQRA_1_2"></a><a id="Tc_SGPDRMzjK02ivKByoajGNw_2_2"></a><a id="Tc_cdSXLegoBEelDewQVClGPQ_2_5"></a><a id="Tc_F0BKhNH34Uy_Q_4UZX-Inw_3_0"></a><a id="Tc_biUvyQxbU0SY5EbcKStV0A_4_0"></a><a id="Tc_vvXtkTRmvkqMZ3sDRI2HEw_4_2"></a><a id="Tc_rA5b39t5QkeGiVNo9Rgg6Q_4_5"></a><a id="Tc_KzGbWA77fkeW4LQkn0ns4g_5_0"></a><a id="Tc_qO0UUBWTPkqn7ZL8_nngXQ_5_6"></a><a id="Tc_WoBGgTzpRESwEBthtkfy6g_6_0"></a><a id="Tc_b0L2gZX9zkGWtDCRarrJ3w_6_6"></a><a id="Tc_wawrWqNrgEyXStGGWpJqcg_7_0"></a><a id="Tc_kjB7A3iTa0KI9A7uCRarqQ_7_6"></a><a id="Tc_K13YON9D9kGhRR84h_Vy0w_8_0"></a><a id="Tc_SBs4U2Pjt0aJQZkHciB4-g_8_6"></a><a id="Tc_6Z2vWjjvkk60G2tWHHa9iA_9_0"></a><a id="Tc_SX2nLdZKe0OtD3X0PNEnWQ_9_6"></a><a id="Tc_jk-SVwe560aotv7ftMcTLw_10_0"></a><a id="Tc_lZVNwDv4gk2v32mjNaemcQ_10_6"></a><a id="Tc_Hd4_rWIEYk-k2HsPwf0jng_11_0"></a><a id="Tc_WhQZc1pDH0e3dKR9A33otA_11_6"></a><a id="Tc_IizExf-YN0-fmVtrtqe7HA_12_0"></a><a id="Tc_EJr8omYeyE2A3bzBYsrEHg_13_0"></a><a id="Tc_gjDJBVcbmUeO136R5GKt8Q_13_6"></a><a id="Tc_hpIAlFrf9Ey8FXCqn1FfjA_14_0"></a><a id="Tc_lHdjVYJWA0qt45OyOboX0Q_15_0"></a><a id="Tc_zPTyL8m_dE-jfhUY7awIzg_16_0"></a><a id="Tc_tmj4GEJQmkeyu_8aeFNOPQ_17_0"></a><a id="Tc_7jJ33xrxy0qQqstXbwdHhg_17_3"></a><a id="Tc_TJfoG54u_Eq2JtMHW9Tt6g_18_0"></a><a id="Tc_OIMSGBv7PUSs4in5SaWsJg_18_3"></a><a id="Tc_gOf9bSdGuUeS47ty8fVqQA_19_0"></a><a id="Tc_30FMnBLXdkK34Z4vvKDBOQ_19_6"></a><a id="Tc_K63geQ5FE0KbHOd6OheAkQ_20_0"></a><a id="Tc_iCxaGxE1U0WVkDyCADv6Cw_22_0"></a><a id="Tc_ONz5A78Zl0i8Ms5oA025fw_23_0"></a><a id="Tc_HsG0QzFYuUWhIPS43m9Ukw_24_0"></a><a id="Tc_qqhZXK8hnUSd9XRJHgD7IA_24_6"></a><a id="Tc_rwDjK499Q0K_ZgEEbRb3YA_25_0"></a><a id="Tc_cynManL5W02uFAlnkWYtVg_27_0"></a><a id="Tc_ScijQ3xUz0iGXZ_aWW0aQg_28_0"></a><a id="Tc_5xS64hi7xEmCJ4X78DK2xQ_28_6"></a><a id="Tc_TslXRaPCbkKs2_u0n931wg_29_0"></a><a id="Tc_nP1iuVO7NUWkw1HLtaWW2g_29_6"></a><a id="Tc_wuVHfMJaBEKlOa4EKLQXTw_30_0"></a><a id="Tc_NL7Gs2-TQUy-U1DQ0NL0CQ_31_0"></a><a id="Tc_kk--M4UcNUexcGZscWQUCQ_31_6"></a><a id="Tc_vRt7oIfBJEeyBpPAFmzACA_32_0"></a><a id="Tc_pQhscSNW3ECA5qtWx85juQ_34_0"></a><a id="Tc_p_0l9MCLREyxIljSCjIkeg_36_0"></a><a id="Tc_cUXsRAQNhki59kxM_1UCEg_37_0"></a><a id="Tc_jecM9mFDRUKOuc1mXEmIqw_37_2"></a><a id="Tc_OkRkDe9Ld0yC1mVL4O91sA_37_5"></a><a id="Tc_ktCRe8D9KEuZ-4YY4PuQHA_39_0"></a><a id="Tc__cg5TAlh-U-5DyZxnfU9Mw_40_0"></a><a id="Tc_szggIGwMsEG59vJ9WF96Xg_40_2"></a><a id="Tc_-dU-m5GJ5E6XD1AQ8PuD8w_40_5"></a><a id="Tc_rFO7IJVqQEqbd9flQNuzkQ_40_6"></a><a id="Tc__ZgHegaiL0qqKQgB9URXCQ_41_0"></a><a id="Tc_jBNPxpT8Y0SHjqADj3EG-Q_41_2"></a><a id="Tc_GkaQkH0hc0OC-6juCmm2Jg_41_5"></a><a id="Tc_GfpWO7uv_kmvsj25aYg5Sw_41_6"></a><a id="Tc_VM62mzfCy0GoEoLKW6j10g_42_0"></a><a id="Tc_TUxAR4434k-TI4ABEN0pig_42_2"></a><a id="Tc_hY2Axpv4vECBY7a8mecwfQ_42_5"></a><a id="Tc_s4_9pKSNH0eQDE3hHbdVhg_42_6"></a><a id="Tc_RwKZc7cfx0yhk5T7sSZdAQ_43_0"></a><a id="Tc_Itc73s7UHUW3Ch8mxpGw-Q_43_2"></a><a id="Tc_xsGAfqKGAUGpPGfPHCFwHQ_43_5"></a><a id="Tc_fwscYSB-506DmOM8a9TpCQ_43_6"></a><a id="Tc_xSRK4eZQAUm6nE1TjcwpiQ_44_0"></a><a id="Tc_PRAA7OVu7USM0wJbI29XtA_44_2"></a><a id="Tc_bTPuvCPLykKjElR1UvcQng_44_5"></a><a id="Tc_zQWZ1Pqc0kiwzIZPTAPsCA_44_6"></a><a id="Tc_KNYOCBorDkaGjTeShgJDgg_45_0"></a><a id="Tc_WxJwVHxjkkCBTCn5LKn_zg_45_2"></a><a id="Tc_ePSEQmqp2kOnmHA1KZluRA_45_5"></a><a id="Tc_u8J03InQMEK-xUCqMZOv3A_45_6"></a><a id="Tc_fz_IfSSxAUCAB56ztKc56Q_46_0"></a><a id="Tc_L_v2i-9wA06N88JJLTkSwg_46_2"></a><a id="Tc_fGpf6EVxRkqLvyKFYF8CMQ_46_5"></a><a id="Tc_hgrw3gIUkkqQ4JVEpsFlsg_46_6"></a><a id="Tc_Kh799HdSAEqusq3lRjNyuQ_47_0"></a><a id="Tc_Hc6Nc7lWoEapTjAT85DwoQ_47_2"></a><a id="Tc_kWQ6S9vBgkSC_y_WkRLceA_47_5"></a><a id="Tc_PbevSWKL4ku5kdGrz1xdfg_47_6"></a><a id="Tc_SfABPu1f60yM0fPftiwwOQ_48_0"></a><a id="Tc_-W7SPvluM0CIsx8dUf5BLw_48_2"></a><a id="Tc_Qdi9ERg5WEKiN_dgUlkdew_48_5"></a><a id="Tc_iAFKWSFuBkeoWunt5io8SQ_48_6"></a><a id="Tc_EO6wO0Wou0CsSXmMpj95hg_49_0"></a><a id="Tc_vB_eKtFkR0mnzumXXg7jFA_49_2"></a><a id="Tc_oip3CF7eF0it5fVQGrNOUw_49_3"></a><a id="Tc_K6g6g1Wb50Omiom5PGODdg_49_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:385.8pt;padding:0pt;"/><td style="width:12.2pt;padding:0pt;"/><td style="width:7.65pt;padding:0pt;"/><td style="width:57.25pt;padding:0pt;"/><td style="width:12.2pt;padding:0pt;"/><td style="width:7.65pt;padding:0pt;"/><td style="width:57.25pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:142pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended December&#160;31,&#160;</b></p></td></tr><tr style="height:9.69pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Operating Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_Fm2DCzPltEGt5eoOJoCSzw_4_3">10,206,517</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_4q5iFECBqk-fyvvrEx6hVA_4_6">3,546,309</ix:nonFraction>)</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Forgiveness of unrelated vendor payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:ForgivenessOfUnrelatedVendorPayable" scale="0" id="Tc_DiaFO7AGlEuMYKZs77sxog_5_3">2,142,297</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Forgiveness of related party receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:OtherReceivableWriteOff" scale="0" id="Tc_hh-rFgMXGU2VqnOtgPdQQg_6_3">126,275</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" id="Tc_FvlsFDKhDkWQ4Afsl9b78g_7_3">1,828</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style="height:12.2pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Change in fair value of deferred underwriting fee <span style="font-family:'Aptos Narrow';">&#8211;</span> paid in common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue" sign="-" scale="0" id="Tc_t6rdQv3cXUCSdDtJ4Fr2kA_8_3">196,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Change in the fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="0" id="Tc_uiJ9JocUlkqr_NoujUjugA_9_3">54,312</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Loss on issuance of common stock in connection with the surrendar of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:GainLossOnIssuanceOfCommonStockForWarrants" sign="-" scale="0" id="Tc_JLCw5QdjrEa-CJGcSlOZaQ_10_3">1,740,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Fair value of common stock to be issued for contingent liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:FairValueOfCommonStockIssuanceForContingentLiability" scale="0" id="Tc__9d6rifr4EWHoKf2tMhx0A_11_3">7,360,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Changes in operating assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Due from related party, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent" scale="0" id="Tc_gd3EOLUdJEmZNHCzeagvXg_13_3">3,427,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Prepaid and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="0" id="Tc_RYcMCAklmUylGkcrXc_40A_14_3">324,609</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_HvIFkTuZLEi4FKKzKN1ifw_14_6">133,251</ix:nonFraction>)</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="0" id="Tc_-LMTpRVUDU6PcRU5Cqje-A_15_3">4,035,340</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="0" id="Tc_N-OytFREv0y1OSk9HbMMyg_15_6">10,747</ix:nonFraction>)</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Accrued interest, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent" sign="-" scale="0" id="Tc__TeQdcuI70qpAb_7JuGwxQ_16_3">215,903</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="limn:IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent" sign="-" scale="0" id="Tc_rKjxCytMUE6yqgsoBd28QA_16_6">338,882</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Accrued maintenance fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="limn:IncreaseDecreaseInAccruedMaintenanceFeesCurrent" sign="-" scale="0" id="Tc_nF91bDRf8067-tI49rGVpA_17_6">360,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Due to research and development partner</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="limn:IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent" sign="-" scale="0" id="Tc_7nztPmx2A0qYbrKv8qt6vg_18_6">1,540,359</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Due to related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" sign="-" scale="0" id="Tc_xpAC3hYoEEmMuuv8fdgX-Q_19_3">62,467</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Net cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_tBzZFr22B0-JeMG8X5GPag_20_3">9,963,318</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_0DhqcEaAj0S_BYf_6yzL6Q_20_6">1,451,066</ix:nonFraction>)</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Cash Flows from Investing Activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Loans to Iris Acquisition Corp</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireLoansReceivable" scale="0" id="Tc_knF5DzgFB0u-de_iJP3Q6w_23_3">775,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireLoansReceivable" scale="0" id="Tc_fhqjyrJXZUCCGUKwca_oFQ_23_6">2,850,000</ix:nonFraction>)</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_j3Yn7PM4DEKj84B-JABJ6w_24_3">13,108</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Net cash used in investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_5oKn_K-nwU-w7TvUtFW92A_25_3">788,108</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_Kke8crljbUGkbUAjJFYk8Q_25_6">2,850,000</ix:nonFraction>)</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Financing Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Gross proceeds from issuance of common stock for PIPE investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" id="Tc_ZHEZPMS9NUm0YO8Q-y-VlA_28_3">10,556,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Payment of transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" scale="0" id="Tc_J2jF8hMfwkelXOq3zw8m3A_29_3">2,563,738</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of short-term debt, related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="0" id="Tc_ZIK_kaHcV0K_KzvlxKuLbw_30_3">4,340,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="0" id="Tc_NTnAZPzB40GmLipNINyEuw_30_6">3,923,000</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Repayment of short-term debt, related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="0" id="Tc_p0XBxU6J5kyyOeRb2eS58Q_31_3">1,300,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.99pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Net cash provided by financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_XnUu_C90B0OS-BTcTjfAgQ_32_3">11,032,762</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_yGd70DfqYkS4n1LGdOVVVw_32_6">3,923,000</ix:nonFraction></b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net change in cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_3oeyvalVCESz2ImYCAfUWg_34_3">281,336</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_87IKmVrT1kie26njOYce6g_34_6">378,066</ix:nonFraction>)</b></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash, beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" id="Tc_QRdDTz5CxEOxsmlwU4fdag_36_3">56,319</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2023_hJv_UjccpUSIXy-caXvHdA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" id="Tc_cB_jkHWnG0-8uI36590Nfg_36_6">434,385</ix:nonFraction></p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash, end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" id="Tc_zGtJAfi6UkeztfjR10s04g_37_3">337,655</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" id="Tc_2sufpSoZYUKy9JpXPQciFg_37_6">56,319</ix:nonFraction></b></p></td></tr><tr style="height:12.24pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Non-cash investing and financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Liabilities assumed in connection with the Business Combination</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAssumed1" scale="0" id="Tc_0mDbo_fc50WSv6yaPS29TA_40_3">10,694,604</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Fair value of shares to be issued to underwriter on date of the Business Combination</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination" scale="0" id="Tc_2ZsSZ1mgXkKWTVAxFD5Tjg_41_3">7,049,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Transaction costs incurred upon closing of the Business Combination</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction" scale="0" id="Tc_BOEInazRhEqp3NzDHMuFRg_42_3">1,518,381</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Settlement of loans to Iris Acquisition Corp upon closing of the Business Combination</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:LoansSettled" scale="0" id="Tc_s4NZEx8TO0KMeSPnu4nhwA_43_3">4,443,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock to Iris Acquisition Holdings, LLC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="0" id="Tc_uMaryVC4OkWaz3ZSupobDA_44_3">690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Conversion of related party short-term debt into common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Tc_E_XrfqllpUi2SGSQsFhbYQ_45_3">14,797,901</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Non-cash conversion of short term debt, related parties for PIPE Funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:NoncashConversionOfAmountBorrowedForPipeFunds" scale="0" id="Tc_60TgJxw9UEyHCNK07Ugtdw_46_3">3,427,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:22.99pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Non-cash impact to APIC for the forgiveness of accrued interest on converted related party debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest" scale="0" id="Tc_Uff7tQTn3U24StVKVJUlVg_47_3">169,201</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock to underwriter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:SharesIssuableUponClosingOfMergerToUnderwriters" scale="0" id="Tc_XmPlIieuMECuI2zOScWUaQ_48_3">7,245,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:385.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Deferred transaction costs in accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredTransactionCostsInAccountsPayable" scale="0" id="Tc_7HZ8kkXZq0C-LyR_9NQtlw_49_6">561,441</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-25</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_bba44543_d311_4282_a5a4_dbf515ad325a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LIMINATUS PHARMA,&#160;INC.</b></p><a id="NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_8MjlDCPnH0yPg0ajfe_lVQ" continuedAt="Tb_8MjlDCPnH0yPg0ajfe_lVQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;1. Description of Organization and Business Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Liminatus Pharma, Inc. (the &#8220;Company&#8221;), a Delaware corporation, is a pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company&#8217;s candidate IBA101, is a humanized anti CD47 monoclonal antibody. The next generation CD47 checkpoint inhibitor&#8217;s initial indication is expected to be patients with advanced solid cancers including non-small cell lung cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the uncertainty of whether the Company&#8217;s intellectual property will develop into successful commercial products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 30, 2022, Iris Acquisition Corp, a Delaware corporation (&#8220;Iris&#8221;), the Company, Liminatus Pharma, LLC, a Delaware limited liability company (&#8220;Liminatus&#8221;), Liminatus Pharma Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#8220;Liminatus Merger Sub&#8221;), and SPAC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#8220;SPAC Merger Sub&#8221;), entered into a business combination agreement (as it may be amended, supplemented or otherwise modified from time to time, the &#8220;Business Combination Agreement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;4, 2025, Iris held a special meeting of stockholders. At the special meeting, Iris&#8217;s stockholders voted to approve the Business Combination and adopt the Business Combination Agreement, among other items. In connection with the special meeting, stockholders holding <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw" decimals="INF" format="ixt:num-dot-decimal" name="limn:CommonStockCashRedemptionShares" scale="0" id="Narr_2dMaaxQJtUiUdyHcKJvdOw">59,844</ix:nonFraction> Iris Class&#160;A Shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw" decimals="2" format="ixt:num-dot-decimal" name="limn:CommonStockCashRedemptionPricePerShare" scale="0" id="Narr_zkAbkgZrskinD0_WtkomQw">11.74</ix:nonFraction> per share, subject to adjustment for taxes payable from the trust account, for an aggregate redemption amount of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw" decimals="0" format="ixt:num-dot-decimal" name="limn:CommonStockCashRedemptionAmount" scale="0" id="Narr_TX3g3uUnEEOXGARpCU5DsQ">702,359</ix:nonFraction>. The redemptions were settled on April 30, 2025 upon the consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April&#160;30, 2025 (the &#8220;Closing Date&#8221;), the Company consummated the business combination contemplated by the Business Combination Agreement, pursuant to which <span style="color:#231f20;">(a)&#160;Liminatus Merger Sub merged with and into Liminatus (the &#8220;Liminatus Merger&#8221;), with Liminatus surviving the Liminatus Merger as a direct wholly-owned subsidiary of the Company, and (b)&#160;simultaneously with the Liminatus Merger, SPAC Merger Sub merged with and into Iris (the &#8220;SPAC Merger&#8221; and, together with the Liminatus Merger, the &#8220;Mergers&#8221;), with Iris surviving the SPAC Merger as a direct wholly-owned subsidiary of the Company (the transactions contemplated by the foregoing clauses (a)&#160;and (b)&#160;the &#8220;Business Combination&#8221;)</span>, and in connection therewith the Company changed its name from &#8220;Iris Parent Holding Corp.&#8221; to &#8220;Liminatus Pharma,&#160;Inc.<span style="color:#231f20;">&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Business Combination Agreement, among other matters, at the effective time of the Business Combination (the &#8220;Effective Time&#8221;), (i)&#160;every issued and outstanding security issued by Iris during its initial public offering (each, an &#8220;Iris Unit&#8221;) was automatically separated and broken out into its constituent parts and the holder thereof was deemed to hold <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw" decimals="INF" format="ixt-sec:numwordsen" name="limn:NumberOfSharesHeldInEachUnit" scale="0" id="Narr__zH1hPEYUE66c5DVJ_LTXw">one</ix:nonFraction> share of Iris Class&#160;A common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_LtZLOsdPy0utFF3tgG3K3g">0.0001</ix:nonFraction> per share (the &#8220;Iris Class&#160;A Shares&#8221;) and <span style="-sec-ix-hidden:Hidden_ZxKK64VsEUG8mm4V7fNrqQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-fourth</span></span> of one redeemable warrant that was included as part of each Iris Unit (the &#8220;Public Warrants&#8221;), and such underlying constituent securities of Iris were converted in accordance with the applicable terms of the Business Combination Agreement, (ii)&#160;at the Effective Time, each issued and outstanding Iris Class&#160;A Share was converted automatically into and thereafter represent the right to receive <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_cgSRAUkHA0i2y04jy71KAw" decimals="0" format="ixt-sec:numwordsen" name="limn:CommonStockConversionRatioBusinessCombination" scale="0" id="Narr_idNQR85O80uUoXA1j68zSg">one</ix:nonFraction> share of common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_cgSRAUkHA0i2y04jy71KAw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_KLlcZkaVZEW5L-B4A8fVPw">0.0001</ix:nonFraction> per share (&#8220;Common Stock&#8221;), of the Company, following which all Iris Class&#160;A Shares ceased to be outstanding and were automatically canceled and ceased to exist, (iii)&#160;at the Effective Time, each issued and outstanding Public Warrant immediately and automatically represented the right to purchase shares of Common Stock on the same terms and conditions as are set forth in the applicable warrant agreement, (iv)&#160;at the Effective Time, each issued and outstanding non-redeemable warrant of Iris that was issued by Iris in a private placement at the time of the consummation of its initial public offering, entitling the holder thereof to purchase <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_us-gaap_ClassOfWarrantOrRightAxis_limn_NonRedeemableWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_ZG-LffBZq0OabS0uAuJI-Q" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_OVFGgTfV4kSXuBH7tXFFUw">one</ix:nonFraction> Iris Class&#160;A Share at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_us-gaap_ClassOfWarrantOrRightAxis_limn_NonRedeemableWarrantMember_xHQZeSCsiEGkdYLlyBZaXA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_tTu30AfYCkG2akIZP7Kstg">11.50</ix:nonFraction> per share, except those issued to Cantor Fitzgerald&#160;&amp; Co. (&#8220;Cantor&#8221;), were forfeited, and (v)&#160;the private placement warrants issued to Cantor immediately and automatically represented the right to purchase shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the consummation of the Business Combination, the Company&#8217;s certificate of incorporation was amended and restated to, among other things, set the total number of authorized shares of capital to <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="INF" format="ixt:num-dot-decimal" name="limn:SharesAuthorized" scale="0" id="Narr_8_70vjzEP0ishRDMj-WE0A">501,000,000</ix:nonFraction> shares, of which <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_UmqRGu5CQEGmsiZAYdjyzA">500,000,000</ix:nonFraction> were designated as common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_5X31IiG7Uka4NtjzJ8CV5A">0.0001</ix:nonFraction> par value per share, and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_Ww4ZlE-FD0OKHMXVgpianw">1,000,000</ix:nonFraction> shares were designated as preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_902-pLCjo06Q9qtP7mOYgg">0.0001</ix:nonFraction> par value per share.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-26</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_8MjlDCPnH0yPg0ajfe_lVQ_cont1" continuedAt="Tb_8MjlDCPnH0yPg0ajfe_lVQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing Date, <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Gi0t5_gUYU-FQON95jjxrA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_q7H9uDmYpU2fMsT6meRDqA">7,014,633</ix:nonFraction> shares of Iris Class A Shares automatically converted into shares of the Company&#8217;s common stock, on a <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_zu3KxzCVkkuK5CuyZXWLYA" decimals="0" format="ixt-sec:numwordsen" name="limn:ConversionOfStockOrUnitConversionRatio" scale="0" id="Narr_o_ZxK_0gE0CQJJDuG-9OMA">one</ix:nonFraction>-for-one basis. Of the total <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Gi0t5_gUYU-FQON95jjxrA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_cgHHUIQI706QLpJPqoMrdg">7,014,633</ix:nonFraction> newly converted shares, <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionHoldingsLlcMember_HNZDVq5GE0GEgfHcGTUA1A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_fFaItmFg3kCNjnTmWymcww">6,900,000</ix:nonFraction> were issued to Iris Acquisition Holdings, LLC, the sponsor of Iris, and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_aADDeFhV70K5BS2735863Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_AW6-pImGykaVaYRJNquTwQ">114,633</ix:nonFraction> were issued to Iris&#8217; public stockholders in a noncash transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing Date, the Company issued an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_ML9wK_VTZkm9PpD3aooVIw">1,500,000</ix:nonFraction> shares of the Company&#8217;s common stock in a private placement (the &#8220;PIPE Shares&#8221;) for the total consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_ROPQ5452KkOrTtv8fSjvgw">15,000,000</ix:nonFraction> (the &#8220;PIPE Financing&#8221;). The PIPE Financing consisted of a cash and non-cash component. Under the cash component, the Company received gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" id="Narr_ouQFNO-41kqYqguPIA_GTA">10,556,500</ix:nonFraction>, of which $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ" decimals="0" format="ixt:num-dot-decimal" name="limn:ProceedsFromIssuanceOfPrivatePlacementInvestor" scale="0" id="Narr_I3x1D6Uw-0-Ndci19mC2Tg">7,129,500</ix:nonFraction> came directly from the PIPE investor and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ" decimals="0" format="ixt:num-dot-decimal" name="limn:ProceedsFromIssuanceOfPrivatePlacementInvestorFunded" scale="0" id="Narr_zQlDMZnaa02nUK9jxtdpag">3,427,000</ix:nonFraction> was funded indirectly by the PIPE investor, through promissory notes between Prophase Sciences, LLC, a related party of the Company, and Liminatus. At the Closing Date, the $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_BG18PWxQe0CnYGGKH4560A">3,427,000</ix:nonFraction> in related party debts between Prophase Sciences, LLC and Liminatus was ultimately converted into shares as part of the PIPE Financing. As part of the PIPE Financing, the gross proceeds satisfied principal and accrued interest totaling $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VYxJe3-ZlEKGtf77rNoRJQ" decimals="0" format="ixt:num-dot-decimal" name="limn:PrincipalAndAccruedInterestOnPrivatePlacement" scale="0" id="Narr_5SCpXHAJB0GfK5l0CcyYhg">3,316,756</ix:nonFraction>, which was ultimately converted into shares as part of the PIPE Financing. The non-cash component of the PIPE Financing included the conversion of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ConsortiumLoanOfRelatedPartiesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4nTHRjjm9E64EIS8-8O57A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_A9Qg9PeXpU-LQl0pa0uO_Q">4,443,500</ix:nonFraction> in amounts borrowed from a consortium of related parties. The $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VYxJe3-ZlEKGtf77rNoRJQ" decimals="0" format="ixt:num-dot-decimal" name="limn:RelatedPartiesDebtToUnsecuredPromissoryNote" scale="0" id="Narr_3SR9RArgbUyDCWYq65u-FQ">4,443,500</ix:nonFraction> borrowed from the related parties were used to fund an unsecured promissory note between Liminatus and Iris. At the Closing Date, the unsecured promissory note was settled and the $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VYxJe3-ZlEKGtf77rNoRJQ" decimals="0" format="ixt:num-dot-decimal" name="limn:UnsecuredPromissoryNoteSettledAndConverted" scale="0" id="Narr_kLKi8q9dnE2KekDHG1BtQA">4,443,500</ix:nonFraction> in related party debts were ultimately converted into shares of the Company in a noncash transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing Date, <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_9PPk1IhN6EmJm5MGsGwEDA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_-ZZCIIwFrUGIwvdA1dbGHA">112,222,220</ix:nonFraction> Liminatus&#8217; member units converted into <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_9PPk1IhN6EmJm5MGsGwEDA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_Vd74P6r7ZUOcJGxDk8Xklw">17,500,000</ix:nonFraction> shares of the Company&#8217;s common stock. Of the <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_9PPk1IhN6EmJm5MGsGwEDA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_QpEUDHMbJEqIk-Bj9PyJMA">17,500,000</ix:nonFraction> shares of common stock, <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_gsYeVbSjA0ijBUxcCNZtvA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_8rf_QJXszkaIovV0zHm2Yg">4,000,000</ix:nonFraction> were issued to Feelux Co, Ltd. as part of an agreement between the Company, Feelux Co, Ltd. and Car-Tcellkor, Inc. As part of the agreement, the outstanding principal and accrued interest on the Feelux and Car-Tcellkor bonds, totaling $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxAndCarTcellkorMember_IRaHwKWzMU-DElAHyQN8Tg" decimals="0" format="ixt:num-dot-decimal" name="limn:ConversionOfPrincipalAndAccruedInterestAmount" scale="0" id="Narr_xKae4piBVUm2icSVCa1vlg">11,481,146</ix:nonFraction>, and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxAndCarTcellkorMember_zWurOUpaU0i-IKmnDLLc4w" decimals="INF" format="ixt:num-dot-decimal" name="limn:ConversionOfPrincipalAndAccruedInterestShares" scale="0" id="Narr_zEUDHdEeZU6Dk53X29Xxdg">9,999,999</ix:nonFraction> member units of Liminatus were converted into <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_gsYeVbSjA0ijBUxcCNZtvA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_58K483Qg2EOGnoYHJXV7xw">4,000,000</ix:nonFraction> shares of the Company&#8217;s common stock. The remaining Liminatus member units were converted based on a conversion ratio of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="4" format="ixt:num-dot-decimal" name="limn:ConversionOfStockOrUnitConversionRatio" scale="0" id="Narr_DMnmXouyhUubQDmT2mVSGA">0.1559</ix:nonFraction> shares per member unit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon consummation of the Business Combination, the Company assumed a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_qUlxIbYw4Uyvh13v3JGs3g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="0" id="Narr_SuC15c_dIUKC1mrT5G31OA">10,694,604</ix:nonFraction> in liabilities from Iris. The Company incurred $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_aADDeFhV70K5BS2735863Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="Narr_KYmEYKKqs0ySMV0eFvDsJQ">1,518,381</ix:nonFraction> in transaction costs associated with the closing of the Business Combination. The Company converted a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_aADDeFhV70K5BS2735863Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_2oRDau0VVU65ocpEhEealQ">14,797,901</ix:nonFraction> of related party debt and accrued interest, <span style="-sec-ix-hidden:Hidden_5_bKoANxokGAW-xbn0qRBA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3,316,755</span></span> from the PIPE investor and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_qUlxIbYw4Uyvh13v3JGs3g" decimals="0" format="ixt:num-dot-decimal" name="limn:ConversionOfPrincipalAndAccruedInterestAmount" scale="0" id="Narr_yjTjf9TvyUOXchEEawK6YA">11,481,146</ix:nonFraction> from Feelux and Car-Tcellkor (as described above) into common stock. Additionally, a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_aADDeFhV70K5BS2735863Q" decimals="0" format="ixt:num-dot-decimal" name="limn:ConversionOfAccruedInterestOnRelatedPartyDebts" scale="0" id="Narr_N5SpC9_I40-NSNUIHPFSFg">169,201</ix:nonFraction> in accrued interest on related party debts that were converted, as discussed above, was forgiven upon consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, at the Closing Date, the Company settled Iris&#8217; liabilities for $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" scale="0" id="Narr_LJF5QCtQikGUqEgotoYW8A">7,000,000</ix:nonFraction> of the deferred underwriting fees incurred prior to the Closing Date for <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="INF" format="ixt:num-dot-decimal" name="limn:StockIssuableForSettlementOfDeferredUnderwritingFees" scale="0" id="Narr_4g82SMlWl0ydz4sLYUiNUQ">700,000</ix:nonFraction> shares of common stock to the underwriters in Iris&#8217;s initial public offering. At the Closing Date, the shares were not issued to the underwriter and the Company recorded as a liability with a fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="0" format="ixt:num-dot-decimal" name="limn:LiabilityOfUnderwritingFeesFairValue" scale="0" id="Narr_bGbcOPkJ7E21Wopo-idlNg">7,049,000</ix:nonFraction>. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_7_1_2025_CZJvPOCOcUySCDRAwOkqBA" decimals="0" format="ixt:num-dot-decimal" name="limn:FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" scale="0" id="Narr_Ck3S2bqPwEmB-kfg00Kaew">7,245,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Liminatus was deemed the accounting acquirer in the Business Combination based on an analysis of the criteria outlined in Accounting Standards Codification (&#8220;ASC&#8221;) 805, <i style="font-style:italic;">Business Combinations</i> (&#8220;ASC 805&#8221;). The determination was primarily based on Liminatus&#8217; members prior to the Business Combination having a majority of the voting interests in the combined company, Liminatus&#8217; ability to exert control over the majority of the board of directors of the combined company, Liminatus&#8217; ability to maintain control of the board of directors on a go-forward basis, Liminatus&#8217; senior management comprising the senior management of the combined company, and Liminatus&#8217; operations prior to the Business Combination comprise the ongoing operations of the combined company. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Liminatus&#8217; issuing stock for the net assets of Iris, accompanied by a recapitalization. The net assets of Iris were stated at fair value, with no goodwill or other intangible assets recorded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the consummation of the Business Combination, the Iris Class&#160;A Shares, Iris Units and Public Warrants ceased trading on the OTC Pink Marketplace, and the Common Stock and Public Warrants began trading on The Nasdaq Stock Market (&#8220;Nasdaq&#8221;) under the trading symbols &#8220;LIMN&#8221; and &#8220;LIMNW,&#8221; respectively, on May&#160;1, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nasdaq Notices</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On August 22, 2025, the Company received a notice from the Nasdaq Listing Qualifications Department indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025. The deficiency letter had no immediate effect on the listing of the Company&#8217;s common stock, and its common stock continued to trade on Nasdaq under the symbol &#8220;LIMN&#8221;. Under the Nasdaq rules, the Company had 60 calendar days, or until October 21, 2025, to submit a plan to regain compliance and if the plan was accepted, Nasdaq can grant an exception of up to 180 calendar days from the filing&#8217;s due date, or until February 16, 2026, to regain compliance. If the compliance plan was not accepted, </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-27</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_8MjlDCPnH0yPg0ajfe_lVQ_cont2" continuedAt="Tb_8MjlDCPnH0yPg0ajfe_lVQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Company had the opportunity to appeal that decision to a Nasdaq Hearings Panel. On October 6, 2025, the Company filed its Form 10-Q for the period ended June 30, 2025 and the matter was closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 19, 2025, the Company received notices from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value of Listed Securities (MVLS) of $50,000,000 (the &#8220;MVLS Rule&#8221;), based upon a review of the Company&#8217;s MVLS for the last 30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly Held Shares (MVPHS) of $15,000,000 (the &#8220;MVPHS Rule&#8221;), based upon a review of the Company&#8217;s MVPHS for the last 30 consecutive business days. The Nasdaq staff noted that the Company also does not meet the requirements under Listing Rule 5450(b)(3)(A), which requires the Company to have total assets and total revenue of at least $50 million each for the most recently completed fiscal year or two of the three most recently completed fiscal years. Under the Nasdaq rules, the Company has 180 calendar days, or until May 18, 2026, to regain compliance with the MVLS Rule and MVPHS Rule. In the event the Company does not regain compliance with the MVLS Rule and MVPHS Rule prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Hearings Panel. Alternatively, the Company may consider applying to transfer the Company&#8217;s securities to the Capital Market, provided it meets the Capital Market&#8217;s continued listing requirements. The Company is working diligently to regain compliance with Nasdaq&#8217;s listing rules. However, there can be no assurance that the Company will be able to regain compliance within the prescribed time period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 15, 2026, the Company received a notice from Nasdaq indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rule 5450(a)(1) (the &#8220;Bid Price Rule&#8221;) which requires listed securities to maintain a minimum bid price of $1 per share. Under the Nasdaq rules, the Company has 180 calendar days, or until July 14, 2026, to regain compliance with the Bid Price Rule. In the event the Company does not regain compliance during the initial compliance period, the Company may be eligible for additional time to regain compliance with the Bid Price Rule. The Company is working diligently to regain compliance with Nasdaq&#8217;s listing rules. However, there can be no assurance that the Company will be able to regain compliance within the prescribed time period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity and Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for one year after the date that the consolidated financial statements are issued. Through December 31, 2025, the Company has funded its operations mainly through equity and debt financings, including the proceeds from the Mergers and the PIPE Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" id="Narr_ja_oS3DkakeHW51Cf3VgUw">337,655</ix:nonFraction> of cash in its bank accounts. As of December 31, 2025 and 2024, there was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_ZQJSWghC_kWyh3eqIzF4ow">1,442,500</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_hLS2tVFDXUCzxscjPry_pQ">19,973,000</ix:nonFraction>, respectively, of related party debts, which are included in Short-term debt, related parties in the accompanying consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Narr_IWkA6FPEaEGpLbOsZKBz0w">38,871,733</ix:nonFraction> as of December 31, 2025. The Company had a loss from operations and net loss of $(<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Narr_k-nFwlp9306odsVfJILojg">2,967,812</ix:nonFraction>) and $(<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Narr_RXpTo5fVBUuGTQtk2bFEhg">10,206,517</ix:nonFraction>), respectively, for the year ended December 31, 2025. The Company had a loss from operations and net loss of $(<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Narr_uC20G4tQ3Ee4KsJG6Jegyw">3,329,953</ix:nonFraction>) and $(<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Narr_Fg3iwuVyMEGNCrTZRyaMVw">3,546,309</ix:nonFraction>), respectively, for the year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 18, 2026, the Company completed a &#8220;best efforts&#8221; public offering of (i) <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_JSVgKnyZI0uvIBPJsCar7A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_yFxu93UazUi5EH17vzChnQ">8,270,000</ix:nonFraction> shares of its common stock, (ii) <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_BC5_6M-QyUmQOf1sjtWaMg" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="0" id="Narr_aw8PasfbB0G7PCSSEKojHQ">5,543,000</ix:nonFraction> pre-funded warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_eTUFwzCAf0WPdoyAqoxppg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_fsF3vUQpcU2X9dNw-mGZYA">5,543,000</ix:nonFraction> shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) and (ii) <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_YV5sLiK4506wsErDca1zNw" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="0" id="Narr__ngp8DPEn0WZnLkQ8u_K3w">13,813,000</ix:nonFraction> common stock purchase warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_Y7EtLUI_pk6RZ-oTbRPBxg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_rlwR9peATEGCx8dPKCZ46w">20,719,500</ix:nonFraction> shares of common stock, at a combined public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_2_18_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_1t1X0h92206D-tAJKXlt8Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_Xgc2U9amhkiAlqNoW_0WIg">0.29</ix:nonFraction> per share (or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_eTUFwzCAf0WPdoyAqoxppg" decimals="4" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightIssuePricePerWarrant" scale="0" id="Narr_pPye_wQLWkadEB8t0FBaVw">0.2899</ix:nonFraction> per Pre-Funded Warrant) and accompanying warrant (the &#8220;Offering&#8221;). In connection with the Offering, the Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_JSVgKnyZI0uvIBPJsCar7A" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_WK2Y35sI4Um8xdup7CIcag">3.46</ix:nonFraction> million, after deducting the estimated offering expenses payable by the Company, including the placement agent fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 205-40, <i style="font-style:italic;">Presentation of Financial Statements&#8212;Going Concern</i>, management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying consolidated financial statements are issued. The Company&#8217;s consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-28</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_8MjlDCPnH0yPg0ajfe_lVQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management&#8217;s plans relating to the above include raising additional cash through further equity and debt financings or other arrangements to fund operations. There can be no assurance that the Company will be able to raise adequate capital under acceptable terms, if at all. The sale of additional equity may dilute existing members and newly issued equity securities may contain senior rights and preferences compared to currently outstanding common stock. Issued debt securities may contain covenants and limit the Company&#8217;s ability to pay dividends or make other distributions to stockholders. If the Company is unable to obtain such additional financing, future operations would need to be reevaluated.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_ZdyxbxRFs0CVG5T08pXm6Q" continuedAt="Tb_ZdyxbxRFs0CVG5T08pXm6Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;2. Significant Accounting Policies</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_-gEPds688U-8ofLfKXA8iw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) as determined by the FASB ASC and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="limn:EmergingGrowthCompanyPolicyPolicyTextBlock" id="Tb_yaLwgZrk7UOV4b-HGinyAg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company Status</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the closing of the Business Combination, the Company has elected to be an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart our Business Startups Act of 2012, (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:UseOfEstimates" id="Tb_Md5KVpM4NUmCNm1VpNJYTQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results may differ materially and adversely from these estimates. The Company is not aware of any significant estimates that required management to exercise significant judgment with the exception of the Company&#8217;s warrant liability. If the underlying estimates and assumptions upon which the estimates are based change in the future, actual amounts may differ from those included in the Company&#8217;s consolidated financial statements.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_j54wbF6cPUWSaOP5eBq8VA" continuedAt="Tb_j54wbF6cPUWSaOP5eBq8VA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), the Chief Executive Officer, manages the Company&#8217;s business activities as a single operating and reportable segment. Accordingly, the Company&#8217;s CODM uses net income/loss to measure the Company&#8217;s single segment&#8217;s performance and allocate resources. Further, the CODM reviews and utilizes functional expenses (general and administrative and research and development) to manage the Company&#8217;s operations. The Company&#8217;s general and administrative expenses for each of the years ended December 31, 2025 and 2024 included $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_ILl90TwynkGTc6BgSwur3g" decimals="0" format="ixt:num-dot-decimal" name="limn:FranchiseTaxExpenseIncludingInterestAndPenalty" scale="0" id="Narr_HWGuatMJZEKZs3BenxGRTw">202,833</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_hXB18br9yUGm2G-QE5h2uQ" decimals="0" format="ixt:num-dot-decimal" name="limn:FranchiseTaxExpenseIncludingInterestAndPenalty" scale="0" id="Narr_xhsp3lXUWEeMWYfh9xLVlg">150,000</ix:nonFraction> of compensation expenses related to the compensation agreements the Company has executed with its executive team. The remaining general and administrative expenses </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-29</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_ZdyxbxRFs0CVG5T08pXm6Q_cont1" continuedAt="Tb_ZdyxbxRFs0CVG5T08pXm6Q_cont2"><ix:continuation id="Tb_j54wbF6cPUWSaOP5eBq8VA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">are related to legal and accounting-related expenses for contractors. The Company&#8217;s research and development expenses did not include any compensation-related expenses. Other segment items included in net income (loss) are interest expense, related parties and interest income which are reflected in the Company&#8217;s consolidated statements of operations.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_595SdYHXdEWBtE-PiljRHQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which can exceed government insured limits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company did <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" id="Narr_oyd_TN8dw0CKWkcMIh5Z5Q"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" id="Narr_KOyVOeaIoki3vtdbnft9TQ">no</ix:nonFraction></ix:nonFraction>t have any cash equivalents as of December 31, 2025 and 2024.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:FinanceLoansAndLeasesReceivablePolicy" id="Tb_BPxWNA6irE-ZlOJxOBdf3g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Loan Receivable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its loan receivable at amortized cost, net of expected credit losses. The Company provides reserves against its loan receivable balance for estimated credit losses, if any, that may result from a counterparty&#8217;s inability to pay based on the composition of the loan receivable, current economic conditions and, historical credit loss activity and future expected conditions and market trends (such as general economic conditions, other macroeconomic and microeconomic events, etc.). Changes in circumstances relating to these factors may result in the need to increase or decrease the allowance for credit losses in the future. Amounts deemed uncollectible are charged or written-off against the reserve. On April 30, 2025, in connection with the Business Combination, the loan receivable was eliminated in consolidation as Iris and Liminatus are now consolidated subsidiaries of the Company. As of January 1, 2024 and December 31, 2024, <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_1_1_2024_0fsIJRo8qkmwqwDgqs1FdA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForNotesAndLoansReceivableCurrent" scale="0" id="Narr_cunH3a8tIUO5dNWT2IfKEg"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForNotesAndLoansReceivableCurrent" scale="0" id="Narr_OAaRY2XuLEqWbnVxCoNCuw">no</ix:nonFraction></ix:nonFraction> expected credit loss was recorded related to the loan receivable.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:DeferredChargesPolicyTextBlock" id="Tb_4KhxflQwY0iwv2s-tWRjJw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Deferred Transaction Costs </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Costs incurred in connection with preparation for the proposed business combination were deferred on the balance sheets as of December 31, 2024. <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DeferredCostsCurrent" scale="0" id="Narr_vG9G_zuvV0yLhz-0eI8prg">No</ix:nonFraction> such costs were deferred on the balance sheets as of December 31, 2025 due to the completion of the Company&#8217;s business combination with Iris. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_b2AzxXuS_ECHZLELR0xtig" continuedAt="Tb_b2AzxXuS_ECHZLELR0xtig_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial assets and liabilities are accounted for in accordance with FASB ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures,</i> which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value hierarchy requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 1 &#8212; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 2 &#8212; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the instrument&#8217;s anticipated life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 3 &#8212; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgement. Accordingly, the degree of judgement exercised by management in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the warrant liability reported in the Company&#8217;s consolidated balance sheets represent a Level 3 instrument. See Note 8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The carrying values reported in the Company&#8217;s consolidated balance sheets for prepaid expenses and other current assets, due from related party, accounts payable and accrued expenses, accrued interest, short-term debt with related parties, due to research and </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-30</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_ZdyxbxRFs0CVG5T08pXm6Q_cont2" continuedAt="Tb_ZdyxbxRFs0CVG5T08pXm6Q_cont3"><ix:continuation id="Tb_b2AzxXuS_ECHZLELR0xtig_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">development partner, due to related parties, settlement payable, and its deferred underwriting fee payable are reasonable estimates of their fair values due to the short-term nature of these items.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="limn:WarrantsPolicyPolicyTextBlock" id="Tb_b5UnRRW09Ue1x4RZGdNwMw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC 480, <i style="font-style:italic;">Distinguishing liabilities from equity</i> (&#8220;ASC 480&#8221;), and ASC 815, <i style="font-style:italic;">Derivatives and Hedging</i> (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance, modification, and as of each subsequent quarterly period end date while the warrants are outstanding. As of December 31, 2025, <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z416a0UcpESjBa-8wQ9m5Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_BLxhzNq7oEaZl6iHbRHNtA">5,899,975</ix:nonFraction> of the Company&#8217;s Public Warrants were accounted for as equity-classified instruments and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PrivatePlacementWarrantsMember_ioEniwa8PEunNaQ7J6fSnA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_vYMh1AJzJ0qhU1MRjjH_4g">835,555</ix:nonFraction> private placement warrants were accounted for as liability-classified instruments. As of December 31, 2025, there were <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z416a0UcpESjBa-8wQ9m5Q" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" id="Narr_UxhD8IpVl0-v6QaRUJT3MQ">no</ix:nonFraction> other public or <span style="-sec-ix-hidden:Hidden_wUaYXsrirkKbOmu3ilr3Zg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">private</span></span> warrants outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the liability-classified warrants are recognized as a non-cash gain or loss on the accompanying consolidated statements of operations. The Company assesses the classification of its warrants at each reporting date to determine whether a change in classification between equity and liability is required. During the year ended December 31, 2025, the Company had an unrealized gain on the change in fair value of the warrant liabilities of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="0" id="Narr_skGWsZbu8EaLABIlHfqq_w">54,312</ix:nonFraction>. During the year ended December 31, 2024, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="Narr_hWPyria92EmwYXRmnHbW6w">no</ix:nonFraction> unrealized gain or loss on the change in fair value of the warrant liabilities. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="limn:NetIncomeLossPerCommonStockPolicyPolicyTextBlock" id="Tb_XvTcLjeToUeWhIjs9wf0CA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net loss per Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company complies with accounting and disclosure requirements of ASC Topic 260, <i style="font-style:italic;">Earnings Per Share</i>. The Company has one class of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities if their effect is antidilutive. Diluted net loss per share is computed by the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined by using the treasury stock method. Dilutive common stock equivalents are comprised of <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="0" id="Narr_eus0gSluYEmmL5yKnwl3Xw">6,735,530</ix:nonFraction> warrants. For all periods presented, there is no difference in the number of shares used to calculated basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive given that their exercise price is greater than that of the average market price of the Company&#8217;s common stock during the years ended December 31, 2025 and 2024.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_o7xl9igDRES1r6gufOdbzg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of costs incurred by Targeted Diagnostics &amp; Therapeutics, Inc. (&#8220;TDT&#8221;) who was performing the research and development activities for the Company in accordance with the license agreements with TDT and the annual fee paid to TDT and are recorded as research and development expenses as incurred (see Note 3).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_KvrUDEDtwEy8n2V2GlWH1Q" continuedAt="Tb_KvrUDEDtwEy8n2V2GlWH1Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes its leases in accordance with ASC Topic 842, <i style="font-style:italic;">Leases</i> (&#8220;ASC 842&#8221;). Under ASC 842, lessees are required to recognize all qualified operating leases at the commencement date including a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use (&#8220;ROU&#8221;) asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. The initial lease liability is equal to the future fixed minimum lease payments discounted using the Company&#8217;s incremental borrowing rate, on a secured basis. The lease term includes option renewal periods and early termination payments when it is reasonably certain that the Company will exercise those rights. The initial measurement of the ROU asset is equal to the initial lease liability plus any initial direct costs and prepayments, less any lease incentives.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-31</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_ZdyxbxRFs0CVG5T08pXm6Q_cont3"><ix:continuation id="Tb_KvrUDEDtwEy8n2V2GlWH1Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has leased office space for a fixed period of <ix:nonNumeric contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_rcEK9ZI6MUuvnNre92MDCQ">10</ix:nonNumeric> months. In accordance with ASC 842, a short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The short-term lease election can only be made at the commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A lessee that makes this accounting policy election does not recognize a lease liability or right-of-use asset on its balance sheet. Instead, the lessee recognizes lease payments on a straight-line basis over the lease term.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_Q8NVmh80zkyCrRUgoMqCWw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes in accordance with ASC Topic 740,&#160;<i style="font-style:italic;">Income Taxes</i>&#160;(&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. There were <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_i_OYQkIYcE6jIbqX3LkZ8Q">no</ix:nonFraction> tax accruals relating to uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax positions as income tax expense. There were <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_Q9gEjiO5BU-UxiGrNzHgZA"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_xSDVwNTZZUOfJS8HXZq_Ww">no</ix:nonFraction></ix:nonFraction> unrecognized tax positions, and <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" id="Narr_s3amLLNUoEOLNJKOTtWx8g"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" id="Narr_8DTdLqjSxkKGgwzEHl_rJQ">no</ix:nonFraction></ix:nonFraction> amounts accrued for interest and penalties as of December 31, 2025 and 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only &#8220;major&#8221; tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_4IIn1wXQqEGvVRRHq_WFYA"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_zZjWH93WFkyof0badDxZJw">No</ix:nonFraction></ix:nonFraction> unrecognized tax benefits were identified as of December 31, 2025 or 2024.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_DbkXMZuR_UOsnwK05-LjZw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The Company adopted this standard on January 1, 2025 and determined that the adoption does not have a material impact on these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements&#160;&#8211; Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2024, the FASB issued ASU 2024-03, Accounting Standards Update 2024-03, <i style="font-style:italic;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i> to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#8217;s consolidated financial statements.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-32</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="limn:LicenseAgreementsTextBlock" id="Tb_JIP5QkTmKkaDI_mJ2huWoA" continuedAt="Tb_JIP5QkTmKkaDI_mJ2huWoA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 3. License Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CAR-T Products License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June 2018, the Company entered into a license and development agreement with TDT (the &#8220;CAR-T License&#8221;), whereby the Company received an exclusive license to develop and commercialize chimeric antigen receptor (&#8220;CAR-T&#8221;) products and a non-exclusive license to develop and commercialize companion diagnostics used to monitor treatment with a CAR-T product (the &#8220;CAR-T Diagnostics&#8221;). Under the CAR-T License, the Company made an upfront payment recorded as research and development expenses in the year ended December 31, 2018 and funded all of the development costs for the CAR-T products and the CAR-T Diagnostics which began with an upfront payment made during the year ended December 31, 2018 of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2018_To_12_31_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_PCxMs4QP-k2uBuXoZKiE1A" decimals="0" format="ixt:num-dot-decimal" name="limn:UpfrontPaymentOfLicenseAgreementFees" scale="0" id="Narr_iho7jb607kqH8am59jNjKA">5,000,000</ix:nonFraction>, recorded as advances for research and development in the balance sheets. The Company amortizes the advances to research and development expenses in the consolidated statements of operations as costs are incurred by TDT, based on annual budgets approved jointly by Liminatus and TDT. As of December 31, 2025 and 2024, all of the amounts funded have been utilized. The Company was also obligated to pay an approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_0lDWBPW2vkuWvH-HiGeZyg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostMaintenance" scale="0" id="Narr_au4JRj_lKE2oAgMnNeRSmQ">500,000</ix:nonFraction> annual maintenance fee for the license which is included in research and development expenses in the consolidated statements of operations. Unpaid annual maintenance fees become short-term debt that bears interest of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_0lDWBPW2vkuWvH-HiGeZyg" decimals="3" format="ixt:num-dot-decimal" name="limn:UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate" scale="-2" id="Narr_l02Q0PjkU0SDKApt9u9TbQ">1.5</ix:nonFraction>% per month on a compounded basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the completion of the Phase I and Phase II clinical trials for the CAR-T product, the Company was obligated to advance the funding for the Phase II and Phase III clinical trials, respectively, estimated at approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_6_30_2018_srt_ProductOrServiceAxis_limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember_srt_StatementScenarioAxis_limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_5kAI3vX6BkKP69_x9ufqDQ" decimals="0" format="ixt:num-dot-decimal" name="limn:LicenseMilestoneCommitmentFundPayableForEachPhase" scale="0" id="Narr_0ra1CQ_bmE-pW-6tcR0dMg">20,000,000</ix:nonFraction> for each phase. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the funding for the CAR-T development, the Company was obligated to make <ix:nonFraction unitRef="Unit_Standard_Milestone_17WZ1k4BqkSsiQd-8K0NPw" contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_0lDWBPW2vkuWvH-HiGeZyg" decimals="INF" format="ixt-sec:numwordsen" name="limn:NumberOfMilestonePaymentsForFirstProductDevelopment" scale="0" id="Narr_PAJho9u6UEO6X5GXK9a5iQ">four</ix:nonFraction> developmental and regulatory milestone payments for the first CAR-T product that was developed aggregating up to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_c5l6cvRI4EqXlctlS8Hl9Q" decimals="0" format="ixt:num-dot-decimal" name="limn:LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment" scale="0" id="Narr_GSOQIvaUHkG55jlAogVBAQ">15,000,000</ix:nonFraction>. After the first <ix:nonFraction unitRef="Unit_Standard_Milestone_17WZ1k4BqkSsiQd-8K0NPw" contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_0lDWBPW2vkuWvH-HiGeZyg" decimals="INF" format="ixt-sec:numwordsen" name="limn:NumberOfMilestonePaymentsForFirstProductDevelopment" scale="0" id="Narr_g0yy3dRiDUyYYQk4LzcArw">four</ix:nonFraction> developmental and regulatory milestone payments were made, the Company was obligated to pay <ix:nonFraction unitRef="Unit_Standard_Milestone_17WZ1k4BqkSsiQd-8K0NPw" contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_0lDWBPW2vkuWvH-HiGeZyg" decimals="INF" format="ixt-sec:numwordsen" name="limn:NumberOfMilestonePaymentsForEachAdditionalProductDevelopment" scale="0" id="Narr_ODikxMNJXEGawfOKvA3ONg">four</ix:nonFraction> developmental and regulatory milestones aggregating up to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_c5l6cvRI4EqXlctlS8Hl9Q" decimals="0" format="ixt:num-dot-decimal" name="limn:LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment" scale="0" id="Narr_9Hih62JSFkuDSGfcMDpJzw">7,500,000</ix:nonFraction> for each additional CAR-T product that was developed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In further consideration of the license, the Company also agreed to pay a low double digit royalty rate (<ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_tvMLwMEPF0OgoT8qvqNtOw" decimals="2" format="ixt:num-dot-decimal" name="limn:RoyaltyFeesPercentage" scale="-2" id="Narr_n6VKIkc96km4PJupvay49A">10</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_e8pHl9vKL0iD2UdUCsGsVg" decimals="2" format="ixt:num-dot-decimal" name="limn:RoyaltyFeesPercentage" scale="-2" id="Narr_jaDrjFM2S0KltZJZw7uxNw">15</ix:nonFraction>%) based on annual net sales of CAR-T products or CAR-T Diagnostics on a country-by-country basis for the period from the first commercial sale of the CAR-T product or CAR-T Diagnostic until the CAR-T product or CAR-T Diagnostic&#8217;s patent expires in an individual country. Once the CAR-T product or CAR-T Diagnostic&#8217;s patent expires in an individual country, the Company agreed to pay a mid-single digit royalty rate (<ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_F5M5DAEMCUGaVGfvYeyHNA" decimals="2" format="ixt:num-dot-decimal" name="limn:RoyaltyFeesPercentage" scale="-2" id="Narr_kC_plO-AKUCHJ1O2WmCjAA">5</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_Ze3T2NMaj0Ge4Cdvcxk6nQ" decimals="2" format="ixt:num-dot-decimal" name="limn:RoyaltyFeesPercentage" scale="-2" id="Narr_G2wrv2AxjE6KLGf_7OtWcw">9</ix:nonFraction>%) based on annual net sales of CAR-T products and CAR-T Diagnostics on a country- by-country basis. Royalties were payable on a country-by-country basis for a period of <ix:nonNumeric contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_8RdOebh7f0C05gFluwIFFA" format="ixt-sec:durwordsen" name="limn:RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts" id="Narr_IsLZ6M-EsUu3NVAFAxcX3Q">ten years</ix:nonNumeric> from the first commercial sale of the CAR-T product or CAR-T Diagnostic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 11, 2024, the Company received notice from TDT, exercising its right to terminate the license and development agreement. Please refer to &#8220;Termination and Settlement of CAR-T Products and Vaccine Products Licenses from TDT&#8221; below for further details related the termination and settlement of the CAR-T Products and Vaccine Products Licenses from TDT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Vaccine Products License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 10, 2020, the Company was assigned a license and development agreement with TDT (the &#8220;Vaccine License&#8221;), whereby the Company received an exclusive license to develop and commercialize vaccine products (the &#8220;Vaccine Products&#8221;) and a non-exclusive license to develop and commercialize companion diagnostics used to monitor treatment with a Vaccine Product (the &#8220;Vaccine Diagnostics&#8221;). Under the Vaccine License, the Company was responsible for all of the development costs for the Vaccine Products after the upfront payment of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_o6DHM9UbBkSNjCOhIS_9VA" decimals="0" format="ixt:num-dot-decimal" name="limn:UpfrontPaymentOfLicenseAgreementFees" scale="0" id="Narr_rjGE554XhEeK-I9uLMUpeQ">4,000,000</ix:nonFraction>, which was paid by Viral Gene, Inc (&#8220;Viral Gene&#8221;), of which Chris Kim is also the CEO, to TDT. The Company was also obligated to pay an approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_o6DHM9UbBkSNjCOhIS_9VA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostMaintenance" scale="0" id="Narr_nRqW3xsZKEiNPvZbcZ8EIw">400,000</ix:nonFraction> annual maintenance fee for the license which is included in research and development expenses in the Company&#8217;s consolidated statements of operations for the year ended December&#160;31, 2024. There was <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_jBCIg7TF3U2nA2e4ZL4LPw" decimals="0" format="ixt-sec:numwordsen" name="limn:LicenseAgreementMaintenanceFees" scale="0" id="Narr_vZZH3HZ0uUC6u1SrJKUtjA">no</ix:nonFraction> maintenance fee for the year ended December 31, 2025. Unpaid annual maintenance fees will become short-term debt that bears interest of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_o6DHM9UbBkSNjCOhIS_9VA" decimals="3" format="ixt:num-dot-decimal" name="limn:UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate" scale="-2" id="Narr_cidW_z7IRk65UZ7zt9qDog">1.5</ix:nonFraction>% per month on a compounded basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company amortizes the amounts due to research and development partner in the Company&#8217;s consolidated balance sheets to research and development expenses in the consolidated statements of operations as costs are incurred by TDT, based on annual budgets approved jointly by Liminatus and TDT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In addition to the funding for the Vaccine Products development, the Company was obligated to make <ix:nonFraction unitRef="Unit_Standard_Milestone_17WZ1k4BqkSsiQd-8K0NPw" contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_o6DHM9UbBkSNjCOhIS_9VA" decimals="INF" format="ixt-sec:numwordsen" name="limn:NumberOfMilestonePaymentsForFirstProductDevelopment" scale="0" id="Narr_gwMtsNwZeUiiyg9Dog_jbw">four</ix:nonFraction> developmental and regulatory milestone payments for the first Vaccine Product that was developed aggregating up to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_h1stl_iThEi0wHNuwBrmew" decimals="0" format="ixt:num-dot-decimal" name="limn:LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment" scale="0" id="Narr_b_kWdP0YoE2cA56zSs116Q">12,000,000</ix:nonFraction>. After the first <ix:nonFraction unitRef="Unit_Standard_Milestone_17WZ1k4BqkSsiQd-8K0NPw" contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_o6DHM9UbBkSNjCOhIS_9VA" decimals="INF" format="ixt-sec:numwordsen" name="limn:NumberOfMilestonePaymentsForFirstProductDevelopment" scale="0" id="Narr_G9wqE205skmg1M0Kqm-Thg">four</ix:nonFraction> developmental and regulatory milestone payments are made, the Company was obligated to pay <ix:nonFraction unitRef="Unit_Standard_Milestone_17WZ1k4BqkSsiQd-8K0NPw" contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_o6DHM9UbBkSNjCOhIS_9VA" decimals="INF" format="ixt-sec:numwordsen" name="limn:NumberOfMilestonePaymentsForEachAdditionalProductDevelopment" scale="0" id="Narr_9PgpxF19mE-GjihszoaPDg">four</ix:nonFraction> developmental and </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-33</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_3373aebb_ec2c_40cf_9781_b42b0f1108dd"></a><ix:continuation id="Tb_JIP5QkTmKkaDI_mJ2huWoA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">regulatory milestones aggregating up to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_h1stl_iThEi0wHNuwBrmew" decimals="0" format="ixt:num-dot-decimal" name="limn:LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment" scale="0" id="Narr_7e_OZJj6KEaiYKqSiMQ15A">6,000,000</ix:nonFraction> for each additional Vaccine Product that is developed. As of December 31, 2025 and 2024, all the amounts funded have been utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In further consideration of the license, the Company also agreed pay a low double digit royalty rate (<ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_AysCyyacDk6EgeXu96kqgw" decimals="2" format="ixt:num-dot-decimal" name="limn:RoyaltyFeesPercentage" scale="-2" id="Narr_nhEjcelIQUyhD-YRU-dTYQ">10</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_xdnRdKDui0uO30li7vEb9g" decimals="2" format="ixt:num-dot-decimal" name="limn:RoyaltyFeesPercentage" scale="-2" id="Narr_Vjs2Vnr7bkWdx96-KksM4Q">15</ix:nonFraction>%) based on annual net sales of Vaccine Products or Vaccine Diagnostics on a country-by-country basis for the period from the first commercial sale of the Vaccine Product or Vaccine Diagnostic until the Vaccine Product or Vaccine Diagnostic&#8217;s patent expires in an individual country. Once the Vaccine Product or Vaccine Diagnostic&#8217;s patent expires in an individual country, the Company agreed to pay a mid-single digit royalty rate (<ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_BXcmOS2BJEKYVp-Znixfsg" decimals="2" format="ixt:num-dot-decimal" name="limn:RoyaltyFeesPercentage" scale="-2" id="Narr_N_wSqQXI2kmMc8CldMnQPg">5</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_kzj2YTUmsUqdNgLEb6ecrQ" decimals="2" format="ixt:num-dot-decimal" name="limn:RoyaltyFeesPercentage" scale="-2" id="Narr_wsZ4by0Ajkyxs7cV6Eg-Mg">9</ix:nonFraction>%) based on annual net sales of Vaccine Products and Vaccine Diagnostics on a country- by-country basis. Royalties were payable on a country-by-country basis for a period of <ix:nonNumeric contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_9RVHQy9tTkeZj8t4JvLMeA" format="ixt-sec:durwordsen" name="limn:RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts" id="Narr_0mc28FewNECQ8mn13NfQtg">ten years</ix:nonNumeric> from the first commercial sale of the Vaccine Product or Vaccine Diagnostic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 11, 2024, the Company received notice from TDT, exercising its right to terminate the license and development agreement. Please refer to &#8220;Termination of CAR-T Products and Vaccine Products Licenses from TDT&#8221; below for further details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Termination and Settlement of CAR-T Products and Vaccine Products Licenses from TDT</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 11, 2024, the Company received notice from TDT, exercising its right to terminate the license and development agreement, dated June 10, 2018, between TDT and Liminatus. As of August 2024, the CAR-T License and Vaccine License have been terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 16, 2025, the Company and TDT entered and executed a settlement agreement. Pursuant to the terms of the settlement agreement, the Company was released and discharged from all agreements, promises, suites, disputes, claims and demands, debts and amounts due to TDT. As of December 31, 2025, the Company reversed the amounts due to TDT and recognized a gain of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_TypeOfArrangementAxis_limn_CarTLicenseAndVaccineLicenseWithTdtMember_cvbZ4e18Jk2WLlTRj8K7eQ" decimals="0" format="ixt:num-dot-decimal" name="limn:ForgivenessOfUnrelatedVendorPayable" scale="0" id="Narr_p5TS92mFqUy7S6GGNfJQGA">2,142,297</ix:nonFraction>, which is included in Forgiveness of unrelated vendor payables on the Company&#8217;s consolidated statement of operations in accordance with ASC 450-30, Contingencies - Gain Contingencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and, 2024, the Company owed $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_limn_CarTLicenseAndVaccineLicenseWithTdtMember_mWk8tah9gUuCRPqsFLhQWg" decimals="0" format="ixt:num-dot-decimal" name="limn:LicenseAgreementsTerminationAmountDue" scale="0" id="Narr_9Pwhx2voskiQ2Gy1rHO0VA">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_limn_CarTLicenseAndVaccineLicenseWithTdtMember_aVFA-tb0MUC-EmBUAPe-xw" decimals="0" format="ixt:num-dot-decimal" name="limn:LicenseAgreementsTerminationAmountDue" scale="0" id="Narr_vkInUWhy4UacNFyHosW-tw">2,142,297</ix:nonFraction>, respectively, to TDT for research and development for the aggregate CAR-T Products and Vaccine Licenses, which is included in the due to research and development partner and accrued maintenance fees on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CD47 License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October 2022, the Company was assigned a license and development agreement, as amended, with InnoBation Bio Co., Ltd. (the &#8220;CD47 License&#8221;), whereby, effective March 31, 2023, the Company received an exclusive license to develop and commercialize products for the CD47 immune checkpoint inhibitor to treat solid cancers, and companion diagnostics used to monitor treatment with CD47 products (collectively, &#8220;CD47 Products&#8221;), from Curis Biotech Holdings LLC, the parent company of Valetudo, a related party of the Company, in exchange for <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_10_31_2022_srt_CounterpartyNameAxis_limn_CurisBiotechHoldingsLlcMember_us-gaap_CapitalUnitsByClassAxis_us-gaap_CapitalUnitClassAMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_MfcULb3sYEWNTNOdJMM4Mg" decimals="INF" format="ixt:num-dot-decimal" name="limn:NumberOfUnitsExchangeForLicenseRights" scale="0" id="Narr_lUuBoXt6AESI75MUMqwKxw">78,555,554</ix:nonFraction> of Liminatus&#8217; Class A member units. The license was recorded at Valetudo&#8217;s cost basis of zero, and the Company recorded an approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_10_31_2022_srt_CounterpartyNameAxis_limn_CurisBiotechHoldingsLlcMember_us-gaap_CapitalUnitsByClassAxis_us-gaap_CapitalUnitClassAMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_MfcULb3sYEWNTNOdJMM4Mg" decimals="0" format="ixt:num-dot-decimal" name="limn:LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital" scale="0" id="Narr_UmoqC2y1lEuFCDCfkgc7mQ">800,000</ix:nonFraction> Class A membership interest with an offset to additional paid-in capital on the balance sheets. The Company is obligated to pay all development costs for CD47 Products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company has not paid and does not owe any license fees, management fees, developmental or regulatory milestone payments or royalty payments under the CD47 License through December 2025.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_0pV7sQQuqkWNcKDRN_1_dw" continuedAt="Tb_0pV7sQQuqkWNcKDRN_1_dw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;4. Related Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Related Party Debt</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Feelux Bonds</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 15, 2018, the Company issued $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_WLsbY18woU2Mgt3ogJQjXQ">10,000,000</ix:nonFraction> of bonds to Feelux Co., Ltd., the parent company of Car-Tcellkor, Inc. (&#8220;Car-Tcellkor&#8221;) (see below), the only holder of Liminatus&#8217; Class A member units (the &#8220;Feelux Bonds&#8221;). The bonds bear interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_wBakAONCNk21bS-Ucw2aSA">1</ix:nonFraction>% per annum, compounded annually, and were due on October 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In connection with the issuance of the Feelux Bonds, Liminatus issued <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_oqCuwnE-2EmgBdACggRo-g">6,666,666</ix:nonFraction> equity-classified warrants to purchase member units at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Ylb1e9aFRkKkZsGbgpulRg">1.50</ix:nonFraction> per unit, which expired on June 30, 2023. The fair value of the warrants to purchase member units of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" id="Narr_l9ImBzTPyEO617Wk3ax6PA">6,400,000</ix:nonFraction> was estimated using the option pricing framework on the issuance date. The Company&#8217;s assumptions included </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-34</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_0pV7sQQuqkWNcKDRN_1_dw_cont1" continuedAt="Tb_0pV7sQQuqkWNcKDRN_1_dw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(a) its expected stock volatility of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NcxMLUOjV0-W98TcYBomsA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Narr_o6qrf0BUQ02Kr59CrJA9Ew">82.0</ix:nonFraction>% based on the historical volatility of a publicly traded set of peer companies, (b) the contractual term of <ix:nonNumeric contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_Yvwy-gBB2kijwyQo6SzL_w">five years</ix:nonNumeric>, (c) the risk-free interest rate of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GUMRHws20E-hQftGj0JvTA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Narr_Jj00OVh_vUyD9AneTUDUGw">2.9</ix:nonFraction>% based on the U.S. Treasury yield curve in effect at the time of grant of the award for a <ix:nonNumeric contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_vWRxRoFAu0G4-zdzrqDc5w">five-year</ix:nonNumeric> contractual term and (d) <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gZkGDq_I9UKTee9n9IgYZw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_iKachQW8C0i4EFdQjaOG9w">no</ix:nonFraction> expected dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_9_15_2018_To_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Ue0f9e9AF0CCuPCxkaHeGw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="0" id="Narr_WDMSgh97C02XHrOPU740Xw">10,000,000</ix:nonFraction> of proceeds from the Feelux Bonds were allocated to the bonds and warrants using the relative fair value method resulting in a debt discount for the relative fair value of the warrants of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" id="Narr_M028fU-8NkKIQdSwWEAuVA">4,499,142</ix:nonFraction> that was amortized to interest expense over the term of the Feelux Bonds using the effective interest method using an effective interest rate of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="Narr_ppvdeMXML0mz-c02G3uFjA">21.0</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, upon consummation of the Business Combination, the outstanding principal and accrued interest on the Feelux Bonds, totaling $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_AHn-E6mSh0WMg57djpR6sA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_5vtvks5b_0KPRuvRyPWnJQ">10,681,146</ix:nonFraction>, and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_nnP7Qz9VeUGy0wjX4yxcQA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_VLp5bmYp1kWwVGz2BvEJrA">9,999,999</ix:nonFraction> member units of Liminatus were converted into <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_nnP7Qz9VeUGy0wjX4yxcQA" decimals="INF" format="ixt:num-dot-decimal" name="limn:StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits" scale="0" id="Narr_wH7qsQ2SEkyZJZSBye5OYw">4,000,000</ix:nonFraction> shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the Feelux Bonds have a carrying amount of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_PowKVbIlSEav6_it2o0cuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="0" id="Narr_Zs6maygRYU-dgQxpW54skg">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_5jXRkTedV06dtacIjxLWQQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="0" id="Narr_cgauoo4sB0uCIm_m0bFR7A">10,000,000</ix:nonFraction>, respectively, and are included in short-term debt, related parties in the consolidated balance sheets. As of December 31, 2025 and 2024, the related accrued interest of the Feelux Bonds was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UCZY1ZeR3UG6JVOXPTBI8g" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr_DAdSjYm-u02G_-962Llrog">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6wD9AAP08UeDG0Qs6p5Q2A" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr_Bzhchhm0kEeaW5Fgja8XIg">646,124</ix:nonFraction>, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_m79xoi74tEWD31ya03Rcmw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_eswaqcknckCEnJAFzf8c_w">35,023</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_uBbaU3A6rUOpfYYDB4euDw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_ytRQzO7M50a31qceH0An8g">106,087</ix:nonFraction>, respectively, of interest expense in the consolidated statements of operations for the Feelux Bonds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Car-Tcellkor Loan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 18, 2019, the Company borrowed $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_5_18_2019_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_zVHTzo-UxEy__UArL1VThQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_ETrUmeqztEOl4yL_f7dbRA">800,000</ix:nonFraction> from its parent at the time of the loan, Car- Tcellkor (the &#8220;Car-Tcellkor Loan&#8221;). The Car-Tcellkor Loan does not bear interest and was due on March 18, 2020. In November 2022, the maturity date was extended to May 18, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_v60EouUdLUqn8toxvOltkQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentDecreaseForgiveness" scale="0" id="Narr_ia7bx2mhykK-WgUGIgmXSQ">800,000</ix:nonFraction> was forgiven.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the Car-Tcellkor Loan had a carrying amount of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wmmbaObSukiDB_4zDCmrgA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_ZF7ZFD_34UmRN6m4Rsy19g">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_TpCVK5HsVEK8Wyv55C0lig" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_GFHJxexMNUqDZLkQanqUBQ">800,000</ix:nonFraction>, respectively, and is recorded in short-term debt, related parties in the consolidated balance sheets (see Note 5). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Valetudo Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 1, 2022, the Company borrowed $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_1_2022_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_35Sjj6Gfl0yNGiX5Qt5Qmw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_RRutzk5EKUCfGCEmFyiqJA">700,000</ix:nonFraction> from Valetudo Therapeutics LLC (&#8220;Valetudo&#8221;), a related party of the Company due to having common executives, in conjunction with the repayment of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_1_2022_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_35Sjj6Gfl0yNGiX5Qt5Qmw" decimals="0" format="ixt:num-dot-decimal" name="limn:RepaymentOfMembershipInterest" scale="0" id="Narr_SLTcA-VaAEOMD6aaLflWqQ">700,000</ix:nonFraction> of membership interest from a member (the &#8220;Valetudo Loan&#8221;). The Valetudo Loan bears no interest and was due on June 1, 2023. On May 1, 2025, the Company paid the outstanding principal balance of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_5_1_2025_To_5_1_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_qNI4ieKD3kSp3GUUyiiVsA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="0" id="Narr_GLCTy5M_vkeytvC63OVvdw">700,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June 2023, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_u39Cd4S7GEqUxTPP5qv_Qg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_QmN3nfblAEuEux_9P5l-Eg">300,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoanTwoMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_uvAg88eC10OdVCXZ0b8E3A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_YsA5ZuSUvU-gmxliQ8to0Q">200,000</ix:nonFraction> (the &#8220;Valetudo June 2023 Loans&#8221;). The Valetudo June 2023 Loans bear no interest and were due in December 2023. On May 1, 2025, the Company paid $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_5_1_2025_To_5_1_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Tvb57Yoz8kWjg8oYPKuxig" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="0" id="Narr_tRdPaG0aSkqQu3ZciJ6Bmg">300,000</ix:nonFraction> of the outstanding principal balance on the Valetudo June 2023 Loans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July 2023, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_7_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RoR1eW_fpUmHYmBoFmDg1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_iK0OYxImWEKbMHKaGrGVjA">250,000</ix:nonFraction> (the &#8220;Valetudo July 2023 Loan&#8221;). The Valetudo July 2023 Loan bears interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_7_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RoR1eW_fpUmHYmBoFmDg1w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_FXLLcX2heE-SYaq1m2-P6w">6</ix:nonFraction>% per annum and was due on January 9, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2023, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KWt-xK4eN0-5OFBxkx3LGw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_grU7cNUp4EisJITbJjBmLg">250,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoanTwoMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_jZaCTxa_V0CXdNygheYPjA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_0RZq7MChC0idbE8cZi9OFw">150,000</ix:nonFraction> (the &#8220;Valetudo August 2023 Loans&#8221;). The Valetudo August 2023 Loans each bear interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_K45l7DmgQE-CQ-xyraew7w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_CyNKRDxMXkKhXDJ0I0UccA">6</ix:nonFraction>% interest per annum and were due on January 31, 2024 and February 2, 2024, respectively. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_rDx80SlYbU-El3v0ZF9uAw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" id="Narr_VYnJ0RV9cEuuPXdeRbjukA">400,000</ix:nonFraction>, along with accrued interest, of the Valetudo August 2023 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2023, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_11_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1Od3S-eoaUCXHX3nnz2htg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_QU-N2jC4lkmJRFQfgtkUWw">200,000</ix:nonFraction> (the &#8220;Valetudo November 2023 Loan&#8221;). The Valetudo November 2023 Loan bears interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_11_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1Od3S-eoaUCXHX3nnz2htg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_MBZ_TZBwoUSyJsQStvPSFg">6</ix:nonFraction>% per annum and was due on January 26, 2024. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6Oq29UcKvkeSSN5rpNIW6w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" id="Narr_YYGJKR2DDECb_eB6wl76SQ">200,000</ix:nonFraction>, along with accrued interest, on the Valetudo November 2023 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In January 2024, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_1_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6andgdbpxkqRlyLXl4XDHg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_LaOgWeaxdE6kAZ-3lDAaUQ">600,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_1_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoanTwoMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_roRuh60jM0eb54g1Pq5hLQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_qaluR78KQEGuh3w__xgKZw">150,000</ix:nonFraction> (the &#8220;Valetudo January 2024 Loans&#8221;). The Valetudo January 2024 Loans each bear interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_1_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1AItK1QO2kitXmKJcOl1Fg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_f5WeDKerqkOAr8qsGajdeA">6</ix:nonFraction>% per annum and were due on February 28, 2024. On April 30, 2025, upon consummation of </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-35</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_0pV7sQQuqkWNcKDRN_1_dw_cont2" continuedAt="Tb_0pV7sQQuqkWNcKDRN_1_dw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Business Combination, outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ZaQ3e71ewUK0aSmJ56rcsw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" id="Narr_LuyHInnKpUSefjmNdD6Bsw">750,000</ix:nonFraction>, along with accrued interest, of the Valetudo August 2023 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the loans from Valetudo of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_148jP040dUadKsjmVdStxQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_hu_k1Qa_xEO0rBUPOgQ2uw">450,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EegrTR0jGkqYkwr1xCASoA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_NBeTzxDJYEqrwz8jac0g1A">2,800,000</ix:nonFraction>, respectively, are recorded in short-term debt, related parties in the consolidated balance sheets (see Note 5). As of December 31, 2025 and 2024, the related accrued interest of the loans from Valetudo was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ValetudoTherapeuticsLlcMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_u2V6Q8F86kqWl2rCR_ZLxg" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr_bYKm6zsnDUm8KmPfY559wQ">113,308</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_ValetudoTherapeuticsLlcMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_4VRhmQHacUKineZTnXswaw" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr_tBnVGdyhBEupjmMyKFLPtw">115,328</ix:nonFraction>, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Valetudo loans was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_aIiVDq13L0qm8FpFM6Fe7A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_y_ynBTPkJUWqFpQ8YhAKSA">42,208</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_BrctH0R4SUmey2o6z162mg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_6-h7zWsWkEe9a5j0PIMsRw">96,484</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Ewon Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 12, 2022, the Company borrowed $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_12_2022_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RpHDxwA5eU6MNdXkdEU0lg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_IymsztLJOUyMIxoIV0-WRg">5,000,000</ix:nonFraction> from Ewon Comfortech Co., Ltd. (&#8220;Ewon&#8221;), a member and related party of the Company (the &#8220;Ewon Loan&#8221;). The Ewon Loan bears interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_12_12_2022_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RpHDxwA5eU6MNdXkdEU0lg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_gGApUDe5HEOERlq2iKBuhw">2</ix:nonFraction>% per annum and was due on December 12, 2023, which may be extended one year upon mutual agreement of the parties, or upon failure to close the Business Combination. In February 2023, the Company repaid $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_2_1_2023_To_2_28_2023_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_fyxYB55LcESYXg1VrFa0SQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="0" id="Narr_b-5WSDI6UkSHst_4EpV-ew">1,000,000</ix:nonFraction> of the short-term loan. In March 2023, the Company repaid an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1IIHRUTkZkq60Pm0ATLdfg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="0" id="Narr_BLgxXbrru0ii7J3MPc0udg">2,000,000</ix:nonFraction> of the loan. On April 30, 2025, upon consummation of the Business Combination, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YHOGjDLmVUK3iyhkoffTvQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_nfVYRM6mF0qYuVw-fWbz1Q">2,000,000</ix:nonFraction>, along with accrued interest, of the Ewon Loan was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 10, 2023, the Company entered into a loan agreement to borrow $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_9_10_2023_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DWdmZjGmCEiRashhGcBpXQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_GVWRQDI7n0O9pI653Fjc6A">200,000</ix:nonFraction> from Ewon (&#8220;Ewon September 2023 Loan&#8221;). The Ewon September 2023 Loan bears interest of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_9_10_2023_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DWdmZjGmCEiRashhGcBpXQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_gw1I8Zzr8UqpSp1aTx9r1w">2</ix:nonFraction>% per annum and was due on September 9, 2024, which may be extended one year upon mutual agreement of the parties, or upon failure to close the Business Combination. On April 30, 2025, upon consummation of the Business Combination, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-A5AQrt620qPuuH6l9tvXw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_fheIRZ7Jj0ONwEK68-lFxg">200,000</ix:nonFraction>, along with accrued interest, of the Ewon September 2023 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 19, 2023, the Company and Ewon entered into an additional loan agreement and the Company borrowed $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_19_2023_us-gaap_DebtInstrumentAxis_limn_EwonDecember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_PobELNhVp0CNZjEIGlpjlg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_G7SvjJhQ_Eqtby-cBtQ-0g">1,000,000</ix:nonFraction> (the &#8220;Ewon December 2023 Loan&#8221;). The Ewon December 2023 Loan bears no interest. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_EwonDecember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FAzAi_otIkiuLKLUZIGGZQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_TDS2ydDY6US96Enxy0cBkQ">1,000,000</ix:nonFraction>, along with accrued interest, of the Ewon December 2023 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the balance of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_r25euOvngkmrw8iQThV-hQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_oztZqOw2A0qLYCE_SW-jEg">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KnFjty5H1UqDezjsL8ecyA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_znX8KGKRa0axUpI_uW-DSQ">3,200,000</ix:nonFraction> of the Ewon loans is recorded in short-term debt, related parties in the consolidated balance sheets (see Note 5). As of December 31, 2025 and 2024, the related accrued interest of the loans from Ewon was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_EwonComfortechCoLtdMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0bsPPj_X9U-t6aFyc57i1w" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr_c2C2TKvqD0-lb77qvOaWbQ">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_EwonComfortechCoLtdMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_LGib2VMD3kWL01MA1301Pg" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr_npnPYOh3x06TfpbKQHrR0A">102,089</ix:nonFraction>, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Ewon loans was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gXDAk9MAnEC31blcdud-TQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_xYDCUvN3gE6xg40qroyDBA">14,667</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ykDgVNc-WUGp-HHNFZJzIw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_t7hAE3wnN0a44crbWHPqFQ">44,733</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Prophase Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 26, 2024, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_2_26_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_dMLi4mVbI0mnfUUmfRTl1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_Iks97r1XI0Gy8lHzLvDL7Q">200,000</ix:nonFraction> from Prophase Sciences LLC (&#8220;Prophase&#8221;) (the &#8220;Prophase February 2024 Loan&#8221;). The loan bears <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_2_26_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_dMLi4mVbI0mnfUUmfRTl1w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_RmRemCuNr0ChXUR1qi0y7w">6</ix:nonFraction>% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VgfZxKguUE6IvyhFTK0bgw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_ibePIy8F2kKqPrZmei1rYA">168,500</ix:nonFraction>, along with accrued interest, of the Prophase February 2024 Loan was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 6, 2024, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_6_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_U0Xo3fqs00OpXo_SeuDtWg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_md8hUaUvukCnPS302MGDzw">250,000</ix:nonFraction> from Prophase (the &#8220;Prophase March 2024 Loan&#8221;). The loan bears <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_3_6_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_U0Xo3fqs00OpXo_SeuDtWg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_Hpuf4Ra8rUC4RgocC_MKEQ">6</ix:nonFraction>% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 1, 2024, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KWzMWCDwzEShWHgZreE_vw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_vSD-HFXWIEqPwMM5vTyTOg">250,000</ix:nonFraction> from Prophase (the &#8220;Prophase April 2024 Loan&#8221;). The loan bears <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_4_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KWzMWCDwzEShWHgZreE_vw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_VxfAXGQKwUu47G1U4QgvdQ">6</ix:nonFraction>% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_WqQ7kEZqMUGKJ2Civ5wmHQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_2IKG6ZiSSEW2VL0LY3vDtQ">250,000</ix:nonFraction>, along with accrued interest, on the Prophase April 2024 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In May 2024, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_5_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPL1Zq0iyE2-9FTal0qJ5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_4CdWUUbwKUaqEiluhqu1CA">790,000</ix:nonFraction> from Prophase (the &#8220;Prophase May 2024 Loans&#8221;). The loans bear <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_5_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPL1Zq0iyE2-9FTal0qJ5A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_umCyPSl7LUCbWgrAfZKzbQ">6</ix:nonFraction>% interest per annum. Of the aggregate $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_5_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPL1Zq0iyE2-9FTal0qJ5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_ZZMIvuYyO0mQ-MKbpMYiaQ">790,000</ix:nonFraction> Prophase May 2024 Loans, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_6_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VxMZqFXR_UaO5azmVes0dA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_aERR8D2bnkCX_qyNDse6dg">270,000</ix:nonFraction> was due on June 1, 2024 and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_7_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_mxhubmgnJ06DzAurKf0Uug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_MZzjV-mqTEC4NDtRsAXk9Q">520,000</ix:nonFraction> was due on July 1, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-36</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_0pV7sQQuqkWNcKDRN_1_dw_cont3" continuedAt="Tb_0pV7sQQuqkWNcKDRN_1_dw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">consummation of the Business Combination, outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_hxqxTUYPkUOVXBEWPh59bw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_7AJ_EnNqNEe-D924RhgG9g">550,000</ix:nonFraction>, along with accrued interest of the Prophase May 2024 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July 2024, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_7_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0HW6FGsO8Ei7AXcLtjboyA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_Ug_I8tlnd0WkmJ541QFXWA">83,000</ix:nonFraction> from Prophase (the &#8220;Prophase July 2024 Loans&#8221;). The loans bear <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_7_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0HW6FGsO8Ei7AXcLtjboyA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_3FBQW2nFekinb3yiZMoxsQ">6</ix:nonFraction>% interest per annum. Of the aggregate $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_7_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0HW6FGsO8Ei7AXcLtjboyA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_m_zto5CkY0aTbNm6-Ix7HA">83,000</ix:nonFraction> Prophase July 2024 Loans, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_9_14_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-IXbBujRXkiVzw9mXk784w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_7uFARoiYAkKitzkx8DC31w">30,000</ix:nonFraction> was due on September 14, 2024, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_9_24_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_4Vld9uwuRkuuQHHIzYvKZg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_Wyk52oPxJUKfbzOvLkCYPw">3,000</ix:nonFraction> was due on September 24, 2024 and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_9_29_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_hOP6gIf6X0uZ7Ge6Uhb8yA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_xgCfhzksZUOWF_zTjbWO7g">50,000</ix:nonFraction> was due on September 29, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2024, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_8_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wdQAw9pClkqJCJydARCG4g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_V9uobdkbMEWE6zaogw8Yiw">50,000</ix:nonFraction> from Prophase (the &#8220;Prophase August 2024 Loans&#8221;). The loans bear <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_8_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wdQAw9pClkqJCJydARCG4g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_VhdJh8-VmUKQ9Xi9qkulOg">6</ix:nonFraction>% interest per annum. Of the aggregate $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_8_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wdQAw9pClkqJCJydARCG4g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_ahrp325Ld0exvS-PY4fbdA">50,000</ix:nonFraction> Prophase August 2024 Loans, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_10_12_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NGQDh1rA3UGEJwXQpQqNWA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_Kc2lbIVSX0mjEiPEf4Z_OQ">30,000</ix:nonFraction> was due on October 12, 2024 and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_10_13_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DqH0O8M-DkKolyZ-CdcShA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_aY_wypq3bEC__N_xUgg2LQ">20,000</ix:nonFraction> was due on October 13, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February of 2025, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_2_28_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Rs3R6YntuECvjfLJCKGrWA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_HlBbFEiS0ku1DryndQG36g">206,000</ix:nonFraction> from Prophase (the &#8220;Prophase February 2025 Loan&#8221;). The Prophase February 2025 Loan bears interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_2_28_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Rs3R6YntuECvjfLJCKGrWA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_bvCbBozw5Ei97lGiX6IKxw">6</ix:nonFraction>% per annum and was due on April 11, 2025, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gHk208o8a02buGlMK7GoGA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_kz9p4cps7k2sXgtqREN3sg">125,000</ix:nonFraction>, along with accrued interest, on the Prophase February 2025 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March of 2025, the Company borrowed $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xe3qXzjS0EC39aN_LENA8g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_5S1KiBOvzkm563YT-ISqXQ">207,000</ix:nonFraction> from Prophase (the &#8220;Prophase March 2025 Loan&#8221;). The Prophase March 2025 Loan bears interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xe3qXzjS0EC39aN_LENA8g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_N0At4SIRik6uJH387762ag">6</ix:nonFraction>% per annum and was due on June 6, 2025, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_XNzgVBB9EUSW9XJBeTQYXg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_C3nBBMQMt0uQGoZuIuM4Ew">200,000</ix:nonFraction>, along with accrued interest, on the Prophase March 2025 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April of 2025, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xvNc1S3hqkGpqvsF2_IC5g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_xBkSSGS3q0WTncyMqkE_zQ">3,627,000</ix:nonFraction> from Prophase (the &#8220;Prophase April 2025 Loans&#8221;). The loans bear <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xvNc1S3hqkGpqvsF2_IC5g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_wVILBk7EDE-dcFM-0HZmOQ">6</ix:nonFraction>% interest per annum. Of the aggregate $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xvNc1S3hqkGpqvsF2_IC5g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_PEWdXwzS-ESDUvor3Fb2rA">3,627,000</ix:nonFraction> Prophase April 2025 Loans, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_5_2_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GRnA5Kx7-kGf8N58SRLWrw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_bjIMrcxyu06rdOY-a_W-bg">200,000</ix:nonFraction> was due on May 2, 2025, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_5_13_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_99oewdhpVEC5wJhe7rhkyQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_b1hGCIYEdUSMTJe31_8Ahw">1,920,120</ix:nonFraction> was due on May 13, 2025 and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_5_14_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_176IvMRvuUeNEtEQXDudUQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr__smGJqyjWk6QU2Kl-HvjDg">1,506,880</ix:nonFraction> was due on May 14, 2025. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_MxNDVYopJUCTnAtVRr2BCQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_iJ3-55uebU6hOeNVD6mXgA">3,627,000</ix:nonFraction>, along with accrued interest, on the Prophase April 2025 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the balance of the Prophase loans is $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Hjob6bfNJ0yH9IccwyqnFw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_Beg4_CjzW0SXbtnEiyn5uw">742,500</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Rea6tsWHW0yjkY8Ibu9urQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_O831g0Pr0UivgMi4Wnd26w">1,623,000</ix:nonFraction>, respectively. As of December 31, 2025 and 2024, the related accrued interest of the loans from Prophase was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Hjob6bfNJ0yH9IccwyqnFw" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr_yXiceY79O0yQL8NkiWZpmQ">79,283</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Rea6tsWHW0yjkY8Ibu9urQ" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr_uJpV9WksuUSbzEbJpQZDTQ">66,728</ix:nonFraction>, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Prophase loans was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y7jrRcuOPU6wYyUiEQtHhg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_EltwxiUvbECkWZkLy4cpMQ">77,073</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_2rdRQZDLhkWmVg-aznAVoQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_soJmo8TmbkCGwA6G0u41Cw">66,728</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Hana Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 1, 2024, the Company borrowed $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_8_1_2024_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_lO3aHrFMUE2_9b_GTJGSBw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_yx2PrkFqpUe27VAa6q_FBQ">850,000</ix:nonFraction> from Hana Immunotherapeutics, LLC (&#8220;Hana&#8221;), a related party of the Company due to having common executives (the &#8220;Hana Loans&#8221;). The Hana Loans bear interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_8_1_2024_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_lO3aHrFMUE2_9b_GTJGSBw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_5KngFKeDZEa55z8coNp-DQ">6</ix:nonFraction>% per annum and were due on September 30, 2024 and October 26, 2024, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VtKf0F4u50yYAUlGncV4kA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_iiVHygArPkuRlFMkX3RLGA">800,000</ix:nonFraction>, along with accrued interest, of the Hana Loans was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the balance of the Hana Loans is $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0PybUMyl7UupuiSkslBW7Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_ucwMKBVf6EKbVUsZCaxRUg">50,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GP3ES2qH4USRDiPV41OBjg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_OsIPkpW3R0WmW-jLlMyTyw">850,000</ix:nonFraction>, respectively. As of December 31, 2025 and 2024, the related accrued interest of the loans from Hana was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_HanaImmunotherapeuticsLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_M0xZpqNfSUiePS0rqmBJQQ" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr_0pWeSsxUnEOSpcInjT1r8Q">2,042</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_HanaImmunotherapeuticsLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NKk10HcAC0izvcIcwzePTQ" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr_hfW7jQLjzkWDEXbPwCFLhQ">19,150</ix:nonFraction>, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Hana Loans was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_meaC4-NT6kOsHGvZt--vtw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_g7TAZgFLYU2FGmAsZDG46g">19,042</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_PKtruhg-mke1cWwu6HOpJQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_B-jgoqovjUGFk28fyupTpQ">19,150</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Amantes Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On November 1, 2024, the Company borrowed $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_11_1_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_skGpvhLamkmTX8ZC32NJjg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_m7hdIHpQ_062Lvb1RmgkfA">400,000</ix:nonFraction> from Amantes LLC (&#8220;Amantes&#8221;), a related party of the Company due to having common executives, pursuant to a loan agreement between the Company and Amantes (the &#8220;Amantes Loan&#8221;). On November 27, 2024, the Company borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_11_27_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xZbOD6QvXU2eioglXc3B9Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_6JK9Xl6k50G421dAOaLm0g">300,000</ix:nonFraction> from Amantes (the &#8220;Additional Amantes Loan&#8221;) (together with the Amantes Loan, the &#8220;Amantes November 2024 Loans&#8221;). The Amantes November 2024 Loans bear interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_11_27_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xZbOD6QvXU2eioglXc3B9Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_G9K7mo5iNEGPcAsN-ItzIA">6</ix:nonFraction>% per annum and are due on January 1, </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-37</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_0pV7sQQuqkWNcKDRN_1_dw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">2025. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y5QPj6cnBkqxLO8bzZMweA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_U3d_qmAW9kaARXeRAhg50w">550,000</ix:nonFraction>, along with accrued interest, on the Amantes November 2024 Loans was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 2, 2025 and January 23, 2025, the Company borrowed a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_1_2_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UoLTcnkgY0ia4LxmBqWZzA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_AFNm2B-od0K2PoX9nV8awA"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_1_23_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPR03tDKjUmpyRyQld8qmA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_1rlcfLkjEEicjGyBweP_iw">300,000</ix:nonFraction></ix:nonFraction> from Amantes, pursuant to loan agreements between the Company and Amantes (the &#8220;Amantes January 2025 Loans&#8221;). The Amantes January 2025 Loans bear interest at <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_1_2_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UoLTcnkgY0ia4LxmBqWZzA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_Z3KjlL15qkmbBQxvCGFlEA"><ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="As_Of_1_23_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPR03tDKjUmpyRyQld8qmA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_6EqXrtmqX02sOXvJM61Olg">6</ix:nonFraction></ix:nonFraction>% per annum and are due on March 1, 2025 and March 22, 2025, respectively, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_mmocMhxQQE-9TDe7UCuBDQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_XIbix_4AN0ipUlbIj0ta4g">250,000</ix:nonFraction>, along with accrued interest, on the Amantes January 2025 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the balance of the Amantes Loans is $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_s7XNeN2VrkyoKgFvQn08HQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_zfhVHjRKXECJkDIDTkPCNw">200,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VyY5JFYy4EKLtKt2cqj8Iw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Narr_BiZfh7wP2U2svisdfCTIIA">700,000</ix:nonFraction>, respectively. As of December 31, 2025 and 2024, the related accrued interest of the loans from Amantes was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_AmantesLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_HgSigzsdAE2ZWAOutjYfWA" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr_evdLiXKXzku-AtwoPeT-Sg">9,288</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_AmantesLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_uroe3WmRfk2-MXkmturUGQ" decimals="0" format="ixt:num-dot-decimal" name="limn:AccruedInterestCurrent" scale="0" id="Narr_ONzZ8eW_8UKrOI8qb4QM5A">5,700</ix:nonFraction>, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Amantes Loans was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Ol_1m0h-L0KQZ73KaVpZtg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_jBKu3jnCz0WFh1Zb4TTKlw">27,890</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Vyrd4E71aEKV2JlX3zDSMw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_hoLFujsoSUyh4V7k01S1gQ">5,700</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Due to Related Party</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_limn_EmploymentAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_bhT6iPgTMUSC0cikBkivgg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Narr_TXEunhNY00CyyDo0q64GSQ">209,586</ix:nonFraction> due to the Company&#8217;s executive team for compensation under their employment agreements. As of December 31, 2024, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_limn_EmploymentAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8W6kVGwgx0651YJT0suHMA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Narr_GKPE_o0RNEa5Yn7B6D0quw">195,253</ix:nonFraction> due to the Company&#8217;s executive team for compensation under their employment agreements and Amantes. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Viral Gene</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of December 31, 2025 and 2024, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ViralGeneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_7wxNNnmVW0OOyrl6dcdkLg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" id="Narr_NmrL7Ls_1EqSi0hB5OX7lQ">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_ViralGeneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FJJZ1ZZ6TEyxVYe-BaGI8w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" id="Narr_6YxAPQ8LLU21uPFL1KPC1A">126,275</ix:nonFraction>, respectively, due from Viral Gene included in due from related party in the consolidated balance sheets for a loan to Viral Gene and expenses paid on behalf of Viral Gene. During the year ended December 31, 2025, the Company determined the due from related party was uncollectible and wrote off $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_ViralGeneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_a0Rd98uIckinvKo03Da_gQ" decimals="0" format="ixt:num-dot-decimal" name="limn:OtherReceivableWriteOff" scale="0" id="Narr_u-4tNcS85E65nNJ93tskXg">126,275</ix:nonFraction> and is included in general and administrative on the consolidated statement of operations. The Company&#8217;s CEO is also the CEO of Viral Gene. The loan does not bear any interest.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-38</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="Tc_-f2dvCGkJUivN_aD7kgtdQ_1_4"></a><a id="Tc__HRASGHIOU-dgvhevbvZkQ_2_5"></a><a id="Tc_ZwzS48xXzUK7DbLCA-Ej3g_2_8"></a><a id="Tc_psri0A7WnkCyRZywH7DpTg_3_0"></a><a id="Tc_RfnzEeMSnkKVMJIC9rY7MQ_3_2"></a><a id="Tc_TBvb7fUzU0GH5yz2GdzF4w_3_4"></a><a id="Tc_fz7vpw8VG0C6vDDs6k5Pgw_3_5"></a><a id="Tc_I9JIcZGWT0SQIvmakpmhSg_3_7"></a><a id="Tc_dTyijB5LlEmEr4KFS9yvXw_4_0"></a><a id="Tc_-yCnj6Bn2k2Un-9U0RoSnQ_4_2"></a><a id="Tc_aEqQ0_LvTkaMUwqr6C42cw_4_5"></a><a id="Tc_SFLyuCsZ3kGkqPSPf6yY5Q_5_0"></a><a id="Tc_qE5wQKB7LES0j-KAXttL-A_5_2"></a><a id="Tc_5UKsvoUqGUChL0YekioXCQ_5_5"></a><a id="Tc_ZPyXBkTz90yf3HzLw4UqDA_6_0"></a><a id="Tc_pIeDWkARKUiCJ-O-XWNqDw_6_2"></a><a id="Tc_WMpM90ho60Oy0AYENsvvHw_6_5"></a><a id="Tc_NAivsv2B3EO7d6Kzxrcuaw_7_0"></a><a id="Tc_y_OF7v4jfUO_GOy6oR7QzQ_7_2"></a><a id="Tc_8jJgpduRVUeY0FEDdt8nDw_8_0"></a><a id="Tc_1N8VAQ0xhUSJYom_DQ4Tug_8_2"></a><a id="Tc_338E5vg-8UiN2AQ2KZs_rw_9_0"></a><a id="Tc_eI1iL9PaBEqslyXmA8aI4Q_9_2"></a><a id="Tc_j6GvtDUKY0azA-9IfTSlXQ_9_5"></a><a id="Tc_XpyfDLUPNkuXz9cpgoP2sA_10_0"></a><a id="Tc_RFA21RPh506FAp41MaYg5Q_10_2"></a><a id="Tc_jeyucW5Zb0WYZTFwqScUng_10_5"></a><a id="Tc_XZ13THF3Ik6DnNV4BDlb5g_11_0"></a><a id="Tc_WloMcio7A0-8rMzDKoQFcw_11_2"></a><a id="Tc_MUse0oEKuka8fFjvFfGC2Q_11_5"></a><a id="Tc_73nHUXZNVUOmY5-m-v9U8Q_12_0"></a><a id="Tc_I2iY_r9omEuvRIR5-UyMig_12_2"></a><a id="Tc_kMUEs26CxEGMVQ9TaG-lAA_12_5"></a><a id="Tc_mLWhU7clWUuLfzZSZZyELw_13_0"></a><a id="Tc_kV6tK03nT0iZqcM-ZNO0xA_13_2"></a><a id="Tc_nSx8SDdGkE-7E1ujjZ1kog_13_5"></a><a id="Tc_9KTmoselO0q8qbFiaxknpw_14_0"></a><a id="Tc_cYi7mIxZy0Oy4OfKADm7eg_14_2"></a><a id="Tc_Wk6oTXrH_ku0muJJnGjuPA_15_0"></a><a id="Tc_KHIiBZj7vkWrJn4RPInftg_15_2"></a><a id="Tc_9vrEixke2keXdkiN4ey0Og_16_0"></a><a id="Tc_AsFUNKGm9EeNBwy2Gzo9rg_16_2"></a><a id="Tc_mgDRSbOK_kmZemObKnc2Sg_16_5"></a><a id="Tc_Rgb2CwTRAUK5J0LC8ZR7rg_17_0"></a><a id="Tc_HJKdw4ZwzU6afTjoAG_4XQ_17_2"></a><a id="Tc_qEPbp4zzr0KZlM5D5uGgPg_18_0"></a><a id="Tc_5pvrRlmC606rhze-Kr_DNg_18_2"></a><a id="Tc_uEsLee6Y6EycD6qQ5C_F2w_19_0"></a><a id="Tc_AaqKTOvf6k-Q5j_ghXMZiA_19_2"></a><a id="Tc_j_MdBWr4g0yKOza-QQdayQ_20_0"></a><a id="Tc_wC8a-_idpkemL5eXqUWqJQ_20_2"></a><a id="Tc_eIMR5kAfTEKFEvt0wvZi5g_21_0"></a><a id="Tc_nCa9lcAGIESdSkup43X1Rg_21_2"></a><a id="Tc_S5KzxDevGEyrMsjR9ybxtQ_22_0"></a><a id="Tc_7iHGph40DEWbkbyDP8jvow_22_2"></a><a id="Tc_JiehwGsdVUGrR-wrsmEIhw_22_8"></a><a id="Tc_lI024VEKP0aCuG2hMFeWlA_23_0"></a><a id="Tc_voRQvhi1_0CDovdRGGaY5g_23_2"></a><a id="Tc_hKTTpbWY80uLaJfUGe-tdQ_23_8"></a><a id="Tc_SQ-qGbWF2UCorihX8IAHkQ_24_0"></a><a id="Tc_3pbiPa4wDEKaD46gQfpGAg_24_2"></a><a id="Tc_5LfNBaIKWEmXtB5TMRI3RQ_24_8"></a><a id="Tc_fPAFWaNkS0O1jIjn4HZc5A_26_0"></a><a id="Tc_qzxYaCkw2Eqn6MM8SsZ-SQ_26_4"></a><a id="Tc_aWtAyb0-MUOS6qotWycyLQ_26_7"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:DebtDisclosureTextBlock" id="Tb_TJJrbRMQN0CrKAWkvcNWbQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 5. Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Outstanding debt classified as short-term debt as of December 31, 2025 and 2024 consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:ScheduleOfShortTermDebtTextBlock" id="Tb_3SJgLQdCzEKuoE1mWqN4bQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:202.45pt;padding:0pt;"/><td style="width:13.39pt;padding:0pt;"/><td style="width:162pt;padding:0pt;"/><td style="width:12.85pt;padding:0pt;"/><td style="width:8pt;padding:0pt;"/><td style="width:60.5pt;padding:0pt;"/><td style="width:12.86pt;padding:0pt;"/><td style="width:8pt;padding:0pt;"/><td style="width:59.95pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:149.3pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style="height:9.69pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Feelux Bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6wD9AAP08UeDG0Qs6p5Q2A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_BoXEQiAvCEm9lq5sMtXGcA_3_8">10,000,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Car-Tcellkor Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_TpCVK5HsVEK8Wyv55C0lig" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_rR0_2apWv06Qf6M9zyXSgA_4_8">800,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ewon Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3egjKmWE3UiVynBt7G9rJg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_iRD2T6jbREu-U9eKxA5Xqg_5_8">2,000,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_lrwGKHLBAESOZpAyQq956w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_egb6Tr0QDU6QOVl2fQQRiA_6_8">700,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo June 2023 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VlA87RaJeEq06zmKK_H7kg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_jOM7a6A7ukmPjQijwU3Bhw_7_5">200,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_x5Od1Z7sZ0CQp8ZF554jRw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_TODJ419hfUWzGxitHxZNww_7_8">500,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo July 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_eAOXFYGTJk-hpkYZ9yVryA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_kXjt1__tOEq0kjUl5nkIBw_8_5">250,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ASPx2q5_QU-KM6mmU-4OjQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_wq58e0Ckl0eEQDbHGFL1Ow_8_8">250,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo August 2023 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_CQA91rS8pUClgpt3N0razg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_dT_HlHb_aUS_gPFwE-sCEA_9_8">400,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ewon September 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8mMfG6ZJX0COX4Qohfx8lg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_JeMx-hS_E0m_aiVjWWUg9A_10_8">200,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo November 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_sFe_sIQl8kC62ZR9mOyaiQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_NM_rYhti7EuAn2oTXkbu8w_11_8">200,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ewon December 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_EwonDecember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_7O7aQgSHYU6aHfIWbXQSzg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_23eU3w_pB06fEmdfT4gKNQ_12_8">1,000,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo January 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gfQEfMTEl0ObGw-d3_mziQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_4qH4_YZQkUCFVALL_ud_pA_13_8">750,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_9WDN8eHoHUWQK3nMpHkYtQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_7VKGBM12ik6tEE_wDuoa7Q_14_5">31,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_rkyvImjcI02ndBME1T3Fyg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_PsNb2-qzD0izvTUvYeM-4g_14_8">200,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tPoEXxTBuEas6Sj74xYwPA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_7E1v36sUskijdhhD1fBYXw_15_5">250,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Jq1v2ZuaPEej3PGvRk2DSg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_5J_mV7x6k0CsM_X30LF87w_15_8">250,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase April 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_obg_hYZhh0yPZ2jeTy8gQQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_WyzChfPcKkCWgKL_z9U5lQ_16_8">250,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase May 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ay2QMWFbV0SdpGM1KxxUJw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_mbpvMbF_eU61_QWjJEDUPw_17_5">240,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_QRBk_Nfwt0WDpSDktLsbZg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_x_6sAnOpmkKxN7hIAe1WWg_17_8">790,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase July 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Wgs8NC0FrEu0hK8Qjljnog" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_x1dyhtQMKE-xox8xbZaMqw_18_5">83,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_HDV6ibzOjEy9uUy1EA4FRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_lNYvlHDm-USLEsty_UGgWA_18_8">83,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__dCVK3BY3EeDKZi28xUkew" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_Xtvr7wpva06_4m74MRBC_Q_19_5">50,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ANKNxWmzXk2q4khG39LhMA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_9DwcH0VO7kCk3dn0-MvmBQ_19_8">50,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hana August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NQoRaZtKZUCGus-3AHoDuQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_YegEp8LcYU6X5wAIZRVmNw_20_5">50,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wQjd250e8E-nWSdS93gx4Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_OjF5qLvK_E-x5rPVVMeXeQ_20_8">850,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes November 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_j5CQtBVz5UqKzenH5qp4Pg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_GZ1VdJvoLEWYPJpyRuxwpQ_21_5">150,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_JMZfrNFf_E-RRAz3gORKJw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_ElqktbNOlUmPjPkOA79l5g_21_8">700,000</ix:nonFraction></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes January 2025 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_vlYz7WYM0065Rv0yQrEanA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_OInyrMQ8vE-C9RfYczM5Lw_22_5">50,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YhVm-9q0AUSPz-vllz68rg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_M2BK9Cpe3EWj9JUYkIeo5Q_23_5">81,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tu28ZL0W00ydtm8NRLecmQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_KR8kfGLFF0WEaLmy2lPInA_24_5">7,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short-term debt, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FbpcEF3_bUqHFwpcC9Wy4w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_1co8YaB9TU6Q-qn1chKcsg_26_5">1,442,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_eXLYHI_roUaYmfoOmSYVxA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" id="Tc_RON6zgFbsUWaq37wSzi0ng_26_8">19,973,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the Company&#8217;s outstanding debt agreements are all past due and are classified as current in the accompanying consolidated balance sheets. All of the loans are with related parties (see Note 4). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As the Company&#8217;s loans are with related parties, the Company and its related parties have mutually agreed to defer repayment until a time that is mutually agreed upon between the Company and its related parties. Accordingly, none of these notes are considered to be in default.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_997puwpl3k6ae7vFcZDD5Q" continuedAt="Tb_997puwpl3k6ae7vFcZDD5Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 6. Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Business Combination, the Company&#8217;s certificate of incorporation was amended and restated to designate two classes of stock; preferred and common stock. The certificate of incorporation authorized <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_3L7AM_E20kadTSZc5xEJ_Q">1,000,000</ix:nonFraction> shares of preferred stock and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_omTXK91e0EeqlzbLBxBfGQ">500,000,000</ix:nonFraction> shares of common stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preferred Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Amended and Restated Certificate of Incorporation provides the Company&#8217;s board of directors with the authority to issue up to <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_15uUj50ij0acb3GG0a4I8Q">1,000,000</ix:nonFraction> shares of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_1rkLZ-8ME0iB6UQ_PjFTJA">0.0001</ix:nonFraction> par value preferred stock in one or more series and to establish from time to time the number of shares to be included in each such series, by adopting a resolution and filing a certification of designations. Voting powers, designations, powers, preferences and relative, participating, optional, special and other rights will be stated and expressed in such resolutions. There were <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_x3lEphKQ4km-912J3JM36A"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_-W9uuBel90qUqjwl0h43kg">zero</ix:nonFraction></ix:nonFraction> preferred shares outstanding as of December 31, 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Common Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is authorized to issue <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_ixx9FzuYrUKs3oCCdpknrg">500,000,000</ix:nonFraction> shares of common stock, with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_4Kx3HSYJ3kO_AYsIhvPdug">0.0001</ix:nonFraction> per share.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-39</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_997puwpl3k6ae7vFcZDD5Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, the Company settled deferred underwriting fees incurred by Iris prior to the closing date of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" scale="0" id="Narr_QdUlmDlrfE2Gvmak3y8Wrg">7,000,000</ix:nonFraction> for <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="INF" format="ixt:num-dot-decimal" name="limn:StockIssuableForSettlementOfDeferredUnderwritingFees" scale="0" id="Narr_vcNfiDlLCEaSZny5SAKKAA">700,000</ix:nonFraction> shares of common stock to the underwriters in Iris&#8217;s initial public offering. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_7_1_2025_CZJvPOCOcUySCDRAwOkqBA" decimals="0" format="ixt:num-dot-decimal" name="limn:FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" scale="0" id="Narr_EPZU22zcuUqzfM8tlm2Ajg">7,245,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 16, 2025, the Company entered into a settlement and release agreement with Alta Partners, LLC (&#8220;Alta&#8221;), pursuant to which the Company agreed to issue <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_7_16_2025_To_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_bvbBg5HF0E2idzp2cAdrIg" decimals="INF" format="ixt:num-dot-decimal" name="limn:SharesIssuedForSurrenderAndCancellationOfWarrants" scale="0" id="Narr_W0t_T4f0mkKZFs9LwloonQ">350,000</ix:nonFraction> shares of its common stock to Alta in exchange for the surrender and cancellation of <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_7_16_2025_To_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_bvbBg5HF0E2idzp2cAdrIg" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" scale="0" id="Narr_U-j_17lDjUWAoRjCrjfH2w">1,000,000</ix:nonFraction> Public Warrants held by Alta. On July 16, 2025, the common stock issued to Alta and Public Warrants surrendered by Alta had a fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_3KBXe2AusUautripdVqXLA" decimals="0" format="ixt:num-dot-decimal" name="limn:FairValueOfCommonStockIssued" scale="0" id="Narr_mvAEtSPVB0mjak9hgG0aVg">1,890,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_3KBXe2AusUautripdVqXLA" decimals="0" format="ixt:num-dot-decimal" name="limn:FairValueOfWarrantsSurrendered" scale="0" id="Narr_LHwdDOPnl0y60fHcr4xxCg">150,000</ix:nonFraction>, respectively. As a result of the exchange, the Company recognized a loss of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_7_16_2025_To_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_bvbBg5HF0E2idzp2cAdrIg" decimals="0" format="ixt:num-dot-decimal" name="limn:GainLossOnIssuanceOfCommonStockForWarrants" sign="-" scale="0" id="Narr_L4STvNJ3fkqI0t_0Hap6Zg">1,740,000</ix:nonFraction> on the difference in fair value between the common stock and Public Warrants, which is included in Loss on issuance of common stock on the Company&#8217;s consolidated statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, there were <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_LxBo1bBBl0yMY18IH7IVrQ"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_htk19E2mDESRxBeEIz_XOA">27,064,633</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_hTIC__6zw0GNwCfYQ1-ijA"><ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_m87XrE1hn0Cez8af0DhbSg">17,500,000</ix:nonFraction></ix:nonFraction> shares of common stock issued and outstanding, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of the Company&#8217;s common stock are entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_pVdT3YsDMEiv7zpsvfY2UA" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt-sec:numwordsen" name="limn:CommonStockNumberOfVotesPerShare" scale="0" id="Narr_rafEAW50hUGLfaMrKMWt2w">one</ix:nonFraction> vote for each share held of record, on all matters submitted to a vote of stockholders. Additionally, holders of common stock have dividend rights, in the event of a declared dividend declared by the Company&#8217;s Board of Directors, and liquidation rights, in the event of an involuntary or voluntary event of liquidation that allow for the Company&#8217;s common stockholders to receive all remaining assets of the Company, after payments of debts and other liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of December 31, 2025, <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z416a0UcpESjBa-8wQ9m5Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_yzkg8yIts0meZFr4uFmjEA">5,899,975</ix:nonFraction> Public Warrants and <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PrivatePlacementWarrantsMember_ioEniwa8PEunNaQ7J6fSnA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_KosC_hCPTEStDOSYhAcS4w">835,555</ix:nonFraction> private placement warrants were outstanding. Each warrant entitles the holder to purchase <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_1ZiTicliwUiaQwQj6gry6A">one</ix:nonFraction> share of the Company&#8217;s common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_gbe8X3bYnEmA8Q4gfYUiow">11.50</ix:nonFraction> per share. No fractional shares will be issued upon exercise of the warrants. The Company may elect to redeem the Public Warrants, in whole and not in part at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z416a0UcpESjBa-8wQ9m5Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_1dRh8c_EMkidiL_LNeaRTg">0.01</ix:nonFraction> per warrant if (i) <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_jjYhKZRSskurVxz2qWHRfg" format="ixt-sec:durwordsen" name="limn:ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants" id="Narr_Zkd_RCHxMU-SLm-juW29xg">30 days</ix:nonNumeric>&#8217; prior written notice of redemption is provided to the holders, and (ii) the last reported sale price of the Company&#8217;s common stock equals or exceeds $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z416a0UcpESjBa-8wQ9m5Q" decimals="2" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption" scale="0" id="Narr_8HFJ0AjV9kWfsd0rG8N3Bw">18.00</ix:nonFraction> per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any <ix:nonFraction unitRef="Unit_Standard_D_P_lZhqU5gEiyf8nABG1U1w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_jjYhKZRSskurVxz2qWHRfg" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" scale="0" id="Narr_6AAsWoklmkeTgYTY4ldawQ">20</ix:nonFraction> trading days within a <ix:nonFraction unitRef="Unit_Standard_D_P_lZhqU5gEiyf8nABG1U1w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_jjYhKZRSskurVxz2qWHRfg" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" scale="0" id="Narr_JTp89Ru6sU6sRGBIYP9X6w">30</ix:nonFraction>-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders. Upon issuance of a redemption notice by the Company, the warrant holders have a period of <ix:nonNumeric contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z416a0UcpESjBa-8wQ9m5Q" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_8nkCPuxpaEuT_WDDHgi7jA">30 days</ix:nonNumeric> to exercise for cash, or on a cashless basis.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_2KaPi9HWt0OLSV2i9LgWMA" continuedAt="Tb_2KaPi9HWt0OLSV2i9LgWMA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;7. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 17, 2025, the Company entered into a short-term lease for an office space in Cerritos, California (the &#8220;Lease&#8221;). The Lease commenced on September 1, 2025 and expires on June 30, 2026 and does not have any renewal option. The Company has made the short-term lease election and recognizes lease payments for its short-term lease on a straight line basis over the lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2025, lease expense related to the short-term lease was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="0" id="Narr_0UhguKCWsUCL7fcR2O26uA">2,784</ix:nonFraction>. For the year ended December 31, 2024, there was <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShortTermLeaseCost" scale="0" id="Narr_qX73PNc1o0ajmcQpI1p_yg">no</ix:nonFraction> lease expense related to the short-term lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Legal proceedings</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 6, 2026, the Company entered into a settlement and release agreement with Clear Street LLC (the &#8220;Holder&#8221;), pursuant to which the Company agreed to issue <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_IbplB2gb40qdMMz9BIq6qA" decimals="INF" format="ixt:num-dot-decimal" name="limn:SharesIssuedForSurrenderAndCancellationOfWarrants" scale="0" id="Narr_kAq8BreYkEeTPyKlB1C5qw">4,000,000</ix:nonFraction> shares of its common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qRAwhaLP1EWqdsQcq1AtbA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_h0uX_oIM-UmCxmChZkbaGg">0.0001</ix:nonFraction> per share, to the Holder in exchange for the surrender and cancellation of <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_IbplB2gb40qdMMz9BIq6qA" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" scale="0" id="Narr_kG_EaQ5INEKrRFwaFnJ6Vg">805,377</ix:nonFraction> warrants to purchase shares of common stock held by the Holder. The Company has determined this represents a Type I subsequent event in accordance with the guidance of ASC 855, <i style="font-style:italic;">Subsequent Events</i> (&#8220;ASC 855&#8221;), in which the Company obtained additional evidence about conditions that existed at the date of the consolidated balance sheets. As such, the Company has recorded the $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qRAwhaLP1EWqdsQcq1AtbA" decimals="0" format="ixt:num-dot-decimal" name="limn:CommonStockPayable" scale="0" id="Narr_U8TCGAvWhEK1TRrD9SDSGg">7,360,000</ix:nonFraction> as settlement payable, which was calculated using the fair value of the Company&#8217;s common stock on February 6, 2026, which was the day that stock was issued to the Holder, in its consolidated balance sheets as of December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Settlement Agreement, the Company and the Holder agreed to dismiss (a) an action pending in the United States District Court for the Central District of California and (b) an action pending in the United States District Court for the Southern District of New York, in which previously the Court entered a default judgment against the Company in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_10_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_6H9UrA2MZUWmfOm8ySparQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="0" id="Narr_ers8IUGlcE22BI8LRC7EBg">7,500,000</ix:nonFraction> plus approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_10_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_6H9UrA2MZUWmfOm8ySparQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementInterest" scale="0" id="Narr_510A2YmikkGXaSjS-PPJrg">515,000</ix:nonFraction> in interest, which judgment was registered in the Central District of California in the fourth quarter of 2025.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-40</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_2KaPi9HWt0OLSV2i9LgWMA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is not a party to any other material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Underwriting Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Business Combination in connection with its initial public offering, Iris entered into an underwriting agreement in which Cantor was engaged as the underwriters to Iris&#8217; IPO. Cantor was entitled to an underwriting discount of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2025_To_12_31_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_rriXg5_Dp0mBV3id5bODsQ" decimals="2" format="ixt:num-dot-decimal" name="limn:UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" scale="-2" id="Narr_bBwpn_2dSUC-WnthkBX_7g">2</ix:nonFraction>% (or $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_TzHnTBOE4E6UpnLXPy51MA" decimals="0" format="ixt:num-dot-decimal" name="limn:UnderwritingCostsNoncurrent" scale="0" id="Narr_tB8VRm3v90qolff2Mu3DxA">5,520,000</ix:nonFraction>) of the gross proceeds of the IPO and deferred underwriting discount of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2025_To_12_31_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_rriXg5_Dp0mBV3id5bODsQ" decimals="3" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" scale="-2" id="Narr_CaTGLXnxNkKm-ephpTFeIg">3.5</ix:nonFraction>% (or $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_TzHnTBOE4E6UpnLXPy51MA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredOfferingCostsNoncurrent" scale="0" id="Narr_HVEbDeZaqEulp-MuxbUnJA">9,660,000</ix:nonFraction>) of the gross proceeds of the IPO upon the completion of an initial business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 11, 2023, Iris executed a fee reduction agreement with the underwriters to reduce the deferred underwriting discount of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_10_10_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_8jW8A96_rUGTBNiKY7EncA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredOfferingCostsNoncurrent" scale="0" id="Narr__0EQ5pxeFkWpF3RtNyiSJQ">9,660,000</ix:nonFraction> to $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_10_11_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_3xBPTdDIoEKDwiqXuL9Qyg" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredOfferingCostsNoncurrent" scale="0" id="Narr_zbFCkO2TJUC2dYaseKC3gQ">8,000,000</ix:nonFraction> in the event the Business Combination was consummated. Pursuant to the terms of the agreement, the reduced deferred underwriting discount was payable by the Iris to the underwriters in $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_10_11_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_3xBPTdDIoEKDwiqXuL9Qyg" decimals="0" format="ixt:num-dot-decimal" name="limn:PaymentOfOfferingCostsInCash" scale="0" id="Narr_9xpDAjGUTE20d5ogJKAenA">1,000,000</ix:nonFraction> cash and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_10_11_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_3xBPTdDIoEKDwiqXuL9Qyg" decimals="0" format="ixt:num-dot-decimal" name="limn:UnderwritingDiscountPaidInSecurities" scale="0" id="Narr_jwiGEvdlfUOZFEbnJoJlUA">7,000,000</ix:nonFraction> of the common equity securities of the public entity that survives the transaction. The share price is subject to adjustment based on the five day volume-weighted average price prior to the filing of a resale registration statement covering such shares. As of April 30, 2025, Iris and the Company amended the fee reduction agreement with the underwriters to limit the total number of shares of common stock issuable to the underwriters to <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_4_30_2025_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_Lbu1miIqSkupTrmz199Hbw" decimals="INF" format="ixt:num-dot-decimal" name="limn:MaximumNumbersOfSharesIssuable" scale="0" id="Narr_NE8wCNsNXkGKATMNr6rRzg">1,750,000</ix:nonFraction>. Upon the consummation of the Business Combination, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination" scale="0" id="Narr_X1St1VzQG0m67AtiqKERqg">9,160,000</ix:nonFraction> in deferred underwriting fees were settled, of which $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination" scale="0" id="Narr_hDnWBtwk7E28twzQBLv3PQ">7,000,000</ix:nonFraction> will be settled in common shares of the combined company, $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination" scale="0" id="Narr_-iA1mBsoEU6LUpj8T3t1cA">500,000</ix:nonFraction> was settled in cash and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination" scale="0" id="Narr_dhUFh88gs06uSvs1FGWG4w">1,660,000</ix:nonFraction> was waived and no longer payable. The remaining $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering" scale="0" id="Narr_u8slH8q9tUKSQuEnR809LQ">500,000</ix:nonFraction> was to be settled upon the earlier of the consummation of the combined company&#8217;s next share offering, or in <ix:nonNumeric contextRef="Duration_4_30_2025_To_4_30_2025_9PPk1IhN6EmJm5MGsGwEDA" format="ixt-sec:durwordsen" name="limn:ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination" id="Narr_snsM2224nEGltIsauM50Dw">six months</ix:nonNumeric> from the closing date of the Business Combination. As of December 31, 2025, the deferred underwriting fee payable was $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeesPayableInCashCurrent" scale="0" id="Narr_kxnY8UxkekirVXcbHAuENw">500,000</ix:nonFraction>, which is included in Deferred underwriting fee payable in the Company&#8217;s consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, the Company settled Iris&#8217; liabilities for $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" scale="0" id="Narr_mM7Qt3Gcg0am1u727_TqKg">7,000,000</ix:nonFraction> of the deferred underwriting fees incurred prior to the Closing Date for <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA" decimals="INF" format="ixt:num-dot-decimal" name="limn:StockIssuableForSettlementOfDeferredUnderwritingFees" scale="0" id="Narr_LaswXP8sXEWYo0i7Ii0_xg">700,000</ix:nonFraction> shares of common stock to the underwriters in Iris&#8217;s initial public offering. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_7_1_2025_CZJvPOCOcUySCDRAwOkqBA" decimals="0" format="ixt:num-dot-decimal" name="limn:FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" scale="0" id="Narr_2dmziqNKHUG7L4IJrTD-VQ">7,245,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On October 27, 2025, six months from the closing date of the Business Combination, the remaining $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_10_27_2025_WHc2wpxA30auOyOjgUueLA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeesPayableInCashCurrent" scale="0" id="Narr_-xGuxrtyyUC39MWjPSxGYQ">500,000</ix:nonFraction> underwriting fee became due. As of the date of these consolidated financial statements, the $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_10_27_2025_WHc2wpxA30auOyOjgUueLA" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredUnderwritingFeesPayableInCashCurrent" scale="0" id="Narr_QyLjteaEwE2KtYzzYLElkw">500,000</ix:nonFraction> underwriting fees remains unpaid. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_q5ffhDD9xkK6XNDimDzjLw_1_0"></a><a id="Tc_pOshzJcEHk-ENPxEBKHacw_1_2"></a><a id="Tc_aZqvtIgLjEuJmD28vgBeDQ_1_4"></a><a id="Tc_C-SejM1gj063jaVgijCOsA_1_7"></a><a id="Tc_5M4WVAMtaUS01RDtxXnUZQ_2_0"></a><a id="Tc_EKEZMoD0RE-KsK2nTvm8Dg_2_4"></a><a id="Tc_6BeSuXaeoEWQPJUQE1EAZA_2_5"></a><a id="Tc_NkwLp0wG3U-POLW3D2Mdiw_2_7"></a><a id="Tc_Ms-KZh05m0eLlf3iskWLGw_2_8"></a><a id="Tc_AuGQNRDwxUy972ScLZG61w_3_0"></a><a id="Tc_eWJQV_wfYEa_ZGpdqKpkIw_4_0"></a><a id="Tc_OGkHjRrn5Ueln6Hl3wkQRA_4_2"></a><a id="Tc_k2o950EBokGumfexJhahIg_4_4"></a><a id="Tc_-kMbuR6AaECXz2rbDRTPqA_4_7"></a><a id="Tc_Frb4Ovzo7Um2Y_lhwO0kzA_4_8"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_5O3h8A9rBkm6Rn92OXZdbw" continuedAt="Tb_5O3h8A9rBkm6Rn92OXZdbw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 8. Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2025 and 2024 and indicates the fair value hierarchy of the valuation inputs the Company&#8217;s utilized to determine such fair value:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_J-dDLw7htEKBUEUyR6nR6g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:341.85pt;padding:0pt;"/><td style="width:10.8pt;padding:0pt;"/><td style="width:50.65pt;padding:0pt;"/><td style="width:10.79pt;padding:0pt;"/><td style="width:6.8pt;padding:0pt;"/><td style="width:50.75pt;padding:0pt;"/><td style="width:10.8pt;padding:0pt;"/><td style="width:6.8pt;padding:0pt;"/><td style="width:50.75pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:341.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:341.85pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:341.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:341.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:341.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_3B7id13HUEKPGohf_GYnnw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="0" id="Tc_eCgIeMZpgku0c061r7lrJg_4_5">29,244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrant Liability</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon closing of the Mergers, Iris&#8217; public and private placement warrants were converted into warrants of the Company, which entitle the holders to purchase shares of the Company&#8217;s common stock. The Company&#8217;s private placement warrants meet the requirements for liability classification. The fair value of the warrant liabilities were determined using observable data points, such as the fair value of the public warrants as of December 31, 2025 and 2024. The Company further considered specific unobservable inputs, such as the probability and timing of events and the expected equity value of the underlying shares.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-41</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="Tc_edJsS_yoTE2vPjKdkhbwtw_1_2"></a><a id="Tc_a4VbFJHXTkeCITdMBflIUQ_2_0"></a><a id="Tc_razDfF0LFUGXhSpItzAfsA_2_2"></a><a id="Tc_Bh74UGTQGU-fdo_BkFzLqw_2_3"></a><a id="Tc_pKN7R_RNRUSlpJTj4S0ocA_3_0"></a><a id="Tc_RpWJc1x_L0qWd9zb6Py5qg_4_0"></a><a id="Tc_uQJmoPIirECNZikrDsDInQ_5_0"></a><a id="Tc_XIi1qP0PP0enXJOZOezdMw_5_2"></a><ix:continuation id="Tb_5O3h8A9rBkm6Rn92OXZdbw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The changes in fair value of Level 3 financial assets and liabilities for the year ended December 31, 2025 are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="limn:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="Tb_j15F4MK0QkaaI5IFMLfLiQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:360.05pt;padding:0pt;"/><td style="width:11.39pt;padding:0pt;"/><td style="width:7.15pt;padding:0pt;"/><td style="width:53.4pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:60.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant&#160;liability</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Initial measurement at the Closing Date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_yZvCrOb-Wk-Oqgi1kTrEqg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="0" id="Tc_yOMP0EriykySpyRG4nXUNg_3_3">83,556</ix:nonFraction></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_yZvCrOb-Wk-Oqgi1kTrEqg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" sign="-" scale="0" id="Tc_iL01fATiX0aZmoRedXxyNA_4_3">54,312</ix:nonFraction>)</p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_NOD7vwuXLUmAhk-2mkyvLQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_gZcoKt1KG0-wBqt9QQg6EA_5_3">29,244</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_5W7R7AVNVECR8rOaOO4pDQ_1_2"></a><a id="Tc_reGtwdA040edpOIAO_SyKg_2_2"></a><a id="Tc_Eotnt99BeE2i8C2MYMmjzw_2_5"></a><a id="Tc_M4NaI7W-2kSc0A7wxadHpw_3_0"></a><a id="Tc_Isquiac410mWGptFHsSXZg_4_0"></a><a id="Tc_BXI7TDcQ7Uyf-rMMM5eNww_4_2"></a><a id="Tc_ny_13GTOSUymMjEQlL-ZyA_4_3"></a><a id="Tc_jRbjfYaPf0idQl1sfB5vBA_4_5"></a><a id="Tc_ILitqZO6RUmxETGf_TSIsw_4_6"></a><a id="Tc_er923uCjPUOPrMNd3OyrrA_5_0"></a><a id="Tc_21MtCOzqhUiys_ejPdPGww_5_6"></a><a id="Tc_cYTSrn9H7UaVrqWMI1dWmQ_6_0"></a><a id="Tc_nCKdXBUgJ0OCAk7u0CRFng_7_0"></a><a id="Tc_lqDA6-karkKA4sNg1buvWg_7_3"></a><a id="Tc_96eTZqm2A0OGqi_AGYe1Ww_7_6"></a><a id="Tc_WEy7J7OhhUqdZuAkTNfBcg_8_0"></a><a id="Tc_lrpS9ys63ke4y-8KcWzyuw_8_6"></a><a id="Tc_7muXlwoeoU-9xWJMpfLu3Q_9_0"></a><a id="Tc_C0Fm4FxNrUW5bkLr45gKbw_9_6"></a><a id="Tc_XiD2SMLwHESsLyFTZT6zNQ_10_0"></a><a id="Tc_7P_ftWIRLk6VUO116ZS99A_10_2"></a><a id="Tc_cdRXqQfA_kyCPhdFKJ_rYA_10_3"></a><a id="Tc_Lmv01dLhcki8rLGzhr7uzg_10_5"></a><a id="Tc_9n3bEh2SR0GyvOm1d48faw_10_6"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_ypb8Fn3y7E27usil3s6BnA" continuedAt="Tb_ypb8Fn3y7E27usil3s6BnA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 9. Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, the Company consummated the Business Combination. Liminatus, a Delaware limited liability company, was deemed the accounting acquirer in the Business Combination based on an analysis of the criteria outlined in ASC 805, see Note 1. The tax consequences of the Company&#8217;s transactions prior to the consummation of the Business Combination flows through to the members of Liminatus. The tax consequences of the Company&#8217;s transactions for the period from May 1, 2025 through December 31, 2025 are accounted for in accordance with ASC 740. Prior to May 1, 2025, the Company was a non corporate entity that was not subject to U.S. federal income tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company regularly assesses the need for a valuation allowance against its deferred tax assets. In making that assessment, the Company considers both positive and negative evidence related to the likelihood of realization of the deferred tax assets to determine, based on the weight of available evidence, whether it is more-likely-than-not that some or all of the deferred tax assets will not be realized. In assessing the realizability of deferred tax assets, the Company considers taxable income in prior carryback years, as permitted under the tax law, forecasted taxable earnings, tax planning strategies, and the expected timing of the reversal of temporary differences. This determination requires significant judgment, including assumptions about future taxable income that are based on historical and projected information and is performed on a jurisdiction-by-jurisdiction basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company maintains a full valuation allowance against its deferred tax assets. During the years ended December 31, 2025 and 2024, management assessed the positive and negative evidence in its operations, and concluded that it is more likely than not that its deferred tax assets as of December 31, 2025 and 2024 will not be realized given the Company&#8217;s history of operating losses. The valuation allowance against deferred tax assets increased by $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="Narr_pJ3L5WA1akugpimcH4D38w">2,345,773</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="Narr_r2v8-PJsQEioJmDAfYQo4g">0</ix:nonFraction> during the year December 31, 2025 and 2024, respectively, related to a full valuation allowance recorded against additional net operating losses and tax credits generated in the year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 22, 2017, the Tax Cuts and Jobs Act (the &#8220;Act&#8221;) was enacted. Under the Act, research and development expenditures incurred for tax years beginning after December 31, 2021 must be capitalized and amortized ratably over five or fifteen years for tax purposes, depending on if the research activities are conducted in the U.S. or outside the U.S., respectively. For the years ended December 31, 2025 and 2024, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt-sec:numwordsen" name="limn:ResearchAndDevelopmentExpenseMandatoryCapitalization" scale="0" id="Narr_jnVCvHxDIU2Wr23dg4yz7Q"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt-sec:numwordsen" name="limn:ResearchAndDevelopmentExpenseMandatoryCapitalization" scale="0" id="Narr_FsMjAxFTUUaVueZ4IZPMOA">no</ix:nonFraction></ix:nonFraction> research and development expenditures subject to the mandatory capitalization and amortization under the Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the Company had federal net operating losses of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_aJMXR8IfbkCBrGx7ddW08w">822,963</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_Yj6kxWQP60O1Mbqd8JPabQ">0</ix:nonFraction>, respectively, which may be available to offset future federal income tax liabilities, subject limitations under IRC Section 382 of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="-5" format="ixt:num-dot-decimal" name="limn:FederalIncomeTaxExpenseSubjectToLimitationInUse" scale="6" id="Narr_XxQ57YTzfUOFZsnUxuRPxA"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="-5" format="ixt:num-dot-decimal" name="limn:FederalIncomeTaxExpenseSubjectToLimitationInUse" scale="6" id="Narr_Ysi_wAmU_0KvkPPrOvt3Hw">1.1</ix:nonFraction></ix:nonFraction> million per year. As a result of the Act, for U.S. federal income tax purposes, net operating losses generated after December 31, 2017 can be carried forward indefinitely, but are limited to 80% utilization against future taxable income each year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The components of the income tax provision (benefit) are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_MNcDTNsnFk22n9TSEipGAg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:399pt;padding:0pt;"/><td style="width:12.65pt;padding:0pt;"/><td style="width:8pt;padding:0pt;"/><td style="width:49.9pt;padding:0pt;"/><td style="width:12.64pt;padding:0pt;"/><td style="width:8pt;padding:0pt;"/><td style="width:49.81pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.49pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:128.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr style="height:9.74pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal</p></td><td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_qo2Vigob10Se8Ubhnj042Q_5_3">1,604,745</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State and Local</p></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_nxQk2kBCaE-Uol2-WwnUPg_8_3">741,028</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="Tc_AFEtl-Y2uUq0wZdL2r9jGA_9_3">2,345,773</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:12.54pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision</p></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-42</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="Tc_ibglq7akK0-VlfXveOgVOA_1_2"></a><a id="Tc_xh5uf0O40UaApPeRtAhEcQ_2_2"></a><a id="Tc_WxiFfRfP2Uu_sIGhhfI6Cg_2_7"></a><a id="Tc_FljkZMy6GUqzcFyh6bMalA_3_0"></a><a id="Tc_e0W99CZT_Uq12E5QIF4YKA_3_3"></a><a id="Tc_pqiFOqCCzEuYls9qVpr3tQ_3_4"></a><a id="Tc_Ckhn8z0p4ESDlj-lnSTpeQ_3_8"></a><a id="Tc_4sMwI8jd7ECeJcrh_ZYktQ_3_9"></a><a id="Tc_9Qn0Q-vms0qjo6xhFpFztg_3_10"></a><a id="Tc_e345D_iFwkGaYQCWCZHMXw_4_3"></a><a id="Tc_VVUpRbIyB0OAw_kurt5tgw_4_8"></a><a id="Tc_fvalwpCD806y1b55C3wNnA_5_0"></a><a id="Tc_5LHPk4Kxl0ub3ELHSS9glw_5_3"></a><a id="Tc_9oj5tGA0ckm154oOSAjfdQ_5_8"></a><a id="Tc_MYGN-s4nWE2f1A9KujmhLw_5_10"></a><a id="Tc_81-9mVOwSkqT6iQtKbDl2g_6_0"></a><a id="Tc_2P8HxoBHj0-IdMfnXeadMA_6_3"></a><a id="Tc_mgzmAb_VVEWdA-VAKzNKfA_6_8"></a><a id="Tc_9TgDKxFR30CE08IlwZYlxg_6_10"></a><a id="Tc_6x6N1yPHWECEdektEv-QCg_7_0"></a><a id="Tc_A2Bb_mTuFkOQ1j6-iYyrXg_7_3"></a><a id="Tc_FMNexwEogk-1Hkdpt34PGg_7_8"></a><a id="Tc_-Sn2HhG-T0Wb1Wpep2TqAg_7_10"></a><a id="Tc_IrIwF6izc0endO9frKAn6w_8_0"></a><a id="Tc_BwEsQYVxwkyfkW17cpbZ3w_8_3"></a><a id="Tc_de3GPGkZCka_FHd4RDBhbg_8_8"></a><a id="Tc_WdWILV0_vE-WT25oliZitg_8_10"></a><a id="Tc_PQ2MMTtW_06HYG-1jvuIOA_9_0"></a><a id="Tc_Jjb7euPzSkK6JRWpQDIjmg_9_3"></a><a id="Tc_bT_u3WtR6UeN1nznx8DBZg_9_4"></a><a id="Tc__S6529SrfkCQH6TXK17yFA_9_5"></a><a id="Tc_npgNhaHkWEeWcKclIAEVkg_9_8"></a><a id="Tc_83CtHQYzKkOZ9sUITtYQdg_9_9"></a><a id="Tc_1JIbsbfhgEe7awniPkAmDw_9_10"></a><a id="Tc_2Dnn6h59M0G-qxAQEo4e_Q_1_2"></a><a id="Tc_dr7fq69xQECwZuzYNUwYkA_2_2"></a><a id="Tc_fJfgv0WOvk6uzTzS3yZ7UA_2_5"></a><a id="Tc_0E22fYq-lEKaqMBYVvI8uA_3_0"></a><a id="Tc_9WGOifJlw0SB37n8Eyj83Q_4_0"></a><a id="Tc_Ijz2Z0v4ZE6cnPsfXA5odA_4_2"></a><a id="Tc_MezqlVjoyEy1XMEgW_ethQ_4_5"></a><a id="Tc_NxrXe78rw0WEOwLAJYijew_4_6"></a><a id="Tc_8fmlMidWg0CvXdIJVHNAcA_5_0"></a><a id="Tc_QCihI7aV1UumfHG8LLD4kA_5_6"></a><a id="Tc_G6IuyNCAIEuhqDl39pdC-Q_6_0"></a><a id="Tc_GbxFn_4Bp0KD2bp-x5HBAA_6_6"></a><a id="Tc_cGdV7_X0SkiqKc1m813AGg_7_0"></a><a id="Tc_UCFHnlGUpEqjmG-7MzEQQQ_7_6"></a><a id="Tc_qXBcFaq5kU2XkO2nL2ga9w_8_0"></a><a id="Tc_11kMJPmwzki_c-6-V9UF2g_8_6"></a><a id="Tc_tVxvhUmk6U-bnMQBnaWOwA_9_0"></a><a id="Tc_DEErgzWExkSdppoFow4GHQ_9_2"></a><a id="Tc_z92Orkqd8EKx2Y9-rqNH4w_9_3"></a><a id="Tc_vuVCCMVjcEiSxZh_VZG5Bg_9_5"></a><a id="Tc_q77kbKILt0aLjv6y6rH14w_9_6"></a><ix:continuation id="Tb_ypb8Fn3y7E27usil3s6BnA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">A reconciliation of the Company&#8217;s effective income tax rate to the U.S. statutory federal income tax rate of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_1Rox3tVpM06jSpO22paTog">21</ix:nonFraction>% and the Company&#8217;s California income tax rate of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="4" format="ixt:num-dot-decimal" name="limn:StatutoryStateIncomeTaxRate" scale="-2" id="Narr_RmOI5EyPP0WF2o8EHbwKEw">8.84</ix:nonFraction>%for the years ended December 31, 2025 and 2024 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_ip3OtThHdk2o8QI7dks-Tw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:304.85pt;padding:0pt;"/><td style="width:10pt;padding:0pt;"/><td style="width:42.4pt;padding:0pt;"/><td style="width:13.35pt;padding:0pt;"/><td style="width:6pt;padding:0pt;"/><td style="width:49.2pt;padding:0pt;"/><td style="width:10pt;padding:0pt;"/><td style="width:42.45pt;padding:0pt;"/><td style="width:13.35pt;padding:0pt;"/><td style="width:6.05pt;padding:0pt;"/><td style="width:42.35pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.49pt;"><td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:225.15pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style="height:9.74pt;"><td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:110.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:104.2pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_1yxgPT7eKE2PCKKWEyv1TQ_3_2">21.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_aB6xW2P4wEOYFlmnH81pfg_3_5">2,052,583</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_-ArVcktqBEG60e_JS8ND2A_3_7">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_gt31aPXKykC4c-4bEt6laQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">State taxes, net of federal expense</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_qhfpdEDtF0KqXBmxlGrjLQ_4_2">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:fixed-zero" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" id="Tc_A1et0hoDz0WoKaFqH3sbxA_4_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_kPB8_0aMbEOZFrP3axFy0g_4_7">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt:fixed-zero" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" id="Tc_8GGuPBupjUuhuQSX00Zbdg_4_10">&#8212;</ix:nonFraction></p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss on exchange of common stock for warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="4" format="ixt:num-dot-decimal" name="limn:EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent" scale="-2" id="Tc_Qft3Mpb38kGX4_2QUWclYg_5_2">3.74</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount" sign="-" scale="0" id="Tc_MuHuw57cCUCV3FG92_htRg_5_5">365,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="3" format="ixt:num-dot-decimal" name="limn:EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent" scale="-2" id="Tc_iZqoaU4o20SN_pmSmWV1cg_5_7">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of common stock to be issued for contingent liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="4" format="ixt:num-dot-decimal" name="limn:EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent" scale="-2" id="Tc_HvyIY0vmFUK2A_hyJwB3jQ_6_2">15.81</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="limn:EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount" sign="-" scale="0" id="Tc_LniosrZcjUSWheBneUFrJg_6_5">1,545,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="3" format="ixt:num-dot-decimal" name="limn:EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent" scale="-2" id="Tc_1LfrJbC7IUe_3SI6rJAbRA_6_7">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_S9hX2HN0VEKjkKcAFt7qSQ_7_2">0.31</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" id="Tc_6AoYzSOIIki4_XHRYqGdeQ_7_5">30,686</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="Tc_OfOp-PUhwEGWOcgvOuyBtw_7_7">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_JHC2uAOtiUy3Im-2kbKPrw_8_2">1.14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="Tc_3jsEwiDfeki_wYSS4VrVgA_8_5">110,897</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc_CGB0bHfxqkG0Xw4zIROLBw_8_7">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:12.54pt;"><td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision expense/(benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_dUnJdGIoQ0CW38_mC9zSwA_9_2">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_m9tLncCaPE2qcMywmn2cPw_9_7">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The significant components of the Company&#8217;s net deferred tax assets and liabilities as of December 31, 2025 and 2024 are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_si17NDbVF0G0waGb9x2h4w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:400.5pt;padding:0pt;"/><td style="width:13.05pt;padding:0pt;"/><td style="width:8.1pt;padding:0pt;"/><td style="width:51.95pt;padding:0pt;"/><td style="width:13.05pt;padding:0pt;"/><td style="width:8.1pt;padding:0pt;"/><td style="width:45.25pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.49pt;"><td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:126.45pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style="height:9.74pt;"><td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:60.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:53.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_k3uS2s-QwEqxqUmEGYKIFQ_4_3">230,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Startup expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="limn:DeferredTaxAssetsStartupExpenses" scale="0" id="Tc_o_z6jNCF90KCpsHSo-TmbQ_5_3">2,042,605</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Section 163(j) - Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetInterestCarryforward" scale="0" id="Tc_13m_8l-ku0OfTgClbq_QkQ_6_3">72,873</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_8DNmVgH5M0yBUnNh2Vpf_Q_7_3">2,345,773</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_zQOnStHJ8k2OylPkAwc60A_8_3">2,345,773</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:12.54pt;"><td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax asset, net of valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations in a multitude of jurisdictions. The Company recognizes liabilities for uncertain tax positions based on a two-step process. First, management determines whether it is more likely than not that the tax positions will be sustained on audit, including resolution of related appeals or litigation processes, based on their technical merits. Second, management measures the tax benefit of those positions as the largest amount that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes. As of December 31, 2025 and 2024, the Company did <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_pkiytGMEkUuzrU07Knv6Xw"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_5eBDfx6M40S-lvOsTxWd7A">no</ix:nonFraction></ix:nonFraction>t have any uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s policy is to recognize interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations and any accrued interest and penalties on the related tax liability line in the consolidated balance sheet. As of December 31, 2025 and 2024, <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" scale="0" id="Narr_78k9FCMIcEySx8xyjER_aA"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" scale="0" id="Narr_C5ny6z706km9C18Fy58W8w">no</ix:nonFraction></ix:nonFraction> accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet. Further, during the years ended December 31, 2025 and 2024, the Company did <ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxesPaidNet" scale="0" id="Narr_SKp6qWZwx0WH7a8S38sn5g"><ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxesPaidNet" scale="0" id="Narr_EdBig4uPe0uM6dvHCLc3iQ">no</ix:nonFraction></ix:nonFraction>t remit payment for any income tax obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company files income tax returns in the U.S. federal jurisdiction and California jurisdictions. There are currently no pending income tax examinations. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent the tax attributes are utilized in a future period. The Company&#8217;s income tax returns since 2022 are subject to examination by the IRS and state tax authorities.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww" name="us-gaap:SubsequentEventsTextBlock" id="Tb_M32f5vCp4Uye_IqHqOgTSA" continuedAt="Tb_M32f5vCp4Uye_IqHqOgTSA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note&#160;10. Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has completed an evaluation of all subsequent events through the date of this filing to ensure that these consolidated financial statements include appropriate disclosure of events both recognized in the consolidated financial statements and events which occurred but were not recognized in the consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On February 6, 2026, the Company entered into a settlement and release agreement with the Holder, pursuant to which the Company agreed to issue <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_IbplB2gb40qdMMz9BIq6qA" decimals="INF" format="ixt:num-dot-decimal" name="limn:SharesIssuedForSurrenderAndCancellationOfWarrants" scale="0" id="Narr_l6IclT1oJU6N38lMCOjcNQ">4,000,000</ix:nonFraction> shares of its common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qRAwhaLP1EWqdsQcq1AtbA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr__dlc3LnzRkyjKSUswLpNKg">0.0001</ix:nonFraction> per share, to the Holder in exchange for the surrender and cancellation of <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_IbplB2gb40qdMMz9BIq6qA" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" scale="0" id="Narr_BUH3-Rg_RE-RGF-BVsAoPw">805,377</ix:nonFraction> warrants to purchase shares of common stock held by the Holder. The Company has determined this represents a Type I subsequent event in accordance with ASC 855, in which the Company obtained additional evidence about conditions that existed at the date of the consolidated balance sheets. As such, the Company has recorded the $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="As_Of_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qRAwhaLP1EWqdsQcq1AtbA" decimals="0" format="ixt:num-dot-decimal" name="limn:CommonStockPayable" scale="0" id="Narr_AgV6E5-giEyQDox8nBN5eg">7,360,000</ix:nonFraction> as settlement payable, which </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-43</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><ix:continuation id="Tb_M32f5vCp4Uye_IqHqOgTSA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">was calculated using the fair value of the Company&#8217;s common stock on February 6, 2026, which was the day that stock was issued to the Holder, in its consolidated balance sheets as of December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Settlement Agreement, the Company and the Holder agreed to dismiss (a) an action pending in the United States District Court for the Central District of California and (b) an action pending in the United States District Court for the Southern District of New York, in which previously the Court entered a default judgment against the Company in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_10_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_6H9UrA2MZUWmfOm8ySparQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="0" id="Narr_Fy94GQepSUSQUPeb6HhWkw">7,500,000</ix:nonFraction> plus approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_10_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_6H9UrA2MZUWmfOm8ySparQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementInterest" scale="0" id="Narr_o8HteKEgcEqVLRshnFz_fg">515,000</ix:nonFraction> in interest, which judgment was registered in the Central District of California in the fourth quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 18, 2026, the Company completed a &#8220;best efforts&#8221; public offering of (i) <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_JSVgKnyZI0uvIBPJsCar7A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_5IWQ2_ORY0iAdqXjaa8RUQ">8,270,000</ix:nonFraction> shares of its common stock, (ii) <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_BC5_6M-QyUmQOf1sjtWaMg" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="0" id="Narr_sJ08dF6mdkGPHHb3M6b9Iw">5,543,000</ix:nonFraction> Pre-Funded Warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_eTUFwzCAf0WPdoyAqoxppg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_6Yz6p_1U5k-xFqA7Er-jPQ">5,543,000</ix:nonFraction> shares of common stock and (ii) <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_YV5sLiK4506wsErDca1zNw" decimals="INF" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="0" id="Narr_nG8LMFCHtkiTB8hs7eqqXw">13,813,000</ix:nonFraction> common stock purchase warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_Y7EtLUI_pk6RZ-oTbRPBxg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_liSWkTV2QkOU1dAHME6L7w">20,719,500</ix:nonFraction> shares of common stock, at a combined public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_2_18_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_1t1X0h92206D-tAJKXlt8Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_zD-YVbLLQEyz9W7RxzwtiQ">0.29</ix:nonFraction> per share (or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_U70qipalZUSb0nCwfCrzfg" decimals="4" format="ixt:num-dot-decimal" name="limn:ClassOfWarrantOrRightIssuePricePerWarrant" scale="0" id="Narr_KEhNTgeWb0S1PsEwkUil8g">0.2899</ix:nonFraction> per Pre-Funded Warrant) and accompanying warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each Pre-Funded Warrant has an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kX_yWG231E-RYOerQjujQA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_BN3vaCAvhkaI-DapB9sfZg">0.0001</ix:nonFraction> per share upon issuance for <span style="-sec-ix-hidden:Hidden_pRGIcWXwZE-WeEaxj87wJg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> share of common stock and will not expire prior to exercise. Each Warrant has an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wuQDuaMWckW-5cDSn3bI2w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_mg43FjDajEu150tSrkmN6w">0.29</ix:nonFraction> per share, is exercisable upon issuance for<span style="-sec-ix-hidden:Hidden_kq3mrqvJyU-ExJ_p7HGPjQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> one and a half</span></span> shares of common stock, and will expire <ix:nonNumeric contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wuQDuaMWckW-5cDSn3bI2w" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_6d7YW7A_jkKNUWsuvX6SFw">five years</ix:nonNumeric> following the date of issuance. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the common stock and the exercise price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Offering, on February 17, 2026, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers party thereto. The Purchase Agreement contains customary representations, warranties and agreements of the Company and the purchasers and customary indemnification rights and obligations of the parties. Pursuant to the Purchase Agreement, the Company agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock or file any registration statement or prospectus, or any amendment or supplement thereto for <ix:nonNumeric contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_809IbYMTbUCQEIVjWuaGsA" format="ixt-sec:durwordsen" name="limn:PeriodOfNonIssuanceOfCommonStockFollowingClosingDate" id="Narr_A59JFLOeAkKO2EUQ26KWlg">180 days</ix:nonNumeric> after the closing date of the Offering, subject to certain exceptions. The Company also agreed not to effect or enter into an agreement to effect any issuance of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock involving a Variable Rate Transaction (as defined in the Purchase Agreement) until <ix:nonNumeric contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_809IbYMTbUCQEIVjWuaGsA" format="ixt-sec:durwordsen" name="limn:PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate" id="Narr_vIAu79Sxakuf3-FIrmboAw">180 days</ix:nonNumeric> after the closing date of the Offering, subject to certain exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In connection with the Offering, on February 17, 2026, the Company entered into a placement agency agreement with Maxim Group LLC, as placement agent in connection with the Offering (the &#8220;Placement Agent&#8221;). The Company paid the Placement Agent a cash fee of <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_809IbYMTbUCQEIVjWuaGsA" decimals="3" format="ixt:num-dot-decimal" name="limn:PlacementAgentCashFeePercentage" scale="-2" id="Narr_LUFMxpstpEiCKUh4BrZpwQ">8.0</ix:nonFraction>% of the aggregate gross proceeds raised in the Offering. The Company also agreed to reimburse the Placement Agent for all reasonable out-of-pocket costs and expenses incurred in connection with the Offering in an aggregate amount up to $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_809IbYMTbUCQEIVjWuaGsA" decimals="0" format="ixt:num-dot-decimal" name="limn:MaximumReimbursementForPlacementAgentExpenses" scale="0" id="Narr_tP474REI3kSSeZvMIFX6-Q">100,000</ix:nonFraction>. In addition, the Company issued to the Placement Agent warrants (the &#8220;Placement Agent Warrants&#8221;) to purchase <ix:nonFraction unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw" contextRef="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_go0DO65rkkqPaWM8iCPEeg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_r2vPchbpwEGka7BsKuxbYw">690,650</ix:nonFraction> shares of common stock (representing <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_0DwlS1YhD0uVubSzwvOJJQ" decimals="3" format="ixt:num-dot-decimal" name="limn:PercentOfSharesIssuedInOffering" scale="-2" id="Narr_bZRMzEVAXUqL87I-hamsGA">5.0</ix:nonFraction>% of the number of shares of common stock sold in the Offering). The Placement Agent Warrants are immediately exercisable at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw" contextRef="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_01Es_yiBG0a6u9R-nLydbg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_KUtDIRy5dUK2x1kxzANWqA">0.319</ix:nonFraction> (or <ix:nonFraction unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA" contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_0DwlS1YhD0uVubSzwvOJJQ" decimals="2" format="ixt:num-dot-decimal" name="limn:PercentOfOfferingPriceRepresentingExercisePrice" scale="-2" id="Narr_HeAb32_0zU2pjo-hi4SjkA">110</ix:nonFraction>% of the public offering price for the shares of common stock and common warrants offered in the Offering) and will expire on the <span style="-sec-ix-hidden:Hidden_rGRJ0qc7tEGPO6XNQVjRbw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fifth anniversary</span></span> of the commencement of sales of the Offering. On February 18, 2026, in connection with the Offering, the Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_809IbYMTbUCQEIVjWuaGsA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_9MVNbZhrb0yLt4Adjvjl-Q">3.46</ix:nonFraction> million, after deducting the estimated offering expenses payable by the Company, including the placement agent fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On February 20, 2026, the Company issued a payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ" contextRef="Duration_2_20_2026_To_2_20_2026_srt_CounterpartyNameAxis_limn_InnobationBioCoLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_3V203J1Zg0mfoaBaDb3DcQ" decimals="0" format="ixt:num-dot-decimal" name="limn:PaymentForCostsAssociatedWithClinicalTrials" scale="0" id="Narr_aK-snCkrO0G1gziIs4Zp6Q">1,000,000</ix:nonFraction> to InnoBation Bio Co. Ltd. for costs associated to begin the Phase 1 clinical trials of IBA101, the Company&#8217;s product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">F-44</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;display:flex;flex-direction:column;flex-grow:1;justify-content:center;max-width:100%;position:relative;z-index:1;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_664cb280_2c39_4a43_a6fb_454507974e31"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LIMINATUS PHARMA,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Up to 20,688,000 Shares of Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRELIMINARY PROSPECTUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The date of this prospectus is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2026.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_1e420ef5_3e66_4d14_ae17_f3af34d6fa36"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PART&#160;II - INFORMATION NOT REQUIRED IN PROSPECTUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 13. Other Expenses of Issuance and Distribution.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth an estimate of the fees and expenses relating to the issuance and distribution of the securities being registered hereby, all of which shall be borne by the registrant. All of such fees and expenses, except for the SEC registration fee, are estimated:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:449.6pt;padding:0pt;"/><td style="width:14.35pt;padding:0pt;"/><td style="width:9.2pt;padding:0pt;"/><td style="width:66.85pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:449.6pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:66.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:449.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SEC registration fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:66.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">338</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:449.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounting fee and expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:66.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:449.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal fees and expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:66.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:449.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial printing and miscellaneous expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:66.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:top;width:449.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:66.85pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_2c4d704f_74c7_41d2_9b52_082d7be8987c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 14. Indemnification of Officers and Directors.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Section 145(a) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), because he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Section 145(b) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly and reasonably entitled to indemnity for such expenses that the Court of Chancery or other adjudicating court shall deem proper.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Section 145(g) of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the corporation would have the power to indemnify the person against such liability under Section 145 of the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Our charter contains provisions limiting the liability of the members of the Company&#8217;s Board, and the Company&#8217;s bylaws provide that the Company will indemnify each of the members of the Company&#8217;s Board and officers to the fullest extent permitted under Delaware law. The Company&#8217;s bylaws will also provide the Board with discretion to indemnify employees and agents of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has entered into indemnification agreements with each of its directors and executive officers and certain other key employees. The indemnification agreements provide that the Company will indemnify each of its directors and executive officers and such other key employees against any and all expenses incurred by such director, executive officer or other key employee because of his or her status as one of the Company&#8217;s directors, executive officers or other key employees, to the fullest extent permitted by Delaware law, the Company&#8217;s charter and bylaws. In addition, the indemnification agreements provide that, to the fullest extent permitted by Delaware law, the Company will advance all expenses incurred by its directors, executive officers and other key employees in connection with a legal proceeding involving his or her status as a director, executive officer or key employee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See &#8220;Item 17. Undertakings&#8221; for a description of the SEC&#8217;s position regarding such indemnification provisions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">II-1</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_be46ff80_fa17_4085_bd41_0f39f51830c0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 15. Recent Sales of Unregistered Securities.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company issued the following securities in transactions not requiring registration under the Securities Act of 1933, as amended:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">In connection with the Business Combination, pursuant to the terms of a subscription agreement with an accredited investor (the &#8220;PIPE Investor&#8221;), the Company issued and sold to the PIPE Investor, in a private placement closed concurrently with the closing of the Business Combination, 1,500,000 shares of Common Stock at $10.00 per share, for an aggregate purchase price of $15,000,000, issued in reliance on the exemption provided by Section 4(a)(2) of the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">In addition, at the closing of the Business Combination, the Company settled Iris&#8217; liabilities for $7,000,000 of the deferred underwriting fees incurred prior to the closing for 700,000 shares of Common Stock to the underwriters in Iris&#8217;s initial public offering. At the closing of Business Combination, the shares were not issued to the underwriter and the Company recorded as a liability with a fair value of $7,049,000. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $7,245,000. The shares were issued in reliance on the exemption provided by Section 4(a)(2) of the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">On July 16, 2025, the Company entered into a settlement and release agreement (the &#8220;Settlement Agreement&#8221;) with Alta Partners, LLC (&#8220;Alta&#8221;), pursuant to which the Company agreed to issue 350,000 shares of Common Stock to Alta in exchange for the surrender and cancellation of 1,000,000 warrants to purchase shares of Common Stock held by Alta. The issuance of the shares for the warrants was in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 6, 2026, the Company entered into a settlement and release agreement (the &#8220;Settlement Agreement&#8221;) with Clear Street LLC (&#8220;Clear Street&#8221;), pursuant to which the Company agreed to issue 4,000,000 shares of Common Stock to Clear Street in exchange for the surrender and cancellation of 805,377 warrants to purchase shares of Common Stock held by Clear Street. Pursuant to the Settlement Agreement, the Company and Clear Street agreed to dismiss (a) an action pending in the United States District Court for the Central District of California and (b) an action pending in the United States District Court for the Southern District of New York, in which, on September 11, 2025, the Court entered a default judgment against the Company in the amount of $7,500,000 plus approximately $515,000 in interest, which judgment was registered in the Central District of California on October 22, 2025. The issuance of the shares for the warrants was in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 3, 2026, the Company entered into the Inducement Letter Agreement with Armistice Capital Master Fund Ltd. (&#8220;Armistice&#8221;), which was a holder of certain warrants (the &#8220;Existing Warrants&#8221;) to purchase up to 10,344,000 shares of the Common Stock. The Existing Warrants were originally issued on February 18, 2026, with an exercise price of $0.29 per share. The issuance of the shares of Common Stock upon exercise of the Existing Warrants is registered pursuant to a registration statement on Form S-1 (File No. 333-293364), which was declared effective by the Securities and Exchange Commission on February 13, 2026. Pursuant to the Inducement Letter Agreement, Armistice agreed to exercise the Existing Warrants for cash at a reduced exercise price of $0.18 per share in consideration for the Company&#8217;s agreement to issue the Inducement Warrants to purchase up to an aggregate of 20,688,000 shares of Common Stock at an exercise price per share of $0.18. The Inducement Warrants were issued to Armistice in connection with a private placement pursuant to Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder, and the shares underlying the Inducement Warrants are issuable upon exercise of the Inducement Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">II-2</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_493dd83e_0414_4b22_b47f_64ef15f8e35b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 16. Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The list of exhibits in the Exhibit Index to this registration statement is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_91c79e31_79f4_46e5_b694_3510f02ba6ee"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 17. Undertakings.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">The undersigned registrant hereby undertakes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities offered (if the total dollar value of the securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">provided, however, that the undertakings set forth in paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended, that are incorporated by reference in this registration statement or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of this registration statement;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">That, for the purpose of determining any liability under the Securities Act of 1933, as amended, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">That, for the purpose of determining liability under the Securities Act of 1933, as amended, to any purchaser:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Each prospectus filed by the registrant pursuant to Rule 424 (b)(3) shall be deemed to be part of this registration statement as of the date the filed prospectus was deemed part of and included in this registration statement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(l)(i), (vii) or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act of 1933, as amended, shall be deemed to be part of and included in the registration statement as of the earlier of the date such prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date;</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">II-3</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">That, for the purpose of determining liability of the registrant under the Securities Act of 1933, as amended, to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(iv)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">That, for purposes of determining any liability under the Securities Act of 1933, as amended, each filing of the registrant&#8217;s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934, as amended) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933, as amended, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933, as amended, and will be governed by the final adjudication of such issue.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">II-4</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_cf28b216_5e81_4e2b_8645_304e3891d856"></a><a id="SIGNATURES_585796"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fullerton, State of California, on June 23, 2026.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:274.55pt;padding:0pt;"/><td style="width:16.1pt;padding:0pt;"/><td style="width:249.35pt;padding:0pt;"/></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:274.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:265.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LIMINATUS PHARMA, INC.</b></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:274.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:265.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:274.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:249.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Chris Kim</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:274.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:249.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chris Kim</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:274.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:249.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">POWERS OF ATTORNEY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each person whose signature appears below hereby constitutes and appoints Chris Kim as the individual&#8217;s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for the person and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement and any or all amendments, including post-effective amendments to the Registration Statement, including a prospectus or an amended prospectus therein and any Registration Statement for the same offering that is to be effective upon filing pursuant to Rule 462 under the Securities Act, and all other documents in connection therewith to be filed with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact as agents or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Act of 1933, this registration statement and power of attorney have been signed by the following persons in the capacities and on the dates indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:170.95pt;padding:0pt;"/><td style="width:10.8pt;padding:0pt;"/><td style="width:187.9pt;padding:0pt;"/><td style="width:12.54pt;padding:0pt;"/><td style="width:157.81pt;padding:0pt;"/></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:170.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:bottom;width:10.8pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:187.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;width:12.55pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:157.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:170.95pt;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:170.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ Chris Kim</i></p></td><td style="vertical-align:bottom;width:10.8pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and Director</p></td><td style="vertical-align:bottom;width:12.55pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 23, 2026</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:170.95pt;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chris Kim</p></td><td style="vertical-align:bottom;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td><td style="vertical-align:bottom;width:12.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:170.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:170.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ Scott Dam</i></p></td><td style="vertical-align:bottom;width:10.8pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:bottom;width:12.55pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 23, 2026</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:170.95pt;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Scott Dam</p></td><td style="vertical-align:bottom;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Financial and Accounting Officer)</i></p></td><td style="vertical-align:bottom;width:12.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:170.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:170.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ Eun Sook Lee</i></p></td><td style="vertical-align:bottom;width:10.8pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:12.55pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 23, 2026</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:170.95pt;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eun Sook Lee</p></td><td style="vertical-align:bottom;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:170.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:170.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ Nicholas Fernandez</i></p></td><td style="vertical-align:bottom;width:10.8pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:12.55pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 23, 2026</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:170.95pt;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nicholas Fernandez</p></td><td style="vertical-align:bottom;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:170.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:170.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ Ji Yeon Baek</i></p></td><td style="vertical-align:bottom;width:10.8pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:12.55pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 23, 2026</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:170.95pt;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ji Yeon Baek</p></td><td style="vertical-align:bottom;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:170.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:170.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ Philip Lemons</i></p></td><td style="vertical-align:bottom;width:10.8pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:12.55pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 23, 2026</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:170.95pt;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Philip Lemons</p></td><td style="vertical-align:bottom;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:170.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:170.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ Richard Baek</i></p></td><td style="vertical-align:bottom;width:10.8pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:12.55pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 23, 2026</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:170.95pt;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard Baek</p></td><td style="vertical-align:bottom;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:187.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:157.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">II-5</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><a id="_8b065812_dbe2_4f58_938b_4a662314051a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXHIBIT&#160;INDEX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:45pt;padding:0pt;"/><td style="width:12.65pt;padding:0pt;"/><td style="width:482.35pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:top;width:45pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:12.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:482.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:top;width:45pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Exhibit No.</b></p></td><td style="vertical-align:top;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:482.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td></tr><tr style="height:34.74pt;"><td style="vertical-align:top;width:45pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2.1</p></td><td style="vertical-align:top;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:482.35pt;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465925010605/tm2432198-7_424b3.htm#tANNA"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Business Combination Agreement, dated November&#160;30, 2022, as amended, by and among Iris Acquisition Corp, Iris Parent Holding Corp., Liminatus Pharma, LLC, Liminatus Pharma Merger Sub,&#160;Inc. and SPAC Merger Sub,&#160;Inc. (incorporated by reference to Annex A to the proxy statement/prospectus filed with the SEC on February&#160;7, 2025).</span></a></p></td></tr><tr style="height:34.49pt;"><td style="vertical-align:top;width:45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2.2</p></td><td style="vertical-align:top;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465925045127/tm2513673d1_ex2-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Merger of Liminatus Pharma, LLC and Liminatus Pharma Merger Sub,&#160;Inc. filed on April&#160;30, 2025 (incorporated by reference to Exhibit&#160;2.2 to the Registrant&#8217;s Current Report on Form&#160;8-K filed with the SEC on May&#160;6, 2025).</span></a></p></td></tr><tr style="height:22.99pt;"><td style="vertical-align:top;width:45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2.3</p></td><td style="vertical-align:top;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465925045127/tm2513673d1_ex2-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Merger of Iris Acquisition Corp and SPAC Merger Sub,&#160;Inc. filed on April&#160;30, 2025 (incorporated by reference to Exhibit&#160;2.3 to the Registrant&#8217;s Current Report on Form&#160;8-K filed with the SEC on May&#160;6, 2025).</span></a></p></td></tr><tr style="height:34.49pt;"><td style="vertical-align:top;width:45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2.4</p></td><td style="vertical-align:top;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465926064585/tm2615228d1_ex2-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Merger Agreement, dated May&#160;17, 2026, by and among Liminatus Pharma,&#160;Inc., InnocsAI LLC and NamChul Jung, as the Members&#8217; Representative (incorporated by reference to Exhibit&#160;2.1 to the Current Report on Form&#160;8-K filed by the Registrant with the SEC on May&#160;20, 2026).</span></a></p></td></tr><tr style="height:34.49pt;"><td style="vertical-align:top;width:45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465925045127/tm2513673d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation of Iris Parent Holding Corp. (renamed Liminatus Pharma,&#160;Inc.) filed on April&#160;30, 2025 (incorporated by reference to Exhibit&#160;3.1 to the Registrant&#8217;s Current Report on Form&#160;8-K filed with the SEC on May&#160;6, 2025).</span></a></p></td></tr><tr style="height:22.99pt;"><td style="vertical-align:top;width:45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465926023467/tm267974d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of Liminatus Pharma,&#160;Inc., as amended (incorporated by reference to Exhibit&#160;3.1 to the Current Report on Form&#160;8-K filed by the Registrant with the SEC on March&#160;4, 2026).</span></a></p></td></tr><tr style="height:22.99pt;"><td style="vertical-align:top;width:45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465924082709/tm2314369d12_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Common Stock Certificate (incorporated by reference to Exhibit&#160;4.1 of the Registration Statement on Form&#160;S-4 (File No.&#160;333-275409), filed by the Registrant with the SEC on November&#160;8, 2023).</span></a></p></td></tr><tr style="height:22.99pt;"><td style="vertical-align:top;width:45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1831874/000110465921012972/tm215406d1_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Warrant Certificate (incorporated by reference to Exhibit&#160;4.3 of the Registration Statement on Form&#160;S-1 (File No.&#160;333-252413), filed by Iris Acquisition Corp with the SEC on January&#160;25, 2021).</span></a></p></td></tr><tr style="height:34.49pt;"><td style="vertical-align:top;width:45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1831874/000110465921034552/tm2192631d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Warrant Agreement, dated as of March&#160;4, 2021, between Continental Stock Transfer&#160;&amp; Trust Company and Iris Acquisition Corp (incorporated by reference to Exhibit&#160;4.1 of Form&#160;8-K of Iris Acquisition Corp filed with the SEC on March&#160;10, 2021).</span></a></p></td></tr><tr style="height:34.49pt;"><td style="vertical-align:top;width:45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.4</p></td><td style="vertical-align:top;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465925045127/tm2513673d1_ex4-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Assumption of Warrant Agreement, dated as of April&#160;30, 2025, by and among Iris Acquisition Corp, Iris Parent Holding Corp. and Continental Stock Transfer&#160;&amp; Trust Company (incorporated by reference to Exhibit&#160;4.4 to the Registrant&#8217;s Current Report on Form&#160;8-K filed with the SEC on May&#160;6, 2025).</span></a></p></td></tr><tr style="height:22.99pt;"><td style="vertical-align:top;width:45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465926017134/tm266571d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Common Stock Purchase Warrant (incorporated by reference to Exhibit&#160;4.1 to the Current Report on Form&#160;8-K filed by the Registrant with the SEC on February&#160;18, 2026).</span></a></p></td></tr><tr style="height:22.99pt;"><td style="vertical-align:top;width:45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.6</p></td><td style="vertical-align:top;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465926012942/limn-20250930xex4d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Pre-Funded Warrant (incorporated by reference to Exhibit&#160;4.7 of the Company&#8217;s Registration Statement on Form&#160;S-1 (File No.&#160;333-293364), filed by the Registrant with the SEC on February&#160;11, 2026).</span></a></p></td></tr><tr style="height:22.99pt;"><td style="vertical-align:top;width:45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.7</p></td><td style="vertical-align:top;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465926017134/tm266571d1_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Placement Agent Warrant, dated February&#160;18, 2026 (incorporated by reference to Exhibit&#160;4.3 to the Current Report on Form&#160;8-K filed by the Registrant with the SEC on February&#160;18, 2026).</span></a></p></td></tr><tr style="height:22.99pt;"><td style="vertical-align:top;width:45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.8</p></td><td style="vertical-align:top;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465926070173/tm2616851d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of New Black-Scholes Warrant (incorporated by reference to Exhibit&#160;4.1 to the Current Report on Form&#160;8-K filed by the Registrant with the SEC on June&#160;3, 2026).</span></a></p></td></tr><tr style="height:22.99pt;"><td style="vertical-align:top;width:45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.9</p></td><td style="vertical-align:top;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465926070173/tm2616851d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of New Change of Control Warrant (incorporated by reference to Exhibit&#160;4.2 to the Current Report on Form&#160;8-K filed by the Registrant with the SEC on June&#160;3, 2026).</span></a></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">5.1*</p></td><td style="vertical-align:top;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="limn-20260331xex5d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Opinion of Loeb&#160;&amp; Loeb LLP</span></a></p></td></tr><tr style="height:45.99pt;"><td style="vertical-align:top;width:45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465925045127/tm2513673d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Registration Rights Agreement, dated as of April&#160;30, 2025, by and among Iris Acquisition Corp, Iris Parent Holding Corp, Iris Acquisition Holdings LLC, Cantor Fitzgerald&#160;&amp; Co. and certain other parties thereto (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form&#160;8-K filed with the SEC on May&#160;6, 2025).</span></a></p></td></tr><tr style="height:34.49pt;"><td style="vertical-align:top;width:45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465925010605/tm2432198-7_424b3.htm#tANNG"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lock-Up Agreement, dated November&#160;30, 2022, by and among Iris Parent Holding Corp., Iris Acquisition Holdings LLC and certain members of Liminatus Pharma, LLC (incorporated by reference to Annex G to the proxy statement/prospectus filed with the SEC on February&#160;7, 2025).</span></a></p></td></tr><tr style="height:34.49pt;"><td style="vertical-align:top;width:45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465925003835/tm2432198d3_ex10-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Waiver and Consent, dated January&#160;2, 2025, by and between Iris Parent Holding Corp. and Iris Acquisition Holdings LLC (incorporated by reference to Exhibit&#160;10.8 of the Registration Statement on Form&#160;POS-AM (File No.&#160;333-275409), filed by the Registrant with the SEC on January&#160;16, 2025).</span></a></p></td></tr><tr style="height:22.99pt;"><td style="vertical-align:top;width:45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465924082709/tm2314369d12_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Indemnity Agreement (incorporated by reference to Exhibit&#160;10.4 of the Registration Statement on Form&#160;S-4 (File No.&#160;333-275409), filed by the Registrant with the SEC on November&#160;8, 2023).</span></a></p></td></tr><tr style="height:22.99pt;"><td style="vertical-align:top;width:45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.5</p></td><td style="vertical-align:top;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465925010605/tm2432198-7_424b3.htm#tANNB"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Liminatus Pharma,&#160;Inc. 2025 Omnibus Equity Incentive Plan (incorporated by reference to Annex B to the proxy statement/prospectus filed with the SEC on February&#160;7, 2025).</span></a></p></td></tr><tr style="height:34.49pt;"><td style="vertical-align:top;width:45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.6</p></td><td style="vertical-align:top;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465924071657/tm2314369d7_ex10-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License and Development Agreement entered into as of March&#160;30, 2022, by and between InnoBation Bio Co.,&#160;Ltd., as licensor, and Valetudo Therapeutics LLC, as licensee (incorporated by reference to Exhibit&#160;10.7 of the Registration Statement on Form&#160;S-4/A (File No.&#160;333-275409), filed by the Registrant with the SEC on June&#160;14, 2024).</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">II-6</p></div></div></div>
<div style="align-items:stretch;break-after:page;clear:both;display:flex;flex-direction:column;min-height:792pt;overflow:hidden;position:relative;width:612pt;border:1px solid #ccc;margin:10pt auto 10pt auto;"><div style="display:flex;flex-direction:column;flex-grow:1;padding-left:36pt;padding-right:36pt;position:relative;width:540pt;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:20pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;flex-grow:1;max-width:100%;position:relative;z-index:1;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:45pt;padding:0pt;"/><td style="width:12.65pt;padding:0pt;"/><td style="width:482.35pt;padding:0pt;"/></tr><tr style="height:34.49pt;"><td style="vertical-align:top;width:45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.7</p></td><td style="vertical-align:top;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465924071657/tm2314369d7_ex10-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Assignment of Contract entered into as of October&#160;1, 2022 by and between Valetudo Therapeutics and Liminatus Pharma, LLC (incorporated by reference to Exhibit&#160;10.8 of the Registration Statement on Form&#160;S-4/A (File No.&#160;333-275409), filed by the Registrant with the SEC on June&#160;14, 2024).</span></a></p></td></tr><tr style="height:34.49pt;"><td style="vertical-align:top;width:45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.8</p></td><td style="vertical-align:top;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465925006325/tm2432198d5_ex10-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Acknowledgement and Release, dated as of January&#160;24, 2025, by and between Viral Gene,&#160;Inc. and Liminatus Pharma, LLC (incorporated by reference to Exhibit&#160;10.9 of the Registration Statement on Form&#160;POS AM (File No.&#160;333-275409), filed by the Registrant with the SEC on January&#160;27, 2025).</span></a></p></td></tr><tr style="height:34.49pt;"><td style="vertical-align:top;width:45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:482.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465926012942/limn-20250930xex10d11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated as of April&#160;15, 2018, by and between the Registrant and Chris Kim (incorporated by reference to Exhibit&#160;10.11 of the Registration Statement on Form&#160;S-1 (File No.&#160;333-293364), filed by the Registrant with the SEC on February&#160;11, 2026).</span></a></p></td></tr><tr style="height:22.99pt;"><td style="vertical-align:top;width:45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.10</p></td><td style="vertical-align:top;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:482.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465926017134/tm266571d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Placement Agency Agreement dated February&#160;17, 2026, between the Company and Maxim Group LLC (incorporated by reference to Exhibit&#160;10.1 to the Current Report on Form&#160;8-K filed by the Registrant with the SEC on February&#160;18, 2026).</span></a></p></td></tr><tr style="height:34.49pt;"><td style="vertical-align:top;width:45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.11</p></td><td style="vertical-align:top;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:482.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465926017134/tm266571d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Securities Purchase Agreement, dated February&#160;17, 2026, between the Company and the purchasers party thereto (incorporated by reference to Exhibit&#160;10.2 to the Current Report on Form&#160;8-K filed by the Registrant with the SEC on February&#160;18, 2026).</span></a></p></td></tr><tr style="height:22.99pt;"><td style="vertical-align:top;width:45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.12</p></td><td style="vertical-align:top;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:482.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465926017134/tm266571d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Lock-up Agreement (incorporated by reference to Exhibit&#160;10.3 to the Current Report on Form&#160;8-K filed by the Registrant with the SEC on February&#160;18, 2026).</span></a></p></td></tr><tr style="height:22.99pt;"><td style="vertical-align:top;width:45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.13</p></td><td style="vertical-align:top;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:482.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465926070173/tm2616851d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Inducement Letter (incorporated by reference to Exhibit&#160;10.1 to the Current Report on Form&#160;8-K filed by the Registrant with the SEC on June&#160;3, 2026).</span></a></p></td></tr><tr style="height:22.99pt;"><td style="vertical-align:top;width:45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">21.1</p></td><td style="vertical-align:top;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1971387/000110465925045127/tm2513673d1_ex21-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of Subsidiaries of Liminatus Pharma,&#160;Inc. (incorporated by reference to Exhibit&#160;21.1 to the Registrant&#8217;s Current Report on Form&#160;8-K filed with the SEC on May&#160;6, 2025).</span></a></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">23.1*</p></td><td style="vertical-align:top;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="limn-20260331xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of WithumSmith+Brown, PC&#160;&#8212; independent registered public accounting firm.</span></a></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">23.2*</p></td><td style="vertical-align:top;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="limn-20260331xex5d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Loeb&#160;&amp; Loeb LLP (included as part of Exhibit&#160;5.1 hereto).</span></a></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">24.1*</p></td><td style="vertical-align:top;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#SIGNATURES_585796"><span style="font-style:normal;font-weight:normal;">Power of Attorney (contained on the signature page&#160;to this registration statement).</span></a></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:top;width:45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">107*</p></td><td style="vertical-align:top;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:482.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="limn-20260331xexfees.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Calculation of Registration Fee Table.</span></a></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*</span></span>Filed herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 18pt 0pt;">II-7</p></div></div></div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>limn-20260331xex5d1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 6/24/2026 01:16:37 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 5.1</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.9%;"><tr style=""><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><img src="limn-20260331xex5d1001.jpg" alt="Graphic" style="display:inline-block;height:89.98pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:89.98pt;"></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LOEB &amp; LOEB LLP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">345 Park Avenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">New York, NY 10154</p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Main</b>&#160;&#160;&#160;&#160;212.407.4000</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Fax</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;212.407.4990</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">June 23, 2026</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:45.23%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liminatus Pharma, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2251 Stern Goodman Street, Suite E,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fullerton, CA 92833</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ladies and Gentlemen:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have acted as counsel to Liminatus Pharma, Inc., a Delaware corporation (the &#8220;Company&#8221;), in connection with the Registration Statement on Form S-1 to which this opinion is filed as an exhibit (the &#8220;Registration Statement&#8221;), filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), for the registration for resale by the selling securityholder listed therein (the &#8220;Selling Securityholder&#8221;) of up to 20,688,000 shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;), that are issuable upon the exercise of the Company&#8217;s warrants at an exercise price per share of $0.18 (the &#8220;Inducement Warrants&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Shares may be offered from time to time, pursuant to Rule 415 of the General Rules and Regulations of the Commission promulgated under the Securities Act as set forth in the Registration Statement, any amendment thereto, the prospectus contained in the Registration Statement (the &#8220;Prospectus&#8221;) and one or more supplements to the Prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with this opinion, we have examined and relied upon the Registration Statement and the Inducement Warrants. We have also examined originals or copies, certified or otherwise identified to our satisfaction, of the Company&#8217;s certificate of incorporation and bylaws, each as amended, and such corporate records of the Company and other certificates and documents of officials of the Company, public officials and others as we have deemed appropriate for purposes of this letter. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, and the conformity to authentic original documents of all copies submitted to us as conformed and certified or reproduced copies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based upon the foregoing and subject to the assumptions, exceptions, qualifications and limitations set forth hereinafter, we are of the opinion that the Shares have been duly authorized for issuance and, when issued and paid for in accordance with the terms and conditions of the Inducement Warrants, will be validly issued, fully paid and nonassessable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The opinions we express herein are limited to matters involving the Delaware General Corporation Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference made to us under the caption &#8220;Legal Matters&#8221; in the prospectus constituting part of the Registration Statement. In giving this consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Act, the rules and regulations of the Securities and Exchange Commission promulgated thereunder or Item 509 of Regulation S-K promulgated under the Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 0pt;">Sincerely yours,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Loeb &amp; Loeb LLP</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;">Los Angeles&#160;&#160;&#160;&#160;New York&#160;&#160;&#160;&#160;Chicago&#160;&#160;&#160;&#160;Nashville&#160;&#160;&#160;&#160;Washington, DC&#160;&#160;&#160;&#160;San Francisco&#160;&#160;&#160;&#160;Beijing&#160;&#160;&#160;&#160;Hong Kong&#160;&#160;&#160;&#160;&#160;www.loeb.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:12pt 0pt 0pt 0pt;">For the United States offices, a limited liability partnership including professional corporations. For Hong Kong office, a limited liability partnership.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>limn-20260331xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 6/24/2026 01:16:37 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We hereby consent to the use in the Prospectus constituting a part of this Registration Statement on Form S-1 of our report dated March 31, 2026 (which includes an explanatory paragraph relating to Liminatus Pharma, Inc.<font style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</font>s ability to continue as a going concern) relating to the consolidated financial statements of Liminatus Pharma, Inc. as of and for the years ended December 31, 2025 and 2024, which is contained in the Prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We also consent to the reference to our Firm under the heading <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font>Experts<font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font> in the Prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ WithumSmith+Brown, PC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Whippany, New Jersey</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">June 23, 2026</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>limn-20260331xexfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:ffd="http://xbrl.sec.gov/ffd/2026">
  <head>
    <title>EX-FILING FEES</title>
  </head>
  <body>
    <div style="display: none">
      <ix:header>
        <ix:hidden>
          <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-331">S-1</ix:nonNumeric>
          <ix:nonNumeric name="ffd:SubmissnTp" contextRef="rc" id="ixv-332">S-1</ix:nonNumeric>
          <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="rc" id="ixv-333">EX-FILING FEES</ix:nonNumeric>
          <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="rc" id="ixv-334">0001971387</ix:nonNumeric>
          <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-335">Liminatus Pharma, Inc.</ix:nonNumeric>
          <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"></ix:nonNumeric>
          <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ix:nonNumeric>
          <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ix:nonNumeric>
        </ix:hidden>
        <ix:references>
          <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd" xlink:type="simple"/>
        </ix:references>
        <ix:resources>
          <xbrli:context id="rc">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-06-22</xbrli:startDate>
              <xbrli:endDate>2026-06-22</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_1">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971387</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-06-22</xbrli:startDate>
              <xbrli:endDate>2026-06-22</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:unit id="USD">
            <xbrli:measure>iso4217:USD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="pure">
            <xbrli:measure>xbrli:pure</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="Shares">
            <xbrli:measure>xbrli:shares</xbrli:measure>
          </xbrli:unit>
        </ix:resources>
      </ix:header>
    </div>
    <div>
      <table style="width: 99%; font-family: Arial, Helvetica, sans-serif; font-size: 20pt; text-align: center;">
        <tr>
          <td colspan="4" style="padding-bottom: .5em">
            <p>
              <b>Calculation of Filing Fee Tables</b>
            </p>
          </td>
        </tr>
        <tr>
          <td style="padding-bottom: .25em">
            <p>
              <b>
                <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-363">S-1</ix:nonNumeric>
              </b>
            </p>
          </td>
        </tr>
        <tr>
          <td style="padding-bottom: .25em">
            <p>
              <b>
                <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-364">Liminatus Pharma, Inc.</ix:nonNumeric>
              </b>
            </p>
          </td>
        </tr>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="float: center; width: 100%; text-align: left;  ">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
          <th style="vertical-align: bottom; text-align: left; word-wrap: break-word">
            <b>Table 1: Newly Registered and Carry Forward Securities</b>
          </th>
          <th style="vertical-align: bottom; word-wrap: break-word; text-align: right;">
            <span style="-sec-ix-hidden: hiddenrcOfferingTableNa">&#9744;Not Applicable</span>
          </th>
        </tr>
      </table>
      <table style="font-family: Arial, Helvetica, sans-serif; float: center; width: 100%; text-align: center; border: 1px solid black; font-size: 16px;">
        <tr style="background-color:#9ADAF6">
          <th style="width: 12%;">
            <!-- BLANK -->
          </th>
          <th style="width: 2%;">
            <!-- BLANK -->
          </th>
          <th style="width: 12%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Type</b>
            </p>
          </th>
          <th style="width: 14%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Class Title </b>
            </p>
          </th>
          <th style="width: 2%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Fee Calculation or Carry Forward Rule</b>
            </p>
          </th>
          <th style="width: 5%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Amount Registered</b>
            </p>
          </th>
          <th style="width: 15%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Proposed Maximum Offering Price Per Unit</b>
            </p>
          </th>
          <th style="width: 10%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Maximum Aggregate Offering Price</b>
            </p>
          </th>
          <th style="width: 5%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Fee Rate</b>
            </p>
          </th>
          <th style="width: 6%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Amount of Registration Fee</b>
            </p>
          </th>
          <th style="width: 1%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Carry Forward Form Type</b>
            </p>
          </th>
          <th style="width: 7%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Carry Forward File Number</b>
            </p>
          </th>
          <th style="width: 6%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Carry Forward Initial Effective Date</b>
            </p>
          </th>
          <th style="width: 7%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward</b>
            </p>
          </th>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Newly Registered Securities</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="offrl_1" format="ixt:booleanfalse" id="ixv-365">Fees to be Paid</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
		1
	</td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_1" id="ixv-366">Equity</ix:nonNumeric>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_1" id="ixv-367">Shares of common stock, par value $0.0001 per share, underlying the common warrants</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:FeesOthrRuleFlg" contextRef="offrl_1" format="ixt:booleantrue" id="ixv-368">Other</ix:nonNumeric>
          </td>
          <td style="text-align: right;">
            <ix:nonFraction name="ffd:AmtSctiesRegd" unitRef="Shares" decimals="0" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-369">20,688,000</ix:nonFraction>
          </td>
          <td style="text-align: right;">
            <span>$</span>
            <ix:nonFraction name="ffd:MaxOfferingPricPerScty" unitRef="USD" decimals="4" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-370">0.1183</ix:nonFraction>
          </td>
          <td style="text-align: right;">
            <span>$</span>
            <ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="2" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-371">2,447,390.40</ix:nonFraction>
          </td>
          <td style="text-align: right;">
            <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="7" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-372">0.0001381</ix:nonFraction>
          </td>
          <td style="text-align: right;">
            <span>$</span>
            <ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="2" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-373">337.98</ix:nonFraction>
          </td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fees Previously Paid
	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Carry Forward Securities</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Carry Forward Securities
	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">Total Offering Amounts:</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top; width: 16%;">
            <p id="MaxAggtOfferingPrice" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-374">2,447,390.40</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top; border-bottom: 1px black; width: 16%;">
            <p id="TotalFeeAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlFeeAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-375">337.98</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">
					Total Fees Previously Paid:
				</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top">
            <p id="TotalPreviouslyPaidAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-376">0.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">
					Total Fee Offsets:
				</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top">
            <p id="TotalOffsetAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-377">0.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">
					Net Fee Due:
				</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top">
            <p id="NetFeeAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:NetFeeAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-378">337.98</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
      </table>
    </div>
    <div>
      <table style="width: 100%; text-indent: 0px;">
        <tbody>
          <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
            <td>
              <p style="margin:0pt;text-align:left; margin-bottom: 5px;">
                <b>Offering Note</b>
              </p>
            </td>
            <td/>
          </tr>
        </tbody>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="width: 100%; text-indent: 0px;">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
          <td style="width:10pt;">
            <p style="margin:0pt;text-align:left;">
              <sup style="vertical-align:top;line-height:120%;font-size:10px">1</sup>
            </p>
          </td>
          <td colspan="7" style="white-space: pre-line;">
            <ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="offrl_1" id="ixv-379">Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended, based upon the average of the high and low sale price of the Registrant's common stock on June 18, 2026, as reported in The Nasdaq Stock Market.</ix:nonNumeric>
          </td>
        </tr>
        <tr>
          <td colspan="7">
            <hr style="width:100%;text-align:left;margin-left:0"/>
          </td>
        </tr>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="float: center; width: 100%; text-align: left;  ">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
          <th style="vertical-align: bottom; text-align: left; word-wrap: break-word">
            <b>Table 2: Fee Offset Claims and Sources</b>
          </th>
          <th style="vertical-align: bottom; word-wrap: break-word; text-align: right;">
            <span style="-sec-ix-hidden: hiddenrcOffsetTableNa">&#9745;Not Applicable</span>
          </th>
        </tr>
      </table>
      <table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; text-align: center;  border: 1px solid black;">
        <tr style="background-color:#9ADAF6">
          <th style="width: 10%; text-align: left;">
            <!-- BLANK -->
          </th>
          <th style="width: 8%; text-align: left;">
            <!-- BLANK -->
          </th>
          <th style="width: 16%;">
				Registrant or Filer Name
			</th>
          <th style="width: 6%;">
				Form or Filing Type
			</th>
          <th style="width: 7%;">
				File Number
			</th>
          <th style="width: 6%;">
				Initial Filing Date
			</th>
          <th style="width: 6%;">
				Filing Date
			</th>
          <th style="width: 6%;">
				Fee Offset Claimed
			</th>
          <th style="width: 6%;">
				Security Type Associated with Fee Offset Claimed
			</th>
          <th style="width: 8%;">
				Security Title Associated with Fee Offset Claimed
			</th>
          <th style="width: 6%;">
				Unsold Securities Associated with Fee Offset Claimed
			</th>
          <th style="width: 9%;">
				Unsold Aggregate Offering Amount Associated with Fee Offset Claimed
			</th>
          <th style="width: 6%;">
				Fee Paid with Fee Offset Source
			</th>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Rules 457(b) and 0-11(a)(2)</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Claims
	</td>
          <td>

	</td>
          <td style="text-align: left;">

	</td>
          <td>

	</td>
          <td>

	</td>
          <td>

	</td>
          <td>

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Sources
	</td>
          <td>

	</td>
          <td style="text-align: left;">

	</td>
          <td>

	</td>
          <td>

	</td>
          <td>

	</td>
          <td>

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Rule 457(p)</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Claims
	</td>
          <td>

	</td>
          <td style="text-align: left;">

	</td>
          <td>

	</td>
          <td>

	</td>
          <td>

	</td>
          <td>

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Sources
	</td>
          <td>

	</td>
          <td style="text-align: left;">

	</td>
          <td>

	</td>
          <td>

	</td>
          <td>

	</td>
          <td>

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="float: center; width: 100%; text-align: left;  ">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
          <th style="vertical-align: bottom; text-align: left; word-wrap: break-word">
            <b>Table 3: Combined Prospectuses</b>
          </th>
          <th style="vertical-align: bottom; word-wrap: break-word; text-align: right;">
            <span style="-sec-ix-hidden: hiddenrcCombinedProspectusTableNa">&#9745;Not Applicable</span>
          </th>
        </tr>
      </table>
      <table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; border: 1px solid black;">
        <tr style="background-color:#9ADAF6">
          <th style="width: 4%">
            <!-- Note column -->
          </th>
          <th style="width: 14%">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Type</b>
            </p>
          </th>
          <th style="width: 25%">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Class Title</b>
            </p>
          </th>
          <th style="width: 14%">
            <p style="margin: 0pt; text-align: center;">
              <b>Amount of Securities Previously Registered</b>
            </p>
          </th>
          <th style="width: 18%">
            <p style="margin: 0pt; text-align: center;">
              <b>Maximum Aggregate Offering Price of Securities Previously Registered</b>
            </p>
          </th>
          <th style="width: 6%">
            <p style="margin: 0pt; text-align: center;">
              <b>Form Type</b>
            </p>
          </th>
          <th style="width: 10%">
            <p style="margin: 0pt; text-align: center;">
              <b>File Number</b>
            </p>
          </th>
          <th style="width: 8%">
            <p style="margin: 0pt; text-align: center;">
              <b>Initial Effective Date</b>
            </p>
          </th>
        </tr>
        <tr style="background-color:#E7E7E2;">
          <td style="text-align: center;">

	</td>
          <td>

	</td>
          <td>

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
        </tr>
      </table>
    </div>
  </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>limn-20260331xs1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 limn-20260331xs1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "G @ # 2(  A$! Q$!_\0
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M]BN67+S6T[EVBBBF2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"^N/$7C31-5\,-=++8Z!JFGR16ULFY=BN8IT,S[L?,QP21A17OT">7"B\#:
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M>E:7D^WZT>3[?K1RA]9,W[,/2C[,/2M+R?;]:/)]OUHY0^LF]\';<+\5_")
MZ:G#_P"A5^C K\]OA%%CXI>$SC&-2A_]"K]",]:^ARQ6A+U/S?BFI[2O3?E^
MHZBO()_VIO 4%U/"MUJ=P896A:2WTR>2,LI(.&"X(R.HIG_#57@3^_K/_@GN
M/_B*]#ZS1_G7WG@+*,P?_+B7_@+.X^*__),/%W_8)NO_ $4U5/@K_P DC\&_
M]@FV_P#1:UYIX_\ VEO!6M^!?$6GVSZM]HNM/N(8_,TJ=5W-&P&25P!D]37I
MGP7&/A+X.'_4)MO_ $6*B%2%2M>#OI^IU5\+7PN7\M>#BW/JK?9.TILF=C;<
M;L<9Z9IU)78?/GPK\ KKX?-XD\)2>(KGQ%)^T-+K5\FMQ6LMR;I'#3[A>(3L
M%B(Q'LXV_P"KV\YKA?V?-6T*PM_A!??#V2]U;XI)=ZA)XOTVQNIW:XL4CN6*
M7:N3&C%Q;K&6P=S#'&:_2$01B5I1&HE8;2X W$>A-$=O%#GRXT3=UVJ!F@9^
M>?A#7;G4-/\ VAM1^*GA;Q)J5_!9:9X@FT_5B]M##>B&016<1AERL89T5<$[
ME5F;DXKV3XE_#=_@S^P#XH\/VMS=2ZG;Z&US<W/FR/(UU(RO*5.2P4,2%4'A
M0!7U2T,;;LHIW?>R.OUI617&&4$>A% 'PRWQ7\1^,M;T6P;Q*GCC1M$^(&AC
M3O$.GV7V);MY;.ZDGLV5#M/ELJ*<\CS &RPJKHO[6?Q,?0-7U.RU&Q\7:LWA
MN_U;4M"@T9HF\(7<4R)'!+M^>4;7DRC_ #L82P^4U]VI:PQC"Q(HW%\!0!N/
M4_7WI8[>*)Y'2-$>0Y=E4 L?4^M 'P/\2OBYXQG7P%K7@CQ9!\8=:TK6-7BM
M=0M-.-A"Z?V3YC[D0B*Z:+<[*$P&("'# FND\0?M3^(+?XH^"M/\-^,%UO1Y
MY]"MKN&[TJ"V74(;U07N%.3*3R.4"1QG*-N(K[3BM88$1(X8XT3.Q44 +GKC
MTIHLK<,&$$08+M!V#(&<X^F>: /SPN_V@?'.I>+M(\6C6HO$'B_2M%\47+>#
M+?37A_L6>+8D=O-M.9<*N_#_ #':2IVL*^A_V<?B]XK\=^ /'.H:MK%EX@CT
MGG3=8MU@\R0FV$CI*L&8<H_ V$G:0&PP-?1:V\22,ZQ(KL=Q8* 2<8SGZ40V
MT5O$(XHDCC&?D10!SUXH ^!1^T3\:;?P;'K[^+[&=E\%Z7XT>U_X1^-59Y[H
MV[V8;.1&5&XM]_)X*CBM_P 2?M6>,[#XP>)--TG7([S2;>+7K9=,N]-AB>RG
MLK)YH750S2L"Z$;Y2%D'*(!S7VU]FBQCRDQC;C:.GI1]EAWN_DQ[WY9MHRW&
M.?PXH ^!?$_Q-^)G@WQIX$\2WFM?VG<ZKX*M[_7_ !!#IZI%H5A/?0M)+'9@
ME93'NV[FR0I9F!"XK:U3]H+XF>*O'?Q$\,VVJPZ9'%!KMG!IL<4/VJS@M[5G
MM+Z#;F5WE(0Y?$9$HV<KS]PF",]8U/R[>1V]/I2+:PI*95B19"H0N% )4=!G
MTH ^68/B;XB\.?L.^"/$OA[Q?I][K4MCIT4FNZDJJN&95F3<5:-95^:,/*-F
MY<OU->>M^T7>36'ACQ?K.L7&F-:^&=?:X\12:+%)=K)!>6\:>3%&[03!R0H9
M?D<X8;17W0+2!8# (8Q"05,84;<'J,=*/LD&Q4\F/8J[%7:,!?0>U 'Y]S?M
M9?$R'P!X3NQXYT*]N-2&I75UK5G:VOV>TN(DB:UTN9G(C\PHY>39\YY$>=N3
M]X^#]0O=7\*Z-?ZE!%:ZA=64,US! Q:..1D!95) ) )(&1G%:)L;9D"&WB*!
M@X4H,!AT/U]ZFH$+1110 4444 %%%% 'RO\ M*>&=*UKXFQ6^O0ZZECJ.E0P
M6DECIB7\$]T'G5%4$AEDB$QD"#(9S$_6( _0OB#5=0\,^&X6TC2)M=ND"1)#
M-=);A5"\R32O]T #D@,<] :^9?VB-5BUOXAZU9Q^&[V]:738]*:ZU#2;6YC
M#R'S-/GDN4\F0,Y5F92 RH<93!^@OB?%IR?!GQ/%K37:Z8NB3K=M#B:X$?DD
M,1V9\9]B>O% S*^'GQ2UGQ7J_P!CN;'P[J=K_P M-0\*:^FH):D@E5G1DC9<
MX(#+N&>PZUZ?U%>'?LZZGJ$&J:QH6LF,:A#8VEY&EO#8^68'WJC&2T55WDH<
MH1@8RI(/'N5 CB]?^$GA_P 1SZO<W"7,-[J4UK<R7=O<,DL,UL/W$D1_@9?R
M/((()%95O^S]X1M+K2YH8KY$LA"9(/MLABOGBF>>*2Y4G]ZZS2/("?XF.<@
M#T:::.WB:25UCC0%F=S@*!U)/:F?:X-\2>='OE!,:[AEP!DD>O'I0!*!BEI
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MEMVDW[$9AQN^1LJ#D<9Q3(_B5X?EL/$-VM\#%H#7"Z@NT[XO(7=*0O5@ 1R
M03Q61X7\#W>A?%SQ=KJ6MO;:-J6G6$%N("%+31O<M,2@'&3,ISW)->)Z_P#
M3Q3JGBCQ8UIX4TZRNK[6M3U2+Q2+V/SKFUFL&MTLV4#>-SLN0?D"IN^]@4 ?
M36D>(M/URTLI[.YCD%Y:I>0QD[9&A< J^P\@<CM5/4_&VCZ3?Z39SWB-<:I?
M-IMLL7[P&X6)Y61BN=I"1N><=/>OF_2/@!XSM=0M;3^RK.TU8:A'J"^.DNT-
MQ:VPLA#]B51^\.UOD"_ZLK\_WN*HW/[-WBCQ+H.@Z58>&[#X:36+6\-YJVE:
M@LL]V\5G=1-,548:-WF12QQ,RR29*X6@9]8C5K,S00B[@,TZEHHQ*NZ0#J5&
M>0/:LYO&FD#Q.OA\7B-JIM9;PQ+R$BC9%<LW12#*G!YYKYB\0_!#Q_XD\7Z!
MJ2>%-)\._8;C1)XGTJ:VV6L5LT?VB,2,IFR,2;$C*1LC#>2Q8'/E_9L\:76E
M7>GVGAG3]!O8- .F7>LV^HH9/$$PU"VN'9AM) FCBE!:4$YE*L"O)!'V':7D
M-]!'/;RQSP2#<DD3AE8>H(X-35Y7^SUX U#P#X:U>+4+*?2S?ZE)>1:?/<02
M>0I1%X2W1(8MQ4L4CR,DG.6->J4 ?'GQV\3P7/CO58FL+333:VSQ:,YOM'CC
MN+X3R>;+<),6D>(ML!4X.5D!7<P8>[_&77=:\/?#ZUN]+4SWYECAE2W28JRO
M&RL0L4$[8!(8#9C@9..#Y!\:]>U*'XJRP:WIWVG34MD&G:;IGB6\M9E'FONN
MI8[6V; DRJ@2,<&(XZFO;?B]/>0?#N]DTKPY)XFU@P,EA9K DX2=HF5'<.R#
M8-Q#'.<,>.M SS7]D;2;C1(/$ML]DUA;M)#*L?V9X59R&W-AK*VR>!TW?\![
M_1%>%?LX^%]0\+ZMKT1\/ZAH^D2VEHRS:QIEE9W4ES^\\U%^R?*T2C9C<,@L
M0"17NM ,\K_:1T6^\0?#B.SLK.>\3^T[*6Z-M;?:GB@297=_LW_+PHV@&(Y!
M!/!Q@^$^&_AWXBMHM%MKCPMJ@UL'2%\/ZM):$+I\$&HS27+.<D6A>!@QB/:1
M8AG9@?95% A%[TM%% !1110 4444 %%%)F@!:*0-DTM !1110 4444 %%%%
M!5;4O^0?=?\ 7)OY&K-5]1_Y!]S_ -<F_D:!K<_/SR^3]31Y=6_+Y/U-'EUY
M/LCZ;ZR5/+H\NK?ET>71[(/K)4\NCRZM^71Y='L@^LE3RZ/+JWY='ET>R#ZR
M:'@K5;7P[XLTK5KV016=C.+F5VZ!4!)_EBOI?]G/1+J/P9<^*-3C*:SXKNWU
M>XWCE8W.(4^@3'YU\H)I \5>)O#OA?>8QK%]'#,PZK"&!?\ ,<5^@5K;16=M
M%;PHL<,2B-$7HJ@8 'X5I0A>H^T?S?\ P/S#'5?9X.*^U5=_^W8O3[Y7_P#
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MJJ?!7_DD?@W_ +!-M_Z+6N?_ )?_ "_4];_F6_\ ;_\ [:=K11170>2%%%%
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M?FOP]9>(/L/@I;_3-=LO%J:9X<C\.QSM-+Y"I.1J/F2+E-QB!,OFG)5D')H
M^RZ*:O>G4 %%%% 'R!^U)\1?&'A;XI?8M$\17^F6)L(9/(MI J;B6R<8Z\"O
M(O\ A=/Q'_Z'/5_^_H_PKU']JZT\_P"*^[_J'PC]7KQS^S_I7RF)]K[:5I/?
MN?K^65L+'!4E*G%NRWBO\C2_X73\1_\ H<]7_P"_H_PH_P"%T_$?_H<]7_[^
MC_"LW^S_ *4?V?\ 2N?]]_,_O9Z?M\'_ ,^H?^ K_(TO^%T_$?\ Z'/5_P#O
MZ/\ "C_A=/Q'_P"ASU?_ +^C_"LW^S_I1_9_TH_??S/[V'M\'_SZA_X"O\C2
M_P"%T_$?_H<]7_[^C_"C_A=/Q'_Z'/5_^_H_PK-_L_Z4?V?]*/WW\S^]A[?!
M_P#/J'_@*_R-+_A=/Q'_ .ASU?\ [^C_  K[=^ ^KW^O?"/PS?ZI=RWVH3VQ
M::XF.7<[V&2?H!7PA_9_TK[K_9_C\KX.>%E]+8_^AM7J9?S^T?,V]/\ (^2X
MDJ8>>%@J4$GS=$ET?8]#HHHKWS\Z"H+T9LY_^N;?RJ>HKL9M9A_L-_*@#Y!^
MP\GCO1]A]C6]]C//%'V,^E2:F#]A]C7/^-_"5[XFTB/3[.YCM8Y)T-RSYRT0
MZA<=^E=]]C/I1]C/I43@JD7&6S.C#XB>%JQKT_BB[J^NIY%XTTV+3/$O@2U@
M01P1W+1HH[ !0*V5\$W%IXZ_MJSFCBLKF$I>V[9W.P^ZR]NPSGT]Z3XDVVSQ
MQX!!&-UZ_P#[+7HILN37)"$95)WZ--?<CW\3BJM'!X9Q?QPFG?6Z=27XWU3Z
M/4P?L-<?JEK_ ,)#\0;#35&ZUTB+[=<^AE;B-3].37I%Z(M/L[B[N&"001M+
M(Q[*HR:Y+X6:3-<:)<Z]=IMO-<N&O&!'*Q=(E_!>?QK6K[THT_F_1?\ !L<&
M"_<4:N+>Z7+'_%*Z_"/-Z.QV7@6TV>--$;N+N,_K7U+7SGX.M-OBS2&QTN4/
MZU]&UU'B,****9)ROQ7_ .28>+O^P3=?^BFJI\%?^21^#?\ L$VW_HM:M_%?
M_DF'B[_L$W7_ **:JGP5_P"21^#?^P3;?^BUKG_Y?_+]3UO^9;_V_P#^VG:T
MUR0I(&3C@4ZBN@\DX3X->+O%WC;P>VH^-?!Y\$:R+R:$:6;M;G,*MB.7>HQ\
MPYQVKNCQ2TA.* /GOQ#>7NB_'+QW!KOCV_TO09?!0U 3K(D$6CQBYE0R1#!&
M\*"3(V22!C  %:G[/,[0:/XLUG3I-0N/"\\D<VCZ)=:@;^_CC6+YI7+NS1M.
MV&6)FXP"=I8@>L7]AH6L75[!>6NG7TYMQ#=13I'(Y@)+!) <G83DX/'4U4T#
M3?"GA33Y+K1;31M(L;HAWFT^.&"*8@[02RX#=<?CB@"GX4^(,_BG46M)?"/B
M/0E$1D^TZM;11Q'!'R@I*QW<^G8U\ZZSJB3:KXXU'P=X_E@AL-,U6VU7Q%KF
MLL;:ZOG(6-8H5)$4=H<@RQHH& OS?,1],:_X]T/PT=/6_P!0CA%]?_V9$ZG<
MJW'EO)M<CA,+&Q);&,#U%95CX?\ !.FZ]=?9?#6E65Y]D^T2ZC'IL<4<D4I8
M,//"X8G:2RYZ$$\&@#S'X2:A)HW@SXF>'0PEOM!BW/JUCK%UJ$$[26GF+LDN
M'=TD0 ;D!P-RL,;L#@?#OQE\1'P]X TC4M7TKQ/]LC\/7BZEI<LT36WVDO&T
M4K+*?-?]WO4M@/\ /N3@5]1Z58>&?#.CVUAIMOI6E:7=MBWMK5(H8)F<9PBK
M@,6'IG-<_P"'+_P%)JL^C>']*T]Y(M0ECNO[/TU1#;WD"(S>:RJ%60*Z[2>3
MR >#0!\K^&?C;KO@S1],UB62?Q'<16T=PD=Y>S$*R^'4G+$*V&4OEWW!L#<P
MPW->H/\ &GQS_P );9>![/7?#6JZE>ZG;6J^)K2Q=[6..>RNKDIY(F.94^S
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MA$4=E P!^0JE9^![Z3XGZAXEU!H7M(K)++2XHV):,$[I68$<$GCCM77?8_\
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MR (U8_,2!TUW\)?$K_ ?P#X>N]/MM<OO#]S9SZEH<]T/)U&&'</(WM\K8RC
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M .R?RKTS_A'O]FC_ (1[_9HL%SS/_A'_ /9/Y4?\(_\ [)_*O3/^$>_V:/\
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MV5/2IJ*9!$+9%(('(J6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDDHH ]2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>limn-20260331xs1003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 limn-20260331xs1003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %3 BP# 2(  A$! Q$!_\0
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M'_P%C_PH_L/3/^@98_\ @+'_ (5:^T0_\]HO^_B_XT?:(?\ GM%_W\7_ !H
MJ_V'IG_0,L?_  %C_P */[#TS_H&6/\ X"Q_X5:^T0_\]HO^_B_XT?:(?^>T
M7_?Q?\: *O\ 8>F?] RQ_P# 6/\ PH_L/3/^@98_^ L?^%6OM$/_ #VB_P"_
MB_XT?:(?^>T7_?Q?\: *O]AZ9_T#+'_P%C_PH_L/3/\ H&6/_@+'_A5K[1#_
M ,]HO^_B_P"-'VB'_GM%_P!_%_QH J_V'IG_ $#+'_P%C_PH_L/3/^@98_\
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M@11L&V!6) #8 ;V'&*L1?&G5X%\M3IP@"JB0[CLC51$%51O^Z/)7@\<MZT6
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M:/M$/_/:+_OXO^- %7^P],_Z!EC_ . L?^%']AZ9_P! RQ_\!8_\*M?:(?\
MGM%_W\7_ !H^T0_\]HO^_B_XT 5?[#TS_H&6/_@+'_A1_8>F?] RQ_\  6/_
M  JU]HA_Y[1?]_%_QH^T0_\ /:+_ +^+_C0!5_L/3/\ H&6/_@+'_A1_8>F?
M] RQ_P# 6/\ PJU]HA_Y[1?]_%_QH^T0_P#/:+_OXO\ C0!5_L/3/^@98_\
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MD_\ 0*L?_ 9/\*[O4/B_K6KFY>^N=/NKBXMI+1K@QJKB-V<E<*0IQYCA=P.
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M#O\ X*H/_B*/^%1>!?\ H2O#O_@J@_\ B*ZS(HR/6@#D_P#A47@7_H2O#O\
MX*H/_B*/^%1>!?\ H2O#O_@J@_\ B*ZS(-+0!R7_  J+P+_T)7AW_P %4'_Q
M%'_"HO O_0E>'?\ P50?_$5UM)F@#D_^%1>!?^A*\._^"J#_ .(H_P"%1>!?
M^A*\._\ @J@_^(KK,BC(H Y/_A47@7_H2O#O_@J@_P#B*/\ A47@7_H2O#O_
M (*H/_B*ZVB@#DO^%1>!?^A*\._^"J#_ .(H_P"%1>!?^A*\._\ @J@_^(KK
M:3(H Y/_ (5%X%_Z$KP[_P""J#_XBC_A47@7_H2O#O\ X*H/_B*ZP$&C(H Y
M/_A47@7_ *$KP[_X*H/_ (BC_A47@7_H2O#O_@J@_P#B*ZS(I: .2_X5%X%_
MZ$KP[_X*H/\ XBC_ (5%X%_Z$KP[_P""J#_XBNMI"0* .3_X5%X%_P"A*\._
M^"J#_P"(H_X5%X%_Z$KP[_X*H/\ XBNL!!HS0!R?_"HO O\ T)7AW_P50?\
MQ%'_  J+P+_T)7AW_P %4'_Q%=;10!R7_"HO O\ T)7AW_P50?\ Q%'_  J+
MP+_T)7AW_P %4'_Q%=;10!R7_"HO O\ T)7AW_P50?\ Q%'_  J+P+_T)7AW
M_P %4'_Q%=9D>M&10!R?_"HO O\ T)7AW_P50?\ Q%'_  J+P+_T)7AW_P %
M4'_Q%=8#FEH Y+_A47@7_H2O#O\ X*H/_B*/^%1>!?\ H2O#O_@J@_\ B*ZV
MDS0!R?\ PJ+P+_T)7AW_ ,%4'_Q%'_"HO O_ $)7AW_P50?_ !%=9D4%@.IQ
M0!R?_"HO O\ T)7AW_P50?\ Q%'_  J+P+_T)7AW_P %4'_Q%=9D4 YH Y/_
M (5%X%_Z$KP[_P""J#_XBC_A47@7_H2O#O\ X*H/_B*ZVDS0!R?_  J+P+_T
M)7AW_P %4'_Q%'_"HO O_0E>'?\ P50?_$5UF11D4 <G_P *B\"_]"5X=_\
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M/?C1^- '0?\ "5#_ )]3_P!]_P#UJ/\ A*A_SZG_ +[_ /K5S_XT?C0!T/\
MPE8_Y]3_ -]__6H_X2L?\^I_[[_^M7/?C1^- '0_\)6/^?4_]]__ %J/^$K!
M_P"74_\ ??\ ]:N>_&C\: .@_P"$J'_/J?\ OO\ ^M1_PE0_Y]3_ -]__6KG
M_P :/QH Z$>*P/\ EU/_ 'W_ /6H_P"$K'_/J?\ OO\ ^M7/?C1^- '0_P#"
M5C_GU/\ WW_]:C_A*Q_SZG_OO_ZU<]^-'XT ;_\ PE?/_'J?^^__ *U+_P )
M4/\ GU_\?_\ K5S_ .-'XT =#_PEF/\ EU/_ 'W_ /6H_P"$L'_/J?\ OO\
M^M7/?C1^- '0_P#"5C_GU/\ WW_]:C_A*Q_SZG_OO_ZU<]^-'XT =!_PE>?^
M74_]]_\ UJ/^$J'_ #ZG_OY_]:N?_&C\: .@'BO'_+J?^_G_ -:E_P"$K'_/
MJ?\ OO\ ^M7/?C1^- '0_P#"5C_GU/\ WW_]:C_A*Q_SZG_OO_ZU<]^-'XT
M= ?%0_Y]3_WW_P#6H_X2H?\ /J?^_G_UJY_\:/QH Z#_ (2O _X]3_WW_P#6
MH'BS_IU/_??_ -:N?_&C\: .A_X2L?\ /J?^^_\ ZU'_  E8_P"?4_\ ??\
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M/[\O_?0_PH_X1>T_OR_]]#_"@#EJ*ZG_ (1>T_OR_P#?0_PH_P"$7M/[\O\
MWT/\* .6HKJ?^$7M/[\O_?0_PH_X1>T_OR_]]#_"@#EJ*ZG_ (1>T_OR_P#?
M0_PH_P"$7M/[\O\ WT/\* .6HKJ?^$7M/[\O_?0_PH_X1>T_OR_]]#_"@#EJ
M*ZG_ (1>T_OR_P#?0_PH_P"$7M/[\O\ WT/\* .6HKJ?^$7M/[\O_?0_PH_X
M1>T_OR_]]#_"@#EJ*ZG_ (1>T_OR_P#?0_PH_P"$7M/[\O\ WT/\* .6HKJ?
M^$7M/[\O_?0_PH_X1>T_OR_]]#_"@#EJ*ZG_ (1>T_OR_P#?0_PH_P"$7M/[
M\O\ WT/\* .6HKJ?^$7M/[\O_?0_PH_X1>T_OR_]]#_"@#EJ*ZG_ (1>T_OR
M_P#?0_PH_P"$7M/[\O\ WT/\* .6HKJ?^$7M/[\O_?0_PH_X1>T_OR_]]#_"
M@#+\-?\ (2_X :ZRL^RT2"PG\V-G+8(PQXJ_0,6BBB@ HHHH **** "BBB@
MHHHH ***I:O<26NGRRQ-M=<8.,]Z +M%<?\ \)!??\]O_'11_P )!??\]?\
MQT4 =A17'_\ "07W_/7_ ,=%'_"07W_/7_QT4 =A17'_ /"07W_/7_QT4?\
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M!??\]?\ QT4?\)!??\]?_'10!V%%<?\ \)!??\]?_'11_P )!??\]?\ QT4
M=A17'_\ "07W_/7_ ,=%'_"07W_/7_QT4 =A17'_ /"07W_/7_QT4?\ "07W
M_/7_ ,=% '845Q__  D%]_SU_P#'11_PD%]_SU_\=% '845Q_P#PD%]_SU_\
M=%'_  D%]_SU_P#'10!V%%<?_P )!??\]?\ QT4?\)!??\]?_'10!V%%<?\
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M\9F"A2C45-2C3G-2;AS_ &=5I=:JUUOJC]/_ +%;?\\(O^^!1]BMO^>$7_?
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MGA^1U8.*GM=JS^>ROTO;73<^]J<)82E4J4IYE3YH-J2Y:FC6C7PGW)]BM_\
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MC=?85['2$9K*K3C6@Z<MF=^ QE7+\53Q5%M2@[Z.S\]>EUH>#0?M%2R?L_\
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M^S:/M</Q;C\/AZ>&Y*<HTU9<U.,FEO:[5^I\Z_\ "C?VD_\ HK-K_P!_Y/\
MXS5;4?V>OVB-7M&M;WXHV-U;L03')-(02#D?\L?6OI/^W;[_ )[G_OD4?V[?
M?\]S_P!\BDLNI+:4O_ F;/C'&O1T*/\ X)A_D?*D/[)7QMMT9(O'FCQ(S!RL
M;.OS   _ZGC@#\J=+^R=\;YUF67Q_I$HF4K)O>0EP?4^3R>3S[U]4_V[??\
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MK:I+KZ'YC#495BDB6X=(Y$$<B(Q42*#D!@/O 'IGI7W]_P $\6W?"'6L'/\
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M0M)'-D954900S, 2%')_*F!T?YT?G7(GXL>%C+;Q)J7F27$D,42K"_SM*A=
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M+J?PKT+5KY[J4W\3FUBLT2"\=$ACC&$$8_@.,@D=<G.:]6_X16V_YZ2_F/\
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M<KQ:1TTWAHP<:B;>MGHNUDUJN]S(UGX]:3;>&!JNE6=QJMR%BDFLB#"UG&Y
M\VX)!V1KD$L W'(R,D1Q?M0_#5H;N27Q/:Q+:()))-DC1.N0NZ-PN)%W'&5]
M">@K,U[X>^&O[(O[*T\-+KD6H3VPDM;NZ-O';Q0IMC",OS;4&["@DG><G%7(
M/ G@BU:Z$/@*P$<LTESL/EE#(8C%D(>$W([+@8 #$]ZWI?#:IOY')B8^_P V
M'?N>>]^NWX=S=\)?'7P9XWUBTTS2-4:XO+H.$C:VD0!T7<T3,5 $@7YMF<X&
M:SOBY?RR>(?#&BWNI7^A^'=26Z^T:CITS0R"X14,$?FJ/ESER!_$5 YZ'/\
M#NA6/A!M*&E^#=-M8[)I)0;>YS)&QC\M-C/U;82K$\8Z&NVC\6RW$A6;2Y(H
M]PPS31N!U^; YXP/S]JIVZ&4.>WOVOY'SW+\5?%MQK?AG6[B>&UBG2YMD@4N
MTU@I,:/]HB.U7D0A6 ;!^9^PYN:5\:OB+J\%@JZEX=CDFO)-,N7MX6N#'(D;
MNL\2@X,;[<99L9P!WKTCQ8^L>(/%VG*VFVMSX7ML3.?M1@N?M.#B5"OS#;PN
M,\ACFM+0=7N_#FAQ65KX6L[<0HY%O9W:^67+%AAF /))+$\Y.>:35CHDN5+9
MW,KX%?$CQ'\23<7VK+9V5LL"HVG $7$4HQ^\((^XX)89SVQT->O9KAI?&>K*
MT36^@0C+JLHDO$4A-K9(P#G!"@ ]0Q/&.;<7C2]%M;F71W^T-$&F2.YC*QR<
M94$XW <\X[4C,Z[-+7%KXTU07K;M'C-B50(5NE\X,1E]PQMP#P,')QG'-)+X
MWU5+J5$T-9;<,OES?;$4E2/F)4C@@]NX]Z .NO;V#3;.>[NI4M[:!&EEFD.%
M1%&68GL  3FN>\,?%#PCXU>Y30/$FF:PUM$)IQ97*RF-#T9L'@<'FI]5UZTN
MM(O(3:C4&D@=?L<H"QSDJ?W;$C #=,D8YYKY\^'7PJG\"^)_$&N:%X3MO!S:
MS:20W-@FJ)?1R/EV0<!1$F6 &P'&#D=*[*-.E.G-SE:2VVU^]W^XYZM25-KE
MC=/L>M^)/VA/ WA_P3?^*HM9BUO2+">.VN'T=EN6CD<@*" ??/TKS=/V]_AE
M*ZHD6OLS= -/'_Q=>2_$OX,7GPX^!WB'0O"V@RR6>ISZ9=W,,$SWD[70R+C:
M.3L!"8QQ@DU\SQ_#SQA&ZR)X4UU74Y!_LV;C_P =KYC.,75PF*=/">]"R:;6
MOX'Z[P?P_E>=99+$X]N-12:MS*.B2:T:OUW/T?\ "'[6'P_\5HTTE[<^'K0H
M'@N]>B6TANOF(Q$Y8AR"#G%=[XG^)WA+P4UJNO\ B/3=':ZC,L O;E8_,08R
MRY/(Y'YU^>?P/^ 6J?$Z_OM&\5Z;J>D:+:HEQ'/>12Q>2^6 6%#@')/('0<U
M],^./AB?&WBC3M9\3>$X/&1T5WM]+LOMT5K;BV.W#2AR?,)*\J1@5[N5>RQ.
M&IU<3.TGS<R5EL[1M=]>M_4^!XEPT,KS6K@L)%N$>6SW6L4W=KM>VV^AW?QP
ML/B=?RZ!J?PTUC1Q!;EFO-'U8[8=15L;07VDA0,YP1G->,^,OV3M>T_0_#]Q
MX+T?1[?5+J<7&MZ/<7SK8VK, TJVIV[@I?=@$\ \8KU#XO\ P;T;XOZ[X+U:
M?6[W1&\-3+/':6<(=)</&^PG(X'E@<>M6/CE?>/_ !'I4>D^!(K6U2X4_;-3
MN;Q89$7_ )Y1+@D9[MVZ#UKW<+BI4?91HSBGK>ZMI_>=_>[KKT/C,PH4JE*<
MZU)U.75):MOR[?D<7XJ\:P_ ;QAH.G^%SX<F\.W,RQZ[)>7,DNI1G?\ <A5.
M&PN< \Y[5Q=Y^W'HR_%V2%]!M6^'RQLLMXUBW]IM,%.1L+;=ID]><>]>D_#3
MX#Z'X0BLGU1[C4M8N4_T^_A<1B)NOEQM]\1]ODP3C+'FOA;Q%\./%/\ PD>L
MB#PIKC0?;KCRV&GS,"GFMM.=O.1CFOD\TQ-/+80HY=27+JFVM_-);/>S;=^Q
M^D< Y'2SOV[SIJFHJ#C&+MRWO=-OXMELE;SW/K7X>?MB1^+OB?JVG:KX9A;P
ME))''I-U96#/=(9)4CB:Z!;;&ISU'M7L'A2Q^)VH>%_%[>)M%\+Z3XD\J1-!
MGT=V<%MC[&E9Q\I#E3QZFOS^^'W@[QE8>//#4LGAW7X+:/4K3SC]AEC5HUF5
ML.< $#&>>!7ZA?\ "2Q":<%)-J'Y#P0_';TYXYK++<PKXF-1UH17PVLFMOGU
MZG;Q;D>"R>M1A@IMJ2;?O)]NR];'F/[-'_";/I.I2>._'FF>*]9W*C:?I<D$
MJ6&UF&2\8!)?T(&-I]Z]MKQGX.?"'PA\%]4\1ZGHL^HO=>()1<7B7C*ZJ^YW
M^3:!CF1NY[5ZC_PDMEZR?]\&O>Q<X5*\IT]GY6Z=D? TDXP2E_F:,\JP022-
MG:BECCK@<U\X-^WU\,%)!CU[@D'_ (EX_P#BZ]WO?$-G-9W"*TFYHV ^3V-?
MDNWPY\7,SG_A$M=P6/739O7_ ':^8S+%5\-R>Q5[WOI?L?IO!^1Y;G*K_P!H
M2:Y.6UI*._-???9'Z)>#?VOO!7CO7['2=+L/$#375Q':B>73\0PR29V"1PQV
MYQWKW$=*_+_X">%?%VE_&CP;<7NA:Y9V"ZG ]R\MG+'#A<X:3@#CU/2OTK'B
M2R'\3_\ ?-7EN(KXF$I5U9IZ:6Z+]3SN*\HP>3XFG2P<KJ4;[WZV-:D)P,GI
M67_PDME_>?\ [X-']OVMPLB1#?)L8A)/E5CCH2>F:]@^(*WAGQYX=\9Z4^IZ
M%K5EJVGK-+;FYM)@\?F1DB1<CJ5(.?I7'^-OVB_!'@CX9IX^EU)M7\,O<K:I
M=:2!/ND+%<#D#J".M?*?BS]FOXD?%GQ/X1\1Z"]G\*-,LIWANM!$V&T\QW#.
MUS;;,"439)^8+DC^Z17J_C[P/#\3/V>+G0M5\$-X4\_6VN8]&TR<+,0LS%;A
M]B$*[\L5P1SUY%;04(2C*L_=ZVWM]V_WG3*G3DH1HR;D][JR3[)W=_6R-'P[
M^WS\,/%,DZ6*ZUNA57<3VL<?!) QF3VKU'X8_&OP]\6;F_AT070>R57E^T*@
M&&SC&UF]*^./"'[.L/@*2[DT/1-2CDNE"S&[D:XR 20 &C^7&>U?0O[.NFW'
MA.]UU]1M)+19HX@A,.W=@MG^%<UQ5ZL98JV&;]GYK7;7\3V983#TL Y5%^]7
MGIOV]#Z#K'\86$6J^$]:LI[P:?!<V4T,EX2!Y"LA!DY(^Z#GKVIW_"2V7]Z3
M_OBI-?TF#Q+X?U#2[AG6VU"VDMI&CX8)(A4D>^#73%VDF?./8^*;+5K?X$:1
M9^'M(GTOXG^!-+G?4]<\1ZG%]H%I=78,%BD.UF1MDD>9<Y*I(I&#6IH7[8\<
MGAG1+Z?X7V5I>7FD"],L]W#80^?AMR!Y%  4QMN 8D;XP-V2:]HL?V4?".G_
M  2NOA?#=ZF-!N;K[7)/YB?:"^]6^]MQCY0.G2G>-/V5?"GCGX6>%_ 6H7NJ
M1Z1X>V_99894$S;4*#>2I!X8] *].I*A6JN<ZKUD]>7IWW6K?0YHQE&-N1;=
M^IX[K7[:L^AW&G1>'O!]O8VDUU ]S<:FTUNAMB@W2E#&'19'D01,%<L%;<J\
M5!+^VKX]\0V<FG^%OAZ[^*C<M)'HVK(R7;VI+D%(%.6"!0'<L.6&%.>/>_B#
M^SIX<^)7B'P;K&IW>HQ77A4K]B6VD55?:R-\^5)/W!TQU-2ZO^SYX>UKXUZ=
M\3YKJ_77[&)88X$D7[.557497;GHY[UAAXX6DXRD[V3;5M+]%OL^KZ&E1U))
MI+YW/%OVA1X3\=ZQHWAR[T>[LOCGKOAM1HM_&TL,-A.Z2D!G5\IM<2\[217A
MG@WX;?$?Q5\3+[X9K\2+\ZEIUS=ZAJ"K>W"R:>SZC;R?N9CQ*@A2-PA'#&1>
MC5^BMWX+T&_\16FOW.CV4^N6B>7!J,D"M/$O/"OC('S-T]33+'P+X>TOQ#=:
M]9Z)8VVMW8*W&HQ6ZK/*#C(9P,GH.OH*<ZM"I%)J5U&RUT3O^5NG<48SB]+;
M_P!?,_.?X6>%O&GC^/7WD\01ZYXC\,W*RS^)&O[F ^&VCU*XN+B6VA(/GB>$
M;=G&,!2=M:ZIXC\=_L]^,_$/ASQ7-I7A:YN;:#5M4GN;A+FWCA=Y96B2,;R7
M+P(""&QNR<#%??ND?#SPQX?_ +2_LS0-.T_^TL_;?LULD?VG.<^9@?-G<W7U
M-1V/PU\*:;X<NM M/#FF6VAW9+7&G16J+!*3C)9 ,'H.OH*SFL'*?,HRT:MJ
MMOM7TW[=CJI5Z]*E.DK6EOIVVM^I\"W5AJ-A\/+CXS:AKKZ(OB!] 2#4K&[N
MI3#=Q-,NIRK;Y 42.B.%Q\V,<=\;Q?X1\4?#6R^&NLQZZ_PZLM2:SFA_LW4;
MG4!JM]%:39OYT(&!,]Q KQGDKN).5%?HG<_#3PG>>&H/#T_AS3)M!@?S(M->
MU0V\;9)R$Q@')/YFGZS\._"_B*TTZUU3P_IVH6VF@"RBN;9'6V   V CY>%
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MY.3R3GA?[HKU:U@%K:PP*S,L48C#.<D@#&2>YXI!8D_&E')XY/I24H."#Z4
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M'_"*2?\ /PO_ 'R?\:Z/%&* .<_X123_ )^%_P"^3_C1_P (I)_S\+_WR?\
M&NCQ1B@#G/\ A%)/^?A?^^3_ (T?\(I)_P _"_\ ?)_QKH\48H YS_A%)/\
MGX7_ +Y/^-'_  BDG_/PO_?)_P :Z/%&* .<_P"$4D_Y^%_[Y/\ C1_PBDG_
M #\+_P!\G_&NCQ1B@#G/^$4D_P"?A?\ OD_XT?\ "*2?\_"_]\G_ !KH\48H
M YS_ (123_GX7_OD_P"-'_"*2?\ /PO_ 'R:Z/%&* .<_P"$4D_Y^%_[Y/\
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# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>limn-20260331xex5d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 limn-20260331xex5d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !X '@# 2(  A$! Q$!_\0
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M]?:A<V#^$_#DNMVZ6ZJ1/(AP$?<.%/MS7K5*D:4>:6QRTZ<JDN6.YY110#D
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M3UQ17HVG^'=&;X8?$N_BB2[ETS5].M].OG)WK"\ER&QV^=43/TJII>B:;/\
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<)5 .S@^O4\URU%%:1BHJT49N3D[L****HD__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>limn-20260331.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.3.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 6/24/2026 1:16:50 AM-->
<!--Modified on: 6/24/2026 1:16:50 AM-->
<xsd:schema targetNamespace="http://www.liminatuspharma.com/20260331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:attributeFormDefault="unqualified" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:limn="http://www.liminatuspharma.com/20260331">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>1100100 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1100400 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>1200100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>1200200 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>1200400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetailss" id="DisclosureIncomeTaxesIncomeTaxProvisionDetailss">
        <link:definition>1240902 - Disclosure - Income Taxes - Income tax provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss">
        <link:definition>1240903 - Disclosure - Income Taxes - Reconciliation of income tax rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetailss" id="DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetailss">
        <link:definition>1240904 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>1100090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>1100200 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit">
        <link:definition>1100300 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails" id="DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails">
        <link:definition>1140101 - Disclosure - Description of Organization and Business Operations - Business Combination (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails" id="DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails">
        <link:definition>1140102 - Disclosure - Description of Organization and Business Operations - February 2026 Public Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails" id="DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails">
        <link:definition>1140103 - Disclosure - Description of Organization and Business Operations - Liquidity and Capital Resources (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>1140201 - Disclosure - Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails" id="DisclosureLicenseAgreementsCd47LicenseDetails">
        <link:definition>1140301 - Disclosure - License Agreements - CD47 License (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails" id="DisclosureRelatedPartyTransactionsFeeluxBondsDetails">
        <link:definition>1140401 - Disclosure - Related Party Transactions - Feelux Bonds (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails" id="DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails">
        <link:definition>1140402 - Disclosure - Related Party Transactions - Car-Tcellkor Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails" id="DisclosureRelatedPartyTransactionsValetudoLoansDetails">
        <link:definition>1140403 - Disclosure - Related Party Transactions - Valetudo Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails" id="DisclosureRelatedPartyTransactionsEwonLoansDetails">
        <link:definition>1140404 - Disclosure - Related Party Transactions - Ewon Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails" id="DisclosureRelatedPartyTransactionsProphaseLoansDetails">
        <link:definition>1140405 - Disclosure - Related Party Transactions - Prophase Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails" id="DisclosureRelatedPartyTransactionsHanaLoansDetails">
        <link:definition>1140406 - Disclosure - Related Party Transactions - Hana Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails" id="DisclosureRelatedPartyTransactionsAmantesLoansDetails">
        <link:definition>1140407 - Disclosure - Related Party Transactions - Amantes Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails" id="DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails">
        <link:definition>1140408 - Disclosure - Related Party Transactions - Due to Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureDebtDetails" id="DisclosureDebtDetails">
        <link:definition>1140501 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails" id="DisclosureStockholderSEquityDetails">
        <link:definition>1140601 - Disclosure - Stockholder's Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails" id="DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails">
        <link:definition>1140602 - Disclosure - Stockholder's Equity - Assumptions used for estimating fair value of warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails" id="DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails">
        <link:definition>1140603 - Disclosure - Stockholder's Equity - Offering proceeds and related issuance costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>1140701 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>1140801 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details" id="DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details">
        <link:definition>1140802 - Disclosure - Fair Value Measurements - Changes in fair value of Level 3 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" id="StatementConsolidatedStatementsOfChangesInStockholderSDeficit">
        <link:definition>1200300 - Statement - Consolidated Statements of Changes in Stockholder's Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" id="DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss">
        <link:definition>1240101 - Disclosure - Description of Organization and Business Operations - Business Combination (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss" id="DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss">
        <link:definition>1240102 - Disclosure - Description of Organization and Business Operations - Liquidity and Capital Resources (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss" id="DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss">
        <link:definition>1240201 - Disclosure - Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails" id="DisclosureLicenseAgreementsCarTProductsLicenseDetails">
        <link:definition>1240301 - Disclosure - License Agreements - CAR-T Products License (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" id="DisclosureLicenseAgreementsVaccineProductsLicenseDetails">
        <link:definition>1240302 - Disclosure - License Agreements - Vaccine Products License (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails" id="DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails">
        <link:definition>1240303 - Disclosure - License Agreements - Termination of license agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss" id="DisclosureLicenseAgreementsCd47LicenseDetailss">
        <link:definition>1240304 - Disclosure - License Agreements - CD47 License (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss" id="DisclosureRelatedPartyTransactionsFeeluxBondsDetailss">
        <link:definition>1240401 - Disclosure - Related Party Transactions - Feelux Bonds (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss" id="DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss">
        <link:definition>1240402 - Disclosure - Related Party Transactions - Car-Tcellkor Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" id="DisclosureRelatedPartyTransactionsValetudoLoansDetailss">
        <link:definition>1240403 - Disclosure - Related Party Transactions - Valetudo Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss" id="DisclosureRelatedPartyTransactionsEwonLoansDetailss">
        <link:definition>1240404 - Disclosure - Related Party Transactions - Ewon Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss" id="DisclosureRelatedPartyTransactionsProphaseLoansDetailss">
        <link:definition>1240405 - Disclosure - Related Party Transactions - Prophase Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss" id="DisclosureRelatedPartyTransactionsHanaLoansDetailss">
        <link:definition>1240406 - Disclosure - Related Party Transactions - Hana Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss" id="DisclosureRelatedPartyTransactionsAmantesLoansDetailss">
        <link:definition>1240407 - Disclosure - Related Party Transactions - Amantes Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss" id="DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss">
        <link:definition>1240408 - Disclosure - Related Party Transactions - Due to Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails" id="DisclosureRelatedPartyTransactionsViralGeneDetails">
        <link:definition>1240409 - Disclosure - Related Party Transactions - Viral Gene (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureDebtDetailss" id="DisclosureDebtDetailss">
        <link:definition>1240501 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss" id="DisclosureStockholderSEquityDetailss">
        <link:definition>1240601 - Disclosure - Stockholder's Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" id="DisclosureCommitmentsAndContingenciesDetailss">
        <link:definition>1240701 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss" id="DisclosureFairValueMeasurementsDetailss">
        <link:definition>1240801 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss" id="DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss">
        <link:definition>1240802 - Disclosure - Fair Value Measurements - Changes in fair value of Level 3 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>1241001 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals" id="StatementCondensedConsolidatedBalanceSheetsParentheticals">
        <link:definition>1100105 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical">
        <link:definition>1100305 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficit (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations" id="DisclosureDescriptionOfOrganizationAndBusinessOperations">
        <link:definition>1110101 - Disclosure - Description of Organization and Business Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>1110201 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureLicenseAgreements" id="DisclosureLicenseAgreements">
        <link:definition>1110301 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>1110401 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>1110501 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureStockholderSEquity" id="DisclosureStockholderSEquity">
        <link:definition>1110601 - Disclosure - Stockholder's Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>1110701 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>1110801 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>1110901 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>1120202 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>1130503 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityTables" id="DisclosureStockholderSEquityTables">
        <link:definition>1130603 - Disclosure - Stockholder's Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>1130803 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetails" id="DisclosureSignificantAccountingPoliciesIncomeTaxesDetails">
        <link:definition>1140202 - Disclosure - Significant Accounting Policies - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals" id="StatementConsolidatedBalanceSheetsParentheticals">
        <link:definition>1200105 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationss" id="DisclosureDescriptionOfOrganizationAndBusinessOperationss">
        <link:definition>1210101 - Disclosure - Description of Organization and Business Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciess" id="DisclosureSignificantAccountingPoliciess">
        <link:definition>1210201 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementss" id="DisclosureLicenseAgreementss">
        <link:definition>1210301 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionss" id="DisclosureRelatedPartyTransactionss">
        <link:definition>1210401 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureDebts" id="DisclosureDebts">
        <link:definition>1210501 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureStockholderSEquitys" id="DisclosureStockholderSEquitys">
        <link:definition>1210601 - Disclosure - Stockholder's Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciess" id="DisclosureCommitmentsAndContingenciess">
        <link:definition>1210701 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementss" id="DisclosureFairValueMeasurementss">
        <link:definition>1210801 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>1210901 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureSubsequentEventss" id="DisclosureSubsequentEventss">
        <link:definition>1211001 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess" id="DisclosureSignificantAccountingPoliciesPoliciess">
        <link:definition>1220202 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureDebtTabless" id="DisclosureDebtTabless">
        <link:definition>1230503 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTabless" id="DisclosureFairValueMeasurementsTabless">
        <link:definition>1230803 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>1230903 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetailss" id="DisclosureSignificantAccountingPoliciesIncomeTaxesDetailss">
        <link:definition>1240202 - Disclosure - Significant Accounting Policies - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>1240901 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetails" id="DisclosureIncomeTaxesIncomeTaxProvisionDetails">
        <link:definition>1240902 - Disclosure - Income Taxes - Income tax provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails">
        <link:definition>1240903 - Disclosure - Income Taxes - Reconciliation of income tax rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>1240904 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="limn-20260331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="limn-20260331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="limn-20260331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="limn-20260331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.liminatuspharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:element name="ClassOfWarrantOrRightNumberOfWarrantsExercised" id="limn_ClassOfWarrantOrRightNumberOfWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants" id="limn_StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants" id="limn_StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="CommonStockIssuedInConnectionWithSettlement" id="limn_CommonStockIssuedInConnectionWithSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="CostsIncurredInConnectionWithIssuanceOfCommonStock" id="limn_CostsIncurredInConnectionWithIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LiminatusAndIrisMember" id="limn_LiminatusAndIrisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IrisAcquisitionCorpMember" id="limn_IrisAcquisitionCorpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RedeemableWarrantMember" id="limn_RedeemableWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NonRedeemableWarrantMember" id="limn_NonRedeemableWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockCashRedemptionShares" id="limn_CommonStockCashRedemptionShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="CommonStockCashRedemptionPricePerShare" id="limn_CommonStockCashRedemptionPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="CommonStockCashRedemptionAmount" id="limn_CommonStockCashRedemptionAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="NumberOfSharesHeldInEachUnit" id="limn_NumberOfSharesHeldInEachUnit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="NumberOfWarrantsHeldInEachUnit" id="limn_NumberOfWarrantsHeldInEachUnit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="CommonStockConversionRatioBusinessCombination" id="limn_CommonStockConversionRatioBusinessCombination" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="EmergingGrowthCompanyPolicyPolicyTextBlock" id="limn_EmergingGrowthCompanyPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FranchiseTaxExpenseIncludingInterestAndPenalty" id="limn_FranchiseTaxExpenseIncludingInterestAndPenalty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="TenYearsPeriodFromFirstCommercialSaleOfProductMember" id="limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockNumberOfVotesPerShare" id="limn_CommonStockNumberOfVotesPerShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember" id="limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedInterestCurrent" id="limn_AccruedInterestCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember" id="limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredUnderwritingFeesPayableInCashCurrent" id="limn_DeferredUnderwritingFeesPayableInCashCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember" id="limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncreaseDecreaseInAccruedMaintenanceFeesCurrent" id="limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent" id="limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent" id="limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="DeferredTransactionCostsInAccountsPayable" id="limn_DeferredTransactionCostsInAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ForgivenessOfUnrelatedVendorPayable" id="limn_ForgivenessOfUnrelatedVendorPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue" id="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="SharesIssuableUponClosingOfMergerToUnderwriters" id="limn_SharesIssuableUponClosingOfMergerToUnderwriters" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction" id="limn_MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LoansSettled" id="limn_LoansSettled" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="NoncashConversionOfAmountBorrowedForPipeFunds" id="limn_NoncashConversionOfAmountBorrowedForPipeFunds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="FeeluxBondsMember" id="limn_FeeluxBondsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CarTcellkorLoanMember" id="limn_CarTcellkorLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EwonLoanMember" id="limn_EwonLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ValetudoJune2023LoansMember" id="limn_ValetudoJune2023LoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ValetudoJuly2023LoanMember" id="limn_ValetudoJuly2023LoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ValetudoAugust2023LoansMember" id="limn_ValetudoAugust2023LoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EwonSeptember2023LoanMember" id="limn_EwonSeptember2023LoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ValetudoNovember2023LoanMember" id="limn_ValetudoNovember2023LoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EwonDecember2023LoanMember" id="limn_EwonDecember2023LoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ValetudoJanuary2024LoansMember" id="limn_ValetudoJanuary2024LoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProphaseFebruary2024LoanMember" id="limn_ProphaseFebruary2024LoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProphaseMarch2024LoanMember" id="limn_ProphaseMarch2024LoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProphaseApril2024LoanMember" id="limn_ProphaseApril2024LoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProphaseMay2024LoansMember" id="limn_ProphaseMay2024LoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProphaseJuly2024LoansMember" id="limn_ProphaseJuly2024LoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProphaseAugust2024LoansMember" id="limn_ProphaseAugust2024LoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="HanaAugust2024LoansMember" id="limn_HanaAugust2024LoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmantesNovember2024LoansMember" id="limn_AmantesNovember2024LoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmantesJanuary2025LoansMember" id="limn_AmantesJanuary2025LoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProphaseFebruary2025LoanMember" id="limn_ProphaseFebruary2025LoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProphaseMarch2025LoanMember" id="limn_ProphaseMarch2025LoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ValetudoDecember2022LoansMember" id="limn_ValetudoDecember2022LoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination" id="limn_StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PublicWarrantsMember" id="limn_PublicWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrivatePlacementWarrantsMember" id="limn_PrivatePlacementWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SharesAuthorized" id="limn_SharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ConversionOfStockOrUnitConversionRatio" id="limn_ConversionOfStockOrUnitConversionRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" id="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="StockIssuableForSettlementOfDeferredUnderwritingFees" id="limn_StockIssuableForSettlementOfDeferredUnderwritingFees" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="LicenseAgreementsAbstract" id="limn_LicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CurisBiotechHoldingsLlcMember" id="limn_CurisBiotechHoldingsLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfUnitsExchangeForLicenseRights" id="limn_NumberOfUnitsExchangeForLicenseRights" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital" id="limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="FeeluxCo.LtdMember" id="limn_FeeluxCo.LtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ValetudoLoanMember" id="limn_ValetudoLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ValetudoDecember2022LoanMember" id="limn_ValetudoDecember2022LoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ValetudoJune2023LoanOneMember" id="limn_ValetudoJune2023LoanOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ValetudoJune2023LoanTwoMember" id="limn_ValetudoJune2023LoanTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ValetudoAugust2023LoanOneMember" id="limn_ValetudoAugust2023LoanOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ValetudoAugust2023LoanTwoMember" id="limn_ValetudoAugust2023LoanTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ValetudoJanuary2024LoanOneMember" id="limn_ValetudoJanuary2024LoanOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ValetudoJanuary2024LoanTwoMember" id="limn_ValetudoJanuary2024LoanTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ValetudoTherapeuticsLlcMember" id="limn_ValetudoTherapeuticsLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RepaymentOfMembershipInterest" id="limn_RepaymentOfMembershipInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="EwonDecember2022LoanMember" id="limn_EwonDecember2022LoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EwonComfortechCoLtdMember" id="limn_EwonComfortechCoLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProphaseLoanMember" id="limn_ProphaseLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProphaseFebruary2025LoansMember" id="limn_ProphaseFebruary2025LoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProphaseMarch2025LoansMember" id="limn_ProphaseMarch2025LoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProphaseSciencesLlcMember" id="limn_ProphaseSciencesLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="HanaImmunotherapeuticsLlcMember" id="limn_HanaImmunotherapeuticsLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmantesLlcMember" id="limn_AmantesLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementsTextBlock" id="limn_LicenseAgreementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants" id="limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption" id="limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" id="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" id="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FeeReductionAgreementMember" id="limn_FeeReductionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" id="limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="UnderwritingCostsNoncurrent" id="limn_UnderwritingCostsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" id="limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredOfferingCostsNoncurrent" id="limn_DeferredOfferingCostsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PaymentOfOfferingCostsInCash" id="limn_PaymentOfOfferingCostsInCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="UnderwritingDiscountPaidInSecurities" id="limn_UnderwritingDiscountPaidInSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="MaximumNumbersOfSharesIssuable" id="limn_MaximumNumbersOfSharesIssuable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" id="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AltaPartnersLlcMember" id="limn_AltaPartnersLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SharesIssuedForSurrenderAndCancellationOfWarrants" id="limn_SharesIssuedForSurrenderAndCancellationOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination" id="limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination" id="limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination" id="limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination" id="limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering" id="limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination" id="limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits" id="limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="WarrantsPolicyPolicyTextBlock" id="limn_WarrantsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NetIncomeLossPerCommonStockPolicyPolicyTextBlock" id="limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProphaseApril2025LoansMember" id="limn_ProphaseApril2025LoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmantesLoansMember" id="limn_AmantesLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="HanaLoansMember" id="limn_HanaLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Cd47LicenseAndDevelopmentAgreementWithInnobationMember" id="limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesBusinessCombination" id="limn_StockIssuedDuringPeriodSharesBusinessCombination" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueBusinessCombination" id="limn_StockIssuedDuringPeriodValueBusinessCombination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="EmploymentAgreementMember" id="limn_EmploymentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans" id="limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IrisAcquisitionHoldingsLlcMember" id="limn_IrisAcquisitionHoldingsLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromIssuanceOfPrivatePlacementInvestor" id="limn_ProceedsFromIssuanceOfPrivatePlacementInvestor" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromIssuanceOfPrivatePlacementInvestorFunded" id="limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="PrincipalAndAccruedInterestOnPrivatePlacement" id="limn_PrincipalAndAccruedInterestOnPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ConsortiumLoanOfRelatedPartiesMember" id="limn_ConsortiumLoanOfRelatedPartiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RelatedPartiesDebtToUnsecuredPromissoryNote" id="limn_RelatedPartiesDebtToUnsecuredPromissoryNote" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="UnsecuredPromissoryNoteSettledAndConverted" id="limn_UnsecuredPromissoryNoteSettledAndConverted" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ConversionOfPrincipalAndAccruedInterestAmount" id="limn_ConversionOfPrincipalAndAccruedInterestAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="FeeluxAndCarTcellkorMember" id="limn_FeeluxAndCarTcellkorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConversionOfPrincipalAndAccruedInterestShares" id="limn_ConversionOfPrincipalAndAccruedInterestShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConversionOfAccruedInterestOnRelatedPartyDebts" id="limn_ConversionOfAccruedInterestOnRelatedPartyDebts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LiabilityOfUnderwritingFeesFairValue" id="limn_LiabilityOfUnderwritingFeesFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" id="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="FairValueOfCommonStockIssued" id="limn_FairValueOfCommonStockIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="FairValueOfWarrantsSurrendered" id="limn_FairValueOfWarrantsSurrendered" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="GainLossOnIssuanceOfCommonStockForWarrants" id="limn_GainLossOnIssuanceOfCommonStockForWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants" id="limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedPeriodValueOfCommonStockToUnderwriter" id="limn_StockIssuedPeriodValueOfCommonStockToUnderwriter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedPeriodOfCommonStockToUnderwriter" id="limn_StockIssuedPeriodOfCommonStockToUnderwriter" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember" id="limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockPayable" id="limn_CommonStockPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="FairValueOfCommonStockIssuanceForContingentLiability" id="limn_FairValueOfCommonStockIssuanceForContingentLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="OtherReceivableWriteOff" id="limn_OtherReceivableWriteOff" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="BestEffortsPublicOfferingMember" id="limn_BestEffortsPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightNumberOfWarrantsIssued" id="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PreFundedWarrantsMember" id="limn_PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockPurchaseWarrantsMember" id="limn_CommonStockPurchaseWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightIssuePricePerWarrant" id="limn_ClassOfWarrantOrRightIssuePricePerWarrant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="LicenseAndDevelopmentAgreementWithTdtMember" id="limn_LicenseAndDevelopmentAgreementWithTdtMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClearStreetLlcMember" id="limn_ClearStreetLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedMaintenanceFeeCurrent" id="limn_AccruedMaintenanceFeeCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="CommonStockShareOutstanding" id="limn_CommonStockShareOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="PlacementAgentWarrantsMember" id="limn_PlacementAgentWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PeriodOfNonIssuanceOfCommonStockFollowingClosingDate" id="limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate" id="limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PlacementAgentCashFeePercentage" id="limn_PlacementAgentCashFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumReimbursementForPlacementAgentExpenses" id="limn_MaximumReimbursementForPlacementAgentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="PercentOfSharesIssuedInOffering" id="limn_PercentOfSharesIssuedInOffering" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PercentOfOfferingPriceRepresentingExercisePrice" id="limn_PercentOfOfferingPriceRepresentingExercisePrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest" id="limn_DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="PaymentForCostsAssociatedWithClinicalTrials" id="limn_PaymentForCostsAssociatedWithClinicalTrials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="InnobationBioCo.LtdMember" id="limn_InnobationBioCo.LtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EstimatedPercentageOfActivitiesCompleted" id="limn_EstimatedPercentageOfActivitiesCompleted" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="PrepaidResearchAndDevelopmentExpenseCurrent" id="limn_PrepaidResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions" id="limn_ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OfferingCosts" id="limn_OfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock" id="limn_ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockWarrantsAndPlacementAgentWarrantsMember" id="limn_CommonStockWarrantsAndPlacementAgentWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockWarrantsMember" id="limn_CommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GrossProceedsFromIssuanceOfWarrants" id="limn_GrossProceedsFromIssuanceOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="NetProceedsFromIssuanceOfWarrants" id="limn_NetProceedsFromIssuanceOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="CommonStockAndPreFundedWarrantsMember" id="limn_CommonStockAndPreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="UpfrontPaymentOfLicenseAgreementFees" id="limn_UpfrontPaymentOfLicenseAgreementFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate" id="limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseMilestoneCommitmentFundPayableForEachPhase" id="limn_LicenseMilestoneCommitmentFundPayableForEachPhase" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="NumberOfMilestonePaymentsForFirstProductDevelopment" id="limn_NumberOfMilestonePaymentsForFirstProductDevelopment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment" id="limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="NumberOfMilestonePaymentsForEachAdditionalProductDevelopment" id="limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment" id="limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="RoyaltyFeesPercentage" id="limn_RoyaltyFeesPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts" id="limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VaccineLicenseAndDevelopmentAgreementWithTdtMember" id="limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VaccineProductsAndVaccineDiagnosticsMember" id="limn_VaccineProductsAndVaccineDiagnosticsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CarTLicenseAndVaccineLicenseWithTdtMember" id="limn_CarTLicenseAndVaccineLicenseWithTdtMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementsTerminationAmountDue" id="limn_LicenseAgreementsTerminationAmountDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ViralGeneMember" id="limn_ViralGeneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ResearchAndDevelopmentExpenseMandatoryCapitalization" id="limn_ResearchAndDevelopmentExpenseMandatoryCapitalization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent" id="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent" id="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount" id="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount" id="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxAssetsStartupExpenses" id="limn_DeferredTaxAssetsStartupExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="FederalIncomeTaxExpenseSubjectToLimitationInUse" id="limn_FederalIncomeTaxExpenseSubjectToLimitationInUse" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementMaintenanceFees" id="limn_LicenseAgreementMaintenanceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="StatutoryStateIncomeTaxRate" id="limn_StatutoryStateIncomeTaxRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>limn-20260331_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  11.3.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 6/24/2026 1:16:50 AM-->
<!--Modified on: 6/24/2026 1:16:50 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureIncomeTaxesIncomeTaxProvisionDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details" xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details" />
  <link:roleRef roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureFairValueMeasurementsDetails" />
  <link:roleRef roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTables" xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureFairValueMeasurementsTables" />
  <link:roleRef roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurements" xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureFairValueMeasurements" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <calculationLink xlink:role="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="1100100 - Statement - Condensed Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_639178606082987389" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639178606082987389" xlink:to="us-gaap_Cash_639178606082987389" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639178606082987389" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_639178606082987389" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639178606082987389" xlink:to="us-gaap_DeferredCostsCurrent_639178606082987389" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639178606082987389" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639178606082987389" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent_639178606082987389" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_639178606082987389" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent_639178606082987389" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_639178606082987389" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_639178606082987389" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_639178606082987389" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_639178606082987389" xlink:to="us-gaap_LiabilitiesCurrent_639178606082987389" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639178606082987389" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_639178606082987389" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639178606082987389" xlink:to="limn_AccruedInterestCurrent_639178606082987389" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639178606082987389" xlink:to="us-gaap_OtherLiabilitiesCurrent_639178606082987389" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639178606082987389" xlink:to="us-gaap_ShortTermBorrowings_639178606082987389" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableInCashCurrent" xlink:label="limn_DeferredUnderwritingFeesPayableInCashCurrent_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639178606082987389" xlink:to="limn_DeferredUnderwritingFeesPayableInCashCurrent_639178606082987389" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPayable" xlink:label="limn_CommonStockPayable_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639178606082987389" xlink:to="limn_CommonStockPayable_639178606082987389" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_639178606082987389" xlink:to="us-gaap_WarrantsAndRightsOutstanding_639178606082987389" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_639178606082987389" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_639178606082987389" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639178606082987389" xlink:to="us-gaap_PreferredStockValue_639178606082987389" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639178606082987389" xlink:to="us-gaap_CommonStockValue_639178606082987389" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639178606082987389" xlink:to="us-gaap_AdditionalPaidInCapital_639178606082987389" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639178606082987389" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639178606082987389" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="1100400 - Statement - Condensed Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606082987389" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606082987389" xlink:to="us-gaap_ProfitLoss_639178606082987389" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ForgivenessOfUnrelatedVendorPayable" xlink:label="limn_ForgivenessOfUnrelatedVendorPayable_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606082987389" xlink:to="limn_ForgivenessOfUnrelatedVendorPayable_639178606082987389" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_OtherReceivableWriteOff" xlink:label="limn_OtherReceivableWriteOff_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606082987389" xlink:to="limn_OtherReceivableWriteOff_639178606082987389" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606082987389" xlink:to="us-gaap_Depreciation_639178606082987389" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue" xlink:label="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606082987389" xlink:to="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_639178606082987389" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606082987389" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639178606082987389" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonStockIssuanceForContingentLiability" xlink:label="limn_FairValueOfCommonStockIssuanceForContingentLiability_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606082987389" xlink:to="limn_FairValueOfCommonStockIssuanceForContingentLiability_639178606082987389" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606082987389" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_639178606082987389" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606082987389" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639178606082987389" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606082987389" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_639178606082987389" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent" xlink:label="limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606082987389" xlink:to="limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent_639178606082987389" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent" xlink:label="limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606082987389" xlink:to="limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent_639178606082987389" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent" xlink:label="limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606082987389" xlink:to="limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent_639178606082987389" order="13" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606082987389" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_639178606082987389" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_639178606082987389" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLoansReceivable" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_639178606082987389" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable_639178606082987389" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_639178606082987389" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639178606082987389" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_639178606082987389" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639178606082987389" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_639178606082987389" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_639178606082987389" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639178606082987389" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_639178606082987389" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639178606082987389" xlink:to="us-gaap_ProceedsFromShortTermDebt_639178606083179918" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639178606082987389" xlink:to="us-gaap_RepaymentsOfShortTermDebt_639178606083179918" order="4" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="1200100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_1" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_639178606083179918" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_1" xlink:to="limn_AccruedInterestCurrent_639178606083179918" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_1" xlink:to="us-gaap_OtherLiabilitiesCurrent_639178606083179918" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_1" xlink:to="us-gaap_ShortTermBorrowings_639178606083179918" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedMaintenanceFeeCurrent" xlink:label="limn_AccruedMaintenanceFeeCurrent_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_1" xlink:to="limn_AccruedMaintenanceFeeCurrent_639178606083179918" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableInCashCurrent" xlink:label="limn_DeferredUnderwritingFeesPayableInCashCurrent_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_1" xlink:to="limn_DeferredUnderwritingFeesPayableInCashCurrent_639178606083179918" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPayable" xlink:label="limn_CommonStockPayable_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_1" xlink:to="limn_CommonStockPayable_639178606083179918" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="1200200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_639178606083179918" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_639178606083179918" xlink:to="us-gaap_OperatingExpenses_639178606083179918" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639178606083179918" xlink:to="us-gaap_GeneralAndAdministrativeExpense_639178606083179918" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639178606083179918" xlink:to="us-gaap_ResearchAndDevelopmentExpense_639178606083179918" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense_639178606083179918" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_639178606083179918" xlink:to="us-gaap_InterestExpenseNonoperating_639178606083179918" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_639178606083179918" xlink:to="us-gaap_InvestmentIncomeInterest_639178606083179918" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ForgivenessOfUnrelatedVendorPayable" xlink:label="limn_ForgivenessOfUnrelatedVendorPayable_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_639178606083179918" xlink:to="limn_ForgivenessOfUnrelatedVendorPayable_639178606083179918" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue" xlink:label="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_639178606083179918" xlink:to="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_639178606083179918" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_639178606083179918" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639178606083179918" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_GainLossOnIssuanceOfCommonStockForWarrants" xlink:label="limn_GainLossOnIssuanceOfCommonStockForWarrants_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_639178606083179918" xlink:to="limn_GainLossOnIssuanceOfCommonStockForWarrants_639178606083179918" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonStockIssuanceForContingentLiability" xlink:label="limn_FairValueOfCommonStockIssuanceForContingentLiability_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_639178606083179918" xlink:to="limn_FairValueOfCommonStockIssuanceForContingentLiability_639178606083179918" order="7" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="1200400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_639178606083179918" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent" xlink:label="limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent_639178606083179918" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent" xlink:label="limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent_639178606083179918" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent" xlink:label="limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent_639178606083179918" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_639178606083179918" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639178606083179918" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_639178606083179918" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonStockIssuanceForContingentLiability" xlink:label="limn_FairValueOfCommonStockIssuanceForContingentLiability_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="limn_FairValueOfCommonStockIssuanceForContingentLiability_639178606083179918" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_GainLossOnIssuanceOfCommonStockForWarrants" xlink:label="limn_GainLossOnIssuanceOfCommonStockForWarrants_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="limn_GainLossOnIssuanceOfCommonStockForWarrants_639178606083179918" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639178606083179918" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue" xlink:label="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_639178606083179918" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_Depreciation_639178606083179918" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_OtherReceivableWriteOff" xlink:label="limn_OtherReceivableWriteOff_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="limn_OtherReceivableWriteOff_639178606083179918" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ForgivenessOfUnrelatedVendorPayable" xlink:label="limn_ForgivenessOfUnrelatedVendorPayable_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="limn_ForgivenessOfUnrelatedVendorPayable_639178606083179918" order="14" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_ProfitLoss_639178606083179918" order="15" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetailss" xlink:type="extended" xlink:title="1240902 - Disclosure - Income Taxes - Income tax provision (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_639178606083179918" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_639178606083179918" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss" xlink:type="extended" xlink:title="1240903 - Disclosure - Income Taxes - Reconciliation of income tax rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639178606083179918" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_639178606083179918" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent" xlink:label="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent_639178606083179918" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent" xlink:label="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent_639178606083179918" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_639178606083179918" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639178606083179918" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639178606083179918" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount" xlink:label="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount_639178606083179918" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount" xlink:label="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount_639178606083179918" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_639178606083179918" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639178606083179918" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetailss" xlink:type="extended" xlink:title="1240904 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_639178606083179918" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_639178606083179918" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward_639178606083179918" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredTaxAssetsStartupExpenses" xlink:label="limn_DeferredTaxAssetsStartupExpenses_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="limn_DeferredTaxAssetsStartupExpenses_639178606083179918" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639178606083179918" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639178606083179918" order="5" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>limn-20260331_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.3.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 6/24/2026 1:16:50 AM-->
<!--Modified on: 6/24/2026 1:16:50 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" roleURI="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureLicenseAgreementsCd47LicenseDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsFeeluxBondsDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsValetudoLoansDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsEwonLoansDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsProphaseLoansDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsHanaLoansDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsAmantesLoansDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDebtDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureStockholderSEquityDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details" roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementConsolidatedStatementsOfChangesInStockholderSDeficit" roleURI="http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureLicenseAgreementsCarTProductsLicenseDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureLicenseAgreementsVaccineProductsLicenseDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureLicenseAgreementsCd47LicenseDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsFeeluxBondsDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsValetudoLoansDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsEwonLoansDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsProphaseLoansDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsHanaLoansDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsAmantesLoansDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsViralGeneDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDebtDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureDebtDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureStockholderSEquityDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureCommitmentsAndContingenciesDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureFairValueMeasurementsDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss" roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" />
  <link:roleRef roleURI="http://www.liminatuspharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.liminatuspharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="EntityAddressesAddressTypeAxis" xlink:title="EntityAddressesAddressTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="AddressTypeDomain" xlink:title="AddressTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="EntityAddressesAddressTypeAxis" xlink:to="AddressTypeDomain" xlink:title="definition: EntityAddressesAddressTypeAxis to AddressTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis" xlink:label="RestatementAxis" xlink:title="RestatementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain" xlink:label="RestatementDomain" xlink:title="RestatementDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestatementAxis" xlink:to="RestatementDomain" xlink:title="definition: RestatementAxis to RestatementDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="definition: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="CapitalUnitsByClassAxis" xlink:title="CapitalUnitsByClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="CapitalUnitClassDomain" xlink:title="CapitalUnitClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CapitalUnitsByClassAxis" xlink:to="CapitalUnitClassDomain" xlink:title="definition: CapitalUnitsByClassAxis to CapitalUnitClassDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:title="AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableTypeDomain" xlink:label="ReceivableTypeDomain" xlink:title="ReceivableTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="ReceivableTypeDomain" xlink:title="definition: AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis to ReceivableTypeDomain" use="optional" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="RelatedPartyMember" xlink:title="RelatedPartyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="RelatedPartyMember" xlink:title="definition: RelatedPartyDomain to RelatedPartyMember" use="optional" priority="0" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants_2" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="OtherReceivablesNetCurrent" xlink:title="OtherReceivablesNetCurrent" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="1100100 - Statement - Condensed Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_NonrelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="limn_AccruedInterestCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableInCashCurrent" xlink:label="limn_DeferredUnderwritingFeesPayableInCashCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="limn_DeferredUnderwritingFeesPayableInCashCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPayable" xlink:label="limn_CommonStockPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="limn_CommonStockPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" xlink:type="extended" xlink:title="1100300 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficit" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants" xlink:label="limn_StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="limn_StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants" xlink:label="limn_StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="limn_StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodValueBusinessCombination" xlink:label="limn_StockIssuedDuringPeriodValueBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="limn_StockIssuedDuringPeriodValueBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodSharesBusinessCombination" xlink:label="limn_StockIssuedDuringPeriodSharesBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="limn_StockIssuedDuringPeriodSharesBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans" xlink:label="limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedPeriodValueOfCommonStockToUnderwriter" xlink:label="limn_StockIssuedPeriodValueOfCommonStockToUnderwriter" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="limn_StockIssuedPeriodValueOfCommonStockToUnderwriter" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedPeriodOfCommonStockToUnderwriter" xlink:label="limn_StockIssuedPeriodOfCommonStockToUnderwriter" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="limn_StockIssuedPeriodOfCommonStockToUnderwriter" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants" xlink:label="limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails" xlink:type="extended" xlink:title="1140101 - Disclosure - Description of Organization and Business Operations - Business Combination (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LiminatusAndIrisMember" xlink:label="limn_LiminatusAndIrisMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="limn_LiminatusAndIrisMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IrisAcquisitionHoldingsLlcMember" xlink:label="limn_IrisAcquisitionHoldingsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="limn_IrisAcquisitionHoldingsLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IrisAcquisitionCorpMember" xlink:label="limn_IrisAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_EntityDomain" xlink:to="limn_IrisAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConsortiumLoanOfRelatedPartiesMember" xlink:label="limn_ConsortiumLoanOfRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ConsortiumLoanOfRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RedeemableWarrantMember" xlink:label="limn_RedeemableWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_RedeemableWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NonRedeemableWarrantMember" xlink:label="limn_NonRedeemableWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_NonRedeemableWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxCo.LtdMember" xlink:label="limn_FeeluxCo.LtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_FeeluxCo.LtdMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxAndCarTcellkorMember" xlink:label="limn_FeeluxAndCarTcellkorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_FeeluxAndCarTcellkorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockCashRedemptionShares" xlink:label="limn_CommonStockCashRedemptionShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_CommonStockCashRedemptionShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockCashRedemptionPricePerShare" xlink:label="limn_CommonStockCashRedemptionPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_CommonStockCashRedemptionPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockCashRedemptionAmount" xlink:label="limn_CommonStockCashRedemptionAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_CommonStockCashRedemptionAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfSharesHeldInEachUnit" xlink:label="limn_NumberOfSharesHeldInEachUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_NumberOfSharesHeldInEachUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfWarrantsHeldInEachUnit" xlink:label="limn_NumberOfWarrantsHeldInEachUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_NumberOfWarrantsHeldInEachUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockConversionRatioBusinessCombination" xlink:label="limn_CommonStockConversionRatioBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_CommonStockConversionRatioBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesAuthorized" xlink:label="limn_SharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_SharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfStockOrUnitConversionRatio" xlink:label="limn_ConversionOfStockOrUnitConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_ConversionOfStockOrUnitConversionRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProceedsFromIssuanceOfPrivatePlacementInvestor" xlink:label="limn_ProceedsFromIssuanceOfPrivatePlacementInvestor" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_ProceedsFromIssuanceOfPrivatePlacementInvestor" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded" xlink:label="limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PrincipalAndAccruedInterestOnPrivatePlacement" xlink:label="limn_PrincipalAndAccruedInterestOnPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_PrincipalAndAccruedInterestOnPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RelatedPartiesDebtToUnsecuredPromissoryNote" xlink:label="limn_RelatedPartiesDebtToUnsecuredPromissoryNote" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_RelatedPartiesDebtToUnsecuredPromissoryNote" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnsecuredPromissoryNoteSettledAndConverted" xlink:label="limn_UnsecuredPromissoryNoteSettledAndConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_UnsecuredPromissoryNoteSettledAndConverted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfPrincipalAndAccruedInterestAmount" xlink:label="limn_ConversionOfPrincipalAndAccruedInterestAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_ConversionOfPrincipalAndAccruedInterestAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfPrincipalAndAccruedInterestShares" xlink:label="limn_ConversionOfPrincipalAndAccruedInterestShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_ConversionOfPrincipalAndAccruedInterestShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfAccruedInterestOnRelatedPartyDebts" xlink:label="limn_ConversionOfAccruedInterestOnRelatedPartyDebts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_ConversionOfAccruedInterestOnRelatedPartyDebts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuableForSettlementOfDeferredUnderwritingFees" xlink:label="limn_StockIssuableForSettlementOfDeferredUnderwritingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_StockIssuableForSettlementOfDeferredUnderwritingFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LiabilityOfUnderwritingFeesFairValue" xlink:label="limn_LiabilityOfUnderwritingFeesFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_LiabilityOfUnderwritingFeesFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" xlink:label="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails" xlink:type="extended" xlink:title="1140102 - Disclosure - Description of Organization and Business Operations - February 2026 Public Offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PreFundedWarrantsMember" xlink:label="limn_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPurchaseWarrantsMember" xlink:label="limn_CommonStockPurchaseWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_CommonStockPurchaseWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PlacementAgentWarrantsMember" xlink:label="limn_PlacementAgentWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_PlacementAgentWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_BestEffortsPublicOfferingMember" xlink:label="limn_BestEffortsPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="limn_BestEffortsPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightIssuePricePerWarrant" xlink:label="limn_ClassOfWarrantOrRightIssuePricePerWarrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="limn_ClassOfWarrantOrRightIssuePricePerWarrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate" xlink:label="limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate" xlink:label="limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PlacementAgentCashFeePercentage" xlink:label="limn_PlacementAgentCashFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="limn_PlacementAgentCashFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_MaximumReimbursementForPlacementAgentExpenses" xlink:label="limn_MaximumReimbursementForPlacementAgentExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="limn_MaximumReimbursementForPlacementAgentExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PercentOfSharesIssuedInOffering" xlink:label="limn_PercentOfSharesIssuedInOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="limn_PercentOfSharesIssuedInOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PercentOfOfferingPriceRepresentingExercisePrice" xlink:label="limn_PercentOfOfferingPriceRepresentingExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="limn_PercentOfOfferingPriceRepresentingExercisePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails" xlink:type="extended" xlink:title="1140103 - Disclosure - Description of Organization and Business Operations - Liquidity and Capital Resources (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_BestEffortsPublicOfferingMember" xlink:label="limn_BestEffortsPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="limn_BestEffortsPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PreFundedWarrantsMember" xlink:label="limn_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPurchaseWarrantsMember" xlink:label="limn_CommonStockPurchaseWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_CommonStockPurchaseWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Cash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightIssuePricePerWarrant" xlink:label="limn_ClassOfWarrantOrRightIssuePricePerWarrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_ClassOfWarrantOrRightIssuePricePerWarrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="1140201 - Disclosure - Significant Accounting Policies - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPurchaseWarrantsMember" xlink:label="limn_CommonStockPurchaseWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_CommonStockPurchaseWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PlacementAgentWarrantsMember" xlink:label="limn_PlacementAgentWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_PlacementAgentWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PublicWarrantsMember" xlink:label="limn_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_PublicWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PrivatePlacementWarrantsMember" xlink:label="limn_PrivatePlacementWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_PrivatePlacementWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyMember" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FranchiseTaxExpenseIncludingInterestAndPenalty" xlink:label="limn_FranchiseTaxExpenseIncludingInterestAndPenalty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="limn_FranchiseTaxExpenseIncludingInterestAndPenalty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails" xlink:type="extended" xlink:title="1140301 - Disclosure - License Agreements - CD47 License (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember" xlink:label="limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CurisBiotechHoldingsLlcMember" xlink:label="limn_CurisBiotechHoldingsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_CurisBiotechHoldingsLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_InnobationBioCo.LtdMember" xlink:label="limn_InnobationBioCo.LtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_InnobationBioCo.LtdMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="us-gaap_CapitalUnitsByClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CapitalUnitsByClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="us-gaap_CapitalUnitClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CapitalUnitsByClassAxis" xlink:to="us-gaap_CapitalUnitClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="us-gaap_CapitalUnitClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CapitalUnitClassDomain" xlink:to="us-gaap_CapitalUnitClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfUnitsExchangeForLicenseRights" xlink:label="limn_NumberOfUnitsExchangeForLicenseRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_NumberOfUnitsExchangeForLicenseRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital" xlink:label="limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PaymentForCostsAssociatedWithClinicalTrials" xlink:label="limn_PaymentForCostsAssociatedWithClinicalTrials" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_PaymentForCostsAssociatedWithClinicalTrials" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EstimatedPercentageOfActivitiesCompleted" xlink:label="limn_EstimatedPercentageOfActivitiesCompleted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_EstimatedPercentageOfActivitiesCompleted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:label="limn_PrepaidResearchAndDevelopmentExpenseCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_PrepaidResearchAndDevelopmentExpenseCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails" xlink:type="extended" xlink:title="1140401 - Disclosure - Related Party Transactions - Feelux Bonds (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxBondsMember" xlink:label="limn_FeeluxBondsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_FeeluxBondsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxCo.LtdMember" xlink:label="limn_FeeluxCo.LtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_FeeluxCo.LtdMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639178606083459088" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_639178606083459088" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromShortTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits" xlink:label="limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="limn_AccruedInterestCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails" xlink:type="extended" xlink:title="1140402 - Disclosure - Related Party Transactions - Car-Tcellkor Loan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CarTcellkorLoanMember" xlink:label="limn_CarTcellkorLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_CarTcellkorLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails" xlink:type="extended" xlink:title="1140403 - Disclosure - Related Party Transactions - Valetudo Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoLoanMember" xlink:label="limn_ValetudoLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ValetudoLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoDecember2022LoanMember" xlink:label="limn_ValetudoDecember2022LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="limn_ValetudoLoanMember" xlink:to="limn_ValetudoDecember2022LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJune2023LoansMember" xlink:label="limn_ValetudoJune2023LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="limn_ValetudoLoanMember" xlink:to="limn_ValetudoJune2023LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJune2023LoanOneMember" xlink:label="limn_ValetudoJune2023LoanOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="limn_ValetudoJune2023LoansMember" xlink:to="limn_ValetudoJune2023LoanOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJune2023LoanTwoMember" xlink:label="limn_ValetudoJune2023LoanTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="limn_ValetudoJune2023LoansMember" xlink:to="limn_ValetudoJune2023LoanTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJuly2023LoanMember" xlink:label="limn_ValetudoJuly2023LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="limn_ValetudoLoanMember" xlink:to="limn_ValetudoJuly2023LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoAugust2023LoansMember" xlink:label="limn_ValetudoAugust2023LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="limn_ValetudoLoanMember" xlink:to="limn_ValetudoAugust2023LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoAugust2023LoanOneMember" xlink:label="limn_ValetudoAugust2023LoanOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="limn_ValetudoAugust2023LoansMember" xlink:to="limn_ValetudoAugust2023LoanOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoAugust2023LoanTwoMember" xlink:label="limn_ValetudoAugust2023LoanTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="limn_ValetudoAugust2023LoansMember" xlink:to="limn_ValetudoAugust2023LoanTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoNovember2023LoanMember" xlink:label="limn_ValetudoNovember2023LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="limn_ValetudoLoanMember" xlink:to="limn_ValetudoNovember2023LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJanuary2024LoansMember" xlink:label="limn_ValetudoJanuary2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="limn_ValetudoLoanMember" xlink:to="limn_ValetudoJanuary2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJanuary2024LoanOneMember" xlink:label="limn_ValetudoJanuary2024LoanOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="limn_ValetudoJanuary2024LoansMember" xlink:to="limn_ValetudoJanuary2024LoanOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJanuary2024LoanTwoMember" xlink:label="limn_ValetudoJanuary2024LoanTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="limn_ValetudoJanuary2024LoansMember" xlink:to="limn_ValetudoJanuary2024LoanTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoTherapeuticsLlcMember" xlink:label="limn_ValetudoTherapeuticsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_ValetudoTherapeuticsLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RepaymentOfMembershipInterest" xlink:label="limn_RepaymentOfMembershipInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="limn_RepaymentOfMembershipInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfShortTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="limn_AccruedInterestCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails" xlink:type="extended" xlink:title="1140404 - Disclosure - Related Party Transactions - Ewon Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonLoanMember" xlink:label="limn_EwonLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_EwonLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonDecember2022LoanMember" xlink:label="limn_EwonDecember2022LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="limn_EwonLoanMember" xlink:to="limn_EwonDecember2022LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonSeptember2023LoanMember" xlink:label="limn_EwonSeptember2023LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="limn_EwonLoanMember" xlink:to="limn_EwonSeptember2023LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonDecember2023LoanMember" xlink:label="limn_EwonDecember2023LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="limn_EwonLoanMember" xlink:to="limn_EwonDecember2023LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonComfortechCoLtdMember" xlink:label="limn_EwonComfortechCoLtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_EwonComfortechCoLtdMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfShortTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="limn_AccruedInterestCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails" xlink:type="extended" xlink:title="1140405 - Disclosure - Related Party Transactions - Prophase Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseLoanMember" xlink:label="limn_ProphaseLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ProphaseLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseFebruary2024LoanMember" xlink:label="limn_ProphaseFebruary2024LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="limn_ProphaseLoanMember" xlink:to="limn_ProphaseFebruary2024LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMarch2024LoanMember" xlink:label="limn_ProphaseMarch2024LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="limn_ProphaseLoanMember" xlink:to="limn_ProphaseMarch2024LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseApril2024LoanMember" xlink:label="limn_ProphaseApril2024LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="limn_ProphaseLoanMember" xlink:to="limn_ProphaseApril2024LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMay2024LoansMember" xlink:label="limn_ProphaseMay2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="limn_ProphaseLoanMember" xlink:to="limn_ProphaseMay2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseJuly2024LoansMember" xlink:label="limn_ProphaseJuly2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="limn_ProphaseLoanMember" xlink:to="limn_ProphaseJuly2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseAugust2024LoansMember" xlink:label="limn_ProphaseAugust2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="limn_ProphaseLoanMember" xlink:to="limn_ProphaseAugust2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseFebruary2025LoansMember" xlink:label="limn_ProphaseFebruary2025LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="limn_ProphaseLoanMember" xlink:to="limn_ProphaseFebruary2025LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMarch2025LoansMember" xlink:label="limn_ProphaseMarch2025LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="limn_ProphaseLoanMember" xlink:to="limn_ProphaseMarch2025LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseApril2025LoansMember" xlink:label="limn_ProphaseApril2025LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="limn_ProphaseLoanMember" xlink:to="limn_ProphaseApril2025LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseSciencesLlcMember" xlink:label="limn_ProphaseSciencesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_ProphaseSciencesLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="limn_AccruedInterestCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails" xlink:type="extended" xlink:title="1140406 - Disclosure - Related Party Transactions - Hana Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_HanaLoansMember" xlink:label="limn_HanaLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_HanaLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_HanaAugust2024LoansMember" xlink:label="limn_HanaAugust2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="limn_HanaLoansMember" xlink:to="limn_HanaAugust2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_HanaImmunotherapeuticsLlcMember" xlink:label="limn_HanaImmunotherapeuticsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_HanaImmunotherapeuticsLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="limn_AccruedInterestCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails" xlink:type="extended" xlink:title="1140407 - Disclosure - Related Party Transactions - Amantes Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesLoansMember" xlink:label="limn_AmantesLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_AmantesLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesNovember2024LoansMember" xlink:label="limn_AmantesNovember2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="limn_AmantesLoansMember" xlink:to="limn_AmantesNovember2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesJanuary2025LoansMember" xlink:label="limn_AmantesJanuary2025LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="limn_AmantesLoansMember" xlink:to="limn_AmantesJanuary2025LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesLlcMember" xlink:label="limn_AmantesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_AmantesLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="limn_AccruedInterestCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails" xlink:type="extended" xlink:title="1140408 - Disclosure - Related Party Transactions - Due to Related Party (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EmploymentAgreementMember" xlink:label="limn_EmploymentAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="limn_EmploymentAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDebtDetails" xlink:type="extended" xlink:title="1140501 - Disclosure - Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoDecember2022LoansMember" xlink:label="limn_ValetudoDecember2022LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ValetudoDecember2022LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJune2023LoansMember" xlink:label="limn_ValetudoJune2023LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ValetudoJune2023LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJuly2023LoanMember" xlink:label="limn_ValetudoJuly2023LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ValetudoJuly2023LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseFebruary2024LoanMember" xlink:label="limn_ProphaseFebruary2024LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ProphaseFebruary2024LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMarch2024LoanMember" xlink:label="limn_ProphaseMarch2024LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ProphaseMarch2024LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMay2024LoansMember" xlink:label="limn_ProphaseMay2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ProphaseMay2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseJuly2024LoansMember" xlink:label="limn_ProphaseJuly2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ProphaseJuly2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseAugust2024LoansMember" xlink:label="limn_ProphaseAugust2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ProphaseAugust2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_HanaAugust2024LoansMember" xlink:label="limn_HanaAugust2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_HanaAugust2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesNovember2024LoansMember" xlink:label="limn_AmantesNovember2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_AmantesNovember2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesJanuary2025LoansMember" xlink:label="limn_AmantesJanuary2025LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_AmantesJanuary2025LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseFebruary2025LoanMember" xlink:label="limn_ProphaseFebruary2025LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ProphaseFebruary2025LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMarch2025LoanMember" xlink:label="limn_ProphaseMarch2025LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ProphaseMarch2025LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails" xlink:type="extended" xlink:title="1140601 - Disclosure - Stockholder's Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PublicWarrantsMember" xlink:label="limn_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_PublicWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PrivatePlacementWarrantsMember" xlink:label="limn_PrivatePlacementWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_PrivatePlacementWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PreFundedWarrantsMember" xlink:label="limn_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPurchaseWarrantsMember" xlink:label="limn_CommonStockPurchaseWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_CommonStockPurchaseWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PlacementAgentWarrantsMember" xlink:label="limn_PlacementAgentWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_PlacementAgentWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockAndPreFundedWarrantsMember" xlink:label="limn_CommonStockAndPreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_CommonStockAndPreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AltaPartnersLlcMember" xlink:label="limn_AltaPartnersLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_AltaPartnersLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClearStreetLlcMember" xlink:label="limn_ClearStreetLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_ClearStreetLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_BestEffortsPublicOfferingMember" xlink:label="limn_BestEffortsPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="limn_BestEffortsPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesIssuedForSurrenderAndCancellationOfWarrants" xlink:label="limn_SharesIssuedForSurrenderAndCancellationOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_SharesIssuedForSurrenderAndCancellationOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" xlink:label="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonStockIssued" xlink:label="limn_FairValueOfCommonStockIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_FairValueOfCommonStockIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfWarrantsSurrendered" xlink:label="limn_FairValueOfWarrantsSurrendered" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_FairValueOfWarrantsSurrendered" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_GainLossOnIssuanceOfCommonStockForWarrants" xlink:label="limn_GainLossOnIssuanceOfCommonStockForWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_GainLossOnIssuanceOfCommonStockForWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuableForSettlementOfDeferredUnderwritingFees" xlink:label="limn_StockIssuableForSettlementOfDeferredUnderwritingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_StockIssuableForSettlementOfDeferredUnderwritingFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" xlink:label="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightIssuePricePerWarrant" xlink:label="limn_ClassOfWarrantOrRightIssuePricePerWarrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_ClassOfWarrantOrRightIssuePricePerWarrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_ClassOfWarrantOrRightNumberOfWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockNumberOfVotesPerShare" xlink:label="limn_CommonStockNumberOfVotesPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_CommonStockNumberOfVotesPerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants" xlink:label="limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption" xlink:label="limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails" xlink:type="extended" xlink:title="1140602 - Disclosure - Stockholder's Equity - Assumptions used for estimating fair value of warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockWarrantsAndPlacementAgentWarrantsMember" xlink:label="limn_CommonStockWarrantsAndPlacementAgentWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_CommonStockWarrantsAndPlacementAgentWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails" xlink:type="extended" xlink:title="1140603 - Disclosure - Stockholder's Equity - Offering proceeds and related issuance costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockWarrantsMember" xlink:label="limn_CommonStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_CommonStockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PreFundedWarrantsMember" xlink:label="limn_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PlacementAgentWarrantsMember" xlink:label="limn_PlacementAgentWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_PlacementAgentWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_GrossProceedsFromIssuanceOfWarrants" xlink:label="limn_GrossProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_GrossProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_OfferingCosts" xlink:label="limn_OfferingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_OfferingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NetProceedsFromIssuanceOfWarrants" xlink:label="limn_NetProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_NetProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="1140701 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeReductionAgreementMember" xlink:label="limn_FeeReductionAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="limn_FeeReductionAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IrisAcquisitionCorpMember" xlink:label="limn_IrisAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="limn_IrisAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClearStreetLlcMember" xlink:label="limn_ClearStreetLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_ClearStreetLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_ShortTermLeaseCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesIssuedForSurrenderAndCancellationOfWarrants" xlink:label="limn_SharesIssuedForSurrenderAndCancellationOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_SharesIssuedForSurrenderAndCancellationOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" xlink:label="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPayable" xlink:label="limn_CommonStockPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_CommonStockPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="us-gaap_LossContingencyDamagesAwardedValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_LossContingencyDamagesAwardedValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementInterest" xlink:label="us-gaap_LitigationSettlementInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_LitigationSettlementInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" xlink:label="limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnderwritingCostsNoncurrent" xlink:label="limn_UnderwritingCostsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_UnderwritingCostsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" xlink:label="limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredOfferingCostsNoncurrent" xlink:label="limn_DeferredOfferingCostsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_DeferredOfferingCostsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PaymentOfOfferingCostsInCash" xlink:label="limn_PaymentOfOfferingCostsInCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_PaymentOfOfferingCostsInCash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnderwritingDiscountPaidInSecurities" xlink:label="limn_UnderwritingDiscountPaidInSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_UnderwritingDiscountPaidInSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_MaximumNumbersOfSharesIssuable" xlink:label="limn_MaximumNumbersOfSharesIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_MaximumNumbersOfSharesIssuable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering" xlink:label="limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination" xlink:label="limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableInCashCurrent" xlink:label="limn_DeferredUnderwritingFeesPayableInCashCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_DeferredUnderwritingFeesPayableInCashCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuableForSettlementOfDeferredUnderwritingFees" xlink:label="limn_StockIssuableForSettlementOfDeferredUnderwritingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_StockIssuableForSettlementOfDeferredUnderwritingFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" xlink:label="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="1140801 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details" xlink:type="extended" xlink:title="1140802 - Disclosure - Fair Value Measurements - Changes in fair value of Level 3 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="1200100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_NonrelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="limn_AccruedInterestCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedMaintenanceFeeCurrent" xlink:label="limn_AccruedMaintenanceFeeCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="limn_AccruedMaintenanceFeeCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableInCashCurrent" xlink:label="limn_DeferredUnderwritingFeesPayableInCashCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="limn_DeferredUnderwritingFeesPayableInCashCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPayable" xlink:label="limn_CommonStockPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="limn_CommonStockPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" xlink:type="extended" xlink:title="1200300 - Statement - Consolidated Statements of Changes in Stockholder's Deficit" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodValueBusinessCombination" xlink:label="limn_StockIssuedDuringPeriodValueBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="limn_StockIssuedDuringPeriodValueBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodSharesBusinessCombination" xlink:label="limn_StockIssuedDuringPeriodSharesBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="limn_StockIssuedDuringPeriodSharesBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans" xlink:label="limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedPeriodValueOfCommonStockToUnderwriter" xlink:label="limn_StockIssuedPeriodValueOfCommonStockToUnderwriter" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="limn_StockIssuedPeriodValueOfCommonStockToUnderwriter" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedPeriodOfCommonStockToUnderwriter" xlink:label="limn_StockIssuedPeriodOfCommonStockToUnderwriter" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="limn_StockIssuedPeriodOfCommonStockToUnderwriter" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants" xlink:label="limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesIssuedForSurrenderAndCancellationOfWarrants" xlink:label="limn_SharesIssuedForSurrenderAndCancellationOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="limn_SharesIssuedForSurrenderAndCancellationOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" xlink:type="extended" xlink:title="1240101 - Disclosure - Description of Organization and Business Operations - Business Combination (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LiminatusAndIrisMember" xlink:label="limn_LiminatusAndIrisMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="limn_LiminatusAndIrisMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IrisAcquisitionHoldingsLlcMember" xlink:label="limn_IrisAcquisitionHoldingsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="limn_IrisAcquisitionHoldingsLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IrisAcquisitionCorpMember" xlink:label="limn_IrisAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_EntityDomain" xlink:to="limn_IrisAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConsortiumLoanOfRelatedPartiesMember" xlink:label="limn_ConsortiumLoanOfRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ConsortiumLoanOfRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RedeemableWarrantMember" xlink:label="limn_RedeemableWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_RedeemableWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NonRedeemableWarrantMember" xlink:label="limn_NonRedeemableWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_NonRedeemableWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxCo.LtdMember" xlink:label="limn_FeeluxCo.LtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_FeeluxCo.LtdMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxAndCarTcellkorMember" xlink:label="limn_FeeluxAndCarTcellkorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_FeeluxAndCarTcellkorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockCashRedemptionShares" xlink:label="limn_CommonStockCashRedemptionShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_CommonStockCashRedemptionShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockCashRedemptionPricePerShare" xlink:label="limn_CommonStockCashRedemptionPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_CommonStockCashRedemptionPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockCashRedemptionAmount" xlink:label="limn_CommonStockCashRedemptionAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_CommonStockCashRedemptionAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfSharesHeldInEachUnit" xlink:label="limn_NumberOfSharesHeldInEachUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_NumberOfSharesHeldInEachUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfWarrantsHeldInEachUnit" xlink:label="limn_NumberOfWarrantsHeldInEachUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_NumberOfWarrantsHeldInEachUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockConversionRatioBusinessCombination" xlink:label="limn_CommonStockConversionRatioBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_CommonStockConversionRatioBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesAuthorized" xlink:label="limn_SharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_SharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfStockOrUnitConversionRatio" xlink:label="limn_ConversionOfStockOrUnitConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_ConversionOfStockOrUnitConversionRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProceedsFromIssuanceOfPrivatePlacementInvestor" xlink:label="limn_ProceedsFromIssuanceOfPrivatePlacementInvestor" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_ProceedsFromIssuanceOfPrivatePlacementInvestor" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded" xlink:label="limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RelatedPartiesDebtToUnsecuredPromissoryNote" xlink:label="limn_RelatedPartiesDebtToUnsecuredPromissoryNote" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_RelatedPartiesDebtToUnsecuredPromissoryNote" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnsecuredPromissoryNoteSettledAndConverted" xlink:label="limn_UnsecuredPromissoryNoteSettledAndConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_UnsecuredPromissoryNoteSettledAndConverted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfPrincipalAndAccruedInterestShares" xlink:label="limn_ConversionOfPrincipalAndAccruedInterestShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_ConversionOfPrincipalAndAccruedInterestShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuableForSettlementOfDeferredUnderwritingFees" xlink:label="limn_StockIssuableForSettlementOfDeferredUnderwritingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_StockIssuableForSettlementOfDeferredUnderwritingFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LiabilityOfUnderwritingFeesFairValue" xlink:label="limn_LiabilityOfUnderwritingFeesFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_LiabilityOfUnderwritingFeesFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" xlink:label="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfPrincipalAndAccruedInterestAmount" xlink:label="limn_ConversionOfPrincipalAndAccruedInterestAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_ConversionOfPrincipalAndAccruedInterestAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PrincipalAndAccruedInterestOnPrivatePlacement" xlink:label="limn_PrincipalAndAccruedInterestOnPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_PrincipalAndAccruedInterestOnPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfAccruedInterestOnRelatedPartyDebts" xlink:label="limn_ConversionOfAccruedInterestOnRelatedPartyDebts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_ConversionOfAccruedInterestOnRelatedPartyDebts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss" xlink:type="extended" xlink:title="1240102 - Disclosure - Description of Organization and Business Operations - Liquidity and Capital Resources (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_BestEffortsPublicOfferingMember" xlink:label="limn_BestEffortsPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="limn_BestEffortsPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PreFundedWarrantsMember" xlink:label="limn_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPurchaseWarrantsMember" xlink:label="limn_CommonStockPurchaseWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_CommonStockPurchaseWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Cash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightIssuePricePerWarrant" xlink:label="limn_ClassOfWarrantOrRightIssuePricePerWarrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="limn_ClassOfWarrantOrRightIssuePricePerWarrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss" xlink:type="extended" xlink:title="1240201 - Disclosure - Significant Accounting Policies - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PublicWarrantsMember" xlink:label="limn_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_PublicWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PrivatePlacementWarrantsMember" xlink:label="limn_PrivatePlacementWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_PrivatePlacementWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyMember" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:label="us-gaap_AllowanceForNotesAndLoansReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AllowanceForNotesAndLoansReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DeferredCostsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FranchiseTaxExpenseIncludingInterestAndPenalty" xlink:label="limn_FranchiseTaxExpenseIncludingInterestAndPenalty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="limn_FranchiseTaxExpenseIncludingInterestAndPenalty" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails" xlink:type="extended" xlink:title="1240301 - Disclosure - License Agreements - CAR-T Products License (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAndDevelopmentAgreementWithTdtMember" xlink:label="limn_LicenseAndDevelopmentAgreementWithTdtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="limn_LicenseAndDevelopmentAgreementWithTdtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember" xlink:label="limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember" xlink:label="limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember" xlink:to="limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember" xlink:label="limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember" xlink:label="limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember" xlink:label="limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UpfrontPaymentOfLicenseAgreementFees" xlink:label="limn_UpfrontPaymentOfLicenseAgreementFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_UpfrontPaymentOfLicenseAgreementFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CostMaintenance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate" xlink:label="limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseMilestoneCommitmentFundPayableForEachPhase" xlink:label="limn_LicenseMilestoneCommitmentFundPayableForEachPhase" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_LicenseMilestoneCommitmentFundPayableForEachPhase" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfMilestonePaymentsForFirstProductDevelopment" xlink:label="limn_NumberOfMilestonePaymentsForFirstProductDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_NumberOfMilestonePaymentsForFirstProductDevelopment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment" xlink:label="limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment" xlink:label="limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment" xlink:label="limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RoyaltyFeesPercentage" xlink:label="limn_RoyaltyFeesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_RoyaltyFeesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts" xlink:label="limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" xlink:type="extended" xlink:title="1240302 - Disclosure - License Agreements - Vaccine Products License (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember" xlink:label="limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CarTLicenseAndVaccineLicenseWithTdtMember" xlink:label="limn_CarTLicenseAndVaccineLicenseWithTdtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="limn_CarTLicenseAndVaccineLicenseWithTdtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_VaccineProductsAndVaccineDiagnosticsMember" xlink:label="limn_VaccineProductsAndVaccineDiagnosticsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="limn_VaccineProductsAndVaccineDiagnosticsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember" xlink:label="limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember" xlink:label="limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UpfrontPaymentOfLicenseAgreementFees" xlink:label="limn_UpfrontPaymentOfLicenseAgreementFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_UpfrontPaymentOfLicenseAgreementFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CostMaintenance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAgreementMaintenanceFees" xlink:label="limn_LicenseAgreementMaintenanceFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_LicenseAgreementMaintenanceFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate" xlink:label="limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfMilestonePaymentsForFirstProductDevelopment" xlink:label="limn_NumberOfMilestonePaymentsForFirstProductDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_NumberOfMilestonePaymentsForFirstProductDevelopment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment" xlink:label="limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment" xlink:label="limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment" xlink:label="limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RoyaltyFeesPercentage" xlink:label="limn_RoyaltyFeesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_RoyaltyFeesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ForgivenessOfUnrelatedVendorPayable" xlink:label="limn_ForgivenessOfUnrelatedVendorPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_ForgivenessOfUnrelatedVendorPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts" xlink:label="limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails" xlink:type="extended" xlink:title="1240303 - Disclosure - License Agreements - Termination of license agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CarTLicenseAndVaccineLicenseWithTdtMember" xlink:label="limn_CarTLicenseAndVaccineLicenseWithTdtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="limn_CarTLicenseAndVaccineLicenseWithTdtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAgreementsTerminationAmountDue" xlink:label="limn_LicenseAgreementsTerminationAmountDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_LicenseAgreementsTerminationAmountDue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss" xlink:type="extended" xlink:title="1240304 - Disclosure - License Agreements - CD47 License (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember" xlink:label="limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CurisBiotechHoldingsLlcMember" xlink:label="limn_CurisBiotechHoldingsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_CurisBiotechHoldingsLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="us-gaap_CapitalUnitsByClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CapitalUnitsByClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="us-gaap_CapitalUnitClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CapitalUnitsByClassAxis" xlink:to="us-gaap_CapitalUnitClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="us-gaap_CapitalUnitClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CapitalUnitClassDomain" xlink:to="us-gaap_CapitalUnitClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfUnitsExchangeForLicenseRights" xlink:label="limn_NumberOfUnitsExchangeForLicenseRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_NumberOfUnitsExchangeForLicenseRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital" xlink:label="limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss" xlink:type="extended" xlink:title="1240401 - Disclosure - Related Party Transactions - Feelux Bonds (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxBondsMember" xlink:label="limn_FeeluxBondsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_FeeluxBondsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxCo.LtdMember" xlink:label="limn_FeeluxCo.LtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_FeeluxCo.LtdMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromShortTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits" xlink:label="limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="limn_AccruedInterestCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss" xlink:type="extended" xlink:title="1240402 - Disclosure - Related Party Transactions - Car-Tcellkor Loan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CarTcellkorLoanMember" xlink:label="limn_CarTcellkorLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_CarTcellkorLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" xlink:type="extended" xlink:title="1240403 - Disclosure - Related Party Transactions - Valetudo Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoLoanMember" xlink:label="limn_ValetudoLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ValetudoLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoDecember2022LoanMember" xlink:label="limn_ValetudoDecember2022LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="limn_ValetudoLoanMember" xlink:to="limn_ValetudoDecember2022LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJune2023LoansMember" xlink:label="limn_ValetudoJune2023LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="limn_ValetudoLoanMember" xlink:to="limn_ValetudoJune2023LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJune2023LoanOneMember" xlink:label="limn_ValetudoJune2023LoanOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="limn_ValetudoJune2023LoansMember" xlink:to="limn_ValetudoJune2023LoanOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJune2023LoanTwoMember" xlink:label="limn_ValetudoJune2023LoanTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="limn_ValetudoJune2023LoansMember" xlink:to="limn_ValetudoJune2023LoanTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJuly2023LoanMember" xlink:label="limn_ValetudoJuly2023LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="limn_ValetudoLoanMember" xlink:to="limn_ValetudoJuly2023LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoAugust2023LoansMember" xlink:label="limn_ValetudoAugust2023LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="limn_ValetudoLoanMember" xlink:to="limn_ValetudoAugust2023LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoAugust2023LoanOneMember" xlink:label="limn_ValetudoAugust2023LoanOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="limn_ValetudoAugust2023LoansMember" xlink:to="limn_ValetudoAugust2023LoanOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoAugust2023LoanTwoMember" xlink:label="limn_ValetudoAugust2023LoanTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="limn_ValetudoAugust2023LoansMember" xlink:to="limn_ValetudoAugust2023LoanTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoNovember2023LoanMember" xlink:label="limn_ValetudoNovember2023LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="limn_ValetudoLoanMember" xlink:to="limn_ValetudoNovember2023LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJanuary2024LoansMember" xlink:label="limn_ValetudoJanuary2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="limn_ValetudoLoanMember" xlink:to="limn_ValetudoJanuary2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJanuary2024LoanOneMember" xlink:label="limn_ValetudoJanuary2024LoanOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="limn_ValetudoJanuary2024LoansMember" xlink:to="limn_ValetudoJanuary2024LoanOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJanuary2024LoanTwoMember" xlink:label="limn_ValetudoJanuary2024LoanTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="limn_ValetudoJanuary2024LoansMember" xlink:to="limn_ValetudoJanuary2024LoanTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoTherapeuticsLlcMember" xlink:label="limn_ValetudoTherapeuticsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_ValetudoTherapeuticsLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RepaymentOfMembershipInterest" xlink:label="limn_RepaymentOfMembershipInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="limn_RepaymentOfMembershipInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfShortTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="limn_AccruedInterestCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss" xlink:type="extended" xlink:title="1240404 - Disclosure - Related Party Transactions - Ewon Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonLoanMember" xlink:label="limn_EwonLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_EwonLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonDecember2022LoanMember" xlink:label="limn_EwonDecember2022LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="limn_EwonLoanMember" xlink:to="limn_EwonDecember2022LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonSeptember2023LoanMember" xlink:label="limn_EwonSeptember2023LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="limn_EwonLoanMember" xlink:to="limn_EwonSeptember2023LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonDecember2023LoanMember" xlink:label="limn_EwonDecember2023LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="limn_EwonLoanMember" xlink:to="limn_EwonDecember2023LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonComfortechCoLtdMember" xlink:label="limn_EwonComfortechCoLtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_EwonComfortechCoLtdMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfShortTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="limn_AccruedInterestCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss" xlink:type="extended" xlink:title="1240405 - Disclosure - Related Party Transactions - Prophase Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseLoanMember" xlink:label="limn_ProphaseLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ProphaseLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseFebruary2024LoanMember" xlink:label="limn_ProphaseFebruary2024LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="limn_ProphaseLoanMember" xlink:to="limn_ProphaseFebruary2024LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMarch2024LoanMember" xlink:label="limn_ProphaseMarch2024LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="limn_ProphaseLoanMember" xlink:to="limn_ProphaseMarch2024LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseApril2024LoanMember" xlink:label="limn_ProphaseApril2024LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="limn_ProphaseLoanMember" xlink:to="limn_ProphaseApril2024LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMay2024LoansMember" xlink:label="limn_ProphaseMay2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="limn_ProphaseLoanMember" xlink:to="limn_ProphaseMay2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseJuly2024LoansMember" xlink:label="limn_ProphaseJuly2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="limn_ProphaseLoanMember" xlink:to="limn_ProphaseJuly2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseAugust2024LoansMember" xlink:label="limn_ProphaseAugust2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="limn_ProphaseLoanMember" xlink:to="limn_ProphaseAugust2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseFebruary2025LoansMember" xlink:label="limn_ProphaseFebruary2025LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="limn_ProphaseLoanMember" xlink:to="limn_ProphaseFebruary2025LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMarch2025LoansMember" xlink:label="limn_ProphaseMarch2025LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="limn_ProphaseLoanMember" xlink:to="limn_ProphaseMarch2025LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseApril2025LoansMember" xlink:label="limn_ProphaseApril2025LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="limn_ProphaseLoanMember" xlink:to="limn_ProphaseApril2025LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseSciencesLlcMember" xlink:label="limn_ProphaseSciencesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_ProphaseSciencesLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="limn_AccruedInterestCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss" xlink:type="extended" xlink:title="1240406 - Disclosure - Related Party Transactions - Hana Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_HanaLoansMember" xlink:label="limn_HanaLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_HanaLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_HanaAugust2024LoansMember" xlink:label="limn_HanaAugust2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="limn_HanaLoansMember" xlink:to="limn_HanaAugust2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_HanaImmunotherapeuticsLlcMember" xlink:label="limn_HanaImmunotherapeuticsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_HanaImmunotherapeuticsLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="limn_AccruedInterestCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss" xlink:type="extended" xlink:title="1240407 - Disclosure - Related Party Transactions - Amantes Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesLoansMember" xlink:label="limn_AmantesLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_AmantesLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesNovember2024LoansMember" xlink:label="limn_AmantesNovember2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="limn_AmantesLoansMember" xlink:to="limn_AmantesNovember2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesJanuary2025LoansMember" xlink:label="limn_AmantesJanuary2025LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="limn_AmantesLoansMember" xlink:to="limn_AmantesJanuary2025LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesLlcMember" xlink:label="limn_AmantesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_AmantesLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="limn_AccruedInterestCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss" xlink:type="extended" xlink:title="1240408 - Disclosure - Related Party Transactions - Due to Related Party (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EmploymentAgreementMember" xlink:label="limn_EmploymentAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="limn_EmploymentAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails" xlink:type="extended" xlink:title="1240409 - Disclosure - Related Party Transactions - Viral Gene (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ViralGeneMember" xlink:label="limn_ViralGeneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_ViralGeneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_OtherReceivableWriteOff" xlink:label="limn_OtherReceivableWriteOff" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="limn_OtherReceivableWriteOff" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDebtDetailss" xlink:type="extended" xlink:title="1240501 - Disclosure - Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxBondsMember" xlink:label="limn_FeeluxBondsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_FeeluxBondsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CarTcellkorLoanMember" xlink:label="limn_CarTcellkorLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_CarTcellkorLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonLoanMember" xlink:label="limn_EwonLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_EwonLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoDecember2022LoansMember" xlink:label="limn_ValetudoDecember2022LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ValetudoDecember2022LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJune2023LoansMember" xlink:label="limn_ValetudoJune2023LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ValetudoJune2023LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJuly2023LoanMember" xlink:label="limn_ValetudoJuly2023LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ValetudoJuly2023LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoAugust2023LoansMember" xlink:label="limn_ValetudoAugust2023LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ValetudoAugust2023LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonSeptember2023LoanMember" xlink:label="limn_EwonSeptember2023LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_EwonSeptember2023LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoNovember2023LoanMember" xlink:label="limn_ValetudoNovember2023LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ValetudoNovember2023LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonDecember2023LoanMember" xlink:label="limn_EwonDecember2023LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_EwonDecember2023LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJanuary2024LoansMember" xlink:label="limn_ValetudoJanuary2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ValetudoJanuary2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseFebruary2024LoanMember" xlink:label="limn_ProphaseFebruary2024LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ProphaseFebruary2024LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMarch2024LoanMember" xlink:label="limn_ProphaseMarch2024LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ProphaseMarch2024LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseApril2024LoanMember" xlink:label="limn_ProphaseApril2024LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ProphaseApril2024LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMay2024LoansMember" xlink:label="limn_ProphaseMay2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ProphaseMay2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseJuly2024LoansMember" xlink:label="limn_ProphaseJuly2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ProphaseJuly2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseAugust2024LoansMember" xlink:label="limn_ProphaseAugust2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ProphaseAugust2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_HanaAugust2024LoansMember" xlink:label="limn_HanaAugust2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_HanaAugust2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesNovember2024LoansMember" xlink:label="limn_AmantesNovember2024LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_AmantesNovember2024LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesJanuary2025LoansMember" xlink:label="limn_AmantesJanuary2025LoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_AmantesJanuary2025LoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseFebruary2025LoanMember" xlink:label="limn_ProphaseFebruary2025LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ProphaseFebruary2025LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMarch2025LoanMember" xlink:label="limn_ProphaseMarch2025LoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="limn_ProphaseMarch2025LoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss" xlink:type="extended" xlink:title="1240601 - Disclosure - Stockholder's Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PublicWarrantsMember" xlink:label="limn_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_PublicWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PrivatePlacementWarrantsMember" xlink:label="limn_PrivatePlacementWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_PrivatePlacementWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AltaPartnersLlcMember" xlink:label="limn_AltaPartnersLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_AltaPartnersLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuableForSettlementOfDeferredUnderwritingFees" xlink:label="limn_StockIssuableForSettlementOfDeferredUnderwritingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_StockIssuableForSettlementOfDeferredUnderwritingFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" xlink:label="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesIssuedForSurrenderAndCancellationOfWarrants" xlink:label="limn_SharesIssuedForSurrenderAndCancellationOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_SharesIssuedForSurrenderAndCancellationOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" xlink:label="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonStockIssued" xlink:label="limn_FairValueOfCommonStockIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_FairValueOfCommonStockIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfWarrantsSurrendered" xlink:label="limn_FairValueOfWarrantsSurrendered" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_FairValueOfWarrantsSurrendered" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_GainLossOnIssuanceOfCommonStockForWarrants" xlink:label="limn_GainLossOnIssuanceOfCommonStockForWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_GainLossOnIssuanceOfCommonStockForWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockNumberOfVotesPerShare" xlink:label="limn_CommonStockNumberOfVotesPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_CommonStockNumberOfVotesPerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants" xlink:label="limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption" xlink:label="limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" xlink:type="extended" xlink:title="1240701 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeReductionAgreementMember" xlink:label="limn_FeeReductionAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="limn_FeeReductionAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IrisAcquisitionCorpMember" xlink:label="limn_IrisAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="limn_IrisAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClearStreetLlcMember" xlink:label="limn_ClearStreetLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_ClearStreetLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_ShortTermLeaseCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesIssuedForSurrenderAndCancellationOfWarrants" xlink:label="limn_SharesIssuedForSurrenderAndCancellationOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_SharesIssuedForSurrenderAndCancellationOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" xlink:label="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPayable" xlink:label="limn_CommonStockPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_CommonStockPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="us-gaap_LossContingencyDamagesAwardedValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_LossContingencyDamagesAwardedValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementInterest" xlink:label="us-gaap_LitigationSettlementInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_LitigationSettlementInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" xlink:label="limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnderwritingCostsNoncurrent" xlink:label="limn_UnderwritingCostsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_UnderwritingCostsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" xlink:label="limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredOfferingCostsNoncurrent" xlink:label="limn_DeferredOfferingCostsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_DeferredOfferingCostsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PaymentOfOfferingCostsInCash" xlink:label="limn_PaymentOfOfferingCostsInCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_PaymentOfOfferingCostsInCash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnderwritingDiscountPaidInSecurities" xlink:label="limn_UnderwritingDiscountPaidInSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_UnderwritingDiscountPaidInSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_MaximumNumbersOfSharesIssuable" xlink:label="limn_MaximumNumbersOfSharesIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_MaximumNumbersOfSharesIssuable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering" xlink:label="limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination" xlink:label="limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableInCashCurrent" xlink:label="limn_DeferredUnderwritingFeesPayableInCashCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_DeferredUnderwritingFeesPayableInCashCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuableForSettlementOfDeferredUnderwritingFees" xlink:label="limn_StockIssuableForSettlementOfDeferredUnderwritingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_StockIssuableForSettlementOfDeferredUnderwritingFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" xlink:label="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss" xlink:type="extended" xlink:title="1240801 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss" xlink:type="extended" xlink:title="1240802 - Disclosure - Fair Value Measurements - Changes in fair value of Level 3 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="1241001 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClearStreetLlcMember" xlink:label="limn_ClearStreetLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_ClearStreetLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_InnobationBioCo.LtdMember" xlink:label="limn_InnobationBioCo.LtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="limn_InnobationBioCo.LtdMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PreFundedWarrantsMember" xlink:label="limn_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPurchaseWarrantsMember" xlink:label="limn_CommonStockPurchaseWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_CommonStockPurchaseWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PlacementAgentWarrantsMember" xlink:label="limn_PlacementAgentWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="limn_PlacementAgentWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_BestEffortsPublicOfferingMember" xlink:label="limn_BestEffortsPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="limn_BestEffortsPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember" xlink:label="limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesIssuedForSurrenderAndCancellationOfWarrants" xlink:label="limn_SharesIssuedForSurrenderAndCancellationOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="limn_SharesIssuedForSurrenderAndCancellationOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" xlink:label="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPayable" xlink:label="limn_CommonStockPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="limn_CommonStockPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="us-gaap_LossContingencyDamagesAwardedValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LossContingencyDamagesAwardedValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementInterest" xlink:label="us-gaap_LitigationSettlementInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LitigationSettlementInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightIssuePricePerWarrant" xlink:label="limn_ClassOfWarrantOrRightIssuePricePerWarrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="limn_ClassOfWarrantOrRightIssuePricePerWarrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate" xlink:label="limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate" xlink:label="limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PlacementAgentCashFeePercentage" xlink:label="limn_PlacementAgentCashFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="limn_PlacementAgentCashFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_MaximumReimbursementForPlacementAgentExpenses" xlink:label="limn_MaximumReimbursementForPlacementAgentExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="limn_MaximumReimbursementForPlacementAgentExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PercentOfSharesIssuedInOffering" xlink:label="limn_PercentOfSharesIssuedInOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="limn_PercentOfSharesIssuedInOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PercentOfOfferingPriceRepresentingExercisePrice" xlink:label="limn_PercentOfOfferingPriceRepresentingExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="limn_PercentOfOfferingPriceRepresentingExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PaymentForCostsAssociatedWithClinicalTrials" xlink:label="limn_PaymentForCostsAssociatedWithClinicalTrials" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="limn_PaymentForCostsAssociatedWithClinicalTrials" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>limn-20260331_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.3.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 6/24/2026 1:16:50 AM-->
<!--Modified on: 6/24/2026 1:16:50 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related and Nonrelated Parties [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related and Nonrelated Parties [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonrelated Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Costs, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred transaction costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Receivable, after Allowance for Credit Loss, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due from related party, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND STOCKHOLDERS' DEFICIT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND STOCKHOLDERS' DEFICIT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_AccruedInterestCurrent" xlink:to="limn_AccruedInterestCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_AccruedInterestCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of accrued interest as of the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_AccruedInterestCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Interest, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_AccruedInterestCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest, related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term debt, related parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount borrowed</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableInCashCurrent" xlink:label="limn_DeferredUnderwritingFeesPayableInCashCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_DeferredUnderwritingFeesPayableInCashCurrent" xlink:to="limn_DeferredUnderwritingFeesPayableInCashCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_DeferredUnderwritingFeesPayableInCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred underwriting fees payable in cash and are classified as current as of the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_DeferredUnderwritingFeesPayableInCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Underwriting Fees Payable In Cash, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_DeferredUnderwritingFeesPayableInCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred underwriting fee payable</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPayable" xlink:label="limn_CommonStockPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_CommonStockPayable" xlink:to="limn_CommonStockPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_CommonStockPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of common stock payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_CommonStockPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_CommonStockPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies (Note 7)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.0001 par value; 500,000,000 shares authorized; 44,877,633 and 27,064,633 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.0001 par value; 500,000,000 shares authorized; 27,064,633 and 17,500,000 shares issued and outstanding as of December 31, 2025 and 2024, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense related to the CD47 License</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Nonoperating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense, related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ForgivenessOfUnrelatedVendorPayable" xlink:label="limn_ForgivenessOfUnrelatedVendorPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ForgivenessOfUnrelatedVendorPayable" xlink:to="limn_ForgivenessOfUnrelatedVendorPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ForgivenessOfUnrelatedVendorPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of forgiveness of unrelated vendor payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ForgivenessOfUnrelatedVendorPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forgiveness Of Unrelated Vendor Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="limn_ForgivenessOfUnrelatedVendorPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forgiveness of unrelated vendor payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ForgivenessOfUnrelatedVendorPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forgiveness of unrelated vendor payables</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue" xlink:label="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue" xlink:to="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) from change in fair value of deferred underwriting fees that would be settled in common stock of the combined entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Settlement, Deferred Underwriting Fees, Effect Of Change In Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of deferred underwriting fee - paid in common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of deferred underwriting fee - paid in common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of deferred underwriting fee - paid in common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of deferred underwriting fee - paid in common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in the fair value of warrant liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in the fair value of warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in the fair value of warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonStockIssuanceForContingentLiability" xlink:label="limn_FairValueOfCommonStockIssuanceForContingentLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_FairValueOfCommonStockIssuanceForContingentLiability" xlink:to="limn_FairValueOfCommonStockIssuanceForContingentLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_FairValueOfCommonStockIssuanceForContingentLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense related to fair value of common stock to be issued for contingent liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_FairValueOfCommonStockIssuanceForContingentLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Of Common Stock Issuance For Contingent Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="limn_FairValueOfCommonStockIssuanceForContingentLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of common stock to be issued for contingent liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_FairValueOfCommonStockIssuanceForContingentLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of common stock to be issued for contingent liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other expense, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares outstanding - basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares outstanding - diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net loss per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net loss per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Changes in Stockholders' Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants" xlink:label="limn_StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants" xlink:to="limn_StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued during the period for surrender and cancellation of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued during The Period, Shares, Surrender And Cancellation Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock in connection with the Clear Street settlement (in shares)</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants" xlink:label="limn_StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants" xlink:to="limn_StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares issued during the period for surrender and cancellation of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued during The Period, Values, Surrender And Cancellation Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock in connection with the Clear Street settlement</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodValueBusinessCombination" xlink:label="limn_StockIssuedDuringPeriodValueBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_StockIssuedDuringPeriodValueBusinessCombination" xlink:to="limn_StockIssuedDuringPeriodValueBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_StockIssuedDuringPeriodValueBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued pursuant to business combination during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_StockIssuedDuringPeriodValueBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_StockIssuedDuringPeriodValueBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combination with IRIS, net of transaction costs</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodSharesBusinessCombination" xlink:label="limn_StockIssuedDuringPeriodSharesBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_StockIssuedDuringPeriodSharesBusinessCombination" xlink:to="limn_StockIssuedDuringPeriodSharesBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_StockIssuedDuringPeriodSharesBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of stock issued during the period pursuant to business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_StockIssuedDuringPeriodSharesBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_StockIssuedDuringPeriodSharesBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combination with IRIS, net of transaction costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans" xlink:label="limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans" xlink:to="limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of decrease to additional paid in capital (APIC) resulting from Settlement of loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Settlement of Loans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement of loans to Iris Acquisition Corp upon closing of the business combination</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock to Iris Acquisition Holdings, LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock to Iris Acquisition Holdings, LLC (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for the PIPE investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock in connection with the Offering, net of offering costs of $559,962</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock in connection with the Offering, net of offering costs of $559,962 (in shares)</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedPeriodValueOfCommonStockToUnderwriter" xlink:label="limn_StockIssuedPeriodValueOfCommonStockToUnderwriter" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_StockIssuedPeriodValueOfCommonStockToUnderwriter" xlink:to="limn_StockIssuedPeriodValueOfCommonStockToUnderwriter_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_StockIssuedPeriodValueOfCommonStockToUnderwriter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued value of common stock to underwriter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_StockIssuedPeriodValueOfCommonStockToUnderwriter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued Period Value of Common Stock to Underwriter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_StockIssuedPeriodValueOfCommonStockToUnderwriter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock to underwriter</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedPeriodOfCommonStockToUnderwriter" xlink:label="limn_StockIssuedPeriodOfCommonStockToUnderwriter" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_StockIssuedPeriodOfCommonStockToUnderwriter" xlink:to="limn_StockIssuedPeriodOfCommonStockToUnderwriter_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_StockIssuedPeriodOfCommonStockToUnderwriter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued of common stock to underwriter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_StockIssuedPeriodOfCommonStockToUnderwriter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued Period of Common Stock to Underwriter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_StockIssuedPeriodOfCommonStockToUnderwriter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock to underwriter (In shares)</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants" xlink:label="limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants" xlink:to="limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued value for surrender and cancellation of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued Period Value For Surrender And Cancellation Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock in connection with the surrender of warrants</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_OfferingCosts" xlink:label="limn_OfferingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_OfferingCosts" xlink:to="limn_OfferingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_OfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of offering costs involved in the issuance of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_OfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_OfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_OfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Issuance Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Operating Activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_OtherReceivableWriteOff" xlink:label="limn_OtherReceivableWriteOff" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_OtherReceivableWriteOff" xlink:to="limn_OtherReceivableWriteOff_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_OtherReceivableWriteOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of receivable deemed as uncollectible and written off.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_OtherReceivableWriteOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Receivable, Write Off</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_OtherReceivableWriteOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forgiveness of related party receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_OtherReceivableWriteOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncollectible due from related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Due from Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due from related party, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent" xlink:label="limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent" xlink:to="limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in accrued interest to related party classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Accrued Interest to Related Party, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest, related parties</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent" xlink:label="limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent" xlink:to="limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in accrued maintenance fee classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Accrued Maintenance Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued maintenance fee</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent" xlink:label="limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent" xlink:to="limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in due to research and development partner classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Due to Research And Development Partner, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to research and development partner</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to related parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Investing Activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Investing Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLoansReceivable" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLoansReceivable" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Loans Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans to Iris Acquisition Corp</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Financing Activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from issuance of common stock for PIPE investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Merger Related Costs, Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of transaction costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Short-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of short-term debt, related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from bonds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Short-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of short-term debt, related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net change in cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, beginning of the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash investing and financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAssumed1" xlink:to="us-gaap_LiabilitiesAssumed1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Assumed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities assumed in connection with the Business Combination</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination" xlink:label="limn_StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination" xlink:to="limn_StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares issued or issuable to underwriters upon consummation of business combination in a non-cash transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued Or issuable To Underwriters Upon Consummation Of Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of shares to be issued to underwriter on date of the Business Combination</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction" xlink:label="limn_MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction" xlink:to="limn_MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of transaction costs incurred upon closing of merger during the period in a non-cash or part non-cash transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merger Transaction Costs Incurred In Noncash Or Partial Noncash Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs incurred upon closing of the Business Combination</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LoansSettled" xlink:label="limn_LoansSettled" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_LoansSettled" xlink:to="limn_LoansSettled_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_LoansSettled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of loans settled upon closing of merger in a non-cash transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_LoansSettled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans Settled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_LoansSettled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement of loans to Iris Acquisition Corp upon closing of the Business Combination</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock to Iris Acquisition Holdings, LLC</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NoncashConversionOfAmountBorrowedForPipeFunds" xlink:label="limn_NoncashConversionOfAmountBorrowedForPipeFunds" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_NoncashConversionOfAmountBorrowedForPipeFunds" xlink:to="limn_NoncashConversionOfAmountBorrowedForPipeFunds_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_NoncashConversionOfAmountBorrowedForPipeFunds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of borrowed funds for PIPE transactions that are converted in a non-cash or part non-cash transactions.  "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_NoncashConversionOfAmountBorrowedForPipeFunds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Conversion Of Amount Borrowed For PIPE Funds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_NoncashConversionOfAmountBorrowedForPipeFunds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash conversion of short term debt, related parties for PIPE Funds</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest" xlink:label="limn_DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest" xlink:to="limn_DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of non-cash impact to additional paid in capital upon forgiveness of accrued interest on the converted debt instrument in a non-cash transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion, Noncash Impact To Additional paid In Capital For Forgiveness Of Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash impact to APIC for the forgiveness of accrued interest on converted related party debt</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesIssuableUponClosingOfMergerToUnderwriters" xlink:label="limn_SharesIssuableUponClosingOfMergerToUnderwriters" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_SharesIssuableUponClosingOfMergerToUnderwriters" xlink:to="limn_SharesIssuableUponClosingOfMergerToUnderwriters_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_SharesIssuableUponClosingOfMergerToUnderwriters_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The fair value of stock issuable to underwriters upon closing of merger in a non-cash financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_SharesIssuableUponClosingOfMergerToUnderwriters_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issuable Upon Closing Of Merger To Underwriters</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_SharesIssuableUponClosingOfMergerToUnderwriters_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock to underwriter</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockIssuedInConnectionWithSettlement" xlink:label="limn_CommonStockIssuedInConnectionWithSettlement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_CommonStockIssuedInConnectionWithSettlement" xlink:to="limn_CommonStockIssuedInConnectionWithSettlement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_CommonStockIssuedInConnectionWithSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The fair value of stock issued in connection with settlement in noncash financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_CommonStockIssuedInConnectionWithSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Issued In Connection With Settlement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_CommonStockIssuedInConnectionWithSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock in connection with the Clear Street settlement</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CostsIncurredInConnectionWithIssuanceOfCommonStock" xlink:label="limn_CostsIncurredInConnectionWithIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_CostsIncurredInConnectionWithIssuanceOfCommonStock" xlink:to="limn_CostsIncurredInConnectionWithIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_CostsIncurredInConnectionWithIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of common stock issuance costs that were incurred during a noncash or partial noncash transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_CostsIncurredInConnectionWithIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs Incurred In Connection With Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_CostsIncurredInConnectionWithIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs incurred in connection with the issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredTransactionCostsInAccountsPayable" xlink:label="limn_DeferredTransactionCostsInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_DeferredTransactionCostsInAccountsPayable" xlink:to="limn_DeferredTransactionCostsInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_DeferredTransactionCostsInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred transaction costs in accounts payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_DeferredTransactionCostsInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Transaction Costs In Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_DeferredTransactionCostsInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred transaction costs in accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Organization and Business Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Organization and Business Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAgreementsAbstract" xlink:label="limn_LicenseAgreementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_LicenseAgreementsAbstract" xlink:to="limn_LicenseAgreementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_LicenseAgreementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_LicenseAgreementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreements</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAgreementsTextBlock" xlink:label="limn_LicenseAgreementsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_LicenseAgreementsTextBlock" xlink:to="limn_LicenseAgreementsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_LicenseAgreementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for License Agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_LicenseAgreementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreements [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_LicenseAgreementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholder's Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholder's Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EmergingGrowthCompanyPolicyPolicyTextBlock" xlink:label="limn_EmergingGrowthCompanyPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_EmergingGrowthCompanyPolicyPolicyTextBlock" xlink:to="limn_EmergingGrowthCompanyPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_EmergingGrowthCompanyPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policies on emerging growth company status.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_EmergingGrowthCompanyPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Emerging Growth Company Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_EmergingGrowthCompanyPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Emerging Growth Company Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:label="us-gaap_FinanceLoansAndLeasesReceivablePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:to="us-gaap_FinanceLoansAndLeasesReceivablePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLoansAndLeasesReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Receivable [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLoansAndLeasesReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Charges, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Transaction Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_WarrantsPolicyPolicyTextBlock" xlink:label="limn_WarrantsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_WarrantsPolicyPolicyTextBlock" xlink:to="limn_WarrantsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_WarrantsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_WarrantsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_WarrantsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock" xlink:label="limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock" xlink:to="limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of policy for net income (loss) per common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net income (loss) per Common Stock Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Issued Accounting Pronouncements - Not Yet Adopted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Adopted Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Short-Term Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of debt outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assumptions used for estimating fair value of warrants</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock" xlink:label="limn_ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock" xlink:to="limn_ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of offering proceeds and related issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Offering Proceeds and Related Issuance Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of offering proceeds and related issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value, assets and liabilities measured on recurring basis.</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the fair value measurement of assets and  liability using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings  are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset and liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of changes in fair value of Level 3 financial assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination [Domain]</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LiminatusAndIrisMember" xlink:label="limn_LiminatusAndIrisMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_LiminatusAndIrisMember" xlink:to="limn_LiminatusAndIrisMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_LiminatusAndIrisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to business combination with Liminatus and Iris.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_LiminatusAndIrisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liminatus And Iris [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_LiminatusAndIrisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liminatus and Iris</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All Entities [Member]</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IrisAcquisitionCorpMember" xlink:label="limn_IrisAcquisitionCorpMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_IrisAcquisitionCorpMember" xlink:to="limn_IrisAcquisitionCorpMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_IrisAcquisitionCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Iris Acquisition Corp.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_IrisAcquisitionCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Iris Acquisition Corp [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_IrisAcquisitionCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Iris</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IrisAcquisitionHoldingsLlcMember" xlink:label="limn_IrisAcquisitionHoldingsLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_IrisAcquisitionHoldingsLlcMember" xlink:to="limn_IrisAcquisitionHoldingsLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_IrisAcquisitionHoldingsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Iris Acquisition Holdings, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_IrisAcquisitionHoldingsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Iris Acquisition Holdings, LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_IrisAcquisitionHoldingsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Iris Acquisition Holdings, LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Class A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConsortiumLoanOfRelatedPartiesMember" xlink:label="limn_ConsortiumLoanOfRelatedPartiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ConsortiumLoanOfRelatedPartiesMember" xlink:to="limn_ConsortiumLoanOfRelatedPartiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ConsortiumLoanOfRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent the information pertaining to consortium loan of  related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ConsortiumLoanOfRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consortium Loan of Related Parties [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ConsortiumLoanOfRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consortium Loan of related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NonRedeemableWarrantMember" xlink:label="limn_NonRedeemableWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_NonRedeemableWarrantMember" xlink:to="limn_NonRedeemableWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_NonRedeemableWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to non-redeemable warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_NonRedeemableWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Redeemable Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_NonRedeemableWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-redeemable warrant</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RedeemableWarrantMember" xlink:label="limn_RedeemableWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_RedeemableWarrantMember" xlink:to="limn_RedeemableWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_RedeemableWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to redeemable warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_RedeemableWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_RedeemableWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable warrant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private placement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxCo.LtdMember" xlink:label="limn_FeeluxCo.LtdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_FeeluxCo.LtdMember" xlink:to="limn_FeeluxCo.LtdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_FeeluxCo.LtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Feelux bonds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_FeeluxCo.LtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Feelux Co. Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_FeeluxCo.LtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Feelux Co. Ltd</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxAndCarTcellkorMember" xlink:label="limn_FeeluxAndCarTcellkorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_FeeluxAndCarTcellkorMember" xlink:to="limn_FeeluxAndCarTcellkorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_FeeluxAndCarTcellkorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Feelux and Car-Tcellkor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_FeeluxAndCarTcellkorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Feelux and Car-Tcellkor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_FeeluxAndCarTcellkorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Feelux and Car-Tcellkor</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Organization and Business Operations</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockCashRedemptionShares" xlink:label="limn_CommonStockCashRedemptionShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_CommonStockCashRedemptionShares" xlink:to="limn_CommonStockCashRedemptionShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_CommonStockCashRedemptionShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of common shares redeemed for cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_CommonStockCashRedemptionShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Cash Redemption, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_CommonStockCashRedemptionShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares redeemed (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_CommonStockCashRedemptionShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares redeemed</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockCashRedemptionPricePerShare" xlink:label="limn_CommonStockCashRedemptionPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_CommonStockCashRedemptionPricePerShare" xlink:to="limn_CommonStockCashRedemptionPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_CommonStockCashRedemptionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The price per share at which the common stock of the entity is redeemed or may be called at.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_CommonStockCashRedemptionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Cash Redemption Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_CommonStockCashRedemptionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash redemption price per share (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_CommonStockCashRedemptionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash redemption price per share</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockCashRedemptionAmount" xlink:label="limn_CommonStockCashRedemptionAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_CommonStockCashRedemptionAmount" xlink:to="limn_CommonStockCashRedemptionAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_CommonStockCashRedemptionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate cash redemption of value of common stock of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_CommonStockCashRedemptionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Cash Redemption Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_CommonStockCashRedemptionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate cash redemption amount</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfSharesHeldInEachUnit" xlink:label="limn_NumberOfSharesHeldInEachUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_NumberOfSharesHeldInEachUnit" xlink:to="limn_NumberOfSharesHeldInEachUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_NumberOfSharesHeldInEachUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of common shares held in each Iris unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_NumberOfSharesHeldInEachUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Shares Held In Each Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_NumberOfSharesHeldInEachUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares held in each unit (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_NumberOfSharesHeldInEachUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares held in each unit</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfWarrantsHeldInEachUnit" xlink:label="limn_NumberOfWarrantsHeldInEachUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_NumberOfWarrantsHeldInEachUnit" xlink:to="limn_NumberOfWarrantsHeldInEachUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_NumberOfWarrantsHeldInEachUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of warrants held in each Iris unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_NumberOfWarrantsHeldInEachUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Warrants Held In Each Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_NumberOfWarrantsHeldInEachUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants held in each unit (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_NumberOfWarrantsHeldInEachUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants held in each unit</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockConversionRatioBusinessCombination" xlink:label="limn_CommonStockConversionRatioBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_CommonStockConversionRatioBusinessCombination" xlink:to="limn_CommonStockConversionRatioBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_CommonStockConversionRatioBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common shares issuable upon conversion for each share of common stock in business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_CommonStockConversionRatioBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Conversion Ratio, Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_CommonStockConversionRatioBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common shares converted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares called by each warrant (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares called by each warrant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per share (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesAuthorized" xlink:label="limn_SharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_SharesAuthorized" xlink:to="limn_SharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_SharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum number of cumulative shares of all kinds permitted to be issued by an entity's charter and bylaws.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_SharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_SharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares authorized (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_SharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares converted into (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares converted into</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total consideration</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfStockOrUnitConversionRatio" xlink:label="limn_ConversionOfStockOrUnitConversionRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ConversionOfStockOrUnitConversionRatio" xlink:to="limn_ConversionOfStockOrUnitConversionRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ConversionOfStockOrUnitConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock issuable upon conversion of each share of stock or unit to be converted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ConversionOfStockOrUnitConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion Of Stock Or Unit, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ConversionOfStockOrUnitConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share conversion ratio</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProceedsFromIssuanceOfPrivatePlacementInvestor" xlink:label="limn_ProceedsFromIssuanceOfPrivatePlacementInvestor" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ProceedsFromIssuanceOfPrivatePlacementInvestor" xlink:to="limn_ProceedsFromIssuanceOfPrivatePlacementInvestor_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ProceedsFromIssuanceOfPrivatePlacementInvestor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow associated with the amount received from entity's raising of capital via private placement investor rather than public placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ProceedsFromIssuanceOfPrivatePlacementInvestor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Private Placement Investor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ProceedsFromIssuanceOfPrivatePlacementInvestor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of private placement investor</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded" xlink:label="limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded" xlink:to="limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow associated with the amount received from private placement investor funded indirectly.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Private Placement Investor Funded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of private placement investor funded</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion, Original Debt, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of related party short-term debt into common stock</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PrincipalAndAccruedInterestOnPrivatePlacement" xlink:label="limn_PrincipalAndAccruedInterestOnPrivatePlacement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_PrincipalAndAccruedInterestOnPrivatePlacement" xlink:to="limn_PrincipalAndAccruedInterestOnPrivatePlacement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_PrincipalAndAccruedInterestOnPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of principal and accrued interest converted into shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_PrincipalAndAccruedInterestOnPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal and Accrued Interest on Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_PrincipalAndAccruedInterestOnPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal and accrued interest</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RelatedPartiesDebtToUnsecuredPromissoryNote" xlink:label="limn_RelatedPartiesDebtToUnsecuredPromissoryNote" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_RelatedPartiesDebtToUnsecuredPromissoryNote" xlink:to="limn_RelatedPartiesDebtToUnsecuredPromissoryNote_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_RelatedPartiesDebtToUnsecuredPromissoryNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of borrowed from the related parties were used to fund an unsecured promissory note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_RelatedPartiesDebtToUnsecuredPromissoryNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Parties Debt to Unsecured Promissory Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_RelatedPartiesDebtToUnsecuredPromissoryNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related parties debt</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnsecuredPromissoryNoteSettledAndConverted" xlink:label="limn_UnsecuredPromissoryNoteSettledAndConverted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_UnsecuredPromissoryNoteSettledAndConverted" xlink:to="limn_UnsecuredPromissoryNoteSettledAndConverted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_UnsecuredPromissoryNoteSettledAndConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of unsecured promissory note was settled and related party debts were ultimately converted into shares of the Company in a noncash transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_UnsecuredPromissoryNoteSettledAndConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unsecured Promissory Note Settled and Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_UnsecuredPromissoryNoteSettledAndConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unsecured promissory note settled and converted</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfPrincipalAndAccruedInterestAmount" xlink:label="limn_ConversionOfPrincipalAndAccruedInterestAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ConversionOfPrincipalAndAccruedInterestAmount" xlink:to="limn_ConversionOfPrincipalAndAccruedInterestAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ConversionOfPrincipalAndAccruedInterestAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of conversion of principal and accrued interest amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ConversionOfPrincipalAndAccruedInterestAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Principal and Accrued Interest Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ConversionOfPrincipalAndAccruedInterestAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of principal and accrued interest amount</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfPrincipalAndAccruedInterestShares" xlink:label="limn_ConversionOfPrincipalAndAccruedInterestShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ConversionOfPrincipalAndAccruedInterestShares" xlink:to="limn_ConversionOfPrincipalAndAccruedInterestShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ConversionOfPrincipalAndAccruedInterestShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of conversion of principal and accrued interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ConversionOfPrincipalAndAccruedInterestShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Principal and Accrued Interest Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ConversionOfPrincipalAndAccruedInterestShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of principal and accrued interest shares (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_ConversionOfPrincipalAndAccruedInterestShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of principal and accrued interest shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Liability Assumed, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognized liability assumed</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Businesses, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to acquire businesses</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfAccruedInterestOnRelatedPartyDebts" xlink:label="limn_ConversionOfAccruedInterestOnRelatedPartyDebts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ConversionOfAccruedInterestOnRelatedPartyDebts" xlink:to="limn_ConversionOfAccruedInterestOnRelatedPartyDebts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ConversionOfAccruedInterestOnRelatedPartyDebts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of accrued interest on related party debts that were converted into common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ConversionOfAccruedInterestOnRelatedPartyDebts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Accrued Interest on Related party Debts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ConversionOfAccruedInterestOnRelatedPartyDebts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" xlink:to="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred underwriting fees liabilities of acquiree to be settled by way of issuance of common stock of the entity upon consummation of business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Underwriting Fees Payable, To Be Settled In Shares Upon Consummation Of Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred underwriting fees payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred underwriting fees liabilities</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuableForSettlementOfDeferredUnderwritingFees" xlink:label="limn_StockIssuableForSettlementOfDeferredUnderwritingFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_StockIssuableForSettlementOfDeferredUnderwritingFees" xlink:to="limn_StockIssuableForSettlementOfDeferredUnderwritingFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_StockIssuableForSettlementOfDeferredUnderwritingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issuable for settlement of deferred underwriting fees in connection with the underwriting services provided by the underwriters in the initial public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_StockIssuableForSettlementOfDeferredUnderwritingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issuable For Settlement Of Deferred Underwriting Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_StockIssuableForSettlementOfDeferredUnderwritingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issuable for settlement of deferred underwriting fees (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_StockIssuableForSettlementOfDeferredUnderwritingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issuable for settlement of deferred underwriting fees</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LiabilityOfUnderwritingFeesFairValue" xlink:label="limn_LiabilityOfUnderwritingFeesFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_LiabilityOfUnderwritingFeesFairValue" xlink:to="limn_LiabilityOfUnderwritingFeesFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_LiabilityOfUnderwritingFeesFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of liability of underwriting fees fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_LiabilityOfUnderwritingFeesFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability of Underwriting Fees Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_LiabilityOfUnderwritingFeesFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability of underwriting fees</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" xlink:label="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" xlink:to="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of common shares issued for settlement of deferred underwriting fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Of Common Shares Issued For Settlement Of Deferred Underwriting Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of common shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PreFundedWarrantsMember" xlink:label="limn_PreFundedWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_PreFundedWarrantsMember" xlink:to="limn_PreFundedWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to pre funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre Funded Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-Funded Warrants</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPurchaseWarrantsMember" xlink:label="limn_CommonStockPurchaseWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_CommonStockPurchaseWarrantsMember" xlink:to="limn_CommonStockPurchaseWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_CommonStockPurchaseWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to common stock purchase warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_CommonStockPurchaseWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Purchase Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_CommonStockPurchaseWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock purchase warrants</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PlacementAgentWarrantsMember" xlink:label="limn_PlacementAgentWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_PlacementAgentWarrantsMember" xlink:to="limn_PlacementAgentWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_PlacementAgentWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to placement agent warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_PlacementAgentWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Placement Agent Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_PlacementAgentWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Placement Agent Warrants</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_BestEffortsPublicOfferingMember" xlink:label="limn_BestEffortsPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_BestEffortsPublicOfferingMember" xlink:to="limn_BestEffortsPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_BestEffortsPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to Best Efforts Public Offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_BestEffortsPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Best Efforts Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_BestEffortsPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Best efforts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Organization and Business Operations</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:to="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants to purchase shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering price (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightIssuePricePerWarrant" xlink:label="limn_ClassOfWarrantOrRightIssuePricePerWarrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ClassOfWarrantOrRightIssuePricePerWarrant" xlink:to="limn_ClassOfWarrantOrRightIssuePricePerWarrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ClassOfWarrantOrRightIssuePricePerWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Per unit amount of warrants issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ClassOfWarrantOrRightIssuePricePerWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Issue Price Per Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ClassOfWarrantOrRightIssuePricePerWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering price of pre-funded warrants (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual term</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate" xlink:label="limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate" xlink:to="limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period during which shares will not be issued after the closing date of the offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period Of Non Issuance Of Common Stock Following Closing Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of non issuance of common stock following closing date</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate" xlink:label="limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate" xlink:to="limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period during which common stock or any securities convertible into or exercisable or exchangeable for shares of common stock involving a variable rate transaction will not be issued after the closing date of the offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period Of Non Issuance Of Common Stock Involving Variable Rate Transaction Following Closing Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of non issuance of common stock involving variable rate transaction following closing date</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PlacementAgentCashFeePercentage" xlink:label="limn_PlacementAgentCashFeePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_PlacementAgentCashFeePercentage" xlink:to="limn_PlacementAgentCashFeePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_PlacementAgentCashFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of cash fee for placement agent, calculated on aggregate gross proceeds raised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_PlacementAgentCashFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Placement Agent Cash Fee, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_PlacementAgentCashFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Placement agent fee, percent</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_MaximumReimbursementForPlacementAgentExpenses" xlink:label="limn_MaximumReimbursementForPlacementAgentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_MaximumReimbursementForPlacementAgentExpenses" xlink:to="limn_MaximumReimbursementForPlacementAgentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_MaximumReimbursementForPlacementAgentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of maximum out-of-pocket costs and expenses incurred in connection with the Offering that will be reimbursed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_MaximumReimbursementForPlacementAgentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Reimbursement For Placement Agent Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_MaximumReimbursementForPlacementAgentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Placement agent fee, maximum reimbursement</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PercentOfSharesIssuedInOffering" xlink:label="limn_PercentOfSharesIssuedInOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_PercentOfSharesIssuedInOffering" xlink:to="limn_PercentOfSharesIssuedInOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_PercentOfSharesIssuedInOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of common stock sold in the offering, threshold percentage on the total number of outstanding shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_PercentOfSharesIssuedInOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent Of Shares Issued In The Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_PercentOfSharesIssuedInOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of shares issued</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PercentOfOfferingPriceRepresentingExercisePrice" xlink:label="limn_PercentOfOfferingPriceRepresentingExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_PercentOfOfferingPriceRepresentingExercisePrice" xlink:to="limn_PercentOfOfferingPriceRepresentingExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_PercentOfOfferingPriceRepresentingExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the public offering price for the shares of common stock and common warrants offered in the Offering representing exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_PercentOfOfferingPriceRepresentingExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of Offering Price Representing Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_PercentOfOfferingPriceRepresentingExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of offering price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PublicWarrantsMember" xlink:label="limn_PublicWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_PublicWarrantsMember" xlink:to="limn_PublicWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_PublicWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to public warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_PublicWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_PublicWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Warrants</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PrivatePlacementWarrantsMember" xlink:label="limn_PrivatePlacementWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_PrivatePlacementWarrantsMember" xlink:to="limn_PrivatePlacementWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_PrivatePlacementWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to private placement warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_PrivatePlacementWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_PrivatePlacementWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private placement warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FranchiseTaxExpenseIncludingInterestAndPenalty" xlink:label="limn_FranchiseTaxExpenseIncludingInterestAndPenalty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_FranchiseTaxExpenseIncludingInterestAndPenalty" xlink:to="limn_FranchiseTaxExpenseIncludingInterestAndPenalty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_FranchiseTaxExpenseIncludingInterestAndPenalty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of franchise tax expense and related interest and penalties incurred by the company during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_FranchiseTaxExpenseIncludingInterestAndPenalty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Franchise Tax Expense Including Interest And Penalty</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_FranchiseTaxExpenseIncludingInterestAndPenalty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Franchise tax, penalties and interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants issued (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental common shares (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental common shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of contract</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of reportable segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits, interest and penalties accrued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember" xlink:label="limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember" xlink:to="limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Metavagen License Agreement with respects to license right to develop, market and sell YN1203, InnoBation Bio CAR NK biomarkers, including devices, compounds and products used to detect analyte in body or tissue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CD47 License And Development Agreement With InnoBation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CD47 License agreement with InnoBation</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CurisBiotechHoldingsLlcMember" xlink:label="limn_CurisBiotechHoldingsLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_CurisBiotechHoldingsLlcMember" xlink:to="limn_CurisBiotechHoldingsLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_CurisBiotechHoldingsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Metavagen LLC ("Metavagen") owned by Chris Kim, the CEO of Liminatus.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_CurisBiotechHoldingsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Curis Biotech Holdings Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_CurisBiotechHoldingsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Curis Biotech Holdings LLC</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_InnobationBioCo.LtdMember" xlink:label="limn_InnobationBioCo.LtdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_InnobationBioCo.LtdMember" xlink:to="limn_InnobationBioCo.LtdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_InnobationBioCo.LtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to InnoBation Bio Co. Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_InnobationBioCo.LtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Innobation Bio Co. Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_InnobationBioCo.LtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Innobation Bio Co. Ltd</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="us-gaap_CapitalUnitsByClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsByClassAxis" xlink:to="us-gaap_CapitalUnitsByClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalUnitsByClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Units by Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="us-gaap_CapitalUnitClassDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitClassDomain" xlink:to="us-gaap_CapitalUnitClassDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalUnitClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Unit, Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="us-gaap_CapitalUnitClassAMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitClassAMember" xlink:to="us-gaap_CapitalUnitClassAMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalUnitClassAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Unit, Class A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalUnitClassAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A Member Units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreements</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfUnitsExchangeForLicenseRights" xlink:label="limn_NumberOfUnitsExchangeForLicenseRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_NumberOfUnitsExchangeForLicenseRights" xlink:to="limn_NumberOfUnitsExchangeForLicenseRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_NumberOfUnitsExchangeForLicenseRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of member units exchanged as a consideration for license rights to develop, market and sell YN1203, InnoBation Bio CAR NK biomarkers, including devices, compounds and products used to detect analyte in body or tissue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_NumberOfUnitsExchangeForLicenseRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Units Exchange For License Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_NumberOfUnitsExchangeForLicenseRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of member units exchange for license rights to develop</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_NumberOfUnitsExchangeForLicenseRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of member units exchange for license rights to develop, market and sell YN1203, InnoBation Bio CAR NK biomarker</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital" xlink:label="limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital" xlink:to="limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of membership interest exchange for license fees being offset to additional paid-in capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Rights, Value Of Units Offset From Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of membership interest offset to additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PaymentForCostsAssociatedWithClinicalTrials" xlink:label="limn_PaymentForCostsAssociatedWithClinicalTrials" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_PaymentForCostsAssociatedWithClinicalTrials" xlink:to="limn_PaymentForCostsAssociatedWithClinicalTrials_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_PaymentForCostsAssociatedWithClinicalTrials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of payment made for costs associated with clinical trials.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_PaymentForCostsAssociatedWithClinicalTrials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment For Costs Associated With Clinical Trials</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_PaymentForCostsAssociatedWithClinicalTrials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Company issued a payment</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EstimatedPercentageOfActivitiesCompleted" xlink:label="limn_EstimatedPercentageOfActivitiesCompleted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_EstimatedPercentageOfActivitiesCompleted" xlink:to="limn_EstimatedPercentageOfActivitiesCompleted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_EstimatedPercentageOfActivitiesCompleted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The estimated percentage of activities completed by the company as per agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_EstimatedPercentageOfActivitiesCompleted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Percentage Of Activities Completed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_EstimatedPercentageOfActivitiesCompleted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of activities completed</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:label="limn_PrepaidResearchAndDevelopmentExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:to="limn_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of prepaid research and development classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Research And Development Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid research and development costs</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxBondsMember" xlink:label="limn_FeeluxBondsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_FeeluxBondsMember" xlink:to="limn_FeeluxBondsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_FeeluxBondsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Feelux Bonds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_FeeluxBondsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Feelux Bonds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_FeeluxBondsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Feelux Bonds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Option Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected stock volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Risk Free Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Expected Dividend Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividends</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Effective Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective interest rate</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits" xlink:label="limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits" xlink:to="limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of common stock issued in exchange for original debt being and member units being converted in connection with the consummation of business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion Of Debt And Member Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense relating to loan</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CarTcellkorLoanMember" xlink:label="limn_CarTcellkorLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_CarTcellkorLoanMember" xlink:to="limn_CarTcellkorLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_CarTcellkorLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Car-Tcellkor Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_CarTcellkorLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Car Tcellkor Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_CarTcellkorLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Car-Tcellkor Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Decrease, Forgiveness</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consumption of outstanding principal</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoLoanMember" xlink:label="limn_ValetudoLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ValetudoLoanMember" xlink:to="limn_ValetudoLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ValetudoLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Valetudo Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ValetudoLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ValetudoLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo Loan</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoDecember2022LoanMember" xlink:label="limn_ValetudoDecember2022LoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ValetudoDecember2022LoanMember" xlink:to="limn_ValetudoDecember2022LoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ValetudoDecember2022LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Valetudo December 2022 Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ValetudoDecember2022LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo December 2022 Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ValetudoDecember2022LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo December 2022 Loan</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJune2023LoansMember" xlink:label="limn_ValetudoJune2023LoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ValetudoJune2023LoansMember" xlink:to="limn_ValetudoJune2023LoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ValetudoJune2023LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Valetudo June 2023 Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ValetudoJune2023LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo June 2023 Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ValetudoJune2023LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo June 2023 Loans</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJune2023LoanOneMember" xlink:label="limn_ValetudoJune2023LoanOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ValetudoJune2023LoanOneMember" xlink:to="limn_ValetudoJune2023LoanOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ValetudoJune2023LoanOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Valetudo June 2023 Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ValetudoJune2023LoanOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo June 2023 Loan One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ValetudoJune2023LoanOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo June 2023 Loan One</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJune2023LoanTwoMember" xlink:label="limn_ValetudoJune2023LoanTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ValetudoJune2023LoanTwoMember" xlink:to="limn_ValetudoJune2023LoanTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ValetudoJune2023LoanTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Valetudo June 2023 Loan one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ValetudoJune2023LoanTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo June 2023 Loan Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ValetudoJune2023LoanTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo June 2023 Loan Two</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJuly2023LoanMember" xlink:label="limn_ValetudoJuly2023LoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ValetudoJuly2023LoanMember" xlink:to="limn_ValetudoJuly2023LoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ValetudoJuly2023LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Valetudo July 2023 Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ValetudoJuly2023LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo July 2023 Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ValetudoJuly2023LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo July 2023 Loan</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoAugust2023LoansMember" xlink:label="limn_ValetudoAugust2023LoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ValetudoAugust2023LoansMember" xlink:to="limn_ValetudoAugust2023LoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ValetudoAugust2023LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Valetudo August 2023 Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ValetudoAugust2023LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo August 2023 Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ValetudoAugust2023LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo August 2023 Loans</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoAugust2023LoanOneMember" xlink:label="limn_ValetudoAugust2023LoanOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ValetudoAugust2023LoanOneMember" xlink:to="limn_ValetudoAugust2023LoanOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ValetudoAugust2023LoanOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Valetudo August 2023 Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ValetudoAugust2023LoanOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo August 2023 Loan One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ValetudoAugust2023LoanOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo August 2023 Loan One</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoAugust2023LoanTwoMember" xlink:label="limn_ValetudoAugust2023LoanTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ValetudoAugust2023LoanTwoMember" xlink:to="limn_ValetudoAugust2023LoanTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ValetudoAugust2023LoanTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Valetudo August 2023 Loan one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ValetudoAugust2023LoanTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo August 2023 Loan Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ValetudoAugust2023LoanTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo August 2023 Loan Two</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoNovember2023LoanMember" xlink:label="limn_ValetudoNovember2023LoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ValetudoNovember2023LoanMember" xlink:to="limn_ValetudoNovember2023LoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ValetudoNovember2023LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining toValetudo January 2024 Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ValetudoNovember2023LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo November 2023 Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ValetudoNovember2023LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo November 2023 Loan</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJanuary2024LoansMember" xlink:label="limn_ValetudoJanuary2024LoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ValetudoJanuary2024LoansMember" xlink:to="limn_ValetudoJanuary2024LoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ValetudoJanuary2024LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Valetudo January 2024 Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ValetudoJanuary2024LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo January 2024 Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ValetudoJanuary2024LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo January 2024 Loans</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJanuary2024LoanOneMember" xlink:label="limn_ValetudoJanuary2024LoanOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ValetudoJanuary2024LoanOneMember" xlink:to="limn_ValetudoJanuary2024LoanOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ValetudoJanuary2024LoanOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Valetudo January 2024 Loan one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ValetudoJanuary2024LoanOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo January 2024 Loan One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ValetudoJanuary2024LoanOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo January 2024 Loan One</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJanuary2024LoanTwoMember" xlink:label="limn_ValetudoJanuary2024LoanTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ValetudoJanuary2024LoanTwoMember" xlink:to="limn_ValetudoJanuary2024LoanTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ValetudoJanuary2024LoanTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Valetudo January 2024 Loan two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ValetudoJanuary2024LoanTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo January 2024 Loan Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ValetudoJanuary2024LoanTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo January 2024 Loan Two</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoTherapeuticsLlcMember" xlink:label="limn_ValetudoTherapeuticsLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ValetudoTherapeuticsLlcMember" xlink:to="limn_ValetudoTherapeuticsLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ValetudoTherapeuticsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Valetudo Therapeutics LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ValetudoTherapeuticsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo Therapeutics LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ValetudoTherapeuticsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo Therapeutics LLC</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RepaymentOfMembershipInterest" xlink:label="limn_RepaymentOfMembershipInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_RepaymentOfMembershipInterest" xlink:to="limn_RepaymentOfMembershipInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_RepaymentOfMembershipInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of repayment of membership interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_RepaymentOfMembershipInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment Of Membership Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_RepaymentOfMembershipInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of membership interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion, Converted Instrument, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of outstanding principal</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonLoanMember" xlink:label="limn_EwonLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_EwonLoanMember" xlink:to="limn_EwonLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_EwonLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Ewon Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_EwonLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ewon Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_EwonLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ewon Loan</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonDecember2022LoanMember" xlink:label="limn_EwonDecember2022LoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_EwonDecember2022LoanMember" xlink:to="limn_EwonDecember2022LoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_EwonDecember2022LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Ewon December 2022 Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_EwonDecember2022LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ewon December 2022 Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_EwonDecember2022LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ewon December 2022 Loan</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonSeptember2023LoanMember" xlink:label="limn_EwonSeptember2023LoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_EwonSeptember2023LoanMember" xlink:to="limn_EwonSeptember2023LoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_EwonSeptember2023LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Ewon September 2023 Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_EwonSeptember2023LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ewon September 2023 Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_EwonSeptember2023LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ewon September 2023 Loan</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonDecember2023LoanMember" xlink:label="limn_EwonDecember2023LoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_EwonDecember2023LoanMember" xlink:to="limn_EwonDecember2023LoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_EwonDecember2023LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Ewon December 2023 Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_EwonDecember2023LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ewon December 2023 Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_EwonDecember2023LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ewon December 2023 Loan</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonComfortechCoLtdMember" xlink:label="limn_EwonComfortechCoLtdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_EwonComfortechCoLtdMember" xlink:to="limn_EwonComfortechCoLtdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_EwonComfortechCoLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Ewon Comfortech Co, Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_EwonComfortechCoLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ewon Comfortech Co Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_EwonComfortechCoLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ewon Comfortech Co Ltd</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseLoanMember" xlink:label="limn_ProphaseLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ProphaseLoanMember" xlink:to="limn_ProphaseLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ProphaseLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Prophase Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ProphaseLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ProphaseLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase Loan</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseFebruary2024LoanMember" xlink:label="limn_ProphaseFebruary2024LoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ProphaseFebruary2024LoanMember" xlink:to="limn_ProphaseFebruary2024LoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ProphaseFebruary2024LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Prophase February 2024 Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ProphaseFebruary2024LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase February 2024 Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ProphaseFebruary2024LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase February 2024 Loan</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMarch2024LoanMember" xlink:label="limn_ProphaseMarch2024LoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ProphaseMarch2024LoanMember" xlink:to="limn_ProphaseMarch2024LoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ProphaseMarch2024LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Prophase March 2024 Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ProphaseMarch2024LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase March 2024 Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ProphaseMarch2024LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase March 2024 Loan</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseApril2024LoanMember" xlink:label="limn_ProphaseApril2024LoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ProphaseApril2024LoanMember" xlink:to="limn_ProphaseApril2024LoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ProphaseApril2024LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Prophase April 2024 Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ProphaseApril2024LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase April 2024 Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ProphaseApril2024LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase April 2024 Loan</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMay2024LoansMember" xlink:label="limn_ProphaseMay2024LoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ProphaseMay2024LoansMember" xlink:to="limn_ProphaseMay2024LoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ProphaseMay2024LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Prophase May 2024 Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ProphaseMay2024LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase May 2024 Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ProphaseMay2024LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase May 2024 Loans</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseJuly2024LoansMember" xlink:label="limn_ProphaseJuly2024LoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ProphaseJuly2024LoansMember" xlink:to="limn_ProphaseJuly2024LoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ProphaseJuly2024LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Prophase July 2024 Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ProphaseJuly2024LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase July 2024 Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ProphaseJuly2024LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase July 2024 Loans</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseAugust2024LoansMember" xlink:label="limn_ProphaseAugust2024LoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ProphaseAugust2024LoansMember" xlink:to="limn_ProphaseAugust2024LoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ProphaseAugust2024LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Prophase August 2024 Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ProphaseAugust2024LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase August 2024 Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ProphaseAugust2024LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase August 2024 Loans</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseFebruary2025LoansMember" xlink:label="limn_ProphaseFebruary2025LoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ProphaseFebruary2025LoansMember" xlink:to="limn_ProphaseFebruary2025LoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ProphaseFebruary2025LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Prophase February 2025 Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ProphaseFebruary2025LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase February 2025 Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ProphaseFebruary2025LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase February 2025 Loan</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMarch2025LoansMember" xlink:label="limn_ProphaseMarch2025LoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ProphaseMarch2025LoansMember" xlink:to="limn_ProphaseMarch2025LoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ProphaseMarch2025LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Prophase March 2025 Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ProphaseMarch2025LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase March 2025 Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ProphaseMarch2025LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase March 2025 Loans</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseApril2025LoansMember" xlink:label="limn_ProphaseApril2025LoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ProphaseApril2025LoansMember" xlink:to="limn_ProphaseApril2025LoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ProphaseApril2025LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Prophase April 2025 Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ProphaseApril2025LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase April 2025 Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ProphaseApril2025LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase April 2025 Loans</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseSciencesLlcMember" xlink:label="limn_ProphaseSciencesLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ProphaseSciencesLlcMember" xlink:to="limn_ProphaseSciencesLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ProphaseSciencesLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Prophase Sciences LLC .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ProphaseSciencesLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase Sciences LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ProphaseSciencesLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_HanaLoansMember" xlink:label="limn_HanaLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_HanaLoansMember" xlink:to="limn_HanaLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_HanaLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Hana Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_HanaLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hana Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_HanaLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hana Loans</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_HanaAugust2024LoansMember" xlink:label="limn_HanaAugust2024LoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_HanaAugust2024LoansMember" xlink:to="limn_HanaAugust2024LoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_HanaAugust2024LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Hana August 2024 Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_HanaAugust2024LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hana August 2024 Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_HanaAugust2024LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hana August 2024 Loans</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_HanaImmunotherapeuticsLlcMember" xlink:label="limn_HanaImmunotherapeuticsLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_HanaImmunotherapeuticsLlcMember" xlink:to="limn_HanaImmunotherapeuticsLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_HanaImmunotherapeuticsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Hana Immunotherapeutics, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_HanaImmunotherapeuticsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hana Immunotherapeutics, LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_HanaImmunotherapeuticsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hana Immunotherapeutics, LLC</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesLoansMember" xlink:label="limn_AmantesLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_AmantesLoansMember" xlink:to="limn_AmantesLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_AmantesLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Amantes Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_AmantesLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amantes Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_AmantesLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amantes Loans</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesNovember2024LoansMember" xlink:label="limn_AmantesNovember2024LoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_AmantesNovember2024LoansMember" xlink:to="limn_AmantesNovember2024LoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_AmantesNovember2024LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Amantes November 2024 Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_AmantesNovember2024LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amantes November 2024 Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_AmantesNovember2024LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amantes November 2024 Loans</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesJanuary2025LoansMember" xlink:label="limn_AmantesJanuary2025LoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_AmantesJanuary2025LoansMember" xlink:to="limn_AmantesJanuary2025LoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_AmantesJanuary2025LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Amantes January 2025 Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_AmantesJanuary2025LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amantes January 2025 Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_AmantesJanuary2025LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amantes January 2025 Loans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_AmantesJanuary2025LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amantes January 2025 Loans</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesLlcMember" xlink:label="limn_AmantesLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_AmantesLlcMember" xlink:to="limn_AmantesLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_AmantesLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Amantes LLC .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_AmantesLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amantes LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_AmantesLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amantes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EmploymentAgreementMember" xlink:label="limn_EmploymentAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_EmploymentAgreementMember" xlink:to="limn_EmploymentAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_EmploymentAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to employment agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_EmploymentAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_EmploymentAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Debt [Table]</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseFebruary2025LoanMember" xlink:label="limn_ProphaseFebruary2025LoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ProphaseFebruary2025LoanMember" xlink:to="limn_ProphaseFebruary2025LoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ProphaseFebruary2025LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Prophase February 2025 Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ProphaseFebruary2025LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase February 2025 Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ProphaseFebruary2025LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase February 2025 Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_ProphaseFebruary2025LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase February 2025 Loan</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMarch2025LoanMember" xlink:label="limn_ProphaseMarch2025LoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ProphaseMarch2025LoanMember" xlink:to="limn_ProphaseMarch2025LoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ProphaseMarch2025LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Prophase March 2025 Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ProphaseMarch2025LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase March 2025 Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ProphaseMarch2025LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase March 2025 Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_ProphaseMarch2025LoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prophase March 2025 Loan</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoDecember2022LoansMember" xlink:label="limn_ValetudoDecember2022LoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ValetudoDecember2022LoansMember" xlink:to="limn_ValetudoDecember2022LoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ValetudoDecember2022LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Valetudo December 2022 Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ValetudoDecember2022LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo December 2022 Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ValetudoDecember2022LoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valetudo Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Debt [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockAndPreFundedWarrantsMember" xlink:label="limn_CommonStockAndPreFundedWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_CommonStockAndPreFundedWarrantsMember" xlink:to="limn_CommonStockAndPreFundedWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_CommonStockAndPreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to common stock and pre-funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_CommonStockAndPreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock and Pre Funded Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_CommonStockAndPreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock and Pre-Funded Warrants</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AltaPartnersLlcMember" xlink:label="limn_AltaPartnersLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_AltaPartnersLlcMember" xlink:to="limn_AltaPartnersLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_AltaPartnersLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Alta Partners Llc..</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_AltaPartnersLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Alta Partners Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_AltaPartnersLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Alta Partners Llc</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClearStreetLlcMember" xlink:label="limn_ClearStreetLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ClearStreetLlcMember" xlink:to="limn_ClearStreetLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ClearStreetLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Clear Street LLC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ClearStreetLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clear Street Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ClearStreetLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clear Street Llc</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesIssuedForSurrenderAndCancellationOfWarrants" xlink:label="limn_SharesIssuedForSurrenderAndCancellationOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_SharesIssuedForSurrenderAndCancellationOfWarrants" xlink:to="limn_SharesIssuedForSurrenderAndCancellationOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_SharesIssuedForSurrenderAndCancellationOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued for surrender and cancellation of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_SharesIssuedForSurrenderAndCancellationOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued For Surrender And Cancellation Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_SharesIssuedForSurrenderAndCancellationOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued for surrender and cancellation of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_SharesIssuedForSurrenderAndCancellationOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock in connection with the surrender of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" xlink:label="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" xlink:to="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants surrendered and canceled.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Number Of Securities Surrendered And Canceled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surrender and cancellation of warrants to purchase shares of common stock</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonStockIssued" xlink:label="limn_FairValueOfCommonStockIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_FairValueOfCommonStockIssued" xlink:to="limn_FairValueOfCommonStockIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_FairValueOfCommonStockIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The fair value of common stock issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_FairValueOfCommonStockIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Common Stock Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_FairValueOfCommonStockIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of common stock</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfWarrantsSurrendered" xlink:label="limn_FairValueOfWarrantsSurrendered" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_FairValueOfWarrantsSurrendered" xlink:to="limn_FairValueOfWarrantsSurrendered_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_FairValueOfWarrantsSurrendered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The fair value of warrants surrendered.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_FairValueOfWarrantsSurrendered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Warrants Surrendered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_FairValueOfWarrantsSurrendered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of warrants surrendered</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_GainLossOnIssuanceOfCommonStockForWarrants" xlink:label="limn_GainLossOnIssuanceOfCommonStockForWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_GainLossOnIssuanceOfCommonStockForWarrants" xlink:to="limn_GainLossOnIssuanceOfCommonStockForWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_GainLossOnIssuanceOfCommonStockForWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The profit or loss on exchange of common stock for surrender of warrants classified as non-operating income. Represents the difference in the fair value of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_GainLossOnIssuanceOfCommonStockForWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Issuance of Common Stock for Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="limn_GainLossOnIssuanceOfCommonStockForWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on issuance of common stock in connection with the surrendar of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_GainLossOnIssuanceOfCommonStockForWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_GainLossOnIssuanceOfCommonStockForWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on exchange of common stock for warrants</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions" xlink:to="limn_ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants issued on conversion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Warrants Issued on Conversions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded warrants issued on conversion (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing stock price</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:to="limn_ClassOfWarrantOrRightNumberOfWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of warrants exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number Of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-Funded warrants exercised</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockNumberOfVotesPerShare" xlink:label="limn_CommonStockNumberOfVotesPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_CommonStockNumberOfVotesPerShare" xlink:to="limn_CommonStockNumberOfVotesPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_CommonStockNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes for each share of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_CommonStockNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Number Of Votes Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_CommonStockNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes per share</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants" xlink:label="limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants" xlink:to="limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The threshold period during which a written notice is required for redemption of warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Threshold Written Notice Period For Redemption Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold written notice period for redemption of warrants</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption" xlink:label="limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption" xlink:to="limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The threshold trigger price for redemption of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Threshold Share Price Trigger For Redemption</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Share Price for redemption of warrants</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:to="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold number of specified trading days for stock price trigger considered for redemption of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Redemption Of Warrants Or Rights, Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold number of specified trading days for stock price</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:to="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Redemption Of Warrants Or Rights, Threshold Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold number of specified consecutive trading days for stock price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected life of warrants (years)</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockWarrantsAndPlacementAgentWarrantsMember" xlink:label="limn_CommonStockWarrantsAndPlacementAgentWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_CommonStockWarrantsAndPlacementAgentWarrantsMember" xlink:to="limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to common stock warrants and placement agent warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants and Placement Agent Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants and Placement Agent Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholder's Equity</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockWarrantsMember" xlink:label="limn_CommonStockWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_CommonStockWarrantsMember" xlink:to="limn_CommonStockWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_CommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to common stock warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_CommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_CommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_GrossProceedsFromIssuanceOfWarrants" xlink:label="limn_GrossProceedsFromIssuanceOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_GrossProceedsFromIssuanceOfWarrants" xlink:to="limn_GrossProceedsFromIssuanceOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_GrossProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The gross cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_GrossProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_GrossProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Gross Proceeds</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NetProceedsFromIssuanceOfWarrants" xlink:label="limn_NetProceedsFromIssuanceOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_NetProceedsFromIssuanceOfWarrants" xlink:to="limn_NetProceedsFromIssuanceOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_NetProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The net cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_NetProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_NetProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Net Proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeReductionAgreementMember" xlink:label="limn_FeeReductionAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_FeeReductionAgreementMember" xlink:to="limn_FeeReductionAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_FeeReductionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Fee reduction agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_FeeReductionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fee Reduction Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_FeeReductionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fee Reduction Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short term lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="us-gaap_LossContingencyDamagesAwardedValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesAwardedValue" xlink:to="us-gaap_LossContingencyDamagesAwardedValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesAwardedValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency, Damages Awarded, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyDamagesAwardedValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss contingency on damaged value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementInterest" xlink:label="us-gaap_LitigationSettlementInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementInterest" xlink:to="us-gaap_LitigationSettlementInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Settlement Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationSettlementInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation settlement interest</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" xlink:label="limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" xlink:to="limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of underwriting discount on gross proceeds of the IPO.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting Discount as Percentage of Gross Proceeds from Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting discount (in percentage)</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnderwritingCostsNoncurrent" xlink:label="limn_UnderwritingCostsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_UnderwritingCostsNoncurrent" xlink:to="limn_UnderwritingCostsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_UnderwritingCostsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of the carrying value as of balance sheet date of underwriting fees payable or classified as noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_UnderwritingCostsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting Costs Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_UnderwritingCostsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting discount</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" xlink:label="limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" xlink:to="limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of deferred underwriting discount on gross proceeds of the IPO.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Underwriting Discount as Percentage of Gross Proceeds from Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred underwriting discount (in percentage)</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredOfferingCostsNoncurrent" xlink:label="limn_DeferredOfferingCostsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_DeferredOfferingCostsNoncurrent" xlink:to="limn_DeferredOfferingCostsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_DeferredOfferingCostsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of the carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_DeferredOfferingCostsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="limn_DeferredOfferingCostsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred underwriting discount</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PaymentOfOfferingCostsInCash" xlink:label="limn_PaymentOfOfferingCostsInCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_PaymentOfOfferingCostsInCash" xlink:to="limn_PaymentOfOfferingCostsInCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_PaymentOfOfferingCostsInCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount paid in cash for offering costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_PaymentOfOfferingCostsInCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of Offering Costs in Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_PaymentOfOfferingCostsInCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting discount paid in cash</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnderwritingDiscountPaidInSecurities" xlink:label="limn_UnderwritingDiscountPaidInSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_UnderwritingDiscountPaidInSecurities" xlink:to="limn_UnderwritingDiscountPaidInSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_UnderwritingDiscountPaidInSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount paid in shares for offering costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_UnderwritingDiscountPaidInSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting discount paid in securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_UnderwritingDiscountPaidInSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting discount paid in securities</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_MaximumNumbersOfSharesIssuable" xlink:label="limn_MaximumNumbersOfSharesIssuable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_MaximumNumbersOfSharesIssuable" xlink:to="limn_MaximumNumbersOfSharesIssuable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_MaximumNumbersOfSharesIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum number of shares issuable to underwriters.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_MaximumNumbersOfSharesIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Numbers Of Shares Issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_MaximumNumbersOfSharesIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issuable to underwriters</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination" xlink:to="limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred underwriting fee payable settled upon consummation of business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Underwriting Fee Payable Settled Upon Consummation Of Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred underwriting fees settled</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination" xlink:to="limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred underwriting fee payable settled in shares upon consummation of business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Underwriting Fee Payable Settled In Shares Upon Consummation Of Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred underwriting fee payable settled in shares</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination" xlink:to="limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred underwriting fee payable settled in cash upon consummation of business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Underwriting Fee Payable Settled In Cash Upon Consummation Of Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred underwriting fee payable settled in cash</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination" xlink:to="limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred underwriting fee waived upon consummation of business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Underwriting Fee Waived Upon Consummation Of Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred underwriting fee waived</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering" xlink:label="limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering" xlink:to="limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining amount of deferred underwriting fee settled upon consummation of combined company next share offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Underwriting Fee, Remaining Amount Settlement Upon Consummation Of Combined Company Next Share Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining amount of deferred underwriting fee settled</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination" xlink:label="limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination" xlink:to="limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the threshold period for settling remaining deferred underwriting fee from the date of business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Period For Remaining Deferred Underwriting Fee Settlement From Date of Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold period for settling remaining deferred underwriting fee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Liabilities Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value inputs level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance, fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance, fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial measurement at the Closing Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedMaintenanceFeeCurrent" xlink:label="limn_AccruedMaintenanceFeeCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_AccruedMaintenanceFeeCurrent" xlink:to="limn_AccruedMaintenanceFeeCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_AccruedMaintenanceFeeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of accrued maintenance fee as of balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_AccruedMaintenanceFeeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Maintenance Fee, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_AccruedMaintenanceFeeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued maintenance fee</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockShareOutstanding" xlink:label="limn_CommonStockShareOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_CommonStockShareOutstanding" xlink:to="limn_CommonStockShareOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_CommonStockShareOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_CommonStockShareOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Share Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_CommonStockShareOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of income tax provision (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of the effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of deferred tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:label="us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:to="us-gaap_AllowanceForNotesAndLoansReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForNotesAndLoansReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Receivable, Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForNotesAndLoansReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit losses relating to loan receivable</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAndDevelopmentAgreementWithTdtMember" xlink:label="limn_LicenseAndDevelopmentAgreementWithTdtMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_LicenseAndDevelopmentAgreementWithTdtMember" xlink:to="limn_LicenseAndDevelopmentAgreementWithTdtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_LicenseAndDevelopmentAgreementWithTdtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to license and development agreement with TDT (the "CAR-T License"), whereby the Company received an exclusive license to develop and commercialize chimeric antigen receptor ("CAR-T") products and a non-exclusive license to develop and commercialize companion diagnostics used to monitor treatment with a CAR-T product (the "CAR-T Diagnostics").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_LicenseAndDevelopmentAgreementWithTdtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License And Development Agreement With Tdt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_LicenseAndDevelopmentAgreementWithTdtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License And Development Agreement With TDT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember" xlink:label="limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember" xlink:to="limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to product being commercialize chimeric antigen receptor ("CAR-T") and CAR-T Diagnostics.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercialize Chimeric Antigen Receptor And CAR-T Diagnostics [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CAR-T products and CAR-T Diagnostics</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember" xlink:label="limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember" xlink:to="limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Phase II and Phase III clinical trials of CAR-T product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Phase II and Phase III Clinical Trials Of Car T Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Phase II and Phase III clinical trials of CAR-T Product</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember" xlink:label="limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember" xlink:to="limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining scenario being the scenario prior to the completion of the Phase I and Phase II clinical trials for the CAR-T product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Prior To Completion of Phase One and Two Clinical Trials for CAR-T Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior to the completion of the Phase I and Phase II clinical trials for the CAR-T product</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember" xlink:label="limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember" xlink:to="limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining scenario being the net sale of period from the first commercial sale of the CAR-T product or CAR-T Diagnostic until the product's patent expires in an individual country.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual Sales Of Period From First Commercial Sale Until Patent Expires [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net sales of period from first commercial sale until patent expires</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember" xlink:label="limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember" xlink:to="limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining scenario being the net sale of period of 10 years from the first commercial sale of the CAR-T product or CAR-T Diagnostic until the product's patent expires in an individual country.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ten Years Period From First Commercial Sale Of Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">10 years from first commercial sale of products</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UpfrontPaymentOfLicenseAgreementFees" xlink:label="limn_UpfrontPaymentOfLicenseAgreementFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_UpfrontPaymentOfLicenseAgreementFees" xlink:to="limn_UpfrontPaymentOfLicenseAgreementFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_UpfrontPaymentOfLicenseAgreementFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of upfront payment of license agreement fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_UpfrontPaymentOfLicenseAgreementFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront Payment Of License Agreement Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_UpfrontPaymentOfLicenseAgreementFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment of license agreement fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostMaintenance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost, Maintenance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostMaintenance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual maintenance fees</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate" xlink:label="limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate" xlink:to="limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of interest rate of short-term debt being converted from the unpaid annual maintenance fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unpaid Annual Maintenance Fees, Short - Term Debt, Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unpaid annual maintenance fees, short term debt interest rate (%)</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseMilestoneCommitmentFundPayableForEachPhase" xlink:label="limn_LicenseMilestoneCommitmentFundPayableForEachPhase" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_LicenseMilestoneCommitmentFundPayableForEachPhase" xlink:to="limn_LicenseMilestoneCommitmentFundPayableForEachPhase_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_LicenseMilestoneCommitmentFundPayableForEachPhase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of license milestone commitment fund obligated to pay for each phase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_LicenseMilestoneCommitmentFundPayableForEachPhase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Milestone Commitment Fund Payable For Each Phase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_LicenseMilestoneCommitmentFundPayableForEachPhase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of fund obligated to advance for each phase</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfMilestonePaymentsForFirstProductDevelopment" xlink:label="limn_NumberOfMilestonePaymentsForFirstProductDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_NumberOfMilestonePaymentsForFirstProductDevelopment" xlink:to="limn_NumberOfMilestonePaymentsForFirstProductDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_NumberOfMilestonePaymentsForFirstProductDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of milestone developmental and regulatory milestone payments for first product development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_NumberOfMilestonePaymentsForFirstProductDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Milestone Payments For First Product Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_NumberOfMilestonePaymentsForFirstProductDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of developmental and regulatory milestone payments for first product development</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment" xlink:label="limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment" xlink:to="limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of maximum aggregate milestone commitment fund for first product development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Maximum Aggregate Milestone Commitments Fund For First Product Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum aggregate milestone commitment fund for first product development</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment" xlink:label="limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment" xlink:to="limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of milestone developmental and regulatory milestone payments for each additional product development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Milestone Payments For Each Additional Product Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of developmental and regulatory milestone payments for each additional product development</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment" xlink:label="limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment" xlink:to="limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of maximum milestone commitment fund for each additional product development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Maximum Milestone Commitment Fund For Each Additional Product Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum milestone commitment fund for each additional product development</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RoyaltyFeesPercentage" xlink:label="limn_RoyaltyFeesPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_RoyaltyFeesPercentage" xlink:to="limn_RoyaltyFeesPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_RoyaltyFeesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of royalty fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_RoyaltyFeesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Fees, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_RoyaltyFeesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of royalty fees (%)</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts" xlink:label="limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts" xlink:to="limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of years from the first commercial sale of CAR-T product or CAR-T Diagnostic.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Fees, Number of Years From First Commercial Sale Of Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of years from first commercial sale of products (in years)</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember" xlink:label="limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember" xlink:to="limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to license and development agreement with TDT (the "Vaccine License"), whereby the Company received an exclusive license to develop and commercialize vaccine products (the "Vaccine Products") and a non-exclusive license to develop and commercialize companion diagnostics used to monitor treatment with a Vaccine Product (the "Vaccine Diagnostics").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vaccine License And Development Agreement With Tdt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vaccine license and development agreement with TDT</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CarTLicenseAndVaccineLicenseWithTdtMember" xlink:label="limn_CarTLicenseAndVaccineLicenseWithTdtMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_CarTLicenseAndVaccineLicenseWithTdtMember" xlink:to="limn_CarTLicenseAndVaccineLicenseWithTdtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_CarTLicenseAndVaccineLicenseWithTdtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to CAR-T Products and Vaccine Licenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_CarTLicenseAndVaccineLicenseWithTdtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CAR T License And Vaccine License With Tdt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_CarTLicenseAndVaccineLicenseWithTdtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CAR-T License and Vaccine License with TDT</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_VaccineProductsAndVaccineDiagnosticsMember" xlink:label="limn_VaccineProductsAndVaccineDiagnosticsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_VaccineProductsAndVaccineDiagnosticsMember" xlink:to="limn_VaccineProductsAndVaccineDiagnosticsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_VaccineProductsAndVaccineDiagnosticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to product being vaccine products (the "Vaccine Products") and Vaccine Diagnostics.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_VaccineProductsAndVaccineDiagnosticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vaccine Products And Vaccine Diagnostics [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_VaccineProductsAndVaccineDiagnosticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vaccine Products and Vaccine Diagnostics</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAgreementMaintenanceFees" xlink:label="limn_LicenseAgreementMaintenanceFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_LicenseAgreementMaintenanceFees" xlink:to="limn_LicenseAgreementMaintenanceFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_LicenseAgreementMaintenanceFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of license agreement incurred in maintenance fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_LicenseAgreementMaintenanceFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement maintenance fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_LicenseAgreementMaintenanceFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maintenance fee</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAgreementsTerminationAmountDue" xlink:label="limn_LicenseAgreementsTerminationAmountDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_LicenseAgreementsTerminationAmountDue" xlink:to="limn_LicenseAgreementsTerminationAmountDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_LicenseAgreementsTerminationAmountDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount owes pursuant to termination of license agreements by TDT.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_LicenseAgreementsTerminationAmountDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreements Termination, Amount Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_LicenseAgreementsTerminationAmountDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount owes pursuant to termination of license agreement</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ViralGeneMember" xlink:label="limn_ViralGeneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ViralGeneMember" xlink:to="limn_ViralGeneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ViralGeneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Viral Gene.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ViralGeneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Viral Gene [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ViralGeneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Viral Gene</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due from related party, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ResearchAndDevelopmentExpenseMandatoryCapitalization" xlink:label="limn_ResearchAndDevelopmentExpenseMandatoryCapitalization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_ResearchAndDevelopmentExpenseMandatoryCapitalization" xlink:to="limn_ResearchAndDevelopmentExpenseMandatoryCapitalization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_ResearchAndDevelopmentExpenseMandatoryCapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of research and development expense subject to mandatory capitalization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_ResearchAndDevelopmentExpenseMandatoryCapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Mandatory Capitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_ResearchAndDevelopmentExpenseMandatoryCapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating losses</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FederalIncomeTaxExpenseSubjectToLimitationInUse" xlink:label="limn_FederalIncomeTaxExpenseSubjectToLimitationInUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_FederalIncomeTaxExpenseSubjectToLimitationInUse" xlink:to="limn_FederalIncomeTaxExpenseSubjectToLimitationInUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_FederalIncomeTaxExpenseSubjectToLimitationInUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_FederalIncomeTaxExpenseSubjectToLimitationInUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal Income Tax Expense Subject To Limitation In Use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_FederalIncomeTaxExpenseSubjectToLimitationInUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal income tax liabilities, subject limitations</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StatutoryStateIncomeTaxRate" xlink:label="limn_StatutoryStateIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_StatutoryStateIncomeTaxRate" xlink:to="limn_StatutoryStateIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_StatutoryStateIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of state statutory tax rate applicable to pretax income (loss).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_StatutoryStateIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statutory State Income Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_StatutoryStateIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">California income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination, Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest or penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Federal Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred State and Local Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax provision expense/(benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statutory federal income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes, net of federal expense</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent" xlink:label="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent" xlink:to="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to gain loss on exchange of common stock for warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Gain (Loss) On Exchange Of Common Stock, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on exchange of common stock for warrants</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent" xlink:label="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent" xlink:to="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value of common stock to be issued for contingent liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Fair Value Of Common Stock For Contingent Liability, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of common stock to be issued for contingent liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other permanent differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax provision expense/(benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statutory federal income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes, net of federal expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Jurisdiction, Contribution Greater than 50 Percent, Tax Effect [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Jurisdiction, Contribution Greater than 50 Percent, Tax Effect [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount" xlink:label="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount" xlink:to="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to gain (loss) on exchange of common stock for warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Gain (Loss) On Exchange Of Common Stock, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on exchange of common stock for warrants</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount" xlink:label="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount" xlink:to="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value of common stock to be issued for contingent liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Fair Value Of Common Stock For Contingent Liability, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of common stock to be issued for contingent liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other permanent differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforward</label>
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredTaxAssetsStartupExpenses" xlink:label="limn_DeferredTaxAssetsStartupExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="limn_DeferredTaxAssetsStartupExpenses" xlink:to="limn_DeferredTaxAssetsStartupExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="limn_DeferredTaxAssetsStartupExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from startup expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="limn_DeferredTaxAssetsStartupExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Startup Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="limn_DeferredTaxAssetsStartupExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Startup expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Asset, Interest Carryforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Section 163(j) - Interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax asset, net of valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>limn-20260331_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.3.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 6/24/2026 1:16:50 AM-->
<!--Modified on: 6/24/2026 1:16:50 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementCondensedConsolidatedBalanceSheetsParentheticals" roleURI="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" roleURI="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical" roleURI="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperations" roleURI="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureLicenseAgreements" roleURI="http://www.liminatuspharma.com/role/DisclosureLicenseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDebt" roleURI="http://www.liminatuspharma.com/role/DisclosureDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureStockholderSEquity" roleURI="http://www.liminatuspharma.com/role/DisclosureStockholderSEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureFairValueMeasurements" roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureSubsequentEvents" roleURI="http://www.liminatuspharma.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDebtTables" roleURI="http://www.liminatuspharma.com/role/DisclosureDebtTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureStockholderSEquityTables" roleURI="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureSignificantAccountingPoliciesIncomeTaxesDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureLicenseAgreementsCd47LicenseDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsFeeluxBondsDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsValetudoLoansDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsEwonLoansDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsProphaseLoansDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsHanaLoansDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsAmantesLoansDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDebtDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureStockholderSEquityDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details" roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementConsolidatedBalanceSheetsParentheticals" roleURI="http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementConsolidatedStatementsOfChangesInStockholderSDeficit" roleURI="http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationss" roleURI="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureSignificantAccountingPoliciess" roleURI="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciess" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureLicenseAgreementss" roleURI="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionss" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDebts" roleURI="http://www.liminatuspharma.com/role/DisclosureDebts" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureStockholderSEquitys" roleURI="http://www.liminatuspharma.com/role/DisclosureStockholderSEquitys" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureCommitmentsAndContingenciess" roleURI="http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciess" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureFairValueMeasurementss" roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureIncomeTaxes" roleURI="http://www.liminatuspharma.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureSubsequentEventss" roleURI="http://www.liminatuspharma.com/role/DisclosureSubsequentEventss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureSignificantAccountingPoliciesPoliciess" roleURI="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDebtTabless" roleURI="http://www.liminatuspharma.com/role/DisclosureDebtTabless" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureFairValueMeasurementsTabless" roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTabless" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureSignificantAccountingPoliciesIncomeTaxesDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureLicenseAgreementsCarTProductsLicenseDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureLicenseAgreementsVaccineProductsLicenseDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureLicenseAgreementsCd47LicenseDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsFeeluxBondsDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsValetudoLoansDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsEwonLoansDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsProphaseLoansDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsHanaLoansDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsAmantesLoansDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureRelatedPartyTransactionsViralGeneDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureDebtDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureDebtDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureStockholderSEquityDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureCommitmentsAndContingenciesDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureFairValueMeasurementsDetailss" roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss" roleURI="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureIncomeTaxesIncomeTaxProvisionDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="limn-20260331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="1100090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType_639178606084753835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_639178606084753835" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_639178606084759005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_639178606084759005" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_639178606084759553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_639178606084759553" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_639178606084759553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_639178606084759553" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_639178606084759553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_639178606084759553" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_639178606084759553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_639178606084759553" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_639178606084759553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_639178606084759553" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_639178606084759553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_639178606084759553" order="8" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="1100100 - Statement - Condensed Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639178606084765163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_639178606084765163" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606084765163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639178606084765163" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606084765163" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606084765163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606084765163" xlink:to="us-gaap_RelatedPartyDomain_639178606084765163" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember_639178606084765163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606084765163" xlink:to="us-gaap_NonrelatedPartyMember_639178606084765163" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606084765163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606084765163" xlink:to="us-gaap_RelatedPartyMember_639178606084765163" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639178606084765163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639178606084765163" xlink:to="us-gaap_StatementLineItems_639178606084765163" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_639178606084765163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606084765163" xlink:to="us-gaap_AssetsAbstract_639178606084765163" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_639178606084770699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639178606084765163" xlink:to="us-gaap_AssetsCurrentAbstract_639178606084770699" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_639178606084770963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639178606084770699" xlink:to="us-gaap_Cash_639178606084770963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_639178606084770963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639178606084770699" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_639178606084770963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent_639178606084770963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639178606084770699" xlink:to="us-gaap_DeferredCostsCurrent_639178606084770963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639178606084770963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639178606084770699" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639178606084770963" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_639178606084770963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639178606084770699" xlink:to="us-gaap_AssetsCurrent_639178606084770963" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_639178606084770963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639178606084765163" xlink:to="us-gaap_AssetsNoncurrentAbstract_639178606084770963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent_639178606084770963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_639178606084770963" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent_639178606084770963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_639178606084776883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_639178606084770963" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_639178606084776883" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_639178606084776883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_639178606084770963" xlink:to="us-gaap_AssetsNoncurrent_639178606084776883" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_639178606084776883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639178606084765163" xlink:to="us-gaap_Assets_639178606084776883" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639178606084776883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606084765163" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639178606084776883" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_639178606084776883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639178606084776883" xlink:to="us-gaap_LiabilitiesCurrentAbstract_639178606084776883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_639178606084776883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639178606084776883" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_639178606084776883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent_639178606084776883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639178606084776883" xlink:to="limn_AccruedInterestCurrent_639178606084776883" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_639178606084782355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639178606084776883" xlink:to="us-gaap_OtherLiabilitiesCurrent_639178606084782355" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606084782355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639178606084776883" xlink:to="us-gaap_ShortTermBorrowings_639178606084782355" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableInCashCurrent" xlink:label="limn_DeferredUnderwritingFeesPayableInCashCurrent_639178606084782355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639178606084776883" xlink:to="limn_DeferredUnderwritingFeesPayableInCashCurrent_639178606084782355" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPayable" xlink:label="limn_CommonStockPayable_639178606084782355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639178606084776883" xlink:to="limn_CommonStockPayable_639178606084782355" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_639178606084786071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639178606084776883" xlink:to="us-gaap_LiabilitiesCurrent_639178606084786071" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_639178606084786071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639178606084776883" xlink:to="us-gaap_WarrantsAndRightsOutstanding_639178606084786071" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_639178606084786071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639178606084776883" xlink:to="us-gaap_Liabilities_639178606084786071" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_639178606084786071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639178606084776883" xlink:to="us-gaap_CommitmentsAndContingencies_639178606084786071" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_639178606084786071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639178606084776883" xlink:to="us-gaap_StockholdersEquityAbstract_639178606084786071" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_639178606084786071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639178606084786071" xlink:to="us-gaap_PreferredStockValue_639178606084786071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_639178606084791563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639178606084786071" xlink:to="us-gaap_CommonStockValue_639178606084791563" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_639178606084793600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639178606084786071" xlink:to="us-gaap_AdditionalPaidInCapital_639178606084793600" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639178606084794184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639178606084786071" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639178606084794184" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639178606084794184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639178606084786071" xlink:to="us-gaap_StockholdersEquity_639178606084794184" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_639178606084794184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639178606084776883" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_639178606084794184" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals" xlink:type="extended" xlink:title="1100105 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_639178606084799908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_639178606084799908" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_639178606084799908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_639178606084799908" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_639178606084799908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_639178606084799908" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_639178606084799908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_639178606084799908" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_639178606084799908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_639178606084799908" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_639178606084799908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_639178606084799908" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_639178606084799908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_639178606084799908" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_639178606084806102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_639178606084806102" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="1100200 - Statement - Condensed Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_639178606084806883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense_639178606084806883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_639178606084806883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense_639178606084806883" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_639178606084806883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses_639178606084806883" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639178606084806883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_639178606084806883" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_639178606084806883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_639178606084806883" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_639178606084806883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639178606084806883" xlink:to="us-gaap_InterestExpenseNonoperating_639178606084806883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_639178606084812606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639178606084806883" xlink:to="us-gaap_InvestmentIncomeInterest_639178606084812606" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ForgivenessOfUnrelatedVendorPayable" xlink:label="limn_ForgivenessOfUnrelatedVendorPayable_639178606084812606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639178606084806883" xlink:to="limn_ForgivenessOfUnrelatedVendorPayable_639178606084812606" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue" xlink:label="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_639178606084812606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639178606084806883" xlink:to="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_639178606084812606" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639178606084812606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639178606084806883" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639178606084812606" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonStockIssuanceForContingentLiability" xlink:label="limn_FairValueOfCommonStockIssuanceForContingentLiability_639178606084812606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639178606084806883" xlink:to="limn_FairValueOfCommonStockIssuanceForContingentLiability_639178606084812606" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_639178606084812606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639178606084806883" xlink:to="us-gaap_NonoperatingIncomeExpense_639178606084812606" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639178606084812606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_639178606084812606" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639178606084812606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639178606084812606" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639178606084818278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639178606084818278" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_639178606084818278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_639178606084818278" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_639178606084818278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_639178606084818278" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" xlink:type="extended" xlink:title="1100300 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficit" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639178606084823919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_639178606084823919" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_639178606084823919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639178606084823919" xlink:to="us-gaap_StatementEquityComponentsAxis_639178606084823919" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_639178606084823919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639178606084823919" xlink:to="us-gaap_CommonStockMember_639178606084823919" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_639178606084823919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639178606084823919" xlink:to="us-gaap_AdditionalPaidInCapitalMember_639178606084823919" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_639178606084823919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639178606084823919" xlink:to="us-gaap_RetainedEarningsMember_639178606084823919" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_639178606084823919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639178606084823919" xlink:to="us-gaap_EquityComponentDomain_639178606084823919" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639178606084823919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639178606084823919" xlink:to="us-gaap_StatementLineItems_639178606084823919" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639178606084823919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606084823919" xlink:to="us-gaap_StockholdersEquity_639178606084823919" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_639178606084829556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606084823919" xlink:to="us-gaap_CommonStockSharesIssued_639178606084829556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants" xlink:label="limn_StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants_639178606084829556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606084823919" xlink:to="limn_StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants_639178606084829556" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants" xlink:label="limn_StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants_639178606084829556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606084823919" xlink:to="limn_StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants_639178606084829556" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodValueBusinessCombination" xlink:label="limn_StockIssuedDuringPeriodValueBusinessCombination_639178606084829556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606084823919" xlink:to="limn_StockIssuedDuringPeriodValueBusinessCombination_639178606084829556" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodSharesBusinessCombination" xlink:label="limn_StockIssuedDuringPeriodSharesBusinessCombination_639178606084829556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606084823919" xlink:to="limn_StockIssuedDuringPeriodSharesBusinessCombination_639178606084829556" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans" xlink:label="limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans_639178606084829556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606084823919" xlink:to="limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans_639178606084829556" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_639178606084829556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606084823919" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_639178606084829556" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_639178606084829556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606084823919" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_639178606084829556" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_639178606084834995" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606084823919" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_639178606084834995" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639178606084835803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606084823919" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639178606084835803" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedPeriodValueOfCommonStockToUnderwriter" xlink:label="limn_StockIssuedPeriodValueOfCommonStockToUnderwriter_639178606084835803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606084823919" xlink:to="limn_StockIssuedPeriodValueOfCommonStockToUnderwriter_639178606084835803" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedPeriodOfCommonStockToUnderwriter" xlink:label="limn_StockIssuedPeriodOfCommonStockToUnderwriter_639178606084835803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606084823919" xlink:to="limn_StockIssuedPeriodOfCommonStockToUnderwriter_639178606084835803" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants" xlink:label="limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants_639178606084835803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606084823919" xlink:to="limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants_639178606084835803" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639178606084835803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606084823919" xlink:to="us-gaap_NetIncomeLoss_639178606084835803" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639178606084835803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606084823919" xlink:to="us-gaap_StockholdersEquity_639178606084835803" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_639178606084835803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606084823919" xlink:to="us-gaap_CommonStockSharesIssued_639178606084835803" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical" xlink:type="extended" xlink:title="1100305 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficit (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_OfferingCosts" xlink:label="limn_OfferingCosts_639178606084841395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="limn_OfferingCosts_639178606084841395" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="1100400 - Statement - Condensed Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639178606084841395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639178606084841395" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639178606084847025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639178606084841395" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639178606084847025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_639178606084847025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639178606084847025" xlink:to="us-gaap_ProfitLoss_639178606084847025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ForgivenessOfUnrelatedVendorPayable" xlink:label="limn_ForgivenessOfUnrelatedVendorPayable_639178606084847025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639178606084847025" xlink:to="limn_ForgivenessOfUnrelatedVendorPayable_639178606084847025" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_OtherReceivableWriteOff" xlink:label="limn_OtherReceivableWriteOff_639178606084847025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639178606084847025" xlink:to="limn_OtherReceivableWriteOff_639178606084847025" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_639178606084847025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639178606084847025" xlink:to="us-gaap_Depreciation_639178606084847025" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue" xlink:label="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_639178606084847025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639178606084847025" xlink:to="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_639178606084847025" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639178606084847025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639178606084847025" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639178606084847025" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonStockIssuanceForContingentLiability" xlink:label="limn_FairValueOfCommonStockIssuanceForContingentLiability_639178606084847025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639178606084847025" xlink:to="limn_FairValueOfCommonStockIssuanceForContingentLiability_639178606084847025" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639178606084847025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639178606084847025" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639178606084847025" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_639178606084852716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639178606084847025" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_639178606084852716" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639178606084852716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639178606084847025" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639178606084852716" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_639178606084852716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639178606084847025" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_639178606084852716" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent" xlink:label="limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent_639178606084852716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639178606084847025" xlink:to="limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent_639178606084852716" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent" xlink:label="limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent_639178606084852716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639178606084847025" xlink:to="limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent_639178606084852716" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent" xlink:label="limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent_639178606084852716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639178606084847025" xlink:to="limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent_639178606084852716" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_639178606084852716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639178606084847025" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_639178606084852716" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606084858175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639178606084847025" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606084858175" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639178606084858417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639178606084858417" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLoansReceivable" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable_639178606084858417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639178606084858417" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable_639178606084858417" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639178606084858417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639178606084858417" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639178606084858417" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_639178606084858417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639178606084858417" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_639178606084858417" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639178606084858417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639178606084858417" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_639178606084858417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639178606084858417" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_639178606084858417" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_639178606084863990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639178606084858417" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_639178606084863990" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt_639178606084863990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639178606084858417" xlink:to="us-gaap_ProceedsFromShortTermDebt_639178606084863990" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt_639178606084863990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639178606084858417" xlink:to="us-gaap_RepaymentsOfShortTermDebt_639178606084863990" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_639178606084863990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639178606084858417" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_639178606084863990" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_639178606084863990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_639178606084863990" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_639178606084869176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_639178606084869176" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_639178606084886714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_639178606084886714" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606084886714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606084886714" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1_639178606084886714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606084886714" xlink:to="us-gaap_LiabilitiesAssumed1_639178606084886714" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination" xlink:label="limn_StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination_639178606084886714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606084886714" xlink:to="limn_StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination_639178606084886714" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction" xlink:label="limn_MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction_639178606084886714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606084886714" xlink:to="limn_MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction_639178606084886714" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LoansSettled" xlink:label="limn_LoansSettled_639178606084886714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606084886714" xlink:to="limn_LoansSettled_639178606084886714" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1_639178606084892680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606084886714" xlink:to="us-gaap_StockIssued1_639178606084892680" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NoncashConversionOfAmountBorrowedForPipeFunds" xlink:label="limn_NoncashConversionOfAmountBorrowedForPipeFunds_639178606084894170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606084886714" xlink:to="limn_NoncashConversionOfAmountBorrowedForPipeFunds_639178606084894170" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest" xlink:label="limn_DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest_639178606084895000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606084886714" xlink:to="limn_DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest_639178606084895000" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesIssuableUponClosingOfMergerToUnderwriters" xlink:label="limn_SharesIssuableUponClosingOfMergerToUnderwriters_639178606084895000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606084886714" xlink:to="limn_SharesIssuableUponClosingOfMergerToUnderwriters_639178606084895000" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockIssuedInConnectionWithSettlement" xlink:label="limn_CommonStockIssuedInConnectionWithSettlement_639178606084895000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606084886714" xlink:to="limn_CommonStockIssuedInConnectionWithSettlement_639178606084895000" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CostsIncurredInConnectionWithIssuanceOfCommonStock" xlink:label="limn_CostsIncurredInConnectionWithIssuanceOfCommonStock_639178606084895000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606084886714" xlink:to="limn_CostsIncurredInConnectionWithIssuanceOfCommonStock_639178606084895000" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredTransactionCostsInAccountsPayable" xlink:label="limn_DeferredTransactionCostsInAccountsPayable_639178606084895000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606084886714" xlink:to="limn_DeferredTransactionCostsInAccountsPayable_639178606084895000" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations" xlink:type="extended" xlink:title="1110101 - Disclosure - Description of Organization and Business Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_639178606084900906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_639178606084900906" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="1110201 - Disclosure - Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_639178606084900906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_639178606084900906" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureLicenseAgreements" xlink:type="extended" xlink:title="1110301 - Disclosure - License Agreements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAgreementsAbstract" xlink:label="LicenseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAgreementsTextBlock" xlink:label="limn_LicenseAgreementsTextBlock_639178606084900906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseAgreementsAbstract" xlink:to="limn_LicenseAgreementsTextBlock_639178606084900906" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="1110401 - Disclosure - Related Party Transactions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_639178606084900906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_639178606084900906" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDebt" xlink:type="extended" xlink:title="1110501 - Disclosure - Debt" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_639178606084911644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_639178606084911644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureStockholderSEquity" xlink:type="extended" xlink:title="1110601 - Disclosure - Stockholder's Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_639178606084911644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_639178606084911644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="1110701 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_639178606084911644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_639178606084911644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="1110801 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_639178606084917512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_639178606084917512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="1110901 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_639178606084917512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_639178606084917512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="1120202 - Disclosure - Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_639178606084923674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_639178606084923674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EmergingGrowthCompanyPolicyPolicyTextBlock" xlink:label="limn_EmergingGrowthCompanyPolicyPolicyTextBlock_639178606084923674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="limn_EmergingGrowthCompanyPolicyPolicyTextBlock_639178606084923674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_639178606084923674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_639178606084923674" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_639178606084923674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_639178606084923674" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_639178606084923674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_639178606084923674" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:label="us-gaap_FinanceLoansAndLeasesReceivablePolicy_639178606084923674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FinanceLoansAndLeasesReceivablePolicy_639178606084923674" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_639178606084923674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_639178606084923674" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_639178606084923674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_639178606084923674" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_WarrantsPolicyPolicyTextBlock" xlink:label="limn_WarrantsPolicyPolicyTextBlock_639178606084928943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="limn_WarrantsPolicyPolicyTextBlock_639178606084928943" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock" xlink:label="limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock_639178606084929528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock_639178606084929528" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_639178606084930185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_639178606084930185" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_639178606084930766" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_639178606084930766" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_639178606084931955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_639178606084931955" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_639178606084932569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_639178606084932569" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDebtTables" xlink:type="extended" xlink:title="1130503 - Disclosure - Debt (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock_639178606084936131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock_639178606084936131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityTables" xlink:type="extended" xlink:title="1130603 - Disclosure - Stockholder's Equity (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_639178606084938798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_639178606084938798" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock" xlink:label="limn_ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock_639178606084939684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="limn_ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock_639178606084939684" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="1130803 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_639178606084940904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_639178606084940904" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_639178606084940904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_639178606084940904" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails" xlink:type="extended" xlink:title="1140101 - Disclosure - Description of Organization and Business Operations - Business Combination (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606084940904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606084940904" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_639178606084940904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606084940904" xlink:to="us-gaap_BusinessAcquisitionAxis_639178606084940904" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_639178606084946336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_639178606084940904" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_639178606084946336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LiminatusAndIrisMember" xlink:label="limn_LiminatusAndIrisMember_639178606084946936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_639178606084946336" xlink:to="limn_LiminatusAndIrisMember_639178606084946936" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_639178606084946936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606084940904" xlink:to="dei_LegalEntityAxis_639178606084946936" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_639178606084946936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_639178606084946936" xlink:to="dei_EntityDomain_639178606084946936" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IrisAcquisitionCorpMember" xlink:label="limn_IrisAcquisitionCorpMember_639178606084946936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_639178606084946936" xlink:to="limn_IrisAcquisitionCorpMember_639178606084946936" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IrisAcquisitionHoldingsLlcMember" xlink:label="limn_IrisAcquisitionHoldingsLlcMember_639178606084946936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_639178606084946936" xlink:to="limn_IrisAcquisitionHoldingsLlcMember_639178606084946936" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_639178606084946936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606084940904" xlink:to="us-gaap_StatementClassOfStockAxis_639178606084946936" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639178606084946936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_639178606084946936" xlink:to="us-gaap_ClassOfStockDomain_639178606084946936" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_639178606084946936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639178606084946936" xlink:to="us-gaap_CommonClassAMember_639178606084946936" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639178606084951535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606084940904" xlink:to="us-gaap_DebtInstrumentAxis_639178606084951535" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639178606084951535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639178606084951535" xlink:to="us-gaap_DebtInstrumentNameDomain_639178606084951535" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConsortiumLoanOfRelatedPartiesMember" xlink:label="limn_ConsortiumLoanOfRelatedPartiesMember_639178606084951535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606084951535" xlink:to="limn_ConsortiumLoanOfRelatedPartiesMember_639178606084951535" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639178606084951535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606084940904" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639178606084951535" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639178606084951535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639178606084951535" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639178606084951535" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NonRedeemableWarrantMember" xlink:label="limn_NonRedeemableWarrantMember_639178606084951535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606084951535" xlink:to="limn_NonRedeemableWarrantMember_639178606084951535" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RedeemableWarrantMember" xlink:label="limn_RedeemableWarrantMember_639178606084951535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606084951535" xlink:to="limn_RedeemableWarrantMember_639178606084951535" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639178606084956950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606084940904" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639178606084956950" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639178606084957666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639178606084956950" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639178606084957666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_639178606084957666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639178606084957666" xlink:to="us-gaap_PrivatePlacementMember_639178606084957666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606084957666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606084940904" xlink:to="srt_CounterpartyNameAxis_639178606084957666" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606084957666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606084957666" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606084957666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxCo.LtdMember" xlink:label="limn_FeeluxCo.LtdMember_639178606084957666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606084957666" xlink:to="limn_FeeluxCo.LtdMember_639178606084957666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxAndCarTcellkorMember" xlink:label="limn_FeeluxAndCarTcellkorMember_639178606084957666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606084957666" xlink:to="limn_FeeluxAndCarTcellkorMember_639178606084957666" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_639178606084963104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606084940904" xlink:to="us-gaap_BusinessAcquisitionLineItems_639178606084963104" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockCashRedemptionShares" xlink:label="limn_CommonStockCashRedemptionShares_639178606084963352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_CommonStockCashRedemptionShares_639178606084963352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockCashRedemptionPricePerShare" xlink:label="limn_CommonStockCashRedemptionPricePerShare_639178606084963352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_CommonStockCashRedemptionPricePerShare_639178606084963352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockCashRedemptionAmount" xlink:label="limn_CommonStockCashRedemptionAmount_639178606084963352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_CommonStockCashRedemptionAmount_639178606084963352" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfSharesHeldInEachUnit" xlink:label="limn_NumberOfSharesHeldInEachUnit_639178606084963352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_NumberOfSharesHeldInEachUnit_639178606084963352" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_639178606084963352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_639178606084963352" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfWarrantsHeldInEachUnit" xlink:label="limn_NumberOfWarrantsHeldInEachUnit_639178606084963352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_NumberOfWarrantsHeldInEachUnit_639178606084963352" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockConversionRatioBusinessCombination" xlink:label="limn_CommonStockConversionRatioBusinessCombination_639178606084969039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_CommonStockConversionRatioBusinessCombination_639178606084969039" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_639178606084969039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_639178606084969039" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639178606084969039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639178606084969039" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesAuthorized" xlink:label="limn_SharesAuthorized_639178606084969039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_SharesAuthorized_639178606084969039" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_639178606084969039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="us-gaap_CommonStockSharesAuthorized_639178606084969039" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_639178606084969039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="us-gaap_PreferredStockSharesAuthorized_639178606084969039" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_639178606084974710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_639178606084974710" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_639178606084974710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="us-gaap_ConversionOfStockSharesConverted1_639178606084974710" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_639178606084974710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="us-gaap_ConversionOfStockSharesIssued1_639178606084974710" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639178606084974710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639178606084974710" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639178606084974710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639178606084974710" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfStockOrUnitConversionRatio" xlink:label="limn_ConversionOfStockOrUnitConversionRatio_639178606084980392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_ConversionOfStockOrUnitConversionRatio_639178606084980392" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_639178606084980392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_639178606084980392" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProceedsFromIssuanceOfPrivatePlacementInvestor" xlink:label="limn_ProceedsFromIssuanceOfPrivatePlacementInvestor_639178606084980392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_ProceedsFromIssuanceOfPrivatePlacementInvestor_639178606084980392" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded" xlink:label="limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded_639178606084980392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded_639178606084980392" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_639178606084980392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_639178606084980392" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PrincipalAndAccruedInterestOnPrivatePlacement" xlink:label="limn_PrincipalAndAccruedInterestOnPrivatePlacement_639178606084986685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_PrincipalAndAccruedInterestOnPrivatePlacement_639178606084986685" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RelatedPartiesDebtToUnsecuredPromissoryNote" xlink:label="limn_RelatedPartiesDebtToUnsecuredPromissoryNote_639178606084987477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_RelatedPartiesDebtToUnsecuredPromissoryNote_639178606084987477" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnsecuredPromissoryNoteSettledAndConverted" xlink:label="limn_UnsecuredPromissoryNoteSettledAndConverted_639178606084987477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_UnsecuredPromissoryNoteSettledAndConverted_639178606084987477" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfPrincipalAndAccruedInterestAmount" xlink:label="limn_ConversionOfPrincipalAndAccruedInterestAmount_639178606084987477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_ConversionOfPrincipalAndAccruedInterestAmount_639178606084987477" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfPrincipalAndAccruedInterestShares" xlink:label="limn_ConversionOfPrincipalAndAccruedInterestShares_639178606084987477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_ConversionOfPrincipalAndAccruedInterestShares_639178606084987477" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_639178606084987477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_639178606084987477" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_639178606084994128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_639178606084994128" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfAccruedInterestOnRelatedPartyDebts" xlink:label="limn_ConversionOfAccruedInterestOnRelatedPartyDebts_639178606084994496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_ConversionOfAccruedInterestOnRelatedPartyDebts_639178606084994496" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination_639178606084994496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination_639178606084994496" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuableForSettlementOfDeferredUnderwritingFees" xlink:label="limn_StockIssuableForSettlementOfDeferredUnderwritingFees_639178606084994496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_StockIssuableForSettlementOfDeferredUnderwritingFees_639178606084994496" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LiabilityOfUnderwritingFeesFairValue" xlink:label="limn_LiabilityOfUnderwritingFeesFairValue_639178606084994496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_LiabilityOfUnderwritingFeesFairValue_639178606084994496" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" xlink:label="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees_639178606085000765" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606084963104" xlink:to="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees_639178606085000765" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails" xlink:type="extended" xlink:title="1140102 - Disclosure - Description of Organization and Business Operations - February 2026 Public Offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639178606085001357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639178606085001357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639178606085001357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639178606085001357" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639178606085001357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639178606085001357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639178606085001357" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639178606085001357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PreFundedWarrantsMember" xlink:label="limn_PreFundedWarrantsMember_639178606085001357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085001357" xlink:to="limn_PreFundedWarrantsMember_639178606085001357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPurchaseWarrantsMember" xlink:label="limn_CommonStockPurchaseWarrantsMember_639178606085007216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085001357" xlink:to="limn_CommonStockPurchaseWarrantsMember_639178606085007216" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PlacementAgentWarrantsMember" xlink:label="limn_PlacementAgentWarrantsMember_639178606085007759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085001357" xlink:to="limn_PlacementAgentWarrantsMember_639178606085007759" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639178606085007759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639178606085001357" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639178606085007759" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639178606085007759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639178606085007759" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639178606085007759" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_BestEffortsPublicOfferingMember" xlink:label="limn_BestEffortsPublicOfferingMember_639178606085007759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639178606085007759" xlink:to="limn_BestEffortsPublicOfferingMember_639178606085007759" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_639178606085007759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639178606085001357" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_639178606085007759" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639178606085007759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639178606085007759" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639178606085007759" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued_639178606085007759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639178606085007759" xlink:to="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued_639178606085007759" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639178606085007759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639178606085007759" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639178606085007759" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639178606085013260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639178606085007759" xlink:to="us-gaap_SharesIssuedPricePerShare_639178606085013260" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightIssuePricePerWarrant" xlink:label="limn_ClassOfWarrantOrRightIssuePricePerWarrant_639178606085014372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639178606085007759" xlink:to="limn_ClassOfWarrantOrRightIssuePricePerWarrant_639178606085014372" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639178606085015364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639178606085007759" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639178606085015364" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_639178606085016388" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639178606085007759" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_639178606085016388" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639178606085017586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639178606085007759" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639178606085017586" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_639178606085018823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639178606085007759" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_639178606085018823" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate" xlink:label="limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate_639178606085018823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639178606085007759" xlink:to="limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate_639178606085018823" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate" xlink:label="limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate_639178606085018823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639178606085007759" xlink:to="limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate_639178606085018823" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PlacementAgentCashFeePercentage" xlink:label="limn_PlacementAgentCashFeePercentage_639178606085018823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639178606085007759" xlink:to="limn_PlacementAgentCashFeePercentage_639178606085018823" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_MaximumReimbursementForPlacementAgentExpenses" xlink:label="limn_MaximumReimbursementForPlacementAgentExpenses_639178606085018823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639178606085007759" xlink:to="limn_MaximumReimbursementForPlacementAgentExpenses_639178606085018823" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PercentOfSharesIssuedInOffering" xlink:label="limn_PercentOfSharesIssuedInOffering_639178606085018823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639178606085007759" xlink:to="limn_PercentOfSharesIssuedInOffering_639178606085018823" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PercentOfOfferingPriceRepresentingExercisePrice" xlink:label="limn_PercentOfOfferingPriceRepresentingExercisePrice_639178606085018823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639178606085007759" xlink:to="limn_PercentOfOfferingPriceRepresentingExercisePrice_639178606085018823" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails" xlink:type="extended" xlink:title="1140103 - Disclosure - Description of Organization and Business Operations - Liquidity and Capital Resources (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085024468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085024468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639178606085024468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085024468" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639178606085024468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639178606085024468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639178606085024468" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639178606085024468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_BestEffortsPublicOfferingMember" xlink:label="limn_BestEffortsPublicOfferingMember_639178606085024468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639178606085024468" xlink:to="limn_BestEffortsPublicOfferingMember_639178606085024468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639178606085024468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085024468" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639178606085024468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639178606085024468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639178606085024468" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639178606085024468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PreFundedWarrantsMember" xlink:label="limn_PreFundedWarrantsMember_639178606085029687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085024468" xlink:to="limn_PreFundedWarrantsMember_639178606085029687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPurchaseWarrantsMember" xlink:label="limn_CommonStockPurchaseWarrantsMember_639178606085030215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085024468" xlink:to="limn_CommonStockPurchaseWarrantsMember_639178606085030215" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_639178606085030215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085024468" xlink:to="us-gaap_BusinessAcquisitionLineItems_639178606085030215" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_639178606085030215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085030215" xlink:to="us-gaap_Cash_639178606085030215" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606085030215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085030215" xlink:to="us-gaap_ShortTermBorrowings_639178606085030215" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639178606085030215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085030215" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639178606085030215" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639178606085030215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085030215" xlink:to="us-gaap_OperatingIncomeLoss_639178606085030215" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639178606085030215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085030215" xlink:to="us-gaap_NetIncomeLoss_639178606085030215" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639178606085030215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085030215" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639178606085030215" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued_639178606085036343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085030215" xlink:to="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued_639178606085036343" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639178606085037578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085030215" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639178606085037578" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639178606085038437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085030215" xlink:to="us-gaap_SharesIssuedPricePerShare_639178606085038437" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightIssuePricePerWarrant" xlink:label="limn_ClassOfWarrantOrRightIssuePricePerWarrant_639178606085038437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085030215" xlink:to="limn_ClassOfWarrantOrRightIssuePricePerWarrant_639178606085038437" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639178606085038437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085030215" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639178606085038437" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="1140201 - Disclosure - Significant Accounting Policies - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085038437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085038437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085038437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085038437" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085038437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085043957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085038437" xlink:to="us-gaap_RelatedPartyDomain_639178606085043957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085044714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085043957" xlink:to="us-gaap_RelatedPartyMember_639178606085044714" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_639178606085044714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyMember_639178606085044714" xlink:to="srt_ChiefExecutiveOfficerMember_639178606085044714" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639178606085044714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085038437" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639178606085044714" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639178606085044714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639178606085044714" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639178606085044714" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPurchaseWarrantsMember" xlink:label="limn_CommonStockPurchaseWarrantsMember_639178606085044714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085044714" xlink:to="limn_CommonStockPurchaseWarrantsMember_639178606085044714" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PlacementAgentWarrantsMember" xlink:label="limn_PlacementAgentWarrantsMember_639178606085044714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085044714" xlink:to="limn_PlacementAgentWarrantsMember_639178606085044714" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PublicWarrantsMember" xlink:label="limn_PublicWarrantsMember_639178606085044714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085044714" xlink:to="limn_PublicWarrantsMember_639178606085044714" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PrivatePlacementWarrantsMember" xlink:label="limn_PrivatePlacementWarrantsMember_639178606085044714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085044714" xlink:to="limn_PrivatePlacementWarrantsMember_639178606085044714" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639178606085044714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085038437" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639178606085044714" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FranchiseTaxExpenseIncludingInterestAndPenalty" xlink:label="limn_FranchiseTaxExpenseIncludingInterestAndPenalty_639178606085050395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085044714" xlink:to="limn_FranchiseTaxExpenseIncludingInterestAndPenalty_639178606085050395" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_639178606085050395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085044714" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_639178606085050395" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_639178606085050395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085044714" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_639178606085050395" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639178606085050395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085044714" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639178606085050395" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_639178606085050395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085044714" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_639178606085050395" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_639178606085050395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085044714" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_639178606085050395" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_639178606085050395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085044714" xlink:to="us-gaap_NumberOfReportableSegments_639178606085050395" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_639178606085055915" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085044714" xlink:to="us-gaap_NumberOfOperatingSegments_639178606085055915" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="extended" xlink:title="1140202 - Disclosure - Significant Accounting Policies - Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_639178606085056712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_639178606085056712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_639178606085056712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_639178606085056712" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails" xlink:type="extended" xlink:title="1140301 - Disclosure - License Agreements - CD47 License (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAgreementsAbstract" xlink:label="LicenseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085056712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085056712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_639178606085062435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085056712" xlink:to="us-gaap_TypeOfArrangementAxis_639178606085062435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639178606085063205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_639178606085062435" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639178606085063205" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember" xlink:label="limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_639178606085063522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639178606085063205" xlink:to="limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_639178606085063522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085063522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085056712" xlink:to="srt_CounterpartyNameAxis_639178606085063522" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085063522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085063522" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085063522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CurisBiotechHoldingsLlcMember" xlink:label="limn_CurisBiotechHoldingsLlcMember_639178606085063522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085063522" xlink:to="limn_CurisBiotechHoldingsLlcMember_639178606085063522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_InnobationBioCo.LtdMember" xlink:label="limn_InnobationBioCo.LtdMember_639178606085063522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085063522" xlink:to="limn_InnobationBioCo.LtdMember_639178606085063522" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="us-gaap_CapitalUnitsByClassAxis_639178606085063522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085056712" xlink:to="us-gaap_CapitalUnitsByClassAxis_639178606085063522" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="us-gaap_CapitalUnitClassDomain_639178606085063522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalUnitsByClassAxis_639178606085063522" xlink:to="us-gaap_CapitalUnitClassDomain_639178606085063522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="us-gaap_CapitalUnitClassAMember_639178606085063522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalUnitClassDomain_639178606085063522" xlink:to="us-gaap_CapitalUnitClassAMember_639178606085063522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085068998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085056712" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085068998" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfUnitsExchangeForLicenseRights" xlink:label="limn_NumberOfUnitsExchangeForLicenseRights_639178606085069966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085068998" xlink:to="limn_NumberOfUnitsExchangeForLicenseRights_639178606085069966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital" xlink:label="limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital_639178606085069966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085068998" xlink:to="limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital_639178606085069966" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PaymentForCostsAssociatedWithClinicalTrials" xlink:label="limn_PaymentForCostsAssociatedWithClinicalTrials_639178606085069966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085068998" xlink:to="limn_PaymentForCostsAssociatedWithClinicalTrials_639178606085069966" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EstimatedPercentageOfActivitiesCompleted" xlink:label="limn_EstimatedPercentageOfActivitiesCompleted_639178606085069966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085068998" xlink:to="limn_EstimatedPercentageOfActivitiesCompleted_639178606085069966" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:label="limn_PrepaidResearchAndDevelopmentExpenseCurrent_639178606085069966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085068998" xlink:to="limn_PrepaidResearchAndDevelopmentExpenseCurrent_639178606085069966" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_639178606085069966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085068998" xlink:to="us-gaap_ResearchAndDevelopmentExpense_639178606085069966" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails" xlink:type="extended" xlink:title="1140401 - Disclosure - Related Party Transactions - Feelux Bonds (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085076088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085076088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085076486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085076088" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085076486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085076486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085076486" xlink:to="us-gaap_RelatedPartyDomain_639178606085076486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085076486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085076486" xlink:to="us-gaap_RelatedPartyMember_639178606085076486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639178606085076486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085076088" xlink:to="us-gaap_DebtInstrumentAxis_639178606085076486" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639178606085076486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639178606085076486" xlink:to="us-gaap_DebtInstrumentNameDomain_639178606085076486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxBondsMember" xlink:label="limn_FeeluxBondsMember_639178606085076486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085076486" xlink:to="limn_FeeluxBondsMember_639178606085076486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085076486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085076088" xlink:to="srt_CounterpartyNameAxis_639178606085076486" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085076486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085076486" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085076486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxCo.LtdMember" xlink:label="limn_FeeluxCo.LtdMember_639178606085081666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085076486" xlink:to="limn_FeeluxCo.LtdMember_639178606085081666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639178606085082114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085076088" xlink:to="srt_RangeAxis_639178606085082114" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639178606085082114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639178606085082114" xlink:to="srt_RangeMember_639178606085082114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639178606085082114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639178606085082114" xlink:to="srt_MaximumMember_639178606085082114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_639178606085082114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085076088" xlink:to="us-gaap_MeasurementInputTypeAxis_639178606085082114" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_639178606085082114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_639178606085082114" xlink:to="us-gaap_MeasurementInputTypeDomain_639178606085082114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_639178606085082114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639178606085082114" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_639178606085082114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_639178606085082114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639178606085082114" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_639178606085082114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_639178606085087817" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639178606085082114" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_639178606085087817" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639178606085088879" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085076088" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639178606085088879" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606085089987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085088879" xlink:to="us-gaap_ShortTermBorrowings_639178606085089987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085091235" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085088879" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085091235" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_639178606085092226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085088879" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_639178606085092226" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639178606085093281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085088879" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639178606085093281" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_639178606085094044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085088879" xlink:to="us-gaap_WarrantsAndRightsOutstanding_639178606085094044" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_639178606085094044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085088879" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_639178606085094044" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_639178606085094044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085088879" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_639178606085094044" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt_639178606085094044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085088879" xlink:to="us-gaap_ProceedsFromShortTermDebt_639178606085094044" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_639178606085094044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085088879" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_639178606085094044" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_639178606085094044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085088879" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_639178606085094044" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_639178606085099832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085088879" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_639178606085099832" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_639178606085099832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085088879" xlink:to="us-gaap_ConversionOfStockSharesConverted1_639178606085099832" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits" xlink:label="limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits_639178606085099832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085088879" xlink:to="limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits_639178606085099832" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent_639178606085099832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085088879" xlink:to="limn_AccruedInterestCurrent_639178606085099832" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_639178606085099832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085088879" xlink:to="us-gaap_InterestExpenseDebt_639178606085099832" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails" xlink:type="extended" xlink:title="1140402 - Disclosure - Related Party Transactions - Car-Tcellkor Loan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085105806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085105806" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085105806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085105806" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085105806" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085105806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085105806" xlink:to="us-gaap_RelatedPartyDomain_639178606085105806" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085105806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085105806" xlink:to="us-gaap_RelatedPartyMember_639178606085105806" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639178606085105806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085105806" xlink:to="us-gaap_DebtInstrumentAxis_639178606085105806" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639178606085105806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639178606085105806" xlink:to="us-gaap_DebtInstrumentNameDomain_639178606085105806" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CarTcellkorLoanMember" xlink:label="limn_CarTcellkorLoanMember_639178606085105806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085105806" xlink:to="limn_CarTcellkorLoanMember_639178606085105806" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639178606085111334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085105806" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639178606085111334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606085112102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085111334" xlink:to="us-gaap_ShortTermBorrowings_639178606085112102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_639178606085112102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085111334" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_639178606085112102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails" xlink:type="extended" xlink:title="1140403 - Disclosure - Related Party Transactions - Valetudo Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085112102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085112102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085112102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085112102" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085112102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085112102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085112102" xlink:to="us-gaap_RelatedPartyDomain_639178606085112102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085112102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085112102" xlink:to="us-gaap_RelatedPartyMember_639178606085112102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639178606085118030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085112102" xlink:to="us-gaap_DebtInstrumentAxis_639178606085118030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639178606085118976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639178606085118030" xlink:to="us-gaap_DebtInstrumentNameDomain_639178606085118976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoLoanMember" xlink:label="limn_ValetudoLoanMember_639178606085119655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085118976" xlink:to="limn_ValetudoLoanMember_639178606085119655" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoDecember2022LoanMember" xlink:label="limn_ValetudoDecember2022LoanMember_639178606085119655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoLoanMember_639178606085119655" xlink:to="limn_ValetudoDecember2022LoanMember_639178606085119655" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJune2023LoansMember" xlink:label="limn_ValetudoJune2023LoansMember_639178606085119655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoLoanMember_639178606085119655" xlink:to="limn_ValetudoJune2023LoansMember_639178606085119655" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJune2023LoanOneMember" xlink:label="limn_ValetudoJune2023LoanOneMember_639178606085119655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoJune2023LoansMember_639178606085119655" xlink:to="limn_ValetudoJune2023LoanOneMember_639178606085119655" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJune2023LoanTwoMember" xlink:label="limn_ValetudoJune2023LoanTwoMember_639178606085119655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoJune2023LoansMember_639178606085119655" xlink:to="limn_ValetudoJune2023LoanTwoMember_639178606085119655" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJuly2023LoanMember" xlink:label="limn_ValetudoJuly2023LoanMember_639178606085119655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoLoanMember_639178606085119655" xlink:to="limn_ValetudoJuly2023LoanMember_639178606085119655" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoAugust2023LoansMember" xlink:label="limn_ValetudoAugust2023LoansMember_639178606085119655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoLoanMember_639178606085119655" xlink:to="limn_ValetudoAugust2023LoansMember_639178606085119655" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoAugust2023LoanOneMember" xlink:label="limn_ValetudoAugust2023LoanOneMember_639178606085119655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoAugust2023LoansMember_639178606085119655" xlink:to="limn_ValetudoAugust2023LoanOneMember_639178606085119655" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoAugust2023LoanTwoMember" xlink:label="limn_ValetudoAugust2023LoanTwoMember_639178606085119655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoAugust2023LoansMember_639178606085119655" xlink:to="limn_ValetudoAugust2023LoanTwoMember_639178606085119655" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoNovember2023LoanMember" xlink:label="limn_ValetudoNovember2023LoanMember_639178606085119655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoLoanMember_639178606085119655" xlink:to="limn_ValetudoNovember2023LoanMember_639178606085119655" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJanuary2024LoansMember" xlink:label="limn_ValetudoJanuary2024LoansMember_639178606085125218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoLoanMember_639178606085119655" xlink:to="limn_ValetudoJanuary2024LoansMember_639178606085125218" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJanuary2024LoanOneMember" xlink:label="limn_ValetudoJanuary2024LoanOneMember_639178606085125525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoJanuary2024LoansMember_639178606085125218" xlink:to="limn_ValetudoJanuary2024LoanOneMember_639178606085125525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJanuary2024LoanTwoMember" xlink:label="limn_ValetudoJanuary2024LoanTwoMember_639178606085125525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoJanuary2024LoansMember_639178606085125218" xlink:to="limn_ValetudoJanuary2024LoanTwoMember_639178606085125525" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085125525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085112102" xlink:to="srt_CounterpartyNameAxis_639178606085125525" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085125525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085125525" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085125525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoTherapeuticsLlcMember" xlink:label="limn_ValetudoTherapeuticsLlcMember_639178606085125525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085125525" xlink:to="limn_ValetudoTherapeuticsLlcMember_639178606085125525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639178606085125525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085112102" xlink:to="srt_RangeAxis_639178606085125525" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639178606085147109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639178606085125525" xlink:to="srt_RangeMember_639178606085147109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639178606085147510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639178606085147109" xlink:to="srt_MaximumMember_639178606085147510" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639178606085147510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085112102" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639178606085147510" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606085147510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085147510" xlink:to="us-gaap_ShortTermBorrowings_639178606085147510" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RepaymentOfMembershipInterest" xlink:label="limn_RepaymentOfMembershipInterest_639178606085147510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085147510" xlink:to="limn_RepaymentOfMembershipInterest_639178606085147510" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt_639178606085147510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085147510" xlink:to="us-gaap_RepaymentsOfShortTermDebt_639178606085147510" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085152997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085147510" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085152997" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_639178606085154391" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085147510" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_639178606085154391" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent_639178606085155547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085147510" xlink:to="limn_AccruedInterestCurrent_639178606085155547" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_639178606085156679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085147510" xlink:to="us-gaap_InterestExpenseDebt_639178606085156679" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails" xlink:type="extended" xlink:title="1140404 - Disclosure - Related Party Transactions - Ewon Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085160454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085160454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085160454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085160454" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085160454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085160454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085160454" xlink:to="us-gaap_RelatedPartyDomain_639178606085160454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085160454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085160454" xlink:to="us-gaap_RelatedPartyMember_639178606085160454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639178606085160454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085160454" xlink:to="us-gaap_DebtInstrumentAxis_639178606085160454" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639178606085160454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639178606085160454" xlink:to="us-gaap_DebtInstrumentNameDomain_639178606085160454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonLoanMember" xlink:label="limn_EwonLoanMember_639178606085160454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085160454" xlink:to="limn_EwonLoanMember_639178606085160454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonDecember2022LoanMember" xlink:label="limn_EwonDecember2022LoanMember_639178606085160454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_EwonLoanMember_639178606085160454" xlink:to="limn_EwonDecember2022LoanMember_639178606085160454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonSeptember2023LoanMember" xlink:label="limn_EwonSeptember2023LoanMember_639178606085160454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_EwonLoanMember_639178606085160454" xlink:to="limn_EwonSeptember2023LoanMember_639178606085160454" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonDecember2023LoanMember" xlink:label="limn_EwonDecember2023LoanMember_639178606085165996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_EwonLoanMember_639178606085160454" xlink:to="limn_EwonDecember2023LoanMember_639178606085165996" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085166479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085160454" xlink:to="srt_CounterpartyNameAxis_639178606085166479" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085166479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085166479" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085166479" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonComfortechCoLtdMember" xlink:label="limn_EwonComfortechCoLtdMember_639178606085166479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085166479" xlink:to="limn_EwonComfortechCoLtdMember_639178606085166479" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639178606085166479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085160454" xlink:to="srt_RangeAxis_639178606085166479" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639178606085166479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639178606085166479" xlink:to="srt_RangeMember_639178606085166479" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639178606085166479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639178606085166479" xlink:to="srt_MaximumMember_639178606085166479" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639178606085166479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085160454" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639178606085166479" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606085166479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085166479" xlink:to="us-gaap_ShortTermBorrowings_639178606085166479" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085172414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085166479" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085172414" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt_639178606085172960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085166479" xlink:to="us-gaap_RepaymentsOfShortTermDebt_639178606085172960" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_639178606085172960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085166479" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_639178606085172960" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent_639178606085172960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085166479" xlink:to="limn_AccruedInterestCurrent_639178606085172960" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_639178606085172960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085166479" xlink:to="us-gaap_InterestExpenseDebt_639178606085172960" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails" xlink:type="extended" xlink:title="1140405 - Disclosure - Related Party Transactions - Prophase Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085178457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085178457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085178457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085178457" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085178457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085178457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085178457" xlink:to="us-gaap_RelatedPartyDomain_639178606085178457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085178457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085178457" xlink:to="us-gaap_RelatedPartyMember_639178606085178457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639178606085178457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085178457" xlink:to="us-gaap_DebtInstrumentAxis_639178606085178457" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639178606085178457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639178606085178457" xlink:to="us-gaap_DebtInstrumentNameDomain_639178606085178457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseLoanMember" xlink:label="limn_ProphaseLoanMember_639178606085178457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085178457" xlink:to="limn_ProphaseLoanMember_639178606085178457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseFebruary2024LoanMember" xlink:label="limn_ProphaseFebruary2024LoanMember_639178606085178457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ProphaseLoanMember_639178606085178457" xlink:to="limn_ProphaseFebruary2024LoanMember_639178606085178457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMarch2024LoanMember" xlink:label="limn_ProphaseMarch2024LoanMember_639178606085178457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ProphaseLoanMember_639178606085178457" xlink:to="limn_ProphaseMarch2024LoanMember_639178606085178457" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseApril2024LoanMember" xlink:label="limn_ProphaseApril2024LoanMember_639178606085183957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ProphaseLoanMember_639178606085178457" xlink:to="limn_ProphaseApril2024LoanMember_639178606085183957" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMay2024LoansMember" xlink:label="limn_ProphaseMay2024LoansMember_639178606085184402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ProphaseLoanMember_639178606085178457" xlink:to="limn_ProphaseMay2024LoansMember_639178606085184402" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseJuly2024LoansMember" xlink:label="limn_ProphaseJuly2024LoansMember_639178606085185115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ProphaseLoanMember_639178606085178457" xlink:to="limn_ProphaseJuly2024LoansMember_639178606085185115" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseAugust2024LoansMember" xlink:label="limn_ProphaseAugust2024LoansMember_639178606085185810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ProphaseLoanMember_639178606085178457" xlink:to="limn_ProphaseAugust2024LoansMember_639178606085185810" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseFebruary2025LoansMember" xlink:label="limn_ProphaseFebruary2025LoansMember_639178606085186507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ProphaseLoanMember_639178606085178457" xlink:to="limn_ProphaseFebruary2025LoansMember_639178606085186507" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMarch2025LoansMember" xlink:label="limn_ProphaseMarch2025LoansMember_639178606085187228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ProphaseLoanMember_639178606085178457" xlink:to="limn_ProphaseMarch2025LoansMember_639178606085187228" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseApril2025LoansMember" xlink:label="limn_ProphaseApril2025LoansMember_639178606085187955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ProphaseLoanMember_639178606085178457" xlink:to="limn_ProphaseApril2025LoansMember_639178606085187955" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085188638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085178457" xlink:to="srt_CounterpartyNameAxis_639178606085188638" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085188638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085188638" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085188638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseSciencesLlcMember" xlink:label="limn_ProphaseSciencesLlcMember_639178606085188638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085188638" xlink:to="limn_ProphaseSciencesLlcMember_639178606085188638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639178606085188638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085178457" xlink:to="srt_RangeAxis_639178606085188638" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639178606085188638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639178606085188638" xlink:to="srt_RangeMember_639178606085188638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639178606085188638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639178606085188638" xlink:to="srt_MaximumMember_639178606085188638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639178606085188638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085178457" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639178606085188638" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606085194588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085188638" xlink:to="us-gaap_ShortTermBorrowings_639178606085194588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085195794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085188638" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085195794" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_639178606085196960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085188638" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_639178606085196960" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent_639178606085198163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085188638" xlink:to="limn_AccruedInterestCurrent_639178606085198163" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_639178606085199355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085188638" xlink:to="us-gaap_InterestExpenseDebt_639178606085199355" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails" xlink:type="extended" xlink:title="1140406 - Disclosure - Related Party Transactions - Hana Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085199355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085199355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085199355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085199355" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085199355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085199355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085199355" xlink:to="us-gaap_RelatedPartyDomain_639178606085199355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085199355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085199355" xlink:to="us-gaap_RelatedPartyMember_639178606085199355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639178606085204824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085199355" xlink:to="us-gaap_DebtInstrumentAxis_639178606085204824" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639178606085204824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639178606085204824" xlink:to="us-gaap_DebtInstrumentNameDomain_639178606085204824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_HanaLoansMember" xlink:label="limn_HanaLoansMember_639178606085204824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085204824" xlink:to="limn_HanaLoansMember_639178606085204824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_HanaAugust2024LoansMember" xlink:label="limn_HanaAugust2024LoansMember_639178606085204824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_HanaLoansMember_639178606085204824" xlink:to="limn_HanaAugust2024LoansMember_639178606085204824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639178606085204824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085199355" xlink:to="srt_RangeAxis_639178606085204824" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639178606085204824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639178606085204824" xlink:to="srt_RangeMember_639178606085204824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639178606085204824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639178606085204824" xlink:to="srt_MaximumMember_639178606085204824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085204824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085199355" xlink:to="srt_CounterpartyNameAxis_639178606085204824" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085204824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085204824" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085204824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_HanaImmunotherapeuticsLlcMember" xlink:label="limn_HanaImmunotherapeuticsLlcMember_639178606085210659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085204824" xlink:to="limn_HanaImmunotherapeuticsLlcMember_639178606085210659" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639178606085211220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085199355" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639178606085211220" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606085211220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085211220" xlink:to="us-gaap_ShortTermBorrowings_639178606085211220" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085211220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085211220" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085211220" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_639178606085211220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085211220" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_639178606085211220" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent_639178606085211220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085211220" xlink:to="limn_AccruedInterestCurrent_639178606085211220" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_639178606085211220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085211220" xlink:to="us-gaap_InterestExpenseDebt_639178606085211220" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails" xlink:type="extended" xlink:title="1140407 - Disclosure - Related Party Transactions - Amantes Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085216998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085216998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085216998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085216998" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085216998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085216998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085216998" xlink:to="us-gaap_RelatedPartyDomain_639178606085216998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085216998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085216998" xlink:to="us-gaap_RelatedPartyMember_639178606085216998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639178606085216998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085216998" xlink:to="us-gaap_DebtInstrumentAxis_639178606085216998" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639178606085216998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639178606085216998" xlink:to="us-gaap_DebtInstrumentNameDomain_639178606085216998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesLoansMember" xlink:label="limn_AmantesLoansMember_639178606085216998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085216998" xlink:to="limn_AmantesLoansMember_639178606085216998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesNovember2024LoansMember" xlink:label="limn_AmantesNovember2024LoansMember_639178606085222225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_AmantesLoansMember_639178606085216998" xlink:to="limn_AmantesNovember2024LoansMember_639178606085222225" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesJanuary2025LoansMember" xlink:label="limn_AmantesJanuary2025LoansMember_639178606085222225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_AmantesLoansMember_639178606085216998" xlink:to="limn_AmantesJanuary2025LoansMember_639178606085222225" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639178606085222836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085216998" xlink:to="srt_RangeAxis_639178606085222836" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639178606085223457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639178606085222836" xlink:to="srt_RangeMember_639178606085223457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639178606085223457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639178606085223457" xlink:to="srt_MaximumMember_639178606085223457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085223457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085216998" xlink:to="srt_CounterpartyNameAxis_639178606085223457" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085223457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085223457" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085223457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesLlcMember" xlink:label="limn_AmantesLlcMember_639178606085223457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085223457" xlink:to="limn_AmantesLlcMember_639178606085223457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639178606085223457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085216998" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639178606085223457" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606085223457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085223457" xlink:to="us-gaap_ShortTermBorrowings_639178606085223457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085228689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085223457" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085228689" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_639178606085229802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085223457" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_639178606085229802" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent_639178606085229802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085223457" xlink:to="limn_AccruedInterestCurrent_639178606085229802" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_639178606085229802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085223457" xlink:to="us-gaap_InterestExpenseDebt_639178606085229802" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails" xlink:type="extended" xlink:title="1140408 - Disclosure - Related Party Transactions - Due to Related Party (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085229802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085229802" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085229802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085229802" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085229802" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085235001" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085229802" xlink:to="us-gaap_RelatedPartyDomain_639178606085235001" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085235433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085235001" xlink:to="us-gaap_RelatedPartyMember_639178606085235433" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_639178606085235433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085229802" xlink:to="us-gaap_FinancialInstrumentAxis_639178606085235433" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639178606085235433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_639178606085235433" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639178606085235433" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EmploymentAgreementMember" xlink:label="limn_EmploymentAgreementMember_639178606085235433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639178606085235433" xlink:to="limn_EmploymentAgreementMember_639178606085235433" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639178606085235433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085229802" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639178606085235433" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_639178606085235433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085235433" xlink:to="us-gaap_OtherLiabilitiesCurrent_639178606085235433" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDebtDetails" xlink:type="extended" xlink:title="1140501 - Disclosure - Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_639178606085241182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_639178606085241182" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639178606085241182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_639178606085241182" xlink:to="us-gaap_DebtInstrumentAxis_639178606085241182" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639178606085241182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639178606085241182" xlink:to="us-gaap_DebtInstrumentNameDomain_639178606085241182" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJune2023LoansMember" xlink:label="limn_ValetudoJune2023LoansMember_639178606085241182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085241182" xlink:to="limn_ValetudoJune2023LoansMember_639178606085241182" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJuly2023LoanMember" xlink:label="limn_ValetudoJuly2023LoanMember_639178606085241182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085241182" xlink:to="limn_ValetudoJuly2023LoanMember_639178606085241182" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseFebruary2024LoanMember" xlink:label="limn_ProphaseFebruary2024LoanMember_639178606085241182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085241182" xlink:to="limn_ProphaseFebruary2024LoanMember_639178606085241182" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMarch2024LoanMember" xlink:label="limn_ProphaseMarch2024LoanMember_639178606085241182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085241182" xlink:to="limn_ProphaseMarch2024LoanMember_639178606085241182" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMay2024LoansMember" xlink:label="limn_ProphaseMay2024LoansMember_639178606085241182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085241182" xlink:to="limn_ProphaseMay2024LoansMember_639178606085241182" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseJuly2024LoansMember" xlink:label="limn_ProphaseJuly2024LoansMember_639178606085241182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085241182" xlink:to="limn_ProphaseJuly2024LoansMember_639178606085241182" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseAugust2024LoansMember" xlink:label="limn_ProphaseAugust2024LoansMember_639178606085246430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085241182" xlink:to="limn_ProphaseAugust2024LoansMember_639178606085246430" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_HanaAugust2024LoansMember" xlink:label="limn_HanaAugust2024LoansMember_639178606085246999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085241182" xlink:to="limn_HanaAugust2024LoansMember_639178606085246999" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesNovember2024LoansMember" xlink:label="limn_AmantesNovember2024LoansMember_639178606085247581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085241182" xlink:to="limn_AmantesNovember2024LoansMember_639178606085247581" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesJanuary2025LoansMember" xlink:label="limn_AmantesJanuary2025LoansMember_639178606085248100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085241182" xlink:to="limn_AmantesJanuary2025LoansMember_639178606085248100" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseFebruary2025LoanMember" xlink:label="limn_ProphaseFebruary2025LoanMember_639178606085248100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085241182" xlink:to="limn_ProphaseFebruary2025LoanMember_639178606085248100" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMarch2025LoanMember" xlink:label="limn_ProphaseMarch2025LoanMember_639178606085248100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085241182" xlink:to="limn_ProphaseMarch2025LoanMember_639178606085248100" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoDecember2022LoansMember" xlink:label="limn_ValetudoDecember2022LoansMember_639178606085248100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085241182" xlink:to="limn_ValetudoDecember2022LoansMember_639178606085248100" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085248100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_639178606085241182" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085248100" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085248100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085248100" xlink:to="us-gaap_RelatedPartyDomain_639178606085248100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085248100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085248100" xlink:to="us-gaap_RelatedPartyMember_639178606085248100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems_639178606085253331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_639178606085241182" xlink:to="us-gaap_ShortTermDebtLineItems_639178606085253331" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606085254373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_639178606085253331" xlink:to="us-gaap_ShortTermBorrowings_639178606085254373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails" xlink:type="extended" xlink:title="1140601 - Disclosure - Stockholder's Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_639178606085254373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_639178606085254373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639178606085254373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639178606085254373" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639178606085254373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639178606085254373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639178606085254373" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639178606085254373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PublicWarrantsMember" xlink:label="limn_PublicWarrantsMember_639178606085254373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085254373" xlink:to="limn_PublicWarrantsMember_639178606085254373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PrivatePlacementWarrantsMember" xlink:label="limn_PrivatePlacementWarrantsMember_639178606085259609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085254373" xlink:to="limn_PrivatePlacementWarrantsMember_639178606085259609" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PreFundedWarrantsMember" xlink:label="limn_PreFundedWarrantsMember_639178606085260123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085254373" xlink:to="limn_PreFundedWarrantsMember_639178606085260123" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPurchaseWarrantsMember" xlink:label="limn_CommonStockPurchaseWarrantsMember_639178606085260644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085254373" xlink:to="limn_CommonStockPurchaseWarrantsMember_639178606085260644" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PlacementAgentWarrantsMember" xlink:label="limn_PlacementAgentWarrantsMember_639178606085260644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085254373" xlink:to="limn_PlacementAgentWarrantsMember_639178606085260644" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockAndPreFundedWarrantsMember" xlink:label="limn_CommonStockAndPreFundedWarrantsMember_639178606085260644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085254373" xlink:to="limn_CommonStockAndPreFundedWarrantsMember_639178606085260644" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085260644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639178606085254373" xlink:to="srt_CounterpartyNameAxis_639178606085260644" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085260644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085260644" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085260644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AltaPartnersLlcMember" xlink:label="limn_AltaPartnersLlcMember_639178606085260644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085260644" xlink:to="limn_AltaPartnersLlcMember_639178606085260644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClearStreetLlcMember" xlink:label="limn_ClearStreetLlcMember_639178606085260644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085260644" xlink:to="limn_ClearStreetLlcMember_639178606085260644" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639178606085260644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639178606085254373" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639178606085260644" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639178606085265876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639178606085260644" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639178606085265876" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_BestEffortsPublicOfferingMember" xlink:label="limn_BestEffortsPublicOfferingMember_639178606085266386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639178606085265876" xlink:to="limn_BestEffortsPublicOfferingMember_639178606085266386" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639178606085254373" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_639178606085266386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="us-gaap_PreferredStockSharesAuthorized_639178606085266386" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_639178606085266386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="us-gaap_CommonStockSharesAuthorized_639178606085266386" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_639178606085266386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_639178606085266386" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_639178606085266386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="us-gaap_PreferredStockSharesOutstanding_639178606085266386" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_639178606085266386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_639178606085266386" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesIssuedForSurrenderAndCancellationOfWarrants" xlink:label="limn_SharesIssuedForSurrenderAndCancellationOfWarrants_639178606085272131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="limn_SharesIssuedForSurrenderAndCancellationOfWarrants_639178606085272131" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" xlink:label="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled_639178606085272131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled_639178606085272131" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonStockIssued" xlink:label="limn_FairValueOfCommonStockIssued_639178606085272131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="limn_FairValueOfCommonStockIssued_639178606085272131" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfWarrantsSurrendered" xlink:label="limn_FairValueOfWarrantsSurrendered_639178606085272131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="limn_FairValueOfWarrantsSurrendered_639178606085272131" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_GainLossOnIssuanceOfCommonStockForWarrants" xlink:label="limn_GainLossOnIssuanceOfCommonStockForWarrants_639178606085272131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="limn_GainLossOnIssuanceOfCommonStockForWarrants_639178606085272131" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination_639178606085272131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination_639178606085272131" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuableForSettlementOfDeferredUnderwritingFees" xlink:label="limn_StockIssuableForSettlementOfDeferredUnderwritingFees_639178606085272131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="limn_StockIssuableForSettlementOfDeferredUnderwritingFees_639178606085272131" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" xlink:label="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees_639178606085277795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees_639178606085277795" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639178606085277795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639178606085277795" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued_639178606085277795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued_639178606085277795" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions_639178606085277795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="limn_ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions_639178606085277795" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_639178606085277795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="us-gaap_SharePrice_639178606085277795" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639178606085277795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639178606085277795" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639178606085283084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="us-gaap_SharesIssuedPricePerShare_639178606085283084" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightIssuePricePerWarrant" xlink:label="limn_ClassOfWarrantOrRightIssuePricePerWarrant_639178606085283656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="limn_ClassOfWarrantOrRightIssuePricePerWarrant_639178606085283656" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsExercised_639178606085283656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="limn_ClassOfWarrantOrRightNumberOfWarrantsExercised_639178606085283656" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_639178606085283656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="us-gaap_CommonStockSharesOutstanding_639178606085283656" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_639178606085283656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="us-gaap_CommonStockSharesIssued_639178606085283656" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockNumberOfVotesPerShare" xlink:label="limn_CommonStockNumberOfVotesPerShare_639178606085283656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="limn_CommonStockNumberOfVotesPerShare_639178606085283656" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_639178606085289484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_639178606085289484" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639178606085289993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639178606085289993" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants" xlink:label="limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants_639178606085289993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants_639178606085289993" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption" xlink:label="limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption_639178606085289993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption_639178606085289993" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_639178606085289993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_639178606085289993" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_639178606085295206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_639178606085295206" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_639178606085295739" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085266386" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_639178606085295739" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails" xlink:type="extended" xlink:title="1140602 - Disclosure - Stockholder's Equity - Assumptions used for estimating fair value of warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_639178606085295739" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_639178606085295739" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_639178606085295739" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_639178606085295739" xlink:to="us-gaap_MeasurementInputTypeAxis_639178606085295739" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_639178606085301070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_639178606085295739" xlink:to="us-gaap_MeasurementInputTypeDomain_639178606085301070" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_639178606085302205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639178606085301070" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_639178606085302205" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_639178606085302621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639178606085301070" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_639178606085302621" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_639178606085302621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639178606085301070" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_639178606085302621" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_639178606085302621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639178606085301070" xlink:to="us-gaap_MeasurementInputExpectedTermMember_639178606085302621" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639178606085302621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_639178606085295739" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639178606085302621" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639178606085302621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639178606085302621" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639178606085302621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockWarrantsAndPlacementAgentWarrantsMember" xlink:label="limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_639178606085302621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085302621" xlink:to="limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_639178606085302621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_639178606085302621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_639178606085295739" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_639178606085302621" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_639178606085302621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_639178606085302621" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_639178606085302621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails" xlink:type="extended" xlink:title="1140603 - Disclosure - Stockholder's Equity - Offering proceeds and related issuance costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_639178606085309005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_639178606085309005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_639178606085309005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639178606085309005" xlink:to="us-gaap_StatementEquityComponentsAxis_639178606085309005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_639178606085309005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639178606085309005" xlink:to="us-gaap_EquityComponentDomain_639178606085309005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_639178606085309005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_639178606085309005" xlink:to="us-gaap_CommonStockMember_639178606085309005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639178606085309005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639178606085309005" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639178606085309005" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639178606085309005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639178606085309005" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639178606085309005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockWarrantsMember" xlink:label="limn_CommonStockWarrantsMember_639178606085309005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085309005" xlink:to="limn_CommonStockWarrantsMember_639178606085309005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PreFundedWarrantsMember" xlink:label="limn_PreFundedWarrantsMember_639178606085309005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085309005" xlink:to="limn_PreFundedWarrantsMember_639178606085309005" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PlacementAgentWarrantsMember" xlink:label="limn_PlacementAgentWarrantsMember_639178606085314354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085309005" xlink:to="limn_PlacementAgentWarrantsMember_639178606085314354" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_639178606085315395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639178606085309005" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_639178606085315395" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_GrossProceedsFromIssuanceOfWarrants" xlink:label="limn_GrossProceedsFromIssuanceOfWarrants_639178606085315395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085315395" xlink:to="limn_GrossProceedsFromIssuanceOfWarrants_639178606085315395" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_OfferingCosts" xlink:label="limn_OfferingCosts_639178606085315395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085315395" xlink:to="limn_OfferingCosts_639178606085315395" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NetProceedsFromIssuanceOfWarrants" xlink:label="limn_NetProceedsFromIssuanceOfWarrants_639178606085315395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085315395" xlink:to="limn_NetProceedsFromIssuanceOfWarrants_639178606085315395" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="1140701 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_639178606085315395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_639178606085315395" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_639178606085315395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_639178606085315395" xlink:to="us-gaap_FinancialInstrumentAxis_639178606085315395" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639178606085321175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_639178606085315395" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639178606085321175" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeReductionAgreementMember" xlink:label="limn_FeeReductionAgreementMember_639178606085321175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639178606085321175" xlink:to="limn_FeeReductionAgreementMember_639178606085321175" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_639178606085321175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_639178606085315395" xlink:to="dei_LegalEntityAxis_639178606085321175" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_639178606085321175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_639178606085321175" xlink:to="dei_EntityDomain_639178606085321175" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IrisAcquisitionCorpMember" xlink:label="limn_IrisAcquisitionCorpMember_639178606085321175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_639178606085321175" xlink:to="limn_IrisAcquisitionCorpMember_639178606085321175" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085321175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_639178606085315395" xlink:to="srt_CounterpartyNameAxis_639178606085321175" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085321175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085321175" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085321175" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClearStreetLlcMember" xlink:label="limn_ClearStreetLlcMember_639178606085321175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085321175" xlink:to="limn_ClearStreetLlcMember_639178606085321175" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_639178606085315395" xlink:to="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_639178606085327021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="us-gaap_ShortTermLeaseCost_639178606085327021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesIssuedForSurrenderAndCancellationOfWarrants" xlink:label="limn_SharesIssuedForSurrenderAndCancellationOfWarrants_639178606085327021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_SharesIssuedForSurrenderAndCancellationOfWarrants_639178606085327021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" xlink:label="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled_639178606085327021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled_639178606085327021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPayable" xlink:label="limn_CommonStockPayable_639178606085327021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_CommonStockPayable_639178606085327021" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="us-gaap_LossContingencyDamagesAwardedValue_639178606085327021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="us-gaap_LossContingencyDamagesAwardedValue_639178606085327021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementInterest" xlink:label="us-gaap_LitigationSettlementInterest_639178606085327021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="us-gaap_LitigationSettlementInterest_639178606085327021" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" xlink:label="limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering_639178606085327021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering_639178606085327021" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnderwritingCostsNoncurrent" xlink:label="limn_UnderwritingCostsNoncurrent_639178606085327021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_UnderwritingCostsNoncurrent_639178606085327021" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" xlink:label="limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering_639178606085332266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering_639178606085332266" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredOfferingCostsNoncurrent" xlink:label="limn_DeferredOfferingCostsNoncurrent_639178606085332266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_DeferredOfferingCostsNoncurrent_639178606085332266" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PaymentOfOfferingCostsInCash" xlink:label="limn_PaymentOfOfferingCostsInCash_639178606085332266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_PaymentOfOfferingCostsInCash_639178606085332266" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnderwritingDiscountPaidInSecurities" xlink:label="limn_UnderwritingDiscountPaidInSecurities_639178606085332266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_UnderwritingDiscountPaidInSecurities_639178606085332266" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_MaximumNumbersOfSharesIssuable" xlink:label="limn_MaximumNumbersOfSharesIssuable_639178606085335095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_MaximumNumbersOfSharesIssuable_639178606085335095" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination_639178606085335095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination_639178606085335095" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination_639178606085335095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination_639178606085335095" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination_639178606085335095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination_639178606085335095" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination_639178606085335095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination_639178606085335095" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering" xlink:label="limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering_639178606085335095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering_639178606085335095" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination" xlink:label="limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination_639178606085340816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination_639178606085340816" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableInCashCurrent" xlink:label="limn_DeferredUnderwritingFeesPayableInCashCurrent_639178606085340816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_DeferredUnderwritingFeesPayableInCashCurrent_639178606085340816" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination_639178606085340816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination_639178606085340816" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuableForSettlementOfDeferredUnderwritingFees" xlink:label="limn_StockIssuableForSettlementOfDeferredUnderwritingFees_639178606085342979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_StockIssuableForSettlementOfDeferredUnderwritingFees_639178606085342979" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" xlink:label="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees_639178606085342979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085326369" xlink:to="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees_639178606085342979" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="1140801 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639178606085342979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639178606085342979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_639178606085342979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639178606085342979" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_639178606085342979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_639178606085348209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_639178606085342979" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_639178606085348209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_639178606085348209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_639178606085348209" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_639178606085348209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639178606085348209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639178606085342979" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639178606085348209" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_639178606085348209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639178606085348209" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_639178606085348209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details" xlink:type="extended" xlink:title="1140802 - Disclosure - Fair Value Measurements - Changes in fair value of Level 3 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639178606085348209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639178606085348209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_639178606085348209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639178606085348209" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_639178606085348209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639178606085353845" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_639178606085348209" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639178606085353845" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_639178606085354565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639178606085353845" xlink:to="us-gaap_FairValueInputsLevel3Member_639178606085354565" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_639178606085355097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639178606085348209" xlink:to="us-gaap_FinancialInstrumentAxis_639178606085355097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639178606085355097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_639178606085355097" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639178606085355097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_639178606085355097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639178606085355097" xlink:to="us-gaap_WarrantMember_639178606085355097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639178606085355097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639178606085348209" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639178606085355097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_639178606085355097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639178606085355097" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_639178606085355097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_639178606085355097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639178606085355097" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_639178606085355097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_639178606085355097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639178606085355097" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_639178606085355097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6391786060853550971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639178606085355097" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6391786060853550971" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="1200100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639178606085361996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_639178606085361996" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085361996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639178606085361996" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085361996" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085361996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085361996" xlink:to="us-gaap_RelatedPartyDomain_639178606085361996" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember_639178606085361996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085361996" xlink:to="us-gaap_NonrelatedPartyMember_639178606085361996" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085361996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085361996" xlink:to="us-gaap_RelatedPartyMember_639178606085361996" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639178606085361996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639178606085361996" xlink:to="us-gaap_StatementLineItems_639178606085361996" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_639178606085361996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606085361996" xlink:to="us-gaap_AssetsAbstract_639178606085361996" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_639178606085367227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639178606085361996" xlink:to="us-gaap_AssetsCurrentAbstract_639178606085367227" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_639178606085368310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639178606085367227" xlink:to="us-gaap_Cash_639178606085368310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_639178606085368310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639178606085367227" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_639178606085368310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent_639178606085368310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639178606085367227" xlink:to="us-gaap_DeferredCostsCurrent_639178606085368310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639178606085368310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639178606085367227" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639178606085368310" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_639178606085368310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639178606085367227" xlink:to="us-gaap_AssetsCurrent_639178606085368310" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_639178606085368310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639178606085361996" xlink:to="us-gaap_AssetsNoncurrentAbstract_639178606085368310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent_639178606085368310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_639178606085368310" xlink:to="us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent_639178606085368310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_639178606085373528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_639178606085368310" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_639178606085373528" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_639178606085374065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_639178606085368310" xlink:to="us-gaap_AssetsNoncurrent_639178606085374065" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_639178606085374065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639178606085361996" xlink:to="us-gaap_Assets_639178606085374065" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639178606085374065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606085361996" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639178606085374065" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_639178606085374065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639178606085374065" xlink:to="us-gaap_LiabilitiesCurrentAbstract_639178606085374065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_639178606085374065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639178606085374065" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_639178606085374065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent_639178606085374065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639178606085374065" xlink:to="limn_AccruedInterestCurrent_639178606085374065" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedMaintenanceFeeCurrent" xlink:label="limn_AccruedMaintenanceFeeCurrent_639178606085379263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639178606085374065" xlink:to="limn_AccruedMaintenanceFeeCurrent_639178606085379263" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_639178606085379798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639178606085374065" xlink:to="us-gaap_OtherLiabilitiesCurrent_639178606085379798" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606085379798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639178606085374065" xlink:to="us-gaap_ShortTermBorrowings_639178606085379798" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableInCashCurrent" xlink:label="limn_DeferredUnderwritingFeesPayableInCashCurrent_639178606085379798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639178606085374065" xlink:to="limn_DeferredUnderwritingFeesPayableInCashCurrent_639178606085379798" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPayable" xlink:label="limn_CommonStockPayable_639178606085379798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639178606085374065" xlink:to="limn_CommonStockPayable_639178606085379798" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_639178606085409472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639178606085374065" xlink:to="us-gaap_LiabilitiesCurrent_639178606085409472" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_639178606085411121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639178606085374065" xlink:to="us-gaap_WarrantsAndRightsOutstanding_639178606085411121" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_639178606085411597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639178606085374065" xlink:to="us-gaap_Liabilities_639178606085411597" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_639178606085411597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639178606085374065" xlink:to="us-gaap_CommitmentsAndContingencies_639178606085411597" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_639178606085411597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639178606085374065" xlink:to="us-gaap_StockholdersEquityAbstract_639178606085411597" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_639178606085411597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639178606085411597" xlink:to="us-gaap_PreferredStockValue_639178606085411597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_639178606085411597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639178606085411597" xlink:to="us-gaap_CommonStockValue_639178606085411597" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_639178606085416825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639178606085411597" xlink:to="us-gaap_AdditionalPaidInCapital_639178606085416825" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639178606085417951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639178606085411597" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639178606085417951" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639178606085417951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639178606085411597" xlink:to="us-gaap_StockholdersEquity_639178606085417951" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_639178606085417951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639178606085374065" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_639178606085417951" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals" xlink:type="extended" xlink:title="1200105 - Statement - Consolidated Balance Sheets (Parentheticals)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_639178606085423669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_639178606085423669" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_639178606085423669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_639178606085423669" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_639178606085423669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_639178606085423669" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_639178606085423669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_639178606085423669" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_639178606085423669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_639178606085423669" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_639178606085423669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_639178606085423669" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_639178606085423669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_639178606085423669" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockShareOutstanding" xlink:label="limn_CommonStockShareOutstanding_639178606085423669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="limn_CommonStockShareOutstanding_639178606085423669" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="1200200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_639178606085429930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense_639178606085429930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_639178606085429930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense_639178606085429930" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_639178606085429930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses_639178606085429930" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639178606085429930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_639178606085429930" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_639178606085429930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_639178606085429930" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_639178606085429930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639178606085429930" xlink:to="us-gaap_InterestExpenseNonoperating_639178606085429930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_639178606085429930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639178606085429930" xlink:to="us-gaap_InvestmentIncomeInterest_639178606085429930" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ForgivenessOfUnrelatedVendorPayable" xlink:label="limn_ForgivenessOfUnrelatedVendorPayable_639178606085435604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639178606085429930" xlink:to="limn_ForgivenessOfUnrelatedVendorPayable_639178606085435604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue" xlink:label="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_639178606085435604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639178606085429930" xlink:to="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_639178606085435604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639178606085435604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639178606085429930" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639178606085435604" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_GainLossOnIssuanceOfCommonStockForWarrants" xlink:label="limn_GainLossOnIssuanceOfCommonStockForWarrants_639178606085435604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639178606085429930" xlink:to="limn_GainLossOnIssuanceOfCommonStockForWarrants_639178606085435604" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonStockIssuanceForContingentLiability" xlink:label="limn_FairValueOfCommonStockIssuanceForContingentLiability_639178606085435604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639178606085429930" xlink:to="limn_FairValueOfCommonStockIssuanceForContingentLiability_639178606085435604" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_639178606085435604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639178606085429930" xlink:to="us-gaap_NonoperatingIncomeExpense_639178606085435604" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639178606085435604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_639178606085435604" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639178606085435604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639178606085435604" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639178606085440802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639178606085440802" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_639178606085441364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_639178606085441364" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_639178606085441945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_639178606085441945" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" xlink:type="extended" xlink:title="1200300 - Statement - Consolidated Statements of Changes in Stockholder's Deficit" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639178606085441945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_639178606085441945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_639178606085441945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639178606085441945" xlink:to="us-gaap_StatementEquityComponentsAxis_639178606085441945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_639178606085441945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639178606085441945" xlink:to="us-gaap_CommonStockMember_639178606085441945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_639178606085441945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639178606085441945" xlink:to="us-gaap_AdditionalPaidInCapitalMember_639178606085441945" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_639178606085447630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639178606085441945" xlink:to="us-gaap_RetainedEarningsMember_639178606085447630" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_639178606085447630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639178606085441945" xlink:to="us-gaap_EquityComponentDomain_639178606085447630" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639178606085447630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639178606085441945" xlink:to="us-gaap_StatementLineItems_639178606085447630" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639178606085447630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606085447630" xlink:to="us-gaap_StockholdersEquity_639178606085447630" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_639178606085447630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606085447630" xlink:to="us-gaap_CommonStockSharesIssued_639178606085447630" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodValueBusinessCombination" xlink:label="limn_StockIssuedDuringPeriodValueBusinessCombination_639178606085447630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606085447630" xlink:to="limn_StockIssuedDuringPeriodValueBusinessCombination_639178606085447630" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodSharesBusinessCombination" xlink:label="limn_StockIssuedDuringPeriodSharesBusinessCombination_639178606085447630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606085447630" xlink:to="limn_StockIssuedDuringPeriodSharesBusinessCombination_639178606085447630" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans" xlink:label="limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans_639178606085447630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606085447630" xlink:to="limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans_639178606085447630" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_639178606085452814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606085447630" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_639178606085452814" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_639178606085453302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606085447630" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_639178606085453302" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_639178606085453302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606085447630" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_639178606085453302" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639178606085453302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606085447630" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639178606085453302" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedPeriodValueOfCommonStockToUnderwriter" xlink:label="limn_StockIssuedPeriodValueOfCommonStockToUnderwriter_639178606085453302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606085447630" xlink:to="limn_StockIssuedPeriodValueOfCommonStockToUnderwriter_639178606085453302" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedPeriodOfCommonStockToUnderwriter" xlink:label="limn_StockIssuedPeriodOfCommonStockToUnderwriter_639178606085453302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606085447630" xlink:to="limn_StockIssuedPeriodOfCommonStockToUnderwriter_639178606085453302" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants" xlink:label="limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants_639178606085453302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606085447630" xlink:to="limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants_639178606085453302" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesIssuedForSurrenderAndCancellationOfWarrants" xlink:label="limn_SharesIssuedForSurrenderAndCancellationOfWarrants_639178606085453302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606085447630" xlink:to="limn_SharesIssuedForSurrenderAndCancellationOfWarrants_639178606085453302" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639178606085458570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606085447630" xlink:to="us-gaap_NetIncomeLoss_639178606085458570" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639178606085459829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606085447630" xlink:to="us-gaap_StockholdersEquity_639178606085459829" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_639178606085460853" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639178606085447630" xlink:to="us-gaap_CommonStockSharesIssued_639178606085460853" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="1200400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639178606085461058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639178606085461058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_639178606085461058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639178606085461058" xlink:to="us-gaap_ProfitLoss_639178606085461058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ForgivenessOfUnrelatedVendorPayable" xlink:label="limn_ForgivenessOfUnrelatedVendorPayable_639178606085461058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639178606085461058" xlink:to="limn_ForgivenessOfUnrelatedVendorPayable_639178606085461058" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_OtherReceivableWriteOff" xlink:label="limn_OtherReceivableWriteOff_639178606085461058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639178606085461058" xlink:to="limn_OtherReceivableWriteOff_639178606085461058" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_639178606085461058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639178606085461058" xlink:to="us-gaap_Depreciation_639178606085461058" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue" xlink:label="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_639178606085466734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639178606085461058" xlink:to="limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue_639178606085466734" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639178606085466734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639178606085461058" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639178606085466734" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_GainLossOnIssuanceOfCommonStockForWarrants" xlink:label="limn_GainLossOnIssuanceOfCommonStockForWarrants_639178606085466734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639178606085461058" xlink:to="limn_GainLossOnIssuanceOfCommonStockForWarrants_639178606085466734" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonStockIssuanceForContingentLiability" xlink:label="limn_FairValueOfCommonStockIssuanceForContingentLiability_639178606085466734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639178606085461058" xlink:to="limn_FairValueOfCommonStockIssuanceForContingentLiability_639178606085466734" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639178606085466734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639178606085461058" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639178606085466734" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_639178606085466734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639178606085466734" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_639178606085466734" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639178606085466734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639178606085466734" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639178606085466734" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_639178606085466734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639178606085466734" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_639178606085466734" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent" xlink:label="limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent_639178606085471932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639178606085466734" xlink:to="limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent_639178606085471932" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent" xlink:label="limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent_639178606085472718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639178606085466734" xlink:to="limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent_639178606085472718" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent" xlink:label="limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent_639178606085473578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639178606085466734" xlink:to="limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent_639178606085473578" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_639178606085474076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639178606085466734" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_639178606085474076" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606085474076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639178606085461058" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_639178606085474076" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639178606085474076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639178606085474076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLoansReceivable" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable_639178606085474076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639178606085474076" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable_639178606085474076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639178606085474076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639178606085474076" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639178606085474076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_639178606085474076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639178606085474076" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_639178606085474076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639178606085479275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639178606085479275" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_639178606085480212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639178606085479275" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_639178606085480212" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_639178606085480212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639178606085479275" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_639178606085480212" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt_639178606085480212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639178606085479275" xlink:to="us-gaap_ProceedsFromShortTermDebt_639178606085480212" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt_639178606085480212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639178606085479275" xlink:to="us-gaap_RepaymentsOfShortTermDebt_639178606085480212" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_639178606085480212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639178606085479275" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_639178606085480212" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_639178606085480212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_639178606085480212" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_639178606085485390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_639178606085485390" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_639178606085485831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_639178606085485831" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606085485831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606085485831" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1_639178606085485831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606085485831" xlink:to="us-gaap_LiabilitiesAssumed1_639178606085485831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination" xlink:label="limn_StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination_639178606085485831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606085485831" xlink:to="limn_StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination_639178606085485831" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction" xlink:label="limn_MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction_639178606085485831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606085485831" xlink:to="limn_MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction_639178606085485831" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LoansSettled" xlink:label="limn_LoansSettled_639178606085491013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606085485831" xlink:to="limn_LoansSettled_639178606085491013" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1_639178606085491505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606085485831" xlink:to="us-gaap_StockIssued1_639178606085491505" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_639178606085491505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606085485831" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_639178606085491505" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NoncashConversionOfAmountBorrowedForPipeFunds" xlink:label="limn_NoncashConversionOfAmountBorrowedForPipeFunds_639178606085491505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606085485831" xlink:to="limn_NoncashConversionOfAmountBorrowedForPipeFunds_639178606085491505" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest" xlink:label="limn_DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest_639178606085491505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606085485831" xlink:to="limn_DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest_639178606085491505" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesIssuableUponClosingOfMergerToUnderwriters" xlink:label="limn_SharesIssuableUponClosingOfMergerToUnderwriters_639178606085491505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606085485831" xlink:to="limn_SharesIssuableUponClosingOfMergerToUnderwriters_639178606085491505" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredTransactionCostsInAccountsPayable" xlink:label="limn_DeferredTransactionCostsInAccountsPayable_639178606085497180" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639178606085485831" xlink:to="limn_DeferredTransactionCostsInAccountsPayable_639178606085497180" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationss" xlink:type="extended" xlink:title="1210101 - Disclosure - Description of Organization and Business Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_639178606085497180" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_639178606085497180" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciess" xlink:type="extended" xlink:title="1210201 - Disclosure - Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_639178606085502939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_639178606085502939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementss" xlink:type="extended" xlink:title="1210301 - Disclosure - License Agreements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAgreementsAbstract" xlink:label="LicenseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAgreementsTextBlock" xlink:label="limn_LicenseAgreementsTextBlock_639178606085502939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseAgreementsAbstract" xlink:to="limn_LicenseAgreementsTextBlock_639178606085502939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionss" xlink:type="extended" xlink:title="1210401 - Disclosure - Related Party Transactions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_639178606085509256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_639178606085509256" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDebts" xlink:type="extended" xlink:title="1210501 - Disclosure - Debt" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_639178606085509256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_639178606085509256" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureStockholderSEquitys" xlink:type="extended" xlink:title="1210601 - Disclosure - Stockholder's Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_639178606085514453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_639178606085514453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciess" xlink:type="extended" xlink:title="1210701 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_639178606085514950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_639178606085514950" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementss" xlink:type="extended" xlink:title="1210801 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_639178606085514950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_639178606085514950" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="1210901 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_639178606085520649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_639178606085520649" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureSubsequentEventss" xlink:type="extended" xlink:title="1211001 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_639178606085520649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_639178606085520649" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess" xlink:type="extended" xlink:title="1220202 - Disclosure - Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_639178606085527547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_639178606085527547" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EmergingGrowthCompanyPolicyPolicyTextBlock" xlink:label="limn_EmergingGrowthCompanyPolicyPolicyTextBlock_639178606085527547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="limn_EmergingGrowthCompanyPolicyPolicyTextBlock_639178606085527547" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_639178606085527547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_639178606085527547" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_639178606085527547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_639178606085527547" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_639178606085527547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_639178606085527547" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:label="us-gaap_FinanceLoansAndLeasesReceivablePolicy_639178606085527547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FinanceLoansAndLeasesReceivablePolicy_639178606085527547" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_639178606085527547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_639178606085527547" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_639178606085527547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_639178606085527547" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_WarrantsPolicyPolicyTextBlock" xlink:label="limn_WarrantsPolicyPolicyTextBlock_639178606085533232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="limn_WarrantsPolicyPolicyTextBlock_639178606085533232" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock" xlink:label="limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock_639178606085533232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock_639178606085533232" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_639178606085533232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_639178606085533232" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_639178606085533232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_639178606085533232" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_639178606085533232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_639178606085533232" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_639178606085533232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_639178606085533232" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDebtTabless" xlink:type="extended" xlink:title="1230503 - Disclosure - Debt (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock_639178606085538956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock_639178606085538956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTabless" xlink:type="extended" xlink:title="1230803 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_639178606085538956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_639178606085538956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_639178606085538956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_639178606085538956" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="1230903 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_639178606085544623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_639178606085544623" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_639178606085544623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_639178606085544623" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_639178606085544623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_639178606085544623" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" xlink:type="extended" xlink:title="1240101 - Disclosure - Description of Organization and Business Operations - Business Combination (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085544623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085544623" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_639178606085550327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085544623" xlink:to="us-gaap_BusinessAcquisitionAxis_639178606085550327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_639178606085550327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_639178606085550327" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_639178606085550327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LiminatusAndIrisMember" xlink:label="limn_LiminatusAndIrisMember_639178606085550327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_639178606085550327" xlink:to="limn_LiminatusAndIrisMember_639178606085550327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_639178606085550327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085544623" xlink:to="dei_LegalEntityAxis_639178606085550327" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_639178606085550327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_639178606085550327" xlink:to="dei_EntityDomain_639178606085550327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IrisAcquisitionHoldingsLlcMember" xlink:label="limn_IrisAcquisitionHoldingsLlcMember_639178606085550327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_639178606085550327" xlink:to="limn_IrisAcquisitionHoldingsLlcMember_639178606085550327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IrisAcquisitionCorpMember" xlink:label="limn_IrisAcquisitionCorpMember_639178606085550327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_639178606085550327" xlink:to="limn_IrisAcquisitionCorpMember_639178606085550327" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_639178606085550327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085544623" xlink:to="us-gaap_StatementClassOfStockAxis_639178606085550327" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639178606085550327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_639178606085550327" xlink:to="us-gaap_ClassOfStockDomain_639178606085550327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_639178606085555559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639178606085550327" xlink:to="us-gaap_CommonClassAMember_639178606085555559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639178606085556537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085544623" xlink:to="us-gaap_DebtInstrumentAxis_639178606085556537" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639178606085556537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639178606085556537" xlink:to="us-gaap_DebtInstrumentNameDomain_639178606085556537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConsortiumLoanOfRelatedPartiesMember" xlink:label="limn_ConsortiumLoanOfRelatedPartiesMember_639178606085556537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085556537" xlink:to="limn_ConsortiumLoanOfRelatedPartiesMember_639178606085556537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639178606085556537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085544623" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639178606085556537" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639178606085556537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639178606085556537" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639178606085556537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RedeemableWarrantMember" xlink:label="limn_RedeemableWarrantMember_639178606085556537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085556537" xlink:to="limn_RedeemableWarrantMember_639178606085556537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NonRedeemableWarrantMember" xlink:label="limn_NonRedeemableWarrantMember_639178606085556537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085556537" xlink:to="limn_NonRedeemableWarrantMember_639178606085556537" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639178606085556537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085544623" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639178606085556537" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639178606085562250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639178606085556537" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639178606085562250" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_639178606085562250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639178606085562250" xlink:to="us-gaap_PrivatePlacementMember_639178606085562250" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085562250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085544623" xlink:to="srt_CounterpartyNameAxis_639178606085562250" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085562250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085562250" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085562250" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxCo.LtdMember" xlink:label="limn_FeeluxCo.LtdMember_639178606085562250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085562250" xlink:to="limn_FeeluxCo.LtdMember_639178606085562250" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxAndCarTcellkorMember" xlink:label="limn_FeeluxAndCarTcellkorMember_639178606085562250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085562250" xlink:to="limn_FeeluxAndCarTcellkorMember_639178606085562250" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_639178606085567458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085544623" xlink:to="us-gaap_BusinessAcquisitionLineItems_639178606085567458" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockCashRedemptionShares" xlink:label="limn_CommonStockCashRedemptionShares_639178606085568251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_CommonStockCashRedemptionShares_639178606085568251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockCashRedemptionPricePerShare" xlink:label="limn_CommonStockCashRedemptionPricePerShare_639178606085569353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_CommonStockCashRedemptionPricePerShare_639178606085569353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockCashRedemptionAmount" xlink:label="limn_CommonStockCashRedemptionAmount_639178606085569353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_CommonStockCashRedemptionAmount_639178606085569353" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfSharesHeldInEachUnit" xlink:label="limn_NumberOfSharesHeldInEachUnit_639178606085569353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_NumberOfSharesHeldInEachUnit_639178606085569353" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfWarrantsHeldInEachUnit" xlink:label="limn_NumberOfWarrantsHeldInEachUnit_639178606085569353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_NumberOfWarrantsHeldInEachUnit_639178606085569353" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockConversionRatioBusinessCombination" xlink:label="limn_CommonStockConversionRatioBusinessCombination_639178606085569353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_CommonStockConversionRatioBusinessCombination_639178606085569353" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_639178606085569353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_639178606085569353" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639178606085574560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639178606085574560" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesAuthorized" xlink:label="limn_SharesAuthorized_639178606085575094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_SharesAuthorized_639178606085575094" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_639178606085575094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="us-gaap_CommonStockSharesAuthorized_639178606085575094" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_639178606085575094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_639178606085575094" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_639178606085575094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="us-gaap_PreferredStockSharesAuthorized_639178606085575094" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_639178606085575094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_639178606085575094" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_639178606085580311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="us-gaap_ConversionOfStockSharesConverted1_639178606085580311" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfStockOrUnitConversionRatio" xlink:label="limn_ConversionOfStockOrUnitConversionRatio_639178606085581458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_ConversionOfStockOrUnitConversionRatio_639178606085581458" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639178606085581458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639178606085581458" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639178606085581458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639178606085581458" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_639178606085581458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_639178606085581458" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProceedsFromIssuanceOfPrivatePlacementInvestor" xlink:label="limn_ProceedsFromIssuanceOfPrivatePlacementInvestor_639178606085581458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_ProceedsFromIssuanceOfPrivatePlacementInvestor_639178606085581458" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded" xlink:label="limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded_639178606085587217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded_639178606085587217" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RelatedPartiesDebtToUnsecuredPromissoryNote" xlink:label="limn_RelatedPartiesDebtToUnsecuredPromissoryNote_639178606085587217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_RelatedPartiesDebtToUnsecuredPromissoryNote_639178606085587217" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnsecuredPromissoryNoteSettledAndConverted" xlink:label="limn_UnsecuredPromissoryNoteSettledAndConverted_639178606085587217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_UnsecuredPromissoryNoteSettledAndConverted_639178606085587217" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfPrincipalAndAccruedInterestShares" xlink:label="limn_ConversionOfPrincipalAndAccruedInterestShares_639178606085587217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_ConversionOfPrincipalAndAccruedInterestShares_639178606085587217" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_639178606085587217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="us-gaap_ConversionOfStockSharesIssued1_639178606085587217" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination_639178606085592583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination_639178606085592583" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuableForSettlementOfDeferredUnderwritingFees" xlink:label="limn_StockIssuableForSettlementOfDeferredUnderwritingFees_639178606085593901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_StockIssuableForSettlementOfDeferredUnderwritingFees_639178606085593901" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LiabilityOfUnderwritingFeesFairValue" xlink:label="limn_LiabilityOfUnderwritingFeesFairValue_639178606085595141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_LiabilityOfUnderwritingFeesFairValue_639178606085595141" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" xlink:label="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees_639178606085596343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees_639178606085596343" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_639178606085597567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_639178606085597567" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_639178606085599393" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_639178606085599393" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_639178606085600589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_639178606085600589" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfPrincipalAndAccruedInterestAmount" xlink:label="limn_ConversionOfPrincipalAndAccruedInterestAmount_639178606085601866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_ConversionOfPrincipalAndAccruedInterestAmount_639178606085601866" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PrincipalAndAccruedInterestOnPrivatePlacement" xlink:label="limn_PrincipalAndAccruedInterestOnPrivatePlacement_639178606085603642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_PrincipalAndAccruedInterestOnPrivatePlacement_639178606085603642" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ConversionOfAccruedInterestOnRelatedPartyDebts" xlink:label="limn_ConversionOfAccruedInterestOnRelatedPartyDebts_639178606085604828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085567458" xlink:to="limn_ConversionOfAccruedInterestOnRelatedPartyDebts_639178606085604828" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss" xlink:type="extended" xlink:title="1240102 - Disclosure - Description of Organization and Business Operations - Liquidity and Capital Resources (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085609217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085609217" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639178606085609899" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085609217" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639178606085609899" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639178606085610624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639178606085609899" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639178606085610624" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_BestEffortsPublicOfferingMember" xlink:label="limn_BestEffortsPublicOfferingMember_639178606085611249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639178606085610624" xlink:to="limn_BestEffortsPublicOfferingMember_639178606085611249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639178606085611843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085609217" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639178606085611843" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639178606085612537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639178606085611843" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639178606085612537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PreFundedWarrantsMember" xlink:label="limn_PreFundedWarrantsMember_639178606085613241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085612537" xlink:to="limn_PreFundedWarrantsMember_639178606085613241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPurchaseWarrantsMember" xlink:label="limn_CommonStockPurchaseWarrantsMember_639178606085613886" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085612537" xlink:to="limn_CommonStockPurchaseWarrantsMember_639178606085613886" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_639178606085614513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085609217" xlink:to="us-gaap_SubsequentEventTypeAxis_639178606085614513" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_639178606085615738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_639178606085614513" xlink:to="us-gaap_SubsequentEventTypeDomain_639178606085615738" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_639178606085616365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_639178606085615738" xlink:to="us-gaap_SubsequentEventMember_639178606085616365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_639178606085616973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_639178606085609217" xlink:to="us-gaap_BusinessAcquisitionLineItems_639178606085616973" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_639178606085618220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085616973" xlink:to="us-gaap_Cash_639178606085618220" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606085618837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085616973" xlink:to="us-gaap_ShortTermBorrowings_639178606085618837" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639178606085619529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085616973" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639178606085619529" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639178606085619529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085616973" xlink:to="us-gaap_OperatingIncomeLoss_639178606085619529" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639178606085619529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085616973" xlink:to="us-gaap_NetIncomeLoss_639178606085619529" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639178606085619529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085616973" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639178606085619529" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued_639178606085619529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085616973" xlink:to="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued_639178606085619529" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639178606085619529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085616973" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639178606085619529" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639178606085619529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085616973" xlink:to="us-gaap_SharesIssuedPricePerShare_639178606085619529" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightIssuePricePerWarrant" xlink:label="limn_ClassOfWarrantOrRightIssuePricePerWarrant_639178606085624825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085616973" xlink:to="limn_ClassOfWarrantOrRightIssuePricePerWarrant_639178606085624825" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639178606085625439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_639178606085616973" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639178606085625439" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss" xlink:type="extended" xlink:title="1240201 - Disclosure - Significant Accounting Policies - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085625439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085625439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085625439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085625439" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085625439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085625439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085625439" xlink:to="us-gaap_RelatedPartyDomain_639178606085625439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085630658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085625439" xlink:to="us-gaap_RelatedPartyMember_639178606085630658" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_639178606085631197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyMember_639178606085630658" xlink:to="srt_ChiefExecutiveOfficerMember_639178606085631197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639178606085631197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085625439" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639178606085631197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639178606085631197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639178606085631197" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639178606085631197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PublicWarrantsMember" xlink:label="limn_PublicWarrantsMember_639178606085631197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085631197" xlink:to="limn_PublicWarrantsMember_639178606085631197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PrivatePlacementWarrantsMember" xlink:label="limn_PrivatePlacementWarrantsMember_639178606085631197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085631197" xlink:to="limn_PrivatePlacementWarrantsMember_639178606085631197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639178606085631197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085625439" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639178606085631197" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_639178606085631197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085631197" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_639178606085631197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_639178606085631197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085631197" xlink:to="us-gaap_WarrantsAndRightsOutstanding_639178606085631197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639178606085637075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085631197" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639178606085637075" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_639178606085637075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085631197" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_639178606085637075" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_639178606085637075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085631197" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_639178606085637075" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_639178606085637075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085631197" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_639178606085637075" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:label="us-gaap_AllowanceForNotesAndLoansReceivableCurrent_639178606085637075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085631197" xlink:to="us-gaap_AllowanceForNotesAndLoansReceivableCurrent_639178606085637075" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent_639178606085637075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085631197" xlink:to="us-gaap_DeferredCostsCurrent_639178606085637075" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FranchiseTaxExpenseIncludingInterestAndPenalty" xlink:label="limn_FranchiseTaxExpenseIncludingInterestAndPenalty_639178606085637075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085631197" xlink:to="limn_FranchiseTaxExpenseIncludingInterestAndPenalty_639178606085637075" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetailss" xlink:type="extended" xlink:title="1240202 - Disclosure - Significant Accounting Policies - Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_639178606085642883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_639178606085642883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_639178606085642883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_639178606085642883" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails" xlink:type="extended" xlink:title="1240301 - Disclosure - License Agreements - CAR-T Products License (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAgreementsAbstract" xlink:label="LicenseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085642883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085642883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_639178606085642883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085642883" xlink:to="us-gaap_TypeOfArrangementAxis_639178606085642883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639178606085642883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_639178606085642883" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639178606085642883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAndDevelopmentAgreementWithTdtMember" xlink:label="limn_LicenseAndDevelopmentAgreementWithTdtMember_639178606085642883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639178606085642883" xlink:to="limn_LicenseAndDevelopmentAgreementWithTdtMember_639178606085642883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_639178606085642883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085642883" xlink:to="srt_ProductOrServiceAxis_639178606085642883" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_639178606085642883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_639178606085642883" xlink:to="srt_ProductsAndServicesDomain_639178606085642883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember" xlink:label="limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_639178606085642883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639178606085642883" xlink:to="limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_639178606085642883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember" xlink:label="limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember_639178606085642883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_639178606085642883" xlink:to="limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember_639178606085642883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_639178606085642883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085642883" xlink:to="srt_StatementScenarioAxis_639178606085642883" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639178606085653754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_639178606085642883" xlink:to="srt_ScenarioUnspecifiedDomain_639178606085653754" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember" xlink:label="limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember_639178606085669025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639178606085653754" xlink:to="limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember_639178606085669025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember" xlink:label="limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639178606085653754" xlink:to="limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_639178606085669638" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember" xlink:label="limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639178606085653754" xlink:to="limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_639178606085669638" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085642883" xlink:to="srt_RangeAxis_639178606085669638" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639178606085669638" xlink:to="srt_RangeMember_639178606085669638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639178606085669638" xlink:to="srt_MinimumMember_639178606085669638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639178606085669638" xlink:to="srt_MaximumMember_639178606085669638" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085642883" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UpfrontPaymentOfLicenseAgreementFees" xlink:label="limn_UpfrontPaymentOfLicenseAgreementFees_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="limn_UpfrontPaymentOfLicenseAgreementFees_639178606085669638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="us-gaap_CostMaintenance_639178606085669638" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate" xlink:label="limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate_639178606085669638" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseMilestoneCommitmentFundPayableForEachPhase" xlink:label="limn_LicenseMilestoneCommitmentFundPayableForEachPhase_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="limn_LicenseMilestoneCommitmentFundPayableForEachPhase_639178606085669638" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfMilestonePaymentsForFirstProductDevelopment" xlink:label="limn_NumberOfMilestonePaymentsForFirstProductDevelopment_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="limn_NumberOfMilestonePaymentsForFirstProductDevelopment_639178606085669638" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment" xlink:label="limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment_639178606085669638" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment" xlink:label="limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment_639178606085669638" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment" xlink:label="limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment_639178606085669638" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RoyaltyFeesPercentage" xlink:label="limn_RoyaltyFeesPercentage_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="limn_RoyaltyFeesPercentage_639178606085669638" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts" xlink:label="limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts_639178606085669638" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" xlink:type="extended" xlink:title="1240302 - Disclosure - License Agreements - Vaccine Products License (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAgreementsAbstract" xlink:label="LicenseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085669638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085669638" xlink:to="us-gaap_TypeOfArrangementAxis_639178606085669638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_639178606085669638" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639178606085669638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember" xlink:label="limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639178606085669638" xlink:to="limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_639178606085669638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CarTLicenseAndVaccineLicenseWithTdtMember" xlink:label="limn_CarTLicenseAndVaccineLicenseWithTdtMember_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639178606085669638" xlink:to="limn_CarTLicenseAndVaccineLicenseWithTdtMember_639178606085669638" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085669638" xlink:to="srt_ProductOrServiceAxis_639178606085669638" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_639178606085669638" xlink:to="srt_ProductsAndServicesDomain_639178606085669638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_VaccineProductsAndVaccineDiagnosticsMember" xlink:label="limn_VaccineProductsAndVaccineDiagnosticsMember_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639178606085669638" xlink:to="limn_VaccineProductsAndVaccineDiagnosticsMember_639178606085669638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085669638" xlink:to="srt_StatementScenarioAxis_639178606085669638" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_639178606085669638" xlink:to="srt_ScenarioUnspecifiedDomain_639178606085669638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember" xlink:label="limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639178606085669638" xlink:to="limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_639178606085669638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember" xlink:label="limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639178606085669638" xlink:to="limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_639178606085669638" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085669638" xlink:to="srt_RangeAxis_639178606085669638" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639178606085669638" xlink:to="srt_RangeMember_639178606085669638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639178606085669638" xlink:to="srt_MinimumMember_639178606085669638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639178606085669638" xlink:to="srt_MaximumMember_639178606085669638" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085669638" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UpfrontPaymentOfLicenseAgreementFees" xlink:label="limn_UpfrontPaymentOfLicenseAgreementFees_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="limn_UpfrontPaymentOfLicenseAgreementFees_639178606085669638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="us-gaap_CostMaintenance_639178606085669638" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAgreementMaintenanceFees" xlink:label="limn_LicenseAgreementMaintenanceFees_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="limn_LicenseAgreementMaintenanceFees_639178606085669638" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate" xlink:label="limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate_639178606085669638" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfMilestonePaymentsForFirstProductDevelopment" xlink:label="limn_NumberOfMilestonePaymentsForFirstProductDevelopment_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="limn_NumberOfMilestonePaymentsForFirstProductDevelopment_639178606085669638" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment" xlink:label="limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment_639178606085669638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment_639178606085669638" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment" xlink:label="limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment_639178606085699942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment_639178606085699942" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment" xlink:label="limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment_639178606085700735" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment_639178606085700735" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RoyaltyFeesPercentage" xlink:label="limn_RoyaltyFeesPercentage_639178606085701676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="limn_RoyaltyFeesPercentage_639178606085701676" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ForgivenessOfUnrelatedVendorPayable" xlink:label="limn_ForgivenessOfUnrelatedVendorPayable_639178606085701676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="limn_ForgivenessOfUnrelatedVendorPayable_639178606085701676" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts" xlink:label="limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts_639178606085701676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085669638" xlink:to="limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts_639178606085701676" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails" xlink:type="extended" xlink:title="1240303 - Disclosure - License Agreements - Termination of license agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAgreementsAbstract" xlink:label="LicenseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085701676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085701676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_639178606085706847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085701676" xlink:to="us-gaap_TypeOfArrangementAxis_639178606085706847" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639178606085707646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_639178606085706847" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639178606085707646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CarTLicenseAndVaccineLicenseWithTdtMember" xlink:label="limn_CarTLicenseAndVaccineLicenseWithTdtMember_639178606085707646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639178606085707646" xlink:to="limn_CarTLicenseAndVaccineLicenseWithTdtMember_639178606085707646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085707646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085701676" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085707646" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAgreementsTerminationAmountDue" xlink:label="limn_LicenseAgreementsTerminationAmountDue_639178606085707646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085707646" xlink:to="limn_LicenseAgreementsTerminationAmountDue_639178606085707646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss" xlink:type="extended" xlink:title="1240304 - Disclosure - License Agreements - CD47 License (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseAgreementsAbstract" xlink:label="LicenseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085707646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085707646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_639178606085707646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085707646" xlink:to="us-gaap_TypeOfArrangementAxis_639178606085707646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639178606085707646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_639178606085707646" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639178606085707646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember" xlink:label="limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_639178606085712871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639178606085707646" xlink:to="limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_639178606085712871" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085712871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085707646" xlink:to="srt_CounterpartyNameAxis_639178606085712871" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085712871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085712871" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085712871" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CurisBiotechHoldingsLlcMember" xlink:label="limn_CurisBiotechHoldingsLlcMember_639178606085712871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085712871" xlink:to="limn_CurisBiotechHoldingsLlcMember_639178606085712871" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="us-gaap_CapitalUnitsByClassAxis_639178606085712871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085707646" xlink:to="us-gaap_CapitalUnitsByClassAxis_639178606085712871" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="us-gaap_CapitalUnitClassDomain_639178606085712871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalUnitsByClassAxis_639178606085712871" xlink:to="us-gaap_CapitalUnitClassDomain_639178606085712871" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="us-gaap_CapitalUnitClassAMember_639178606085712871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalUnitClassDomain_639178606085712871" xlink:to="us-gaap_CapitalUnitClassAMember_639178606085712871" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085712871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639178606085707646" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085712871" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_NumberOfUnitsExchangeForLicenseRights" xlink:label="limn_NumberOfUnitsExchangeForLicenseRights_639178606085712871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085712871" xlink:to="limn_NumberOfUnitsExchangeForLicenseRights_639178606085712871" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital" xlink:label="limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital_639178606085712871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639178606085712871" xlink:to="limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital_639178606085712871" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss" xlink:type="extended" xlink:title="1240401 - Disclosure - Related Party Transactions - Feelux Bonds (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085720691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085720691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085720691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085720691" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085720691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085720691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085720691" xlink:to="us-gaap_RelatedPartyDomain_639178606085720691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085720691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085720691" xlink:to="us-gaap_RelatedPartyMember_639178606085720691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639178606085720691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085720691" xlink:to="us-gaap_DebtInstrumentAxis_639178606085720691" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639178606085720691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639178606085720691" xlink:to="us-gaap_DebtInstrumentNameDomain_639178606085720691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxBondsMember" xlink:label="limn_FeeluxBondsMember_639178606085720691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085720691" xlink:to="limn_FeeluxBondsMember_639178606085720691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085720691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085720691" xlink:to="srt_CounterpartyNameAxis_639178606085720691" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085725912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085720691" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085725912" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxCo.LtdMember" xlink:label="limn_FeeluxCo.LtdMember_639178606085726931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085725912" xlink:to="limn_FeeluxCo.LtdMember_639178606085726931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639178606085726931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085720691" xlink:to="srt_RangeAxis_639178606085726931" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639178606085726931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639178606085726931" xlink:to="srt_RangeMember_639178606085726931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639178606085726931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639178606085726931" xlink:to="srt_MaximumMember_639178606085726931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_639178606085726931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085720691" xlink:to="us-gaap_MeasurementInputTypeAxis_639178606085726931" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_639178606085726931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_639178606085726931" xlink:to="us-gaap_MeasurementInputTypeDomain_639178606085726931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_639178606085726931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639178606085726931" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_639178606085726931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_639178606085732148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639178606085726931" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_639178606085732148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_639178606085732713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639178606085726931" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_639178606085732713" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639178606085732713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085720691" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639178606085732713" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606085732713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085732713" xlink:to="us-gaap_ShortTermBorrowings_639178606085732713" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085732713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085732713" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085732713" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_639178606085732713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085732713" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_639178606085732713" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639178606085732713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085732713" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639178606085732713" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_639178606085737928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085732713" xlink:to="us-gaap_WarrantsAndRightsOutstanding_639178606085737928" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_639178606085737928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085732713" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_639178606085737928" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_639178606085737928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085732713" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_639178606085737928" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt_639178606085737928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085732713" xlink:to="us-gaap_ProceedsFromShortTermDebt_639178606085737928" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_639178606085737928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085732713" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_639178606085737928" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_639178606085737928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085732713" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_639178606085737928" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_639178606085737928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085732713" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_639178606085737928" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_639178606085737928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085732713" xlink:to="us-gaap_ConversionOfStockSharesConverted1_639178606085737928" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits" xlink:label="limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits_639178606085737928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085732713" xlink:to="limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits_639178606085737928" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent_639178606085737928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085732713" xlink:to="limn_AccruedInterestCurrent_639178606085737928" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_639178606085737928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085732713" xlink:to="us-gaap_InterestExpenseDebt_639178606085737928" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss" xlink:type="extended" xlink:title="1240402 - Disclosure - Related Party Transactions - Car-Tcellkor Loan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085750164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085750164" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085750164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085750164" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085750164" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085750164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085750164" xlink:to="us-gaap_RelatedPartyDomain_639178606085750164" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085750164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085750164" xlink:to="us-gaap_RelatedPartyMember_639178606085750164" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639178606085750164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085750164" xlink:to="us-gaap_DebtInstrumentAxis_639178606085750164" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639178606085750164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639178606085750164" xlink:to="us-gaap_DebtInstrumentNameDomain_639178606085750164" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CarTcellkorLoanMember" xlink:label="limn_CarTcellkorLoanMember_639178606085750164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085750164" xlink:to="limn_CarTcellkorLoanMember_639178606085750164" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639178606085750164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085750164" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639178606085750164" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606085755399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085750164" xlink:to="us-gaap_ShortTermBorrowings_639178606085755399" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_639178606085755949" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085750164" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_639178606085755949" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" xlink:type="extended" xlink:title="1240403 - Disclosure - Related Party Transactions - Valetudo Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085755949" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085755949" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085755949" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085755949" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085755949" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085755949" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085755949" xlink:to="us-gaap_RelatedPartyDomain_639178606085755949" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085755949" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085755949" xlink:to="us-gaap_RelatedPartyMember_639178606085755949" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639178606085761153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085755949" xlink:to="us-gaap_DebtInstrumentAxis_639178606085761153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639178606085761744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639178606085761153" xlink:to="us-gaap_DebtInstrumentNameDomain_639178606085761744" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoLoanMember" xlink:label="limn_ValetudoLoanMember_639178606085762420" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085761744" xlink:to="limn_ValetudoLoanMember_639178606085762420" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoDecember2022LoanMember" xlink:label="limn_ValetudoDecember2022LoanMember_639178606085762869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoLoanMember_639178606085762420" xlink:to="limn_ValetudoDecember2022LoanMember_639178606085762869" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJune2023LoansMember" xlink:label="limn_ValetudoJune2023LoansMember_639178606085762869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoLoanMember_639178606085762420" xlink:to="limn_ValetudoJune2023LoansMember_639178606085762869" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJune2023LoanOneMember" xlink:label="limn_ValetudoJune2023LoanOneMember_639178606085762869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoJune2023LoansMember_639178606085762869" xlink:to="limn_ValetudoJune2023LoanOneMember_639178606085762869" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJune2023LoanTwoMember" xlink:label="limn_ValetudoJune2023LoanTwoMember_639178606085762869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoJune2023LoansMember_639178606085762869" xlink:to="limn_ValetudoJune2023LoanTwoMember_639178606085762869" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJuly2023LoanMember" xlink:label="limn_ValetudoJuly2023LoanMember_639178606085762869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoLoanMember_639178606085762420" xlink:to="limn_ValetudoJuly2023LoanMember_639178606085762869" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoAugust2023LoansMember" xlink:label="limn_ValetudoAugust2023LoansMember_639178606085762869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoLoanMember_639178606085762420" xlink:to="limn_ValetudoAugust2023LoansMember_639178606085762869" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoAugust2023LoanOneMember" xlink:label="limn_ValetudoAugust2023LoanOneMember_639178606085762869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoAugust2023LoansMember_639178606085762869" xlink:to="limn_ValetudoAugust2023LoanOneMember_639178606085762869" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoAugust2023LoanTwoMember" xlink:label="limn_ValetudoAugust2023LoanTwoMember_639178606085762869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoAugust2023LoansMember_639178606085762869" xlink:to="limn_ValetudoAugust2023LoanTwoMember_639178606085762869" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoNovember2023LoanMember" xlink:label="limn_ValetudoNovember2023LoanMember_639178606085762869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoLoanMember_639178606085762420" xlink:to="limn_ValetudoNovember2023LoanMember_639178606085762869" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJanuary2024LoansMember" xlink:label="limn_ValetudoJanuary2024LoansMember_639178606085762869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoLoanMember_639178606085762420" xlink:to="limn_ValetudoJanuary2024LoansMember_639178606085762869" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJanuary2024LoanOneMember" xlink:label="limn_ValetudoJanuary2024LoanOneMember_639178606085762869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoJanuary2024LoansMember_639178606085762869" xlink:to="limn_ValetudoJanuary2024LoanOneMember_639178606085762869" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJanuary2024LoanTwoMember" xlink:label="limn_ValetudoJanuary2024LoanTwoMember_639178606085768225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ValetudoJanuary2024LoansMember_639178606085762869" xlink:to="limn_ValetudoJanuary2024LoanTwoMember_639178606085768225" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085769386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085755949" xlink:to="srt_CounterpartyNameAxis_639178606085769386" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085769977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085769386" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085769977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoTherapeuticsLlcMember" xlink:label="limn_ValetudoTherapeuticsLlcMember_639178606085771213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085769977" xlink:to="limn_ValetudoTherapeuticsLlcMember_639178606085771213" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639178606085771809" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085755949" xlink:to="srt_RangeAxis_639178606085771809" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639178606085773027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639178606085771809" xlink:to="srt_RangeMember_639178606085773027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639178606085773624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639178606085773027" xlink:to="srt_MaximumMember_639178606085773624" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639178606085774804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085755949" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639178606085774804" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606085775969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085774804" xlink:to="us-gaap_ShortTermBorrowings_639178606085775969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_RepaymentOfMembershipInterest" xlink:label="limn_RepaymentOfMembershipInterest_639178606085776476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085774804" xlink:to="limn_RepaymentOfMembershipInterest_639178606085776476" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt_639178606085776476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085774804" xlink:to="us-gaap_RepaymentsOfShortTermDebt_639178606085776476" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085776476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085774804" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085776476" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_639178606085776476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085774804" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_639178606085776476" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent_639178606085776476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085774804" xlink:to="limn_AccruedInterestCurrent_639178606085776476" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_639178606085776476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085774804" xlink:to="us-gaap_InterestExpenseDebt_639178606085776476" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss" xlink:type="extended" xlink:title="1240404 - Disclosure - Related Party Transactions - Ewon Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085782835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085782835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085782835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085782835" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085782835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085782835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085782835" xlink:to="us-gaap_RelatedPartyDomain_639178606085782835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085782835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085782835" xlink:to="us-gaap_RelatedPartyMember_639178606085782835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639178606085782835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085782835" xlink:to="us-gaap_DebtInstrumentAxis_639178606085782835" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639178606085788043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639178606085782835" xlink:to="us-gaap_DebtInstrumentNameDomain_639178606085788043" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonLoanMember" xlink:label="limn_EwonLoanMember_639178606085788526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085788043" xlink:to="limn_EwonLoanMember_639178606085788526" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonDecember2022LoanMember" xlink:label="limn_EwonDecember2022LoanMember_639178606085788526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_EwonLoanMember_639178606085788526" xlink:to="limn_EwonDecember2022LoanMember_639178606085788526" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonSeptember2023LoanMember" xlink:label="limn_EwonSeptember2023LoanMember_639178606085788526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_EwonLoanMember_639178606085788526" xlink:to="limn_EwonSeptember2023LoanMember_639178606085788526" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonDecember2023LoanMember" xlink:label="limn_EwonDecember2023LoanMember_639178606085788526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_EwonLoanMember_639178606085788526" xlink:to="limn_EwonDecember2023LoanMember_639178606085788526" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085788526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085782835" xlink:to="srt_CounterpartyNameAxis_639178606085788526" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085788526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085788526" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085788526" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonComfortechCoLtdMember" xlink:label="limn_EwonComfortechCoLtdMember_639178606085788526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085788526" xlink:to="limn_EwonComfortechCoLtdMember_639178606085788526" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639178606085788526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085782835" xlink:to="srt_RangeAxis_639178606085788526" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639178606085788526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639178606085788526" xlink:to="srt_RangeMember_639178606085788526" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639178606085794379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639178606085788526" xlink:to="srt_MaximumMember_639178606085794379" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639178606085795402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085782835" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639178606085795402" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606085796309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085795402" xlink:to="us-gaap_ShortTermBorrowings_639178606085796309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085796309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085795402" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085796309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt_639178606085796309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085795402" xlink:to="us-gaap_RepaymentsOfShortTermDebt_639178606085796309" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_639178606085796309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085795402" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_639178606085796309" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent_639178606085796309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085795402" xlink:to="limn_AccruedInterestCurrent_639178606085796309" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_639178606085796309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085795402" xlink:to="us-gaap_InterestExpenseDebt_639178606085796309" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss" xlink:type="extended" xlink:title="1240405 - Disclosure - Related Party Transactions - Prophase Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085802594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085802594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085802594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085802594" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085802594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085802594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085802594" xlink:to="us-gaap_RelatedPartyDomain_639178606085802594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085802594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085802594" xlink:to="us-gaap_RelatedPartyMember_639178606085802594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639178606085802594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085802594" xlink:to="us-gaap_DebtInstrumentAxis_639178606085802594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639178606085802594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639178606085802594" xlink:to="us-gaap_DebtInstrumentNameDomain_639178606085802594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseLoanMember" xlink:label="limn_ProphaseLoanMember_639178606085802594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085802594" xlink:to="limn_ProphaseLoanMember_639178606085802594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseFebruary2024LoanMember" xlink:label="limn_ProphaseFebruary2024LoanMember_639178606085807789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ProphaseLoanMember_639178606085802594" xlink:to="limn_ProphaseFebruary2024LoanMember_639178606085807789" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMarch2024LoanMember" xlink:label="limn_ProphaseMarch2024LoanMember_639178606085808255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ProphaseLoanMember_639178606085802594" xlink:to="limn_ProphaseMarch2024LoanMember_639178606085808255" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseApril2024LoanMember" xlink:label="limn_ProphaseApril2024LoanMember_639178606085808255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ProphaseLoanMember_639178606085802594" xlink:to="limn_ProphaseApril2024LoanMember_639178606085808255" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMay2024LoansMember" xlink:label="limn_ProphaseMay2024LoansMember_639178606085808255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ProphaseLoanMember_639178606085802594" xlink:to="limn_ProphaseMay2024LoansMember_639178606085808255" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseJuly2024LoansMember" xlink:label="limn_ProphaseJuly2024LoansMember_639178606085808255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ProphaseLoanMember_639178606085802594" xlink:to="limn_ProphaseJuly2024LoansMember_639178606085808255" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseAugust2024LoansMember" xlink:label="limn_ProphaseAugust2024LoansMember_639178606085808255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ProphaseLoanMember_639178606085802594" xlink:to="limn_ProphaseAugust2024LoansMember_639178606085808255" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseFebruary2025LoansMember" xlink:label="limn_ProphaseFebruary2025LoansMember_639178606085808255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ProphaseLoanMember_639178606085802594" xlink:to="limn_ProphaseFebruary2025LoansMember_639178606085808255" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMarch2025LoansMember" xlink:label="limn_ProphaseMarch2025LoansMember_639178606085808255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ProphaseLoanMember_639178606085802594" xlink:to="limn_ProphaseMarch2025LoansMember_639178606085808255" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseApril2025LoansMember" xlink:label="limn_ProphaseApril2025LoansMember_639178606085808255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_ProphaseLoanMember_639178606085802594" xlink:to="limn_ProphaseApril2025LoansMember_639178606085808255" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085808255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085802594" xlink:to="srt_CounterpartyNameAxis_639178606085808255" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085808255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085808255" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085808255" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseSciencesLlcMember" xlink:label="limn_ProphaseSciencesLlcMember_639178606085813896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085808255" xlink:to="limn_ProphaseSciencesLlcMember_639178606085813896" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639178606085813896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085802594" xlink:to="srt_RangeAxis_639178606085813896" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639178606085813896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639178606085813896" xlink:to="srt_RangeMember_639178606085813896" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639178606085813896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639178606085813896" xlink:to="srt_MaximumMember_639178606085813896" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639178606085813896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085802594" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639178606085813896" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606085813896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085813896" xlink:to="us-gaap_ShortTermBorrowings_639178606085813896" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085813896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085813896" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085813896" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_639178606085819583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085813896" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_639178606085819583" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent_639178606085819583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085813896" xlink:to="limn_AccruedInterestCurrent_639178606085819583" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_639178606085819583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085813896" xlink:to="us-gaap_InterestExpenseDebt_639178606085819583" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss" xlink:type="extended" xlink:title="1240406 - Disclosure - Related Party Transactions - Hana Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085825211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085825211" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085825211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085825211" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085825211" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085825211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085825211" xlink:to="us-gaap_RelatedPartyDomain_639178606085825211" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085825211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085825211" xlink:to="us-gaap_RelatedPartyMember_639178606085825211" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639178606085825211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085825211" xlink:to="us-gaap_DebtInstrumentAxis_639178606085825211" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639178606085825211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639178606085825211" xlink:to="us-gaap_DebtInstrumentNameDomain_639178606085825211" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_HanaLoansMember" xlink:label="limn_HanaLoansMember_639178606085825211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085825211" xlink:to="limn_HanaLoansMember_639178606085825211" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_HanaAugust2024LoansMember" xlink:label="limn_HanaAugust2024LoansMember_639178606085825211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_HanaLoansMember_639178606085825211" xlink:to="limn_HanaAugust2024LoansMember_639178606085825211" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639178606085825211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085825211" xlink:to="srt_RangeAxis_639178606085825211" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639178606085830898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639178606085825211" xlink:to="srt_RangeMember_639178606085830898" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639178606085830898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639178606085830898" xlink:to="srt_MaximumMember_639178606085830898" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085830898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085825211" xlink:to="srt_CounterpartyNameAxis_639178606085830898" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085830898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085830898" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085830898" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_HanaImmunotherapeuticsLlcMember" xlink:label="limn_HanaImmunotherapeuticsLlcMember_639178606085830898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085830898" xlink:to="limn_HanaImmunotherapeuticsLlcMember_639178606085830898" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639178606085830898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085825211" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639178606085830898" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606085830898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085830898" xlink:to="us-gaap_ShortTermBorrowings_639178606085830898" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085836578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085830898" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085836578" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_639178606085836578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085830898" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_639178606085836578" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent_639178606085836578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085830898" xlink:to="limn_AccruedInterestCurrent_639178606085836578" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_639178606085836578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085830898" xlink:to="us-gaap_InterestExpenseDebt_639178606085836578" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss" xlink:type="extended" xlink:title="1240407 - Disclosure - Related Party Transactions - Amantes Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085842244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085842244" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085842244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085842244" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085842244" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085842244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085842244" xlink:to="us-gaap_RelatedPartyDomain_639178606085842244" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085842244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085842244" xlink:to="us-gaap_RelatedPartyMember_639178606085842244" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639178606085842244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085842244" xlink:to="us-gaap_DebtInstrumentAxis_639178606085842244" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639178606085842244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639178606085842244" xlink:to="us-gaap_DebtInstrumentNameDomain_639178606085842244" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesLoansMember" xlink:label="limn_AmantesLoansMember_639178606085842244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085842244" xlink:to="limn_AmantesLoansMember_639178606085842244" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesNovember2024LoansMember" xlink:label="limn_AmantesNovember2024LoansMember_639178606085842244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_AmantesLoansMember_639178606085842244" xlink:to="limn_AmantesNovember2024LoansMember_639178606085842244" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesJanuary2025LoansMember" xlink:label="limn_AmantesJanuary2025LoansMember_639178606085847452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="limn_AmantesLoansMember_639178606085842244" xlink:to="limn_AmantesJanuary2025LoansMember_639178606085847452" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639178606085847902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085842244" xlink:to="srt_RangeAxis_639178606085847902" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639178606085847902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639178606085847902" xlink:to="srt_RangeMember_639178606085847902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639178606085847902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639178606085847902" xlink:to="srt_MaximumMember_639178606085847902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085847902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085842244" xlink:to="srt_CounterpartyNameAxis_639178606085847902" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085847902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085847902" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085847902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesLlcMember" xlink:label="limn_AmantesLlcMember_639178606085847902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085847902" xlink:to="limn_AmantesLlcMember_639178606085847902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639178606085847902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085842244" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639178606085847902" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606085853660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085847902" xlink:to="us-gaap_ShortTermBorrowings_639178606085853660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085854130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085847902" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_639178606085854130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_639178606085854130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085847902" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_639178606085854130" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AccruedInterestCurrent" xlink:label="limn_AccruedInterestCurrent_639178606085854130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085847902" xlink:to="limn_AccruedInterestCurrent_639178606085854130" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_639178606085854130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085847902" xlink:to="us-gaap_InterestExpenseDebt_639178606085854130" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss" xlink:type="extended" xlink:title="1240408 - Disclosure - Related Party Transactions - Due to Related Party (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085860092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085860092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085860092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085860092" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085860092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085860092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085860092" xlink:to="us-gaap_RelatedPartyDomain_639178606085860092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085860092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085860092" xlink:to="us-gaap_RelatedPartyMember_639178606085860092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_639178606085860092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085860092" xlink:to="us-gaap_FinancialInstrumentAxis_639178606085860092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639178606085860092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_639178606085860092" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639178606085860092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EmploymentAgreementMember" xlink:label="limn_EmploymentAgreementMember_639178606085860092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639178606085860092" xlink:to="limn_EmploymentAgreementMember_639178606085860092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639178606085860092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085860092" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639178606085860092" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_639178606085865489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085860092" xlink:to="us-gaap_OtherLiabilitiesCurrent_639178606085865489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails" xlink:type="extended" xlink:title="1240409 - Disclosure - Related Party Transactions - Viral Gene (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085866625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085866625" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085866625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085866625" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085866625" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085866625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085866625" xlink:to="us-gaap_RelatedPartyDomain_639178606085866625" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085866625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085866625" xlink:to="us-gaap_RelatedPartyMember_639178606085866625" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085866625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085866625" xlink:to="srt_CounterpartyNameAxis_639178606085866625" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085866625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085866625" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085866625" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ViralGeneMember" xlink:label="limn_ViralGeneMember_639178606085872250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085866625" xlink:to="limn_ViralGeneMember_639178606085872250" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639178606085872609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639178606085866625" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639178606085872609" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_639178606085872609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085872609" xlink:to="us-gaap_OtherReceivablesNetCurrent_639178606085872609" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_OtherReceivableWriteOff" xlink:label="limn_OtherReceivableWriteOff_639178606085872609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639178606085872609" xlink:to="limn_OtherReceivableWriteOff_639178606085872609" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureDebtDetailss" xlink:type="extended" xlink:title="1240501 - Disclosure - Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_639178606085872609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_639178606085872609" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639178606085872609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_639178606085872609" xlink:to="us-gaap_DebtInstrumentAxis_639178606085872609" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639178606085878077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639178606085872609" xlink:to="us-gaap_DebtInstrumentNameDomain_639178606085878077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeluxBondsMember" xlink:label="limn_FeeluxBondsMember_639178606085878077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_FeeluxBondsMember_639178606085878077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CarTcellkorLoanMember" xlink:label="limn_CarTcellkorLoanMember_639178606085878077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_CarTcellkorLoanMember_639178606085878077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonLoanMember" xlink:label="limn_EwonLoanMember_639178606085878077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_EwonLoanMember_639178606085878077" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoDecember2022LoansMember" xlink:label="limn_ValetudoDecember2022LoansMember_639178606085878077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_ValetudoDecember2022LoansMember_639178606085878077" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJune2023LoansMember" xlink:label="limn_ValetudoJune2023LoansMember_639178606085878077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_ValetudoJune2023LoansMember_639178606085878077" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJuly2023LoanMember" xlink:label="limn_ValetudoJuly2023LoanMember_639178606085878077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_ValetudoJuly2023LoanMember_639178606085878077" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoAugust2023LoansMember" xlink:label="limn_ValetudoAugust2023LoansMember_639178606085882150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_ValetudoAugust2023LoansMember_639178606085882150" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonSeptember2023LoanMember" xlink:label="limn_EwonSeptember2023LoanMember_639178606085882150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_EwonSeptember2023LoanMember_639178606085882150" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoNovember2023LoanMember" xlink:label="limn_ValetudoNovember2023LoanMember_639178606085882150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_ValetudoNovember2023LoanMember_639178606085882150" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EwonDecember2023LoanMember" xlink:label="limn_EwonDecember2023LoanMember_639178606085882150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_EwonDecember2023LoanMember_639178606085882150" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ValetudoJanuary2024LoansMember" xlink:label="limn_ValetudoJanuary2024LoansMember_639178606085882150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_ValetudoJanuary2024LoansMember_639178606085882150" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseFebruary2024LoanMember" xlink:label="limn_ProphaseFebruary2024LoanMember_639178606085882150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_ProphaseFebruary2024LoanMember_639178606085882150" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMarch2024LoanMember" xlink:label="limn_ProphaseMarch2024LoanMember_639178606085882150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_ProphaseMarch2024LoanMember_639178606085882150" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseApril2024LoanMember" xlink:label="limn_ProphaseApril2024LoanMember_639178606085882150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_ProphaseApril2024LoanMember_639178606085882150" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMay2024LoansMember" xlink:label="limn_ProphaseMay2024LoansMember_639178606085887367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_ProphaseMay2024LoansMember_639178606085887367" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseJuly2024LoansMember" xlink:label="limn_ProphaseJuly2024LoansMember_639178606085888417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_ProphaseJuly2024LoansMember_639178606085888417" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseAugust2024LoansMember" xlink:label="limn_ProphaseAugust2024LoansMember_639178606085888417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_ProphaseAugust2024LoansMember_639178606085888417" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_HanaAugust2024LoansMember" xlink:label="limn_HanaAugust2024LoansMember_639178606085888417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_HanaAugust2024LoansMember_639178606085888417" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesNovember2024LoansMember" xlink:label="limn_AmantesNovember2024LoansMember_639178606085890773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_AmantesNovember2024LoansMember_639178606085890773" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AmantesJanuary2025LoansMember" xlink:label="limn_AmantesJanuary2025LoansMember_639178606085890773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_AmantesJanuary2025LoansMember_639178606085890773" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseFebruary2025LoanMember" xlink:label="limn_ProphaseFebruary2025LoanMember_639178606085890773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_ProphaseFebruary2025LoanMember_639178606085890773" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ProphaseMarch2025LoanMember" xlink:label="limn_ProphaseMarch2025LoanMember_639178606085890773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639178606085878077" xlink:to="limn_ProphaseMarch2025LoanMember_639178606085890773" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085890773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_639178606085872609" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085890773" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639178606085890773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639178606085890773" xlink:to="us-gaap_RelatedPartyDomain_639178606085890773" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639178606085890773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639178606085890773" xlink:to="us-gaap_RelatedPartyMember_639178606085890773" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems_639178606085896219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_639178606085872609" xlink:to="us-gaap_ShortTermDebtLineItems_639178606085896219" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_639178606085896219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_639178606085896219" xlink:to="us-gaap_ShortTermBorrowings_639178606085896219" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss" xlink:type="extended" xlink:title="1240601 - Disclosure - Stockholder's Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_639178606085957437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_639178606085957437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639178606085957822" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639178606085957437" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639178606085957822" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639178606085957822" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639178606085957822" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639178606085957822" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PublicWarrantsMember" xlink:label="limn_PublicWarrantsMember_639178606085957822" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085957822" xlink:to="limn_PublicWarrantsMember_639178606085957822" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PrivatePlacementWarrantsMember" xlink:label="limn_PrivatePlacementWarrantsMember_639178606085957822" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606085957822" xlink:to="limn_PrivatePlacementWarrantsMember_639178606085957822" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085957822" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639178606085957437" xlink:to="srt_CounterpartyNameAxis_639178606085957822" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085957822" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085957822" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085957822" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_AltaPartnersLlcMember" xlink:label="limn_AltaPartnersLlcMember_639178606085957822" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085957822" xlink:to="limn_AltaPartnersLlcMember_639178606085957822" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639178606085957437" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_639178606085957822" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="us-gaap_PreferredStockSharesAuthorized_639178606085957822" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_639178606085963695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="us-gaap_CommonStockSharesAuthorized_639178606085963695" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_639178606085963695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_639178606085963695" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_639178606085963695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="us-gaap_PreferredStockSharesOutstanding_639178606085963695" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_639178606085963695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_639178606085963695" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination_639178606085963695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination_639178606085963695" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuableForSettlementOfDeferredUnderwritingFees" xlink:label="limn_StockIssuableForSettlementOfDeferredUnderwritingFees_639178606085963695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="limn_StockIssuableForSettlementOfDeferredUnderwritingFees_639178606085963695" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" xlink:label="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees_639178606085963695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees_639178606085963695" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesIssuedForSurrenderAndCancellationOfWarrants" xlink:label="limn_SharesIssuedForSurrenderAndCancellationOfWarrants_639178606085963695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="limn_SharesIssuedForSurrenderAndCancellationOfWarrants_639178606085963695" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" xlink:label="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled_639178606085969631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled_639178606085969631" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonStockIssued" xlink:label="limn_FairValueOfCommonStockIssued_639178606085970554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="limn_FairValueOfCommonStockIssued_639178606085970554" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfWarrantsSurrendered" xlink:label="limn_FairValueOfWarrantsSurrendered_639178606085970982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="limn_FairValueOfWarrantsSurrendered_639178606085970982" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_GainLossOnIssuanceOfCommonStockForWarrants" xlink:label="limn_GainLossOnIssuanceOfCommonStockForWarrants_639178606085970982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="limn_GainLossOnIssuanceOfCommonStockForWarrants_639178606085970982" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_639178606085970982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="us-gaap_CommonStockSharesOutstanding_639178606085970982" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_639178606085970982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="us-gaap_CommonStockSharesIssued_639178606085970982" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockNumberOfVotesPerShare" xlink:label="limn_CommonStockNumberOfVotesPerShare_639178606085970982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="limn_CommonStockNumberOfVotesPerShare_639178606085970982" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_639178606085970982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_639178606085970982" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639178606085970982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639178606085970982" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639178606085977301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639178606085977301" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants" xlink:label="limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants_639178606085978543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants_639178606085978543" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption" xlink:label="limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption_639178606085979816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption_639178606085979816" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_639178606085980828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_639178606085980828" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_639178606085981890" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_639178606085981890" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_639178606085981890" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639178606085957822" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_639178606085981890" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" xlink:type="extended" xlink:title="1240701 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_639178606085981890" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_639178606085981890" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_639178606085987214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_639178606085981890" xlink:to="us-gaap_FinancialInstrumentAxis_639178606085987214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639178606085987893" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_639178606085987214" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639178606085987893" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FeeReductionAgreementMember" xlink:label="limn_FeeReductionAgreementMember_639178606085987893" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639178606085987893" xlink:to="limn_FeeReductionAgreementMember_639178606085987893" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_639178606085987893" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_639178606085981890" xlink:to="dei_LegalEntityAxis_639178606085987893" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_639178606085987893" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_639178606085987893" xlink:to="dei_EntityDomain_639178606085987893" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_IrisAcquisitionCorpMember" xlink:label="limn_IrisAcquisitionCorpMember_639178606085987893" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_639178606085987893" xlink:to="limn_IrisAcquisitionCorpMember_639178606085987893" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606085987893" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_639178606085981890" xlink:to="srt_CounterpartyNameAxis_639178606085987893" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085987893" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606085987893" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085987893" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClearStreetLlcMember" xlink:label="limn_ClearStreetLlcMember_639178606085987893" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606085987893" xlink:to="limn_ClearStreetLlcMember_639178606085987893" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_639178606085987893" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_639178606085981890" xlink:to="us-gaap_SubsequentEventTypeAxis_639178606085987893" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_639178606085993794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_639178606085987893" xlink:to="us-gaap_SubsequentEventTypeDomain_639178606085993794" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_639178606085993794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_639178606085993794" xlink:to="us-gaap_SubsequentEventMember_639178606085993794" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_639178606085981890" xlink:to="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_639178606085993794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="us-gaap_ShortTermLeaseCost_639178606085993794" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesIssuedForSurrenderAndCancellationOfWarrants" xlink:label="limn_SharesIssuedForSurrenderAndCancellationOfWarrants_639178606085993794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_SharesIssuedForSurrenderAndCancellationOfWarrants_639178606085993794" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_639178606085993794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_639178606085993794" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" xlink:label="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled_639178606085993794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled_639178606085993794" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPayable" xlink:label="limn_CommonStockPayable_639178606085993794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_CommonStockPayable_639178606085993794" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="us-gaap_LossContingencyDamagesAwardedValue_639178606085999625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="us-gaap_LossContingencyDamagesAwardedValue_639178606085999625" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementInterest" xlink:label="us-gaap_LitigationSettlementInterest_639178606085999625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="us-gaap_LitigationSettlementInterest_639178606085999625" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" xlink:label="limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering_639178606085999625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering_639178606085999625" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnderwritingCostsNoncurrent" xlink:label="limn_UnderwritingCostsNoncurrent_639178606085999625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_UnderwritingCostsNoncurrent_639178606085999625" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering" xlink:label="limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering_639178606085999625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering_639178606085999625" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredOfferingCostsNoncurrent" xlink:label="limn_DeferredOfferingCostsNoncurrent_639178606085999625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_DeferredOfferingCostsNoncurrent_639178606085999625" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PaymentOfOfferingCostsInCash" xlink:label="limn_PaymentOfOfferingCostsInCash_639178606085999625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_PaymentOfOfferingCostsInCash_639178606085999625" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_UnderwritingDiscountPaidInSecurities" xlink:label="limn_UnderwritingDiscountPaidInSecurities_639178606086005091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_UnderwritingDiscountPaidInSecurities_639178606086005091" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_MaximumNumbersOfSharesIssuable" xlink:label="limn_MaximumNumbersOfSharesIssuable_639178606086005514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_MaximumNumbersOfSharesIssuable_639178606086005514" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination_639178606086005514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination_639178606086005514" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination_639178606086005514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination_639178606086005514" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination_639178606086005514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination_639178606086005514" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination_639178606086005514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination_639178606086005514" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering" xlink:label="limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering_639178606086005514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering_639178606086005514" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination" xlink:label="limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination_639178606086011407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination_639178606086011407" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableInCashCurrent" xlink:label="limn_DeferredUnderwritingFeesPayableInCashCurrent_639178606086011407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_DeferredUnderwritingFeesPayableInCashCurrent_639178606086011407" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination" xlink:label="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination_639178606086011407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination_639178606086011407" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StockIssuableForSettlementOfDeferredUnderwritingFees" xlink:label="limn_StockIssuableForSettlementOfDeferredUnderwritingFees_639178606086011407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_StockIssuableForSettlementOfDeferredUnderwritingFees_639178606086011407" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees" xlink:label="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees_639178606086011407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_639178606085993794" xlink:to="limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees_639178606086011407" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss" xlink:type="extended" xlink:title="1240801 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639178606086017796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639178606086017796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_639178606086017796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639178606086017796" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_639178606086017796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_639178606086017796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_639178606086017796" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_639178606086017796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_639178606086017796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_639178606086017796" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_639178606086017796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639178606086017796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639178606086017796" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639178606086017796" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_639178606086017796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639178606086017796" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_639178606086017796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_639178606086023016" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639178606086017796" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_639178606086023016" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss" xlink:type="extended" xlink:title="1240802 - Disclosure - Fair Value Measurements - Changes in fair value of Level 3 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639178606086023477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639178606086023477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_639178606086023477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639178606086023477" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_639178606086023477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639178606086023477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_639178606086023477" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639178606086023477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_639178606086023477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639178606086023477" xlink:to="us-gaap_FairValueInputsLevel3Member_639178606086023477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_639178606086023477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639178606086023477" xlink:to="us-gaap_FinancialInstrumentAxis_639178606086023477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639178606086028942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_639178606086023477" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639178606086028942" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_639178606086028942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639178606086028942" xlink:to="us-gaap_WarrantMember_639178606086028942" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639178606086028942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639178606086023477" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639178606086028942" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_639178606086028942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639178606086028942" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_639178606086028942" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_639178606086028942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639178606086028942" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_639178606086028942" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_639178606086028942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639178606086028942" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_639178606086028942" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6391786060860289421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639178606086028942" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6391786060860289421" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="1240901 - Disclosure - Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_639178606086035760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_639178606086035760" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ResearchAndDevelopmentExpenseMandatoryCapitalization" xlink:label="limn_ResearchAndDevelopmentExpenseMandatoryCapitalization_639178606086035760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="limn_ResearchAndDevelopmentExpenseMandatoryCapitalization_639178606086035760" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_639178606086035760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwards_639178606086035760" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_FederalIncomeTaxExpenseSubjectToLimitationInUse" xlink:label="limn_FederalIncomeTaxExpenseSubjectToLimitationInUse_639178606086035760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="limn_FederalIncomeTaxExpenseSubjectToLimitationInUse_639178606086035760" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_StatutoryStateIncomeTaxRate" xlink:label="limn_StatutoryStateIncomeTaxRate_639178606086035760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="limn_StatutoryStateIncomeTaxRate_639178606086035760" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_639178606086035760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_639178606086035760" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_639178606086035760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_639178606086035760" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet_639178606086041211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet_639178606086041211" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetails" xlink:type="extended" xlink:title="1240902 - Disclosure - Income Taxes - Income tax provision (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_639178606086041465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_639178606086041465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_639178606086041465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_639178606086041465" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_639178606086041465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_639178606086041465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_639178606086041465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_639178606086041465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_639178606086041465" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_639178606086041465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_639178606086047165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_639178606086047165" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_639178606086047165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_639178606086047165" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" xlink:type="extended" xlink:title="1240903 - Disclosure - Income Taxes - Reconciliation of income tax rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639178606086047165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639178606086047165" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639178606086047165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639178606086047165" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639178606086047165" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_639178606086052619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639178606086047165" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_639178606086052619" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent" xlink:label="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent_639178606086052879" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639178606086047165" xlink:to="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent_639178606086052879" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent" xlink:label="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent_639178606086052879" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639178606086047165" xlink:to="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent_639178606086052879" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_639178606086052879" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639178606086047165" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_639178606086052879" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639178606086052879" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639178606086047165" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639178606086052879" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_639178606086052879" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639178606086047165" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_639178606086052879" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639178606086052879" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639178606086052879" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639178606086052879" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639178606086052879" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639178606086052879" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_639178606086052879" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639178606086052879" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_639178606086052879" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration_639178606086058684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_639178606086052879" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration_639178606086058684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount" xlink:label="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount_639178606086058684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639178606086052879" xlink:to="limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount_639178606086058684" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount" xlink:label="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount_639178606086058684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639178606086052879" xlink:to="limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount_639178606086058684" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_639178606086058684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639178606086052879" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_639178606086058684" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639178606086058684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639178606086052879" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639178606086058684" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_639178606086058684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639178606086052879" xlink:to="us-gaap_IncomeTaxExpenseBenefit_639178606086058684" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="1240904 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639178606086064181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639178606086064181" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639178606086064181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639178606086064181" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639178606086064181" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_DeferredTaxAssetsStartupExpenses" xlink:label="limn_DeferredTaxAssetsStartupExpenses_639178606086067170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639178606086064181" xlink:to="limn_DeferredTaxAssetsStartupExpenses_639178606086067170" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_639178606086067170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639178606086064181" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward_639178606086067170" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_639178606086067170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639178606086064181" xlink:to="us-gaap_DeferredTaxAssetsGross_639178606086067170" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_639178606086067170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639178606086064181" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_639178606086067170" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_639178606086067170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639178606086064181" xlink:to="us-gaap_DeferredTaxAssetsNet_639178606086067170" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="1241001 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_639178606086072908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_639178606086072908" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_639178606086072908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639178606086072908" xlink:to="us-gaap_SubsequentEventTypeAxis_639178606086072908" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_639178606086072908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_639178606086072908" xlink:to="us-gaap_SubsequentEventTypeDomain_639178606086072908" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_639178606086072908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_639178606086072908" xlink:to="us-gaap_SubsequentEventMember_639178606086072908" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639178606086072908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639178606086072908" xlink:to="srt_CounterpartyNameAxis_639178606086072908" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639178606086072908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639178606086072908" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639178606086072908" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClearStreetLlcMember" xlink:label="limn_ClearStreetLlcMember_639178606086072908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606086072908" xlink:to="limn_ClearStreetLlcMember_639178606086072908" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_InnobationBioCo.LtdMember" xlink:label="limn_InnobationBioCo.LtdMember_639178606086072908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639178606086072908" xlink:to="limn_InnobationBioCo.LtdMember_639178606086072908" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639178606086072908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639178606086072908" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639178606086072908" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639178606086078518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639178606086072908" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639178606086078518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PreFundedWarrantsMember" xlink:label="limn_PreFundedWarrantsMember_639178606086078757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606086078518" xlink:to="limn_PreFundedWarrantsMember_639178606086078757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPurchaseWarrantsMember" xlink:label="limn_CommonStockPurchaseWarrantsMember_639178606086078757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606086078518" xlink:to="limn_CommonStockPurchaseWarrantsMember_639178606086078757" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PlacementAgentWarrantsMember" xlink:label="limn_PlacementAgentWarrantsMember_639178606086078757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639178606086078518" xlink:to="limn_PlacementAgentWarrantsMember_639178606086078757" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639178606086078757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639178606086072908" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639178606086078757" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639178606086078757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639178606086078757" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639178606086078757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_BestEffortsPublicOfferingMember" xlink:label="limn_BestEffortsPublicOfferingMember_639178606086078757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639178606086078757" xlink:to="limn_BestEffortsPublicOfferingMember_639178606086078757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_639178606086078757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639178606086072908" xlink:to="us-gaap_TypeOfArrangementAxis_639178606086078757" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639178606086083974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_639178606086078757" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639178606086083974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember" xlink:label="limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_639178606086084777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639178606086083974" xlink:to="limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_639178606086084777" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_639178606086084777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639178606086072908" xlink:to="us-gaap_SubsequentEventLineItems_639178606086084777" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_SharesIssuedForSurrenderAndCancellationOfWarrants" xlink:label="limn_SharesIssuedForSurrenderAndCancellationOfWarrants_639178606086084777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="limn_SharesIssuedForSurrenderAndCancellationOfWarrants_639178606086084777" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_639178606086084777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_639178606086084777" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled" xlink:label="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled_639178606086084777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled_639178606086084777" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_CommonStockPayable" xlink:label="limn_CommonStockPayable_639178606086084777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="limn_CommonStockPayable_639178606086084777" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="us-gaap_LossContingencyDamagesAwardedValue_639178606086084777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="us-gaap_LossContingencyDamagesAwardedValue_639178606086084777" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementInterest" xlink:label="us-gaap_LitigationSettlementInterest_639178606086090328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="us-gaap_LitigationSettlementInterest_639178606086090328" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639178606086091177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639178606086091177" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued_639178606086091177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="limn_ClassOfWarrantOrRightNumberOfWarrantsIssued_639178606086091177" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639178606086091177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639178606086091177" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639178606086091177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="us-gaap_SharesIssuedPricePerShare_639178606086091177" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_ClassOfWarrantOrRightIssuePricePerWarrant" xlink:label="limn_ClassOfWarrantOrRightIssuePricePerWarrant_639178606086095063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="limn_ClassOfWarrantOrRightIssuePricePerWarrant_639178606086095063" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639178606086095480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639178606086095480" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_639178606086095480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_639178606086095480" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_639178606086095480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_639178606086095480" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate" xlink:label="limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate_639178606086095480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate_639178606086095480" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate" xlink:label="limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate_639178606086095480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate_639178606086095480" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PlacementAgentCashFeePercentage" xlink:label="limn_PlacementAgentCashFeePercentage_639178606086100911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="limn_PlacementAgentCashFeePercentage_639178606086100911" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_MaximumReimbursementForPlacementAgentExpenses" xlink:label="limn_MaximumReimbursementForPlacementAgentExpenses_639178606086101340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="limn_MaximumReimbursementForPlacementAgentExpenses_639178606086101340" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PercentOfSharesIssuedInOffering" xlink:label="limn_PercentOfSharesIssuedInOffering_639178606086101340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="limn_PercentOfSharesIssuedInOffering_639178606086101340" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PercentOfOfferingPriceRepresentingExercisePrice" xlink:label="limn_PercentOfOfferingPriceRepresentingExercisePrice_639178606086101340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="limn_PercentOfOfferingPriceRepresentingExercisePrice_639178606086101340" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639178606086101340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639178606086101340" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="limn-20260331.xsd#limn_PaymentForCostsAssociatedWithClinicalTrials" xlink:label="limn_PaymentForCostsAssociatedWithClinicalTrials_639178606086101340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639178606086084777" xlink:to="limn_PaymentForCostsAssociatedWithClinicalTrials_639178606086101340" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIMINATUS PHARMA, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001971387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Oct. 27, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 1,907,674<span></span>
</td>
<td class="nump">$ 337,655<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,319<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,668,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,401,323<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">870,872<span></span>
</td>
<td class="nump">162,919<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,501<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,778,546<span></span>
</td>
<td class="nump">500,574<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,281,643<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent', window );">Due from related party, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,275<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">11,703<span></span>
</td>
<td class="nump">12,221<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">11,703<span></span>
</td>
<td class="nump">12,221<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,216<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,790,249<span></span>
</td>
<td class="nump">512,795<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,408,859<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">529,778<span></span>
</td>
<td class="nump">582,234<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,483,253<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="nump">222,558<span></span>
</td>
<td class="nump">203,921<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">955,119<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,973,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingFeesPayableInCashCurrent', window );">Deferred underwriting fee payable</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockPayable', window );">Settlement payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,360,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,889,423<span></span>
</td>
<td class="nump">10,298,241<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,748,922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">33,422<span></span>
</td>
<td class="nump">29,244<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,922,845<span></span>
</td>
<td class="nump">10,327,485<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,748,922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 500,000,000 shares authorized; 44,877,633 and 27,064,633 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively</a></td>
<td class="nump">4,823<span></span>
</td>
<td class="nump">2,706<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">39,858,028<span></span>
</td>
<td class="nump">29,054,337<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,323,403<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(39,995,447)<span></span>
</td>
<td class="num">(38,871,733)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,665,216)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(132,596)<span></span>
</td>
<td class="num">(9,814,690)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19,667,589)<span></span>
</td>
<td class="num">(19,340,063)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td colspan="2" class="num">$ (15,793,754)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">2,790,249<span></span>
</td>
<td class="nump">512,795<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,408,859<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Non related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,782,297<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">194,587<span></span>
</td>
<td class="nump">209,586<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,253<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,973,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Shares, preferred stock amount, common stock amount and additional paid-in capital data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Shares, preferred stock amount, common stock amount and additional paid - in capital data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_AccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_AccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_CommonStockPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_CommonStockPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingFeesPayableInCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred underwriting fees payable in cash and are classified as current as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingFeesPayableInCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of receivable classified as other and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">44,877,633<span></span>
</td>
<td class="nump">27,064,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">44,877,633<span></span>
</td>
<td class="nump">27,064,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Mar. 31, 2026</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Condensed Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 700,898<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 264,220<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,967,812<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 644,619<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,685,334<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,100,898<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">264,220<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,967,812<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,329,953<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,100,898)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(264,220)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,967,812)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,329,953)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense, related parties</a></td>
<td class="num">(18,638)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(115,512)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(215,903)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(338,882)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">52,206<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">76,589<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">122,526<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ForgivenessOfUnrelatedVendorPayable', window );">Forgiveness of unrelated vendor payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,142,297<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue', window );">Change in fair value of deferred underwriting fee - paid in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(196,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in the fair value of warrant liabilities</a></td>
<td class="num">(4,178)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">54,312<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_FairValueOfCommonStockIssuanceForContingentLiability', window );">Fair value of common stock to be issued for contingent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,360,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(22,816)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(63,306)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,238,705)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(216,356)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,123,714)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (327,526)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (10,206,517)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (3,546,309)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in shares)</a></td>
<td class="nump">35,999,589<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">23,753,561<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted (in shares)</a></td>
<td class="nump">35,999,589<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">23,753,561<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Shares and per share data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Shares and per share data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from change in fair value of deferred underwriting fees that would be settled in common stock of the combined entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_FairValueOfCommonStockIssuanceForContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to fair value of common stock to be issued for contingent liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_FairValueOfCommonStockIssuanceForContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ForgivenessOfUnrelatedVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of forgiveness of unrelated vendor payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ForgivenessOfUnrelatedVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Deficit - USD ($)<br></strong></div></th>
<th class="th" colspan="2"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 9,323,403<span></span>
</td>
<td class="num">$ (25,118,907)<span></span>
</td>
<td class="num">$ (15,793,754)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,546,309)<span></span>
</td>
<td class="num">(3,546,309)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,323,403<span></span>
</td>
<td class="num">(28,665,216)<span></span>
</td>
<td class="num">$ (19,340,063)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(327,526)<span></span>
</td>
<td class="num">$ (327,526)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,323,403<span></span>
</td>
<td class="num">(28,992,742)<span></span>
</td>
<td class="num">(19,667,589)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,323,403<span></span>
</td>
<td class="num">(28,665,216)<span></span>
</td>
<td class="num">$ (19,340,063)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuedDuringPeriodValueBusinessCombination', window );">Business combination with IRIS, net of transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">190,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuedDuringPeriodSharesBusinessCombination', window );">Business combination with IRIS, net of transaction costs (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">114,633<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans', window );">Settlement of loans to Iris Acquisition Corp upon closing of the business combination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,443,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,443,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock to Iris Acquisition Holdings, LLC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 690<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock to Iris Acquisition Holdings, LLC (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,900,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with the Offering, net of offering costs of $559,962</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 150<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14,999,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with the Offering, net of offering costs of $559,962 (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuedPeriodValueOfCommonStockToUnderwriter', window );">Issuance of common stock to underwriter</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 70<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,244,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,245,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuedPeriodOfCommonStockToUnderwriter', window );">Issuance of common stock to underwriter (In shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants', window );">Issuance of common stock in connection with the surrender of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 35<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,739,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,740,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,206,517)<span></span>
</td>
<td class="num">(10,206,517)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 2,706<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29,054,337<span></span>
</td>
<td class="num">(38,871,733)<span></span>
</td>
<td class="num">$ (9,814,690)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,064,633<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,064,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants', window );">Issuance of common stock in connection with the Clear Street settlement (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants', window );">Issuance of common stock in connection with the Clear Street settlement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 736<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,359,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,360,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with the Offering, net of offering costs of $559,962</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,381<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,444,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,445,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with the Offering, net of offering costs of $559,962 (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,813,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,123,714)<span></span>
</td>
<td class="num">(1,123,714)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,823<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 39,858,028<span></span>
</td>
<td class="num">$ (39,995,447)<span></span>
</td>
<td class="num">$ (132,596)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,877,633<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,877,633<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Shares, preferred stock amount, common stock amount and additional paid-in capital data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Shares, preferred stock amount, common stock amount and additional paid - in capital data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to additional paid in capital (APIC) resulting from Settlement of loans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuedDuringPeriodSharesBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuedDuringPeriodSharesBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period for surrender and cancellation of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuedDuringPeriodValueBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to business combination during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuedDuringPeriodValueBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period for surrender and cancellation of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuedPeriodOfCommonStockToUnderwriter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued of common stock to underwriter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuedPeriodOfCommonStockToUnderwriter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued value for surrender and cancellation of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuedPeriodValueOfCommonStockToUnderwriter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued value of common stock to underwriter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuedPeriodValueOfCommonStockToUnderwriter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Deficit (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Condensed Consolidated Statements of Changes in Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_OfferingCosts', window );">Offering costs</a></td>
<td class="nump">$ 559,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_OfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of offering costs involved in the issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_OfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (1,123,714)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in the fair value of warrant liabilities</a></td>
<td class="num">(4,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="num">(707,953)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(191,956)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent', window );">Accrued interest, related parties</a></td>
<td class="nump">18,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="num">(14,999)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,015,289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">3,585,308<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">3,585,308<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash</a></td>
<td class="nump">1,570,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, beginning of the period</a></td>
<td class="nump">337,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, end of the period</a></td>
<td class="nump">1,907,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockIssuedInConnectionWithSettlement', window );">Issuance of common stock in connection with the Clear Street settlement</a></td>
<td class="nump">7,360,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CostsIncurredInConnectionWithIssuanceOfCommonStock', window );">Costs incurred in connection with the issuance of common stock</a></td>
<td class="nump">$ 139,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_CommonStockIssuedInConnectionWithSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in connection with settlement in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_CommonStockIssuedInConnectionWithSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_CostsIncurredInConnectionWithIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of common stock issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_CostsIncurredInConnectionWithIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued interest to related party classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Organization and Business Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Organization and Business Operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;1. Description of Organization and Business Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Liminatus Pharma, Inc. (the &#8220;Company&#8221;), a Delaware corporation, is a pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company&#8217;s candidate, IBA101, is a humanized anti CD47 monoclonal antibody. The next generation CD47 checkpoint inhibitor&#8217;s initial indication is expected to be patients with advanced solid cancers including non-small cell lung cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the uncertainty of whether the Company&#8217;s intellectual property will develop into successful commercial products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 30, 2022, Iris Acquisition Corp, a Delaware corporation (&#8220;Iris&#8221;), the Company, Liminatus Pharma, LLC, a Delaware limited liability company (&#8220;Liminatus&#8221;), Liminatus Pharma Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#8220;Liminatus Merger Sub&#8221;), and SPAC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#8220;SPAC Merger Sub&#8221;), entered into a business combination agreement (as amended, the &#8220;Business Combination Agreement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;4, 2025, Iris held a special meeting of stockholders. At the special meeting, Iris&#8217;s stockholders voted to approve the Business Combination and adopt the Business Combination Agreement, among other items. In connection with the special meeting, stockholders holding 59,844 Iris Class&#160;A Shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $11.74 per share, subject to adjustment for taxes payable from the trust account, for an aggregate redemption amount of $702,359. The redemptions were settled on April 30, 2025 upon the consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April&#160;30, 2025 (the &#8220;Closing Date&#8221;), the Company consummated the business combination contemplated by the Business Combination Agreement, pursuant to which <span style="color:#231f20;">(a)&#160;Liminatus Merger Sub merged with and into Liminatus (the &#8220;Liminatus Merger&#8221;), with Liminatus surviving the Liminatus Merger as a direct wholly-owned subsidiary of the Company, and (b)&#160;simultaneously with the Liminatus Merger, SPAC Merger Sub merged with and into Iris (the &#8220;SPAC Merger&#8221; and, together with the Liminatus Merger, the &#8220;Mergers&#8221;), with Iris surviving the SPAC Merger as a direct wholly-owned subsidiary of the Company (the transactions contemplated by the foregoing clauses (a)&#160;and (b)&#160;the &#8220;Business Combination&#8221;)</span>, and in connection therewith the Company changed its name from &#8220;Iris Parent Holding Corp.&#8221; to &#8220;Liminatus Pharma,&#160;Inc.<span style="color:#231f20;">&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Business Combination Agreement, among other matters, at the effective time of the Business Combination (the &#8220;Effective Time&#8221;), (i)&#160;every issued and outstanding security issued by Iris during its initial public offering (each, an &#8220;Iris Unit&#8221;) was automatically separated and broken out into its constituent parts and the holder thereof was deemed to hold one share of Iris Class&#160;A common stock, par value $0.0001 per share (the &#8220;Iris Class&#160;A Shares&#8221;) and <span style="-sec-ix-hidden:Hidden_V3HXcsnI6E-gQG2CW85ZjA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-fourth</span></span> of one redeemable warrant that was included as part of each Iris Unit (the &#8220;Public Warrants&#8221;), and such underlying constituent securities of Iris were converted in accordance with the applicable terms of the Business Combination Agreement, (ii)&#160;at the Effective Time, each issued and outstanding Iris Class&#160;A Share was converted automatically into and thereafter represent the right to receive one share of common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;), of the Company, following which all Iris Class&#160;A Shares ceased to be outstanding and were automatically canceled and ceased to exist, (iii)&#160;at the Effective Time, each issued and outstanding Public Warrant immediately and automatically represented the right to purchase shares of Common Stock on the same terms and conditions as are set forth in the applicable warrant agreement, (iv)&#160;at the Effective Time, each issued and outstanding non-redeemable warrant of Iris that was issued by Iris in a private placement at the time of the consummation of its initial public offering, entitling the holder thereof to purchase one Iris Class&#160;A Share at $11.50 per share, except those issued to Cantor Fitzgerald&#160;&amp; Co. (&#8220;Cantor&#8221;), were forfeited, and (v)&#160;the private placement warrants issued to Cantor immediately and automatically represented the right to purchase shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the consummation of the Business Combination, the Company&#8217;s certificate of incorporation was amended and restated to, among other things, set the total number of authorized shares of capital to 501,000,000 shares, of which 500,000,000 were designated as common stock, $0.0001 par value per share, and 1,000,000 shares were designated as preferred stock, $0.0001 par value per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing Date, 7,014,633 shares of Iris Class A Shares automatically converted into shares of the Company&#8217;s common stock, on a one-for-one basis. Of the total 7,014,633 newly converted shares, 6,900,000 were issued to Iris Acquisition Holdings, LLC, the sponsor of Iris, and 114,633 were issued to Iris&#8217; public stockholders in a noncash transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing Date, the Company issued an aggregate of 1,500,000 shares of the Company&#8217;s common stock in a private placement (the &#8220;PIPE Shares&#8221;) for the total consideration of $15,000,000 (the &#8220;PIPE Financing&#8221;). The PIPE Financing consisted of a cash and non-cash component. Under the cash component, the Company received gross proceeds of $10,556,500, of which $7,129,500 came directly from the PIPE investor and $3,427,000 were funded indirectly by the PIPE investor, through promissory notes between Prophase Sciences, LLC, a related party of the Company, and Liminatus. At the Closing Date, the $3,427,000 in related party debts between Prophase Sciences, LLC and Liminatus was ultimately converted into shares as part of the PIPE Financing. As part of the PIPE Financing, the gross proceeds satisfied principal and accrued interest totaling $3,316,756, which was ultimately converted into shares as part of the PIPE Financing. The non-cash component of the PIPE Financing included the conversion of $4,443,500 in amounts borrowed from a consortium of related parties. The $4,443,500 borrowed from the related parties was used to fund an unsecured promissory note between Liminatus and Iris. At the Closing Date, the unsecured promissory note was settled and the $4,443,500 in related party debts were ultimately converted into shares of the Company in a noncash transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing Date, 112,222,220 of Liminatus&#8217; member units converted into 17,500,000 shares of the Company&#8217;s common stock. Of the 17,500,000 shares of common stock, 4,000,000 were issued to Feelux Co, Ltd. as part of an agreement between the Company, Feelux Co, Ltd. and Car-Tcellkor, Inc. As part of the agreement, the outstanding principal and accrued interest on the Feelux and Car-Tcellkor bonds, totaling $11,481,146, and 9,999,999 member units of Liminatus were converted into 4,000,000 shares of the Company&#8217;s common stock. The remaining Liminatus member units were converted based on a conversion ratio of 0.1559 shares per member unit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon consummation of the Business Combination, the Company assumed a total of $10,694,604 in liabilities from Iris. The Company incurred $1,518,381 in transaction costs associated with the closing of the Business Combination. The Company converted a total of $14,797,901 of related party debt and accrued interest, $3,316,756 from the PIPE investor and $11,481,146 from Feelux and Car-Tcellkor (as described above) into common stock. Additionally, a total of $169,201 in accrued interest on related party debts that were converted, as discussed above, was eliminated upon consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, at the Closing Date, the Company settled Iris&#8217; liabilities for $7,000,000 of the deferred underwriting fees incurred prior to the Closing Date for 700,000 shares of common stock to the underwriters in Iris&#8217;s initial public offering. At the Closing Date, the shares were not issued to the underwriter and the Company recorded as a liability with a fair value of $7,049,000. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $7,245,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Liminatus was deemed the accounting acquirer in the Business Combination based on an analysis of the criteria outlined in Accounting Standards Codification (&#8220;ASC&#8221;) 805, <i style="font-style:italic;">Business Combinations</i> (&#8220;ASC 805&#8221;). The determination was primarily based on Liminatus&#8217; members prior to the Business Combination having a majority of the voting interests in the combined company, Liminatus&#8217; ability to exert control over the majority of the board of directors of the combined company, Liminatus&#8217; ability to maintain control of the board of directors on a go-forward basis, Liminatus&#8217; senior management comprising the senior management of the combined company, and Liminatus&#8217; operations prior to the Business Combination comprise the ongoing operations of the combined company. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Liminatus&#8217; issuing stock for the net assets of Iris, accompanied by a recapitalization. The net assets of Iris were stated at fair value, with no goodwill or other intangible assets recorded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the consummation of the Business Combination, the Iris Class&#160;A Shares, Iris Units and Public Warrants ceased trading on the OTC Pink Marketplace, and the Common Stock and Public Warrants began trading on The Nasdaq Stock Market (&#8220;Nasdaq&#8221;) under the trading symbols &#8220;LIMN&#8221; and &#8220;LIMNW,&#8221; respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Notices from Nasdaq</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 22, 2025, the Company received a notice from the Nasdaq Listing Qualifications Department indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025. The deficiency letter had no immediate effect on the listing of the Company&#8217;s common stock, and its common stock continued to trade on Nasdaq under the symbol &#8220;LIMN&#8221;. Under the Nasdaq rules, the Company had 60 calendar days, or until October 21, 2025, to submit a plan to regain compliance and if the plan was accepted, Nasdaq can grant an exception of up to 180 calendar days from the filing&#8217;s due date, or until February 16, 2026, to regain compliance. If the compliance plan was not accepted, the Company had the opportunity to appeal that decision to a Nasdaq Hearings Panel. On October 6, 2025, the Company filed its Form 10-Q for the period ended June 30, 2025 and the matter was closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On November 19, 2025, the Company received notices from the Nasdaq indicating that the Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value of Listed Securities (&#8220;MVLS&#8221;) of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$50,000,000 (the &#8220;MVLS Rule&#8221;), based upon a review of the Company&#8217;s MVLS for the last 30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly Held Shares (&#8220;MVPHS&#8221;) of $15,000,000 (the &#8220;MVPHS Rule&#8221;), based upon a review of the Company&#8217;s MVPHS for the last 30 consecutive business days. The Nasdaq staff noted that the Company also does not meet the requirements under Listing Rule 5450(b)(3)(A), which requires the Company to have total assets and total revenue of at least $50 million each for the most recently completed fiscal year or two of the three most recently completed fiscal years. Under the Nasdaq rules, the Company has 180 calendar days, or until May 18, 2026, to regain compliance with the MVLS Rule and MVPHS Rule. In the event the Company does not regain compliance with the MVLS Rule and MVPHS Rule prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Hearings Panel. Alternatively, the Company may consider applying to transfer the Company&#8217;s securities to the Capital Market, provided it meets the Capital Market&#8217;s continued listing requirements. The Company is working diligently to regain compliance with Nasdaq&#8217;s listing rules. However, there can be no assurance that the Company will be able to regain compliance within the prescribed time period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 15, 2026, the Company received a notice from Nasdaq indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rule 5450(a)(1) (the &#8220;Bid Price Rule&#8221;) which requires listed securities to maintain a minimum bid price of $1 per share. Under the Nasdaq rules, the Company has 180 calendar days, or until July 14, 2026, to regain compliance with the Bid Price Rule. In the event the Company does not regain compliance during the initial compliance period, the Company may be eligible for additional time to regain compliance with the Bid Price Rule. The Company is working diligently to regain compliance with Nasdaq&#8217;s listing rules. However, there can be no assurance that the Company will be able to regain compliance within the prescribed time period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">February 2026 Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 18, 2026, the Company closed a best efforts public offering for the sale of (i) 8,270,000 shares of common stock, (ii) 5,543,000 pre-funded warrants to purchase up to 5,543,000 shares of common stock and (iii) 13,813,000 common stock purchase warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per pre-funded warrant) and accompanying warrant (the &#8220;Offering&#8221;), for aggregate net proceeds of approximately $3.44 million after deducting the estimated offering expenses, including the placement agent fees. Each pre-funded warrant has an exercise price of $0.0001 per share upon issuance for one share of common stock and will not expire prior to exercise. Each warrant has an exercise price of $0.29 per share, is exercisable upon issuance for <span style="-sec-ix-hidden:Hidden_nl21qyvNY06G3jQDgQwLzg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one and a half</span></span> shares of common stock, and will expire five years following the date of issuance. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the common stock and the exercise price. Maxim Group LLC acted as the placement agent in connection with the Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Offering, on February 17, 2026, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers party thereto. Pursuant to the Purchase Agreement, the Company agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock or file any registration statement or prospectus, or any amendment or supplement thereto for 180 days after the closing date of the Offering, subject to certain exceptions. The Company also agreed not to effect or enter into an agreement to effect any issuance of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock involving a Variable Rate Transaction (as defined in the Purchase Agreement) until 180 days after the closing date of the Offering, subject to certain exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Offering, on February 17, 2026, the Company entered into a placement agency agreement with Maxim Group LLC, as placement agent in connection with the Offering (the &#8220;Placement Agent&#8221;). The Company paid the Placement Agent a cash fee of 8.0% of the aggregate gross proceeds raised in the Offering. The Company also agreed to reimburse the Placement Agent for all reasonable out-of-pocket costs and expenses incurred in connection with the Offering in an aggregate amount up to $100,000. In addition, the Company issued to the Placement Agent warrants (the &#8220;Placement Agent Warrants&#8221;) to purchase 690,650 shares of common stock (representing 5.0% of the number of shares of common stock sold in the Offering). The Placement Agent Warrants are immediately exercisable at an exercise price of $0.319 (or 110% of the public offering price for the shares of common stock and common warrants offered in the Offering) and will expire on the <span style="-sec-ix-hidden:Hidden_y0XoPBMFT0K_m6ZKSdgGew;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fifth anniversary</span></span> of the commencement of sales of the Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity and Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for one year after the date that the condensed consolidated financial statements are issued. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Through March 31, 2026, the Company has funded its operations mainly through equity and debt financings, including the proceeds from the Mergers and the PIPE Financing and the Offering (as described below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026, the Company had $1,907,674 of cash in its bank accounts. As of March 31, 2026 and December 31, 2025, there was $1,442,500 of related party debts, which are included in short-term debt, related parties in the accompanying unaudited condensed consolidated balance sheets (see Note 4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has an accumulated deficit of $39,995,447 as of March 31, 2026. The Company had a loss from operations and net loss of $1,100,898 and $1,123,714, respectively, for the three months ended March 31, 2026. The Company had a loss from operations and net loss of $264,220 and $327,526, respectively, for the three months ended March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 18, 2026, the Company completed a &#8220;best efforts&#8221; public offering of (i) 8,270,000 shares of its common stock, (ii) 5,543,000 Pre-Funded Warrants to purchase up to 5,543,000 shares of common stock and (ii) 13,813,000 Common Stock Warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per Pre-Funded Warrant) and accompanying warrant. In connection with the Offering, the Company received net proceeds of approximately $3.44 million, after deducting the estimated offering expenses payable by the Company, including the placement agent fees. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 205-40, <i style="font-style:italic;">Presentation of Financial Statements&#8212;Going Concern</i>, management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying unaudited condensed consolidated financial statements are issued. The Company&#8217;s unaudited condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management&#8217;s plans relating to the above include raising additional cash through further equity and debt financings or other arrangements to fund operations. There can be no assurance that the Company will be able to raise adequate capital under acceptable terms, if at all. The sale of additional equity may dilute existing members and newly issued equity securities may contain senior rights and preferences compared to currently outstanding common stock. Issued debt securities may contain covenants and limit the Company&#8217;s ability to pay dividends or make other distributions to stockholders. If the Company is unable to obtain such additional financing, future operations would need to be reevaluated.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;1. Description of Organization and Business Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Liminatus Pharma, Inc. (the &#8220;Company&#8221;), a Delaware corporation, is a pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company&#8217;s candidate IBA101, is a humanized anti CD47 monoclonal antibody. The next generation CD47 checkpoint inhibitor&#8217;s initial indication is expected to be patients with advanced solid cancers including non-small cell lung cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the uncertainty of whether the Company&#8217;s intellectual property will develop into successful commercial products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 30, 2022, Iris Acquisition Corp, a Delaware corporation (&#8220;Iris&#8221;), the Company, Liminatus Pharma, LLC, a Delaware limited liability company (&#8220;Liminatus&#8221;), Liminatus Pharma Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#8220;Liminatus Merger Sub&#8221;), and SPAC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#8220;SPAC Merger Sub&#8221;), entered into a business combination agreement (as it may be amended, supplemented or otherwise modified from time to time, the &#8220;Business Combination Agreement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;4, 2025, Iris held a special meeting of stockholders. At the special meeting, Iris&#8217;s stockholders voted to approve the Business Combination and adopt the Business Combination Agreement, among other items. In connection with the special meeting, stockholders holding 59,844 Iris Class&#160;A Shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $11.74 per share, subject to adjustment for taxes payable from the trust account, for an aggregate redemption amount of $702,359. The redemptions were settled on April 30, 2025 upon the consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April&#160;30, 2025 (the &#8220;Closing Date&#8221;), the Company consummated the business combination contemplated by the Business Combination Agreement, pursuant to which <span style="color:#231f20;">(a)&#160;Liminatus Merger Sub merged with and into Liminatus (the &#8220;Liminatus Merger&#8221;), with Liminatus surviving the Liminatus Merger as a direct wholly-owned subsidiary of the Company, and (b)&#160;simultaneously with the Liminatus Merger, SPAC Merger Sub merged with and into Iris (the &#8220;SPAC Merger&#8221; and, together with the Liminatus Merger, the &#8220;Mergers&#8221;), with Iris surviving the SPAC Merger as a direct wholly-owned subsidiary of the Company (the transactions contemplated by the foregoing clauses (a)&#160;and (b)&#160;the &#8220;Business Combination&#8221;)</span>, and in connection therewith the Company changed its name from &#8220;Iris Parent Holding Corp.&#8221; to &#8220;Liminatus Pharma,&#160;Inc.<span style="color:#231f20;">&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Business Combination Agreement, among other matters, at the effective time of the Business Combination (the &#8220;Effective Time&#8221;), (i)&#160;every issued and outstanding security issued by Iris during its initial public offering (each, an &#8220;Iris Unit&#8221;) was automatically separated and broken out into its constituent parts and the holder thereof was deemed to hold one share of Iris Class&#160;A common stock, par value $0.0001 per share (the &#8220;Iris Class&#160;A Shares&#8221;) and <span style="-sec-ix-hidden:Hidden_ZxKK64VsEUG8mm4V7fNrqQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-fourth</span></span> of one redeemable warrant that was included as part of each Iris Unit (the &#8220;Public Warrants&#8221;), and such underlying constituent securities of Iris were converted in accordance with the applicable terms of the Business Combination Agreement, (ii)&#160;at the Effective Time, each issued and outstanding Iris Class&#160;A Share was converted automatically into and thereafter represent the right to receive one share of common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;), of the Company, following which all Iris Class&#160;A Shares ceased to be outstanding and were automatically canceled and ceased to exist, (iii)&#160;at the Effective Time, each issued and outstanding Public Warrant immediately and automatically represented the right to purchase shares of Common Stock on the same terms and conditions as are set forth in the applicable warrant agreement, (iv)&#160;at the Effective Time, each issued and outstanding non-redeemable warrant of Iris that was issued by Iris in a private placement at the time of the consummation of its initial public offering, entitling the holder thereof to purchase one Iris Class&#160;A Share at $11.50 per share, except those issued to Cantor Fitzgerald&#160;&amp; Co. (&#8220;Cantor&#8221;), were forfeited, and (v)&#160;the private placement warrants issued to Cantor immediately and automatically represented the right to purchase shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the consummation of the Business Combination, the Company&#8217;s certificate of incorporation was amended and restated to, among other things, set the total number of authorized shares of capital to 501,000,000 shares, of which 500,000,000 were designated as common stock, $0.0001 par value per share, and 1,000,000 shares were designated as preferred stock, $0.0001 par value per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing Date, 7,014,633 shares of Iris Class A Shares automatically converted into shares of the Company&#8217;s common stock, on a one-for-one basis. Of the total 7,014,633 newly converted shares, 6,900,000 were issued to Iris Acquisition Holdings, LLC, the sponsor of Iris, and 114,633 were issued to Iris&#8217; public stockholders in a noncash transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing Date, the Company issued an aggregate of 1,500,000 shares of the Company&#8217;s common stock in a private placement (the &#8220;PIPE Shares&#8221;) for the total consideration of $15,000,000 (the &#8220;PIPE Financing&#8221;). The PIPE Financing consisted of a cash and non-cash component. Under the cash component, the Company received gross proceeds of $10,556,500, of which $7,129,500 came directly from the PIPE investor and $3,427,000 was funded indirectly by the PIPE investor, through promissory notes between Prophase Sciences, LLC, a related party of the Company, and Liminatus. At the Closing Date, the $3,427,000 in related party debts between Prophase Sciences, LLC and Liminatus was ultimately converted into shares as part of the PIPE Financing. As part of the PIPE Financing, the gross proceeds satisfied principal and accrued interest totaling $3,316,756, which was ultimately converted into shares as part of the PIPE Financing. The non-cash component of the PIPE Financing included the conversion of $4,443,500 in amounts borrowed from a consortium of related parties. The $4,443,500 borrowed from the related parties were used to fund an unsecured promissory note between Liminatus and Iris. At the Closing Date, the unsecured promissory note was settled and the $4,443,500 in related party debts were ultimately converted into shares of the Company in a noncash transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing Date, 112,222,220 Liminatus&#8217; member units converted into 17,500,000 shares of the Company&#8217;s common stock. Of the 17,500,000 shares of common stock, 4,000,000 were issued to Feelux Co, Ltd. as part of an agreement between the Company, Feelux Co, Ltd. and Car-Tcellkor, Inc. As part of the agreement, the outstanding principal and accrued interest on the Feelux and Car-Tcellkor bonds, totaling $11,481,146, and 9,999,999 member units of Liminatus were converted into 4,000,000 shares of the Company&#8217;s common stock. The remaining Liminatus member units were converted based on a conversion ratio of 0.1559 shares per member unit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon consummation of the Business Combination, the Company assumed a total of $10,694,604 in liabilities from Iris. The Company incurred $1,518,381 in transaction costs associated with the closing of the Business Combination. The Company converted a total of $14,797,901 of related party debt and accrued interest, <span style="-sec-ix-hidden:Hidden_5_bKoANxokGAW-xbn0qRBA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3,316,755</span></span> from the PIPE investor and $11,481,146 from Feelux and Car-Tcellkor (as described above) into common stock. Additionally, a total of $169,201 in accrued interest on related party debts that were converted, as discussed above, was forgiven upon consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, at the Closing Date, the Company settled Iris&#8217; liabilities for $7,000,000 of the deferred underwriting fees incurred prior to the Closing Date for 700,000 shares of common stock to the underwriters in Iris&#8217;s initial public offering. At the Closing Date, the shares were not issued to the underwriter and the Company recorded as a liability with a fair value of $7,049,000. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $7,245,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Liminatus was deemed the accounting acquirer in the Business Combination based on an analysis of the criteria outlined in Accounting Standards Codification (&#8220;ASC&#8221;) 805, <i style="font-style:italic;">Business Combinations</i> (&#8220;ASC 805&#8221;). The determination was primarily based on Liminatus&#8217; members prior to the Business Combination having a majority of the voting interests in the combined company, Liminatus&#8217; ability to exert control over the majority of the board of directors of the combined company, Liminatus&#8217; ability to maintain control of the board of directors on a go-forward basis, Liminatus&#8217; senior management comprising the senior management of the combined company, and Liminatus&#8217; operations prior to the Business Combination comprise the ongoing operations of the combined company. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Liminatus&#8217; issuing stock for the net assets of Iris, accompanied by a recapitalization. The net assets of Iris were stated at fair value, with no goodwill or other intangible assets recorded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the consummation of the Business Combination, the Iris Class&#160;A Shares, Iris Units and Public Warrants ceased trading on the OTC Pink Marketplace, and the Common Stock and Public Warrants began trading on The Nasdaq Stock Market (&#8220;Nasdaq&#8221;) under the trading symbols &#8220;LIMN&#8221; and &#8220;LIMNW,&#8221; respectively, on May&#160;1, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nasdaq Notices</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On August 22, 2025, the Company received a notice from the Nasdaq Listing Qualifications Department indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025. The deficiency letter had no immediate effect on the listing of the Company&#8217;s common stock, and its common stock continued to trade on Nasdaq under the symbol &#8220;LIMN&#8221;. Under the Nasdaq rules, the Company had 60 calendar days, or until October 21, 2025, to submit a plan to regain compliance and if the plan was accepted, Nasdaq can grant an exception of up to 180 calendar days from the filing&#8217;s due date, or until February 16, 2026, to regain compliance. If the compliance plan was not accepted, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Company had the opportunity to appeal that decision to a Nasdaq Hearings Panel. On October 6, 2025, the Company filed its Form 10-Q for the period ended June 30, 2025 and the matter was closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 19, 2025, the Company received notices from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value of Listed Securities (MVLS) of $50,000,000 (the &#8220;MVLS Rule&#8221;), based upon a review of the Company&#8217;s MVLS for the last 30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly Held Shares (MVPHS) of $15,000,000 (the &#8220;MVPHS Rule&#8221;), based upon a review of the Company&#8217;s MVPHS for the last 30 consecutive business days. The Nasdaq staff noted that the Company also does not meet the requirements under Listing Rule 5450(b)(3)(A), which requires the Company to have total assets and total revenue of at least $50 million each for the most recently completed fiscal year or two of the three most recently completed fiscal years. Under the Nasdaq rules, the Company has 180 calendar days, or until May 18, 2026, to regain compliance with the MVLS Rule and MVPHS Rule. In the event the Company does not regain compliance with the MVLS Rule and MVPHS Rule prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Hearings Panel. Alternatively, the Company may consider applying to transfer the Company&#8217;s securities to the Capital Market, provided it meets the Capital Market&#8217;s continued listing requirements. The Company is working diligently to regain compliance with Nasdaq&#8217;s listing rules. However, there can be no assurance that the Company will be able to regain compliance within the prescribed time period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 15, 2026, the Company received a notice from Nasdaq indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rule 5450(a)(1) (the &#8220;Bid Price Rule&#8221;) which requires listed securities to maintain a minimum bid price of $1 per share. Under the Nasdaq rules, the Company has 180 calendar days, or until July 14, 2026, to regain compliance with the Bid Price Rule. In the event the Company does not regain compliance during the initial compliance period, the Company may be eligible for additional time to regain compliance with the Bid Price Rule. The Company is working diligently to regain compliance with Nasdaq&#8217;s listing rules. However, there can be no assurance that the Company will be able to regain compliance within the prescribed time period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity and Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for one year after the date that the consolidated financial statements are issued. Through December 31, 2025, the Company has funded its operations mainly through equity and debt financings, including the proceeds from the Mergers and the PIPE Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, the Company had $337,655 of cash in its bank accounts. As of December 31, 2025 and 2024, there was $1,442,500 and $19,973,000, respectively, of related party debts, which are included in Short-term debt, related parties in the accompanying consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has an accumulated deficit of $38,871,733 as of December 31, 2025. The Company had a loss from operations and net loss of $(2,967,812) and $(10,206,517), respectively, for the year ended December 31, 2025. The Company had a loss from operations and net loss of $(3,329,953) and $(3,546,309), respectively, for the year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 18, 2026, the Company completed a &#8220;best efforts&#8221; public offering of (i) 8,270,000 shares of its common stock, (ii) 5,543,000 pre-funded warrants to purchase up to 5,543,000 shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) and (ii) 13,813,000 common stock purchase warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per Pre-Funded Warrant) and accompanying warrant (the &#8220;Offering&#8221;). In connection with the Offering, the Company received net proceeds of approximately $3.46 million, after deducting the estimated offering expenses payable by the Company, including the placement agent fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 205-40, <i style="font-style:italic;">Presentation of Financial Statements&#8212;Going Concern</i>, management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying consolidated financial statements are issued. The Company&#8217;s consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management&#8217;s plans relating to the above include raising additional cash through further equity and debt financings or other arrangements to fund operations. There can be no assurance that the Company will be able to raise adequate capital under acceptable terms, if at all. The sale of additional equity may dilute existing members and newly issued equity securities may contain senior rights and preferences compared to currently outstanding common stock. Issued debt securities may contain covenants and limit the Company&#8217;s ability to pay dividends or make other distributions to stockholders. If the Company is unable to obtain such additional financing, future operations would need to be reevaluated.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;2. Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) as determined by the FASB ASC and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The unaudited condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements do not include all of the disclosures required by U.S. GAAP for annual consolidated financial statements and should be read in conjunction with the audited consolidated financial statements of the Company as of and for the year ended December 31, 2025 (the &#8220;Annual Financial Statements&#8221;). In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary to fairly present its financial position as of March 31, 2026, its results of operations for the three months ended March 31, 2026 and 2025, its cash flows for the three months ended March 31, 2026 and 2025, and its changes in stockholders&#8217; deficit for the three months ended March 31, 2026 and 2025. Results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year ending December 31, 2026 or any future period. The condensed consolidated balance sheet as of December 31, 2025 was derived from the Annual Financial Statements but does not contain all of the footnote disclosures from the Annual Financial Statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company Status</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">After the closing of the Business Combination, the Company has elected to be an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s unaudited condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results may differ materially and adversely from these estimates. The Company is not aware of any significant estimates that required management to exercise significant judgment with the exception of the Company&#8217;s warrant liability and research and development costs. If the underlying estimates and assumptions upon which the estimates are based change in the future, actual amounts may differ from those included in the Company&#8217;s unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), the Chief Executive Officer, manages the Company&#8217;s business activities as a <span style="-sec-ix-hidden:Hidden_skpW_fMTs0qgK5TqjOzinQ;"><span style="-sec-ix-hidden:Hidden_oRglHBbi5kiQPSddjK0rrg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">single</span></span></span> operating and reportable segment. Accordingly, the Company&#8217;s CODM uses net income/loss to measure the Company&#8217;s single segment&#8217;s performance and allocate resources. Further, the CODM reviews and utilizes functional expenses (general and administrative and research and development) to manage the Company&#8217;s operations. The Company&#8217;s general and administrative expenses for the three months ended March 31, 2026 and 2025 included $60,500 and $37,500, respectively, of compensation expenses related to the compensation agreement the Company has executed with its Chief Executive Officer. The remaining general and administrative expenses are related to legal and accounting-related expenses for contractors. The Company&#8217;s research and development expenses did not include any compensation-related expenses. Other segment items included in net loss are interest expense, related parties and interest income which are reflected in the Company&#8217;s unaudited condensed consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which can exceed government insured limits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company did not have any cash equivalents as of March 31, 2026 and December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial assets and liabilities are accounted for in accordance with FASB ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures,</i> which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value hierarchy requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 1 &#8212; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 2 &#8212; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the instrument&#8217;s anticipated life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 3 &#8212; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgement. Accordingly, the degree of judgement exercised by management in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the warrant liability reported in the Company&#8217;s unaudited condensed consolidated balance sheets represent a Level 3 instrument (see Note 8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying values reported in the Company&#8217;s unaudited condensed consolidated balance sheets for prepaid expenses and other current assets, due from related party, accounts payable and accrued expenses, accrued interest, short-term debt with related parties, due to related parties and its deferred underwriting fee payable are reasonable estimates of their fair values due to the short-term nature of these items.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC 480, <i style="font-style:italic;">Distinguishing liabilities from equity</i> (&#8220;ASC 480&#8221;), and ASC 815, <i style="font-style:italic;">Derivatives and Hedging</i> (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance, modification, and as of each subsequent quarterly period end date while the warrants are outstanding. As of March 31, 2026, 13,813,000 of the Company&#8217;s Common Stock Warrants, 690,650 Placement Agent Warrants and 5,094,623 Public Warrants were accounted for as equity-classified instruments and 835,555 private placement warrants were accounted for as liability-classified instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the liability-classified warrants are recognized as a non-cash gain or loss on the accompanying condensed consolidated statements of operations. The Company assesses the classification of its warrants at each reporting date to determine whether a change in classification between equity and liability is required. During the three months ended March 31, 2026, the Company had an unrealized gain on the change in fair value of the warrant liabilities of $4,178. During the three months ended March 31, 2025, the Company had no unrealized gain or loss on the change in fair value of the warrant liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss per Share of Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company complies with accounting and disclosure requirements of ASC Topic 260, <i style="font-style:italic;">Earnings Per Share</i>. The Company has one class of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities if their effect is antidilutive. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined by using the treasury stock method. Dilutive common stock equivalents are comprised of 19,598,273 warrants, comprised of 13,813,000 Common Stock Warrants, 690,650 Placement Agent Warrants and 5,094,623 Public Warrants. For all periods </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">presented, there is no difference in the number of shares used to calculated basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive given that their inclusion would reduce the net loss per share during the three months ended March 31, 2026 and 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of costs incurred by InnoBation Bio Co, Ltd. (&#8220;Innobation&#8221;) in accordance with the license agreement with Innobation and are recorded as research and development expenses as incurred (see Note 3).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes its leases in accordance with ASC Topic 842, <i style="font-style:italic;">Leases</i> (&#8220;ASC 842&#8221;). Under ASC 842, lessees are required to recognize all qualified operating leases at the commencement date including a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use (&#8220;ROU&#8221;) asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. The initial lease liability is equal to the future fixed minimum lease payments discounted using the Company&#8217;s incremental borrowing rate, on a secured basis. The lease term includes option renewal periods and early termination payments when it is reasonably certain that the Company will exercise those rights. The initial measurement of the ROU asset is equal to the initial lease liability plus any initial direct costs and prepayments, less any lease incentives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has leased office space for a fixed period of 10 months. In accordance with ASC 842, a short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The short-term lease election can only be made at the commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A lessee that makes this accounting policy election does not recognize a lease liability or right-of-use asset on its balance sheets. Instead, the lessee recognizes lease payments on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes in accordance with ASC Topic 740,&#160;<i style="font-style:italic;">Income Taxes</i>&#160;(&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. There were no tax accruals relating to uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax positions as income tax expense. There were no unrecognized tax positions, and no amounts accrued for interest and penalties as of March 31, 2026 and December 31, 2025. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only &#8220;major&#8221; tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. No unrecognized tax benefits were identified as of March 31, 2026 or December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements&#160;&#8211; Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On November 4, 2024, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2024-03, <i style="font-style:italic;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i> (&#8220;ASU 2024-03&#8221;), to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this standard will have on its unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#8217;s unaudited condensed consolidated financial statements.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;2. Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) as determined by the FASB ASC and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company Status</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the closing of the Business Combination, the Company has elected to be an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart our Business Startups Act of 2012, (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results may differ materially and adversely from these estimates. The Company is not aware of any significant estimates that required management to exercise significant judgment with the exception of the Company&#8217;s warrant liability. If the underlying estimates and assumptions upon which the estimates are based change in the future, actual amounts may differ from those included in the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), the Chief Executive Officer, manages the Company&#8217;s business activities as a single operating and reportable segment. Accordingly, the Company&#8217;s CODM uses net income/loss to measure the Company&#8217;s single segment&#8217;s performance and allocate resources. Further, the CODM reviews and utilizes functional expenses (general and administrative and research and development) to manage the Company&#8217;s operations. The Company&#8217;s general and administrative expenses for each of the years ended December 31, 2025 and 2024 included $202,833 and $150,000 of compensation expenses related to the compensation agreements the Company has executed with its executive team. The remaining general and administrative expenses </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">are related to legal and accounting-related expenses for contractors. The Company&#8217;s research and development expenses did not include any compensation-related expenses. Other segment items included in net income (loss) are interest expense, related parties and interest income which are reflected in the Company&#8217;s consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which can exceed government insured limits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Loan Receivable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its loan receivable at amortized cost, net of expected credit losses. The Company provides reserves against its loan receivable balance for estimated credit losses, if any, that may result from a counterparty&#8217;s inability to pay based on the composition of the loan receivable, current economic conditions and, historical credit loss activity and future expected conditions and market trends (such as general economic conditions, other macroeconomic and microeconomic events, etc.). Changes in circumstances relating to these factors may result in the need to increase or decrease the allowance for credit losses in the future. Amounts deemed uncollectible are charged or written-off against the reserve. On April 30, 2025, in connection with the Business Combination, the loan receivable was eliminated in consolidation as Iris and Liminatus are now consolidated subsidiaries of the Company. As of January 1, 2024 and December 31, 2024, no expected credit loss was recorded related to the loan receivable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Deferred Transaction Costs </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Costs incurred in connection with preparation for the proposed business combination were deferred on the balance sheets as of December 31, 2024. No such costs were deferred on the balance sheets as of December 31, 2025 due to the completion of the Company&#8217;s business combination with Iris. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial assets and liabilities are accounted for in accordance with FASB ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures,</i> which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value hierarchy requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 1 &#8212; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 2 &#8212; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the instrument&#8217;s anticipated life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 3 &#8212; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgement. Accordingly, the degree of judgement exercised by management in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the warrant liability reported in the Company&#8217;s consolidated balance sheets represent a Level 3 instrument. See Note 8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The carrying values reported in the Company&#8217;s consolidated balance sheets for prepaid expenses and other current assets, due from related party, accounts payable and accrued expenses, accrued interest, short-term debt with related parties, due to research and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">development partner, due to related parties, settlement payable, and its deferred underwriting fee payable are reasonable estimates of their fair values due to the short-term nature of these items.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC 480, <i style="font-style:italic;">Distinguishing liabilities from equity</i> (&#8220;ASC 480&#8221;), and ASC 815, <i style="font-style:italic;">Derivatives and Hedging</i> (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance, modification, and as of each subsequent quarterly period end date while the warrants are outstanding. As of December 31, 2025, 5,899,975 of the Company&#8217;s Public Warrants were accounted for as equity-classified instruments and 835,555 private placement warrants were accounted for as liability-classified instruments. As of December 31, 2025, there were no other public or <span style="-sec-ix-hidden:Hidden_wUaYXsrirkKbOmu3ilr3Zg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">private</span></span> warrants outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the liability-classified warrants are recognized as a non-cash gain or loss on the accompanying consolidated statements of operations. The Company assesses the classification of its warrants at each reporting date to determine whether a change in classification between equity and liability is required. During the year ended December 31, 2025, the Company had an unrealized gain on the change in fair value of the warrant liabilities of $54,312. During the year ended December 31, 2024, the Company had no unrealized gain or loss on the change in fair value of the warrant liabilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net loss per Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company complies with accounting and disclosure requirements of ASC Topic 260, <i style="font-style:italic;">Earnings Per Share</i>. The Company has one class of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities if their effect is antidilutive. Diluted net loss per share is computed by the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined by using the treasury stock method. Dilutive common stock equivalents are comprised of 6,735,530 warrants. For all periods presented, there is no difference in the number of shares used to calculated basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive given that their exercise price is greater than that of the average market price of the Company&#8217;s common stock during the years ended December 31, 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of costs incurred by Targeted Diagnostics &amp; Therapeutics, Inc. (&#8220;TDT&#8221;) who was performing the research and development activities for the Company in accordance with the license agreements with TDT and the annual fee paid to TDT and are recorded as research and development expenses as incurred (see Note 3).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes its leases in accordance with ASC Topic 842, <i style="font-style:italic;">Leases</i> (&#8220;ASC 842&#8221;). Under ASC 842, lessees are required to recognize all qualified operating leases at the commencement date including a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use (&#8220;ROU&#8221;) asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. The initial lease liability is equal to the future fixed minimum lease payments discounted using the Company&#8217;s incremental borrowing rate, on a secured basis. The lease term includes option renewal periods and early termination payments when it is reasonably certain that the Company will exercise those rights. The initial measurement of the ROU asset is equal to the initial lease liability plus any initial direct costs and prepayments, less any lease incentives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has leased office space for a fixed period of 10 months. In accordance with ASC 842, a short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The short-term lease election can only be made at the commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A lessee that makes this accounting policy election does not recognize a lease liability or right-of-use asset on its balance sheet. Instead, the lessee recognizes lease payments on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes in accordance with ASC Topic 740,&#160;<i style="font-style:italic;">Income Taxes</i>&#160;(&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. There were no tax accruals relating to uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax positions as income tax expense. There were no unrecognized tax positions, and no amounts accrued for interest and penalties as of December 31, 2025 and 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only &#8220;major&#8221; tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. No unrecognized tax benefits were identified as of December 31, 2025 or 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The Company adopted this standard on January 1, 2025 and determined that the adoption does not have a material impact on these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements&#160;&#8211; Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2024, the FASB issued ASU 2024-03, Accounting Standards Update 2024-03, <i style="font-style:italic;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i> to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_LicenseAgreementsAbstract', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_LicenseAgreementsTextBlock', window );">License Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 3. License Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CD47 License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October 2022, the Company was assigned a license and development agreement, as amended, with InnoBation Bio Co., Ltd. (the &#8220;CD47 License&#8221;), whereby, effective March 31, 2023, the Company received an exclusive license to develop and commercialize products for the CD47 immune checkpoint inhibitor to treat solid cancers, and companion diagnostics used to monitor treatment with CD47 products (collectively, &#8220;CD47 Products&#8221;), from Curis Biotech Holdings LLC, the parent company of Valetudo, a related party of the Company, in exchange for 78,555,554 of Liminatus&#8217; Class A member units. The license was recorded at Valetudo&#8217;s cost basis of zero, and the Company recorded an approximately $800,000 Class A membership interest with an offset to additional paid-in capital on the balance sheets. The Company is obligated to pay all development costs for CD47 Products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 20, 2026, the Company issued a payment of $1,000,000 to Innobation for the total estimated costs associated with the preparation activities for Phase 1 clinical trials of IBA101, the Company&#8217;s product candidate. As of March 31, 2026, the Company estimated approximately 40% of the activities were completed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of March 31, 2026 and December 31, 2025, prepaid research and development costs of $600,000 and $0, respectively, are recorded in prepaid and other current assets in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, research and development expense related to the CD47 License was $400,000 and $0, respectively.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 3. License Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CAR-T Products License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June 2018, the Company entered into a license and development agreement with TDT (the &#8220;CAR-T License&#8221;), whereby the Company received an exclusive license to develop and commercialize chimeric antigen receptor (&#8220;CAR-T&#8221;) products and a non-exclusive license to develop and commercialize companion diagnostics used to monitor treatment with a CAR-T product (the &#8220;CAR-T Diagnostics&#8221;). Under the CAR-T License, the Company made an upfront payment recorded as research and development expenses in the year ended December 31, 2018 and funded all of the development costs for the CAR-T products and the CAR-T Diagnostics which began with an upfront payment made during the year ended December 31, 2018 of approximately $5,000,000, recorded as advances for research and development in the balance sheets. The Company amortizes the advances to research and development expenses in the consolidated statements of operations as costs are incurred by TDT, based on annual budgets approved jointly by Liminatus and TDT. As of December 31, 2025 and 2024, all of the amounts funded have been utilized. The Company was also obligated to pay an approximately $500,000 annual maintenance fee for the license which is included in research and development expenses in the consolidated statements of operations. Unpaid annual maintenance fees become short-term debt that bears interest of 1.5% per month on a compounded basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the completion of the Phase I and Phase II clinical trials for the CAR-T product, the Company was obligated to advance the funding for the Phase II and Phase III clinical trials, respectively, estimated at approximately $20,000,000 for each phase. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the funding for the CAR-T development, the Company was obligated to make four developmental and regulatory milestone payments for the first CAR-T product that was developed aggregating up to approximately $15,000,000. After the first four developmental and regulatory milestone payments were made, the Company was obligated to pay four developmental and regulatory milestones aggregating up to approximately $7,500,000 for each additional CAR-T product that was developed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In further consideration of the license, the Company also agreed to pay a low double digit royalty rate (10% &#8211; 15%) based on annual net sales of CAR-T products or CAR-T Diagnostics on a country-by-country basis for the period from the first commercial sale of the CAR-T product or CAR-T Diagnostic until the CAR-T product or CAR-T Diagnostic&#8217;s patent expires in an individual country. Once the CAR-T product or CAR-T Diagnostic&#8217;s patent expires in an individual country, the Company agreed to pay a mid-single digit royalty rate (5% &#8211; 9%) based on annual net sales of CAR-T products and CAR-T Diagnostics on a country- by-country basis. Royalties were payable on a country-by-country basis for a period of ten years from the first commercial sale of the CAR-T product or CAR-T Diagnostic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 11, 2024, the Company received notice from TDT, exercising its right to terminate the license and development agreement. Please refer to &#8220;Termination and Settlement of CAR-T Products and Vaccine Products Licenses from TDT&#8221; below for further details related the termination and settlement of the CAR-T Products and Vaccine Products Licenses from TDT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Vaccine Products License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 10, 2020, the Company was assigned a license and development agreement with TDT (the &#8220;Vaccine License&#8221;), whereby the Company received an exclusive license to develop and commercialize vaccine products (the &#8220;Vaccine Products&#8221;) and a non-exclusive license to develop and commercialize companion diagnostics used to monitor treatment with a Vaccine Product (the &#8220;Vaccine Diagnostics&#8221;). Under the Vaccine License, the Company was responsible for all of the development costs for the Vaccine Products after the upfront payment of approximately $4,000,000, which was paid by Viral Gene, Inc (&#8220;Viral Gene&#8221;), of which Chris Kim is also the CEO, to TDT. The Company was also obligated to pay an approximately $400,000 annual maintenance fee for the license which is included in research and development expenses in the Company&#8217;s consolidated statements of operations for the year ended December&#160;31, 2024. There was no maintenance fee for the year ended December 31, 2025. Unpaid annual maintenance fees will become short-term debt that bears interest of 1.5% per month on a compounded basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company amortizes the amounts due to research and development partner in the Company&#8217;s consolidated balance sheets to research and development expenses in the consolidated statements of operations as costs are incurred by TDT, based on annual budgets approved jointly by Liminatus and TDT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In addition to the funding for the Vaccine Products development, the Company was obligated to make four developmental and regulatory milestone payments for the first Vaccine Product that was developed aggregating up to approximately $12,000,000. After the first four developmental and regulatory milestone payments are made, the Company was obligated to pay four developmental and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">regulatory milestones aggregating up to approximately $6,000,000 for each additional Vaccine Product that is developed. As of December 31, 2025 and 2024, all the amounts funded have been utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In further consideration of the license, the Company also agreed pay a low double digit royalty rate (10% &#8211; 15%) based on annual net sales of Vaccine Products or Vaccine Diagnostics on a country-by-country basis for the period from the first commercial sale of the Vaccine Product or Vaccine Diagnostic until the Vaccine Product or Vaccine Diagnostic&#8217;s patent expires in an individual country. Once the Vaccine Product or Vaccine Diagnostic&#8217;s patent expires in an individual country, the Company agreed to pay a mid-single digit royalty rate (5% &#8211; 9%) based on annual net sales of Vaccine Products and Vaccine Diagnostics on a country- by-country basis. Royalties were payable on a country-by-country basis for a period of ten years from the first commercial sale of the Vaccine Product or Vaccine Diagnostic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 11, 2024, the Company received notice from TDT, exercising its right to terminate the license and development agreement. Please refer to &#8220;Termination of CAR-T Products and Vaccine Products Licenses from TDT&#8221; below for further details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Termination and Settlement of CAR-T Products and Vaccine Products Licenses from TDT</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 11, 2024, the Company received notice from TDT, exercising its right to terminate the license and development agreement, dated June 10, 2018, between TDT and Liminatus. As of August 2024, the CAR-T License and Vaccine License have been terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 16, 2025, the Company and TDT entered and executed a settlement agreement. Pursuant to the terms of the settlement agreement, the Company was released and discharged from all agreements, promises, suites, disputes, claims and demands, debts and amounts due to TDT. As of December 31, 2025, the Company reversed the amounts due to TDT and recognized a gain of $2,142,297, which is included in Forgiveness of unrelated vendor payables on the Company&#8217;s consolidated statement of operations in accordance with ASC 450-30, Contingencies - Gain Contingencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and, 2024, the Company owed $0 and $2,142,297, respectively, to TDT for research and development for the aggregate CAR-T Products and Vaccine Licenses, which is included in the due to research and development partner and accrued maintenance fees on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CD47 License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October 2022, the Company was assigned a license and development agreement, as amended, with InnoBation Bio Co., Ltd. (the &#8220;CD47 License&#8221;), whereby, effective March 31, 2023, the Company received an exclusive license to develop and commercialize products for the CD47 immune checkpoint inhibitor to treat solid cancers, and companion diagnostics used to monitor treatment with CD47 products (collectively, &#8220;CD47 Products&#8221;), from Curis Biotech Holdings LLC, the parent company of Valetudo, a related party of the Company, in exchange for 78,555,554 of Liminatus&#8217; Class A member units. The license was recorded at Valetudo&#8217;s cost basis of zero, and the Company recorded an approximately $800,000 Class A membership interest with an offset to additional paid-in capital on the balance sheets. The Company is obligated to pay all development costs for CD47 Products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company has not paid and does not owe any license fees, management fees, developmental or regulatory milestone payments or royalty payments under the CD47 License through December 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_LicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_LicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_LicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for License Agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_LicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;4. Related Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Related Party Debt</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Feelux Bonds</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 15, 2018, the Company issued $10,000,000 of bonds to Feelux Co., Ltd., the parent company of Car-Tcellkor, Inc. (&#8220;Car-Tcellkor&#8221;) (see below), the only holder of Liminatus&#8217; Class A member units (the &#8220;Feelux Bonds&#8221;). The bonds bear interest at 1% per annum, compounded annually, and were due on October 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the issuance of the Feelux Bonds, Liminatus issued 6,666,666 equity-classified warrants to purchase member units at a price of $1.50 per unit, which expired on June 30, 2023. The fair value of the warrants to purchase member units of approximately $6,400,000 was estimated using the option pricing framework on the issuance date. The Company&#8217;s assumptions included (a) its expected stock volatility of 82.0% based on the historical volatility of a publicly traded set of peer companies, (b) the contractual term of five years, (c) the risk-free interest rate of 2.9% based on the U.S. Treasury yield curve in effect at the time of grant of the award for a five-year contractual term and (d) no expected dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The $10,000,000 of proceeds from the Feelux Bonds were allocated to the bonds and warrants using the relative fair value method resulting in a debt discount for the relative fair value of the warrants of $4,499,142 that was amortized to interest expense over the term of the Feelux Bonds using the effective interest method using an effective interest rate of 21.0%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, upon consummation of the Business Combination, the outstanding principal and accrued interest on the Feelux Bonds, totaling $10,681,146, and 9,999,999 member units of Liminatus were converted into 4,000,000 shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, there was no outstanding balance on the Feelux Bonds. As of March 31, 2026 and December 31, 2025, there was no accrued interest on the Feelux Bonds. For the three months ended March 31, 2026 and 2025, the Company recorded $0 and $26,251, respectively, of interest expense in the unaudited condensed consolidated statements of operations for the Feelux Bonds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Car-Tcellkor Loan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 18, 2019, the Company borrowed $800,000 from its parent at the time of the loan, Car- Tcellkor (the &#8220;Car-Tcellkor Loan&#8221;). The Car-Tcellkor Loan does not bear interest and was due on March 18, 2020. In November 2022, the maturity date was extended to May 18, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $800,000 was forgiven.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, there was no outstanding balance on the Car-Tcellkor Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Valetudo Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 1, 2022, the Company borrowed $700,000 from Valetudo Therapeutics LLC (&#8220;Valetudo&#8221;), a related party of the Company due to having common executives, in conjunction with the repayment of $700,000 of membership interest from a member (the &#8220;Valetudo Loan&#8221;). The Valetudo Loan bears no interest and was due on June 1, 2023. On May 1, 2025, the Company paid the outstanding principal balance of $700,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June 2023, the Company borrowed an additional $300,000 and $200,000 (the &#8220;Valetudo June 2023 Loans&#8221;). The Valetudo June 2023 Loans bear no interest and were due in December 2023. On May 1, 2025, the Company paid $300,000 of the outstanding principal balance on the Valetudo June 2023 Loans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July 2023, the Company borrowed an additional $250,000 (the &#8220;Valetudo July 2023 Loan&#8221;). The Valetudo July 2023 Loan bears interest at 6% per annum and was due on January 9, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2023, the Company borrowed an additional $250,000 and $150,000 (the &#8220;Valetudo August 2023 Loans&#8221;). The Valetudo August 2023 Loans each bear interest at 6% interest per annum and were due on January 31, 2024 and February 2, 2024, respectively. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $400,000, along with accrued interest, of the Valetudo August 2023 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2023, the Company borrowed an additional $200,000 (the &#8220;Valetudo November 2023 Loan&#8221;). The Valetudo November 2023 Loan bears interest at 6% per annum and was due on January 26, 2024. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $200,000, along with accrued interest, on the Valetudo November 2023 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2024, the Company borrowed an additional $600,000 and $150,000 (the &#8220;Valetudo January 2024 Loans&#8221;). The Valetudo January 2024 Loans each bear interest at 6% per annum and were due on February 28, 2024. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $750,000, along with accrued interest, of the Valetudo August 2023 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, the loans from Valetudo of $450,000 are recorded in short-term debt, related parties in the unaudited condensed consolidated balance sheets (see Note 5). As of March 31, 2026 and December 31, 2025, the related accrued interest of the loans from Valetudo was $117,058 and $113,308, respectively, and is included in accrued interest, related parties in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, interest expense related to the Valetudo loans was $3,750 and $24,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Ewon Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 12, 2022, the Company borrowed $5,000,000 from Ewon Comfortech Co., Ltd. (&#8220;Ewon&#8221;), a member and related party of the Company (the &#8220;Ewon Loan&#8221;). The Ewon Loan bears interest at 2% per annum and was due on December 12, 2023, which may be extended one year upon mutual agreement of the parties, or upon failure to close the Business Combination. In February 2023, the Company repaid $1,000,000 of the short-term loan. In March 2023, the Company repaid an additional $2,000,000 of the loan. On April 30, 2025, upon consummation of the Business Combination, $2,000,000, along with accrued interest, of the Ewon Loan was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 10, 2023, the Company entered into a loan agreement to borrow $200,000 from Ewon (&#8220;Ewon September 2023 Loan&#8221;). The Ewon September 2023 Loan bears interest of 2% per annum and was due on September 9, 2024, which may be extended one year upon mutual agreement of the parties, or upon failure to close the Business Combination. On April 30, 2025, upon consummation of the Business Combination, $200,000, along with accrued interest, of the Ewon September 2023 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 19, 2023, the Company and Ewon entered into an additional loan agreement and the Company borrowed $1,000,000 (the &#8220;Ewon December 2023 Loan&#8221;). The Ewon December 2023 Loan bears no interest. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $1,000,000, along with accrued interest, of the Ewon December 2023 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, there was no outstanding balance on the Ewon. As of March 31, 2026 and December 31, 2025, there was no accrued interest on the loans from Ewon. For the three months ended March 31, 2026 and 2025, interest expense related to the Ewon loans was $0 and $11,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Prophase Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 26, 2024, the Company borrowed an additional $200,000 from Prophase Sciences LLC (&#8220;Prophase&#8221;) (the &#8220;Prophase February 2024 Loan&#8221;). The loan bears 6% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, $168,500, along with accrued interest, of the Prophase February 2024 Loan was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 6, 2024, the Company borrowed an additional $250,000 from Prophase (the &#8220;Prophase March 2024 Loan&#8221;). The loan bears 6% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 1, 2024, the Company borrowed an additional $250,000 from Prophase (the &#8220;Prophase April 2024 Loan&#8221;). The loan bears 6% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $250,000, along with accrued interest, on the Prophase April 2024 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May 2024, the Company borrowed an additional $790,000 from Prophase (the &#8220;Prophase May 2024 Loans&#8221;). The loans bear 6% interest per annum. Of the aggregate $790,000 Prophase May 2024 Loans, $270,000 was due on June 1, 2024 and $520,000 was due on July 1, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $550,000, along with accrued interest of the Prophase May 2024 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July 2024, the Company borrowed an additional $83,000 from Prophase (the &#8220;Prophase July 2024 Loans&#8221;). The loans bear 6% interest per annum. Of the aggregate $83,000 Prophase July 2024 Loans, $30,000 was due on September 14, 2024, $3,000 was due on September 24, 2024 and $50,000 was due on September 29, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2024, the Company borrowed an additional $50,000 from Prophase (the &#8220;Prophase August 2024 Loans&#8221;). The loans bear 6% interest per annum. Of the aggregate $50,000 Prophase August 2024 Loans, $30,000 was due on October 12, 2024 and $20,000 was due on October 13, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February of 2025, the Company borrowed an additional $206,000 from Prophase (the &#8220;Prophase February 2025 Loan&#8221;). The Prophase February 2025 Loan bears interest at 6% per annum and was due on April 11, 2025, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $125,000, along with accrued interest, on the Prophase February 2025 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March of 2025, the Company borrowed $207,000 from Prophase (the &#8220;Prophase March 2025 Loan&#8221;). The Prophase March 2025 Loan bears interest at 6% per annum and was due on June 6, 2025, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $200,000, along with accrued interest, on the Prophase March 2025 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April of 2025, the Company borrowed an additional $3,627,000 from Prophase (the &#8220;Prophase April 2025 Loans&#8221;). The loans bear 6% interest per annum. Of the aggregate $3,627,000 Prophase April 2025 Loans, $200,000 was due on May 2, 2025, $1,920,120 was due on May 13, 2025 and $1,506,880 was due on May 14, 2025. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $3,627,000, along with accrued interest, on the Prophase April 2025 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, the balance of the Prophase loans is $742,500. As of March 31, 2026 and December 31, 2025, the related accrued interest of the loans from Prophase was $90,421 and $79,283, respectively, and is included in accrued interest, related parties in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, interest expense related to the Prophase Loans was $11,138 and $26,787, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Hana Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 1, 2024, the Company borrowed $850,000 from Hana Immunotherapeutics, LLC (&#8220;Hana&#8221;), a related party of the Company due to having common executives (the &#8220;Hana Loans&#8221;). The Hana Loans bear interest at 6% per annum and were due on September 30, 2024 and October 26, 2024, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $800,000, along with accrued interest, of the Hana Loans was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, the balance of the Hana Loans is $50,000. As of March 31, 2026 and December 31, 2025, the related accrued interest of the loans from Hana was $2,792 and $2,042, respectively, and is included in accrued interest, related parties in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, interest expense related to the Hana Loans was $750 and $12,750, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Amantes Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 1, 2024, the Company borrowed $400,000 from Amantes LLC (&#8220;Amantes&#8221;), a related party of the Company due to having common executives, pursuant to a loan agreement between the Company and Amantes (the &#8220;Amantes Loan&#8221;). On November 27, 2024, the Company borrowed an additional $300,000 from Amantes (the &#8220;Additional Amantes Loan&#8221;) (together with the Amantes Loan, the &#8220;Amantes November 2024 Loans&#8221;). The Amantes November 2024 Loans bear interest at 6% per annum and are due on January 1, 2025. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $550,000, along with accrued interest, on the Amantes November 2024 Loans was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 2, 2025 and January 23, 2025, the Company borrowed a total of $300,000 from Amantes, pursuant to loan agreements between the Company and Amantes (the &#8220;Amantes January 2025 Loans&#8221;). The Amantes January 2025 Loans bear interest at 6% per annum and are due on March 1, 2025 and March 22, 2025, respectively, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $250,000, along with accrued interest, on the Amantes January 2025 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, the balance of the Amantes Loans is $200,000. As of March 31, 2026 and December 31, 2025, the related accrued interest of the loans from Amantes was $12,287 and $9,288, respectively, and is included in accrued interest, related parties in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, interest expense related to the Amantes Loans was $3,000 and $14,724, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Due to Related Party</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of March 31, 2026 and December 31, 2025, the Company has $194,587 and $209,586, respectively, due to the Company&#8217;s executive team for compensation under their employment agreements. </p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;4. Related Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Related Party Debt</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Feelux Bonds</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 15, 2018, the Company issued $10,000,000 of bonds to Feelux Co., Ltd., the parent company of Car-Tcellkor, Inc. (&#8220;Car-Tcellkor&#8221;) (see below), the only holder of Liminatus&#8217; Class A member units (the &#8220;Feelux Bonds&#8221;). The bonds bear interest at 1% per annum, compounded annually, and were due on October 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In connection with the issuance of the Feelux Bonds, Liminatus issued 6,666,666 equity-classified warrants to purchase member units at a price of $1.50 per unit, which expired on June 30, 2023. The fair value of the warrants to purchase member units of approximately $6,400,000 was estimated using the option pricing framework on the issuance date. The Company&#8217;s assumptions included </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(a) its expected stock volatility of 82.0% based on the historical volatility of a publicly traded set of peer companies, (b) the contractual term of five years, (c) the risk-free interest rate of 2.9% based on the U.S. Treasury yield curve in effect at the time of grant of the award for a five-year contractual term and (d) no expected dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The $10,000,000 of proceeds from the Feelux Bonds were allocated to the bonds and warrants using the relative fair value method resulting in a debt discount for the relative fair value of the warrants of $4,499,142 that was amortized to interest expense over the term of the Feelux Bonds using the effective interest method using an effective interest rate of 21.0%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, upon consummation of the Business Combination, the outstanding principal and accrued interest on the Feelux Bonds, totaling $10,681,146, and 9,999,999 member units of Liminatus were converted into 4,000,000 shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the Feelux Bonds have a carrying amount of $0 and $10,000,000, respectively, and are included in short-term debt, related parties in the consolidated balance sheets. As of December 31, 2025 and 2024, the related accrued interest of the Feelux Bonds was $0 and $646,124, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, the Company recorded $35,023 and $106,087, respectively, of interest expense in the consolidated statements of operations for the Feelux Bonds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Car-Tcellkor Loan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 18, 2019, the Company borrowed $800,000 from its parent at the time of the loan, Car- Tcellkor (the &#8220;Car-Tcellkor Loan&#8221;). The Car-Tcellkor Loan does not bear interest and was due on March 18, 2020. In November 2022, the maturity date was extended to May 18, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $800,000 was forgiven.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the Car-Tcellkor Loan had a carrying amount of $0 and $800,000, respectively, and is recorded in short-term debt, related parties in the consolidated balance sheets (see Note 5). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Valetudo Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 1, 2022, the Company borrowed $700,000 from Valetudo Therapeutics LLC (&#8220;Valetudo&#8221;), a related party of the Company due to having common executives, in conjunction with the repayment of $700,000 of membership interest from a member (the &#8220;Valetudo Loan&#8221;). The Valetudo Loan bears no interest and was due on June 1, 2023. On May 1, 2025, the Company paid the outstanding principal balance of $700,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June 2023, the Company borrowed an additional $300,000 and $200,000 (the &#8220;Valetudo June 2023 Loans&#8221;). The Valetudo June 2023 Loans bear no interest and were due in December 2023. On May 1, 2025, the Company paid $300,000 of the outstanding principal balance on the Valetudo June 2023 Loans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July 2023, the Company borrowed an additional $250,000 (the &#8220;Valetudo July 2023 Loan&#8221;). The Valetudo July 2023 Loan bears interest at 6% per annum and was due on January 9, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2023, the Company borrowed an additional $250,000 and $150,000 (the &#8220;Valetudo August 2023 Loans&#8221;). The Valetudo August 2023 Loans each bear interest at 6% interest per annum and were due on January 31, 2024 and February 2, 2024, respectively. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $400,000, along with accrued interest, of the Valetudo August 2023 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2023, the Company borrowed an additional $200,000 (the &#8220;Valetudo November 2023 Loan&#8221;). The Valetudo November 2023 Loan bears interest at 6% per annum and was due on January 26, 2024. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $200,000, along with accrued interest, on the Valetudo November 2023 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In January 2024, the Company borrowed an additional $600,000 and $150,000 (the &#8220;Valetudo January 2024 Loans&#8221;). The Valetudo January 2024 Loans each bear interest at 6% per annum and were due on February 28, 2024. On April 30, 2025, upon consummation of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Business Combination, outstanding principal of $750,000, along with accrued interest, of the Valetudo August 2023 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the loans from Valetudo of $450,000 and $2,800,000, respectively, are recorded in short-term debt, related parties in the consolidated balance sheets (see Note 5). As of December 31, 2025 and 2024, the related accrued interest of the loans from Valetudo was $113,308 and $115,328, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Valetudo loans was $42,208 and $96,484, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Ewon Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 12, 2022, the Company borrowed $5,000,000 from Ewon Comfortech Co., Ltd. (&#8220;Ewon&#8221;), a member and related party of the Company (the &#8220;Ewon Loan&#8221;). The Ewon Loan bears interest at 2% per annum and was due on December 12, 2023, which may be extended one year upon mutual agreement of the parties, or upon failure to close the Business Combination. In February 2023, the Company repaid $1,000,000 of the short-term loan. In March 2023, the Company repaid an additional $2,000,000 of the loan. On April 30, 2025, upon consummation of the Business Combination, $2,000,000, along with accrued interest, of the Ewon Loan was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 10, 2023, the Company entered into a loan agreement to borrow $200,000 from Ewon (&#8220;Ewon September 2023 Loan&#8221;). The Ewon September 2023 Loan bears interest of 2% per annum and was due on September 9, 2024, which may be extended one year upon mutual agreement of the parties, or upon failure to close the Business Combination. On April 30, 2025, upon consummation of the Business Combination, $200,000, along with accrued interest, of the Ewon September 2023 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 19, 2023, the Company and Ewon entered into an additional loan agreement and the Company borrowed $1,000,000 (the &#8220;Ewon December 2023 Loan&#8221;). The Ewon December 2023 Loan bears no interest. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $1,000,000, along with accrued interest, of the Ewon December 2023 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the balance of $0 and $3,200,000 of the Ewon loans is recorded in short-term debt, related parties in the consolidated balance sheets (see Note 5). As of December 31, 2025 and 2024, the related accrued interest of the loans from Ewon was $0 and $102,089, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Ewon loans was $14,667 and $44,733, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Prophase Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 26, 2024, the Company borrowed an additional $200,000 from Prophase Sciences LLC (&#8220;Prophase&#8221;) (the &#8220;Prophase February 2024 Loan&#8221;). The loan bears 6% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, $168,500, along with accrued interest, of the Prophase February 2024 Loan was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 6, 2024, the Company borrowed an additional $250,000 from Prophase (the &#8220;Prophase March 2024 Loan&#8221;). The loan bears 6% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 1, 2024, the Company borrowed an additional $250,000 from Prophase (the &#8220;Prophase April 2024 Loan&#8221;). The loan bears 6% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $250,000, along with accrued interest, on the Prophase April 2024 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In May 2024, the Company borrowed an additional $790,000 from Prophase (the &#8220;Prophase May 2024 Loans&#8221;). The loans bear 6% interest per annum. Of the aggregate $790,000 Prophase May 2024 Loans, $270,000 was due on June 1, 2024 and $520,000 was due on July 1, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">consummation of the Business Combination, outstanding principal of $550,000, along with accrued interest of the Prophase May 2024 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July 2024, the Company borrowed an additional $83,000 from Prophase (the &#8220;Prophase July 2024 Loans&#8221;). The loans bear 6% interest per annum. Of the aggregate $83,000 Prophase July 2024 Loans, $30,000 was due on September 14, 2024, $3,000 was due on September 24, 2024 and $50,000 was due on September 29, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2024, the Company borrowed an additional $50,000 from Prophase (the &#8220;Prophase August 2024 Loans&#8221;). The loans bear 6% interest per annum. Of the aggregate $50,000 Prophase August 2024 Loans, $30,000 was due on October 12, 2024 and $20,000 was due on October 13, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February of 2025, the Company borrowed an additional $206,000 from Prophase (the &#8220;Prophase February 2025 Loan&#8221;). The Prophase February 2025 Loan bears interest at 6% per annum and was due on April 11, 2025, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $125,000, along with accrued interest, on the Prophase February 2025 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March of 2025, the Company borrowed $207,000 from Prophase (the &#8220;Prophase March 2025 Loan&#8221;). The Prophase March 2025 Loan bears interest at 6% per annum and was due on June 6, 2025, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $200,000, along with accrued interest, on the Prophase March 2025 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April of 2025, the Company borrowed an additional $3,627,000 from Prophase (the &#8220;Prophase April 2025 Loans&#8221;). The loans bear 6% interest per annum. Of the aggregate $3,627,000 Prophase April 2025 Loans, $200,000 was due on May 2, 2025, $1,920,120 was due on May 13, 2025 and $1,506,880 was due on May 14, 2025. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $3,627,000, along with accrued interest, on the Prophase April 2025 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the balance of the Prophase loans is $742,500 and $1,623,000, respectively. As of December 31, 2025 and 2024, the related accrued interest of the loans from Prophase was $79,283 and $66,728, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Prophase loans was $77,073 and $66,728, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Hana Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 1, 2024, the Company borrowed $850,000 from Hana Immunotherapeutics, LLC (&#8220;Hana&#8221;), a related party of the Company due to having common executives (the &#8220;Hana Loans&#8221;). The Hana Loans bear interest at 6% per annum and were due on September 30, 2024 and October 26, 2024, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $800,000, along with accrued interest, of the Hana Loans was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the balance of the Hana Loans is $50,000 and $850,000, respectively. As of December 31, 2025 and 2024, the related accrued interest of the loans from Hana was $2,042 and $19,150, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Hana Loans was $19,042 and $19,150, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Amantes Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On November 1, 2024, the Company borrowed $400,000 from Amantes LLC (&#8220;Amantes&#8221;), a related party of the Company due to having common executives, pursuant to a loan agreement between the Company and Amantes (the &#8220;Amantes Loan&#8221;). On November 27, 2024, the Company borrowed an additional $300,000 from Amantes (the &#8220;Additional Amantes Loan&#8221;) (together with the Amantes Loan, the &#8220;Amantes November 2024 Loans&#8221;). The Amantes November 2024 Loans bear interest at 6% per annum and are due on January 1, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">2025. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $550,000, along with accrued interest, on the Amantes November 2024 Loans was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 2, 2025 and January 23, 2025, the Company borrowed a total of $300,000 from Amantes, pursuant to loan agreements between the Company and Amantes (the &#8220;Amantes January 2025 Loans&#8221;). The Amantes January 2025 Loans bear interest at 6% per annum and are due on March 1, 2025 and March 22, 2025, respectively, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $250,000, along with accrued interest, on the Amantes January 2025 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the balance of the Amantes Loans is $200,000 and $700,000, respectively. As of December 31, 2025 and 2024, the related accrued interest of the loans from Amantes was $9,288 and $5,700, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Amantes Loans was $27,890 and $5,700, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Due to Related Party</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, the Company had $209,586 due to the Company&#8217;s executive team for compensation under their employment agreements. As of December 31, 2024, the Company had $195,253 due to the Company&#8217;s executive team for compensation under their employment agreements and Amantes. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Viral Gene</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of December 31, 2025 and 2024, the Company had $0 and $126,275, respectively, due from Viral Gene included in due from related party in the consolidated balance sheets for a loan to Viral Gene and expenses paid on behalf of Viral Gene. During the year ended December 31, 2025, the Company determined the due from related party was uncollectible and wrote off $126,275 and is included in general and administrative on the consolidated statement of operations. The Company&#8217;s CEO is also the CEO of Viral Gene. The loan does not bear any interest.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 5. Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Outstanding debt classified as short-term debt as of March 31, 2026 and December 31, 2025 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:225.1pt;padding:0pt;"></td><td style="width:8.9pt;padding:0pt;"></td><td style="width:157.4pt;padding:0pt;"></td><td style="width:8.85pt;padding:0pt;"></td><td style="width:5.85pt;padding:0pt;"></td><td style="width:53.25pt;padding:0pt;"></td><td style="width:8.85pt;padding:0pt;"></td><td style="width:7pt;padding:0pt;"></td><td style="width:64.8pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:59.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:71.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2025</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo June 2023 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo July 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,500</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase May 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase July 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hana August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes November 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes January 2025 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,000</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short-term debt, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,442,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,442,500</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, the Company&#8217;s outstanding debt agreements are all past due and are classified as current in the accompanying unaudited condensed consolidated balance sheets. All of the loans are with related parties (see Note 4). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As the Company&#8217;s loans are with related parties, the Company and its related parties have agreed to defer repayment until a time that is mutually agreed upon between the Company and its related parties. Accordingly, none of these notes are considered to be in default.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 5. Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Outstanding debt classified as short-term debt as of December 31, 2025 and 2024 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:202.45pt;padding:0pt;"></td><td style="width:13.39pt;padding:0pt;"></td><td style="width:162pt;padding:0pt;"></td><td style="width:12.85pt;padding:0pt;"></td><td style="width:8pt;padding:0pt;"></td><td style="width:60.5pt;padding:0pt;"></td><td style="width:12.86pt;padding:0pt;"></td><td style="width:8pt;padding:0pt;"></td><td style="width:59.95pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:149.3pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style="height:9.69pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Feelux Bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Car-Tcellkor Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 800,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ewon Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,000,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo June 2023 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo July 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo August 2023 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 400,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ewon September 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo November 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ewon December 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,000,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo January 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 750,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase April 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase May 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 790,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase July 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hana August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 850,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes November 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes January 2025 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short-term debt, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,442,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,973,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the Company&#8217;s outstanding debt agreements are all past due and are classified as current in the accompanying consolidated balance sheets. All of the loans are with related parties (see Note 4). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As the Company&#8217;s loans are with related parties, the Company and its related parties have mutually agreed to defer repayment until a time that is mutually agreed upon between the Company and its related parties. Accordingly, none of these notes are considered to be in default.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholder's Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholder's Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 6. Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Business Company, the Company&#8217;s certificate of incorporation was amended and restated to designate two classes of stock; preferred and common stock. The certificate of incorporation authorized 1,000,000 shares of preferred stock and 500,000,000 shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preferred Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Amended and Restated Certificate of Incorporation provides the Company&#8217;s board of directors with the authority to issue up to 1,000,000 shares of $0.0001 par value preferred stock in one or more series and to establish from time to time the number of shares to be included in each such series, by adopting a resolution and filing a certification of designations. Voting powers, designations, powers, preferences and relative, participating, optional, special and other rights will be stated and expressed in such resolutions. There were zero preferred shares outstanding as of March 31, 2026 and December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Common Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is authorized to issue 500,000,000 shares of common stock, with a par value of $0.0001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 16, 2025, the Company entered into a settlement and release agreement with Alta Partners, LLC (&#8220;Alta&#8221;), pursuant to which the Company agreed to issue 350,000 shares of its common stock to Alta in exchange for the surrender and cancellation of 1,000,000 Public Warrants held by Alta. On July 16, 2025, the common stock issued to Alta and Public Warrants surrendered by Alta had a fair value of $1,890,000 and $150,000, respectively. As a result of the exchange, the Company recognized a loss of $1,740,000 on the difference in fair value between the common stock and Public Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, the Company settled Iris&#8217; liabilities for $7,000,000 of the deferred underwriting fees incurred prior to the Closing Date for 700,000 shares of common stock to the underwriters in Iris&#8217;s initial public offering. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $7,245,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 6, 2026, the Company entered into a settlement and release agreement with the Holder (as defined in Note 7), pursuant to which the Company agreed to issue 4,000,000 shares of its common stock to the Holder in exchange for the surrender and cancellation of 805,377 warrants to purchase shares of common stock held by the Holder. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 18, 2026, the Company completed a &#8220;best efforts&#8221; public offering of (i) 8,270,000 shares of its common stock, (ii) 5,543,000 Pre-Funded Warrants to purchase up to 5,543,000 shares of common stock and (ii) 13,813,000 Common Stock Warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per Pre-Funded Warrant) and accompanying warrant. Immediately upon closing of the Offering, 4,281,000 Pre-Funded Warrants were exercised and converted into 4,281,000 shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company allocated the Offering proceeds between the common stock, Pre-Funded Warrants, Common Stock Warrants and Placement Agent Warrants based on their relative fair values in accordance with ASC 505, <i style="font-style:italic;">Equity</i>. The fair value of the common stock and Pre-Funded Warrants was based on the Company&#8217;s closing stock price on the closing date of $0.2449 per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of the Common Stock Warrants and Placement Agent Warrants was estimated using a Black-Scholes option pricing model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:369.05pt;padding:0pt;"></td><td style="width:10pt;padding:0pt;"></td><td style="width:44.6pt;padding:0pt;"></td><td style="width:8.35pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:369.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:369.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 92.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:369.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:369.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:369.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected life of warrants (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Offering proceeds and related issuance costs were allocated to the common stock, Pre-Funded Warrants, Common Stock Warrants and Placement Agent Warrants as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:259.65pt;padding:0pt;"></td><td style="width:8pt;padding:0pt;"></td><td style="width:52.7pt;padding:0pt;"></td><td style="width:8.05pt;padding:0pt;"></td><td style="width:50.04pt;padding:0pt;"></td><td style="width:8.05pt;padding:0pt;"></td><td style="width:45.5pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.24pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Allocated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Allocated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Allocated</b></p></td></tr><tr style="height:9.49pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross&#160;Proceeds</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuance&#160;Costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net&#160;Proceeds</b></p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:259.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,208,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 168,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,039,295</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Common Stock Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,977,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 276,502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,701,497</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:259.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Pre-Funded Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 755,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 649,471</p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Placement Agent Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,546</p></td></tr><tr style="height:12.54pt;"><td style="vertical-align:bottom;width:259.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,005,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 559,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,445,808</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The amount allocated to the common stock and Pre-Funded Warrants was recorded in common stock at par value and the excess over par value in additional paid-in capital in the accompanying unaudited condensed consolidated balance sheet as of March 31, 2026. The amounts allocated to the Common Stock Warrants and Placement Agent Warrants were recorded in additional paid-in capital as the Common Stock Warrants and Placement Agent Warrants are equity-classified instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Issuance costs, including placement agent fees, legal fees and accountant related expenses were recorded as reduction to additional paid-in capital in proportion to the allocation of proceeds between the equity instruments issued, as summarized above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 19, 2026, the remaining 1,262,000 Pre-Funded Warrants were exercised and converted into 1,262,000 shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, there were 44,877,633 and 27,064,633 shares of common stock issued and outstanding, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of the Company&#8217;s common stock are entitled to one vote for each share held of record, on all matters submitted to a vote of stockholders. Additionally, holders of common stock have dividend rights, in the event of a declared dividend declared by the Company&#8217;s Board of Directors, and liquidation rights, in the event of an involuntary or voluntary event of liquidation that allow for the Company&#8217;s common stockholders to receive all remaining assets of the Company, after payments of debts and other liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of March 31, 2026, 5,094,623 Public Warrants and 835,555 private placement warrants (together, the &#8220;Warrants&#8221;) were outstanding. Each Warrant entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $11.50 per share. No </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">fractional shares will be issued upon exercise of the Warrants. The Company may elect to redeem the Public Warrants, in whole and not in part at a price of $0.01 per Warrant if (i) 30 days&#8217; prior written notice of redemption is provided to the holders, and (ii) the last reported sale price of the Company&#8217;s common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders. Upon issuance of a redemption notice by the Company, the warrant holders have a period of 30 days to exercise for cash, or on a cashless basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of March 31, 2026, 13,813,000 Common Stock Warrants were outstanding. Each Common Stock Warrant entitles the holder to purchase one and a half shares of the Company&#8217;s common stock at a price of $0.29 per share and will expire five years following the date of issuance. No fractional shares will be issued upon exercise of the Common Stock Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of March 31, 2026, 690,650 Placement Agent Warrants were outstanding. Each Placement Agent Warrant entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $0.319 per share and will expire five years following the date of issuance. No fractional shares will be issued upon exercise of the Placement Agent Warrants.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 6. Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Business Combination, the Company&#8217;s certificate of incorporation was amended and restated to designate two classes of stock; preferred and common stock. The certificate of incorporation authorized 1,000,000 shares of preferred stock and 500,000,000 shares of common stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preferred Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Amended and Restated Certificate of Incorporation provides the Company&#8217;s board of directors with the authority to issue up to 1,000,000 shares of $0.0001 par value preferred stock in one or more series and to establish from time to time the number of shares to be included in each such series, by adopting a resolution and filing a certification of designations. Voting powers, designations, powers, preferences and relative, participating, optional, special and other rights will be stated and expressed in such resolutions. There were zero preferred shares outstanding as of December 31, 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Common Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is authorized to issue 500,000,000 shares of common stock, with a par value of $0.0001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, the Company settled deferred underwriting fees incurred by Iris prior to the closing date of $7,000,000 for 700,000 shares of common stock to the underwriters in Iris&#8217;s initial public offering. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $7,245,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 16, 2025, the Company entered into a settlement and release agreement with Alta Partners, LLC (&#8220;Alta&#8221;), pursuant to which the Company agreed to issue 350,000 shares of its common stock to Alta in exchange for the surrender and cancellation of 1,000,000 Public Warrants held by Alta. On July 16, 2025, the common stock issued to Alta and Public Warrants surrendered by Alta had a fair value of $1,890,000 and $150,000, respectively. As a result of the exchange, the Company recognized a loss of $1,740,000 on the difference in fair value between the common stock and Public Warrants, which is included in Loss on issuance of common stock on the Company&#8217;s consolidated statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, there were 27,064,633 and 17,500,000 shares of common stock issued and outstanding, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of the Company&#8217;s common stock are entitled to one vote for each share held of record, on all matters submitted to a vote of stockholders. Additionally, holders of common stock have dividend rights, in the event of a declared dividend declared by the Company&#8217;s Board of Directors, and liquidation rights, in the event of an involuntary or voluntary event of liquidation that allow for the Company&#8217;s common stockholders to receive all remaining assets of the Company, after payments of debts and other liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of December 31, 2025, 5,899,975 Public Warrants and 835,555 private placement warrants were outstanding. Each warrant entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $11.50 per share. No fractional shares will be issued upon exercise of the warrants. The Company may elect to redeem the Public Warrants, in whole and not in part at a price of $0.01 per warrant if (i) 30 days&#8217; prior written notice of redemption is provided to the holders, and (ii) the last reported sale price of the Company&#8217;s common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders. Upon issuance of a redemption notice by the Company, the warrant holders have a period of 30 days to exercise for cash, or on a cashless basis.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;7. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 17, 2025, the Company entered into a short-term lease for an office space in Cerritos, California (the &#8220;Lease&#8221;). The Lease commenced on September 1, 2025 and expires on June 30, 2026 and does not have any renewal option. The Company has made the short-term lease election and recognizes lease payments for its short-term lease on a straight line basis over the lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2026, lease expense related to the short-term lease was $22,272. <span style="background:#ffffff;">For the three months ended March 31, 2025,</span> there was no lease expense related to the short-term lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Legal Proceedings</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 6, 2026, the Company entered into a settlement and release agreement with Clear Street LLC (the &#8220;Holder&#8221;), pursuant to which the Company agreed to issue 4,000,000 shares of its common stock to the Holder in exchange for the surrender and cancellation of 805,377 warrants to purchase shares of common stock held by the Holder. As of December 31, 2025, the Company determined this represented a Type I subsequent event in accordance with the guidance of ASC 855, <i style="font-style:italic;">Subsequent Events</i> (&#8220;ASC 855&#8221;), in which the Company obtained additional evidence about conditions that existed at the date of the consolidated balance sheets. The Company estimated a settlement of $7,360,000, which was calculated using the fair value of the Company&#8217;s common stock on February 6, 2026, which was the day that stock was issued to the Holder. As of March 31, 2026 and December 31, 2025, the Company&#8217;s settlement payable was $0 and $7,360,000, respectively, which is included in settlement payable in the Company&#8217;s unaudited condensed consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Settlement Agreement, the Company and the Holder agreed to dismiss (a) an action pending in the United States District Court for the Central District of California and (b) an action pending in the United States District Court for the Southern District of New York, in which previously the Court entered a default judgment against the Company in the amount of $7,500,000 plus approximately $515,000 in interest, which judgment was registered in the Central District of California in the fourth quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims other than those already disclosed. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Underwriting Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Business Combination in connection with its initial public offering, Iris entered into an underwriting agreement with Cantor was engaged as the underwriters to Iris&#8217; IPO. Cantor was entitled to an underwriting discount of 2% (or $5,520,000) of the gross proceeds of the IPO and deferred underwriting discount of 3.5% (or $9,660,000) of the gross proceeds of the IPO upon the completion of an initial business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On October 11, 2023, Iris executed a fee reduction agreement with the underwriters to reduce the deferred underwriting discount of $9,660,000 to $8,000,000 in the event the Business Combination was consummated. Pursuant to the terms of the agreement, the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">reduced deferred underwriting discount was payable by the Iris to the underwriters in $1,000,000 cash and $7,000,000 of the common equity securities of the public entity that survives the transaction. The share price is subject to adjustment based on the five day volume-weighted average price prior to the filing of a resale registration statement covering such shares. As of April 30, 2025, Iris and the Company amended the fee reduction agreement with the underwriters to limit the total number of shares of common stock issuable to the underwriters to 1,750,000. Upon the consummation of the Business Combination, $9,160,000 in deferred underwriting fees were settled, of which $7,000,000 will be settled in common shares of the combined company, $500,000 was settled in cash and $1,660,000 was waived and no longer payable. The remaining $500,000 was to be settled upon the earlier of the consummation of the combined company&#8217;s next share offering, or in six months from the closing date of the Business Combination. As of March 31, 2026, the deferred underwriting fee payable was $500,000, which is included in deferred underwriting fee payable in the Company&#8217;s unaudited condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, the Company settled Iris&#8217; liabilities for $7,000,000 of the deferred underwriting fees incurred prior to the Closing Date for 700,000 shares of common stock to the underwriters in Iris&#8217;s initial public offering. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $7,245,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On October 27, 2025, six months from the closing date of the Business Combination, the remaining $500,000 underwriting fee became due. As of the date of this Form 10-Q, the $500,000 underwriting fees remains unpaid.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;7. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 17, 2025, the Company entered into a short-term lease for an office space in Cerritos, California (the &#8220;Lease&#8221;). The Lease commenced on September 1, 2025 and expires on June 30, 2026 and does not have any renewal option. The Company has made the short-term lease election and recognizes lease payments for its short-term lease on a straight line basis over the lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2025, lease expense related to the short-term lease was $2,784. For the year ended December 31, 2024, there was no lease expense related to the short-term lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Legal proceedings</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 6, 2026, the Company entered into a settlement and release agreement with Clear Street LLC (the &#8220;Holder&#8221;), pursuant to which the Company agreed to issue 4,000,000 shares of its common stock, par value $0.0001 per share, to the Holder in exchange for the surrender and cancellation of 805,377 warrants to purchase shares of common stock held by the Holder. The Company has determined this represents a Type I subsequent event in accordance with the guidance of ASC 855, <i style="font-style:italic;">Subsequent Events</i> (&#8220;ASC 855&#8221;), in which the Company obtained additional evidence about conditions that existed at the date of the consolidated balance sheets. As such, the Company has recorded the $7,360,000 as settlement payable, which was calculated using the fair value of the Company&#8217;s common stock on February 6, 2026, which was the day that stock was issued to the Holder, in its consolidated balance sheets as of December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Settlement Agreement, the Company and the Holder agreed to dismiss (a) an action pending in the United States District Court for the Central District of California and (b) an action pending in the United States District Court for the Southern District of New York, in which previously the Court entered a default judgment against the Company in the amount of $7,500,000 plus approximately $515,000 in interest, which judgment was registered in the Central District of California in the fourth quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is not a party to any other material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Underwriting Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Business Combination in connection with its initial public offering, Iris entered into an underwriting agreement in which Cantor was engaged as the underwriters to Iris&#8217; IPO. Cantor was entitled to an underwriting discount of 2% (or $5,520,000) of the gross proceeds of the IPO and deferred underwriting discount of 3.5% (or $9,660,000) of the gross proceeds of the IPO upon the completion of an initial business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 11, 2023, Iris executed a fee reduction agreement with the underwriters to reduce the deferred underwriting discount of $9,660,000 to $8,000,000 in the event the Business Combination was consummated. Pursuant to the terms of the agreement, the reduced deferred underwriting discount was payable by the Iris to the underwriters in $1,000,000 cash and $7,000,000 of the common equity securities of the public entity that survives the transaction. The share price is subject to adjustment based on the five day volume-weighted average price prior to the filing of a resale registration statement covering such shares. As of April 30, 2025, Iris and the Company amended the fee reduction agreement with the underwriters to limit the total number of shares of common stock issuable to the underwriters to 1,750,000. Upon the consummation of the Business Combination, $9,160,000 in deferred underwriting fees were settled, of which $7,000,000 will be settled in common shares of the combined company, $500,000 was settled in cash and $1,660,000 was waived and no longer payable. The remaining $500,000 was to be settled upon the earlier of the consummation of the combined company&#8217;s next share offering, or in six months from the closing date of the Business Combination. As of December 31, 2025, the deferred underwriting fee payable was $500,000, which is included in Deferred underwriting fee payable in the Company&#8217;s consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, the Company settled Iris&#8217; liabilities for $7,000,000 of the deferred underwriting fees incurred prior to the Closing Date for 700,000 shares of common stock to the underwriters in Iris&#8217;s initial public offering. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $7,245,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On October 27, 2025, six months from the closing date of the Business Combination, the remaining $500,000 underwriting fee became due. As of the date of these consolidated financial statements, the $500,000 underwriting fees remains unpaid. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 8. Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2026 and December 31, 2025 and indicates the fair value hierarchy of the valuation inputs the Company&#8217;s utilized to determine such fair value:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:340.7pt;padding:0pt;"></td><td style="width:9.8pt;padding:0pt;"></td><td style="width:49.65pt;padding:0pt;"></td><td style="width:9.85pt;padding:0pt;"></td><td style="width:6.25pt;padding:0pt;"></td><td style="width:49.25pt;padding:0pt;"></td><td style="width:9.85pt;padding:0pt;"></td><td style="width:7.7pt;padding:0pt;"></td><td style="width:56.95pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:340.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:340.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:55.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2025</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:340.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:340.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:340.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,244</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrant Liability</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon closing of the Mergers, Iris&#8217; public and private placement warrants were converted into warrants of the Company, which entitle the holders to purchase shares of the Company&#8217;s common stock. The Company&#8217;s private placement warrants meet the requirements for liability classification. The fair value of the warrant liabilities were determined using observable data points, such as the fair value of the public warrants as of March 31, 2026 and December 31, 2025. The Company further considered specific unobservable inputs, such as the probability and timing of events and the expected equity value of the underlying shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The changes in fair value of Level 3 financial assets and liabilities for the three months ended March 31, 2026 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:360.05pt;padding:0pt;"></td><td style="width:11.39pt;padding:0pt;"></td><td style="width:7.15pt;padding:0pt;"></td><td style="width:53.4pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:60.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant&#160;liability</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of January 1, 2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 29,244</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,178</p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of March&#160;31,&#160;2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 33,422</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 8. Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2025 and 2024 and indicates the fair value hierarchy of the valuation inputs the Company&#8217;s utilized to determine such fair value:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:341.85pt;padding:0pt;"></td><td style="width:10.8pt;padding:0pt;"></td><td style="width:50.65pt;padding:0pt;"></td><td style="width:10.79pt;padding:0pt;"></td><td style="width:6.8pt;padding:0pt;"></td><td style="width:50.75pt;padding:0pt;"></td><td style="width:10.8pt;padding:0pt;"></td><td style="width:6.8pt;padding:0pt;"></td><td style="width:50.75pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:341.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:341.85pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:341.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:341.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:341.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrant Liability</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon closing of the Mergers, Iris&#8217; public and private placement warrants were converted into warrants of the Company, which entitle the holders to purchase shares of the Company&#8217;s common stock. The Company&#8217;s private placement warrants meet the requirements for liability classification. The fair value of the warrant liabilities were determined using observable data points, such as the fair value of the public warrants as of December 31, 2025 and 2024. The Company further considered specific unobservable inputs, such as the probability and timing of events and the expected equity value of the underlying shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The changes in fair value of Level 3 financial assets and liabilities for the year ended December 31, 2025 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:360.05pt;padding:0pt;"></td><td style="width:11.39pt;padding:0pt;"></td><td style="width:7.15pt;padding:0pt;"></td><td style="width:53.4pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:60.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant&#160;liability</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Initial measurement at the Closing Date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,556</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (54,312)</p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 29,244</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;9. Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has completed an evaluation of all subsequent events through the date of this filing to ensure that these unaudited condensed consolidated financial statements include appropriate disclosure of events both recognized in the unaudited condensed consolidated financial statements and events which occurred but were not recognized in the unaudited condensed consolidated financial statements. </p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note&#160;10. Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has completed an evaluation of all subsequent events through the date of this filing to ensure that these consolidated financial statements include appropriate disclosure of events both recognized in the consolidated financial statements and events which occurred but were not recognized in the consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On February 6, 2026, the Company entered into a settlement and release agreement with the Holder, pursuant to which the Company agreed to issue 4,000,000 shares of its common stock, par value $0.0001 per share, to the Holder in exchange for the surrender and cancellation of 805,377 warrants to purchase shares of common stock held by the Holder. The Company has determined this represents a Type I subsequent event in accordance with ASC 855, in which the Company obtained additional evidence about conditions that existed at the date of the consolidated balance sheets. As such, the Company has recorded the $7,360,000 as settlement payable, which </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">was calculated using the fair value of the Company&#8217;s common stock on February 6, 2026, which was the day that stock was issued to the Holder, in its consolidated balance sheets as of December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Settlement Agreement, the Company and the Holder agreed to dismiss (a) an action pending in the United States District Court for the Central District of California and (b) an action pending in the United States District Court for the Southern District of New York, in which previously the Court entered a default judgment against the Company in the amount of $7,500,000 plus approximately $515,000 in interest, which judgment was registered in the Central District of California in the fourth quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 18, 2026, the Company completed a &#8220;best efforts&#8221; public offering of (i) 8,270,000 shares of its common stock, (ii) 5,543,000 Pre-Funded Warrants to purchase up to 5,543,000 shares of common stock and (ii) 13,813,000 common stock purchase warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per Pre-Funded Warrant) and accompanying warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each Pre-Funded Warrant has an exercise price of $0.0001 per share upon issuance for <span style="-sec-ix-hidden:Hidden_pRGIcWXwZE-WeEaxj87wJg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> share of common stock and will not expire prior to exercise. Each Warrant has an exercise price of $0.29 per share, is exercisable upon issuance for<span style="-sec-ix-hidden:Hidden_kq3mrqvJyU-ExJ_p7HGPjQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> one and a half</span></span> shares of common stock, and will expire five years following the date of issuance. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the common stock and the exercise price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Offering, on February 17, 2026, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers party thereto. The Purchase Agreement contains customary representations, warranties and agreements of the Company and the purchasers and customary indemnification rights and obligations of the parties. Pursuant to the Purchase Agreement, the Company agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock or file any registration statement or prospectus, or any amendment or supplement thereto for 180 days after the closing date of the Offering, subject to certain exceptions. The Company also agreed not to effect or enter into an agreement to effect any issuance of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock involving a Variable Rate Transaction (as defined in the Purchase Agreement) until 180 days after the closing date of the Offering, subject to certain exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In connection with the Offering, on February 17, 2026, the Company entered into a placement agency agreement with Maxim Group LLC, as placement agent in connection with the Offering (the &#8220;Placement Agent&#8221;). The Company paid the Placement Agent a cash fee of 8.0% of the aggregate gross proceeds raised in the Offering. The Company also agreed to reimburse the Placement Agent for all reasonable out-of-pocket costs and expenses incurred in connection with the Offering in an aggregate amount up to $100,000. In addition, the Company issued to the Placement Agent warrants (the &#8220;Placement Agent Warrants&#8221;) to purchase 690,650 shares of common stock (representing 5.0% of the number of shares of common stock sold in the Offering). The Placement Agent Warrants are immediately exercisable at an exercise price of $0.319 (or 110% of the public offering price for the shares of common stock and common warrants offered in the Offering) and will expire on the <span style="-sec-ix-hidden:Hidden_rGRJ0qc7tEGPO6XNQVjRbw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fifth anniversary</span></span> of the commencement of sales of the Offering. On February 18, 2026, in connection with the Offering, the Company received net proceeds of approximately $3.46 million, after deducting the estimated offering expenses payable by the Company, including the placement agent fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On February 20, 2026, the Company issued a payment of $1,000,000 to InnoBation Bio Co. Ltd. for costs associated to begin the Phase 1 clinical trials of IBA101, the Company&#8217;s product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) as determined by the FASB ASC and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The unaudited condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements do not include all of the disclosures required by U.S. GAAP for annual consolidated financial statements and should be read in conjunction with the audited consolidated financial statements of the Company as of and for the year ended December 31, 2025 (the &#8220;Annual Financial Statements&#8221;). In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary to fairly present its financial position as of March 31, 2026, its results of operations for the three months ended March 31, 2026 and 2025, its cash flows for the three months ended March 31, 2026 and 2025, and its changes in stockholders&#8217; deficit for the three months ended March 31, 2026 and 2025. Results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year ending December 31, 2026 or any future period. The condensed consolidated balance sheet as of December 31, 2025 was derived from the Annual Financial Statements but does not contain all of the footnote disclosures from the Annual Financial Statements.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) as determined by the FASB ASC and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_EmergingGrowthCompanyPolicyPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company Status</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">After the closing of the Business Combination, the Company has elected to be an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s unaudited condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company Status</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the closing of the Business Combination, the Company has elected to be an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart our Business Startups Act of 2012, (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results may differ materially and adversely from these estimates. The Company is not aware of any significant estimates that required management to exercise significant judgment with the exception of the Company&#8217;s warrant liability and research and development costs. If the underlying estimates and assumptions upon which the estimates are based change in the future, actual amounts may differ from those included in the Company&#8217;s unaudited condensed consolidated financial statements.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results may differ materially and adversely from these estimates. The Company is not aware of any significant estimates that required management to exercise significant judgment with the exception of the Company&#8217;s warrant liability. If the underlying estimates and assumptions upon which the estimates are based change in the future, actual amounts may differ from those included in the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), the Chief Executive Officer, manages the Company&#8217;s business activities as a <span style="-sec-ix-hidden:Hidden_skpW_fMTs0qgK5TqjOzinQ;"><span style="-sec-ix-hidden:Hidden_oRglHBbi5kiQPSddjK0rrg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">single</span></span></span> operating and reportable segment. Accordingly, the Company&#8217;s CODM uses net income/loss to measure the Company&#8217;s single segment&#8217;s performance and allocate resources. Further, the CODM reviews and utilizes functional expenses (general and administrative and research and development) to manage the Company&#8217;s operations. The Company&#8217;s general and administrative expenses for the three months ended March 31, 2026 and 2025 included $60,500 and $37,500, respectively, of compensation expenses related to the compensation agreement the Company has executed with its Chief Executive Officer. The remaining general and administrative expenses are related to legal and accounting-related expenses for contractors. The Company&#8217;s research and development expenses did not include any compensation-related expenses. Other segment items included in net loss are interest expense, related parties and interest income which are reflected in the Company&#8217;s unaudited condensed consolidated statements of operations.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), the Chief Executive Officer, manages the Company&#8217;s business activities as a single operating and reportable segment. Accordingly, the Company&#8217;s CODM uses net income/loss to measure the Company&#8217;s single segment&#8217;s performance and allocate resources. Further, the CODM reviews and utilizes functional expenses (general and administrative and research and development) to manage the Company&#8217;s operations. The Company&#8217;s general and administrative expenses for each of the years ended December 31, 2025 and 2024 included $202,833 and $150,000 of compensation expenses related to the compensation agreements the Company has executed with its executive team. The remaining general and administrative expenses </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">are related to legal and accounting-related expenses for contractors. The Company&#8217;s research and development expenses did not include any compensation-related expenses. Other segment items included in net income (loss) are interest expense, related parties and interest income which are reflected in the Company&#8217;s consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which can exceed government insured limits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company did not have any cash equivalents as of March 31, 2026 and December 31, 2025.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which can exceed government insured limits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2025 and 2024.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLoansAndLeasesReceivablePolicy', window );">Loan Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Loan Receivable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its loan receivable at amortized cost, net of expected credit losses. The Company provides reserves against its loan receivable balance for estimated credit losses, if any, that may result from a counterparty&#8217;s inability to pay based on the composition of the loan receivable, current economic conditions and, historical credit loss activity and future expected conditions and market trends (such as general economic conditions, other macroeconomic and microeconomic events, etc.). Changes in circumstances relating to these factors may result in the need to increase or decrease the allowance for credit losses in the future. Amounts deemed uncollectible are charged or written-off against the reserve. On April 30, 2025, in connection with the Business Combination, the loan receivable was eliminated in consolidation as Iris and Liminatus are now consolidated subsidiaries of the Company. As of January 1, 2024 and December 31, 2024, no expected credit loss was recorded related to the loan receivable.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Transaction Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Deferred Transaction Costs </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Costs incurred in connection with preparation for the proposed business combination were deferred on the balance sheets as of December 31, 2024. No such costs were deferred on the balance sheets as of December 31, 2025 due to the completion of the Company&#8217;s business combination with Iris. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial assets and liabilities are accounted for in accordance with FASB ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures,</i> which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value hierarchy requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 1 &#8212; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 2 &#8212; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the instrument&#8217;s anticipated life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 3 &#8212; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgement. Accordingly, the degree of judgement exercised by management in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the warrant liability reported in the Company&#8217;s unaudited condensed consolidated balance sheets represent a Level 3 instrument (see Note 8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying values reported in the Company&#8217;s unaudited condensed consolidated balance sheets for prepaid expenses and other current assets, due from related party, accounts payable and accrued expenses, accrued interest, short-term debt with related parties, due to related parties and its deferred underwriting fee payable are reasonable estimates of their fair values due to the short-term nature of these items.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial assets and liabilities are accounted for in accordance with FASB ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures,</i> which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value hierarchy requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 1 &#8212; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 2 &#8212; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the instrument&#8217;s anticipated life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 3 &#8212; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgement. Accordingly, the degree of judgement exercised by management in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the warrant liability reported in the Company&#8217;s consolidated balance sheets represent a Level 3 instrument. See Note 8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The carrying values reported in the Company&#8217;s consolidated balance sheets for prepaid expenses and other current assets, due from related party, accounts payable and accrued expenses, accrued interest, short-term debt with related parties, due to research and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">development partner, due to related parties, settlement payable, and its deferred underwriting fee payable are reasonable estimates of their fair values due to the short-term nature of these items.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_WarrantsPolicyPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC 480, <i style="font-style:italic;">Distinguishing liabilities from equity</i> (&#8220;ASC 480&#8221;), and ASC 815, <i style="font-style:italic;">Derivatives and Hedging</i> (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance, modification, and as of each subsequent quarterly period end date while the warrants are outstanding. As of March 31, 2026, 13,813,000 of the Company&#8217;s Common Stock Warrants, 690,650 Placement Agent Warrants and 5,094,623 Public Warrants were accounted for as equity-classified instruments and 835,555 private placement warrants were accounted for as liability-classified instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the liability-classified warrants are recognized as a non-cash gain or loss on the accompanying condensed consolidated statements of operations. The Company assesses the classification of its warrants at each reporting date to determine whether a change in classification between equity and liability is required. During the three months ended March 31, 2026, the Company had an unrealized gain on the change in fair value of the warrant liabilities of $4,178. During the three months ended March 31, 2025, the Company had no unrealized gain or loss on the change in fair value of the warrant liabilities.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC 480, <i style="font-style:italic;">Distinguishing liabilities from equity</i> (&#8220;ASC 480&#8221;), and ASC 815, <i style="font-style:italic;">Derivatives and Hedging</i> (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance, modification, and as of each subsequent quarterly period end date while the warrants are outstanding. As of December 31, 2025, 5,899,975 of the Company&#8217;s Public Warrants were accounted for as equity-classified instruments and 835,555 private placement warrants were accounted for as liability-classified instruments. As of December 31, 2025, there were no other public or <span style="-sec-ix-hidden:Hidden_wUaYXsrirkKbOmu3ilr3Zg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">private</span></span> warrants outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the liability-classified warrants are recognized as a non-cash gain or loss on the accompanying consolidated statements of operations. The Company assesses the classification of its warrants at each reporting date to determine whether a change in classification between equity and liability is required. During the year ended December 31, 2025, the Company had an unrealized gain on the change in fair value of the warrant liabilities of $54,312. During the year ended December 31, 2024, the Company had no unrealized gain or loss on the change in fair value of the warrant liabilities. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock', window );">Net Loss per Share of Common Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss per Share of Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company complies with accounting and disclosure requirements of ASC Topic 260, <i style="font-style:italic;">Earnings Per Share</i>. The Company has one class of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities if their effect is antidilutive. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined by using the treasury stock method. Dilutive common stock equivalents are comprised of 19,598,273 warrants, comprised of 13,813,000 Common Stock Warrants, 690,650 Placement Agent Warrants and 5,094,623 Public Warrants. For all periods </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">presented, there is no difference in the number of shares used to calculated basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive given that their inclusion would reduce the net loss per share during the three months ended March 31, 2026 and 2025.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net loss per Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company complies with accounting and disclosure requirements of ASC Topic 260, <i style="font-style:italic;">Earnings Per Share</i>. The Company has one class of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities if their effect is antidilutive. Diluted net loss per share is computed by the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined by using the treasury stock method. Dilutive common stock equivalents are comprised of 6,735,530 warrants. For all periods presented, there is no difference in the number of shares used to calculated basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive given that their exercise price is greater than that of the average market price of the Company&#8217;s common stock during the years ended December 31, 2025 and 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of costs incurred by InnoBation Bio Co, Ltd. (&#8220;Innobation&#8221;) in accordance with the license agreement with Innobation and are recorded as research and development expenses as incurred (see Note 3).</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of costs incurred by Targeted Diagnostics &amp; Therapeutics, Inc. (&#8220;TDT&#8221;) who was performing the research and development activities for the Company in accordance with the license agreements with TDT and the annual fee paid to TDT and are recorded as research and development expenses as incurred (see Note 3).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes its leases in accordance with ASC Topic 842, <i style="font-style:italic;">Leases</i> (&#8220;ASC 842&#8221;). Under ASC 842, lessees are required to recognize all qualified operating leases at the commencement date including a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use (&#8220;ROU&#8221;) asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. The initial lease liability is equal to the future fixed minimum lease payments discounted using the Company&#8217;s incremental borrowing rate, on a secured basis. The lease term includes option renewal periods and early termination payments when it is reasonably certain that the Company will exercise those rights. The initial measurement of the ROU asset is equal to the initial lease liability plus any initial direct costs and prepayments, less any lease incentives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has leased office space for a fixed period of 10 months. In accordance with ASC 842, a short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The short-term lease election can only be made at the commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A lessee that makes this accounting policy election does not recognize a lease liability or right-of-use asset on its balance sheets. Instead, the lessee recognizes lease payments on a straight-line basis over the lease term.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes its leases in accordance with ASC Topic 842, <i style="font-style:italic;">Leases</i> (&#8220;ASC 842&#8221;). Under ASC 842, lessees are required to recognize all qualified operating leases at the commencement date including a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use (&#8220;ROU&#8221;) asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. The initial lease liability is equal to the future fixed minimum lease payments discounted using the Company&#8217;s incremental borrowing rate, on a secured basis. The lease term includes option renewal periods and early termination payments when it is reasonably certain that the Company will exercise those rights. The initial measurement of the ROU asset is equal to the initial lease liability plus any initial direct costs and prepayments, less any lease incentives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has leased office space for a fixed period of 10 months. In accordance with ASC 842, a short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The short-term lease election can only be made at the commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A lessee that makes this accounting policy election does not recognize a lease liability or right-of-use asset on its balance sheet. Instead, the lessee recognizes lease payments on a straight-line basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes in accordance with ASC Topic 740,&#160;<i style="font-style:italic;">Income Taxes</i>&#160;(&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. There were no tax accruals relating to uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax positions as income tax expense. There were no unrecognized tax positions, and no amounts accrued for interest and penalties as of March 31, 2026 and December 31, 2025. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only &#8220;major&#8221; tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. No unrecognized tax benefits were identified as of March 31, 2026 or December 31, 2025.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes in accordance with ASC Topic 740,&#160;<i style="font-style:italic;">Income Taxes</i>&#160;(&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. There were no tax accruals relating to uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax positions as income tax expense. There were no unrecognized tax positions, and no amounts accrued for interest and penalties as of December 31, 2025 and 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only &#8220;major&#8221; tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. No unrecognized tax benefits were identified as of December 31, 2025 or 2024.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements - Not Yet Adopted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements&#160;&#8211; Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On November 4, 2024, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2024-03, <i style="font-style:italic;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i> (&#8220;ASU 2024-03&#8221;), to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this standard will have on its unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#8217;s unaudited condensed consolidated financial statements.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The Company adopted this standard on January 1, 2025 and determined that the adoption does not have a material impact on these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements&#160;&#8211; Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2024, the FASB issued ASU 2024-03, Accounting Standards Update 2024-03, <i style="font-style:italic;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i> to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_EmergingGrowthCompanyPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policies on emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_EmergingGrowthCompanyPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of policy for net income (loss) per common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_WarrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_WarrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLoansAndLeasesReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLoansAndLeasesReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of debt outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:225.1pt;padding:0pt;"></td><td style="width:8.9pt;padding:0pt;"></td><td style="width:157.4pt;padding:0pt;"></td><td style="width:8.85pt;padding:0pt;"></td><td style="width:5.85pt;padding:0pt;"></td><td style="width:53.25pt;padding:0pt;"></td><td style="width:8.85pt;padding:0pt;"></td><td style="width:7pt;padding:0pt;"></td><td style="width:64.8pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:59.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:71.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2025</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo June 2023 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo July 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,500</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase May 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase July 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hana August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes November 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes January 2025 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,000</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short-term debt, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,442,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,442,500</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:202.45pt;padding:0pt;"></td><td style="width:13.39pt;padding:0pt;"></td><td style="width:162pt;padding:0pt;"></td><td style="width:12.85pt;padding:0pt;"></td><td style="width:8pt;padding:0pt;"></td><td style="width:60.5pt;padding:0pt;"></td><td style="width:12.86pt;padding:0pt;"></td><td style="width:8pt;padding:0pt;"></td><td style="width:59.95pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:149.3pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style="height:9.69pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Feelux Bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Car-Tcellkor Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 800,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ewon Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,000,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo June 2023 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo July 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo August 2023 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 400,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ewon September 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo November 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ewon December 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,000,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo January 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 750,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase April 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase May 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 790,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase July 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hana August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 850,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes November 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes January 2025 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short-term debt, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,442,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,973,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholder's Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of assumptions used for estimating fair value of warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:369.05pt;padding:0pt;"></td><td style="width:10pt;padding:0pt;"></td><td style="width:44.6pt;padding:0pt;"></td><td style="width:8.35pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:369.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:369.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 92.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:369.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:369.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:369.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected life of warrants (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock', window );">Schedule of offering proceeds and related issuance costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:259.65pt;padding:0pt;"></td><td style="width:8pt;padding:0pt;"></td><td style="width:52.7pt;padding:0pt;"></td><td style="width:8.05pt;padding:0pt;"></td><td style="width:50.04pt;padding:0pt;"></td><td style="width:8.05pt;padding:0pt;"></td><td style="width:45.5pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.24pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Allocated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Allocated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Allocated</b></p></td></tr><tr style="height:9.49pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross&#160;Proceeds</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuance&#160;Costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net&#160;Proceeds</b></p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:259.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,208,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 168,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,039,295</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Common Stock Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,977,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 276,502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,701,497</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:259.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Pre-Funded Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 755,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 649,471</p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Placement Agent Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,546</p></td></tr><tr style="height:12.54pt;"><td style="vertical-align:bottom;width:259.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,005,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 559,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,445,808</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of offering proceeds and related issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of fair value, assets and liabilities measured on recurring basis.</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:340.7pt;padding:0pt;"></td><td style="width:9.8pt;padding:0pt;"></td><td style="width:49.65pt;padding:0pt;"></td><td style="width:9.85pt;padding:0pt;"></td><td style="width:6.25pt;padding:0pt;"></td><td style="width:49.25pt;padding:0pt;"></td><td style="width:9.85pt;padding:0pt;"></td><td style="width:7.7pt;padding:0pt;"></td><td style="width:56.95pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:340.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:340.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:55.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2025</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:340.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:340.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:340.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,244</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:341.85pt;padding:0pt;"></td><td style="width:10.8pt;padding:0pt;"></td><td style="width:50.65pt;padding:0pt;"></td><td style="width:10.79pt;padding:0pt;"></td><td style="width:6.8pt;padding:0pt;"></td><td style="width:50.75pt;padding:0pt;"></td><td style="width:10.8pt;padding:0pt;"></td><td style="width:6.8pt;padding:0pt;"></td><td style="width:50.75pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:341.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:341.85pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:341.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:341.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:341.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Schedule of changes in fair value of Level 3 financial assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:360.05pt;padding:0pt;"></td><td style="width:11.39pt;padding:0pt;"></td><td style="width:7.15pt;padding:0pt;"></td><td style="width:53.4pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:60.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant&#160;liability</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of January 1, 2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 29,244</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,178</p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of March&#160;31,&#160;2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 33,422</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:360.05pt;padding:0pt;"></td><td style="width:11.39pt;padding:0pt;"></td><td style="width:7.15pt;padding:0pt;"></td><td style="width:53.4pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:60.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant&#160;liability</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Initial measurement at the Closing Date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,556</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (54,312)</p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 29,244</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets and  liability using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings  are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset and liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Organization and Business Operations - Business Combination (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 01, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_SharesAuthorized', window );">Shares authorized (in shares) | shares</a></td>
<td class="nump">501,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares) | shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock (in shares) | shares</a></td>
<td class="nump">112,222,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares converted into (in shares) | shares</a></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ConversionOfStockOrUnitConversionRatio', window );">Share conversion ratio</a></td>
<td class="nump">0.1559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from issuance of common stock for PIPE investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,585,308<span></span>
</td>
<td class="nump">$ 10,556,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,797,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination', window );">Deferred underwriting fees payable</a></td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuableForSettlementOfDeferredUnderwritingFees', window );">Stock issuable for settlement of deferred underwriting fees (in shares) | shares</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_LiabilityOfUnderwritingFeesFairValue', window );">Liability of underwriting fees</a></td>
<td class="nump">$ 7,049,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees', window );">Fair value of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=limn_FeeluxCo.LtdMember', window );">Feelux Co. Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares converted into (in shares) | shares</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=limn_FeeluxAndCarTcellkorMember', window );">Feelux and Car-Tcellkor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ConversionOfPrincipalAndAccruedInterestAmount', window );">Conversion of principal and accrued interest amount</a></td>
<td class="nump">$ 11,481,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ConversionOfPrincipalAndAccruedInterestShares', window );">Conversion of principal and accrued interest shares (in shares) | shares</a></td>
<td class="nump">9,999,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Total consideration</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from issuance of common stock for PIPE investment</a></td>
<td class="nump">10,556,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ProceedsFromIssuanceOfPrivatePlacementInvestor', window );">Proceeds from issuance of private placement investor</a></td>
<td class="nump">7,129,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded', window );">Proceeds from issuance of private placement investor funded</a></td>
<td class="nump">3,427,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">3,427,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PrincipalAndAccruedInterestOnPrivatePlacement', window );">Principal and accrued interest</a></td>
<td class="nump">3,316,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_RelatedPartiesDebtToUnsecuredPromissoryNote', window );">Related parties debt</a></td>
<td class="nump">4,443,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_UnsecuredPromissoryNoteSettledAndConverted', window );">Unsecured promissory note settled and converted</a></td>
<td class="nump">4,443,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ConsortiumLoanOfRelatedPartiesMember', window );">Consortium Loan of related parties | Private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">$ 4,443,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=limn_IrisAcquisitionCorpMember', window );">Iris</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares converted into (in shares) | shares</a></td>
<td class="nump">114,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">$ 14,797,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PrincipalAndAccruedInterestOnPrivatePlacement', window );">Principal and accrued interest</a></td>
<td class="nump">3,316,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ConversionOfPrincipalAndAccruedInterestAmount', window );">Conversion of principal and accrued interest amount</a></td>
<td class="nump">11,481,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Recognized liability assumed</a></td>
<td class="nump">10,694,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="nump">1,518,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ConversionOfAccruedInterestOnRelatedPartyDebts', window );">Accrued interest</a></td>
<td class="nump">$ 169,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=limn_IrisAcquisitionCorpMember', window );">Iris | Redeemable warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_NumberOfWarrantsHeldInEachUnit', window );">Number of warrants held in each unit (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=limn_IrisAcquisitionCorpMember', window );">Iris | Class A shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockCashRedemptionShares', window );">Shares redeemed (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockCashRedemptionPricePerShare', window );">Cash redemption price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockCashRedemptionAmount', window );">Aggregate cash redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 702,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_NumberOfSharesHeldInEachUnit', window );">Number of shares held in each unit (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock (in shares) | shares</a></td>
<td class="nump">7,014,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ConversionOfStockOrUnitConversionRatio', window );">Share conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=limn_IrisAcquisitionHoldingsLlcMember', window );">Iris Acquisition Holdings, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares converted into (in shares) | shares</a></td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=limn_LiminatusAndIrisMember', window );">Liminatus and Iris</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockConversionRatioBusinessCombination', window );">Number of common shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=limn_LiminatusAndIrisMember', window );">Liminatus and Iris | Non-redeemable warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=limn_LiminatusAndIrisMember', window );">Liminatus and Iris | Class A shares | Non-redeemable warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_CommonStockCashRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash redemption of value of common stock of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_CommonStockCashRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_CommonStockCashRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the common stock of the entity is redeemed or may be called at.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_CommonStockCashRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_CommonStockCashRedemptionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of common shares redeemed for cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_CommonStockCashRedemptionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_CommonStockConversionRatioBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of common stock in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_CommonStockConversionRatioBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ConversionOfAccruedInterestOnRelatedPartyDebts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest on related party debts that were converted into common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ConversionOfAccruedInterestOnRelatedPartyDebts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ConversionOfPrincipalAndAccruedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of conversion of principal and accrued interest amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ConversionOfPrincipalAndAccruedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ConversionOfPrincipalAndAccruedInterestShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of conversion of principal and accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ConversionOfPrincipalAndAccruedInterestShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ConversionOfStockOrUnitConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock issuable upon conversion of each share of stock or unit to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ConversionOfStockOrUnitConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred underwriting fees liabilities of acquiree to be settled by way of issuance of common stock of the entity upon consummation of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of common shares issued for settlement of deferred underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_LiabilityOfUnderwritingFeesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability of underwriting fees fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_LiabilityOfUnderwritingFeesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_NumberOfSharesHeldInEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of common shares held in each Iris unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_NumberOfSharesHeldInEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_NumberOfWarrantsHeldInEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants held in each Iris unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_NumberOfWarrantsHeldInEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_PrincipalAndAccruedInterestOnPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal and accrued interest converted into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_PrincipalAndAccruedInterestOnPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ProceedsFromIssuanceOfPrivatePlacementInvestor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private placement investor rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ProceedsFromIssuanceOfPrivatePlacementInvestor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from private placement investor funded indirectly.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_RelatedPartiesDebtToUnsecuredPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowed from the related parties were used to fund an unsecured promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_RelatedPartiesDebtToUnsecuredPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_SharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of cumulative shares of all kinds permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_SharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuableForSettlementOfDeferredUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issuable for settlement of deferred underwriting fees in connection with the underwriting services provided by the underwriters in the initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuableForSettlementOfDeferredUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_UnsecuredPromissoryNoteSettledAndConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unsecured promissory note was settled and related party debts were ultimately converted into shares of the Company in a noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_UnsecuredPromissoryNoteSettledAndConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability assumed in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_FeeluxCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_FeeluxCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_FeeluxAndCarTcellkorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_FeeluxAndCarTcellkorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ConsortiumLoanOfRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ConsortiumLoanOfRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=limn_IrisAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=limn_IrisAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_RedeemableWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_RedeemableWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=limn_IrisAcquisitionHoldingsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=limn_IrisAcquisitionHoldingsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=limn_LiminatusAndIrisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=limn_LiminatusAndIrisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_NonRedeemableWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_NonRedeemableWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Organization and Business Operations - February 2026 Public Offering (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Feb. 19, 2026</div></th>
<th class="th"><div>Feb. 18, 2026</div></th>
<th class="th"><div>Feb. 17, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember', window );">Best efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate', window );">Period of non issuance of common stock following closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate', window );">Period of non issuance of common stock involving variable rate transaction following closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PlacementAgentCashFeePercentage', window );">Placement agent fee, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_MaximumReimbursementForPlacementAgentExpenses', window );">Placement agent fee, maximum reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Pre-funded warrants (in shares)</a></td>
<td class="nump">1,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember', window );">Pre-funded warrants | Best efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightIssuePricePerWarrant', window );">Offering price of pre-funded warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember', window );">Common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember', window );">Common stock purchase warrants | Best efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,813,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,719,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PlacementAgentWarrantsMember', window );">Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.319<span></span>
</td>
<td class="nump">$ 0.319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PlacementAgentWarrantsMember', window );">Placement Agent Warrants | Best efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PercentOfSharesIssuedInOffering', window );">Percent of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PercentOfOfferingPriceRepresentingExercisePrice', window );">Percent of offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightIssuePricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per unit amount of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightIssuePricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightNumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_MaximumReimbursementForPlacementAgentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum out-of-pocket costs and expenses incurred in connection with the Offering that will be reimbursed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_MaximumReimbursementForPlacementAgentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_PercentOfOfferingPriceRepresentingExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the public offering price for the shares of common stock and common warrants offered in the Offering representing exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_PercentOfOfferingPriceRepresentingExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_PercentOfSharesIssuedInOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock sold in the offering, threshold percentage on the total number of outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_PercentOfSharesIssuedInOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period during which shares will not be issued after the closing date of the offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period during which common stock or any securities convertible into or exercisable or exchangeable for shares of common stock involving a variable rate transaction will not be issued after the closing date of the offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_PlacementAgentCashFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of cash fee for placement agent, calculated on aggregate gross proceeds raised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_PlacementAgentCashFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Organization and Business Operations - Liquidity and Capital Resources (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 19, 2026</div></th>
<th class="th"><div>Feb. 18, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,907,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 337,655<span></span>
</td>
<td class="nump">$ 56,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">19,973,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,995,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,871,733<span></span>
</td>
<td class="nump">28,665,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,898<span></span>
</td>
<td class="nump">$ 264,220<span></span>
</td>
<td class="nump">2,967,812<span></span>
</td>
<td class="nump">3,329,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,123,714<span></span>
</td>
<td class="nump">$ 327,526<span></span>
</td>
<td class="nump">$ 10,206,517<span></span>
</td>
<td class="nump">$ 3,546,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Pre-funded warrants (in shares)</a></td>
<td class="nump">1,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember', window );">Common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember', window );">Best efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember', window );">Best efforts | Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightIssuePricePerWarrant', window );">Offering price of pre-funded warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember', window );">Best efforts | Common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,813,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,719,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightIssuePricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per unit amount of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightIssuePricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightNumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in the fair value of warrant liabilities | $</a></td>
<td class="nump">$ 4,178<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (54,312)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Incremental common shares (in shares)</a></td>
<td class="nump">19,598,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,735,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember', window );">Common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued (in shares)</a></td>
<td class="nump">13,813,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Incremental common shares (in shares)</a></td>
<td class="nump">13,813,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PlacementAgentWarrantsMember', window );">Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued (in shares)</a></td>
<td class="nump">690,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Incremental common shares (in shares)</a></td>
<td class="nump">690,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued (in shares)</a></td>
<td class="nump">5,094,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,899,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Incremental common shares (in shares)</a></td>
<td class="nump">5,094,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PrivatePlacementWarrantsMember', window );">Private placement warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued (in shares)</a></td>
<td class="nump">835,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_FranchiseTaxExpenseIncludingInterestAndPenalty', window );">Franchise tax, penalties and interest | $</a></td>
<td class="nump">$ 60,500<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="nump">$ 202,833<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_FranchiseTaxExpenseIncludingInterestAndPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of franchise tax expense and related interest and penalties incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_FranchiseTaxExpenseIncludingInterestAndPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-26<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, interest and penalties accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - CD47 License (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 20, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense related to the CD47 License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,685,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember', window );">CD47 License agreement with InnoBation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_EstimatedPercentageOfActivitiesCompleted', window );">Percentage of activities completed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PrepaidResearchAndDevelopmentExpenseCurrent', window );">Prepaid research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense related to the CD47 License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember', window );">CD47 License agreement with InnoBation | Curis Biotech Holdings LLC | Class A Member Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_NumberOfUnitsExchangeForLicenseRights', window );">Number of member units exchange for license rights to develop</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,555,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital', window );">Value of membership interest offset to additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember', window );">CD47 License agreement with InnoBation | Innobation Bio Co. Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PaymentForCostsAssociatedWithClinicalTrials', window );">Company issued a payment</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_EstimatedPercentageOfActivitiesCompleted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated percentage of activities completed by the company as per agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_EstimatedPercentageOfActivitiesCompleted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of membership interest exchange for license fees being offset to additional paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_NumberOfUnitsExchangeForLicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of member units exchanged as a consideration for license rights to develop, market and sell YN1203, InnoBation Bio CAR NK biomarkers, including devices, compounds and products used to detect analyte in body or tissue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_NumberOfUnitsExchangeForLicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_PaymentForCostsAssociatedWithClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment made for costs associated with clinical trials.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_PaymentForCostsAssociatedWithClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_PrepaidResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prepaid research and development classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_PrepaidResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_CurisBiotechHoldingsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_CurisBiotechHoldingsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_InnobationBioCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_InnobationBioCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Feelux Bonds (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Sep. 15, 2018</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="nump">$ 19,973,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 713,000<span></span>
</td>
<td class="nump">4,340,000<span></span>
</td>
<td class="nump">3,923,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,797,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock (in shares)</a></td>
<td class="nump">112,222,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,921<span></span>
</td>
<td class="nump">955,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">19,973,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Feelux Co. Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock (in shares)</a></td>
<td class="nump">9,999,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits', window );">Conversion of debt</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Feelux Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,666,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,499,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">$ 10,681,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">646,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Feelux Bonds | Expected stock volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Feelux Bonds | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Feelux Bonds | Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Feelux Bonds | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense relating to loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Feelux Bonds | Feelux Co. Ltd | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense relating to loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,023<span></span>
</td>
<td class="nump">$ 106,087<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_AccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_AccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued in exchange for original debt being and member units being converted in connection with the consummation of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_FeeluxCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_FeeluxCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_FeeluxBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_FeeluxBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions - Car-Tcellkor Loan (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>May 18, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="nump">$ 19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Car-Tcellkor Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Consumption of outstanding principal</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_CarTcellkorLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_CarTcellkorLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Valetudo Loans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 01, 2025</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="nump">$ 19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,921<span></span>
</td>
<td class="nump">955,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo Loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense relating to loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">42,208<span></span>
</td>
<td class="nump">96,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo Loan | Valetudo Therapeutics LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,308<span></span>
</td>
<td class="nump">115,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo December 2022 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_RepaymentOfMembershipInterest', window );">Repayment of membership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of debt</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo June 2023 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo June 2023 Loan One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of debt</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo June 2023 Loan Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo July 2023 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo August 2023 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo August 2023 Loan One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo August 2023 Loan Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo November 2023 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo January 2024 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo January 2024 Loan One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo January 2024 Loan Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_AccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_AccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_RepaymentOfMembershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of repayment of membership interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_RepaymentOfMembershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_ValetudoTherapeuticsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_ValetudoTherapeuticsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoDecember2022LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoDecember2022LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJune2023LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoJune2023LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJune2023LoanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoJune2023LoanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJune2023LoanTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoJune2023LoanTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJuly2023LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoJuly2023LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoAugust2023LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoAugust2023LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoAugust2023LoanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoAugust2023LoanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoAugust2023LoanTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoAugust2023LoanTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoNovember2023LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoNovember2023LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJanuary2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoJanuary2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJanuary2024LoanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoJanuary2024LoanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJanuary2024LoanTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoJanuary2024LoanTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Ewon Loans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 19, 2023</div></th>
<th class="th"><div>Sep. 10, 2023</div></th>
<th class="th"><div>Dec. 12, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="nump">$ 19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,797,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,921<span></span>
</td>
<td class="nump">955,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Ewon Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense relating to loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="nump">14,667<span></span>
</td>
<td class="nump">44,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Ewon Loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Ewon Loan | Ewon Comfortech Co Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">102,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Ewon December 2022 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Ewon September 2023 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Ewon December 2023 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_AccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_AccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_EwonLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_EwonLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_EwonComfortechCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_EwonComfortechCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_EwonDecember2022LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_EwonDecember2022LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_EwonSeptember2023LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_EwonSeptember2023LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_EwonDecember2023LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_EwonDecember2023LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Prophase Loans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>May 14, 2025</div></th>
<th class="th"><div>May 13, 2025</div></th>
<th class="th"><div>May 02, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Oct. 13, 2024</div></th>
<th class="th"><div>Oct. 12, 2024</div></th>
<th class="th"><div>Sep. 29, 2024</div></th>
<th class="th"><div>Sep. 24, 2024</div></th>
<th class="th"><div>Sep. 14, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Jul. 01, 2024</div></th>
<th class="th"><div>Jun. 01, 2024</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Apr. 01, 2024</div></th>
<th class="th"><div>Mar. 06, 2024</div></th>
<th class="th"><div>Feb. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="nump">$ 19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,797,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,921<span></span>
</td>
<td class="nump">955,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense relating to loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,138<span></span>
</td>
<td class="nump">$ 26,787<span></span>
</td>
<td class="nump">77,073<span></span>
</td>
<td class="nump">66,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase Loan | Prophase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742,500<span></span>
</td>
<td class="nump">1,623,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,283<span></span>
</td>
<td class="nump">66,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase February 2024 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,500<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">$ 168,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase March 2024 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase April 2024 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase May 2024 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="nump">790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 520,000<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="nump">$ 790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase July 2024 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase August 2024 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase February 2025 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase March 2025 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase April 2025 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="nump">$ 3,627,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,506,880<span></span>
</td>
<td class="nump">$ 1,920,120<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">$ 3,627,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_AccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_AccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_ProphaseSciencesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_ProphaseSciencesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2024LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2024LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2024LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2024LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseApril2024LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseApril2024LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseMay2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseMay2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseJuly2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseJuly2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseAugust2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseAugust2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2025LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2025LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2025LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2025LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseApril2025LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseApril2025LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Hana Loans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="nump">$ 19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,797,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,921<span></span>
</td>
<td class="nump">955,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Hana Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense relating to loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="nump">$ 12,750<span></span>
</td>
<td class="nump">19,042<span></span>
</td>
<td class="nump">19,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Hana Loans | Maximum | Hana Immunotherapeutics, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,042<span></span>
</td>
<td class="nump">19,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Hana August 2024 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 850,000<span></span>
</td>
<td class="nump">$ 850,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_AccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_AccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_HanaLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_HanaLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_HanaImmunotherapeuticsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_HanaImmunotherapeuticsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_HanaAugust2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_HanaAugust2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Amantes Loans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 23, 2025</div></th>
<th class="th"><div>Jan. 02, 2025</div></th>
<th class="th"><div>Nov. 27, 2024</div></th>
<th class="th"><div>Nov. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="nump">$ 19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,797,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,921<span></span>
</td>
<td class="nump">955,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Amantes Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense relating to loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">$ 14,724<span></span>
</td>
<td class="nump">27,890<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Amantes Loans | Maximum | Amantes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,288<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Amantes November 2024 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">$ 550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Amantes January 2025 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_AccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_AccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_AmantesLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_AmantesLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_AmantesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_AmantesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_AmantesNovember2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_AmantesNovember2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_AmantesJanuary2025LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_AmantesJanuary2025LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions - Due to Related Party (Details) - Related party - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">$ 194,587<span></span>
</td>
<td class="nump">$ 209,586<span></span>
</td>
<td class="nump">$ 195,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Employment Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">$ 194,587<span></span>
</td>
<td class="nump">$ 209,586<span></span>
</td>
<td class="nump">$ 195,253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=limn_EmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=limn_EmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jan. 23, 2025</div></th>
<th class="th"><div>Jan. 02, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 27, 2024</div></th>
<th class="th"><div>Nov. 01, 2024</div></th>
<th class="th"><div>Oct. 13, 2024</div></th>
<th class="th"><div>Oct. 12, 2024</div></th>
<th class="th"><div>Sep. 29, 2024</div></th>
<th class="th"><div>Sep. 24, 2024</div></th>
<th class="th"><div>Sep. 14, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Aug. 01, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Jul. 01, 2024</div></th>
<th class="th"><div>Jun. 01, 2024</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Mar. 06, 2024</div></th>
<th class="th"><div>Feb. 26, 2024</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJune2023LoansMember', window );">Valetudo June 2023 Loans | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJuly2023LoanMember', window );">Valetudo July 2023 Loan | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2024LoanMember', window );">Prophase February 2024 Loan | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">31,500<span></span>
</td>
<td class="nump">31,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2024LoanMember', window );">Prophase March 2024 Loan | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ProphaseMay2024LoansMember', window );">Prophase May 2024 Loans | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 520,000<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="nump">$ 790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ProphaseJuly2024LoansMember', window );">Prophase July 2024 Loans | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">83,000<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ProphaseAugust2024LoansMember', window );">Prophase August 2024 Loans | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_HanaAugust2024LoansMember', window );">Hana August 2024 Loans | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_AmantesNovember2024LoansMember', window );">Amantes November 2024 Loans | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_AmantesJanuary2025LoansMember', window );">Amantes January 2025 Loans | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2025LoanMember', window );">Prophase February 2025 Loan | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">81,000<span></span>
</td>
<td class="nump">81,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2025LoanMember', window );">Prophase March 2025 Loan | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ValetudoDecember2022LoansMember', window );">Valetudo Loan | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJune2023LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoJune2023LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJuly2023LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoJuly2023LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2024LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2024LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2024LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2024LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseMay2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseMay2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseJuly2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseJuly2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseAugust2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseAugust2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_HanaAugust2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_HanaAugust2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_AmantesNovember2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_AmantesNovember2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_AmantesJanuary2025LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_AmantesJanuary2025LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2025LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2025LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2025LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2025LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoDecember2022LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoDecember2022LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 19, 2026 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 18, 2026 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 06, 2026 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 16, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>D </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>D </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 17, 2026 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 01, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_GainLossOnIssuanceOfCommonStockForWarrants', window );">Loss on issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,740,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination', window );">Deferred underwriting fees liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuableForSettlementOfDeferredUnderwritingFees', window );">Stock issuable for settlement of deferred underwriting fees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees', window );">Fair value of common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,877,633<span></span>
</td>
<td class="nump">27,064,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,877,633<span></span>
</td>
<td class="nump">27,064,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockNumberOfVotesPerShare', window );">Number of votes per share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember', window );">Best efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=limn_AltaPartnersLlcMember', window );">Alta Partners Llc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_SharesIssuedForSurrenderAndCancellationOfWarrants', window );">Number of shares issued for surrender and cancellation of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled', window );">Surrender and cancellation of warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_FairValueOfCommonStockIssued', window );">Fair value of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,890,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_FairValueOfWarrantsSurrendered', window );">Fair value of warrants surrendered | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_GainLossOnIssuanceOfCommonStockForWarrants', window );">Loss on issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,740,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=limn_ClearStreetLlcMember', window );">Clear Street Llc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_SharesIssuedForSurrenderAndCancellationOfWarrants', window );">Number of shares issued for surrender and cancellation of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled', window );">Surrender and cancellation of warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,094,623<span></span>
</td>
<td class="nump">5,899,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants', window );">Threshold written notice period for redemption of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption', window );">Threshold Share Price for redemption of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays', window );">Threshold number of specified trading days for stock price | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays', window );">Threshold number of specified consecutive trading days for stock price | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PrivatePlacementWarrantsMember', window );">Private placement warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835,555<span></span>
</td>
<td class="nump">835,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Pre-funded warrants (in shares)</a></td>
<td class="nump">1,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Pre-Funded warrants exercised</a></td>
<td class="nump">1,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember', window );">Pre-funded warrants | Best efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions', window );">Pre-funded warrants issued on conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightIssuePricePerWarrant', window );">Offering price of pre-funded warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Pre-Funded warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember', window );">Common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,813,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember', window );">Common stock purchase warrants | Best efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,813,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,719,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PlacementAgentWarrantsMember', window );">Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PlacementAgentWarrantsMember', window );">Placement Agent Warrants | Best efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockAndPreFundedWarrantsMember', window );">Common stock and Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing stock price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightIssuePricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per unit amount of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightIssuePricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants surrendered and canceled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightNumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightNumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightNumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued on conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days for stock price trigger considered for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The threshold trigger price for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The threshold period during which a written notice is required for redemption of warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_CommonStockNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of votes for each share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_CommonStockNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred underwriting fees liabilities of acquiree to be settled by way of issuance of common stock of the entity upon consummation of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of common shares issued for settlement of deferred underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_FairValueOfCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_FairValueOfCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_FairValueOfWarrantsSurrendered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of warrants surrendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_FairValueOfWarrantsSurrendered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_GainLossOnIssuanceOfCommonStockForWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit or loss on exchange of common stock for surrender of warrants classified as non-operating income. Represents the difference in the fair value of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_GainLossOnIssuanceOfCommonStockForWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_SharesIssuedForSurrenderAndCancellationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for surrender and cancellation of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_SharesIssuedForSurrenderAndCancellationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuableForSettlementOfDeferredUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issuable for settlement of deferred underwriting fees in connection with the underwriting services provided by the underwriters in the initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuableForSettlementOfDeferredUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_AltaPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_AltaPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_ClearStreetLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_ClearStreetLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockAndPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockAndPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholder's Equity - Assumptions used for estimating fair value of warrants (Details) - Common Stock Warrants and Placement Agent Warrants<br></strong></div></th>
<th class="th">
<div>Feb. 18, 2026 </div>
<div>Y</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Stockholder's Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.9251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Stockholder's Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.0366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected life of warrants (years)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Stockholder's Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockWarrantsAndPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockWarrantsAndPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity - Offering proceeds and related issuance costs (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_GrossProceedsFromIssuanceOfWarrants', window );">Allocated Gross Proceeds</a></td>
<td class="nump">$ 4,005,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_OfferingCosts', window );">Allocated Issuance Costs</a></td>
<td class="nump">559,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_NetProceedsFromIssuanceOfWarrants', window );">Allocated Net Proceeds</a></td>
<td class="nump">3,445,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockWarrantsMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_GrossProceedsFromIssuanceOfWarrants', window );">Allocated Gross Proceeds</a></td>
<td class="nump">1,977,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_OfferingCosts', window );">Allocated Issuance Costs</a></td>
<td class="nump">276,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_NetProceedsFromIssuanceOfWarrants', window );">Allocated Net Proceeds</a></td>
<td class="nump">1,701,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_GrossProceedsFromIssuanceOfWarrants', window );">Allocated Gross Proceeds</a></td>
<td class="nump">755,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_OfferingCosts', window );">Allocated Issuance Costs</a></td>
<td class="nump">105,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_NetProceedsFromIssuanceOfWarrants', window );">Allocated Net Proceeds</a></td>
<td class="nump">649,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PlacementAgentWarrantsMember', window );">Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_GrossProceedsFromIssuanceOfWarrants', window );">Allocated Gross Proceeds</a></td>
<td class="nump">64,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_OfferingCosts', window );">Allocated Issuance Costs</a></td>
<td class="nump">9,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_NetProceedsFromIssuanceOfWarrants', window );">Allocated Net Proceeds</a></td>
<td class="nump">55,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_GrossProceedsFromIssuanceOfWarrants', window );">Allocated Gross Proceeds</a></td>
<td class="nump">1,208,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_OfferingCosts', window );">Allocated Issuance Costs</a></td>
<td class="nump">168,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_NetProceedsFromIssuanceOfWarrants', window );">Allocated Net Proceeds</a></td>
<td class="nump">$ 1,039,295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_GrossProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_GrossProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_NetProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_NetProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_OfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of offering costs involved in the issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_OfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 06, 2026</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 27, 2025</div></th>
<th class="th"><div>Jul. 01, 2025</div></th>
<th class="th"><div>Oct. 11, 2023</div></th>
<th class="th"><div>Oct. 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,784<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockPayable', window );">Settlement payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination', window );">Deferred underwriting fees settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination', window );">Deferred underwriting fee payable settled in shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination', window );">Deferred underwriting fee payable settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination', window );">Deferred underwriting fee waived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering', window );">Remaining amount of deferred underwriting fee settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination', window );">Threshold period for settling remaining deferred underwriting fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingFeesPayableInCashCurrent', window );">Deferred underwriting fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination', window );">Deferred underwriting fees liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuableForSettlementOfDeferredUnderwritingFees', window );">Stock issuable for settlement of deferred underwriting fees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees', window );">Fair value of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=limn_ClearStreetLlcMember', window );">Clear Street Llc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_SharesIssuedForSurrenderAndCancellationOfWarrants', window );">Issuance of common stock in connection with the surrender of warrants (in shares)</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled', window );">Surrender and cancellation of warrants to purchase shares of common stock</a></td>
<td class="nump">805,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockPayable', window );">Settlement payable</a></td>
<td class="nump">$ 7,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">7,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Loss contingency on damaged value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementInterest', window );">Litigation settlement interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=limn_IrisAcquisitionCorpMember', window );">Iris</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering', window );">Underwriting discount (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_UnderwritingCostsNoncurrent', window );">Underwriting discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,520,000<span></span>
</td>
<td class="nump">5,520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering', window );">Deferred underwriting discount (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredOfferingCostsNoncurrent', window );">Deferred underwriting discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,660,000<span></span>
</td>
<td class="nump">$ 9,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=limn_FeeReductionAgreementMember', window );">Fee Reduction Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_MaximumNumbersOfSharesIssuable', window );">Number of shares issuable to underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=limn_FeeReductionAgreementMember', window );">Fee Reduction Agreement | Iris</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredOfferingCostsNoncurrent', window );">Deferred underwriting discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="nump">$ 9,660,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PaymentOfOfferingCostsInCash', window );">Underwriting discount paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_UnderwritingDiscountPaidInSecurities', window );">Underwriting discount paid in securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants surrendered and canceled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_CommonStockPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_CommonStockPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredOfferingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredOfferingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of deferred underwriting discount on gross proceeds of the IPO.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred underwriting fee payable settled in cash upon consummation of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred underwriting fee payable settled in shares upon consummation of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred underwriting fee payable settled upon consummation of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amount of deferred underwriting fee settled upon consummation of combined company next share offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred underwriting fee waived upon consummation of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingFeesPayableInCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred underwriting fees payable in cash and are classified as current as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingFeesPayableInCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred underwriting fees liabilities of acquiree to be settled by way of issuance of common stock of the entity upon consummation of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of common shares issued for settlement of deferred underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_MaximumNumbersOfSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares issuable to underwriters.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_MaximumNumbersOfSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_PaymentOfOfferingCostsInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount paid in cash for offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_PaymentOfOfferingCostsInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_SharesIssuedForSurrenderAndCancellationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for surrender and cancellation of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_SharesIssuedForSurrenderAndCancellationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuableForSettlementOfDeferredUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issuable for settlement of deferred underwriting fees in connection with the underwriting services provided by the underwriters in the initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuableForSettlementOfDeferredUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold period for settling remaining deferred underwriting fee from the date of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_UnderwritingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the carrying value as of balance sheet date of underwriting fees payable or classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_UnderwritingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of underwriting discount on gross proceeds of the IPO.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_UnderwritingDiscountPaidInSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount paid in shares for offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_UnderwritingDiscountPaidInSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense (income) directly attributable to an award in settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_ClearStreetLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_ClearStreetLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=limn_IrisAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=limn_IrisAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=limn_FeeReductionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=limn_FeeReductionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Warrant liability</a></td>
<td class="nump">$ 33,422<span></span>
</td>
<td class="nump">$ 29,244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Changes in fair value of Level 3 (Details) - Fair value inputs level 3 - Warrants - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance, fair value</a></td>
<td class="nump">$ 29,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Initial measurement at the Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="nump">4,178<span></span>
</td>
<td class="num">(54,312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance, fair value</a></td>
<td class="nump">$ 33,422<span></span>
</td>
<td class="nump">$ 29,244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets<br></strong></div></th>
<th class="th" colspan="2">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 56,319<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="nump">3,668,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred transaction costs</a></td>
<td class="nump">1,401,323<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">155,501<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,281,643<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent', window );">Due from related party, non-current</a></td>
<td class="nump">126,275<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">941<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">127,216<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,408,859<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,483,253<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="nump">955,119<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedMaintenanceFeeCurrent', window );">Accrued maintenance fee</a></td>
<td class="nump">360,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">19,973,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,748,922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">24,748,922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 500,000,000 shares authorized; 27,064,633 and 17,500,000 shares issued and outstanding as of December 31, 2025 and 2024, respectively</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">9,323,403<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(28,665,216)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(19,340,063)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">5,408,859<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Non related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">1,782,297<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">195,253<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">$ 19,973,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Shares, preferred stock amount, common stock amount and additional paid-in capital data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Shares, preferred stock amount, common stock amount and additional paid - in capital data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_AccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_AccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_AccruedMaintenanceFeeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued maintenance fee as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_AccruedMaintenanceFeeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of receivable classified as other and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">27,064,633<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockShareOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">27,064,633<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_CommonStockShareOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_CommonStockShareOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Mar. 31, 2026</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Condensed Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 700,898<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 264,220<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,967,812<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 644,619<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,685,334<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,100,898<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">264,220<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,967,812<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,329,953<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,100,898)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(264,220)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,967,812)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,329,953)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense, related parties</a></td>
<td class="num">(18,638)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(115,512)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(215,903)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(338,882)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">52,206<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">76,589<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">122,526<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ForgivenessOfUnrelatedVendorPayable', window );">Forgiveness of unrelated vendor payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,142,297<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue', window );">Change in fair value of deferred underwriting fee - paid in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(196,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in the fair value of warrant liability</a></td>
<td class="num">(4,178)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">54,312<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_GainLossOnIssuanceOfCommonStockForWarrants', window );">Loss on exchange of common stock for warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,740,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_FairValueOfCommonStockIssuanceForContingentLiability', window );">Fair value of common stock to be issued for contingent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,360,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(22,816)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(63,306)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,238,705)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(216,356)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,123,714)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (327,526)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (10,206,517)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (3,546,309)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in shares)</a></td>
<td class="nump">35,999,589<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">23,753,561<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted (in shares)</a></td>
<td class="nump">35,999,589<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">23,753,561<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Shares and per share data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Shares and per share data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from change in fair value of deferred underwriting fees that would be settled in common stock of the combined entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_FairValueOfCommonStockIssuanceForContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to fair value of common stock to be issued for contingent liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_FairValueOfCommonStockIssuanceForContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ForgivenessOfUnrelatedVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of forgiveness of unrelated vendor payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ForgivenessOfUnrelatedVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_GainLossOnIssuanceOfCommonStockForWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit or loss on exchange of common stock for surrender of warrants classified as non-operating income. Represents the difference in the fair value of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_GainLossOnIssuanceOfCommonStockForWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholder's Deficit - USD ($)<br></strong></div></th>
<th class="th" colspan="2"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 9,323,403<span></span>
</td>
<td class="num">$ (25,118,907)<span></span>
</td>
<td class="num">$ (15,793,754)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,546,309)<span></span>
</td>
<td class="num">(3,546,309)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,323,403<span></span>
</td>
<td class="num">(28,665,216)<span></span>
</td>
<td class="num">$ (19,340,063)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(327,526)<span></span>
</td>
<td class="num">$ (327,526)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,323,403<span></span>
</td>
<td class="num">(28,992,742)<span></span>
</td>
<td class="num">(19,667,589)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,323,403<span></span>
</td>
<td class="num">(28,665,216)<span></span>
</td>
<td class="num">$ (19,340,063)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuedDuringPeriodValueBusinessCombination', window );">Business combination with IRIS, net of transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">190,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuedDuringPeriodSharesBusinessCombination', window );">Business combination with IRIS, net of transaction costs (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">114,633<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans', window );">Settlement of loans to Iris Acquisition Corp upon closing of the business combination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,443,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,443,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock to Iris Acquisition Holdings, LLC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 690<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock to Iris Acquisition Holdings, LLC (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,900,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for the PIPE investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 150<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14,999,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with the Offering, net of offering costs of $559,962 (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuedPeriodValueOfCommonStockToUnderwriter', window );">Issuance of common stock to underwriter</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 70<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,244,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,245,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuedPeriodOfCommonStockToUnderwriter', window );">Issuance of common stock to underwriter (In shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants', window );">Issuance of common stock in connection with the surrender of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 35<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,739,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,740,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_SharesIssuedForSurrenderAndCancellationOfWarrants', window );">Issuance of common stock in connection with the surrender of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">350,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,206,517)<span></span>
</td>
<td class="num">(10,206,517)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 2,706<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29,054,337<span></span>
</td>
<td class="num">(38,871,733)<span></span>
</td>
<td class="num">$ (9,814,690)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,064,633<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,064,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for the PIPE investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,381<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,444,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,445,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with the Offering, net of offering costs of $559,962 (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,813,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,123,714)<span></span>
</td>
<td class="num">(1,123,714)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,823<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 39,858,028<span></span>
</td>
<td class="num">$ (39,995,447)<span></span>
</td>
<td class="num">$ (132,596)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,877,633<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,877,633<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Shares, preferred stock amount, common stock amount and additional paid-in capital data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Shares, preferred stock amount, common stock amount and additional paid - in capital data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to additional paid in capital (APIC) resulting from Settlement of loans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_SharesIssuedForSurrenderAndCancellationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for surrender and cancellation of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_SharesIssuedForSurrenderAndCancellationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuedDuringPeriodSharesBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuedDuringPeriodSharesBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuedDuringPeriodValueBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to business combination during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuedDuringPeriodValueBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuedPeriodOfCommonStockToUnderwriter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued of common stock to underwriter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuedPeriodOfCommonStockToUnderwriter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued value for surrender and cancellation of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuedPeriodValueOfCommonStockToUnderwriter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued value of common stock to underwriter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuedPeriodValueOfCommonStockToUnderwriter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (327,526)<span></span>
</td>
<td class="num">$ (10,206,517)<span></span>
</td>
<td class="num">$ (3,546,309)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ForgivenessOfUnrelatedVendorPayable', window );">Forgiveness of unrelated vendor payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,142,297)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_OtherReceivableWriteOff', window );">Forgiveness of related party receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue', window );">Change in fair value of deferred underwriting fee - paid in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in the fair value of warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,312<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_GainLossOnIssuanceOfCommonStockForWarrants', window );">Loss on issuance of common stock in connection with the surrendar of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_FairValueOfCommonStockIssuanceForContingentLiability', window );">Fair value of common stock to be issued for contingent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent', window );">Due from related party, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,427,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="num">(50,846)<span></span>
</td>
<td class="nump">324,609<span></span>
</td>
<td class="num">(133,251)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">121,467<span></span>
</td>
<td class="num">(4,035,340)<span></span>
</td>
<td class="num">(10,747)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent', window );">Accrued interest, related parties</a></td>
<td class="nump">115,512<span></span>
</td>
<td class="nump">215,903<span></span>
</td>
<td class="nump">338,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent', window );">Accrued maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent', window );">Due to research and development partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,540,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent', window );">Due to related party</a></td>
<td class="num">(18,000)<span></span>
</td>
<td class="num">(62,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(159,393)<span></span>
</td>
<td class="num">(9,963,318)<span></span>
</td>
<td class="num">(1,451,066)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLoansReceivable', window );">Loans to Iris Acquisition Corp</a></td>
<td class="num">(575,000)<span></span>
</td>
<td class="num">(775,000)<span></span>
</td>
<td class="num">(2,850,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,108)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(575,000)<span></span>
</td>
<td class="num">(788,108)<span></span>
</td>
<td class="num">(2,850,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from issuance of common stock for PIPE investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,556,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities', window );">Payment of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,563,738)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from issuance of short-term debt, related party</a></td>
<td class="nump">713,000<span></span>
</td>
<td class="nump">4,340,000<span></span>
</td>
<td class="nump">3,923,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short-term debt, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">713,000<span></span>
</td>
<td class="nump">11,032,762<span></span>
</td>
<td class="nump">3,923,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash</a></td>
<td class="num">(21,393)<span></span>
</td>
<td class="nump">281,336<span></span>
</td>
<td class="num">(378,066)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, beginning of the period</a></td>
<td class="nump">56,319<span></span>
</td>
<td class="nump">56,319<span></span>
</td>
<td class="nump">434,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, end of the period</a></td>
<td class="nump">34,926<span></span>
</td>
<td class="nump">337,655<span></span>
</td>
<td class="nump">56,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities assumed in connection with the Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,694,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination', window );">Fair value of shares to be issued to underwriter on date of the Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,049,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction', window );">Transaction costs incurred upon closing of the Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,518,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_LoansSettled', window );">Settlement of loans to Iris Acquisition Corp upon closing of the Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,443,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock to Iris Acquisition Holdings, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,797,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_NoncashConversionOfAmountBorrowedForPipeFunds', window );">Non-cash conversion of short term debt, related parties for PIPE Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,427,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest', window );">Non-cash impact to APIC for the forgiveness of accrued interest on converted related party debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_SharesIssuableUponClosingOfMergerToUnderwriters', window );">Issuance of common stock to underwriter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredTransactionCostsInAccountsPayable', window );">Deferred transaction costs in accounts payable</a></td>
<td class="nump">$ 112,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 561,441<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non-cash impact to additional paid in capital upon forgiveness of accrued interest on the converted debt instrument in a non-cash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredTransactionCostsInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred transaction costs in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredTransactionCostsInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from change in fair value of deferred underwriting fees that would be settled in common stock of the combined entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_FairValueOfCommonStockIssuanceForContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to fair value of common stock to be issued for contingent liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_FairValueOfCommonStockIssuanceForContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ForgivenessOfUnrelatedVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of forgiveness of unrelated vendor payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ForgivenessOfUnrelatedVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_GainLossOnIssuanceOfCommonStockForWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit or loss on exchange of common stock for surrender of warrants classified as non-operating income. Represents the difference in the fair value of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_GainLossOnIssuanceOfCommonStockForWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued interest to related party classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued maintenance fee classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in due to research and development partner classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_LoansSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loans settled upon closing of merger in a non-cash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_LoansSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transaction costs incurred upon closing of merger during the period in a non-cash or part non-cash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_NoncashConversionOfAmountBorrowedForPipeFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of borrowed funds for PIPE transactions that are converted in a non-cash or part non-cash transactions.  "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_NoncashConversionOfAmountBorrowedForPipeFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_OtherReceivableWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable deemed as uncollectible and written off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_OtherReceivableWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_SharesIssuableUponClosingOfMergerToUnderwriters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issuable to underwriters upon closing of merger in a non-cash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_SharesIssuableUponClosingOfMergerToUnderwriters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued or issuable to underwriters upon consummation of business combination in a non-cash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for financing costs associated with business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLoansReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of loan receivable arising from the financing of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLoansReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Organization and Business Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Organization and Business Operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;1. Description of Organization and Business Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Liminatus Pharma, Inc. (the &#8220;Company&#8221;), a Delaware corporation, is a pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company&#8217;s candidate, IBA101, is a humanized anti CD47 monoclonal antibody. The next generation CD47 checkpoint inhibitor&#8217;s initial indication is expected to be patients with advanced solid cancers including non-small cell lung cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the uncertainty of whether the Company&#8217;s intellectual property will develop into successful commercial products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 30, 2022, Iris Acquisition Corp, a Delaware corporation (&#8220;Iris&#8221;), the Company, Liminatus Pharma, LLC, a Delaware limited liability company (&#8220;Liminatus&#8221;), Liminatus Pharma Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#8220;Liminatus Merger Sub&#8221;), and SPAC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#8220;SPAC Merger Sub&#8221;), entered into a business combination agreement (as amended, the &#8220;Business Combination Agreement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;4, 2025, Iris held a special meeting of stockholders. At the special meeting, Iris&#8217;s stockholders voted to approve the Business Combination and adopt the Business Combination Agreement, among other items. In connection with the special meeting, stockholders holding 59,844 Iris Class&#160;A Shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $11.74 per share, subject to adjustment for taxes payable from the trust account, for an aggregate redemption amount of $702,359. The redemptions were settled on April 30, 2025 upon the consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April&#160;30, 2025 (the &#8220;Closing Date&#8221;), the Company consummated the business combination contemplated by the Business Combination Agreement, pursuant to which <span style="color:#231f20;">(a)&#160;Liminatus Merger Sub merged with and into Liminatus (the &#8220;Liminatus Merger&#8221;), with Liminatus surviving the Liminatus Merger as a direct wholly-owned subsidiary of the Company, and (b)&#160;simultaneously with the Liminatus Merger, SPAC Merger Sub merged with and into Iris (the &#8220;SPAC Merger&#8221; and, together with the Liminatus Merger, the &#8220;Mergers&#8221;), with Iris surviving the SPAC Merger as a direct wholly-owned subsidiary of the Company (the transactions contemplated by the foregoing clauses (a)&#160;and (b)&#160;the &#8220;Business Combination&#8221;)</span>, and in connection therewith the Company changed its name from &#8220;Iris Parent Holding Corp.&#8221; to &#8220;Liminatus Pharma,&#160;Inc.<span style="color:#231f20;">&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Business Combination Agreement, among other matters, at the effective time of the Business Combination (the &#8220;Effective Time&#8221;), (i)&#160;every issued and outstanding security issued by Iris during its initial public offering (each, an &#8220;Iris Unit&#8221;) was automatically separated and broken out into its constituent parts and the holder thereof was deemed to hold one share of Iris Class&#160;A common stock, par value $0.0001 per share (the &#8220;Iris Class&#160;A Shares&#8221;) and <span style="-sec-ix-hidden:Hidden_V3HXcsnI6E-gQG2CW85ZjA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-fourth</span></span> of one redeemable warrant that was included as part of each Iris Unit (the &#8220;Public Warrants&#8221;), and such underlying constituent securities of Iris were converted in accordance with the applicable terms of the Business Combination Agreement, (ii)&#160;at the Effective Time, each issued and outstanding Iris Class&#160;A Share was converted automatically into and thereafter represent the right to receive one share of common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;), of the Company, following which all Iris Class&#160;A Shares ceased to be outstanding and were automatically canceled and ceased to exist, (iii)&#160;at the Effective Time, each issued and outstanding Public Warrant immediately and automatically represented the right to purchase shares of Common Stock on the same terms and conditions as are set forth in the applicable warrant agreement, (iv)&#160;at the Effective Time, each issued and outstanding non-redeemable warrant of Iris that was issued by Iris in a private placement at the time of the consummation of its initial public offering, entitling the holder thereof to purchase one Iris Class&#160;A Share at $11.50 per share, except those issued to Cantor Fitzgerald&#160;&amp; Co. (&#8220;Cantor&#8221;), were forfeited, and (v)&#160;the private placement warrants issued to Cantor immediately and automatically represented the right to purchase shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the consummation of the Business Combination, the Company&#8217;s certificate of incorporation was amended and restated to, among other things, set the total number of authorized shares of capital to 501,000,000 shares, of which 500,000,000 were designated as common stock, $0.0001 par value per share, and 1,000,000 shares were designated as preferred stock, $0.0001 par value per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing Date, 7,014,633 shares of Iris Class A Shares automatically converted into shares of the Company&#8217;s common stock, on a one-for-one basis. Of the total 7,014,633 newly converted shares, 6,900,000 were issued to Iris Acquisition Holdings, LLC, the sponsor of Iris, and 114,633 were issued to Iris&#8217; public stockholders in a noncash transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing Date, the Company issued an aggregate of 1,500,000 shares of the Company&#8217;s common stock in a private placement (the &#8220;PIPE Shares&#8221;) for the total consideration of $15,000,000 (the &#8220;PIPE Financing&#8221;). The PIPE Financing consisted of a cash and non-cash component. Under the cash component, the Company received gross proceeds of $10,556,500, of which $7,129,500 came directly from the PIPE investor and $3,427,000 were funded indirectly by the PIPE investor, through promissory notes between Prophase Sciences, LLC, a related party of the Company, and Liminatus. At the Closing Date, the $3,427,000 in related party debts between Prophase Sciences, LLC and Liminatus was ultimately converted into shares as part of the PIPE Financing. As part of the PIPE Financing, the gross proceeds satisfied principal and accrued interest totaling $3,316,756, which was ultimately converted into shares as part of the PIPE Financing. The non-cash component of the PIPE Financing included the conversion of $4,443,500 in amounts borrowed from a consortium of related parties. The $4,443,500 borrowed from the related parties was used to fund an unsecured promissory note between Liminatus and Iris. At the Closing Date, the unsecured promissory note was settled and the $4,443,500 in related party debts were ultimately converted into shares of the Company in a noncash transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing Date, 112,222,220 of Liminatus&#8217; member units converted into 17,500,000 shares of the Company&#8217;s common stock. Of the 17,500,000 shares of common stock, 4,000,000 were issued to Feelux Co, Ltd. as part of an agreement between the Company, Feelux Co, Ltd. and Car-Tcellkor, Inc. As part of the agreement, the outstanding principal and accrued interest on the Feelux and Car-Tcellkor bonds, totaling $11,481,146, and 9,999,999 member units of Liminatus were converted into 4,000,000 shares of the Company&#8217;s common stock. The remaining Liminatus member units were converted based on a conversion ratio of 0.1559 shares per member unit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon consummation of the Business Combination, the Company assumed a total of $10,694,604 in liabilities from Iris. The Company incurred $1,518,381 in transaction costs associated with the closing of the Business Combination. The Company converted a total of $14,797,901 of related party debt and accrued interest, $3,316,756 from the PIPE investor and $11,481,146 from Feelux and Car-Tcellkor (as described above) into common stock. Additionally, a total of $169,201 in accrued interest on related party debts that were converted, as discussed above, was eliminated upon consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, at the Closing Date, the Company settled Iris&#8217; liabilities for $7,000,000 of the deferred underwriting fees incurred prior to the Closing Date for 700,000 shares of common stock to the underwriters in Iris&#8217;s initial public offering. At the Closing Date, the shares were not issued to the underwriter and the Company recorded as a liability with a fair value of $7,049,000. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $7,245,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Liminatus was deemed the accounting acquirer in the Business Combination based on an analysis of the criteria outlined in Accounting Standards Codification (&#8220;ASC&#8221;) 805, <i style="font-style:italic;">Business Combinations</i> (&#8220;ASC 805&#8221;). The determination was primarily based on Liminatus&#8217; members prior to the Business Combination having a majority of the voting interests in the combined company, Liminatus&#8217; ability to exert control over the majority of the board of directors of the combined company, Liminatus&#8217; ability to maintain control of the board of directors on a go-forward basis, Liminatus&#8217; senior management comprising the senior management of the combined company, and Liminatus&#8217; operations prior to the Business Combination comprise the ongoing operations of the combined company. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Liminatus&#8217; issuing stock for the net assets of Iris, accompanied by a recapitalization. The net assets of Iris were stated at fair value, with no goodwill or other intangible assets recorded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the consummation of the Business Combination, the Iris Class&#160;A Shares, Iris Units and Public Warrants ceased trading on the OTC Pink Marketplace, and the Common Stock and Public Warrants began trading on The Nasdaq Stock Market (&#8220;Nasdaq&#8221;) under the trading symbols &#8220;LIMN&#8221; and &#8220;LIMNW,&#8221; respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Notices from Nasdaq</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 22, 2025, the Company received a notice from the Nasdaq Listing Qualifications Department indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025. The deficiency letter had no immediate effect on the listing of the Company&#8217;s common stock, and its common stock continued to trade on Nasdaq under the symbol &#8220;LIMN&#8221;. Under the Nasdaq rules, the Company had 60 calendar days, or until October 21, 2025, to submit a plan to regain compliance and if the plan was accepted, Nasdaq can grant an exception of up to 180 calendar days from the filing&#8217;s due date, or until February 16, 2026, to regain compliance. If the compliance plan was not accepted, the Company had the opportunity to appeal that decision to a Nasdaq Hearings Panel. On October 6, 2025, the Company filed its Form 10-Q for the period ended June 30, 2025 and the matter was closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On November 19, 2025, the Company received notices from the Nasdaq indicating that the Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value of Listed Securities (&#8220;MVLS&#8221;) of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$50,000,000 (the &#8220;MVLS Rule&#8221;), based upon a review of the Company&#8217;s MVLS for the last 30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly Held Shares (&#8220;MVPHS&#8221;) of $15,000,000 (the &#8220;MVPHS Rule&#8221;), based upon a review of the Company&#8217;s MVPHS for the last 30 consecutive business days. The Nasdaq staff noted that the Company also does not meet the requirements under Listing Rule 5450(b)(3)(A), which requires the Company to have total assets and total revenue of at least $50 million each for the most recently completed fiscal year or two of the three most recently completed fiscal years. Under the Nasdaq rules, the Company has 180 calendar days, or until May 18, 2026, to regain compliance with the MVLS Rule and MVPHS Rule. In the event the Company does not regain compliance with the MVLS Rule and MVPHS Rule prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Hearings Panel. Alternatively, the Company may consider applying to transfer the Company&#8217;s securities to the Capital Market, provided it meets the Capital Market&#8217;s continued listing requirements. The Company is working diligently to regain compliance with Nasdaq&#8217;s listing rules. However, there can be no assurance that the Company will be able to regain compliance within the prescribed time period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 15, 2026, the Company received a notice from Nasdaq indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rule 5450(a)(1) (the &#8220;Bid Price Rule&#8221;) which requires listed securities to maintain a minimum bid price of $1 per share. Under the Nasdaq rules, the Company has 180 calendar days, or until July 14, 2026, to regain compliance with the Bid Price Rule. In the event the Company does not regain compliance during the initial compliance period, the Company may be eligible for additional time to regain compliance with the Bid Price Rule. The Company is working diligently to regain compliance with Nasdaq&#8217;s listing rules. However, there can be no assurance that the Company will be able to regain compliance within the prescribed time period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">February 2026 Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 18, 2026, the Company closed a best efforts public offering for the sale of (i) 8,270,000 shares of common stock, (ii) 5,543,000 pre-funded warrants to purchase up to 5,543,000 shares of common stock and (iii) 13,813,000 common stock purchase warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per pre-funded warrant) and accompanying warrant (the &#8220;Offering&#8221;), for aggregate net proceeds of approximately $3.44 million after deducting the estimated offering expenses, including the placement agent fees. Each pre-funded warrant has an exercise price of $0.0001 per share upon issuance for one share of common stock and will not expire prior to exercise. Each warrant has an exercise price of $0.29 per share, is exercisable upon issuance for <span style="-sec-ix-hidden:Hidden_nl21qyvNY06G3jQDgQwLzg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one and a half</span></span> shares of common stock, and will expire five years following the date of issuance. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the common stock and the exercise price. Maxim Group LLC acted as the placement agent in connection with the Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Offering, on February 17, 2026, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers party thereto. Pursuant to the Purchase Agreement, the Company agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock or file any registration statement or prospectus, or any amendment or supplement thereto for 180 days after the closing date of the Offering, subject to certain exceptions. The Company also agreed not to effect or enter into an agreement to effect any issuance of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock involving a Variable Rate Transaction (as defined in the Purchase Agreement) until 180 days after the closing date of the Offering, subject to certain exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Offering, on February 17, 2026, the Company entered into a placement agency agreement with Maxim Group LLC, as placement agent in connection with the Offering (the &#8220;Placement Agent&#8221;). The Company paid the Placement Agent a cash fee of 8.0% of the aggregate gross proceeds raised in the Offering. The Company also agreed to reimburse the Placement Agent for all reasonable out-of-pocket costs and expenses incurred in connection with the Offering in an aggregate amount up to $100,000. In addition, the Company issued to the Placement Agent warrants (the &#8220;Placement Agent Warrants&#8221;) to purchase 690,650 shares of common stock (representing 5.0% of the number of shares of common stock sold in the Offering). The Placement Agent Warrants are immediately exercisable at an exercise price of $0.319 (or 110% of the public offering price for the shares of common stock and common warrants offered in the Offering) and will expire on the <span style="-sec-ix-hidden:Hidden_y0XoPBMFT0K_m6ZKSdgGew;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fifth anniversary</span></span> of the commencement of sales of the Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity and Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for one year after the date that the condensed consolidated financial statements are issued. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Through March 31, 2026, the Company has funded its operations mainly through equity and debt financings, including the proceeds from the Mergers and the PIPE Financing and the Offering (as described below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026, the Company had $1,907,674 of cash in its bank accounts. As of March 31, 2026 and December 31, 2025, there was $1,442,500 of related party debts, which are included in short-term debt, related parties in the accompanying unaudited condensed consolidated balance sheets (see Note 4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has an accumulated deficit of $39,995,447 as of March 31, 2026. The Company had a loss from operations and net loss of $1,100,898 and $1,123,714, respectively, for the three months ended March 31, 2026. The Company had a loss from operations and net loss of $264,220 and $327,526, respectively, for the three months ended March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 18, 2026, the Company completed a &#8220;best efforts&#8221; public offering of (i) 8,270,000 shares of its common stock, (ii) 5,543,000 Pre-Funded Warrants to purchase up to 5,543,000 shares of common stock and (ii) 13,813,000 Common Stock Warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per Pre-Funded Warrant) and accompanying warrant. In connection with the Offering, the Company received net proceeds of approximately $3.44 million, after deducting the estimated offering expenses payable by the Company, including the placement agent fees. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 205-40, <i style="font-style:italic;">Presentation of Financial Statements&#8212;Going Concern</i>, management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying unaudited condensed consolidated financial statements are issued. The Company&#8217;s unaudited condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management&#8217;s plans relating to the above include raising additional cash through further equity and debt financings or other arrangements to fund operations. There can be no assurance that the Company will be able to raise adequate capital under acceptable terms, if at all. The sale of additional equity may dilute existing members and newly issued equity securities may contain senior rights and preferences compared to currently outstanding common stock. Issued debt securities may contain covenants and limit the Company&#8217;s ability to pay dividends or make other distributions to stockholders. If the Company is unable to obtain such additional financing, future operations would need to be reevaluated.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;1. Description of Organization and Business Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Liminatus Pharma, Inc. (the &#8220;Company&#8221;), a Delaware corporation, is a pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company&#8217;s candidate IBA101, is a humanized anti CD47 monoclonal antibody. The next generation CD47 checkpoint inhibitor&#8217;s initial indication is expected to be patients with advanced solid cancers including non-small cell lung cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the uncertainty of whether the Company&#8217;s intellectual property will develop into successful commercial products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 30, 2022, Iris Acquisition Corp, a Delaware corporation (&#8220;Iris&#8221;), the Company, Liminatus Pharma, LLC, a Delaware limited liability company (&#8220;Liminatus&#8221;), Liminatus Pharma Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#8220;Liminatus Merger Sub&#8221;), and SPAC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#8220;SPAC Merger Sub&#8221;), entered into a business combination agreement (as it may be amended, supplemented or otherwise modified from time to time, the &#8220;Business Combination Agreement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;4, 2025, Iris held a special meeting of stockholders. At the special meeting, Iris&#8217;s stockholders voted to approve the Business Combination and adopt the Business Combination Agreement, among other items. In connection with the special meeting, stockholders holding 59,844 Iris Class&#160;A Shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $11.74 per share, subject to adjustment for taxes payable from the trust account, for an aggregate redemption amount of $702,359. The redemptions were settled on April 30, 2025 upon the consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April&#160;30, 2025 (the &#8220;Closing Date&#8221;), the Company consummated the business combination contemplated by the Business Combination Agreement, pursuant to which <span style="color:#231f20;">(a)&#160;Liminatus Merger Sub merged with and into Liminatus (the &#8220;Liminatus Merger&#8221;), with Liminatus surviving the Liminatus Merger as a direct wholly-owned subsidiary of the Company, and (b)&#160;simultaneously with the Liminatus Merger, SPAC Merger Sub merged with and into Iris (the &#8220;SPAC Merger&#8221; and, together with the Liminatus Merger, the &#8220;Mergers&#8221;), with Iris surviving the SPAC Merger as a direct wholly-owned subsidiary of the Company (the transactions contemplated by the foregoing clauses (a)&#160;and (b)&#160;the &#8220;Business Combination&#8221;)</span>, and in connection therewith the Company changed its name from &#8220;Iris Parent Holding Corp.&#8221; to &#8220;Liminatus Pharma,&#160;Inc.<span style="color:#231f20;">&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Business Combination Agreement, among other matters, at the effective time of the Business Combination (the &#8220;Effective Time&#8221;), (i)&#160;every issued and outstanding security issued by Iris during its initial public offering (each, an &#8220;Iris Unit&#8221;) was automatically separated and broken out into its constituent parts and the holder thereof was deemed to hold one share of Iris Class&#160;A common stock, par value $0.0001 per share (the &#8220;Iris Class&#160;A Shares&#8221;) and <span style="-sec-ix-hidden:Hidden_ZxKK64VsEUG8mm4V7fNrqQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-fourth</span></span> of one redeemable warrant that was included as part of each Iris Unit (the &#8220;Public Warrants&#8221;), and such underlying constituent securities of Iris were converted in accordance with the applicable terms of the Business Combination Agreement, (ii)&#160;at the Effective Time, each issued and outstanding Iris Class&#160;A Share was converted automatically into and thereafter represent the right to receive one share of common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;), of the Company, following which all Iris Class&#160;A Shares ceased to be outstanding and were automatically canceled and ceased to exist, (iii)&#160;at the Effective Time, each issued and outstanding Public Warrant immediately and automatically represented the right to purchase shares of Common Stock on the same terms and conditions as are set forth in the applicable warrant agreement, (iv)&#160;at the Effective Time, each issued and outstanding non-redeemable warrant of Iris that was issued by Iris in a private placement at the time of the consummation of its initial public offering, entitling the holder thereof to purchase one Iris Class&#160;A Share at $11.50 per share, except those issued to Cantor Fitzgerald&#160;&amp; Co. (&#8220;Cantor&#8221;), were forfeited, and (v)&#160;the private placement warrants issued to Cantor immediately and automatically represented the right to purchase shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the consummation of the Business Combination, the Company&#8217;s certificate of incorporation was amended and restated to, among other things, set the total number of authorized shares of capital to 501,000,000 shares, of which 500,000,000 were designated as common stock, $0.0001 par value per share, and 1,000,000 shares were designated as preferred stock, $0.0001 par value per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing Date, 7,014,633 shares of Iris Class A Shares automatically converted into shares of the Company&#8217;s common stock, on a one-for-one basis. Of the total 7,014,633 newly converted shares, 6,900,000 were issued to Iris Acquisition Holdings, LLC, the sponsor of Iris, and 114,633 were issued to Iris&#8217; public stockholders in a noncash transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing Date, the Company issued an aggregate of 1,500,000 shares of the Company&#8217;s common stock in a private placement (the &#8220;PIPE Shares&#8221;) for the total consideration of $15,000,000 (the &#8220;PIPE Financing&#8221;). The PIPE Financing consisted of a cash and non-cash component. Under the cash component, the Company received gross proceeds of $10,556,500, of which $7,129,500 came directly from the PIPE investor and $3,427,000 was funded indirectly by the PIPE investor, through promissory notes between Prophase Sciences, LLC, a related party of the Company, and Liminatus. At the Closing Date, the $3,427,000 in related party debts between Prophase Sciences, LLC and Liminatus was ultimately converted into shares as part of the PIPE Financing. As part of the PIPE Financing, the gross proceeds satisfied principal and accrued interest totaling $3,316,756, which was ultimately converted into shares as part of the PIPE Financing. The non-cash component of the PIPE Financing included the conversion of $4,443,500 in amounts borrowed from a consortium of related parties. The $4,443,500 borrowed from the related parties were used to fund an unsecured promissory note between Liminatus and Iris. At the Closing Date, the unsecured promissory note was settled and the $4,443,500 in related party debts were ultimately converted into shares of the Company in a noncash transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing Date, 112,222,220 Liminatus&#8217; member units converted into 17,500,000 shares of the Company&#8217;s common stock. Of the 17,500,000 shares of common stock, 4,000,000 were issued to Feelux Co, Ltd. as part of an agreement between the Company, Feelux Co, Ltd. and Car-Tcellkor, Inc. As part of the agreement, the outstanding principal and accrued interest on the Feelux and Car-Tcellkor bonds, totaling $11,481,146, and 9,999,999 member units of Liminatus were converted into 4,000,000 shares of the Company&#8217;s common stock. The remaining Liminatus member units were converted based on a conversion ratio of 0.1559 shares per member unit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon consummation of the Business Combination, the Company assumed a total of $10,694,604 in liabilities from Iris. The Company incurred $1,518,381 in transaction costs associated with the closing of the Business Combination. The Company converted a total of $14,797,901 of related party debt and accrued interest, <span style="-sec-ix-hidden:Hidden_5_bKoANxokGAW-xbn0qRBA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3,316,755</span></span> from the PIPE investor and $11,481,146 from Feelux and Car-Tcellkor (as described above) into common stock. Additionally, a total of $169,201 in accrued interest on related party debts that were converted, as discussed above, was forgiven upon consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, at the Closing Date, the Company settled Iris&#8217; liabilities for $7,000,000 of the deferred underwriting fees incurred prior to the Closing Date for 700,000 shares of common stock to the underwriters in Iris&#8217;s initial public offering. At the Closing Date, the shares were not issued to the underwriter and the Company recorded as a liability with a fair value of $7,049,000. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $7,245,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Liminatus was deemed the accounting acquirer in the Business Combination based on an analysis of the criteria outlined in Accounting Standards Codification (&#8220;ASC&#8221;) 805, <i style="font-style:italic;">Business Combinations</i> (&#8220;ASC 805&#8221;). The determination was primarily based on Liminatus&#8217; members prior to the Business Combination having a majority of the voting interests in the combined company, Liminatus&#8217; ability to exert control over the majority of the board of directors of the combined company, Liminatus&#8217; ability to maintain control of the board of directors on a go-forward basis, Liminatus&#8217; senior management comprising the senior management of the combined company, and Liminatus&#8217; operations prior to the Business Combination comprise the ongoing operations of the combined company. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Liminatus&#8217; issuing stock for the net assets of Iris, accompanied by a recapitalization. The net assets of Iris were stated at fair value, with no goodwill or other intangible assets recorded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the consummation of the Business Combination, the Iris Class&#160;A Shares, Iris Units and Public Warrants ceased trading on the OTC Pink Marketplace, and the Common Stock and Public Warrants began trading on The Nasdaq Stock Market (&#8220;Nasdaq&#8221;) under the trading symbols &#8220;LIMN&#8221; and &#8220;LIMNW,&#8221; respectively, on May&#160;1, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nasdaq Notices</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On August 22, 2025, the Company received a notice from the Nasdaq Listing Qualifications Department indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025. The deficiency letter had no immediate effect on the listing of the Company&#8217;s common stock, and its common stock continued to trade on Nasdaq under the symbol &#8220;LIMN&#8221;. Under the Nasdaq rules, the Company had 60 calendar days, or until October 21, 2025, to submit a plan to regain compliance and if the plan was accepted, Nasdaq can grant an exception of up to 180 calendar days from the filing&#8217;s due date, or until February 16, 2026, to regain compliance. If the compliance plan was not accepted, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Company had the opportunity to appeal that decision to a Nasdaq Hearings Panel. On October 6, 2025, the Company filed its Form 10-Q for the period ended June 30, 2025 and the matter was closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 19, 2025, the Company received notices from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value of Listed Securities (MVLS) of $50,000,000 (the &#8220;MVLS Rule&#8221;), based upon a review of the Company&#8217;s MVLS for the last 30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly Held Shares (MVPHS) of $15,000,000 (the &#8220;MVPHS Rule&#8221;), based upon a review of the Company&#8217;s MVPHS for the last 30 consecutive business days. The Nasdaq staff noted that the Company also does not meet the requirements under Listing Rule 5450(b)(3)(A), which requires the Company to have total assets and total revenue of at least $50 million each for the most recently completed fiscal year or two of the three most recently completed fiscal years. Under the Nasdaq rules, the Company has 180 calendar days, or until May 18, 2026, to regain compliance with the MVLS Rule and MVPHS Rule. In the event the Company does not regain compliance with the MVLS Rule and MVPHS Rule prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Hearings Panel. Alternatively, the Company may consider applying to transfer the Company&#8217;s securities to the Capital Market, provided it meets the Capital Market&#8217;s continued listing requirements. The Company is working diligently to regain compliance with Nasdaq&#8217;s listing rules. However, there can be no assurance that the Company will be able to regain compliance within the prescribed time period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 15, 2026, the Company received a notice from Nasdaq indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rule 5450(a)(1) (the &#8220;Bid Price Rule&#8221;) which requires listed securities to maintain a minimum bid price of $1 per share. Under the Nasdaq rules, the Company has 180 calendar days, or until July 14, 2026, to regain compliance with the Bid Price Rule. In the event the Company does not regain compliance during the initial compliance period, the Company may be eligible for additional time to regain compliance with the Bid Price Rule. The Company is working diligently to regain compliance with Nasdaq&#8217;s listing rules. However, there can be no assurance that the Company will be able to regain compliance within the prescribed time period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity and Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for one year after the date that the consolidated financial statements are issued. Through December 31, 2025, the Company has funded its operations mainly through equity and debt financings, including the proceeds from the Mergers and the PIPE Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, the Company had $337,655 of cash in its bank accounts. As of December 31, 2025 and 2024, there was $1,442,500 and $19,973,000, respectively, of related party debts, which are included in Short-term debt, related parties in the accompanying consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has an accumulated deficit of $38,871,733 as of December 31, 2025. The Company had a loss from operations and net loss of $(2,967,812) and $(10,206,517), respectively, for the year ended December 31, 2025. The Company had a loss from operations and net loss of $(3,329,953) and $(3,546,309), respectively, for the year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 18, 2026, the Company completed a &#8220;best efforts&#8221; public offering of (i) 8,270,000 shares of its common stock, (ii) 5,543,000 pre-funded warrants to purchase up to 5,543,000 shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) and (ii) 13,813,000 common stock purchase warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per Pre-Funded Warrant) and accompanying warrant (the &#8220;Offering&#8221;). In connection with the Offering, the Company received net proceeds of approximately $3.46 million, after deducting the estimated offering expenses payable by the Company, including the placement agent fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 205-40, <i style="font-style:italic;">Presentation of Financial Statements&#8212;Going Concern</i>, management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying consolidated financial statements are issued. The Company&#8217;s consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management&#8217;s plans relating to the above include raising additional cash through further equity and debt financings or other arrangements to fund operations. There can be no assurance that the Company will be able to raise adequate capital under acceptable terms, if at all. The sale of additional equity may dilute existing members and newly issued equity securities may contain senior rights and preferences compared to currently outstanding common stock. Issued debt securities may contain covenants and limit the Company&#8217;s ability to pay dividends or make other distributions to stockholders. If the Company is unable to obtain such additional financing, future operations would need to be reevaluated.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;2. Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) as determined by the FASB ASC and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The unaudited condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements do not include all of the disclosures required by U.S. GAAP for annual consolidated financial statements and should be read in conjunction with the audited consolidated financial statements of the Company as of and for the year ended December 31, 2025 (the &#8220;Annual Financial Statements&#8221;). In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary to fairly present its financial position as of March 31, 2026, its results of operations for the three months ended March 31, 2026 and 2025, its cash flows for the three months ended March 31, 2026 and 2025, and its changes in stockholders&#8217; deficit for the three months ended March 31, 2026 and 2025. Results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year ending December 31, 2026 or any future period. The condensed consolidated balance sheet as of December 31, 2025 was derived from the Annual Financial Statements but does not contain all of the footnote disclosures from the Annual Financial Statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company Status</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">After the closing of the Business Combination, the Company has elected to be an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s unaudited condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results may differ materially and adversely from these estimates. The Company is not aware of any significant estimates that required management to exercise significant judgment with the exception of the Company&#8217;s warrant liability and research and development costs. If the underlying estimates and assumptions upon which the estimates are based change in the future, actual amounts may differ from those included in the Company&#8217;s unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), the Chief Executive Officer, manages the Company&#8217;s business activities as a <span style="-sec-ix-hidden:Hidden_skpW_fMTs0qgK5TqjOzinQ;"><span style="-sec-ix-hidden:Hidden_oRglHBbi5kiQPSddjK0rrg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">single</span></span></span> operating and reportable segment. Accordingly, the Company&#8217;s CODM uses net income/loss to measure the Company&#8217;s single segment&#8217;s performance and allocate resources. Further, the CODM reviews and utilizes functional expenses (general and administrative and research and development) to manage the Company&#8217;s operations. The Company&#8217;s general and administrative expenses for the three months ended March 31, 2026 and 2025 included $60,500 and $37,500, respectively, of compensation expenses related to the compensation agreement the Company has executed with its Chief Executive Officer. The remaining general and administrative expenses are related to legal and accounting-related expenses for contractors. The Company&#8217;s research and development expenses did not include any compensation-related expenses. Other segment items included in net loss are interest expense, related parties and interest income which are reflected in the Company&#8217;s unaudited condensed consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which can exceed government insured limits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company did not have any cash equivalents as of March 31, 2026 and December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial assets and liabilities are accounted for in accordance with FASB ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures,</i> which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value hierarchy requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 1 &#8212; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 2 &#8212; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the instrument&#8217;s anticipated life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 3 &#8212; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgement. Accordingly, the degree of judgement exercised by management in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the warrant liability reported in the Company&#8217;s unaudited condensed consolidated balance sheets represent a Level 3 instrument (see Note 8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying values reported in the Company&#8217;s unaudited condensed consolidated balance sheets for prepaid expenses and other current assets, due from related party, accounts payable and accrued expenses, accrued interest, short-term debt with related parties, due to related parties and its deferred underwriting fee payable are reasonable estimates of their fair values due to the short-term nature of these items.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC 480, <i style="font-style:italic;">Distinguishing liabilities from equity</i> (&#8220;ASC 480&#8221;), and ASC 815, <i style="font-style:italic;">Derivatives and Hedging</i> (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance, modification, and as of each subsequent quarterly period end date while the warrants are outstanding. As of March 31, 2026, 13,813,000 of the Company&#8217;s Common Stock Warrants, 690,650 Placement Agent Warrants and 5,094,623 Public Warrants were accounted for as equity-classified instruments and 835,555 private placement warrants were accounted for as liability-classified instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the liability-classified warrants are recognized as a non-cash gain or loss on the accompanying condensed consolidated statements of operations. The Company assesses the classification of its warrants at each reporting date to determine whether a change in classification between equity and liability is required. During the three months ended March 31, 2026, the Company had an unrealized gain on the change in fair value of the warrant liabilities of $4,178. During the three months ended March 31, 2025, the Company had no unrealized gain or loss on the change in fair value of the warrant liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss per Share of Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company complies with accounting and disclosure requirements of ASC Topic 260, <i style="font-style:italic;">Earnings Per Share</i>. The Company has one class of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities if their effect is antidilutive. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined by using the treasury stock method. Dilutive common stock equivalents are comprised of 19,598,273 warrants, comprised of 13,813,000 Common Stock Warrants, 690,650 Placement Agent Warrants and 5,094,623 Public Warrants. For all periods </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">presented, there is no difference in the number of shares used to calculated basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive given that their inclusion would reduce the net loss per share during the three months ended March 31, 2026 and 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of costs incurred by InnoBation Bio Co, Ltd. (&#8220;Innobation&#8221;) in accordance with the license agreement with Innobation and are recorded as research and development expenses as incurred (see Note 3).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes its leases in accordance with ASC Topic 842, <i style="font-style:italic;">Leases</i> (&#8220;ASC 842&#8221;). Under ASC 842, lessees are required to recognize all qualified operating leases at the commencement date including a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use (&#8220;ROU&#8221;) asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. The initial lease liability is equal to the future fixed minimum lease payments discounted using the Company&#8217;s incremental borrowing rate, on a secured basis. The lease term includes option renewal periods and early termination payments when it is reasonably certain that the Company will exercise those rights. The initial measurement of the ROU asset is equal to the initial lease liability plus any initial direct costs and prepayments, less any lease incentives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has leased office space for a fixed period of 10 months. In accordance with ASC 842, a short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The short-term lease election can only be made at the commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A lessee that makes this accounting policy election does not recognize a lease liability or right-of-use asset on its balance sheets. Instead, the lessee recognizes lease payments on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes in accordance with ASC Topic 740,&#160;<i style="font-style:italic;">Income Taxes</i>&#160;(&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. There were no tax accruals relating to uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax positions as income tax expense. There were no unrecognized tax positions, and no amounts accrued for interest and penalties as of March 31, 2026 and December 31, 2025. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only &#8220;major&#8221; tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. No unrecognized tax benefits were identified as of March 31, 2026 or December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements&#160;&#8211; Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On November 4, 2024, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2024-03, <i style="font-style:italic;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i> (&#8220;ASU 2024-03&#8221;), to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this standard will have on its unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#8217;s unaudited condensed consolidated financial statements.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;2. Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) as determined by the FASB ASC and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company Status</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the closing of the Business Combination, the Company has elected to be an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart our Business Startups Act of 2012, (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results may differ materially and adversely from these estimates. The Company is not aware of any significant estimates that required management to exercise significant judgment with the exception of the Company&#8217;s warrant liability. If the underlying estimates and assumptions upon which the estimates are based change in the future, actual amounts may differ from those included in the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), the Chief Executive Officer, manages the Company&#8217;s business activities as a single operating and reportable segment. Accordingly, the Company&#8217;s CODM uses net income/loss to measure the Company&#8217;s single segment&#8217;s performance and allocate resources. Further, the CODM reviews and utilizes functional expenses (general and administrative and research and development) to manage the Company&#8217;s operations. The Company&#8217;s general and administrative expenses for each of the years ended December 31, 2025 and 2024 included $202,833 and $150,000 of compensation expenses related to the compensation agreements the Company has executed with its executive team. The remaining general and administrative expenses </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">are related to legal and accounting-related expenses for contractors. The Company&#8217;s research and development expenses did not include any compensation-related expenses. Other segment items included in net income (loss) are interest expense, related parties and interest income which are reflected in the Company&#8217;s consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which can exceed government insured limits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Loan Receivable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its loan receivable at amortized cost, net of expected credit losses. The Company provides reserves against its loan receivable balance for estimated credit losses, if any, that may result from a counterparty&#8217;s inability to pay based on the composition of the loan receivable, current economic conditions and, historical credit loss activity and future expected conditions and market trends (such as general economic conditions, other macroeconomic and microeconomic events, etc.). Changes in circumstances relating to these factors may result in the need to increase or decrease the allowance for credit losses in the future. Amounts deemed uncollectible are charged or written-off against the reserve. On April 30, 2025, in connection with the Business Combination, the loan receivable was eliminated in consolidation as Iris and Liminatus are now consolidated subsidiaries of the Company. As of January 1, 2024 and December 31, 2024, no expected credit loss was recorded related to the loan receivable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Deferred Transaction Costs </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Costs incurred in connection with preparation for the proposed business combination were deferred on the balance sheets as of December 31, 2024. No such costs were deferred on the balance sheets as of December 31, 2025 due to the completion of the Company&#8217;s business combination with Iris. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial assets and liabilities are accounted for in accordance with FASB ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures,</i> which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value hierarchy requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 1 &#8212; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 2 &#8212; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the instrument&#8217;s anticipated life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 3 &#8212; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgement. Accordingly, the degree of judgement exercised by management in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the warrant liability reported in the Company&#8217;s consolidated balance sheets represent a Level 3 instrument. See Note 8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The carrying values reported in the Company&#8217;s consolidated balance sheets for prepaid expenses and other current assets, due from related party, accounts payable and accrued expenses, accrued interest, short-term debt with related parties, due to research and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">development partner, due to related parties, settlement payable, and its deferred underwriting fee payable are reasonable estimates of their fair values due to the short-term nature of these items.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC 480, <i style="font-style:italic;">Distinguishing liabilities from equity</i> (&#8220;ASC 480&#8221;), and ASC 815, <i style="font-style:italic;">Derivatives and Hedging</i> (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance, modification, and as of each subsequent quarterly period end date while the warrants are outstanding. As of December 31, 2025, 5,899,975 of the Company&#8217;s Public Warrants were accounted for as equity-classified instruments and 835,555 private placement warrants were accounted for as liability-classified instruments. As of December 31, 2025, there were no other public or <span style="-sec-ix-hidden:Hidden_wUaYXsrirkKbOmu3ilr3Zg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">private</span></span> warrants outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the liability-classified warrants are recognized as a non-cash gain or loss on the accompanying consolidated statements of operations. The Company assesses the classification of its warrants at each reporting date to determine whether a change in classification between equity and liability is required. During the year ended December 31, 2025, the Company had an unrealized gain on the change in fair value of the warrant liabilities of $54,312. During the year ended December 31, 2024, the Company had no unrealized gain or loss on the change in fair value of the warrant liabilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net loss per Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company complies with accounting and disclosure requirements of ASC Topic 260, <i style="font-style:italic;">Earnings Per Share</i>. The Company has one class of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities if their effect is antidilutive. Diluted net loss per share is computed by the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined by using the treasury stock method. Dilutive common stock equivalents are comprised of 6,735,530 warrants. For all periods presented, there is no difference in the number of shares used to calculated basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive given that their exercise price is greater than that of the average market price of the Company&#8217;s common stock during the years ended December 31, 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of costs incurred by Targeted Diagnostics &amp; Therapeutics, Inc. (&#8220;TDT&#8221;) who was performing the research and development activities for the Company in accordance with the license agreements with TDT and the annual fee paid to TDT and are recorded as research and development expenses as incurred (see Note 3).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes its leases in accordance with ASC Topic 842, <i style="font-style:italic;">Leases</i> (&#8220;ASC 842&#8221;). Under ASC 842, lessees are required to recognize all qualified operating leases at the commencement date including a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use (&#8220;ROU&#8221;) asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. The initial lease liability is equal to the future fixed minimum lease payments discounted using the Company&#8217;s incremental borrowing rate, on a secured basis. The lease term includes option renewal periods and early termination payments when it is reasonably certain that the Company will exercise those rights. The initial measurement of the ROU asset is equal to the initial lease liability plus any initial direct costs and prepayments, less any lease incentives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has leased office space for a fixed period of 10 months. In accordance with ASC 842, a short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The short-term lease election can only be made at the commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A lessee that makes this accounting policy election does not recognize a lease liability or right-of-use asset on its balance sheet. Instead, the lessee recognizes lease payments on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes in accordance with ASC Topic 740,&#160;<i style="font-style:italic;">Income Taxes</i>&#160;(&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. There were no tax accruals relating to uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax positions as income tax expense. There were no unrecognized tax positions, and no amounts accrued for interest and penalties as of December 31, 2025 and 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only &#8220;major&#8221; tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. No unrecognized tax benefits were identified as of December 31, 2025 or 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The Company adopted this standard on January 1, 2025 and determined that the adoption does not have a material impact on these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements&#160;&#8211; Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2024, the FASB issued ASU 2024-03, Accounting Standards Update 2024-03, <i style="font-style:italic;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i> to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_LicenseAgreementsAbstract', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_LicenseAgreementsTextBlock', window );">License Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 3. License Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CD47 License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October 2022, the Company was assigned a license and development agreement, as amended, with InnoBation Bio Co., Ltd. (the &#8220;CD47 License&#8221;), whereby, effective March 31, 2023, the Company received an exclusive license to develop and commercialize products for the CD47 immune checkpoint inhibitor to treat solid cancers, and companion diagnostics used to monitor treatment with CD47 products (collectively, &#8220;CD47 Products&#8221;), from Curis Biotech Holdings LLC, the parent company of Valetudo, a related party of the Company, in exchange for 78,555,554 of Liminatus&#8217; Class A member units. The license was recorded at Valetudo&#8217;s cost basis of zero, and the Company recorded an approximately $800,000 Class A membership interest with an offset to additional paid-in capital on the balance sheets. The Company is obligated to pay all development costs for CD47 Products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 20, 2026, the Company issued a payment of $1,000,000 to Innobation for the total estimated costs associated with the preparation activities for Phase 1 clinical trials of IBA101, the Company&#8217;s product candidate. As of March 31, 2026, the Company estimated approximately 40% of the activities were completed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of March 31, 2026 and December 31, 2025, prepaid research and development costs of $600,000 and $0, respectively, are recorded in prepaid and other current assets in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, research and development expense related to the CD47 License was $400,000 and $0, respectively.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 3. License Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CAR-T Products License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June 2018, the Company entered into a license and development agreement with TDT (the &#8220;CAR-T License&#8221;), whereby the Company received an exclusive license to develop and commercialize chimeric antigen receptor (&#8220;CAR-T&#8221;) products and a non-exclusive license to develop and commercialize companion diagnostics used to monitor treatment with a CAR-T product (the &#8220;CAR-T Diagnostics&#8221;). Under the CAR-T License, the Company made an upfront payment recorded as research and development expenses in the year ended December 31, 2018 and funded all of the development costs for the CAR-T products and the CAR-T Diagnostics which began with an upfront payment made during the year ended December 31, 2018 of approximately $5,000,000, recorded as advances for research and development in the balance sheets. The Company amortizes the advances to research and development expenses in the consolidated statements of operations as costs are incurred by TDT, based on annual budgets approved jointly by Liminatus and TDT. As of December 31, 2025 and 2024, all of the amounts funded have been utilized. The Company was also obligated to pay an approximately $500,000 annual maintenance fee for the license which is included in research and development expenses in the consolidated statements of operations. Unpaid annual maintenance fees become short-term debt that bears interest of 1.5% per month on a compounded basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the completion of the Phase I and Phase II clinical trials for the CAR-T product, the Company was obligated to advance the funding for the Phase II and Phase III clinical trials, respectively, estimated at approximately $20,000,000 for each phase. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the funding for the CAR-T development, the Company was obligated to make four developmental and regulatory milestone payments for the first CAR-T product that was developed aggregating up to approximately $15,000,000. After the first four developmental and regulatory milestone payments were made, the Company was obligated to pay four developmental and regulatory milestones aggregating up to approximately $7,500,000 for each additional CAR-T product that was developed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In further consideration of the license, the Company also agreed to pay a low double digit royalty rate (10% &#8211; 15%) based on annual net sales of CAR-T products or CAR-T Diagnostics on a country-by-country basis for the period from the first commercial sale of the CAR-T product or CAR-T Diagnostic until the CAR-T product or CAR-T Diagnostic&#8217;s patent expires in an individual country. Once the CAR-T product or CAR-T Diagnostic&#8217;s patent expires in an individual country, the Company agreed to pay a mid-single digit royalty rate (5% &#8211; 9%) based on annual net sales of CAR-T products and CAR-T Diagnostics on a country- by-country basis. Royalties were payable on a country-by-country basis for a period of ten years from the first commercial sale of the CAR-T product or CAR-T Diagnostic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 11, 2024, the Company received notice from TDT, exercising its right to terminate the license and development agreement. Please refer to &#8220;Termination and Settlement of CAR-T Products and Vaccine Products Licenses from TDT&#8221; below for further details related the termination and settlement of the CAR-T Products and Vaccine Products Licenses from TDT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Vaccine Products License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 10, 2020, the Company was assigned a license and development agreement with TDT (the &#8220;Vaccine License&#8221;), whereby the Company received an exclusive license to develop and commercialize vaccine products (the &#8220;Vaccine Products&#8221;) and a non-exclusive license to develop and commercialize companion diagnostics used to monitor treatment with a Vaccine Product (the &#8220;Vaccine Diagnostics&#8221;). Under the Vaccine License, the Company was responsible for all of the development costs for the Vaccine Products after the upfront payment of approximately $4,000,000, which was paid by Viral Gene, Inc (&#8220;Viral Gene&#8221;), of which Chris Kim is also the CEO, to TDT. The Company was also obligated to pay an approximately $400,000 annual maintenance fee for the license which is included in research and development expenses in the Company&#8217;s consolidated statements of operations for the year ended December&#160;31, 2024. There was no maintenance fee for the year ended December 31, 2025. Unpaid annual maintenance fees will become short-term debt that bears interest of 1.5% per month on a compounded basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company amortizes the amounts due to research and development partner in the Company&#8217;s consolidated balance sheets to research and development expenses in the consolidated statements of operations as costs are incurred by TDT, based on annual budgets approved jointly by Liminatus and TDT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In addition to the funding for the Vaccine Products development, the Company was obligated to make four developmental and regulatory milestone payments for the first Vaccine Product that was developed aggregating up to approximately $12,000,000. After the first four developmental and regulatory milestone payments are made, the Company was obligated to pay four developmental and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">regulatory milestones aggregating up to approximately $6,000,000 for each additional Vaccine Product that is developed. As of December 31, 2025 and 2024, all the amounts funded have been utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In further consideration of the license, the Company also agreed pay a low double digit royalty rate (10% &#8211; 15%) based on annual net sales of Vaccine Products or Vaccine Diagnostics on a country-by-country basis for the period from the first commercial sale of the Vaccine Product or Vaccine Diagnostic until the Vaccine Product or Vaccine Diagnostic&#8217;s patent expires in an individual country. Once the Vaccine Product or Vaccine Diagnostic&#8217;s patent expires in an individual country, the Company agreed to pay a mid-single digit royalty rate (5% &#8211; 9%) based on annual net sales of Vaccine Products and Vaccine Diagnostics on a country- by-country basis. Royalties were payable on a country-by-country basis for a period of ten years from the first commercial sale of the Vaccine Product or Vaccine Diagnostic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 11, 2024, the Company received notice from TDT, exercising its right to terminate the license and development agreement. Please refer to &#8220;Termination of CAR-T Products and Vaccine Products Licenses from TDT&#8221; below for further details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Termination and Settlement of CAR-T Products and Vaccine Products Licenses from TDT</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 11, 2024, the Company received notice from TDT, exercising its right to terminate the license and development agreement, dated June 10, 2018, between TDT and Liminatus. As of August 2024, the CAR-T License and Vaccine License have been terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 16, 2025, the Company and TDT entered and executed a settlement agreement. Pursuant to the terms of the settlement agreement, the Company was released and discharged from all agreements, promises, suites, disputes, claims and demands, debts and amounts due to TDT. As of December 31, 2025, the Company reversed the amounts due to TDT and recognized a gain of $2,142,297, which is included in Forgiveness of unrelated vendor payables on the Company&#8217;s consolidated statement of operations in accordance with ASC 450-30, Contingencies - Gain Contingencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and, 2024, the Company owed $0 and $2,142,297, respectively, to TDT for research and development for the aggregate CAR-T Products and Vaccine Licenses, which is included in the due to research and development partner and accrued maintenance fees on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CD47 License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October 2022, the Company was assigned a license and development agreement, as amended, with InnoBation Bio Co., Ltd. (the &#8220;CD47 License&#8221;), whereby, effective March 31, 2023, the Company received an exclusive license to develop and commercialize products for the CD47 immune checkpoint inhibitor to treat solid cancers, and companion diagnostics used to monitor treatment with CD47 products (collectively, &#8220;CD47 Products&#8221;), from Curis Biotech Holdings LLC, the parent company of Valetudo, a related party of the Company, in exchange for 78,555,554 of Liminatus&#8217; Class A member units. The license was recorded at Valetudo&#8217;s cost basis of zero, and the Company recorded an approximately $800,000 Class A membership interest with an offset to additional paid-in capital on the balance sheets. The Company is obligated to pay all development costs for CD47 Products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company has not paid and does not owe any license fees, management fees, developmental or regulatory milestone payments or royalty payments under the CD47 License through December 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_LicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_LicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_LicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for License Agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_LicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;4. Related Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Related Party Debt</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Feelux Bonds</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 15, 2018, the Company issued $10,000,000 of bonds to Feelux Co., Ltd., the parent company of Car-Tcellkor, Inc. (&#8220;Car-Tcellkor&#8221;) (see below), the only holder of Liminatus&#8217; Class A member units (the &#8220;Feelux Bonds&#8221;). The bonds bear interest at 1% per annum, compounded annually, and were due on October 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the issuance of the Feelux Bonds, Liminatus issued 6,666,666 equity-classified warrants to purchase member units at a price of $1.50 per unit, which expired on June 30, 2023. The fair value of the warrants to purchase member units of approximately $6,400,000 was estimated using the option pricing framework on the issuance date. The Company&#8217;s assumptions included (a) its expected stock volatility of 82.0% based on the historical volatility of a publicly traded set of peer companies, (b) the contractual term of five years, (c) the risk-free interest rate of 2.9% based on the U.S. Treasury yield curve in effect at the time of grant of the award for a five-year contractual term and (d) no expected dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The $10,000,000 of proceeds from the Feelux Bonds were allocated to the bonds and warrants using the relative fair value method resulting in a debt discount for the relative fair value of the warrants of $4,499,142 that was amortized to interest expense over the term of the Feelux Bonds using the effective interest method using an effective interest rate of 21.0%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, upon consummation of the Business Combination, the outstanding principal and accrued interest on the Feelux Bonds, totaling $10,681,146, and 9,999,999 member units of Liminatus were converted into 4,000,000 shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, there was no outstanding balance on the Feelux Bonds. As of March 31, 2026 and December 31, 2025, there was no accrued interest on the Feelux Bonds. For the three months ended March 31, 2026 and 2025, the Company recorded $0 and $26,251, respectively, of interest expense in the unaudited condensed consolidated statements of operations for the Feelux Bonds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Car-Tcellkor Loan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 18, 2019, the Company borrowed $800,000 from its parent at the time of the loan, Car- Tcellkor (the &#8220;Car-Tcellkor Loan&#8221;). The Car-Tcellkor Loan does not bear interest and was due on March 18, 2020. In November 2022, the maturity date was extended to May 18, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $800,000 was forgiven.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, there was no outstanding balance on the Car-Tcellkor Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Valetudo Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 1, 2022, the Company borrowed $700,000 from Valetudo Therapeutics LLC (&#8220;Valetudo&#8221;), a related party of the Company due to having common executives, in conjunction with the repayment of $700,000 of membership interest from a member (the &#8220;Valetudo Loan&#8221;). The Valetudo Loan bears no interest and was due on June 1, 2023. On May 1, 2025, the Company paid the outstanding principal balance of $700,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June 2023, the Company borrowed an additional $300,000 and $200,000 (the &#8220;Valetudo June 2023 Loans&#8221;). The Valetudo June 2023 Loans bear no interest and were due in December 2023. On May 1, 2025, the Company paid $300,000 of the outstanding principal balance on the Valetudo June 2023 Loans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July 2023, the Company borrowed an additional $250,000 (the &#8220;Valetudo July 2023 Loan&#8221;). The Valetudo July 2023 Loan bears interest at 6% per annum and was due on January 9, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2023, the Company borrowed an additional $250,000 and $150,000 (the &#8220;Valetudo August 2023 Loans&#8221;). The Valetudo August 2023 Loans each bear interest at 6% interest per annum and were due on January 31, 2024 and February 2, 2024, respectively. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $400,000, along with accrued interest, of the Valetudo August 2023 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2023, the Company borrowed an additional $200,000 (the &#8220;Valetudo November 2023 Loan&#8221;). The Valetudo November 2023 Loan bears interest at 6% per annum and was due on January 26, 2024. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $200,000, along with accrued interest, on the Valetudo November 2023 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2024, the Company borrowed an additional $600,000 and $150,000 (the &#8220;Valetudo January 2024 Loans&#8221;). The Valetudo January 2024 Loans each bear interest at 6% per annum and were due on February 28, 2024. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $750,000, along with accrued interest, of the Valetudo August 2023 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, the loans from Valetudo of $450,000 are recorded in short-term debt, related parties in the unaudited condensed consolidated balance sheets (see Note 5). As of March 31, 2026 and December 31, 2025, the related accrued interest of the loans from Valetudo was $117,058 and $113,308, respectively, and is included in accrued interest, related parties in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, interest expense related to the Valetudo loans was $3,750 and $24,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Ewon Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 12, 2022, the Company borrowed $5,000,000 from Ewon Comfortech Co., Ltd. (&#8220;Ewon&#8221;), a member and related party of the Company (the &#8220;Ewon Loan&#8221;). The Ewon Loan bears interest at 2% per annum and was due on December 12, 2023, which may be extended one year upon mutual agreement of the parties, or upon failure to close the Business Combination. In February 2023, the Company repaid $1,000,000 of the short-term loan. In March 2023, the Company repaid an additional $2,000,000 of the loan. On April 30, 2025, upon consummation of the Business Combination, $2,000,000, along with accrued interest, of the Ewon Loan was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 10, 2023, the Company entered into a loan agreement to borrow $200,000 from Ewon (&#8220;Ewon September 2023 Loan&#8221;). The Ewon September 2023 Loan bears interest of 2% per annum and was due on September 9, 2024, which may be extended one year upon mutual agreement of the parties, or upon failure to close the Business Combination. On April 30, 2025, upon consummation of the Business Combination, $200,000, along with accrued interest, of the Ewon September 2023 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 19, 2023, the Company and Ewon entered into an additional loan agreement and the Company borrowed $1,000,000 (the &#8220;Ewon December 2023 Loan&#8221;). The Ewon December 2023 Loan bears no interest. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $1,000,000, along with accrued interest, of the Ewon December 2023 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, there was no outstanding balance on the Ewon. As of March 31, 2026 and December 31, 2025, there was no accrued interest on the loans from Ewon. For the three months ended March 31, 2026 and 2025, interest expense related to the Ewon loans was $0 and $11,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Prophase Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 26, 2024, the Company borrowed an additional $200,000 from Prophase Sciences LLC (&#8220;Prophase&#8221;) (the &#8220;Prophase February 2024 Loan&#8221;). The loan bears 6% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, $168,500, along with accrued interest, of the Prophase February 2024 Loan was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 6, 2024, the Company borrowed an additional $250,000 from Prophase (the &#8220;Prophase March 2024 Loan&#8221;). The loan bears 6% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 1, 2024, the Company borrowed an additional $250,000 from Prophase (the &#8220;Prophase April 2024 Loan&#8221;). The loan bears 6% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $250,000, along with accrued interest, on the Prophase April 2024 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May 2024, the Company borrowed an additional $790,000 from Prophase (the &#8220;Prophase May 2024 Loans&#8221;). The loans bear 6% interest per annum. Of the aggregate $790,000 Prophase May 2024 Loans, $270,000 was due on June 1, 2024 and $520,000 was due on July 1, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $550,000, along with accrued interest of the Prophase May 2024 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July 2024, the Company borrowed an additional $83,000 from Prophase (the &#8220;Prophase July 2024 Loans&#8221;). The loans bear 6% interest per annum. Of the aggregate $83,000 Prophase July 2024 Loans, $30,000 was due on September 14, 2024, $3,000 was due on September 24, 2024 and $50,000 was due on September 29, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2024, the Company borrowed an additional $50,000 from Prophase (the &#8220;Prophase August 2024 Loans&#8221;). The loans bear 6% interest per annum. Of the aggregate $50,000 Prophase August 2024 Loans, $30,000 was due on October 12, 2024 and $20,000 was due on October 13, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February of 2025, the Company borrowed an additional $206,000 from Prophase (the &#8220;Prophase February 2025 Loan&#8221;). The Prophase February 2025 Loan bears interest at 6% per annum and was due on April 11, 2025, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $125,000, along with accrued interest, on the Prophase February 2025 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March of 2025, the Company borrowed $207,000 from Prophase (the &#8220;Prophase March 2025 Loan&#8221;). The Prophase March 2025 Loan bears interest at 6% per annum and was due on June 6, 2025, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $200,000, along with accrued interest, on the Prophase March 2025 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April of 2025, the Company borrowed an additional $3,627,000 from Prophase (the &#8220;Prophase April 2025 Loans&#8221;). The loans bear 6% interest per annum. Of the aggregate $3,627,000 Prophase April 2025 Loans, $200,000 was due on May 2, 2025, $1,920,120 was due on May 13, 2025 and $1,506,880 was due on May 14, 2025. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $3,627,000, along with accrued interest, on the Prophase April 2025 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, the balance of the Prophase loans is $742,500. As of March 31, 2026 and December 31, 2025, the related accrued interest of the loans from Prophase was $90,421 and $79,283, respectively, and is included in accrued interest, related parties in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, interest expense related to the Prophase Loans was $11,138 and $26,787, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Hana Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 1, 2024, the Company borrowed $850,000 from Hana Immunotherapeutics, LLC (&#8220;Hana&#8221;), a related party of the Company due to having common executives (the &#8220;Hana Loans&#8221;). The Hana Loans bear interest at 6% per annum and were due on September 30, 2024 and October 26, 2024, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $800,000, along with accrued interest, of the Hana Loans was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, the balance of the Hana Loans is $50,000. As of March 31, 2026 and December 31, 2025, the related accrued interest of the loans from Hana was $2,792 and $2,042, respectively, and is included in accrued interest, related parties in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, interest expense related to the Hana Loans was $750 and $12,750, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Amantes Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 1, 2024, the Company borrowed $400,000 from Amantes LLC (&#8220;Amantes&#8221;), a related party of the Company due to having common executives, pursuant to a loan agreement between the Company and Amantes (the &#8220;Amantes Loan&#8221;). On November 27, 2024, the Company borrowed an additional $300,000 from Amantes (the &#8220;Additional Amantes Loan&#8221;) (together with the Amantes Loan, the &#8220;Amantes November 2024 Loans&#8221;). The Amantes November 2024 Loans bear interest at 6% per annum and are due on January 1, 2025. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $550,000, along with accrued interest, on the Amantes November 2024 Loans was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 2, 2025 and January 23, 2025, the Company borrowed a total of $300,000 from Amantes, pursuant to loan agreements between the Company and Amantes (the &#8220;Amantes January 2025 Loans&#8221;). The Amantes January 2025 Loans bear interest at 6% per annum and are due on March 1, 2025 and March 22, 2025, respectively, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $250,000, along with accrued interest, on the Amantes January 2025 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, the balance of the Amantes Loans is $200,000. As of March 31, 2026 and December 31, 2025, the related accrued interest of the loans from Amantes was $12,287 and $9,288, respectively, and is included in accrued interest, related parties in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, interest expense related to the Amantes Loans was $3,000 and $14,724, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Due to Related Party</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of March 31, 2026 and December 31, 2025, the Company has $194,587 and $209,586, respectively, due to the Company&#8217;s executive team for compensation under their employment agreements. </p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;4. Related Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Related Party Debt</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Feelux Bonds</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 15, 2018, the Company issued $10,000,000 of bonds to Feelux Co., Ltd., the parent company of Car-Tcellkor, Inc. (&#8220;Car-Tcellkor&#8221;) (see below), the only holder of Liminatus&#8217; Class A member units (the &#8220;Feelux Bonds&#8221;). The bonds bear interest at 1% per annum, compounded annually, and were due on October 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In connection with the issuance of the Feelux Bonds, Liminatus issued 6,666,666 equity-classified warrants to purchase member units at a price of $1.50 per unit, which expired on June 30, 2023. The fair value of the warrants to purchase member units of approximately $6,400,000 was estimated using the option pricing framework on the issuance date. The Company&#8217;s assumptions included </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(a) its expected stock volatility of 82.0% based on the historical volatility of a publicly traded set of peer companies, (b) the contractual term of five years, (c) the risk-free interest rate of 2.9% based on the U.S. Treasury yield curve in effect at the time of grant of the award for a five-year contractual term and (d) no expected dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The $10,000,000 of proceeds from the Feelux Bonds were allocated to the bonds and warrants using the relative fair value method resulting in a debt discount for the relative fair value of the warrants of $4,499,142 that was amortized to interest expense over the term of the Feelux Bonds using the effective interest method using an effective interest rate of 21.0%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, upon consummation of the Business Combination, the outstanding principal and accrued interest on the Feelux Bonds, totaling $10,681,146, and 9,999,999 member units of Liminatus were converted into 4,000,000 shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the Feelux Bonds have a carrying amount of $0 and $10,000,000, respectively, and are included in short-term debt, related parties in the consolidated balance sheets. As of December 31, 2025 and 2024, the related accrued interest of the Feelux Bonds was $0 and $646,124, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, the Company recorded $35,023 and $106,087, respectively, of interest expense in the consolidated statements of operations for the Feelux Bonds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Car-Tcellkor Loan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 18, 2019, the Company borrowed $800,000 from its parent at the time of the loan, Car- Tcellkor (the &#8220;Car-Tcellkor Loan&#8221;). The Car-Tcellkor Loan does not bear interest and was due on March 18, 2020. In November 2022, the maturity date was extended to May 18, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $800,000 was forgiven.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the Car-Tcellkor Loan had a carrying amount of $0 and $800,000, respectively, and is recorded in short-term debt, related parties in the consolidated balance sheets (see Note 5). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Valetudo Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 1, 2022, the Company borrowed $700,000 from Valetudo Therapeutics LLC (&#8220;Valetudo&#8221;), a related party of the Company due to having common executives, in conjunction with the repayment of $700,000 of membership interest from a member (the &#8220;Valetudo Loan&#8221;). The Valetudo Loan bears no interest and was due on June 1, 2023. On May 1, 2025, the Company paid the outstanding principal balance of $700,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June 2023, the Company borrowed an additional $300,000 and $200,000 (the &#8220;Valetudo June 2023 Loans&#8221;). The Valetudo June 2023 Loans bear no interest and were due in December 2023. On May 1, 2025, the Company paid $300,000 of the outstanding principal balance on the Valetudo June 2023 Loans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July 2023, the Company borrowed an additional $250,000 (the &#8220;Valetudo July 2023 Loan&#8221;). The Valetudo July 2023 Loan bears interest at 6% per annum and was due on January 9, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2023, the Company borrowed an additional $250,000 and $150,000 (the &#8220;Valetudo August 2023 Loans&#8221;). The Valetudo August 2023 Loans each bear interest at 6% interest per annum and were due on January 31, 2024 and February 2, 2024, respectively. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $400,000, along with accrued interest, of the Valetudo August 2023 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2023, the Company borrowed an additional $200,000 (the &#8220;Valetudo November 2023 Loan&#8221;). The Valetudo November 2023 Loan bears interest at 6% per annum and was due on January 26, 2024. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $200,000, along with accrued interest, on the Valetudo November 2023 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In January 2024, the Company borrowed an additional $600,000 and $150,000 (the &#8220;Valetudo January 2024 Loans&#8221;). The Valetudo January 2024 Loans each bear interest at 6% per annum and were due on February 28, 2024. On April 30, 2025, upon consummation of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Business Combination, outstanding principal of $750,000, along with accrued interest, of the Valetudo August 2023 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the loans from Valetudo of $450,000 and $2,800,000, respectively, are recorded in short-term debt, related parties in the consolidated balance sheets (see Note 5). As of December 31, 2025 and 2024, the related accrued interest of the loans from Valetudo was $113,308 and $115,328, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Valetudo loans was $42,208 and $96,484, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Ewon Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 12, 2022, the Company borrowed $5,000,000 from Ewon Comfortech Co., Ltd. (&#8220;Ewon&#8221;), a member and related party of the Company (the &#8220;Ewon Loan&#8221;). The Ewon Loan bears interest at 2% per annum and was due on December 12, 2023, which may be extended one year upon mutual agreement of the parties, or upon failure to close the Business Combination. In February 2023, the Company repaid $1,000,000 of the short-term loan. In March 2023, the Company repaid an additional $2,000,000 of the loan. On April 30, 2025, upon consummation of the Business Combination, $2,000,000, along with accrued interest, of the Ewon Loan was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 10, 2023, the Company entered into a loan agreement to borrow $200,000 from Ewon (&#8220;Ewon September 2023 Loan&#8221;). The Ewon September 2023 Loan bears interest of 2% per annum and was due on September 9, 2024, which may be extended one year upon mutual agreement of the parties, or upon failure to close the Business Combination. On April 30, 2025, upon consummation of the Business Combination, $200,000, along with accrued interest, of the Ewon September 2023 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 19, 2023, the Company and Ewon entered into an additional loan agreement and the Company borrowed $1,000,000 (the &#8220;Ewon December 2023 Loan&#8221;). The Ewon December 2023 Loan bears no interest. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $1,000,000, along with accrued interest, of the Ewon December 2023 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the balance of $0 and $3,200,000 of the Ewon loans is recorded in short-term debt, related parties in the consolidated balance sheets (see Note 5). As of December 31, 2025 and 2024, the related accrued interest of the loans from Ewon was $0 and $102,089, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Ewon loans was $14,667 and $44,733, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Prophase Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 26, 2024, the Company borrowed an additional $200,000 from Prophase Sciences LLC (&#8220;Prophase&#8221;) (the &#8220;Prophase February 2024 Loan&#8221;). The loan bears 6% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, $168,500, along with accrued interest, of the Prophase February 2024 Loan was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 6, 2024, the Company borrowed an additional $250,000 from Prophase (the &#8220;Prophase March 2024 Loan&#8221;). The loan bears 6% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 1, 2024, the Company borrowed an additional $250,000 from Prophase (the &#8220;Prophase April 2024 Loan&#8221;). The loan bears 6% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $250,000, along with accrued interest, on the Prophase April 2024 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In May 2024, the Company borrowed an additional $790,000 from Prophase (the &#8220;Prophase May 2024 Loans&#8221;). The loans bear 6% interest per annum. Of the aggregate $790,000 Prophase May 2024 Loans, $270,000 was due on June 1, 2024 and $520,000 was due on July 1, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">consummation of the Business Combination, outstanding principal of $550,000, along with accrued interest of the Prophase May 2024 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July 2024, the Company borrowed an additional $83,000 from Prophase (the &#8220;Prophase July 2024 Loans&#8221;). The loans bear 6% interest per annum. Of the aggregate $83,000 Prophase July 2024 Loans, $30,000 was due on September 14, 2024, $3,000 was due on September 24, 2024 and $50,000 was due on September 29, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2024, the Company borrowed an additional $50,000 from Prophase (the &#8220;Prophase August 2024 Loans&#8221;). The loans bear 6% interest per annum. Of the aggregate $50,000 Prophase August 2024 Loans, $30,000 was due on October 12, 2024 and $20,000 was due on October 13, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February of 2025, the Company borrowed an additional $206,000 from Prophase (the &#8220;Prophase February 2025 Loan&#8221;). The Prophase February 2025 Loan bears interest at 6% per annum and was due on April 11, 2025, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $125,000, along with accrued interest, on the Prophase February 2025 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March of 2025, the Company borrowed $207,000 from Prophase (the &#8220;Prophase March 2025 Loan&#8221;). The Prophase March 2025 Loan bears interest at 6% per annum and was due on June 6, 2025, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $200,000, along with accrued interest, on the Prophase March 2025 Loan was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April of 2025, the Company borrowed an additional $3,627,000 from Prophase (the &#8220;Prophase April 2025 Loans&#8221;). The loans bear 6% interest per annum. Of the aggregate $3,627,000 Prophase April 2025 Loans, $200,000 was due on May 2, 2025, $1,920,120 was due on May 13, 2025 and $1,506,880 was due on May 14, 2025. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $3,627,000, along with accrued interest, on the Prophase April 2025 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the balance of the Prophase loans is $742,500 and $1,623,000, respectively. As of December 31, 2025 and 2024, the related accrued interest of the loans from Prophase was $79,283 and $66,728, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Prophase loans was $77,073 and $66,728, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Hana Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 1, 2024, the Company borrowed $850,000 from Hana Immunotherapeutics, LLC (&#8220;Hana&#8221;), a related party of the Company due to having common executives (the &#8220;Hana Loans&#8221;). The Hana Loans bear interest at 6% per annum and were due on September 30, 2024 and October 26, 2024, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $800,000, along with accrued interest, of the Hana Loans was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the balance of the Hana Loans is $50,000 and $850,000, respectively. As of December 31, 2025 and 2024, the related accrued interest of the loans from Hana was $2,042 and $19,150, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Hana Loans was $19,042 and $19,150, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Amantes Loans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On November 1, 2024, the Company borrowed $400,000 from Amantes LLC (&#8220;Amantes&#8221;), a related party of the Company due to having common executives, pursuant to a loan agreement between the Company and Amantes (the &#8220;Amantes Loan&#8221;). On November 27, 2024, the Company borrowed an additional $300,000 from Amantes (the &#8220;Additional Amantes Loan&#8221;) (together with the Amantes Loan, the &#8220;Amantes November 2024 Loans&#8221;). The Amantes November 2024 Loans bear interest at 6% per annum and are due on January 1, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">2025. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $550,000, along with accrued interest, on the Amantes November 2024 Loans was converted into common stock of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 2, 2025 and January 23, 2025, the Company borrowed a total of $300,000 from Amantes, pursuant to loan agreements between the Company and Amantes (the &#8220;Amantes January 2025 Loans&#8221;). The Amantes January 2025 Loans bear interest at 6% per annum and are due on March 1, 2025 and March 22, 2025, respectively, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $250,000, along with accrued interest, on the Amantes January 2025 Loans was converted into common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the balance of the Amantes Loans is $200,000 and $700,000, respectively. As of December 31, 2025 and 2024, the related accrued interest of the loans from Amantes was $9,288 and $5,700, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Amantes Loans was $27,890 and $5,700, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to Note 5 for discussion related to notes which have passed their maturity dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Due to Related Party</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, the Company had $209,586 due to the Company&#8217;s executive team for compensation under their employment agreements. As of December 31, 2024, the Company had $195,253 due to the Company&#8217;s executive team for compensation under their employment agreements and Amantes. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Viral Gene</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of December 31, 2025 and 2024, the Company had $0 and $126,275, respectively, due from Viral Gene included in due from related party in the consolidated balance sheets for a loan to Viral Gene and expenses paid on behalf of Viral Gene. During the year ended December 31, 2025, the Company determined the due from related party was uncollectible and wrote off $126,275 and is included in general and administrative on the consolidated statement of operations. The Company&#8217;s CEO is also the CEO of Viral Gene. The loan does not bear any interest.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 5. Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Outstanding debt classified as short-term debt as of March 31, 2026 and December 31, 2025 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:225.1pt;padding:0pt;"></td><td style="width:8.9pt;padding:0pt;"></td><td style="width:157.4pt;padding:0pt;"></td><td style="width:8.85pt;padding:0pt;"></td><td style="width:5.85pt;padding:0pt;"></td><td style="width:53.25pt;padding:0pt;"></td><td style="width:8.85pt;padding:0pt;"></td><td style="width:7pt;padding:0pt;"></td><td style="width:64.8pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:59.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:71.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2025</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo June 2023 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo July 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,500</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase May 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase July 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hana August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes November 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes January 2025 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,000</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short-term debt, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,442,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,442,500</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, the Company&#8217;s outstanding debt agreements are all past due and are classified as current in the accompanying unaudited condensed consolidated balance sheets. All of the loans are with related parties (see Note 4). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As the Company&#8217;s loans are with related parties, the Company and its related parties have agreed to defer repayment until a time that is mutually agreed upon between the Company and its related parties. Accordingly, none of these notes are considered to be in default.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 5. Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Outstanding debt classified as short-term debt as of December 31, 2025 and 2024 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:202.45pt;padding:0pt;"></td><td style="width:13.39pt;padding:0pt;"></td><td style="width:162pt;padding:0pt;"></td><td style="width:12.85pt;padding:0pt;"></td><td style="width:8pt;padding:0pt;"></td><td style="width:60.5pt;padding:0pt;"></td><td style="width:12.86pt;padding:0pt;"></td><td style="width:8pt;padding:0pt;"></td><td style="width:59.95pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:149.3pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style="height:9.69pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Feelux Bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Car-Tcellkor Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 800,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ewon Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,000,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo June 2023 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo July 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo August 2023 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 400,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ewon September 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo November 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ewon December 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,000,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo January 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 750,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase April 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase May 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 790,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase July 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hana August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 850,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes November 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes January 2025 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short-term debt, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,442,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,973,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the Company&#8217;s outstanding debt agreements are all past due and are classified as current in the accompanying consolidated balance sheets. All of the loans are with related parties (see Note 4). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As the Company&#8217;s loans are with related parties, the Company and its related parties have mutually agreed to defer repayment until a time that is mutually agreed upon between the Company and its related parties. Accordingly, none of these notes are considered to be in default.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholder's Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholder's Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 6. Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Business Company, the Company&#8217;s certificate of incorporation was amended and restated to designate two classes of stock; preferred and common stock. The certificate of incorporation authorized 1,000,000 shares of preferred stock and 500,000,000 shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preferred Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Amended and Restated Certificate of Incorporation provides the Company&#8217;s board of directors with the authority to issue up to 1,000,000 shares of $0.0001 par value preferred stock in one or more series and to establish from time to time the number of shares to be included in each such series, by adopting a resolution and filing a certification of designations. Voting powers, designations, powers, preferences and relative, participating, optional, special and other rights will be stated and expressed in such resolutions. There were zero preferred shares outstanding as of March 31, 2026 and December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Common Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is authorized to issue 500,000,000 shares of common stock, with a par value of $0.0001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 16, 2025, the Company entered into a settlement and release agreement with Alta Partners, LLC (&#8220;Alta&#8221;), pursuant to which the Company agreed to issue 350,000 shares of its common stock to Alta in exchange for the surrender and cancellation of 1,000,000 Public Warrants held by Alta. On July 16, 2025, the common stock issued to Alta and Public Warrants surrendered by Alta had a fair value of $1,890,000 and $150,000, respectively. As a result of the exchange, the Company recognized a loss of $1,740,000 on the difference in fair value between the common stock and Public Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, the Company settled Iris&#8217; liabilities for $7,000,000 of the deferred underwriting fees incurred prior to the Closing Date for 700,000 shares of common stock to the underwriters in Iris&#8217;s initial public offering. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $7,245,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 6, 2026, the Company entered into a settlement and release agreement with the Holder (as defined in Note 7), pursuant to which the Company agreed to issue 4,000,000 shares of its common stock to the Holder in exchange for the surrender and cancellation of 805,377 warrants to purchase shares of common stock held by the Holder. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 18, 2026, the Company completed a &#8220;best efforts&#8221; public offering of (i) 8,270,000 shares of its common stock, (ii) 5,543,000 Pre-Funded Warrants to purchase up to 5,543,000 shares of common stock and (ii) 13,813,000 Common Stock Warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per Pre-Funded Warrant) and accompanying warrant. Immediately upon closing of the Offering, 4,281,000 Pre-Funded Warrants were exercised and converted into 4,281,000 shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company allocated the Offering proceeds between the common stock, Pre-Funded Warrants, Common Stock Warrants and Placement Agent Warrants based on their relative fair values in accordance with ASC 505, <i style="font-style:italic;">Equity</i>. The fair value of the common stock and Pre-Funded Warrants was based on the Company&#8217;s closing stock price on the closing date of $0.2449 per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of the Common Stock Warrants and Placement Agent Warrants was estimated using a Black-Scholes option pricing model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:369.05pt;padding:0pt;"></td><td style="width:10pt;padding:0pt;"></td><td style="width:44.6pt;padding:0pt;"></td><td style="width:8.35pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:369.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:369.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 92.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:369.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:369.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:369.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected life of warrants (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Offering proceeds and related issuance costs were allocated to the common stock, Pre-Funded Warrants, Common Stock Warrants and Placement Agent Warrants as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:259.65pt;padding:0pt;"></td><td style="width:8pt;padding:0pt;"></td><td style="width:52.7pt;padding:0pt;"></td><td style="width:8.05pt;padding:0pt;"></td><td style="width:50.04pt;padding:0pt;"></td><td style="width:8.05pt;padding:0pt;"></td><td style="width:45.5pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.24pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Allocated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Allocated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Allocated</b></p></td></tr><tr style="height:9.49pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross&#160;Proceeds</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuance&#160;Costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net&#160;Proceeds</b></p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:259.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,208,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 168,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,039,295</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Common Stock Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,977,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 276,502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,701,497</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:259.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Pre-Funded Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 755,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 649,471</p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Placement Agent Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,546</p></td></tr><tr style="height:12.54pt;"><td style="vertical-align:bottom;width:259.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,005,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 559,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,445,808</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The amount allocated to the common stock and Pre-Funded Warrants was recorded in common stock at par value and the excess over par value in additional paid-in capital in the accompanying unaudited condensed consolidated balance sheet as of March 31, 2026. The amounts allocated to the Common Stock Warrants and Placement Agent Warrants were recorded in additional paid-in capital as the Common Stock Warrants and Placement Agent Warrants are equity-classified instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Issuance costs, including placement agent fees, legal fees and accountant related expenses were recorded as reduction to additional paid-in capital in proportion to the allocation of proceeds between the equity instruments issued, as summarized above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 19, 2026, the remaining 1,262,000 Pre-Funded Warrants were exercised and converted into 1,262,000 shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, there were 44,877,633 and 27,064,633 shares of common stock issued and outstanding, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of the Company&#8217;s common stock are entitled to one vote for each share held of record, on all matters submitted to a vote of stockholders. Additionally, holders of common stock have dividend rights, in the event of a declared dividend declared by the Company&#8217;s Board of Directors, and liquidation rights, in the event of an involuntary or voluntary event of liquidation that allow for the Company&#8217;s common stockholders to receive all remaining assets of the Company, after payments of debts and other liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of March 31, 2026, 5,094,623 Public Warrants and 835,555 private placement warrants (together, the &#8220;Warrants&#8221;) were outstanding. Each Warrant entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $11.50 per share. No </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">fractional shares will be issued upon exercise of the Warrants. The Company may elect to redeem the Public Warrants, in whole and not in part at a price of $0.01 per Warrant if (i) 30 days&#8217; prior written notice of redemption is provided to the holders, and (ii) the last reported sale price of the Company&#8217;s common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders. Upon issuance of a redemption notice by the Company, the warrant holders have a period of 30 days to exercise for cash, or on a cashless basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of March 31, 2026, 13,813,000 Common Stock Warrants were outstanding. Each Common Stock Warrant entitles the holder to purchase one and a half shares of the Company&#8217;s common stock at a price of $0.29 per share and will expire five years following the date of issuance. No fractional shares will be issued upon exercise of the Common Stock Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of March 31, 2026, 690,650 Placement Agent Warrants were outstanding. Each Placement Agent Warrant entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $0.319 per share and will expire five years following the date of issuance. No fractional shares will be issued upon exercise of the Placement Agent Warrants.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 6. Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Business Combination, the Company&#8217;s certificate of incorporation was amended and restated to designate two classes of stock; preferred and common stock. The certificate of incorporation authorized 1,000,000 shares of preferred stock and 500,000,000 shares of common stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preferred Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Amended and Restated Certificate of Incorporation provides the Company&#8217;s board of directors with the authority to issue up to 1,000,000 shares of $0.0001 par value preferred stock in one or more series and to establish from time to time the number of shares to be included in each such series, by adopting a resolution and filing a certification of designations. Voting powers, designations, powers, preferences and relative, participating, optional, special and other rights will be stated and expressed in such resolutions. There were zero preferred shares outstanding as of December 31, 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Common Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is authorized to issue 500,000,000 shares of common stock, with a par value of $0.0001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, the Company settled deferred underwriting fees incurred by Iris prior to the closing date of $7,000,000 for 700,000 shares of common stock to the underwriters in Iris&#8217;s initial public offering. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $7,245,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 16, 2025, the Company entered into a settlement and release agreement with Alta Partners, LLC (&#8220;Alta&#8221;), pursuant to which the Company agreed to issue 350,000 shares of its common stock to Alta in exchange for the surrender and cancellation of 1,000,000 Public Warrants held by Alta. On July 16, 2025, the common stock issued to Alta and Public Warrants surrendered by Alta had a fair value of $1,890,000 and $150,000, respectively. As a result of the exchange, the Company recognized a loss of $1,740,000 on the difference in fair value between the common stock and Public Warrants, which is included in Loss on issuance of common stock on the Company&#8217;s consolidated statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, there were 27,064,633 and 17,500,000 shares of common stock issued and outstanding, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of the Company&#8217;s common stock are entitled to one vote for each share held of record, on all matters submitted to a vote of stockholders. Additionally, holders of common stock have dividend rights, in the event of a declared dividend declared by the Company&#8217;s Board of Directors, and liquidation rights, in the event of an involuntary or voluntary event of liquidation that allow for the Company&#8217;s common stockholders to receive all remaining assets of the Company, after payments of debts and other liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">As of December 31, 2025, 5,899,975 Public Warrants and 835,555 private placement warrants were outstanding. Each warrant entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $11.50 per share. No fractional shares will be issued upon exercise of the warrants. The Company may elect to redeem the Public Warrants, in whole and not in part at a price of $0.01 per warrant if (i) 30 days&#8217; prior written notice of redemption is provided to the holders, and (ii) the last reported sale price of the Company&#8217;s common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders. Upon issuance of a redemption notice by the Company, the warrant holders have a period of 30 days to exercise for cash, or on a cashless basis.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;7. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 17, 2025, the Company entered into a short-term lease for an office space in Cerritos, California (the &#8220;Lease&#8221;). The Lease commenced on September 1, 2025 and expires on June 30, 2026 and does not have any renewal option. The Company has made the short-term lease election and recognizes lease payments for its short-term lease on a straight line basis over the lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2026, lease expense related to the short-term lease was $22,272. <span style="background:#ffffff;">For the three months ended March 31, 2025,</span> there was no lease expense related to the short-term lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Legal Proceedings</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 6, 2026, the Company entered into a settlement and release agreement with Clear Street LLC (the &#8220;Holder&#8221;), pursuant to which the Company agreed to issue 4,000,000 shares of its common stock to the Holder in exchange for the surrender and cancellation of 805,377 warrants to purchase shares of common stock held by the Holder. As of December 31, 2025, the Company determined this represented a Type I subsequent event in accordance with the guidance of ASC 855, <i style="font-style:italic;">Subsequent Events</i> (&#8220;ASC 855&#8221;), in which the Company obtained additional evidence about conditions that existed at the date of the consolidated balance sheets. The Company estimated a settlement of $7,360,000, which was calculated using the fair value of the Company&#8217;s common stock on February 6, 2026, which was the day that stock was issued to the Holder. As of March 31, 2026 and December 31, 2025, the Company&#8217;s settlement payable was $0 and $7,360,000, respectively, which is included in settlement payable in the Company&#8217;s unaudited condensed consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Settlement Agreement, the Company and the Holder agreed to dismiss (a) an action pending in the United States District Court for the Central District of California and (b) an action pending in the United States District Court for the Southern District of New York, in which previously the Court entered a default judgment against the Company in the amount of $7,500,000 plus approximately $515,000 in interest, which judgment was registered in the Central District of California in the fourth quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims other than those already disclosed. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Underwriting Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Business Combination in connection with its initial public offering, Iris entered into an underwriting agreement with Cantor was engaged as the underwriters to Iris&#8217; IPO. Cantor was entitled to an underwriting discount of 2% (or $5,520,000) of the gross proceeds of the IPO and deferred underwriting discount of 3.5% (or $9,660,000) of the gross proceeds of the IPO upon the completion of an initial business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On October 11, 2023, Iris executed a fee reduction agreement with the underwriters to reduce the deferred underwriting discount of $9,660,000 to $8,000,000 in the event the Business Combination was consummated. Pursuant to the terms of the agreement, the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">reduced deferred underwriting discount was payable by the Iris to the underwriters in $1,000,000 cash and $7,000,000 of the common equity securities of the public entity that survives the transaction. The share price is subject to adjustment based on the five day volume-weighted average price prior to the filing of a resale registration statement covering such shares. As of April 30, 2025, Iris and the Company amended the fee reduction agreement with the underwriters to limit the total number of shares of common stock issuable to the underwriters to 1,750,000. Upon the consummation of the Business Combination, $9,160,000 in deferred underwriting fees were settled, of which $7,000,000 will be settled in common shares of the combined company, $500,000 was settled in cash and $1,660,000 was waived and no longer payable. The remaining $500,000 was to be settled upon the earlier of the consummation of the combined company&#8217;s next share offering, or in six months from the closing date of the Business Combination. As of March 31, 2026, the deferred underwriting fee payable was $500,000, which is included in deferred underwriting fee payable in the Company&#8217;s unaudited condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, the Company settled Iris&#8217; liabilities for $7,000,000 of the deferred underwriting fees incurred prior to the Closing Date for 700,000 shares of common stock to the underwriters in Iris&#8217;s initial public offering. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $7,245,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On October 27, 2025, six months from the closing date of the Business Combination, the remaining $500,000 underwriting fee became due. As of the date of this Form 10-Q, the $500,000 underwriting fees remains unpaid.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;7. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 17, 2025, the Company entered into a short-term lease for an office space in Cerritos, California (the &#8220;Lease&#8221;). The Lease commenced on September 1, 2025 and expires on June 30, 2026 and does not have any renewal option. The Company has made the short-term lease election and recognizes lease payments for its short-term lease on a straight line basis over the lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2025, lease expense related to the short-term lease was $2,784. For the year ended December 31, 2024, there was no lease expense related to the short-term lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Legal proceedings</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 6, 2026, the Company entered into a settlement and release agreement with Clear Street LLC (the &#8220;Holder&#8221;), pursuant to which the Company agreed to issue 4,000,000 shares of its common stock, par value $0.0001 per share, to the Holder in exchange for the surrender and cancellation of 805,377 warrants to purchase shares of common stock held by the Holder. The Company has determined this represents a Type I subsequent event in accordance with the guidance of ASC 855, <i style="font-style:italic;">Subsequent Events</i> (&#8220;ASC 855&#8221;), in which the Company obtained additional evidence about conditions that existed at the date of the consolidated balance sheets. As such, the Company has recorded the $7,360,000 as settlement payable, which was calculated using the fair value of the Company&#8217;s common stock on February 6, 2026, which was the day that stock was issued to the Holder, in its consolidated balance sheets as of December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Settlement Agreement, the Company and the Holder agreed to dismiss (a) an action pending in the United States District Court for the Central District of California and (b) an action pending in the United States District Court for the Southern District of New York, in which previously the Court entered a default judgment against the Company in the amount of $7,500,000 plus approximately $515,000 in interest, which judgment was registered in the Central District of California in the fourth quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is not a party to any other material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Underwriting Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Business Combination in connection with its initial public offering, Iris entered into an underwriting agreement in which Cantor was engaged as the underwriters to Iris&#8217; IPO. Cantor was entitled to an underwriting discount of 2% (or $5,520,000) of the gross proceeds of the IPO and deferred underwriting discount of 3.5% (or $9,660,000) of the gross proceeds of the IPO upon the completion of an initial business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 11, 2023, Iris executed a fee reduction agreement with the underwriters to reduce the deferred underwriting discount of $9,660,000 to $8,000,000 in the event the Business Combination was consummated. Pursuant to the terms of the agreement, the reduced deferred underwriting discount was payable by the Iris to the underwriters in $1,000,000 cash and $7,000,000 of the common equity securities of the public entity that survives the transaction. The share price is subject to adjustment based on the five day volume-weighted average price prior to the filing of a resale registration statement covering such shares. As of April 30, 2025, Iris and the Company amended the fee reduction agreement with the underwriters to limit the total number of shares of common stock issuable to the underwriters to 1,750,000. Upon the consummation of the Business Combination, $9,160,000 in deferred underwriting fees were settled, of which $7,000,000 will be settled in common shares of the combined company, $500,000 was settled in cash and $1,660,000 was waived and no longer payable. The remaining $500,000 was to be settled upon the earlier of the consummation of the combined company&#8217;s next share offering, or in six months from the closing date of the Business Combination. As of December 31, 2025, the deferred underwriting fee payable was $500,000, which is included in Deferred underwriting fee payable in the Company&#8217;s consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, the Company settled Iris&#8217; liabilities for $7,000,000 of the deferred underwriting fees incurred prior to the Closing Date for 700,000 shares of common stock to the underwriters in Iris&#8217;s initial public offering. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $7,245,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On October 27, 2025, six months from the closing date of the Business Combination, the remaining $500,000 underwriting fee became due. As of the date of these consolidated financial statements, the $500,000 underwriting fees remains unpaid. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 8. Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2026 and December 31, 2025 and indicates the fair value hierarchy of the valuation inputs the Company&#8217;s utilized to determine such fair value:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:340.7pt;padding:0pt;"></td><td style="width:9.8pt;padding:0pt;"></td><td style="width:49.65pt;padding:0pt;"></td><td style="width:9.85pt;padding:0pt;"></td><td style="width:6.25pt;padding:0pt;"></td><td style="width:49.25pt;padding:0pt;"></td><td style="width:9.85pt;padding:0pt;"></td><td style="width:7.7pt;padding:0pt;"></td><td style="width:56.95pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:340.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:340.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:55.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2025</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:340.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:340.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:340.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,244</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrant Liability</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon closing of the Mergers, Iris&#8217; public and private placement warrants were converted into warrants of the Company, which entitle the holders to purchase shares of the Company&#8217;s common stock. The Company&#8217;s private placement warrants meet the requirements for liability classification. The fair value of the warrant liabilities were determined using observable data points, such as the fair value of the public warrants as of March 31, 2026 and December 31, 2025. The Company further considered specific unobservable inputs, such as the probability and timing of events and the expected equity value of the underlying shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The changes in fair value of Level 3 financial assets and liabilities for the three months ended March 31, 2026 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:360.05pt;padding:0pt;"></td><td style="width:11.39pt;padding:0pt;"></td><td style="width:7.15pt;padding:0pt;"></td><td style="width:53.4pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:60.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant&#160;liability</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of January 1, 2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 29,244</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,178</p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of March&#160;31,&#160;2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 33,422</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 8. Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2025 and 2024 and indicates the fair value hierarchy of the valuation inputs the Company&#8217;s utilized to determine such fair value:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:341.85pt;padding:0pt;"></td><td style="width:10.8pt;padding:0pt;"></td><td style="width:50.65pt;padding:0pt;"></td><td style="width:10.79pt;padding:0pt;"></td><td style="width:6.8pt;padding:0pt;"></td><td style="width:50.75pt;padding:0pt;"></td><td style="width:10.8pt;padding:0pt;"></td><td style="width:6.8pt;padding:0pt;"></td><td style="width:50.75pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:341.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:341.85pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:341.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:341.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:341.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrant Liability</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon closing of the Mergers, Iris&#8217; public and private placement warrants were converted into warrants of the Company, which entitle the holders to purchase shares of the Company&#8217;s common stock. The Company&#8217;s private placement warrants meet the requirements for liability classification. The fair value of the warrant liabilities were determined using observable data points, such as the fair value of the public warrants as of December 31, 2025 and 2024. The Company further considered specific unobservable inputs, such as the probability and timing of events and the expected equity value of the underlying shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The changes in fair value of Level 3 financial assets and liabilities for the year ended December 31, 2025 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:360.05pt;padding:0pt;"></td><td style="width:11.39pt;padding:0pt;"></td><td style="width:7.15pt;padding:0pt;"></td><td style="width:53.4pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:60.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant&#160;liability</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Initial measurement at the Closing Date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,556</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (54,312)</p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 29,244</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 9. Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2025, the Company consummated the Business Combination. Liminatus, a Delaware limited liability company, was deemed the accounting acquirer in the Business Combination based on an analysis of the criteria outlined in ASC 805, see Note 1. The tax consequences of the Company&#8217;s transactions prior to the consummation of the Business Combination flows through to the members of Liminatus. The tax consequences of the Company&#8217;s transactions for the period from May 1, 2025 through December 31, 2025 are accounted for in accordance with ASC 740. Prior to May 1, 2025, the Company was a non corporate entity that was not subject to U.S. federal income tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company regularly assesses the need for a valuation allowance against its deferred tax assets. In making that assessment, the Company considers both positive and negative evidence related to the likelihood of realization of the deferred tax assets to determine, based on the weight of available evidence, whether it is more-likely-than-not that some or all of the deferred tax assets will not be realized. In assessing the realizability of deferred tax assets, the Company considers taxable income in prior carryback years, as permitted under the tax law, forecasted taxable earnings, tax planning strategies, and the expected timing of the reversal of temporary differences. This determination requires significant judgment, including assumptions about future taxable income that are based on historical and projected information and is performed on a jurisdiction-by-jurisdiction basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company maintains a full valuation allowance against its deferred tax assets. During the years ended December 31, 2025 and 2024, management assessed the positive and negative evidence in its operations, and concluded that it is more likely than not that its deferred tax assets as of December 31, 2025 and 2024 will not be realized given the Company&#8217;s history of operating losses. The valuation allowance against deferred tax assets increased by $2,345,773 and $0 during the year December 31, 2025 and 2024, respectively, related to a full valuation allowance recorded against additional net operating losses and tax credits generated in the year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 22, 2017, the Tax Cuts and Jobs Act (the &#8220;Act&#8221;) was enacted. Under the Act, research and development expenditures incurred for tax years beginning after December 31, 2021 must be capitalized and amortized ratably over five or fifteen years for tax purposes, depending on if the research activities are conducted in the U.S. or outside the U.S., respectively. For the years ended December 31, 2025 and 2024, the Company had no research and development expenditures subject to the mandatory capitalization and amortization under the Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the Company had federal net operating losses of $822,963 and $0, respectively, which may be available to offset future federal income tax liabilities, subject limitations under IRC Section 382 of approximately $1.1 million per year. As a result of the Act, for U.S. federal income tax purposes, net operating losses generated after December 31, 2017 can be carried forward indefinitely, but are limited to 80% utilization against future taxable income each year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The components of the income tax provision (benefit) are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:399pt;padding:0pt;"></td><td style="width:12.65pt;padding:0pt;"></td><td style="width:8pt;padding:0pt;"></td><td style="width:49.9pt;padding:0pt;"></td><td style="width:12.64pt;padding:0pt;"></td><td style="width:8pt;padding:0pt;"></td><td style="width:49.81pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.49pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:128.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr style="height:9.74pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal</p></td><td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,604,745)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State and Local</p></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (741,028)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,345,773</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:12.54pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision</p></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">A reconciliation of the Company&#8217;s effective income tax rate to the U.S. statutory federal income tax rate of 21% and the Company&#8217;s California income tax rate of 8.84%for the years ended December 31, 2025 and 2024 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:304.85pt;padding:0pt;"></td><td style="width:10pt;padding:0pt;"></td><td style="width:42.4pt;padding:0pt;"></td><td style="width:13.35pt;padding:0pt;"></td><td style="width:6pt;padding:0pt;"></td><td style="width:49.2pt;padding:0pt;"></td><td style="width:10pt;padding:0pt;"></td><td style="width:42.45pt;padding:0pt;"></td><td style="width:13.35pt;padding:0pt;"></td><td style="width:6.05pt;padding:0pt;"></td><td style="width:42.35pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.49pt;"><td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:225.15pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style="height:9.74pt;"><td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:110.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:104.2pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,052,583)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_gt31aPXKykC4c-4bEt6laQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">State taxes, net of federal expense</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss on exchange of common stock for warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.74)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 365,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of common stock to be issued for contingent liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15.81)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,545,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.31)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,686</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 110,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:12.54pt;"><td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision expense/(benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The significant components of the Company&#8217;s net deferred tax assets and liabilities as of December 31, 2025 and 2024 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:400.5pt;padding:0pt;"></td><td style="width:13.05pt;padding:0pt;"></td><td style="width:8.1pt;padding:0pt;"></td><td style="width:51.95pt;padding:0pt;"></td><td style="width:13.05pt;padding:0pt;"></td><td style="width:8.1pt;padding:0pt;"></td><td style="width:45.25pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.49pt;"><td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:126.45pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style="height:9.74pt;"><td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:60.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:53.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Startup expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,042,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Section 163(j) - Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,345,773</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,345,773)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:12.54pt;"><td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax asset, net of valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations in a multitude of jurisdictions. The Company recognizes liabilities for uncertain tax positions based on a two-step process. First, management determines whether it is more likely than not that the tax positions will be sustained on audit, including resolution of related appeals or litigation processes, based on their technical merits. Second, management measures the tax benefit of those positions as the largest amount that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes. As of December 31, 2025 and 2024, the Company did not have any uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s policy is to recognize interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations and any accrued interest and penalties on the related tax liability line in the consolidated balance sheet. As of December 31, 2025 and 2024, no accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet. Further, during the years ended December 31, 2025 and 2024, the Company did not remit payment for any income tax obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company files income tax returns in the U.S. federal jurisdiction and California jurisdictions. There are currently no pending income tax examinations. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent the tax attributes are utilized in a future period. The Company&#8217;s income tax returns since 2022 are subject to examination by the IRS and state tax authorities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;9. Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has completed an evaluation of all subsequent events through the date of this filing to ensure that these unaudited condensed consolidated financial statements include appropriate disclosure of events both recognized in the unaudited condensed consolidated financial statements and events which occurred but were not recognized in the unaudited condensed consolidated financial statements. </p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note&#160;10. Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has completed an evaluation of all subsequent events through the date of this filing to ensure that these consolidated financial statements include appropriate disclosure of events both recognized in the consolidated financial statements and events which occurred but were not recognized in the consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On February 6, 2026, the Company entered into a settlement and release agreement with the Holder, pursuant to which the Company agreed to issue 4,000,000 shares of its common stock, par value $0.0001 per share, to the Holder in exchange for the surrender and cancellation of 805,377 warrants to purchase shares of common stock held by the Holder. The Company has determined this represents a Type I subsequent event in accordance with ASC 855, in which the Company obtained additional evidence about conditions that existed at the date of the consolidated balance sheets. As such, the Company has recorded the $7,360,000 as settlement payable, which </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">was calculated using the fair value of the Company&#8217;s common stock on February 6, 2026, which was the day that stock was issued to the Holder, in its consolidated balance sheets as of December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Settlement Agreement, the Company and the Holder agreed to dismiss (a) an action pending in the United States District Court for the Central District of California and (b) an action pending in the United States District Court for the Southern District of New York, in which previously the Court entered a default judgment against the Company in the amount of $7,500,000 plus approximately $515,000 in interest, which judgment was registered in the Central District of California in the fourth quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 18, 2026, the Company completed a &#8220;best efforts&#8221; public offering of (i) 8,270,000 shares of its common stock, (ii) 5,543,000 Pre-Funded Warrants to purchase up to 5,543,000 shares of common stock and (ii) 13,813,000 common stock purchase warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per Pre-Funded Warrant) and accompanying warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each Pre-Funded Warrant has an exercise price of $0.0001 per share upon issuance for <span style="-sec-ix-hidden:Hidden_pRGIcWXwZE-WeEaxj87wJg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> share of common stock and will not expire prior to exercise. Each Warrant has an exercise price of $0.29 per share, is exercisable upon issuance for<span style="-sec-ix-hidden:Hidden_kq3mrqvJyU-ExJ_p7HGPjQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> one and a half</span></span> shares of common stock, and will expire five years following the date of issuance. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the common stock and the exercise price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Offering, on February 17, 2026, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers party thereto. The Purchase Agreement contains customary representations, warranties and agreements of the Company and the purchasers and customary indemnification rights and obligations of the parties. Pursuant to the Purchase Agreement, the Company agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock or file any registration statement or prospectus, or any amendment or supplement thereto for 180 days after the closing date of the Offering, subject to certain exceptions. The Company also agreed not to effect or enter into an agreement to effect any issuance of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock involving a Variable Rate Transaction (as defined in the Purchase Agreement) until 180 days after the closing date of the Offering, subject to certain exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In connection with the Offering, on February 17, 2026, the Company entered into a placement agency agreement with Maxim Group LLC, as placement agent in connection with the Offering (the &#8220;Placement Agent&#8221;). The Company paid the Placement Agent a cash fee of 8.0% of the aggregate gross proceeds raised in the Offering. The Company also agreed to reimburse the Placement Agent for all reasonable out-of-pocket costs and expenses incurred in connection with the Offering in an aggregate amount up to $100,000. In addition, the Company issued to the Placement Agent warrants (the &#8220;Placement Agent Warrants&#8221;) to purchase 690,650 shares of common stock (representing 5.0% of the number of shares of common stock sold in the Offering). The Placement Agent Warrants are immediately exercisable at an exercise price of $0.319 (or 110% of the public offering price for the shares of common stock and common warrants offered in the Offering) and will expire on the <span style="-sec-ix-hidden:Hidden_rGRJ0qc7tEGPO6XNQVjRbw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fifth anniversary</span></span> of the commencement of sales of the Offering. On February 18, 2026, in connection with the Offering, the Company received net proceeds of approximately $3.46 million, after deducting the estimated offering expenses payable by the Company, including the placement agent fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On February 20, 2026, the Company issued a payment of $1,000,000 to InnoBation Bio Co. Ltd. for costs associated to begin the Phase 1 clinical trials of IBA101, the Company&#8217;s product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) as determined by the FASB ASC and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The unaudited condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements do not include all of the disclosures required by U.S. GAAP for annual consolidated financial statements and should be read in conjunction with the audited consolidated financial statements of the Company as of and for the year ended December 31, 2025 (the &#8220;Annual Financial Statements&#8221;). In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary to fairly present its financial position as of March 31, 2026, its results of operations for the three months ended March 31, 2026 and 2025, its cash flows for the three months ended March 31, 2026 and 2025, and its changes in stockholders&#8217; deficit for the three months ended March 31, 2026 and 2025. Results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year ending December 31, 2026 or any future period. The condensed consolidated balance sheet as of December 31, 2025 was derived from the Annual Financial Statements but does not contain all of the footnote disclosures from the Annual Financial Statements.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) as determined by the FASB ASC and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_EmergingGrowthCompanyPolicyPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company Status</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">After the closing of the Business Combination, the Company has elected to be an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s unaudited condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company Status</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the closing of the Business Combination, the Company has elected to be an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart our Business Startups Act of 2012, (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results may differ materially and adversely from these estimates. The Company is not aware of any significant estimates that required management to exercise significant judgment with the exception of the Company&#8217;s warrant liability and research and development costs. If the underlying estimates and assumptions upon which the estimates are based change in the future, actual amounts may differ from those included in the Company&#8217;s unaudited condensed consolidated financial statements.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results may differ materially and adversely from these estimates. The Company is not aware of any significant estimates that required management to exercise significant judgment with the exception of the Company&#8217;s warrant liability. If the underlying estimates and assumptions upon which the estimates are based change in the future, actual amounts may differ from those included in the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), the Chief Executive Officer, manages the Company&#8217;s business activities as a <span style="-sec-ix-hidden:Hidden_skpW_fMTs0qgK5TqjOzinQ;"><span style="-sec-ix-hidden:Hidden_oRglHBbi5kiQPSddjK0rrg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">single</span></span></span> operating and reportable segment. Accordingly, the Company&#8217;s CODM uses net income/loss to measure the Company&#8217;s single segment&#8217;s performance and allocate resources. Further, the CODM reviews and utilizes functional expenses (general and administrative and research and development) to manage the Company&#8217;s operations. The Company&#8217;s general and administrative expenses for the three months ended March 31, 2026 and 2025 included $60,500 and $37,500, respectively, of compensation expenses related to the compensation agreement the Company has executed with its Chief Executive Officer. The remaining general and administrative expenses are related to legal and accounting-related expenses for contractors. The Company&#8217;s research and development expenses did not include any compensation-related expenses. Other segment items included in net loss are interest expense, related parties and interest income which are reflected in the Company&#8217;s unaudited condensed consolidated statements of operations.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), the Chief Executive Officer, manages the Company&#8217;s business activities as a single operating and reportable segment. Accordingly, the Company&#8217;s CODM uses net income/loss to measure the Company&#8217;s single segment&#8217;s performance and allocate resources. Further, the CODM reviews and utilizes functional expenses (general and administrative and research and development) to manage the Company&#8217;s operations. The Company&#8217;s general and administrative expenses for each of the years ended December 31, 2025 and 2024 included $202,833 and $150,000 of compensation expenses related to the compensation agreements the Company has executed with its executive team. The remaining general and administrative expenses </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">are related to legal and accounting-related expenses for contractors. The Company&#8217;s research and development expenses did not include any compensation-related expenses. Other segment items included in net income (loss) are interest expense, related parties and interest income which are reflected in the Company&#8217;s consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which can exceed government insured limits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company did not have any cash equivalents as of March 31, 2026 and December 31, 2025.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which can exceed government insured limits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2025 and 2024.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLoansAndLeasesReceivablePolicy', window );">Loan Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Loan Receivable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its loan receivable at amortized cost, net of expected credit losses. The Company provides reserves against its loan receivable balance for estimated credit losses, if any, that may result from a counterparty&#8217;s inability to pay based on the composition of the loan receivable, current economic conditions and, historical credit loss activity and future expected conditions and market trends (such as general economic conditions, other macroeconomic and microeconomic events, etc.). Changes in circumstances relating to these factors may result in the need to increase or decrease the allowance for credit losses in the future. Amounts deemed uncollectible are charged or written-off against the reserve. On April 30, 2025, in connection with the Business Combination, the loan receivable was eliminated in consolidation as Iris and Liminatus are now consolidated subsidiaries of the Company. As of January 1, 2024 and December 31, 2024, no expected credit loss was recorded related to the loan receivable.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Transaction Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Deferred Transaction Costs </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Costs incurred in connection with preparation for the proposed business combination were deferred on the balance sheets as of December 31, 2024. No such costs were deferred on the balance sheets as of December 31, 2025 due to the completion of the Company&#8217;s business combination with Iris. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial assets and liabilities are accounted for in accordance with FASB ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures,</i> which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value hierarchy requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 1 &#8212; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 2 &#8212; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the instrument&#8217;s anticipated life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 3 &#8212; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgement. Accordingly, the degree of judgement exercised by management in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the warrant liability reported in the Company&#8217;s unaudited condensed consolidated balance sheets represent a Level 3 instrument (see Note 8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying values reported in the Company&#8217;s unaudited condensed consolidated balance sheets for prepaid expenses and other current assets, due from related party, accounts payable and accrued expenses, accrued interest, short-term debt with related parties, due to related parties and its deferred underwriting fee payable are reasonable estimates of their fair values due to the short-term nature of these items.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial assets and liabilities are accounted for in accordance with FASB ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures,</i> which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value hierarchy requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 1 &#8212; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 2 &#8212; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the instrument&#8217;s anticipated life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 3 &#8212; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgement. Accordingly, the degree of judgement exercised by management in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the warrant liability reported in the Company&#8217;s consolidated balance sheets represent a Level 3 instrument. See Note 8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The carrying values reported in the Company&#8217;s consolidated balance sheets for prepaid expenses and other current assets, due from related party, accounts payable and accrued expenses, accrued interest, short-term debt with related parties, due to research and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">development partner, due to related parties, settlement payable, and its deferred underwriting fee payable are reasonable estimates of their fair values due to the short-term nature of these items.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_WarrantsPolicyPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC 480, <i style="font-style:italic;">Distinguishing liabilities from equity</i> (&#8220;ASC 480&#8221;), and ASC 815, <i style="font-style:italic;">Derivatives and Hedging</i> (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance, modification, and as of each subsequent quarterly period end date while the warrants are outstanding. As of March 31, 2026, 13,813,000 of the Company&#8217;s Common Stock Warrants, 690,650 Placement Agent Warrants and 5,094,623 Public Warrants were accounted for as equity-classified instruments and 835,555 private placement warrants were accounted for as liability-classified instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the liability-classified warrants are recognized as a non-cash gain or loss on the accompanying condensed consolidated statements of operations. The Company assesses the classification of its warrants at each reporting date to determine whether a change in classification between equity and liability is required. During the three months ended March 31, 2026, the Company had an unrealized gain on the change in fair value of the warrant liabilities of $4,178. During the three months ended March 31, 2025, the Company had no unrealized gain or loss on the change in fair value of the warrant liabilities.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC 480, <i style="font-style:italic;">Distinguishing liabilities from equity</i> (&#8220;ASC 480&#8221;), and ASC 815, <i style="font-style:italic;">Derivatives and Hedging</i> (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance, modification, and as of each subsequent quarterly period end date while the warrants are outstanding. As of December 31, 2025, 5,899,975 of the Company&#8217;s Public Warrants were accounted for as equity-classified instruments and 835,555 private placement warrants were accounted for as liability-classified instruments. As of December 31, 2025, there were no other public or <span style="-sec-ix-hidden:Hidden_wUaYXsrirkKbOmu3ilr3Zg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">private</span></span> warrants outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the liability-classified warrants are recognized as a non-cash gain or loss on the accompanying consolidated statements of operations. The Company assesses the classification of its warrants at each reporting date to determine whether a change in classification between equity and liability is required. During the year ended December 31, 2025, the Company had an unrealized gain on the change in fair value of the warrant liabilities of $54,312. During the year ended December 31, 2024, the Company had no unrealized gain or loss on the change in fair value of the warrant liabilities. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock', window );">Net loss per Common Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss per Share of Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company complies with accounting and disclosure requirements of ASC Topic 260, <i style="font-style:italic;">Earnings Per Share</i>. The Company has one class of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities if their effect is antidilutive. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined by using the treasury stock method. Dilutive common stock equivalents are comprised of 19,598,273 warrants, comprised of 13,813,000 Common Stock Warrants, 690,650 Placement Agent Warrants and 5,094,623 Public Warrants. For all periods </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">presented, there is no difference in the number of shares used to calculated basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive given that their inclusion would reduce the net loss per share during the three months ended March 31, 2026 and 2025.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net loss per Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company complies with accounting and disclosure requirements of ASC Topic 260, <i style="font-style:italic;">Earnings Per Share</i>. The Company has one class of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities if their effect is antidilutive. Diluted net loss per share is computed by the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined by using the treasury stock method. Dilutive common stock equivalents are comprised of 6,735,530 warrants. For all periods presented, there is no difference in the number of shares used to calculated basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive given that their exercise price is greater than that of the average market price of the Company&#8217;s common stock during the years ended December 31, 2025 and 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of costs incurred by InnoBation Bio Co, Ltd. (&#8220;Innobation&#8221;) in accordance with the license agreement with Innobation and are recorded as research and development expenses as incurred (see Note 3).</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of costs incurred by Targeted Diagnostics &amp; Therapeutics, Inc. (&#8220;TDT&#8221;) who was performing the research and development activities for the Company in accordance with the license agreements with TDT and the annual fee paid to TDT and are recorded as research and development expenses as incurred (see Note 3).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes its leases in accordance with ASC Topic 842, <i style="font-style:italic;">Leases</i> (&#8220;ASC 842&#8221;). Under ASC 842, lessees are required to recognize all qualified operating leases at the commencement date including a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use (&#8220;ROU&#8221;) asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. The initial lease liability is equal to the future fixed minimum lease payments discounted using the Company&#8217;s incremental borrowing rate, on a secured basis. The lease term includes option renewal periods and early termination payments when it is reasonably certain that the Company will exercise those rights. The initial measurement of the ROU asset is equal to the initial lease liability plus any initial direct costs and prepayments, less any lease incentives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has leased office space for a fixed period of 10 months. In accordance with ASC 842, a short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The short-term lease election can only be made at the commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A lessee that makes this accounting policy election does not recognize a lease liability or right-of-use asset on its balance sheets. Instead, the lessee recognizes lease payments on a straight-line basis over the lease term.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes its leases in accordance with ASC Topic 842, <i style="font-style:italic;">Leases</i> (&#8220;ASC 842&#8221;). Under ASC 842, lessees are required to recognize all qualified operating leases at the commencement date including a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use (&#8220;ROU&#8221;) asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. The initial lease liability is equal to the future fixed minimum lease payments discounted using the Company&#8217;s incremental borrowing rate, on a secured basis. The lease term includes option renewal periods and early termination payments when it is reasonably certain that the Company will exercise those rights. The initial measurement of the ROU asset is equal to the initial lease liability plus any initial direct costs and prepayments, less any lease incentives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has leased office space for a fixed period of 10 months. In accordance with ASC 842, a short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The short-term lease election can only be made at the commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A lessee that makes this accounting policy election does not recognize a lease liability or right-of-use asset on its balance sheet. Instead, the lessee recognizes lease payments on a straight-line basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes in accordance with ASC Topic 740,&#160;<i style="font-style:italic;">Income Taxes</i>&#160;(&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. There were no tax accruals relating to uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax positions as income tax expense. There were no unrecognized tax positions, and no amounts accrued for interest and penalties as of March 31, 2026 and December 31, 2025. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only &#8220;major&#8221; tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. No unrecognized tax benefits were identified as of March 31, 2026 or December 31, 2025.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes in accordance with ASC Topic 740,&#160;<i style="font-style:italic;">Income Taxes</i>&#160;(&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. There were no tax accruals relating to uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax positions as income tax expense. There were no unrecognized tax positions, and no amounts accrued for interest and penalties as of December 31, 2025 and 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only &#8220;major&#8221; tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. No unrecognized tax benefits were identified as of December 31, 2025 or 2024.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements&#160;&#8211; Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On November 4, 2024, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2024-03, <i style="font-style:italic;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i> (&#8220;ASU 2024-03&#8221;), to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this standard will have on its unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#8217;s unaudited condensed consolidated financial statements.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The Company adopted this standard on January 1, 2025 and determined that the adoption does not have a material impact on these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements&#160;&#8211; Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2024, the FASB issued ASU 2024-03, Accounting Standards Update 2024-03, <i style="font-style:italic;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i> to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_EmergingGrowthCompanyPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policies on emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_EmergingGrowthCompanyPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of policy for net income (loss) per common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_WarrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_WarrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLoansAndLeasesReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLoansAndLeasesReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of debt outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:225.1pt;padding:0pt;"></td><td style="width:8.9pt;padding:0pt;"></td><td style="width:157.4pt;padding:0pt;"></td><td style="width:8.85pt;padding:0pt;"></td><td style="width:5.85pt;padding:0pt;"></td><td style="width:53.25pt;padding:0pt;"></td><td style="width:8.85pt;padding:0pt;"></td><td style="width:7pt;padding:0pt;"></td><td style="width:64.8pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:59.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:71.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2025</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo June 2023 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo July 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,500</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase May 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase July 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hana August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes November 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes January 2025 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,000</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short-term debt, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,442,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,442,500</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:202.45pt;padding:0pt;"></td><td style="width:13.39pt;padding:0pt;"></td><td style="width:162pt;padding:0pt;"></td><td style="width:12.85pt;padding:0pt;"></td><td style="width:8pt;padding:0pt;"></td><td style="width:60.5pt;padding:0pt;"></td><td style="width:12.86pt;padding:0pt;"></td><td style="width:8pt;padding:0pt;"></td><td style="width:59.95pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:149.3pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style="height:9.69pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Feelux Bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Car-Tcellkor Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 800,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ewon Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,000,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo June 2023 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo July 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo August 2023 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 400,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ewon September 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo November 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ewon December 2023 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,000,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valetudo January 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 750,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase April 2024 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase May 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 790,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase July 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hana August 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 850,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes November 2024 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700,000</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amantes January 2025 Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase February 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prophase March 2025 Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt, net, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short-term debt, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,442,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,973,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of fair value, assets and liabilities measured on recurring basis.</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:340.7pt;padding:0pt;"></td><td style="width:9.8pt;padding:0pt;"></td><td style="width:49.65pt;padding:0pt;"></td><td style="width:9.85pt;padding:0pt;"></td><td style="width:6.25pt;padding:0pt;"></td><td style="width:49.25pt;padding:0pt;"></td><td style="width:9.85pt;padding:0pt;"></td><td style="width:7.7pt;padding:0pt;"></td><td style="width:56.95pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:340.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:340.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:55.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2025</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:340.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:340.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:340.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,244</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:341.85pt;padding:0pt;"></td><td style="width:10.8pt;padding:0pt;"></td><td style="width:50.65pt;padding:0pt;"></td><td style="width:10.79pt;padding:0pt;"></td><td style="width:6.8pt;padding:0pt;"></td><td style="width:50.75pt;padding:0pt;"></td><td style="width:10.8pt;padding:0pt;"></td><td style="width:6.8pt;padding:0pt;"></td><td style="width:50.75pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:341.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:341.85pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:341.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:341.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:341.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Schedule of changes in fair value of Level 3 financial assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:360.05pt;padding:0pt;"></td><td style="width:11.39pt;padding:0pt;"></td><td style="width:7.15pt;padding:0pt;"></td><td style="width:53.4pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:60.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant&#160;liability</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of January 1, 2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 29,244</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,178</p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of March&#160;31,&#160;2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 33,422</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"><tr><td style="width:360.05pt;padding:0pt;"></td><td style="width:11.39pt;padding:0pt;"></td><td style="width:7.15pt;padding:0pt;"></td><td style="width:53.4pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.44pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:60.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant&#160;liability</b></p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style="height:11.49pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Initial measurement at the Closing Date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,556</p></td></tr><tr style="height:11.74pt;"><td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (54,312)</p></td></tr><tr style="height:12.49pt;"><td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 29,244</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets and  liability using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings  are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset and liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of income tax provision (benefit)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:399pt;padding:0pt;"></td><td style="width:12.65pt;padding:0pt;"></td><td style="width:8pt;padding:0pt;"></td><td style="width:49.9pt;padding:0pt;"></td><td style="width:12.64pt;padding:0pt;"></td><td style="width:8pt;padding:0pt;"></td><td style="width:49.81pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.49pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:128.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr style="height:9.74pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal</p></td><td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,604,745)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State and Local</p></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (741,028)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,345,773</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:12.54pt;"><td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision</p></td><td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of the effective income tax rate</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:304.85pt;padding:0pt;"></td><td style="width:10pt;padding:0pt;"></td><td style="width:42.4pt;padding:0pt;"></td><td style="width:13.35pt;padding:0pt;"></td><td style="width:6pt;padding:0pt;"></td><td style="width:49.2pt;padding:0pt;"></td><td style="width:10pt;padding:0pt;"></td><td style="width:42.45pt;padding:0pt;"></td><td style="width:13.35pt;padding:0pt;"></td><td style="width:6.05pt;padding:0pt;"></td><td style="width:42.35pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.49pt;"><td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:225.15pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style="height:9.74pt;"><td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:110.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:104.2pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,052,583)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_gt31aPXKykC4c-4bEt6laQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">State taxes, net of federal expense</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss on exchange of common stock for warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.74)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 365,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of common stock to be issued for contingent liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15.81)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,545,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.31)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,686</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 110,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:12.54pt;"><td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision expense/(benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of deferred tax assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="width:400.5pt;padding:0pt;"></td><td style="width:13.05pt;padding:0pt;"></td><td style="width:8.1pt;padding:0pt;"></td><td style="width:51.95pt;padding:0pt;"></td><td style="width:13.05pt;padding:0pt;"></td><td style="width:8.1pt;padding:0pt;"></td><td style="width:45.25pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.49pt;"><td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:126.45pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style="height:9.74pt;"><td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:60.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:53.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Startup expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,042,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Section 163(j) - Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.54pt;"><td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,345,773</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:11.79pt;"><td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,345,773)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style="height:12.54pt;"><td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax asset, net of valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Organization and Business Operations - Business Combination (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 01, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_SharesAuthorized', window );">Shares authorized | shares</a></td>
<td class="nump">501,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted | shares</a></td>
<td class="nump">112,222,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ConversionOfStockOrUnitConversionRatio', window );">Share conversion ratio</a></td>
<td class="nump">0.1559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from issuance of common stock for PIPE investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,585,308<span></span>
</td>
<td class="nump">$ 10,556,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares converted into | shares</a></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination', window );">Deferred underwriting fees payable</a></td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuableForSettlementOfDeferredUnderwritingFees', window );">Stock issuable for settlement of deferred underwriting fees | shares</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_LiabilityOfUnderwritingFeesFairValue', window );">Liability of underwriting fees</a></td>
<td class="nump">$ 7,049,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees', window );">Fair value of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,797,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=limn_FeeluxCo.LtdMember', window );">Feelux Co. Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares converted into | shares</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=limn_FeeluxAndCarTcellkorMember', window );">Feelux and Car-Tcellkor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ConversionOfPrincipalAndAccruedInterestShares', window );">Conversion of principal and accrued interest shares | shares</a></td>
<td class="nump">9,999,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ConversionOfPrincipalAndAccruedInterestAmount', window );">Conversion of principal and accrued interest amount</a></td>
<td class="nump">$ 11,481,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Total consideration</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from issuance of common stock for PIPE investment</a></td>
<td class="nump">10,556,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ProceedsFromIssuanceOfPrivatePlacementInvestor', window );">Proceeds from issuance of private placement investor</a></td>
<td class="nump">7,129,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded', window );">Proceeds from issuance of private placement investor funded</a></td>
<td class="nump">3,427,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_RelatedPartiesDebtToUnsecuredPromissoryNote', window );">Related parties debt</a></td>
<td class="nump">4,443,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_UnsecuredPromissoryNoteSettledAndConverted', window );">Unsecured promissory note settled and converted</a></td>
<td class="nump">4,443,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">3,427,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PrincipalAndAccruedInterestOnPrivatePlacement', window );">Principal and accrued interest</a></td>
<td class="nump">3,316,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ConsortiumLoanOfRelatedPartiesMember', window );">Consortium Loan of related parties | Private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">$ 4,443,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=limn_IrisAcquisitionHoldingsLlcMember', window );">Iris Acquisition Holdings, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares converted into | shares</a></td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=limn_IrisAcquisitionCorpMember', window );">Iris</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares converted into | shares</a></td>
<td class="nump">114,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Recognized liability assumed</a></td>
<td class="nump">$ 10,694,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="nump">1,518,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">14,797,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ConversionOfPrincipalAndAccruedInterestAmount', window );">Conversion of principal and accrued interest amount</a></td>
<td class="nump">11,481,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PrincipalAndAccruedInterestOnPrivatePlacement', window );">Principal and accrued interest</a></td>
<td class="nump">3,316,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ConversionOfAccruedInterestOnRelatedPartyDebts', window );">Accrued interest</a></td>
<td class="nump">$ 169,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=limn_IrisAcquisitionCorpMember', window );">Iris | Redeemable warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_NumberOfWarrantsHeldInEachUnit', window );">Number of warrants held in each unit | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=limn_IrisAcquisitionCorpMember', window );">Iris | Class A shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockCashRedemptionShares', window );">Shares redeemed | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockCashRedemptionPricePerShare', window );">Cash redemption price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockCashRedemptionAmount', window );">Aggregate cash redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 702,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_NumberOfSharesHeldInEachUnit', window );">Number of shares held in each unit | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted | shares</a></td>
<td class="nump">7,014,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ConversionOfStockOrUnitConversionRatio', window );">Share conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=limn_LiminatusAndIrisMember', window );">Liminatus and Iris</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockConversionRatioBusinessCombination', window );">Number of common shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=limn_LiminatusAndIrisMember', window );">Liminatus and Iris | Non-redeemable warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=limn_LiminatusAndIrisMember', window );">Liminatus and Iris | Class A shares | Non-redeemable warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_CommonStockCashRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash redemption of value of common stock of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_CommonStockCashRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_CommonStockCashRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the common stock of the entity is redeemed or may be called at.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_CommonStockCashRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_CommonStockCashRedemptionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of common shares redeemed for cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_CommonStockCashRedemptionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_CommonStockConversionRatioBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of common stock in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_CommonStockConversionRatioBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ConversionOfAccruedInterestOnRelatedPartyDebts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest on related party debts that were converted into common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ConversionOfAccruedInterestOnRelatedPartyDebts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ConversionOfPrincipalAndAccruedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of conversion of principal and accrued interest amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ConversionOfPrincipalAndAccruedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ConversionOfPrincipalAndAccruedInterestShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of conversion of principal and accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ConversionOfPrincipalAndAccruedInterestShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ConversionOfStockOrUnitConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock issuable upon conversion of each share of stock or unit to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ConversionOfStockOrUnitConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred underwriting fees liabilities of acquiree to be settled by way of issuance of common stock of the entity upon consummation of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of common shares issued for settlement of deferred underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_LiabilityOfUnderwritingFeesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability of underwriting fees fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_LiabilityOfUnderwritingFeesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_NumberOfSharesHeldInEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of common shares held in each Iris unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_NumberOfSharesHeldInEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_NumberOfWarrantsHeldInEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants held in each Iris unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_NumberOfWarrantsHeldInEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_PrincipalAndAccruedInterestOnPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal and accrued interest converted into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_PrincipalAndAccruedInterestOnPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ProceedsFromIssuanceOfPrivatePlacementInvestor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private placement investor rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ProceedsFromIssuanceOfPrivatePlacementInvestor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from private placement investor funded indirectly.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_RelatedPartiesDebtToUnsecuredPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowed from the related parties were used to fund an unsecured promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_RelatedPartiesDebtToUnsecuredPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_SharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of cumulative shares of all kinds permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_SharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuableForSettlementOfDeferredUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issuable for settlement of deferred underwriting fees in connection with the underwriting services provided by the underwriters in the initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuableForSettlementOfDeferredUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_UnsecuredPromissoryNoteSettledAndConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unsecured promissory note was settled and related party debts were ultimately converted into shares of the Company in a noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_UnsecuredPromissoryNoteSettledAndConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability assumed in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_FeeluxCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_FeeluxCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_FeeluxAndCarTcellkorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_FeeluxAndCarTcellkorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ConsortiumLoanOfRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ConsortiumLoanOfRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=limn_IrisAcquisitionHoldingsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=limn_IrisAcquisitionHoldingsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=limn_IrisAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=limn_IrisAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_RedeemableWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_RedeemableWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=limn_LiminatusAndIrisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=limn_LiminatusAndIrisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_NonRedeemableWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_NonRedeemableWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Organization and Business Operations - Liquidity and Capital Resources (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 19, 2026</div></th>
<th class="th"><div>Feb. 18, 2026</div></th>
<th class="th"><div>Feb. 17, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,907,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 337,655<span></span>
</td>
<td class="nump">$ 56,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">19,973,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,995,447)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,871,733)<span></span>
</td>
<td class="num">(28,665,216)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,100,898)<span></span>
</td>
<td class="num">$ (264,220)<span></span>
</td>
<td class="num">(2,967,812)<span></span>
</td>
<td class="num">(3,329,953)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,123,714)<span></span>
</td>
<td class="num">$ (327,526)<span></span>
</td>
<td class="num">$ (10,206,517)<span></span>
</td>
<td class="num">$ (3,546,309)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Pre-funded warrants (in shares)</a></td>
<td class="nump">1,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember', window );">Common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember', window );">Best efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember', window );">Best efforts | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,460,000<span></span>
</td>
<td class="nump">$ 3,460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember', window );">Best efforts | Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightIssuePricePerWarrant', window );">Offering price of pre-funded warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember', window );">Best efforts | Pre-funded warrants | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightIssuePricePerWarrant', window );">Offering price of pre-funded warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember', window );">Best efforts | Common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,813,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,719,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember', window );">Best efforts | Common stock purchase warrants | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Description of Organization and Business Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,813,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,719,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightIssuePricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per unit amount of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightIssuePricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightNumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">$ 33,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in the fair value of warrant liabilities</a></td>
<td class="nump">$ 4,178<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (54,312)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Incremental common shares</a></td>
<td class="nump">19,598,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,735,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForNotesAndLoansReceivableCurrent', window );">Credit losses relating to loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,401,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued</a></td>
<td class="nump">5,094,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,899,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Incremental common shares</a></td>
<td class="nump">5,094,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PrivatePlacementWarrantsMember', window );">Private placement warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued</a></td>
<td class="nump">835,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_FranchiseTaxExpenseIncludingInterestAndPenalty', window );">Franchise tax, penalties and interest</a></td>
<td class="nump">$ 60,500<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="nump">$ 202,833<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_FranchiseTaxExpenseIncludingInterestAndPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of franchise tax expense and related interest and penalties incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_FranchiseTaxExpenseIncludingInterestAndPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForNotesAndLoansReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on financing receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForNotesAndLoansReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-26<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, interest and penalties accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - CAR-T Products License (Details) - License And Development Agreement With TDT<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($) </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=limn_LicenseAndDevelopmentAgreementWithTdtMember', window );">CAR-T products and CAR-T Diagnostics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_UpfrontPaymentOfLicenseAgreementFees', window );">Upfront payment of license agreement fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Annual maintenance fees</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate', window );">Unpaid annual maintenance fees, short term debt interest rate (%)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_NumberOfMilestonePaymentsForFirstProductDevelopment', window );">Number of developmental and regulatory milestone payments for first product development | Milestone</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment', window );">Maximum aggregate milestone commitment fund for first product development</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment', window );">Number of developmental and regulatory milestone payments for each additional product development | Milestone</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment', window );">Maximum milestone commitment fund for each additional product development</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=limn_LicenseAndDevelopmentAgreementWithTdtMember', window );">CAR-T products and CAR-T Diagnostics | Net sales of period from first commercial sale until patent expires | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_RoyaltyFeesPercentage', window );">Percentage of royalty fees (%)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=limn_LicenseAndDevelopmentAgreementWithTdtMember', window );">CAR-T products and CAR-T Diagnostics | Net sales of period from first commercial sale until patent expires | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_RoyaltyFeesPercentage', window );">Percentage of royalty fees (%)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=limn_LicenseAndDevelopmentAgreementWithTdtMember', window );">CAR-T products and CAR-T Diagnostics | 10 years from first commercial sale of products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts', window );">Number of years from first commercial sale of products (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=limn_LicenseAndDevelopmentAgreementWithTdtMember', window );">CAR-T products and CAR-T Diagnostics | 10 years from first commercial sale of products | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_RoyaltyFeesPercentage', window );">Percentage of royalty fees (%)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=limn_LicenseAndDevelopmentAgreementWithTdtMember', window );">CAR-T products and CAR-T Diagnostics | 10 years from first commercial sale of products | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_RoyaltyFeesPercentage', window );">Percentage of royalty fees (%)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=limn_LicenseAndDevelopmentAgreementWithTdtMember', window );">Phase II and Phase III clinical trials of CAR-T Product | Prior to the completion of the Phase I and Phase II clinical trials for the CAR-T product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_LicenseMilestoneCommitmentFundPayableForEachPhase', window );">Amount of fund obligated to advance for each phase</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum aggregate milestone commitment fund for first product development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum milestone commitment fund for each additional product development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_LicenseMilestoneCommitmentFundPayableForEachPhase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of license milestone commitment fund obligated to pay for each phase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_LicenseMilestoneCommitmentFundPayableForEachPhase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of milestone developmental and regulatory milestone payments for each additional product development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_NumberOfMilestonePaymentsForFirstProductDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of milestone developmental and regulatory milestone payments for first product development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_NumberOfMilestonePaymentsForFirstProductDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of years from the first commercial sale of CAR-T product or CAR-T Diagnostic.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_RoyaltyFeesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_RoyaltyFeesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of interest rate of short-term debt being converted from the unpaid annual maintenance fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_UpfrontPaymentOfLicenseAgreementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payment of license agreement fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_UpfrontPaymentOfLicenseAgreementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=limn_LicenseAndDevelopmentAgreementWithTdtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=limn_LicenseAndDevelopmentAgreementWithTdtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Vaccine Products License (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 10, 2020 </div>
<div>USD ($) </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ForgivenessOfUnrelatedVendorPayable', window );">Forgiveness of unrelated vendor payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,142,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember', window );">Vaccine license and development agreement with TDT | Vaccine Products and Vaccine Diagnostics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_UpfrontPaymentOfLicenseAgreementFees', window );">Upfront payment of license agreement fees</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Annual maintenance fees</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_LicenseAgreementMaintenanceFees', window );">Maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate', window );">Unpaid annual maintenance fees, short term debt interest rate (%)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_NumberOfMilestonePaymentsForFirstProductDevelopment', window );">Number of developmental and regulatory milestone payments for first product development | Milestone</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment', window );">Maximum aggregate milestone commitment fund for first product development</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment', window );">Number of developmental and regulatory milestone payments for each additional product development | Milestone</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment', window );">Maximum milestone commitment fund for each additional product development</a></td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember', window );">Vaccine license and development agreement with TDT | Vaccine Products and Vaccine Diagnostics | Net sales of period from first commercial sale until patent expires | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_RoyaltyFeesPercentage', window );">Percentage of royalty fees (%)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember', window );">Vaccine license and development agreement with TDT | Vaccine Products and Vaccine Diagnostics | Net sales of period from first commercial sale until patent expires | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_RoyaltyFeesPercentage', window );">Percentage of royalty fees (%)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember', window );">Vaccine license and development agreement with TDT | Vaccine Products and Vaccine Diagnostics | 10 years from first commercial sale of products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts', window );">Number of years from first commercial sale of products (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember', window );">Vaccine license and development agreement with TDT | Vaccine Products and Vaccine Diagnostics | 10 years from first commercial sale of products | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_RoyaltyFeesPercentage', window );">Percentage of royalty fees (%)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember', window );">Vaccine license and development agreement with TDT | Vaccine Products and Vaccine Diagnostics | 10 years from first commercial sale of products | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_RoyaltyFeesPercentage', window );">Percentage of royalty fees (%)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=limn_CarTLicenseAndVaccineLicenseWithTdtMember', window );">CAR-T License and Vaccine License with TDT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ForgivenessOfUnrelatedVendorPayable', window );">Forgiveness of unrelated vendor payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,142,297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ForgivenessOfUnrelatedVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of forgiveness of unrelated vendor payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ForgivenessOfUnrelatedVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_LicenseAgreementMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of license agreement incurred in maintenance fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_LicenseAgreementMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum aggregate milestone commitment fund for first product development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum milestone commitment fund for each additional product development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of milestone developmental and regulatory milestone payments for each additional product development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_NumberOfMilestonePaymentsForFirstProductDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of milestone developmental and regulatory milestone payments for first product development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_NumberOfMilestonePaymentsForFirstProductDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of years from the first commercial sale of CAR-T product or CAR-T Diagnostic.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_RoyaltyFeesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_RoyaltyFeesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of interest rate of short-term debt being converted from the unpaid annual maintenance fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_UpfrontPaymentOfLicenseAgreementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payment of license agreement fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_UpfrontPaymentOfLicenseAgreementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=limn_VaccineProductsAndVaccineDiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=limn_VaccineProductsAndVaccineDiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=limn_CarTLicenseAndVaccineLicenseWithTdtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=limn_CarTLicenseAndVaccineLicenseWithTdtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License Agreements - Termination of license agreement (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=limn_CarTLicenseAndVaccineLicenseWithTdtMember', window );">CAR-T License and Vaccine License with TDT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_LicenseAgreementsTerminationAmountDue', window );">Amount owes pursuant to termination of license agreement</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,142,297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_LicenseAgreementsTerminationAmountDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount owes pursuant to termination of license agreements by TDT.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_LicenseAgreementsTerminationAmountDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=limn_CarTLicenseAndVaccineLicenseWithTdtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=limn_CarTLicenseAndVaccineLicenseWithTdtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License Agreements - CD47 License (Details) - CD47 License agreement with InnoBation - Curis Biotech Holdings LLC - Class A Member Units<br></strong></div></th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_NumberOfUnitsExchangeForLicenseRights', window );">Number of member units exchange for license rights to develop, market and sell YN1203, InnoBation Bio CAR NK biomarker | shares</a></td>
<td class="nump">78,555,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital', window );">Value of membership interest offset to additional paid-in capital | $</a></td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of membership interest exchange for license fees being offset to additional paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_NumberOfUnitsExchangeForLicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of member units exchanged as a consideration for license rights to develop, market and sell YN1203, InnoBation Bio CAR NK biomarkers, including devices, compounds and products used to detect analyte in body or tissue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_NumberOfUnitsExchangeForLicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_CurisBiotechHoldingsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_CurisBiotechHoldingsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Feelux Bonds (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Sep. 15, 2018</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="nump">$ 19,973,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 713,000<span></span>
</td>
<td class="nump">4,340,000<span></span>
</td>
<td class="nump">3,923,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,797,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock</a></td>
<td class="nump">112,222,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,921<span></span>
</td>
<td class="nump">955,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">19,973,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Feelux Co. Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock</a></td>
<td class="nump">9,999,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits', window );">Conversion of debt</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Feelux Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,666,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,499,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">$ 10,681,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">646,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Feelux Bonds | Expected stock volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Feelux Bonds | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Feelux Bonds | Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Feelux Bonds | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense relating to loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Feelux Bonds | Feelux Co. Ltd | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense relating to loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,023<span></span>
</td>
<td class="nump">$ 106,087<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_AccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_AccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued in exchange for original debt being and member units being converted in connection with the consummation of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_FeeluxCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_FeeluxCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_FeeluxBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_FeeluxBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions - Car-Tcellkor Loan (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>May 18, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="nump">$ 19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Car-Tcellkor Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Consumption of outstanding principal</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_CarTcellkorLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_CarTcellkorLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Valetudo Loans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 01, 2025</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="nump">$ 19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,921<span></span>
</td>
<td class="nump">955,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo Loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense relating to loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">42,208<span></span>
</td>
<td class="nump">96,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo Loan | Valetudo Therapeutics LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,308<span></span>
</td>
<td class="nump">115,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo December 2022 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_RepaymentOfMembershipInterest', window );">Repayment of membership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of debt</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo June 2023 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo June 2023 Loan One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of debt</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo June 2023 Loan Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo July 2023 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo August 2023 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo August 2023 Loan One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo August 2023 Loan Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo November 2023 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo January 2024 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo January 2024 Loan One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Valetudo January 2024 Loan Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_AccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_AccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_RepaymentOfMembershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of repayment of membership interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_RepaymentOfMembershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_ValetudoTherapeuticsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_ValetudoTherapeuticsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoDecember2022LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoDecember2022LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJune2023LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoJune2023LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJune2023LoanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoJune2023LoanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJune2023LoanTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoJune2023LoanTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJuly2023LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoJuly2023LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoAugust2023LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoAugust2023LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoAugust2023LoanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoAugust2023LoanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoAugust2023LoanTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoAugust2023LoanTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoNovember2023LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoNovember2023LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJanuary2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoJanuary2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJanuary2024LoanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoJanuary2024LoanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJanuary2024LoanTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoJanuary2024LoanTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Ewon Loans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 19, 2023</div></th>
<th class="th"><div>Sep. 10, 2023</div></th>
<th class="th"><div>Dec. 12, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="nump">$ 19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,797,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,921<span></span>
</td>
<td class="nump">955,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Ewon Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense relating to loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="nump">14,667<span></span>
</td>
<td class="nump">44,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Ewon Loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Ewon Loan | Ewon Comfortech Co Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">102,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Ewon December 2022 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Ewon September 2023 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Ewon December 2023 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_AccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_AccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_EwonLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_EwonLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_EwonComfortechCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_EwonComfortechCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_EwonDecember2022LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_EwonDecember2022LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_EwonSeptember2023LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_EwonSeptember2023LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_EwonDecember2023LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_EwonDecember2023LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Prophase Loans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>May 14, 2025</div></th>
<th class="th"><div>May 13, 2025</div></th>
<th class="th"><div>May 02, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Oct. 13, 2024</div></th>
<th class="th"><div>Oct. 12, 2024</div></th>
<th class="th"><div>Sep. 29, 2024</div></th>
<th class="th"><div>Sep. 24, 2024</div></th>
<th class="th"><div>Sep. 14, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Jul. 01, 2024</div></th>
<th class="th"><div>Jun. 01, 2024</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Apr. 01, 2024</div></th>
<th class="th"><div>Mar. 06, 2024</div></th>
<th class="th"><div>Feb. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="nump">$ 19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,797,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,921<span></span>
</td>
<td class="nump">955,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense relating to loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,138<span></span>
</td>
<td class="nump">$ 26,787<span></span>
</td>
<td class="nump">77,073<span></span>
</td>
<td class="nump">66,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase Loan | Prophase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742,500<span></span>
</td>
<td class="nump">1,623,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,283<span></span>
</td>
<td class="nump">66,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase February 2024 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,500<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">$ 168,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase March 2024 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase April 2024 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase May 2024 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="nump">790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 520,000<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="nump">$ 790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase July 2024 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase August 2024 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase February 2025 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase March 2025 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Prophase April 2025 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Amount borrowed</a></td>
<td class="nump">$ 3,627,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,506,880<span></span>
</td>
<td class="nump">$ 1,920,120<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">$ 3,627,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_AccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_AccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_ProphaseSciencesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_ProphaseSciencesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2024LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2024LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2024LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2024LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseApril2024LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseApril2024LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseMay2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseMay2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseJuly2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseJuly2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseAugust2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseAugust2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2025LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2025LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2025LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2025LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseApril2025LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseApril2025LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Hana Loans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="nump">$ 19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,797,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,921<span></span>
</td>
<td class="nump">955,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Hana Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense relating to loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="nump">$ 12,750<span></span>
</td>
<td class="nump">19,042<span></span>
</td>
<td class="nump">19,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Hana Loans | Maximum | Hana Immunotherapeutics, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,042<span></span>
</td>
<td class="nump">19,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Hana August 2024 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 850,000<span></span>
</td>
<td class="nump">$ 850,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_AccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_AccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_HanaLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_HanaLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_HanaImmunotherapeuticsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_HanaImmunotherapeuticsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_HanaAugust2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_HanaAugust2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Amantes Loans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 23, 2025</div></th>
<th class="th"><div>Jan. 02, 2025</div></th>
<th class="th"><div>Nov. 27, 2024</div></th>
<th class="th"><div>Nov. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="nump">$ 19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,797,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,921<span></span>
</td>
<td class="nump">955,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Amantes Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense relating to loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">$ 14,724<span></span>
</td>
<td class="nump">27,890<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Amantes Loans | Maximum | Amantes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_AccruedInterestCurrent', window );">Accrued interest, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,288<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Amantes November 2024 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">$ 550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Amantes January 2025 Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of related party short-term debt into common stock</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_AccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_AccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_AmantesLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_AmantesLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_AmantesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_AmantesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_AmantesNovember2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_AmantesNovember2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_AmantesJanuary2025LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_AmantesJanuary2025LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions - Due to Related Party (Details) - Related party - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">$ 194,587<span></span>
</td>
<td class="nump">$ 209,586<span></span>
</td>
<td class="nump">$ 195,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Employment Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">$ 194,587<span></span>
</td>
<td class="nump">$ 209,586<span></span>
</td>
<td class="nump">$ 195,253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=limn_EmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=limn_EmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Viral Gene (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_OtherReceivableWriteOff', window );">Uncollectible due from related party</a></td>
<td class="nump">$ 126,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Viral Gene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related party, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 126,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_OtherReceivableWriteOff', window );">Uncollectible due from related party</a></td>
<td class="nump">$ 126,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_OtherReceivableWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable deemed as uncollectible and written off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_OtherReceivableWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_ViralGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_ViralGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jan. 23, 2025</div></th>
<th class="th"><div>Jan. 02, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 27, 2024</div></th>
<th class="th"><div>Nov. 01, 2024</div></th>
<th class="th"><div>Oct. 13, 2024</div></th>
<th class="th"><div>Oct. 12, 2024</div></th>
<th class="th"><div>Sep. 29, 2024</div></th>
<th class="th"><div>Sep. 24, 2024</div></th>
<th class="th"><div>Sep. 14, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Aug. 01, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Jul. 01, 2024</div></th>
<th class="th"><div>Jun. 01, 2024</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Apr. 01, 2024</div></th>
<th class="th"><div>Mar. 06, 2024</div></th>
<th class="th"><div>Feb. 26, 2024</div></th>
<th class="th"><div>Dec. 19, 2023</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Sep. 10, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>May 18, 2019</div></th>
<th class="th"><div>Sep. 15, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="nump">$ 1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">1,442,500<span></span>
</td>
<td class="nump">1,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_FeeluxBondsMember', window );">Feelux Bonds | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_CarTcellkorLoanMember', window );">Car-Tcellkor Loan | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_EwonLoanMember', window );">Ewon Loan | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ValetudoDecember2022LoansMember', window );">Valetudo Loan | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJune2023LoansMember', window );">Valetudo June 2023 Loans | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJuly2023LoanMember', window );">Valetudo July 2023 Loan | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ValetudoAugust2023LoansMember', window );">Valetudo August 2023 Loans | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_EwonSeptember2023LoanMember', window );">Ewon September 2023 Loan | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ValetudoNovember2023LoanMember', window );">Valetudo November 2023 Loan | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_EwonDecember2023LoanMember', window );">Ewon December 2023 Loan | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJanuary2024LoansMember', window );">Valetudo January 2024 Loans | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2024LoanMember', window );">Prophase February 2024 Loan | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">31,500<span></span>
</td>
<td class="nump">31,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2024LoanMember', window );">Prophase March 2024 Loan | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ProphaseApril2024LoanMember', window );">Prophase April 2024 Loan | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ProphaseMay2024LoansMember', window );">Prophase May 2024 Loans | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 520,000<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="nump">$ 790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ProphaseJuly2024LoansMember', window );">Prophase July 2024 Loans | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">83,000<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ProphaseAugust2024LoansMember', window );">Prophase August 2024 Loans | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_HanaAugust2024LoansMember', window );">Hana August 2024 Loans | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_AmantesNovember2024LoansMember', window );">Amantes November 2024 Loans | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_AmantesJanuary2025LoansMember', window );">Amantes January 2025 Loans | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2025LoanMember', window );">Prophase February 2025 Loan | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">81,000<span></span>
</td>
<td class="nump">81,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2025LoanMember', window );">Prophase March 2025 Loan | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, related parties</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_FeeluxBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_FeeluxBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_CarTcellkorLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_CarTcellkorLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_EwonLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_EwonLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoDecember2022LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoDecember2022LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJune2023LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoJune2023LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJuly2023LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoJuly2023LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoAugust2023LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoAugust2023LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_EwonSeptember2023LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_EwonSeptember2023LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoNovember2023LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoNovember2023LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_EwonDecember2023LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_EwonDecember2023LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ValetudoJanuary2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ValetudoJanuary2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2024LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2024LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2024LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2024LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseApril2024LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseApril2024LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseMay2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseMay2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseJuly2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseJuly2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseAugust2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseAugust2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_HanaAugust2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_HanaAugust2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_AmantesNovember2024LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_AmantesNovember2024LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_AmantesJanuary2025LoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_AmantesJanuary2025LoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2025LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseFebruary2025LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2025LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=limn_ProphaseMarch2025LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 16, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>D </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>D </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 01, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination', window );">Deferred underwriting fees liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuableForSettlementOfDeferredUnderwritingFees', window );">Stock issuable for settlement of deferred underwriting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees', window );">Fair value of common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_GainLossOnIssuanceOfCommonStockForWarrants', window );">Loss on issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,740,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,877,633<span></span>
</td>
<td class="nump">27,064,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,877,633<span></span>
</td>
<td class="nump">27,064,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockNumberOfVotesPerShare', window );">Number of votes per share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=limn_AltaPartnersLlcMember', window );">Alta Partners Llc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_SharesIssuedForSurrenderAndCancellationOfWarrants', window );">Number of shares issued for surrender and cancellation of warrants</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled', window );">Surrender and cancellation of warrants to purchase shares of common stock</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_FairValueOfCommonStockIssued', window );">Fair value of common stock | $</a></td>
<td class="nump">$ 1,890,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_FairValueOfWarrantsSurrendered', window );">Fair value of warrants surrendered | $</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_GainLossOnIssuanceOfCommonStockForWarrants', window );">Loss on issuance of common stock | $</a></td>
<td class="num">$ (1,740,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,094,623<span></span>
</td>
<td class="nump">5,899,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants', window );">Threshold written notice period for redemption of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption', window );">Threshold Share Price for redemption of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays', window );">Threshold number of specified trading days for stock price | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays', window );">Threshold number of specified consecutive trading days for stock price | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PrivatePlacementWarrantsMember', window );">Private placement warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835,555<span></span>
</td>
<td class="nump">835,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants surrendered and canceled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days for stock price trigger considered for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The threshold trigger price for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The threshold period during which a written notice is required for redemption of warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_CommonStockNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of votes for each share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_CommonStockNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred underwriting fees liabilities of acquiree to be settled by way of issuance of common stock of the entity upon consummation of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of common shares issued for settlement of deferred underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_FairValueOfCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_FairValueOfCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_FairValueOfWarrantsSurrendered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of warrants surrendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_FairValueOfWarrantsSurrendered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_GainLossOnIssuanceOfCommonStockForWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit or loss on exchange of common stock for surrender of warrants classified as non-operating income. Represents the difference in the fair value of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_GainLossOnIssuanceOfCommonStockForWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_SharesIssuedForSurrenderAndCancellationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for surrender and cancellation of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_SharesIssuedForSurrenderAndCancellationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuableForSettlementOfDeferredUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issuable for settlement of deferred underwriting fees in connection with the underwriting services provided by the underwriters in the initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuableForSettlementOfDeferredUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_AltaPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_AltaPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 06, 2026</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 27, 2025</div></th>
<th class="th"><div>Jul. 01, 2025</div></th>
<th class="th"><div>Oct. 11, 2023</div></th>
<th class="th"><div>Oct. 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,784<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockPayable', window );">Settlement payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination', window );">Deferred underwriting fees settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination', window );">Deferred underwriting fee payable settled in shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination', window );">Deferred underwriting fee payable settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination', window );">Deferred underwriting fee waived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering', window );">Remaining amount of deferred underwriting fee settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination', window );">Threshold period for settling remaining deferred underwriting fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingFeesPayableInCashCurrent', window );">Deferred underwriting fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination', window );">Deferred underwriting fees liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StockIssuableForSettlementOfDeferredUnderwritingFees', window );">Stock issuable for settlement of deferred underwriting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees', window );">Fair value of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=limn_ClearStreetLlcMember', window );">Clear Street Llc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_SharesIssuedForSurrenderAndCancellationOfWarrants', window );">Issuance of common stock in connection with the surrender of warrants (in shares)</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled', window );">Surrender and cancellation of warrants to purchase shares of common stock</a></td>
<td class="nump">805,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockPayable', window );">Settlement payable</a></td>
<td class="nump">$ 7,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">7,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Loss contingency on damaged value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementInterest', window );">Litigation settlement interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=limn_ClearStreetLlcMember', window );">Clear Street Llc | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_SharesIssuedForSurrenderAndCancellationOfWarrants', window );">Issuance of common stock in connection with the surrender of warrants (in shares)</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled', window );">Surrender and cancellation of warrants to purchase shares of common stock</a></td>
<td class="nump">805,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockPayable', window );">Settlement payable</a></td>
<td class="nump">$ 7,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=limn_IrisAcquisitionCorpMember', window );">Iris</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering', window );">Underwriting discount (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_UnderwritingCostsNoncurrent', window );">Underwriting discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,520,000<span></span>
</td>
<td class="nump">5,520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering', window );">Deferred underwriting discount (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredOfferingCostsNoncurrent', window );">Deferred underwriting discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,660,000<span></span>
</td>
<td class="nump">$ 9,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=limn_FeeReductionAgreementMember', window );">Fee Reduction Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_MaximumNumbersOfSharesIssuable', window );">Number of shares issuable to underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=limn_FeeReductionAgreementMember', window );">Fee Reduction Agreement | Iris</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredOfferingCostsNoncurrent', window );">Deferred underwriting discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="nump">$ 9,660,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PaymentOfOfferingCostsInCash', window );">Underwriting discount paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_UnderwritingDiscountPaidInSecurities', window );">Underwriting discount paid in securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants surrendered and canceled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_CommonStockPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_CommonStockPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredOfferingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredOfferingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of deferred underwriting discount on gross proceeds of the IPO.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred underwriting fee payable settled in cash upon consummation of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred underwriting fee payable settled in shares upon consummation of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred underwriting fee payable settled upon consummation of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amount of deferred underwriting fee settled upon consummation of combined company next share offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred underwriting fee waived upon consummation of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingFeesPayableInCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred underwriting fees payable in cash and are classified as current as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingFeesPayableInCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred underwriting fees liabilities of acquiree to be settled by way of issuance of common stock of the entity upon consummation of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of common shares issued for settlement of deferred underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_MaximumNumbersOfSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares issuable to underwriters.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_MaximumNumbersOfSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_PaymentOfOfferingCostsInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount paid in cash for offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_PaymentOfOfferingCostsInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_SharesIssuedForSurrenderAndCancellationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for surrender and cancellation of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_SharesIssuedForSurrenderAndCancellationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StockIssuableForSettlementOfDeferredUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issuable for settlement of deferred underwriting fees in connection with the underwriting services provided by the underwriters in the initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StockIssuableForSettlementOfDeferredUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold period for settling remaining deferred underwriting fee from the date of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_UnderwritingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the carrying value as of balance sheet date of underwriting fees payable or classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_UnderwritingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of underwriting discount on gross proceeds of the IPO.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_UnderwritingDiscountPaidInSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount paid in shares for offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_UnderwritingDiscountPaidInSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense (income) directly attributable to an award in settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_ClearStreetLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_ClearStreetLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=limn_IrisAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=limn_IrisAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=limn_FeeReductionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=limn_FeeReductionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Warrant liability</a></td>
<td class="nump">$ 33,422<span></span>
</td>
<td class="nump">$ 29,244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Changes in fair value of Level 3 (Details) - Fair value inputs level 3 - Warrants - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance, fair value</a></td>
<td class="nump">$ 29,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Initial measurement at the Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="nump">4,178<span></span>
</td>
<td class="num">(54,312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance, fair value</a></td>
<td class="nump">$ 33,422<span></span>
</td>
<td class="nump">$ 29,244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">$ 2,345,773<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ResearchAndDevelopmentExpenseMandatoryCapitalization', window );">Research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">822,963<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_FederalIncomeTaxExpenseSubjectToLimitationInUse', window );">Federal income tax liabilities, subject limitations</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_StatutoryStateIncomeTaxRate', window );">California income tax rate</a></td>
<td class="nump">8.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income tax obligations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_FederalIncomeTaxExpenseSubjectToLimitationInUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_FederalIncomeTaxExpenseSubjectToLimitationInUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ResearchAndDevelopmentExpenseMandatoryCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of research and development expense subject to mandatory capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ResearchAndDevelopmentExpenseMandatoryCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_StatutoryStateIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of state statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_StatutoryStateIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income tax provision (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Federal</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="num">$ (1,604,745)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State and Local</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="num">(741,028)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">$ 2,345,773<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of income tax rate (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal expense</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent', window );">Loss on exchange of common stock for warrants</a></td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent', window );">Fair value of common stock to be issued for contingent liability</a></td>
<td class="nump">15.81%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other permanent differences</a></td>
<td class="num">(0.31%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(1.14%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax provision expense/(benefit)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="num">$ (2,052,583)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration', window );">Effective Income Tax Rate Reconciliation, State and Local Jurisdiction, Contribution Greater than 50 Percent, Tax Effect [Extensible Enumeration]</a></td>
<td class="text">country:CA<span></span>
</td>
<td class="text">country:CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount', window );">Loss on exchange of common stock for warrants</a></td>
<td class="nump">$ 365,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount', window );">Fair value of common stock to be issued for contingent liability</a></td>
<td class="nump">1,545,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other permanent differences</a></td>
<td class="nump">30,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 110,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value of common stock to be issued for contingent liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value of common stock to be issued for contingent liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to gain (loss) on exchange of common stock for warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to gain loss on exchange of common stock for warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates name of state or local jurisdiction that makes up greater than 50 percent of effect of state and local income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred tax assets and liabilities (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 230,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_DeferredTaxAssetsStartupExpenses', window );">Startup expenses</a></td>
<td class="nump">2,042,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Section 163(j) - Interest</a></td>
<td class="nump">72,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">2,345,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">$ (2,345,773)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_DeferredTaxAssetsStartupExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from startup expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_DeferredTaxAssetsStartupExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 20, 2026</div></th>
<th class="th"><div>Feb. 19, 2026</div></th>
<th class="th"><div>Feb. 18, 2026</div></th>
<th class="th"><div>Feb. 17, 2026</div></th>
<th class="th"><div>Feb. 06, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockPayable', window );">Settlement payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember', window );">Best efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate', window );">Period of non issuance of common stock following closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate', window );">Period of non issuance of common stock involving variable rate transaction following closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PlacementAgentCashFeePercentage', window );">Placement agent fee, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_MaximumReimbursementForPlacementAgentExpenses', window );">Placement agent fee, maximum reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember', window );">Pre-funded warrants | Best efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightIssuePricePerWarrant', window );">Offering price of pre-funded warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember', window );">Common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember', window );">Common stock purchase warrants | Best efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,813,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,719,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PlacementAgentWarrantsMember', window );">Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PlacementAgentWarrantsMember', window );">Placement Agent Warrants | Best efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PercentOfSharesIssuedInOffering', window );">Percent of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PercentOfOfferingPriceRepresentingExercisePrice', window );">Percent of offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=limn_ClearStreetLlcMember', window );">Clear Street Llc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_SharesIssuedForSurrenderAndCancellationOfWarrants', window );">Number of shares issued for surrender and cancellation of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled', window );">Surrender and cancellation of warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockPayable', window );">Settlement payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,360,000<span></span>
</td>
<td class="nump">$ 7,360,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Loss contingency on damaged value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementInterest', window );">Litigation settlement interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 515,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=limn_InnobationBioCo.LtdMember', window );">Innobation Bio Co. Ltd | CD47 License agreement with InnoBation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PaymentForCostsAssociatedWithClinicalTrials', window );">Company issued a payment</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Best efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate', window );">Period of non issuance of common stock following closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate', window );">Period of non issuance of common stock involving variable rate transaction following closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PlacementAgentCashFeePercentage', window );">Placement agent fee, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_MaximumReimbursementForPlacementAgentExpenses', window );">Placement agent fee, maximum reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,460,000<span></span>
</td>
<td class="nump">$ 3,460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pre-funded warrants | Best efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightIssuePricePerWarrant', window );">Offering price of pre-funded warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common stock purchase warrants | Best efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,813,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,719,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Placement Agent Warrants | Best efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PercentOfSharesIssuedInOffering', window );">Percent of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PercentOfOfferingPriceRepresentingExercisePrice', window );">Percent of offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Clear Street Llc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_SharesIssuedForSurrenderAndCancellationOfWarrants', window );">Number of shares issued for surrender and cancellation of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled', window );">Surrender and cancellation of warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_CommonStockPayable', window );">Settlement payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Innobation Bio Co. Ltd | CD47 License agreement with InnoBation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_limn_PaymentForCostsAssociatedWithClinicalTrials', window );">Company issued a payment</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightIssuePricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per unit amount of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightIssuePricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants surrendered and canceled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_ClassOfWarrantOrRightNumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_ClassOfWarrantOrRightNumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_CommonStockPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_CommonStockPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_MaximumReimbursementForPlacementAgentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum out-of-pocket costs and expenses incurred in connection with the Offering that will be reimbursed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_MaximumReimbursementForPlacementAgentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_PaymentForCostsAssociatedWithClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment made for costs associated with clinical trials.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_PaymentForCostsAssociatedWithClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_PercentOfOfferingPriceRepresentingExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the public offering price for the shares of common stock and common warrants offered in the Offering representing exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_PercentOfOfferingPriceRepresentingExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_PercentOfSharesIssuedInOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock sold in the offering, threshold percentage on the total number of outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_PercentOfSharesIssuedInOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period during which shares will not be issued after the closing date of the offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period during which common stock or any securities convertible into or exercisable or exchangeable for shares of common stock involving a variable rate transaction will not be issued after the closing date of the offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_PlacementAgentCashFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of cash fee for placement agent, calculated on aggregate gross proceeds raised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_PlacementAgentCashFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_limn_SharesIssuedForSurrenderAndCancellationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for surrender and cancellation of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">limn_SharesIssuedForSurrenderAndCancellationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>limn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense (income) directly attributable to an award in settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=limn_BestEffortsPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_CommonStockPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=limn_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=limn_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_ClearStreetLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_ClearStreetLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=limn_InnobationBioCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=limn_InnobationBioCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Jun. 22, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001971387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">Liminatus Pharma, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings - Offering: 1<br></strong></div></th>
<th class="th">
<div>Jun. 22, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Shares of common stock, par value $0.0001 per share, underlying the common warrants<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">20,688,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit</a></td>
<td class="nump">0.1183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 2,447,390.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 337.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended, based upon the average of the high and low sale price of the Registrant's common stock on June 18, 2026, as reported in The Nasdaq Stock Market.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesOthrRuleFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesOthrRuleFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Jun. 22, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 2,447,390.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">337.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 337.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>328</ContextCount>
  <ElementCount>299</ElementCount>
  <EntityCount>2</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>96</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1100090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1100100 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1100105 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1100200 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1100300 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1100305 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficit (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Deficit (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1100400 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1110101 - Disclosure - Description of Organization and Business Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations</Role>
      <ShortName>Description of Organization and Business Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1110201 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1110301 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureLicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1110401 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1110501 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1110601 - Disclosure - Stockholder's Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureStockholderSEquity</Role>
      <ShortName>Stockholder's Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1110701 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1110801 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1110901 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1120202 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1130503 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.liminatuspharma.com/role/DisclosureDebt</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1130603 - Disclosure - Stockholder's Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureStockholderSEquityTables</Role>
      <ShortName>Stockholder's Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.liminatuspharma.com/role/DisclosureStockholderSEquity</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1130803 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.liminatuspharma.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1140101 - Disclosure - Description of Organization and Business Operations - Business Combination (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails</Role>
      <ShortName>Description of Organization and Business Operations - Business Combination (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1140102 - Disclosure - Description of Organization and Business Operations - February 2026 Public Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails</Role>
      <ShortName>Description of Organization and Business Operations - February 2026 Public Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1140103 - Disclosure - Description of Organization and Business Operations - Liquidity and Capital Resources (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails</Role>
      <ShortName>Description of Organization and Business Operations - Liquidity and Capital Resources (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1140201 - Disclosure - Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1140202 - Disclosure - Significant Accounting Policies - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetails</Role>
      <ShortName>Significant Accounting Policies - Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1140301 - Disclosure - License Agreements - CD47 License (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails</Role>
      <ShortName>License Agreements - CD47 License (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1140401 - Disclosure - Related Party Transactions - Feelux Bonds (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails</Role>
      <ShortName>Related Party Transactions - Feelux Bonds (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1140402 - Disclosure - Related Party Transactions - Car-Tcellkor Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails</Role>
      <ShortName>Related Party Transactions - Car-Tcellkor Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1140403 - Disclosure - Related Party Transactions - Valetudo Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails</Role>
      <ShortName>Related Party Transactions - Valetudo Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1140404 - Disclosure - Related Party Transactions - Ewon Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails</Role>
      <ShortName>Related Party Transactions - Ewon Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1140405 - Disclosure - Related Party Transactions - Prophase Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails</Role>
      <ShortName>Related Party Transactions - Prophase Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1140406 - Disclosure - Related Party Transactions - Hana Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails</Role>
      <ShortName>Related Party Transactions - Hana Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1140407 - Disclosure - Related Party Transactions - Amantes Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails</Role>
      <ShortName>Related Party Transactions - Amantes Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1140408 - Disclosure - Related Party Transactions - Due to Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails</Role>
      <ShortName>Related Party Transactions - Due to Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1140501 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureDebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.liminatuspharma.com/role/DisclosureDebtTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1140601 - Disclosure - Stockholder's Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails</Role>
      <ShortName>Stockholder's Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.liminatuspharma.com/role/DisclosureStockholderSEquityTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1140602 - Disclosure - Stockholder's Equity - Assumptions used for estimating fair value of warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails</Role>
      <ShortName>Stockholder's Equity - Assumptions used for estimating fair value of warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1140603 - Disclosure - Stockholder's Equity - Offering proceeds and related issuance costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails</Role>
      <ShortName>Stockholder's Equity - Offering proceeds and related issuance costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1140701 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1140801 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1140802 - Disclosure - Fair Value Measurements - Changes in fair value of Level 3 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details</Role>
      <ShortName>Fair Value Measurements - Changes in fair value of Level 3 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1200100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1200105 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1200200 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1200300 - Statement - Consolidated Statements of Changes in Stockholder's Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Stockholder's Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1200400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1210101 - Disclosure - Description of Organization and Business Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationss</Role>
      <ShortName>Description of Organization and Business Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1210201 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciess</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1210301 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureLicenseAgreementss</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1210401 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionss</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1210501 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureDebts</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1210601 - Disclosure - Stockholder's Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureStockholderSEquitys</Role>
      <ShortName>Stockholder's Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1210701 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciess</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1210801 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementss</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1210901 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1211001 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureSubsequentEventss</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1220202 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1230503 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureDebtTabless</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.liminatuspharma.com/role/DisclosureDebt</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1230803 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTabless</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.liminatuspharma.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1230903 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.liminatuspharma.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1240101 - Disclosure - Description of Organization and Business Operations - Business Combination (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss</Role>
      <ShortName>Description of Organization and Business Operations - Business Combination (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1240102 - Disclosure - Description of Organization and Business Operations - Liquidity and Capital Resources (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss</Role>
      <ShortName>Description of Organization and Business Operations - Liquidity and Capital Resources (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1240201 - Disclosure - Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1240202 - Disclosure - Significant Accounting Policies - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetailss</Role>
      <ShortName>Significant Accounting Policies - Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1240301 - Disclosure - License Agreements - CAR-T Products License (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails</Role>
      <ShortName>License Agreements - CAR-T Products License (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1240302 - Disclosure - License Agreements - Vaccine Products License (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails</Role>
      <ShortName>License Agreements - Vaccine Products License (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1240303 - Disclosure - License Agreements - Termination of license agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails</Role>
      <ShortName>License Agreements - Termination of license agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1240304 - Disclosure - License Agreements - CD47 License (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss</Role>
      <ShortName>License Agreements - CD47 License (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1240401 - Disclosure - Related Party Transactions - Feelux Bonds (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss</Role>
      <ShortName>Related Party Transactions - Feelux Bonds (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1240402 - Disclosure - Related Party Transactions - Car-Tcellkor Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss</Role>
      <ShortName>Related Party Transactions - Car-Tcellkor Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1240403 - Disclosure - Related Party Transactions - Valetudo Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss</Role>
      <ShortName>Related Party Transactions - Valetudo Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1240404 - Disclosure - Related Party Transactions - Ewon Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss</Role>
      <ShortName>Related Party Transactions - Ewon Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1240405 - Disclosure - Related Party Transactions - Prophase Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss</Role>
      <ShortName>Related Party Transactions - Prophase Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1240406 - Disclosure - Related Party Transactions - Hana Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss</Role>
      <ShortName>Related Party Transactions - Hana Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1240407 - Disclosure - Related Party Transactions - Amantes Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss</Role>
      <ShortName>Related Party Transactions - Amantes Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1240408 - Disclosure - Related Party Transactions - Due to Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss</Role>
      <ShortName>Related Party Transactions - Due to Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1240409 - Disclosure - Related Party Transactions - Viral Gene (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails</Role>
      <ShortName>Related Party Transactions - Viral Gene (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1240501 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureDebtDetailss</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.liminatuspharma.com/role/DisclosureDebtTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1240601 - Disclosure - Stockholder's Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss</Role>
      <ShortName>Stockholder's Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.liminatuspharma.com/role/DisclosureStockholderSEquityTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>1240701 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>1240801 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>1240802 - Disclosure - Fair Value Measurements - Changes in fair value of Level 3 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss</Role>
      <ShortName>Fair Value Measurements - Changes in fair value of Level 3 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>1240901 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.liminatuspharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>1240902 - Disclosure - Income Taxes - Income tax provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetails</Role>
      <ShortName>Income Taxes - Income tax provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>1240903 - Disclosure - Income Taxes - Reconciliation of income tax rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of income tax rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>1240904 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="limn-20260331xs1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>1241001 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.liminatuspharma.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="limn-20260331xexfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="limn-20260331xexfees.htm">
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="limn-20260331xexfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>limn-20260331.xsd</File>
    <File>limn-20260331_cal.xml</File>
    <File>limn-20260331_def.xml</File>
    <File>limn-20260331_lab.xml</File>
    <File>limn-20260331_pre.xml</File>
    <File doctype="S-1" isDefinitelyFs="true" isUsgaap="true" original="limn-20260331xs1.htm">limn-20260331xs1.htm</File>
    <File doctype="EX-FILING FEES" original="limn-20260331xexfees.htm">limn-20260331xexfees.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>limn-20260331xs1002.jpg</File>
    <File>limn-20260331xs1003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="876">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="3">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/ffd/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>112
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "limn-20260331xs1.htm": {
   "nsprefix": "limn",
   "nsuri": "http://www.liminatuspharma.com/20260331",
   "dts": {
    "schema": {
     "local": [
      "limn-20260331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "limn-20260331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "limn-20260331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "limn-20260331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "limn-20260331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "limn-20260331xs1.htm"
     ]
    }
   },
   "keyStandard": 158,
   "keyCustom": 118,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 19,
   "memberCustom": 76,
   "hidden": {
    "total": 27,
    "http://fasb.org/us-gaap/2025": 22,
    "http://www.liminatuspharma.com/20260331": 3,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 326,
   "entityCount": 1,
   "segmentCount": 95,
   "elementCount": 466,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 876,
    "http://xbrl.sec.gov/dei/2025": 8
   },
   "report": {
    "R1": {
     "role": "http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation",
     "longName": "1100090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
     "longName": "1100100 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:Cash",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
     "longName": "1100105 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "us-gaap:PreferredStockSharesOutstanding",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "longName": "1100200 - Statement - Condensed Consolidated Statements of Operations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
     "longName": "1100300 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficit",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HFF_MgUngEePnxJ9ysVB6Q",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0P2Hk6Fm0UCfvB5hIDbvbw",
      "name": "limn:StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants",
      "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical",
     "longName": "1100305 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficit (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Deficit (Parenthetical)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "limn:OfferingCosts",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "longName": "1100400 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations",
     "longName": "1110101 - Disclosure - Description of Organization and Business Operations",
     "shortName": "Description of Organization and Business Operations",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPolicies",
     "longName": "1110201 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://www.liminatuspharma.com/role/DisclosureLicenseAgreements",
     "longName": "1110301 - Disclosure - License Agreements",
     "shortName": "License Agreements",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "limn:LicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R11": {
     "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactions",
     "longName": "1110401 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R12": {
     "role": "http://www.liminatuspharma.com/role/DisclosureDebt",
     "longName": "1110501 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R13": {
     "role": "http://www.liminatuspharma.com/role/DisclosureStockholderSEquity",
     "longName": "1110601 - Disclosure - Stockholder's Equity",
     "shortName": "Stockholder's Equity",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R14": {
     "role": "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "1110701 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R15": {
     "role": "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurements",
     "longName": "1110801 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R16": {
     "role": "http://www.liminatuspharma.com/role/DisclosureSubsequentEvents",
     "longName": "1110901 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R17": {
     "role": "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "1120202 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R18": {
     "role": "http://www.liminatuspharma.com/role/DisclosureDebtTables",
     "longName": "1130503 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R19": {
     "role": "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityTables",
     "longName": "1130603 - Disclosure - Stockholder's Equity (Tables)",
     "shortName": "Stockholder's Equity (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTables",
     "longName": "1130803 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
     "longName": "1140101 - Disclosure - Description of Organization and Business Operations - Business Combination (Details)",
     "shortName": "Description of Organization and Business Operations - Business Combination (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
     "longName": "1140102 - Disclosure - Description of Organization and Business Operations - February 2026 Public Offering (Details)",
     "shortName": "Description of Organization and Business Operations - February 2026 Public Offering (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R23": {
     "role": "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
     "longName": "1140103 - Disclosure - Description of Organization and Business Operations - Liquidity and Capital Resources (Details)",
     "shortName": "Description of Organization and Business Operations - Liquidity and Capital Resources (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:Cash",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "1140201 - Disclosure - Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_JogJT3JKnkStw7CCF--1Dw",
      "name": "us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
      "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "limn:NetIncomeLossPerCommonStockPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetails",
     "longName": "1140202 - Disclosure - Significant Accounting Policies - Income Taxes (Details)",
     "shortName": "Significant Accounting Policies - Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R26": {
     "role": "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails",
     "longName": "1140301 - Disclosure - License Agreements - CD47 License (Details)",
     "shortName": "License Agreements - CD47 License (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2026_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_tzr9osJ2S0C-6yY56Bt5Ug",
      "name": "limn:EstimatedPercentageOfActivitiesCompleted",
      "unitRef": "Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "limn:LicenseAgreementsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
     "longName": "1140401 - Disclosure - Related Party Transactions - Feelux Bonds (Details)",
     "shortName": "Related Party Transactions - Feelux Bonds (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R28": {
     "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails",
     "longName": "1140402 - Disclosure - Related Party Transactions - Car-Tcellkor Loan (Details)",
     "shortName": "Related Party Transactions - Car-Tcellkor Loan (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
     "longName": "1140403 - Disclosure - Related Party Transactions - Valetudo Loans (Details)",
     "shortName": "Related Party Transactions - Valetudo Loans (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
     "longName": "1140404 - Disclosure - Related Party Transactions - Ewon Loans (Details)",
     "shortName": "Related Party Transactions - Ewon Loans (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
     "longName": "1140405 - Disclosure - Related Party Transactions - Prophase Loans (Details)",
     "shortName": "Related Party Transactions - Prophase Loans (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R32": {
     "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
     "longName": "1140406 - Disclosure - Related Party Transactions - Hana Loans (Details)",
     "shortName": "Related Party Transactions - Hana Loans (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
     "longName": "1140407 - Disclosure - Related Party Transactions - Amantes Loans (Details)",
     "shortName": "Related Party Transactions - Amantes Loans (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails",
     "longName": "1140408 - Disclosure - Related Party Transactions - Due to Related Party (Details)",
     "shortName": "Related Party Transactions - Due to Related Party (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y6Lx3mXqwk-nBkJ5KlLBYg",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
     "longName": "1140501 - Disclosure - Debt (Details)",
     "shortName": "Debt (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
     "longName": "1140601 - Disclosure - Stockholder's Equity (Details)",
     "shortName": "Stockholder's Equity (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_2_19_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_nVZL2iH4ikeTyIHCOmUqAA",
      "name": "limn:ClassOfWarrantOrRightNumberOfWarrantsExercised",
      "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails",
     "longName": "1140602 - Disclosure - Stockholder's Equity - Assumptions used for estimating fair value of warrants (Details)",
     "shortName": "Stockholder's Equity - Assumptions used for estimating fair value of warrants (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_KxviRH7DfUuHBTu5r6l8NQ",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_KxviRH7DfUuHBTu5r6l8NQ",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails",
     "longName": "1140603 - Disclosure - Stockholder's Equity - Offering proceeds and related issuance costs (Details)",
     "shortName": "Stockholder's Equity - Offering proceeds and related issuance costs (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "limn:GrossProceedsFromIssuanceOfWarrants",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "limn:ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "limn:GrossProceedsFromIssuanceOfWarrants",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "limn:ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "longName": "1140701 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:ShortTermLeaseCost",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails",
     "longName": "1140801 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_doQ-5t8E_kahW9UFnsMLNA",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details",
     "longName": "1140802 - Disclosure - Fair Value Measurements - Changes in fair value of Level 3 (Details)",
     "shortName": "Fair Value Measurements - Changes in fair value of Level 3 (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_NOD7vwuXLUmAhk-2mkyvLQ",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "limn:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets",
     "longName": "1200100 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Uncategorized",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA",
      "name": "us-gaap:Cash",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA",
      "name": "limn:AccruedMaintenanceFeeCurrent",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals",
     "longName": "1200105 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "parenthetical",
     "menuCat": "Cover",
     "order": "43",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg",
      "name": "limn:CommonStockShareOutstanding",
      "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations",
     "longName": "1200200 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit",
     "longName": "1200300 - Statement - Consolidated Statements of Changes in Stockholder's Deficit",
     "shortName": "Consolidated Statements of Changes in Stockholder's Deficit",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "45",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HFF_MgUngEePnxJ9ysVB6Q",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg",
      "name": "limn:SharesIssuedForSurrenderAndCancellationOfWarrants",
      "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "1200400 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationss",
     "longName": "1210101 - Disclosure - Description of Organization and Business Operations",
     "shortName": "Description of Organization and Business Operations",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "47",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R48": {
     "role": "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciess",
     "longName": "1210201 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementss",
     "longName": "1210301 - Disclosure - License Agreements",
     "shortName": "License Agreements",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "limn:LicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionss",
     "longName": "1210401 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R51": {
     "role": "http://www.liminatuspharma.com/role/DisclosureDebts",
     "longName": "1210501 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R52": {
     "role": "http://www.liminatuspharma.com/role/DisclosureStockholderSEquitys",
     "longName": "1210601 - Disclosure - Stockholder's Equity",
     "shortName": "Stockholder's Equity",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "52",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R53": {
     "role": "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciess",
     "longName": "1210701 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "53",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementss",
     "longName": "1210801 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R55": {
     "role": "http://www.liminatuspharma.com/role/DisclosureIncomeTaxes",
     "longName": "1210901 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "55",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.liminatuspharma.com/role/DisclosureSubsequentEventss",
     "longName": "1211001 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R57": {
     "role": "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess",
     "longName": "1220202 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R58": {
     "role": "http://www.liminatuspharma.com/role/DisclosureDebtTabless",
     "longName": "1230503 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "58",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R59": {
     "role": "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTabless",
     "longName": "1230803 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "59",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R60": {
     "role": "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesTables",
     "longName": "1230903 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "60",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
     "longName": "1240101 - Disclosure - Description of Organization and Business Operations - Business Combination (Details)",
     "shortName": "Description of Organization and Business Operations - Business Combination (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
     "longName": "1240102 - Disclosure - Description of Organization and Business Operations - Liquidity and Capital Resources (Details)",
     "shortName": "Description of Organization and Business Operations - Liquidity and Capital Resources (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:Cash",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R63": {
     "role": "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss",
     "longName": "1240201 - Disclosure - Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA",
      "name": "us-gaap:AllowanceForNotesAndLoansReceivableCurrent",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:AllowanceForNotesAndLoansReceivableCurrent",
       "p",
       "us-gaap:FinanceLoansAndLeasesReceivablePolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetailss",
     "longName": "1240202 - Disclosure - Significant Accounting Policies - Income Taxes (Details)",
     "shortName": "Significant Accounting Policies - Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R65": {
     "role": "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
     "longName": "1240301 - Disclosure - License Agreements - CAR-T Products License (Details)",
     "shortName": "License Agreements - CAR-T Products License (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2018_To_12_31_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_PCxMs4QP-k2uBuXoZKiE1A",
      "name": "limn:UpfrontPaymentOfLicenseAgreementFees",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "limn:LicenseAgreementsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2018_To_12_31_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_PCxMs4QP-k2uBuXoZKiE1A",
      "name": "limn:UpfrontPaymentOfLicenseAgreementFees",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "limn:LicenseAgreementsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails",
     "longName": "1240302 - Disclosure - License Agreements - Vaccine Products License (Details)",
     "shortName": "License Agreements - Vaccine Products License (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww",
      "name": "limn:ForgivenessOfUnrelatedVendorPayable",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_o6DHM9UbBkSNjCOhIS_9VA",
      "name": "limn:UpfrontPaymentOfLicenseAgreementFees",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "limn:LicenseAgreementsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails",
     "longName": "1240303 - Disclosure - License Agreements - Termination of license agreement (Details)",
     "shortName": "License Agreements - Termination of license agreement (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_limn_CarTLicenseAndVaccineLicenseWithTdtMember_mWk8tah9gUuCRPqsFLhQWg",
      "name": "limn:LicenseAgreementsTerminationAmountDue",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_limn_CarTLicenseAndVaccineLicenseWithTdtMember_mWk8tah9gUuCRPqsFLhQWg",
      "name": "limn:LicenseAgreementsTerminationAmountDue",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss",
     "longName": "1240304 - Disclosure - License Agreements - CD47 License (Details)",
     "shortName": "License Agreements - CD47 License (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "As_Of_10_31_2022_srt_CounterpartyNameAxis_limn_CurisBiotechHoldingsLlcMember_us-gaap_CapitalUnitsByClassAxis_us-gaap_CapitalUnitClassAMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_MfcULb3sYEWNTNOdJMM4Mg",
      "name": "limn:NumberOfUnitsExchangeForLicenseRights",
      "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "limn:LicenseAgreementsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R69": {
     "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
     "longName": "1240401 - Disclosure - Related Party Transactions - Feelux Bonds (Details)",
     "shortName": "Related Party Transactions - Feelux Bonds (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R70": {
     "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss",
     "longName": "1240402 - Disclosure - Related Party Transactions - Car-Tcellkor Loan (Details)",
     "shortName": "Related Party Transactions - Car-Tcellkor Loan (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R71": {
     "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss",
     "longName": "1240403 - Disclosure - Related Party Transactions - Valetudo Loans (Details)",
     "shortName": "Related Party Transactions - Valetudo Loans (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R72": {
     "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss",
     "longName": "1240404 - Disclosure - Related Party Transactions - Ewon Loans (Details)",
     "shortName": "Related Party Transactions - Ewon Loans (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R73": {
     "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss",
     "longName": "1240405 - Disclosure - Related Party Transactions - Prophase Loans (Details)",
     "shortName": "Related Party Transactions - Prophase Loans (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R74": {
     "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss",
     "longName": "1240406 - Disclosure - Related Party Transactions - Hana Loans (Details)",
     "shortName": "Related Party Transactions - Hana Loans (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R75": {
     "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss",
     "longName": "1240407 - Disclosure - Related Party Transactions - Amantes Loans (Details)",
     "shortName": "Related Party Transactions - Amantes Loans (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R76": {
     "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss",
     "longName": "1240408 - Disclosure - Related Party Transactions - Due to Related Party (Details)",
     "shortName": "Related Party Transactions - Due to Related Party (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y6Lx3mXqwk-nBkJ5KlLBYg",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R77": {
     "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails",
     "longName": "1240409 - Disclosure - Related Party Transactions - Viral Gene (Details)",
     "shortName": "Related Party Transactions - Viral Gene (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww",
      "name": "limn:OtherReceivableWriteOff",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ViralGeneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_7wxNNnmVW0OOyrl6dcdkLg",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
     "longName": "1240501 - Disclosure - Debt (Details)",
     "shortName": "Debt (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R79": {
     "role": "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
     "longName": "1240601 - Disclosure - Stockholder's Equity (Details)",
     "shortName": "Stockholder's Equity (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R80": {
     "role": "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
     "longName": "1240701 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw",
      "name": "us-gaap:ShortTermLeaseCost",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R81": {
     "role": "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss",
     "longName": "1240801 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_doQ-5t8E_kahW9UFnsMLNA",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R82": {
     "role": "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss",
     "longName": "1240802 - Disclosure - Fair Value Measurements - Changes in fair value of Level 3 (Details)",
     "shortName": "Fair Value Measurements - Changes in fair value of Level 3 (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_NOD7vwuXLUmAhk-2mkyvLQ",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "limn:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R83": {
     "role": "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails",
     "longName": "1240901 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww",
      "name": "limn:ResearchAndDevelopmentExpenseMandatoryCapitalization",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "limn:ResearchAndDevelopmentExpenseMandatoryCapitalization",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetails",
     "longName": "1240902 - Disclosure - Income Taxes - Income tax provision (Details)",
     "shortName": "Income Taxes - Income tax provision (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails",
     "longName": "1240903 - Disclosure - Income Taxes - Reconciliation of income tax rate (Details)",
     "shortName": "Income Taxes - Reconciliation of income tax rate (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "1240904 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)",
     "shortName": "Income Taxes - Deferred tax assets and liabilities (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails",
     "longName": "1241001 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_2_17_2026_To_2_17_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_809IbYMTbUCQEIVjWuaGsA",
      "name": "limn:PeriodOfNonIssuanceOfCommonStockFollowingClosingDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xs1.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20"
     ]
    },
    "limn_AccruedInterestCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "AccruedInterestCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued interest as of the balance sheet date.",
        "label": "Accrued Interest, Current",
        "terseLabel": "Accrued interest, related parties"
       }
      }
     },
     "auth_ref": []
    },
    "limn_AccruedMaintenanceFeeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "AccruedMaintenanceFeeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued maintenance fee as of balance sheet date.",
        "label": "Accrued Maintenance Fee, Current",
        "terseLabel": "Accrued maintenance fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r731",
      "r966"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid in Capital",
        "verboseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r847",
      "r848",
      "r849",
      "r850",
      "r903",
      "r969"
     ]
    },
    "limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to additional paid in capital (APIC) resulting from Settlement of loans.",
        "label": "Adjustments to Additional Paid in Capital, Settlement of Loans",
        "negatedLabel": "Settlement of loans to Iris Acquisition Corp upon closing of the business combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForNotesAndLoansReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllowanceForNotesAndLoansReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Credit losses relating to loan receivable",
        "documentation": "Amount of allowance for credit loss on financing receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r159",
      "r194"
     ]
    },
    "limn_AltaPartnersLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "AltaPartnersLlcMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Alta Partners Llc..",
        "label": "Alta Partners Llc [Member]",
        "terseLabel": "Alta Partners Llc"
       }
      }
     },
     "auth_ref": []
    },
    "limn_AmantesJanuary2025LoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "AmantesJanuary2025LoansMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Amantes January 2025 Loans.",
        "label": "Amantes January 2025 Loans [Member]",
        "terseLabel": "Amantes January 2025 Loans",
        "verboseLabel": "Amantes January 2025 Loans"
       }
      }
     },
     "auth_ref": []
    },
    "limn_AmantesLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "AmantesLlcMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Amantes LLC .",
        "label": "Amantes LLC [Member]",
        "terseLabel": "Amantes"
       }
      }
     },
     "auth_ref": []
    },
    "limn_AmantesLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "AmantesLoansMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Amantes Loans.",
        "label": "Amantes Loans [Member]",
        "terseLabel": "Amantes Loans"
       }
      }
     },
     "auth_ref": []
    },
    "limn_AmantesNovember2024LoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "AmantesNovember2024LoansMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Amantes November 2024 Loans.",
        "label": "Amantes November 2024 Loans [Member]",
        "terseLabel": "Amantes November 2024 Loans"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining scenario being the net sale of period from the first commercial sale of the CAR-T product or CAR-T Diagnostic until the product's patent expires in an individual country.",
        "label": "Annual Sales Of Period From First Commercial Sale Until Patent Expires [Member]",
        "terseLabel": "Net sales of period from first commercial sale until patent expires"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r56",
      "r75",
      "r95",
      "r97",
      "r98",
      "r134",
      "r142",
      "r153",
      "r154",
      "r191",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r411",
      "r415",
      "r455",
      "r520",
      "r521",
      "r527",
      "r611",
      "r687",
      "r688",
      "r698",
      "r731",
      "r737",
      "r738",
      "r750",
      "r883",
      "r884",
      "r924"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r80",
      "r95",
      "r97",
      "r98",
      "r191",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r411",
      "r415",
      "r455",
      "r731",
      "r883",
      "r884",
      "r924"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r97",
      "r98",
      "r191",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r411",
      "r415",
      "r455",
      "r883",
      "r884",
      "r924"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "limn_BestEffortsPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "BestEffortsPublicOfferingMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to Best Efforts Public Offering.",
        "label": "Best Efforts Public Offering [Member]",
        "terseLabel": "Best efforts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r559",
      "r707",
      "r708",
      "r896",
      "r897",
      "r898"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r559",
      "r707",
      "r708",
      "r896",
      "r897",
      "r898"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Line Items]",
        "terseLabel": "Description of Organization and Business Operations",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r354",
      "r355",
      "r356",
      "r357",
      "r363",
      "r364",
      "r365",
      "r366",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r401",
      "r402",
      "r403",
      "r406",
      "r712",
      "r715",
      "r896",
      "r897",
      "r898"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Liability Assumed, Liability",
        "terseLabel": "Recognized liability assumed",
        "documentation": "Amount of liability assumed in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r384"
     ]
    },
    "us-gaap_CapitalUnitClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalUnitClassAMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Unit, Class A [Member]",
        "terseLabel": "Class A Member Units",
        "documentation": "Class A of capital units, which are a type of ownership interest in a corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalUnitClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalUnitClassDomain",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Unit, Class [Domain]",
        "documentation": "Description of the type or class of capital units or capital shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalUnitsByClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalUnitsByClassAxis",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Units by Class [Axis]",
        "documentation": "Information by type or class of the entity's capital units."
       }
      }
     },
     "auth_ref": []
    },
    "limn_CarTLicenseAndVaccineLicenseWithTdtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "CarTLicenseAndVaccineLicenseWithTdtMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to CAR-T Products and Vaccine Licenses.",
        "label": "CAR T License And Vaccine License With Tdt [Member]",
        "terseLabel": "CAR-T License and Vaccine License with TDT"
       }
      }
     },
     "auth_ref": []
    },
    "limn_CarTcellkorLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "CarTcellkorLoanMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Car-Tcellkor Loan.",
        "label": "Car Tcellkor Loan [Member]",
        "terseLabel": "Car-Tcellkor Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r530",
      "r586",
      "r606",
      "r731",
      "r737",
      "r738",
      "r750",
      "r777"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "periodEndLabel": "Cash, end of the period",
        "periodStartLabel": "Cash, beginning of the period",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r40",
      "r92"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "totalLabel": "Net change in cash",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r40"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r935"
     ]
    },
    "limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "Cd47LicenseAndDevelopmentAgreementWithInnobationMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Metavagen License Agreement with respects to license right to develop, market and sell YN1203, InnoBation Bio CAR NK biomarkers, including devices, compounds and products used to detect analyte in body or tissue.",
        "label": "CD47 License And Development Agreement With InnoBation [Member]",
        "terseLabel": "CD47 License agreement with InnoBation"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r76",
      "r77",
      "r78",
      "r95",
      "r98",
      "r124",
      "r128",
      "r130",
      "r132",
      "r136",
      "r137",
      "r191",
      "r223",
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r263",
      "r264",
      "r266",
      "r267",
      "r269",
      "r272",
      "r275",
      "r276",
      "r279",
      "r282",
      "r289",
      "r455",
      "r564",
      "r565",
      "r566",
      "r567",
      "r574",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r587",
      "r598",
      "r619",
      "r641",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r765",
      "r838",
      "r840",
      "r851"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Price per share (in dollars per share)",
        "verboseLabel": "Exercise price of warrants",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r100",
      "r290"
     ]
    },
    "limn_ClassOfWarrantOrRightIssuePricePerWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ClassOfWarrantOrRightIssuePricePerWarrant",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per unit amount of warrants issued.",
        "label": "Class of Warrant or Right, Issue Price Per Warrant",
        "terseLabel": "Offering price of pre-funded warrants (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Stockholders' Equity",
        "verboseLabel": "Stockholders' Equity",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of shares called by each warrant (in shares)",
        "verboseLabel": "Number of shares called by each warrant",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants to purchase shares issued (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants surrendered and canceled.",
        "label": "Class Of Warrant Or Right, Number Of Securities Surrendered And Canceled",
        "terseLabel": "Surrender and cancellation of warrants to purchase shares of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ClassOfWarrantOrRightNumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsExercised",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants exercised.",
        "label": "Class of Warrant or Right, Number Of Warrants Exercised",
        "terseLabel": "Pre-Funded warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ClassOfWarrantOrRightNumberOfWarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsIssued",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants issued.",
        "label": "Class of Warrant or Right, Number of Warrants Issued",
        "terseLabel": "Pre-funded warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants issued on conversion.",
        "label": "Class of Warrant or Right, Number of Warrants Issued on Conversions",
        "verboseLabel": "Pre-funded warrants issued on conversion (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants issued (in shares)",
        "verboseLabel": "Warrants issued",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.",
        "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold number of specified consecutive trading days for stock price"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days for stock price trigger considered for redemption of warrants.",
        "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, Threshold Trading Days",
        "terseLabel": "Threshold number of specified trading days for stock price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The threshold trigger price for redemption of warrants.",
        "label": "Class Of Warrant Or Right, Threshold Share Price Trigger For Redemption",
        "terseLabel": "Threshold Share Price for redemption of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The threshold period during which a written notice is required for redemption of warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Class Of Warrant Or Right, Threshold Written Notice Period For Redemption Of Warrants",
        "terseLabel": "Threshold written notice period for redemption of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ClearStreetLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ClearStreetLlcMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Clear Street LLC",
        "label": "Clear Street Llc [Member]",
        "terseLabel": "Clear Street Llc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "License Agreements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to product being commercialize chimeric antigen receptor (\"CAR-T\") and CAR-T Diagnostics.",
        "label": "Commercialize Chimeric Antigen Receptor And CAR-T Diagnostics [Member]",
        "terseLabel": "CAR-T products and CAR-T Diagnostics"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 7)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r52",
      "r529",
      "r597"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingencies",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r215",
      "r216",
      "r664",
      "r872",
      "r877"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "terseLabel": "Class A shares",
        "verboseLabel": "Common Stock",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "limn_CommonStockAndPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "CommonStockAndPreFundedWarrantsMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to common stock and pre-funded warrants.",
        "label": "Common Stock and Pre Funded Warrants [Member]",
        "terseLabel": "Common stock and Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "limn_CommonStockCashRedemptionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "CommonStockCashRedemptionAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash redemption of value of common stock of the entity.",
        "label": "Common Stock, Cash Redemption Amount",
        "terseLabel": "Aggregate cash redemption amount"
       }
      }
     },
     "auth_ref": []
    },
    "limn_CommonStockCashRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "CommonStockCashRedemptionPricePerShare",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share at which the common stock of the entity is redeemed or may be called at.",
        "label": "Common Stock, Cash Redemption Price Per Share",
        "terseLabel": "Cash redemption price per share (in dollars per share)",
        "verboseLabel": "Cash redemption price per share"
       }
      }
     },
     "auth_ref": []
    },
    "limn_CommonStockCashRedemptionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "CommonStockCashRedemptionShares",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of common shares redeemed for cash.",
        "label": "Common Stock, Cash Redemption, Shares",
        "terseLabel": "Shares redeemed (in shares)",
        "verboseLabel": "Shares redeemed"
       }
      }
     },
     "auth_ref": []
    },
    "limn_CommonStockConversionRatioBusinessCombination": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "CommonStockConversionRatioBusinessCombination",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion for each share of common stock in business combination.",
        "label": "Common Stock, Conversion Ratio, Business Combination",
        "terseLabel": "Number of common shares converted"
       }
      }
     },
     "auth_ref": []
    },
    "limn_CommonStockIssuedInConnectionWithSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "CommonStockIssuedInConnectionWithSettlement",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in connection with settlement in noncash financing activities.",
        "label": "Common Stock Issued In Connection With Settlement",
        "terseLabel": "Issuance of common stock in connection with the Clear Street settlement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r741",
      "r742",
      "r744",
      "r745",
      "r746",
      "r747",
      "r847",
      "r848",
      "r850",
      "r903",
      "r965",
      "r969"
     ]
    },
    "limn_CommonStockNumberOfVotesPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "CommonStockNumberOfVotesPerShare",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of votes for each share of common stock.",
        "label": "Common Stock, Number Of Votes Per Share",
        "terseLabel": "Number of votes per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "limn_CommonStockPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "CommonStockPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of common stock payable.",
        "label": "Common Stock Payable",
        "terseLabel": "Settlement payable"
       }
      }
     },
     "auth_ref": []
    },
    "limn_CommonStockPurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "CommonStockPurchaseWarrantsMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to common stock purchase warrants",
        "label": "Common Stock Purchase Warrants [Member]",
        "terseLabel": "Common stock purchase warrants"
       }
      }
     },
     "auth_ref": []
    },
    "limn_CommonStockShareOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "CommonStockShareOutstanding",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Share Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)",
        "verboseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r598"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r28",
      "r598",
      "r617",
      "r969",
      "r970"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 500,000,000 shares authorized; 44,877,633 and 27,064,633 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively",
        "verboseLabel": "Common stock, $0.0001 par value; 500,000,000 shares authorized; 27,064,633 and 17,500,000 shares issued and outstanding as of December 31, 2025 and 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r264",
      "r271",
      "r532",
      "r731"
     ]
    },
    "limn_CommonStockWarrantsAndPlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "CommonStockWarrantsAndPlacementAgentWarrantsMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to common stock warrants and placement agent warrants.",
        "label": "Common Stock Warrants and Placement Agent Warrants [Member]",
        "terseLabel": "Common Stock Warrants and Placement Agent Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "limn_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to common stock warrants.",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ConsortiumLoanOfRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ConsortiumLoanOfRelatedPartiesMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the information pertaining to consortium loan of  related parties.",
        "label": "Consortium Loan of Related Parties [Member]",
        "terseLabel": "Consortium Loan of related parties"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ConversionOfAccruedInterestOnRelatedPartyDebts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ConversionOfAccruedInterestOnRelatedPartyDebts",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued interest on related party debts that were converted into common stock.",
        "label": "Conversion of Accrued Interest on Related party Debts",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ConversionOfPrincipalAndAccruedInterestAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ConversionOfPrincipalAndAccruedInterestAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of conversion of principal and accrued interest amount.",
        "label": "Conversion of Principal and Accrued Interest Amount",
        "terseLabel": "Conversion of principal and accrued interest amount"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ConversionOfPrincipalAndAccruedInterestShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ConversionOfPrincipalAndAccruedInterestShares",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of conversion of principal and accrued interest.",
        "label": "Conversion of Principal and Accrued Interest Shares",
        "terseLabel": "Conversion of principal and accrued interest shares (in shares)",
        "verboseLabel": "Conversion of principal and accrued interest shares"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ConversionOfStockOrUnitConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ConversionOfStockOrUnitConversionRatio",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock issuable upon conversion of each share of stock or unit to be converted.",
        "label": "Conversion Of Stock Or Unit, Conversion Ratio",
        "terseLabel": "Share conversion ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of stock (in shares)",
        "verboseLabel": "Conversion of stock",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r16"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Number of shares converted into (in shares)",
        "verboseLabel": "Number of shares converted into",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r16"
     ]
    },
    "us-gaap_CostMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostMaintenance",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost, Maintenance",
        "terseLabel": "Annual maintenance fees",
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "limn_CostsIncurredInConnectionWithIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "CostsIncurredInConnectionWithIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of common stock issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Costs Incurred In Connection With Issuance Of Common Stock",
        "terseLabel": "Costs incurred in connection with the issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r95",
      "r103",
      "r104",
      "r236",
      "r277",
      "r478",
      "r499",
      "r526",
      "r670",
      "r671",
      "r672",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r899",
      "r900",
      "r901",
      "r902"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "limn_CurisBiotechHoldingsLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "CurisBiotechHoldingsLlcMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Metavagen LLC (\"Metavagen\") owned by Chris Kim, the CEO of Liminatus.",
        "label": "Curis Biotech Holdings Llc [Member]",
        "terseLabel": "Curis Biotech Holdings LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of outstanding principal",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r16"
     ]
    },
    "limn_DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of non-cash impact to additional paid in capital upon forgiveness of accrued interest on the converted debt instrument in a non-cash transaction.",
        "label": "Debt Conversion, Noncash Impact To Additional paid In Capital For Forgiveness Of Accrued Interest",
        "terseLabel": "Non-cash impact to APIC for the forgiveness of accrued interest on converted related party debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Original Debt, Amount",
        "terseLabel": "Conversion of related party short-term debt into common stock",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r16"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebt",
      "http://www.liminatuspharma.com/role/DisclosureDebts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r95",
      "r96",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r221",
      "r222",
      "r232",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r248",
      "r255",
      "r256",
      "r258",
      "r417",
      "r464"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r19",
      "r20",
      "r50",
      "r51",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r729",
      "r836",
      "r837",
      "r839",
      "r846",
      "r873",
      "r874",
      "r875",
      "r920",
      "r921",
      "r933"
     ]
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentDecreaseForgiveness",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Decrease, Forgiveness",
        "terseLabel": "Consumption of outstanding principal",
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r839"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r259",
      "r464",
      "r465",
      "r729"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt interest rate",
        "verboseLabel": "Interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r234"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r729",
      "r836",
      "r837",
      "r839",
      "r846",
      "r873",
      "r874",
      "r875",
      "r920",
      "r921",
      "r933"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Debt discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r886",
      "r919",
      "r920",
      "r921"
     ]
    },
    "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]",
        "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Transaction Costs",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_DeferredCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Current",
        "terseLabel": "Deferred transaction costs",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Deferred",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r842",
      "r894",
      "r895"
     ]
    },
    "limn_DeferredOfferingCostsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "DeferredOfferingCostsNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.",
        "label": "Deferred Offering Costs Noncurrent",
        "verboseLabel": "Deferred underwriting discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetailss": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "Deferred",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r842",
      "r894",
      "r895"
     ]
    },
    "us-gaap_DeferredTaxAssetInterestCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetInterestCarryforward",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetailss": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, Interest Carryforward",
        "terseLabel": "Section 163(j) - Interest",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetailss": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax asset, net of valuation allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetailss": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "limn_DeferredTaxAssetsStartupExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "DeferredTaxAssetsStartupExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetailss": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from startup expenses",
        "label": "Deferred Tax Assets, Startup Expenses",
        "terseLabel": "Startup expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetailss": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "limn_DeferredTransactionCostsInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "DeferredTransactionCostsInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred transaction costs in accounts payable.",
        "label": "Deferred Transaction Costs In Accounts Payable",
        "terseLabel": "Deferred transaction costs in accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of deferred underwriting discount on gross proceeds of the IPO.",
        "label": "Deferred Underwriting Discount as Percentage of Gross Proceeds from Initial Public Offering",
        "terseLabel": "Deferred underwriting discount (in percentage)"
       }
      }
     },
     "auth_ref": []
    },
    "limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred underwriting fee payable settled in cash upon consummation of business combination.",
        "label": "Deferred Underwriting Fee Payable Settled In Cash Upon Consummation Of Business Combination",
        "terseLabel": "Deferred underwriting fee payable settled in cash"
       }
      }
     },
     "auth_ref": []
    },
    "limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred underwriting fee payable settled in shares upon consummation of business combination.",
        "label": "Deferred Underwriting Fee Payable Settled In Shares Upon Consummation Of Business Combination",
        "terseLabel": "Deferred underwriting fee payable settled in shares"
       }
      }
     },
     "auth_ref": []
    },
    "limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred underwriting fee payable settled upon consummation of business combination.",
        "label": "Deferred Underwriting Fee Payable Settled Upon Consummation Of Business Combination",
        "terseLabel": "Deferred underwriting fees settled"
       }
      }
     },
     "auth_ref": []
    },
    "limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amount of deferred underwriting fee settled upon consummation of combined company next share offering.",
        "label": "Deferred Underwriting Fee, Remaining Amount Settlement Upon Consummation Of Combined Company Next Share Offering",
        "terseLabel": "Remaining amount of deferred underwriting fee settled"
       }
      }
     },
     "auth_ref": []
    },
    "limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred underwriting fee waived upon consummation of business combination.",
        "label": "Deferred Underwriting Fee Waived Upon Consummation Of Business Combination",
        "terseLabel": "Deferred underwriting fee waived"
       }
      }
     },
     "auth_ref": []
    },
    "limn_DeferredUnderwritingFeesPayableInCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "DeferredUnderwritingFeesPayableInCashCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred underwriting fees payable in cash and are classified as current as of the balance sheet date.",
        "label": "Deferred Underwriting Fees Payable In Cash, Current",
        "terseLabel": "Deferred underwriting fee payable"
       }
      }
     },
     "auth_ref": []
    },
    "limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred underwriting fees liabilities of acquiree to be settled by way of issuance of common stock of the entity upon consummation of business combination.",
        "label": "Deferred Underwriting Fees Payable, To Be Settled In Shares Upon Consummation Of Business Combination",
        "terseLabel": "Deferred underwriting fees payable",
        "verboseLabel": "Deferred underwriting fees liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r17",
      "r88",
      "r673",
      "r674",
      "r676",
      "r678"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r87",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r122",
      "r124",
      "r130",
      "r131",
      "r132",
      "r133",
      "r262",
      "r312",
      "r352",
      "r408",
      "r431",
      "r432",
      "r519",
      "r541",
      "r680"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r87",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r124",
      "r130",
      "r131",
      "r132",
      "r133",
      "r262",
      "r312",
      "r352",
      "r408",
      "r431",
      "r432",
      "r519",
      "r541",
      "r680"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Income tax provision expense/(benefit)",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r711"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory federal income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r99",
      "r321",
      "r343",
      "r711"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r711",
      "r836",
      "r843",
      "r888"
     ]
    },
    "limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value of common stock to be issued for contingent liability",
        "label": "Effective Income Tax Rate Reconciliation, Fair Value Of Common Stock For Contingent Liability, Amount",
        "negatedLabel": "Fair value of common stock to be issued for contingent liability"
       }
      }
     },
     "auth_ref": []
    },
    "limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value of common stock to be issued for contingent liability",
        "label": "Effective Income Tax Rate Reconciliation, Fair Value Of Common Stock For Contingent Liability, Percent",
        "terseLabel": "Fair value of common stock to be issued for contingent liability"
       }
      }
     },
     "auth_ref": []
    },
    "limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to gain (loss) on exchange of common stock for warrants",
        "label": "Effective Income Tax Rate Reconciliation, Gain (Loss) On Exchange Of Common Stock, Amount",
        "negatedLabel": "Loss on exchange of common stock for warrants"
       }
      }
     },
     "auth_ref": []
    },
    "limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to gain loss on exchange of common stock for warrants",
        "label": "Effective Income Tax Rate Reconciliation, Gain (Loss) On Exchange Of Common Stock, Percent",
        "terseLabel": "Loss on exchange of common stock for warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other permanent differences",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r711",
      "r836",
      "r843",
      "r888",
      "r889"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal expense",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r711",
      "r836",
      "r843",
      "r888"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Jurisdiction, Contribution Greater than 50 Percent, Tax Effect [Extensible Enumeration]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, State and Local Jurisdiction, Contribution Greater than 50 Percent, Tax Effect [Extensible Enumeration]",
        "documentation": "Indicates name of state or local jurisdiction that makes up greater than 50 percent of effect of state and local income tax."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r711"
     ]
    },
    "limn_EmergingGrowthCompanyPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "EmergingGrowthCompanyPolicyPolicyTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policies on emerging growth company status.",
        "label": "Emerging Growth Company Policy [Policy Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "auth_ref": []
    },
    "limn_EmploymentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "EmploymentAgreementMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to employment agreement.",
        "label": "Employment Agreement [Member]",
        "terseLabel": "Employment Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Entities [Member]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r63",
      "r64",
      "r65",
      "r84",
      "r85",
      "r86",
      "r105",
      "r106",
      "r107",
      "r109",
      "r116",
      "r118",
      "r120",
      "r135",
      "r192",
      "r193",
      "r209",
      "r261",
      "r291",
      "r312",
      "r341",
      "r342",
      "r349",
      "r350",
      "r351",
      "r353",
      "r407",
      "r408",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r430",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r466",
      "r467",
      "r471",
      "r539",
      "r552",
      "r553",
      "r554",
      "r574",
      "r641"
     ]
    },
    "limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from change in fair value of deferred underwriting fees that would be settled in common stock of the combined entity.",
        "label": "Equity Settlement, Deferred Underwriting Fees, Effect Of Change In Fair Value",
        "negatedLabel": "Change in fair value of deferred underwriting fee - paid in common stock",
        "negatedTerseLabel": "Change in fair value of deferred underwriting fee - paid in common stock",
        "terseLabel": "Change in fair value of deferred underwriting fee - paid in common stock",
        "verboseLabel": "Change in fair value of deferred underwriting fee - paid in common stock"
       }
      }
     },
     "auth_ref": []
    },
    "limn_EstimatedPercentageOfActivitiesCompleted": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "EstimatedPercentageOfActivitiesCompleted",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated percentage of activities completed by the company as per agreement.",
        "label": "Estimated Percentage Of Activities Completed",
        "verboseLabel": "Percentage of activities completed"
       }
      }
     },
     "auth_ref": []
    },
    "limn_EwonComfortechCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "EwonComfortechCoLtdMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Ewon Comfortech Co, Ltd.",
        "label": "Ewon Comfortech Co Ltd [Member]",
        "terseLabel": "Ewon Comfortech Co Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "limn_EwonDecember2022LoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "EwonDecember2022LoanMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Ewon December 2022 Loan.",
        "label": "Ewon December 2022 Loan [Member]",
        "terseLabel": "Ewon December 2022 Loan"
       }
      }
     },
     "auth_ref": []
    },
    "limn_EwonDecember2023LoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "EwonDecember2023LoanMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Ewon December 2023 Loan.",
        "label": "Ewon December 2023 Loan [Member]",
        "terseLabel": "Ewon December 2023 Loan"
       }
      }
     },
     "auth_ref": []
    },
    "limn_EwonLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "EwonLoanMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Ewon Loan.",
        "label": "Ewon Loan [Member]",
        "terseLabel": "Ewon Loan"
       }
      }
     },
     "auth_ref": []
    },
    "limn_EwonSeptember2023LoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "EwonSeptember2023LoanMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Ewon September 2023 Loan.",
        "label": "Ewon September 2023 Loan [Member]",
        "terseLabel": "Ewon September 2023 Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Change in the fair value of warrant liabilities",
        "negatedTerseLabel": "Change in the fair value of warrant liability",
        "terseLabel": "Change in the fair value of warrant liabilities",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r445",
      "r719"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r445",
      "r719"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Stockholder's Equity",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r438",
      "r712",
      "r714",
      "r721"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r438",
      "r712",
      "r714",
      "r721"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of assumptions used for estimating fair value of warrants",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r721"
     ]
    },
    "limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTables",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets and  liability using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings  are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset and liability.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of changes in fair value of Level 3 financial assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r433",
      "r435",
      "r436",
      "r437",
      "r438",
      "r444",
      "r445",
      "r447",
      "r453",
      "r486",
      "r487",
      "r488",
      "r668",
      "r694",
      "r695",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r719",
      "r721",
      "r728"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r438",
      "r719",
      "r908",
      "r913"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurements",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r441",
      "r442",
      "r443",
      "r444",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r517",
      "r719",
      "r722"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair value inputs level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r435",
      "r436",
      "r437",
      "r438",
      "r445",
      "r453",
      "r488",
      "r668",
      "r694",
      "r695",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r719",
      "r721",
      "r728"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r438",
      "r719",
      "r908",
      "r913"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Initial measurement at the Closing Date",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r446"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Change in fair value",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r910",
      "r912"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance, fair value",
        "periodStartLabel": "Beginning balance, fair value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r446"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r433",
      "r435",
      "r436",
      "r437",
      "r438",
      "r444",
      "r445",
      "r447",
      "r453",
      "r486",
      "r487",
      "r488",
      "r668",
      "r694",
      "r695",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r719",
      "r721",
      "r728"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r913"
     ]
    },
    "limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of common shares issued for settlement of deferred underwriting fees.",
        "label": "Fair Value Of Common Shares Issued For Settlement Of Deferred Underwriting Fees",
        "terseLabel": "Fair value of common shares"
       }
      }
     },
     "auth_ref": []
    },
    "limn_FairValueOfCommonStockIssuanceForContingentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "FairValueOfCommonStockIssuanceForContingentLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 7.0
      },
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to fair value of common stock to be issued for contingent liability.",
        "label": "Fair Value Of Common Stock Issuance For Contingent Liability",
        "negatedLabel": "Fair value of common stock to be issued for contingent liability",
        "terseLabel": "Fair value of common stock to be issued for contingent liability"
       }
      }
     },
     "auth_ref": []
    },
    "limn_FairValueOfCommonStockIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "FairValueOfCommonStockIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of common stock issued.",
        "label": "Fair Value of Common Stock Issued",
        "terseLabel": "Fair value of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "limn_FairValueOfWarrantsSurrendered": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "FairValueOfWarrantsSurrendered",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of warrants surrendered.",
        "label": "Fair Value of Warrants Surrendered",
        "terseLabel": "Fair value of warrants surrendered"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Federal"
       }
      }
     },
     "auth_ref": []
    },
    "limn_FederalIncomeTaxExpenseSubjectToLimitationInUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "FederalIncomeTaxExpenseSubjectToLimitationInUse",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Federal Income Tax Expense Subject To Limitation In Use",
        "terseLabel": "Federal income tax liabilities, subject limitations"
       }
      }
     },
     "auth_ref": []
    },
    "limn_FeeReductionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "FeeReductionAgreementMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Fee reduction agreement.",
        "label": "Fee Reduction Agreement [Member]",
        "terseLabel": "Fee Reduction Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "limn_FeeluxAndCarTcellkorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "FeeluxAndCarTcellkorMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Feelux and Car-Tcellkor.",
        "label": "Feelux and Car-Tcellkor [Member]",
        "terseLabel": "Feelux and Car-Tcellkor"
       }
      }
     },
     "auth_ref": []
    },
    "limn_FeeluxBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "FeeluxBondsMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Feelux Bonds.",
        "label": "Feelux Bonds [Member]",
        "terseLabel": "Feelux Bonds"
       }
      }
     },
     "auth_ref": []
    },
    "limn_FeeluxCo.LtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "FeeluxCo.LtdMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Feelux bonds.",
        "label": "Feelux Co. Ltd [Member]",
        "terseLabel": "Feelux Co. Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLoansAndLeasesReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLoansAndLeasesReceivablePolicy",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable [Policy Text Block]",
        "terseLabel": "Loan Receivable",
        "documentation": "Disclosure of accounting policy for financing receivable."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r257",
      "r287",
      "r417",
      "r428",
      "r452",
      "r454",
      "r456",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r525",
      "r540",
      "r692",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r732",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r866",
      "r867",
      "r868",
      "r869",
      "r904",
      "r907",
      "r908",
      "r909",
      "r911",
      "r913",
      "r914",
      "r915"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Warrant liability",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r905",
      "r906",
      "r911",
      "r914",
      "r915",
      "r916",
      "r917"
     ]
    },
    "limn_ForgivenessOfUnrelatedVendorPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ForgivenessOfUnrelatedVendorPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of forgiveness of unrelated vendor payable.",
        "label": "Forgiveness Of Unrelated Vendor Payable",
        "negatedLabel": "Forgiveness of unrelated vendor payables",
        "terseLabel": "Forgiveness of unrelated vendor payables"
       }
      }
     },
     "auth_ref": []
    },
    "limn_FranchiseTaxExpenseIncludingInterestAndPenalty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "FranchiseTaxExpenseIncludingInterestAndPenalty",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of franchise tax expense and related interest and penalties incurred by the company during the period.",
        "label": "Franchise Tax Expense Including Interest And Penalty",
        "terseLabel": "Franchise tax, penalties and interest"
       }
      }
     },
     "auth_ref": []
    },
    "limn_GainLossOnIssuanceOfCommonStockForWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "GainLossOnIssuanceOfCommonStockForWarrants",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The profit or loss on exchange of common stock for surrender of warrants classified as non-operating income. Represents the difference in the fair value of common stock and warrants.",
        "label": "Gain (Loss) on Issuance of Common Stock for Warrants",
        "negatedLabel": "Loss on issuance of common stock in connection with the surrendar of warrants",
        "terseLabel": "Loss on issuance of common stock",
        "verboseLabel": "Loss on exchange of common stock for warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r621"
     ]
    },
    "limn_GrossProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "GrossProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Gross Proceeds from Issuance of Warrants",
        "terseLabel": "Allocated Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "limn_HanaAugust2024LoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "HanaAugust2024LoansMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Hana August 2024 Loans.",
        "label": "Hana August 2024 Loans [Member]",
        "terseLabel": "Hana August 2024 Loans"
       }
      }
     },
     "auth_ref": []
    },
    "limn_HanaImmunotherapeuticsLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "HanaImmunotherapeuticsLlcMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Hana Immunotherapeutics, LLC.",
        "label": "Hana Immunotherapeutics, LLC [Member]",
        "terseLabel": "Hana Immunotherapeutics, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "limn_HanaLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "HanaLoansMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Hana Loans.",
        "label": "Hana Loans [Member]",
        "terseLabel": "Hana Loans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r99",
      "r316",
      "r321",
      "r325",
      "r326",
      "r327",
      "r330",
      "r336",
      "r344",
      "r346",
      "r347",
      "r348",
      "r524",
      "r558",
      "r569",
      "r711"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Accrued interest or penalties",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetails",
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax provision expense/(benefit)",
        "totalLabel": "Income tax provision",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r61",
      "r95",
      "r119",
      "r120",
      "r134",
      "r145",
      "r154",
      "r320",
      "r321",
      "r345",
      "r542",
      "r675",
      "r677",
      "r679",
      "r711"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r318",
      "r319",
      "r330",
      "r331",
      "r335",
      "r340",
      "r563"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r711",
      "r888"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Statutory federal income tax rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r711"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other permanent differences",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r711",
      "r888",
      "r889"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes, net of federal expense",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r711",
      "r888"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net",
        "verboseLabel": "Income tax obligations",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r91",
      "r337",
      "r338"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued interest to related party classified as current.",
        "label": "Increase (Decrease) In Accrued Interest to Related Party, Current",
        "negatedLabel": "Accrued interest, related parties"
       }
      }
     },
     "auth_ref": []
    },
    "limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "IncreaseDecreaseInAccruedMaintenanceFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued maintenance fee classified as current.",
        "label": "Increase (Decrease) In Accrued Maintenance Fees, Current",
        "negatedLabel": "Accrued maintenance fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDueFromRelatedPartiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      },
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Due from Related Parties, Current",
        "negatedLabel": "Due from related party, current",
        "documentation": "The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Due to Related Parties, Current",
        "terseLabel": "Due to related parties",
        "verboseLabel": "Due to related party",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in due to research and development partner classified as current.",
        "label": "Increase (Decrease) In Due to Research And Development Partner, Current",
        "negatedLabel": "Due to research and development partner"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      },
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants",
        "terseLabel": "Incremental common shares (in shares)",
        "verboseLabel": "Incremental common shares",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r132"
     ]
    },
    "limn_InnobationBioCo.LtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "InnobationBioCo.LtdMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to InnoBation Bio Co. Ltd.",
        "label": "Innobation Bio Co. Ltd [Member]",
        "terseLabel": "Innobation Bio Co. Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense relating to loan",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r252",
      "r260",
      "r696",
      "r697",
      "r968"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Nonoperating",
        "negatedLabel": "Interest expense, related parties",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r675",
      "r679",
      "r793"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r143",
      "r154",
      "r687",
      "r792"
     ]
    },
    "limn_IrisAcquisitionCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "IrisAcquisitionCorpMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Iris Acquisition Corp.",
        "label": "Iris Acquisition Corp [Member]",
        "terseLabel": "Iris"
       }
      }
     },
     "auth_ref": []
    },
    "limn_IrisAcquisitionHoldingsLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "IrisAcquisitionHoldingsLlcMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Iris Acquisition Holdings, LLC.",
        "label": "Iris Acquisition Holdings, LLC [Member]",
        "terseLabel": "Iris Acquisition Holdings, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r19",
      "r20",
      "r21",
      "r23",
      "r24",
      "r25",
      "r26",
      "r95",
      "r97",
      "r98",
      "r191",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r412",
      "r415",
      "r416",
      "r455",
      "r596",
      "r682",
      "r698",
      "r750",
      "r883",
      "r924",
      "r925"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' deficit",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r53",
      "r534",
      "r731",
      "r737",
      "r738",
      "r836",
      "r841",
      "r870",
      "r918"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' DEFICIT",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' DEFICIT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Assumed",
        "terseLabel": "Liabilities assumed in connection with the Business Combination",
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r16"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r73",
      "r95",
      "r97",
      "r98",
      "r191",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r412",
      "r415",
      "r416",
      "r455",
      "r731",
      "r883",
      "r924",
      "r925"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "limn_LiabilityOfUnderwritingFeesFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "LiabilityOfUnderwritingFeesFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability of underwriting fees fair value.",
        "label": "Liability of Underwriting Fees Fair Value",
        "terseLabel": "Liability of underwriting fees"
       }
      }
     },
     "auth_ref": []
    },
    "limn_LicenseAgreementMaintenanceFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "LicenseAgreementMaintenanceFees",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of license agreement incurred in maintenance fees.",
        "label": "License agreement maintenance fees",
        "terseLabel": "Maintenance fee"
       }
      }
     },
     "auth_ref": []
    },
    "limn_LicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "LicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "limn_LicenseAgreementsTerminationAmountDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "LicenseAgreementsTerminationAmountDue",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount owes pursuant to termination of license agreements by TDT.",
        "label": "License Agreements Termination, Amount Due",
        "terseLabel": "Amount owes pursuant to termination of license agreement"
       }
      }
     },
     "auth_ref": []
    },
    "limn_LicenseAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "LicenseAgreementsTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreements",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for License Agreements.",
        "label": "License Agreements [Text Block]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "limn_LicenseAndDevelopmentAgreementWithTdtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "LicenseAndDevelopmentAgreementWithTdtMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to license and development agreement with TDT (the \"CAR-T License\"), whereby the Company received an exclusive license to develop and commercialize chimeric antigen receptor (\"CAR-T\") products and a non-exclusive license to develop and commercialize companion diagnostics used to monitor treatment with a CAR-T product (the \"CAR-T Diagnostics\").",
        "label": "License And Development Agreement With Tdt [Member]",
        "terseLabel": "License And Development Agreement With TDT"
       }
      }
     },
     "auth_ref": []
    },
    "limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maximum aggregate milestone commitment fund for first product development.",
        "label": "License Maximum Aggregate Milestone Commitments Fund For First Product Development",
        "terseLabel": "Maximum aggregate milestone commitment fund for first product development"
       }
      }
     },
     "auth_ref": []
    },
    "limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maximum milestone commitment fund for each additional product development.",
        "label": "License Maximum Milestone Commitment Fund For Each Additional Product Development",
        "terseLabel": "Maximum milestone commitment fund for each additional product development"
       }
      }
     },
     "auth_ref": []
    },
    "limn_LicenseMilestoneCommitmentFundPayableForEachPhase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "LicenseMilestoneCommitmentFundPayableForEachPhase",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of license milestone commitment fund obligated to pay for each phase.",
        "label": "License Milestone Commitment Fund Payable For Each Phase",
        "terseLabel": "Amount of fund obligated to advance for each phase"
       }
      }
     },
     "auth_ref": []
    },
    "limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of membership interest exchange for license fees being offset to additional paid-in capital.",
        "label": "License Rights, Value Of Units Offset From Additional Paid In Capital",
        "terseLabel": "Value of membership interest offset to additional paid-in capital"
       }
      }
     },
     "auth_ref": []
    },
    "limn_LiminatusAndIrisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "LiminatusAndIrisMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to business combination with Liminatus and Iris.",
        "label": "Liminatus And Iris [Member]",
        "terseLabel": "Liminatus and Iris"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LitigationSettlementInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Settlement Interest",
        "terseLabel": "Litigation settlement interest",
        "documentation": "Interest expense (income) directly attributable to an award in settlement of litigation."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "limn_LoansSettled": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "LoansSettled",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loans settled upon closing of merger in a non-cash transaction.",
        "label": "Loans Settled",
        "terseLabel": "Settlement of loans to Iris Acquisition Corp upon closing of the Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyDamagesAwardedValue",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Loss contingency on damaged value",
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r879",
      "r880"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r217",
      "r218",
      "r219",
      "r220",
      "r303",
      "r307",
      "r308",
      "r309",
      "r313",
      "r438",
      "r515",
      "r550",
      "r551",
      "r557",
      "r588",
      "r589",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665",
      "r666",
      "r691",
      "r699",
      "r709",
      "r712",
      "r714",
      "r715",
      "r721",
      "r722",
      "r726",
      "r727",
      "r734",
      "r885",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931"
     ]
    },
    "limn_MaximumNumbersOfSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "MaximumNumbersOfSharesIssuable",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of shares issuable to underwriters.",
        "label": "Maximum Numbers Of Shares Issuable",
        "terseLabel": "Number of shares issuable to underwriters"
       }
      }
     },
     "auth_ref": []
    },
    "limn_MaximumReimbursementForPlacementAgentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "MaximumReimbursementForPlacementAgentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maximum out-of-pocket costs and expenses incurred in connection with the Offering that will be reimbursed",
        "label": "Maximum Reimbursement For Placement Agent Expenses",
        "terseLabel": "Placement agent fee, maximum reimbursement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Expected dividends",
        "verboseLabel": "Dividend yield",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r907",
      "r908",
      "r909"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected life of warrants (years)",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r907",
      "r908",
      "r909"
     ]
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Option Volatility [Member]",
        "terseLabel": "Expected stock volatility",
        "verboseLabel": "Expected volatility",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r908",
      "r909"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r907",
      "r908",
      "r909"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r436",
      "r437",
      "r438",
      "r712",
      "r714",
      "r715",
      "r721"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r438",
      "r712",
      "r714",
      "r715",
      "r721"
     ]
    },
    "limn_MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of transaction costs incurred upon closing of merger during the period in a non-cash or part non-cash transaction.",
        "label": "Merger Transaction Costs Incurred In Noncash Or Partial Noncash Transaction",
        "terseLabel": "Transaction costs incurred upon closing of the Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r217",
      "r218",
      "r219",
      "r220",
      "r303",
      "r307",
      "r308",
      "r309",
      "r313",
      "r438",
      "r515",
      "r550",
      "r551",
      "r557",
      "r588",
      "r589",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665",
      "r666",
      "r691",
      "r699",
      "r709",
      "r712",
      "r714",
      "r715",
      "r721",
      "r722",
      "r726",
      "r734",
      "r885",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:",
        "verboseLabel": "Cash Flows from Investing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r42",
      "r54",
      "r65",
      "r71",
      "r81",
      "r82",
      "r86",
      "r95",
      "r97",
      "r98",
      "r102",
      "r108",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r119",
      "r120",
      "r129",
      "r191",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r262",
      "r265",
      "r268",
      "r273",
      "r312",
      "r352",
      "r408",
      "r432",
      "r455",
      "r538",
      "r618",
      "r639",
      "r640",
      "r675",
      "r677",
      "r679",
      "r748",
      "r883"
     ]
    },
    "limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "NetIncomeLossPerCommonStockPolicyPolicyTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of policy for net income (loss) per common stock.",
        "label": "Net income (loss) per Common Stock Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share of Common Stock",
        "verboseLabel": "Net loss per Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "limn_NetProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "NetProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Net Proceeds from Issuance of Warrants",
        "terseLabel": "Allocated Net Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements - Not Yet Adopted",
        "verboseLabel": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "limn_NonRedeemableWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "NonRedeemableWarrantMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to non-redeemable warrant.",
        "label": "Non Redeemable Warrant [Member]",
        "terseLabel": "Non-redeemable warrant"
       }
      }
     },
     "auth_ref": []
    },
    "limn_NoncashConversionOfAmountBorrowedForPipeFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "NoncashConversionOfAmountBorrowedForPipeFunds",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of borrowed funds for PIPE transactions that are converted in a non-cash or part non-cash transactions.  \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash Conversion Of Amount Borrowed For PIPE Funds",
        "terseLabel": "Non-cash conversion of short term debt, related parties for PIPE Funds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "terseLabel": "Non related party",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r844",
      "r845"
     ]
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesAndLoansReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Loan receivable",
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r859"
     ]
    },
    "limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "NumberOfMilestonePaymentsForEachAdditionalProductDevelopment",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of milestone developmental and regulatory milestone payments for each additional product development.",
        "label": "Number Of Milestone Payments For Each Additional Product Development",
        "terseLabel": "Number of developmental and regulatory milestone payments for each additional product development"
       }
      }
     },
     "auth_ref": []
    },
    "limn_NumberOfMilestonePaymentsForFirstProductDevelopment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "NumberOfMilestonePaymentsForFirstProductDevelopment",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of milestone developmental and regulatory milestone payments for first product development.",
        "label": "Number Of Milestone Payments For First Product Development",
        "terseLabel": "Number of developmental and regulatory milestone payments for first product development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r853"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segment",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r684",
      "r690",
      "r853"
     ]
    },
    "limn_NumberOfSharesHeldInEachUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "NumberOfSharesHeldInEachUnit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of common shares held in each Iris unit.",
        "label": "Number Of Shares Held In Each Unit",
        "terseLabel": "Number of shares held in each unit (in shares)",
        "verboseLabel": "Number of shares held in each unit"
       }
      }
     },
     "auth_ref": []
    },
    "limn_NumberOfUnitsExchangeForLicenseRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "NumberOfUnitsExchangeForLicenseRights",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of member units exchanged as a consideration for license rights to develop, market and sell YN1203, InnoBation Bio CAR NK biomarkers, including devices, compounds and products used to detect analyte in body or tissue.",
        "label": "Number Of Units Exchange For License Rights",
        "terseLabel": "Number of member units exchange for license rights to develop",
        "verboseLabel": "Number of member units exchange for license rights to develop, market and sell YN1203, InnoBation Bio CAR NK biomarker"
       }
      }
     },
     "auth_ref": []
    },
    "limn_NumberOfWarrantsHeldInEachUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "NumberOfWarrantsHeldInEachUnit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants held in each Iris unit.",
        "label": "Number Of Warrants Held In Each Unit",
        "terseLabel": "Number of warrants held in each unit (in shares)",
        "verboseLabel": "Number of warrants held in each unit"
       }
      }
     },
     "auth_ref": []
    },
    "limn_OfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "OfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of offering costs involved in the issuance of common stock.",
        "label": "Offering Costs",
        "terseLabel": "Offering costs",
        "verboseLabel": "Allocated Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "negatedLabel": "Loss from operations",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r675",
      "r679",
      "r683",
      "r852",
      "r854",
      "r855",
      "r856",
      "r857"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating losses",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Organization and Business Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of Organization and Business Operations",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r66",
      "r67",
      "r69",
      "r560",
      "r561"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Due to related parties",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r731"
     ]
    },
    "us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivableAfterAllowanceForCreditLossNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Due from related party, non-current",
        "documentation": "Amount, after allowance for credit loss, of receivable classified as other and noncurrent."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "limn_OtherReceivableWriteOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "OtherReceivableWriteOff",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable deemed as uncollectible and written off.",
        "label": "Other Receivable, Write Off",
        "terseLabel": "Forgiveness of related party receivables",
        "verboseLabel": "Uncollectible due from related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Due from related party, current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "limn_PaymentForCostsAssociatedWithClinicalTrials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "PaymentForCostsAssociatedWithClinicalTrials",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment made for costs associated with clinical trials.",
        "label": "Payment For Costs Associated With Clinical Trials",
        "terseLabel": "Company issued a payment"
       }
      }
     },
     "auth_ref": []
    },
    "limn_PaymentOfOfferingCostsInCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "PaymentOfOfferingCostsInCash",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid in cash for offering costs.",
        "label": "Payment of Offering Costs in Cash",
        "terseLabel": "Underwriting discount paid in cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfMergerRelatedCostsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Merger Related Costs, Financing Activities",
        "negatedLabel": "Payment of transaction costs",
        "documentation": "The cash outflow for financing costs associated with business combinations."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to acquire businesses",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r392",
      "r712",
      "r713",
      "r716"
     ]
    },
    "us-gaap_PaymentsToAcquireLoansReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireLoansReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Loans Receivable",
        "negatedLabel": "Loans to Iris Acquisition Corp",
        "documentation": "The cash outflow for the purchase of loan receivable arising from the financing of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "limn_PercentOfOfferingPriceRepresentingExercisePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "PercentOfOfferingPriceRepresentingExercisePrice",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the public offering price for the shares of common stock and common warrants offered in the Offering representing exercise price.",
        "label": "Percent of Offering Price Representing Exercise Price",
        "terseLabel": "Percent of offering price"
       }
      }
     },
     "auth_ref": []
    },
    "limn_PercentOfSharesIssuedInOffering": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "PercentOfSharesIssuedInOffering",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock sold in the offering, threshold percentage on the total number of outstanding shares.",
        "label": "Percent Of Shares Issued In The Offering",
        "terseLabel": "Percent of shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "PeriodOfNonIssuanceOfCommonStockFollowingClosingDate",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period during which shares will not be issued after the closing date of the offering",
        "label": "Period Of Non Issuance Of Common Stock Following Closing Date",
        "terseLabel": "Period of non issuance of common stock following closing date"
       }
      }
     },
     "auth_ref": []
    },
    "limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period during which common stock or any securities convertible into or exercisable or exchangeable for shares of common stock involving a variable rate transaction will not be issued after the closing date of the offering.",
        "label": "Period Of Non Issuance Of Common Stock Involving Variable Rate Transaction Following Closing Date",
        "terseLabel": "Period of non issuance of common stock involving variable rate transaction following closing date"
       }
      }
     },
     "auth_ref": []
    },
    "limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Phase II and Phase III clinical trials of CAR-T product.",
        "label": "Phase II and Phase III Clinical Trials Of Car T Product [Member]",
        "terseLabel": "Phase II and Phase III clinical trials of CAR-T Product"
       }
      }
     },
     "auth_ref": []
    },
    "limn_PlacementAgentCashFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "PlacementAgentCashFeePercentage",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of cash fee for placement agent, calculated on aggregate gross proceeds raised.",
        "label": "Placement Agent Cash Fee, Percentage",
        "terseLabel": "Placement agent fee, percent"
       }
      }
     },
     "auth_ref": []
    },
    "limn_PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "PlacementAgentWarrantsMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to placement agent warrants.",
        "label": "Placement Agent Warrants [Member]",
        "terseLabel": "Placement Agent Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "limn_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to pre funded warrants.",
        "label": "Pre Funded Warrants [Member]",
        "terseLabel": "Pre-funded warrants",
        "verboseLabel": "Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r275"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "verboseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r598"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r275"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r598",
      "r617",
      "r969",
      "r970"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r264",
      "r270",
      "r531",
      "r731"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "limn_PrepaidResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "PrepaidResearchAndDevelopmentExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prepaid research and development classified as current.",
        "label": "Prepaid Research And Development Expense, Current",
        "terseLabel": "Prepaid research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "limn_PrincipalAndAccruedInterestOnPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "PrincipalAndAccruedInterestOnPrivatePlacement",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of principal and accrued interest converted into shares.",
        "label": "Principal and Accrued Interest on Private Placement",
        "terseLabel": "Principal and accrued interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "limn_PrivatePlacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "PrivatePlacementWarrantsMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to private placement warrants.",
        "label": "Private Placement Warrants [Member]",
        "terseLabel": "Private placement warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Total consideration",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Gross proceeds from issuance of common stock for PIPE investment",
        "verboseLabel": "Proceeds from issuance of common stock, net",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "limn_ProceedsFromIssuanceOfPrivatePlacementInvestor": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ProceedsFromIssuanceOfPrivatePlacementInvestor",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private placement investor rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement Investor",
        "terseLabel": "Proceeds from issuance of private placement investor"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ProceedsFromIssuanceOfPrivatePlacementInvestorFunded",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from private placement investor funded indirectly.",
        "label": "Proceeds from Issuance of Private Placement Investor Funded",
        "terseLabel": "Proceeds from issuance of private placement investor funded"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromShortTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Short-Term Debt",
        "terseLabel": "Proceeds from issuance of short-term debt, related party",
        "verboseLabel": "Proceeds from bonds",
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r156",
      "r516",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r669",
      "r674",
      "r677",
      "r679",
      "r700",
      "r701",
      "r733",
      "r734",
      "r735",
      "r736",
      "r739",
      "r768",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r881",
      "r882",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r156",
      "r516",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r669",
      "r674",
      "r677",
      "r679",
      "r700",
      "r701",
      "r733",
      "r734",
      "r735",
      "r736",
      "r739",
      "r768",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r881",
      "r882",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r71",
      "r81",
      "r82",
      "r89",
      "r95",
      "r97",
      "r98",
      "r102",
      "r108",
      "r116",
      "r119",
      "r120",
      "r191",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r262",
      "r312",
      "r352",
      "r408",
      "r410",
      "r413",
      "r414",
      "r432",
      "r455",
      "r520",
      "r522",
      "r537",
      "r573",
      "r618",
      "r639",
      "r640",
      "r717",
      "r718",
      "r749",
      "r790",
      "r883"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r470",
      "r523",
      "r536",
      "r731"
     ]
    },
    "limn_ProphaseApril2024LoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ProphaseApril2024LoanMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Prophase April 2024 Loan.",
        "label": "Prophase April 2024 Loan [Member]",
        "terseLabel": "Prophase April 2024 Loan"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ProphaseApril2025LoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ProphaseApril2025LoansMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Prophase April 2025 Loans.",
        "label": "Prophase April 2025 Loans [Member]",
        "terseLabel": "Prophase April 2025 Loans"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ProphaseAugust2024LoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ProphaseAugust2024LoansMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Prophase August 2024 Loans.",
        "label": "Prophase August 2024 Loans [Member]",
        "terseLabel": "Prophase August 2024 Loans"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ProphaseFebruary2024LoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ProphaseFebruary2024LoanMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Prophase February 2024 Loan.",
        "label": "Prophase February 2024 Loan [Member]",
        "terseLabel": "Prophase February 2024 Loan"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ProphaseFebruary2025LoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ProphaseFebruary2025LoanMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Prophase February 2025 Loan.",
        "label": "Prophase February 2025 Loan [Member]",
        "terseLabel": "Prophase February 2025 Loan",
        "verboseLabel": "Prophase February 2025 Loan"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ProphaseFebruary2025LoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ProphaseFebruary2025LoansMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Prophase February 2025 Loans.",
        "label": "Prophase February 2025 Loans [Member]",
        "terseLabel": "Prophase February 2025 Loan"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ProphaseJuly2024LoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ProphaseJuly2024LoansMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Prophase July 2024 Loans.",
        "label": "Prophase July 2024 Loans [Member]",
        "terseLabel": "Prophase July 2024 Loans"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ProphaseLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ProphaseLoanMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Prophase Loan.",
        "label": "Prophase Loan [Member]",
        "terseLabel": "Prophase Loan"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ProphaseMarch2024LoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ProphaseMarch2024LoanMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Prophase March 2024 Loan.",
        "label": "Prophase March 2024 Loan [Member]",
        "terseLabel": "Prophase March 2024 Loan"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ProphaseMarch2025LoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ProphaseMarch2025LoanMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Prophase March 2025 Loan.",
        "label": "Prophase March 2025 Loan [Member]",
        "terseLabel": "Prophase March 2025 Loan",
        "verboseLabel": "Prophase March 2025 Loan"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ProphaseMarch2025LoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ProphaseMarch2025LoansMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Prophase March 2025 Loans.",
        "label": "Prophase March 2025 Loans [Member]",
        "terseLabel": "Prophase March 2025 Loans"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ProphaseMay2024LoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ProphaseMay2024LoansMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Prophase May 2024 Loans.",
        "label": "Prophase May 2024 Loans [Member]",
        "terseLabel": "Prophase May 2024 Loans"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ProphaseSciencesLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ProphaseSciencesLlcMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Prophase Sciences LLC .",
        "label": "Prophase Sciences LLC [Member]",
        "terseLabel": "Prophase"
       }
      }
     },
     "auth_ref": []
    },
    "limn_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to public warrants.",
        "label": "Public Warrants [Member]",
        "terseLabel": "Public Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r217",
      "r218",
      "r219",
      "r220",
      "r292",
      "r303",
      "r307",
      "r308",
      "r309",
      "r311",
      "r313",
      "r438",
      "r489",
      "r498",
      "r515",
      "r550",
      "r551",
      "r557",
      "r588",
      "r589",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665",
      "r666",
      "r691",
      "r699",
      "r709",
      "r712",
      "r714",
      "r715",
      "r721",
      "r722",
      "r726",
      "r727",
      "r734",
      "r742",
      "r876",
      "r885",
      "r908",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r217",
      "r218",
      "r219",
      "r220",
      "r292",
      "r303",
      "r307",
      "r308",
      "r309",
      "r311",
      "r313",
      "r438",
      "r489",
      "r498",
      "r515",
      "r550",
      "r551",
      "r557",
      "r588",
      "r589",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665",
      "r666",
      "r691",
      "r699",
      "r709",
      "r712",
      "r714",
      "r715",
      "r721",
      "r722",
      "r726",
      "r727",
      "r734",
      "r742",
      "r876",
      "r885",
      "r908",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931"
     ]
    },
    "limn_RedeemableWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "RedeemableWarrantMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to redeemable warrant.",
        "label": "Redeemable Warrant [Member]",
        "terseLabel": "Redeemable warrant"
       }
      }
     },
     "auth_ref": []
    },
    "limn_RelatedPartiesDebtToUnsecuredPromissoryNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "RelatedPartiesDebtToUnsecuredPromissoryNote",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowed from the related parties were used to fund an unsecured promissory note.",
        "label": "Related Parties Debt to Unsecured Promissory Note",
        "terseLabel": "Related parties debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r101",
      "r102",
      "r158",
      "r299",
      "r302",
      "r475",
      "r476",
      "r528",
      "r535",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r616",
      "r648",
      "r967"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related party",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r101",
      "r102",
      "r475",
      "r476",
      "r477",
      "r478",
      "r528",
      "r535",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r616",
      "r648"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Significant Accounting Policies",
        "verboseLabel": "Related Party Transactions",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r101",
      "r102",
      "r158",
      "r475",
      "r476",
      "r478",
      "r622",
      "r623",
      "r626"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r101",
      "r102",
      "r158",
      "r299",
      "r302",
      "r475",
      "r476",
      "r528",
      "r535",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r616",
      "r648",
      "r923",
      "r967"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactions",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r476",
      "r479",
      "r570",
      "r571",
      "r572",
      "r624",
      "r625",
      "r626",
      "r645",
      "r647"
     ]
    },
    "limn_RepaymentOfMembershipInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "RepaymentOfMembershipInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of repayment of membership interest.",
        "label": "Repayment Of Membership Interest",
        "terseLabel": "Repayment of membership interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfShortTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Short-Term Debt",
        "negatedLabel": "Repayment of short-term debt, related party",
        "terseLabel": "Repayment of debt",
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r95",
      "r103",
      "r104",
      "r236",
      "r277",
      "r478",
      "r499",
      "r526",
      "r670",
      "r671",
      "r672",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r899",
      "r900",
      "r901",
      "r902"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense related to the CD47 License",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r667",
      "r675",
      "r676",
      "r687",
      "r932"
     ]
    },
    "limn_ResearchAndDevelopmentExpenseMandatoryCapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ResearchAndDevelopmentExpenseMandatoryCapitalization",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of research and development expense subject to mandatory capitalization.",
        "label": "Research and Development Expense, Mandatory Capitalization",
        "terseLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r47",
      "r533",
      "r555",
      "r556",
      "r568",
      "r599",
      "r731"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65",
      "r105",
      "r106",
      "r107",
      "r109",
      "r116",
      "r118",
      "r120",
      "r192",
      "r193",
      "r209",
      "r261",
      "r312",
      "r341",
      "r342",
      "r349",
      "r350",
      "r351",
      "r353",
      "r407",
      "r408",
      "r418",
      "r420",
      "r421",
      "r423",
      "r430",
      "r466",
      "r467",
      "r552",
      "r554",
      "r574",
      "r969"
     ]
    },
    "limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of years from the first commercial sale of CAR-T product or CAR-T Diagnostic.",
        "label": "Royalty Fees, Number of Years From First Commercial Sale Of Products",
        "terseLabel": "Number of years from first commercial sale of products (in years)"
       }
      }
     },
     "auth_ref": []
    },
    "limn_RoyaltyFeesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "RoyaltyFeesPercentage",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty fees",
        "label": "Royalty Fees, Percentage",
        "terseLabel": "Percentage of royalty fees (%)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining scenario being the scenario prior to the completion of the Phase I and Phase II clinical trials for the CAR-T product.",
        "label": "Scenario, Prior To Completion of Phase One and Two Clinical Trials for CAR-T Product [Member]",
        "terseLabel": "Prior to the completion of the Phase I and Phase II clinical trials for the CAR-T product"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r68",
      "r70",
      "r121",
      "r304",
      "r766"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r354",
      "r355",
      "r356",
      "r357",
      "r363",
      "r364",
      "r365",
      "r366",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r401",
      "r402",
      "r403",
      "r406",
      "r712",
      "r715",
      "r896",
      "r897",
      "r898"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of income tax provision (benefit)",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of components of deferred tax assets and liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of the effective income tax rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r711",
      "r888"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTables",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value, assets and liabilities measured on recurring basis.",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r905",
      "r906"
     ]
    },
    "limn_ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of offering proceeds and related issuance costs.",
        "label": "Schedule of Offering Proceeds and Related Issuance Costs [Table Text Block]",
        "terseLabel": "Schedule of offering proceeds and related issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r101",
      "r102",
      "r475",
      "r476",
      "r478",
      "r622",
      "r623",
      "r626"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShortTermDebtTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtTables",
      "http://www.liminatuspharma.com/role/DisclosureDebtTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Short-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of debt outstanding",
        "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r155",
      "r157",
      "r685",
      "r686",
      "r689"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Closing stock price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "limn_SharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "SharesAuthorized",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of cumulative shares of all kinds permitted to be issued by an entity's charter and bylaws.",
        "label": "Shares Authorized",
        "terseLabel": "Shares authorized (in shares)",
        "verboseLabel": "Shares authorized"
       }
      }
     },
     "auth_ref": []
    },
    "limn_SharesIssuableUponClosingOfMergerToUnderwriters": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "SharesIssuableUponClosingOfMergerToUnderwriters",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issuable to underwriters upon closing of merger in a non-cash financing activities.",
        "label": "Shares Issuable Upon Closing Of Merger To Underwriters",
        "terseLabel": "Issuance of common stock to underwriter"
       }
      }
     },
     "auth_ref": []
    },
    "limn_SharesIssuedForSurrenderAndCancellationOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "SharesIssuedForSurrenderAndCancellationOfWarrants",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for surrender and cancellation of warrants.",
        "label": "Shares Issued For Surrender And Cancellation Of Warrants",
        "terseLabel": "Number of shares issued for surrender and cancellation of warrants",
        "verboseLabel": "Issuance of common stock in connection with the surrender of warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Offering price (in dollar per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt",
        "terseLabel": "Short-term debt, related parties",
        "verboseLabel": "Amount borrowed",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r50",
      "r731",
      "r934"
     ]
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "terseLabel": "Debt",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short term lease expense",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r730"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPolicies",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94"
     ]
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "State and Local"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r76",
      "r77",
      "r78",
      "r95",
      "r98",
      "r124",
      "r128",
      "r130",
      "r132",
      "r136",
      "r137",
      "r191",
      "r223",
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r263",
      "r264",
      "r266",
      "r267",
      "r269",
      "r272",
      "r275",
      "r276",
      "r279",
      "r282",
      "r289",
      "r455",
      "r564",
      "r565",
      "r566",
      "r567",
      "r574",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r587",
      "r598",
      "r619",
      "r641",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r765",
      "r838",
      "r840",
      "r851"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r28",
      "r31",
      "r32",
      "r63",
      "r64",
      "r65",
      "r84",
      "r85",
      "r86",
      "r105",
      "r106",
      "r107",
      "r109",
      "r116",
      "r118",
      "r120",
      "r135",
      "r192",
      "r193",
      "r209",
      "r261",
      "r291",
      "r312",
      "r341",
      "r342",
      "r349",
      "r350",
      "r351",
      "r353",
      "r407",
      "r408",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r430",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r466",
      "r467",
      "r471",
      "r539",
      "r552",
      "r553",
      "r554",
      "r574",
      "r641"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r135",
      "r263",
      "r264",
      "r266",
      "r269",
      "r467",
      "r516",
      "r562",
      "r575",
      "r587",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r598",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r607",
      "r608",
      "r609",
      "r610",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r620",
      "r621",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r641",
      "r677",
      "r679",
      "r743",
      "r967"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Changes in Stockholders' Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r68",
      "r70",
      "r121",
      "r304",
      "r766",
      "r767"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r135",
      "r158",
      "r263",
      "r264",
      "r266",
      "r269",
      "r467",
      "r516",
      "r562",
      "r575",
      "r587",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r598",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r607",
      "r608",
      "r609",
      "r610",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r620",
      "r621",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r641",
      "r677",
      "r679",
      "r743",
      "r967"
     ]
    },
    "limn_StatutoryStateIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "StatutoryStateIncomeTaxRate",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of state statutory tax rate applicable to pretax income (loss).",
        "label": "Statutory State Income Tax Rate",
        "terseLabel": "California income tax rate"
       }
      }
     },
     "auth_ref": []
    },
    "limn_StockIssuableForSettlementOfDeferredUnderwritingFees": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "StockIssuableForSettlementOfDeferredUnderwritingFees",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issuable for settlement of deferred underwriting fees in connection with the underwriting services provided by the underwriters in the initial public offering.",
        "label": "Stock Issuable For Settlement Of Deferred Underwriting Fees",
        "terseLabel": "Stock issuable for settlement of deferred underwriting fees (in shares)",
        "verboseLabel": "Stock issuable for settlement of deferred underwriting fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued",
        "terseLabel": "Issuance of common stock to Iris Acquisition Holdings, LLC",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r16"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of common stock to Iris Acquisition Holdings, LLC (in shares)",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r47"
     ]
    },
    "limn_StockIssuedDuringPeriodSharesBusinessCombination": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "StockIssuedDuringPeriodSharesBusinessCombination",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to business combination.",
        "label": "Stock Issued During Period, Shares, Business Combination",
        "terseLabel": "Business combination with IRIS, net of transaction costs (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock issued in exchange for original debt being and member units being converted in connection with the consummation of business combination.",
        "label": "Stock Issued During Period, Shares, Conversion Of Debt And Member Units",
        "terseLabel": "Conversion of debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares issued (in shares)",
        "verboseLabel": "Issuance of common stock in connection with the Offering, net of offering costs of $559,962 (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r27",
      "r28",
      "r47",
      "r564",
      "r641",
      "r655"
     ]
    },
    "limn_StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period for surrender and cancellation of warrants.",
        "label": "Stock Issued during The Period, Shares, Surrender And Cancellation Of Warrants",
        "terseLabel": "Issuance of common stock in connection with the Clear Street settlement (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of common stock to Iris Acquisition Holdings, LLC",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r28",
      "r31",
      "r32",
      "r47"
     ]
    },
    "limn_StockIssuedDuringPeriodValueBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "StockIssuedDuringPeriodValueBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to business combination during the period.",
        "label": "Stock Issued During Period Value Business Combination",
        "terseLabel": "Business combination with IRIS, net of transaction costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock for the PIPE investment",
        "verboseLabel": "Issuance of common stock in connection with the Offering, net of offering costs of $559,962",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r27",
      "r28",
      "r47",
      "r574",
      "r641",
      "r655",
      "r749"
     ]
    },
    "limn_StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during the period for surrender and cancellation of warrants.",
        "label": "Stock Issued during The Period, Values, Surrender And Cancellation Of Warrants",
        "terseLabel": "Issuance of common stock in connection with the Clear Street settlement"
       }
      }
     },
     "auth_ref": []
    },
    "limn_StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued or issuable to underwriters upon consummation of business combination in a non-cash transaction.",
        "label": "Stock Issued Or issuable To Underwriters Upon Consummation Of Business Combination",
        "terseLabel": "Fair value of shares to be issued to underwriter on date of the Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "limn_StockIssuedPeriodOfCommonStockToUnderwriter": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "StockIssuedPeriodOfCommonStockToUnderwriter",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued of common stock to underwriter",
        "label": "Stock issued Period of Common Stock to Underwriter",
        "terseLabel": "Issuance of common stock to underwriter (In shares)"
       }
      }
     },
     "auth_ref": []
    },
    "limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued value for surrender and cancellation of warrants.",
        "label": "Stock issued Period Value For Surrender And Cancellation Of Warrants",
        "terseLabel": "Issuance of common stock in connection with the surrender of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "limn_StockIssuedPeriodValueOfCommonStockToUnderwriter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "StockIssuedPeriodValueOfCommonStockToUnderwriter",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued value of common stock to underwriter",
        "label": "Stock issued Period Value of Common Stock to Underwriter",
        "terseLabel": "Issuance of common stock to underwriter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' deficit",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r31",
      "r32",
      "r43",
      "r600",
      "r617",
      "r642",
      "r643",
      "r731",
      "r750",
      "r836",
      "r840",
      "r841",
      "r870",
      "r918",
      "r969"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholder's Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquity",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquitys"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholder's Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r274",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r291",
      "r417",
      "r429",
      "r644",
      "r646",
      "r659"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Events",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r481"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r481"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r481"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r481"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r481"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEvents",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r482"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Description of Organization and Business Operations",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "TenYearsPeriodFromFirstCommercialSaleOfProductMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining scenario being the net sale of period of 10 years from the first commercial sale of the CAR-T product or CAR-T Diagnostic until the product's patent expires in an individual country.",
        "label": "Ten Years Period From First Commercial Sale Of Product [Member]",
        "terseLabel": "10 years from first commercial sale of products"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold period for settling remaining deferred underwriting fee from the date of business combination.",
        "label": "Threshold Period For Remaining Deferred Underwriting Fee Settlement From Date of Business Combination",
        "terseLabel": "Threshold period for settling remaining deferred underwriting fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r257",
      "r287",
      "r417",
      "r428",
      "r452",
      "r454",
      "r456",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r525",
      "r540",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r732",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r866",
      "r867",
      "r868",
      "r869",
      "r904",
      "r907",
      "r908",
      "r909",
      "r911",
      "r913",
      "r914",
      "r915"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "limn_UnderwritingCostsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "UnderwritingCostsNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the carrying value as of balance sheet date of underwriting fees payable or classified as noncurrent.",
        "label": "Underwriting Costs Noncurrent",
        "terseLabel": "Underwriting discount"
       }
      }
     },
     "auth_ref": []
    },
    "limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of underwriting discount on gross proceeds of the IPO.",
        "label": "Underwriting Discount as Percentage of Gross Proceeds from Initial Public Offering",
        "terseLabel": "Underwriting discount (in percentage)"
       }
      }
     },
     "auth_ref": []
    },
    "limn_UnderwritingDiscountPaidInSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "UnderwritingDiscountPaidInSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid in shares for offering costs.",
        "label": "Underwriting discount paid in securities",
        "terseLabel": "Underwriting discount paid in securities"
       }
      }
     },
     "auth_ref": []
    },
    "limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of interest rate of short-term debt being converted from the unpaid annual maintenance fees.",
        "label": "Unpaid Annual Maintenance Fees, Short - Term Debt, Interest Rate",
        "terseLabel": "Unpaid annual maintenance fees, short term debt interest rate (%)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits",
        "verboseLabel": "Uncertain tax positions",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r329",
      "r710"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetails",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, interest and penalties accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r710"
     ]
    },
    "limn_UnsecuredPromissoryNoteSettledAndConverted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "UnsecuredPromissoryNoteSettledAndConverted",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails",
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unsecured promissory note was settled and related party debts were ultimately converted into shares of the Company in a noncash transaction.",
        "label": "Unsecured Promissory Note Settled and Converted",
        "terseLabel": "Unsecured promissory note settled and converted"
       }
      }
     },
     "auth_ref": []
    },
    "limn_UpfrontPaymentOfLicenseAgreementFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "UpfrontPaymentOfLicenseAgreementFees",
     "crdr": "credit",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails",
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront payment of license agreement fee.",
        "label": "Upfront Payment Of License Agreement Fees",
        "terseLabel": "Upfront payment of license agreement fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r138",
      "r139",
      "r140",
      "r141",
      "r520",
      "r522",
      "r681"
     ]
    },
    "limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "VaccineLicenseAndDevelopmentAgreementWithTdtMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to license and development agreement with TDT (the \"Vaccine License\"), whereby the Company received an exclusive license to develop and commercialize vaccine products (the \"Vaccine Products\") and a non-exclusive license to develop and commercialize companion diagnostics used to monitor treatment with a Vaccine Product (the \"Vaccine Diagnostics\").",
        "label": "Vaccine License And Development Agreement With Tdt [Member]",
        "terseLabel": "Vaccine license and development agreement with TDT"
       }
      }
     },
     "auth_ref": []
    },
    "limn_VaccineProductsAndVaccineDiagnosticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "VaccineProductsAndVaccineDiagnosticsMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to product being vaccine products (the \"Vaccine Products\") and Vaccine Diagnostics.",
        "label": "Vaccine Products And Vaccine Diagnostics [Member]",
        "terseLabel": "Vaccine Products and Vaccine Diagnostics"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ValetudoAugust2023LoanOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ValetudoAugust2023LoanOneMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Valetudo August 2023 Loans.",
        "label": "Valetudo August 2023 Loan One [Member]",
        "terseLabel": "Valetudo August 2023 Loan One"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ValetudoAugust2023LoanTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ValetudoAugust2023LoanTwoMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Valetudo August 2023 Loan one.",
        "label": "Valetudo August 2023 Loan Two [Member]",
        "terseLabel": "Valetudo August 2023 Loan Two"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ValetudoAugust2023LoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ValetudoAugust2023LoansMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Valetudo August 2023 Loans.",
        "label": "Valetudo August 2023 Loans [Member]",
        "terseLabel": "Valetudo August 2023 Loans"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ValetudoDecember2022LoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ValetudoDecember2022LoanMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Valetudo December 2022 Loan.",
        "label": "Valetudo December 2022 Loan [Member]",
        "terseLabel": "Valetudo December 2022 Loan"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ValetudoDecember2022LoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ValetudoDecember2022LoansMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Valetudo December 2022 Loans.",
        "label": "Valetudo December 2022 Loans [Member]",
        "terseLabel": "Valetudo Loan"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ValetudoJanuary2024LoanOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ValetudoJanuary2024LoanOneMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Valetudo January 2024 Loan one.",
        "label": "Valetudo January 2024 Loan One [Member]",
        "terseLabel": "Valetudo January 2024 Loan One"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ValetudoJanuary2024LoanTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ValetudoJanuary2024LoanTwoMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Valetudo January 2024 Loan two.",
        "label": "Valetudo January 2024 Loan Two [Member]",
        "terseLabel": "Valetudo January 2024 Loan Two"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ValetudoJanuary2024LoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ValetudoJanuary2024LoansMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Valetudo January 2024 Loans.",
        "label": "Valetudo January 2024 Loans [Member]",
        "terseLabel": "Valetudo January 2024 Loans"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ValetudoJuly2023LoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ValetudoJuly2023LoanMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Valetudo July 2023 Loan.",
        "label": "Valetudo July 2023 Loan [Member]",
        "terseLabel": "Valetudo July 2023 Loan"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ValetudoJune2023LoanOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ValetudoJune2023LoanOneMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Valetudo June 2023 Loans.",
        "label": "Valetudo June 2023 Loan One [Member]",
        "terseLabel": "Valetudo June 2023 Loan One"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ValetudoJune2023LoanTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ValetudoJune2023LoanTwoMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Valetudo June 2023 Loan one.",
        "label": "Valetudo June 2023 Loan Two [Member]",
        "terseLabel": "Valetudo June 2023 Loan Two"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ValetudoJune2023LoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ValetudoJune2023LoansMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetails",
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Valetudo June 2023 Loans.",
        "label": "Valetudo June 2023 Loans [Member]",
        "terseLabel": "Valetudo June 2023 Loans"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ValetudoLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ValetudoLoanMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Valetudo Loan.",
        "label": "Valetudo Loan [Member]",
        "terseLabel": "Valetudo Loan"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ValetudoNovember2023LoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ValetudoNovember2023LoanMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDebtDetailss",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining toValetudo January 2024 Loans.",
        "label": "Valetudo November 2023 Loan [Member]",
        "terseLabel": "Valetudo November 2023 Loan"
       }
      }
     },
     "auth_ref": []
    },
    "limn_ValetudoTherapeuticsLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ValetudoTherapeuticsLlcMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Valetudo Therapeutics LLC.",
        "label": "Valetudo Therapeutics LLC [Member]",
        "terseLabel": "Valetudo Therapeutics LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetailss": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails",
      "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "limn_ViralGeneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "ViralGeneMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Viral Gene.",
        "label": "Viral Gene [Member]",
        "terseLabel": "Viral Gene"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details",
      "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r741",
      "r744",
      "r745",
      "r746",
      "r747"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss",
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrant liability",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r908",
      "r909"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r908",
      "r909"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails",
      "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails",
      "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss",
      "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Contractual term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r908",
      "r909"
     ]
    },
    "limn_WarrantsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.liminatuspharma.com/20260331",
     "localname": "WarrantsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies",
      "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for warrants.",
        "label": "Warrants, Policy [Policy Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding - diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r132"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding - basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r132"
     ]
    }
   }
  },
  "limn-20260331xexfees.htm": {
   "dts": {
    "inline": {
     "local": [
      "limn-20260331xexfees.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 8,
    "http://xbrl.sec.gov/ffd/2026": 6,
    "http://xbrl.sec.gov/dei/2026": 2
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2026": 22,
    "http://xbrl.sec.gov/dei/2026": 3
   },
   "report": {
    "R88": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "88",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R89": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "89",
     "firstAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xexfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xexfees.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "90",
     "firstAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xexfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "limn-20260331xexfees.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r759"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r759"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r759"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r759"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r759"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r759"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal8ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r759"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r759"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r756",
      "r759"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r759"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r759"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-26"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-4"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>113
<FILENAME>0001104659-26-076958-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-26-076958-xbrl.zip
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M>N-5X:=]E$+Z4SHC/_\O4$L#!!0    ( 'T+V%PP!E35: T  #[;   5
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MEK0A^NN"__/,JM084$0OWBC\TELXSNIB,%BOUR?KR0DF+^S]X6CPQ_W=H[$
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M@<2&LR\XM<J"[@*0R+\FF)*4(:LLX"\"B0V_!6E@E07=!2"1/U_3_1QE5CG
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MB/UE)ZCZ#SM#N$B"+%NNRIB/S!B*X X-8A=N NK:2' 54@Q0T\,# & +A5+
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MT(GI'8IOU"4F2XBQP2E^\LQXIAE*9DT3V2T-UMDS=1$HSN>8U"=*;JVWR4
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MT24 F@RDG ?$;S67(?&V=4'+DOM8$PW69@F1C'V1^8O",] ?#D ^>N$P?9)
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M<6I=8E7EM?*#C(HA $Z1N@+4(\CATP'["%!'+T37B)2(&,GB8"2 1@'CB.2
MKLDD,U\S8VTDDF8(@/8 X\BB(<BV$*X*1A,])I6?XV\HB2[2LR!\_)QVNIUJ
MP ,H^#=BOYP:5[QOJA?TN2\: :!POQ?_1?2X-$$X?4*$G9)N6!*^9D\,PPD
M%.+W-D\:Y,$ION%&NK=?.PH+4K9A75!_%44G+TSC]F%-;JO,Y@50Q&_J@H]
M-7#5.'M&)(PS5+I .WM4_YJ]-U$']5P V@",H@)J2MT44,Z+_)$N\T^GR9<
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M:;+]B9W6L;5M=UIZ>CQ'*+L.7EB.Y!T^:3[]BSH3[_.&-5))LV*]KIMJ:J9
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M$MU-G/UU3MVZ=A,M(_'))@!P-3I,A#+B0(GQ['F#0FKF3^.G.$)I9"Q&V00
M+CR'B5%&')B0>&O;OE1DM:B'39:IHDL1/_O$R(UQGF R_+*U:5MX@@G!7UBR
MJ>@JE0<)P)SV$B^/%CA-</=#K&U+7[Z.$@F[,/69 ( I[2-"$Q+A2+9,=5RN
M_BC+7_(E*3-:ED6>Y4'*,KU%.8/*80 :Z_:1HIHPX+([>V9=@S)T3>(0;7_,
MZE^S]R8"5<\%H+_N:%)64PM'] UR<^JHE=BI/UGY$ !M<_L(4D[4<<CKT!/O
M(;_N%  ZW8XMSRZ1QR%?YM;UD&DU#$!CVK'E6!$&1W;7!(<(167KO;VFZ0*A
M2> !M(CM(RT)17#$M.]??TZ#-44T_H=%++*07;9J'3VXXR#T@QU^Y."2!E5^
M[?/1V6J%0I:&/^ 8R9T#0L_8<8^27#)AR7B!TR=$V'7/DL0/,<6"_;7J7B0Z
M?6B,@] 1MJ\L%:3!D5\+T=5MCL._;A\#JGK5GRGEPM.C>IQ3^8T8UM$@S799
M5[GL1985U+ 7A'I0U;.G;40J_$JM2NL\HK(<B9<_-6@ZIV(<(:XSG&+;TIV'
M(:&(-59^41""^$\9B""=RF2$*(R4&#C&L$&-W8R5G>V$)P(NI%.IC!A2X1(#
MM&:1=5\-49+\A<DE#M(>=8L?C.H6Z7IOF@5G;$5?O.B+%]VFN?GB10ZBOG@1
M0LJ;+UX$$%CQQ8N^>-&JT0)8O'C@!LK?)N   K ]VD6, A+ &'Z?HN=3]'R*
MWM2[S"D*":)GS=:C<EK;#7?<JTC(XU(&-*SQ>Y"@O(@P,_!]FC%UGE"3!C6:
MU<J AF_'Y",:/J(QO1OE(QH^HN$C&CZBX2,:7V5$H^T!BL,9/"@ 5D<[EL'#
MWR(SZ1&@7(1"?-!CK&C$A$Q6J$>'MR(2+/+Y/T6*Z*\?R_.$FLE<\ F#!*8<
MYN+OB+W+E%_"K#, BA)+U$7*ZQ8ICKA]]P6;<;LU (I"]^5VBQ2KW$Y>FA5U
M6-V%GC!896XXNNA;Y.V\>"BRW, P"P9,6-EIRF$!!<Z8K&6>A4.@&&BIXBAX
M[L9([Z^I9::%0Z 8ZB%<=V.LK_!3XUIJ&FS1B G+B$U-BH@$FYMBD!8!85O%
M=[HNM6#$A%6^QINC@ 1W?-;SK85CH%AON?:H^.[(R=Y?5,_/%HZ!8L&'<7XD
M&^Z[5/LNU;Y+M0VC=?>(2+!!11Z'\H=A%0.F[DS;NW>U@B[?QMJWL?9MK'T;
M:Y^0ZA-2?4+JL26D"IP?ZBT$+TSPRU7UI6>/\:8I&>4Y/XH!1Y9;JD,2G)S@
M+:+9<J73V4@"?Z3M'"44P1'3J^VN.F+'QN/LKKK?_&7;,Z25;&30%D<V_$C;
M-^H3Z+MPC-QQT3?A -P^\9AZ<)Q]H5/W+%3YSJA0A:WDBU1\D8HO4@$26O%%
M*KY(Q1>I^"(57Z3R51:I-)Z?^.;S$ * M=$N3CG$W1(#]8M29-!3)QOQ56&/
MEPX+4=ARMVB3:V8G2L&G3B;2X*P0=_LJJ\%9$?34B?IF*CL:7WT^EL_'\OE8
M8YND!5ZO,,E1^+C EWDDMT@"X*E3*WKG84EH\CE8/@?+YV#Y'"R?@^5SL'P.
MUK'E8/G,$O]NKT_M.O;4KE?P(-;(B5RNWL-Z%;D^(Z1;^5P?@ E8QYCK<TWP
MAD4H^N;[?&^4[].LYG-^?,Z/S_D!<I3W.3\^Y\?G_/B<'Y_S\U7F_+0]0/$M
M&P\*@-71SOWAX6^1F>?HGK1;OZ@9*QHQ=1Z06#TZO!618)'/GRA!C_I,YH)/
MG0]DP&$N_A;9.Z>GUD2?O5SPJ;."#-C+Q=^J]NJT@)-!3]VYTTAWG;1^:Y:K
M6['J,I<+/G430P/N<O&W:1F:[I2Z#!8,F+I_H8EUX%/@QHOX7I/-PB$3QE('
M^!'?NV)UL[/J\ID//V%Q:E]7PAF'F\U5E\-\>)<<_GD<;V(\#OM,8Y]I[#.-
M;1BGVS!&:8CD71\EP%,G$/;.-);0Y#.-?::QSS3VF<8^T]AG&OM,8Y]I[#.-
M.R(\SDSC5Y+".F+FL4]A=9\^[%-8 >85'V,*ZV]!&O1-7_W!*'V5K>135WWJ
MJD]=!7(V]*FK/G75IZ[ZU%6?NOI5IJYN/3_QG4T'!("]T4Y:[2!OB8?:R3P2
MX*GS5 6ZL,=+"QD\K^NBR^;EN[_H\A==7\=%U^M*R+%Y^>T3<GQ"3M<=N5BO
MBQ3GNH^Q*H=,;8IZ)^<H*0-S[/>7]/Z2WE_23QUC\)?T_I+>7]+[2WI_2>\O
MZ8%=TL_7 <4VZWM/_Z/1/7V]F+^J]U?U_JH>R G17]7[JWI_5>^OZOU5_5=Y
M5=_V_\2A7!X4 *NC?6'/P]\>,Z_P4_.8E>KB7C5BZMM[L7H<\E9(@CT^_R=(
M-;MP* 9,W6E*G\LB"GRJA$^5\*D2/E7"ITKX5 F?*C%MJD2SF\MR([HP4QN;
MWLD075+ 1%)\]H//?O#9#U.';7SV@\]^\-D//OO!9S_X[ =@V0^G!;K#>W=7
MYBD0/QFE0- 59SD^@/&9$#X3PF="3'U:])D0/A/BJ\V$.*=;:!K&0:*5#B&$
M?GTY$4)2)Q572<B*GCGF:72+R%,<QNG#<L5!-KNC:&3\GZ06;]PE8-A*A9:W
MY3XN^19.?6?K38++9[FW$5MQO%D"#,!FVM#F[3E10CJ8C<X'JE]]H'K)2D4O
MX^ ^3JA,4,:/TBBACS1@+:0':&#@]Y@$R;]1BNJ3N4$\X&>C>$"YT(RMY*,
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M?"5O@"<+2=Z2BBTI^+ZNX%'&Z,B?H;D,,_%B+ZP]BJ8L8OFEE,Q-?2U7%N0
M(^YDG)F-,?NCF]*=TIV#SQ0\,HQHXXW$AV0>=#+$"C=^F;1OL[[H_'SP8J!1
M;:=?.(*<;B45D=ZI99\/PE+72(G<SORB4EH9NGK*A7T*__;!U$=A75(_Q>U5
M(KD 7&:I;9AW/$W=:( ;W,YUD2&I_A8OD+3(.#HS??H<M1P(W24ICWQ.7ZC^
MQ(S, B0F9Q3R5^*92]+,U5G6F:TQ\EUD51H4'I=G&$3#9[#>7V"[;+/=MB9
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M)@!;4'<_(=G3&(NWP\V',!=;'7&PYJ\^/=$8=OFT5S1#:>#V^E$6:3RS-X0
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MFR*/DC4$-WHH)D[B=VDE0%EWS/)[3N9L\(E?\:S4*UW37=1K5M>6GW(^T!F
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M[AKV*/B1DB$1]=6:892+L,F=24Z'R)QO&G-$OF. '-(,D/\A^1)G<$&$?<I
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M>]V=7[UH'3X3-_AFN+W*6-^E86WVDQ,XC08X<52M2_-F:ODMWB-M+3)..L)
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M76K0Z3RV=!X^&HV"4 6")C6=L:I4FF3979KXE ;9-7//NA!'U[4!O6Z(X6>
MWG4!J?X^R"%IB 933DP^ 1_B>]D. "I*7@B8OE%Z)N7;5XWZL25BB3*R7@[/
M-P:4.=Z>S=M!L3WZYLAH1-%K64P@3YYHOJ.I*.WC)^DA2;V<DH ^YF\M5X*R
M8%W.@Y1,A%GE.E#N3L';T/XBXMC&?O:F'>;#PT\T'XZ&.IT08Z&VSA42]O9
MCH/Z\D^ZS$[S?SH,-&]9Q@$E_IG7O$8_V08NTGOPZGU=@?[/- H>DH]>#G^_
M@I0OH/EUDJ[9X US*+W6=6QB/#6<H#J3E>0<VTA2>%-G4Q4:ZT/ 5WKN846
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M'K$WZT@]>AQ7Q$E-G93DW7BO)7VS6M^P7=\)&<(O\)(25/.""YUAYB?'.+^
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M>C--FR,V-U69;,2%N_F*/)FI]8SMKS?54*C&[^]_*O]&O/[^?U!+ P04
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M!+3B&T1]C2Z"]>(4"73JJ74T))X?C_8>G;0+=;<I2E(@8:6<AO2R8= ^2O0
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M7NV#]FF)T C].6ON-!5$T=%PSVT"[:/KT68A:7R'?U*-=VZ",&,Y"9;L7E[
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M\.$5=.62.BOL[ZZQ@Z#1?2/H!"8*=F):6&/J]50@S7"G0EEIVV^0W0@WFPU
M.1= "U\,IHVSD$\3&V1>O:'66KKR7-CK!?#-U[Z]M>'[H]]>[- 71%I8U]8K
MV6NUG,A-7BA0,_RX,YWHNUV=P[QY#CWSC^2NW>37T*Y$!TQ=O9[JI!GN3">J
MI>"*$=P%002'ULA'%Z8!W_:L/*8$:OPAN&E,=9R*#!=IWJ*YGLFE$W-D*E(M
M#U=Z&UXVT%(2)^%+]I%[#J09K=*2A[8>1#*4:08>RE(74[)G[/,BS=@7[EJ5
MEYCHRO!?3. X?WC^O6>X_,F)*C<*4Y,3P<?]G#UO@![XE:&HZX 1I3(4C8:S
MY5#.OK"<#$498)W#JF5E*)(H%O$"8 YA8[5*7Q35)D.1 @IIR2)=%A3(?:&_
M388BQ>BGL$6GF0)-^S,6HC(4*<!UEX,!(_JO#$7*#0",S-517@-0O806I94C
MY0I&7$&U6:PAH^0_8@>H?6]^BI,KH]%H,M']2#;WM)]N"T$!Q?TXN3(:C4=#
MC1R/&8D8_P(C4NW[C6+W>@U,'Q@!NG]I:[\#%P1LDT),O9X*HQGNK@[5RG-/
M_V8X((PL#XVK#3+G3[B<T]G#8L?T5^[\,_-,R^L[)'FFQ8XMTAU))_5,RQ]H
MQ E G&>Z9XIJY9F6KY"6+/)[IGM&?RO/M%KT4]CB]TSW<TW2PC,]6@XGP]X.
M!HSHOSS3Y>]KN5JHY-,D,M?4,YT"5,\SG5\TDMW2U5(E>*OY3&[&"RX:2CYI
M1G2R._$:!J^!&;\[+#%F8Q-?0Q5F>:@A$,H!4'%R_SMR ?SK)/:VU#.+*=XC
M6EG1R<Z;Q\'IVL4GP*NOH"2OK PQ$$P'JM%G^_+#XZ/X4*'O%-.!*O\5.Y\9
M$!9^RZ65)+=IO\P$3G;"IQI"+Z)M%(0<@RVV0H]H9<<G*,_2:9AE&G()591D
MEYTG)J*U'GB+4)B&7D*5<Z!:ZP'XP7O/%GF,@S"^AI)$-^NQ.0#*3H!6-[LR
MW,CPT:QBRKKTQ=8H8A_/QB,Y5[^+F&6Q Y2=E8R/7+8U,*%.&?]LK,#7RT$5
M&]ETN(J/R24L;.MA0IWSH)L.5_:XC-]*.M%UKA(Y[W(CD0O[UW6N===I2E0)
M%Y-% ;3#JNX>X\L;\(T]B$+;#.X=L[[WQU90B>!V3!$& 7;4L@?\9KT ]WVO
M/>[KZ8#/X[[7T70Q&LJY?:>> @Q=% C*A?-U=M\K1#P;R0GD8B&B2%L]##5[
M4M4.&\KC7&(D-]T6@OQG/3EL*%\@C4BL:H$5J?QKL@AS;C@S-3[1?'2]2;J]
MX,W>9[G;<'-N:H6>L=P0L)H.%ZY!(H4<K#<L"?R)Y7NFAV9X9<<Q=)B7O=L+
M\D:S\6JET6V*9,&T-$ /[J4JYA<_I(O.A=)SI&4G5R^9;PI_ZHM^&L-7=.M6
M:-;DT6PVFVK=5? BE;UGJU#2Y-%L/I=\+;.@[YP5:5=71,E+2G'S S;=+"'%
ME"LA!7K05S**<TQ&,1].9W)28$E*1I$"5L[9K$,R"GEB$2\ 9A<FJU7ZHJA6
MR2CD*Z0EBW194"#WA?Y6R2C4HI_"%IUF"C3M][J$):.0SW67@P$C^J]D%,H-
M (S,U5%> U"]0+%LL4B.#"N64)NW&O.77$0,R&1WW!36V)-/D$NKPB8K'1@"
M.8 I3.8SV(>,1ZHHQ7M )P\RV9O#;!\G YWXTB7,L]5*3KXF,1]G'3 UMW9/
M=;1B/I]*=KMW,2WFPOYUM*(VB%V>2KB8+ J@'58U9\Q7WF[C^2$PWZZ\^]"B
M]^[8PBH1VXXA3+?/CECVE.Q4QRGZV[_3 9_)<0K)WR^5 @Q=W7^0.ARG4( T
MRFL5::N'H69/JMIQBG[VPZUL\76<0BV!-"(1$_3 B%3^<0I]@ZH7X^E(G8W+
M%F)I:0!!CCB9&NKHG,9BO)KK=$Z#J! ^O&HZ\QK'V*]]>VO#]T>_Y0FNQ]3K
MJ3R:X58T>:78<'KM.>9%*ON0A$KA]-J3SXNTJ[,4\L+I'WUOCWRC#4/J9UPA
M]=G#OL+JSS&L?K&<SN2<O)(45I\"5L[IJ$-8O3RQB!< LRN+U2I]452KL'KY
M"FG)(ET6%,A]H;]56+U:]%/8HM-,@:;]GH>PL'KY7'<Y&#"B_PJK5VX 8&2N
MCO(:@.H%">47C>3HH&HIM?FKH:'D,F)$)[L3KV'P%KSZ^03A]6SB:ZC"+ \U
M!$(Y "I.[C=HKS=V9C'%>T0K*SI%P^XS&!=[WW;8.<44+Z)>3E;Z<LJ*3O:&
M7>UWRG(?#;ET"?-TBM*1ZLDH(SA%M]8R%.F]A:R,8HJ74,]&(XG7D;2CE!6=
M[(VUNHXWN^",E55LA3+RI:0\ER(Z7V9\LC.0L<^!9XS<$JJ4T,]G0VV'5AZ$
M7249$SP-9B475[Z$>S$>2[SN3<Q$N!9>2NM245JSR1\KK;CR9=PKF5<TBID+
MU\)+:5VIY58^U5'4Y7(^D?/I=NE*YL+^=12U]O"?/)5P,5D40#NLZGJ9GTT;
MN":@W_!%+*P2L>T8(G3\;(AENRI/=12UO_T['?"9'$65_/U2*<#0U?T'J<-1
M5 5(H[Q6D;9Z&&KVI*H=1>UG/]S*%E]'4?-&64UG2[D":41B50NL2+^.HC8_
MB;F:+58Z'44EBJ6E 7IP%/5$9P]7<[V.)E$5PX];T1UOL6</5\O1?*(SQ[Q(
M96][JW3V<+6:2'+6"_[ 69%VM3\N[^SA/PW7:'CN<,YU[A ]Z.O,X3F>.937
M2T@Z<UCL+-3Q+NEPYE#^D"). ,P^"U:K]$51K<X<RE=(2Q;ILJ! [@O]K<X<
MJD4_A2TZS11HVCNW19TY' ^GR['V5_D0Y<"(_NO,H:N:*AB9JZ.\!J!ZT2"'
MQ2(Y!J141&WF:@@H.8E8H,GNNRG$,0?/$PNK0B8S&Q@"V8')IO)$T3H*?)1=
M#++U@+4+P6P4K2.1WGH*V*)U%!@/3QRMHP)I3-TJ&PPM>U)1T>X][E^9L6L7
M&'GR:'?)7SPSDZ4>NQ56-=<W=[M=Y'KA&_"-/8A"VZ3'O-=4*0(?#><SW2YA
MHLRE>7&K.0XH%K4Y'HW&8[E1,Q)V0.BV^(K:5$L@C4C$;+4R(M6^WY 5L]D?
MJ;0T@.R$0II$;/9++_RXSR%B4W^.>9%^16SVB'Q>I/V+V+S8&1![T#!H<\$5
MM)D^ZRMN\PSC-L>C^6HEYW28G+C-#+!R^PP:Q&U*%(MX 3![+5BMTA=%M8G;
M5$ A+5FDRX("N2_TMXG;5(Q^"EMTFBG0>N:F:A&W*9_K+@<#1O1?<9O*#0",
MS-517@-0O7W-_)*1O)59+:4V?S4TE!U&;.AD=^)T!A^\]_C5&:(XZ36*V-'_
M24RZR4@-GE >@&J3^]^&RY@"F5JA/]1RX%-S@T=\L.YXO)S,>S>SJ@=\)L&Z
MXXFLVUWJ*<#018&@W)JWNV!=!4BCO%:1MGH8LL=(N<&Z\KCLNG]EQOX5K%L;
M$BGWBV=FLM1CM\*J[J*6%IU;+J,2C>WX(*QNJ4#5[-I5B[_MYQ#0RA9?\;=J
M":01B9@M<T:DVO<;TN)OQ\OY4LZ!#\%2:6D -=TSZL7?CE=+2?=&=J 7?MQG
M$7^K/<>\2+_B;WM$/B_2_L7?7D?@Q2O$DG 'X2ZY@G#A P>A5RKS%8M[5K&X
M\OH-2;&XQ>Y#G6T$'6)QY0\RX@3 [,%@M4I?%-4J%G<R&PY'*DY#6%FDRX("
MN2_TMXK%G<RF$W4N;:"P1:>9 DU[E]4MG)ZZIFTX3 &YA-*JL=[EL,!C IU#
M<V-KP9<,+ESK&?COMFF[V_4& S]X@:\1X/]$'3U$/D(U"?+(I"JRSBVCWC;K
MS6[O>)^QG;)M2O)^*[&P:C+HG,B2NXS/,-J/7B?9J)6O(@G+'+HM!#G096[4
MKE$^L7O;>+4=.[1!@/>VUY1632B-R*QJ@@=M5WU(]XY7Y$OF]:G.AJ.R3Q4U
MH[Z;- 9[>&V"<Y142)9+]! X@%Z,S?-9K5)4[70T6LKQ6=$9P+LU&='H[&P0
M=AA4'K.->:N+?R""[ _A@LY\RB>?D;DZRFL JK=N^\UP0!A9WG]'+H!_G=0<
M*:,45YO1&F)*ZS!>F+)78K7D.I\9#!9NRZ7[22T32MDA:01F'WUOCV+";\&K
MGQY^G-+9I=?H$\,-D"H:498A^08-]\9.,:9X'_EEA2D[L*R6W(-"*0,ON70_
MJ65"V574F"!FTR&&E5I,\3YRRPHS)7>N*+G,]Z11*Y20SZ<3N6E711#,#C2E
M>*$8Q5U<@S>=KU9RCWBTH98/9$KK4C%:NTV.,UW,EG)CI=H0W !IRO)*398[
MR9(S78Z&^O;/_$ SM\90,8XQ*[P9]^IW1EPV:,UR Z09S:JYK\H+/4:.,<7[
M2# KS(Q=U5Q8F2/N&IC9F#-F]#X3JO2)Y290,Z:EN;'T/0LA7RP"=A];@M<Y
MW%78D0?Y0FC)(ET6%,@Z;TH+._*@%OT4MN@T,PP2VHX1A>[QOB94%%^X:)C9
M!,Y+=._[.8#*WNQ2*4G/;#I92 X.9B>.PGH-/GVC/)]#S_SCS7/@^S_?_!G9
M_.?HY]68SURC?PD&2;/JQX#FWCI(WOG!"TFQH'6%3_O%7CE&$*PWOQL^G-"$
M:__)WKY1(T+)%53Y?MG8R'^LG)ATGH]AH5*6;<3RJK#=D$-&$1"1]DX#U+49
MI886.B#2R"@#"E3U D<?HU?'-E, M.UO3#DMV*2P4?;(LD*4O?8B^MGM=[AT
M?'0,,SYRR$ JM48)^VH^E+OSW99>?K#*1HV"VPA-DUD8QA8MHH53Z['>7RX'
M2MG+9@*G5]YNY[GQ;/0Q311=SVYMI;(%YM.ISCPWPZMJX&C6$5ULV3IK2OF>
M\<P-5=$(TIQ>+UR+H]MFJM@STIMCEAUBVN@B"V&7F"A*/,MJF@N@<ON:ZMU4
M(D\*7$P6!= .JWHKZ@LG--#NG0N[$_IU);B"*A':CIE2]\Z.5M'E]94##/\Y
MA(8(J;3BRO6656:PLI?2[;=MHM? MFS#_WPVXBW>>*)"]H43RZNB!6&^<#ZD
MLM??[85P!(F^E?4F%]U#]8O75RP9;+9<2+[]DXM9C#*:(59O3+]$N>\W&\\/
M@\1+O-[ %['=+7D8J*E2 CZ?+"53W8RJTG#0!+3LX;Z;';+[FH@F>B75U-'-
M?BD=KFRW76M=/&;O&7]5SV_0RL%%%+YYOOWO8XA+21?T2EKH@DYK51L-(.O?
M9QR=78S"H-3HI2IX\6J_P"A^!G"IO/:3V]9^,YP(/ (_-@-3MT&JW$NAM("N
M_5H$UW6NHS (#=>"LRZ.,297ZPQ4PH99^QE(?K^4KS]AJ-E+F33%K>@&9*+S
MNR"(@'7K^<]Q!F'XIA>N=66X)G"<F*&#U<JKE6:-%"VT&(\DG\MHI0R!)I"]
M3TET;&/,\Q"A!?MZ\PS,R(_33Q]  ^L NS);;=]@_\0CWAR*)MRY-6P_[BK7
MFUP_FGPU.)W0RO=/!MQH%<V_D\.1]78YZ=;PC*G1:Z99\2J:A><?ANW>>] <
M+M(IZI(*XH5#(6WBP%Z[?QIHB5W5E#W7Z<._(RW_0 .7N[T%('@T/I$W^,6[
M!,\@#!UT5W0R:?J^]]PKSPVBW2Z=(UU& ;1D$$!SO*)S@_"7./5T]*C^2>V4
MAA*58ZC%G3.DI4XVFB+,:(X>0T;1#>L-R4+8U4Z#=OJG*6%64#5M474V5EKB
M-92/B'9+AEPL5C/-Y=295?3/E91;!5Q':*O\$?BV9R4&>@ _XC\1@XR8*O=*
M3P*@9Z)1[40(U5&031?)RVF.ZKU2A!#PF294\^!RX%JC.1V<6 4HS51+@13:
M.FNUU%LBDTY;OZ[,>QCC;O/1MTWBW6Z' KU2 R.\C&)I'M=N@M2J3N@KPX'K
MQ,O/[!M("W)%L;&WVDLI=6&33'_2?,%B.IBT2XV_LYH-:&+YHGV6D^%2P?#Y
M1MT/,]I,#:IYB[&FB$%EF-(_,4].<)7+)IG/-(X[$  ]"WQ3S57,-,>Z^0"^
M:0<M%C2'%LY$%WSX,W'T*%*V/KZ-5J57*FD,.).%OM&R%<A8OTA-Z?,0 P5K
MI@.%L^%D_=UO7@@"PJ21J4ZOR&Z..*-<XZA6G.$81H6::B5KK:9]6%@T IU)
M1)HOM!N)9#.E>%)]G$!E"^\1CV[JVBK;=;52,,&:$#$ULD2F,"U"85]@E0"E
M"/[=M\,0N ]>F*S*; _M73X!"^SV]6'4HMKNE;2ZMTPF-=6"9>F@C_[H%]_>
M;H%?@,PO+WI[YR:I!M;(9*1:-"X6*.[CR#KD@Q%>? /- *Z-3_;NBK?A,Q&6
M$+-D"M/"J\N$&(48 C,*[7?0F=CPSR@:>#4;#[5?ZYW"0MEY6&FNY-83_\P*
M%ZZ5F"&WUD$7K!#F^'75RM9:3!1,A<T[G6\$.I-(+^Z@N0B"*/E^@N]!'(AX
M$X0VBHEVMYA#'/Q7UHR9KJSY>9![$616:[#Q_ $XO,M@ U]F\([>9N!M!C_2
M]_FZZZ;#5S_P#[D!\4=R;QNOMA-OWG\#!B+46KM/:$,?A1_" @^>ZV<_7AJ!
M':#ZL7)?@/GFVG]&(*#=EM/E(U7IP?COVSFY572^K26U!XJDOG/W4?@"GT5)
M4D@JKHI:I&F@*D,N4_5-0M2\AN0*!=M,AJ/A0NZEG%P<LDF  K1/(EC'+_^;
MA_(<P*^.?CLK6^62S<;CH=S@/TYVZ^7! 5N05&1&$)?1/]G!'[<^ '<HLS"<
MRCX9(>!2#;F!L@GG8[G'[80KAQ.Z]JG/ROAO/O; #(%U;;_;%EQ=<6N'W$#O
MM<,)75 *-)5ZGLP"R(?12#7'BF>CEAK(^F="Z^0F4P44H<#*B,]6V@]6W5V(
MJH"<^+ADU (%JGJIWG-!=3D'.>]E;?RM:*$$"I/DV,0V!M ^T7-'_?-AK^>T
MKF3\%I,":E5@&)1B<NTS&-,V(<N3U0:;M^4FSD2W=-'P;04SF;"K?EK&KG!V
M9\FC[YD 6+%1@(/R &>IW*Z\H,EN\(1Q-SA[ 6B\Y T&D(F!G[S#P$Y?8F"B
MM_C: S[U5)^V@\MX3\IDN!I*\G;S[[]R8M)YUR/.]HTZNL0R< Z[]UR ^D7*
M/6^T.JJPWI#+JACXT>JLAQ)(ZB(?6U8U_OGIJTJ ':C.U.?6KU0?<J6<:I2S
MTX7I^IG ]6#SLBOWL'3V6W?X?$B_G+L4/YF:8N#H^7FA:N'<Y?+AJMG%\_)2
M[ZKMOK<7?4KET0>W$5IYU_-**-HS5GE0"NJVQ2?UYMUV8=]?&$TG,P7/]W/P
MRPM5>U=QU_?L3D:SB8H)"%M/U^AP9>N"=/6([P5!YH*]A58ZWJ-!.V7/4$T+
MTNF<E?J"IJ 5'<LS_W?L9L>17"C0/SKKX2D[8#^ D/^;K:W4/XJ;0>ZJJ^Y^
MEPVM,>QP!Y(]QBO/1<<:@6O:@'L?;3$<E??1<JW'6V6%]M7?(:,9YP"3L&'&
M6?>T,[9K\!H>,Q[_$SC6B_<-"L5'9V\=Q_N!-'_K^5=0N7:(KLNB;:XU;$V5
MSJ,1R_FYG4C\.KOF;V%G \UF.'<N-%84KX'(KEI":554T06YF-@D#B/H+(T7
M.'8&\"71%_8,_'?;A-_8>H.!'Z#0^0#_)ZJ_5^0CBO8?CT8+N2+DD4E59)U;
M1CU_\BT 3\"*S)BCK0]BAPS9/44IKIH4.B>S-"'F-8WLI6NAJPJ ^<O6>__5
M G;22\%_'#LG^,._[L'6<&[@D ][\^I8A2FAFAZZ&9]8@0M:[[8>D^J)3H!@
M1Y#RGU6AF)6$(FVU2-3KK>]\.[@P_XSLP$;O<N7Y>W)?32RL$FVU))1Z63Y0
M2O6QA^E@X(>YJ2#\Z?@!PA_@8CI"IZ:AW<+/!V.'RWY"*J8*L]WVN5SH!7F<
MQ"T&:MA_ OO(-]^, !PF$66LV+Z9JZXJ.N%BLBB =EC5Z]JO'&#XSR&$$MX[
M)B6F U-.)3K;\5(.[& %JV9'W\K1&$(KT7K*NGWC%BV63#R?S.4FS^K6M23:
M4-JG&GA^\_P0Y5.X!_ S1GMXI),#E8(E@RR&DD^GB>:VJAY&&\CNH BC3OD6
M\PB^";JU'/GWD6D<QZB_%X"[D?-1B4#[*+MCSGA=Z $VL [ &]R:5]?@F6E+
MO*T4C:;*Q?@^&I^8359"J7/3 YL!M)^C(,,<=Z _KXV=L07!Q0\# K/B\^B$
M.4M]Q?-13$N;I"+2]Y*M>VC1;4SE,PA#)\T0D&0L),F'4N4,A<-KC50RJMV:
M]1T-C3^0G=PM"F5!#HL+= NAB2C;@O6F&J#JPM*&\QB].K:9Q3OBAB11;9^/
MNKHW6RI#U6[4RF..0V<?/->,9V[8"\<IQ<]8+"R62/E7[2JLZ_3A779'HI]1
MM.]D/)[+O:BH8Z6=Q'RI/%6[1RO#7HCNIW=1-57.5#P\UL@<AVUOM.K@:*/Q
MB>9[ZTT!SIU[901O."W0RI^9$+A-D:E -?\QKAM\-&SKSCU:CW527*YW9IIH
M;)),&])R5A"T\<WXL'?1+G%&!NO-T0U.\M[1:Y3 SX;*!;P+U4,#8V1*4,UW
MBYLTW0*0.B@3UX'U?8_"N=P@VNW2[9#+*( &0ZZIW2LZGF7C[PT6U_J9*:QC
MPV5JE.9D;J-&V.O&WUNWJN1ZRI<ZNS!@IE)I7NQV*D4SQJXUROR,+X6*-U^F
M3]5<Y@3POQOVN_BQG*/5+PV*,%BF.M4\Y 2X3P!%E*+LXCNT;#IN1E4MD" '
M%LHG:;B?#^ CC(<07I^IV*=^J?84!LU4K9K?_W#3_2-\=P_%B!TL0;#4T33(
MLWQMA("YB^WL84633X?+4:_]-:>U8R9=5?<$2E"#=!*4S'ZNZC<(6.J?F<!:
MFR:+&&V[=7!BS;QXEUVOPML^ZDN)G5DQ$ZW$9-RD6'D45)GY7U$<]Z$[7V](
M%L*&RS=HIV2J\6JAVHD<L1'SHDR4J4FUO9'#K4GQ3!9%[);."#34EHAVSTQK
MG9DLTYZ&R>X.-LE=G<6=YFY937.'VAW$#0_R+:N?X.Y@D".<@)#/CEY4O[L;
M:0GMA+6O2I_#PK/H*Q/)!M YD=G!,I>?N4_]U@=_1NB, 2W?77U-5>1R&AE0
M9,=IHEX("H>8FO".H6;)6LOQ4!%!<1),D0HG^+Y))3A\?-3;L%BJ*BL63HK9
MQ,*$7O;Q=B5F2H=E1X>S)<+21B$1GGH([,R8VE\%=LAGF;,,9H)+4BM;[3[J
MD*X+C!9;F$K?>Z>Q@\75F^%N07#GYMPJ]^ =.!-^]\&8U7WP\R!][,!V!QM4
MZ#TNY&T&\;,'DR\/@\+CI@P/@[1^2A4/0X]F^9>?AW_^TP8^Y.#M,_[NV9P,
ME,JJB.8T8J#Z&7BMU MEY4>9J@&XG0[$-HH6G$V64\EI])OSSKBHY+)$+[1T
MY^ZC,$CF0FPNB&J-DG6FL[DB.FE,+44NC/#U=SV(OPUF-ANN%FHHXU0C%8=9
M5,G%?W;WPR@@2PZ95$76N65T'NC2%(34H:U01C5M=,YN55#U]M!_=-/;L2Y?
MEM+6?)T94W:&T4[6A[_;X=MWUWL-8,^1A&>CV2NTD@=[",>.%7/<2DNME-CU
MDY:OLI-G]5'C=,VQ+4N[,:R@/GP?GS-Y#@T_U$KU!'O] PZ3*%CSSC6=R$*A
MXS>&CT[/U/;R73__Z^N0;6S]MU[%FB\Y8@:-YZ-+!JY!\K^G^4[PS_[Z1F0:
M^FL&I> ,2FZ&59T^@ :6%92P/IE#W;C6*4(EX%0M3"_ <@//L2WXHW5I..B\
MRO,; "%C, 1\_=%P./AY<&@013SDVARDC0X.K2H9XG!X_9SGY-%++G(DA#JP
M53GQ]4C9.]'B%HJ%BIJ>CU8K.>=%>1@H7')4CT9GU^43<-!G](@NJ(N]@$9\
MBW-P^9G_"V53AKT!593 P6Q5#BWA]D4JU%V4:D'5J&_)(ET6%,@ZTQ]/F8XH
MJ9L=V+(JBX#"695L=G3:;V$\L3)>+=@;NAFA:>^X.8R'=7M.U8*J<=UH:&>$
MI3W/Z2H9O^K %U*67SI558X98&G?9R<8T^Q(3#27RI;,LAB/Y3HX&4@C,<V"
M3'O",;=.Y/]4 KV<H LUI-/)PDR552(>[4E\\$(0NRX](W82 COV(3Z $)]"
MCKE>G^AO!E;[$3O+O1-?E4*7 ZYHGQ3 C$_[?:)''^P-V[KYV ,W %#TZ_ -
M^ 7;$33 4+-/DF@*5_N+@%FTT%O6F?EM?;N!%QJ.1'Z/EZ0QS>6KQ=5DO=%T
MGA&<]@-^W(,=YS<7&_@J^'Q_Q#L(VS2EIF(8R:]J1Y@)M%]D//K>'OCAYZ-C
M0"NZULV?D;U'?A0X@R9.)LA5BD9:3&;CI<XZX8:J?3]3-ACCR%(RQG0H^2QF
M2]Z9X(E:3TB>35 95I/71C.%?G*8BVM#)[50JFAT#0/L/U!?%7[6S!!9JZNF
M@\;N_E: !?7N+;*QB]0+VWX N8)JFFA%+54I+,"UGPE>F/$MN]D]!M"$\#=^
M!*RJ(4A#!GL+"FN'A6S,&-,2NVSY$%+SIR#N7-@P" @;#Y22O>&9%Z/LA0"=
MSV^&#3&X\6H7@'I6L>5+N%?C^41_;MF1:K^=$#M!F#MW0NFR:18KN0O^UATY
M#T[M]PN>WSP_? '^[M+S?>\'Y;PIIF3OJ&?%*&H;H3>WSVG,O1CDJ2)4NY8X
MO<('K812*#C>JZ7ZQ2XCOI1#:9?\=K"T9U[2%PPR':ZFB[&>A'-"3#EO?06N
M-/=?FC,).3R>[.U;&*RC, @-UZI>WLQ2I6BDT6@TEGN.5[!+AQNZ[%6<R#ZA
MOC,HFV F.8U!=PX]+%+M]P+00&>'<>(U:*\KST7S&.":9/(I-7HN!E[D^B_U
M>+>&&$W</VEP I>]&A015IJ\9PR<ECP$4U(U+7"2APOY8,,HVV$O9+1(ET4T
MSLO%>D<X$\ >[/Q>6):=O/6C85O(I[&W0P0!OY>'+UTRSGPYEAT'T))]'IS:
M>_R?T+4_+K"R=',7IAGMHO@L\S78V*9-F@O45RP9;+&:R5TYMA9&0\@]G"<R
MSP][IP%&B-H?*ZB;0#<,'E--#]WY$]CAB]HI*&M%7MJVQ]CN;R"T38/U1KLX
MB=N,/8G;X*_%IRA[<5U/LKH5%T'0]FL_?DTKGB$_ O\9RH1ME4BJ7/PZQI/Y
M7,YM8DVSP+5 J?W2L8@]!AI<1.&;Y]O_/G[L5%F4*_5+#DSH>K"FQ*&^"X*(
M2P1)A3X*@(),^[4D#F_]YF--K3Z*H Z>]BO&0GP%UTR!H:;NBF@*4?M=A1QP
MQ@D"I4:/5, S-6B[2I0Y-:A ILX+"*5[QWO]C$!:_%E]#&$,@3S&UQ77E<Q&
MN$1%EI79/*F?Y_#+8+U9[X&?W%? [.(9T_/T'UL?>)M!H7TE?3MW+K06.+PU
MP9U#+'7:[O<?P(7V=- Y- M2;J.W".UWD.9$(G3#-;5*2E^M)G*R@-0PD>^!
MFR#2WC_S!)F 5GR#J*_1C=%>G+."3CVUCH;$\^/1/M@S[4+=;8J2%/57*:<A
MO6P8M _I/,!,3(,R$M61>BRI,ZTU*$0Y3:01^^"Y7A%KEJV0'I596T]#TIMA
MTMY#DATC3\'FK4 @GU)#%=K;<5K5!B_DMG.W5:(*%VS1&D62+MXA8/31)(;+
M3$ 4!;YX?Q7!@5?VG([@5+F%S<-%B L"N++^GMT=\QM<2'L^Y:0F0[6B%2:S
M^7"J->NM<,O>9".PGX0'/8,P=.*QD73\^&:S 6:XWER]&>X6ZOQPPR1.&ZT;
M[:5RNK&*H-FG3/?\\894ZW^BI#M=;[+SD821AEJG;_)I#KKMQ+0X!7D1W/ED
MEX^O7;07@6+LH.J/SFW8U1)4P%F[;WH0 5_^MAYI/I*)O  GPX@2(F<'),/#
M_<38"4J#=GHI%&&&:+LKJ,!ZAFA07A='WY32#+#V.2L>0%CKS2R4485W'I=6
M[?MW=1#@=*E' $JA :P+.!P96_ 0H7LPUYM*T!NZU=XDT,S5AH8R:(]/=E1(
M5S*YMIT(11@PQHURME(TY72X',K)9]1>*EP(NPHZ.9E8LL.666@DK>_ EBV9
M9329*]]'L.-(Z5WUAMY4W(P$IZ7+IEE-Y1Q!;T$Q#4FV@3'L3>18XE,+[MS<
M$<GGTGGSVEBR"4\L6?K$@>T.<L_\2S X/E7)"+-<9")SNA[&.I(N#G_!;&7@
M"ZGR67-Q@+TLG Q'4&"9(R<O0 HOL<25M]M[+OK@+C[LVFOA<754(9R#/PKI
MS AUUD#.E?4-H/EI?31_4DY9KIEIJU+/!E+[6%)"@APJ_]0Z?=0"/^ >'/XM
M9\BA2@)?N&2:Q5QRC(H(+7 @E1V?T'Y!5S33M;>#T$G+.5S9/@J ':B@. *Y
M\\'[[ :VNDG@/?:J-I5(;S3SH\.2'8"F3CXPA7BF4X;CF@F:H+G>'OBVASPH
M?MB7D[L:<\^#3]#'WE( A!B/0P0"L*XC'\Y,'N/'Q%$*EU%@H^A*"/85>?G@
M:^/".SB;T%X#PD#+GNCQ22+1>3M-$-OHM2CX4,O._$*Z(_ 0Z!B\>(25[3&B
M=KVY]PP7&RS8J*%^Z$,<=+'1I/*FD(0>],*$\ZDD]P)Y <%6O6B^V7@YDAL>
MUFZZV12P[*O(NE)+FC>GL5RJ]4OFFTPD!8ETI1=&Q-I'&-$^EP?P(_Y+D[[E
M4+?O0F% JWUD$?4;::B24N6^RX0%KJ 0)?$G''*8<J(O1.>_>(=3895MC$9M
M:"\(<:@[BVH2+8N6BC@[,334@;3]<*[NX=;SG^/;0^%+HUOBT-D=QXE9(AZ6
M;-M<3W72T@"9;E0[R)]W"3=7"V\C/=&($-B9,MKZ5F5&4K0\$35;SA::.<G8
M467\ZGS87M@>ZFRU',M)FMKY'FH*+:.[;5JG9 _MQI7C\>Q@"S6^BTA/ZGGP
M9?RW]5]B^9=W!,((WFX=[P=[[MPIUWD'V/P@:U_UDPT'6]0?:, 4/?G C-[A
MT??>;<C3Y>?W %AW[B%+X849VN_)#6 U:?NX&RI]':/A;"G[/ 21N=*(+@*I
M]G'3T  ;.Z1,Z(X%5*%:,(55;=1 %L1Y!^E13I2NK8?4MS)$VWBJ]GO?!$&L
MPS?@/P$3V._HY7]'#J_U9H,3 :'H>1#/ UYVC%3K'O\:P#<U;5RD%*Y([Q7
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MT5,;0E!FFFGK,,3,$4YS".@%.3N8-W,GP]EP@CL*-/AKTI"R^[4:G0EZ-M^
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M@@A8UQ'*8P][1-NS$NT_@!_QG\A),5@J]T@O H!GDM'7$?OH>R8 5G +K8J
MHNNVXPSHV:2=. 6IJ==#H33#G&E$W]NH\;C+(>9<0BE7/ANU, '/)*.:[Y,-
MTAT<:H-<D_E)"5\+/5*%*/29-%2[\YH/VFV4S[/>7"!).R5#+<8CY1*?=B@3
MB@VR\*^V_E;18BGFJXBO"_2^NP':BH2_A:CM(/#\SP<OQ(8!<E3OFS3:0L\4
MH=J)  *&9Q"&#K!0('RV<L<)@KUVW_30$GDF!VDG!QB\'K#?<TU[;S@0S85I
M^G"9=H>.5<#.CQ8?SM% WT31'GRFB[;.4KD;=5@78++0Y_25II5Z))06@#-Q
MJ!>"FMV)]!W.B/P?**S)W=X"$#P:G_%U2-YEUC/>I2<GON^3BTRBW2Z]N(0Q
M@+&C1Q4-OAK/EMJ&GYW<3)DNI?EO21%#F7\1(;[U_ 0PFL(?;_$JVP<;5=2@
MG9*A)JNAMEL[8FV0B:6MYU9\)Y9=XO:YWI21'*ZQQ<F#I5[)%+/15&\Y-,:<
MT2_-*5MW:_3!KYP;CEOT'2+:+1ER/IGJ/39U9I-,7-+<M\+.8^>&7'1/Z=9%
M,3EW%C2)O;%1%YQ>/9E<ZV,5KZ"$?XMV(/\;PJ2[HZ>5N%E &>BJ5QF6RE0L
MS=/<?M_*^(PO'GSQ4D-DY@/!/WPO(,FQKEK)6G!"H6T_V IR=MI4FG=92/KP
MW +8M[?PHW+0;Y-#MB0O06V]@KWFP^%L*?<V 0$2:88YTXAJ_F9&%QGM-#I'
M R73C);SN:YR$ 0^TX5JCF<*FK5;$_' WT#)-)/Y=*RU+MJ#SW2A6@J#O.(K
MR'*;<I^H0ZS=D:AOH62<Z7*L=^2# /29--JZG96_K_[>AC:VT.V+*/_7W@X-
MYPD$7N2;:,>7^^+ZL9B+ZP]O%9=)WVMP>+&O.^R_[K#G2&HV'ZYD;9X)U8&P
M.^PS@^B<D+F;1.[0,LN5W.63$&8Q@N'"K[4R3I3(?3X:SL=R3[GQD8H113/$
MZN7LO81SNYO-QO/#X#%Z=6QSO8$O8KM;<J;7FBHEX'!Z([E;:$95:6K<!+3L
MO+Z*WN,%S;.4O"G5T5#!AU]0VD<I0T5W]WC-1V/9-\+PT<@H PI4]48%.,-.
M M:S)$#DT8!0M 1T,I8<P\#+2<5GQHY2=K=?GPWP,<V!7L]N;:6R!99+N4[S
MECPWPZM]9G<T'09_1M"V-^_POU[@HVI6A)C2)=-,9Z->#O(\Z 6E^I7F)RCA
MI"\"2>5+EIDM)I+S_',0R$0_!:;6[H B4NK%7=BR)8O,)_.9:L13J*NEG@)2
M]A1 Z:L^H)%6BUX.#=PF$)0F7**'P C>2 L^^*<2Z.5XK$GJU(P@S.*.!$O[
M;_[YS?/#%^#O+CW?]W[8[I8X :R6+)MD*7D-+X!I5I3:S_Z?T)ZP"ZP;PW<1
MR@O3C'91O-M_#3:V6;D7@+UBR6"KV5B3$#NR+!J"EGWK1_N=^23.P-W>N::W
M _?DT%Q,R1[J@!6E]F/\ PAK*2^4Z2'9]?CDWP*B76*Z?DBC!7#9%X20/,6T
MJR@R=VB"&.LS9J_>(SD(@2[HN@[%=HS)MYB4[YC@V3MD;[5'*NO2(K*O\A"P
M@#V>#*7=4EE;OH>"X<,JZ%:0DPQ,,:8,4OHGYF$)5[EHD?%T.9;KMNYD4&(&
M+NHV$(G=PC$ #$42VU8:+_\$3&"_ VOMYB+"ZB,<Z]LHV7$VG>C??;3&W]E-
M(=T?#'FVMZZ]L4WXB5R8)CHMAV;YGF.;Z)RV9=D)DCMWX_E).ASN R#CX:A\
M "3WU,'QL8/LN;#$\=&#W+/5/^.!,2+^X :MH*S3&/EC4#G-!Y>?A;\P'<G@
M:$N5/J6>._QAB[90==Y(9\-.";AA;T 5F8@7 ,X1W\HJ?5$4-2BG6E UA;1D
MD2X+"N2^T$\-RZD6+-IB,IQ+3M;.R!:=9@HT-7?E S_,\0Q_.G(,?_C7U9L-
M-C<?P(Q".+E>;^ L$/A8HFM*ETPR&JWD[LHSDG9DNPD^-2F7?^Q&/OU=S@;X
MC/!U]@8;%"]?(GPT,LJ  E7!LS?Q\4*&@S>8<EJP26&CY+EDABB[RR?G*2HD
MTV$Y346KT3=Z^<'V(-8.._#=UP17UU5331D2UOUT6V@??H?]UM91&(2&:]GN
MEF?HSU5333B-R&6<!M3!%C2*R SARKK0"]=*=OKK%4*KTE-U<$/6?M@Y9-&^
ML/XG"L(D779F!H(PJ'5*9EH,%W(WR04I@Q^S]@/+/4H@# [1S/? "  Z]8#R
MK;NX73GVBCT524/@V@>"W[FF'T_4#2>?BO\B#'W[-0J3JV)0R-DZAH:ZUYHN
MID6+/=66:(OT("P=G;B[^3.":T4G3NX77D' G_##PUVRPE:II^)I %IV"'K[
M8!+'\7Z@NU=O/1]=JHB^B'L/FC )34(?S%7D(P((2F%OH*>J:6D [6/6LUMC
MKKP@#.A:P17MJ2J8H<H.&R?=T02A0RO!F9GQ<?.Q!VX X-CJ1%9\8B]-?>]:
MCP"^:_B)\\7RM= S&8BR0%>1Y)*C/I/#@- L#9)]CZO)ONMC/9,'#N(G?D5X
M=O#*WUW_<$<3M/(E<,'&)BY<"*6+G\!TO)1T,2A?E"8/&-D[;5WQ?/B@D\[,
MCF=!ASXNN0N!3PLL+?9*+XT!=^5=[7Z,N+=--"A>;'V09)Z'"ZZ71]^S(C,,
MTC^F?37S\#"I'@5(6QH<GP-_>77Q]//+('O8H4S78P/Q/M22)0@=/J6<K(C^
M*\^!+^<A9]X[N$"^E&WZ:J[UX$%1X_^<W\QD"_<7]2!5>HU:SO%' 3HU@\YA
MO2@AW7J3@TR)^<.65448)^:\*C9VZ^BLEZH=#;SIJ#'BG*VHIC%VJC&>+P'0
MU0L@S+IEU[H&[\#Q]K%5LD[Z=SM\>['PV3QYJZNF!1%\EEP@;:VAYGJIYOQ!
M.JE<^\_ ?X<&P(Q#I&*J2>+D0Q"7890+0V<3!C)9"BW !IY3RZHB$2ZFL 0S
M8E-OB$!;R\!'EZ;!-?S5FPU_L,T+-[2W(#[2OX<-Q?<:^B_7MK%UO2"TS9IK
M IJVIZ <&'DM#17"C2![["!%M:-;$>YLY/A/_F5?P4JV:3@O/@0?P*[VZ 6A
MA+KS-Z.*5+JANR0G4?:1K:)& \WA+L=G./TR?-LC3$&PY521B=0Y"+MEE+ND
MHDX;*:#O;K 'IKVQ@46<A!#+%BTQFRQF<BXDY*.J1#$7./5F(=G[/\+_^"\>
M[%#W#D!OM=[$7=[:1>NNEQ]>L>.[]7RF 49@\T6#SE=#22G!^%DO#2I=VT3V
M8$-0VH7K1H:#DEC!83/)SWH+#7IK^T%X',?1W[_# =QYA-^C&]Y\[&U(+5E@
M[5LMVW NZ6J<UKKJR!2RSUT0Y/0"W/\/&'Y !0KM4-=#-6FG-Y(1!E[-$Q@U
MDY@G-+<C3&H/?U.%:ZD36;HU!!VJ.-GD-49#3.62^ZLJW-=3@*&K_FM59\.M
MAK!O<!ZTBW9$R@I_5XXTRFL5::N'(7MJUXP]XX/.7O[O&K-7"T/V3*K]*:#V
M(\Y]39(%D8]014O20S$Z-ZJ@$VZBUPC?]Y  -WPT/I-#Q.5@J5M0N4J%N9YJ
MXNJ<X]+2H;&-U!S#N'K!(/P&%UAP^8Q.;!$[LD*I,Y8+CT5D#Y&DCL3=&[:5
M.%AR$)#&#S<47H/7,(NT?C+"LBX:MW/&RA%K,]D^"GJHV#?;@2_ON0 Y7^PX
MZ\5MY%JP?T4#_:WGWQCF6^P?I@2,L3=R[JH28S#9Z20(DLHN(3J@2T=IM(<0
M._A2AUXNG XGJ@;-G+NL1)E,T0EU]M4D2]V++9SL;6%WB_F* O09\<E-6./G
M+L)N#2D[6T6#/@]UXL>+6MIW?G7MG;L A=M.=GX+INZ0,)=HJ#]1;9^[%CNU
MHZ)Y-YZ\3Y0, BV1'H%O(H:WV&4#MN"Y*X;=*(I>T9@#D/7$\2Y_W?X^UA?:
MN+$O&8DT7&=70$HXH/^;89K0DJW/Z%=2N&#/Z*=/^SJE?_:G].7U04J=TE<U
M"$3>*7WY@].).*^*C=TZ.NM%@5/Z\C7&3G55)B*@JW?X(9T:M#RLS]^*:LH0
MP6YI]BO(*+*#!4AG=PW_Y0BMB+56+\R5ST F[6PA.UI ;F('^8(X^:R%RS!?
MB1TDQ\\R,X4EF!&;LK.*'(ST-TQI'-AK*T@U(V?XN4)3R++G"+(/UY_I.,!N
MF:_#];+/*#)35:*8"YQZ(\'7D6=AYU?Q(T>W1YY56W5^'7D6(!G11Y[U6GQ^
M'7EFG5Y\'7F6_IU_'7G^.O(L?2S^.O+\=>3YZ\BS-D/WUY'GKR//7T>>OXX\
MRY5+#XX\E\5=.GI+.;) JG+&>FAL'D7/+'^=A^_/>?BOP\M?1Z6^#B]_'5Y6
M1(1?AY>5.KR\6JVFX[,2H'#;?1U>%G/H=C$<+B9R+W3OQ>'ES([]/[R\&([F
MB_E9*8;=*(H>7H9JWD);N" (UAMTR[4#1W_K-^!:GI^F9<*)@:':N4NCJ8DZ
M.WK<OV/N9Z@JL8;+M";<52[AF#MRQ*!*-KK9I?Q7_M/N$Z;3[KF'#KS-P$G+
M&%F9KU/O9W;J76*7I-*I]W('HTP<D+13[XOA?#E=]#DZ(..\*C9VZ^BL%_FG
MWA?#Q7PJ=S[$3G55)B*@JW<J0<+A905T((++TM2WG2UZ$!2B;VB< H*4-OAU
M;E1-(EKR"[2+G1?!15E$2ZY.KZB:O#IGN2:ZA=U(776$$I;\5]9T44QGQ[/"
MGS*M\*^NIXNO''9GNYJ7UK&HM9J7/KE6;C4O?<0Y$>?-5O/ZZ^5K-<]%]=FL
MYH]3#DJ6M3O7]5YCHBA+^T8M%<TT&B\7H]ZM\\491LU%?\UIQBLT>P<^M'WX
M^6#L2.?'<<544\?)QR@NP^B6L>P)["/?1+=C';Z$,E9BXAKFNJI(B(O)H@#:
M855PS(E\.[BTO1"8;__T',MVM\&]8U*&%EH%E0ANQU1YW.!&K>;PP.,3-O9V
M:#C?73L,+C^O'",(*,L:0FE5!"%]8<-C'^62G#5330P2.VC0"ZNF&1[JJ,37
M8=1Y25N&>4%=NA)**\Q\'7?UQ-,PZC]8Z+R!*%]H\H:EKHVJ^,G4N%._^8#3
M1(CLUO-3W\"3O7W#!Q<S551-7IVS7)HM-S>2H([P'?BO7A<[SLFK_V8X$4CA
MK3>; (0H1#IW:L>PK3LW'0 HV] -6CMW:0FV7%?Q#=UO6#\E9SX>T5HV;\U;
M )SHX])SK8![WWHZ')7WK=/'#.+G#/(/@G],GC6('];Y_G7K.0K)8H0-[_KB
MLO:]26]V^5GX"]/6-D=;Q0]H/)ROY'0]K#SB-['; M9YD<:&G>+E86] %;&(
M%T!57"VMTA=%45T]U8*J*:0EBW194"#WA7ZJPZ=:4&7Z*6S1::9 T][%DR2B
M@D-L5!/A5"VH&M==#@:,Z)7;'VZL!.+6<%UQU53!R%P=Y34 U=L"SJT8R=N^
ME4)JLU=#0LFIP 9.S1[\5 $_\AGNHM?FPJ[<OJQZ,3WCV6HD)\<8%Y-"8GI2
MK*IVZ%?>+_>A5=>CYTN5X,U7$^VB=U).L/U[+50M._@G[FN )#+;=5=.!WP>
M-_W(_G"I%&#HZOZ#/!EAS>^*48$TRFL5::N'H1QQ'*O;;\! >U]HQ+ES]U&(
MSJE0O!VDXJK0>PJ?!Y<-!*645D8;5-\'N8)J^N#BD$T"%*!]ZB#6\<O_YL%O
MQW;L&D<X6V4=Q$%AMUX>'+#5G)6WT,N3'?QQ"]<T^5L=N#1#;J!HP,EX-)6;
M<5ZX;CBARTY?(EP[-Q][8,(A^MI^MRW@6MS:(3=0-N!B-.F7=CBAR[ZOIZMH
MC_N:..NZ:JKI1$)D!]T6@BZF:!'#VC[6++M]Z-+S?>\'.NU&BB2KEE1-((U(
MK&J!%:G\$&;!&[SYL?8YC$U)2N;/WT!/Q=+2 (+F+3(U%)]Y6F]^CU,VA&L_
MCMA>1V$0&BXZ/DLZY5-3K:=Z:01;T Q%.97<?* D\P%X]&T3'/X8I'\-1CS2
MJ6OKG/34R!:"-DUDBBP#>@'G_#'2^FZ(5J5DIL5J+'>1+4@RW)!EWPW8J2[*
MB\<&.BDW<8:Z83*![(O\.M416C TT ZJ=H9Z(<*6??%>:XT\^IX)@!7?I5.X
MVY<@#F+YGJJ"#Z^@^^[466-_=XT=!&W_&[DG Q-%.C$MK3'U>BJ09KAEWXS7
MH2OF9K,!)CI6W<(;@VGC+.33Q ;2[\X3HJ4KSX6]7@#??.W;6QN^/_IMDM6=
MM+"NK==CS?#C[NS>NQ,F\SE@WCR'GOG'\QLT>9#\&MJ5Z("IJ]=3G33#G>E$
MHI.7$#\>8[@+@@@.KI$/I^6P9[0]*X\J 1M_"FX:4AUGX< %FK=HKF>"Z<0<
MF8ZD;5035'1AFC[$F VU5Y&/K(L3"+YD'[GG0)K1*BUS5NMA)$.)XB[B6U2(
MBUU,R9ZQSXLT8U^X<U5>8B)TQ9H)'.</S[_W#+=!<J(Q5W(B^+R?LP<.T!._
M,A1U'36B5H:BV7 TGYY3AJ(4L,ZQU=(R%,D3BW@!,,>QL5JE+XIJE:%(OD):
MLDB7!05R7^AOE:%(+?HI;-%IID#3_J"%L Q%\KGN<C!@1/^5H4BY 8"1N3K*
M:P"JE]"BM'2D7VE>*:@VBS5DE!Q([ "U[\U/<GQ%OAHD3/OIMNA!5+' XRNS
MV62U4F;:QTPBQK_ B%3[?J/8O5X#TP=&@&X?V-KOP 4!VZ004Z]LKM6T%\)H
MAKM_B?-_,QP01I:'QM4FJ?,G7-[I[&FQ9_HK>?ZYN::E=1ZR7-.%7D-[3])I
M7=/21QIQ A#HFNZ7HMJYIJ4KI"6+#5S3_:*_G6M:*?HI;#5P30NE695%20O7
M]'PTFFF?;X,H!T;T7ZYIMVR7Q50EIR:1N::NZ12@>J[I_*J1[)>NEBK!&T_'
M0X7XJZ&AY)1F1">[$Z]A\!J8\;O#$F,V-O$URMB7<SEC,P\U!$(Y "I.[G]'
M[O_?WK4MMXUKV5_QVSS-.;I?JJ:FRE'L;I]R+%?L[CQ.T1)D\QR:=//BQ/WU
M U"D+%( "!"@L 'I)8EC .3::Q&7C8T-A'\[S+TMS<Q2BCM$JR@ZT]GS)#A=
MAO0T>,T50/(JRI  P7R@%GVVCS\C.8IW%5RGF \4_%<<?)1 1/BMEP9);MM^
M60B<Z<24#81>9L]9DDH,MM0*#M$JCD]3KJ7C,"LTY#*J@&17G"<AHJT>>*M0
MA(9>1I53H-KJ ?@N>B\7>8*#,+T&2*+;]=@2 $TG06N:77EAYL5D5C$27?I2
M:SA$K@1 TYG)Y,@56P,SZH D6((J,;*M'I-K6,36PXPZ-?RSP6#L(-U\N*;'
M9?I6TK'N<YW,A[.)<QN)4MC/][DVWJ<YF<^G4\#WN19,5@6@AA7N'N/C"XJ]
M-Y2E_BJY#5;-O3^U0A7TM#\PE/%:G2G&("".VO2 WZX7D+_P==J?]=R+(&P&
M?"(7ODZ'O8&Y3II/ 84N#@1PX7S=7?@Z'>)E*KP+7PLBJK0UPX#9DT([;3@=
MS7KVGS:4C.3FVT*3_\R1TX;3\=R0WT6)Q$,MB"(U?UD68\Z-9Z;>!YF/+C?;
M;B]Y\=_*[&VT.3>W0@W[9#0UN_169+DE8)@.%ZE!HH"<+#<B2?R9Y1W30SN\
MIN,8.LS-WO$U><X(1M$ #MQ-5<TQODL9O1=*+Y&:G5W=8?VTA@]TZU9OWF3K
MJ99%:GK/%E+:9.O)ET7:U351YK)27/W$3;?,2#&2RDA!GG3.1G&*V2AF@]G0
MS/:_H6P4!6!PWF8;LE&8$XM^ 0C[,$6MXHJBE+)1F%>((HM\67 @NT*_4C8*
M6/1SV.+3S(%F_6:7MFP4YKGN<C 01'_.1E'_OO JSFR.$D'FFBAO  @O4JQ<
M+;)#PZHEZK#& [/N BGSUWQ$ LA,=]P<UL2S3[!+0V%3E X*@1+  )/Y@-Y2
MP3-5G.(.T"F#S/3NL-C'*4 GO;0#;$H @[FW>ZRS%>8'TBZFQ5+8SV<K&J/8
MS:E$BLFJ -2PPIPQ+Z+7312G:/6RB&[3-;]WIQ:&1*P:0Y1N7QRQZ2G9L<Y3
MN-N_\P&?R'D*P]\OEP(*7=U_D#:<IYB/AE,SH=,B1%1I:X8!LR>%=IYB/A[U
M!L[UPTJV.)^GJ!AE,C1\\+$5B92@!T&DYL]3V!M5[8Q8% V@R1%G4D,='=1P
M1B%R>&$Z\UH'V2]C_]G'[T_^5R:ZGE+/47FTPPTT>Z7>>'KK.99%:OJ4!*1X
M>NO)ET7:U6$*<_'T]W'T1GRC;6/JQU(Q]>73SG'U)QA7/\.O-S>3[L%,7'T)
M&)S7T8*X>H-BT2\ 85^6J%5<491*7#T A2BRR)<%![(K]*O$U0.CG\,6GV8.
M-.LW/73%U0/@NLO!0!#].:X>W  @R%P3Y0T X44)[:\:V>%!AZ5@\]= 0\UG
M)(C.="?>P. U>HKW4X0WLTFO4<,^G<X,YLL7I(9!J 1 X.1^P_9Z$6>64KR&
M>C88&\R+KT:K*#J@<?<EC,NWV _$.:44=XA3472F=^P:OU.1&VG8I1UB5! <
MT+VU$D5Q<Z$HHY3B#E$JBL[TSEI3QUM><2;**K6"0[R*XS.=@TQ\#CP6Y)91
MQ2%V91!VE69,\S18E%Q:>8>8%897T#H#2FLY^1.EE5;>(5J%X16TSF&YE8]T
M%M4@QUVZDJ6PG\^B-IW^,Z@2*2:K E##"M?+_+#R4;A"_#N^F(6K8/O#V=RV
MLZB';+= ;-I5>:2SJ 8)[KI_YP,^C;.HIK]?+@44NKK_("TXBPJ!-,YK56EK
MA@&S)P5V%M71?EC)%N>SJ+ $THK$0RV((CV?16U]%-,=L2@:P(&SJ,<Y?#CK
MS\<SLTE7-2I&'C?0'6^MAP_MYU@6J>EM;T"'#^TG7Q9I5_OCY@X?_NZ%7MN#
MAQ.I@X?D2>=#AZ=XZ' P'O3[IW3HL  ,SKUDPZ%#<V+1+P!AIX6H55Q1E-*A
M0_,*4621+PL.9%?H5SIT"(M^#EM\FCG0K/=N:SMT:)[K+@<#0?3G0X?@!@!!
MYIHH;P (+QQDMUID!X'4BL!FKH& FI=(!)KIOIM#G'#T/+,P%#*%V: 0* [,
M-)7'"M<Q_U%V,<@V [8N!K-=N,ZP-YO/H(7KL.GB0 "W_.DN7 < :9S7$@[7
MT4N<I>'NYKCLNG\5QFY=9.3QP]W-?O'"3-9Z;"6L,-<W-Z^O61BE+RCVWE"6
M^BM^T'M#%4@DJ[%%F4O+XH8Y#D +VW1SO%"RQ3EL$Y9 6I%(V6H51&I]OV$L
M:',X&4^=D(JB 4QG%+(E9-,IO<CC/HF03>LYED5Z#METB'Q9I.Z%;%Z^>AA[
MTC9J<RH5M5D\[!RX>8J!FZ/!8'12MT44@,%M--@0N&E.+/H%(.RV$+6**XI2
M"MPTKQ!%%OFRX$!VA7ZEP$U8]'/8XM/,@>:8GTHA<-,\UUT.!H+HSX&;X 8
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M85E-MUULYU!7X?JXL1+XHXY>T:/W"Y5'<X3#(.:')W.VK5WDS<$/;-AA_\3
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MIPPW36!=1W$5(B]_L50#-=/TAR-[.PEUX*4FC/F,V<,0D3*>J.]YH&["\L@
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M4[LX:E"_%L&-4N[40OM/4$L#!!0    ( 'T+V%RS/F['60D  $4H   7
M;&EM;BTR,#(V,#,S,7AE>#5D,2YH=&WM6OMSVS82_E=0IWET1I))R79DR<E,
MXL9IKDXO$SN3Z8\0"4E(0( %0#WZU_=;\"'*L9S<3'QU[^P92R*YV%WL?OL
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M-,]7 _ZX=Y#6%W5@>M$K<-[@_^L#[?]02P,$%     @ ?0O87/-+A! 6204
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MT;6B07L=X.XHL:?* R*4\5ZAQ'"E'M^7$15K&K4%&_4Q<FYQ[&L)\'9TO(L
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M^'U_W^+*%\>2R?718IUM3(8.-+6TC>*E#N6ON/+G<^[]FCCNPAW+?_T;?WW
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MRDW/E5W:C-X"+BBLAP<F)J\3LP%WNA6!T<FENN!5>6II<NK<P->B\D=DSZ2
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M7U-"2+I]U8T$XCKD:( ;Z(AP3WFRA31+!IOH";LAQP4@ @6C\ P3)0&6"HJ
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MU)*JNL1D3S1NR&11J%^ -B&*&JL4\6H PY1>V0P^@+^"AX"FX@YEK9GDZW<
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M24F:FB[O:Z959M1NR'N@ 1$-&"+B=#P*#;&!A-B)?T@6![W/6A4^/AS/7W@
M-0%=W&'YP6I9NA>A=1DIDPSQ+A&%A3WWI&FI96WI2,M)S*^ Y\ATN=5&5%+
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M,TN0N-"UY; 'V+].IMK)YS/'89Q8]P=:V9@XA<$545R%I"BF*_D/$WC#"LV
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M40-I#J39?V.+08]$)!:ND\8A>N0U(TQRL=C"<\?9_!PT6$TYF;6]I*J("F^
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M=5GJ!L8'69@NRH0:?WXP:P'FYV8>],RY=(V 1\Y,^\15_;H+I>#L2FXA4+(
MIGVK4F4F\G=J"?)/V.Q#."UX$;Q9^H7 ZT[LJLVP7[(4F]Y1HP,415\K[LAP
MAYWWI$4!G 92#74Y4-0>H&-KI;F!3$3:%8ST:YROSM5U@AUSL\I\*]_<J>8G
M0 @=VPT$H3^E.>&[/R8S;/(,$_D\#6&1(VZ<<Y)%JS#[X A(Y Y;/T1Y,1?
MSA&-F7 S![H:B8JPPT42)V$!A+L:'/@+Q_U-LL9BW^=A$;=FA ^,\1L\4+XS
M@7H:/416__QC\FWTRD=(3!0V9D;/*1&7'"+*IA![U:Q$H*6B88F2X!K[[4V
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M/=.$:S;,*("FAPEE&"XH"\C?V?J2@X8<!)4X(KOW1R;;A/;+9!P$[RQ:AIL
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MV*#+=O39R?CA)I:' N^<GO6EW&^ 48*&8^\XL39\'_M>)BD<+<42_40+TIO
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M=I97J.0WS#8M?(:\GX'D^DG.W+8&1ZLC2&*Q!ZEUJE>8X%7B?S@ZH/\]_G2
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M"Z+>J@%UL2D9:MUW.WO$Q)C#VCTQ"_^%H%0F^TI[-$CQ=-L<<.A:O['72?[
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M>TD6L_0;_G2N+>JOP>AK&2$5/;Z[<8!2&LCQ$>0HNO!]#2/81=3RFCZHC\1
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M3*V47H>W8YJZ][R]/YTD8P8]P.(ZQ<Z2COHZL0!LV>^0<3GX0U#R6PVZJXR
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M6V4R,B?+')X^#F72/,7PD+80%4?+>DLKS^"#<+O03B"G"%*D\,JV4LD]$D"
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MX9! 7(=:=AT<$Z^+QEB^?,CG%>OU.I<Z]0W1L]I!ZL+ ZZ5 $@^)WT_!Q"'
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MI^-^TF[/S?EMH6:VT>Y,9LZ/YAW:*&*=L^+Z0.#BZ"\9(6FLT'[@<T _7LT
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M9DR@/_(4TR4AKR4L"8G/[%H5\.*[\N@$?YRR,=.?4F/P3R1X&LWK1EB$+-S
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M<'NVX/RU]O 8N( 7%V)"VG0(Q!*4:M^%:./ 6KWR5J71&4^*AZ#)ZO5&.XH
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M'WY*J7[+HEHVN2(DP 6=]5)YYK#5 !W1S\X/\+7ID<YS@BPKP&3#E+7'JCQ
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M)/^#K-:XO#97X.MQ?$,RP90EXQ(B0T)_'7-2/N;LM>A/5!OW[<7P%\.?-?S
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MO"#,/*@,7D?FGM.3DN[.E'ZW*Z_;#9]_?5G][]B1Z72E<Q<(8'RDAR$SXK.
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MB&(W^5[I"4(Q)$C6UL*0P(E?$M\T\ZDK,V/1U_8:2A_;9.!OUC'*SYDR_GO
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M/N^:"2:!X"F*5?!]]AG_G=!C;5.> 4Y(RT\92_H2]!KBM>:RPKY1=_1Z/C'
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M#G-K@0R8NP;&>OR<\!\ G;XN\:7?]4.H6@$&_; =%'GG[FD-)URA1E6F13)
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M(N%UHMYS&_-%(\<0&,PDJL0TOILP8EOPDU><,64H3E':H37]83#P/!L];I6
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MAN3C9IA^O"!*%D3)@BCYXZJ8EBN/=L(^%*?;EPWLKKB=<5ZW&E0)SHL;>]E
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MEX!ND A95U3F=2]>]4#,<=T.6"9,3P-X%5IG9+6(;:50>;/JS8)W,0KJ-?!
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MO"D#8!X9@GOZOD^#\AZ</_SB\6I-TT*6M$E<DP1X,"Z4$[<&K#_H!I4UHQH
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MN_*OUU\PPB/KKLVI7\WYBCAEUUR^&+UI-IA4:JG70]F&B2X;!"_R_NHT<X8
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M06B&/@7G(@<&A=>9AQ/:M^L$8>87&1*;B#)Q/46)07<%V#J&.X\G+IW80RL
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M>D<X;\6UXE;6+U:Q'EB":MQQYK(+:K#;'Y[<LI_50PY<IF:^]Q^Z[-FSY,P
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M5(HA6D>E__XO^\3TZA9PBEGV!DQ*D?O3MZ-4>)<M;PR[>3/W)N*M!98@S.;
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MG^IU80K/RQ'_XU5YCE+U-PW(#*\$I(\60 @:9&(JP6/,"59E,HNC*0Y")'9
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M\18UE+/O IL^)]<1Z?46Z\/W)FK!];HI*>UW!OK/Q(97( 0R[ G=8 ,RL%M
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MD?O3 -G12SHZI2MN<:(PN8UH$VD^ [&&<15)V_FH+[TA,'9OKC6)5WSG1L"
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MM4%,;K"/'<9+W4@V[Z7<7@-'Y7FG'$5O"RYUKDSS<U-EBA$2,U#>C%V"K\]
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MH&15V,8<IN<LY72!X*,&'TT5=QI^<"\ZXX\@MPFL7J(/I/(-NG,M<6X!S<2
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MO,K/X<XP=744O=3<A94&J)VJ_P,"YO'3B>M9:]8/M_'N$Z#%));_1L=Y76K
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MJN,^)HN96ZB P+;)6M1L4RMO_]X.Q =3(=^M-/  V&ZB%BI)49N(.?J#F6(
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MG< %%M@_[B*M=$Q?TIYELQ=IED5C;=]*9+0 V&NX 9 4>L)O@#>B'U"=X7+
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MU*-E)2;5L1C+6U+B1[.O,325]ZF>][VO<='%,3RFZHK923_K)C3%31T8U!4
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ML.87!DAO.?Z-Z+UB0TEPG?6^"]]#OE9#GVZJNS#S=K_N1%3?-HZ.1U;O\6]
M2Q?@NI7.FM(V*S<WMJXF(I2(T(=LS.,1H:\==^N-KX&^HIMK2TMAI.@&BJ"1
M6;4M>[WOE3S7L_TO!1'3];Z)8XE^6@$.):[WM6@ =KUOX"@M>=%/Z44UO/5U
MR,>)WC: Z@9FA;[F#(OX:L^?HO+KUZR4+'=*\AF>7],E6:6/YKV4C[50_V=;
M$;+=I>@NN4P,Q'MAES8*!;+$BM]Y__JO*C'(J)L]%W?(#4L7NV]FR'Y:%./
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MA$ZZ2G;?P;N/8D8S3@=D K6+@U:1;<1,,A>!F'OJBHA$AJI/!2\0><TW.O4
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M@BZ\02'O]&8W>%+"<0G'K=9SQ,4Q)E&_)6HC)MR3<,]*[G& ZQI^MADJV$%
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M,![F<FC_GU, X@ ?;$4.JW]BPC,6%=.]X9RC<P<9WC.:%ZG R!]0>0IND!'
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MR-Z-'A^9(IL/_,I96F#RF]!E$8X+>.43CUP9+7;\</%\M'@/C+Q_KMU&*/B
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MFGY3TS3A]0/E]8V?8;'+NM_EL1:W,VPNL[Z@JG!C7(<:*!/<.!9EV"NJ:GM
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M)!(2.SY().2[F1Y%J]^WS+IKJ3W?VEAB8/ OZ;IL.H^]7O7D)7W?:1=X/E^
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M41*73H3S>POG4U7W*D)OT*?/>*8P/!<!V[R(I7 N#Y&P[/$4%A',G ,/ALP
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M:A<VFZ)%?DT^\97+\K (I3B4U::N%5OM4AR3HI!TX$&G0,5=J8)/!=34R!D
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M7$[FVRH-F2P'#9T<PZNLH/*BT/*WP_\&+^1R.5K@9<"+K,SS6EM6-*XM9X'
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M*!N:1-N#LVO)(3^QG>R=Z#R^]BX+CB8K=*_U8A<0+#)J\<&F6'JQ=>$15';
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MW#AT98QN'-<TN0D7RVUCXG#W%SU'JN9*SV/AL7-5.!_OU:$.!*Y Y*WB]5O
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M= Q3*CX9*$6!'AP,M=IP.Y'3""<""8U J>'VF@0*GAKK;A=#/Q<13CE5=VT
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M+?4:]5U$FZ9'CVFN!1W+00%*!&/A2QSRSAKNK.'.&JZM-WT2:\C74\U)IM9
MN8[Q_%PIQ]/M>HNP!M">V&@PRIZ.V/RT1C+74Y6R)J+E^Y^D'_UPPK<YWO6:
M)-T"%!SV=STP_([^(4R[!WP/$^XK.-\LVNJU^CN]S0R*H6Z^L*KJP\P49K.
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M/XF!.Z[OU\7 9U$MT2VM\OV<R>5#RKZ4$90XUHOB+^A%]QCXW1R\1PQOH(?
M'8?O./Q;X_#O'.?.2PJO"/<X]SUT=P_=W>/<=V*Y$\LMQ+F_36-(&N?&%C2^
M)M$2J9*NFUBFDA%-@KI<J@ Z55@$ PHR[IKS#6O._^>_V!CS$?':ZRO$/Z/W
MD6<$*R&P/*:ODD5>C4E3DS:\@9HRAO^2%O(>.Z?P]KGZ7.VNF'6LVQF(^5RA
MN)[B34)U6#@8342#8>8^%_%.I;=!I:\?=?0^Q^AM!(U?$IKZ3-6,D(&T)688
MXZ,.A?L?JFO? U8WJGK?;GSJT_/-[@1R$VAP"X#Y$03RO<.U7B6X R*RBR5D
M%@M('[T7<=O18#EHH=Z :ZR?MEN6XU>M$4=:^,79L&]0]M-RU6X],6UE1< #
MXWU@XCC$/RLY[7?UY]T9Z&VG];XII>Q[^Q/.9+XXP;"#S)>3N5C;52@["=66
MBTIUT%$SZT>IWIV...XEG\*=B=R9R)V)?!T3N4[ZW.N82)>=C>.+E?C(A(KS
MP3:]&8NR09C(107M$Y/FKFWL72\'Z=HGOR4S]X<?_":;T;_,)X'NKR^#[^3R
MNQW\3B[?.$GA5>Z/&:],$13E@2/D;J)\MUCH[YCK>TLFQB?[*<"^@/_GUJ:T
MP1:$8NAMI!N:)!A(A"]2BGCX@>?))H:K*IYV0A=D$ZXKMZ/$W^8-E)M,D.#G
M1W[,K?1U.1D>+F*Q2(D?M;,LEVR-N @9B!",QID@PYYVU[TSDCLCN7U&\B+S
M^.;U?5_./<[6"!8*[&R0TLQ8KS+KHZ=9-??8RQ,V$OOC7X[]I3:YW[-(X^[M
MN)MO/]1\^SXM=W\_C+B3P@\EA>]<00^:1S P1O@3!1(OU$G F*' BF@@/\&,
MN$=([Q'2KTI*2^FCQH1,++2LB@:2'\>[^>R9V4OM46PR[W;2PO1*5H5C/V0E
M?:7JO%S O'B%?X'_#:>0%!.)UA .5?$+G&ZWCZ&!L'I<+P;%H9CB=HW:;CH=
M<3&2?1&.!V/1Z+V>X\Y$[DSDXYA(9%2L1Q[U63E3750>A[-'651"C5+JVS*1
M^)/0G#\KF5;/G U7*;PUHYS; A.!GD6Q8-C7I_F"KL5]4U<$5;^0(GZ6XG7M
M ]Z2F77(4L*8I8BJ.9;1E5CK)??G?W^0%__5I0-?"XT;CC)1]NN&E:JQSB"<
M7K1D9C"L-;/YS>*9C7Y?[KMEUM&$VE7S"S38<9-B/9,N-%LC+DZ#2DD&*W'Q
MR"<'E>Y,Z3;(\,Z4OB53BH[ZF?RNQ5?JI9RY8)Z31K.B*M*UHE6_SI2:\VA_
MIC#\HA?2.FQ;7A7CC[$I,"6L$H8CP207>U\^+F8WM^^"NS< O,?R;SN6_WVB
M2C_\KN\8_>TP^H?E3ES.:E65$"GJ]4R94$3?LMY[G\M[>/D>7O[],BWNM'&G
MC=N5KE=KR%4ZT[>25(>HBH*H&V$K&3,2)LC(B-<"'4-#R CHR#!DTH7OKDC?
ML"+]W]]#-;ZMOCZ?5.0A2TOE[PPAM [0&= ?%)!G'%H;8%+K.(3EX[1:-MD!
MG^R'6TPFOBPL6]'XLIM+C<*DO64\&(XQ+S3ZN9/HG42_A$1?W]GR&]JD1X(T
MH^J&CJ6F8&H:G7CH)S[/M8G^H4KW[Z1C?R0)WU3I]8\2O#H)&Q$:/1:Z;H]I
MCWSVD;_KY^FSGN=KNT5G'LI7MZGI8S*9@@U#)#N<#$8_5?I>&\_O!/[3"?RS
MQ?;59'0631"1SH;&*[K%O@1+< =X0< 7@O^^XO<P#OJN,-\5YFM3WAWS[ICW
M$Y2Z3RIZ)TJ=S=6[+E.W]+R4Q=&;E*'[Z'+/3*\S;$L;A:D,=Q&IV2I+9ACK
M<J0C'\MR0?S_EY+"_V/ XC=#41_N1!<0OE>-?B(I^+W&W^'8\4Z[V+@% ;K$
M^]A#Q%51#?Q"7L,?*UBZ&FBJ\3(9YF!EG.L((QEOBA(,><"X@Q?6Z=](O069
M_6 %</$/=0-_  XQ_>$#3_GK[$N4-O_^#_[#_IT _G&@_YFUN)-2""^Q>#/#
M_.]/"7=8-V6=*N;IBFV1>3X4]6S;\^?_\IZ!+!;"][+4_]8-#1G"[)^QAOA%
MB)_@]?]>\5/TC^>@HJ2O9'[_]T1&NW_@CY H:=2N^EM097.I_+/$@+#4QG@2
M!).*.>9$5K<V=%>J+I$?D+$?T@99L(JQQ.8AV9G>8AQ!$.QS A0"O&FH >=O
M %W/@5ZQ0?(IULBW?[,V*P[):&*ANOT)X:+61V<V'(U8V.1YOX4)AKKZFV,?
M".VX\& C#Y%/0@T+0)RM!;,NP_\?/C#3@%/_5[>1\8V*P=\QV\,\6#X8^&9]
MA$D>V!X0<P88/Z9,AS#XEXG#"^\EOPMYCG\*V6?"=W;X4;)QX-TC+IP0HRB>
M''$H'AU%4"R*Q5!B,HJ+/!=/BASBXO$_Z%X^F<XL@%[*3ZF6:J5ZJMOK!)K%
M5+N6"M)Q1J5ZYL%)1Z'GJC>ZN4ZWT:NG>ME2-Y?--.K97+U#_M)I5$O9%/XP
M7ZI_V=$HXG"O2S\FNZ=GZS8"SB$"SBD"WF,$\#E2]4PI50UTNOB#6J[>[3CP
MH$*W;B[QEH6/\!@=9AXWM"FO2,\\51=LF8/_D5+$IH:EDV*0?S8F>5L(=1P9
M! G&LJJ;&NKB3:5EXB@B*L5XM.7TV*3#/9D]M*XM&',D=-.%%%6/2$9RRKCP
MW @>8_\((*RJK/!V#<U$GV48O_I6L2BGE\H^!+)X9YJT(DHBIGTO&$G.5=K4
M)07I>L!-O':N],.Q=6[JAC39'^@F;.+B2:L2YKV\8>J!YHS'G"P8*"G"0^!/
M\,Z#@.>8?S)4BR'_8O_Y*QC@\:EE?@O*C*!J*Y6>*QB0L((36&DH),B2 NH_
MJ"E3%!A+ZHHL+B"3F 4!2S'""NX&R>J**DCXKWB-Y=)44&BIBB9P._R% $Y(
M#50D;#!(2'\(@'+EV10;_T>'IT2B)>$#I%,LPUK;F9E+N!"L//$8WP*9;"0>
M6*J*BO%5P1N!#\>JN*>+*AAN@2E2K)NB3PLS)"Q6*M;9L-XVPUJ0H6K.:_$Y
M#=#',+#QP<B/\&O1;H4@03^ A? 882W/D(!,:-R#%S=P(M$2W?1X)%1"L_<Q
M))20CF4*!A/"?\BF X2/U/5^#6T\5P 'ULWQ')\8S@N(8\)F#1Z#; ]$L9TA
MN#V:,'%T;Z *RS+^K0GJL*9B*L$_VDKXX!9RP",J?H,@8#*:F 1Y,!,D:C#^
M@6@*GZ4$GW"%,UJ!9& X"J=C8/_XUZ%^?.PQT!E&D$\U3MYQE0TE4,>TMQSC
M&PHSP0 6&APF(@U?:TI8FQ+5/O )M-4YT@_\:;$*^)7+)SSW'0R<,IIJ-7.P
M(+9>B?$C2SPU-1PV82_OK.&^XWC90 UI4WR2CCFFK.SLGH$[;V>J+.]#ZE8!
M>C3'NB1*O+:WBX SY][O>8N'+>(%.\U4YE.W</0"]^U$42&15DPM?&!L8Y[@
M8EZ GVJ(2.S GSQFCOAO(A+I/5G+^R%L(&7_S'[;[? AC+PU7A-F5!Y'"/9&
M+>R=(1ES_8".>3'PBB5"AM59A\28,=RQ$87%2<H@$#AZCB[B\"GO3P(;U6+N
M_ K&)B'R>U_0P0WSHKHRSC_B0!>C"99,>(.$61)[\P'CCV_@_&2S!_N#_\)1
M7^G%TC'E('TTD?=Z>%!>Z+E&(C_?1I^FU51QZU\ %Z&.*Q%)HRJ:\G(.RU%C
MG]I)^@B<4". G8=[ /.H$18SLA3.D:,]9F1>UQL3$EXD"]A/T+ C^3IE_3B+
MVKO%,]<6>XU<9[C1N'!!JAXXRDKU_+L2CZ"6KHU$M"2J7(= Y-A!5N<U;11O
M[!_E6D$8YD*5T##*:IO46M[^\6\T&4Q$3@MV*2J20U <307HXI:PD_=86P!I
M!LX>?+.2%B!6-6 7)F>,&=:G])+@:'1>%X]->_($W3%>3J)Y% 0G=_BL6+#N
M _]]&0>R$LSM('Y,"POJL55:0T8RP@P2[56J51-B3^OOA@7<!^! $P#:1!JY
M+E]4B(9ZV.K:ZKE%+%;8]Q;553.VV8*C],&G=!M:2M!;#'KU)5X$MD>8,MRM
MP>^0$W*C8V&!WK'=HQMV2"Y(GN2!GV/>,<40]"("9B+X&<"$%^[^W=6O-WOM
M[\LY/+SV% &?[WW/NBOE:6>N5[W]HIZM#I]W\VZR]<>_<88+AJ.GW5*H4>%>
M#38 L(BVTH3% /!^3+6RK75% ^8*?P;7#5Y?<[GD;;/RG/"X*4%,#D.9G'.B
M SM25G602ED>[&<?)=$]-N6%_DH,P<CEBDY#'N]?)5A7I@;)+(3@MC-)F!W6
M^@JJK&I__Q<79B=XGW_\^R?_%SV'G\*'92[^JV@9<XJE<;E/>H]\_'OWV.37
M[M>ZJ6TP*\;0@5^?O!:TM0!UTKY28:3JZ)]CZR"ZM#1E3.](-75Y[^H1QV\*
M'FNP_J<E0LU[4,^OK#/"P_AVU2FU_2Z\T;,,_4@_ A-YVR&$O+M\.W#HUCU9
M#[HO5F%>@J8J\4'(O*EC:G(0XP"X+^C/]FDLPR]H@=&KUP&(D%M48),#Z2Z-
MGS5TPKJH./"86H$FEB88JXN6O@><]L&&/[ZF$RRT3"_+W8I-DXMD8*UT:P9K
MTT/,;]6J,6_!9I(>!/4)?HM(VVX)5'B\XTNL]@#=<\[/X* NNOXI62B!-DC;
MD_16XGG"S-XT=)"W<$TZ$DP-[%OK>XQNY#9%_"G^6C)<O]+*',N2@/<U0>2[
M/Q$OS "##M  Q+F]B< 6Z,$T5) >6(9A:M?1BM<(8L-.QIJZ0 ILB-(RO X8
M+Y;A)B 3Q"1U\B0<F)H4%$'!E8,7!Z64FC_PY=W(P(B+;Q2TC:VJB3I2#A2-
MN@F+XE>3\Q>Q35I2<O@2 3J^6H9L"/JP+"WW3*6^3Y;'\\6L"@:&JJ!3G9)
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M.TN*_4I_>5.+,*D\NVY7F-#3Z%%>"*M4>XVO-'I)WKSH?=%5^43JV&-(S_
MDJ;O5!?+^P/5GS>NX>7]0'RI[$<C7C*5P0*A&,]EFHEA]S#YY'47_?$.WD9?
M*$4KD>J@QU4G*-2HU]I,A#AXPZR/A_?/U\=,?D^"?9VC_I!@[9>0BVM[>./!
MC?H3L/XTZ7;G3YD$8ZJ3S*C ]GK;-6E9>8& _;-$G'S<\\EDU@>.="<KG&J8
M?YWXOJW2A%<X_??,H]I,U_)=IC):QH:5CC@MH.TUG/X3:0+=TA1%@I:4&&6.
M_/YNK=(2AD':370@G5D_MF,_TE#]R,3SJK0V,3T8>ZMW*2T5:B-=Q7H8TJ^=
M>@Z5LH=E"5:I"%$\$73- 4MA.T.D20ZM+^!I>TZJM!)_//7#!YVB*Q=C'6LC
M2$L0B,4$/@<(<9 Z#%$UH8/Q&-LYI++,T[?)+J&B7?9H5R/\F8 TA1 31(U(
M':#KZR ^#J?8 78)RKI(A_G)DLC34D RR!&_W/&D6O*1R/2''U-0G[@7U-\+
MZG^S@OHKE<AWK2'6-1[;UX$PZ^> A&P*>R@V"'>W01N4X$$!F+4(\&!+9)#^
M[A-[\NQIPI3MBG(ZF]20-H7@FAWY/!I=:W_LNB@/6FB/$2;3OV['[9LBDOXR
M4#^K\WIX%&:IAER-=0;A]*(E,X-AK9G-;Q;/;/07QMN"L]+??[0SF+%HL/L>
MM^ 'S?9^V(ZDH;=V,,G$@[&X3^8=J)'@&<8"%Y!JS"L+NXN?3J:+G<"/X$ 6
M";1S3MC;?%6C,TV_&SP[,VQ10+)$FLR+!4+QS[:)-KN176\8RW6P-;0KQV>-
M]*I%V<R''Y?EK/-&1PTD/XYW\]DSLY?:H]ADWNVDA5^8_?+:\[9GJ4HIFN\/
M>X5Z-O)<R)6FH2@$.8.1".>;!O_*B1-.WUVB-=G3L#$*ZK"S$-3PD^>")_-Z
M;;W0FP9L*CSF: 95T_P4MC$ODR"G/B-5]W_J" 5@S&P@<D.LJGO$Z7G2]MY<
MFA0 M.6;\7F-B#^/O-H(PH)(S/$:#.K24^ZQLO14&/LPU+#)Z8N&F=HD493D
M4IZI% :9\H9Y3G55C(9A&.46Q;@8/T4[WH=Q'096:(MG&0(R1/AYQ"E)84(&
M_?(SISRP(]9QJ+CPW_;1(-I.%&>YM5;,E?7>,)1:OB,H8<._04^F3$L*IAI4
MI;.!+@!<*A1+S<%>FB\*J^%4FBZ7F_&0B!$(1"22"1]X?\( DR\&4QT9KP50
M<JA.(OIV$NE5&$D8Q)N[;C.S)0#BPL$X>RIG@P<M0X..,\=N.J,8,]WJG?=-
MD#;JO8WH",W3PZ=1PFPLEF*ES\G/N8IA?B72EL1=B<M-^6RNPA@[?2<ML]H4
MWPD7B_C/=?X*E/UD(+T!995B-ZSNV;S*K#/54#,\G!83&ZC'X.+!*.<WA/1]
M"!N]'8GZBD8(3GLGW@Z">ELBV-U^C_VQ]V8(']@,P>CP>U4:QN;, (DC]C'5
MDYZSKVV&<-RF]MX0X98:(LC%+F=D\ENMQQDY@1W/U>YVW+I8*8\!%*(0<D./
M-UPX??4BSEO(.WA<+>9B.S&)]Y;L;(6B##95D]-?:(APPP3\N_9#8)OYYV&S
MQ49RH9FPZ_3V3,XT6I?[(1ST\O\.U'QO@W!PYV-D+*-:N+E==#*UT;0=K6[#
MH^F]#<)-M$$0%D_&\"FK=7M<C>51L1L2^Y&7*__N;1"NU@9!&TC)XF8VSRU"
M]73M<3SJ-_>SZ>4V"*?JT/DV""09]'*2NW]S^WM'A"_IB+"31HOP1FBT>Y7'
MZ2*K3^1G>3!]H2-"\*TM$0(K.OT2AAYYKOMUG1)NQG0_@\G'/7>A1;2NVYD]
MAQD>@O>6=&N*K*J);E?,O)/'X3N?+4W&>]G=N_.I3MI)A(:A:AP3#468EP:T
M-6FRF-,]V7UGQ\D=(<?A_BF0[6?H]F&&6] [_@M" G T&BJQ4U0TNV;V2_)A
MWA9U>3%-INMSH^];553I $X*'EK$Z!0,ZS2(9/=P)AW+!4@I<0;%><9QTDE@
M=N$3_K?;O-IZV#LRET!F"5* =$S%K$"'1#0(8YGRX<C/,0R>M+NE7KB)VW&?
MU1SD<VX'1M&<@I/,5': #RE:)%/ [79+ LQV<L+$U$@RV/DD!7>J&A%L4^N2
MH?(4BT*/SYN@T+L[UI)4,E[$^P DMX;#60WLZ9@=^BC2EI W09K.8_69XJW=
M%-5S2NM T/E7E&039C#MK$:[]N1$ZJ/?RDYYAO4;3YFEU7R<%-)90P!)(A']
M\4J#89V0SJC3*7Q6JATIX2%-@%6W_/] !<?: 7TE ?:9%P)9*#3=6X'&XS!7
MR9?ONDQE18YKU=X'R,C"!;*N3X2:8VEL4@X,HYI@)S-5QB#6G5%'GNQ!ET+4
M,86 "4%B%\8.D@0Q+A@PF,$3 =D2HE.L2JDQT+6=@F@U&S[-R7M%V>C;HD]'
M6@.F/<)!%,.5,4W,S 0,^BY^55K&$/G#SDO*;#AVDXWI\URAL.-;)6Y8+^>V
MIR,^_)\C^4OL'U@[P,B,-V%H)OKH]#"_K-;QP0M.)LXA.C:0>PAXH.$5N38\
M_N<_8YH+]LF7DH:AG&1^O?="]O3/TTN9K^;CXN+QJ;<8+!9,>MD5*YE=Z^O!
M_.;D87).,I;$HX1<.V7X0MK#+RH!9'3(&"$%N"3EC#Y*GW="*5:<!6D%Z>!8
M!\9L1,;\TQZP9F>:@)4#8[3@/028*8*5O*,8]AXZ#X%"*M5TM$.2$4?G4-#A
MH[ .Z(]$;R1L_*A5!6G$3K[1T!0R(R3/V%7/!"]X(F<5V1/W&A8CDF=Z<">7
M.:P+?A\D;5%NZWPFK24X[)[A# GTK*;;1IL$UD0*"UPRZ5>P=2":AV,E%[KF
MDO?ND$QGOCH%J=;JDCVQ]6,T1-F9XHN%%%2XF^"V<K+7\:4Y]TJK:A4L,N37
M*+CX:);Z1R00;Y]C;BI'UHSG'"\L>@Q[:J?C-]E16:*VTVCL26;>08UGBI[C
MG!E",<<:D:"N),6C^#J6Y >9 K;2 7?AT=:M,@!G7J4*F:TTCQ@4=:SH4.W2
M\P-7\08=D9=@O*95I4.'.#FOM].%??.#@N1A_#M3IC#WZ!:OSM<@UT(3(@EY
MD*I[6=V^;PF'R@C)$RO6JT/98Y'MY+"WO^(!BDDNG)?0K[2T1C90^PT(R08Y
M3 RW!YYLD&M0T36I&@:N"=(?R5YT8LJR@[)PF\<X&[/[CUA*GC4P@M#_:W+\
MK.L])04Z^%TC?B\GY?D"302P\NH.!O%BK'72B:H:,"[K@(V\9F57(?5TW?@L
MS8=X+W-X42R$IP5-W1HSBYHOJSZ5Q"*3$$,#M)"JO2A;W"P7Z6SJ5!_U?^Y:
M^NB;%24;,@$*&H?/PFV9MU!DE3IIQO+BU&YO*BF2*?U1<L3 L80!LL\]I>>V
M6+HSY?JP 4_'\L9Q?_)_^>@F*8$XX=AD.$QZG9 N4OB77NES^+C;HA<_OE1%
M;!JX^E+97*ZPL-",0,/4W'-VX"-SY;R.8UCNX!7E1KISM+A")VYA0]4 VY07
M-SQI\4&B5$[/&K1<6:P/J'>#69MJ@C2 B;K'X[>H=P%X(8P'P\S/MEJ)V6M%
MM^SY\YZG2>M,7Z#3W&;+0QLD; <>)B8XN;D@^?<8>;9"+7](8=H?*150!>S'
M7D[^_=TJTI+WBK1[1=I/K$B[[-%Y@_^'._^.BU+Z*E5O, ]<MX(C!_P57XLM
M;B),Q)$VO#;FL1@(-78RV@.7ARQ5T13 K>GH7P$5L]^II<="]; FT@"9/5(/
M6";6("W8T+HGJF%BKDT9ONUM57=[C\D2M#HG'8H*JO >;A[T<]K?#K/;L42U
M7"QX)%W%5LH&%$;:]]1O2\2$=+5\&I#=\++=3'(*'RM0$L,+,_ SK_@]?3.(
MB!5,A\6B2]Y;/[SFF/7C"\]3YW_0N5V6X6 V+.MH%+;\ML"L7Y"7!/J7):("
M8W(U,C!7/[!#/6X@W8GXT5:"*VP>D(B \Z(_Z=Q2,J50U:W8 G%9 ,!I3OZ1
M)G2FX::(!)EXIF@/1F(R:;9S@JS(T[ 3Z53@+DF7(Y7Q-$#A>9WC$'(UL,A9
M#<S[L.NPTM!%G>)-4*16FG.-UM!36PFR=4P2LR%Z*=&;,() P-+" 8Q/=.?$
M1T0-=DJ@=I>+@^WY:&8PM!46QM07.H] H&61+I<092";D>C46'L_$E;*-'QL
ME6AXQZ48KF)M==_T'(,N>?X<M/QMB2">1K:\G2&8H&F#D;R:!FP\D+=467@U
MUI9)),BP55"RNDB\E&!GVRE6VBD^'Q@(%%.4,V2&OX:+XD4XF@\J.-NU@FUT
MO.,) ;WX>P"M1&-1)'Y$8UN86QY[GW[11TQ=P(J/GKZWK@3O0D$2C3Z>A0KX
MHRY]39>":U*)+]E""E-W$CC.8P9<K"28,NGB*BVQ.J&3GJMC)/"F[KA85BHH
M+23B;V&"@)PLAU/.IE\M!-;346.2LQ)6=,>U$)[JT4VL&LOGN%(W.WDNJL^)
M\?8;. MZ] Z<$UW;/> 74*$!D(.TA?=& N A2)."<"^A'M<O[C?#W:%/3^H*
MF1&\<+.6J'(%H7I;CZ),F[8EIAP=E#!@>$LG^. 9!^]-P2#Y Q[=;V(IR[3K
MZ9G?&&YRRR^!Q^Z&X+=?)R'+,SS8]298_M0'D)$F\6Q3CRG-'@""#@"H-(D&
MI0!>(K0Y@I0\6^O4/2 ]F0\,(HG?6H,\B)#S!%_=FZ!==6S9?WAI3D,W[T_G
MICAUF]Q27F:U^SW'JNUI(/85[*U(EXZ(3YIF@&R0K*[(PJ1'J9,=0-0=.H']
M//Z0*0*4Z7K3XZB[FH[?MM0>*ZI'_<I!Z-L/T+>OS0-]"\B@[GD+U#],%'VI
M_]=)1T#D[MHV&E[V_O:%W2H?>=H-%E(ZNUO66,3GC.DW8-'6,6^2-1\CCS"3
MD!-Y@2[;"),<$!.P3,V)[&8:V9KKTB182'Z8<TS(!J@-8%I1(O;GRLXT>0B\
M;BQN"#EHK^C\IB]6@]&DUM69];02[:[GC6=):1U?D/]OU?94+J;'4G0AM9H=
M49Q7&$V[RJ@84,%D=-@JSND8Y]P"95! )<1+I%.$>B!9*\2=(.^#O@"&>P)M
M2R=IU1(ISOT/*<D&*8AX(J3\?DCW9;_)S;A#&DE25JS)*E@<8&/$("$VV@/N
M(> 8U61=V "HUVA+^23&#AD#B;0.$NQ4-5LV_6DE/E@29BDIEM6Z01>9]%]4
MJ .B^9[F*$?OY/L+KW7V]O9@ILNIO[@5@9VTWJ;=2IK0Z,23#JZG]]YO2!:[
MKADC0L(.!5L$;"6PUR/-15X8ZY-%0QW,6&VFQZ?Q]W:FSD-.)#:P4)??60VH
M2W:PH43:VNM&2A&;"".'L?<O $-LT2AF^!13B&S#_51:%>;,]H]_8XQ_(= 5
MJNL_X190:=_?AH?;]&)0GS]*]74OLN!;U[N%56X]?4['>I4>EXK54[7BC"V1
M&H*X[RT<%_'3LBS7T^C0FMUFQ\I'.G1'NK-#CMT?!&@P41%T07"CGA%*E EH
M"/J4$7/Y%>1/G5+.MF0TM7_@&+@A^_L#G@$8 P!0M3/,YZSFZ:KLDGB24.Z%
MR<F+'P(-XC*PV'> 1)\.%$>G-0=M>41OV_[]:9\CXNFQGZ)BQ-,R24,3R_/T
M7I7T,+G(PZZOH99"/S.,^/"?'+9$-ACM\<;.J:69LCX(M<*U62^3[2=2V_@@
MG%.^@UH*Y[LUE=1-39$43(.FQXGJ>)CDO3OEQ<,!:!T#!&U=3X. K4@)&Y22
MOK#3N)P.<TXF(3BI/#81O%@R3)H;1U"<^(9W4) 6F$*D5;'FOH'R9*6EWU*Q
MDM?RMJN.=)(D-,/7CZ$GDRZ^,/8(V24IEB,RH&H27A5# 4L0<.A;-2D>C0=S
M-)EH[(=."Z>&FB9U$ @CEW@._0' SVZL:=A+8U />4'*R&#QMR?CCV33OR+V
ML5XTE 4G1YC89*/O'J5M-B1.;Z\[W\>?/%(?5=?S2C&>XR>/7(G/KKKQ0>N/
M?Q7UY09]=MB)A&0.<<@W2=*_^^-5Q$:>ES0"E!JUJX"R+GLTBD]Z2ZY.2HE>
MQYB8&U.LH,1^>AI?]W_NV^2S 6 "!#*')8<EE\7?FASRT],\<<8S?ES-R4^W
MLDO]JCSMQ/L$]V*UI@=P'IRB+\ZZ"9Y!J,ZT9!5-D--)VG%@0WYJC0&UI^%9
MW0UHE,]-#+>JKVER.3TAB=:1"5XJ#0R!(Y+W^$W_)()1,NB2?]G:GU7( !D"
M&A8;6.8Z.6Z0PX:A#K.?;'O:>96[+AWM1+*4(&[J&<(W1L86TO*M-8AZ"J\B
MBB-]^]*%%)%._KS@![1#AY$-]^RS>_;9;Y5]QKTI^RQ\_AT79>KM""$/'Y])
MV"K&NL_>C70"_\5'HZ6O2YCWAE]-XU0T+*R.\<8V/!V2NC)!TX?$#LHCP?7A
ME1.0RV+5F!-_/0TVD5^1(9/4#I#!0Z'_?3.BN@K["; !JVU!H'%\Y*!5MJL'
MUJ9*G!H@K:SD!.+DH=*$NFN@<AC+%%?*>R03E)'=V+DYY]PE>E,TEP1+=R5@
M0\:Z0R?MV\HGH7P3:K0U4C-C_\N!WSG 33PSRWV!],\II&T0'^2>4_#_XQ;8
M'^_4@[[@2:-U]0)T"<=2A-;9>#=LJP58[/-TEVXG"GGOUOJ0AMY6=-CU,[CE
MY I5*@QBW4_0K=UYV+GSGG)*X)(G]$S[<>!+,2@$%=4+(KOKN<5.CE("7,9B
M^23IE(>MX@UUWPYHNJJ;R41=$[36GK!\W8JZ0QQ3%3'[HCA_B&S$K7&(<>8A
M?*E^20!(HUMV7:WC</*P4X=)+U6\..0IH#-!.Q&!2QM^[CSE)#L0#/?D0>!-
MV"\]8M_XD'@92#,P+-O#=:!!B&ZJ:AC4D*A@,88PWLJ1W^N($ BK)V:+G:?@
M)XV\T"4=2=0M[('^V,KV(+ .6'FK!PD<EHO?L[)'@:=N(\]W%M&>IG X*2_O
M]4 ?->5W9DYB@\>F.A="GI[]B1OKV2]8[AD*,/W# 4.2.2&?2_+$.4!UH!S<
MZOQAR85@0,271G)7#J8N!%WOJ]T?R@JE:*8GC!%T/K%C#\'CD0S4J#X*5]#7
MDO'$/F$,@Y21(<W)7MY"YC(0$T+N=DA8PQE;[*;P4 S$".EBI6Z_#N#KV9_"
M&U8.&,V.(E;8%Z<]DDB?W<ONA?P:<\\\5D/JK%>9<X7>I):8Y[CO$,BPCW?#
M3B07WX%^G(&($+2DRACMO!-R]&_QP"/B_=S+UQV^:[ELW.9C'B[IYG2LD !L
ME_80HA3GU@MB6QNCKF30N.?4E*C3"K,-\%9%$B]ZJ[*T2-Z4]!E0D]<S1C@
M/2+Q5=EI1-;*A\61Q#G&1E]\'2)YW7BS]"A%)$+N\\GZ>*G#)A0>0+GA$<],
M0,_U:,"\$'(Z&/E)2_V@?88#JR74?5/ICG\EV0J"UWWF^SLR"M-O,V1!3ZGW
M09D!8)75O.FH31BMSW!@ZK;=.WMB8I^[P?>37)JMXG1RHMU5SVPY8'4%P$^#
ME]$;O[,U3NN:(!A-O/U89F!-U=9!H.:7!.<$21/,)=R"0";(PYV=R^XDX795
M#D(2)10F4ZGDSG<\"RDKY]_%CB/U6/?:U2M-G2#2[ 3C@IV#&@3=!EYEDEBX
MMP8!_\2&"I11P$&"5HVQ8%5)TR12DJK+X[>"Z8)?#%BZ-K'X(JY0*R<?0:(
MG60IR>CT!CU-M_QG9@4_K<GQ:1+2+S<YGG/;N9'.:F$F4Y"B6ZZM&9W:N[K(
M7^Q.W'"!YC]M:Z&F,NMN/[9 [%H1&6F1Z Q3EUM.G\%1WT[4-W0G%V<CZ_(R
M67I6A=RBDQZSA6&CLE:&'S]\_J7K6'33YGB0JM=RDBBRD8Q9#4WWTPO3Y<^/
M$E=>'8W^ M"3(J CD \XN14K**%Z#JU881A_ZJMY]NLI8*\_193G0FK,A#(I
MK9-H2I7<) 6-]9ED)!CCPCY IS5-#JRWZ"1&!CK0B?+C%:^W=3^TF,Q!IJ.;
M*BRWW<(N7-:92GJU$%LI=K9C/[Z3^DLW5=RDNLWG$K]A!L-&<Y<4V[-$!X:8
MA*/!:#3JT]S9JI%S^_!N+U_92ZKI[1C%>?"%.*6+3E\/YWRT:>J1<B5@11BJ
M7<ZK"\%3L>NM61T?M'&U"DU5Q=+./2TDP9 .05V3U?#S2&NPM86'P*O.897N
M.L?Y^+,8EOE+=%IH@>EQSB@'*4&NHD/*U$&I.>R*9'7SQ?A%8I$/@8S;5LI;
M-R/Z>(!\\>_H!((Z56R7%ZE\#Q$E<PH-5L"Z(I/)? 8XOC5'\2"WB>J/EK9X
MVK(7O _N-@T*%M?I2D&BN@W[',6:]Y0,'2UK!\4]+6P]L72WC=Q#(.O6?KV8
MQGXZEY8'OHLO2R9 I6"DX'.W]K*O3D(_88BAD^R3<CJ_N8-+?'ER(RE.=[U$
MJ+WH9-N2*@RKPY2*%99(D(V?3C!\TUU%3^_JM@?)O9!S]G;@1LW>9"1$9PN&
M6T>>.#FW2$7$K6_*V2D.'[*"-^+RUS=..YBRUT2:UX*ZZ. KM!)SM-3*+:;"
M-,O-:B51G0FMTX"Z_W/?)MT,PR< H"$3*\C$$IK8X-I<M^PH)-TD@$<>MX<]
MJBP^;O$"'IZNNL+8QL5>=-79HV\#31M$X#8[;2@!+?B=_A^'[;NOV7\..@D+
M;@F#.TU&HFW(32LR3!J!VTS4>=SJZ$:1!HDA?H,E.:9XA8PG(MTR_,>!>7N9
MV]EKU",3)+<%;14.QCS08(G'[T4:L8-[U=-+1;(#"K0'"YP! M#VHU@0D.[M
MXD>=-_#J\U*,DYV60.XWWJS<\U Y:COLMILP-!+BVUNK+;&& ^TTLR^^"\X,
M!]9(9!3O]Q,'L[U7CWBK@8=Y.25C7K8X.=ELRJ"]ZL$WWU5A4%:#AMQ3BGA1
M%(8KK5:KI,*4PTY.G(V:\?H\!GZJ9#":A"F6/F;ZUO%!71>Z'^8S+*O3<C=<
MKBB+CK&-9S+Y4(C-WM0U]9?J(I1F!(GAGYA$M=LR2EM^^HX)=I_A-_R8:[KH
M1ISU^JU9:=.O]J3UOC5?[ UNVO@E3\E'WY"8GC.)U?.@SYB39FG7&Q4?>^74
M[7@8/^B2_!R.0ZY=SJ.2&5D@=9UM1';1=(._J<NI,-V]("['C[E!Q2SH<BJ5
M%^7I6WR1U*,"3A*[F?2/311G[XGB]T3QWRQ1//RF1/'(^7=<M(:OTJ;4RDQ#
M8M#-\5143^,UVX%ZHN%#WS52*,O+@BE;Z5U@2SFJ/O@Y+6O H]?S5O&X[FFK
M]))=X]06>:V9P!3_H03L:5C$CVRO2W] &Z@>6C"NP2.^P8'I#A6X3J>YME77
MCT59UJWJMSHM4!^-XYI)[Z0QUXTEIDQ(W/1JSX]*)KGYK*$^;T*VM_M?VMY^
M!IZ3!ZRCWUR>5OO%!@S>VG%H!P98:VK69):2HJAIRC+2DHH98S!0-; Y:R<A
MP?=C\KW3X=2G+I &-01XGZ?%!?G*78 FB6B'L:67^T?PG@V[F:OAOZY2)EN%
M\ BJ(FRTG>VI4):X745F&\5>K#$-]47>3,J?UHWQD\F!GO36<-[KZ7,B93H)
M3\EDPWXXZOH8$Q'N)1^C?>[C=+P(YZ;C]=SD-%A0)JAQ&H!T-DC4];6)WT!3
M))T&6=:>K> I^(] #CHUH)ZT-YX^ZT;(@FZG5=[:@9OKYK3N=KI&TE\[+:ZA
M*RSQ?$&&H[5VT$YAIZF9Q&MK1<]!VNK_4#*F@Q1#ZB0$264VC-J-GF=REXX,
M[_[LPERK3:*E"-!8X]'6R>*P:Q,V9/>A465/%EL0&OS2G%!D#1MU/'CTF."^
MHUYA.]Q[!#S8%4RLE)T\?CHA9R)!!B$4*2S-Y3',//!P?8+'.5*2:S &QE#Q
MLR6-M?%E!BE4B:IA@Y1NTMVTW>N&=+RE[=P5M.5=6X^&I$EYL:>"P]DBJ9*3
M#!H]M;+ ]\YT#O]AGDY_2EHY1\=D'D+/6YMLJ5'XOBW0'X/R',A76%^RBBHD
MJ^,NV#669++&<MHG"5K=.O#C=!V)M$B!K-G;2=$X#CN0G9)ATE"ICAFG@&C>
MB857EGO9]5#Z":O7=@0Y#DMB%9,HE?YRJV&SG/_/WGLVJXIU:Z#?[Z^P^IQS
MJ[MJN5] 0>A^;U<A8LZ*Z8N%B(I$":+^^CLGP; ,VQ4P[&U7]:ZUE@C,.=(S
MQAS!4V]MP#NU"1-T>-H+3\39IH2)K3PI$YK;0'%CN1KFW3_^19'WYC9 L-Z4
MLU/ZUE.,_'Y904#'W3 <WMIJ-<B9;V?5X)NWN_R^G, &[=A1;Q<(),(I4[NF
M4Z$LP3&KVW8OASU1]]333B>=DZ)=2]=@B.W[-6Y[H,/*/V_PV@C67\&7.;/"
MQ^%I.ER\GU\$3 =4TU")[TU\].#/;IG;/=\S>$?B'T[@#0U'T#_!GQMQ6*SS
MPVNQ(?*^HQB^T)ZY?Z>8?;T*>-F[OP+33T;^T,ZE>&06[H$=_7/O-K\Z!QR=
M\:S47:Q*)7;-+C"TF,TB6IM^@D-K?V4QL+3'QHH'=2Q!(S@;OO1EO)A*(F_^
MW-W+H/%P&Z1__>_LXT=PIQU^#/YPF*(?\'>8<;6M]0*O>:YS"UP,C% %):3!
M?$ )+-F?8;'?TS[,MO+0SG$G9;\)-WC4*!QW>Z%3>(BV=B,)??CD?1\@EHED
M!PEXAU,"P<=^\[[@64&?,Z_V#]S3]0=?A+NSRS94]GL'[!7(PC:NKC^GW!^1
M:,&(O 2TR'@?"GF5K(HDBUXQ->!P;]#$C ]2)Z&!]A+9SF^\!Y3\R6&Q, OG
M@71VN&&*I<.\!S/LA"#N:^V)5Q@<6#&_6\V!(.PE'OJ-;+P(O7>J>J*7T+OV
M[1#2"Z8T\@BTS\DPW&7!BAKOLGT@:9@Z''[IO=<IAMR_R_OO>A5)D#[;2:1P
M)IV7$[7E29\E_+][Y3CP>E,$C*KY9R@^W@WXU=K+&/5WX>W](U1 &<^2 W:*
M^^P4A^P4#^:6@(\L< GO@1NOE[JXXK<8':8S\"L/; 05:U+0;]X4_63EYVHM
MQVF[K0)Z+QULX^DC28.6EES2(I":J%BEWJ1MYN-GTMP\J8/EL^"5_$)8S]72
M=[Q[0)4'=0?VP,K[6F!?7KSNM-)ASUAG;TL/%QF$P@)A#2-DOPGWX):8'$DU
MHR S$]0V-Y5E/9FEGZXCX4>67+=)G%IR5).3"),K,X.*6$&FU[4BO,!&;Q\Y
MTG]L3ME!ZE"2:&V\;?_LB]S)K;69%)HLU'(.FROPZK $[D&G?AEN^O2V]+F2
M.; 1-,UBQKK9%4<#VJ2OY;AP\$>HZGR0?5+=?: 9YOM9+$&/!F^.^;NI+%Z!
MB144#?MM^WV )P2'<W LC#?V>Z^%QR[6M+4W^FY>##R2D()T2 A>O?&&@2 =
M9YSZ[9>\@"2$79!GP(_>G&I?>7MN*GCUP"50^;ENAL7"4$;G#@!:8TDXOCUL
M/!+V#=8/K< 675A^NY4Y1#5'( ,.11#\")JQO3T,4^Q_'\YL"4,F"P>6L.C:
M]LA24L-,7I_2/DR&]<*^5O%//5>.1]O@#?TZYG  \/LE6KL1=-+.\9J(XVU#
M<P\(^BX#[\(^Q;^"UCI=8>&.\#8I)[-LJ6A1,Y2JLC/JE]%()Y<L%(<#9;SD
MFO+:,@M279D-VQK0-M5/V;<MA/> T)XHGE0V0$8>H_$NP*7TUCVKF[JF.T%,
M\"<=3RI-N5Z2G0K'87I+M^NY=&NV.C%/_O1U3U,0T10%7]T7_/+!W6;%#G?+
MC[9X3BK0IE5@'/JB':/'WM3 >T>EP$)J&GBII<]Q28_ADK[.])KJ2D>K"T7;
MBG&&=PRX"R3M#MG@7>)(XF?'F4%DJA6ZU?'MU"K/P)CB#'@2,,/%OS >)#O
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M ,&^P7+*W=;S/G1]"W*+@XGVV\A$4'&I1S)']9UU/?K+=_L)[UV#I61)?LI
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M4>S4>O5VND!&O]W5)=961D+.83%MFE[EUE4&&5[; 7,??H59VR=PUNE*GI>
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M1B%*%%MK8(151S-,N@<3,]Y2%/:0P='GIG,%60V,1772XB2QWD+,A9HN-FY
MYVQU,6;PZ;2#M)A2/3?(S68."0,E;TCRF,Z_7/CT'2IZL-!IM"S'.B[='."Y
M*;+N;&HDNQHX_=0-QN5VXTJKT!,D6Y;DIEG+LNIF:,&&^?AS#,R-EBI+M9E<
M=3G.0)BEK7?IA5XK-&\0,:T7]-F J5?F;*NS&E-<J2\(%1C-!AK_!&%>$=/'
MB9C2X'EP$0\9-*WJRZ"QXAW"IBAZ;< KV,/P;:.-,UARSEC.RKPJJ^T>.6 2
M6+4XOT6_1;;37JRJ9I*M,:SHTNO-*)D H"YY<1#PEKWV8J7!W[XK7/H6,QS3
M<L ]X56\/R!L%_H:B;8KBMK!':%A"-]L/]BZ+PR[<.L^(V*INP^? WR)I1Z0
M,5>#42U#-)8]#A,E?:KTA$2:NH$?2\UP0D<,A>+$]69<9)S:<E/T.K=>PY@'
MY-^1[A0G@&OUJ0@=!#]<!K^Y?YW/$^]8:<<Y9_KZ7;CP5I']Y^6HVP;XV;Y%
M-\16#^,P)9.M<@FRK*>GUP3X^5U\O\AK7I,-]/N2HY\F%G]3[EGCC?J<$+2T
MO%B5:^1H,ZBX7TD?^%Q 7A)0>5@LKCIL;C:WZ4R)0QD8T_S4C(EM8O0EI?&T
M$?K:3CBPO5J/[=\2^['$8],+K+\=#=L'6O+:TJN .,%[1YO_S^GEMJ#)TSXB
M\<GR2DTONH/-#5JCD0D"%9:M>HGMZCR%S48]4HA'EN4\Q*ZLI+KEU@OU)I*P
M,Z4YIQKKYKJAC,F%>H.MK_1:&0R7S!;G)/&6:[>24G<U/8]W+@.@0_1\B)VM
M3X'GK;R>*5 ^?]W-\,YS2O*-LQFLP=K@ ,J0<\K0G6@<+Y4:[M42_G&2/*6(
MWY8F3MFP!HC6[B&M4J[C#!;+)4><[)KT$43J!\#1/9,;]+39%L@>!N[OFWCR
M5)6 MV16 /&$RFS5:+!QJIT14QSCI#,W+P4TEYPP7 KB1J[5;937IM)\.J._
M.HGY@LWX32L!#^*VCY"2$KQ0=/P-_F5)O3,><XM-/8,ZMI(<W")/HB=(<WY:
M<3!Y76D5\3XR(9;E&Q3TW7W#K52O*E:QCBFO]=(TNVQH"/F5T>[7;OAHK'6%
MFBF/9*;92J>R*M$VA_3YO@ZWS4P)!>_^R2DA WQ;ED+D'-572TB]D1LR,K&8
MSKGI>*!)XT^<77PT4<'E47[<YJ<%F5@.,-?*JY-2W#^?Q$Y4=#Q"1LKS$3<_
M;4G3C36F66S0I6N./>]//M.E_:/$7725)!U/N1NVE,?I]:QJM8HP"P46\1U7
M4OUR62B'0. !$U$B9[Q*CQ\DUL9088D5WER-\P6UJ7_!3EV;]0 X?,B)2!M%
M,+O.=A(VQS"5Z=D)= ^8C1(Y:4IKQ\RZ1#7+$9E1M]H<%CM*\08)*311QQMC
MEJ)EM9MV:N4L3LT 2_R+)M]26/*5D/+ "2D9_[0_8*:8QTUWS4OYA*\6ADIG
M-\"(H?1E@7>N"1*OG!)T5C44?>W]+0S-1"+OM+NQF1&9;+/K=FVS6+I-MS#X
M0EI@#9ZVER5^)"D2M+R7<(!3;E!D4DWQ'"%L!DX'R>DH',F'4LDW_&XH[Z'(
M,YJU":D^;5>X%H,(DIR6I>7T"[E#'R&//L;G>GV%#CC5M*NS/*.ADZ+7AIL"
MY#F.8+X':D$6T)YXP6,%-/6/M<L%BMDBKWKJ40"7  O!!S0=BV:@ \7M5N^=
M<P2'H,=MN.^D;PZ:)B\E2_(V>!VVM/[C7[AT)/'/MB_R3WHB/V;'<.+5,?S5
M,?RI.X;S?H]P83A=]<Q\EU5-#J/+^GKH))*\TP"8//F'_P[;*_-=M%?/THXE
M.ZV\1BQ2M<UJ#:],O;\RB9+3DKCI,ZS854M)$QUGLFQCB V1]U<RJ0G;SXWT
MJJSVF'*50"Q.V[CPD//]E4:Q1J/QC4ARHK%!RIEU(;%!IN#*H_=TVQK9M]%Z
M7U[H D6R&SN;K,(KC]ZSLVCJ5*.=U[BXQAEVO#MMI&D:()2C]VQ73;E>ES8L
MH@K6<*:M:SVUW@!7'K^GN\EU:94D.6>:6Z8-:FTW97J8/+ZG4:DF+6K"3I!2
MGZ?BHK5R6\TIN/+HGN-28U8V,(E!'$'$<J,FT5,:C2%^?,]5>D:T&TM!9Q?D
MH-0N\;.VY< KC^XY9=M3EF.TAEP:*:VB7->';KDQ)([OJ> 68[3F3@G)+4KI
M84-)JY8+KSRZ9VTF- V[H+=8L6'R)=+$QQ-PS]3Q/8N]1*+I4JN-#'8IWK&:
M7(+-TN#*HWNJ98G0XB[8^=R\Q. %MMHO FJ2Q_?,8YS6-;OC(J<J;*.?*M1T
M!]"(/+[G*I]BVV*S6N1::V$T)F:9>-.@A]3Q/=<YM-%.*8,:YTRLJ4;(W5R_
MX\+1Z.^O+.37_26I6#JR2%.(JV1K9+SEPD&;1S>=E^KC0J'30)%U:SKMD8S9
MQ7K>I<<[6N3'1IE$!FR.+@[H345AS0X-TQZ/[EH>9E*#;-T=R+7FB._I,VL=
M5Z=>AN3[2YTND<H[\5:6B[.UUHB9I=5.I0&QW]%=-_VD#F1>GG/$#.'H;BN7
MFW&N-_'U_:75?KDD)) 5PZFELCCOK/J%88:&K82/[CIV';#V32V)M&2EE9U4
M6G/-]2X]NJN+R)UZF<N/$7[.)7%[B)8<"EQZ@OD+M+/89)U:EHV;8CW;'(R%
M7+(!+SW2$7:^&B^G2LD<PJ#M IELRE(KX5T:*@D?TU4!W#4EX2-!);<C=O$F
MF9^Q"S//%BUN$*=5]]01908XPHIN.:;8!O=.*[H@_Q&.;F@Q0GFVJO6&'+$6
MS+)H#1AU ?"N"/"I >X#@+@8Y0B'"S[PZ."9@3T;Z<H8?.B[^3]B<'G__<_H
M@4HR]L[=Q^#E8H+"6Y8TD>#1B16SX %/', RU?^4O]IM]L*FD@4=_N#$9:(K
MBG=&]+>W^H@9J27,Q+&CB+7)]I *;OXQ1ZW;\?2&IML$ARUS%!4OT(7&N!$1
M1^TA,^0'<M%)V'T3?GBERV![J"FX@X]KXP"#*KQAB7^'/^R_%(2+P0M!H"3X
M8"MT+SR,ZD'>X \^1/7^<H!CD2,8Z[$F?)LXP,:Z8_\]D5;B^!T0M4WP_SA\
M7_\S#,-_H+O;^5OSG^/KR!_4%5>A>,H#P#^_&XE?<1E^Y66)']@UUUWYU-05
MUQ#)'^2)R_[C;;$97AMZ!3Z[[>X!<RTDX.$'BL1W*_\Y),@>JQX\Y0"$[SW@
MO1,6_AYW32"?OLOG A8] <D/[QDXN<B^7\2/@*OFV&*4GLU%H42O%\H#?]@>
M7['O,^ >Q\$-!.@CP>WZ9Y_G7X2X.R%"M?(BQ=U)$>C0%R7N3@G\18E'H42
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M9I/L J_WG+*[5!'HN:?.V\U !8Q#G]W9>\W8!+PG#(,YWD> :A $Z3Z]@$:
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MCXA+R75"+@UZN<9H4,9MPHVJO\,N*0'Y<;EOSNZ;\,,K>VUX/7[".P1]H 1
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M;6Q:F_[_[+UG<^K*EC#\?7X%=6:FWG/G!5])*,#>,Z>*('(&D;ZHA-2 D)!
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M^: [F2S439^AB-T!S)C\J%PD,DL^WXGG6IE%<]Y:0HW>5C=^XM%)29HQCFQ
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M=Y&YG_O75U1 :\M3H+@ZU*=WE)#"8$X92F4/9!^3E+K1"@"91G#$\2^G].(
MNC&:4P2ML4QO.Q&;Y64EV[P0O7Q^U3D/.X."03CN*B9#W)46-O@5_'*X#!3.
MY(<RH4 >V0L&.@ZB(DYBJ/#BT:MBNK2%2/]KK&Z \B0*RK'@_Y5@,=YG<9IX
MX/;3>3O]]^FXY$/B#:/HY /+O&VVMPQC'ZBW#(-O?=.X-[Z5>Q- &/8A>6ZV
M?V,H6\'@("K-0Z#])*BI.60#NL_XO+#&W\=G<H!\1V\Y"@([>,'3(,#@[]C:
M@N3IA1PB7_69D+#C.?T@2^(P+D\:V:;N.N"2D75GR.Q@(/SPC41W%(_I*&^
M^U1U0 R7Q8,L$H'K]R':AP=Q]8,(.$MX%%<_"I^-AB=Q]9/PY6-X$E<_B4 %
M"8_BZD<1LJ=;.0DNU&)OXR "6R4\BL\ZBO-67O*!IM]CZ/E^ 1]*!VE9!/[/
M"^?V86B=.CE><@QF@2U;*B[0O7,"7M; ^I0-/IO4]X8M>Z7L@Y\8,Y[_XY.
M$A@[5\:+CX"M E9 _SP<>9E[77VW'T,2V=01J\%E3][)X)F'.\<7[#[WP!0G
MH]XOR/<<HM 7H1!+WSW/">Y;3M&(.0;8,SY:\H%[G_@^Z ,@RP",QY>$TJE^
MX]VR_/HT:7SM_;SGGN63!.[7[_PUA/]R6/BL\N<A@>]-N_;&_^MS\/E:>SG
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MEFY<T<F",8!*I */7P'6VH)ZI3%!41Q!9DQH$X8VX4^V"3\YWC2@-^& W'(
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M*[9JNUVX/.6 NU9H(>+?$>)?J'B*+[+O!WOO7'X'8@@*\.Q>"#TOO<5QOK$
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MZZPV:"G);MX1W!@HY]E^W9H:>.@)"L!3:*QY:3$4YD[Q,9==K@<;HXF&GG"
MA%FFW+794_AR@N7JPSX=:Y3QK*<LX%$J+.QXJ;PD,D8_PXE\QLZE<%'Y'0_
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MG<^)O)O 5+PJZLH#PA/HO,4C*/E8C^S/WH1/R"3^3ECRN"O6[:JD6K8K7;Z
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M*3CFXC>!_T*,<M@/G/I%?1!M^!M$!'HV?F2@"+&I!7'Y7]U&-JR<)_H98!P
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M %ZBJ^+?(4@17FWA ZV.5QQEPXC5 >O-Q^"$2"P> S*#B(=7E+C&^;$_?:2
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M,/)XR>??/RP;??OPL>U:*P#%8'?@MR]>*T!3V'/H/E/A]-39/\?^0FQU[NJ
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M+'_F32J@WH1BNI8SW8L3]!](N^ SW]9%1L\:["."]RD :0@XGFL=PI>]#Z6
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MHC%F;7-63A3P7?T-Q9/>"#<C8[)(Y9J<@?6'1E5KI=Q1A81.(A(835=(Z82
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ML/[!'-Y#30 &,=Q[N- ,*A(0?O??I+P[DSZ:2&L.SY7[]^XA@&_T;RQZX/!
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M_+?#YW_ \3PDUCO%M9K^H+T:U)D( V-4RNG&V8)H<9(2HKE9BD<$QJCD_V@
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M22*C9SB"G-DEI5%+E_32-S30U^XKY4-VG>379EHFS='"VG299L*$7(!DZG=
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MYZW),]8PY.-9!X"O9"[TRGCJ,17TSK\QB$U_L1^_<<EM]Q"48"\)O.+)#S<
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MJ*+4@_O#(;!.25,F%4K3VTO3=YWYB 0^!PC7%J>O9U#>*U2N+T^_ &TD;RM
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M\=V@TF>&?"3/JAJF'J/GU"HG'JES'A>/8G5SC;)A_T1AEO_-"R[0Y4*(B7O
MA,>6(29NC@E/\H68N+,:I+?5QN>!(_D.<%Q70-\\N_W6!0*0++YZ@8 72W4A
MM7=#?HV2 9^+;GW;D-NY9&[4K\1#S]+<-DJ]'._<^J3'(F0?^Y\B13SCXN:0
M>(T)_GVIBL3HK;!^_@W4JX#874^=Q?_O3 ZZB1;UQI[Z?>KP=05O'W6^_A+Z
M\AXNC-]T%NXZS>DM^_JK9XR\%>,+2"#9_ECP^ROB(&5P#@F.WUEX0?3,X7K^
M[SU+P_O6^GF1,>NC2$^.U.<3B9([)C?_P+R'HP:D>UDN/<F>'@4?K</HXV&H
M<GNCG.<EK:);5M&;YE#4.-Y$O;&/&HAWA.&Z7FV0G"FMY77;6+?R,:W?K4V&
M411G3T8?XG'FE925[V9<97#H^S#R_4T-JAO;3S?T.JXOHN_PO*^G5Q-_A:+\
M+D6Y.[X)"G(3/@YD@?M_*,8A(O_O1R1 GDL5DAJS':E/\L^JW@)B?[6NH6[:
M4)['8P]1BCX>W/ZF0*>_A+5\Y!K[EXXN?T>I!_>'R[K)?ZI/?"#0HE"@B;J#
MK@UO(L$_U4.^]<DOY2_?(.'[-D*^5L\F%DNG7^FJ[%2.T*J\7E2:GR_DK1-2
M'C\K0)9/G@6];%/E/!E9IN=VJMF<,!P[C"-9?C*=_"CXX>?G?GJVP<=N05ZF
M -[]+)1X+]%*L$^U)R[32IIUOEZ/&7ANR5%.DPGR]E)DR1@)1*->9.O#]KH\
M"<I^XG1;LU.I-.!H*9FAJX.J.MLL@V:,5&,UOICH16BY+9!L8KGBQ8(1. ^D
M:,T=B1=B%*GV\H:=*UCM_G-@]E.Z7TQTLD(ST5V/(V:U6HV#VG(9- ]$6P^I
M:+Y3;W?7:G7&-95*Y'GM61N'*V>MT6P\X!MC4A*;"F6-T_%%FG5+(U[LLR+9
M\^<ZT^JJ*ZZ3'P\[[:*%WLZ\7 G,%!UU,K-&M]XPJS4Q6E^;)AN4I45353M3
MW\RG76EM#<&L(3;R2Y2E=?1,8=!IFUJJD.CR3^:\5RU28D]M#IGC9VJ9LMA/
M=R<ELIYAY81#9EHY;3),'*]4YEF6B<B\*9?9F%6;4"-GT4,KCZ"48D#G>:[2
M+%G/SZ4AFQ\ JK>$*X_VV>/6B5*B/IUVY^*SP\J=VC@M3(;)@+>;1CNUMIBH
M#&+K2+(L]#9K9PE7'CTSH3I]9:D#O1M)K7JEJC&N.-'F,'7\S R94V.Y5<WL
M]N(CN6+&XI/R: E7'CVS+V7I=K6R+'!MJ[+.=9X[S*;61#.=CAZ:: S'=J_8
MJLC,4[=.4<QS.Y5B\?BG(RR)K?Z\.6:'\CK3F(JY<FEH#O#2(Y!6U 5)B96I
M($M)LY+?3,V$LYF@I4>4E]*B(VY*MUMD?KVHJY082X[Y)5KJ'^O:4S:@I:^K
MH,.O=F5&Q]EE:V.4S&G1=8*C$XXE*5&+26OL\22:X'5W.XDF]4BXQR?@^<%M
MQ\^\<USH=F"P-]XP>)1M!:7*\[9C/1 \]$T4?HER(!7X*?K>7HW!MB("NC$B
M@.:%^U1>$- D913UYP5<H6#Z,UB#7HCFUL!OHF$VZ%]>6:,Q-OXX8SQM4>()
MW;$57(\ G\2V,T221//X " P3BBW<L#F5_B,;HG>Z?(+&QI=EFN)6(>#.H-&
M*@=N&J5^H$H#4W<F4__;*K;C\&NW0/R-G?GYJ0;VKMV1@U5^-VO2?_N)I%47
M#6@0GCOF&7U@BGC,[1):@1B,B1CY2#1\".P]_)!P$(9Y0D-%-[IIZ":J3,$5
M,&MW2!'ZO:;;A.6,9D"PT;.ZC^U'8@R@"\(K:"HJ8A@(A?L9K;M?:F*"B:/P
MIK+&J<+H7WQ\#7C0X_?F(/$H$1A#D9^@F7@V(=G6;B0LPK2;;XSD!*'R,AX+
MA4<YX6<C*_R8+25<081RX@DW*V@!W!GL8(*3B BP@$O06W%:D3MK"3U$D62@
M2%,=$@BD*1- >&P.R#=@9P=SFAYV#(AK@K#$0U_F%[RDX!1;_]VH^ G@FAS)
M1G.85=T$$;R!=02>4(L@&L!'M1"Z$> 4Y;5]+"7X>_2E$?"V#D0,-A=4+N3\
M7_ER!SXOX%FG0 I7>$5"F 0A'[@,+T#7:XTBH#C]&\DZ"S$:%'*V/]@7/Q&]
M 8K !T0'0. MVWVK"Q?OON(!KS(47L.C/:&K!S$TD0!ZZLLRHUTADGLRZ-Q;
MO LDH"+6,M>$**%)M5A0(/$A65MLN9CU"K\L'%_#55Z:3<P<<>+2ECL>&\M?
M"THSPY4F[OBQL6-#9?T2*MM)8UM2@"^U=1-%';SB.7WF[O]@HAD:)8;!AC[S
MA#C<B"E9HH2%6&2TCNS_W1U2=I]" $VXM/&42QZ""1+FAW@>&E@^V6+".EU8
MX!6]/< 7:_S$NS5WQ8]+,V\( DC*:!<Z!+_KMKO4ACQY=SHZQNJ.4UU1@26V
M1FPY]<1!WIXC%\2[Q 3N,'C<NDM0F'N]'4,H0=/1 IZ*? W:01N4O&BS2(S6
M%Y_H^E$S^:.AFB?_\*Q_=G_J*S0R<2&(>^=7U%@5:?7 .:]&*5J)]UB*EYV)
M(:E"(9:-)I<__J$?HK'X0R(1/9[TBK!Y;=C%#F 7&RZ<;&'6+SM<U^G.2C&N
MH[+YS*UA9]*+9*11LIJ<I)?4+#L>-/78Y,<_ =-QQ4,.?Y6UH9!&<A]RA;)^
MV%?=KX@8J&90Z%;<4C\*SJ(U4!9KP#YB'U?'( ,3'AFQ\P1H:(5K+/O;O!^9
M"YV4+<AH&H&,2KC:&^*+R#A>I59)'UD$"XW)O]"OD!RAR5_P[_@GZM=_L=$)
M-!YII4>BNU78< F&.T!Q6_PD$85F=0,+6*2'-0@E-#P5B1 'BQ5L:<.7NQ)[
M!'6WJ\EQH>L1@BE"A:=&<@^ZIKAB'HD^]"8>RED;_PW"'RI8*.Z@?B?&2&[K
MZ/_P>5 ^NJ_Q7VHXT*2VD+$@ KPY9!Y V>Y;"/Y)$!FYA6N\6ZXN.L(>DK'!
M#1\)M3PR?;:?'1+A(Y';JWH[1SOMFU5HNOV=2XN(!00D,5 NO@6T@]*ZE@=+
M5A.S.YK@$$E8H(HVCE14QD<JWE>@M)AI3YE%894M=NF>24?%26R]231__'/G
M6NA38).SJC-VE>MTN_R3 YYCQ>=&M<[^^$?3 VX!7LK6\_AVS\W$;K>_NQT_
M[NQ3CR5Y#Q][4N)^)"+[AJUUS(2^8QVH#^"SKC3A?D=Z=:#T1ZO9=$.NI=:0
M&<\Z[;3P&PD)=?\0*",L@WPS^.4EW.)1,A@F,KY4[;>2Q?%(SJ3-_"HABCT2
MF3I0-3RDF$\R=%X )38LU&)]:UK*5.1R_WG:5T0M4B^RGP:4P8R15[UF@R'K
M5'4T%Y.E!C]J!MDP+PT3MZ>)RJ^14MOY_9"_]/$8&E"^VW@<S]DOJ'[8,B8.
M%KI.B<=SQ5:&:+N]%HAHDL;Q!0-ZE2L)A2.5ZUOP[]<KD?A9R'*+MEW ;./B
MGMQLN_#HZ)4M0(I:U]I=HC)[Z.NOFO'$H+,9=^NY9TOKKIQ68\7>H5+Y;, ,
M+&FX9-7ND"POY$;#K"_L: $R._5(G:%2H$!7$-@@+[F&,,%:>&ZZY2BV'X?!
M1B,RR$Z$+?>,M$"1NS.Y TU&*@%5D^9:C*8IN18G8F0TB1V,)8A(S(<CQPW#
M^,%VR(!)\C_>?'5/IWE.07 @!_"0CV]K[OOM&:"VTC6PUT%I'YJFCJZOX7'^
M&D'(C27[OY_::.%X6GQFN]WZ^"6QIMTMGFBB4*T)V4[-TG(R36NI3IN3C#Q[
MU=GPAZBXFS8*5YL.GSJG[P%%GS?S_9RAZK'4X[FO#&JB\,%7)JF =9=HR(#A
M]R?6.[LI9CC%DPC@CT\J1#\@SQ -]]8/X$^=#7O?6/%$<(B8>T-,*,CN%3.A
M(+M'K"##+D3,]1!SLOO,^RJ!WK"1;P::BW>B.5.(?Z4#;YO,Q#_:9(:BDX_1
M.^\R$P#!UR>D[R)0Y[2:2+VW&#KDF"L0P&OG?6<GIDN/:4Y]*_:XY)#OVY/&
M77?P@K23_&ZT<_; [P]8(7<PUVL?%-X-SD<%YIV=YO.;2]Q\]LL] ,$+Y]S9
MZ+-[@$S()_?+)Q=KN.(% ;XO^9]4@/$OXU2X@RPS*"%4L^_0/;A3EKWEB2\Q
MTNS-BX9/:H:Q?Z[C"6;W[)R$A'DMPOR,8_PF85Y4\-^-^G=U@5]&$KH^H4EW
MGQ[-$<<>G??36^9=NC+.9\(3B:1>;MYKK>;F.OTD3?011;9!LCN::C,R1C?=
M]D34 T/&'A*Q^&O=YD+?+A0$=^[;W5QUWQ*54(;9;I%T11<^'JG\\UCRSSKQ
M)WEZ]W7HD+C_C!-_DK=X_\'#NS$S+A)/O)O3A);CG^)"?D8T\LXP&I)UZ!!]
M#X?H,H'+/X\7OPOCW?HJZ_O&'W&0 0UC1R&&#T0AM553IN5TAN<B75VA([VE
MUFV@1LC1'_\D8M0#22>O&H,,>?JK\O17O@7\!OF/NV%; <W:0K_NL@;PK>=/
MW=CON_7QWR<&OKAF_]V^D5"ILSG.5B(#VNG.R>6S6*'-U"S/#E-X\LG)KINA
M(QW*D>LZVK<^_G7,"?H+.>+N*XH!+8]"I_QLOK[U!+-/RCV]^3EO'0X.2?L[
MDO9=G/,2FLB?3/=RYMO]MG0[FDZ'^R7L=840%,";"(E3[V5;%*&77J,MQ,E"
M%,8C0=1&T"\YC,3HXVX/Z,__MW\(_+0()$#5^FG9)K"%Z2^W,P9NPOC3X"?@
MU]Y)1<DR%'[]<ZR U2_T1T243+<G*>ISYZC:+Q5"PC,W$BG:..[#<=QNPP46
M@]KY>N2^;W )@N ?%(&!X!U;)[8__3KLU7'&!O&GT-I;_J0.&^Y%F1T+>1WW
MW(].;#@>\\AK[_T>*=BZ\9.F'M&W]^!!Q?!8T2NV#*%]:421._',$U,3>8?_
MZM0S@37_Z&=([-#M4W[M%^MZ'_WX!_=M1$TH,SIN5&AM.87?[RD2S!W[\$;-
M#O>.?PS9#6Z)N8)+?^R-:Y-&$V6>X.4R&7E2QOT%J$^>ZFS0X,75-.Z,R7J,
M[/*LT0 MFYUR0C-H\&)O)>7&K7&#[CI#Z!)/I^,BDT$C&A,O5^:4F?Q<73/Y
M[GPCY-939E3E%39H\"(@>ZE4YKDS[,XIFHLWB[G8H(Q6'LVJ,^92KC[/9#:<
M,U"LU/S),*-V$ZZ,O5R9D:=:<D,:,:Z=568116MW#(!6)E^NC%G593$Y$Q-<
M!I0$<SI\'LCXF:F7*U--C6Q&%JI%SF<ZLYKFC-S&GL"5U/&1H N>'4JYI9SG
M!\U,+_-<J/:707,?GYZZ1FM47*?).KL<RHYIQ^T)6GFTT?&"5Y9&)ILDF34U
MBL<ST65-"YSF&*\4&G*LO%)(9Q3E*H5V.S51EF[B\8LCZ;.XG6=)05:I>$RO
MM]G96$0IRD=OKP[RM8@5TWH</:;85-F9J=,*>N;QX9-4)*4^U9=M>=YAI*9=
M'F45>A(T(I)N) LK/5V8D9&B6!UK?<"+51:N/-JH.MFH[ A"B^N);.2)+6]J
MY3%:>;315&>2+:]RK2B9X<AD45D^#Y05>OOQ1ID54Z/6C4*/RW BD&UN$6EF
M B=4LG1Z-%0[3DZN-ZD9$Y$&:[,?.*$R5ZV!U9+3)W*$*LBB84=CC3Q:>;31
M2%NC"]-\I$/V1E3/  ;=F;-HY?%&BV9QF6.DC4 "3:RGQF:9U9AET##+])*S
MFH.GU5)>C^4>E1",T7-TZ=[V'*X4033?R,O/&9D?Y@IBK)5-3T?H7NAHHSVQ
M5ZP\D<,%%^EUZ#C4+\^2C58>;[31I*O5CMT;DDQAD(]0LX53K+-!$S)+LU$"
M.(U-6RXSI5;/:&:+,W7B1K .5XXZ0R?:LUM,%]0H;:.MDMGT,UIYQ/3#-A.G
M4VUS+&>:!:;3+U.)=0Z]_6B2I69,:E.^(/<XT!/*@E)DN2<9/?/H\,EHQBXT
M!YNR7'].6=UBQQXT1;3R2#Q0I>+(&HVG$PXD^*4F-616S:*9G\=@HK.:QDSC
MJ2J9C\Q7;)/38V 8.!)7-!/C.9-:-;G,\MG9#&K=Y4!F@R3SN#2>+,A>?2$S
MSJ:S:4?7SXDN&S02E^1H>CR81Q2NS,^KZ<'3HIAT B5SJI>O2^.2LB3;Z6A"
M2W+K63+:#!J)6YQMZ&=R$7OF&$%K6.,^&]=%-F@D;A5LYLK33%]S:ZI?Y2:]
M(;"GS:!!M[65V0>)I+DD>UQ]66%+ VD& @?=)L>J4I7$WH3,+/IBL?14J+%"
MH&AL9J1I,<$_45U''1?RR4HE&Y/9H$&W>:;HK&L9ML@YTWE6B:8,,1,)''2;
M'ZURVC"6-LAREAX9D56\D&:1;#H>GIL7GQ+#/MF6I7E9H-0D%67S@0*GF\D5
M-"7?-;CY3,U'$M4-UVPV@P;=SOMI(<?/XW*7[LMU6JO0$SX5*!LH2JZ6&NIR
M(TM#(<)$GE+='#T)&G1K/ZT6TZXJ,]W(2*LVTQK?JR\#V3C+<>9DT^-6<ELT
M##VG+V/Y AJ)>X3W38JNF_)<3'+E%3U(1<QYK1!;!C'\PGG*9*I/,X&3VJOG
MZ?#I.1]/3X+8>)Y(R*-RL6*3?&6V8-:,6:!B^V-V7PS'?GU"K#?Y]6;=RUD\
M@6DW#OW4K$XP'KL3%/8[F^/1F-Y<$MQ+WK)YV\'#20*ZRN/5\/%GWJ08C@F&
MP[1=@T9'+L'EI925JTLB.:RRE[Y*H=]UE<+YH-@F1K3@R0ZGRK.V5\+5]B%R
ML'A[NQ*A]UK_4RU]%;6?C"K)S-I&G:8-OJ-/?OQ#'W?^_\]VUN)+1&4@]N%A
M-(G_&K"/G3]>80M+G)YR!D!;:KT8Y]:-!MG+T7J2*XR690X-3GE,QHY!.G[7
MK"@T:/!V'?S/H<$3+?PE(UJW.]."*$.0-(L)4;8BG>4?V,+?"P#@@ *.3W@?
MN/$$_,G5NOR3L<?D.0W\J:-885 [??KQG,[\5-1M^_C6.N:<5Z8>Z4MN_RQ8
MG+M_'.4\Y[6!C[O$$ (?O:<#OF$CW!MU]"9#M-PA6CP1%B+FWA#C"]T0,_>&
M&2;$RAUBQ3.,0L3<&V)"Q7^7:/&-_Q S]X:94//?*V8\!S=$S+TAQ@\IA)BY
M$F8N-/_F[?#,]QGH\4%[Z"L!8#NU(?71J0TT'7^DON=('+< XUIS<4).NCXG
M?<*HG-B'9TE1Y&/J>S'.)8?E_,F4 44#_=T(XTJ3<'PI>F<%CNVWLCDNQ2)W
M=NX;-+1SKS_NOHO05TT?N6;J#DIR6Z\FC4X"E#FZD2F7>]QZ0750.C>-DG<>
M2?(J5=%>?.;.F.<_^TKG L=D[N^(%RH9H^^/XX^.^N4[&NUX]X#)3_0T>IOW
M3[8\XM/,JD<W8DNN/L@IJE9(4L88%6K$47<$,DX_Q)/'W1$NTO3H#E7HQRW/
MW[M&N#-^.M*@UU:@L0-VB@T73K8PZY<=KNMT9Z48UU'9?.: G:+WH$ CK/DD
MR/8\S>49$@Q+[60M2Z/J@,2/?\A0?U[@LN#.3GD1%4K?#(%WTGOS[J)O$0L(
M$6D5<3VEGP7\O^'$CE)\HU]>RYF8$(F-.)M1^&9@Y.ZC.SRS.M8=G@#=5V ]
M$!JP44J\[]L"UQ+8.G5?)3SXB2UXWDK2^X8*]1X\TN!NG, *TJ3SZ=@0N:R=
M(\OS?EI=*7ES5FFZ-7'7UJ3?2FW>DUC]K*$*KV>NW7' Z6;>)R[XB&R J9_I
M>+[)RWO]]BA@DU,]NR%[>IG/S0M1:[1BW:+5K4EQ!6[^5OKJ,^3272FL>_
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M-G!OCH'\6HA1Z&-"( #;5MQM8&)!#_</BZU#!^X [GS]2/2FD@+VZ1 ^5I'
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M"-BVBN9VLK3APXS51#\]AW6!&\@GB:2<RF6J18%;MU?)U7K&M88\^^5$PR5
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MZ,MO(4"X(-AVU[DS2QZ+!#?&@Z,8D&EW%SW0AN4A7UN[PP!\&,@ INY,7+F
M; 8W'@&] "@*L8D 649#D8MMI,5Z86.,(3MI G+4M_:ZY=LM!X$"4;($1<?/
M0JZ\^_Z1;D^)/0<BR(H)? /B6.\9KF33!2Q;H='CV,02R5L4'_K HQ^)6ZJC
MND;DP,AT>'--,-@*8PZ-+]S:PC4:=2@@]X([""300 0\1!$_,<&+D$\!DC<R
M_@S'M!PTD0%^?Z<4_,?C+V+'3K(L*-7/-'6L*12TUG"LK*UHKR1;7#V9FRWC
M@TF%+2Q/6#OTD$&RB$&2:?NS9=K## IX =/@37M=@_*(74G6$-7Q#3/P=&;;
MAENT*XI0Q=;JT!-6PQ?"JK,VW&^>^+WW[>+(4-+T9!0CYV*UNDFEBW-F?N!?
M%6NY\RL-VQ@0100[,:>;;:SO(=RA/Y%!MKCBAEWKXQ[4UQ +P9$(A2D*2H?2
M2UVF%DTJU4Q])M2@[15[($D2_7?L3+@8\,-<4!"H.M(F4%9#E/,FOO4%Q+]?
MQV=66D@BP(:KA]$:8Z2A6DW%R%ZR9;#-JL ,YLL@1^UV*)RWV.64KS0HKC<7
MK:8PIUA[]"$4^GHO@\'71M!K\&8=[A>)"Y1X QK Q#@.Q-M05(1H1=NTY/6L
MW.Y:RXI1*T_<>4HD=8PT:->XB'OPC2.72Y&P BL!3[[=1E8MGY8PIPM[U(2P
M'C+J^Q@UH_"6M67#NME"-@"TI."KZN,V@,H$&X!;!H:6C,_")V(!Z6XA&FE-
MABTNTLKG(NDGB]4;RQ__),GX0S1Q/'X;FM^N"$"XAU(9HML">WR\S\/$%"BB
M;[&Z-')X,8.T__;J1'1UN D,^"A771((RD3QR 3 9K8@0$\11PJPMF#;&2(9
MCS\<N@W^F_21=Z6"[B/10:#V!$ALH._S(]U!LWXTT;\$0&8#@-C%1HG]PM!X
M+5[A!N0M1Y@^'+D^2*V;(C[GFS+M@W&G>Q9G[ZA\/Y!D:W11&TB[[.2)X>*1
MB<2MFUE]E=32M3B @BOQ$&5.*!R(ACWCPW ?_N 1S-9MVK\0=EME[S4$%Q#P
MT/WYU#."MC?AR!BZ1D?PDTW"&-^X3FZ-ZUPD%CUN](W^_'_[A\!/BTC0>K1^
M6I 0;&'ZRVV*SH_A"WX:_ 3\VCLIM(,-A5__'"M@]0O]$1$ETZU#1G.2'%7[
M!7DXXN6C)5)HMN;+%NS'G=:]9K<4O4W,V\_($P3!/RAV@] 8)6+[TZ_#-NUG
M;!!_.C'AAJC#:4Q19I>IX(UC<C\ZL>%XS//(]M[OD8*M&S]IZA%]>P\>5 Q/
M(;YBMW@ZR&'DB:F)9,._.O5,8$MG]#,D=LB4RJ]]I]+["+IJ>#X6E'IH/J/K
M2'I^/+_?3CZ8._;AC89E[1W_&+(;[%VLX%(W4KD?N7C=;??<\4])W7CIRJ)8
ME)\/@<).EA^A'O.2;[V>R)$X4)1ZD /E"J6E=[,N\FM7+[G?0!]C9T<\-,*P
M_G.-Z9,ZZM0PNO^_O2_K3IO)UK[_?H76VWUZ.><#@@:FI+O7PC9.2#S%V/&;
MW+ $*HQBD(B$/.37G]J[JJ22$!@\@+"5"\<&#37L>O:\=W:<?:>2N@=SZT28
MW11*8IS!@G0IB:*11DB!84P72MDQWX%]@7/;R(K);*24Y]++46+VE7W*^"GV
M3^G# RE(8(^^%&RHX==P+B+S*8Q@I_?4EW2H*#(DGA-["RS[#]>[EH0;*B3=
MV&[@C^[Y,L!#A)IM0AZK&8RFRJ_ NF)Z]A65?_RX/58X,UFL!GW/<PLED3VO
MG&[0>X284OW<N/":VM'/B\OQX&1<O^_0.[\]/E,!*]HAV%Q18?!^WQQ3UN<W
MP2+-E:=4V>/@OF%\^D8FG8O.MXM3TJM^'EY>WX+L49FG[$Y& 8]"N<,8%[IU
M;W+!P_BDZ%0+KV7J4KOUSU/RM775;_W^?GCF#YV#/]T!%?,J:B5]H0$!^0,%
MBH;GX!8%\2L0[;W(OO; T>97#>"0#97?%*;IW7!-ME!3-L.I]30[G&1JQ;A(
MK?RQ!SY<,J SG?KXD?J1ZG6]D=VG$QP0]+G2F>[8[UY66U?KDKHN_GB:3B)_
M:ULV79:."<U.4;&(J'Z7KD"++< I3OR$SYL_YDOG^]57Y_YGNQS<M'=/OT !
MS-J3+#4X &9NVT>O]BFZBI@9CE(+?C4GW*=]^4WKGIS]*-M-Z_??OTRS?G;Q
MC>KK!:WV""/;CKW1?4VU9T0[<^J1@P"\_,+N^"RJZC.1Q>Y>I5L]*GZ[OQA_
M.QFH_J_II7ET]3*F'3%_1C.IA.%_*=>M@^K8NOYT^OES3S^J]AIMRI JA8JA
MIQ,&7=XB6U_E,LVJ$TS@S^>G#F&K>$W40,XO#F[_[#4'Y<M3R[UO_G;O)I-'
M44-HSEW.UD?9U(A8N_=B4?B%Z>A1_?&G.NFJ%Y7KXMW![V:MY15_G7Y;2"1S
M3'LH[68:/&0C$J?H+!+.C^\5_]#^:E3*U5N_Y>WW3?7/\>W&8,3Y5#\\.MC[
M/+VVSW?K0[]&?O^&"%I5+]35.202(XP0/5(-Q1F#E&VAD5IK>GC1[DZNJV<_
MB^YY[^QT]RYSX#*R.Y?7Y]^U;]<G%ZK5_'S4JA[6;J&]3Z&F-D O6A9="F!T
M-^&C'AKMD_+HQ(.8G8<5UJ=Y!C,EA*I3]>_RL$$E]NI^<=K\\O7OT;0>T\*T
MU410R>5["LNYT$7X9[_XXWOO\/!;Z_Y/X[)V=O?G=@IA=>62UEC@(%1V7&^]
M>_0,(L03-NFB5OYM3\S1SXM.K^SLW0[VO#^#V#DUGHCDN&%BO_A7J3OVM34\
M/K\BE[UR1SWU6[?7%_:HCDY=K=Z8LV>S\N [%K<N1[MS6,^.UMLRJ7X_.W26
M\P,>:>+U;<A5V@AH;$2FO?Z[>W_Y2=/55O'LQPGQOOT*?GUKKDZ'"[E%BR\L
M4F,D6P@6H::[FX_U&W.O>3.\-MO%?7.RV_ '/Y>)-6 AG6#Q1D,VF$MC#@T(
M'R[:=T7F:_KP&?_K3LX^M?N7?]_^;!4O2<N\^U6OW7ZY2L8M/HEXE_2DN X)
M?2?X'Y]6FER-B8 0"$;N)K:'E O683>DY9*"1+]5E/[2HM9M\&T_,(\N^]>7
MQ4I_O^/HO;9V^W@&^7PT/[XR](-?^^:O5J!6RM..=ST^KMX^R#P+D-?$]Q3=
M<#,G8(D#</U;'WN_;[[<7Q1;=U^ZD]KG3Z>_OFWB "CT!#!N0NEU-$@[#&ER
MH#@._"@L"![>,KI,ICY8@3<G]4$,I^E8C,Q.@JD/.A)EQ^?$&\OZO57[<5EK
M=G]=?SV^N/2#F[^KG0-*:@/[AF?-).,;Z#B@GHKP6XHH%T%F+%XG@2RP*0[J
M"G#I' ,!/B$DV_ )MB]'MLNAMBQX?\S#>S#F_H;GT;$G6@A7#B0*L _\R<B>
MTK\\XGI7IF/_X;EV%"Q]FQ*SZ8EH6Y/*:?VIF.0,X$YGYI@=\:;M )4[O.9[
M&!@K),]"S'>LUI:*OA7J7:271Z&W.W G]PV( Q$Y7;F'X!T;B$@9%8_Q? 6]
M2O!VRD9<1CVS3\%S"_Y(I4\7A"ZB=Q_%?;%-+ A!$[/* #;$S7["HQ[NH#0*
MC#4,'PT+/7;L@:@K@"$>["(IH4<\%F8 211*T@D].X^$"YKYG#'#GT<B%]C:
M\Y47U^ 2A,'*F&7DN)" RU)/!<)#8AT]'2XD[D<?#O Y<PX=SUB2=IBN-%;^
M@).(HZ"7R$P%_V0QF_@W"%;S'PZY1@I/@ =7&5M/*><5A^Q/*+4&= OY<"B:
M.9;X'E+ON2N?4PD3YI;("J'87I/M@;4,Z>?U<J/=^W%TWKO8^]9J?_]U&9B?
M_.8R,(_*'G, G0R.7:?-M_ID(+&F X'2>R,7@DSVZ8K+D7"5QI>#PQ/2O/YZ
MHK4NOFG5KY<C*E:K]3($CLRB/D9Y,3!D#XS%-T;@(F&U..R47,@DI<H&E;'<
MQ!D@"+M(8_(QB)\"?A$&)$A4OCZZ9M5)8 U,Y;M)F1%<?P;+<4X!R.>B\P[&
MJ@[0'L7YTRP@O*,2]M0>Y=2\F)K;8L7%<L-J2XO] +7?M)M!K=&Y,Z^#@5X\
M:'OCGMN\?7%JWV2&S?-+ 9.1V><I.!CXDLR^.3+O[+'RR7.#B7)XN%> H+'X
M/2BG+1I57)8([VU>28)$'$,FILUX>>)J, :;_E 9$+)"V@ 5"$BWNSL]KNSI
M![76)[OA'YS85KE[U)SO<=JZ,QDIN/KRQL5P?7%Y]^C:'A P*4)\,=W;4(\M
M:M*Y.[PX.+J;^--)R][[>C$T=KV?DUN(/2C-6O;_1YPN\XK2U14<MRLHVLYJ
M$A'+5SS3]B,L%9.=SU.PQ(<][E&IC*32".9K4U71(Z;O.HP+!-.B.RA.Z$(3
MD#I]D83'6ZA!SA]+P'N(E"'CP)$FPX/FF#_KQ<*XMIL>5XCX1[0)QF=B@V%;
M#UPO3J;S&M\A<4Y/C9IQUFKKUYT.^7ESU#[XNUJDQ*G."<<K*113139('"GC
M<;5),@O]F@O0+8RG"/4EV0GZ@N[/VFK6Y]CR9M'S>>66]T^J%>_Z^O>I>7E4
MM_=.6R1SGD]/NSGM#WN3V]:G:[.VZW\-[GH_J$!2;90+U<KR014[H1(,D+,I
M+K?U1%/>OQUUU!_#_7+P/>AU_MS>G'SY\NVQG)(Q13H(R6/:=L0KTSEE[^?9
MT9_6]^;?%[\/Z[5V<6B._4_-O_Y;6<0I'S2I^>YHAE]R 6H>_K""/.,QL6P6
M<2SK2.!D7[_;(#/45E9;?O?>WOU4-JM!XZSH'-Y;O:O5R>3Y/09?+Z;[[;/[
MBG7Q5;M3K^_^-(\O?S?!8Z"K*2Z#G<A^DH/%\X/%<GZC.%B(E^"VGTFH'J.'
M=/#X3)H]7>N6_UQHDU]N<6@;G5_7=/=5=0%XI(?(A%G8\X/X^ >A5(-/F)7+
MW\VX8GAUKR6<4-ZGLR_EW_W:M/7I]*3Z]_&W[[_.>K>;<$(-[ $5[$W'L6^(
MYU.22;BAPOQ>BIA./ZSCYYLCXB?-!24E/=[^ 4TB64BT3^A8+"QS'ZI&8.1=
M3Y[(=BL8JT4Q2(/8<QTZ,EZ<\8SOP8DCF:#"HUF53F;CZ/MQ[^?0ZY7O#Z=&
MT_IU\VL$.H9>,JJSL$PI>82Z!3,_6<0*(A\4G3MNKA4=V5 IY6G)(G.>TXI<
M!!A/?,(8,R!DLS:J;2EJG<B4T<IIUC*N YIA-;B73(_3Z*F33J'X8W&R5MMQ
MW![>OVN[>^[AU'I6M@J7GPR:P!58.6C)96X9M4/*7BBQ-AUKG]R0D3MA3)Z;
M$"\IZD7CXT_6O]/=_Z+^O"J/!ZZY:^[W]/W^(Q+)&*=EVW+@>GM@U6GZOML'
M$=>"5^^-;"QN?>[9]+FI(I;YM>@[>]?>2?F3>O7';OO&STD5S 7SB]50%1[F
MM,N<7G31*;&4%+KN)>2SW+H4#H35M[X2O@+4_%6ESX>F3'%L0%;MW:9:5F/D
M%U6X]5Q #2B<8F$N[]:=\,R6H0N'(4H'T,TF'U<;$Q0Q%4G^*]?]CR8$7RZ[
MG%M7CL+(RU'DY2@R4(YBQ2WAY[?89Z^*2'V50A8;Z"8BW;L\JIC(&+O5JM'O
M:74J?O3U1M<P#;UK5@>]KE$Q*N5:HV80'0IMP&J_,)0L4?+RL'W4/FZ>7W24
MT\_-LZ-F@=6_;!_OE5ZNW&7J*+,@]\X,+!E'MG M+]"-127A:KT.PH_2"0T&
MS&VOH-JTYG5=-.+3LQ8C@+,?RNG92>>TM4=)(=_X?&#YP/*!Y0/+![8QUG2>
M+$L=A<0JML^DE*?_9$:K-R/JO+IA/*/5X?69&)YN=<K-#;FY84NK7W)E7"6&
M5B:#2E<GU6K7L%2C:Q*UUAWHYD WK.K U*N94<9/FV?G7/]N*T6E?7QP0E7R
M\_;)L7)\<JZ<M;Y=M,]:^_2+M6AKJYA)&LLCXYK&N6BAVQ2T%%4O*2?8952$
M1*(?061/@*>>5;+K8:/0%Q02MGJAS[&F7YC^B*?=A_JHX),>8FP4]](*WS_X
M6.,!Q.P(LZ8CL>PMN,J2-D$\0LIAZ1'6T#6L1@CY4+W[ D8QT\M9Z4)_:++N
M1I1'.*%36"1@.=#OCUT.5<=G1UC@*0Q1A='67CQ]B]Y2P#BQT"?]82T2TZ,H
M@^\2>P+O1$TYW,B<^.2#^$4> S CSH@ AKDY-\X"RS,<$,D'7E6D;-4-IA\&
M]AVQ$CP,^DA'#;9YWVRC49(8*IOW^]GK*%/4*TM<URAI2UQ5K9;J:4_#5M=3
M3UPL&#+;BP=[@\<F-+^IM\3_I!<DY1_Q=Q&:C']@TA;D#J5PP_@SN:Q9ED42
MLX=-D,F:A<]'V=9CHNB3>K(+FLFW8N-;P8YEOA$;WPB!?/E6/-=6S.$9:LEH
M/, WJ/J78!H]LW]-=:# L3Y0A9:0P6#!1KW \J3).FS6SP+$FY[>HRPCSX![
MFY[W/Y>8"1+C0ZBQ@8E(2@F*FK++5BLUN"&#O5+7Z]%,G_-<KG6WFOT^!#&"
MK@/YN[)R\HQG\4T<O%<^R8>9^?K/((9B:A]?YAQN&D@/R94YFK49Y"QRZUGD
MY@YOQGGJBY[GM6[Q0=@'>.+9C+_"(1[;/O;8=(@;^#FGS3GMZ^.T-6/K..VY
M.S5'.5]]";[*O0#<$".YT,OX+WNJZ1,XZ:;G^O3S_![=*ADUAF72Y<7C ;2^
M8=7*QJ!;,_JUKJ%:6K?1JVC=<EVS:CU2;]1K_9>*!WBLG]J *COQXION %*A
M[;XHT[F/@2JNY^=>ZKD-1Z,SU>%IY:I1@8:6W*>\_VGO$*(,H2Z'CQGH5\0A
MGCDJL):AT$K#F[C<!CHVHY*H]UA7<4(W W+5AR[VQW,]*--K\EJN[*_IT"/F
ME#@BKY$^Q2+A-;RZ:711(6Q^B9F18=>Y/JNVY >V*!8*&>^8%G\[)!C2T+=O
M;#KPOF>/J8!+?S,M^@LWX=Y@94?;N0%?]17[8,?%^^A,':GY9H^-G&5?(E9%
MV?WA6KPKT*GTS< GRA"?[*,+'WZ#A3 5BU-G =*T@6@+"J&3<>\)*]QZQ5.#
M$\\M\%7CSZ$;S^I+3KGO_G< 7?=F[U-6>JGIL)G'7@P;0O?>']J3@O++I8J!
M MF] 104GWJ!C^O.[L,@'ZH[^.#_Y_U!P\"&G2C;W*3,QG/(O<_34M%@0)=.
M-%6D) =U,7F=7BR,YK-2?G3YI7;;=&<"<S1B%7O#*FWW41$V'MO R3&ED *&
M."PB(GL@;22]D!6RN')="UKR8E '?F)2^J6/]J2KI0'UR,@F-R&IT^OI-5#3
MU)VP<KP\V -[)XI6DW[J?CKT*.#0Z2434?4:.C%R\A;DFIC'T(0BJG(I.T:E
M." <G#)D],4(P,$L8:"UP!F9MX-@],*)PLM!5&];(8I5*J;TM12,8'4WNGOT
MD-'WA;U&>2?F@7E#'R%P1B;P'&B6 9IGP TL;4\&\$+<V0B31-Q48MLSAB-A
M$!>>%0H,R9+F89 8TGPJX(Q,>UR(:HZ/Z6)#HVSLS\8BS:(YL,<-S1L8&W&P
M-K]U%4YDQ&HD\]'+9$71A_B\M+HSNA>74/Q@!;]-T8$:VE5#9.T0@N6\^XA6
M\%4X+4H0?;S.H@?3&R.'@2<4Z ?^A.I.K+YH>#T3+F%L*+HIO0"/X(U-<0Z(
MF$7)X8AMKQ^,H8="/ZKKTS>!/&-B '1QGR4[*.1$R0<7@^\#?1L6F 9*"@G[
MD;-E:V\1*C]#^7?B90+)KYZ Y%&7 3!/TN./E94I"@0>J_9-I34"34%$=7L)
M[-\@1H80"4L1D;/ITY$CA^)?([7QI6)P%,&A_!V6KN4?]<V)V:=/8[7YZ=N0
M_P4X TF@@(K^T*S<Q[LBV9S#5W*A;MU@9#&X0!QV;XDGG8Y!#)YCPX^F!UVP
M/$4B.9G>-G8$3@*ZHT/6[SML6H'$[V//B!&5XL*:3M%D^-#'6/@FV; B+.ZR
MZYJ>50C[5R2_[MU32<X71TV&$U:B"(NQ14M,H"74"B]F("U4<0[45' <84-P
M!M@3P-TI$!W;GGU"AP2APO2_6*7FY*!Q;%B].1H^X>]%[F39?M\C0GB29L'/
MEFCZ068;?FR,&.3*U-!S*U91/<F1I7XE.&&Q/2 1"DP17E?2#YAJ*QM&1 5Z
M!@_71%H;MO0+WK@JS2P]*#RT*2.*81;N'"L4F*BR+9 I M69]T2(*+\@%)_G
MX11TEYI#[>'$4M[FI[^.7OK0@:!3D4]#>ODF 1VP(NQDI)2=7G(?GS8D?B*M
M&Y:<,&]W8H20NEZ(&BD$D")UF\H(XPLBQ5;JM9&ZB^9#E"&_<VTX@*)06.J;
M639K)>4"('%J7M/9B#K?K 8]R*=4OY_(:1^=UEY4U(O'B4)H(@5$6 T\%4E"
MB/A,*2N)F:O4?FJWBVJ>C)DG8[Z&9,P>,:J#0;W<'9AJK6N4ZY5NSS+4;GF@
M-P85M:Z7^^7U.5]6JNW#\*I24J#.*>47'5',]L*14L^BRO=K]<,D9R*+6*(-
M0RQ+3TJ? Z-<5+#51\T$M#G;B]+J0K.$Q1L 1?-4FGU4>]2&KF-W&VQ3]KS)
M;^(D"W^MM@2KF=/J9S?PP0+BP_+T;$<HF(D>=6 H8?6#H9E1Q(42S7W034+E
M;RJ&H/P*[A3*N6(=+=JG+2JKL&]$&XOT&JD@%T)I>M$P0[ZSP*QD5+&]@3S*
MJ&@M=&(B4'Z:21_.='0?35:T:>+,,WWN*K24QVI5?FJU*M#P_ZE"9V&YJ2IR
M:+F32VB=B.K?JQ51!;0@)FD#MZ8*'K=7,*,6E40B1FTQ"4IHL,:.^6Y'"ZTF
M<;I[3M%E21J3@PD&^&^&["*QE&L-2VV#3!',L&HI;<\.;;A"*X:IP^+_LR86
M5SP7++,H@.(QO?5L$2LNR:9A#V1Y7/"XVF(:X'>$3P81ENZE-$#XF[X1Y-1X
M#?62TIQ9AOE+P-]_2]$4D2C>1$9Z?U+?AQK@('!83 ".C A<A@8CI')CC@)&
MFW3UC ;,&.N/?PGHL5&Q%DPEO8E--+24I2APRZ\;?Q*ZGU+>K!D5]N;SQ(0S
M?TA6/1!)OA0N=35MK6.& #/F\D33,15$YO98[407S^FRVAQ-3>646Q(+T(Q-
MV>$WPU<1-LO,@.VK/,BHC1;S >B5APX.OICUP,-&BE$[ 41LB]-R'_9[- HM
M\&$)Y:BI@-S]:,[[AF2$I $OY?8-J1ND1,9B$.'#P:B[D/(&GCN.RP-IM*@#
M+38V0XL+"2^L5%Y=JKGOL]+>'LC0=(?HE],8Y<E?/)8"C9!0YM-@; "KTV*]
M7"GHM=JC*%%^]6PWX+2U2_0#IN.)#3^:/U41QW0-%(CAB4)6A#^:>YNAJ#Q(
MYM!=U^<%/:C(RKQ)8OI[]+4>Y5WAUS ;2EST>\<V<0S@A7_:2SIN !8?)_86
M(/@?KG>-$AYN-G:A[)#)%*W/BIK@2_!$0:U@(QF8P6@:><N%!3'&Q-@@>;,]
MQH2$T#<9@<THWB:CPB0W]+QS=ZI@<>%[ "XDQ8>_XH%UI!,[Z4]=F):FL6GE
M(!7GC@YE*0\"%'S1AF 5=G(."3JAFW'MI.G1PS$%87S/G-A3NBM')NR6<D"9
M-2NX'S) <6F$06R[F<=P2-42UE)+6--3N_>U[N A]% L;-O'>CVJY8)N& G4
MXO,-,831QLQCF;#D>O85A/Z,0B'-36TD(S2UE 9=Y9+6B)2:A9281+=@XDJ/
MY-?.CM2.'1(9U\VYS;_I+%QOK'2*JK)S )W"C]V2HNMZ4:,J=M6([8U%^B,3
M'LW:/X.9ET=Q2#0-Z-42@ ^SH'-$8)?7BQ/=+$(OH+."1&,1*H>KDKXDV.0!
MNM"BD]N#=B[$2M\=M1[M#K>,1_UF(NQ.> M2FL,GYG&9QL887<9T6CH*J9CS
M?/5XEKJB88N9,.I*&X0L^H.X&"YIJB]@U@0@4]52&@$0Q'NZ>&?D*N \?A]@
M<AR,KEC+#:B@A I.Y%;EL\=/1_?"5YLV'Y-/!RV-J><DY:YU>B&R6/=RQN*X
M/54F5W1F:+DS(W=FO 9GAM'0+:NNDV[94(VNT=.T;L^H#;I5@PS4RJ!.]$HO
M:YDDE+^W[H846*:;313)3FH(]Y:,;!:\1OCJ"(6&KQ;FW]PQD2B4Z69$-QLM
MK3RBBQ<BM#&'P@/;+/1"?$X^]^3EY83<4/NU!M'5;JTQH(1<)95NK]HPNGI%
M+0_*6L^L$I)IKUPBBN"Y*7L6C1]H^574XUGL:>XY%*1\^@1B254H>>U*]BV=
M#O$_K%JO\6G45)0*<4E, W=MMI!CRCI(,,IY)M_&>)G')PTUF:8,HUA8J$B?
MJ27YWQWU73*_-)'JN>ZNJN>N,J#J7D&Q H]5(< 07MNU0M,0<ZI@Q ]KI@JR
M-JM_"A'K!= /7']:C+1!],8*96@!=GT(<6$FQ31=C$"IZ"_!8M=.GZKVP@0J
M$4Z\5.CF*=?.(.6R[!/"B#9JU, "">+&-[4,RJD^3SE-B27X.)\X<\);)^%E
MD?*H:#6"!!TNL$G$![0X,/M3Q$MR0YAQ@@7KLV;":#L.L3+6;62.B+?#C4YC
M"K/8=AH,,',A%[BY.W@G[/I4/+!O;(ME847Y<*'!J4"?R'N<@]^8"@'P++#<
M<N,=O\%V6']7'!J9\D+;^.7<D9>48W<*-B3(UPF['],[R96+N9+,4=#WT-'E
M0J-E_CM_Z0VHJ;@^4O"0:'.^8[.S/(7Z'(H%YT[R>:/]:/8FEN\ 7GY(RT*[
MDSF5C)N1Y92U38<16N3&-B-+/^8+N+<8 DLI0R$8C,_V-6P-3;4[>QR,HQ;1
MV(P7<VIZ1-!/Y,. M86'2)0$?-F*XFJ6L*W*1KFS@$*4H1G@0;('A91MQ_ (
M? 8J'GRIX=G,G!B1A>-2TO,PE!D"@K3R_R1H0TQ6MF+&FMDG"":TWN^9HWX0
MN?S.9"HZ(,(SP.N[\ULCHD\GNH\PAPR!]TM+M9G&[BR"MRPVP&&%;LXQ>$OF
M8"+$CTPDT5A? ( 1>DAN;#?P*;I"8@P+C5L,BYC );^<GR;Z*AY,'HUE\9,6
M""G+2-!KU:RQ)_5?_Q6NT8(R=&\I@_0*4:I+("G4<<R8F)YY18EMZ"M4B:+2
M:('];S.49K_#'ST7F*J+6V-.)N"H&\SPKU!"%,F]2! \*W@N9T4GEPONEF@P
M=&=X;IF(H9K0(<? FV[V(/ <VQ]&,65+@/E,LXA4GXNJP_/#ORH[5IJ(&SX_
MDG4-6=85Z9_H\9)L2;(1:0F:3BZ&.9^MS6-5. [HNV9ZTP?$HH^;,5*\N"R^
M>=C6,@?:F$,E?*^4=B %']&8IY<+TT4R)W4Y5:_ DNE8XNV\TQ^FZ4-Z=P@=
MIN+0R<XY$LD&,RGBZ)29:R.79R@XB>H&TDVF2,.G:SIG/ SI6$QLSW7H"80<
MM/"A7#EX4[KMYL^3GKGS!!KL&#CE;.@2Q?PQ,1V>B3#W.,!I6Z(M$E.LZ,L@
M@"=P,-> ,WMV<D/97R;^+-'GZS=*&YDCSV7@_K%0SVNJB! <+S=";Y$^F35*
M;8'<,"/<+A;=A;@+P;U@D4YGY$L(P)@[S]-P3%Y2ATO7T8A8P!X^6#R2%QP)
M59Y%,G9N2\D,[6>>^!-:]4)%C^H8!3P E7=8SP9^K;T#B@ZI=&[ 0SP4FSU4
M+^_&Q&TTUG"A%^MJS8Y#A3*<.R-N3+@!ZP$,Y.Y=&N=A5@MAP4ZU)22]3<N[
MF@H/8,#L@9UG^Y0@@9C>R&8!U"%", U';FE.=\GSITH 1BOFG@B%/<R5XRL1
M>2D(OP,4?<]D\P&W<,)&ST<9[@$KJ]"+QA^-HJ0T_2A@WI9VE,D $:/G^Q%.
M$>-7O=!,SXL4"1."T)9P[*8C)\\5>"D37),%>EV:FV;NTB_0]A;OF91P8T[C
M!VH$J1WK5@Z5>28ZQY5&C:<*C3SS#4+27&8-.W/7 RO<B8=;;C_@QUXR3*&K
M"&>VR%[%-^*YQP?E6 J\^IX9"9(B6!HW -(6DB<DS(-EM>9BM 44"?1++%;A
MS[5$]4R)3M!31=\K5F>UR=V:*Z^^*#T6;<*8KKG-,G863>>)=NGM"S#6\P#C
M/,!XJP.,7YTLOWF1O9(UB7U%PTJ"45#\?YJI)0HE83+(XA[KA<@E.!NR&L6J
M<L[-*Y6,(:\L)B;)-O=%3XR78YFK$1=XY2^LE2L_4=2^&)/IT+681 W,D5!!
M+"$."I>R6)>"\%'*XIQ'0B<!1%[R(BU,@@\7-&:LC2RR4<V=OCL>!PZO2K9X
M2;'*'(J^,&;BS0P3Q5!QE4B+8[/$D;+RS/3KI&@Z,^[<YK9%=H>L@5@3HSW)
M"(OP>['(S[C4N_B\)]6U*%!K63-&EKP4;YI",TFB X\013"%I%*?1G>4IB<F
M-R1!95.YLO8".J:7(J^A_WNB&!-0[OV"FW+*S0KE9HYT(4T(0IBX2(9"!1B&
M5J=G'@K$++ I479F#XJ7+Z9L2(J3! FYK,;R1R1W8F2'X&^R1N_-D,!CHG)D
M1>:.A!F+-AK)%J+LC #]1*O8ZX/FS1-D-6OT&*GHLK?C6>/<J$0K58:,Z#4J
M9N(X 05K%LLZ)^P4'5Q/CSQ5=EB;+7 ]8+PNW=$>Y",F1@K53J)Z\@X9V%,,
MR5YES(\<8A24^D!L[%R3>AXZN)V,=//P5,L:/+4=WQV8V'LJ6?)>]M4R"Q;+
M>EL-H7B"5-09 4ONA5T-XFTVP,-&Z0HE4G3^^K.H-E-G.4P_DXKT%\)>$K?8
MZ2SQ".@8PIMIT1M$TIB0"";TU$C= AX.[4_M&&!'C3AX,=N)2W]"\R#H]^ 1
MWX^\Y\NL)$8-,),?!2H7"B@'#@$!O$_@E& ["XP4N F]BR;K-89[.=O;(J7Y
M#XQ ;N*)\HYY'^5+Q-81:UTD6U< JX.&D_3RE)9-K,-?<I]3MIFO#!U=GR[5
M(!A%7>.8&C._]^0[7'S1HVFVT<GBH<SI6;<@*G:&OIA'F3=@FR4KT(+Z;D#G
M,N+I=E@2+:1*4;J9CCPV/D@5M=!F[0<]>IR8P[HO6IIA <:)!^Y<Y1<=JV_9
M?2[[$@4[:^&$>/^H5*+%MB,O0[K"T'P%+DTGBJH;L-:;B=9Q;'00#U+*?$I4
M1JN!O=KB7T;NF\]]\UOMF^<UD_H#K=[3U&JW0NIJUR!:KUNO&I6N7C:(7F^H
M5KU2Y363V!V=]J?CYOG%6:O3K=0KM8;X]H6/(5_N1364HI&]7$6PU$%ELR!8
MLEA3LAXJ]TF-Y99Z2WG@9^58"VKA8T,V:V%P.5,*N5'+9>V0N;5UUNK%I<P
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MRX9#Y]]V2I 2M%:V^[/N'GM+!;U-PUQVYCW'EHUZ[3X/2=Y2V6W3H+?1>3^
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M>O-BB^:QZUPI;6CJTNRSOL[PR#W7FQ38QZ=HKU8^TV,/M6OAFU)!.;3'\/J
M?C\TZ>#H)X=[LQ\K1\2[(I[2"7H%KBLX_1*^N7/:W)OS]8[M].EK7 ]G ^V=
MR8#04?2QL7+3<<B=TA0]C2>>>W>OA+V)WTO=PI-]MEM[T&/X@/2\P/3NV0MK
MN#B5=Z4976\AH#T8)["T?+PN@-*RQH>7PX27-:\N(6SFV%<I&Q55JP'V552]
M6M,MM4ONM*(&V+<.U-N#'1Q@.W"PSG#0H+^EHA"BRY) Q! ",'3BV:,87E8>
M@"$N +%[Z/$2>'3&6Z8[4R!-M?:1@G7@(8:>$?JP*6(0G1J[LU[\.@>GCDP.
M4=5'0)2FE1HK0M0*LLCZ4$M_:;'JM0%9%J>^A=BF;QS;4F6RAR2GY\,S/5MX
MMI4BEY&+7+G(]2A8JI:K1J6.ZF95K6A:G<.2NBY8XO RHUJ&AUAEBE,UH4G.
M2&01.%%]TG'<OM]LAU+:L3G>&P8CY4O@7*%Z"G!QA+JKS]$&0,8C/AT"FFI7
M S%5@-ARB$6?%D>\^1BF,5"MOC2(99"=ZR]OZWIM4)?%J6<8_=*%,GU]Z-=D
M5C+$J#."MB5+24AJ[1"'0#@3 EN:M4S9H9^98S*KE4KH^.[99#<]@KULR&Z/
MT$4W?3KTW%R6RVZ/EMTTW:@B>E5KC9J1"?#:O1^9MWZJS4R6T"(/P2,1Y_D$
M+;K8[#;C$9+6ZS!_&;FDE4M:+XI51KFNU<H-P"I=-?1JPU(UBE;&^M"J,R%]
M>B.8M\94@U0Z4[=_'9.U5@ B>F  XF1L0>FL([R#<4#J% UEYX B$H2J<"C3
M]:)6JQCEQKO"TF 5][?6$:_TURXB&;F(E(M(2\%.75?K-4.&';6L:HV:!K"C
MTK-611')6)_1/02=2]/#$_UHO-%7PQLU%6\JFJ'J,MZDV_Z3L//%=*(X!JV"
ML*.^08.4D7L)<S'IA?%*-RH5AE=4P=-5#EAKDY($3LW8XTW4Z6:T);6@],CT
MEJ!<!4W'P7X^XL+5.:0A#X2X\B]S//E(/Z-[ C(8G0FSYZ=CT.K"6%S_F^O8
MG&=W"B>FEM<#<)L^!T;N-LSEJF<UG!M%8VVV)]\/QA-A$7\ M5+LW$^,2\5;
M'P-X*\&:L?7F]0RR?Z-4R86X7(A[4;N\2C\ST"Y?K=36+L-%0( 9QI*UZS2@
M,S!]$@+FBE+6,]O>XP'R:GT]]O=-DZY1JN9R5RYW/19:M(:AO1_98Z<(#+S<
MT,MW%%VLVD;0Y=0CQ8, W7B/@I2:L&IQ^2@4;YYBY6KH>M58P:J>@"'U#;L!
M:[EHE(M&ZQ>-UF://QV9?88DS2OXR4%+J(OI LFJAOI<2GH6+*KG4E(N)3T2
M96H49W06U%ZM5S:K@<'C=BGN7!<[T%R:OB ;VA=4YN12TQN6>!JYQ)-+/!O
MHK7E-,]@T=[0=*["ZG.>.WH<'FG9PJ-E6BID3,2IE-3_S66<MRSC"#-.M:SK
MZAVYJUAK$U%.)K;#O6>'+NG)'BOX6SD\/%WA]!F5UR -J.4\#CH7!S;@.%?+
M&\[:B)E;S^ &?VW.],+L#?QKG]5ZVJ/2@NLI!_;TSQ7QS)$E@]6>RYSQ?4JL
MIDWQC$H4GC(Q*>D23//U")535I!L  2RY7??PM@BNHAYT/:;%FU>M 3>IW4
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MWB-!?')Y78)7[@]8A(+O4#Q/S*OI)F05UH-3OO:8O$O%)K+)?O(7VC^0_?>
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MK(C23N=#8SP/*A%:4YD<WF(KKH.T^QE>[-[,,OZ\\+N'FW_ R3UZX.B]/KW
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M^BM%E_9C\K6:7.YS-)-=L@DRII_DO'Y_(C=:'9%#T9!#>8 !;%IJX+]*G#
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M_H\?O14,HL *CEY#.L';^NF>)>O/>DT6WL;G31F=Y9O+-*^:ZS_^D#..K>7
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MS.3(7[_-IO'BTVGC^,B=2!ZL&7>,M4J*V(&35C\UKZ&W-P1I^[URZ- *, Q
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M"QWX-'2)[5;RBVCNL(D5>/H3V@(=;W1;(]U5;<_Z4:H8W$W(5_??%X/:6S$
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MFUGE7O!(H^8I 7>Y11F[<!/5N>IOY0"SR$-C;"P0CR41M3%YX.F*S[=L.\\
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M>NYJU[<-CO<MB.\9I-[UX=[JD8LV9+L,,H@M#UCFKA#\.@<A5ZPM.+/3'>'
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M!YVVK:#F0)1-_-ZX^.1![;W>"&TA+U(/*60!)BP<$7ZK+)B6[/M%.0G17NB
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M*0GGBOT11+0?;/+V3K%SPW[SR//')"8/W9L&QW)#C]*'9,QAA%43)0[8,(=
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MC'3A;;(A5;N:-+F9#R,TGB+?S-.QV1,3R:5\,KST']@7@Y6!XRWI)L6WVXQ
M4=816Q_V19C<HB?DWI"4*+1]JZGDZ<XITK3X+B_W/AIT-:%(@TZ*V/5BY,:<
MA4NJVZ%=0<.)U ^AQ"6*NKR8!@6IUJDW\3U2[V,?M$M6^=7PB]0)KGR0<IO^
MB/H$9OF>%P4AK:P?X:EX-/W#(=6"E:35WN' :/W1Z((-X9?UN'6Y^P%OOB"X
MU&#MISWSFBI=,R^]WZ4RL,6.;#!<87-)B1;E<7O\99G<N;"]=ER!V]R!D2X6
MQ7#'\ZUI_@5NX[UO3 [=K]F"(TF-W.@Z^AG6<@,&KG)+T*8YFH6<HX%.^6 !
M\Z2D&^GJ[TJY>8:&@EIZ]@2SEM:V72O\R:#[X7#?7=U/=5O!="MG0O6#AB&2
M> TAL_<;?-^C3L-\&\V]2[\GSXVMW8"NOI23*/8'*;;-%A@]JHG[,AP&]=\<
M'0"9_@C*BPQT1PJ0!"6"NK)X)N3 U!Z7>5Z<'PAB!V\D$TB31>E0T#MI<FE,
M(C?@$HW=PR8^SO49"SN&CVP=-6RX>(GF-!Z</QM(\.KYP?RP?O=DOM$R.\_:
M++8I%(1O0O9@;ASI=^I^B)1K^+8;4B?7<^NR5$'2O]QTNBZ1J_,F"ZJX,+7Q
MI,:TX^(Q?2G9RQ@/%89JT\L<L$, BAU!T/>5"_[J;6;1ERT]X,C8K,D@5J4Y
M'MLX5;[,0NA.I':V_I2W>]13^Y  3\(.;\<,L[:G'(^6CM;+RWQ0\/54GJ\T
MD??&Q64/R1PA1&_JWDW;>$^_B9J3-;$SZ(T+U?5=2[94::[D7JGQ7B_B;?RZ
MO;\Q>2CW<4!VT+..2SD)2\^U>R+NM [2UKX^TZJBK?>)H'\I9@2VAUAW\L@C
M>=H6&7)BU'\Y+]+H=M@^H*Y-%>R&"%D1(MSJX)KVD:[TUK3%L?$Y,;+FYFOR
MH$X9D(L[WIT:_SZ&K[+R".'LRA59'$>27\ O6J;"]^XA2]QRC==1PH.UU)OZ
M@>>.N9SO)^4D0F#O^=  J>.$<HL+G?!'6L*3]$&FT+!0%1;GF@K-.L_VMM/=
M(Z1V3OS@Y9MOB9:6?B'6$'MWO^*!$-1(@T)$!)]L+'N6M(W#NLZ.+_DM!AJN
MSY70OR5;=:;<G64K5J3<91Y*$-)ML=I3?7;R5E.\1R[!]3K#&?XR\0_+W/1C
MKB<*S J-RUVK9$;]C$GQ5[=GC3X-B.\IS#P@G2#4\KA=MA%^+6RHB^8YWRKO
ME'[)>%OEB#U'1;5;<2E_,G_/"J\-_&5$%/>4_E2!EI>N&S.FIAD4S93-FNTD
M3Z*!&C/(/TK ;TJ-:,>"2,7SL#1*B@9Z+>YCUD)<"G8ZN\N-ERVX>PLJ.#B-
MCY74?&#E&I,2H*MWROPO+"9>PU!Y-!N;<V^>RSU6H]9Z5@LI(S6U-7<?D^D7
MLY![F?B\H[(#RAP,'6%F[8F6R8'46YZ@ ;_RS5FWY'.'2ZX+FD8D+!Z%H(X>
M_4SQ@Q*RA V5D9."J<\//-Z2M&1 1 4%E3G1&M'-4BXL$JZ$/WAQB[<\XJLU
ME6=*OW @I7EF;S6V!0+'KJ\XKOJ'*IUQVCV9+$6_N[TB','M*HJ]YZLUU7)N
MC#EET_EV+)>(5F?7C-979[YZSQXUM?@SWW!85$\:UXJZF[WQ;?&+Z^+6]Z4[
M/]A,S%B?*:&!8&*KWVNDE6RPQV6IA%5DJ-"XG-A;A#:*2NWP.^+ YFC3FN>A
MB2\OKXA[:RY?(AJ(GD%$W$323T,.LY-18O?E>BBTM*@"J[E0=ZV;9*7[/D7?
M2)<^TK20DN:K;'BLG?]CZ??J6[ GB0:.NX4NEHT&_'ZNS^(G)'ZPC*/QV$&3
M]9=$H(3;K^PN'B/F=6.'[&%)YT<2TD)NQX-8I[W*F2=)K+.MC0BK,TQ_42HS
M)B7$(80&K!S1P)'*9ROK1C20^Q/7Y#_,N0[I<4+>0@-O1,HP?8X4"/DH6VJ_
M?FW7WS;#/3(K1T2YZ*L:7G=9R7KJ/3FL7;W+XFB4_2GX2!P-W*\=0 .":V@@
MDN>G^-D\FX91N5B,3(T3/O>S%;I+&-\QJ-?JBB 4,WW2.5'V/BM]O(%SB$3&
MZ'8AY9'*"[&ZJ\?> TY[_&C@T=:22J1QQPS2H-A1RO=4ST3KJ(?]XR<5CB@&
MF@[%;29JE]R<J,$WT7R4\;JYC,GB>O5GJ<=?=FO&7WCT6Z2JIY.N@?:<M7BU
M%#[HO7>MCA-U]AX_I_Q-#>[? HOF[ CR:-?BYJB:Q!(E(ELIUXS0AX2>]-VH
M&Y6)+HVRW0-V3XZ:"!EZEP@/CUWHE]"UGJRBF5>K%O:]@=Z?YLB49?:*D[XQ
M5!K:)OF-ZI??Y3"R8T\?I:"9*GA1#RE' ^MPI.Q\98.<_9.5*$&C;%DT\%E>
MJ]7*0LC>;7/K]VPOV#-<^KMO-[\V7T@[WG0K%<RS7Y,/17GY213550U37PT@
MC%X93NPS8+R;G+_P90#(B@-]:7(RHNPJVLD5:'GI75NVJ.0--ZVCK)BX.XAS
MM;V6B8:=N(> 73SUHTO>-/3(/ROD3G2U^[X]&HC@A;S<7VH ]9$L$7Q%:'<S
M6E\P6UZGH_"38W=^/_!.A2IETDN!XAU.NP=*ZO)E_1@)PD\#[G?25Q=8^3Q%
MV\]M/M6X&8=R)*<V/#Q);*YMK=>*""E4B C:T_-_BYJU1"TT9/=D9BW@K4%5
M&J)R:2G=1?B(TC+ZZ7$F?>5[U! B<!NC: $QDPZ1;<DG] _;VDT4.=8VYE-]
MDP+ ZKL?'>_0I3TNHK',%//HJ!P*:MA8TDH,F:L]VEL32"<=GWIB;T9FP*G^
M)OY)R-+3.=-R#<WS@%>+ WV:(1!['CD-.T&)"\<'#6+BK Z0[R6K?CQ+W ,*
M,3>:A>*@K K7$5;]ACK&_KZ':N\SM5L3ZW9CV5M2#BSOX[T:>,GPH.;0CE-M
M=&&=^.2"(L;W)CA< "E%L]?P3*4^Z^ &$;L";.\+&G",T;X35R&']:"/-.O'
MMZU/;X98!A.'!F6_Q!C2=^X1T%>\$_7V^+YFP<51?Y&RTR)A3]W\:J_A()D%
M=MB?S&)NAK#1FQ;,CU1Q):8_7+_I+-YH6M0M>W>0.G1?_\V&&7 HET"\#7F4
M%WL^V^M5IE+ES+?*_;KV?7.2_43&5!]'2?]=3J)[$00'0U^A?5-&^6B@NZVN
M/4EUM+5$.]=/H%.0?+%Y\(0$D7 J4;\R1DI!H29&=OO@>,1 5]!8&-<^94M+
M*\2Y^*6"O5VUW26XMVDRA[$UT$^BXX^V[MK[!M!1-_ABV2#NV&I.Q:CCDP(>
M8NS^I-"-R</]"D95M\J%BI0&%5Z5.^8_;I1VC7PWDI=C933^J,DO;I&S7A Z
MZ\@:]3/)3I,Q13LD;@D5LO93;+ 0;'XEK]_]J15YA9P=1;_,]\J;!S*</ $^
MD@_U'QD*]H2?JHVHY2,E$=6K/-0F2-]CZQ1D4Y7NCN/UE':<4C:0C26>RTXN
M*&4Z,BYWUFEL\SU48]Y"2N&DF,B:1[]4/2!=P4&RL-G)828QF&LA[R&FJN7Y
MHX&?B]=^#+)UX&?!/F,._0AE&4/.E((/]_L"Q@:$B(+M$#0KK2PV^HAJ2&F?
MG[< +9_LR_3GZ0*I9@G6FCY3 U-%=#+CCD*WK*6U\9*K2269Q(IYAN\VVU<O
M7=T#QRW1(9E@#R>UFN&R\G6F3Y*I\4GN")HH<LFJ,#,>)R,PM3L2<HP&?# Y
M-P3N;ELZ04(UK+""Q3I:R#R9]=J.>38*[Y.Z].06A@6>S]A:U<UV$GW/GB^'
M1%$M6IB)X&C'*#<Z?K-Z/Z" Z/=8$R5$R) +!T:H&-$8MFV/>ZI++BJ47 L;
M?"=C24?WHKMPTV *P4F=R5$Y(Q1"8899:Y804F@ ?&J%X$_[^=8K^NO?[F<A
M/^_Y1B K0<&T4TH_9J)@$?)>*A.6:CZ)RDPD#C.CX_972*(,98N&#Q5,D9W*
M7X!E%DV]U<TN%M MN&&Q)ZP%L^VU+G1EJ3 -*=<,G3 7IQP@/@")^'"1)<F(
M+\VFJ7U@/!/C5J K)=*2=MI7GCU=*3JYX,* 00:%N:,@!U"8"=?/=\V_WAKE
M:L"KET>JZDOZP-U\MI]<TK1R=L>[;#BHND+2G'FO0U_<X6VE;.1KQ,56=I(:
M@$:<,[>(*P@@P 11WV;PVA?SLR8F_/OSY*B&R=:KGL1.G?$G%#_GL$]R:L9L
MUT<HFE\&N5%;'5-8H0&<&#1P/3 B= %"\,9UJ.0KN_>'[?<4VY:5L+'5V9A0
M 83/#RBYN:9G<5'/7&8N_M/&$EUEIASK&(DCK>JW#AUL$QQP=<<.IEI8=+VC
M74CAMJE=?0YC;NY[L[K$DY'E;V+/2:DSAIA4:;:L8-JH4#QSVO57C]9DT$"5
MIP'/JL-L%.]$O*[F1>.D&ZIHMLNVJ>UM!UBPV)"J6%IEZ;EI\,*\*=]94)[>
M?26:[;R\J'^<_/EU@'B"U2\S4-=W\QCKQU@0X'Y:5N;42UWI!?'RFZ\3*9\_
M*WSP?&Q#'PVLY($=\L[Y,?8OG4$1BR%>2@')@F_6-\I:.PY+3X77F#]0ETYX
M%G,2EE0Y>:35&:2V:N9=!WU9.XGF L.:KG'-CF2"SP5+G*S>+PU8/#0S$>K@
M^6+17C'LB?5RPUW00,8(U+HCRWC!&V?UI2YH& U@VPF*?KS:4J2"!G QW>.Z
M=F+R7C-\''7:NR_1\7"A_ <7!QHHVU'%O>0#FUTFA@KXOS_I=K_B?ZHV/3.S
MX0;DJ.5$B#YF9Y"F_];QY4W:L(.:20,:V/]FH2#QL61(ZSF/LD99$>YL@?H:
M^^W7]B7TQ>-*@<6=?X/(?W,?#(/>143!OJT>FVDJ^[<II.X\F]MV*^4_J,E+
MXT^<_6Q4,T&9]:%2>B:R6.#E4EB_P3!<'ZYOIAO9D30V9IEIRDI&L$_#GU>+
M!I#\-V":%R-XG0T6Q,HW'MZ-$%[>^RYS42^4A*G^&M7X2 Y8<2([[%%!J785
M#5G1W3V.^@]B+ /6<C8L!*:G]X@EXWJ^&-:W%VNX-!ZB > '+9C_).YQEX57
ML]F<QK*SJM70[DCKEUP>N-^:;2[%3!O/ROB*V:6N$$T_6\;YR(=LFI0,N=0K
M1W+= >Q%'G//WV_GL7Z'QKSOJM1T]W&H\C$#?P^2GK>V?C%EPZ:2W#ZCPB6S
MMJ/95.!0[KVSV!%:_F:^[.S%'8:P1.E^8[,A9;6. .<;EU_F+\JU+(JFSC2Z
ME _[H/1RMV#G1]J4IGT%7:*)#P:'\8;M +O3L\:0M6-L_VV+O,ZEQ-G<&["!
M!+96V$&I*SB*]MY8X$:>+OL(9R:W2.HK_%!8=> <81^3$J=6F=/QX;C/EV H
MY1A#Y@?1^]TF];AY<G6>B(W-L7F'[W)"W4MU1;-/%7Z>*;AB"WN4;^]9I#XN
M&'?0[YS@TJ7WCM4/#7A?3FK/0AU)VJ\N:\7#:8*9(#X*^:*]<]=E SYM+#[6
M^H@&\$,/X<2GS,38X7I[Y:9?)\W,[* 0!'XU2T:0EGMI4!MRYB05(>!N#[$(
M:-P*3O:#/4=*769V<.YLFG1,C3W]7C<U4G_DZBP_W/J!@$MZ*6GQIE$2DAZ>
M'!W,!3M@4:IL$Q&*6XL^&-B[^:HFP*[1P=:]3O:P"W?U>ACV\-'FC0XT "]^
MXHT&6!!&>C!4V7N%5R7=#YJ,<PJHY3U4U.&4%P1('FLTP&I:C"(%(?G2=2JC
M*AE64AU5,@UGS?*TF7>%1MZ?-YE_*UR3,3"X^L1&@%J&ZBN?TL;DQV,0&6)X
M93]'9QOG'LP]ZONN3%7A$:V(1V:F)JF'&G9-**WJQC,B+>5N ,?&,#D*Q1DL
MFV#\>4?77^M0J3FU_WPK0 !H:$NB,W;]8C$?$#\4?J=!D7YQVAFC<C3YST*K
M<!.C$]/?UH!?[_F*5D7V%[O!B*MH@/V#L2"-V4-GR'(3Y,C^F=-7001DE;YB
M=>H:3/.CE!B+X='WS[BHH7;_SW)8),G"S7'B0J?*HIT'IL?)<XR;W>>MQCNF
M--'ASGY>)7=\/'W>2IT;S.:!7@2ODW>1VO-^'C5.>M$7HH'9*K/ "F0NR$LQ
M*R,^&B#6OWP22MW[8=>N#%^7'K2/OYMS;B3)N58C;J?4SP,^5-@^.9*OR(*2
MK'^)XN]^%3CAX5=;3!/"N)3W<:5#*"=TSHH0O/M!:%/ %UP'WF?W7 D)!6,C
MQ"4.XPXD^8]NXTC4!+LDWEH>_,+BKW-KQW\%[" C^/UPGF"E8+L!Z@:-U,*?
MF<[ASE!\]+DH&8>+0<+]Q.8RM\U^!?+TYEABQS7'\'H_$[<WUE[,_69/B4:%
M5>GQ:G+Q58J"3*B%X:5QO0]-@Y-5EU9]#<\$B_L\D34^'C+*= 3^+<]3O:P>
MRAVW0E5<H2N)4/+0430P;YJ382D %\@M7NT+=Q=T?9NVGVJFO![%0R),/VC]
M396)PX/:4^<+@E4>U/NI#[:[VA#OLTKR2"3Q^K(9=I^_#Q\MB0T!.P.]W$Q_
M"JQUU3!]E0\4*UJ5(A3[=BKK^/YD/ME)\?ML%U>;3;JC+]:)-G;+9' J!?B(
MF=435J&)ND,BEH=K6HSXKU9Y?$BR98/\*P]=C?9UAW"7G.VO38FQBX95&#0<
M#\K[EURZ:1DXMYY)IB[=;6B8F1@KA8D_WI,G=J)V.)HO<Y5JJ"SV/6T_"!R(
M1 E\'O,BB&F[7[;%Z)YX-YK(NYQ%[1'YVMN%Y6CV/'YDS]<JI#I<Z]D249M&
M2:+6Y![5]JRPBL^F4,81M4,W_B@)W9GGK)Q1=K# S>3PNG:ZKDP4]82$4GT;
M^5<."]W9P19\96N_FJ?/1P/3YT)=5N C 0-)**H=>.A8XXD5[+G%<)F9A9J?
M5'3V_7K)E/[,1+X'>(OIVMEN>P=K<\T[X\7#W,?;2RHA/R9MMCPDG/HK;ZSY
M^2 DBO/*%+P0UV"9JUJ5@NEK[GB(0/G[XKO5"QKBXT^NWKA9ZL/%0'.@MVU5
MES@::5>@MOR*>_M$C=]#F96_;(BI'WGV1<:$.51FWS+_ ECIP+8ON5D_=J1^
MKH'=8845F=K3KU/.O63&91<$JO=TI[:2[M7I?> P?>+:I>[A9EZZR'<LV)*7
MC0;H0GF0^K"HOH:TM3'RK6?U!\].*.<UZ5ZPC@52*:B1$_I_BAYD2XC;$ ?-
M90^8$JLSFLE;K-=+:DK6,BT.LH$#Y3$%T1N>9T[ZO5H7TUS&42":%:C0P+M[
M>>?2LQ_BKZD8KO%V(A?BX'#CA4>L%5NWVYJ-LH_ 2D./[\6+#7M\20QNR*S+
M<E?]PB=9UW[A8U]*,>?>-X-BG? .,OZ^?Y.%1;6FZ7V2:E5E#PZ4*F;!#T+K
MU5JZCF,YLJ)RF?_V??V,MQ6!HZ9K2&%1CA[=G6^FM>(%LM]&5^T>\0?(-E>G
M"?W@$?3>VC>Y1GG[2+6BAOMY1O\=M=,7GIWR?#^JEU^#8"5R=&C@09#5)77]
M=,9,GXT=]W2EA*MWVD$P!AN=#P@(D<K5Z&&'8RTM 76I<0$!^ZNKK_268_J7
M&/S+>Z0"9Y^\J:^?%*PTLZN<>BB<\F(R0._:65O3%)7,-;S0*/+G-/AAPB)6
M:G<H]NQXFF5D3/=;VRGZQ5P. BIOBLLG\-S.E.)_D&5YW#K>.&N5+4=PLO8P
MK_;@[8>/%4("'OK+:*"2Y@Q*ME?SL>AM-G/"4_); [CV3;M6[U@E88(Q<";%
M-"4X3<2.J6W2>XG65F[^8M['A:QD 4M(48INH?.KKE#8=7>48%MPCT!Y?/D^
MVX1A Q0V, =KI%U^?*_#^)ZFC+J6YE9ZQ82%Z9X_"'GU^#YC3!S2*-YX/SB1
M=^;&T<ODG&XU,3XWKF\RF\R>5N[DZ;U(!03?,C0JTRA3@?;3ZL2C-J4DOR05
MUYW"9PJ/Y(>JOK;+X;,:FU(6"4QC&GRQU:9XD?RL;V)]*V^F& VU0ZBTRY'=
M;>4G)6@@+0"^=!F)"<#;IC],C]WG[JA X02=8PS;<W8Y<U&7(Y$J9/4M[JG*
M@RLJ7A;T48%B&K7(I'L9Z@RYM+J^ZH7@[X7!NS T8%0_#;5# X0(<?\E)=B3
MM.W,K/X2]V4Z*="79POO4M9BD:U^5QBRWTH3Y 2ZQW3@;'?019CDPY4S>N\R
MFKU@2YKT#NBWN^LN$+VLR'F+(!^_@P-.$2/GN7R(;3Y0[2^F.V%CRQCHW)C2
MIHE7WB,NX/ J0E60\['8\+Y;&=]3S<?6L@L2KW+2F/P%UE(*'K!=*71F>A--
M3$^??G0+;[@&MV9L;!@4Z6^\(J)_EIY^B!?2VA[Z+30O83EX#?1BU8N9Q8%;
MOU02&K@WF>:T(Y4TXO#C(+36$24T*2>KD/)ZU_0R?,9M<7__V4><!5'NQ]##
M*#MIN9Q(*^G0KY;<$VUZL* >NBR#/;]G:F6%94;7&N@WL.)RA'%+<=ASC/K\
MLC**RV6M+$R5 O@-:P<DYDT/7$8GW)I38M2.^7!?K#S'(U;$KD/*PG;[%:0_
MN9K=A7TMKC;YK'F=9%?#BS_JQ8VM]<P,CWPZI[2HA=Z0-1/#@95=ZUS&.->Y
MX:J98Y>#07\QD:%C4X8,WB(A>Z*@$6WGXD7.(VC^J3VF V;O!;,$$RV7LV!5
MZ'_A4_,0*N(F;N-]38J3&_TN& QK.%PN[F*A4)YM,W!?$7!!/'4K2%/S <TE
M'YWY6MIP?^8P3C&&"1?(/>HH^)3O\%U>AO-V*F>=TV /[I4"MDF?,7)'RQMU
M&A966O53^ZD.![1,31GZ5.SXRCW8HH2XC.?<UBN,'8N6^\[S!V#>/GOI. 2]
M75J"Q<W';H)?CUI=JUSWYJ<#! =Z,#N%#BG$_.KLTRPAD+8G;'5,?;8R=<)V
M,G2(M<"373I$T/A%* Q"]W)T0A339G)<EG?@(B9U$,>KSDO[3%== Z3F7*E,
MBMUOT'(Y+2MW>J:%05Z%YCDQXF>76WRVL/QLMKCP6?U1789_9!VY?JDMUT$.
ME:B\<RY<J-N*& $U<-4PG"AH;;,U_EBAY9L4^:-:_57@"Z?<68J"^OK9QC/6
MQ[UZE3QE<'71QN[4^H9&=X7-3DNZ1DVZ'E/#/!^\O4;)C)H>ONYC%]_[$4;<
MTM]76^3!)RJ(M%6)3/-QM[K[;YTJ!:;X2CY.C&QHNIWL,YVEU,RO#U]WN2AC
M>8<E4UVCO7>QS(X&A DAAP4HB85M1J6JF+>FVR?W"04$"BB5Z+?*;A+#BR(-
M;#>Y'OTXM4A^6]SK3D)=JI>HE5&*Q]%^]4L>3L\%;?"#QO!K\7J?V.\VF''.
M2Q)WUE3<9@MNVS^:X@'U$LA4%Z$!N^HGC)M=T.C)K9N[<_)K.V(6/+7/6ESL
M%&78O(ZR3CX2"_.6/LA7=RH6<Q]9Z&'I153X4AE+J;^25GM[QI;O6^T\/QVO
M1&WT.CCL7P^.ZLYPI<YK9ZAFVR0\6/L:)CAN[GZR?XH\!9\.%ESX7J""\B[6
M=0CLE#RA\XU+QPN8'>CUY/WYP[,#R&&*(DLZ33\:<%N"C'FA@> X<*,[=+,9
M#70H ;[Z1DR7K2%H0'[L\H@;M8AI8',W46?46%_N_S\_@:[4'7._?S-% NK3
M4BTT28$3J3LN9[5"YJ?]:7-B+X/P;9.?B:[B@9_@E'6"I$R52S#I92$:V*HT
M_;F=!R-&0FC^S3PTW[2%BF2:%]]>2";7]\#=P!0QQ='KQ=R3AN93:S<R3EJ-
M=H)W,6VWU$D:&GA3B]F00=;1P)J$V?W+7*A#HN5XI7LH]^=%LQK< 8Z)*ZHR
MH*.!F8ZT/\R _&ZSAF!APW,H[(8+8H#QNS=F9['\ I)R5 A^;]0_[VT;/Y E
MI_J1N<)E]Q@ P#O^RQ0?7@GMO8)W^+RT@Z-2N%^J#[6O<W;]4-#F2AMK#]'[
M=Y"A\@G:-M! N*@1W=KU2>- $.)&WAES\=X +-, P0?[C/ R;JYK;;WPGKVN
M<<.&=98D_!CPZJJVJ)*Z>/P3W,'[OTOE:TF7'H\H9DDY>K'GZC)P58\NUB]G
MWFW.:=1^C6!O<D4H<6XZNGB51X*FZ7VCY#B);#CCOD#3NJN,3!4)BAYG)1EY
M,@N!R4 0<2?@WX) Y3=?5G!%]DREY2QGVU='K9IOXBE+!TOR>C[Q5=M*9G)'
M<*&!'EI=N7V_7/#:&4; .44/*Z@!EA?CO4@[.#B30;OM2I3>J-"K4\#5W%E!
M\2_2RXNB"VXU:O&8KP]LFF0XT_>P6!I0^QCYU<KR\B7^.\=LR^F]?].T]"^"
M7I-_B%N#_!ZIH-_#.NR_D@0<@><7UI9QSZ1!<QEYYY35HV )R? FHUVA6%<!
M.:MB%K!%3?T,/TE%]-P)3:I\3_Y 294]BH8K#!.F*K!3%, 9?"++GRO86)>0
M.C&PBQ3J;Y*+%SA/NIZP?I9335M9IE&=?Y8@P6#(<]TL1G7]%G-L@K[JZW5\
MG$,@T+XHY!(-X,)=EPA]*IC10.\W[4L:%C\(K#28 -.\J,2@ 1@67P'L:[;U
M\K",@#B9Y)A2?0IR(+H?+Y$!AK]*$(RE@9.N360VUWS#B,JS@>#F,%=8C\YS
MYB(ZWS57>0K5?P=1]1LPZW\)QEX))K#^D;5_1!8WSOLWS8L4^BVM'5_XBR8=
MI3NKHL.$(2M\5F<8B;-_/Y ]BPH9N_R!!F:J!> _OK8Z>_VLSE4%)[3'H9_F
M--N\M.R8@M.O:^':;RZ$1*LRSTI1Q'9P]#@5?:<_>&F,G?@D]<[08A-+?JA.
M4W^HR[>R;OEY%%4]&LC#*!8"^=LQZDK(YD]?6ETZP5E ?98RTW)Z;^?,'1Z;
M;ITE'@AES0Y]%?8CJ]C39T[V;/Q:NQ_L".?;/\J$O1]V^WA N2JR3T)_@U,V
M26OY=NL#&3=A/%J<)>A_90)N=C^8JJCY94S4S 3A2_4R93O^A)Q4*;(^KU=E
MMS[LCTG@Y26C.)UJ/LQTT#8D#'B,RV3180EWJ1+X+\T&6'=V66J+&U.\_E?Q
MR7\[1UU-\A[NWEO^A5,M6,31EITM=27;8]E::UEF%'F<0,/.+K&$L RZR"/;
M?KQ3IJ<?Y#"W?2_4DG-.*OBE;, 8@WC8/GB%W^KLY+>S\!ITOPFN>FRB2_A5
MC<4FD;I6C!D/L$U#&-(D)[?)0_*[R@?*S92*1ZZDV[YJ>T.76_:9#5G9Q; \
MP; %@F4((2] ?SM^;?"#XDK\KMJU*]2+R=F^GN8&FTEMLL5SG%/G&Q%F+>(E
MJP_FIV]QE+ H$B_*\V94PL5ZSL4_%8U\7![#7E <GU<=OOD.EW 0)-*#K;B.
M,R+"H@EZY>41K S;GX+=(7_S7LTSB#6/T#CO-*WMH8'!6LJ[R-:#9/-9-56<
MXX+C-\U&B((5_WH&E\)I7:;8_]7>6T;%W33[HH,$EP1W"! "P=TM"1XTP35(
M8$(&=W?7(;@'".[N[L%]T$&#.PQ^(:_L9^_SO&>=N]:]7^ZZ'WHMZ']W5775
MK[NKFNJFY( I6Y/&'I6)G:G"1[I-*2S7\5T4DCS 7C_UD:CC,DX3X\^.DY'2
M6= 'BY--+'5!Y[;]T_Q;H'UDD!:%[ZN*19T^M9V7S$UE;\>E>"15E;\__]6&
M@V?C^<; SO.1@LWKU5[_L)ICNIQ-&6M:]O>%Z+?[;PC%4 &4L1KI'PQ.=1U0
M5J.0MZ2V)&P% KM*L8!:0SVQCGE!K"OU-55@NO ZL)UI*#(150'[ZXSY87J$
MG[>_;W=3TE>E_(M7.'F#N"[$*9/]4CCQ.Y^+D9W@M[Z1EUME#:PJ)$7?+KT$
M7F8D6'X.SPZ,X+='A%<$4,AD8,4\:J"$Y7"-T&^/*6G'_:UTEG2<J7I-% ?"
MRT@,GJ/V*6^]+(HUX>\V3&/908XT>29\/>+$>&V.3Q)^FN8V!R'+-$V6&K-K
M0MY/_(+*X4L0OT8HIF*^M_.P'Q3MQL;0GH,LZ'XMFPWU\C>J%S16=7A3-#@\
M16N_W9?//1*4]#J0-6[\ CAM&ODK=*#643, CIH#B<C_91 Y,E?;MJ> J,!&
M_*ICP'I+P!0W^8F<Z%RLGV*E!TT[DR1/#)<8[UL=M)WRL,U00/JC:O%4 $_*
M0+,DAWF,KYZ@I^I-#VM+.6W*Q9\,?$?3.)T$#/:=Y_VQ4\"T)[ A.JLI3 ;$
M];PJ>BAE_[T)(F<-%IZ-&4+6$Y&H^-49_RP4A6S9VCA'%,JO@2KMP3UL@*O(
MHS.A&0-Q)"_<)^2$ $0?)6RO/U[R-LG7GWT<IY;.;(*:-?]L@0EB#P(%40H%
MDO4R/D'N,6[GM7 5(><.W-Y&[,J-#LIX1T3N,\W)Y[F.E%J WP^ 1S)KIK!F
MJ+D3@0PWZHLD4;;WH.PE42>C^3#W_3:?9J<1V=UB"\.6ZH#-)7$FW)Z*7NHS
MN\^Q-#N8 )FKL:LQ"0#EHP:,S2E8QKDP9:<[E5LBAET33.K"!J-\^'IT$QM8
MR3DDK:Q32$I9(^WP)TI8,R:-)@UJ/X&5/R?.X;>_Z6*Q0D%<OT#RXOV'+)'=
M(^A%=+;N]-7//,?EJ]*4U/HT>8T...$S+JDB>AKD<;6J9_;43D;K@QHE^]_@
MV=GSF9@(^:!L?T!O?92#^145]G#D<,A&M65P&N7HN8S=S6Y^<4D634"M&\<#
M #>_!XWUF%=<C%SQ$48ZPZG'-&^GN,W=.1ARY;8WP'@AKD :$4.6S7?1[?.G
M1J.^W79G_S"PZ8(2W.-HQRTH?H1W3BK!/Z+,+CDP+\OJ' _PQ)<.ND._("P!
M8'TD*U/G$L*+K2R&_I<.2+7_OLRA_AKZ RMG!H9I_QWC:#FH= V^AMWIDR3!
M9PY=Z4$*6$5ZHSV+%=O"&C(? G6]?_)J\\+'N !(_^=8/91C=!F! #'E>0?X
M-6=:C"@K3-<'P"WU=.^]EMQ5B"@4O^9Q@P-[&-TR+$B-L-5V.WRFZ-8("V<'
M6U))=PX_^P@7I#H72V6*$"5>*GXDM/0RO7.L-7@U@%RC[R;N&1J/Z<8*#N?,
M4;<+ZRUUS?+IN/ZOIW>,0N8]1S0]V>_Q=+",CG*&[);_U,@\U7AV,((>-\Q7
MM[TP%82$'PV>, E0ZU9V:\+3,Z]0@C_2W!MZ\2T:R=3,V!4V"QQK[K.LFGWY
M9)@37?<Y>H0FLJ>N^.-*?& )=?H-EV*6PLA6YP50N]]'9UTZVA0N0)MHNR[M
M?._1*0C5_L-2ZH]@TT^" 9Q^42(T,6,65V&3[VT#Q#)+%K!CI=L0#GPT$[S#
MXH3K"B&Y'>'8F@TW$@M)W\'N<8P2U.=M[R,/\.]W[?N)AA5L]<H? "C%M;=G
M\:>44*G_&K*@]R:.&\?1Y$R->F1.?GU%&F,H4*@'B2X<_SFKJ"-*HEZ@V9 ]
MN:NZXM]WI^*/[*@;DH-B!W!K[P[.[;,\FYJ(!VL<Z"JLRM!BK+BOS4=[.>'O
MZO^M&I608[1NJ8^FP)!L@ID7W1;X[^5L;HPA-Q-.(T/5%9+N\B(W4#7?//FO
M)^[USXJCRGSX2LE5^#HM,+(J ] <(SQ4A\7P=_[>0A_K*%3MCPH[X^.4(,)%
MVR"2=R]"! -5HZF')ZW3$]RZTC\.V??&])6DW[_0MKS:9MW\<VWBW_84LZ7T
MMTDZ['@ 8,$B/R4KMU3&'GXA<C9*'3TJR,I<\?)%KA7YV2SW]YT!Q[OZ/AYX
M%34A*,P6/SXM$<?M=\J6(*W;IGU:P1$6*\;4AL8%%KN'6Z@<]E>;!\@Y'6@:
M&O'3J0R.QL3X3L*+T= U2_T]94>$?DN1Y["O#P#9@ Y7\T3J8)Y@S(FK\$2,
ML%]S&Z&<.(JEXXTH5'+F3AG!#MTX*&.V*?1$"*+BNNK_$^-_].73RPY3E3>2
MK?X#UPM1@>$#N@"ST_ ^E[ 9D[^W-\"9KO#(L0/2DL-],R=G;O]&TG_O)YO_
M+$ ETV,; I]BC\^2>U3Z=JHT;>>C)VZR1M$859.=M%'89T0C&!8'*KF-;=*Y
MY7^;./^8QO=&M_0(OPX\R,UXU1UXL;^TS0W'/^\J<2O['10<>Z9,8N!2;#<W
M;/[ST4]4F[]WD7O<(++^Z&CW24=>CR@,PY;=?@#\A=Q?FF9@4^C[+!'>V!&"
M.UUM;=$3$>,)*Z0U@X>U7X/Y$&;AAI]IM\#4,[_B:#;>-;";?OF6$<'8^RF<
M]W !V10#[Y#LMC#%.^0_R<VP@,U4#].$-C;*F6LRI<R+O40G3'(H"W487<J(
M-W1-F=%04+#6%?U;"WAMBJ(AC_^/I>0O&NFKMO1=(INJQJXE,JUN!J_*'%B
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M)B_$5%4C 7"C< I_U5W>[6^$XK]4A,@;R7WOTV/;%,._E$AMLT.>(19-M7D
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M4\PF%LX^HZ3Q47O75BPS:TTMF-;PPML(B>94R)7)( '1%\")#),B/_]FC)H
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M1D4CH^Z,S;YW'SP/0E8*__G#.]H?,5Q?O A"/HR/_N/OS71 ,\"/&.JX/U<
M^,NAFE*W3:4K/^/O7P!;MS8\#V-T">B[ ;;,*XNG3+^.$J.>5Q!5#& K82LQ
M/ ".0F0> *+H3ZD'OX\EZ1%2_ID4H'^S_@ (I_ROS^G')9%XAE[\(S )V@=
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M3Y=I>XX] \\> '@PERW9*9#_HG]_N(EW0IX5N?3Z<Q=O"3PX->Q /<)J\)?
MSFN[+R9H-Z!))( 148^ :C-NA\#K@!(+NO&J0GD![13G(=#SMS#:L+4:S0AA
M&>$A/"6D[K]YJOVO!<-%=?=?@CR6YV>9+LH2CSCXQU>4R;')QU]%_GE##9&F
M^>5C+5HS@]D_FK]H4#%JQE-"^-?"\S#W?P%02P$"% ,4    " !]"]A<8(/4
MUP <  !H; $ $0              @ $     ;&EM;BTR,#(V,#,S,2YX<V10
M2P$"% ,4    " !]"]A<, 94U6@-   ^VP  %0              @ $O'
M;&EM;BTR,#(V,#,S,5]C86PN>&UL4$L! A0#%     @ ?0O87#\]];W-9
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M;6XM,C R-C S,S%X97@R,V0Q+FAT;5!+ 0(4 Q0    ( 'T+V%RS/F['60D
M $4H   7              "  ;RK 0!L:6UN+3(P,C8P,S,Q>&5X-60Q+FAT
M;5!+ 0(4 Q0    ( 'T+V%P:VIO^M@L  $QA   8              "  4JU
M 0!L:6UN+3(P,C8P,S,Q>&5X9F5E<RYH=&U02P$"% ,4    " !]"]A<\TN$
M$!9)!0#;]BT %               @ $VP0$ ;&EM;BTR,#(V,#,S,7AS,2YH
M=&U02P$"% ,4    " !]"]A<\F8Q?VLV  #4.@  %P              @ %^
M"@< ;&EM;BTR,#(V,#,S,7AS,3 P,BYJ<&=02P$"% ,4    " !]"]A<:3UL
MJY&#  !6G0  %P              @ $>00< ;&EM;BTR,#(V,#,S,7AS,3 P
;,RYJ<&=02P4&      L "P#H @  Y,0'

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>limn-20260331xs1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:limn="http://www.liminatuspharma.com/20260331"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="limn-20260331.xsd" xlink:type="simple"/>
    <context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Fj9tEUl42E6MBhnKApp0zA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-18</instant>
        </period>
    </context>
    <context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_KxviRH7DfUuHBTu5r6l8NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-18</instant>
        </period>
    </context>
    <context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_6blY871CSEOApTf8LuQfmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-18</instant>
        </period>
    </context>
    <context id="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GUMRHws20E-hQftGj0JvTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-15</instant>
        </period>
    </context>
    <context id="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NcxMLUOjV0-W98TcYBomsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-15</instant>
        </period>
    </context>
    <context id="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gZkGDq_I9UKTee9n9IgYZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-15</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5kfGOGRcqUu2Y62sJIl6Iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Y5cch1GNXkWKRHTF2v1JhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4f2Cj2MzIUuqkE9ozbbB6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_It0aMMr5RUGH0v6aV7qdrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lO_UINB71EmnK4inw1sNDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9gmJIjAObE6K8dYKyoRMyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MuLWEtlz5E2UN4YJiAi4YQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9uu8nJPlZE2Ewx4WJxhvoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mdCeT08ds0iD_QBBfMY-1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_RvqHKU6YWkmEJhD9fotvqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-SnrU4W24kCYErwDqqD2uA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8haIXs4y3EGbc6exykltFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJune2023LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YX6lsxQHS0-d9Bt2ThMAkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJuly2023LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EBIJxgFtuUu-6zOIAkmcqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMay2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_89RhalbceUGFHBdneVrdYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMarch2025LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_A1W50Uj-NUO6hThaQ_OHyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMarch2024LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NWZ-m0WBA0qJ23vP65-HJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseJuly2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_vHGFMJf22kGulBghrO3_RQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseFebruary2025LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DpWp6FQcKk2ToUxk9I8I-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseFebruary2024LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3iko9KeMAkGp5regWs_4Nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseAugust2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Up5NOzVX402q1o88UijPvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_bIvWOEL1hEqZwZYGgrwYpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaAugust2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__TXA9F6q8kWE6TNY3k0qkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_dKxFvloVNESsveu8CClPfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:CarTcellkorLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8q0dzuwVGEShgTwjOwX7bQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesNovember2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_embE8oVddUqzPD1utl4Z7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_HiTcUoWDTEqyHvNgB9TCRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesJanuary2025LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_r25euOvngkmrw8iQThV-hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_148jP040dUadKsjmVdStxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VlA87RaJeEq06zmKK_H7kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJune2023LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_eAOXFYGTJk-hpkYZ9yVryA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJuly2023LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ay2QMWFbV0SdpGM1KxxUJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMay2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tu28ZL0W00ydtm8NRLecmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMarch2025LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tPoEXxTBuEas6Sj74xYwPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMarch2024LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Wgs8NC0FrEu0hK8Qjljnog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseJuly2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YhVm-9q0AUSPz-vllz68rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseFebruary2025LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_9WDN8eHoHUWQK3nMpHkYtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseFebruary2024LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__dCVK3BY3EeDKZi28xUkew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseAugust2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0PybUMyl7UupuiSkslBW7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NQoRaZtKZUCGus-3AHoDuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaAugust2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EnLDESj0oUmykTsMHpBM4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wmmbaObSukiDB_4zDCmrgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:CarTcellkorLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_j5CQtBVz5UqKzenH5qp4Pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesNovember2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_s7XNeN2VrkyoKgFvQn08HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_vlYz7WYM0065Rv0yQrEanA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesJanuary2025LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_14_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_176IvMRvuUeNEtEQXDudUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseApril2025LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-14</instant>
        </period>
    </context>
    <context id="As_Of_5_13_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_99oewdhpVEC5wJhe7rhkyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseApril2025LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-13</instant>
        </period>
    </context>
    <context id="As_Of_5_2_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GRnA5Kx7-kGf8N58SRLWrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseApril2025LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-02</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_7OFPS-3HHUK9zZcMTjtGcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KnFjty5H1UqDezjsL8ecyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_sFe_sIQl8kC62ZR9mOyaiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoNovember2023LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EegrTR0jGkqYkwr1xCASoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_x5Od1Z7sZ0CQp8ZF554jRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJune2023LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ASPx2q5_QU-KM6mmU-4OjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJuly2023LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gfQEfMTEl0ObGw-d3_mziQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJanuary2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_lrwGKHLBAESOZpAyQq956w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoDecember2022LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_CQA91rS8pUClgpt3N0razg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoAugust2023LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_QRBk_Nfwt0WDpSDktLsbZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMay2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Jq1v2ZuaPEej3PGvRk2DSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMarch2024LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_HDV6ibzOjEy9uUy1EA4FRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseJuly2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_rkyvImjcI02ndBME1T3Fyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseFebruary2024LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ANKNxWmzXk2q4khG39LhMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseAugust2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_obg_hYZhh0yPZ2jeTy8gQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseApril2024LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GP3ES2qH4USRDiPV41OBjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wQjd250e8E-nWSdS93gx4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaAugust2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8mMfG6ZJX0COX4Qohfx8lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonSeptember2023LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3egjKmWE3UiVynBt7G9rJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_EwonDecember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_7O7aQgSHYU6aHfIWbXQSzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonDecember2023LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_TpCVK5HsVEK8Wyv55C0lig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:CarTcellkorLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_JMZfrNFf_E-RRAz3gORKJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesNovember2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VyY5JFYy4EKLtKt2cqj8Iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_skGpvhLamkmTX8ZC32NJjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesNovember2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="As_Of_10_13_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DqH0O8M-DkKolyZ-CdcShA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseAugust2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-13</instant>
        </period>
    </context>
    <context id="As_Of_10_12_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NGQDh1rA3UGEJwXQpQqNWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseAugust2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-12</instant>
        </period>
    </context>
    <context id="As_Of_9_29_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_hOP6gIf6X0uZ7Ge6Uhb8yA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseJuly2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-29</instant>
        </period>
    </context>
    <context id="As_Of_9_24_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_4Vld9uwuRkuuQHHIzYvKZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseJuly2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-24</instant>
        </period>
    </context>
    <context id="As_Of_9_14_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-IXbBujRXkiVzw9mXk784w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseJuly2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-14</instant>
        </period>
    </context>
    <context id="As_Of_7_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_mxhubmgnJ06DzAurKf0Uug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMay2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-01</instant>
        </period>
    </context>
    <context id="As_Of_6_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VxMZqFXR_UaO5azmVes0dA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMay2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-01</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoanTwoMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_roRuh60jM0eb54g1Pq5hLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJanuary2024LoanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6andgdbpxkqRlyLXl4XDHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJanuary2024LoanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="As_Of_12_19_2023_us-gaap_DebtInstrumentAxis_limn_EwonDecember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_PobELNhVp0CNZjEIGlpjlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonDecember2023LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-19</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoanTwoMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_jZaCTxa_V0CXdNygheYPjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoAugust2023LoanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KWt-xK4eN0-5OFBxkx3LGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoAugust2023LoanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoanTwoMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_uvAg88eC10OdVCXZ0b8E3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJune2023LoanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_u39Cd4S7GEqUxTPP5qv_Qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJune2023LoanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_18_2019_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_zVHTzo-UxEy__UArL1VThQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:CarTcellkorLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-18</instant>
        </period>
    </context>
    <context id="As_Of_2_18_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_1t1X0h92206D-tAJKXlt8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-18</instant>
        </period>
    </context>
    <context id="As_Of_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_AjxQK7FsCE6Ub2hVGkXXEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-18</instant>
        </period>
    </context>
    <context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockAndPreFundedWarrantsMember_eVpfLX3CYEK8jnIUcxuvGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockAndPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-18</instant>
        </period>
    </context>
    <context id="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_JSVgKnyZI0uvIBPJsCar7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-18</startDate>
            <endDate>2026-02-18</endDate>
        </period>
    </context>
    <context id="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_8Eb_-va_j0mdcFrq6b8KwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-18</startDate>
            <endDate>2026-02-18</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_XYwkzRP4y0ClnxSz9bnyLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:Cd47LicenseAndDevelopmentAgreementWithInnobationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_lUoEyYWXh0OCUietIBRj9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:Cd47LicenseAndDevelopmentAgreementWithInnobationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2025_To_5_1_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Tvb57Yoz8kWjg8oYPKuxig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJune2023LoanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-01</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2025_To_5_1_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_qNI4ieKD3kSp3GUUyiiVsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoDecember2022LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-01</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2023_To_3_31_2023_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1IIHRUTkZkq60Pm0ATLdfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonDecember2022LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2023_To_2_28_2023_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_fyxYB55LcESYXg1VrFa0SQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonDecember2022LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_PowKVbIlSEav6_it2o0cuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_5jXRkTedV06dtacIjxLWQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_15_2018_To_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Ue0f9e9AF0CCuPCxkaHeGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-15</startDate>
            <endDate>2018-09-15</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ViralGeneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_7wxNNnmVW0OOyrl6dcdkLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ViralGeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_ViralGeneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FJJZ1ZZ6TEyxVYe-BaGI8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ViralGeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_limn_EmploymentAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_AwztCb84TEyTOzqvwRwIZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">limn:EmploymentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y6Lx3mXqwk-nBkJ5KlLBYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_limn_EmploymentAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_bhT6iPgTMUSC0cikBkivgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">limn:EmploymentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FbpcEF3_bUqHFwpcC9Wy4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_limn_EmploymentAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8W6kVGwgx0651YJT0suHMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">limn:EmploymentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_eXLYHI_roUaYmfoOmSYVxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_s19qgo8JfkOPRkLjJuXHug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vn8s2LBdIUK1HIqRW6N8fQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XRD_hVv4DkGY6KlSlQA6NA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__4kj97EHqEunWT3sM4bCbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AfWb2cWlZEaFlDlquz3ozQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_6H9UrA2MZUWmfOm8ySparQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ClearStreetLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tviGQUjEIkuzwoMOZhqbEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6WgYpfkMwE2wXyUE6YqM6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_r1BpvCN0KEySovh0Qns8yA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EuwARZ5Gg0yVzO8ExZuY7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_JON9ufuZd0Kog8xAC5tcKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_MXaZ3yp_lE6x5RxdHImRoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_m79xoi74tEWD31ya03Rcmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:FeeluxCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_aIiVDq13L0qm8FpFM6Fe7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GRgwbB0go06YmvYSCv-xlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y7jrRcuOPU6wYyUiEQtHhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_meaC4-NT6kOsHGvZt--vtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gXDAk9MAnEC31blcdud-TQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Ol_1m0h-L0KQZ73KaVpZtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__wyANh8s8EOfWyC9HSPygQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NUKGQueFCUK3NV6S4f6neA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_vmR4xWUUp0CvtoWAqoOIRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_uwAdfAZSGEaAVubIisn7qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KyurFw6NFU6DbWNR_JVlJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_uBbaU3A6rUOpfYYDB4euDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:FeeluxCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_BrctH0R4SUmey2o6z162mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_2rdRQZDLhkWmVg-aznAVoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_PKtruhg-mke1cWwu6HOpJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ykDgVNc-WUGp-HHNFZJzIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Vyrd4E71aEKV2JlX3zDSMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_JogJT3JKnkStw7CCF--1Dw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_doQ-5t8E_kahW9UFnsMLNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_3B7id13HUEKPGohf_GYnnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_pY-u8pAzO0OcP5FC3J0aNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_NOD7vwuXLUmAhk-2mkyvLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_yYxsL6Igmk6L3jX5IPvofQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_yZvCrOb-Wk-Oqgi1kTrEqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xvNc1S3hqkGpqvsF2_IC5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseApril2025LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xe3qXzjS0EC39aN_LENA8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMarch2025LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Rs3R6YntuECvjfLJCKGrWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseFebruary2025LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="As_Of_1_23_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPR03tDKjUmpyRyQld8qmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesJanuary2025LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-23</instant>
        </period>
    </context>
    <context id="As_Of_1_2_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UoLTcnkgY0ia4LxmBqWZzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesJanuary2025LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-02</instant>
        </period>
    </context>
    <context id="As_Of_11_27_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xZbOD6QvXU2eioglXc3B9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesNovember2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-27</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wdQAw9pClkqJCJydARCG4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseAugust2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="As_Of_8_1_2024_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_lO3aHrFMUE2_9b_GTJGSBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaAugust2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-01</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0HW6FGsO8Ei7AXcLtjboyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseJuly2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPL1Zq0iyE2-9FTal0qJ5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMay2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="As_Of_4_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KWzMWCDwzEShWHgZreE_vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseApril2024LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-01</instant>
        </period>
    </context>
    <context id="As_Of_3_6_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_U0Xo3fqs00OpXo_SeuDtWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMarch2024LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-06</instant>
        </period>
    </context>
    <context id="As_Of_2_26_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_dMLi4mVbI0mnfUUmfRTl1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseFebruary2024LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-26</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1AItK1QO2kitXmKJcOl1Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJanuary2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1Od3S-eoaUCXHX3nnz2htg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoNovember2023LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="As_Of_9_10_2023_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DWdmZjGmCEiRashhGcBpXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonSeptember2023LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-10</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_K45l7DmgQE-CQ-xyraew7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoAugust2023LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RoR1eW_fpUmHYmBoFmDg1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJuly2023LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="As_Of_12_12_2022_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RpHDxwA5eU6MNdXkdEU0lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonDecember2022LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-12</instant>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_v60EouUdLUqn8toxvOltkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:CarTcellkorLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_hxqxTUYPkUOVXBEWPh59bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMay2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_XNzgVBB9EUSW9XJBeTQYXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseMarch2025LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gHk208o8a02buGlMK7GoGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseFebruary2025LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VgfZxKguUE6IvyhFTK0bgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseFebruary2024LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_MxNDVYopJUCTnAtVRr2BCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseApril2025LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_WqQ7kEZqMUGKJ2Civ5wmHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseApril2024LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VtKf0F4u50yYAUlGncV4kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaAugust2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_AHn-E6mSh0WMg57djpR6sA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-A5AQrt620qPuuH6l9tvXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonSeptember2023LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_EwonDecember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FAzAi_otIkiuLKLUZIGGZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonDecember2023LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YHOGjDLmVUK3iyhkoffTvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonDecember2022LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ConsortiumLoanOfRelatedPartiesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4nTHRjjm9E64EIS8-8O57A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ConsortiumLoanOfRelatedPartiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y5QPj6cnBkqxLO8bzZMweA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesNovember2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_mmocMhxQQE-9TDe7UCuBDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesJanuary2025LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6Oq29UcKvkeSSN5rpNIW6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoNovember2023LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ZaQ3e71ewUK0aSmJ56rcsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoJanuary2024LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_rDx80SlYbU-El3v0ZF9uAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoAugust2023LoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionHoldingsLlcMember_HNZDVq5GE0GEgfHcGTUA1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionHoldingsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_gsYeVbSjA0ijBUxcCNZtvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:FeeluxCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Gi0t5_gUYU-FQON95jjxrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__vfMa6eSe02_iSgKMlEjFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LJS_bgYOWkOcBywnif6GLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p3dvj_Io2E-N-bZQMUAM-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHu7s1FxgEmdi0qyZEPN4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HFF_MgUngEePnxJ9ysVB6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PrivatePlacementWarrantsMember_GmwTGx3Js0KBpkdQA1hx1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PrivatePlacementWarrantsMember_ioEniwa8PEunNaQ7J6fSnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_Y7EtLUI_pk6RZ-oTbRPBxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-18</instant>
        </period>
    </context>
    <context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_Gx1dPATNHkOGW-Snv4cHLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-18</instant>
        </period>
    </context>
    <context id="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_go0DO65rkkqPaWM8iCPEeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-17</instant>
        </period>
    </context>
    <context id="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_BhVP8T9QzU6thchw3BBoLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-17</instant>
        </period>
    </context>
    <context id="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_us-gaap_ClassOfWarrantOrRightAxis_limn_NonRedeemableWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_ZG-LffBZq0OabS0uAuJI-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">limn:LiminatusAndIrisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:NonRedeemableWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-04</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_slm9IzocEkSBb1GZOKqnZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_j2wjtBDr30CGi5w2RrtSMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kX_yWG231E-RYOerQjujQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-18</instant>
        </period>
    </context>
    <context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wuQDuaMWckW-5cDSn3bI2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-18</instant>
        </period>
    </context>
    <context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_1ZmaX6FlIkeWdeKISX-IUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-18</instant>
        </period>
    </context>
    <context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_ZDd5yizsikO5sTlcUH09FA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-18</instant>
        </period>
    </context>
    <context id="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_01Es_yiBG0a6u9R-nLydbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-17</instant>
        </period>
    </context>
    <context id="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_Ky__aiunWkee6a2CP8ZTOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-17</instant>
        </period>
    </context>
    <context id="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_us-gaap_ClassOfWarrantOrRightAxis_limn_NonRedeemableWarrantMember_xHQZeSCsiEGkdYLlyBZaXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">limn:LiminatusAndIrisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:NonRedeemableWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-04</instant>
        </period>
    </context>
    <context id="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-15</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_VCFxQaKNIEuk0z9tPKoniw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_hJv_UjccpUSIXy-caXvHdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2024_0fsIJRo8qkmwqwDgqs1FdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_PCxMs4QP-k2uBuXoZKiE1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:LicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_9PPk1IhN6EmJm5MGsGwEDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZSeIP3LMQEiCyd2vZgeG5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_nnP7Qz9VeUGy0wjX4yxcQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:FeeluxCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_BXcmOS2BJEKYVp-Znixfsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:VaccineProductsAndVaccineDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:TenYearsPeriodFromFirstCommercialSaleOfProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:VaccineLicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-10</startDate>
            <endDate>2020-04-10</endDate>
        </period>
    </context>
    <context id="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_AysCyyacDk6EgeXu96kqgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:VaccineProductsAndVaccineDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:VaccineLicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-10</startDate>
            <endDate>2020-04-10</endDate>
        </period>
    </context>
    <context id="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_kzj2YTUmsUqdNgLEb6ecrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:VaccineProductsAndVaccineDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:TenYearsPeriodFromFirstCommercialSaleOfProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:VaccineLicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-10</startDate>
            <endDate>2020-04-10</endDate>
        </period>
    </context>
    <context id="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_xdnRdKDui0uO30li7vEb9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:VaccineProductsAndVaccineDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:VaccineLicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-10</startDate>
            <endDate>2020-04-10</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_F5M5DAEMCUGaVGfvYeyHNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:TenYearsPeriodFromFirstCommercialSaleOfProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:LicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_tvMLwMEPF0OgoT8qvqNtOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:LicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_Ze3T2NMaj0Ge4Cdvcxk6nQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:TenYearsPeriodFromFirstCommercialSaleOfProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:LicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_e8pHl9vKL0iD2UdUCsGsVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:LicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_9RVHQy9tTkeZj8t4JvLMeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:VaccineProductsAndVaccineDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:TenYearsPeriodFromFirstCommercialSaleOfProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:VaccineLicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-10</startDate>
            <endDate>2020-04-10</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_8RdOebh7f0C05gFluwIFFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:TenYearsPeriodFromFirstCommercialSaleOfProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:LicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_1_2022_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_35Sjj6Gfl0yNGiX5Qt5Qmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoDecember2022LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-01</instant>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VYxJe3-ZlEKGtf77rNoRJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_tErYwLwjB0maTrnKFX-S_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:Cd47LicenseAndDevelopmentAgreementWithInnobationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_17_2026_To_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_0DwlS1YhD0uVubSzwvOJJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-17</startDate>
            <endDate>2026-02-17</endDate>
        </period>
    </context>
    <context id="Duration_2_17_2026_To_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_xU41UBVWPEGgrfXyxay-nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-17</startDate>
            <endDate>2026-02-17</endDate>
        </period>
    </context>
    <context id="Duration_2_20_2026_To_2_20_2026_srt_CounterpartyNameAxis_limn_InnobationBioCoLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_3V203J1Zg0mfoaBaDb3DcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:InnobationBioCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:Cd47LicenseAndDevelopmentAgreementWithInnobationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-20</startDate>
            <endDate>2026-02-20</endDate>
        </period>
    </context>
    <context id="Duration_2_20_2026_To_2_20_2026_srt_CounterpartyNameAxis_limn_InnobationBioCoLtdMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_uS2EVzFvKkO1OaU1FG7Fdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:InnobationBioCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:Cd47LicenseAndDevelopmentAgreementWithInnobationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-20</startDate>
            <endDate>2026-02-20</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_ViralGeneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_a0Rd98uIckinvKo03Da_gQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ViralGeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_limn_RedeemableWarrantMember_viAcaQl82UKtOAfy6rdZ4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:RedeemableWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-04</instant>
        </period>
    </context>
    <context id="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_o6DHM9UbBkSNjCOhIS_9VA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:VaccineProductsAndVaccineDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:VaccineLicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-10</startDate>
            <endDate>2020-04-10</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_0lDWBPW2vkuWvH-HiGeZyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:LicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_809IbYMTbUCQEIVjWuaGsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-17</startDate>
            <endDate>2026-02-17</endDate>
        </period>
    </context>
    <context id="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_yl8JpI15U0KUQtNmfOFI3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-17</startDate>
            <endDate>2026-02-17</endDate>
        </period>
    </context>
    <context id="As_Of_4_30_2025_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_Lbu1miIqSkupTrmz199Hbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">limn:FeeReductionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_srt_CounterpartyNameAxis_limn_CurisBiotechHoldingsLlcMember_us-gaap_CapitalUnitsByClassAxis_us-gaap_CapitalUnitClassAMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_MfcULb3sYEWNTNOdJMM4Mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:CurisBiotechHoldingsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:Cd47LicenseAndDevelopmentAgreementWithInnobationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2018_srt_ProductOrServiceAxis_limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember_srt_StatementScenarioAxis_limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_5kAI3vX6BkKP69_x9ufqDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">limn:ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:LicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="As_Of_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_h1stl_iThEi0wHNuwBrmew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:VaccineProductsAndVaccineDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:VaccineLicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-10</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_c5l6cvRI4EqXlctlS8Hl9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:LicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_limn_CarTLicenseAndVaccineLicenseWithTdtMember_mWk8tah9gUuCRPqsFLhQWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:CarTLicenseAndVaccineLicenseWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_limn_CarTLicenseAndVaccineLicenseWithTdtMember_aVFA-tb0MUC-EmBUAPe-xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:CarTLicenseAndVaccineLicenseWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_jBCIg7TF3U2nA2e4ZL4LPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">limn:VaccineProductsAndVaccineDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:VaccineLicenseAndDevelopmentAgreementWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0P2Hk6Fm0UCfvB5hIDbvbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_XvqOOBEml06fz43DO14A7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_hUVQhIvVLUiqyQjkyt2gOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsMember_kZc3BMaUdUGTUqWXCxwF2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_N4PkFcbsfkOoWh1rhs7g7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_ILl90TwynkGTc6BgSwur3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_eIyVw3ZwBkWNjXiNqU4kaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_hXB18br9yUGm2G-QE5h2uQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_TypeOfArrangementAxis_limn_CarTLicenseAndVaccineLicenseWithTdtMember_cvbZ4e18Jk2WLlTRj8K7eQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:CarTLicenseAndVaccineLicenseWithTdtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_3KBXe2AusUautripdVqXLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:AltaPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-16</instant>
        </period>
    </context>
    <context id="As_Of_7_1_2025_CZJvPOCOcUySCDRAwOkqBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
        </entity>
        <period>
            <instant>2025-07-01</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_tzr9osJ2S0C-6yY56Bt5Ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">limn:Cd47LicenseAndDevelopmentAgreementWithInnobationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_10_27_2025_WHc2wpxA30auOyOjgUueLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
        </entity>
        <period>
            <instant>2025-10-27</instant>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_brJVgPrmTkGylFftjvNsDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_rriXg5_Dp0mBV3id5bODsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2026_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_13QwrEzmwEyKOTC43D2VFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_TzHnTBOE4E6UpnLXPy51MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_11_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_3xBPTdDIoEKDwiqXuL9Qyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">limn:FeeReductionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-11</instant>
        </period>
    </context>
    <context id="As_Of_10_10_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_8jW8A96_rUGTBNiKY7EncA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">limn:FeeReductionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-10</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_zu3KxzCVkkuK5CuyZXWLYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxAndCarTcellkorMember_zWurOUpaU0i-IKmnDLLc4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:FeeluxAndCarTcellkorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_qUlxIbYw4Uyvh13v3JGs3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxAndCarTcellkorMember_IRaHwKWzMU-DElAHyQN8Tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:FeeluxAndCarTcellkorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_aADDeFhV70K5BS2735863Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_YSNqwrY3BEKU8q1HG1qjeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ClearStreetLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qRAwhaLP1EWqdsQcq1AtbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ClearStreetLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-06</instant>
        </period>
    </context>
    <context id="As_Of_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_c18r92u3KkG5BLQb4LzJlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ClearStreetLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-06</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_thV_eeooNEe0x29eHltR5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ClearStreetLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_cgSRAUkHA0i2y04jy71KAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">limn:LiminatusAndIrisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-04</instant>
        </period>
    </context>
    <context id="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">limn:IrisAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-04</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_W2lQ6Gn-NEep1cZ7YVoF1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z416a0UcpESjBa-8wQ9m5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z2RJFeIu4keoqDO4x5BOag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_jjYhKZRSskurVxz2qWHRfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_19_2026_To_2_19_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_SLmuQgYcLUyKdGqqpYwayw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-19</startDate>
            <endDate>2026-02-19</endDate>
        </period>
    </context>
    <context id="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_BC5_6M-QyUmQOf1sjtWaMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-18</startDate>
            <endDate>2026-02-18</endDate>
        </period>
    </context>
    <context id="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_YV5sLiK4506wsErDca1zNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-18</startDate>
            <endDate>2026-02-18</endDate>
        </period>
    </context>
    <context id="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_ggP8Qf9lAEK8UwvoEQkLpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-18</startDate>
            <endDate>2026-02-18</endDate>
        </period>
    </context>
    <context id="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_rUeXM1hqFEmNCkHtxT9MOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-18</startDate>
            <endDate>2026-02-18</endDate>
        </period>
    </context>
    <context id="As_Of_2_19_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_nVZL2iH4ikeTyIHCOmUqAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-19</instant>
        </period>
    </context>
    <context id="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_IbplB2gb40qdMMz9BIq6qA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ClearStreetLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-06</startDate>
            <endDate>2026-02-06</endDate>
        </period>
    </context>
    <context id="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_c_d3VxIAXUGyxXVEc8AngQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ClearStreetLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-06</startDate>
            <endDate>2026-02-06</endDate>
        </period>
    </context>
    <context id="Duration_7_16_2025_To_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_bvbBg5HF0E2idzp2cAdrIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:AltaPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-16</startDate>
            <endDate>2025-07-16</endDate>
        </period>
    </context>
    <context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_eTUFwzCAf0WPdoyAqoxppg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-18</instant>
        </period>
    </context>
    <context id="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_U70qipalZUSb0nCwfCrzfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">limn:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">limn:BestEffortsPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-18</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uTi3iJsKTUG1RhrJIbdN7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_HanaImmunotherapeuticsLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_k9NmbfrirkmFjETfcoPvjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:HanaImmunotherapeuticsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_AmantesLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YmK0PQG_Ck6qgjUgdZnidg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:AmantesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_ValetudoTherapeuticsLlcMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_zN6GYwa30EiLaz5lZyZFBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ValetudoTherapeuticsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_E0TXzEQ0YEKb3rQzLXh72w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ProphaseSciencesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_EwonComfortechCoLtdMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_SJg_pgNr3UGbcKPDWHQG5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:EwonComfortechCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tBg1QKOCjkulRGKkllXaGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_HanaImmunotherapeuticsLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_M0xZpqNfSUiePS0rqmBJQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:HanaImmunotherapeuticsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_AmantesLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_HgSigzsdAE2ZWAOutjYfWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:AmantesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ValetudoTherapeuticsLlcMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_u2V6Q8F86kqWl2rCR_ZLxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ValetudoTherapeuticsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Hjob6bfNJ0yH9IccwyqnFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ProphaseSciencesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_EwonComfortechCoLtdMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0bsPPj_X9U-t6aFyc57i1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:EwonComfortechCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UCZY1ZeR3UG6JVOXPTBI8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_HanaImmunotherapeuticsLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NKk10HcAC0izvcIcwzePTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:HanaImmunotherapeuticsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:HanaLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_AmantesLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_uroe3WmRfk2-MXkmturUGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:AmantesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:AmantesLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_ValetudoTherapeuticsLlcMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_4VRhmQHacUKineZTnXswaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ValetudoTherapeuticsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ValetudoLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Rea6tsWHW0yjkY8Ibu9urQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:ProphaseSciencesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:ProphaseLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_EwonComfortechCoLtdMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_LGib2VMD3kWL01MA1301Pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">limn:EwonComfortechCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:EwonLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6wD9AAP08UeDG0Qs6p5Q2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">limn:FeeluxBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_D_P_lZhqU5gEiyf8nABG1U1w">
        <measure>limn:D</measure>
    </unit>
    <unit id="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_Vote_pVdT3YsDMEiv7zpsvfY2UA">
        <measure>limn:Vote</measure>
    </unit>
    <unit id="Unit_Standard_Milestone_17WZ1k4BqkSsiQd-8K0NPw">
        <measure>limn:Milestone</measure>
    </unit>
    <unit id="Unit_Standard_segment_pfATFfq5ukiWsqLhRIg_Iw">
        <measure>limn:segment</measure>
    </unit>
    <unit id="Unit_Standard_Y_OxQzCXHfk02aUB5FPKeCrg">
        <measure>limn:Y</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tc_U__4sQzrbke-hSym0dDFMQ_1_1">0001971387</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tc_w9GC9n3kNUWYJzh4ZKfZvQ_2_1">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      id="Hidden_8HWQfwbA_ECbVlKERimhRA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      id="Hidden_Vh0f4VxQ7U6dzZ4_M6Iklg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      id="Hidden_Ksx2stOFWk6AY84IddPepw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      id="Hidden_ZOiuN5kpm0G41AqH6e2UJw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ"
      xsi:nil="true"/>
    <limn:NumberOfWarrantsHeldInEachUnit
      contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_limn_RedeemableWarrantMember_viAcaQl82UKtOAfy6rdZ4Q"
      decimals="2"
      id="Hidden_V3HXcsnI6E-gQG2CW85ZjA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">0.25</limn:NumberOfWarrantsHeldInEachUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_ZDd5yizsikO5sTlcUH09FA"
      decimals="INF"
      id="Hidden_nl21qyvNY06G3jQDgQwLzg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_Ky__aiunWkee6a2CP8ZTOQ"
      id="Hidden_y0XoPBMFT0K_m6ZKSdgGew">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="INF"
      id="Hidden_oRglHBbi5kiQPSddjK0rrg"
      unitRef="Unit_Standard_segment_pfATFfq5ukiWsqLhRIg_Iw">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="INF"
      id="Hidden_skpW_fMTs0qgK5TqjOzinQ"
      unitRef="Unit_Standard_segment_pfATFfq5ukiWsqLhRIg_Iw">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      id="Hidden_j5iZXpaqRUepqSK5i47XiA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      id="Hidden_sQpi6bpFc0qQ5LX21s7swA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      id="Hidden_rF9jsGd2PEyzELvf4YbZ2g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      id="Hidden_W9yMXh1gvU6pZJS4SioUZg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Hidden_VnuFzE-7Pk6xiqbZGsYVKw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">23753561</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Hidden_QfG0tNXDh0OFhH449Pr4Mg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">17500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="2"
      id="Hidden_F4R9DCODRUSd1g3LlIjEqw"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">-0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="2"
      id="Hidden_cM-Z0zzNDUaiQqfL9Zw3UA"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">-0.20</us-gaap:EarningsPerShareDiluted>
    <limn:NumberOfWarrantsHeldInEachUnit
      contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_limn_RedeemableWarrantMember_viAcaQl82UKtOAfy6rdZ4Q"
      decimals="2"
      id="Hidden_ZxKK64VsEUG8mm4V7fNrqQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">0.25</limn:NumberOfWarrantsHeldInEachUnit>
    <limn:PrincipalAndAccruedInterestOnPrivatePlacement
      contextRef="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_qUlxIbYw4Uyvh13v3JGs3g"
      decimals="0"
      id="Hidden_5_bKoANxokGAW-xbn0qRBA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3316756</limn:PrincipalAndAccruedInterestOnPrivatePlacement>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Hidden_gt31aPXKykC4c-4bEt6laQ">http://xbrl.sec.gov/country/2025#CA</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      id="Hidden_sNEuRXTazkSm5Xw7h_81ew">http://xbrl.sec.gov/country/2025#CA</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_01Es_yiBG0a6u9R-nLydbg"
      id="Hidden_rGRJ0qc7tEGPO6XNQVjRbw">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kX_yWG231E-RYOerQjujQA"
      decimals="INF"
      id="Hidden_pRGIcWXwZE-WeEaxj87wJg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wuQDuaMWckW-5cDSn3bI2w"
      decimals="INF"
      id="Hidden_kq3mrqvJyU-ExJ_p7HGPjQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PrivatePlacementWarrantsMember_ioEniwa8PEunNaQ7J6fSnA"
      decimals="0"
      id="Hidden_wUaYXsrirkKbOmu3ilr3Zg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:WarrantsAndRightsOutstanding>
    <dei:DocumentType
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Narr_jutq0ggcwkuJbCEn8-5eJA">S-1</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tc_ZF733adW5US7UWwt-FOrzA_1_0">LIMINATUS PHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tc_MYqs_8un60GOr97htdxxkQ_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tc_DDgcQpNrXU6BXv5oXtVH4Q_2_4">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tc_-Z88PoXu10eke6hnuByTwg_3_4">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Narr_ulCNkQSJtUmuNS-FT74qAg">false</dei:EntityExTransitionPeriod>
    <us-gaap:Cash
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_CwYJHoNvf02oxkG8MDd5Dw_5_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1907674</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_tRVA2e3PTUyFGOYedst8hA_5_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">337655</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_Bi9L9aoh5E-4VpgmTt8-Ig_6_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">870872</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_5P3cGKX4uUGQsmoqNnPnLA_6_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">162919</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_WfADcdHuoEC9estvmKxICw_7_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2778546</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_YrvnpxKNrEm5sJaKYUXwBg_7_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">500574</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_ghQzZLNJqEOs22TlafA5zw_9_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">11703</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_7kHbdOO320a8XLsq0o_IJQ_9_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">12221</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_t1ehY9y1PEqwCykwYrNq9Q_10_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">11703</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_xwYKuQSfW0eUy80T4Be5XA_10_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">12221</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_IQ0uzaqOM0qvBrFJ8M6pVQ_11_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2790249</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_X6z_T0vVYUWkoMFH39uJTw_11_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">512795</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_eYnq5j9330iI9Vg95QitMw_15_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">529778</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc__Tqq4KCmjUSNyDwPheNaKw_15_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">582234</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_NKkRNQixTEir-0TM7sIYfA_16_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">222558</limn:AccruedInterestCurrent>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_J3jqYUIR2kCzIjt8gSwmTg_16_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">203921</limn:AccruedInterestCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_3_31_2026_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y6Lx3mXqwk-nBkJ5KlLBYg"
      decimals="0"
      id="Tc_cOyBa6vBD0yAw-djFPL9Nw_17_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">194587</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FbpcEF3_bUqHFwpcC9Wy4w"
      decimals="0"
      id="Tc_AK5aZiXmMUGIGyLeyIk8Eg_17_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">209586</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_sfbF_kOJqk2aXF9HUaGXeA_18_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1442500</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_MrJ_suHLzkOh8Sm2ECxkdg_18_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1442500</us-gaap:ShortTermBorrowings>
    <limn:DeferredUnderwritingFeesPayableInCashCurrent
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_tSxPr0Yu8U6ArTfBq324hw_19_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">500000</limn:DeferredUnderwritingFeesPayableInCashCurrent>
    <limn:DeferredUnderwritingFeesPayableInCashCurrent
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_EoEDqshKQ0ChlVYMtvVtAw_19_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">500000</limn:DeferredUnderwritingFeesPayableInCashCurrent>
    <limn:CommonStockPayable
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_4x-S_nsYkkOBx-WgfA449A_20_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7360000</limn:CommonStockPayable>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_bGWRUksf-UK98soYTdJLow_21_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2889423</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_ViaevaCnzE2v8oqapzIVUQ_21_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">10298241</us-gaap:LiabilitiesCurrent>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_xvf4qMHYWk-RXDAa2il5Og_22_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">33422</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_bnUjugDb7kycVwavIHt8ZA_22_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">29244</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:Liabilities
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_2oAgteJDcU6K8tnFtUzKRw_23_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2922845</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_e472Jwjdj0iZRXCg54YS0w_23_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">10327485</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="INF"
      id="Narr_geYQ8-Q9fEy3NBXGbpIELA"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_PSSfWujE0U-gQ6Gkb9AU_Q"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="INF"
      id="Narr_VIyeJvL9xUOwCP2VXQ1UzQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_hJ-J4zjI6UWDZpNjdjSREQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="INF"
      id="Narr_2dXQh-v9OEyBuFOQlMaTBg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_doLH6Hjytk2du9T5ppzdKw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="INF"
      id="Narr_ZxihCV3JMUO92DKpK5Y2Xw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_uewSIKB7b0SGA28vfT-SXQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="INF"
      id="Narr_jH-xER_trkeVroskVOVzdQ"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_aj3q42IJv0izPod5Ji2v_w"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="INF"
      id="Narr_FrL-qxj-50mg2U4xGL9fMw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_qO_86bWt30iYhFa47U6KiA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="INF"
      id="Narr_u88Be5NwAEaF28jVo9Q8IQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">44877633</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="INF"
      id="Narr_bY2UQ6SaoEuQcEwM4BLzhw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">44877633</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_sJhOVCpW4keCBVsc_xYBzw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">27064633</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_koV2dT1AwkWSYJJonY9cGA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">27064633</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_LXB9F7ZWJECMi_fRzPpfvQ_29_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4823</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_c6zlSbUgxkibHA7vLbSYuw_29_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2706</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_GwVi0LBfl0O10wcxNJhxQQ_30_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">39858028</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_kT_inCXdo0OBeleTSPw3vQ_30_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">29054337</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_OVuTo7V-KECI7CkjjNMc_Q_31_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-39995447</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_iwiQU5qMzEKQpltrfSYIjA_31_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-38871733</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_FDa2Nd4NVU6OHV85YDq6qA_32_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-132596</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_fGKzZQ-NlUSXI4HhNb2bRA_32_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-9814690</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_vYEqQxKLkEChZcGbze6IeQ_33_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2790249</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_HwERpipsZ0uAUNYVr3itGw_33_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">512795</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_bYd6vtHub0iJBciFP2xhSA_4_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">700898</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_XihrR83u5ES44Bh7BTNZUg_4_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">264220</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_orU4IDl97UKPbAOuHOWFfQ_5_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_e3MRMSMBQUqnKNSytpVOCw_6_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1100898</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_F9hkhmJVwUqrzweWQJFgUA_6_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">264220</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_IE_EN_FUkkmlBqq2ifx0aw_7_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-1100898</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_8BY4U6V8nEWgkzEh98xKBA_7_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-264220</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_IVjUYWcx1k2loLWd_iEGrQ_9_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">18638</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_t3GnswwkjEiJwREptF-vmQ_9_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">115512</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_yrs7V6sYzkKAsd_a0kbxrA_10_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">52206</us-gaap:InvestmentIncomeInterest>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_yqYvqERnWUav_Gt4Ea5QPQ_11_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4178</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_SoL_m1lsGESnvMuN1VSmFg_12_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-22816</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_8Oh6OnVNH0KbQvF0snYCog_12_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-63306</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_uIMgiVBNYEyJ8nK1nq72fg_13_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-1123714</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_G_JafU7-rE2B_vKKKhAGDg_13_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-327526</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_IIJrVh996USagDgLCTa8-A_15_3"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">35999589</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_IIJrVh996USagDgLCTa8-A_15_3_2"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">35999589</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_6zPXfbljDUO3vovR4VpTpA_15_6"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">17500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_6zPXfbljDUO3vovR4VpTpA_15_6_2"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">17500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="2"
      id="Tc_-OJZcUa8QEilwlvS02CGdw_17_3"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="2"
      id="Tc_-OJZcUa8QEilwlvS02CGdw_17_3_2"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="2"
      id="Tc_VCWz9vVrB0qIHg1ZysCVAw_17_6"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="2"
      id="Tc_VCWz9vVrB0qIHg1ZysCVAw_17_6_2"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LJS_bgYOWkOcBywnif6GLQ"
      decimals="INF"
      id="Tc_--g1J3AQv0qKyyz8xQSB9w_4_2"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">27064633</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LJS_bgYOWkOcBywnif6GLQ"
      decimals="0"
      id="Tc_XR-sd7H54kGW0PiFR5oIoA_4_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2706</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_It0aMMr5RUGH0v6aV7qdrw"
      decimals="0"
      id="Tc_Pek-NRLViUyVyREk8mXLgQ_4_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">29054337</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4f2Cj2MzIUuqkE9ozbbB6w"
      decimals="0"
      id="Tc_HA7POEqghEqEeslKVHNRfg_4_11"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-38871733</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc__nGSvNLeEUuD2q3Pv8TGvg_4_14"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-9814690</us-gaap:StockholdersEquity>
    <limn:StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0P2Hk6Fm0UCfvB5hIDbvbw"
      decimals="INF"
      id="Tc_wX0DPmPzbEusasO14M7ESA_5_2"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">4000000</limn:StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants>
    <limn:StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0P2Hk6Fm0UCfvB5hIDbvbw"
      decimals="0"
      id="Tc_FwsvgI3B7ESYmbJ0Kkhd1Q_5_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">736</limn:StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants>
    <limn:StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZSeIP3LMQEiCyd2vZgeG5w"
      decimals="0"
      id="Tc_jdV_9c-n8EepKADKoAM-2A_5_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7359264</limn:StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants>
    <limn:StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_8kOTnPtNdkyDIB501mlsSw_5_14"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7360000</limn:StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants>
    <limn:OfferingCosts
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Narr_BhKdmCitIEucEaPs9VvfEA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">559962</limn:OfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0P2Hk6Fm0UCfvB5hIDbvbw"
      decimals="INF"
      id="Tc_L-Q_D0Sgi0aCiryfXneXNA_6_2"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">13813000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0P2Hk6Fm0UCfvB5hIDbvbw"
      decimals="0"
      id="Tc_--C5WNj7oEe5ksxJBWwCKQ_6_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1381</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZSeIP3LMQEiCyd2vZgeG5w"
      decimals="0"
      id="Tc_TuY6uTFFmkqZcrvhLY_VEw_6_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3444427</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_xVdD5e0r-ECV1qrCYwiATQ_6_14"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3445808</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vn8s2LBdIUK1HIqRW6N8fQ"
      decimals="0"
      id="Tc_SoamhPlcokGoAoME_X6cEw_7_11"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-1123714</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_570XF3kHfEG6RLc26fDSnQ_7_14"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-1123714</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__vfMa6eSe02_iSgKMlEjFQ"
      decimals="INF"
      id="Tc_3fCgSJX0YEKMyJcSCkKgEg_8_2"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">44877633</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__vfMa6eSe02_iSgKMlEjFQ"
      decimals="0"
      id="Tc_qL6VS_XYykqgvA-0MpNMnw_8_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4823</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Y5cch1GNXkWKRHTF2v1JhQ"
      decimals="0"
      id="Tc_3KRaC5FzFUeFEzyb1RLwOw_8_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">39858028</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5kfGOGRcqUu2Y62sJIl6Iw"
      decimals="0"
      id="Tc_9bhZgn_BDEeK5oj3_iOYYA_8_11"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-39995447</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_Qq0wURWxhkSyavWEohmX7g_8_14"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-132596</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHu7s1FxgEmdi0qyZEPN4g"
      decimals="INF"
      id="Tc_zsPKN6SEekWY3d2I44dmXw_4_2"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">17500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHu7s1FxgEmdi0qyZEPN4g"
      decimals="0"
      id="Tc_eKNO23yJNUWFC8dvbXuTTQ_4_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1750</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9uu8nJPlZE2Ewx4WJxhvoQ"
      decimals="0"
      id="Tc_sOXwOs1NWUqL90HO1pSPsQ_4_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">9323403</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MuLWEtlz5E2UN4YJiAi4YQ"
      decimals="0"
      id="Tc_gVrV0xOrV0K_rG-K207NgQ_4_11"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-28665216</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_9g7XhG98L0-hjr-ibTvlWw_4_14"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-19340063</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__4kj97EHqEunWT3sM4bCbw"
      decimals="0"
      id="Tc_Gr4OUhbLSkqiGjMVkLJykA_5_11"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-327526</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_JXltSoX9e0uRgUMkiRMojQ_5_14"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-327526</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p3dvj_Io2E-N-bZQMUAM-w"
      decimals="INF"
      id="Tc_50Q7YqE7lUKdd0j_-dl0DQ_6_2"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">17500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p3dvj_Io2E-N-bZQMUAM-w"
      decimals="0"
      id="Tc_Xt_wJP7dJkKhrFhNXTtlGw_6_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1750</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9gmJIjAObE6K8dYKyoRMyw"
      decimals="0"
      id="Tc_El4IjDSW3UCH26c1m9yFpQ_6_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">9323403</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lO_UINB71EmnK4inw1sNDQ"
      decimals="0"
      id="Tc_FTVM3DYkxEiJuMIrO1_aYA_6_11"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-28992742</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_VCFxQaKNIEuk0z9tPKoniw"
      decimals="0"
      id="Tc_I5daGb_3i0GiMQydwwoksA_6_14"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-19667589</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_YRPAb4AG6EaVuSM7ZuZ92w_5_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-1123714</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_bgSqVndl6E6Q0wqxmT07PQ_5_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-327526</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_sBBHIZLQyEuHRyQFySWjsg_6_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">518</us-gaap:Depreciation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_b_qrb51JZ0OtlNr1XkHCOA_7_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4178</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_y7FqVbahxU-bYSNVoeDk7g_9_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">707953</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_8oLT30H5jU2kFObJMfE4Sw_9_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50846</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_065YO5IHoUSgkKTP6BipSQ_10_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-191956</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_ir74VIkMHEiRHFkEWO0vlQ_10_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">121467</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <limn:IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_vOxfVneRiUONx4rgB_XB2Q_11_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-18637</limn:IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent>
    <limn:IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_FNAPfCMOeEStzzKJ7BRNQQ_11_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-115512</limn:IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_h5QUQVxsR0WH-TFGpLsZCg_12_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-14999</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_JFBRz33GHUS4HJfI7n2ynw_12_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-18000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_s0x2UkSpx0u0UVZiiE39IA_13_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-2015289</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_3V1TrCra0EGcvMbzcTCmPQ_13_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-159393</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireLoansReceivable
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_Aj8ogMJKd0uJZ8D74OP49g_16_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">575000</us-gaap:PaymentsToAcquireLoansReceivable>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_h5r8TIpFVEu2F-nyICcn7g_17_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-575000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_O5k2NjoTp0q6TSWdFEGHqg_20_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3585308</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_e2w_WmWQeUW2OqYww12apQ_21_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">713000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_ywp-Df-MmkKLWSoCqXiNTg_22_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3585308</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_T1hb7kpdX0-HjWwBvbdltg_22_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">713000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_XEpsqJ93Zk664Ia_RD129Q_24_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1570019</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_GG1hWAru6UKhVeYhLEXUFQ_24_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-21393</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_wwX-WcpXqkWHZdA2xOMxgg_26_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">337655</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_7YcPjznCQUuhZpAametJEw_26_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">56319</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Tc_w0q58oToFkeWx2fHNCBGPQ_27_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1907674</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_3_31_2025_VCFxQaKNIEuk0z9tPKoniw"
      decimals="0"
      id="Tc_Pj5Vhn0akU-rS1RlpH7X6g_27_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">34926</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <limn:CommonStockIssuedInConnectionWithSettlement
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_mP1Wa9V3Q0C7mGmQ57mTEA_30_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7360000</limn:CommonStockIssuedInConnectionWithSettlement>
    <limn:CostsIncurredInConnectionWithIssuanceOfCommonStock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_qzgzsFaMxkSj-FLwAgX99A_31_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">139500</limn:CostsIncurredInConnectionWithIssuanceOfCommonStock>
    <limn:DeferredTransactionCostsInAccountsPayable
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Tc_z0USZRivn0KZx4iPQJiu3A_32_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">112112</limn:DeferredTransactionCostsInAccountsPayable>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_w2s6fS2YuUeqMk0u_cTBGA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note&#160;1. Description of Organization and Business Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Liminatus Pharma, Inc. (the &#x201c;Company&#x201d;), a Delaware corporation, is a pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company&#x2019;s candidate, IBA101, is a humanized anti CD47 monoclonal antibody. The next generation CD47 checkpoint inhibitor&#x2019;s initial indication is expected to be patients with advanced solid cancers including non-small cell lung cancer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to the uncertainty of whether the Company&#x2019;s intellectual property will develop into successful commercial products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Business Combination&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 30, 2022, Iris Acquisition Corp, a Delaware corporation (&#x201c;Iris&#x201d;), the Company, Liminatus Pharma, LLC, a Delaware limited liability company (&#x201c;Liminatus&#x201d;), Liminatus Pharma Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#x201c;Liminatus Merger Sub&#x201d;), and SPAC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#x201c;SPAC Merger Sub&#x201d;), entered into a business combination agreement (as amended, the &#x201c;Business Combination Agreement&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On March&#160;4, 2025, Iris held a special meeting of stockholders. At the special meeting, Iris&#x2019;s stockholders voted to approve the Business Combination and adopt the Business Combination Agreement, among other items. In connection with the special meeting, stockholders holding 59,844 Iris Class&#160;A Shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $11.74 per share, subject to adjustment for taxes payable from the trust account, for an aggregate redemption amount of $702,359. The redemptions were settled on April 30, 2025 upon the consummation of the Business Combination.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April&#160;30, 2025 (the &#x201c;Closing Date&#x201d;), the Company consummated the business combination contemplated by the Business Combination Agreement, pursuant to which &lt;span style="color:#231f20;"&gt;(a)&#160;Liminatus Merger Sub merged with and into Liminatus (the &#x201c;Liminatus Merger&#x201d;), with Liminatus surviving the Liminatus Merger as a direct wholly-owned subsidiary of the Company, and (b)&#160;simultaneously with the Liminatus Merger, SPAC Merger Sub merged with and into Iris (the &#x201c;SPAC Merger&#x201d; and, together with the Liminatus Merger, the &#x201c;Mergers&#x201d;), with Iris surviving the SPAC Merger as a direct wholly-owned subsidiary of the Company (the transactions contemplated by the foregoing clauses (a)&#160;and (b)&#160;the &#x201c;Business Combination&#x201d;)&lt;/span&gt;, and in connection therewith the Company changed its name from &#x201c;Iris Parent Holding Corp.&#x201d; to &#x201c;Liminatus Pharma,&#160;Inc.&lt;span style="color:#231f20;"&gt;&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Business Combination Agreement, among other matters, at the effective time of the Business Combination (the &#x201c;Effective Time&#x201d;), (i)&#160;every issued and outstanding security issued by Iris during its initial public offering (each, an &#x201c;Iris Unit&#x201d;) was automatically separated and broken out into its constituent parts and the holder thereof was deemed to hold one share of Iris Class&#160;A common stock, par value $0.0001 per share (the &#x201c;Iris Class&#160;A Shares&#x201d;) and &lt;span style="-sec-ix-hidden:Hidden_V3HXcsnI6E-gQG2CW85ZjA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one-fourth&lt;/span&gt;&lt;/span&gt; of one redeemable warrant that was included as part of each Iris Unit (the &#x201c;Public Warrants&#x201d;), and such underlying constituent securities of Iris were converted in accordance with the applicable terms of the Business Combination Agreement, (ii)&#160;at the Effective Time, each issued and outstanding Iris Class&#160;A Share was converted automatically into and thereafter represent the right to receive one share of common stock, par value $0.0001 per share (&#x201c;Common Stock&#x201d;), of the Company, following which all Iris Class&#160;A Shares ceased to be outstanding and were automatically canceled and ceased to exist, (iii)&#160;at the Effective Time, each issued and outstanding Public Warrant immediately and automatically represented the right to purchase shares of Common Stock on the same terms and conditions as are set forth in the applicable warrant agreement, (iv)&#160;at the Effective Time, each issued and outstanding non-redeemable warrant of Iris that was issued by Iris in a private placement at the time of the consummation of its initial public offering, entitling the holder thereof to purchase one Iris Class&#160;A Share at $11.50 per share, except those issued to Cantor Fitzgerald&#160;&amp;amp; Co. (&#x201c;Cantor&#x201d;), were forfeited, and (v)&#160;the private placement warrants issued to Cantor immediately and automatically represented the right to purchase shares of Common Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon the consummation of the Business Combination, the Company&#x2019;s certificate of incorporation was amended and restated to, among other things, set the total number of authorized shares of capital to 501,000,000 shares, of which 500,000,000 were designated as common stock, $0.0001 par value per share, and 1,000,000 shares were designated as preferred stock, $0.0001 par value per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At the Closing Date, 7,014,633 shares of Iris Class A Shares automatically converted into shares of the Company&#x2019;s common stock, on a one-for-one basis. Of the total 7,014,633 newly converted shares, 6,900,000 were issued to Iris Acquisition Holdings, LLC, the sponsor of Iris, and 114,633 were issued to Iris&#x2019; public stockholders in a noncash transaction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At the Closing Date, the Company issued an aggregate of 1,500,000 shares of the Company&#x2019;s common stock in a private placement (the &#x201c;PIPE Shares&#x201d;) for the total consideration of $15,000,000 (the &#x201c;PIPE Financing&#x201d;). The PIPE Financing consisted of a cash and non-cash component. Under the cash component, the Company received gross proceeds of $10,556,500, of which $7,129,500 came directly from the PIPE investor and $3,427,000 were funded indirectly by the PIPE investor, through promissory notes between Prophase Sciences, LLC, a related party of the Company, and Liminatus. At the Closing Date, the $3,427,000 in related party debts between Prophase Sciences, LLC and Liminatus was ultimately converted into shares as part of the PIPE Financing. As part of the PIPE Financing, the gross proceeds satisfied principal and accrued interest totaling $3,316,756, which was ultimately converted into shares as part of the PIPE Financing. The non-cash component of the PIPE Financing included the conversion of $4,443,500 in amounts borrowed from a consortium of related parties. The $4,443,500 borrowed from the related parties was used to fund an unsecured promissory note between Liminatus and Iris. At the Closing Date, the unsecured promissory note was settled and the $4,443,500 in related party debts were ultimately converted into shares of the Company in a noncash transaction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At the Closing Date, 112,222,220 of Liminatus&#x2019; member units converted into 17,500,000 shares of the Company&#x2019;s common stock. Of the 17,500,000 shares of common stock, 4,000,000 were issued to Feelux Co, Ltd. as part of an agreement between the Company, Feelux Co, Ltd. and Car-Tcellkor, Inc. As part of the agreement, the outstanding principal and accrued interest on the Feelux and Car-Tcellkor bonds, totaling $11,481,146, and 9,999,999 member units of Liminatus were converted into 4,000,000 shares of the Company&#x2019;s common stock. The remaining Liminatus member units were converted based on a conversion ratio of 0.1559 shares per member unit.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon consummation of the Business Combination, the Company assumed a total of $10,694,604 in liabilities from Iris. The Company incurred $1,518,381 in transaction costs associated with the closing of the Business Combination. The Company converted a total of $14,797,901 of related party debt and accrued interest, $3,316,756 from the PIPE investor and $11,481,146 from Feelux and Car-Tcellkor (as described above) into common stock. Additionally, a total of $169,201 in accrued interest on related party debts that were converted, as discussed above, was eliminated upon consummation of the Business Combination.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, at the Closing Date, the Company settled Iris&#x2019; liabilities for $7,000,000 of the deferred underwriting fees incurred prior to the Closing Date for 700,000 shares of common stock to the underwriters in Iris&#x2019;s initial public offering. At the Closing Date, the shares were not issued to the underwriter and the Company recorded as a liability with a fair value of $7,049,000. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $7,245,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Liminatus was deemed the accounting acquirer in the Business Combination based on an analysis of the criteria outlined in Accounting Standards Codification (&#x201c;ASC&#x201d;) 805, &lt;i style="font-style:italic;"&gt;Business Combinations&lt;/i&gt; (&#x201c;ASC 805&#x201d;). The determination was primarily based on Liminatus&#x2019; members prior to the Business Combination having a majority of the voting interests in the combined company, Liminatus&#x2019; ability to exert control over the majority of the board of directors of the combined company, Liminatus&#x2019; ability to maintain control of the board of directors on a go-forward basis, Liminatus&#x2019; senior management comprising the senior management of the combined company, and Liminatus&#x2019; operations prior to the Business Combination comprise the ongoing operations of the combined company. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Liminatus&#x2019; issuing stock for the net assets of Iris, accompanied by a recapitalization. The net assets of Iris were stated at fair value, with no goodwill or other intangible assets recorded.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon the consummation of the Business Combination, the Iris Class&#160;A Shares, Iris Units and Public Warrants ceased trading on the OTC Pink Marketplace, and the Common Stock and Public Warrants began trading on The Nasdaq Stock Market (&#x201c;Nasdaq&#x201d;) under the trading symbols &#x201c;LIMN&#x201d; and &#x201c;LIMNW,&#x201d; respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Notices from Nasdaq&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 22, 2025, the Company received a notice from the Nasdaq Listing Qualifications Department indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025. The deficiency letter had no immediate effect on the listing of the Company&#x2019;s common stock, and its common stock continued to trade on Nasdaq under the symbol &#x201c;LIMN&#x201d;. Under the Nasdaq rules, the Company had 60 calendar days, or until October 21, 2025, to submit a plan to regain compliance and if the plan was accepted, Nasdaq can grant an exception of up to 180 calendar days from the filing&#x2019;s due date, or until February 16, 2026, to regain compliance. If the compliance plan was not accepted, the Company had the opportunity to appeal that decision to a Nasdaq Hearings Panel. On October 6, 2025, the Company filed its Form 10-Q for the period ended June 30, 2025 and the matter was closed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;On November 19, 2025, the Company received notices from the Nasdaq indicating that the Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value of Listed Securities (&#x201c;MVLS&#x201d;) of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;$50,000,000 (the &#x201c;MVLS Rule&#x201d;), based upon a review of the Company&#x2019;s MVLS for the last 30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly Held Shares (&#x201c;MVPHS&#x201d;) of $15,000,000 (the &#x201c;MVPHS Rule&#x201d;), based upon a review of the Company&#x2019;s MVPHS for the last 30 consecutive business days. The Nasdaq staff noted that the Company also does not meet the requirements under Listing Rule 5450(b)(3)(A), which requires the Company to have total assets and total revenue of at least $50 million each for the most recently completed fiscal year or two of the three most recently completed fiscal years. Under the Nasdaq rules, the Company has 180 calendar days, or until May 18, 2026, to regain compliance with the MVLS Rule and MVPHS Rule. In the event the Company does not regain compliance with the MVLS Rule and MVPHS Rule prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Hearings Panel. Alternatively, the Company may consider applying to transfer the Company&#x2019;s securities to the Capital Market, provided it meets the Capital Market&#x2019;s continued listing requirements. The Company is working diligently to regain compliance with Nasdaq&#x2019;s listing rules. However, there can be no assurance that the Company will be able to regain compliance within the prescribed time period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 15, 2026, the Company received a notice from Nasdaq indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rule 5450(a)(1) (the &#x201c;Bid Price Rule&#x201d;) which requires listed securities to maintain a minimum bid price of $1 per share. Under the Nasdaq rules, the Company has 180 calendar days, or until July 14, 2026, to regain compliance with the Bid Price Rule. In the event the Company does not regain compliance during the initial compliance period, the Company may be eligible for additional time to regain compliance with the Bid Price Rule. The Company is working diligently to regain compliance with Nasdaq&#x2019;s listing rules. However, there can be no assurance that the Company will be able to regain compliance within the prescribed time period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;February 2026 Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 18, 2026, the Company closed a best efforts public offering for the sale of (i) 8,270,000 shares of common stock, (ii) 5,543,000 pre-funded warrants to purchase up to 5,543,000 shares of common stock and (iii) 13,813,000 common stock purchase warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per pre-funded warrant) and accompanying warrant (the &#x201c;Offering&#x201d;), for aggregate net proceeds of approximately $3.44 million after deducting the estimated offering expenses, including the placement agent fees. Each pre-funded warrant has an exercise price of $0.0001 per share upon issuance for one share of common stock and will not expire prior to exercise. Each warrant has an exercise price of $0.29 per share, is exercisable upon issuance for &lt;span style="-sec-ix-hidden:Hidden_nl21qyvNY06G3jQDgQwLzg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one and a half&lt;/span&gt;&lt;/span&gt; shares of common stock, and will expire five years following the date of issuance. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the common stock and the exercise price. Maxim Group LLC acted as the placement agent in connection with the Offering.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Offering, on February 17, 2026, the Company entered into a securities purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with certain purchasers party thereto. Pursuant to the Purchase Agreement, the Company agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock or file any registration statement or prospectus, or any amendment or supplement thereto for 180 days after the closing date of the Offering, subject to certain exceptions. The Company also agreed not to effect or enter into an agreement to effect any issuance of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock involving a Variable Rate Transaction (as defined in the Purchase Agreement) until 180 days after the closing date of the Offering, subject to certain exceptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Offering, on February 17, 2026, the Company entered into a placement agency agreement with Maxim Group LLC, as placement agent in connection with the Offering (the &#x201c;Placement Agent&#x201d;). The Company paid the Placement Agent a cash fee of 8.0% of the aggregate gross proceeds raised in the Offering. The Company also agreed to reimburse the Placement Agent for all reasonable out-of-pocket costs and expenses incurred in connection with the Offering in an aggregate amount up to $100,000. In addition, the Company issued to the Placement Agent warrants (the &#x201c;Placement Agent Warrants&#x201d;) to purchase 690,650 shares of common stock (representing 5.0% of the number of shares of common stock sold in the Offering). The Placement Agent Warrants are immediately exercisable at an exercise price of $0.319 (or 110% of the public offering price for the shares of common stock and common warrants offered in the Offering) and will expire on the &lt;span style="-sec-ix-hidden:Hidden_y0XoPBMFT0K_m6ZKSdgGew;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;fifth anniversary&lt;/span&gt;&lt;/span&gt; of the commencement of sales of the Offering.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for one year after the date that the condensed consolidated financial statements are issued. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Through March 31, 2026, the Company has funded its operations mainly through equity and debt financings, including the proceeds from the Mergers and the PIPE Financing and the Offering (as described below).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of March 31, 2026, the Company had $1,907,674 of cash in its bank accounts. As of March 31, 2026 and December 31, 2025, there was $1,442,500 of related party debts, which are included in short-term debt, related parties in the accompanying unaudited condensed consolidated balance sheets (see Note 4).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has an accumulated deficit of $39,995,447 as of March 31, 2026. The Company had a loss from operations and net loss of $1,100,898 and $1,123,714, respectively, for the three months ended March 31, 2026. The Company had a loss from operations and net loss of $264,220 and $327,526, respectively, for the three months ended March 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 18, 2026, the Company completed a &#x201c;best efforts&#x201d; public offering of (i) 8,270,000 shares of its common stock, (ii) 5,543,000 Pre-Funded Warrants to purchase up to 5,543,000 shares of common stock and (ii) 13,813,000 Common Stock Warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per Pre-Funded Warrant) and accompanying warrant. In connection with the Offering, the Company received net proceeds of approximately $3.44 million, after deducting the estimated offering expenses payable by the Company, including the placement agent fees. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Company&#x2019;s assessment of going concern considerations in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 205-40, &lt;i style="font-style:italic;"&gt;Presentation of Financial Statements&#x2014;Going Concern&lt;/i&gt;, management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying unaudited condensed consolidated financial statements are issued. The Company&#x2019;s unaudited condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Management&#x2019;s plans relating to the above include raising additional cash through further equity and debt financings or other arrangements to fund operations. There can be no assurance that the Company will be able to raise adequate capital under acceptable terms, if at all. The sale of additional equity may dilute existing members and newly issued equity securities may contain senior rights and preferences compared to currently outstanding common stock. Issued debt securities may contain covenants and limit the Company&#x2019;s ability to pay dividends or make other distributions to stockholders. If the Company is unable to obtain such additional financing, future operations would need to be reevaluated.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <limn:CommonStockCashRedemptionShares
      contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw"
      decimals="INF"
      id="Narr_7OyXlMGcZE-K-Z51rvAqlw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">59844</limn:CommonStockCashRedemptionShares>
    <limn:CommonStockCashRedemptionPricePerShare
      contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw"
      decimals="2"
      id="Narr_5-Uon_wsEk66GyUkLpP6vw"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">11.74</limn:CommonStockCashRedemptionPricePerShare>
    <limn:CommonStockCashRedemptionAmount
      contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw"
      decimals="0"
      id="Narr_hTpnYxuqpUykNDLZzxjT9Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">702359</limn:CommonStockCashRedemptionAmount>
    <limn:NumberOfSharesHeldInEachUnit
      contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw"
      decimals="INF"
      id="Narr_ltcsZJimy0KNy9JbjkhLlw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1</limn:NumberOfSharesHeldInEachUnit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw"
      decimals="INF"
      id="Narr_9pZCqRynuEm4Rh-oH6kQ2Q"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <limn:CommonStockConversionRatioBusinessCombination
      contextRef="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_cgSRAUkHA0i2y04jy71KAw"
      decimals="0"
      id="Narr_9CGn_H913kia9PtzsuLKmw"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">1</limn:CommonStockConversionRatioBusinessCombination>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_cgSRAUkHA0i2y04jy71KAw"
      decimals="INF"
      id="Narr_6uwY1daGmkWggXZs5z3cLg"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_us-gaap_ClassOfWarrantOrRightAxis_limn_NonRedeemableWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_ZG-LffBZq0OabS0uAuJI-Q"
      decimals="INF"
      id="Narr__p9SgWwt_UOx10zee2Dtag"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_us-gaap_ClassOfWarrantOrRightAxis_limn_NonRedeemableWarrantMember_xHQZeSCsiEGkdYLlyBZaXA"
      decimals="2"
      id="Narr_slmlpEdzIkqeRtd9Tfb_JQ"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <limn:SharesAuthorized
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="INF"
      id="Narr_Aka-xSt4YkCBNGWBJs9Nkg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">501000000</limn:SharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="INF"
      id="Narr_SfciC4M0CkGD2BIPnvMY3Q"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="INF"
      id="Narr__d3U-bg9UUG8umMw1aYKOg"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="INF"
      id="Narr_BpGciHFGZEeO0WSvgcOQLg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="INF"
      id="Narr_G2AEfyqCnkGE-kOo7kiZXQ"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Gi0t5_gUYU-FQON95jjxrA"
      decimals="INF"
      id="Narr_W9l0HTbo4kyrcV2JHgjCeA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">7014633</us-gaap:ConversionOfStockSharesConverted1>
    <limn:ConversionOfStockOrUnitConversionRatio
      contextRef="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_zu3KxzCVkkuK5CuyZXWLYA"
      decimals="0"
      id="Narr_ZKdhJzl-oEmfVpVRQrAV-w"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">1</limn:ConversionOfStockOrUnitConversionRatio>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Gi0t5_gUYU-FQON95jjxrA"
      decimals="INF"
      id="Narr_arTZ7IdWOEi1aSX9nrEnrQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">7014633</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionHoldingsLlcMember_HNZDVq5GE0GEgfHcGTUA1A"
      decimals="INF"
      id="Narr_6egYqLsV_UGlBZjthm8vRw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">6900000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_aADDeFhV70K5BS2735863Q"
      decimals="INF"
      id="Narr_Nm_MhVTdn06SJUIjoE518g"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">114633</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ"
      decimals="INF"
      id="Narr_z8b5svoZ20G3nsK282YqMg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ"
      decimals="0"
      id="Narr_y9iG2hn23U6a7BefO3WrVA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">15000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ"
      decimals="0"
      id="Narr_la7dQlbNSUKR_GfFtkg4Cg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">10556500</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <limn:ProceedsFromIssuanceOfPrivatePlacementInvestor
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ"
      decimals="0"
      id="Narr_uZ-aBlxQfEuiBsvLHCYwEA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7129500</limn:ProceedsFromIssuanceOfPrivatePlacementInvestor>
    <limn:ProceedsFromIssuanceOfPrivatePlacementInvestorFunded
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ"
      decimals="0"
      id="Narr_krTV0uUk802xisscLiRwiA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3427000</limn:ProceedsFromIssuanceOfPrivatePlacementInvestorFunded>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ"
      decimals="0"
      id="Narr_Mrfb0VhrMkud7Exjn01dhg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3427000</us-gaap:DebtConversionOriginalDebtAmount1>
    <limn:PrincipalAndAccruedInterestOnPrivatePlacement
      contextRef="As_Of_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VYxJe3-ZlEKGtf77rNoRJQ"
      decimals="0"
      id="Narr_DjblYAK4vkm6EmecRKMrrw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3316756</limn:PrincipalAndAccruedInterestOnPrivatePlacement>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ConsortiumLoanOfRelatedPartiesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4nTHRjjm9E64EIS8-8O57A"
      decimals="0"
      id="Narr_uYxfg7kKtUSQMWw3nKWo8Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4443500</us-gaap:DebtConversionOriginalDebtAmount1>
    <limn:RelatedPartiesDebtToUnsecuredPromissoryNote
      contextRef="As_Of_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VYxJe3-ZlEKGtf77rNoRJQ"
      decimals="0"
      id="Narr_Fkv_pNPmykiY-6H1gd6q1Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4443500</limn:RelatedPartiesDebtToUnsecuredPromissoryNote>
    <limn:UnsecuredPromissoryNoteSettledAndConverted
      contextRef="As_Of_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VYxJe3-ZlEKGtf77rNoRJQ"
      decimals="0"
      id="Narr_XPaRX8Wu8kOKyHNCsf39Eg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4443500</limn:UnsecuredPromissoryNoteSettledAndConverted>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_4_30_2025_To_4_30_2025_9PPk1IhN6EmJm5MGsGwEDA"
      decimals="INF"
      id="Narr_4JXWb_1aDEGIqYuj6lNMmQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">112222220</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_4_30_2025_To_4_30_2025_9PPk1IhN6EmJm5MGsGwEDA"
      decimals="INF"
      id="Narr_KsFIyEetNEG52ZL3ljjB2Q"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">17500000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_4_30_2025_To_4_30_2025_9PPk1IhN6EmJm5MGsGwEDA"
      decimals="INF"
      id="Narr_tmNHc-YBf026JGYIFXlzBA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">17500000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_gsYeVbSjA0ijBUxcCNZtvA"
      decimals="INF"
      id="Narr_qQgqIdXqkky5UnzuI4JECQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">4000000</us-gaap:ConversionOfStockSharesIssued1>
    <limn:ConversionOfPrincipalAndAccruedInterestAmount
      contextRef="As_Of_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxAndCarTcellkorMember_IRaHwKWzMU-DElAHyQN8Tg"
      decimals="0"
      id="Narr_uifkfOU9M0ScK3jnaGhR3g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">11481146</limn:ConversionOfPrincipalAndAccruedInterestAmount>
    <limn:ConversionOfPrincipalAndAccruedInterestShares
      contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxAndCarTcellkorMember_zWurOUpaU0i-IKmnDLLc4w"
      decimals="INF"
      id="Narr_vcKS9zx7aUm8K-YWtD7tNg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">9999999</limn:ConversionOfPrincipalAndAccruedInterestShares>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_gsYeVbSjA0ijBUxcCNZtvA"
      decimals="INF"
      id="Narr_GP5l7pbcpk6BXbWxlblhiw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">4000000</us-gaap:ConversionOfStockSharesIssued1>
    <limn:ConversionOfStockOrUnitConversionRatio
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="4"
      id="Narr_nM8qkd6JGU2E2jCjjkKSsQ"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.1559</limn:ConversionOfStockOrUnitConversionRatio>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_qUlxIbYw4Uyvh13v3JGs3g"
      decimals="0"
      id="Narr_vtk8fyDYr0aASz3lTZb5WQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">10694604</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_aADDeFhV70K5BS2735863Q"
      decimals="0"
      id="Narr_nJGv7dEai0OhnAerXM1h9Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1518381</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_aADDeFhV70K5BS2735863Q"
      decimals="0"
      id="Narr_E1unWltgs0OQGB4reQabGw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">14797901</us-gaap:DebtConversionOriginalDebtAmount1>
    <limn:PrincipalAndAccruedInterestOnPrivatePlacement
      contextRef="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_qUlxIbYw4Uyvh13v3JGs3g"
      decimals="0"
      id="Narr_jlBhur8tEE23DGiJp_iUpw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3316756</limn:PrincipalAndAccruedInterestOnPrivatePlacement>
    <limn:ConversionOfPrincipalAndAccruedInterestAmount
      contextRef="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_qUlxIbYw4Uyvh13v3JGs3g"
      decimals="0"
      id="Narr_rGSKKKSHB0C4NRZsZOnU6Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">11481146</limn:ConversionOfPrincipalAndAccruedInterestAmount>
    <limn:ConversionOfAccruedInterestOnRelatedPartyDebts
      contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_aADDeFhV70K5BS2735863Q"
      decimals="0"
      id="Narr_qAfjG3CqMEi3NNn33M2MIg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">169201</limn:ConversionOfAccruedInterestOnRelatedPartyDebts>
    <limn:DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="0"
      id="Narr_oM5qLvua-E6lUSUrAXzTPw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7000000</limn:DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination>
    <limn:StockIssuableForSettlementOfDeferredUnderwritingFees
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="INF"
      id="Narr_91Y1GF8Um06UT2IKLaMu1g"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">700000</limn:StockIssuableForSettlementOfDeferredUnderwritingFees>
    <limn:LiabilityOfUnderwritingFeesFairValue
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="0"
      id="Narr_hl50AZVXu0-WTNVzIaoLGQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7049000</limn:LiabilityOfUnderwritingFeesFairValue>
    <limn:FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees
      contextRef="As_Of_7_1_2025_CZJvPOCOcUySCDRAwOkqBA"
      decimals="0"
      id="Narr_SCV6cLfAPkmMrF8BC1XSyA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7245000</limn:FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_8Eb_-va_j0mdcFrq6b8KwQ"
      decimals="INF"
      id="Narr_SVJt5tV4D0i6H5Lz23wmXQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">8270000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <limn:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_ggP8Qf9lAEK8UwvoEQkLpw"
      decimals="INF"
      id="Narr_XQWkQKqkPUGIHTYmgfmcTA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">5543000</limn:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_U70qipalZUSb0nCwfCrzfg"
      decimals="INF"
      id="Narr_28d98P08kUavW1riZr0SIw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">5543000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <limn:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_rUeXM1hqFEmNCkHtxT9MOQ"
      decimals="INF"
      id="Narr_WrjkfeJc0UeAM7VFEYDv4w"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">13813000</limn:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_Gx1dPATNHkOGW-Snv4cHLg"
      decimals="INF"
      id="Narr_1T2B1mY_GkurvcSEFQebtA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">20719500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_AjxQK7FsCE6Ub2hVGkXXEA"
      decimals="2"
      id="Narr_OjOJ2tTM5ES-CPDBr5_HLA"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.29</us-gaap:SharesIssuedPricePerShare>
    <limn:ClassOfWarrantOrRightIssuePricePerWarrant
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_U70qipalZUSb0nCwfCrzfg"
      decimals="4"
      id="Narr_uWsWGi9O5U6CPsFzaDh4QA"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.2899</limn:ClassOfWarrantOrRightIssuePricePerWarrant>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_8Eb_-va_j0mdcFrq6b8KwQ"
      decimals="-4"
      id="Narr_kAwQ-ZPswU-2ZjRQBFpJrw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3440000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_1ZmaX6FlIkeWdeKISX-IUw"
      decimals="4"
      id="Narr_XlG8ks_a0EGn_QepYgM4NA"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_1ZmaX6FlIkeWdeKISX-IUw"
      decimals="INF"
      id="Narr_jLOg6Xv88EqnuWFVdbjJlg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_ZDd5yizsikO5sTlcUH09FA"
      decimals="2"
      id="Narr_zBaRb9gUB0C3pLIvWwBCAg"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.29</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_ZDd5yizsikO5sTlcUH09FA"
      id="Narr_9DYNbAySaEaPZMpiAOjV3A">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <limn:PeriodOfNonIssuanceOfCommonStockFollowingClosingDate
      contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_yl8JpI15U0KUQtNmfOFI3w"
      id="Narr_CECoCqo81kWQ_AGC4SHavA">P180D</limn:PeriodOfNonIssuanceOfCommonStockFollowingClosingDate>
    <limn:PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate
      contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_yl8JpI15U0KUQtNmfOFI3w"
      id="Narr_LAm01GWQO0Wouq4uLbc87w">P180D</limn:PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate>
    <limn:PlacementAgentCashFeePercentage
      contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_yl8JpI15U0KUQtNmfOFI3w"
      decimals="3"
      id="Narr_1jswrHC95kS67yldPcRp4w"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.08</limn:PlacementAgentCashFeePercentage>
    <limn:MaximumReimbursementForPlacementAgentExpenses
      contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_yl8JpI15U0KUQtNmfOFI3w"
      decimals="0"
      id="Narr_WuAF68UOr0mvr_k4W75b8Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">100000</limn:MaximumReimbursementForPlacementAgentExpenses>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_BhVP8T9QzU6thchw3BBoLA"
      decimals="INF"
      id="Narr_PdgPJZRfH0GrJOLldi6fyQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">690650</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <limn:PercentOfSharesIssuedInOffering
      contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_xU41UBVWPEGgrfXyxay-nw"
      decimals="3"
      id="Narr_M40AF1qRK0-Y_XlkcpARqQ"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.05</limn:PercentOfSharesIssuedInOffering>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_Ky__aiunWkee6a2CP8ZTOQ"
      decimals="3"
      id="Narr_OVcI5K4LWU2Lfe-ONMR04g"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.319</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <limn:PercentOfOfferingPriceRepresentingExercisePrice
      contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_xU41UBVWPEGgrfXyxay-nw"
      decimals="2"
      id="Narr_sYfTTjYC80uofC_G1UUwqQ"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">1.10</limn:PercentOfOfferingPriceRepresentingExercisePrice>
    <us-gaap:Cash
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Narr_Wxt0bdt1yU2kaWPRyZR4Bg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1907674</us-gaap:Cash>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Narr_z5PT4xUZ6ESn_2xJ7hOBpQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1442500</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Narr_RhAKI5FVZUGND4zGEIg-5A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1442500</us-gaap:ShortTermBorrowings>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Narr_CMf8HilIF0KGWCJv0zAToA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-39995447</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Narr_iGHIPWyijkGpZgigmmvbZg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-1100898</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Narr_9Zof4swf4UK0icW7PxTPCw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-1123714</us-gaap:NetIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Narr_IdxI2EgaDEK0txsximDrgw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-264220</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Narr_nHT3oy1Fo0qCL-P3ZgH8vw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-327526</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_8Eb_-va_j0mdcFrq6b8KwQ"
      decimals="INF"
      id="Narr_tSayoiZ6j0Wed_1XAUizDQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">8270000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <limn:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_ggP8Qf9lAEK8UwvoEQkLpw"
      decimals="INF"
      id="Narr_lHT2tCFwrU2tEc1bjoTwbQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">5543000</limn:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_U70qipalZUSb0nCwfCrzfg"
      decimals="INF"
      id="Narr_XpkjdR8f7Um1hpe50xjh9g"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">5543000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <limn:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_rUeXM1hqFEmNCkHtxT9MOQ"
      decimals="INF"
      id="Narr_1PFzZPQ14E-hcxSUy0EutQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">13813000</limn:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_Gx1dPATNHkOGW-Snv4cHLg"
      decimals="INF"
      id="Narr_betm5r3PwkSCM_gR5Lw3_g"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">20719500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_AjxQK7FsCE6Ub2hVGkXXEA"
      decimals="2"
      id="Narr_ckYtZYDrTU2M1aeHT-dV4g"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.29</us-gaap:SharesIssuedPricePerShare>
    <limn:ClassOfWarrantOrRightIssuePricePerWarrant
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_U70qipalZUSb0nCwfCrzfg"
      decimals="4"
      id="Narr_rWi9HvhjEk-NBMXb_VPyhg"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.2899</limn:ClassOfWarrantOrRightIssuePricePerWarrant>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_8Eb_-va_j0mdcFrq6b8KwQ"
      decimals="-4"
      id="Narr_xi_k3vcORUKXgkDsflzlWg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3440000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_Cv21vD6sjEGGxaQI2ZNJEw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note&#160;2. Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) as determined by the FASB ASC and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). The unaudited condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements do not include all of the disclosures required by U.S. GAAP for annual consolidated financial statements and should be read in conjunction with the audited consolidated financial statements of the Company as of and for the year ended December 31, 2025 (the &#x201c;Annual Financial Statements&#x201d;). In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary to fairly present its financial position as of March 31, 2026, its results of operations for the three months ended March 31, 2026 and 2025, its cash flows for the three months ended March 31, 2026 and 2025, and its changes in stockholders&#x2019; deficit for the three months ended March 31, 2026 and 2025. Results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year ending December 31, 2026 or any future period. The condensed consolidated balance sheet as of December 31, 2025 was derived from the Annual Financial Statements but does not contain all of the footnote disclosures from the Annual Financial Statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;After the closing of the Business Combination, the Company has elected to be an &#x201c;emerging growth company,&#x201d; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s unaudited condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results may differ materially and adversely from these estimates. The Company is not aware of any significant estimates that required management to exercise significant judgment with the exception of the Company&#x2019;s warrant liability and research and development costs. If the underlying estimates and assumptions upon which the estimates are based change in the future, actual amounts may differ from those included in the Company&#x2019;s unaudited condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), the Chief Executive Officer, manages the Company&#x2019;s business activities as a &lt;span style="-sec-ix-hidden:Hidden_skpW_fMTs0qgK5TqjOzinQ;"&gt;&lt;span style="-sec-ix-hidden:Hidden_oRglHBbi5kiQPSddjK0rrg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; operating and reportable segment. Accordingly, the Company&#x2019;s CODM uses net income/loss to measure the Company&#x2019;s single segment&#x2019;s performance and allocate resources. Further, the CODM reviews and utilizes functional expenses (general and administrative and research and development) to manage the Company&#x2019;s operations. The Company&#x2019;s general and administrative expenses for the three months ended March 31, 2026 and 2025 included $60,500 and $37,500, respectively, of compensation expenses related to the compensation agreement the Company has executed with its Chief Executive Officer. The remaining general and administrative expenses are related to legal and accounting-related expenses for contractors. The Company&#x2019;s research and development expenses did not include any compensation-related expenses. Other segment items included in net loss are interest expense, related parties and interest income which are reflected in the Company&#x2019;s unaudited condensed consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which can exceed government insured limits. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company did not have any cash equivalents as of March 31, 2026 and December 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial assets and liabilities are accounted for in accordance with FASB ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurements and Disclosures,&lt;/i&gt; which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value hierarchy requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 1 &#x2014; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 2 &#x2014; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the instrument&#x2019;s anticipated life.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 3 &#x2014; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgement. Accordingly, the degree of judgement exercised by management in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the warrant liability reported in the Company&#x2019;s unaudited condensed consolidated balance sheets represent a Level 3 instrument (see Note 8).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying values reported in the Company&#x2019;s unaudited condensed consolidated balance sheets for prepaid expenses and other current assets, due from related party, accounts payable and accrued expenses, accrued interest, short-term debt with related parties, due to related parties and its deferred underwriting fee payable are reasonable estimates of their fair values due to the short-term nature of these items.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in ASC 480, &lt;i style="font-style:italic;"&gt;Distinguishing liabilities from equity&lt;/i&gt; (&#x201c;ASC 480&#x201d;), and ASC 815, &lt;i style="font-style:italic;"&gt;Derivatives and Hedging&lt;/i&gt; (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own common shares and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance, modification, and as of each subsequent quarterly period end date while the warrants are outstanding. As of March 31, 2026, 13,813,000 of the Company&#x2019;s Common Stock Warrants, 690,650 Placement Agent Warrants and 5,094,623 Public Warrants were accounted for as equity-classified instruments and 835,555 private placement warrants were accounted for as liability-classified instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the liability-classified warrants are recognized as a non-cash gain or loss on the accompanying condensed consolidated statements of operations. The Company assesses the classification of its warrants at each reporting date to determine whether a change in classification between equity and liability is required. During the three months ended March 31, 2026, the Company had an unrealized gain on the change in fair value of the warrant liabilities of $4,178. During the three months ended March 31, 2025, the Company had no unrealized gain or loss on the change in fair value of the warrant liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Net Loss per Share of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company complies with accounting and disclosure requirements of ASC Topic 260, &lt;i style="font-style:italic;"&gt;Earnings Per Share&lt;/i&gt;. The Company has one class of common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities if their effect is antidilutive. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined by using the treasury stock method. Dilutive common stock equivalents are comprised of 19,598,273 warrants, comprised of 13,813,000 Common Stock Warrants, 690,650 Placement Agent Warrants and 5,094,623 Public Warrants. For all periods &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;presented, there is no difference in the number of shares used to calculated basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive given that their inclusion would reduce the net loss per share during the three months ended March 31, 2026 and 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development expenses consist of costs incurred by InnoBation Bio Co, Ltd. (&#x201c;Innobation&#x201d;) in accordance with the license agreement with Innobation and are recorded as research and development expenses as incurred (see Note 3).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes its leases in accordance with ASC Topic 842, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; (&#x201c;ASC 842&#x201d;). Under ASC 842, lessees are required to recognize all qualified operating leases at the commencement date including a lease liability, which is a lessee&#x2019;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use (&#x201c;ROU&#x201d;) asset, which is an asset that represents the lessee&#x2019;s right to use, or control the use of, a specified asset for the lease term. The initial lease liability is equal to the future fixed minimum lease payments discounted using the Company&#x2019;s incremental borrowing rate, on a secured basis. The lease term includes option renewal periods and early termination payments when it is reasonably certain that the Company will exercise those rights. The initial measurement of the ROU asset is equal to the initial lease liability plus any initial direct costs and prepayments, less any lease incentives.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has leased office space for a fixed period of 10 months. In accordance with ASC 842, a short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The short-term lease election can only be made at the commencement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A lessee that makes this accounting policy election does not recognize a lease liability or right-of-use asset on its balance sheets. Instead, the lessee recognizes lease payments on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes in accordance with ASC Topic 740,&#160;&lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt;&#160;(&#x201c;ASC 740&#x201d;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. There were no tax accruals relating to uncertain tax positions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax positions as income tax expense. There were no unrecognized tax positions, and no amounts accrued for interest and penalties as of March 31, 2026 and December 31, 2025. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only &#x201c;major&#x201d; tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. No unrecognized tax benefits were identified as of March 31, 2026 or December 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Pronouncements&#160;&#x2013; Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;On November 4, 2024, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2024-03, &lt;i style="font-style:italic;"&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt; (&#x201c;ASU 2024-03&#x201d;), to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this standard will have on its unaudited condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#x2019;s unaudited condensed consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_jpjbHkXYUkWkk0BmTdKCxQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) as determined by the FASB ASC and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). The unaudited condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements do not include all of the disclosures required by U.S. GAAP for annual consolidated financial statements and should be read in conjunction with the audited consolidated financial statements of the Company as of and for the year ended December 31, 2025 (the &#x201c;Annual Financial Statements&#x201d;). In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary to fairly present its financial position as of March 31, 2026, its results of operations for the three months ended March 31, 2026 and 2025, its cash flows for the three months ended March 31, 2026 and 2025, and its changes in stockholders&#x2019; deficit for the three months ended March 31, 2026 and 2025. Results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year ending December 31, 2026 or any future period. The condensed consolidated balance sheet as of December 31, 2025 was derived from the Annual Financial Statements but does not contain all of the footnote disclosures from the Annual Financial Statements.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <limn:EmergingGrowthCompanyPolicyPolicyTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_K8kC8d-WekiLU51HvmkBDA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;After the closing of the Business Combination, the Company has elected to be an &#x201c;emerging growth company,&#x201d; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s unaudited condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/p&gt;</limn:EmergingGrowthCompanyPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_3gs5v6L6FE2ITDfzHoz8bw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results may differ materially and adversely from these estimates. The Company is not aware of any significant estimates that required management to exercise significant judgment with the exception of the Company&#x2019;s warrant liability and research and development costs. If the underlying estimates and assumptions upon which the estimates are based change in the future, actual amounts may differ from those included in the Company&#x2019;s unaudited condensed consolidated financial statements.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_VcxpF4YxWkiBDxmM1eaEtg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), the Chief Executive Officer, manages the Company&#x2019;s business activities as a &lt;span style="-sec-ix-hidden:Hidden_skpW_fMTs0qgK5TqjOzinQ;"&gt;&lt;span style="-sec-ix-hidden:Hidden_oRglHBbi5kiQPSddjK0rrg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; operating and reportable segment. Accordingly, the Company&#x2019;s CODM uses net income/loss to measure the Company&#x2019;s single segment&#x2019;s performance and allocate resources. Further, the CODM reviews and utilizes functional expenses (general and administrative and research and development) to manage the Company&#x2019;s operations. The Company&#x2019;s general and administrative expenses for the three months ended March 31, 2026 and 2025 included $60,500 and $37,500, respectively, of compensation expenses related to the compensation agreement the Company has executed with its Chief Executive Officer. The remaining general and administrative expenses are related to legal and accounting-related expenses for contractors. The Company&#x2019;s research and development expenses did not include any compensation-related expenses. Other segment items included in net loss are interest expense, related parties and interest income which are reflected in the Company&#x2019;s unaudited condensed consolidated statements of operations.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <limn:FranchiseTaxExpenseIncludingInterestAndPenalty
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_N4PkFcbsfkOoWh1rhs7g7w"
      decimals="0"
      id="Narr_1e1HtHCaA0G4w3VABocj0w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">60500</limn:FranchiseTaxExpenseIncludingInterestAndPenalty>
    <limn:FranchiseTaxExpenseIncludingInterestAndPenalty
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_eIyVw3ZwBkWNjXiNqU4kaQ"
      decimals="0"
      id="Narr_pEqgzB6UKU2A6NAMHh1IWg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">37500</limn:FranchiseTaxExpenseIncludingInterestAndPenalty>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_CJsW-Q3MhUCDV8Aw7W3Eng">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which can exceed government insured limits. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company did not have any cash equivalents as of March 31, 2026 and December 31, 2025.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Narr_XNHtnk2l406fvsxXiwD-dg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Narr_4N_LqjKH7EafX2IaDpT7WQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_HYsQlLfI8UStfuvudKe8yg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial assets and liabilities are accounted for in accordance with FASB ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurements and Disclosures,&lt;/i&gt; which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value hierarchy requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 1 &#x2014; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 2 &#x2014; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the instrument&#x2019;s anticipated life.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 3 &#x2014; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgement. Accordingly, the degree of judgement exercised by management in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the warrant liability reported in the Company&#x2019;s unaudited condensed consolidated balance sheets represent a Level 3 instrument (see Note 8).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying values reported in the Company&#x2019;s unaudited condensed consolidated balance sheets for prepaid expenses and other current assets, due from related party, accounts payable and accrued expenses, accrued interest, short-term debt with related parties, due to related parties and its deferred underwriting fee payable are reasonable estimates of their fair values due to the short-term nature of these items.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <limn:WarrantsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_Vuy0XL-ohUKj2GUfM8jE2g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in ASC 480, &lt;i style="font-style:italic;"&gt;Distinguishing liabilities from equity&lt;/i&gt; (&#x201c;ASC 480&#x201d;), and ASC 815, &lt;i style="font-style:italic;"&gt;Derivatives and Hedging&lt;/i&gt; (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own common shares and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance, modification, and as of each subsequent quarterly period end date while the warrants are outstanding. As of March 31, 2026, 13,813,000 of the Company&#x2019;s Common Stock Warrants, 690,650 Placement Agent Warrants and 5,094,623 Public Warrants were accounted for as equity-classified instruments and 835,555 private placement warrants were accounted for as liability-classified instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the liability-classified warrants are recognized as a non-cash gain or loss on the accompanying condensed consolidated statements of operations. The Company assesses the classification of its warrants at each reporting date to determine whether a change in classification between equity and liability is required. During the three months ended March 31, 2026, the Company had an unrealized gain on the change in fair value of the warrant liabilities of $4,178. During the three months ended March 31, 2025, the Company had no unrealized gain or loss on the change in fair value of the warrant liabilities.&lt;/p&gt;</limn:WarrantsPolicyPolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_j2wjtBDr30CGi5w2RrtSMw"
      decimals="INF"
      id="Narr_zkoACqTV6ke1qnd0ik8SZA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">13813000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_slm9IzocEkSBb1GZOKqnZA"
      decimals="INF"
      id="Narr_kTBubWANMEidd14CuL-gyg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">690650</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_W2lQ6Gn-NEep1cZ7YVoF1w"
      decimals="INF"
      id="Narr_ysY4nzGAb0-CArS8PiKEfA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">5094623</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PrivatePlacementWarrantsMember_GmwTGx3Js0KBpkdQA1hx1g"
      decimals="INF"
      id="Narr_HvATPzIav0WZOPx9dRh8SQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">835555</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Narr_O9dgxU8-RkSDRiocZLZAog"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4178</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Narr_5uUf_c5hk02q4Y2lEkA4dw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:FairValueAdjustmentOfWarrants>
    <limn:NetIncomeLossPerCommonStockPolicyPolicyTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_GQ8jemrJQ0K0PJPLK8LhcQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Net Loss per Share of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company complies with accounting and disclosure requirements of ASC Topic 260, &lt;i style="font-style:italic;"&gt;Earnings Per Share&lt;/i&gt;. The Company has one class of common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities if their effect is antidilutive. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined by using the treasury stock method. Dilutive common stock equivalents are comprised of 19,598,273 warrants, comprised of 13,813,000 Common Stock Warrants, 690,650 Placement Agent Warrants and 5,094,623 Public Warrants. For all periods &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;presented, there is no difference in the number of shares used to calculated basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive given that their inclusion would reduce the net loss per share during the three months ended March 31, 2026 and 2025.&lt;/p&gt;</limn:NetIncomeLossPerCommonStockPolicyPolicyTextBlock>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="INF"
      id="Narr_3KQQQIowrU2SEdh_P7Nj6A"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">19598273</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_JogJT3JKnkStw7CCF--1Dw"
      decimals="INF"
      id="Narr_Vmok-B0ci0aY08LTQtIwag"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">13813000</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_hUVQhIvVLUiqyQjkyt2gOg"
      decimals="INF"
      id="Narr_dBj08pzWV0ufPIxU_HXUJA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">690650</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z2RJFeIu4keoqDO4x5BOag"
      decimals="INF"
      id="Narr_K0TycdmbXEWKuGslAAFdlg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">5094623</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_Bxib2T68g0-dvUMzXnC9vQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development expenses consist of costs incurred by InnoBation Bio Co, Ltd. (&#x201c;Innobation&#x201d;) in accordance with the license agreement with Innobation and are recorded as research and development expenses as incurred (see Note 3).&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_Ji2xKl1OHU6Og-Vdau9lbw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes its leases in accordance with ASC Topic 842, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; (&#x201c;ASC 842&#x201d;). Under ASC 842, lessees are required to recognize all qualified operating leases at the commencement date including a lease liability, which is a lessee&#x2019;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use (&#x201c;ROU&#x201d;) asset, which is an asset that represents the lessee&#x2019;s right to use, or control the use of, a specified asset for the lease term. The initial lease liability is equal to the future fixed minimum lease payments discounted using the Company&#x2019;s incremental borrowing rate, on a secured basis. The lease term includes option renewal periods and early termination payments when it is reasonably certain that the Company will exercise those rights. The initial measurement of the ROU asset is equal to the initial lease liability plus any initial direct costs and prepayments, less any lease incentives.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has leased office space for a fixed period of 10 months. In accordance with ASC 842, a short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The short-term lease election can only be made at the commencement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A lessee that makes this accounting policy election does not recognize a lease liability or right-of-use asset on its balance sheets. Instead, the lessee recognizes lease payments on a straight-line basis over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      id="Narr_-ERi2eSH8k6nwQ15pvx_Hw">P10M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_udhKWqxKKEyEq21JFF0nTA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes in accordance with ASC Topic 740,&#160;&lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt;&#160;(&#x201c;ASC 740&#x201d;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. There were no tax accruals relating to uncertain tax positions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax positions as income tax expense. There were no unrecognized tax positions, and no amounts accrued for interest and penalties as of March 31, 2026 and December 31, 2025. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only &#x201c;major&#x201d; tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. No unrecognized tax benefits were identified as of March 31, 2026 or December 31, 2025.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Narr_dpAivU4s60OelsKXfTrH-w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Narr_5se4biOpIkCf1trzMvP4FA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Narr_Pt859vU9RUi6rULCZMeM0g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Narr_tC714IOGuEGIam_KeTaA7A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Narr_YUKrZt01BE2pyRWebZArAg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Narr_Owb5T8k4FEKJs9h19NEh9A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Narr_cJ_ZldvURkysrIiPlh_Tng"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_MRkPKkuMUU2oSotPGBShxA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Pronouncements&#160;&#x2013; Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;On November 4, 2024, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2024-03, &lt;i style="font-style:italic;"&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt; (&#x201c;ASU 2024-03&#x201d;), to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this standard will have on its unaudited condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#x2019;s unaudited condensed consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <limn:LicenseAgreementsTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_5A9SSSpMQ0K855oln0rGdg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 3. License Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;CD47 License&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2022, the Company was assigned a license and development agreement, as amended, with InnoBation Bio Co., Ltd. (the &#x201c;CD47 License&#x201d;), whereby, effective March 31, 2023, the Company received an exclusive license to develop and commercialize products for the CD47 immune checkpoint inhibitor to treat solid cancers, and companion diagnostics used to monitor treatment with CD47 products (collectively, &#x201c;CD47 Products&#x201d;), from Curis Biotech Holdings LLC, the parent company of Valetudo, a related party of the Company, in exchange for 78,555,554 of Liminatus&#x2019; Class A member units. The license was recorded at Valetudo&#x2019;s cost basis of zero, and the Company recorded an approximately $800,000 Class A membership interest with an offset to additional paid-in capital on the balance sheets. The Company is obligated to pay all development costs for CD47 Products. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 20, 2026, the Company issued a payment of $1,000,000 to Innobation for the total estimated costs associated with the preparation activities for Phase 1 clinical trials of IBA101, the Company&#x2019;s product candidate. As of March 31, 2026, the Company estimated approximately 40% of the activities were completed. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;As of March 31, 2026 and December 31, 2025, prepaid research and development costs of $600,000 and $0, respectively, are recorded in prepaid and other current assets in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, research and development expense related to the CD47 License was $400,000 and $0, respectively.&lt;/p&gt;</limn:LicenseAgreementsTextBlock>
    <limn:NumberOfUnitsExchangeForLicenseRights
      contextRef="As_Of_10_31_2022_srt_CounterpartyNameAxis_limn_CurisBiotechHoldingsLlcMember_us-gaap_CapitalUnitsByClassAxis_us-gaap_CapitalUnitClassAMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_MfcULb3sYEWNTNOdJMM4Mg"
      decimals="INF"
      id="Narr_DcQrvfjSFES2QFcJauKHIg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">78555554</limn:NumberOfUnitsExchangeForLicenseRights>
    <limn:LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital
      contextRef="As_Of_10_31_2022_srt_CounterpartyNameAxis_limn_CurisBiotechHoldingsLlcMember_us-gaap_CapitalUnitsByClassAxis_us-gaap_CapitalUnitClassAMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_MfcULb3sYEWNTNOdJMM4Mg"
      decimals="0"
      id="Narr_WNr92xUnz0yxmHE3wZZDFA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">800000</limn:LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital>
    <limn:PaymentForCostsAssociatedWithClinicalTrials
      contextRef="Duration_2_20_2026_To_2_20_2026_srt_CounterpartyNameAxis_limn_InnobationBioCoLtdMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_uS2EVzFvKkO1OaU1FG7Fdw"
      decimals="0"
      id="Narr_ICRYwWBDrkGIc-3DC98F0Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1000000</limn:PaymentForCostsAssociatedWithClinicalTrials>
    <limn:EstimatedPercentageOfActivitiesCompleted
      contextRef="As_Of_3_31_2026_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_tzr9osJ2S0C-6yY56Bt5Ug"
      decimals="2"
      id="Narr_jWAX3_EDLUq9Bb80IKgQ2A"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.40</limn:EstimatedPercentageOfActivitiesCompleted>
    <limn:PrepaidResearchAndDevelopmentExpenseCurrent
      contextRef="As_Of_3_31_2026_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_tzr9osJ2S0C-6yY56Bt5Ug"
      decimals="0"
      id="Narr_Bs1FYerfqUediwemUEfctA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">600000</limn:PrepaidResearchAndDevelopmentExpenseCurrent>
    <limn:PrepaidResearchAndDevelopmentExpenseCurrent
      contextRef="As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_tErYwLwjB0maTrnKFX-S_w"
      decimals="0"
      id="Narr_QXsdDNLWhE-WcNwz69yS5A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</limn:PrepaidResearchAndDevelopmentExpenseCurrent>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_XYwkzRP4y0ClnxSz9bnyLw"
      decimals="0"
      id="Narr_-gk1xBWOZ0KDWRNiicYZ-Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_lUoEyYWXh0OCUietIBRj9g"
      decimals="0"
      id="Narr_oV8J7-TkZkqFKeUDWbpVDw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_TPrsIgV8jkiOw9Igf4qC4Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note&#160;4. Related Party Transactions&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Related Party Debt&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Feelux Bonds&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 15, 2018, the Company issued $10,000,000 of bonds to Feelux Co., Ltd., the parent company of Car-Tcellkor, Inc. (&#x201c;Car-Tcellkor&#x201d;) (see below), the only holder of Liminatus&#x2019; Class A member units (the &#x201c;Feelux Bonds&#x201d;). The bonds bear interest at 1% per annum, compounded annually, and were due on October 30, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the issuance of the Feelux Bonds, Liminatus issued 6,666,666 equity-classified warrants to purchase member units at a price of $1.50 per unit, which expired on June 30, 2023. The fair value of the warrants to purchase member units of approximately $6,400,000 was estimated using the option pricing framework on the issuance date. The Company&#x2019;s assumptions included (a) its expected stock volatility of 82.0% based on the historical volatility of a publicly traded set of peer companies, (b) the contractual term of five years, (c) the risk-free interest rate of 2.9% based on the U.S. Treasury yield curve in effect at the time of grant of the award for a five-year contractual term and (d) no expected dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The $10,000,000 of proceeds from the Feelux Bonds were allocated to the bonds and warrants using the relative fair value method resulting in a debt discount for the relative fair value of the warrants of $4,499,142 that was amortized to interest expense over the term of the Feelux Bonds using the effective interest method using an effective interest rate of 21.0%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 30, 2025, upon consummation of the Business Combination, the outstanding principal and accrued interest on the Feelux Bonds, totaling $10,681,146, and 9,999,999 member units of Liminatus were converted into 4,000,000 shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of March 31, 2026 and December 31, 2025, there was no outstanding balance on the Feelux Bonds. As of March 31, 2026 and December 31, 2025, there was no accrued interest on the Feelux Bonds. For the three months ended March 31, 2026 and 2025, the Company recorded $0 and $26,251, respectively, of interest expense in the unaudited condensed consolidated statements of operations for the Feelux Bonds.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Car-Tcellkor Loan&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On May 18, 2019, the Company borrowed $800,000 from its parent at the time of the loan, Car- Tcellkor (the &#x201c;Car-Tcellkor Loan&#x201d;). The Car-Tcellkor Loan does not bear interest and was due on March 18, 2020. In November 2022, the maturity date was extended to May 18, 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $800,000 was forgiven.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of March 31, 2026 and December 31, 2025, there was no outstanding balance on the Car-Tcellkor Loan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Valetudo Loans&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 1, 2022, the Company borrowed $700,000 from Valetudo Therapeutics LLC (&#x201c;Valetudo&#x201d;), a related party of the Company due to having common executives, in conjunction with the repayment of $700,000 of membership interest from a member (the &#x201c;Valetudo Loan&#x201d;). The Valetudo Loan bears no interest and was due on June 1, 2023. On May 1, 2025, the Company paid the outstanding principal balance of $700,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2023, the Company borrowed an additional $300,000 and $200,000 (the &#x201c;Valetudo June 2023 Loans&#x201d;). The Valetudo June 2023 Loans bear no interest and were due in December 2023. On May 1, 2025, the Company paid $300,000 of the outstanding principal balance on the Valetudo June 2023 Loans.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In July 2023, the Company borrowed an additional $250,000 (the &#x201c;Valetudo July 2023 Loan&#x201d;). The Valetudo July 2023 Loan bears interest at 6% per annum and was due on January 9, 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2023, the Company borrowed an additional $250,000 and $150,000 (the &#x201c;Valetudo August 2023 Loans&#x201d;). The Valetudo August 2023 Loans each bear interest at 6% interest per annum and were due on January 31, 2024 and February 2, 2024, respectively. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $400,000, along with accrued interest, of the Valetudo August 2023 Loans was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2023, the Company borrowed an additional $200,000 (the &#x201c;Valetudo November 2023 Loan&#x201d;). The Valetudo November 2023 Loan bears interest at 6% per annum and was due on January 26, 2024. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $200,000, along with accrued interest, on the Valetudo November 2023 Loan was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2024, the Company borrowed an additional $600,000 and $150,000 (the &#x201c;Valetudo January 2024 Loans&#x201d;). The Valetudo January 2024 Loans each bear interest at 6% per annum and were due on February 28, 2024. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $750,000, along with accrued interest, of the Valetudo August 2023 Loans was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of March 31, 2026 and December 31, 2025, the loans from Valetudo of $450,000 are recorded in short-term debt, related parties in the unaudited condensed consolidated balance sheets (see Note 5). As of March 31, 2026 and December 31, 2025, the related accrued interest of the loans from Valetudo was $117,058 and $113,308, respectively, and is included in accrued interest, related parties in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, interest expense related to the Valetudo loans was $3,750 and $24,000, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Please refer to Note 5 for discussion related to notes which have passed their maturity dates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Ewon Loans&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 12, 2022, the Company borrowed $5,000,000 from Ewon Comfortech Co., Ltd. (&#x201c;Ewon&#x201d;), a member and related party of the Company (the &#x201c;Ewon Loan&#x201d;). The Ewon Loan bears interest at 2% per annum and was due on December 12, 2023, which may be extended one year upon mutual agreement of the parties, or upon failure to close the Business Combination. In February 2023, the Company repaid $1,000,000 of the short-term loan. In March 2023, the Company repaid an additional $2,000,000 of the loan. On April 30, 2025, upon consummation of the Business Combination, $2,000,000, along with accrued interest, of the Ewon Loan was converted into common stock of the Company. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 10, 2023, the Company entered into a loan agreement to borrow $200,000 from Ewon (&#x201c;Ewon September 2023 Loan&#x201d;). The Ewon September 2023 Loan bears interest of 2% per annum and was due on September 9, 2024, which may be extended one year upon mutual agreement of the parties, or upon failure to close the Business Combination. On April 30, 2025, upon consummation of the Business Combination, $200,000, along with accrued interest, of the Ewon September 2023 Loan was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 19, 2023, the Company and Ewon entered into an additional loan agreement and the Company borrowed $1,000,000 (the &#x201c;Ewon December 2023 Loan&#x201d;). The Ewon December 2023 Loan bears no interest. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $1,000,000, along with accrued interest, of the Ewon December 2023 Loan was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of March 31, 2026 and December 31, 2025, there was no outstanding balance on the Ewon. As of March 31, 2026 and December 31, 2025, there was no accrued interest on the loans from Ewon. For the three months ended March 31, 2026 and 2025, interest expense related to the Ewon loans was $0 and $11,000, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Prophase Loans&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 26, 2024, the Company borrowed an additional $200,000 from Prophase Sciences LLC (&#x201c;Prophase&#x201d;) (the &#x201c;Prophase February 2024 Loan&#x201d;). The loan bears 6% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, $168,500, along with accrued interest, of the Prophase February 2024 Loan was converted into common stock of the Company. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 6, 2024, the Company borrowed an additional $250,000 from Prophase (the &#x201c;Prophase March 2024 Loan&#x201d;). The loan bears 6% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 1, 2024, the Company borrowed an additional $250,000 from Prophase (the &#x201c;Prophase April 2024 Loan&#x201d;). The loan bears 6% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $250,000, along with accrued interest, on the Prophase April 2024 Loan was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In May 2024, the Company borrowed an additional $790,000 from Prophase (the &#x201c;Prophase May 2024 Loans&#x201d;). The loans bear 6% interest per annum. Of the aggregate $790,000 Prophase May 2024 Loans, $270,000 was due on June 1, 2024 and $520,000 was due on July 1, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $550,000, along with accrued interest of the Prophase May 2024 Loans was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In July 2024, the Company borrowed an additional $83,000 from Prophase (the &#x201c;Prophase July 2024 Loans&#x201d;). The loans bear 6% interest per annum. Of the aggregate $83,000 Prophase July 2024 Loans, $30,000 was due on September 14, 2024, $3,000 was due on September 24, 2024 and $50,000 was due on September 29, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2024, the Company borrowed an additional $50,000 from Prophase (the &#x201c;Prophase August 2024 Loans&#x201d;). The loans bear 6% interest per annum. Of the aggregate $50,000 Prophase August 2024 Loans, $30,000 was due on October 12, 2024 and $20,000 was due on October 13, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In February of 2025, the Company borrowed an additional $206,000 from Prophase (the &#x201c;Prophase February 2025 Loan&#x201d;). The Prophase February 2025 Loan bears interest at 6% per annum and was due on April 11, 2025, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $125,000, along with accrued interest, on the Prophase February 2025 Loan was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In March of 2025, the Company borrowed $207,000 from Prophase (the &#x201c;Prophase March 2025 Loan&#x201d;). The Prophase March 2025 Loan bears interest at 6% per annum and was due on June 6, 2025, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $200,000, along with accrued interest, on the Prophase March 2025 Loan was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In April of 2025, the Company borrowed an additional $3,627,000 from Prophase (the &#x201c;Prophase April 2025 Loans&#x201d;). The loans bear 6% interest per annum. Of the aggregate $3,627,000 Prophase April 2025 Loans, $200,000 was due on May 2, 2025, $1,920,120 was due on May 13, 2025 and $1,506,880 was due on May 14, 2025. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $3,627,000, along with accrued interest, on the Prophase April 2025 Loans was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of March 31, 2026 and December 31, 2025, the balance of the Prophase loans is $742,500. As of March 31, 2026 and December 31, 2025, the related accrued interest of the loans from Prophase was $90,421 and $79,283, respectively, and is included in accrued interest, related parties in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, interest expense related to the Prophase Loans was $11,138 and $26,787, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Please refer to Note 5 for discussion related to notes which have passed their maturity dates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Hana Loans&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 1, 2024, the Company borrowed $850,000 from Hana Immunotherapeutics, LLC (&#x201c;Hana&#x201d;), a related party of the Company due to having common executives (the &#x201c;Hana Loans&#x201d;). The Hana Loans bear interest at 6% per annum and were due on September 30, 2024 and October 26, 2024, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $800,000, along with accrued interest, of the Hana Loans was converted into common stock of the Company. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of March 31, 2026 and December 31, 2025, the balance of the Hana Loans is $50,000. As of March 31, 2026 and December 31, 2025, the related accrued interest of the loans from Hana was $2,792 and $2,042, respectively, and is included in accrued interest, related parties in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, interest expense related to the Hana Loans was $750 and $12,750, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Please refer to Note 5 for discussion related to notes which have passed their maturity dates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Amantes Loans&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 1, 2024, the Company borrowed $400,000 from Amantes LLC (&#x201c;Amantes&#x201d;), a related party of the Company due to having common executives, pursuant to a loan agreement between the Company and Amantes (the &#x201c;Amantes Loan&#x201d;). On November 27, 2024, the Company borrowed an additional $300,000 from Amantes (the &#x201c;Additional Amantes Loan&#x201d;) (together with the Amantes Loan, the &#x201c;Amantes November 2024 Loans&#x201d;). The Amantes November 2024 Loans bear interest at 6% per annum and are due on January 1, 2025. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $550,000, along with accrued interest, on the Amantes November 2024 Loans was converted into common stock of the Company. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 2, 2025 and January 23, 2025, the Company borrowed a total of $300,000 from Amantes, pursuant to loan agreements between the Company and Amantes (the &#x201c;Amantes January 2025 Loans&#x201d;). The Amantes January 2025 Loans bear interest at 6% per annum and are due on March 1, 2025 and March 22, 2025, respectively, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $250,000, along with accrued interest, on the Amantes January 2025 Loans was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of March 31, 2026 and December 31, 2025, the balance of the Amantes Loans is $200,000. As of March 31, 2026 and December 31, 2025, the related accrued interest of the loans from Amantes was $12,287 and $9,288, respectively, and is included in accrued interest, related parties in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2026 and 2025, interest expense related to the Amantes Loans was $3,000 and $14,724, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Please refer to Note 5 for discussion related to notes which have passed their maturity dates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Due to Related Party&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;As of March 31, 2026 and December 31, 2025, the Company has $194,587 and $209,586, respectively, due to the Company&#x2019;s executive team for compensation under their employment agreements. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ"
      decimals="0"
      id="Narr_XYdF0lVEFESS_UvcwZiLjA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">10000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ"
      decimals="2"
      id="Narr_Kva8nxlRY0aokyNftL7hzw"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ"
      decimals="INF"
      id="Narr_gTUs_al0JkWAK9z3Rsbeaw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">6666666</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ"
      decimals="2"
      id="Narr_2Mp-jh0w00iKDFgBkZtZnA"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">1.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ"
      decimals="0"
      id="Narr_DWf8xdNq8U-dWCfCXd5l9g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">6400000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NcxMLUOjV0-W98TcYBomsA"
      decimals="3"
      id="Narr_r2W6uh4PhUaxG7nE6HL0Lw"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.82</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ"
      id="Narr_21BjYfzV9U22bKJDD4GooA">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GUMRHws20E-hQftGj0JvTA"
      decimals="3"
      id="Narr_4Hkdfe51-E22wEA-tlhmJw"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.029</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ"
      id="Narr_DPXQtLR5zk2mYtTgXei1Yw">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gZkGDq_I9UKTee9n9IgYZw"
      decimals="0"
      id="Narr_aq0hr6Egp0Sy5zwNZChEJQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="Duration_9_15_2018_To_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Ue0f9e9AF0CCuPCxkaHeGw"
      decimals="0"
      id="Narr_DB5KX_JXE0GeXqRWgPbjUA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">10000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ"
      decimals="0"
      id="Narr_NqaHX5pH_ECLjKkEsEOHFw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4499142</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ"
      decimals="3"
      id="Narr_pl5_iam_oUOp7GF9NNsOIw"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.21</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_AHn-E6mSh0WMg57djpR6sA"
      decimals="0"
      id="Narr_Pg50N8rWuU6PrOOxJCJXzA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">10681146</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_nnP7Qz9VeUGy0wjX4yxcQA"
      decimals="INF"
      id="Narr_yHkWLX067UKYB9nBzN_LXw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">9999999</us-gaap:ConversionOfStockSharesConverted1>
    <limn:StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits
      contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_nnP7Qz9VeUGy0wjX4yxcQA"
      decimals="INF"
      id="Narr_FDWNKR7aBUS0-NhjiepL7Q"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">4000000</limn:StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tBg1QKOCjkulRGKkllXaGg"
      decimals="0"
      id="Narr_cNmA1YAJvEiSxt-TiBEs5w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UCZY1ZeR3UG6JVOXPTBI8g"
      decimals="0"
      id="Narr_Nv2TlbcGuE2ngBxGyNC0_g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:ShortTermBorrowings>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tBg1QKOCjkulRGKkllXaGg"
      decimals="0"
      id="Narr_R6AGOgjwr0ynA5rwg7F32Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</limn:AccruedInterestCurrent>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UCZY1ZeR3UG6JVOXPTBI8g"
      decimals="0"
      id="Narr_XlzxOkg8nk65BW-x-iaQHg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</limn:AccruedInterestCurrent>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2026_To_3_31_2026_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6WgYpfkMwE2wXyUE6YqM6w"
      decimals="0"
      id="Narr_ebTj4gfyTUiChBtyFmHUnQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GRgwbB0go06YmvYSCv-xlQ"
      decimals="0"
      id="Narr_hF7L6WBSuUyuE-XhYHtx3g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">26251</us-gaap:InterestExpenseDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_5_18_2019_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_zVHTzo-UxEy__UArL1VThQ"
      decimals="0"
      id="Narr_3xmnmYpCJEu75pDy91t-QQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">800000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_v60EouUdLUqn8toxvOltkQ"
      decimals="0"
      id="Narr_aU6vCmgSxki6NQJFIRV9ng"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">800000</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_dKxFvloVNESsveu8CClPfw"
      decimals="0"
      id="Narr_IWFURH2ai0uifKqHhDmpow"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wmmbaObSukiDB_4zDCmrgA"
      decimals="0"
      id="Narr_n53EzuMcI0CnUzZVSt1Xeg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_1_2022_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_35Sjj6Gfl0yNGiX5Qt5Qmw"
      decimals="0"
      id="Narr_e1KBb8ppj06NeZcokGOIXg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">700000</us-gaap:ShortTermBorrowings>
    <limn:RepaymentOfMembershipInterest
      contextRef="As_Of_12_1_2022_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_35Sjj6Gfl0yNGiX5Qt5Qmw"
      decimals="0"
      id="Narr_CYpZMpPiskWMcJQdyQlinQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">700000</limn:RepaymentOfMembershipInterest>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="Duration_5_1_2025_To_5_1_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_qNI4ieKD3kSp3GUUyiiVsA"
      decimals="0"
      id="Narr_vTWpxCsWUkuth4-1kKHXyw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">700000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_u39Cd4S7GEqUxTPP5qv_Qg"
      decimals="0"
      id="Narr_wOGCBD3bTEq57IREB4qS_w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">300000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoanTwoMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_uvAg88eC10OdVCXZ0b8E3A"
      decimals="0"
      id="Narr_M3M9MU2kukegaaU9TH_20g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:ShortTermBorrowings>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="Duration_5_1_2025_To_5_1_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Tvb57Yoz8kWjg8oYPKuxig"
      decimals="0"
      id="Narr_MWcm0ixLR0ScC44frg4k-Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">300000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_7_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RoR1eW_fpUmHYmBoFmDg1w"
      decimals="0"
      id="Narr_2sS7p1aOwkmD5x9XS0J4qQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_7_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RoR1eW_fpUmHYmBoFmDg1w"
      decimals="2"
      id="Narr_HFC4z79KtUaYkqSW01Qp-A"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KWt-xK4eN0-5OFBxkx3LGw"
      decimals="0"
      id="Narr_bvvXmgXzG0qnT_rVWDYENA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoanTwoMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_jZaCTxa_V0CXdNygheYPjA"
      decimals="0"
      id="Narr_RE98dmsTYUKPXN6J4S_bMA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">150000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_K45l7DmgQE-CQ-xyraew7w"
      decimals="2"
      id="Narr_UnDgpSlygEufE3KaJLEq-A"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_rDx80SlYbU-El3v0ZF9uAw"
      decimals="0"
      id="Narr_bZCsjEWxOE-nhSB8XXGM1Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">400000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_11_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1Od3S-eoaUCXHX3nnz2htg"
      decimals="0"
      id="Narr_ak_xQeAsK02xiqnwOFk8UA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1Od3S-eoaUCXHX3nnz2htg"
      decimals="2"
      id="Narr_EQedI-bR0Eqy9Mu0ay5uQA"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6Oq29UcKvkeSSN5rpNIW6w"
      decimals="0"
      id="Narr_e9anC9bbr0CF9YDSNiM6vg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_1_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6andgdbpxkqRlyLXl4XDHg"
      decimals="0"
      id="Narr_sOAOA8KoYEm94_3WvSZaDQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">600000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_1_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoanTwoMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_roRuh60jM0eb54g1Pq5hLQ"
      decimals="0"
      id="Narr_lfqp13hlH0m9dHykpCvNCA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">150000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_1_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1AItK1QO2kitXmKJcOl1Fg"
      decimals="2"
      id="Narr_N8-33mQVE0am4JdFRZBEHA"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ZaQ3e71ewUK0aSmJ56rcsw"
      decimals="0"
      id="Narr_DkN0GpGadUq-SLkuibHzhw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">750000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_7OFPS-3HHUK9zZcMTjtGcg"
      decimals="0"
      id="Narr_TGUx8NswwUe9DKr0c-JVDg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">450000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-SnrU4W24kCYErwDqqD2uA"
      decimals="0"
      id="Narr_ClEZkWEaHka-AGTTVtFN_w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">450000</us-gaap:ShortTermBorrowings>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_ValetudoTherapeuticsLlcMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_zN6GYwa30EiLaz5lZyZFBg"
      decimals="0"
      id="Narr_ex6j-4FQiEqFOPgKm2KRXg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">117058</limn:AccruedInterestCurrent>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ValetudoTherapeuticsLlcMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_u2V6Q8F86kqWl2rCR_ZLxg"
      decimals="0"
      id="Narr_t284qDK2f0mSO_f6HfamgA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">113308</limn:AccruedInterestCurrent>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2026_To_3_31_2026_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tviGQUjEIkuzwoMOZhqbEQ"
      decimals="0"
      id="Narr_8vsolhTiaU6rhwsqC5zHpA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3750</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__wyANh8s8EOfWyC9HSPygQ"
      decimals="0"
      id="Narr__zePHhYie0-L63XGM_vWBQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">24000</us-gaap:InterestExpenseDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_12_2022_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RpHDxwA5eU6MNdXkdEU0lg"
      decimals="0"
      id="Narr_s2kYL-NAuki78R7VSU8eIw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">5000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_12_2022_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RpHDxwA5eU6MNdXkdEU0lg"
      decimals="2"
      id="Narr_7d43xHC5R0CNoGkl76pLrg"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="Duration_2_1_2023_To_2_28_2023_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_fyxYB55LcESYXg1VrFa0SQ"
      decimals="0"
      id="Narr_wwGI9-o2BkWMeVz119WzzQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1IIHRUTkZkq60Pm0ATLdfg"
      decimals="0"
      id="Narr_0_Sj2tFu1UC5MGrav1EqOA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YHOGjDLmVUK3iyhkoffTvQ"
      decimals="0"
      id="Narr_DPyhA6b2306CnW005MQtvg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2000000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_9_10_2023_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DWdmZjGmCEiRashhGcBpXQ"
      decimals="0"
      id="Narr_4P-pymdYu0Gc4PFB7Iqtdg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_10_2023_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DWdmZjGmCEiRashhGcBpXQ"
      decimals="2"
      id="Narr_j29j2-eL4ECRxL0arbJnaQ"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-A5AQrt620qPuuH6l9tvXw"
      decimals="0"
      id="Narr__w4u0iWPmUqwiaaVxxifwQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_19_2023_us-gaap_DebtInstrumentAxis_limn_EwonDecember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_PobELNhVp0CNZjEIGlpjlg"
      decimals="0"
      id="Narr_Q9sQ4PpRpken9U1Lg-K9CQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_EwonDecember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FAzAi_otIkiuLKLUZIGGZQ"
      decimals="0"
      id="Narr_QTN8F8AoU0iuOICMDbbAQg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1000000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__TXA9F6q8kWE6TNY3k0qkg"
      decimals="0"
      id="Narr_VdBQiika40m499PGZbqvsw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EnLDESj0oUmykTsMHpBM4w"
      decimals="0"
      id="Narr__X1STutWjU-Bl9kYs8TQAQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:ShortTermBorrowings>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_EwonComfortechCoLtdMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_SJg_pgNr3UGbcKPDWHQG5A"
      decimals="0"
      id="Narr_XpAk9ZjROUKfDNrkR7TO1w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</limn:AccruedInterestCurrent>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_EwonComfortechCoLtdMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0bsPPj_X9U-t6aFyc57i1w"
      decimals="0"
      id="Narr_7CRET57AfUCWUea5HBaS6w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</limn:AccruedInterestCurrent>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_JON9ufuZd0Kog8xAC5tcKw"
      decimals="0"
      id="Narr_zwChm1u0oUG6OWJLtl3exA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_uwAdfAZSGEaAVubIisn7qg"
      decimals="0"
      id="Narr_93Y9uxI990awzRvYqWmvTA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">11000</us-gaap:InterestExpenseDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_2_26_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_dMLi4mVbI0mnfUUmfRTl1w"
      decimals="0"
      id="Narr_8S0xJ4KA80-I3L3XN2qDRQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_2_26_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_dMLi4mVbI0mnfUUmfRTl1w"
      decimals="2"
      id="Narr_pxQjg9QKlky2sUsBt6NKGQ"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VgfZxKguUE6IvyhFTK0bgw"
      decimals="0"
      id="Narr_4LWB-R4H8UKcG2KJKksR2Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">168500</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_6_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_U0Xo3fqs00OpXo_SeuDtWg"
      decimals="0"
      id="Narr_22Lc1PEVk0yiv1ESuVf8qw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_6_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_U0Xo3fqs00OpXo_SeuDtWg"
      decimals="2"
      id="Narr__GJ6Jx6UFUOvO5w99SgVnQ"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_4_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KWzMWCDwzEShWHgZreE_vw"
      decimals="0"
      id="Narr_vT2UU33_jEe0x0ydsAaMtQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_4_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KWzMWCDwzEShWHgZreE_vw"
      decimals="2"
      id="Narr_0pb-HwKB_kKIK4JaeXNpPQ"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_WqQ7kEZqMUGKJ2Civ5wmHQ"
      decimals="0"
      id="Narr_abK4PH2raUObwthWJipf7g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_5_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPL1Zq0iyE2-9FTal0qJ5A"
      decimals="0"
      id="Narr_Zr5upumiaE2l9UnhAikhRA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">790000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_5_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPL1Zq0iyE2-9FTal0qJ5A"
      decimals="2"
      id="Narr_KkTsWAMt8UyV7Wlrazbl8Q"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_5_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPL1Zq0iyE2-9FTal0qJ5A"
      decimals="0"
      id="Narr_5C0MoIxGjkSmJ0yPwrcohg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">790000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_6_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VxMZqFXR_UaO5azmVes0dA"
      decimals="0"
      id="Narr_nWQLt2mv9E2ArMbGKe3nRQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">270000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_7_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_mxhubmgnJ06DzAurKf0Uug"
      decimals="0"
      id="Narr_YHNQBhUqH06kO_iAD7yKkA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">520000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_hxqxTUYPkUOVXBEWPh59bw"
      decimals="0"
      id="Narr_8XSTSSjjCUCZG3uG8eeFKA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">550000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_7_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0HW6FGsO8Ei7AXcLtjboyA"
      decimals="0"
      id="Narr_SuYhId-o20OEdVdnLUXM-Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">83000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_7_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0HW6FGsO8Ei7AXcLtjboyA"
      decimals="2"
      id="Narr_wsMIZJKGyUiRkiyc8021PA"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_7_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0HW6FGsO8Ei7AXcLtjboyA"
      decimals="0"
      id="Narr_SKveGhKBZUmNNE6n-yFi3A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">83000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_9_14_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-IXbBujRXkiVzw9mXk784w"
      decimals="0"
      id="Narr_h30pwD3y_ki6DecA1l60vQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">30000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_9_24_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_4Vld9uwuRkuuQHHIzYvKZg"
      decimals="0"
      id="Narr_v2CFLRehQkuuBSz9PkIyjw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_9_29_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_hOP6gIf6X0uZ7Ge6Uhb8yA"
      decimals="0"
      id="Narr_hQAs52Tw70yOp9GdRIiKUA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_8_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wdQAw9pClkqJCJydARCG4g"
      decimals="0"
      id="Narr_D7mkEID0pEqaAeibqEOo3w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wdQAw9pClkqJCJydARCG4g"
      decimals="2"
      id="Narr_ZljR98jFXk-Hhp9ydgpTDQ"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_8_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wdQAw9pClkqJCJydARCG4g"
      decimals="0"
      id="Narr_K7dEax5tOkOGn1iMkSnWXw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_10_12_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NGQDh1rA3UGEJwXQpQqNWA"
      decimals="0"
      id="Narr_uKburhh0G0mJZn9smaJNqg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">30000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_10_13_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DqH0O8M-DkKolyZ-CdcShA"
      decimals="0"
      id="Narr_VdbyY81UfEuEZUsOnnhacA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">20000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_2_28_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Rs3R6YntuECvjfLJCKGrWA"
      decimals="0"
      id="Narr_WNcBEFp_VUWRiNvsjCxniA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">206000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_2_28_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Rs3R6YntuECvjfLJCKGrWA"
      decimals="2"
      id="Narr_xAfpPIySxEO070W5RhQq2Q"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gHk208o8a02buGlMK7GoGA"
      decimals="0"
      id="Narr_SbUkcHpLXk6p_Fin5SKumg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">125000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xe3qXzjS0EC39aN_LENA8g"
      decimals="0"
      id="Narr_aqDAaXunIUmGrt8Znb8LAA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">207000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xe3qXzjS0EC39aN_LENA8g"
      decimals="2"
      id="Narr_IWEfgmS8OkG7rkXbhVhgaQ"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_XNzgVBB9EUSW9XJBeTQYXg"
      decimals="0"
      id="Narr_Cdeg1lc6u0-tooXpOuRsCw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xvNc1S3hqkGpqvsF2_IC5g"
      decimals="0"
      id="Narr_RrtmaP-S80ehoJvOBgLReA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3627000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xvNc1S3hqkGpqvsF2_IC5g"
      decimals="2"
      id="Narr_LSTOo1YUT0K8Ga3wVA7QzA"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xvNc1S3hqkGpqvsF2_IC5g"
      decimals="0"
      id="Narr_G4NtsH3kNEqcVivrKZp1ow"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3627000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_5_2_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GRnA5Kx7-kGf8N58SRLWrw"
      decimals="0"
      id="Narr_va3n2SyN4ke6PlzYF-fDSg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_5_13_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_99oewdhpVEC5wJhe7rhkyQ"
      decimals="0"
      id="Narr_6qJwSZNWb0yi43St3nneWw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1920120</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_5_14_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_176IvMRvuUeNEtEQXDudUQ"
      decimals="0"
      id="Narr_xg9TQ_rqWUWtYeQshv6SJA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1506880</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_MxNDVYopJUCTnAtVRr2BCQ"
      decimals="0"
      id="Narr_6ezx4ggjMkSESv2S70aCew"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3627000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_E0TXzEQ0YEKb3rQzLXh72w"
      decimals="0"
      id="Narr_ktBfCDMTGE2mGk_Exx4EXQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">742500</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Hjob6bfNJ0yH9IccwyqnFw"
      decimals="0"
      id="Narr_-8EVpxZIKkucrSsUAMFpaQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">742500</us-gaap:ShortTermBorrowings>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_E0TXzEQ0YEKb3rQzLXh72w"
      decimals="0"
      id="Narr__fvHL1kqp0e7esLxcdxVow"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">90421</limn:AccruedInterestCurrent>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Hjob6bfNJ0yH9IccwyqnFw"
      decimals="0"
      id="Narr_50mRDJCKbUybPt0IaPjU0w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">79283</limn:AccruedInterestCurrent>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_r1BpvCN0KEySovh0Qns8yA"
      decimals="0"
      id="Narr_nTO_7zWA10q-DvaUfuN4tw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">11138</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NUKGQueFCUK3NV6S4f6neA"
      decimals="0"
      id="Narr_nrhot3ip8EidW3z3O0iedA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">26787</us-gaap:InterestExpenseDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_8_1_2024_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_lO3aHrFMUE2_9b_GTJGSBw"
      decimals="0"
      id="Narr_Qbb6UQI4lUWdSW4lBwANmA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">850000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_1_2024_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_lO3aHrFMUE2_9b_GTJGSBw"
      decimals="2"
      id="Narr_XWGYO0L2u0uXPu_DL3U2qA"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VtKf0F4u50yYAUlGncV4kA"
      decimals="0"
      id="Narr_CEYFydEI3U2xFKLCyah6nw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">800000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Up5NOzVX402q1o88UijPvg"
      decimals="0"
      id="Narr_7sAwDkBuX0elxmmu5bs5vg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0PybUMyl7UupuiSkslBW7Q"
      decimals="0"
      id="Narr_hBOCzzqkiE-A5THp_kEjvQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50000</us-gaap:ShortTermBorrowings>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_HanaImmunotherapeuticsLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_k9NmbfrirkmFjETfcoPvjQ"
      decimals="0"
      id="Narr_xepMDl6K9EOQ26sP1DCBXg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2792</limn:AccruedInterestCurrent>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_HanaImmunotherapeuticsLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_M0xZpqNfSUiePS0rqmBJQQ"
      decimals="0"
      id="Narr_FNqdC5ggV0SCKPGZGhhu8A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2042</limn:AccruedInterestCurrent>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EuwARZ5Gg0yVzO8ExZuY7w"
      decimals="0"
      id="Narr_W-lSIXcitkikRrOFEmz_sA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">750</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_vmR4xWUUp0CvtoWAqoOIRA"
      decimals="0"
      id="Narr_PIohZCPMjESVxd9UKYccMw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">12750</us-gaap:InterestExpenseDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_11_1_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_skGpvhLamkmTX8ZC32NJjg"
      decimals="0"
      id="Narr_vEVTqxNr4EOCEewAyzb43g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">400000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_11_27_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xZbOD6QvXU2eioglXc3B9Q"
      decimals="0"
      id="Narr_9h56o0pl9UeyzdJCuOvzJQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">300000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_27_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xZbOD6QvXU2eioglXc3B9Q"
      decimals="2"
      id="Narr_EYsAQeSX2U2lDFNU38LoBg"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y5QPj6cnBkqxLO8bzZMweA"
      decimals="0"
      id="Narr_ic1k_JJxVEGhjtADKU1Cvg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">550000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_1_2_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UoLTcnkgY0ia4LxmBqWZzA"
      decimals="0"
      id="Narr_8361cvSPKEWoa92hbX8c-Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">300000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_1_23_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPR03tDKjUmpyRyQld8qmA"
      decimals="0"
      id="Narr_MXSD25irSUu45SwtS4iWxg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">300000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_1_2_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UoLTcnkgY0ia4LxmBqWZzA"
      decimals="2"
      id="Narr_XsZypUmbikGl_wfnUaiKQw"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_1_23_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPR03tDKjUmpyRyQld8qmA"
      decimals="2"
      id="Narr_uLpsZ0nTX0SKGVuZqvvU6Q"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_mmocMhxQQE-9TDe7UCuBDQ"
      decimals="0"
      id="Narr_rvUc_vcezkOPt1angijghA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_embE8oVddUqzPD1utl4Z7Q"
      decimals="0"
      id="Narr_XcijagMu2kyMSJ5Y0f6vLQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_s7XNeN2VrkyoKgFvQn08HQ"
      decimals="0"
      id="Narr_bdnWcOrkbkCRSB7Fm6Tr_A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:ShortTermBorrowings>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_AmantesLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YmK0PQG_Ck6qgjUgdZnidg"
      decimals="0"
      id="Narr_wa1adTagIk6vZ2wsHmfK-w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">12287</limn:AccruedInterestCurrent>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_AmantesLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_HgSigzsdAE2ZWAOutjYfWA"
      decimals="0"
      id="Narr_qWl4A-7wzEKH5AyhNsSJ8A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">9288</limn:AccruedInterestCurrent>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_MXaZ3yp_lE6x5RxdHImRoQ"
      decimals="0"
      id="Narr_utj_Ue0T102tPEV3tUCCMg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KyurFw6NFU6DbWNR_JVlJA"
      decimals="0"
      id="Narr_A6P5QdE9AkmWBuOLF59hoQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">14724</us-gaap:InterestExpenseDebt>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_limn_EmploymentAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_AwztCb84TEyTOzqvwRwIZw"
      decimals="0"
      id="Narr_uLQ984m7aU6czZuV0Go13w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">194587</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_limn_EmploymentAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_bhT6iPgTMUSC0cikBkivgg"
      decimals="0"
      id="Narr_od5joPx1ZUmrtNhHCn1fJw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">209586</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_SCcLhxOX_U6ycrLesZCmqg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 5. Debt&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Outstanding debt classified as short-term debt as of March 31, 2026 and December 31, 2025 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"&gt;&lt;tr&gt;&lt;td style="width:225.1pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8.9pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:157.4pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8.85pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:5.85pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:53.25pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8.85pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:7pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:64.8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.44pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:59.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:71.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valetudo June 2023 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valetudo July 2023 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase February 2024 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase March 2024 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase May 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 240,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 240,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase July 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase August 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Hana August 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amantes November 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 150,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 150,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amantes January 2025 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase February 2025 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase March 2025 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Short-term debt, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,442,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,442,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of March 31, 2026 and December 31, 2025, the Company&#x2019;s outstanding debt agreements are all past due and are classified as current in the accompanying unaudited condensed consolidated balance sheets. All of the loans are with related parties (see Note 4). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;As the Company&#x2019;s loans are with related parties, the Company and its related parties have agreed to defer repayment until a time that is mutually agreed upon between the Company and its related parties. Accordingly, none of these notes are considered to be in default.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfShortTermDebtTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_yT-BzAAT6U2vG99-IAIQdQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"&gt;&lt;tr&gt;&lt;td style="width:225.1pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8.9pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:157.4pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8.85pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:5.85pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:53.25pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8.85pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:7pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:64.8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.44pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:59.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:71.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valetudo June 2023 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valetudo July 2023 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase February 2024 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase March 2024 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase May 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 240,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 240,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase July 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase August 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Hana August 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amantes November 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 150,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 150,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amantes January 2025 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase February 2025 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase March 2025 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.49pt;"&gt;&lt;td style="vertical-align:bottom;width:225.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Short-term debt, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:157.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.25pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,442,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,442,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8haIXs4y3EGbc6exykltFw"
      decimals="0"
      id="Tc_sLtNpo0nOkyYKYknVSC9Ww_2_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VlA87RaJeEq06zmKK_H7kg"
      decimals="0"
      id="Tc_Et05T5aI-EmPbM5ZRjw0EQ_2_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YX6lsxQHS0-d9Bt2ThMAkQ"
      decimals="0"
      id="Tc_F1wY3mkaO0m0xGaqf-sY2Q_3_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_eAOXFYGTJk-hpkYZ9yVryA"
      decimals="0"
      id="Tc_zcxa0l2h_0mSm5M1Dat2dQ_3_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DpWp6FQcKk2ToUxk9I8I-w"
      decimals="0"
      id="Tc_32h618HS2kyfmMxjrb2iTQ_4_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">31500</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_9WDN8eHoHUWQK3nMpHkYtQ"
      decimals="0"
      id="Tc_Im9tbBXEbUuwcJp4jkNhNg_4_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">31500</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_A1W50Uj-NUO6hThaQ_OHyw"
      decimals="0"
      id="Tc_Vp2LBPc12UW8cXtpSELGog_5_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tPoEXxTBuEas6Sj74xYwPA"
      decimals="0"
      id="Tc_n8Z6EuJKRUKHYj6gxWlt2w_5_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EBIJxgFtuUu-6zOIAkmcqw"
      decimals="0"
      id="Tc_n9rT4iqYXEeHG3j6sz86nQ_6_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">240000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ay2QMWFbV0SdpGM1KxxUJw"
      decimals="0"
      id="Tc_Ebpa1ikHPkqeiDclGs8JoA_6_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">240000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NWZ-m0WBA0qJ23vP65-HJw"
      decimals="0"
      id="Tc_JyRIJXh1E0K8AIQrdB7-jA_7_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">83000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Wgs8NC0FrEu0hK8Qjljnog"
      decimals="0"
      id="Tc_HGMeP-g-pEC39zVvHHbruw_7_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">83000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3iko9KeMAkGp5regWs_4Nw"
      decimals="0"
      id="Tc_DcX8YRL-DESCtdaYdJYbFg_8_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__dCVK3BY3EeDKZi28xUkew"
      decimals="0"
      id="Tc_pgs346P8e0q7Kb6FBOTLNw_8_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_bIvWOEL1hEqZwZYGgrwYpQ"
      decimals="0"
      id="Tc_pLNXol3CqUKUCBogLvKnxg_9_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NQoRaZtKZUCGus-3AHoDuQ"
      decimals="0"
      id="Tc_2_yZ4wapEEGDQLgtasD_9A_9_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8q0dzuwVGEShgTwjOwX7bQ"
      decimals="0"
      id="Tc_TaI4HVWTp0-msS-j_Vq9HA_10_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">150000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_j5CQtBVz5UqKzenH5qp4Pg"
      decimals="0"
      id="Tc_E5kDailJXkiSspPZp7Lrzg_10_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">150000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_HiTcUoWDTEqyHvNgB9TCRA"
      decimals="0"
      id="Tc_XyjRf9kwgEmfEc6T1BOT9g_11_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_vlYz7WYM0065Rv0yQrEanA"
      decimals="0"
      id="Tc_lpXb5xU8v0SMQe_sfE7Utw_11_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_vHGFMJf22kGulBghrO3_RQ"
      decimals="0"
      id="Tc_ttnkvxr3xkCQoSd4cU8Nng_12_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">81000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YhVm-9q0AUSPz-vllz68rg"
      decimals="0"
      id="Tc_q6gP_Dl13EKXhU9FpQLcwQ_12_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">81000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_89RhalbceUGFHBdneVrdYg"
      decimals="0"
      id="Tc_eQvmd8N0S0qvF3HnnmkV0w_13_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tu28ZL0W00ydtm8NRLecmQ"
      decimals="0"
      id="Tc_qqaV4sP7hkGzHVOlOxZrqA_13_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2026_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y6Lx3mXqwk-nBkJ5KlLBYg"
      decimals="0"
      id="Tc_yxlJpXE940WlFUGnglx8EA_15_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1442500</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FbpcEF3_bUqHFwpcC9Wy4w"
      decimals="0"
      id="Tc_XYqETaY88EWZ89vLwkyRcg_15_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1442500</us-gaap:ShortTermBorrowings>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_3-kGuOJTVkuLxAMIgd-S7A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 6. Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Business Company, the Company&#x2019;s certificate of incorporation was amended and restated to designate two classes of stock; preferred and common stock. The certificate of incorporation authorized 1,000,000 shares of preferred stock and 500,000,000 shares of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Preferred Stock&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s Amended and Restated Certificate of Incorporation provides the Company&#x2019;s board of directors with the authority to issue up to 1,000,000 shares of $0.0001 par value preferred stock in one or more series and to establish from time to time the number of shares to be included in each such series, by adopting a resolution and filing a certification of designations. Voting powers, designations, powers, preferences and relative, participating, optional, special and other rights will be stated and expressed in such resolutions. There were zero preferred shares outstanding as of March 31, 2026 and December 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Common Stock&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is authorized to issue 500,000,000 shares of common stock, with a par value of $0.0001 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 16, 2025, the Company entered into a settlement and release agreement with Alta Partners, LLC (&#x201c;Alta&#x201d;), pursuant to which the Company agreed to issue 350,000 shares of its common stock to Alta in exchange for the surrender and cancellation of 1,000,000 Public Warrants held by Alta. On July 16, 2025, the common stock issued to Alta and Public Warrants surrendered by Alta had a fair value of $1,890,000 and $150,000, respectively. As a result of the exchange, the Company recognized a loss of $1,740,000 on the difference in fair value between the common stock and Public Warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 30, 2025, the Company settled Iris&#x2019; liabilities for $7,000,000 of the deferred underwriting fees incurred prior to the Closing Date for 700,000 shares of common stock to the underwriters in Iris&#x2019;s initial public offering. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $7,245,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 6, 2026, the Company entered into a settlement and release agreement with the Holder (as defined in Note 7), pursuant to which the Company agreed to issue 4,000,000 shares of its common stock to the Holder in exchange for the surrender and cancellation of 805,377 warrants to purchase shares of common stock held by the Holder. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 18, 2026, the Company completed a &#x201c;best efforts&#x201d; public offering of (i) 8,270,000 shares of its common stock, (ii) 5,543,000 Pre-Funded Warrants to purchase up to 5,543,000 shares of common stock and (ii) 13,813,000 Common Stock Warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per Pre-Funded Warrant) and accompanying warrant. Immediately upon closing of the Offering, 4,281,000 Pre-Funded Warrants were exercised and converted into 4,281,000 shares of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company allocated the Offering proceeds between the common stock, Pre-Funded Warrants, Common Stock Warrants and Placement Agent Warrants based on their relative fair values in accordance with ASC 505, &lt;i style="font-style:italic;"&gt;Equity&lt;/i&gt;. The fair value of the common stock and Pre-Funded Warrants was based on the Company&#x2019;s closing stock price on the closing date of $0.2449 per share. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of the Common Stock Warrants and Placement Agent Warrants was estimated using a Black-Scholes option pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"&gt;&lt;tr&gt;&lt;td style="width:369.05pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:10pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:44.6pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8.35pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:369.05pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:369.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 92.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:369.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:369.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:369.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected life of warrants (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Offering proceeds and related issuance costs were allocated to the common stock, Pre-Funded Warrants, Common Stock Warrants and Placement Agent Warrants as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"&gt;&lt;tr&gt;&lt;td style="width:259.65pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:52.7pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8.05pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:50.04pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8.05pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:45.5pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.24pt;"&gt;&lt;td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Allocated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Allocated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Allocated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.49pt;"&gt;&lt;td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&#160;Proceeds&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuance&#160;Costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&#160;Proceeds&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.79pt;"&gt;&lt;td style="vertical-align:bottom;width:259.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,208,186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 168,891&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,039,295&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common Stock Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,977,998&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 276,502&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,701,497&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:259.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pre-Funded Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 755,014&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 649,471&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.79pt;"&gt;&lt;td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Placement Agent Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 64,572&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,546&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.54pt;"&gt;&lt;td style="vertical-align:bottom;width:259.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,005,770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 559,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,445,808&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The amount allocated to the common stock and Pre-Funded Warrants was recorded in common stock at par value and the excess over par value in additional paid-in capital in the accompanying unaudited condensed consolidated balance sheet as of March 31, 2026. The amounts allocated to the Common Stock Warrants and Placement Agent Warrants were recorded in additional paid-in capital as the Common Stock Warrants and Placement Agent Warrants are equity-classified instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Issuance costs, including placement agent fees, legal fees and accountant related expenses were recorded as reduction to additional paid-in capital in proportion to the allocation of proceeds between the equity instruments issued, as summarized above.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 19, 2026, the remaining 1,262,000 Pre-Funded Warrants were exercised and converted into 1,262,000 shares of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of March 31, 2026 and December 31, 2025, there were 44,877,633 and 27,064,633 shares of common stock issued and outstanding, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Holders of the Company&#x2019;s common stock are entitled to one vote for each share held of record, on all matters submitted to a vote of stockholders. Additionally, holders of common stock have dividend rights, in the event of a declared dividend declared by the Company&#x2019;s Board of Directors, and liquidation rights, in the event of an involuntary or voluntary event of liquidation that allow for the Company&#x2019;s common stockholders to receive all remaining assets of the Company, after payments of debts and other liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Warrants&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;As of March 31, 2026, 5,094,623 Public Warrants and 835,555 private placement warrants (together, the &#x201c;Warrants&#x201d;) were outstanding. Each Warrant entitles the holder to purchase one share of the Company&#x2019;s common stock at a price of $11.50 per share. No &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;fractional shares will be issued upon exercise of the Warrants. The Company may elect to redeem the Public Warrants, in whole and not in part at a price of $0.01 per Warrant if (i) 30 days&#x2019; prior written notice of redemption is provided to the holders, and (ii) the last reported sale price of the Company&#x2019;s common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders. Upon issuance of a redemption notice by the Company, the warrant holders have a period of 30 days to exercise for cash, or on a cashless basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;As of March 31, 2026, 13,813,000 Common Stock Warrants were outstanding. Each Common Stock Warrant entitles the holder to purchase one and a half shares of the Company&#x2019;s common stock at a price of $0.29 per share and will expire five years following the date of issuance. No fractional shares will be issued upon exercise of the Common Stock Warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;As of March 31, 2026, 690,650 Placement Agent Warrants were outstanding. Each Placement Agent Warrant entitles the holder to purchase one share of the Company&#x2019;s common stock at a price of $0.319 per share and will expire five years following the date of issuance. No fractional shares will be issued upon exercise of the Placement Agent Warrants.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="INF"
      id="Narr_ALz-FckufkKRCKPrbHnexg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="INF"
      id="Narr_g66_j-Bfp0GvLDoUcgL6EQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="INF"
      id="Narr_1LPFHz6gFUCGFfe6Y83L8Q"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="INF"
      id="Narr_HwERAKHXJEi1i2lyY3NKnQ"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="INF"
      id="Narr_puSPePEIE0qAz42NnPHxjQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_EqXPCxGs2UWqwL-WvMbnKQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="INF"
      id="Narr_DKJ-y9BaGECJlXyXNmpong"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="INF"
      id="Narr_EPA3TRjrxUGkBXLEtd-XDA"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <limn:SharesIssuedForSurrenderAndCancellationOfWarrants
      contextRef="Duration_7_16_2025_To_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_bvbBg5HF0E2idzp2cAdrIg"
      decimals="INF"
      id="Narr_zJYro2VM0kmSFas-FzcRAA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">350000</limn:SharesIssuedForSurrenderAndCancellationOfWarrants>
    <limn:ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled
      contextRef="Duration_7_16_2025_To_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_bvbBg5HF0E2idzp2cAdrIg"
      decimals="INF"
      id="Narr_FSivPHoLNEqtwLV5KrRVYA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1000000</limn:ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled>
    <limn:FairValueOfCommonStockIssued
      contextRef="As_Of_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_3KBXe2AusUautripdVqXLA"
      decimals="0"
      id="Narr_U0c0b2ts6ku9gE2Dn97XOQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1890000</limn:FairValueOfCommonStockIssued>
    <limn:FairValueOfWarrantsSurrendered
      contextRef="As_Of_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_3KBXe2AusUautripdVqXLA"
      decimals="0"
      id="Narr_3I5bRCWogUqaFghkpUhxhw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">150000</limn:FairValueOfWarrantsSurrendered>
    <limn:GainLossOnIssuanceOfCommonStockForWarrants
      contextRef="Duration_7_16_2025_To_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_bvbBg5HF0E2idzp2cAdrIg"
      decimals="0"
      id="Narr_WpfC79WME0iXnEJvaHEUNw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-1740000</limn:GainLossOnIssuanceOfCommonStockForWarrants>
    <limn:DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="0"
      id="Narr_vW1mvBLE4Eq5PXuLwvm0KQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7000000</limn:DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination>
    <limn:StockIssuableForSettlementOfDeferredUnderwritingFees
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="INF"
      id="Narr_mW_0d45eAUWjrqJCujcCZw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">700000</limn:StockIssuableForSettlementOfDeferredUnderwritingFees>
    <limn:FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees
      contextRef="As_Of_7_1_2025_CZJvPOCOcUySCDRAwOkqBA"
      decimals="0"
      id="Narr_haB2uTixm0qIPFz8nTAUtw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7245000</limn:FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees>
    <limn:SharesIssuedForSurrenderAndCancellationOfWarrants
      contextRef="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_c_d3VxIAXUGyxXVEc8AngQ"
      decimals="INF"
      id="Narr_ZcbuhDzrFUaCnWTmcZ2_Rw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">4000000</limn:SharesIssuedForSurrenderAndCancellationOfWarrants>
    <limn:ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled
      contextRef="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_c_d3VxIAXUGyxXVEc8AngQ"
      decimals="INF"
      id="Narr_RPgMF71BAUqDtUGIsHQYYQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">805377</limn:ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_8Eb_-va_j0mdcFrq6b8KwQ"
      decimals="INF"
      id="Narr_pBRDvSeUw0ikVc6Iw0G3nw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">8270000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <limn:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_ggP8Qf9lAEK8UwvoEQkLpw"
      decimals="INF"
      id="Narr_g4RmbKPfxEiUKYoLjTE7VQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">5543000</limn:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_U70qipalZUSb0nCwfCrzfg"
      decimals="INF"
      id="Narr_4YKuY6F35EKFacAn9wyRUw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">5543000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <limn:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_rUeXM1hqFEmNCkHtxT9MOQ"
      decimals="INF"
      id="Narr_HzGerzfqaUiQ1vBme5SjVA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">13813000</limn:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_Gx1dPATNHkOGW-Snv4cHLg"
      decimals="INF"
      id="Narr_mUpwjgE7606yDPQDinF82g"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">20719500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_2_18_2026_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_AjxQK7FsCE6Ub2hVGkXXEA"
      decimals="2"
      id="Narr_3uUrZMENxEmJtC_JIIPyPQ"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.29</us-gaap:SharesIssuedPricePerShare>
    <limn:ClassOfWarrantOrRightIssuePricePerWarrant
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_U70qipalZUSb0nCwfCrzfg"
      decimals="4"
      id="Narr_D77PreeMkE2We0CIRl_Row"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.2899</limn:ClassOfWarrantOrRightIssuePricePerWarrant>
    <limn:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_U70qipalZUSb0nCwfCrzfg"
      decimals="INF"
      id="Narr_bN5gtaP6WkenfKtUGjN0Sw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">4281000</limn:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <limn:ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions
      contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_ggP8Qf9lAEK8UwvoEQkLpw"
      decimals="INF"
      id="Narr_TxEWHv33wkWmPZCotvaBJA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">4281000</limn:ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions>
    <us-gaap:SharePrice
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockAndPreFundedWarrantsMember_eVpfLX3CYEK8jnIUcxuvGA"
      decimals="4"
      id="Narr_pAxa2ix8T0CcGhxk95Z6ZA"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.2449</us-gaap:SharePrice>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_UoX6-i4y3kKZXGQbZL5t6w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"&gt;&lt;tr&gt;&lt;td style="width:369.05pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:10pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:44.6pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8.35pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:369.05pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:369.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 92.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:369.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:369.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:369.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected life of warrants (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.6pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_KxviRH7DfUuHBTu5r6l8NQ"
      decimals="4"
      id="Tc_hQ-zde_sjUWjT7-QE3iIHg_1_2"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.9251</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Fj9tEUl42E6MBhnKApp0zA"
      decimals="4"
      id="Tc_tCmGPFNWDUCxAsKLZyF3tQ_2_2"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.0366</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_6blY871CSEOApTf8LuQfmA"
      decimals="INF"
      id="Tc_3fd1eqWfokGgirzxXLCB_Q_4_2"
      unitRef="Unit_Standard_Y_OxQzCXHfk02aUB5FPKeCrg">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <limn:ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_rICnJ36bF0O6-xJMSNFg9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"&gt;&lt;tr&gt;&lt;td style="width:259.65pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:52.7pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8.05pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:50.04pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8.05pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:45.5pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.24pt;"&gt;&lt;td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Allocated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Allocated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Allocated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.49pt;"&gt;&lt;td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&#160;Proceeds&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuance&#160;Costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&#160;Proceeds&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.79pt;"&gt;&lt;td style="vertical-align:bottom;width:259.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,208,186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 168,891&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,039,295&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common Stock Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,977,998&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 276,502&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,701,497&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:259.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pre-Funded Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 755,014&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 649,471&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.79pt;"&gt;&lt;td style="vertical-align:bottom;width:259.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Placement Agent Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 64,572&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,546&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.54pt;"&gt;&lt;td style="vertical-align:bottom;width:259.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.7pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,005,770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 559,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.5pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,445,808&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</limn:ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock>
    <limn:GrossProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0P2Hk6Fm0UCfvB5hIDbvbw"
      decimals="0"
      id="Tc_fti0K2Bcw0Ws4g31Oc6a0w_3_2"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1208186</limn:GrossProceedsFromIssuanceOfWarrants>
    <limn:OfferingCosts
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0P2Hk6Fm0UCfvB5hIDbvbw"
      decimals="0"
      id="Tc_1IzjYS0BekSGtGzOQcmJ_g_3_4"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">168891</limn:OfferingCosts>
    <limn:NetProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0P2Hk6Fm0UCfvB5hIDbvbw"
      decimals="0"
      id="Tc_5VpWN7pOokm8BA3RlNjN6Q_3_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1039295</limn:NetProceedsFromIssuanceOfWarrants>
    <limn:GrossProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsMember_kZc3BMaUdUGTUqWXCxwF2Q"
      decimals="0"
      id="Tc_XrzQkQ_KbkuNARQEJoXF7A_4_2"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1977998</limn:GrossProceedsFromIssuanceOfWarrants>
    <limn:OfferingCosts
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsMember_kZc3BMaUdUGTUqWXCxwF2Q"
      decimals="0"
      id="Tc_FAaxvV10ZEynBIcz5GMP3w_4_4"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">276502</limn:OfferingCosts>
    <limn:NetProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsMember_kZc3BMaUdUGTUqWXCxwF2Q"
      decimals="0"
      id="Tc_213z9ll9C0WcN6q0fA6T7A_4_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1701497</limn:NetProceedsFromIssuanceOfWarrants>
    <limn:GrossProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_XvqOOBEml06fz43DO14A7w"
      decimals="0"
      id="Tc_fQwLDPxxWUOGY2XRD6gEUg_5_2"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">755014</limn:GrossProceedsFromIssuanceOfWarrants>
    <limn:OfferingCosts
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_XvqOOBEml06fz43DO14A7w"
      decimals="0"
      id="Tc_rouQeWak10ijqs-O3Se1lA_5_4"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">105542</limn:OfferingCosts>
    <limn:NetProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_XvqOOBEml06fz43DO14A7w"
      decimals="0"
      id="Tc__I-wBUR9O0CtdiFppIvmjA_5_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">649471</limn:NetProceedsFromIssuanceOfWarrants>
    <limn:GrossProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_hUVQhIvVLUiqyQjkyt2gOg"
      decimals="0"
      id="Tc__VuoIhOqJkSVVGCit_4g3Q_6_2"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">64572</limn:GrossProceedsFromIssuanceOfWarrants>
    <limn:OfferingCosts
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_hUVQhIvVLUiqyQjkyt2gOg"
      decimals="0"
      id="Tc_DorAdBXBd06TWVnT4eIweg_6_4"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">9026</limn:OfferingCosts>
    <limn:NetProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_hUVQhIvVLUiqyQjkyt2gOg"
      decimals="0"
      id="Tc_Rd7H9_BCp0C2w8XaY7J0wA_6_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">55546</limn:NetProceedsFromIssuanceOfWarrants>
    <limn:GrossProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_m6Dtc3umsUqxqLsmvyTqow_7_2"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4005770</limn:GrossProceedsFromIssuanceOfWarrants>
    <limn:OfferingCosts
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_f8YYn-4OxEKfGTyOTvO5Zw_7_4"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">559962</limn:OfferingCosts>
    <limn:NetProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Tc_aakGSslxLE2ZG-N0egdDlg_7_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3445808</limn:NetProceedsFromIssuanceOfWarrants>
    <limn:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="As_Of_2_19_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_nVZL2iH4ikeTyIHCOmUqAA"
      decimals="INF"
      id="Narr_dHuwNtvTKE-OJw7cy3k6Mg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1262000</limn:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <limn:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="Duration_2_19_2026_To_2_19_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_SLmuQgYcLUyKdGqqpYwayw"
      decimals="INF"
      id="Narr_T0jC-hFVEUyTPq71BEXfdg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1262000</limn:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="INF"
      id="Narr_PLZCnY0t-U2TUNEYxhKZlQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">44877633</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="INF"
      id="Narr_siN4o9jjlkiVS46xrH91tA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">44877633</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_MJkunHVC9UmbD0gt9lI9mA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">27064633</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_sBab865rdU64v9D4k2mb3Q"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">27064633</us-gaap:CommonStockSharesIssued>
    <limn:CommonStockNumberOfVotesPerShare
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="INF"
      id="Narr_USd1VT7Vu0SfL9UjQt7gfQ"
      unitRef="Unit_Standard_Vote_pVdT3YsDMEiv7zpsvfY2UA">1</limn:CommonStockNumberOfVotesPerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_W2lQ6Gn-NEep1cZ7YVoF1w"
      decimals="INF"
      id="Narr_9-CqJsdix0W3J2MidQK20A"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">5094623</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PrivatePlacementWarrantsMember_GmwTGx3Js0KBpkdQA1hx1g"
      decimals="INF"
      id="Narr_9uQamXG5oUqx__aKqvegUA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">835555</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="INF"
      id="Narr_48WNPwfF30KmnGhwzUXXGQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="2"
      id="Narr_unGDqsB0YUSEdqaySDaslw"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_W2lQ6Gn-NEep1cZ7YVoF1w"
      decimals="2"
      id="Narr_6evkJt6QJEOjAbN8Kcjfiw"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <limn:ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z2RJFeIu4keoqDO4x5BOag"
      id="Narr_5V1XD4Vpf02hvCGZOIG5sw">P30D</limn:ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants>
    <limn:ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption
      contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_W2lQ6Gn-NEep1cZ7YVoF1w"
      decimals="2"
      id="Narr_kofeWY8Myka1UbAYmKGKZA"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">18</limn:ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption>
    <limn:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z2RJFeIu4keoqDO4x5BOag"
      decimals="INF"
      id="Narr_yGEPh4ZOuEG8DXa8uvYaDg"
      unitRef="Unit_Standard_D_P_lZhqU5gEiyf8nABG1U1w">20</limn:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays>
    <limn:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z2RJFeIu4keoqDO4x5BOag"
      decimals="INF"
      id="Narr_rXyN6LvV90OxcwHCeWy47Q"
      unitRef="Unit_Standard_D_P_lZhqU5gEiyf8nABG1U1w">30</limn:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_W2lQ6Gn-NEep1cZ7YVoF1w"
      id="Narr_BjsZ5ZD6F0W8MWxtublPMg">P30D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_j2wjtBDr30CGi5w2RrtSMw"
      decimals="INF"
      id="Narr_T8S6b9sv7kGhIaxqKCKK-w"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">13813000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_j2wjtBDr30CGi5w2RrtSMw"
      decimals="2"
      id="Narr_lLNONhpI5ESxMHTPuDEAlw"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.29</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_slm9IzocEkSBb1GZOKqnZA"
      decimals="INF"
      id="Narr_6NEbqMTqQEGQCkvz8m-3jg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">690650</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_slm9IzocEkSBb1GZOKqnZA"
      decimals="3"
      id="Narr_uh_7zHB_BEKyI88htRQhqQ"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.319</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_OikZgxD8AkWRcgwWpi_6lA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note&#160;7. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 17, 2025, the Company entered into a short-term lease for an office space in Cerritos, California (the &#x201c;Lease&#x201d;). The Lease commenced on September 1, 2025 and expires on June 30, 2026 and does not have any renewal option. The Company has made the short-term lease election and recognizes lease payments for its short-term lease on a straight line basis over the lease term. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For the three months ended March 31, 2026, lease expense related to the short-term lease was $22,272. &lt;span style="background:#ffffff;"&gt;For the three months ended March 31, 2025,&lt;/span&gt; there was no lease expense related to the short-term lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Legal Proceedings&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 6, 2026, the Company entered into a settlement and release agreement with Clear Street LLC (the &#x201c;Holder&#x201d;), pursuant to which the Company agreed to issue 4,000,000 shares of its common stock to the Holder in exchange for the surrender and cancellation of 805,377 warrants to purchase shares of common stock held by the Holder. As of December 31, 2025, the Company determined this represented a Type I subsequent event in accordance with the guidance of ASC 855, &lt;i style="font-style:italic;"&gt;Subsequent Events&lt;/i&gt; (&#x201c;ASC 855&#x201d;), in which the Company obtained additional evidence about conditions that existed at the date of the consolidated balance sheets. The Company estimated a settlement of $7,360,000, which was calculated using the fair value of the Company&#x2019;s common stock on February 6, 2026, which was the day that stock was issued to the Holder. As of March 31, 2026 and December 31, 2025, the Company&#x2019;s settlement payable was $0 and $7,360,000, respectively, which is included in settlement payable in the Company&#x2019;s unaudited condensed consolidated balance sheets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Settlement Agreement, the Company and the Holder agreed to dismiss (a) an action pending in the United States District Court for the Central District of California and (b) an action pending in the United States District Court for the Southern District of New York, in which previously the Court entered a default judgment against the Company in the amount of $7,500,000 plus approximately $515,000 in interest, which judgment was registered in the Central District of California in the fourth quarter of 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims other than those already disclosed. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Underwriting Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the Business Combination in connection with its initial public offering, Iris entered into an underwriting agreement with Cantor was engaged as the underwriters to Iris&#x2019; IPO. Cantor was entitled to an underwriting discount of 2% (or $5,520,000) of the gross proceeds of the IPO and deferred underwriting discount of 3.5% (or $9,660,000) of the gross proceeds of the IPO upon the completion of an initial business combination.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;On October 11, 2023, Iris executed a fee reduction agreement with the underwriters to reduce the deferred underwriting discount of $9,660,000 to $8,000,000 in the event the Business Combination was consummated. Pursuant to the terms of the agreement, the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;reduced deferred underwriting discount was payable by the Iris to the underwriters in $1,000,000 cash and $7,000,000 of the common equity securities of the public entity that survives the transaction. The share price is subject to adjustment based on the five day volume-weighted average price prior to the filing of a resale registration statement covering such shares. As of April 30, 2025, Iris and the Company amended the fee reduction agreement with the underwriters to limit the total number of shares of common stock issuable to the underwriters to 1,750,000. Upon the consummation of the Business Combination, $9,160,000 in deferred underwriting fees were settled, of which $7,000,000 will be settled in common shares of the combined company, $500,000 was settled in cash and $1,660,000 was waived and no longer payable. The remaining $500,000 was to be settled upon the earlier of the consummation of the combined company&#x2019;s next share offering, or in six months from the closing date of the Business Combination. As of March 31, 2026, the deferred underwriting fee payable was $500,000, which is included in deferred underwriting fee payable in the Company&#x2019;s unaudited condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 30, 2025, the Company settled Iris&#x2019; liabilities for $7,000,000 of the deferred underwriting fees incurred prior to the Closing Date for 700,000 shares of common stock to the underwriters in Iris&#x2019;s initial public offering. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $7,245,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;On October 27, 2025, six months from the closing date of the Business Combination, the remaining $500,000 underwriting fee became due. As of the date of this Form 10-Q, the $500,000 underwriting fees remains unpaid.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ShortTermLeaseCost
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      decimals="0"
      id="Narr_QjUoLS6mB0m8CMejM6W7RQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">22272</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw"
      decimals="0"
      id="Narr_1TCSpeCUsEOF02NEmdz9BQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:ShortTermLeaseCost>
    <limn:SharesIssuedForSurrenderAndCancellationOfWarrants
      contextRef="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_c_d3VxIAXUGyxXVEc8AngQ"
      decimals="INF"
      id="Narr_tWcsEMhxXUqrIWixrpcN3Q"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">4000000</limn:SharesIssuedForSurrenderAndCancellationOfWarrants>
    <limn:ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled
      contextRef="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_c_d3VxIAXUGyxXVEc8AngQ"
      decimals="INF"
      id="Narr_Y_HV_pDnKk2tjNNNs6dxSg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">805377</limn:ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled>
    <limn:CommonStockPayable
      contextRef="As_Of_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_c18r92u3KkG5BLQb4LzJlg"
      decimals="0"
      id="Narr_ULnaHCJeIUqQX832JNWchg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7360000</limn:CommonStockPayable>
    <limn:CommonStockPayable
      contextRef="As_Of_3_31_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_YSNqwrY3BEKU8q1HG1qjeg"
      decimals="0"
      id="Narr_9s6EJM_bw0CS_8c3RTa4NA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</limn:CommonStockPayable>
    <limn:CommonStockPayable
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_thV_eeooNEe0x29eHltR5Q"
      decimals="0"
      id="Narr_ya0xLbXDNEm9ZyJOkJRRjw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7360000</limn:CommonStockPayable>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="Duration_10_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_6H9UrA2MZUWmfOm8ySparQ"
      decimals="0"
      id="Narr_seBa7OEtD0K5_0kCJsSAXw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7500000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LitigationSettlementInterest
      contextRef="Duration_10_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_6H9UrA2MZUWmfOm8ySparQ"
      decimals="0"
      id="Narr_c0_h0_LAK06s11PV6rDPmg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">515000</us-gaap:LitigationSettlementInterest>
    <limn:UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering
      contextRef="Duration_1_1_2026_To_3_31_2026_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_brJVgPrmTkGylFftjvNsDw"
      decimals="2"
      id="Narr_WonNnTKzk0ixO4iIT1bbQg"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.02</limn:UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering>
    <limn:UnderwritingCostsNoncurrent
      contextRef="As_Of_3_31_2026_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_13QwrEzmwEyKOTC43D2VFg"
      decimals="0"
      id="Narr_La3NwImEbE-NiV2G-vZp2A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">5520000</limn:UnderwritingCostsNoncurrent>
    <limn:DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering
      contextRef="Duration_1_1_2026_To_3_31_2026_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_brJVgPrmTkGylFftjvNsDw"
      decimals="3"
      id="Narr_Gpm-YrSaPk6K6wLp4BbfZQ"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.035</limn:DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering>
    <limn:DeferredOfferingCostsNoncurrent
      contextRef="As_Of_3_31_2026_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_13QwrEzmwEyKOTC43D2VFg"
      decimals="0"
      id="Narr_XDyiMCgUlU-2zgX1FPvRSw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">9660000</limn:DeferredOfferingCostsNoncurrent>
    <limn:DeferredOfferingCostsNoncurrent
      contextRef="As_Of_10_10_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_8jW8A96_rUGTBNiKY7EncA"
      decimals="0"
      id="Narr_4YufxaxXA0WazvXYuzhy1A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">9660000</limn:DeferredOfferingCostsNoncurrent>
    <limn:DeferredOfferingCostsNoncurrent
      contextRef="As_Of_10_11_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_3xBPTdDIoEKDwiqXuL9Qyg"
      decimals="0"
      id="Narr_ogGA_AYTb0iOEs7zw98BZg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">8000000</limn:DeferredOfferingCostsNoncurrent>
    <limn:PaymentOfOfferingCostsInCash
      contextRef="As_Of_10_11_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_3xBPTdDIoEKDwiqXuL9Qyg"
      decimals="0"
      id="Narr_h0hEZKdzxE-a2E-s3A6E1g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1000000</limn:PaymentOfOfferingCostsInCash>
    <limn:UnderwritingDiscountPaidInSecurities
      contextRef="As_Of_10_11_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_3xBPTdDIoEKDwiqXuL9Qyg"
      decimals="0"
      id="Narr_Y6_k9RhTMEeSNJVv2rXZXg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7000000</limn:UnderwritingDiscountPaidInSecurities>
    <limn:MaximumNumbersOfSharesIssuable
      contextRef="As_Of_4_30_2025_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_Lbu1miIqSkupTrmz199Hbw"
      decimals="INF"
      id="Narr_b8AlLk5V40eVVETlnjnPGw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1750000</limn:MaximumNumbersOfSharesIssuable>
    <limn:DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="0"
      id="Narr_mmBLUcdHFkmgy9jMj0qtPw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">9160000</limn:DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination>
    <limn:DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="0"
      id="Narr_SMKqYIcL9E2NuDaUs-3yZw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7000000</limn:DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination>
    <limn:DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="0"
      id="Narr_0U01ny_Jb0qiFkq66cdQDw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">500000</limn:DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination>
    <limn:DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="0"
      id="Narr_eTAxsPhyIUmFn0h5zy8piA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1660000</limn:DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination>
    <limn:DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="0"
      id="Narr_25NKnVvv-0-iVfQPVVY9fA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">500000</limn:DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering>
    <limn:ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination
      contextRef="Duration_4_30_2025_To_4_30_2025_9PPk1IhN6EmJm5MGsGwEDA"
      id="Narr_j5GbKI0CqEGT3FRCpQmRqg">P6M</limn:ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination>
    <limn:DeferredUnderwritingFeesPayableInCashCurrent
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Narr_wQKk5cUax02Vb0HP9sx-Ug"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">500000</limn:DeferredUnderwritingFeesPayableInCashCurrent>
    <limn:DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="0"
      id="Narr_g0Mc9P__oUOOQEoxHpGYtg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7000000</limn:DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination>
    <limn:StockIssuableForSettlementOfDeferredUnderwritingFees
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="INF"
      id="Narr_J2KLIRhecEC2PQD1Hoi1sw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">700000</limn:StockIssuableForSettlementOfDeferredUnderwritingFees>
    <limn:FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees
      contextRef="As_Of_7_1_2025_CZJvPOCOcUySCDRAwOkqBA"
      decimals="0"
      id="Narr_DBuUnpU65UONoyEVnnb-Lg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7245000</limn:FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees>
    <limn:DeferredUnderwritingFeesPayableInCashCurrent
      contextRef="As_Of_10_27_2025_WHc2wpxA30auOyOjgUueLA"
      decimals="0"
      id="Narr_zYX4ElEq_0GUPakNdOr7jA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">500000</limn:DeferredUnderwritingFeesPayableInCashCurrent>
    <limn:DeferredUnderwritingFeesPayableInCashCurrent
      contextRef="As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A"
      decimals="0"
      id="Narr_ymJfESJc4kKxcvNa2Yf2kg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">500000</limn:DeferredUnderwritingFeesPayableInCashCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_vCYX-EZGOkaGqMdqxWux4w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 8. Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The following table presents information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2026 and December 31, 2025 and indicates the fair value hierarchy of the valuation inputs the Company&#x2019;s utilized to determine such fair value:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"&gt;&lt;tr&gt;&lt;td style="width:340.7pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:9.8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:49.65pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:9.85pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:6.25pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:49.25pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:9.85pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:7.7pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:56.95pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:340.7pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.44pt;"&gt;&lt;td style="vertical-align:bottom;width:340.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:55.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:340.7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:340.7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:340.7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,422&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,244&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Warrant Liability&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon closing of the Mergers, Iris&#x2019; public and private placement warrants were converted into warrants of the Company, which entitle the holders to purchase shares of the Company&#x2019;s common stock. The Company&#x2019;s private placement warrants meet the requirements for liability classification. The fair value of the warrant liabilities were determined using observable data points, such as the fair value of the public warrants as of March 31, 2026 and December 31, 2025. The Company further considered specific unobservable inputs, such as the probability and timing of events and the expected equity value of the underlying shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The changes in fair value of Level 3 financial assets and liabilities for the three months ended March 31, 2026 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"&gt;&lt;tr&gt;&lt;td style="width:360.05pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:11.39pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:7.15pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:53.4pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.44pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:60.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant&#160;liability&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value as of January 1, 2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 29,244&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,178&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.49pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value as of March&#160;31,&#160;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 33,422&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_te4Pbm204k65Wyg_QKqLDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"&gt;&lt;tr&gt;&lt;td style="width:340.7pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:9.8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:49.65pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:9.85pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:6.25pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:49.25pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:9.85pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:7.7pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:56.95pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:340.7pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.44pt;"&gt;&lt;td style="vertical-align:bottom;width:340.7pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:55.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:64.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:340.7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:340.7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:340.7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,422&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,244&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_3_31_2026_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_doQ-5t8E_kahW9UFnsMLNA"
      decimals="0"
      id="Tc_2avY8QyPs0eeDkSKLna6AQ_4_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">33422</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_3B7id13HUEKPGohf_GYnnw"
      decimals="0"
      id="Tc_P5jC7P4-vUWEeJdc0qs_yA_4_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">29244</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <limn:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_OXDv5hLNm0KsAwpBjXGwKQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"&gt;&lt;tr&gt;&lt;td style="width:360.05pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:11.39pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:7.15pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:53.4pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.44pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:60.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant&#160;liability&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value as of January 1, 2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 29,244&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,178&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.49pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value as of March&#160;31,&#160;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 33,422&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</limn:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_NOD7vwuXLUmAhk-2mkyvLQ"
      decimals="0"
      id="Tc_Gin7nsCoLUOXwLpdrAy96w_2_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">29244</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_yYxsL6Igmk6L3jX5IPvofQ"
      decimals="0"
      id="Tc_CcDxxkcipES9B8ZtNqwu9Q_3_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4178</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_pY-u8pAzO0OcP5FC3J0aNA"
      decimals="0"
      id="Tc_pwsui4Nr5UGuiuWTCpHhYQ_4_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">33422</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw"
      id="Tb_wDENZsvoTkKJxVXgr799yQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note&#160;9. Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has completed an evaluation of all subsequent events through the date of this filing to ensure that these unaudited condensed consolidated financial statements include appropriate disclosure of events both recognized in the unaudited condensed consolidated financial statements and events which occurred but were not recognized in the unaudited condensed consolidated financial statements. &lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_m9pK8RJrnkOWbo_RzwagZg_5_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">337655</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_BXj9gwnH3kim12nZx5SmOw_5_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">56319</us-gaap:Cash>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_20KMK-NnBk6X4WkY5QS7gQ_6_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3668500</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:DeferredCostsCurrent
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_kewJwBDsEEWUW1BQ-UhMJw_7_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1401323</us-gaap:DeferredCostsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_Ynz4YsD7sEO35qKZq05ItA_8_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">162919</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_3NXZoRaxEUCHMiqLAbIC6g_8_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">155501</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_JEwAEaIaNEea73FM7mxXfQ_9_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">500574</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_Wm_rQsltk0eqaIrzY56LcQ_9_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">5281643</us-gaap:AssetsCurrent>
    <us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_5yPKn4eX4UOAJZy7mqjBWw_11_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">126275</us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_CfIe31XL7U-sVR0myqF3UQ_12_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">12221</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_-9Viz0XY0UmflDqSLOJ7pA_12_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">941</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_I8QZG1Nqkk-0TZMs7FoYvg_13_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">12221</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_TYypc-An8EmhwZ6QWeddOg_13_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">127216</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_oU5oiEGiZkaFle4hXYJkOQ_14_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">512795</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_cUJTjw8OWEO2IB7J2ueuTA_14_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">5408859</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_2z8DK-88AEyTQZn_0tlakA_18_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">582234</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_BwWF9Ab2EEaClUP4q89JMQ_18_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1483253</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_bkS8WTKVfk-pkoeuwjyG6g_19_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">203921</limn:AccruedInterestCurrent>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_jRI4aRdREUC_arf02mXE7g_19_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">955119</limn:AccruedInterestCurrent>
    <limn:AccruedMaintenanceFeeCurrent
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_8Ftavxh6hUKlbm44Vtcpew_20_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">360000</limn:AccruedMaintenanceFeeCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_s19qgo8JfkOPRkLjJuXHug"
      decimals="0"
      id="Tc_GubzrkTHV0Oy-xA-ZwVC2w_21_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1782297</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FbpcEF3_bUqHFwpcC9Wy4w"
      decimals="0"
      id="Tc_20VnN7DJBUmEgnoJTuYNHw_22_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">209586</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_eXLYHI_roUaYmfoOmSYVxA"
      decimals="0"
      id="Tc_A99pkPZEe0yZ5K4dZwVItA_22_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">195253</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_HGZM0WDCWEOsGYvYxTrP-Q_23_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1442500</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_v3NJhimAs0Ca6JSsa9XswQ_23_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">19973000</us-gaap:ShortTermBorrowings>
    <limn:DeferredUnderwritingFeesPayableInCashCurrent
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_rhlMBADpGk6Vh3Gv0FNO_Q_24_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">500000</limn:DeferredUnderwritingFeesPayableInCashCurrent>
    <limn:CommonStockPayable
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_rRX0ZbNvLk2lr_l7AwPOYA_25_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7360000</limn:CommonStockPayable>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_qYd6gRtKF06YsmjtgM2jzA_26_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">10298241</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_7ghxd1iQ-0GaDI5mi8-j-g_26_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">24748922</us-gaap:LiabilitiesCurrent>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_xdKLe8ZHzUC_W6ykAFmlkw_27_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">29244</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_oYFpbpE1Gk-WrQYO_B8IjQ_28_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">10327485</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_XAMgndUoykadaqD7D5vhOg_28_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">24748922</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="INF"
      id="Narr_nd9EC6llVEuXahbG6bAoAA"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_t1Xr-jSZS0Wg9UjCMoPpFA"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="INF"
      id="Narr_BCQVMkDnCkuguyRHGU6V1A"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_YTeUEJ8YQkyihUWdXyoCQQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="INF"
      id="Narr_e5Ri4fQb1EqFCSiuM6hRPg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_xuCy8DB9vUW7GbP7_j3qGA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="INF"
      id="Narr_Pf7Aa4mMIkGFeqev-122Aw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_7GIpPa2rqUiZgTwaMcJNfA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="INF"
      id="Narr_Nj2RZ0fIeUyIoMBcaFgK8A"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_TZc1NjJRfk6VMizFdbA-ew"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="INF"
      id="Narr_R1WBxvs1bkWPrjcJvtk7JA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_34e-bd4iQE6KXG-zkQ9KDw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">500000000</us-gaap:CommonStockSharesAuthorized>
    <limn:CommonStockShareOutstanding
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_lgOWyV9AN0u49Ut0nlUYZQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">27064633</limn:CommonStockShareOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_Ju7E-MDODUWRNGd6qTiBgQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">27064633</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="INF"
      id="Narr_o8EjiU18O0CCH8GbZ5P73Q"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">17500000</us-gaap:CommonStockSharesIssued>
    <limn:CommonStockShareOutstanding
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="INF"
      id="Narr_LtlUDHzZ4k-Jdx668lLcPA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">17500000</limn:CommonStockShareOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_gkMv0vRfWUeB1iRn8oy9SQ_34_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2706</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_2WISg8IU-0WKtEuff6lBmQ_34_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1750</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_M3R1-vp2IEeRr1cyHYL5yA_35_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">29054337</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_RG68EkzRNkq_yZwX8Jo2wQ_35_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">9323403</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_MFOkL_t2Gk6HBlT4WsM1XA_36_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-38871733</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_VdtTSX3QqEeRWz_NEz1MgA_36_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-28665216</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_cek9YvuhrUO0Q5Kv4zJ31g_37_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-9814690</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_uvnp0XV5vUePo2lHVK1Nlg_37_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-19340063</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_KDkdAs9BL0G13rEmDUuqrA_38_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">512795</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_b7TFyuZv3UW67dj0BcEHTQ_38_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">5408859</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_yuGMN5Ck20KqVMN_nTaTng_4_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2967812</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_ofZky8kU60WvZ7NYBb6i6w_4_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">644619</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc__fGPpeRoF0KRV4LaUEoKVg_5_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2685334</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_CWEE234ak06xa69kGIv3Gg_6_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2967812</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_zR7OspLiI0-pkBbZd-oRSA_6_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3329953</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_3P1HfU2B7UmVM6Odc5e58g_7_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-2967812</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_PtsKTTwBEE-souLNJ_Zu7w_7_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-3329953</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_ZQ2tT_maCE24DQUpR0FuMA_9_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">215903</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_pZ01VL-yMUy3MdJ7h0Novw_9_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">338882</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_bC74PHp4xkuLck9pXr-xQw_10_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">76589</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_A486Vek3lkWSDGnR_FyQlg_10_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">122526</us-gaap:InvestmentIncomeInterest>
    <limn:ForgivenessOfUnrelatedVendorPayable
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_6yDmWTsHa0OZ1ghq5KfWBA_11_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2142297</limn:ForgivenessOfUnrelatedVendorPayable>
    <limn:EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_wX1xfjUUtk-3TLBX_3iHdw_12_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-196000</limn:EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_ifL0J6OO0k6m6_LUc8drQQ_13_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-54312</us-gaap:FairValueAdjustmentOfWarrants>
    <limn:GainLossOnIssuanceOfCommonStockForWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_OCKwIFkVNkig6n0hZf69Yw_14_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-1740000</limn:GainLossOnIssuanceOfCommonStockForWarrants>
    <limn:FairValueOfCommonStockIssuanceForContingentLiability
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_93v1B_awfEuoOGGo5Wejmg_15_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7360000</limn:FairValueOfCommonStockIssuanceForContingentLiability>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_0LxkHCo1v0-NxvQVRY_R3w_16_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-7238705</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_XKWkOvJFQ06iSSvBC7rjBw_16_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-216356</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_b_hnnHxZ5EC6M_f30f1MeA_17_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-10206517</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_3IFcNIRi3kShU4k2-7_Fqg_17_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-3546309</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_aHtfXI09SECe6XdEMLiOBQ_19_3"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">23753561</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_9RX2rQ0RCU6Dk_ZL1Iek7w_19_6"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">17500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="2"
      id="Tc__FiEmY5-uEmnJvHY1psPwA_21_3"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">-0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="2"
      id="Tc_z_syvq_f3Ee2TH7BNETQUA_21_6"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">-0.2</us-gaap:EarningsPerShareBasic>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHu7s1FxgEmdi0qyZEPN4g"
      decimals="INF"
      id="Tc_7ROUESS25EOckwg8ALPOvA_4_2"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">17500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHu7s1FxgEmdi0qyZEPN4g"
      decimals="0"
      id="Tc_CVIGz5hPNUqu-ltzIf7NHA_4_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1750</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9uu8nJPlZE2Ewx4WJxhvoQ"
      decimals="0"
      id="Tc_rbq935VjbUKRIodNkWRssw_4_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">9323403</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MuLWEtlz5E2UN4YJiAi4YQ"
      decimals="0"
      id="Tc_YP-t6420zUuJGiagviX8Sg_4_11"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-28665216</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_rhAk77c-QUCmJHUppKQptQ_4_14"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-19340063</us-gaap:StockholdersEquity>
    <limn:StockIssuedDuringPeriodSharesBusinessCombination
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg"
      decimals="INF"
      id="Tc_xBWjbP5i2E2yAjFrTsBCyw_5_2"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">114633</limn:StockIssuedDuringPeriodSharesBusinessCombination>
    <limn:StockIssuedDuringPeriodValueBusinessCombination
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg"
      decimals="0"
      id="Tc_2-0Y_lUDcUu-0i1LclfYyw_5_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">11</limn:StockIssuedDuringPeriodValueBusinessCombination>
    <limn:StockIssuedDuringPeriodValueBusinessCombination
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uTi3iJsKTUG1RhrJIbdN7Q"
      decimals="0"
      id="Tc_OPyQAqjN6Uyi4zDFesSqrg_5_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">190379</limn:StockIssuedDuringPeriodValueBusinessCombination>
    <limn:StockIssuedDuringPeriodValueBusinessCombination
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_uiGTHhKjUkayvdbg73rIgg_5_14"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">190390</limn:StockIssuedDuringPeriodValueBusinessCombination>
    <limn:AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uTi3iJsKTUG1RhrJIbdN7Q"
      decimals="0"
      id="Tc_2nZuor5kLUSUC1XPOWfmzg_6_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4443500</limn:AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans>
    <limn:AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_XppqtBOgnEyMoh-4wmu4zQ_6_14"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4443500</limn:AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg"
      decimals="INF"
      id="Tc_sKWZR52_0UWojuY1l6bnKg_7_2"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">6900000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg"
      decimals="0"
      id="Tc_aKCjlA8pQEW5BV2PNSGMSg_7_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">690</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uTi3iJsKTUG1RhrJIbdN7Q"
      decimals="0"
      id="Tc_gtV1Utk0kkirvoEfQcjoqg_7_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-690</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg"
      decimals="INF"
      id="Tc_T-oGFYqr30GqDxzrkYF0aQ_8_2"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg"
      decimals="0"
      id="Tc_auPDbpFnREq36Ut1uflIqQ_8_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">150</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uTi3iJsKTUG1RhrJIbdN7Q"
      decimals="0"
      id="Tc_TmqX78czmEqqq2i1zcHddA_8_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">14999850</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_q3Kls_IdD0OeI0Ew54P9TQ_8_14"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">15000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <limn:StockIssuedPeriodOfCommonStockToUnderwriter
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg"
      decimals="INF"
      id="Tc_yHZaikCaCUO4Q8ii5-EdPQ_9_2"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">700000</limn:StockIssuedPeriodOfCommonStockToUnderwriter>
    <limn:StockIssuedPeriodValueOfCommonStockToUnderwriter
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg"
      decimals="0"
      id="Tc_EMF2NnM_X0mpmqIt8rZ2hw_9_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">70</limn:StockIssuedPeriodValueOfCommonStockToUnderwriter>
    <limn:StockIssuedPeriodValueOfCommonStockToUnderwriter
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uTi3iJsKTUG1RhrJIbdN7Q"
      decimals="0"
      id="Tc_QkhK9BLQ2UeuMRoTJdI8_g_9_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7244930</limn:StockIssuedPeriodValueOfCommonStockToUnderwriter>
    <limn:StockIssuedPeriodValueOfCommonStockToUnderwriter
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_pW8_H7Q8EU6N3QpVf7Px2Q_9_14"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7245000</limn:StockIssuedPeriodValueOfCommonStockToUnderwriter>
    <limn:SharesIssuedForSurrenderAndCancellationOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg"
      decimals="INF"
      id="Tc_rpyNlS5PpUKANgBnP0GcJg_10_2"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">350000</limn:SharesIssuedForSurrenderAndCancellationOfWarrants>
    <limn:StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg"
      decimals="0"
      id="Tc_MK6mQYgiVkGBKNGckVp17g_10_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">35</limn:StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants>
    <limn:StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uTi3iJsKTUG1RhrJIbdN7Q"
      decimals="0"
      id="Tc_pg-72xRs4EKW6MYASps_Tw_10_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1739965</limn:StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants>
    <limn:StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_kSmE-oB2U0aQD6DvkGFQIA_10_14"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1740000</limn:StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XRD_hVv4DkGY6KlSlQA6NA"
      decimals="0"
      id="Tc_HVbYM1q97kCHHIkMz3n87A_11_11"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-10206517</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_1R2QtY-HtUiElq4wob8jpw_11_14"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-10206517</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LJS_bgYOWkOcBywnif6GLQ"
      decimals="INF"
      id="Tc_NAkeP72VvE6R7dQBaDED3Q_12_2"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">27064633</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LJS_bgYOWkOcBywnif6GLQ"
      decimals="0"
      id="Tc_6NAdKmQhdE2x6w3YoPSpOQ_12_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2706</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_It0aMMr5RUGH0v6aV7qdrw"
      decimals="0"
      id="Tc_wqqRgGWmu0SzNJ8uGZVTOA_12_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">29054337</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4f2Cj2MzIUuqkE9ozbbB6w"
      decimals="0"
      id="Tc_ULYhgN8fxkiLCtypOocB9Q_12_11"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-38871733</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_LCsiQAF9rUO1YrrSZKCExQ_12_14"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-9814690</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HFF_MgUngEePnxJ9ysVB6Q"
      decimals="INF"
      id="Tc_sZwEW9zD10aVsHVqFTELDQ_4_2"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">17500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HFF_MgUngEePnxJ9ysVB6Q"
      decimals="0"
      id="Tc_GrnXgKUNgkmBMdi-ZoZ_3w_4_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1750</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_RvqHKU6YWkmEJhD9fotvqw"
      decimals="0"
      id="Tc_PREj0jMsnE6uUWTGBUiLpQ_4_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">9323403</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mdCeT08ds0iD_QBBfMY-1w"
      decimals="0"
      id="Tc_lrp0UnlvWUWv5MwTXJ74KA_4_11"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-25118907</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_hJv_UjccpUSIXy-caXvHdA"
      decimals="0"
      id="Tc_x56Y14AyeUu4PVvsK2xtfA_4_14"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-15793754</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AfWb2cWlZEaFlDlquz3ozQ"
      decimals="0"
      id="Tc_FEgNwtOAJU20z4LR0OUlLQ_5_11"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-3546309</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_k7opdg1mbEuDoDMkurwPQg_5_14"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-3546309</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHu7s1FxgEmdi0qyZEPN4g"
      decimals="INF"
      id="Tc_uHx5DuLpAEO1yylp-kybYA_6_2"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">17500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHu7s1FxgEmdi0qyZEPN4g"
      decimals="0"
      id="Tc_2j-StSoYh0i221VVtJbN8A_6_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1750</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9uu8nJPlZE2Ewx4WJxhvoQ"
      decimals="0"
      id="Tc_WSiTCK1d7kWwjU75pUtOxg_6_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">9323403</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MuLWEtlz5E2UN4YJiAi4YQ"
      decimals="0"
      id="Tc_xBiVk0vTUUuW4SRVVn7nLw_6_11"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-28665216</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_Mlc4m5k8Fkedtj1BUQ0ZWQ_6_14"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-19340063</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_Fm2DCzPltEGt5eoOJoCSzw_4_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-10206517</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_4q5iFECBqk-fyvvrEx6hVA_4_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-3546309</us-gaap:ProfitLoss>
    <limn:ForgivenessOfUnrelatedVendorPayable
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_DiaFO7AGlEuMYKZs77sxog_5_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2142297</limn:ForgivenessOfUnrelatedVendorPayable>
    <limn:OtherReceivableWriteOff
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_hh-rFgMXGU2VqnOtgPdQQg_6_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">126275</limn:OtherReceivableWriteOff>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_FvlsFDKhDkWQ4Afsl9b78g_7_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1828</us-gaap:Depreciation>
    <limn:EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_t6rdQv3cXUCSdDtJ4Fr2kA_8_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-196000</limn:EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_uiJ9JocUlkqr_NoujUjugA_9_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-54312</us-gaap:FairValueAdjustmentOfWarrants>
    <limn:GainLossOnIssuanceOfCommonStockForWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_JLCw5QdjrEa-CJGcSlOZaQ_10_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-1740000</limn:GainLossOnIssuanceOfCommonStockForWarrants>
    <limn:FairValueOfCommonStockIssuanceForContingentLiability
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc__9d6rifr4EWHoKf2tMhx0A_11_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7360000</limn:FairValueOfCommonStockIssuanceForContingentLiability>
    <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_gd3EOLUdJEmZNHCzeagvXg_13_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3427000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_RYcMCAklmUylGkcrXc_40A_14_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-324609</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_HvIFkTuZLEi4FKKzKN1ifw_14_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">133251</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_-LMTpRVUDU6PcRU5Cqje-A_15_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-4035340</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_N-OytFREv0y1OSk9HbMMyg_15_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-10747</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <limn:IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc__TeQdcuI70qpAb_7JuGwxQ_16_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-215903</limn:IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent>
    <limn:IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_rKjxCytMUE6yqgsoBd28QA_16_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-338882</limn:IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent>
    <limn:IncreaseDecreaseInAccruedMaintenanceFeesCurrent
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_nF91bDRf8067-tI49rGVpA_17_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-360000</limn:IncreaseDecreaseInAccruedMaintenanceFeesCurrent>
    <limn:IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_7nztPmx2A0qYbrKv8qt6vg_18_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-1540359</limn:IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_xpAC3hYoEEmMuuv8fdgX-Q_19_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-62467</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_tBzZFr22B0-JeMG8X5GPag_20_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-9963318</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_0DhqcEaAj0S_BYf_6yzL6Q_20_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-1451066</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireLoansReceivable
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_knF5DzgFB0u-de_iJP3Q6w_23_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">775000</us-gaap:PaymentsToAcquireLoansReceivable>
    <us-gaap:PaymentsToAcquireLoansReceivable
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_fhqjyrJXZUCCGUKwca_oFQ_23_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2850000</us-gaap:PaymentsToAcquireLoansReceivable>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_j3Yn7PM4DEKj84B-JABJ6w_24_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">13108</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_5oKn_K-nwU-w7TvUtFW92A_25_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-788108</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_Kke8crljbUGkbUAjJFYk8Q_25_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-2850000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_ZHEZPMS9NUm0YO8Q-y-VlA_28_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">10556500</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_J2jF8hMfwkelXOq3zw8m3A_29_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2563738</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_ZIK_kaHcV0K_KzvlxKuLbw_30_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4340000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_NTnAZPzB40GmLipNINyEuw_30_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3923000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_p0XBxU6J5kyyOeRb2eS58Q_31_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1300000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_XnUu_C90B0OS-BTcTjfAgQ_32_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">11032762</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_yGd70DfqYkS4n1LGdOVVVw_32_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3923000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_3oeyvalVCESz2ImYCAfUWg_34_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">281336</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_87IKmVrT1kie26njOYce6g_34_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-378066</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_QRdDTz5CxEOxsmlwU4fdag_36_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">56319</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2023_hJv_UjccpUSIXy-caXvHdA"
      decimals="0"
      id="Tc_cB_jkHWnG0-8uI36590Nfg_36_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">434385</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_zGtJAfi6UkeztfjR10s04g_37_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">337655</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Tc_2sufpSoZYUKy9JpXPQciFg_37_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">56319</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:LiabilitiesAssumed1
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_0mDbo_fc50WSv6yaPS29TA_40_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">10694604</us-gaap:LiabilitiesAssumed1>
    <limn:StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_2ZsSZ1mgXkKWTVAxFD5Tjg_41_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7049000</limn:StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination>
    <limn:MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_BOEInazRhEqp3NzDHMuFRg_42_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1518381</limn:MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction>
    <limn:LoansSettled
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_s4NZEx8TO0KMeSPnu4nhwA_43_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4443500</limn:LoansSettled>
    <us-gaap:StockIssued1
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_uMaryVC4OkWaz3ZSupobDA_44_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">690</us-gaap:StockIssued1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_E_XrfqllpUi2SGSQsFhbYQ_45_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">14797901</us-gaap:DebtConversionOriginalDebtAmount1>
    <limn:NoncashConversionOfAmountBorrowedForPipeFunds
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_60TgJxw9UEyHCNK07Ugtdw_46_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3427000</limn:NoncashConversionOfAmountBorrowedForPipeFunds>
    <limn:DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_Uff7tQTn3U24StVKVJUlVg_47_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">169201</limn:DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest>
    <limn:SharesIssuableUponClosingOfMergerToUnderwriters
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_XmPlIieuMECuI2zOScWUaQ_48_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7245000</limn:SharesIssuableUponClosingOfMergerToUnderwriters>
    <limn:DeferredTransactionCostsInAccountsPayable
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_7HZ8kkXZq0C-LyR_9NQtlw_49_6"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">561441</limn:DeferredTransactionCostsInAccountsPayable>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_8MjlDCPnH0yPg0ajfe_lVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note&#160;1. Description of Organization and Business Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Liminatus Pharma, Inc. (the &#x201c;Company&#x201d;), a Delaware corporation, is a pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company&#x2019;s candidate IBA101, is a humanized anti CD47 monoclonal antibody. The next generation CD47 checkpoint inhibitor&#x2019;s initial indication is expected to be patients with advanced solid cancers including non-small cell lung cancer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to the uncertainty of whether the Company&#x2019;s intellectual property will develop into successful commercial products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Business Combination&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 30, 2022, Iris Acquisition Corp, a Delaware corporation (&#x201c;Iris&#x201d;), the Company, Liminatus Pharma, LLC, a Delaware limited liability company (&#x201c;Liminatus&#x201d;), Liminatus Pharma Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#x201c;Liminatus Merger Sub&#x201d;), and SPAC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#x201c;SPAC Merger Sub&#x201d;), entered into a business combination agreement (as it may be amended, supplemented or otherwise modified from time to time, the &#x201c;Business Combination Agreement&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On March&#160;4, 2025, Iris held a special meeting of stockholders. At the special meeting, Iris&#x2019;s stockholders voted to approve the Business Combination and adopt the Business Combination Agreement, among other items. In connection with the special meeting, stockholders holding 59,844 Iris Class&#160;A Shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $11.74 per share, subject to adjustment for taxes payable from the trust account, for an aggregate redemption amount of $702,359. The redemptions were settled on April 30, 2025 upon the consummation of the Business Combination.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April&#160;30, 2025 (the &#x201c;Closing Date&#x201d;), the Company consummated the business combination contemplated by the Business Combination Agreement, pursuant to which &lt;span style="color:#231f20;"&gt;(a)&#160;Liminatus Merger Sub merged with and into Liminatus (the &#x201c;Liminatus Merger&#x201d;), with Liminatus surviving the Liminatus Merger as a direct wholly-owned subsidiary of the Company, and (b)&#160;simultaneously with the Liminatus Merger, SPAC Merger Sub merged with and into Iris (the &#x201c;SPAC Merger&#x201d; and, together with the Liminatus Merger, the &#x201c;Mergers&#x201d;), with Iris surviving the SPAC Merger as a direct wholly-owned subsidiary of the Company (the transactions contemplated by the foregoing clauses (a)&#160;and (b)&#160;the &#x201c;Business Combination&#x201d;)&lt;/span&gt;, and in connection therewith the Company changed its name from &#x201c;Iris Parent Holding Corp.&#x201d; to &#x201c;Liminatus Pharma,&#160;Inc.&lt;span style="color:#231f20;"&gt;&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Business Combination Agreement, among other matters, at the effective time of the Business Combination (the &#x201c;Effective Time&#x201d;), (i)&#160;every issued and outstanding security issued by Iris during its initial public offering (each, an &#x201c;Iris Unit&#x201d;) was automatically separated and broken out into its constituent parts and the holder thereof was deemed to hold one share of Iris Class&#160;A common stock, par value $0.0001 per share (the &#x201c;Iris Class&#160;A Shares&#x201d;) and &lt;span style="-sec-ix-hidden:Hidden_ZxKK64VsEUG8mm4V7fNrqQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one-fourth&lt;/span&gt;&lt;/span&gt; of one redeemable warrant that was included as part of each Iris Unit (the &#x201c;Public Warrants&#x201d;), and such underlying constituent securities of Iris were converted in accordance with the applicable terms of the Business Combination Agreement, (ii)&#160;at the Effective Time, each issued and outstanding Iris Class&#160;A Share was converted automatically into and thereafter represent the right to receive one share of common stock, par value $0.0001 per share (&#x201c;Common Stock&#x201d;), of the Company, following which all Iris Class&#160;A Shares ceased to be outstanding and were automatically canceled and ceased to exist, (iii)&#160;at the Effective Time, each issued and outstanding Public Warrant immediately and automatically represented the right to purchase shares of Common Stock on the same terms and conditions as are set forth in the applicable warrant agreement, (iv)&#160;at the Effective Time, each issued and outstanding non-redeemable warrant of Iris that was issued by Iris in a private placement at the time of the consummation of its initial public offering, entitling the holder thereof to purchase one Iris Class&#160;A Share at $11.50 per share, except those issued to Cantor Fitzgerald&#160;&amp;amp; Co. (&#x201c;Cantor&#x201d;), were forfeited, and (v)&#160;the private placement warrants issued to Cantor immediately and automatically represented the right to purchase shares of Common Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon the consummation of the Business Combination, the Company&#x2019;s certificate of incorporation was amended and restated to, among other things, set the total number of authorized shares of capital to 501,000,000 shares, of which 500,000,000 were designated as common stock, $0.0001 par value per share, and 1,000,000 shares were designated as preferred stock, $0.0001 par value per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At the Closing Date, 7,014,633 shares of Iris Class A Shares automatically converted into shares of the Company&#x2019;s common stock, on a one-for-one basis. Of the total 7,014,633 newly converted shares, 6,900,000 were issued to Iris Acquisition Holdings, LLC, the sponsor of Iris, and 114,633 were issued to Iris&#x2019; public stockholders in a noncash transaction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At the Closing Date, the Company issued an aggregate of 1,500,000 shares of the Company&#x2019;s common stock in a private placement (the &#x201c;PIPE Shares&#x201d;) for the total consideration of $15,000,000 (the &#x201c;PIPE Financing&#x201d;). The PIPE Financing consisted of a cash and non-cash component. Under the cash component, the Company received gross proceeds of $10,556,500, of which $7,129,500 came directly from the PIPE investor and $3,427,000 was funded indirectly by the PIPE investor, through promissory notes between Prophase Sciences, LLC, a related party of the Company, and Liminatus. At the Closing Date, the $3,427,000 in related party debts between Prophase Sciences, LLC and Liminatus was ultimately converted into shares as part of the PIPE Financing. As part of the PIPE Financing, the gross proceeds satisfied principal and accrued interest totaling $3,316,756, which was ultimately converted into shares as part of the PIPE Financing. The non-cash component of the PIPE Financing included the conversion of $4,443,500 in amounts borrowed from a consortium of related parties. The $4,443,500 borrowed from the related parties were used to fund an unsecured promissory note between Liminatus and Iris. At the Closing Date, the unsecured promissory note was settled and the $4,443,500 in related party debts were ultimately converted into shares of the Company in a noncash transaction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At the Closing Date, 112,222,220 Liminatus&#x2019; member units converted into 17,500,000 shares of the Company&#x2019;s common stock. Of the 17,500,000 shares of common stock, 4,000,000 were issued to Feelux Co, Ltd. as part of an agreement between the Company, Feelux Co, Ltd. and Car-Tcellkor, Inc. As part of the agreement, the outstanding principal and accrued interest on the Feelux and Car-Tcellkor bonds, totaling $11,481,146, and 9,999,999 member units of Liminatus were converted into 4,000,000 shares of the Company&#x2019;s common stock. The remaining Liminatus member units were converted based on a conversion ratio of 0.1559 shares per member unit.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon consummation of the Business Combination, the Company assumed a total of $10,694,604 in liabilities from Iris. The Company incurred $1,518,381 in transaction costs associated with the closing of the Business Combination. The Company converted a total of $14,797,901 of related party debt and accrued interest, &lt;span style="-sec-ix-hidden:Hidden_5_bKoANxokGAW-xbn0qRBA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$3,316,755&lt;/span&gt;&lt;/span&gt; from the PIPE investor and $11,481,146 from Feelux and Car-Tcellkor (as described above) into common stock. Additionally, a total of $169,201 in accrued interest on related party debts that were converted, as discussed above, was forgiven upon consummation of the Business Combination.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, at the Closing Date, the Company settled Iris&#x2019; liabilities for $7,000,000 of the deferred underwriting fees incurred prior to the Closing Date for 700,000 shares of common stock to the underwriters in Iris&#x2019;s initial public offering. At the Closing Date, the shares were not issued to the underwriter and the Company recorded as a liability with a fair value of $7,049,000. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $7,245,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Liminatus was deemed the accounting acquirer in the Business Combination based on an analysis of the criteria outlined in Accounting Standards Codification (&#x201c;ASC&#x201d;) 805, &lt;i style="font-style:italic;"&gt;Business Combinations&lt;/i&gt; (&#x201c;ASC 805&#x201d;). The determination was primarily based on Liminatus&#x2019; members prior to the Business Combination having a majority of the voting interests in the combined company, Liminatus&#x2019; ability to exert control over the majority of the board of directors of the combined company, Liminatus&#x2019; ability to maintain control of the board of directors on a go-forward basis, Liminatus&#x2019; senior management comprising the senior management of the combined company, and Liminatus&#x2019; operations prior to the Business Combination comprise the ongoing operations of the combined company. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Liminatus&#x2019; issuing stock for the net assets of Iris, accompanied by a recapitalization. The net assets of Iris were stated at fair value, with no goodwill or other intangible assets recorded.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon the consummation of the Business Combination, the Iris Class&#160;A Shares, Iris Units and Public Warrants ceased trading on the OTC Pink Marketplace, and the Common Stock and Public Warrants began trading on The Nasdaq Stock Market (&#x201c;Nasdaq&#x201d;) under the trading symbols &#x201c;LIMN&#x201d; and &#x201c;LIMNW,&#x201d; respectively, on May&#160;1, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Nasdaq Notices&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;On August 22, 2025, the Company received a notice from the Nasdaq Listing Qualifications Department indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025. The deficiency letter had no immediate effect on the listing of the Company&#x2019;s common stock, and its common stock continued to trade on Nasdaq under the symbol &#x201c;LIMN&#x201d;. Under the Nasdaq rules, the Company had 60 calendar days, or until October 21, 2025, to submit a plan to regain compliance and if the plan was accepted, Nasdaq can grant an exception of up to 180 calendar days from the filing&#x2019;s due date, or until February 16, 2026, to regain compliance. If the compliance plan was not accepted, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;the Company had the opportunity to appeal that decision to a Nasdaq Hearings Panel. On October 6, 2025, the Company filed its Form 10-Q for the period ended June 30, 2025 and the matter was closed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 19, 2025, the Company received notices from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value of Listed Securities (MVLS) of $50,000,000 (the &#x201c;MVLS Rule&#x201d;), based upon a review of the Company&#x2019;s MVLS for the last 30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly Held Shares (MVPHS) of $15,000,000 (the &#x201c;MVPHS Rule&#x201d;), based upon a review of the Company&#x2019;s MVPHS for the last 30 consecutive business days. The Nasdaq staff noted that the Company also does not meet the requirements under Listing Rule 5450(b)(3)(A), which requires the Company to have total assets and total revenue of at least $50 million each for the most recently completed fiscal year or two of the three most recently completed fiscal years. Under the Nasdaq rules, the Company has 180 calendar days, or until May 18, 2026, to regain compliance with the MVLS Rule and MVPHS Rule. In the event the Company does not regain compliance with the MVLS Rule and MVPHS Rule prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Hearings Panel. Alternatively, the Company may consider applying to transfer the Company&#x2019;s securities to the Capital Market, provided it meets the Capital Market&#x2019;s continued listing requirements. The Company is working diligently to regain compliance with Nasdaq&#x2019;s listing rules. However, there can be no assurance that the Company will be able to regain compliance within the prescribed time period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 15, 2026, the Company received a notice from Nasdaq indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rule 5450(a)(1) (the &#x201c;Bid Price Rule&#x201d;) which requires listed securities to maintain a minimum bid price of $1 per share. Under the Nasdaq rules, the Company has 180 calendar days, or until July 14, 2026, to regain compliance with the Bid Price Rule. In the event the Company does not regain compliance during the initial compliance period, the Company may be eligible for additional time to regain compliance with the Bid Price Rule. The Company is working diligently to regain compliance with Nasdaq&#x2019;s listing rules. However, there can be no assurance that the Company will be able to regain compliance within the prescribed time period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for one year after the date that the consolidated financial statements are issued. Through December 31, 2025, the Company has funded its operations mainly through equity and debt financings, including the proceeds from the Mergers and the PIPE Financing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025, the Company had $337,655 of cash in its bank accounts. As of December 31, 2025 and 2024, there was $1,442,500 and $19,973,000, respectively, of related party debts, which are included in Short-term debt, related parties in the accompanying consolidated balance sheets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has an accumulated deficit of $38,871,733 as of December 31, 2025. The Company had a loss from operations and net loss of $(2,967,812) and $(10,206,517), respectively, for the year ended December 31, 2025. The Company had a loss from operations and net loss of $(3,329,953) and $(3,546,309), respectively, for the year ended December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 18, 2026, the Company completed a &#x201c;best efforts&#x201d; public offering of (i) 8,270,000 shares of its common stock, (ii) 5,543,000 pre-funded warrants to purchase up to 5,543,000 shares of common stock (the &#x201c;Pre-Funded Warrants&#x201d;) and (ii) 13,813,000 common stock purchase warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per Pre-Funded Warrant) and accompanying warrant (the &#x201c;Offering&#x201d;). In connection with the Offering, the Company received net proceeds of approximately $3.46 million, after deducting the estimated offering expenses payable by the Company, including the placement agent fees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Company&#x2019;s assessment of going concern considerations in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 205-40, &lt;i style="font-style:italic;"&gt;Presentation of Financial Statements&#x2014;Going Concern&lt;/i&gt;, management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying consolidated financial statements are issued. The Company&#x2019;s consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Management&#x2019;s plans relating to the above include raising additional cash through further equity and debt financings or other arrangements to fund operations. There can be no assurance that the Company will be able to raise adequate capital under acceptable terms, if at all. The sale of additional equity may dilute existing members and newly issued equity securities may contain senior rights and preferences compared to currently outstanding common stock. Issued debt securities may contain covenants and limit the Company&#x2019;s ability to pay dividends or make other distributions to stockholders. If the Company is unable to obtain such additional financing, future operations would need to be reevaluated.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <limn:CommonStockCashRedemptionShares
      contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw"
      decimals="INF"
      id="Narr_2dMaaxQJtUiUdyHcKJvdOw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">59844</limn:CommonStockCashRedemptionShares>
    <limn:CommonStockCashRedemptionPricePerShare
      contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw"
      decimals="2"
      id="Narr_zkAbkgZrskinD0_WtkomQw"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">11.74</limn:CommonStockCashRedemptionPricePerShare>
    <limn:CommonStockCashRedemptionAmount
      contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw"
      decimals="0"
      id="Narr_TX3g3uUnEEOXGARpCU5DsQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">702359</limn:CommonStockCashRedemptionAmount>
    <limn:NumberOfSharesHeldInEachUnit
      contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw"
      decimals="INF"
      id="Narr__zH1hPEYUE66c5DVJ_LTXw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1</limn:NumberOfSharesHeldInEachUnit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_4_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_DeRxkz2RdUOESZvr23GiLw"
      decimals="INF"
      id="Narr_LtZLOsdPy0utFF3tgG3K3g"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <limn:CommonStockConversionRatioBusinessCombination
      contextRef="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_cgSRAUkHA0i2y04jy71KAw"
      decimals="0"
      id="Narr_idNQR85O80uUoXA1j68zSg"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">1</limn:CommonStockConversionRatioBusinessCombination>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_cgSRAUkHA0i2y04jy71KAw"
      decimals="INF"
      id="Narr_KLlcZkaVZEW5L-B4A8fVPw"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_us-gaap_ClassOfWarrantOrRightAxis_limn_NonRedeemableWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_ZG-LffBZq0OabS0uAuJI-Q"
      decimals="INF"
      id="Narr_OVFGgTfV4kSXuBH7tXFFUw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_4_2025_us-gaap_BusinessAcquisitionAxis_limn_LiminatusAndIrisMember_us-gaap_ClassOfWarrantOrRightAxis_limn_NonRedeemableWarrantMember_xHQZeSCsiEGkdYLlyBZaXA"
      decimals="2"
      id="Narr_tTu30AfYCkG2akIZP7Kstg"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <limn:SharesAuthorized
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="INF"
      id="Narr_8_70vjzEP0ishRDMj-WE0A"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">501000000</limn:SharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="INF"
      id="Narr_UmqRGu5CQEGmsiZAYdjyzA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="INF"
      id="Narr_5X31IiG7Uka4NtjzJ8CV5A"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="INF"
      id="Narr_Ww4ZlE-FD0OKHMXVgpianw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="INF"
      id="Narr_902-pLCjo06Q9qtP7mOYgg"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Gi0t5_gUYU-FQON95jjxrA"
      decimals="INF"
      id="Narr_q7H9uDmYpU2fMsT6meRDqA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">7014633</us-gaap:ConversionOfStockSharesConverted1>
    <limn:ConversionOfStockOrUnitConversionRatio
      contextRef="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_zu3KxzCVkkuK5CuyZXWLYA"
      decimals="0"
      id="Narr_o_ZxK_0gE0CQJJDuG-9OMA"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">1</limn:ConversionOfStockOrUnitConversionRatio>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Gi0t5_gUYU-FQON95jjxrA"
      decimals="INF"
      id="Narr_cgHHUIQI706QLpJPqoMrdg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">7014633</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionHoldingsLlcMember_HNZDVq5GE0GEgfHcGTUA1A"
      decimals="INF"
      id="Narr_fFaItmFg3kCNjnTmWymcww"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">6900000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_aADDeFhV70K5BS2735863Q"
      decimals="INF"
      id="Narr_AW6-pImGykaVaYRJNquTwQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">114633</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ"
      decimals="INF"
      id="Narr_ML9wK_VTZkm9PpD3aooVIw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ"
      decimals="0"
      id="Narr_ROPQ5452KkOrTtv8fSjvgw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">15000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ"
      decimals="0"
      id="Narr_ouQFNO-41kqYqguPIA_GTA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">10556500</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <limn:ProceedsFromIssuanceOfPrivatePlacementInvestor
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ"
      decimals="0"
      id="Narr_I3x1D6Uw-0-Ndci19mC2Tg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7129500</limn:ProceedsFromIssuanceOfPrivatePlacementInvestor>
    <limn:ProceedsFromIssuanceOfPrivatePlacementInvestorFunded
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ"
      decimals="0"
      id="Narr_zQlDMZnaa02nUK9jxtdpag"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3427000</limn:ProceedsFromIssuanceOfPrivatePlacementInvestorFunded>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GQBhaiZ1wk-tnk9eoG2uUQ"
      decimals="0"
      id="Narr_BG18PWxQe0CnYGGKH4560A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3427000</us-gaap:DebtConversionOriginalDebtAmount1>
    <limn:PrincipalAndAccruedInterestOnPrivatePlacement
      contextRef="As_Of_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VYxJe3-ZlEKGtf77rNoRJQ"
      decimals="0"
      id="Narr_5SCpXHAJB0GfK5l0CcyYhg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3316756</limn:PrincipalAndAccruedInterestOnPrivatePlacement>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ConsortiumLoanOfRelatedPartiesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4nTHRjjm9E64EIS8-8O57A"
      decimals="0"
      id="Narr_A9Qg9PeXpU-LQl0pa0uO_Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4443500</us-gaap:DebtConversionOriginalDebtAmount1>
    <limn:RelatedPartiesDebtToUnsecuredPromissoryNote
      contextRef="As_Of_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VYxJe3-ZlEKGtf77rNoRJQ"
      decimals="0"
      id="Narr_3SR9RArgbUyDCWYq65u-FQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4443500</limn:RelatedPartiesDebtToUnsecuredPromissoryNote>
    <limn:UnsecuredPromissoryNoteSettledAndConverted
      contextRef="As_Of_4_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VYxJe3-ZlEKGtf77rNoRJQ"
      decimals="0"
      id="Narr_kLKi8q9dnE2KekDHG1BtQA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4443500</limn:UnsecuredPromissoryNoteSettledAndConverted>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_4_30_2025_To_4_30_2025_9PPk1IhN6EmJm5MGsGwEDA"
      decimals="INF"
      id="Narr_-ZZCIIwFrUGIwvdA1dbGHA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">112222220</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_4_30_2025_To_4_30_2025_9PPk1IhN6EmJm5MGsGwEDA"
      decimals="INF"
      id="Narr_Vd74P6r7ZUOcJGxDk8Xklw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">17500000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_4_30_2025_To_4_30_2025_9PPk1IhN6EmJm5MGsGwEDA"
      decimals="INF"
      id="Narr_QpEUDHMbJEqIk-Bj9PyJMA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">17500000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_gsYeVbSjA0ijBUxcCNZtvA"
      decimals="INF"
      id="Narr_8rf_QJXszkaIovV0zHm2Yg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">4000000</us-gaap:ConversionOfStockSharesIssued1>
    <limn:ConversionOfPrincipalAndAccruedInterestAmount
      contextRef="As_Of_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxAndCarTcellkorMember_IRaHwKWzMU-DElAHyQN8Tg"
      decimals="0"
      id="Narr_xKae4piBVUm2icSVCa1vlg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">11481146</limn:ConversionOfPrincipalAndAccruedInterestAmount>
    <limn:ConversionOfPrincipalAndAccruedInterestShares
      contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxAndCarTcellkorMember_zWurOUpaU0i-IKmnDLLc4w"
      decimals="INF"
      id="Narr_zEUDHdEeZU6Dk53X29Xxdg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">9999999</limn:ConversionOfPrincipalAndAccruedInterestShares>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_gsYeVbSjA0ijBUxcCNZtvA"
      decimals="INF"
      id="Narr_58K483Qg2EOGnoYHJXV7xw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">4000000</us-gaap:ConversionOfStockSharesIssued1>
    <limn:ConversionOfStockOrUnitConversionRatio
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="4"
      id="Narr_DMnmXouyhUubQDmT2mVSGA"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.1559</limn:ConversionOfStockOrUnitConversionRatio>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_qUlxIbYw4Uyvh13v3JGs3g"
      decimals="0"
      id="Narr_SuC15c_dIUKC1mrT5G31OA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">10694604</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_aADDeFhV70K5BS2735863Q"
      decimals="0"
      id="Narr_KYmEYKKqs0ySMV0eFvDsJQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1518381</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_aADDeFhV70K5BS2735863Q"
      decimals="0"
      id="Narr_2oRDau0VVU65ocpEhEealQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">14797901</us-gaap:DebtConversionOriginalDebtAmount1>
    <limn:ConversionOfPrincipalAndAccruedInterestAmount
      contextRef="As_Of_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_qUlxIbYw4Uyvh13v3JGs3g"
      decimals="0"
      id="Narr_yjTjf9TvyUOXchEEawK6YA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">11481146</limn:ConversionOfPrincipalAndAccruedInterestAmount>
    <limn:ConversionOfAccruedInterestOnRelatedPartyDebts
      contextRef="Duration_4_30_2025_To_4_30_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_aADDeFhV70K5BS2735863Q"
      decimals="0"
      id="Narr_N5SpC9_I40-NSNUIHPFSFg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">169201</limn:ConversionOfAccruedInterestOnRelatedPartyDebts>
    <limn:DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="0"
      id="Narr_LJF5QCtQikGUqEgotoYW8A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7000000</limn:DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination>
    <limn:StockIssuableForSettlementOfDeferredUnderwritingFees
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="INF"
      id="Narr_4g82SMlWl0ydz4sLYUiNUQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">700000</limn:StockIssuableForSettlementOfDeferredUnderwritingFees>
    <limn:LiabilityOfUnderwritingFeesFairValue
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="0"
      id="Narr_bGbcOPkJ7E21Wopo-idlNg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7049000</limn:LiabilityOfUnderwritingFeesFairValue>
    <limn:FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees
      contextRef="As_Of_7_1_2025_CZJvPOCOcUySCDRAwOkqBA"
      decimals="0"
      id="Narr_Ck3S2bqPwEmB-kfg00Kaew"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7245000</limn:FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Narr_ja_oS3DkakeHW51Cf3VgUw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">337655</us-gaap:Cash>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Narr_ZQJSWghC_kWyh3eqIzF4ow"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1442500</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Narr_hLS2tVFDXUCzxscjPry_pQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">19973000</us-gaap:ShortTermBorrowings>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Narr_IWkA6FPEaEGpLbOsZKBz0w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-38871733</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Narr_k-nFwlp9306odsVfJILojg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-2967812</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Narr_RXpTo5fVBUuGTQtk2bFEhg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-10206517</us-gaap:NetIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Narr_uC20G4tQ3Ee4KsJG6Jegyw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-3329953</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Narr_Fg3iwuVyMEGNCrTZRyaMVw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-3546309</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_JSVgKnyZI0uvIBPJsCar7A"
      decimals="INF"
      id="Narr_yFxu93UazUi5EH17vzChnQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">8270000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <limn:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_BC5_6M-QyUmQOf1sjtWaMg"
      decimals="INF"
      id="Narr_aw8PasfbB0G7PCSSEKojHQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">5543000</limn:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_eTUFwzCAf0WPdoyAqoxppg"
      decimals="INF"
      id="Narr_fsF3vUQpcU2X9dNw-mGZYA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">5543000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <limn:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_YV5sLiK4506wsErDca1zNw"
      decimals="INF"
      id="Narr__ngp8DPEn0WZnLkQ8u_K3w"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">13813000</limn:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_Y7EtLUI_pk6RZ-oTbRPBxg"
      decimals="INF"
      id="Narr_rlwR9peATEGCx8dPKCZ46w"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">20719500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_2_18_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_1t1X0h92206D-tAJKXlt8Q"
      decimals="2"
      id="Narr_Xgc2U9amhkiAlqNoW_0WIg"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.29</us-gaap:SharesIssuedPricePerShare>
    <limn:ClassOfWarrantOrRightIssuePricePerWarrant
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_eTUFwzCAf0WPdoyAqoxppg"
      decimals="4"
      id="Narr_pPye_wQLWkadEB8t0FBaVw"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.2899</limn:ClassOfWarrantOrRightIssuePricePerWarrant>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_JSVgKnyZI0uvIBPJsCar7A"
      decimals="-4"
      id="Narr_WK2Y35sI4Um8xdup7CIcag"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3460000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_ZdyxbxRFs0CVG5T08pXm6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note&#160;2. Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) as determined by the FASB ASC and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). The consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;After the closing of the Business Combination, the Company has elected to be an &#x201c;emerging growth company,&#x201d; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), as modified by the Jumpstart our Business Startups Act of 2012, (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results may differ materially and adversely from these estimates. The Company is not aware of any significant estimates that required management to exercise significant judgment with the exception of the Company&#x2019;s warrant liability. If the underlying estimates and assumptions upon which the estimates are based change in the future, actual amounts may differ from those included in the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), the Chief Executive Officer, manages the Company&#x2019;s business activities as a single operating and reportable segment. Accordingly, the Company&#x2019;s CODM uses net income/loss to measure the Company&#x2019;s single segment&#x2019;s performance and allocate resources. Further, the CODM reviews and utilizes functional expenses (general and administrative and research and development) to manage the Company&#x2019;s operations. The Company&#x2019;s general and administrative expenses for each of the years ended December 31, 2025 and 2024 included $202,833 and $150,000 of compensation expenses related to the compensation agreements the Company has executed with its executive team. The remaining general and administrative expenses &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;are related to legal and accounting-related expenses for contractors. The Company&#x2019;s research and development expenses did not include any compensation-related expenses. Other segment items included in net income (loss) are interest expense, related parties and interest income which are reflected in the Company&#x2019;s consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which can exceed government insured limits. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2025 and 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Loan Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for its loan receivable at amortized cost, net of expected credit losses. The Company provides reserves against its loan receivable balance for estimated credit losses, if any, that may result from a counterparty&#x2019;s inability to pay based on the composition of the loan receivable, current economic conditions and, historical credit loss activity and future expected conditions and market trends (such as general economic conditions, other macroeconomic and microeconomic events, etc.). Changes in circumstances relating to these factors may result in the need to increase or decrease the allowance for credit losses in the future. Amounts deemed uncollectible are charged or written-off against the reserve. On April 30, 2025, in connection with the Business Combination, the loan receivable was eliminated in consolidation as Iris and Liminatus are now consolidated subsidiaries of the Company. As of January 1, 2024 and December 31, 2024, no expected credit loss was recorded related to the loan receivable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Deferred Transaction Costs &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Costs incurred in connection with preparation for the proposed business combination were deferred on the balance sheets as of December 31, 2024. No such costs were deferred on the balance sheets as of December 31, 2025 due to the completion of the Company&#x2019;s business combination with Iris. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial assets and liabilities are accounted for in accordance with FASB ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurements and Disclosures,&lt;/i&gt; which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value hierarchy requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 1 &#x2014; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 2 &#x2014; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the instrument&#x2019;s anticipated life.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 3 &#x2014; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgement. Accordingly, the degree of judgement exercised by management in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the warrant liability reported in the Company&#x2019;s consolidated balance sheets represent a Level 3 instrument. See Note 8.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The carrying values reported in the Company&#x2019;s consolidated balance sheets for prepaid expenses and other current assets, due from related party, accounts payable and accrued expenses, accrued interest, short-term debt with related parties, due to research and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;development partner, due to related parties, settlement payable, and its deferred underwriting fee payable are reasonable estimates of their fair values due to the short-term nature of these items.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in ASC 480, &lt;i style="font-style:italic;"&gt;Distinguishing liabilities from equity&lt;/i&gt; (&#x201c;ASC 480&#x201d;), and ASC 815, &lt;i style="font-style:italic;"&gt;Derivatives and Hedging&lt;/i&gt; (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own common shares and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance, modification, and as of each subsequent quarterly period end date while the warrants are outstanding. As of December 31, 2025, 5,899,975 of the Company&#x2019;s Public Warrants were accounted for as equity-classified instruments and 835,555 private placement warrants were accounted for as liability-classified instruments. As of December 31, 2025, there were no other public or &lt;span style="-sec-ix-hidden:Hidden_wUaYXsrirkKbOmu3ilr3Zg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;private&lt;/span&gt;&lt;/span&gt; warrants outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the liability-classified warrants are recognized as a non-cash gain or loss on the accompanying consolidated statements of operations. The Company assesses the classification of its warrants at each reporting date to determine whether a change in classification between equity and liability is required. During the year ended December 31, 2025, the Company had an unrealized gain on the change in fair value of the warrant liabilities of $54,312. During the year ended December 31, 2024, the Company had no unrealized gain or loss on the change in fair value of the warrant liabilities. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Net loss per Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company complies with accounting and disclosure requirements of ASC Topic 260, &lt;i style="font-style:italic;"&gt;Earnings Per Share&lt;/i&gt;. The Company has one class of common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities if their effect is antidilutive. Diluted net loss per share is computed by the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined by using the treasury stock method. Dilutive common stock equivalents are comprised of 6,735,530 warrants. For all periods presented, there is no difference in the number of shares used to calculated basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive given that their exercise price is greater than that of the average market price of the Company&#x2019;s common stock during the years ended December 31, 2025 and 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development expenses consist of costs incurred by Targeted Diagnostics &amp;amp; Therapeutics, Inc. (&#x201c;TDT&#x201d;) who was performing the research and development activities for the Company in accordance with the license agreements with TDT and the annual fee paid to TDT and are recorded as research and development expenses as incurred (see Note 3).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes its leases in accordance with ASC Topic 842, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; (&#x201c;ASC 842&#x201d;). Under ASC 842, lessees are required to recognize all qualified operating leases at the commencement date including a lease liability, which is a lessee&#x2019;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use (&#x201c;ROU&#x201d;) asset, which is an asset that represents the lessee&#x2019;s right to use, or control the use of, a specified asset for the lease term. The initial lease liability is equal to the future fixed minimum lease payments discounted using the Company&#x2019;s incremental borrowing rate, on a secured basis. The lease term includes option renewal periods and early termination payments when it is reasonably certain that the Company will exercise those rights. The initial measurement of the ROU asset is equal to the initial lease liability plus any initial direct costs and prepayments, less any lease incentives.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has leased office space for a fixed period of 10 months. In accordance with ASC 842, a short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The short-term lease election can only be made at the commencement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A lessee that makes this accounting policy election does not recognize a lease liability or right-of-use asset on its balance sheet. Instead, the lessee recognizes lease payments on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes in accordance with ASC Topic 740,&#160;&lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt;&#160;(&#x201c;ASC 740&#x201d;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. There were no tax accruals relating to uncertain tax positions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax positions as income tax expense. There were no unrecognized tax positions, and no amounts accrued for interest and penalties as of December 31, 2025 and 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only &#x201c;major&#x201d; tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. No unrecognized tax benefits were identified as of December 31, 2025 or 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d; that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The Company adopted this standard on January 1, 2025 and determined that the adoption does not have a material impact on these consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Pronouncements&#160;&#x2013; Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2024, the FASB issued ASU 2024-03, Accounting Standards Update 2024-03, &lt;i style="font-style:italic;"&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt; to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_-gEPds688U-8ofLfKXA8iw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) as determined by the FASB ASC and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). The consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. &lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <limn:EmergingGrowthCompanyPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_yaLwgZrk7UOV4b-HGinyAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;After the closing of the Business Combination, the Company has elected to be an &#x201c;emerging growth company,&#x201d; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), as modified by the Jumpstart our Business Startups Act of 2012, (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/p&gt;</limn:EmergingGrowthCompanyPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_Md5KVpM4NUmCNm1VpNJYTQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results may differ materially and adversely from these estimates. The Company is not aware of any significant estimates that required management to exercise significant judgment with the exception of the Company&#x2019;s warrant liability. If the underlying estimates and assumptions upon which the estimates are based change in the future, actual amounts may differ from those included in the Company&#x2019;s consolidated financial statements.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_j54wbF6cPUWSaOP5eBq8VA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), the Chief Executive Officer, manages the Company&#x2019;s business activities as a single operating and reportable segment. Accordingly, the Company&#x2019;s CODM uses net income/loss to measure the Company&#x2019;s single segment&#x2019;s performance and allocate resources. Further, the CODM reviews and utilizes functional expenses (general and administrative and research and development) to manage the Company&#x2019;s operations. The Company&#x2019;s general and administrative expenses for each of the years ended December 31, 2025 and 2024 included $202,833 and $150,000 of compensation expenses related to the compensation agreements the Company has executed with its executive team. The remaining general and administrative expenses &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;are related to legal and accounting-related expenses for contractors. The Company&#x2019;s research and development expenses did not include any compensation-related expenses. Other segment items included in net income (loss) are interest expense, related parties and interest income which are reflected in the Company&#x2019;s consolidated statements of operations.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <limn:FranchiseTaxExpenseIncludingInterestAndPenalty
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_ILl90TwynkGTc6BgSwur3g"
      decimals="0"
      id="Narr_HWGuatMJZEKZs3BenxGRTw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">202833</limn:FranchiseTaxExpenseIncludingInterestAndPenalty>
    <limn:FranchiseTaxExpenseIncludingInterestAndPenalty
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_hXB18br9yUGm2G-QE5h2uQ"
      decimals="0"
      id="Narr_xhsp3lXUWEeMWYfh9xLVlg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">150000</limn:FranchiseTaxExpenseIncludingInterestAndPenalty>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_595SdYHXdEWBtE-PiljRHQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which can exceed government insured limits. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2025 and 2024.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Narr_oyd_TN8dw0CKWkcMIh5Z5Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Narr_KOyVOeaIoki3vtdbnft9TQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:FinanceLoansAndLeasesReceivablePolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_BPxWNA6irE-ZlOJxOBdf3g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Loan Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for its loan receivable at amortized cost, net of expected credit losses. The Company provides reserves against its loan receivable balance for estimated credit losses, if any, that may result from a counterparty&#x2019;s inability to pay based on the composition of the loan receivable, current economic conditions and, historical credit loss activity and future expected conditions and market trends (such as general economic conditions, other macroeconomic and microeconomic events, etc.). Changes in circumstances relating to these factors may result in the need to increase or decrease the allowance for credit losses in the future. Amounts deemed uncollectible are charged or written-off against the reserve. On April 30, 2025, in connection with the Business Combination, the loan receivable was eliminated in consolidation as Iris and Liminatus are now consolidated subsidiaries of the Company. As of January 1, 2024 and December 31, 2024, no expected credit loss was recorded related to the loan receivable.&lt;/p&gt;</us-gaap:FinanceLoansAndLeasesReceivablePolicy>
    <us-gaap:AllowanceForNotesAndLoansReceivableCurrent
      contextRef="As_Of_1_1_2024_0fsIJRo8qkmwqwDgqs1FdA"
      decimals="0"
      id="Narr_cunH3a8tIUO5dNWT2IfKEg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:AllowanceForNotesAndLoansReceivableCurrent>
    <us-gaap:AllowanceForNotesAndLoansReceivableCurrent
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Narr_OAaRY2XuLEqWbnVxCoNCuw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:AllowanceForNotesAndLoansReceivableCurrent>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_4KhxflQwY0iwv2s-tWRjJw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Deferred Transaction Costs &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Costs incurred in connection with preparation for the proposed business combination were deferred on the balance sheets as of December 31, 2024. No such costs were deferred on the balance sheets as of December 31, 2025 due to the completion of the Company&#x2019;s business combination with Iris. &lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredCostsCurrent
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Narr_vG9G_zuvV0yLhz-0eI8prg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:DeferredCostsCurrent>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_b2AzxXuS_ECHZLELR0xtig">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial assets and liabilities are accounted for in accordance with FASB ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurements and Disclosures,&lt;/i&gt; which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value hierarchy requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 1 &#x2014; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 2 &#x2014; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the instrument&#x2019;s anticipated life.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 3 &#x2014; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgement. Accordingly, the degree of judgement exercised by management in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the warrant liability reported in the Company&#x2019;s consolidated balance sheets represent a Level 3 instrument. See Note 8.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The carrying values reported in the Company&#x2019;s consolidated balance sheets for prepaid expenses and other current assets, due from related party, accounts payable and accrued expenses, accrued interest, short-term debt with related parties, due to research and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;development partner, due to related parties, settlement payable, and its deferred underwriting fee payable are reasonable estimates of their fair values due to the short-term nature of these items.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <limn:WarrantsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_b5UnRRW09Ue1x4RZGdNwMw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in ASC 480, &lt;i style="font-style:italic;"&gt;Distinguishing liabilities from equity&lt;/i&gt; (&#x201c;ASC 480&#x201d;), and ASC 815, &lt;i style="font-style:italic;"&gt;Derivatives and Hedging&lt;/i&gt; (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own common shares and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance, modification, and as of each subsequent quarterly period end date while the warrants are outstanding. As of December 31, 2025, 5,899,975 of the Company&#x2019;s Public Warrants were accounted for as equity-classified instruments and 835,555 private placement warrants were accounted for as liability-classified instruments. As of December 31, 2025, there were no other public or &lt;span style="-sec-ix-hidden:Hidden_wUaYXsrirkKbOmu3ilr3Zg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;private&lt;/span&gt;&lt;/span&gt; warrants outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the liability-classified warrants are recognized as a non-cash gain or loss on the accompanying consolidated statements of operations. The Company assesses the classification of its warrants at each reporting date to determine whether a change in classification between equity and liability is required. During the year ended December 31, 2025, the Company had an unrealized gain on the change in fair value of the warrant liabilities of $54,312. During the year ended December 31, 2024, the Company had no unrealized gain or loss on the change in fair value of the warrant liabilities. &lt;/p&gt;</limn:WarrantsPolicyPolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z416a0UcpESjBa-8wQ9m5Q"
      decimals="INF"
      id="Narr_BLxhzNq7oEaZl6iHbRHNtA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">5899975</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PrivatePlacementWarrantsMember_ioEniwa8PEunNaQ7J6fSnA"
      decimals="INF"
      id="Narr_vYMh1AJzJ0qhU1MRjjH_4g"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">835555</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z416a0UcpESjBa-8wQ9m5Q"
      decimals="0"
      id="Narr_UxhD8IpVl0-v6QaRUJT3MQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Narr_skGWsZbu8EaLABIlHfqq_w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-54312</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Narr_hWPyria92EmwYXRmnHbW6w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:FairValueAdjustmentOfWarrants>
    <limn:NetIncomeLossPerCommonStockPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_XvTcLjeToUeWhIjs9wf0CA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Net loss per Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company complies with accounting and disclosure requirements of ASC Topic 260, &lt;i style="font-style:italic;"&gt;Earnings Per Share&lt;/i&gt;. The Company has one class of common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities if their effect is antidilutive. Diluted net loss per share is computed by the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined by using the treasury stock method. Dilutive common stock equivalents are comprised of 6,735,530 warrants. For all periods presented, there is no difference in the number of shares used to calculated basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive given that their exercise price is greater than that of the average market price of the Company&#x2019;s common stock during the years ended December 31, 2025 and 2024.&lt;/p&gt;</limn:NetIncomeLossPerCommonStockPolicyPolicyTextBlock>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="INF"
      id="Narr_eus0gSluYEmmL5yKnwl3Xw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">6735530</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_o7xl9igDRES1r6gufOdbzg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development expenses consist of costs incurred by Targeted Diagnostics &amp;amp; Therapeutics, Inc. (&#x201c;TDT&#x201d;) who was performing the research and development activities for the Company in accordance with the license agreements with TDT and the annual fee paid to TDT and are recorded as research and development expenses as incurred (see Note 3).&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_KvrUDEDtwEy8n2V2GlWH1Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes its leases in accordance with ASC Topic 842, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; (&#x201c;ASC 842&#x201d;). Under ASC 842, lessees are required to recognize all qualified operating leases at the commencement date including a lease liability, which is a lessee&#x2019;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use (&#x201c;ROU&#x201d;) asset, which is an asset that represents the lessee&#x2019;s right to use, or control the use of, a specified asset for the lease term. The initial lease liability is equal to the future fixed minimum lease payments discounted using the Company&#x2019;s incremental borrowing rate, on a secured basis. The lease term includes option renewal periods and early termination payments when it is reasonably certain that the Company will exercise those rights. The initial measurement of the ROU asset is equal to the initial lease liability plus any initial direct costs and prepayments, less any lease incentives.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has leased office space for a fixed period of 10 months. In accordance with ASC 842, a short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The short-term lease election can only be made at the commencement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A lessee that makes this accounting policy election does not recognize a lease liability or right-of-use asset on its balance sheet. Instead, the lessee recognizes lease payments on a straight-line basis over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      id="Narr_rcEK9ZI6MUuvnNre92MDCQ">P10M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_Q8NVmh80zkyCrRUgoMqCWw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes in accordance with ASC Topic 740,&#160;&lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt;&#160;(&#x201c;ASC 740&#x201d;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. There were no tax accruals relating to uncertain tax positions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax positions as income tax expense. There were no unrecognized tax positions, and no amounts accrued for interest and penalties as of December 31, 2025 and 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only &#x201c;major&#x201d; tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. No unrecognized tax benefits were identified as of December 31, 2025 or 2024.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Narr_i_OYQkIYcE6jIbqX3LkZ8Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Narr_Q9gEjiO5BU-UxiGrNzHgZA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Narr_xSDVwNTZZUOfJS8HXZq_Ww"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Narr_s3amLLNUoEOLNJKOTtWx8g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Narr_8DTdLqjSxkKGgwzEHl_rJQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Narr_4IIn1wXQqEGvVRRHq_WFYA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Narr_zZjWH93WFkyof0badDxZJw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_DbkXMZuR_UOsnwK05-LjZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d; that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The Company adopted this standard on January 1, 2025 and determined that the adoption does not have a material impact on these consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Pronouncements&#160;&#x2013; Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2024, the FASB issued ASU 2024-03, Accounting Standards Update 2024-03, &lt;i style="font-style:italic;"&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt; to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <limn:LicenseAgreementsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_JIP5QkTmKkaDI_mJ2huWoA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 3. License Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;CAR-T Products License&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2018, the Company entered into a license and development agreement with TDT (the &#x201c;CAR-T License&#x201d;), whereby the Company received an exclusive license to develop and commercialize chimeric antigen receptor (&#x201c;CAR-T&#x201d;) products and a non-exclusive license to develop and commercialize companion diagnostics used to monitor treatment with a CAR-T product (the &#x201c;CAR-T Diagnostics&#x201d;). Under the CAR-T License, the Company made an upfront payment recorded as research and development expenses in the year ended December 31, 2018 and funded all of the development costs for the CAR-T products and the CAR-T Diagnostics which began with an upfront payment made during the year ended December 31, 2018 of approximately $5,000,000, recorded as advances for research and development in the balance sheets. The Company amortizes the advances to research and development expenses in the consolidated statements of operations as costs are incurred by TDT, based on annual budgets approved jointly by Liminatus and TDT. As of December 31, 2025 and 2024, all of the amounts funded have been utilized. The Company was also obligated to pay an approximately $500,000 annual maintenance fee for the license which is included in research and development expenses in the consolidated statements of operations. Unpaid annual maintenance fees become short-term debt that bears interest of 1.5% per month on a compounded basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the completion of the Phase I and Phase II clinical trials for the CAR-T product, the Company was obligated to advance the funding for the Phase II and Phase III clinical trials, respectively, estimated at approximately $20,000,000 for each phase. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition to the funding for the CAR-T development, the Company was obligated to make four developmental and regulatory milestone payments for the first CAR-T product that was developed aggregating up to approximately $15,000,000. After the first four developmental and regulatory milestone payments were made, the Company was obligated to pay four developmental and regulatory milestones aggregating up to approximately $7,500,000 for each additional CAR-T product that was developed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In further consideration of the license, the Company also agreed to pay a low double digit royalty rate (10% &#x2013; 15%) based on annual net sales of CAR-T products or CAR-T Diagnostics on a country-by-country basis for the period from the first commercial sale of the CAR-T product or CAR-T Diagnostic until the CAR-T product or CAR-T Diagnostic&#x2019;s patent expires in an individual country. Once the CAR-T product or CAR-T Diagnostic&#x2019;s patent expires in an individual country, the Company agreed to pay a mid-single digit royalty rate (5% &#x2013; 9%) based on annual net sales of CAR-T products and CAR-T Diagnostics on a country- by-country basis. Royalties were payable on a country-by-country basis for a period of ten years from the first commercial sale of the CAR-T product or CAR-T Diagnostic.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 11, 2024, the Company received notice from TDT, exercising its right to terminate the license and development agreement. Please refer to &#x201c;Termination and Settlement of CAR-T Products and Vaccine Products Licenses from TDT&#x201d; below for further details related the termination and settlement of the CAR-T Products and Vaccine Products Licenses from TDT.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Vaccine Products License&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 10, 2020, the Company was assigned a license and development agreement with TDT (the &#x201c;Vaccine License&#x201d;), whereby the Company received an exclusive license to develop and commercialize vaccine products (the &#x201c;Vaccine Products&#x201d;) and a non-exclusive license to develop and commercialize companion diagnostics used to monitor treatment with a Vaccine Product (the &#x201c;Vaccine Diagnostics&#x201d;). Under the Vaccine License, the Company was responsible for all of the development costs for the Vaccine Products after the upfront payment of approximately $4,000,000, which was paid by Viral Gene, Inc (&#x201c;Viral Gene&#x201d;), of which Chris Kim is also the CEO, to TDT. The Company was also obligated to pay an approximately $400,000 annual maintenance fee for the license which is included in research and development expenses in the Company&#x2019;s consolidated statements of operations for the year ended December&#160;31, 2024. There was no maintenance fee for the year ended December 31, 2025. Unpaid annual maintenance fees will become short-term debt that bears interest of 1.5% per month on a compounded basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company amortizes the amounts due to research and development partner in the Company&#x2019;s consolidated balance sheets to research and development expenses in the consolidated statements of operations as costs are incurred by TDT, based on annual budgets approved jointly by Liminatus and TDT.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;In addition to the funding for the Vaccine Products development, the Company was obligated to make four developmental and regulatory milestone payments for the first Vaccine Product that was developed aggregating up to approximately $12,000,000. After the first four developmental and regulatory milestone payments are made, the Company was obligated to pay four developmental and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;regulatory milestones aggregating up to approximately $6,000,000 for each additional Vaccine Product that is developed. As of December 31, 2025 and 2024, all the amounts funded have been utilized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In further consideration of the license, the Company also agreed pay a low double digit royalty rate (10% &#x2013; 15%) based on annual net sales of Vaccine Products or Vaccine Diagnostics on a country-by-country basis for the period from the first commercial sale of the Vaccine Product or Vaccine Diagnostic until the Vaccine Product or Vaccine Diagnostic&#x2019;s patent expires in an individual country. Once the Vaccine Product or Vaccine Diagnostic&#x2019;s patent expires in an individual country, the Company agreed to pay a mid-single digit royalty rate (5% &#x2013; 9%) based on annual net sales of Vaccine Products and Vaccine Diagnostics on a country- by-country basis. Royalties were payable on a country-by-country basis for a period of ten years from the first commercial sale of the Vaccine Product or Vaccine Diagnostic.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 11, 2024, the Company received notice from TDT, exercising its right to terminate the license and development agreement. Please refer to &#x201c;Termination of CAR-T Products and Vaccine Products Licenses from TDT&#x201d; below for further details.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Termination and Settlement of CAR-T Products and Vaccine Products Licenses from TDT&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 11, 2024, the Company received notice from TDT, exercising its right to terminate the license and development agreement, dated June 10, 2018, between TDT and Liminatus. As of August 2024, the CAR-T License and Vaccine License have been terminated.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 16, 2025, the Company and TDT entered and executed a settlement agreement. Pursuant to the terms of the settlement agreement, the Company was released and discharged from all agreements, promises, suites, disputes, claims and demands, debts and amounts due to TDT. As of December 31, 2025, the Company reversed the amounts due to TDT and recognized a gain of $2,142,297, which is included in Forgiveness of unrelated vendor payables on the Company&#x2019;s consolidated statement of operations in accordance with ASC 450-30, Contingencies - Gain Contingencies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025 and, 2024, the Company owed $0 and $2,142,297, respectively, to TDT for research and development for the aggregate CAR-T Products and Vaccine Licenses, which is included in the due to research and development partner and accrued maintenance fees on the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;CD47 License&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2022, the Company was assigned a license and development agreement, as amended, with InnoBation Bio Co., Ltd. (the &#x201c;CD47 License&#x201d;), whereby, effective March 31, 2023, the Company received an exclusive license to develop and commercialize products for the CD47 immune checkpoint inhibitor to treat solid cancers, and companion diagnostics used to monitor treatment with CD47 products (collectively, &#x201c;CD47 Products&#x201d;), from Curis Biotech Holdings LLC, the parent company of Valetudo, a related party of the Company, in exchange for 78,555,554 of Liminatus&#x2019; Class A member units. The license was recorded at Valetudo&#x2019;s cost basis of zero, and the Company recorded an approximately $800,000 Class A membership interest with an offset to additional paid-in capital on the balance sheets. The Company is obligated to pay all development costs for CD47 Products. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company has not paid and does not owe any license fees, management fees, developmental or regulatory milestone payments or royalty payments under the CD47 License through December 2025.&lt;/p&gt;</limn:LicenseAgreementsTextBlock>
    <limn:UpfrontPaymentOfLicenseAgreementFees
      contextRef="Duration_1_1_2018_To_12_31_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_PCxMs4QP-k2uBuXoZKiE1A"
      decimals="0"
      id="Narr_iho7jb607kqH8am59jNjKA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">5000000</limn:UpfrontPaymentOfLicenseAgreementFees>
    <us-gaap:CostMaintenance
      contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_0lDWBPW2vkuWvH-HiGeZyg"
      decimals="0"
      id="Narr_au4JRj_lKE2oAgMnNeRSmQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">500000</us-gaap:CostMaintenance>
    <limn:UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate
      contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_0lDWBPW2vkuWvH-HiGeZyg"
      decimals="3"
      id="Narr_l02Q0PjkU0SDKApt9u9TbQ"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.015</limn:UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate>
    <limn:LicenseMilestoneCommitmentFundPayableForEachPhase
      contextRef="As_Of_6_30_2018_srt_ProductOrServiceAxis_limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember_srt_StatementScenarioAxis_limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_5kAI3vX6BkKP69_x9ufqDQ"
      decimals="0"
      id="Narr_0ra1CQ_bmE-pW-6tcR0dMg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">20000000</limn:LicenseMilestoneCommitmentFundPayableForEachPhase>
    <limn:NumberOfMilestonePaymentsForFirstProductDevelopment
      contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_0lDWBPW2vkuWvH-HiGeZyg"
      decimals="INF"
      id="Narr_PAJho9u6UEO6X5GXK9a5iQ"
      unitRef="Unit_Standard_Milestone_17WZ1k4BqkSsiQd-8K0NPw">4</limn:NumberOfMilestonePaymentsForFirstProductDevelopment>
    <limn:LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment
      contextRef="As_Of_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_c5l6cvRI4EqXlctlS8Hl9Q"
      decimals="0"
      id="Narr_GSOQIvaUHkG55jlAogVBAQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">15000000</limn:LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment>
    <limn:NumberOfMilestonePaymentsForFirstProductDevelopment
      contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_0lDWBPW2vkuWvH-HiGeZyg"
      decimals="INF"
      id="Narr_g0yy3dRiDUyYYQk4LzcArw"
      unitRef="Unit_Standard_Milestone_17WZ1k4BqkSsiQd-8K0NPw">4</limn:NumberOfMilestonePaymentsForFirstProductDevelopment>
    <limn:NumberOfMilestonePaymentsForEachAdditionalProductDevelopment
      contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_0lDWBPW2vkuWvH-HiGeZyg"
      decimals="INF"
      id="Narr_ODikxMNJXEGawfOKvA3ONg"
      unitRef="Unit_Standard_Milestone_17WZ1k4BqkSsiQd-8K0NPw">4</limn:NumberOfMilestonePaymentsForEachAdditionalProductDevelopment>
    <limn:LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment
      contextRef="As_Of_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_c5l6cvRI4EqXlctlS8Hl9Q"
      decimals="0"
      id="Narr_9Hih62JSFkuDSGfcMDpJzw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7500000</limn:LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment>
    <limn:RoyaltyFeesPercentage
      contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_tvMLwMEPF0OgoT8qvqNtOw"
      decimals="2"
      id="Narr_n6VKIkc96km4PJupvay49A"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.10</limn:RoyaltyFeesPercentage>
    <limn:RoyaltyFeesPercentage
      contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_e8pHl9vKL0iD2UdUCsGsVg"
      decimals="2"
      id="Narr_jaDrjFM2S0KltZJZw7uxNw"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.15</limn:RoyaltyFeesPercentage>
    <limn:RoyaltyFeesPercentage
      contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_F5M5DAEMCUGaVGfvYeyHNA"
      decimals="2"
      id="Narr_kC_plO-AKUCHJ1O2WmCjAA"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.05</limn:RoyaltyFeesPercentage>
    <limn:RoyaltyFeesPercentage
      contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_Ze3T2NMaj0Ge4Cdvcxk6nQ"
      decimals="2"
      id="Narr_G2wrv2AxjE6KLGf_7OtWcw"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.09</limn:RoyaltyFeesPercentage>
    <limn:RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts
      contextRef="Duration_6_1_2018_To_6_30_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_8RdOebh7f0C05gFluwIFFA"
      id="Narr_IsLZ6M-EsUu3NVAFAxcX3Q">P10Y</limn:RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts>
    <limn:UpfrontPaymentOfLicenseAgreementFees
      contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_o6DHM9UbBkSNjCOhIS_9VA"
      decimals="0"
      id="Narr_rjGE554XhEeK-I9uLMUpeQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4000000</limn:UpfrontPaymentOfLicenseAgreementFees>
    <us-gaap:CostMaintenance
      contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_o6DHM9UbBkSNjCOhIS_9VA"
      decimals="0"
      id="Narr_nRqW3xsZKEiNPvZbcZ8EIw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">400000</us-gaap:CostMaintenance>
    <limn:LicenseAgreementMaintenanceFees
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_jBCIg7TF3U2nA2e4ZL4LPw"
      decimals="0"
      id="Narr_vZZH3HZ0uUC6u1SrJKUtjA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</limn:LicenseAgreementMaintenanceFees>
    <limn:UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate
      contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_o6DHM9UbBkSNjCOhIS_9VA"
      decimals="3"
      id="Narr_cidW_z7IRk65UZ7zt9qDog"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.015</limn:UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate>
    <limn:NumberOfMilestonePaymentsForFirstProductDevelopment
      contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_o6DHM9UbBkSNjCOhIS_9VA"
      decimals="INF"
      id="Narr_gwMtsNwZeUiiyg9Dog_jbw"
      unitRef="Unit_Standard_Milestone_17WZ1k4BqkSsiQd-8K0NPw">4</limn:NumberOfMilestonePaymentsForFirstProductDevelopment>
    <limn:LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment
      contextRef="As_Of_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_h1stl_iThEi0wHNuwBrmew"
      decimals="0"
      id="Narr_b_kWdP0YoE2cA56zSs116Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">12000000</limn:LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment>
    <limn:NumberOfMilestonePaymentsForFirstProductDevelopment
      contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_o6DHM9UbBkSNjCOhIS_9VA"
      decimals="INF"
      id="Narr_G9wqE205skmg1M0Kqm-Thg"
      unitRef="Unit_Standard_Milestone_17WZ1k4BqkSsiQd-8K0NPw">4</limn:NumberOfMilestonePaymentsForFirstProductDevelopment>
    <limn:NumberOfMilestonePaymentsForEachAdditionalProductDevelopment
      contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_o6DHM9UbBkSNjCOhIS_9VA"
      decimals="INF"
      id="Narr_9PgpxF19mE-GjihszoaPDg"
      unitRef="Unit_Standard_Milestone_17WZ1k4BqkSsiQd-8K0NPw">4</limn:NumberOfMilestonePaymentsForEachAdditionalProductDevelopment>
    <limn:LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment
      contextRef="As_Of_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_h1stl_iThEi0wHNuwBrmew"
      decimals="0"
      id="Narr_7e_OZJj6KEaiYKqSiMQ15A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">6000000</limn:LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment>
    <limn:RoyaltyFeesPercentage
      contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_AysCyyacDk6EgeXu96kqgw"
      decimals="2"
      id="Narr_nhEjcelIQUyhD-YRU-dTYQ"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.10</limn:RoyaltyFeesPercentage>
    <limn:RoyaltyFeesPercentage
      contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_xdnRdKDui0uO30li7vEb9g"
      decimals="2"
      id="Narr_Vjs2Vnr7bkWdx96-KksM4Q"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.15</limn:RoyaltyFeesPercentage>
    <limn:RoyaltyFeesPercentage
      contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_BXcmOS2BJEKYVp-Znixfsg"
      decimals="2"
      id="Narr_N_wSqQXI2kmMc8CldMnQPg"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.05</limn:RoyaltyFeesPercentage>
    <limn:RoyaltyFeesPercentage
      contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_kzj2YTUmsUqdNgLEb6ecrQ"
      decimals="2"
      id="Narr_wsZ4by0Ajkyxs7cV6Eg-Mg"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.09</limn:RoyaltyFeesPercentage>
    <limn:RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts
      contextRef="Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_srt_StatementScenarioAxis_limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_9RVHQy9tTkeZj8t4JvLMeA"
      id="Narr_0mc28FewNECQ8mn13NfQtg">P10Y</limn:RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts>
    <limn:ForgivenessOfUnrelatedVendorPayable
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_TypeOfArrangementAxis_limn_CarTLicenseAndVaccineLicenseWithTdtMember_cvbZ4e18Jk2WLlTRj8K7eQ"
      decimals="0"
      id="Narr_p5TS92mFqUy7S6GGNfJQGA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2142297</limn:ForgivenessOfUnrelatedVendorPayable>
    <limn:LicenseAgreementsTerminationAmountDue
      contextRef="As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_limn_CarTLicenseAndVaccineLicenseWithTdtMember_mWk8tah9gUuCRPqsFLhQWg"
      decimals="0"
      id="Narr_9Pwhx2voskiQ2Gy1rHO0VA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</limn:LicenseAgreementsTerminationAmountDue>
    <limn:LicenseAgreementsTerminationAmountDue
      contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_limn_CarTLicenseAndVaccineLicenseWithTdtMember_aVFA-tb0MUC-EmBUAPe-xw"
      decimals="0"
      id="Narr_vkInUWhy4UacNFyHosW-tw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2142297</limn:LicenseAgreementsTerminationAmountDue>
    <limn:NumberOfUnitsExchangeForLicenseRights
      contextRef="As_Of_10_31_2022_srt_CounterpartyNameAxis_limn_CurisBiotechHoldingsLlcMember_us-gaap_CapitalUnitsByClassAxis_us-gaap_CapitalUnitClassAMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_MfcULb3sYEWNTNOdJMM4Mg"
      decimals="INF"
      id="Narr_lUuBoXt6AESI75MUMqwKxw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">78555554</limn:NumberOfUnitsExchangeForLicenseRights>
    <limn:LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital
      contextRef="As_Of_10_31_2022_srt_CounterpartyNameAxis_limn_CurisBiotechHoldingsLlcMember_us-gaap_CapitalUnitsByClassAxis_us-gaap_CapitalUnitClassAMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_MfcULb3sYEWNTNOdJMM4Mg"
      decimals="0"
      id="Narr_UmoqC2y1lEuFCDCfkgc7mQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">800000</limn:LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_0pV7sQQuqkWNcKDRN_1_dw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note&#160;4. Related Party Transactions&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Related Party Debt&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Feelux Bonds&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 15, 2018, the Company issued $10,000,000 of bonds to Feelux Co., Ltd., the parent company of Car-Tcellkor, Inc. (&#x201c;Car-Tcellkor&#x201d;) (see below), the only holder of Liminatus&#x2019; Class A member units (the &#x201c;Feelux Bonds&#x201d;). The bonds bear interest at 1% per annum, compounded annually, and were due on October 30, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;In connection with the issuance of the Feelux Bonds, Liminatus issued 6,666,666 equity-classified warrants to purchase member units at a price of $1.50 per unit, which expired on June 30, 2023. The fair value of the warrants to purchase member units of approximately $6,400,000 was estimated using the option pricing framework on the issuance date. The Company&#x2019;s assumptions included &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;(a) its expected stock volatility of 82.0% based on the historical volatility of a publicly traded set of peer companies, (b) the contractual term of five years, (c) the risk-free interest rate of 2.9% based on the U.S. Treasury yield curve in effect at the time of grant of the award for a five-year contractual term and (d) no expected dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The $10,000,000 of proceeds from the Feelux Bonds were allocated to the bonds and warrants using the relative fair value method resulting in a debt discount for the relative fair value of the warrants of $4,499,142 that was amortized to interest expense over the term of the Feelux Bonds using the effective interest method using an effective interest rate of 21.0%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 30, 2025, upon consummation of the Business Combination, the outstanding principal and accrued interest on the Feelux Bonds, totaling $10,681,146, and 9,999,999 member units of Liminatus were converted into 4,000,000 shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025 and 2024, the Feelux Bonds have a carrying amount of $0 and $10,000,000, respectively, and are included in short-term debt, related parties in the consolidated balance sheets. As of December 31, 2025 and 2024, the related accrued interest of the Feelux Bonds was $0 and $646,124, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, the Company recorded $35,023 and $106,087, respectively, of interest expense in the consolidated statements of operations for the Feelux Bonds.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Car-Tcellkor Loan&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On May 18, 2019, the Company borrowed $800,000 from its parent at the time of the loan, Car- Tcellkor (the &#x201c;Car-Tcellkor Loan&#x201d;). The Car-Tcellkor Loan does not bear interest and was due on March 18, 2020. In November 2022, the maturity date was extended to May 18, 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $800,000 was forgiven.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025 and 2024, the Car-Tcellkor Loan had a carrying amount of $0 and $800,000, respectively, and is recorded in short-term debt, related parties in the consolidated balance sheets (see Note 5). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Valetudo Loans&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 1, 2022, the Company borrowed $700,000 from Valetudo Therapeutics LLC (&#x201c;Valetudo&#x201d;), a related party of the Company due to having common executives, in conjunction with the repayment of $700,000 of membership interest from a member (the &#x201c;Valetudo Loan&#x201d;). The Valetudo Loan bears no interest and was due on June 1, 2023. On May 1, 2025, the Company paid the outstanding principal balance of $700,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2023, the Company borrowed an additional $300,000 and $200,000 (the &#x201c;Valetudo June 2023 Loans&#x201d;). The Valetudo June 2023 Loans bear no interest and were due in December 2023. On May 1, 2025, the Company paid $300,000 of the outstanding principal balance on the Valetudo June 2023 Loans.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In July 2023, the Company borrowed an additional $250,000 (the &#x201c;Valetudo July 2023 Loan&#x201d;). The Valetudo July 2023 Loan bears interest at 6% per annum and was due on January 9, 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2023, the Company borrowed an additional $250,000 and $150,000 (the &#x201c;Valetudo August 2023 Loans&#x201d;). The Valetudo August 2023 Loans each bear interest at 6% interest per annum and were due on January 31, 2024 and February 2, 2024, respectively. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $400,000, along with accrued interest, of the Valetudo August 2023 Loans was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2023, the Company borrowed an additional $200,000 (the &#x201c;Valetudo November 2023 Loan&#x201d;). The Valetudo November 2023 Loan bears interest at 6% per annum and was due on January 26, 2024. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $200,000, along with accrued interest, on the Valetudo November 2023 Loan was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;In January 2024, the Company borrowed an additional $600,000 and $150,000 (the &#x201c;Valetudo January 2024 Loans&#x201d;). The Valetudo January 2024 Loans each bear interest at 6% per annum and were due on February 28, 2024. On April 30, 2025, upon consummation of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;the Business Combination, outstanding principal of $750,000, along with accrued interest, of the Valetudo August 2023 Loans was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025 and 2024, the loans from Valetudo of $450,000 and $2,800,000, respectively, are recorded in short-term debt, related parties in the consolidated balance sheets (see Note 5). As of December 31, 2025 and 2024, the related accrued interest of the loans from Valetudo was $113,308 and $115,328, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Valetudo loans was $42,208 and $96,484, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Please refer to Note 5 for discussion related to notes which have passed their maturity dates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Ewon Loans&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 12, 2022, the Company borrowed $5,000,000 from Ewon Comfortech Co., Ltd. (&#x201c;Ewon&#x201d;), a member and related party of the Company (the &#x201c;Ewon Loan&#x201d;). The Ewon Loan bears interest at 2% per annum and was due on December 12, 2023, which may be extended one year upon mutual agreement of the parties, or upon failure to close the Business Combination. In February 2023, the Company repaid $1,000,000 of the short-term loan. In March 2023, the Company repaid an additional $2,000,000 of the loan. On April 30, 2025, upon consummation of the Business Combination, $2,000,000, along with accrued interest, of the Ewon Loan was converted into common stock of the Company. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 10, 2023, the Company entered into a loan agreement to borrow $200,000 from Ewon (&#x201c;Ewon September 2023 Loan&#x201d;). The Ewon September 2023 Loan bears interest of 2% per annum and was due on September 9, 2024, which may be extended one year upon mutual agreement of the parties, or upon failure to close the Business Combination. On April 30, 2025, upon consummation of the Business Combination, $200,000, along with accrued interest, of the Ewon September 2023 Loan was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 19, 2023, the Company and Ewon entered into an additional loan agreement and the Company borrowed $1,000,000 (the &#x201c;Ewon December 2023 Loan&#x201d;). The Ewon December 2023 Loan bears no interest. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $1,000,000, along with accrued interest, of the Ewon December 2023 Loan was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025 and 2024, the balance of $0 and $3,200,000 of the Ewon loans is recorded in short-term debt, related parties in the consolidated balance sheets (see Note 5). As of December 31, 2025 and 2024, the related accrued interest of the loans from Ewon was $0 and $102,089, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Ewon loans was $14,667 and $44,733, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Prophase Loans&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 26, 2024, the Company borrowed an additional $200,000 from Prophase Sciences LLC (&#x201c;Prophase&#x201d;) (the &#x201c;Prophase February 2024 Loan&#x201d;). The loan bears 6% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, $168,500, along with accrued interest, of the Prophase February 2024 Loan was converted into common stock of the Company. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 6, 2024, the Company borrowed an additional $250,000 from Prophase (the &#x201c;Prophase March 2024 Loan&#x201d;). The loan bears 6% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 1, 2024, the Company borrowed an additional $250,000 from Prophase (the &#x201c;Prophase April 2024 Loan&#x201d;). The loan bears 6% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $250,000, along with accrued interest, on the Prophase April 2024 Loan was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;In May 2024, the Company borrowed an additional $790,000 from Prophase (the &#x201c;Prophase May 2024 Loans&#x201d;). The loans bear 6% interest per annum. Of the aggregate $790,000 Prophase May 2024 Loans, $270,000 was due on June 1, 2024 and $520,000 was due on July 1, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. On April 30, 2025, upon &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;consummation of the Business Combination, outstanding principal of $550,000, along with accrued interest of the Prophase May 2024 Loans was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In July 2024, the Company borrowed an additional $83,000 from Prophase (the &#x201c;Prophase July 2024 Loans&#x201d;). The loans bear 6% interest per annum. Of the aggregate $83,000 Prophase July 2024 Loans, $30,000 was due on September 14, 2024, $3,000 was due on September 24, 2024 and $50,000 was due on September 29, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2024, the Company borrowed an additional $50,000 from Prophase (the &#x201c;Prophase August 2024 Loans&#x201d;). The loans bear 6% interest per annum. Of the aggregate $50,000 Prophase August 2024 Loans, $30,000 was due on October 12, 2024 and $20,000 was due on October 13, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In February of 2025, the Company borrowed an additional $206,000 from Prophase (the &#x201c;Prophase February 2025 Loan&#x201d;). The Prophase February 2025 Loan bears interest at 6% per annum and was due on April 11, 2025, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $125,000, along with accrued interest, on the Prophase February 2025 Loan was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In March of 2025, the Company borrowed $207,000 from Prophase (the &#x201c;Prophase March 2025 Loan&#x201d;). The Prophase March 2025 Loan bears interest at 6% per annum and was due on June 6, 2025, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $200,000, along with accrued interest, on the Prophase March 2025 Loan was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In April of 2025, the Company borrowed an additional $3,627,000 from Prophase (the &#x201c;Prophase April 2025 Loans&#x201d;). The loans bear 6% interest per annum. Of the aggregate $3,627,000 Prophase April 2025 Loans, $200,000 was due on May 2, 2025, $1,920,120 was due on May 13, 2025 and $1,506,880 was due on May 14, 2025. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $3,627,000, along with accrued interest, on the Prophase April 2025 Loans was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025 and 2024, the balance of the Prophase loans is $742,500 and $1,623,000, respectively. As of December 31, 2025 and 2024, the related accrued interest of the loans from Prophase was $79,283 and $66,728, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Prophase loans was $77,073 and $66,728, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Please refer to Note 5 for discussion related to notes which have passed their maturity dates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Hana Loans&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 1, 2024, the Company borrowed $850,000 from Hana Immunotherapeutics, LLC (&#x201c;Hana&#x201d;), a related party of the Company due to having common executives (the &#x201c;Hana Loans&#x201d;). The Hana Loans bear interest at 6% per annum and were due on September 30, 2024 and October 26, 2024, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $800,000, along with accrued interest, of the Hana Loans was converted into common stock of the Company. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025 and 2024, the balance of the Hana Loans is $50,000 and $850,000, respectively. As of December 31, 2025 and 2024, the related accrued interest of the loans from Hana was $2,042 and $19,150, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Hana Loans was $19,042 and $19,150, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Please refer to Note 5 for discussion related to notes which have passed their maturity dates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Amantes Loans&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;On November 1, 2024, the Company borrowed $400,000 from Amantes LLC (&#x201c;Amantes&#x201d;), a related party of the Company due to having common executives, pursuant to a loan agreement between the Company and Amantes (the &#x201c;Amantes Loan&#x201d;). On November 27, 2024, the Company borrowed an additional $300,000 from Amantes (the &#x201c;Additional Amantes Loan&#x201d;) (together with the Amantes Loan, the &#x201c;Amantes November 2024 Loans&#x201d;). The Amantes November 2024 Loans bear interest at 6% per annum and are due on January 1, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;2025. On April 30, 2025, upon consummation of the Business Combination, outstanding principal of $550,000, along with accrued interest, on the Amantes November 2024 Loans was converted into common stock of the Company. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 2, 2025 and January 23, 2025, the Company borrowed a total of $300,000 from Amantes, pursuant to loan agreements between the Company and Amantes (the &#x201c;Amantes January 2025 Loans&#x201d;). The Amantes January 2025 Loans bear interest at 6% per annum and are due on March 1, 2025 and March 22, 2025, respectively, which may be extended upon mutual agreement of the parties. On April 30, 2025, upon consummation of the Business Combination, the outstanding principal of $250,000, along with accrued interest, on the Amantes January 2025 Loans was converted into common stock of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025 and 2024, the balance of the Amantes Loans is $200,000 and $700,000, respectively. As of December 31, 2025 and 2024, the related accrued interest of the loans from Amantes was $9,288 and $5,700, respectively, and is included in accrued interest, related parties in the consolidated balance sheets. For the years ended December 31, 2025 and 2024, interest expense related to the Amantes Loans was $27,890 and $5,700, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Please refer to Note 5 for discussion related to notes which have passed their maturity dates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Due to Related Party&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025, the Company had $209,586 due to the Company&#x2019;s executive team for compensation under their employment agreements. As of December 31, 2024, the Company had $195,253 due to the Company&#x2019;s executive team for compensation under their employment agreements and Amantes. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Viral Gene&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2025 and 2024, the Company had $0 and $126,275, respectively, due from Viral Gene included in due from related party in the consolidated balance sheets for a loan to Viral Gene and expenses paid on behalf of Viral Gene. During the year ended December 31, 2025, the Company determined the due from related party was uncollectible and wrote off $126,275 and is included in general and administrative on the consolidated statement of operations. The Company&#x2019;s CEO is also the CEO of Viral Gene. The loan does not bear any interest.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ"
      decimals="0"
      id="Narr_WLsbY18woU2Mgt3ogJQjXQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">10000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ"
      decimals="2"
      id="Narr_wBakAONCNk21bS-Ucw2aSA"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ"
      decimals="INF"
      id="Narr_oqCuwnE-2EmgBdACggRo-g"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">6666666</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ"
      decimals="2"
      id="Narr_Ylb1e9aFRkKkZsGbgpulRg"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">1.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ"
      decimals="0"
      id="Narr_l9ImBzTPyEO617Wk3ax6PA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">6400000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NcxMLUOjV0-W98TcYBomsA"
      decimals="3"
      id="Narr_o6qrf0BUQ02Kr59CrJA9Ew"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.82</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ"
      id="Narr_Yvwy-gBB2kijwyQo6SzL_w">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GUMRHws20E-hQftGj0JvTA"
      decimals="3"
      id="Narr_Jj00OVh_vUyD9AneTUDUGw"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.029</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ"
      id="Narr_vWRxRoFAu0G4-zdzrqDc5w">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gZkGDq_I9UKTee9n9IgYZw"
      decimals="0"
      id="Narr_iKachQW8C0i4EFdQjaOG9w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="Duration_9_15_2018_To_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Ue0f9e9AF0CCuPCxkaHeGw"
      decimals="0"
      id="Narr_WDMSgh97C02XHrOPU740Xw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">10000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ"
      decimals="0"
      id="Narr_M028fU-8NkKIQdSwWEAuVA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">4499142</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="As_Of_9_15_2018_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b5ED4Z16M02D2V3NgqegMQ"
      decimals="3"
      id="Narr_ppvdeMXML0mz-c02G3uFjA"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.21</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_AHn-E6mSh0WMg57djpR6sA"
      decimals="0"
      id="Narr_5vtvks5b_0KPRuvRyPWnJQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">10681146</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_nnP7Qz9VeUGy0wjX4yxcQA"
      decimals="INF"
      id="Narr_VLp5bmYp1kWwVGz2BvEJrA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">9999999</us-gaap:ConversionOfStockSharesConverted1>
    <limn:StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits
      contextRef="Duration_4_30_2025_To_4_30_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_nnP7Qz9VeUGy0wjX4yxcQA"
      decimals="INF"
      id="Narr_wH7qsQ2SEkyZJZSBye5OYw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">4000000</limn:StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_PowKVbIlSEav6_it2o0cuw"
      decimals="0"
      id="Narr_Zs6maygRYU-dgQxpW54skg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_5jXRkTedV06dtacIjxLWQQ"
      decimals="0"
      id="Narr_cgauoo4sB0uCIm_m0bFR7A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">10000000</us-gaap:ProceedsFromShortTermDebt>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UCZY1ZeR3UG6JVOXPTBI8g"
      decimals="0"
      id="Narr_DAdSjYm-u02G_-962Llrog"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</limn:AccruedInterestCurrent>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6wD9AAP08UeDG0Qs6p5Q2A"
      decimals="0"
      id="Narr_Bzhchhm0kEeaW5Fgja8XIg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">646124</limn:AccruedInterestCurrent>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_m79xoi74tEWD31ya03Rcmw"
      decimals="0"
      id="Narr_eswaqcknckCEnJAFzf8c_w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">35023</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_limn_FeeluxCoLtdMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_uBbaU3A6rUOpfYYDB4euDw"
      decimals="0"
      id="Narr_ytRQzO7M50a31qceH0An8g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">106087</us-gaap:InterestExpenseDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_5_18_2019_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_zVHTzo-UxEy__UArL1VThQ"
      decimals="0"
      id="Narr_ETrUmeqztEOl4yL_f7dbRA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">800000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_v60EouUdLUqn8toxvOltkQ"
      decimals="0"
      id="Narr_ia7bx2mhykK-WgUGIgmXSQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">800000</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wmmbaObSukiDB_4zDCmrgA"
      decimals="0"
      id="Narr_ZF7ZFD_34UmRN6m4Rsy19g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_TpCVK5HsVEK8Wyv55C0lig"
      decimals="0"
      id="Narr_GFHJxexMNUqDZLkQanqUBQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">800000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_1_2022_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_35Sjj6Gfl0yNGiX5Qt5Qmw"
      decimals="0"
      id="Narr_RRutzk5EKUCfGCEmFyiqJA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">700000</us-gaap:ShortTermBorrowings>
    <limn:RepaymentOfMembershipInterest
      contextRef="As_Of_12_1_2022_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_35Sjj6Gfl0yNGiX5Qt5Qmw"
      decimals="0"
      id="Narr_SLTcA-VaAEOMD6aaLflWqQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">700000</limn:RepaymentOfMembershipInterest>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="Duration_5_1_2025_To_5_1_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_qNI4ieKD3kSp3GUUyiiVsA"
      decimals="0"
      id="Narr_GLCTy5M_vkeytvC63OVvdw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">700000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_u39Cd4S7GEqUxTPP5qv_Qg"
      decimals="0"
      id="Narr_QmN3nfblAEuEux_9P5l-Eg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">300000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoanTwoMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_uvAg88eC10OdVCXZ0b8E3A"
      decimals="0"
      id="Narr_YsA5ZuSUvU-gmxliQ8to0Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:ShortTermBorrowings>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="Duration_5_1_2025_To_5_1_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Tvb57Yoz8kWjg8oYPKuxig"
      decimals="0"
      id="Narr_tRdPaG0aSkqQu3ZciJ6Bmg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">300000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_7_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RoR1eW_fpUmHYmBoFmDg1w"
      decimals="0"
      id="Narr_iK0OYxImWEKbMHKaGrGVjA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_7_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RoR1eW_fpUmHYmBoFmDg1w"
      decimals="2"
      id="Narr_FXLLcX2heE-SYaq1m2-P6w"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KWt-xK4eN0-5OFBxkx3LGw"
      decimals="0"
      id="Narr_grU7cNUp4EisJITbJjBmLg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoanTwoMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_jZaCTxa_V0CXdNygheYPjA"
      decimals="0"
      id="Narr_0RZq7MChC0idbE8cZi9OFw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">150000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_31_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_K45l7DmgQE-CQ-xyraew7w"
      decimals="2"
      id="Narr_CyNKRDxMXkKhXDJ0I0UccA"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_rDx80SlYbU-El3v0ZF9uAw"
      decimals="0"
      id="Narr_VYnJ0RV9cEuuPXdeRbjukA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">400000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_11_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1Od3S-eoaUCXHX3nnz2htg"
      decimals="0"
      id="Narr_QU-N2jC4lkmJRFQfgtkUWw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_30_2023_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1Od3S-eoaUCXHX3nnz2htg"
      decimals="2"
      id="Narr_MBZ_TZBwoUSyJsQStvPSFg"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6Oq29UcKvkeSSN5rpNIW6w"
      decimals="0"
      id="Narr_YYGJKR2DDECb_eB6wl76SQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_1_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoanOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6andgdbpxkqRlyLXl4XDHg"
      decimals="0"
      id="Narr_LaOgWeaxdE6kAZ-3lDAaUQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">600000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_1_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoanTwoMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_roRuh60jM0eb54g1Pq5hLQ"
      decimals="0"
      id="Narr_qaluR78KQEGuh3w__xgKZw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">150000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_1_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1AItK1QO2kitXmKJcOl1Fg"
      decimals="2"
      id="Narr_f5WeDKerqkOAr8qsGajdeA"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ZaQ3e71ewUK0aSmJ56rcsw"
      decimals="0"
      id="Narr_LuyHInnKpUSefjmNdD6Bsw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">750000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_148jP040dUadKsjmVdStxQ"
      decimals="0"
      id="Narr_hu_k1Qa_xEO0rBUPOgQ2uw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">450000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EegrTR0jGkqYkwr1xCASoA"
      decimals="0"
      id="Narr_NBeTzxDJYEqrwz8jac0g1A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2800000</us-gaap:ShortTermBorrowings>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ValetudoTherapeuticsLlcMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_u2V6Q8F86kqWl2rCR_ZLxg"
      decimals="0"
      id="Narr_bYKm6zsnDUm8KmPfY559wQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">113308</limn:AccruedInterestCurrent>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_ValetudoTherapeuticsLlcMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_4VRhmQHacUKineZTnXswaw"
      decimals="0"
      id="Narr_tBnVGdyhBEupjmMyKFLPtw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">115328</limn:AccruedInterestCurrent>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_aIiVDq13L0qm8FpFM6Fe7A"
      decimals="0"
      id="Narr_y_ynBTPkJUWqFpQ8YhAKSA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">42208</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_ValetudoLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_BrctH0R4SUmey2o6z162mg"
      decimals="0"
      id="Narr_6-h7zWsWkEe9a5j0PIMsRw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">96484</us-gaap:InterestExpenseDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_12_2022_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RpHDxwA5eU6MNdXkdEU0lg"
      decimals="0"
      id="Narr_IymsztLJOUyMIxoIV0-WRg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">5000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_12_2022_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_RpHDxwA5eU6MNdXkdEU0lg"
      decimals="2"
      id="Narr_gGApUDe5HEOERlq2iKBuhw"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="Duration_2_1_2023_To_2_28_2023_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_fyxYB55LcESYXg1VrFa0SQ"
      decimals="0"
      id="Narr_b-5WSDI6UkSHst_4EpV-ew"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_1IIHRUTkZkq60Pm0ATLdfg"
      decimals="0"
      id="Narr_BLgxXbrru0ii7J3MPc0udg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_EwonDecember2022LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YHOGjDLmVUK3iyhkoffTvQ"
      decimals="0"
      id="Narr_nfVYRM6mF0qYuVw-fWbz1Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2000000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_9_10_2023_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DWdmZjGmCEiRashhGcBpXQ"
      decimals="0"
      id="Narr_GVWRQDI7n0O9pI653Fjc6A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_10_2023_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DWdmZjGmCEiRashhGcBpXQ"
      decimals="2"
      id="Narr_gw1I8Zzr8UqpSp1aTx9r1w"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-A5AQrt620qPuuH6l9tvXw"
      decimals="0"
      id="Narr_fheIRZ7Jj0ONwEK68-lFxg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_19_2023_us-gaap_DebtInstrumentAxis_limn_EwonDecember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_PobELNhVp0CNZjEIGlpjlg"
      decimals="0"
      id="Narr_G7SvjJhQ_Eqtby-cBtQ-0g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_EwonDecember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FAzAi_otIkiuLKLUZIGGZQ"
      decimals="0"
      id="Narr_TDS2ydDY6US96Enxy0cBkQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1000000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_r25euOvngkmrw8iQThV-hQ"
      decimals="0"
      id="Narr_oztZqOw2A0qLYCE_SW-jEg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KnFjty5H1UqDezjsL8ecyA"
      decimals="0"
      id="Narr_znX8KGKRa0axUpI_uW-DSQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3200000</us-gaap:ShortTermBorrowings>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_EwonComfortechCoLtdMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0bsPPj_X9U-t6aFyc57i1w"
      decimals="0"
      id="Narr_c2C2TKvqD0-lb77qvOaWbQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</limn:AccruedInterestCurrent>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_EwonComfortechCoLtdMember_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_LGib2VMD3kWL01MA1301Pg"
      decimals="0"
      id="Narr_npnPYOh3x06TfpbKQHrR0A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">102089</limn:AccruedInterestCurrent>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gXDAk9MAnEC31blcdud-TQ"
      decimals="0"
      id="Narr_xYDCUvN3gE6xg40qroyDBA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">14667</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ykDgVNc-WUGp-HHNFZJzIw"
      decimals="0"
      id="Narr_t7hAE3wnN0a44crbWHPqFQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">44733</us-gaap:InterestExpenseDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_2_26_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_dMLi4mVbI0mnfUUmfRTl1w"
      decimals="0"
      id="Narr_Iks97r1XI0Gy8lHzLvDL7Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_2_26_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_dMLi4mVbI0mnfUUmfRTl1w"
      decimals="2"
      id="Narr_RmRemCuNr0ChXUR1qi0y7w"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VgfZxKguUE6IvyhFTK0bgw"
      decimals="0"
      id="Narr_ibePIy8F2kKqPrZmei1rYA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">168500</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_6_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_U0Xo3fqs00OpXo_SeuDtWg"
      decimals="0"
      id="Narr_md8hUaUvukCnPS302MGDzw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_6_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_U0Xo3fqs00OpXo_SeuDtWg"
      decimals="2"
      id="Narr_Hpuf4Ra8rUC4RgocC_MKEQ"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_4_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KWzMWCDwzEShWHgZreE_vw"
      decimals="0"
      id="Narr_vSD-HFXWIEqPwMM5vTyTOg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_4_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KWzMWCDwzEShWHgZreE_vw"
      decimals="2"
      id="Narr_VxfAXGQKwUu47G1U4QgvdQ"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_WqQ7kEZqMUGKJ2Civ5wmHQ"
      decimals="0"
      id="Narr_2IKG6ZiSSEW2VL0LY3vDtQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_5_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPL1Zq0iyE2-9FTal0qJ5A"
      decimals="0"
      id="Narr_4CdWUUbwKUaqEiluhqu1CA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">790000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_5_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPL1Zq0iyE2-9FTal0qJ5A"
      decimals="2"
      id="Narr_umCyPSl7LUCbWgrAfZKzbQ"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_5_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPL1Zq0iyE2-9FTal0qJ5A"
      decimals="0"
      id="Narr_ZZMIvuYyO0mQ-MKbpMYiaQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">790000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_6_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VxMZqFXR_UaO5azmVes0dA"
      decimals="0"
      id="Narr_aERR8D2bnkCX_qyNDse6dg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">270000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_7_1_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_mxhubmgnJ06DzAurKf0Uug"
      decimals="0"
      id="Narr_MZzjV-mqTEC4NDtRsAXk9Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">520000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_hxqxTUYPkUOVXBEWPh59bw"
      decimals="0"
      id="Narr_7AJ_EnNqNEe-D924RhgG9g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">550000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_7_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0HW6FGsO8Ei7AXcLtjboyA"
      decimals="0"
      id="Narr_Ug_I8tlnd0WkmJ541QFXWA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">83000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_7_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0HW6FGsO8Ei7AXcLtjboyA"
      decimals="2"
      id="Narr_3FBQW2nFekinb3yiZMoxsQ"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_7_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0HW6FGsO8Ei7AXcLtjboyA"
      decimals="0"
      id="Narr_m_zto5CkY0aTbNm6-Ix7HA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">83000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_9_14_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_-IXbBujRXkiVzw9mXk784w"
      decimals="0"
      id="Narr_7uFARoiYAkKitzkx8DC31w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">30000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_9_24_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_4Vld9uwuRkuuQHHIzYvKZg"
      decimals="0"
      id="Narr_Wyk52oPxJUKfbzOvLkCYPw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_9_29_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_hOP6gIf6X0uZ7Ge6Uhb8yA"
      decimals="0"
      id="Narr_xgCfhzksZUOWF_zTjbWO7g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_8_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wdQAw9pClkqJCJydARCG4g"
      decimals="0"
      id="Narr_V9uobdkbMEWE6zaogw8Yiw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wdQAw9pClkqJCJydARCG4g"
      decimals="2"
      id="Narr_VhdJh8-VmUKQ9Xi9qkulOg"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_8_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wdQAw9pClkqJCJydARCG4g"
      decimals="0"
      id="Narr_ahrp325Ld0exvS-PY4fbdA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_10_12_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NGQDh1rA3UGEJwXQpQqNWA"
      decimals="0"
      id="Narr_Kc2lbIVSX0mjEiPEf4Z_OQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">30000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_10_13_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DqH0O8M-DkKolyZ-CdcShA"
      decimals="0"
      id="Narr_aY_wypq3bEC__N_xUgg2LQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">20000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_2_28_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Rs3R6YntuECvjfLJCKGrWA"
      decimals="0"
      id="Narr_HlBbFEiS0ku1DryndQG36g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">206000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_2_28_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Rs3R6YntuECvjfLJCKGrWA"
      decimals="2"
      id="Narr_bvCbBozw5Ei97lGiX6IKxw"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gHk208o8a02buGlMK7GoGA"
      decimals="0"
      id="Narr_kz9p4cps7k2sXgtqREN3sg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">125000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xe3qXzjS0EC39aN_LENA8g"
      decimals="0"
      id="Narr_5S1KiBOvzkm563YT-ISqXQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">207000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xe3qXzjS0EC39aN_LENA8g"
      decimals="2"
      id="Narr_N0At4SIRik6uJH387762ag"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_XNzgVBB9EUSW9XJBeTQYXg"
      decimals="0"
      id="Narr_C3nBBMQMt0uQGoZuIuM4Ew"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xvNc1S3hqkGpqvsF2_IC5g"
      decimals="0"
      id="Narr_xBkSSGS3q0WTncyMqkE_zQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3627000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xvNc1S3hqkGpqvsF2_IC5g"
      decimals="2"
      id="Narr_wVILBk7EDE-dcFM-0HZmOQ"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xvNc1S3hqkGpqvsF2_IC5g"
      decimals="0"
      id="Narr_PEWdXwzS-ESDUvor3Fb2rA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3627000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_5_2_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GRnA5Kx7-kGf8N58SRLWrw"
      decimals="0"
      id="Narr_bjIMrcxyu06rdOY-a_W-bg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_5_13_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_99oewdhpVEC5wJhe7rhkyQ"
      decimals="0"
      id="Narr_b1hGCIYEdUSMTJe31_8Ahw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1920120</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_5_14_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_176IvMRvuUeNEtEQXDudUQ"
      decimals="0"
      id="Narr__smGJqyjWk6QU2Kl-HvjDg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1506880</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_MxNDVYopJUCTnAtVRr2BCQ"
      decimals="0"
      id="Narr_iJ3-55uebU6hOeNVD6mXgA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3627000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Hjob6bfNJ0yH9IccwyqnFw"
      decimals="0"
      id="Narr_Beg4_CjzW0SXbtnEiyn5uw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">742500</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Rea6tsWHW0yjkY8Ibu9urQ"
      decimals="0"
      id="Narr_O831g0Pr0UivgMi4Wnd26w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1623000</us-gaap:ShortTermBorrowings>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Hjob6bfNJ0yH9IccwyqnFw"
      decimals="0"
      id="Narr_yXiceY79O0yQL8NkiWZpmQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">79283</limn:AccruedInterestCurrent>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_ProphaseSciencesLlcMember_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Rea6tsWHW0yjkY8Ibu9urQ"
      decimals="0"
      id="Narr_uJpV9WksuUSbzEbJpQZDTQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">66728</limn:AccruedInterestCurrent>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y7jrRcuOPU6wYyUiEQtHhg"
      decimals="0"
      id="Narr_EltwxiUvbECkWZkLy4cpMQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">77073</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_2rdRQZDLhkWmVg-aznAVoQ"
      decimals="0"
      id="Narr_soJmo8TmbkCGwA6G0u41Cw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">66728</us-gaap:InterestExpenseDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_8_1_2024_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_lO3aHrFMUE2_9b_GTJGSBw"
      decimals="0"
      id="Narr_yx2PrkFqpUe27VAa6q_FBQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">850000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_1_2024_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_lO3aHrFMUE2_9b_GTJGSBw"
      decimals="2"
      id="Narr_5KngFKeDZEa55z8coNp-DQ"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VtKf0F4u50yYAUlGncV4kA"
      decimals="0"
      id="Narr_iiVHygArPkuRlFMkX3RLGA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">800000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_0PybUMyl7UupuiSkslBW7Q"
      decimals="0"
      id="Narr_ucwMKBVf6EKbVUsZCaxRUg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_GP3ES2qH4USRDiPV41OBjg"
      decimals="0"
      id="Narr_OsIPkpW3R0WmW-jLlMyTyw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">850000</us-gaap:ShortTermBorrowings>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_HanaImmunotherapeuticsLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_M0xZpqNfSUiePS0rqmBJQQ"
      decimals="0"
      id="Narr_0pWeSsxUnEOSpcInjT1r8Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2042</limn:AccruedInterestCurrent>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_HanaImmunotherapeuticsLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NKk10HcAC0izvcIcwzePTQ"
      decimals="0"
      id="Narr_hfW7jQLjzkWDEXbPwCFLhQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">19150</limn:AccruedInterestCurrent>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_meaC4-NT6kOsHGvZt--vtw"
      decimals="0"
      id="Narr_g7TAZgFLYU2FGmAsZDG46g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">19042</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_HanaLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_PKtruhg-mke1cWwu6HOpJQ"
      decimals="0"
      id="Narr_B-jgoqovjUGFk28fyupTpQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">19150</us-gaap:InterestExpenseDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_11_1_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_skGpvhLamkmTX8ZC32NJjg"
      decimals="0"
      id="Narr_m7hdIHpQ_062Lvb1RmgkfA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">400000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_11_27_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xZbOD6QvXU2eioglXc3B9Q"
      decimals="0"
      id="Narr_6JK9Xl6k50G421dAOaLm0g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">300000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_27_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_xZbOD6QvXU2eioglXc3B9Q"
      decimals="2"
      id="Narr_G9K7mo5iNEGPcAsN-ItzIA"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y5QPj6cnBkqxLO8bzZMweA"
      decimals="0"
      id="Narr_U3d_qmAW9kaARXeRAhg50w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">550000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_1_2_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UoLTcnkgY0ia4LxmBqWZzA"
      decimals="0"
      id="Narr_AFNm2B-od0K2PoX9nV8awA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">300000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_1_23_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPR03tDKjUmpyRyQld8qmA"
      decimals="0"
      id="Narr_1rlcfLkjEEicjGyBweP_iw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">300000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_1_2_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_UoLTcnkgY0ia4LxmBqWZzA"
      decimals="2"
      id="Narr_Z3KjlL15qkmbBQxvCGFlEA"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_1_23_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_cPR03tDKjUmpyRyQld8qmA"
      decimals="2"
      id="Narr_6EqXrtmqX02sOXvJM61Olg"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_4_30_2025_To_4_30_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_mmocMhxQQE-9TDe7UCuBDQ"
      decimals="0"
      id="Narr_XIbix_4AN0ipUlbIj0ta4g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_s7XNeN2VrkyoKgFvQn08HQ"
      decimals="0"
      id="Narr_zfhVHjRKXECJkDIDTkPCNw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VyY5JFYy4EKLtKt2cqj8Iw"
      decimals="0"
      id="Narr_BiZfh7wP2U2svisdfCTIIA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">700000</us-gaap:ShortTermBorrowings>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_AmantesLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_HgSigzsdAE2ZWAOutjYfWA"
      decimals="0"
      id="Narr_evdLiXKXzku-AtwoPeT-Sg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">9288</limn:AccruedInterestCurrent>
    <limn:AccruedInterestCurrent
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_AmantesLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_uroe3WmRfk2-MXkmturUGQ"
      decimals="0"
      id="Narr_ONzZ8eW_8UKrOI8qb4QM5A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">5700</limn:AccruedInterestCurrent>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Ol_1m0h-L0KQZ73KaVpZtg"
      decimals="0"
      id="Narr_jBKu3jnCz0WFh1Zb4TTKlw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">27890</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_limn_AmantesLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Vyrd4E71aEKV2JlX3zDSMw"
      decimals="0"
      id="Narr_hoLFujsoSUyh4V7k01S1gQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">5700</us-gaap:InterestExpenseDebt>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_limn_EmploymentAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_bhT6iPgTMUSC0cikBkivgg"
      decimals="0"
      id="Narr_TXEunhNY00CyyDo0q64GSQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">209586</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_us-gaap_FinancialInstrumentAxis_limn_EmploymentAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8W6kVGwgx0651YJT0suHMA"
      decimals="0"
      id="Narr_GKPE_o0RNEa5Yn7B6D0quw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">195253</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ViralGeneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_7wxNNnmVW0OOyrl6dcdkLg"
      decimals="0"
      id="Narr_NmrL7Ls_1EqSi0hB5OX7lQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_limn_ViralGeneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FJJZ1ZZ6TEyxVYe-BaGI8w"
      decimals="0"
      id="Narr_6YxAPQ8LLU21uPFL1KPC1A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">126275</us-gaap:OtherReceivablesNetCurrent>
    <limn:OtherReceivableWriteOff
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_ViralGeneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_a0Rd98uIckinvKo03Da_gQ"
      decimals="0"
      id="Narr_u-4tNcS85E65nNJ93tskXg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">126275</limn:OtherReceivableWriteOff>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_TJJrbRMQN0CrKAWkvcNWbQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 5. Debt&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Outstanding debt classified as short-term debt as of December 31, 2025 and 2024 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"&gt;&lt;tr&gt;&lt;td style="width:202.45pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:13.39pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:162pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:12.85pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:60.5pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:12.86pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:59.95pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.44pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:149.3pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.69pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Feelux Bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Car-Tcellkor Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 800,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Ewon Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valetudo Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 700,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valetudo June 2023 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valetudo July 2023 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valetudo August 2023 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 400,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Ewon September 2023 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valetudo November 2023 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Ewon December 2023 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valetudo January 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 750,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase February 2024 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase March 2024 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase April 2024 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase May 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 240,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 790,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase July 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase August 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Hana August 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 850,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amantes November 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 150,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 700,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amantes January 2025 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase February 2025 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase March 2025 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Short-term debt, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,442,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,973,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025 and 2024, the Company&#x2019;s outstanding debt agreements are all past due and are classified as current in the accompanying consolidated balance sheets. All of the loans are with related parties (see Note 4). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;As the Company&#x2019;s loans are with related parties, the Company and its related parties have mutually agreed to defer repayment until a time that is mutually agreed upon between the Company and its related parties. Accordingly, none of these notes are considered to be in default.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfShortTermDebtTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_3SJgLQdCzEKuoE1mWqN4bQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"&gt;&lt;tr&gt;&lt;td style="width:202.45pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:13.39pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:162pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:12.85pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:60.5pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:12.86pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:59.95pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.44pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:149.3pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.69pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Feelux Bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Car-Tcellkor Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 800,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Ewon Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valetudo Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 700,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valetudo June 2023 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valetudo July 2023 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valetudo August 2023 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 400,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Ewon September 2023 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valetudo November 2023 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Ewon December 2023 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valetudo January 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 750,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase February 2024 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase March 2024 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase April 2024 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase May 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 240,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 790,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase July 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase August 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Hana August 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 850,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amantes November 2024 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 150,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 700,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amantes January 2025 Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase February 2025 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prophase March 2025 Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt, net, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.49pt;"&gt;&lt;td style="vertical-align:bottom;width:202.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Short-term debt, related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:162pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.5pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,442,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.95pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,973,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_FeeluxBondsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_6wD9AAP08UeDG0Qs6p5Q2A"
      decimals="0"
      id="Tc_BoXEQiAvCEm9lq5sMtXGcA_3_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">10000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_CarTcellkorLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_TpCVK5HsVEK8Wyv55C0lig"
      decimals="0"
      id="Tc_rR0_2apWv06Qf6M9zyXSgA_4_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">800000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_EwonLoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3egjKmWE3UiVynBt7G9rJg"
      decimals="0"
      id="Tc_iRD2T6jbREu-U9eKxA5Xqg_5_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoDecember2022LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_lrwGKHLBAESOZpAyQq956w"
      decimals="0"
      id="Tc_egb6Tr0QDU6QOVl2fQQRiA_6_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">700000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_VlA87RaJeEq06zmKK_H7kg"
      decimals="0"
      id="Tc_jOM7a6A7ukmPjQijwU3Bhw_7_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJune2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_x5Od1Z7sZ0CQp8ZF554jRw"
      decimals="0"
      id="Tc_TODJ419hfUWzGxitHxZNww_7_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">500000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_eAOXFYGTJk-hpkYZ9yVryA"
      decimals="0"
      id="Tc_kXjt1__tOEq0kjUl5nkIBw_8_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJuly2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ASPx2q5_QU-KM6mmU-4OjQ"
      decimals="0"
      id="Tc_wq58e0Ckl0eEQDbHGFL1Ow_8_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoAugust2023LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_CQA91rS8pUClgpt3N0razg"
      decimals="0"
      id="Tc_dT_HlHb_aUS_gPFwE-sCEA_9_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">400000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_EwonSeptember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8mMfG6ZJX0COX4Qohfx8lg"
      decimals="0"
      id="Tc_JeMx-hS_E0m_aiVjWWUg9A_10_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoNovember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_sFe_sIQl8kC62ZR9mOyaiQ"
      decimals="0"
      id="Tc_NM_rYhti7EuAn2oTXkbu8w_11_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_EwonDecember2023LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_7O7aQgSHYU6aHfIWbXQSzg"
      decimals="0"
      id="Tc_23eU3w_pB06fEmdfT4gKNQ_12_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ValetudoJanuary2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_gfQEfMTEl0ObGw-d3_mziQ"
      decimals="0"
      id="Tc_4qH4_YZQkUCFVALL_ud_pA_13_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">750000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_9WDN8eHoHUWQK3nMpHkYtQ"
      decimals="0"
      id="Tc_7VKGBM12ik6tEE_wDuoa7Q_14_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">31500</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_rkyvImjcI02ndBME1T3Fyg"
      decimals="0"
      id="Tc_PsNb2-qzD0izvTUvYeM-4g_14_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">200000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tPoEXxTBuEas6Sj74xYwPA"
      decimals="0"
      id="Tc_7E1v36sUskijdhhD1fBYXw_15_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Jq1v2ZuaPEej3PGvRk2DSg"
      decimals="0"
      id="Tc_5J_mV7x6k0CsM_X30LF87w_15_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseApril2024LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_obg_hYZhh0yPZ2jeTy8gQQ"
      decimals="0"
      id="Tc_WyzChfPcKkCWgKL_z9U5lQ_16_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">250000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ay2QMWFbV0SdpGM1KxxUJw"
      decimals="0"
      id="Tc_mbpvMbF_eU61_QWjJEDUPw_17_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">240000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseMay2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_QRBk_Nfwt0WDpSDktLsbZg"
      decimals="0"
      id="Tc_x_6sAnOpmkKxN7hIAe1WWg_17_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">790000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Wgs8NC0FrEu0hK8Qjljnog"
      decimals="0"
      id="Tc_x1dyhtQMKE-xox8xbZaMqw_18_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">83000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseJuly2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_HDV6ibzOjEy9uUy1EA4FRA"
      decimals="0"
      id="Tc_lNYvlHDm-USLEsty_UGgWA_18_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">83000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__dCVK3BY3EeDKZi28xUkew"
      decimals="0"
      id="Tc_Xtvr7wpva06_4m74MRBC_Q_19_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_ProphaseAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_ANKNxWmzXk2q4khG39LhMA"
      decimals="0"
      id="Tc_9DwcH0VO7kCk3dn0-MvmBQ_19_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_NQoRaZtKZUCGus-3AHoDuQ"
      decimals="0"
      id="Tc_YegEp8LcYU6X5wAIZRVmNw_20_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_HanaAugust2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_wQjd250e8E-nWSdS93gx4Q"
      decimals="0"
      id="Tc_OjF5qLvK_E-x5rPVVMeXeQ_20_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">850000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_j5CQtBVz5UqKzenH5qp4Pg"
      decimals="0"
      id="Tc_GZ1VdJvoLEWYPJpyRuxwpQ_21_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">150000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_limn_AmantesNovember2024LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_JMZfrNFf_E-RRAz3gORKJw"
      decimals="0"
      id="Tc_ElqktbNOlUmPjPkOA79l5g_21_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">700000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_AmantesJanuary2025LoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_vlYz7WYM0065Rv0yQrEanA"
      decimals="0"
      id="Tc_OInyrMQ8vE-C9RfYczM5Lw_22_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">50000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseFebruary2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YhVm-9q0AUSPz-vllz68rg"
      decimals="0"
      id="Tc_M2BK9Cpe3EWj9JUYkIeo5Q_23_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">81000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_limn_ProphaseMarch2025LoanMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tu28ZL0W00ydtm8NRLecmQ"
      decimals="0"
      id="Tc_KR8kfGLFF0WEaLmy2lPInA_24_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_FbpcEF3_bUqHFwpcC9Wy4w"
      decimals="0"
      id="Tc_1co8YaB9TU6Q-qn1chKcsg_26_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1442500</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_eXLYHI_roUaYmfoOmSYVxA"
      decimals="0"
      id="Tc_RON6zgFbsUWaq37wSzi0ng_26_8"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">19973000</us-gaap:ShortTermBorrowings>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_997puwpl3k6ae7vFcZDD5Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 6. Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Business Combination, the Company&#x2019;s certificate of incorporation was amended and restated to designate two classes of stock; preferred and common stock. The certificate of incorporation authorized 1,000,000 shares of preferred stock and 500,000,000 shares of common stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Preferred Stock&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s Amended and Restated Certificate of Incorporation provides the Company&#x2019;s board of directors with the authority to issue up to 1,000,000 shares of $0.0001 par value preferred stock in one or more series and to establish from time to time the number of shares to be included in each such series, by adopting a resolution and filing a certification of designations. Voting powers, designations, powers, preferences and relative, participating, optional, special and other rights will be stated and expressed in such resolutions. There were zero preferred shares outstanding as of December 31, 2025 and 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Common Stock&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is authorized to issue 500,000,000 shares of common stock, with a par value of $0.0001 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 30, 2025, the Company settled deferred underwriting fees incurred by Iris prior to the closing date of $7,000,000 for 700,000 shares of common stock to the underwriters in Iris&#x2019;s initial public offering. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $7,245,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 16, 2025, the Company entered into a settlement and release agreement with Alta Partners, LLC (&#x201c;Alta&#x201d;), pursuant to which the Company agreed to issue 350,000 shares of its common stock to Alta in exchange for the surrender and cancellation of 1,000,000 Public Warrants held by Alta. On July 16, 2025, the common stock issued to Alta and Public Warrants surrendered by Alta had a fair value of $1,890,000 and $150,000, respectively. As a result of the exchange, the Company recognized a loss of $1,740,000 on the difference in fair value between the common stock and Public Warrants, which is included in Loss on issuance of common stock on the Company&#x2019;s consolidated statement of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025 and 2024, there were 27,064,633 and 17,500,000 shares of common stock issued and outstanding, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Holders of the Company&#x2019;s common stock are entitled to one vote for each share held of record, on all matters submitted to a vote of stockholders. Additionally, holders of common stock have dividend rights, in the event of a declared dividend declared by the Company&#x2019;s Board of Directors, and liquidation rights, in the event of an involuntary or voluntary event of liquidation that allow for the Company&#x2019;s common stockholders to receive all remaining assets of the Company, after payments of debts and other liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Warrants&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2025, 5,899,975 Public Warrants and 835,555 private placement warrants were outstanding. Each warrant entitles the holder to purchase one share of the Company&#x2019;s common stock at a price of $11.50 per share. No fractional shares will be issued upon exercise of the warrants. The Company may elect to redeem the Public Warrants, in whole and not in part at a price of $0.01 per warrant if (i) 30 days&#x2019; prior written notice of redemption is provided to the holders, and (ii) the last reported sale price of the Company&#x2019;s common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders. Upon issuance of a redemption notice by the Company, the warrant holders have a period of 30 days to exercise for cash, or on a cashless basis.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_3L7AM_E20kadTSZc5xEJ_Q"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_omTXK91e0EeqlzbLBxBfGQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_15uUj50ij0acb3GG0a4I8Q"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_1rkLZ-8ME0iB6UQ_PjFTJA"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="INF"
      id="Narr_x3lEphKQ4km-912J3JM36A"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_-W9uuBel90qUqjwl0h43kg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_ixx9FzuYrUKs3oCCdpknrg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_4Kx3HSYJ3kO_AYsIhvPdug"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <limn:DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="0"
      id="Narr_QdUlmDlrfE2Gvmak3y8Wrg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7000000</limn:DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination>
    <limn:StockIssuableForSettlementOfDeferredUnderwritingFees
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="INF"
      id="Narr_vcNfiDlLCEaSZny5SAKKAA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">700000</limn:StockIssuableForSettlementOfDeferredUnderwritingFees>
    <limn:FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees
      contextRef="As_Of_7_1_2025_CZJvPOCOcUySCDRAwOkqBA"
      decimals="0"
      id="Narr_EPZU22zcuUqzfM8tlm2Ajg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7245000</limn:FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees>
    <limn:SharesIssuedForSurrenderAndCancellationOfWarrants
      contextRef="Duration_7_16_2025_To_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_bvbBg5HF0E2idzp2cAdrIg"
      decimals="INF"
      id="Narr_W0t_T4f0mkKZFs9LwloonQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">350000</limn:SharesIssuedForSurrenderAndCancellationOfWarrants>
    <limn:ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled
      contextRef="Duration_7_16_2025_To_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_bvbBg5HF0E2idzp2cAdrIg"
      decimals="INF"
      id="Narr_U-j_17lDjUWAoRjCrjfH2w"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1000000</limn:ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled>
    <limn:FairValueOfCommonStockIssued
      contextRef="As_Of_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_3KBXe2AusUautripdVqXLA"
      decimals="0"
      id="Narr_mvAEtSPVB0mjak9hgG0aVg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1890000</limn:FairValueOfCommonStockIssued>
    <limn:FairValueOfWarrantsSurrendered
      contextRef="As_Of_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_3KBXe2AusUautripdVqXLA"
      decimals="0"
      id="Narr_LHwdDOPnl0y60fHcr4xxCg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">150000</limn:FairValueOfWarrantsSurrendered>
    <limn:GainLossOnIssuanceOfCommonStockForWarrants
      contextRef="Duration_7_16_2025_To_7_16_2025_srt_CounterpartyNameAxis_limn_AltaPartnersLlcMember_bvbBg5HF0E2idzp2cAdrIg"
      decimals="0"
      id="Narr_L4STvNJ3fkqI0t_0Hap6Zg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-1740000</limn:GainLossOnIssuanceOfCommonStockForWarrants>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_LxBo1bBBl0yMY18IH7IVrQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">27064633</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_htk19E2mDESRxBeEIz_XOA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">27064633</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="INF"
      id="Narr_hTIC__6zw0GNwCfYQ1-ijA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">17500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="INF"
      id="Narr_m87XrE1hn0Cez8af0DhbSg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">17500000</us-gaap:CommonStockSharesIssued>
    <limn:CommonStockNumberOfVotesPerShare
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_rafEAW50hUGLfaMrKMWt2w"
      unitRef="Unit_Standard_Vote_pVdT3YsDMEiv7zpsvfY2UA">1</limn:CommonStockNumberOfVotesPerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z416a0UcpESjBa-8wQ9m5Q"
      decimals="INF"
      id="Narr_yzkg8yIts0meZFr4uFmjEA"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">5899975</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PrivatePlacementWarrantsMember_ioEniwa8PEunNaQ7J6fSnA"
      decimals="INF"
      id="Narr_KosC_hCPTEStDOSYhAcS4w"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">835555</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="INF"
      id="Narr_1ZiTicliwUiaQwQj6gry6A"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="2"
      id="Narr_gbe8X3bYnEmA8Q4gfYUiow"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z416a0UcpESjBa-8wQ9m5Q"
      decimals="2"
      id="Narr_1dRh8c_EMkidiL_LNeaRTg"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <limn:ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_jjYhKZRSskurVxz2qWHRfg"
      id="Narr_Zkd_RCHxMU-SLm-juW29xg">P30D</limn:ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants>
    <limn:ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z416a0UcpESjBa-8wQ9m5Q"
      decimals="2"
      id="Narr_8HFJ0AjV9kWfsd0rG8N3Bw"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">18</limn:ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption>
    <limn:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_jjYhKZRSskurVxz2qWHRfg"
      decimals="INF"
      id="Narr_6AAsWoklmkeTgYTY4ldawQ"
      unitRef="Unit_Standard_D_P_lZhqU5gEiyf8nABG1U1w">20</limn:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays>
    <limn:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_jjYhKZRSskurVxz2qWHRfg"
      decimals="INF"
      id="Narr_JTp89Ru6sU6sRGBIYP9X6w"
      unitRef="Unit_Standard_D_P_lZhqU5gEiyf8nABG1U1w">30</limn:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_limn_PublicWarrantsMember_Z416a0UcpESjBa-8wQ9m5Q"
      id="Narr_8nkCPuxpaEuT_WDDHgi7jA">P30D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_2KaPi9HWt0OLSV2i9LgWMA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note&#160;7. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 17, 2025, the Company entered into a short-term lease for an office space in Cerritos, California (the &#x201c;Lease&#x201d;). The Lease commenced on September 1, 2025 and expires on June 30, 2026 and does not have any renewal option. The Company has made the short-term lease election and recognizes lease payments for its short-term lease on a straight line basis over the lease term. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2025, lease expense related to the short-term lease was $2,784. For the year ended December 31, 2024, there was no lease expense related to the short-term lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Legal proceedings&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 6, 2026, the Company entered into a settlement and release agreement with Clear Street LLC (the &#x201c;Holder&#x201d;), pursuant to which the Company agreed to issue 4,000,000 shares of its common stock, par value $0.0001 per share, to the Holder in exchange for the surrender and cancellation of 805,377 warrants to purchase shares of common stock held by the Holder. The Company has determined this represents a Type I subsequent event in accordance with the guidance of ASC 855, &lt;i style="font-style:italic;"&gt;Subsequent Events&lt;/i&gt; (&#x201c;ASC 855&#x201d;), in which the Company obtained additional evidence about conditions that existed at the date of the consolidated balance sheets. As such, the Company has recorded the $7,360,000 as settlement payable, which was calculated using the fair value of the Company&#x2019;s common stock on February 6, 2026, which was the day that stock was issued to the Holder, in its consolidated balance sheets as of December 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Settlement Agreement, the Company and the Holder agreed to dismiss (a) an action pending in the United States District Court for the Central District of California and (b) an action pending in the United States District Court for the Southern District of New York, in which previously the Court entered a default judgment against the Company in the amount of $7,500,000 plus approximately $515,000 in interest, which judgment was registered in the Central District of California in the fourth quarter of 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is not a party to any other material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Underwriting Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the Business Combination in connection with its initial public offering, Iris entered into an underwriting agreement in which Cantor was engaged as the underwriters to Iris&#x2019; IPO. Cantor was entitled to an underwriting discount of 2% (or $5,520,000) of the gross proceeds of the IPO and deferred underwriting discount of 3.5% (or $9,660,000) of the gross proceeds of the IPO upon the completion of an initial business combination.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 11, 2023, Iris executed a fee reduction agreement with the underwriters to reduce the deferred underwriting discount of $9,660,000 to $8,000,000 in the event the Business Combination was consummated. Pursuant to the terms of the agreement, the reduced deferred underwriting discount was payable by the Iris to the underwriters in $1,000,000 cash and $7,000,000 of the common equity securities of the public entity that survives the transaction. The share price is subject to adjustment based on the five day volume-weighted average price prior to the filing of a resale registration statement covering such shares. As of April 30, 2025, Iris and the Company amended the fee reduction agreement with the underwriters to limit the total number of shares of common stock issuable to the underwriters to 1,750,000. Upon the consummation of the Business Combination, $9,160,000 in deferred underwriting fees were settled, of which $7,000,000 will be settled in common shares of the combined company, $500,000 was settled in cash and $1,660,000 was waived and no longer payable. The remaining $500,000 was to be settled upon the earlier of the consummation of the combined company&#x2019;s next share offering, or in six months from the closing date of the Business Combination. As of December 31, 2025, the deferred underwriting fee payable was $500,000, which is included in Deferred underwriting fee payable in the Company&#x2019;s consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 30, 2025, the Company settled Iris&#x2019; liabilities for $7,000,000 of the deferred underwriting fees incurred prior to the Closing Date for 700,000 shares of common stock to the underwriters in Iris&#x2019;s initial public offering. On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $7,245,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;On October 27, 2025, six months from the closing date of the Business Combination, the remaining $500,000 underwriting fee became due. As of the date of these consolidated financial statements, the $500,000 underwriting fees remains unpaid. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ShortTermLeaseCost
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Narr_0UhguKCWsUCL7fcR2O26uA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2784</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Narr_qX73PNc1o0ajmcQpI1p_yg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:ShortTermLeaseCost>
    <limn:SharesIssuedForSurrenderAndCancellationOfWarrants
      contextRef="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_IbplB2gb40qdMMz9BIq6qA"
      decimals="INF"
      id="Narr_kAq8BreYkEeTPyKlB1C5qw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">4000000</limn:SharesIssuedForSurrenderAndCancellationOfWarrants>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qRAwhaLP1EWqdsQcq1AtbA"
      decimals="INF"
      id="Narr_h0uX_oIM-UmCxmChZkbaGg"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <limn:ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled
      contextRef="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_IbplB2gb40qdMMz9BIq6qA"
      decimals="INF"
      id="Narr_kG_EaQ5INEKrRFwaFnJ6Vg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">805377</limn:ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled>
    <limn:CommonStockPayable
      contextRef="As_Of_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qRAwhaLP1EWqdsQcq1AtbA"
      decimals="0"
      id="Narr_U8TCGAvWhEK1TRrD9SDSGg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7360000</limn:CommonStockPayable>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="Duration_10_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_6H9UrA2MZUWmfOm8ySparQ"
      decimals="0"
      id="Narr_ers8IUGlcE22BI8LRC7EBg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7500000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LitigationSettlementInterest
      contextRef="Duration_10_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_6H9UrA2MZUWmfOm8ySparQ"
      decimals="0"
      id="Narr_510A2YmikkGXaSjS-PPJrg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">515000</us-gaap:LitigationSettlementInterest>
    <limn:UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering
      contextRef="Duration_1_1_2025_To_12_31_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_rriXg5_Dp0mBV3id5bODsQ"
      decimals="2"
      id="Narr_bBwpn_2dSUC-WnthkBX_7g"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.02</limn:UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering>
    <limn:UnderwritingCostsNoncurrent
      contextRef="As_Of_12_31_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_TzHnTBOE4E6UpnLXPy51MA"
      decimals="0"
      id="Narr_tB8VRm3v90qolff2Mu3DxA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">5520000</limn:UnderwritingCostsNoncurrent>
    <limn:DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering
      contextRef="Duration_1_1_2025_To_12_31_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_rriXg5_Dp0mBV3id5bODsQ"
      decimals="3"
      id="Narr_CaTGLXnxNkKm-ephpTFeIg"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.035</limn:DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering>
    <limn:DeferredOfferingCostsNoncurrent
      contextRef="As_Of_12_31_2025_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_TzHnTBOE4E6UpnLXPy51MA"
      decimals="0"
      id="Narr_HVEbDeZaqEulp-MuxbUnJA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">9660000</limn:DeferredOfferingCostsNoncurrent>
    <limn:DeferredOfferingCostsNoncurrent
      contextRef="As_Of_10_10_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_8jW8A96_rUGTBNiKY7EncA"
      decimals="0"
      id="Narr__0EQ5pxeFkWpF3RtNyiSJQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">9660000</limn:DeferredOfferingCostsNoncurrent>
    <limn:DeferredOfferingCostsNoncurrent
      contextRef="As_Of_10_11_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_3xBPTdDIoEKDwiqXuL9Qyg"
      decimals="0"
      id="Narr_zbFCkO2TJUC2dYaseKC3gQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">8000000</limn:DeferredOfferingCostsNoncurrent>
    <limn:PaymentOfOfferingCostsInCash
      contextRef="As_Of_10_11_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_3xBPTdDIoEKDwiqXuL9Qyg"
      decimals="0"
      id="Narr_9xpDAjGUTE20d5ogJKAenA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1000000</limn:PaymentOfOfferingCostsInCash>
    <limn:UnderwritingDiscountPaidInSecurities
      contextRef="As_Of_10_11_2023_dei_LegalEntityAxis_limn_IrisAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_3xBPTdDIoEKDwiqXuL9Qyg"
      decimals="0"
      id="Narr_jwiGEvdlfUOZFEbnJoJlUA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7000000</limn:UnderwritingDiscountPaidInSecurities>
    <limn:MaximumNumbersOfSharesIssuable
      contextRef="As_Of_4_30_2025_us-gaap_FinancialInstrumentAxis_limn_FeeReductionAgreementMember_Lbu1miIqSkupTrmz199Hbw"
      decimals="INF"
      id="Narr_NE8wCNsNXkGKATMNr6rRzg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">1750000</limn:MaximumNumbersOfSharesIssuable>
    <limn:DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="0"
      id="Narr_X1St1VzQG0m67AtiqKERqg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">9160000</limn:DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination>
    <limn:DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="0"
      id="Narr_hDnWBtwk7E28twzQBLv3PQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7000000</limn:DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination>
    <limn:DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="0"
      id="Narr_-iA1mBsoEU6LUpj8T3t1cA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">500000</limn:DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination>
    <limn:DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="0"
      id="Narr_dhUFh88gs06uSvs1FGWG4w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1660000</limn:DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination>
    <limn:DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="0"
      id="Narr_u8slH8q9tUKSQuEnR809LQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">500000</limn:DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering>
    <limn:ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination
      contextRef="Duration_4_30_2025_To_4_30_2025_9PPk1IhN6EmJm5MGsGwEDA"
      id="Narr_snsM2224nEGltIsauM50Dw">P6M</limn:ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination>
    <limn:DeferredUnderwritingFeesPayableInCashCurrent
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Narr_kxnY8UxkekirVXcbHAuENw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">500000</limn:DeferredUnderwritingFeesPayableInCashCurrent>
    <limn:DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="0"
      id="Narr_mM7Qt3Gcg0am1u727_TqKg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7000000</limn:DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination>
    <limn:StockIssuableForSettlementOfDeferredUnderwritingFees
      contextRef="As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA"
      decimals="INF"
      id="Narr_LaswXP8sXEWYo0i7Ii0_xg"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">700000</limn:StockIssuableForSettlementOfDeferredUnderwritingFees>
    <limn:FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees
      contextRef="As_Of_7_1_2025_CZJvPOCOcUySCDRAwOkqBA"
      decimals="0"
      id="Narr_2dmziqNKHUG7L4IJrTD-VQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7245000</limn:FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees>
    <limn:DeferredUnderwritingFeesPayableInCashCurrent
      contextRef="As_Of_10_27_2025_WHc2wpxA30auOyOjgUueLA"
      decimals="0"
      id="Narr_-xGuxrtyyUC39MWjPSxGYQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">500000</limn:DeferredUnderwritingFeesPayableInCashCurrent>
    <limn:DeferredUnderwritingFeesPayableInCashCurrent
      contextRef="As_Of_10_27_2025_WHc2wpxA30auOyOjgUueLA"
      decimals="0"
      id="Narr_QyLjteaEwE2KtYzzYLElkw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">500000</limn:DeferredUnderwritingFeesPayableInCashCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_5O3h8A9rBkm6Rn92OXZdbw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 8. Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The following table presents information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2025 and 2024 and indicates the fair value hierarchy of the valuation inputs the Company&#x2019;s utilized to determine such fair value:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"&gt;&lt;tr&gt;&lt;td style="width:341.85pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:10.8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:50.65pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:10.79pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:6.8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:50.75pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:10.8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:6.8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:50.75pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:341.85pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.44pt;"&gt;&lt;td style="vertical-align:bottom;width:341.85pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:341.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:341.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:341.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,244&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Warrant Liability&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon closing of the Mergers, Iris&#x2019; public and private placement warrants were converted into warrants of the Company, which entitle the holders to purchase shares of the Company&#x2019;s common stock. The Company&#x2019;s private placement warrants meet the requirements for liability classification. The fair value of the warrant liabilities were determined using observable data points, such as the fair value of the public warrants as of December 31, 2025 and 2024. The Company further considered specific unobservable inputs, such as the probability and timing of events and the expected equity value of the underlying shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The changes in fair value of Level 3 financial assets and liabilities for the year ended December 31, 2025 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"&gt;&lt;tr&gt;&lt;td style="width:360.05pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:11.39pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:7.15pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:53.4pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.44pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:60.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant&#160;liability&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value as of January 1, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Initial measurement at the Closing Date&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,556&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (54,312)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.49pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value as of December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 29,244&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_J-dDLw7htEKBUEUyR6nR6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"&gt;&lt;tr&gt;&lt;td style="width:341.85pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:10.8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:50.65pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:10.79pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:6.8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:50.75pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:10.8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:6.8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:50.75pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:341.85pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.44pt;"&gt;&lt;td style="vertical-align:bottom;width:341.85pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:341.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:341.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:341.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,244&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.75pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_3B7id13HUEKPGohf_GYnnw"
      decimals="0"
      id="Tc_eCgIeMZpgku0c061r7lrJg_4_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">29244</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <limn:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_j15F4MK0QkaaI5IFMLfLiQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:432pt;"&gt;&lt;tr&gt;&lt;td style="width:360.05pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:11.39pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:7.15pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:53.4pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.44pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:60.55pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant&#160;liability&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value as of January 1, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.49pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Initial measurement at the Closing Date&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,556&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.74pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (54,312)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.49pt;"&gt;&lt;td style="vertical-align:bottom;width:360.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value as of December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.4pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 29,244&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</limn:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_yZvCrOb-Wk-Oqgi1kTrEqg"
      decimals="0"
      id="Tc_yOMP0EriykySpyRG4nXUNg_3_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">83556</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_yZvCrOb-Wk-Oqgi1kTrEqg"
      decimals="0"
      id="Tc_iL01fATiX0aZmoRedXxyNA_4_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-54312</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_NOD7vwuXLUmAhk-2mkyvLQ"
      decimals="0"
      id="Tc_gZcoKt1KG0-wBqt9QQg6EA_5_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">29244</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_ypb8Fn3y7E27usil3s6BnA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 9. Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 30, 2025, the Company consummated the Business Combination. Liminatus, a Delaware limited liability company, was deemed the accounting acquirer in the Business Combination based on an analysis of the criteria outlined in ASC 805, see Note 1. The tax consequences of the Company&#x2019;s transactions prior to the consummation of the Business Combination flows through to the members of Liminatus. The tax consequences of the Company&#x2019;s transactions for the period from May 1, 2025 through December 31, 2025 are accounted for in accordance with ASC 740. Prior to May 1, 2025, the Company was a non corporate entity that was not subject to U.S. federal income tax.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company regularly assesses the need for a valuation allowance against its deferred tax assets. In making that assessment, the Company considers both positive and negative evidence related to the likelihood of realization of the deferred tax assets to determine, based on the weight of available evidence, whether it is more-likely-than-not that some or all of the deferred tax assets will not be realized. In assessing the realizability of deferred tax assets, the Company considers taxable income in prior carryback years, as permitted under the tax law, forecasted taxable earnings, tax planning strategies, and the expected timing of the reversal of temporary differences. This determination requires significant judgment, including assumptions about future taxable income that are based on historical and projected information and is performed on a jurisdiction-by-jurisdiction basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains a full valuation allowance against its deferred tax assets. During the years ended December 31, 2025 and 2024, management assessed the positive and negative evidence in its operations, and concluded that it is more likely than not that its deferred tax assets as of December 31, 2025 and 2024 will not be realized given the Company&#x2019;s history of operating losses. The valuation allowance against deferred tax assets increased by $2,345,773 and $0 during the year December 31, 2025 and 2024, respectively, related to a full valuation allowance recorded against additional net operating losses and tax credits generated in the year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 22, 2017, the Tax Cuts and Jobs Act (the &#x201c;Act&#x201d;) was enacted. Under the Act, research and development expenditures incurred for tax years beginning after December 31, 2021 must be capitalized and amortized ratably over five or fifteen years for tax purposes, depending on if the research activities are conducted in the U.S. or outside the U.S., respectively. For the years ended December 31, 2025 and 2024, the Company had no research and development expenditures subject to the mandatory capitalization and amortization under the Act.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025 and 2024, the Company had federal net operating losses of $822,963 and $0, respectively, which may be available to offset future federal income tax liabilities, subject limitations under IRC Section 382 of approximately $1.1 million per year. As a result of the Act, for U.S. federal income tax purposes, net operating losses generated after December 31, 2017 can be carried forward indefinitely, but are limited to 80% utilization against future taxable income each year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The components of the income tax provision (benefit) are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"&gt;&lt;tr&gt;&lt;td style="width:399pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:12.65pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:49.9pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:12.64pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:49.81pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.49pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:128.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.74pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.79pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,604,745)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State and Local&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (741,028)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.79pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,345,773&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.54pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;A reconciliation of the Company&#x2019;s effective income tax rate to the U.S. statutory federal income tax rate of 21% and the Company&#x2019;s California income tax rate of 8.84%for the years ended December 31, 2025 and 2024 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"&gt;&lt;tr&gt;&lt;td style="width:304.85pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:10pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:42.4pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:13.35pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:6pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:49.2pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:10pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:42.45pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:13.35pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:6.05pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:42.35pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.49pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:225.15pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.74pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:110.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:104.2pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.79pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statutory federal income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,052,583)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_gt31aPXKykC4c-4bEt6laQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;State taxes, net of federal expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss on exchange of common stock for warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.74)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 365,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fair value of common stock to be issued for contingent liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (15.81)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,545,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.31)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,686&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.79pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 110,897&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.54pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax provision expense/(benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The significant components of the Company&#x2019;s net deferred tax assets and liabilities as of December 31, 2025 and 2024 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"&gt;&lt;tr&gt;&lt;td style="width:400.5pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:13.05pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8.1pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:51.95pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:13.05pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8.1pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:45.25pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.49pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:126.45pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.74pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:60.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:53.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.79pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Startup expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,042,605&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Section 163(j) - Interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 72,873&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,345,773&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.79pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,345,773)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.54pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax asset, net of valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The calculation of the Company&#x2019;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations in a multitude of jurisdictions. The Company recognizes liabilities for uncertain tax positions based on a two-step process. First, management determines whether it is more likely than not that the tax positions will be sustained on audit, including resolution of related appeals or litigation processes, based on their technical merits. Second, management measures the tax benefit of those positions as the largest amount that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes. As of December 31, 2025 and 2024, the Company did not have any uncertain tax positions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s policy is to recognize interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations and any accrued interest and penalties on the related tax liability line in the consolidated balance sheet. As of December 31, 2025 and 2024, no accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet. Further, during the years ended December 31, 2025 and 2024, the Company did not remit payment for any income tax obligations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company files income tax returns in the U.S. federal jurisdiction and California jurisdictions. There are currently no pending income tax examinations. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent the tax attributes are utilized in a future period. The Company&#x2019;s income tax returns since 2022 are subject to examination by the IRS and state tax authorities.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Narr_pJ3L5WA1akugpimcH4D38w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2345773</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Narr_r2v8-PJsQEioJmDAfYQo4g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <limn:ResearchAndDevelopmentExpenseMandatoryCapitalization
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Narr_jnVCvHxDIU2Wr23dg4yz7Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</limn:ResearchAndDevelopmentExpenseMandatoryCapitalization>
    <limn:ResearchAndDevelopmentExpenseMandatoryCapitalization
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Narr_FsMjAxFTUUaVueZ4IZPMOA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</limn:ResearchAndDevelopmentExpenseMandatoryCapitalization>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Narr_aJMXR8IfbkCBrGx7ddW08w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">822963</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Narr_Yj6kxWQP60O1Mbqd8JPabQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:OperatingLossCarryforwards>
    <limn:FederalIncomeTaxExpenseSubjectToLimitationInUse
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="-5"
      id="Narr_XxQ57YTzfUOFZsnUxuRPxA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1100000</limn:FederalIncomeTaxExpenseSubjectToLimitationInUse>
    <limn:FederalIncomeTaxExpenseSubjectToLimitationInUse
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="-5"
      id="Narr_Ysi_wAmU_0KvkPPrOvt3Hw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1100000</limn:FederalIncomeTaxExpenseSubjectToLimitationInUse>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_MNcDTNsnFk22n9TSEipGAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"&gt;&lt;tr&gt;&lt;td style="width:399pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:12.65pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:49.9pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:12.64pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:49.81pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.49pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:128.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.74pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.9pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:57.8pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.79pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,604,745)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State and Local&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (741,028)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.79pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,345,773&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.54pt;"&gt;&lt;td style="vertical-align:bottom;width:399pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.65pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.8pt;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_qo2Vigob10Se8Ubhnj042Q_5_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-1604745</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_nxQk2kBCaE-Uol2-WwnUPg_8_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-741028</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_AFEtl-Y2uUq0wZdL2r9jGA_9_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2345773</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="2"
      id="Narr_1Rox3tVpM06jSpO22paTog"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <limn:StatutoryStateIncomeTaxRate
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="4"
      id="Narr_RmOI5EyPP0WF2o8EHbwKEw"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.0884</limn:StatutoryStateIncomeTaxRate>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_ip3OtThHdk2o8QI7dks-Tw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"&gt;&lt;tr&gt;&lt;td style="width:304.85pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:10pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:42.4pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:13.35pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:6pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:49.2pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:10pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:42.45pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:13.35pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:6.05pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:42.35pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.49pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:225.15pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.74pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:110.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:104.2pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.79pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statutory federal income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,052,583)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_gt31aPXKykC4c-4bEt6laQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;State taxes, net of federal expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss on exchange of common stock for warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.74)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 365,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fair value of common stock to be issued for contingent liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (15.81)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,545,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.31)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,686&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.79pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 110,897&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.54pt;"&gt;&lt;td style="vertical-align:bottom;width:304.85pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax provision expense/(benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.4pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.2pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.45pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.35pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.35pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="4"
      id="Tc_1yxgPT7eKE2PCKKWEyv1TQ_3_2"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_aB6xW2P4wEOYFlmnH81pfg_3_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-2052583</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="3"
      id="Tc_-ArVcktqBEG60e_JS8ND2A_3_7"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="4"
      id="Tc_qhfpdEDtF0KqXBmxlGrjLQ_4_2"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_A1et0hoDz0WoKaFqH3sbxA_4_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="3"
      id="Tc_kPB8_0aMbEOZFrP3axFy0g_4_7"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Tc_8GGuPBupjUuhuQSX00Zbdg_4_10"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <limn:EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="4"
      id="Tc_Qft3Mpb38kGX4_2QUWclYg_5_2"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.0374</limn:EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent>
    <limn:EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_MuHuw57cCUCV3FG92_htRg_5_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-365400</limn:EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount>
    <limn:EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="3"
      id="Tc_iZqoaU4o20SN_pmSmWV1cg_5_7"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0</limn:EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent>
    <limn:EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="4"
      id="Tc_HvyIY0vmFUK2A_hyJwB3jQ_6_2"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.1581</limn:EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent>
    <limn:EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_LniosrZcjUSWheBneUFrJg_6_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">-1545600</limn:EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount>
    <limn:EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="3"
      id="Tc_1LfrJbC7IUe_3SI6rJAbRA_6_7"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0</limn:EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="4"
      id="Tc_S9hX2HN0VEKjkKcAFt7qSQ_7_2"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">-0.0031</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_6AoYzSOIIki4_XHRYqGdeQ_7_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">30686</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="3"
      id="Tc_OfOp-PUhwEGWOcgvOuyBtw_7_7"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="4"
      id="Tc_JHC2uAOtiUy3Im-2kbKPrw_8_2"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">-0.0114</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Tc_3jsEwiDfeki_wYSS4VrVgA_8_5"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">110897</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="3"
      id="Tc_CGB0bHfxqkG0Xw4zIROLBw_8_7"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="4"
      id="Tc_dUnJdGIoQ0CW38_mC9zSwA_9_2"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="3"
      id="Tc_m9tLncCaPE2qcMywmn2cPw_9_7"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_si17NDbVF0G0waGb9x2h4w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"&gt;&lt;tr&gt;&lt;td style="width:400.5pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:13.05pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8.1pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:51.95pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:13.05pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:8.1pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="width:45.25pt;padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.49pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:126.45pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.74pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:60.05pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:53.35pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.79pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Startup expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,042,605&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Section 163(j) - Interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 72,873&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.54pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,345,773&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.79pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,345,773)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.54pt;"&gt;&lt;td style="vertical-align:bottom;width:400.5pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax asset, net of valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.95pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05pt;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.25pt;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_k3uS2s-QwEqxqUmEGYKIFQ_4_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">230295</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <limn:DeferredTaxAssetsStartupExpenses
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_o_z6jNCF90KCpsHSo-TmbQ_5_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2042605</limn:DeferredTaxAssetsStartupExpenses>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_13m_8l-ku0OfTgClbq_QkQ_6_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">72873</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_8DNmVgH5M0yBUnNh2Vpf_Q_7_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2345773</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Tc_zQOnStHJ8k2OylPkAwc60A_8_3"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">2345773</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Narr_pkiytGMEkUuzrU07Knv6Xw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Narr_5eBDfx6M40S-lvOsTxWd7A"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA"
      decimals="0"
      id="Narr_78k9FCMIcEySx8xyjER_aA"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg"
      decimals="0"
      id="Narr_C5ny6z706km9C18Fy58W8w"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2024_To_12_31_2024_vuDHjXKuEUuUjJ4ETmAGCw"
      decimals="0"
      id="Narr_SKp6qWZwx0WH7a8S38sn5g"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      decimals="0"
      id="Narr_EdBig4uPe0uM6dvHCLc3iQ"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww"
      id="Tb_M32f5vCp4Uye_IqHqOgTSA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note&#160;10. Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has completed an evaluation of all subsequent events through the date of this filing to ensure that these consolidated financial statements include appropriate disclosure of events both recognized in the consolidated financial statements and events which occurred but were not recognized in the consolidated financial statements. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;On February 6, 2026, the Company entered into a settlement and release agreement with the Holder, pursuant to which the Company agreed to issue 4,000,000 shares of its common stock, par value $0.0001 per share, to the Holder in exchange for the surrender and cancellation of 805,377 warrants to purchase shares of common stock held by the Holder. The Company has determined this represents a Type I subsequent event in accordance with ASC 855, in which the Company obtained additional evidence about conditions that existed at the date of the consolidated balance sheets. As such, the Company has recorded the $7,360,000 as settlement payable, which &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;was calculated using the fair value of the Company&#x2019;s common stock on February 6, 2026, which was the day that stock was issued to the Holder, in its consolidated balance sheets as of December 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Settlement Agreement, the Company and the Holder agreed to dismiss (a) an action pending in the United States District Court for the Central District of California and (b) an action pending in the United States District Court for the Southern District of New York, in which previously the Court entered a default judgment against the Company in the amount of $7,500,000 plus approximately $515,000 in interest, which judgment was registered in the Central District of California in the fourth quarter of 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 18, 2026, the Company completed a &#x201c;best efforts&#x201d; public offering of (i) 8,270,000 shares of its common stock, (ii) 5,543,000 Pre-Funded Warrants to purchase up to 5,543,000 shares of common stock and (ii) 13,813,000 common stock purchase warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per Pre-Funded Warrant) and accompanying warrant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Each Pre-Funded Warrant has an exercise price of $0.0001 per share upon issuance for &lt;span style="-sec-ix-hidden:Hidden_pRGIcWXwZE-WeEaxj87wJg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; share of common stock and will not expire prior to exercise. Each Warrant has an exercise price of $0.29 per share, is exercisable upon issuance for&lt;span style="-sec-ix-hidden:Hidden_kq3mrqvJyU-ExJ_p7HGPjQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; one and a half&lt;/span&gt;&lt;/span&gt; shares of common stock, and will expire five years following the date of issuance. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the common stock and the exercise price.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Offering, on February 17, 2026, the Company entered into a securities purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with certain purchasers party thereto. The Purchase Agreement contains customary representations, warranties and agreements of the Company and the purchasers and customary indemnification rights and obligations of the parties. Pursuant to the Purchase Agreement, the Company agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock or file any registration statement or prospectus, or any amendment or supplement thereto for 180 days after the closing date of the Offering, subject to certain exceptions. The Company also agreed not to effect or enter into an agreement to effect any issuance of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock involving a Variable Rate Transaction (as defined in the Purchase Agreement) until 180 days after the closing date of the Offering, subject to certain exceptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;In connection with the Offering, on February 17, 2026, the Company entered into a placement agency agreement with Maxim Group LLC, as placement agent in connection with the Offering (the &#x201c;Placement Agent&#x201d;). The Company paid the Placement Agent a cash fee of 8.0% of the aggregate gross proceeds raised in the Offering. The Company also agreed to reimburse the Placement Agent for all reasonable out-of-pocket costs and expenses incurred in connection with the Offering in an aggregate amount up to $100,000. In addition, the Company issued to the Placement Agent warrants (the &#x201c;Placement Agent Warrants&#x201d;) to purchase 690,650 shares of common stock (representing 5.0% of the number of shares of common stock sold in the Offering). The Placement Agent Warrants are immediately exercisable at an exercise price of $0.319 (or 110% of the public offering price for the shares of common stock and common warrants offered in the Offering) and will expire on the &lt;span style="-sec-ix-hidden:Hidden_rGRJ0qc7tEGPO6XNQVjRbw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;fifth anniversary&lt;/span&gt;&lt;/span&gt; of the commencement of sales of the Offering. On February 18, 2026, in connection with the Offering, the Company received net proceeds of approximately $3.46 million, after deducting the estimated offering expenses payable by the Company, including the placement agent fees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;On February 20, 2026, the Company issued a payment of $1,000,000 to InnoBation Bio Co. Ltd. for costs associated to begin the Phase 1 clinical trials of IBA101, the Company&#x2019;s product candidate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <limn:SharesIssuedForSurrenderAndCancellationOfWarrants
      contextRef="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_IbplB2gb40qdMMz9BIq6qA"
      decimals="INF"
      id="Narr_l6IclT1oJU6N38lMCOjcNQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">4000000</limn:SharesIssuedForSurrenderAndCancellationOfWarrants>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qRAwhaLP1EWqdsQcq1AtbA"
      decimals="INF"
      id="Narr__dlc3LnzRkyjKSUswLpNKg"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <limn:ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled
      contextRef="Duration_2_6_2026_To_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_IbplB2gb40qdMMz9BIq6qA"
      decimals="INF"
      id="Narr_BUH3-Rg_RE-RGF-BVsAoPw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">805377</limn:ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled>
    <limn:CommonStockPayable
      contextRef="As_Of_2_6_2026_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qRAwhaLP1EWqdsQcq1AtbA"
      decimals="0"
      id="Narr_AgV6E5-giEyQDox8nBN5eg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7360000</limn:CommonStockPayable>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="Duration_10_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_6H9UrA2MZUWmfOm8ySparQ"
      decimals="0"
      id="Narr_Fy94GQepSUSQUPeb6HhWkw"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">7500000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LitigationSettlementInterest
      contextRef="Duration_10_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_limn_ClearStreetLlcMember_6H9UrA2MZUWmfOm8ySparQ"
      decimals="0"
      id="Narr_o8HteKEgcEqVLRshnFz_fg"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">515000</us-gaap:LitigationSettlementInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_JSVgKnyZI0uvIBPJsCar7A"
      decimals="INF"
      id="Narr_5IWQ2_ORY0iAdqXjaa8RUQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">8270000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <limn:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_BC5_6M-QyUmQOf1sjtWaMg"
      decimals="INF"
      id="Narr_sJ08dF6mdkGPHHb3M6b9Iw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">5543000</limn:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_eTUFwzCAf0WPdoyAqoxppg"
      decimals="INF"
      id="Narr_6Yz6p_1U5k-xFqA7Er-jPQ"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">5543000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <limn:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="Duration_2_18_2026_To_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_YV5sLiK4506wsErDca1zNw"
      decimals="INF"
      id="Narr_nG8LMFCHtkiTB8hs7eqqXw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">13813000</limn:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_Y7EtLUI_pk6RZ-oTbRPBxg"
      decimals="INF"
      id="Narr_liSWkTV2QkOU1dAHME6L7w"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">20719500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_2_18_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_1t1X0h92206D-tAJKXlt8Q"
      decimals="2"
      id="Narr_zD-YVbLLQEyz9W7RxzwtiQ"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.29</us-gaap:SharesIssuedPricePerShare>
    <limn:ClassOfWarrantOrRightIssuePricePerWarrant
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_U70qipalZUSb0nCwfCrzfg"
      decimals="4"
      id="Narr_KEhNTgeWb0S1PsEwkUil8g"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.2899</limn:ClassOfWarrantOrRightIssuePricePerWarrant>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kX_yWG231E-RYOerQjujQA"
      decimals="4"
      id="Narr_BN3vaCAvhkaI-DapB9sfZg"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wuQDuaMWckW-5cDSn3bI2w"
      decimals="2"
      id="Narr_mg43FjDajEu150tSrkmN6w"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.29</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wuQDuaMWckW-5cDSn3bI2w"
      id="Narr_6d7YW7A_jkKNUWsuvX6SFw">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <limn:PeriodOfNonIssuanceOfCommonStockFollowingClosingDate
      contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_809IbYMTbUCQEIVjWuaGsA"
      id="Narr_A59JFLOeAkKO2EUQ26KWlg">P180D</limn:PeriodOfNonIssuanceOfCommonStockFollowingClosingDate>
    <limn:PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate
      contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_809IbYMTbUCQEIVjWuaGsA"
      id="Narr_vIAu79Sxakuf3-FIrmboAw">P180D</limn:PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate>
    <limn:PlacementAgentCashFeePercentage
      contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_809IbYMTbUCQEIVjWuaGsA"
      decimals="3"
      id="Narr_LUFMxpstpEiCKUh4BrZpwQ"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.08</limn:PlacementAgentCashFeePercentage>
    <limn:MaximumReimbursementForPlacementAgentExpenses
      contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_809IbYMTbUCQEIVjWuaGsA"
      decimals="0"
      id="Narr_tP474REI3kSSeZvMIFX6-Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">100000</limn:MaximumReimbursementForPlacementAgentExpenses>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_go0DO65rkkqPaWM8iCPEeg"
      decimals="INF"
      id="Narr_r2vPchbpwEGka7BsKuxbYw"
      unitRef="Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw">690650</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <limn:PercentOfSharesIssuedInOffering
      contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_0DwlS1YhD0uVubSzwvOJJQ"
      decimals="3"
      id="Narr_bZRMzEVAXUqL87I-hamsGA"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">0.05</limn:PercentOfSharesIssuedInOffering>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_01Es_yiBG0a6u9R-nLydbg"
      decimals="3"
      id="Narr_KUtDIRy5dUK2x1kxzANWqA"
      unitRef="Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw">0.319</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <limn:PercentOfOfferingPriceRepresentingExercisePrice
      contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PlacementAgentWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_0DwlS1YhD0uVubSzwvOJJQ"
      decimals="2"
      id="Narr_HeAb32_0zU2pjo-hi4SjkA"
      unitRef="Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA">1.10</limn:PercentOfOfferingPriceRepresentingExercisePrice>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_2_17_2026_To_2_17_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_809IbYMTbUCQEIVjWuaGsA"
      decimals="4"
      id="Narr_9MVNbZhrb0yLt4Adjvjl-Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">3460000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <limn:PaymentForCostsAssociatedWithClinicalTrials
      contextRef="Duration_2_20_2026_To_2_20_2026_srt_CounterpartyNameAxis_limn_InnobationBioCoLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_3V203J1Zg0mfoaBaDb3DcQ"
      decimals="0"
      id="Narr_aK-snCkrO0G1gziIs4Zp6Q"
      unitRef="Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ">1000000</limn:PaymentForCostsAssociatedWithClinicalTrials>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_sZwEW9zD10aVsHVqFTELDQ_4_2"
          xlink:label="Tc_sZwEW9zD10aVsHVqFTELDQ_4_2"
          xlink:type="locator"/>
        <link:footnote id="_0a013712_0ec7_4e02_8987_4de262708134" xlink:label="_0a013712_0ec7_4e02_8987_4de262708134" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Shares, preferred stock amount, common stock amount and additional paid-in capital data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_sZwEW9zD10aVsHVqFTELDQ_4_2"
          xlink:to="_0a013712_0ec7_4e02_8987_4de262708134"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_uHx5DuLpAEO1yylp-kybYA_6_2"
          xlink:label="Tc_uHx5DuLpAEO1yylp-kybYA_6_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_uHx5DuLpAEO1yylp-kybYA_6_2"
          xlink:to="_0a013712_0ec7_4e02_8987_4de262708134"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_7ROUESS25EOckwg8ALPOvA_4_2"
          xlink:label="Tc_7ROUESS25EOckwg8ALPOvA_4_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_7ROUESS25EOckwg8ALPOvA_4_2"
          xlink:to="_0a013712_0ec7_4e02_8987_4de262708134"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_2WISg8IU-0WKtEuff6lBmQ_34_6"
          xlink:label="Tc_2WISg8IU-0WKtEuff6lBmQ_34_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_2WISg8IU-0WKtEuff6lBmQ_34_6"
          xlink:to="_0a013712_0ec7_4e02_8987_4de262708134"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_gkMv0vRfWUeB1iRn8oy9SQ_34_3"
          xlink:label="Tc_gkMv0vRfWUeB1iRn8oy9SQ_34_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_gkMv0vRfWUeB1iRn8oy9SQ_34_3"
          xlink:to="_0a013712_0ec7_4e02_8987_4de262708134"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Hidden_W9yMXh1gvU6pZJS4SioUZg"
          xlink:label="Hidden_W9yMXh1gvU6pZJS4SioUZg"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Hidden_W9yMXh1gvU6pZJS4SioUZg"
          xlink:to="_0a013712_0ec7_4e02_8987_4de262708134"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Hidden_rF9jsGd2PEyzELvf4YbZ2g"
          xlink:label="Hidden_rF9jsGd2PEyzELvf4YbZ2g"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Hidden_rF9jsGd2PEyzELvf4YbZ2g"
          xlink:to="_0a013712_0ec7_4e02_8987_4de262708134"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_x56Y14AyeUu4PVvsK2xtfA_4_14"
          xlink:label="Tc_x56Y14AyeUu4PVvsK2xtfA_4_14"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_x56Y14AyeUu4PVvsK2xtfA_4_14"
          xlink:to="_0a013712_0ec7_4e02_8987_4de262708134"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_PREj0jMsnE6uUWTGBUiLpQ_4_8"
          xlink:label="Tc_PREj0jMsnE6uUWTGBUiLpQ_4_8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_PREj0jMsnE6uUWTGBUiLpQ_4_8"
          xlink:to="_0a013712_0ec7_4e02_8987_4de262708134"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_GrnXgKUNgkmBMdi-ZoZ_3w_4_5"
          xlink:label="Tc_GrnXgKUNgkmBMdi-ZoZ_3w_4_5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_GrnXgKUNgkmBMdi-ZoZ_3w_4_5"
          xlink:to="_0a013712_0ec7_4e02_8987_4de262708134"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_lrp0UnlvWUWv5MwTXJ74KA_4_11"
          xlink:label="Tc_lrp0UnlvWUWv5MwTXJ74KA_4_11"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_lrp0UnlvWUWv5MwTXJ74KA_4_11"
          xlink:to="_0a013712_0ec7_4e02_8987_4de262708134"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Mlc4m5k8Fkedtj1BUQ0ZWQ_6_14"
          xlink:label="Tc_Mlc4m5k8Fkedtj1BUQ0ZWQ_6_14"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Mlc4m5k8Fkedtj1BUQ0ZWQ_6_14"
          xlink:to="_0a013712_0ec7_4e02_8987_4de262708134"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_rhAk77c-QUCmJHUppKQptQ_4_14"
          xlink:label="Tc_rhAk77c-QUCmJHUppKQptQ_4_14"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_rhAk77c-QUCmJHUppKQptQ_4_14"
          xlink:to="_0a013712_0ec7_4e02_8987_4de262708134"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_rbq935VjbUKRIodNkWRssw_4_8"
          xlink:label="Tc_rbq935VjbUKRIodNkWRssw_4_8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_rbq935VjbUKRIodNkWRssw_4_8"
          xlink:to="_0a013712_0ec7_4e02_8987_4de262708134"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_WSiTCK1d7kWwjU75pUtOxg_6_8"
          xlink:label="Tc_WSiTCK1d7kWwjU75pUtOxg_6_8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_WSiTCK1d7kWwjU75pUtOxg_6_8"
          xlink:to="_0a013712_0ec7_4e02_8987_4de262708134"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_CVIGz5hPNUqu-ltzIf7NHA_4_5"
          xlink:label="Tc_CVIGz5hPNUqu-ltzIf7NHA_4_5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_CVIGz5hPNUqu-ltzIf7NHA_4_5"
          xlink:to="_0a013712_0ec7_4e02_8987_4de262708134"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_2j-StSoYh0i221VVtJbN8A_6_5"
          xlink:label="Tc_2j-StSoYh0i221VVtJbN8A_6_5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_2j-StSoYh0i221VVtJbN8A_6_5"
          xlink:to="_0a013712_0ec7_4e02_8987_4de262708134"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_xBiVk0vTUUuW4SRVVn7nLw_6_11"
          xlink:label="Tc_xBiVk0vTUUuW4SRVVn7nLw_6_11"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_xBiVk0vTUUuW4SRVVn7nLw_6_11"
          xlink:to="_0a013712_0ec7_4e02_8987_4de262708134"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_YP-t6420zUuJGiagviX8Sg_4_11"
          xlink:label="Tc_YP-t6420zUuJGiagviX8Sg_4_11"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_YP-t6420zUuJGiagviX8Sg_4_11"
          xlink:to="_0a013712_0ec7_4e02_8987_4de262708134"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_zsPKN6SEekWY3d2I44dmXw_4_2"
          xlink:label="Tc_zsPKN6SEekWY3d2I44dmXw_4_2"
          xlink:type="locator"/>
        <link:footnote id="_3ff2511c_245c_4e73_aadd_3aa97d52401a" xlink:label="_3ff2511c_245c_4e73_aadd_3aa97d52401a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Shares, preferred stock amount, common stock amount and additional paid - in capital data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_zsPKN6SEekWY3d2I44dmXw_4_2"
          xlink:to="_3ff2511c_245c_4e73_aadd_3aa97d52401a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_--g1J3AQv0qKyyz8xQSB9w_4_2"
          xlink:label="Tc_--g1J3AQv0qKyyz8xQSB9w_4_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_--g1J3AQv0qKyyz8xQSB9w_4_2"
          xlink:to="_3ff2511c_245c_4e73_aadd_3aa97d52401a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_9g7XhG98L0-hjr-ibTvlWw_4_14"
          xlink:label="Tc_9g7XhG98L0-hjr-ibTvlWw_4_14"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_9g7XhG98L0-hjr-ibTvlWw_4_14"
          xlink:to="_3ff2511c_245c_4e73_aadd_3aa97d52401a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_sOXwOs1NWUqL90HO1pSPsQ_4_8"
          xlink:label="Tc_sOXwOs1NWUqL90HO1pSPsQ_4_8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_sOXwOs1NWUqL90HO1pSPsQ_4_8"
          xlink:to="_3ff2511c_245c_4e73_aadd_3aa97d52401a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_eKNO23yJNUWFC8dvbXuTTQ_4_5"
          xlink:label="Tc_eKNO23yJNUWFC8dvbXuTTQ_4_5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_eKNO23yJNUWFC8dvbXuTTQ_4_5"
          xlink:to="_3ff2511c_245c_4e73_aadd_3aa97d52401a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_gVrV0xOrV0K_rG-K207NgQ_4_11"
          xlink:label="Tc_gVrV0xOrV0K_rG-K207NgQ_4_11"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_gVrV0xOrV0K_rG-K207NgQ_4_11"
          xlink:to="_3ff2511c_245c_4e73_aadd_3aa97d52401a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc__nGSvNLeEUuD2q3Pv8TGvg_4_14"
          xlink:label="Tc__nGSvNLeEUuD2q3Pv8TGvg_4_14"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc__nGSvNLeEUuD2q3Pv8TGvg_4_14"
          xlink:to="_3ff2511c_245c_4e73_aadd_3aa97d52401a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Pek-NRLViUyVyREk8mXLgQ_4_8"
          xlink:label="Tc_Pek-NRLViUyVyREk8mXLgQ_4_8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Pek-NRLViUyVyREk8mXLgQ_4_8"
          xlink:to="_3ff2511c_245c_4e73_aadd_3aa97d52401a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_XR-sd7H54kGW0PiFR5oIoA_4_5"
          xlink:label="Tc_XR-sd7H54kGW0PiFR5oIoA_4_5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_XR-sd7H54kGW0PiFR5oIoA_4_5"
          xlink:to="_3ff2511c_245c_4e73_aadd_3aa97d52401a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_HA7POEqghEqEeslKVHNRfg_4_11"
          xlink:label="Tc_HA7POEqghEqEeslKVHNRfg_4_11"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_HA7POEqghEqEeslKVHNRfg_4_11"
          xlink:to="_3ff2511c_245c_4e73_aadd_3aa97d52401a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_z_syvq_f3Ee2TH7BNETQUA_21_6"
          xlink:label="Tc_z_syvq_f3Ee2TH7BNETQUA_21_6"
          xlink:type="locator"/>
        <link:footnote id="_458cdbcf_7aee_4fc0_9cbc_944ad97ef513" xlink:label="_458cdbcf_7aee_4fc0_9cbc_944ad97ef513" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Shares and per share data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_z_syvq_f3Ee2TH7BNETQUA_21_6"
          xlink:to="_458cdbcf_7aee_4fc0_9cbc_944ad97ef513"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc__FiEmY5-uEmnJvHY1psPwA_21_3"
          xlink:label="Tc__FiEmY5-uEmnJvHY1psPwA_21_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc__FiEmY5-uEmnJvHY1psPwA_21_3"
          xlink:to="_458cdbcf_7aee_4fc0_9cbc_944ad97ef513"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Hidden_cM-Z0zzNDUaiQqfL9Zw3UA"
          xlink:label="Hidden_cM-Z0zzNDUaiQqfL9Zw3UA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Hidden_cM-Z0zzNDUaiQqfL9Zw3UA"
          xlink:to="_458cdbcf_7aee_4fc0_9cbc_944ad97ef513"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Hidden_F4R9DCODRUSd1g3LlIjEqw"
          xlink:label="Hidden_F4R9DCODRUSd1g3LlIjEqw"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Hidden_F4R9DCODRUSd1g3LlIjEqw"
          xlink:to="_458cdbcf_7aee_4fc0_9cbc_944ad97ef513"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Hidden_QfG0tNXDh0OFhH449Pr4Mg"
          xlink:label="Hidden_QfG0tNXDh0OFhH449Pr4Mg"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Hidden_QfG0tNXDh0OFhH449Pr4Mg"
          xlink:to="_458cdbcf_7aee_4fc0_9cbc_944ad97ef513"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Hidden_VnuFzE-7Pk6xiqbZGsYVKw"
          xlink:label="Hidden_VnuFzE-7Pk6xiqbZGsYVKw"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Hidden_VnuFzE-7Pk6xiqbZGsYVKw"
          xlink:to="_458cdbcf_7aee_4fc0_9cbc_944ad97ef513"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_9RX2rQ0RCU6Dk_ZL1Iek7w_19_6"
          xlink:label="Tc_9RX2rQ0RCU6Dk_ZL1Iek7w_19_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_9RX2rQ0RCU6Dk_ZL1Iek7w_19_6"
          xlink:to="_458cdbcf_7aee_4fc0_9cbc_944ad97ef513"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_aHtfXI09SECe6XdEMLiOBQ_19_3"
          xlink:label="Tc_aHtfXI09SECe6XdEMLiOBQ_19_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_aHtfXI09SECe6XdEMLiOBQ_19_3"
          xlink:to="_458cdbcf_7aee_4fc0_9cbc_944ad97ef513"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_VCWz9vVrB0qIHg1ZysCVAw_17_6"
          xlink:label="Tc_VCWz9vVrB0qIHg1ZysCVAw_17_6"
          xlink:type="locator"/>
        <link:footnote id="_ad033d65_277e_4e5e_9e19_7b37ba4f3ada" xlink:label="_ad033d65_277e_4e5e_9e19_7b37ba4f3ada" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Shares and per share data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_VCWz9vVrB0qIHg1ZysCVAw_17_6"
          xlink:to="_ad033d65_277e_4e5e_9e19_7b37ba4f3ada"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_-OJZcUa8QEilwlvS02CGdw_17_3"
          xlink:label="Tc_-OJZcUa8QEilwlvS02CGdw_17_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_-OJZcUa8QEilwlvS02CGdw_17_3"
          xlink:to="_ad033d65_277e_4e5e_9e19_7b37ba4f3ada"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_VCWz9vVrB0qIHg1ZysCVAw_17_6_2"
          xlink:label="Tc_VCWz9vVrB0qIHg1ZysCVAw_17_6_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_VCWz9vVrB0qIHg1ZysCVAw_17_6_2"
          xlink:to="_ad033d65_277e_4e5e_9e19_7b37ba4f3ada"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_-OJZcUa8QEilwlvS02CGdw_17_3_2"
          xlink:label="Tc_-OJZcUa8QEilwlvS02CGdw_17_3_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_-OJZcUa8QEilwlvS02CGdw_17_3_2"
          xlink:to="_ad033d65_277e_4e5e_9e19_7b37ba4f3ada"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_6zPXfbljDUO3vovR4VpTpA_15_6"
          xlink:label="Tc_6zPXfbljDUO3vovR4VpTpA_15_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_6zPXfbljDUO3vovR4VpTpA_15_6"
          xlink:to="_ad033d65_277e_4e5e_9e19_7b37ba4f3ada"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_IIJrVh996USagDgLCTa8-A_15_3"
          xlink:label="Tc_IIJrVh996USagDgLCTa8-A_15_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_IIJrVh996USagDgLCTa8-A_15_3"
          xlink:to="_ad033d65_277e_4e5e_9e19_7b37ba4f3ada"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_6zPXfbljDUO3vovR4VpTpA_15_6_2"
          xlink:label="Tc_6zPXfbljDUO3vovR4VpTpA_15_6_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_6zPXfbljDUO3vovR4VpTpA_15_6_2"
          xlink:to="_ad033d65_277e_4e5e_9e19_7b37ba4f3ada"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_IIJrVh996USagDgLCTa8-A_15_3_2"
          xlink:label="Tc_IIJrVh996USagDgLCTa8-A_15_3_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_IIJrVh996USagDgLCTa8-A_15_3_2"
          xlink:to="_ad033d65_277e_4e5e_9e19_7b37ba4f3ada"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>limn-20260331xexfees_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd"
      xlink:type="simple"/>
    <context id="rc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
        </entity>
        <period>
            <startDate>2026-06-22</startDate>
            <endDate>2026-06-22</endDate>
        </period>
    </context>
    <context id="offrl_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971387</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-22</startDate>
            <endDate>2026-06-22</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <ffd:FormTp contextRef="rc" id="ixv-331">S-1</ffd:FormTp>
    <ffd:SubmissnTp contextRef="rc" id="ixv-332">S-1</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="rc" id="ixv-333">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="rc" id="ixv-334">0001971387</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-335">Liminatus Pharma, Inc.</dei:EntityRegistrantName>
    <ffd:OfferingTableNa contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FormTp contextRef="rc" id="ixv-363">S-1</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-364">Liminatus Pharma, Inc.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="offrl_1" id="ixv-365">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="offrl_1" id="ixv-366">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_1" id="ixv-367">Shares of common stock, par value $0.0001 per share, underlying the common warrants</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="offrl_1" id="ixv-368">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="offrl_1"
      decimals="0"
      id="ixv-369"
      unitRef="Shares">20688000</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="offrl_1"
      decimals="4"
      id="ixv-370"
      unitRef="USD">0.1183</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_1"
      decimals="2"
      id="ixv-371"
      unitRef="USD">2447390.40</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_1"
      decimals="7"
      id="ixv-372"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_1"
      decimals="2"
      id="ixv-373"
      unitRef="USD">337.98</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="rc" decimals="2" id="ixv-374" unitRef="USD">2447390.40</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="rc" decimals="2" id="ixv-375" unitRef="USD">337.98</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt contextRef="rc" decimals="2" id="ixv-376" unitRef="USD">0.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt contextRef="rc" decimals="2" id="ixv-377" unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="rc" decimals="2" id="ixv-378" unitRef="USD">337.98</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="offrl_1" id="ixv-379">Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended, based upon the average of the high and low sale price of the Registrant's common stock on June 18, 2026, as reported in The Nasdaq Stock Market.</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
